	sample_name	run_prefix	experimental_strategy	cgc_base_name	filename	analyte_amount	analyte_A260A280Ratio	aliquot_concentration	cgc_id	cgc_filename	vital_status	gender	race	ethnicity	disease_type	data_subtype	tcga_sample_id	cgc_case_uuid	sample_type	cgc_platform	gdc_file_uuid	primary_site	age_at_diagnosis	cgc_sample_uuid	cgc_aliquot_uuid	tcga_aliquot_id	reference_genome	tcga_case_id	investigation	days_to_death	knightlabID	data_submitting_center_label	tissue_source_site_label	country_of_sample_procurement	portion_is_ffpe	pathologic_t_label	pathologic_n_label	histological_diagnosis_label	pathologic_stage_label	PlateCenter	PlateCenterFlag	TCGAStudy	ImmuneSubtype	TCGASubtype	LeukocyteFraction	StromalFraction	IntratumorHeterogeneity	TILRegionalFraction	Proliferation	WoundHealing	MacrophageRegulation	LymphocyteInfiltrationSignatureScore	IFNgammaResponse	TGFbetaResponse	SNVNeoantigens	IndelNeoantigens	SilentMutationRate	NonsilentMutationRate	NumberofSegments	FractionAltered	AneuploidyScore	HomologousRecombinationDefects	BCREvenness	BCRShannon	BCRRichness	TCRShannon	TCRRichness	TCREvenness	CTAScore	Th1Cells	Th2Cells	Th17Cells	OS	OSTime	PFI	PFITime	flr_F1_F2	blr_F1_F2	ilr_F1_F2	flr_F1_F3	blr_F1_F3	ilr_F1_F3	flr_F2_F3	blr_F2_F3	ilr_F2_F3
13722.58cfa82ee4b0c9d6adf6ae48	58cfa82ee4b0c9d6adf6ae48	TCGA-05-4384-01A-01D-1751_120228_SN1120_0117_BC0DKWACXX_s_4_rg.sorted.filtered.	WGS	TCGA-05-4384-01A-01D-1751_120228_SN1120_0117_BC0DKWACXX_s_4_rg.sorted	TCGA-05-4384-01A-01D-1751_120228_SN1120_0117_BC0DKWACXX_s_4_rg.sorted.bam	486.4	1.9	0.15	58cfa82ee4b0c9d6adf6ae48	TCGA-05-4384-01A-01D-1751_120228_SN1120_0117_BC0DKWACXX_s_4_rg.sorted.bam	Alive	MALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4384-01A	9A50E7E4-831D-489F-87D2-979E987561CC	Primary Tumor	Illumina HiSeq	985192a3-1403-4393-895a-ca9a4d12268f	Lung	66.0	E4416303-50B0-4316-BFEE-030C7B29FAC6	5253B1A2-8C57-414A-8E19-6E8390A6C18D	TCGA-05-4384-01A-01D-1751-02	HG19_Broad_variant	TCGA-05-4384	TCGA-LUAD		s10982	Harvard Medical School	Indivumed	Germany	NO	T2	N2	Lung Adenocarcinoma Mixed Subtype	Stage IIIA	1751-02	True	LUAD	C3	LUAD.1	0.199447265	0.51	0.02	0.0	-1.2215	-0.2755	0.6438	0.1829	-0.3167	0.0162	51.0	4.0	1.165266489	3.256770445	59.0	0.066063506	1.0	8.0	0.696424099	0.7651000729999999	3.0	2.197224577	9.0	1.0	2.706536803	-555.4953232999999	-1303.858707	3929.1928700000003	0.0	426.0	1.0	183.0	3.243429054922978	7.299290481556804	-0.659144054480926	2.2095669500030297	5.227692117337994	4.392389421709429	-1.0338621049199483	-2.07159836421881	5.051533476190355
13722.58cfa82ee4b0c9d6adf6ae50	58cfa82ee4b0c9d6adf6ae50	TCGA-05-4382-01A-01D-1203_120318_SN1120_0124_AC0HNPACXX_s_3_rg.sorted.filtered.	WGS	TCGA-05-4382-01A-01D-1203_120318_SN1120_0124_AC0HNPACXX_s_3_rg.sorted	TCGA-05-4382-01A-01D-1203_120318_SN1120_0124_AC0HNPACXX_s_3_rg.sorted.bam	445.53	1.9	0.14	58cfa82ee4b0c9d6adf6ae50	TCGA-05-4382-01A-01D-1203_120318_SN1120_0124_AC0HNPACXX_s_3_rg.sorted.bam	Alive	MALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4382-01A	3434B91A-C05F-460F-A078-7B1BB6E7085D	Primary Tumor	Illumina HiSeq	42d76c95-55a7-4160-b22f-4338315e6146	Lung	68.0	CCE6D71F-369E-467F-BD7E-03D20E97B7F3	EE1D241A-B371-433A-9AF7-F1C9074C155F	TCGA-05-4382-01A-01D-1203-02	HG19_Broad_variant	TCGA-05-4382	TCGA-LUAD		s11435	Harvard Medical School	Indivumed	None	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1203-02	True	LUAD	C6	LUAD.6	0.460245264	0.79	0.5	5.399125961	-0.1487	-0.0135	1.2892	1.3548	0.2834	0.6156	955.0	291.0	11.61873302	43.39182847	194.0	0.495305039	18.0	33.0	0.804021992	4.5587089569999995	290.0	4.046385053	61.0	0.984312627	5.599278237	-387.7732495	-175.4016867	3395.632436	0.0	607.0	1.0	334.0	7.477534507920421	6.86287413130942	0.30777342299465227	6.230659682050275	6.6278357923430615	3.6820379222972197	-1.2468748258701456	-0.2350383389663584	3.3742644993025674
13722.58cfa82ee4b0c9d6adf6ae52	58cfa82ee4b0c9d6adf6ae52	TCGA-05-4389-01A-01D-1203_120318_SN1120_0124_AC0HNPACXX_s_5_rg.sorted.filtered.	WGS	TCGA-05-4389-01A-01D-1203_120318_SN1120_0124_AC0HNPACXX_s_5_rg.sorted	TCGA-05-4389-01A-01D-1203_120318_SN1120_0124_AC0HNPACXX_s_5_rg.sorted.bam	372.53	1.9	0.14	58cfa82ee4b0c9d6adf6ae52	TCGA-05-4389-01A-01D-1203_120318_SN1120_0124_AC0HNPACXX_s_5_rg.sorted.bam	Alive	MALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4389-01A	A3DE401D-91FE-49A2-BB07-81C1A06506E6	Primary Tumor	Illumina HiSeq	63a06f9b-e1c2-495a-8f7e-88e19c550049	Lung	70.0	ED61AC6A-F21F-4B88-928A-029340D4AEBD	575D4BEF-5610-41F4-B219-C9BBBA72F047	TCGA-05-4389-01A-01D-1203-02	HG19_Broad_variant	TCGA-05-4389	TCGA-LUAD		s10769	Harvard Medical School	Indivumed	Germany	NO	T1	N0	Lung Adenocarcinoma Mixed Subtype	Stage IA	1203-02	True	LUAD	C2	LUAD.2	0.33617597299999996	0.52	0.5		0.2406	0.1405	0.9496	1.6249	0.6881	-0.1812	116.0	112.0	2.041442974	5.794095499	251.0	0.8140696340000001	18.0	45.0	0.8309696740000001	2.8535392280000003	31.0	4.36921797	95.0	0.959450173	4.2789271730000005	-664.3550031000001	181.31803689999998	3382.8557990000004	0.0	1369.0	0.0	1369.0	7.242905887921124	7.030595464520609	0.3687810252723691	6.042713806435095	6.36561916092736	1.998232947976538	-1.2001920814860294	-0.6649763035932486	1.6294519227041686
13722.58cfa82ee4b0c9d6adf6ae5a	58cfa82ee4b0c9d6adf6ae5a	TCGA-04-1514-01A-01D-A324-10_wgs_Illumina.filtered.	WGS	TCGA-04-1514-01A-01D-A324-10_wgs_Illumina	TCGA-04-1514-01A-01D-A324-10_wgs_Illumina.bam	279.67	1.9	0.07	58cfa82ee4b0c9d6adf6ae5a	TCGA-04-1514-01A-01D-A324-10_wgs_Illumina.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Ovarian Serous Cystadenocarcinoma	Aligned reads	TCGA-04-1514-01A	E9483296-CB91-497A-B955-39A3C3289DAC	Primary Tumor	Illumina HiSeq	07a37a5e-5fa5-415b-9814-363bf0a7bc48	Ovary	45.0	18E0F4ED-43E2-451F-82BD-102260A30AAA	C691D6B3-8E70-4951-8551-2EE4E4D0D10B	TCGA-04-1514-01A-01D-A324-10	GRCh37-lite	TCGA-04-1514	TCGA-OV	1720.0	s17412	Baylor College of Medicine	Gynecologic Oncology Group	None	NO			Serous Cystadenocarcinoma		A324-10	True	OV	C2	OVCA.Proliferative	0.03777766				0.6666	0.225	-1.5608	-2.1464	0.0832	-0.0666					285.0	0.862190272	9.0	42.0				1.732867951	6.0	0.9671320179999999	5.646226018999999	-1576.159539	486.3232356000001	-1796.02898	1.0	1720.0	1.0	1221.0	6.849066282633458	3.314669249110679	-0.9694005571881036	4.49769102546998	2.2349806285333207	0.7014459833746403	-2.3513752571634776	-1.0796886205773584	1.670846540562744
13722.58cfa82ee4b0c9d6adf6ae60	58cfa82ee4b0c9d6adf6ae60	TCGA-05-4390-01A-02D-1751_120305_SN1120_0118_AD0L4HACXX_s_1_rg.sorted.filtered.	WGS	TCGA-05-4390-01A-02D-1751_120305_SN1120_0118_AD0L4HACXX_s_1_rg.sorted	TCGA-05-4390-01A-02D-1751_120305_SN1120_0118_AD0L4HACXX_s_1_rg.sorted.bam	827.4	1.9	0.14	58cfa82ee4b0c9d6adf6ae60	TCGA-05-4390-01A-02D-1751_120305_SN1120_0118_AD0L4HACXX_s_1_rg.sorted.bam	Alive	FEMALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4390-01A	B8475929-2D9D-4909-BD62-59684A140BD7	Primary Tumor	Illumina HiSeq	625e3715-ed9e-4946-8c92-f5a93e92e6d4	Lung	58.0	C7F76210-D0F2-4FB8-80F1-35098DBE03DE	4BC393B5-F924-4D66-BC93-58A3CB2EBBC5	TCGA-05-4390-01A-02D-1751-02	HG19_Broad_variant	TCGA-05-4390	TCGA-LUAD		s11328	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1751-02	True	LUAD	C1	LUAD.2	0.189849228	0.43	0.36	0.0	0.5341	0.1485	0.2115	0.4356	-1.1596	0.1018	265.0	290.0	4.358562789	14.63875916	163.0	0.6931165840000001	16.0	27.0	0.921415619	3.874269453	67.0	2.197224577	9.0	1.0	2.278939296	-839.663958	159.24507830000002	1448.640421	0.0	1126.0	1.0	395.0	3.6025671334268043	3.6640550164757624	-0.9171146710990754	2.7787897073035523	3.732933333864416	1.4078820201280933	-0.823777426123252	0.0688783173886538	2.3249966912271685
13722.58cfa82ee4b0c9d6adf6ae62	58cfa82ee4b0c9d6adf6ae62	TCGA-05-4395-01A-01D-1203_110913_SN208_0238_BC008YACXX_s_8_rg.sorted.filtered.	WGS	TCGA-05-4395-01A-01D-1203_110913_SN208_0238_BC008YACXX_s_8_rg.sorted	TCGA-05-4395-01A-01D-1203_110913_SN208_0238_BC008YACXX_s_8_rg.sorted.bam	385.2	1.9	0.14	58cfa82ee4b0c9d6adf6ae62	TCGA-05-4395-01A-01D-1203_110913_SN208_0238_BC008YACXX_s_8_rg.sorted.bam	Dead	MALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4395-01A	762DEA8A-5B41-4058-979A-B7876ED13D7E	Primary Tumor	Illumina HiSeq	dcb07672-8bde-427e-9d94-ac644e457e91	Lung	76.0	9DED6605-39A3-4C0F-AD2E-7F6863960DBE	5E9E0A0C-75C0-48AA-BD85-A2E102787EF9	TCGA-05-4395-01A-01D-1203-02	HG19_Broad_variant	TCGA-05-4395	TCGA-LUAD	0.0	s11115	Harvard Medical School	Indivumed	Germany	NO	T4	N2	Lung Adenocarcinoma Mixed Subtype	Stage IIIB	1203-02	True	LUAD	C2	LUAD.3	0.202136549	0.39	0.15	0.090033936	0.2672	0.2735	0.3337	0.3167	0.4369	0.1311	123.0	1.0	2.3827142830000003	6.725889684	197.0	0.633570216	22.0	36.0	0.958556217	2.5958183569999997	15.0	2.6941537039999996	17.0	0.950918048		-789.5480405000001	-367.3401437	3205.151901	1.0	0.0	0.0	0.0	5.934516195237086	6.545708791241493	1.0906141279412762	4.513130514305926	5.48965611699218	1.4338571258055808	-1.421385680931161	-1.056052674249314	0.34324299786430457
13722.58cfa82ee4b0c9d6adf6ae64	58cfa82ee4b0c9d6adf6ae64	TCGA-05-4396-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-05-4396-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_1_rg.sorted	TCGA-05-4396-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_1_rg.sorted.bam	301.7	1.9	0.16	58cfa82ee4b0c9d6adf6ae64	TCGA-05-4396-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_1_rg.sorted.bam	Dead	MALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4396-01A	9F81C602-8AFA-4588-B0B6-6E5A1A128D5A	Primary Tumor	Illumina HiSeq	61bb72a1-5c87-411d-af04-3e058c2beab2	Lung	76.0	4D85772B-287E-4790-B1E8-CD1C0E88AD48	1F0C98A3-3EED-45E0-BF81-78632C02D375	TCGA-05-4396-01A-21D-1853-02	HG19_Broad_variant	TCGA-05-4396	TCGA-LUAD	303.0	s10640	Harvard Medical School	Indivumed	Germany	NO	T4	N1	Lung Adenocarcinoma Mixed Subtype	Stage IIIB	1853-02	True	LUAD	C3	LUAD.4	0.118303025	0.18	0.16	0.009099733	-0.4474	-0.2715	-0.2088	-0.1143	-0.3666	-0.0432	137.0	63.0	1.7959414219999998	7.062006948	200.0	0.699200259	8.0	13.0	0.798553965	2.214061718	16.0	1.9459101490000001	7.0	1.0	4.440018171	-1431.270232	-225.02198030000002	3090.921889	1.0	303.0	0.0	303.0	8.270269111436624	7.045083432053811	-0.24070186352758838	7.038125430143992	7.395285861486927	3.556959665383755	-1.2321436812926325	0.35020242943311475	3.7976615289113433
13722.58cfa82ee4b0c9d6adf6ae68	58cfa82ee4b0c9d6adf6ae68	TCGA-05-4403-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-05-4403-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-05-4403-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	211.2	1.9	0.15	58cfa82ee4b0c9d6adf6ae68	TCGA-05-4403-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4403-01A	CE15F31F-2BAD-4485-96FA-495BFA262E66	Primary Tumor	Illumina HiSeq	80e2118c-7ebf-42fc-8600-573afcbb3fe6	Lung	76.0	44B1D21C-0794-428C-BA01-82812D74DA2F	48F1FF7F-84F4-4420-96F9-DA1917577B6D	TCGA-05-4403-01A-01D-1203-02	GRCh37	TCGA-05-4403	TCGA-LUAD		s10980	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1203-02	True	LUAD	C6	LUAD.4	0.255515653	0.54	0.01	0.40500614100000004	-0.8043	-0.068	0.9554	1.0769	0.7037	0.2989	39.0	4.0	1.142155416	3.485038321	87.0	0.027215039	0.0	10.0	0.934386829	3.6738460839999996	51.0	3.662040914	41.0	0.9861235620000001	2.280830611	-102.216841	-614.7957152	1552.259906	0.0	578.0	0.0	578.0	7.712108357615428	8.409417062098878	0.04291456665547533	6.153963739568878	7.829598566845936	3.409794855393501	-1.5581446180465497	-0.5798184952529422	3.3668802887380256
13722.58cfa82ee4b0c9d6adf6ae6a	58cfa82ee4b0c9d6adf6ae6a	TCGA-05-4398-01A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-05-4398-01A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_1_rg.sorted	TCGA-05-4398-01A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_1_rg.sorted.bam	403.53	1.9	0.15	58cfa82ee4b0c9d6adf6ae6a	TCGA-05-4398-01A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_1_rg.sorted.bam	Alive	FEMALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4398-01A	31C96E35-5E2F-429C-B12A-7BC5A497A300	Primary Tumor	Illumina HiSeq	af507e03-fa73-4b22-88ae-8d5d9cee85dc	Lung	47.0	DA010683-C537-478F-8F95-E606B05DBC5C	CC8C5E2D-1878-49EC-9D63-D65EB4FE8256	TCGA-05-4398-01A-01D-1203-02	HG19_Broad_variant	TCGA-05-4398	TCGA-LUAD		s10981	Harvard Medical School	Indivumed	Germany	NO	T4	N3	Lung Adenocarcinoma Mixed Subtype	Stage IIIB	1203-02	True	LUAD	C2	LUAD.3	0.286317881	0.67	0.25	7.390615283	0.3394	0.1785	1.0578	1.311	0.7471	0.3573	319.0	258.0	6.382111753999999	18.73075589	235.0	0.486607549	19.0	47.0	0.86773412	3.89494293	89.0	4.256652064	75.0	0.9859093879999999	4.624980391999999	-60.11473046	-608.7003592	4026.3850799999996	0.0	1431.0	0.0	1431.0	7.490138482557227	7.436551788069365	-0.10776374207754136	6.385986013513501	6.531434356793335	2.001390055975489	-1.1041524690437257	-0.9051174312760297	2.10915379805303
13722.58cfa82ee4b0c9d6adf6ae6c	58cfa82ee4b0c9d6adf6ae6c	TCGA-05-4405-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_2.rg.sorted.filtered.	WGS	TCGA-05-4405-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_2.rg.sorted	TCGA-05-4405-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_2.rg.sorted.bam	175.7	1.9	0.17	58cfa82ee4b0c9d6adf6ae6c	TCGA-05-4405-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_2.rg.sorted.bam	Alive	FEMALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4405-01A	F587C9AB-2949-4410-80D6-A050865D48AA	Primary Tumor	Illumina HiSeq	47fe3db4-7a54-4703-b3a4-7ad7def2469c	Lung	74.0	9CE83CC4-7B9B-4CE7-98F5-5CE8A8D70902	8A9ADFB9-6266-490D-B1B6-F66F43F3F657	TCGA-05-4405-01A-21D-1853-02	HG19_Broad_variant	TCGA-05-4405	TCGA-LUAD		s10768	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1853-02	True	LUAD	C3	LUAD.3	0.304388607	0.62	0.49	0.144851961	-0.6193	-0.175	0.6655	0.8356	0.4333	0.4508	197.0	233.0	3.198758029	9.740362286	143.0	0.506204314	22.0	21.0	0.936154887	4.253227613	94.0	1.7478680969999998	6.0	0.9755037590000001	3.151559027	383.0049971	-374.0148147	1380.78794	0.0	610.0	0.0	610.0	7.061220009314109	7.204133128983061	-0.5264847631804328	6.63377599448717	7.700570015296952		-0.4274440148269396	0.49643688631389127	
13722.58cfa82ee4b0c9d6adf6ae74	58cfa82ee4b0c9d6adf6ae74	TCGA-05-4402-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-05-4402-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-05-4402-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	176.2	1.9	0.14	58cfa82ee4b0c9d6adf6ae74	TCGA-05-4402-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4402-01A	722D6818-F1CB-49F4-B68A-FD0A31304681	Primary Tumor	Illumina HiSeq	603e16bf-9b05-49c9-a925-f409626c969a	Lung	57.0	07C1FCE4-EC48-47A4-8391-E553936B67F2	5E791B10-E5FD-412D-9F42-72CAC197F253	TCGA-05-4402-01A-01D-1203-02	GRCh37	TCGA-05-4402	TCGA-LUAD	244.0	s10900	Harvard Medical School	Indivumed	Germany	NO	T2	NX	Lung Adenocarcinoma Mixed Subtype	Stage IV	1203-02	True	LUAD	C2	LUAD.2	0.28506428899999997	0.56	0.55	0.868542477	-0.0694	0.0185	0.7332	1.0036	1.4453	0.4149	58.0	48.0	1.050809163	3.0648600569999997	99.0	0.714184253	27.0	21.0	0.7761351259999999	3.448097694	85.0	3.1604362010000004	26.0	0.97002534	6.582860002	-83.24075531	-578.1871083	2362.627316	1.0	244.0	0.0	244.0	6.6138722017978075	4.266485897596456	-0.0371609801902707	5.920725021237862	2.9715792880659944	3.9244455254267034	-0.6931471805599454	-1.2949066095304618	3.961606505616974
13722.58cfa82ee4b0c9d6adf6aee7	58cfa82ee4b0c9d6adf6aee7	TCGA-05-4410-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-05-4410-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_4_rg.sorted	TCGA-05-4410-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_4_rg.sorted.bam	182.7	1.9	0.16	58cfa82ee4b0c9d6adf6aee7	TCGA-05-4410-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_4_rg.sorted.bam	Alive	MALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4410-01A	D28E465C-E553-4C53-8BB7-3D8199B9A8A5	Primary Tumor	Illumina HiSeq	bdcc8e9a-8d27-4167-ae6f-3c41b38c6c51	Lung	62.0	F8961F5C-E28B-44A2-8E4E-B5759FE2D849	51E2038A-2D9D-481D-A3B6-D5D5D6B33E4F	TCGA-05-4410-01A-21D-1853-02	HG19_Broad_variant	TCGA-05-4410	TCGA-LUAD		s10773	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1853-02	True	LUAD	C3	LUAD.3	0.428618499	0.76	0.39	0.0	-0.2923	-0.166	0.9173	1.8069	0.7625	0.0366	276.0	47.0	8.582490904	28.06152316	95.0	0.45283054899999997	17.0	32.0	0.706298751	3.5101729269999997	144.0	3.332936633	35.0	0.937443135		-49.76588274	-133.2584347	2783.173406	0.0	0.0	0.0	0.0	6.463895782886661	7.518461553284507	-0.18842759852403834	6.325745444405844	7.766297717189088	3.9209716110041604	-0.13815033848081715	0.2478361639045814	4.109399209528199
13722.58cfa82ee4b0c9d6adf6af20	58cfa82ee4b0c9d6adf6af20	TCGA-05-4415-01A-22D-1853_111204_SN208_0256_C0562ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-05-4415-01A-22D-1853_111204_SN208_0256_C0562ACXX_s_5_rg.sorted	TCGA-05-4415-01A-22D-1853_111204_SN208_0256_C0562ACXX_s_5_rg.sorted.bam	143.7	1.9	0.14	58cfa82ee4b0c9d6adf6af20	TCGA-05-4415-01A-22D-1853_111204_SN208_0256_C0562ACXX_s_5_rg.sorted.bam	Dead	MALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4415-01A	D15B7B29-C5C5-41D8-B83B-7CC12FE92820	Primary Tumor	Illumina HiSeq	ae778c61-5e62-4f34-9b62-f28d9acf21b1	Lung	57.0	57E160F5-45FC-44EF-95C6-54E112E3B7F5	4CD99514-20D0-439F-9B9F-BDDCEE5D950F	TCGA-05-4415-01A-22D-1853-02	HG19_Broad_variant	TCGA-05-4415	TCGA-LUAD	91.0	s11220	Harvard Medical School	Indivumed	Germany	NO	T4	N2	Lung Adenocarcinoma Mixed Subtype	Stage IIIB	1853-02	True	LUAD	C2	LUAD.6	0.176539342	0.33	0.22	0.411905395	0.9129	0.4435	-0.0966	0.1968	0.6154	-0.2839	82.0	40.0	1.623972149	5.161911473	171.0	0.815406165	19.0	24.0	0.859637402	3.253030945	44.0	2.428339239	16.0	0.8758382440000001	4.793929052	-271.8174716	1400.252582	-1836.4401460000001	1.0	91.0	1.0	60.0	6.0246025497785425	8.584327131859933	0.051592722482131426	6.145230537567158	8.760217798323596	1.1220940305628266	0.12062798778861472	0.17589066646366414	1.070501308080695
13722.58cfa82ee4b0c9d6adf6afae	58cfa82ee4b0c9d6adf6afae	TCGA-05-4425-01A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_3_rg.sorted.filtered.	WGS	TCGA-05-4425-01A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_3_rg.sorted	TCGA-05-4425-01A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_3_rg.sorted.bam	357.4	1.9	0.15	58cfa82ee4b0c9d6adf6afae	TCGA-05-4425-01A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_3_rg.sorted.bam	Alive	FEMALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4425-01A	69B23036-ADD9-42C9-941F-02FB74D9B08C	Primary Tumor	Illumina HiSeq	bf137f71-691f-42f6-a29c-e37a457bad18	Lung	70.0	98BEE17E-0B07-40D8-A70F-3163DBFD9C79	C0DC5772-8A3E-43BE-9059-FC524A5183C9	TCGA-05-4425-01A-01D-1751-02	HG19_Broad_variant	TCGA-05-4425	TCGA-LUAD		s10775	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IV	1751-02	True	LUAD	C6	LUAD.4	0.228394485	0.39	0.08	0.0	-0.0918	-0.017	1.1021	0.9734	0.6359	0.2405			0.382436537	1.029636831	83.0	0.23523482	9.0	10.0	0.842612562	2.387301156	17.0	3.127386308	27.0	0.948889898	2.022140034	-89.59658552	-457.0587766	1403.118289	0.0	669.0	0.0	669.0	4.8388157744021205	3.8766726553429685	-0.2596783881122793	4.017917192904901	4.013480948769806	1.9559580218515942	-0.8208985814972198	0.13680829342683776	2.2156364099638735
13722.58cfa82ee4b0c9d6adf6afc4	58cfa82ee4b0c9d6adf6afc4	TCGA-05-4418-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-05-4418-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-05-4418-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	313.3	1.9	0.15	58cfa82ee4b0c9d6adf6afc4	TCGA-05-4418-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	MALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4418-01A	D2C1E896-6886-4122-BB48-5FBCD3F641F4	Primary Tumor	Illumina HiSeq	961e7ff2-7efc-46b6-9fe6-3f19366eeab8	Lung	69.0	C9E092B2-D6C3-4161-BD9E-0FA4015BEBBB	AA7559AC-F8C0-40E5-A313-3914A6E4559A	TCGA-05-4418-01A-01D-1203-02	GRCh37	TCGA-05-4418	TCGA-LUAD	274.0	s11440	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Lung Adenocarcinoma Mixed Subtype	Stage IIIA	1203-02	True	LUAD	C2	LUAD.6	0.43781692899999997	0.45	0.59	22.47367449	0.1704	0.273	0.7954	1.8467	1.4031	0.1044	70.0	13.0	2.086539836	6.91538917	65.0	0.22372985199999998	5.0	5.0	0.8223541670000001	3.850370126	108.0	4.260094393999999	77.0	0.980728642	6.027494862999999	-233.03516859999996	-541.3422128999999	2657.651757	1.0	274.0	0.0	274.0	7.705994189080156	7.782876733818221	0.13577745957063903	6.789703457206002	6.612805481167967	3.967457712316246	-0.9162907318741551	-1.1700712526502546	3.831680252745607
13722.58cfa82ee4b0c9d6adf6b001	58cfa82ee4b0c9d6adf6b001	TCGA-05-4430-01A-02D-1203_111013_SN208_0253_B00PJACXX_s_6_rg.sorted.filtered.	WGS	TCGA-05-4430-01A-02D-1203_111013_SN208_0253_B00PJACXX_s_6_rg.sorted	TCGA-05-4430-01A-02D-1203_111013_SN208_0253_B00PJACXX_s_6_rg.sorted.bam	342.2	1.9	0.15	58cfa82ee4b0c9d6adf6b001	TCGA-05-4430-01A-02D-1203_111013_SN208_0253_B00PJACXX_s_6_rg.sorted.bam	Alive	FEMALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4430-01A	3A23CDB5-2327-45AC-B0B5-D4AFE038C757	Primary Tumor	Illumina HiSeq	e4ae6498-889f-4900-a73c-2e61a6e154d1	Lung	59.0	122AAA4F-8FD5-4C41-BFF8-8A45BDFB3F81	C14A77D1-DB59-434E-BD3C-DBBE647D790C	TCGA-05-4430-01A-02D-1203-02	HG19_Broad_variant	TCGA-05-4430	TCGA-LUAD		s10646	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1203-02	True	LUAD	C2	LUAD.5	0.295727418	0.8	0.32	1.700862485	-0.2684	0.1235	0.9349	1.2705	0.9454	0.6665	120.0	51.0	2.116684341	7.05561447	133.0	0.299412544	17.0	20.0	0.92181649	3.194772506	32.0	3.271689322	27.0	0.99267332	4.732450341	-297.724818	-771.266982	1792.795915	0.0	761.0	0.0	761.0	7.0695096305503995	5.26859426509583	-0.027075445265711928	5.924377326247397	6.168535858968456	3.3268536021619415	-1.1451323043030028	0.8999415938726254	3.3539290474276537
13722.58cfa82ee4b0c9d6adf6b00e	58cfa82ee4b0c9d6adf6b00e	TCGA-05-4422-01A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-05-4422-01A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_5_rg.sorted	TCGA-05-4422-01A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_5_rg.sorted.bam	631.63	1.9	0.15	58cfa82ee4b0c9d6adf6b00e	TCGA-05-4422-01A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_5_rg.sorted.bam	Alive	MALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4422-01A	44DEC838-B653-42A7-A58B-A1FD232CD68C	Primary Tumor	Illumina HiSeq	9fcb53c6-7d0c-4468-8a77-40e6ea3d43d8	Lung	68.0	DACBC55D-25C6-4E86-BD1B-38345B4DF7A7	09DD9098-5702-44A6-B9EA-F148ECE1E264	TCGA-05-4422-01A-01D-1203-02	HG19_Broad_variant	TCGA-05-4422	TCGA-LUAD		s11223	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1203-02	True	LUAD	C2	LUAD.1	0.321979601	0.38	0.01	26.50796492	-0.1697	-0.0085	0.9237	1.9779	-0.3273	-0.4185	13.0	26.0	0.44391327399999997	1.03579764	281.0	0.23091268899999998	6.0	20.0	0.909719886	4.284353277	111.0	3.859738826	86.0	0.866510528	1.922788947	151.1896341	-595.6018196	3493.228004	0.0	365.0	0.0	365.0	7.150536834989471	6.756630879543117	0.20157078553192043	5.896011751500704	5.866608074489572	3.7721170526839916	-1.2545250834887671	-0.8900228050535448	3.5705462671520714
13722.58cfa82ee4b0c9d6adf6b014	58cfa82ee4b0c9d6adf6b014	TCGA-05-4433-01A-22D-1853_120312_SN1120_0120_AD0PYGACXX_s_3_rg.sorted.filtered.	WGS	TCGA-05-4433-01A-22D-1853_120312_SN1120_0120_AD0PYGACXX_s_3_rg.sorted	TCGA-05-4433-01A-22D-1853_120312_SN1120_0120_AD0PYGACXX_s_3_rg.sorted.bam	199.7	1.9	0.16	58cfa82ee4b0c9d6adf6b014	TCGA-05-4433-01A-22D-1853_120312_SN1120_0120_AD0PYGACXX_s_3_rg.sorted.bam	Alive	MALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4433-01A	AEA68827-DC0F-484D-A00D-06DEEAA4B3CE	Primary Tumor	Illumina HiSeq	d1b6064d-6736-4aad-8ad3-70ab64c92e3d	Lung	82.0	1E9DAC94-1A10-47D0-AE92-81D38A264376	61B1812A-9455-437F-ACF7-D1AC3FA9F215	TCGA-05-4433-01A-22D-1853-02	HG19_Broad_variant	TCGA-05-4433	TCGA-LUAD		s10986	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1853-02	True	LUAD	C3	LUAD.6	0.280132698	0.38	0.09	2.7180032030000003	-0.1754	-0.195	1.0706	1.0588	0.7906	-0.0091	18.0	0.0	0.29175708300000003	0.87527125	127.0	0.18890197600000003	6.0	17.0				3.2331834839999996	26.0	0.9923534940000001	1.801427889	-68.4494889	-76.77195903	3536.57571	0.0	730.0	0.0	730.0	5.916767940204352	6.721973196013737	-0.44828945388290975	5.033000400035757	6.554919111350571	1.8420213040089433	-0.8837675401685949	-0.1670540846631665	2.290310757891853
13722.58cfa82ee4b0c9d6adf6b020	58cfa82ee4b0c9d6adf6b020	TCGA-05-4432-01A-01D-1203_111013_SN208_0253_B00PJACXX_s_4_rg.sorted.filtered.	WGS	TCGA-05-4432-01A-01D-1203_111013_SN208_0253_B00PJACXX_s_4_rg.sorted	TCGA-05-4432-01A-01D-1203_111013_SN208_0253_B00PJACXX_s_4_rg.sorted.bam	306.53	1.9	0.14	58cfa82ee4b0c9d6adf6b020	TCGA-05-4432-01A-01D-1203_111013_SN208_0253_B00PJACXX_s_4_rg.sorted.bam	Alive	MALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4432-01A	E737F650-B72D-44E7-B750-558A56716803	Primary Tumor	Illumina HiSeq	6110bc85-6f14-48d5-b166-2b3f42776573	Lung	66.0	2A675528-1ABC-4220-A61A-25109850CE0D	A4E437A5-1603-4AE4-89C2-CD741FDE5015	TCGA-05-4432-01A-01D-1203-02	HG19_Broad_variant	TCGA-05-4432	TCGA-LUAD		s11334	Harvard Medical School	Indivumed	Germany	NO	T2	N1	Lung Adenocarcinoma Mixed Subtype	Stage IIB	1203-02	True	LUAD	C2	LUAD.2	0.34603879	0.64	0.49	11.57628634	0.2749	0.11	0.6707	1.5551	-0.1633	0.2037	275.0	338.0	5.038556516	14.49325963	267.0	0.642010219	18.0	29.0	0.794396922	4.031702459	160.0	3.726795348	43.0	0.9908527159999999	5.670477559	-551.6964212	-71.35945646	3693.555629	0.0	761.0	0.0	761.0	6.959279796635528	6.574976214198541	-0.141119715835619	5.860667507967419	6.574976214198541	2.521274293958875	-1.09861228866811	0.0	2.662394009794494
13722.58cfa82ee4b0c9d6adf6b02c	58cfa82ee4b0c9d6adf6b02c	TCGA-05-4420-01A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-05-4420-01A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_3_rg.sorted	TCGA-05-4420-01A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_3_rg.sorted.bam	651.3	1.9	0.16	58cfa82ee4b0c9d6adf6b02c	TCGA-05-4420-01A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_3_rg.sorted.bam	Alive	MALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4420-01A	3D2AA654-1B5F-4EB4-A1C2-AF31F5760069	Primary Tumor	Illumina HiSeq	067a9600-61b8-4de1-ac32-914605c3033e	Lung	41.0	4B202550-9744-4C6C-AD17-97F764EA3F18	A50583F2-BB90-4848-9A5F-EAF4656A1866	TCGA-05-4420-01A-01D-1203-02	HG19_Broad_variant	TCGA-05-4420	TCGA-LUAD		s11332	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1203-02	True	LUAD	C1	LUAD.2	0.204150962	0.41	0.28	2.0026058	0.6729999999999999	0.33299999999999996	-0.0875	0.1669	-0.8136	0.1043	118.0	16.0	2.335529155	7.243096745	243.0	0.809257599	21.0	46.0	0.875894699	3.988716627	95.0	2.163955657	9.0	0.984858662	4.242182912	-1758.011664	272.1653441	-361.7889162	0.0	912.0	0.0	912.0	7.597732884780803	7.563262895713127	-0.00833886771984682	6.564503355375545	6.512441270881366	1.633524714734706	-1.0332295294052578	-1.050821624831761	1.6418635824545529
13722.58cfa82ee4b0c9d6adf6b034	58cfa82ee4b0c9d6adf6b034	TCGA-05-4426-01A-01D-1203_111013_SN208_0253_B00PJACXX_s_8_rg.sorted.filtered.	WGS	TCGA-05-4426-01A-01D-1203_111013_SN208_0253_B00PJACXX_s_8_rg.sorted	TCGA-05-4426-01A-01D-1203_111013_SN208_0253_B00PJACXX_s_8_rg.sorted.bam	666.2	1.9	0.14	58cfa82ee4b0c9d6adf6b034	TCGA-05-4426-01A-01D-1203_111013_SN208_0253_B00PJACXX_s_8_rg.sorted.bam	Alive	MALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4426-01A	36BF02F8-C1C8-49F9-A417-ADF88A205C70	Primary Tumor	Illumina HiSeq	63037227-adb0-4505-bd71-2527743ec736	Lung	71.0	0C06CF85-61EB-4E6D-AE54-B8F5CBAB9B63	EA6C652F-4896-4D57-978D-7528578BB153	TCGA-05-4426-01A-01D-1203-02	HG19_Broad_variant	TCGA-05-4426	TCGA-LUAD		s10645	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1203-02	True	LUAD	C6	LUAD.5	0.226345684	0.3	0.08	2.094842609	-0.2883	-0.055	0.5145	0.2404	0.4557	0.2166	24.0	80.0	0.177638462	1.3026820540000001	133.0	0.148541168	4.0	14.0	0.8426645290000001	0.584090542	2.0	3.1265850239999997	27.0	0.948646778	2.044923911	-407.97463039999997	-763.9785381	2513.969668	0.0	791.0	1.0	457.0	7.076442644500288	6.245844841385669	-0.16996755012469267	5.371694552261863	6.861030480475902	4.898936652095539	-1.7047480922384255	0.6151856390902335	5.0689042022202315
13722.58cfa82ee4b0c9d6adf6b038	58cfa82ee4b0c9d6adf6b038	TCGA-05-4424-01A-22D-1853_120312_SN1120_0120_AD0PYGACXX_s_1_rg.sorted.filtered.	WGS	TCGA-05-4424-01A-22D-1853_120312_SN1120_0120_AD0PYGACXX_s_1_rg.sorted	TCGA-05-4424-01A-22D-1853_120312_SN1120_0120_AD0PYGACXX_s_1_rg.sorted.bam	16.7	1.9	0.14	58cfa82ee4b0c9d6adf6b038	TCGA-05-4424-01A-22D-1853_120312_SN1120_0120_AD0PYGACXX_s_1_rg.sorted.bam	Alive	MALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4424-01A	66763A0C-6CDA-4832-A0CC-E7B496D78EAA	Primary Tumor	Illumina HiSeq	1e635509-6178-417e-9452-bc77482ee8ed	Lung	70.0	A4D06D63-8DA9-4C3C-A75D-4079C2238AA8	D1052F23-44EC-4C05-A164-6FBD72DFC9E2	TCGA-05-4424-01A-22D-1853-02	HG19_Broad_variant	TCGA-05-4424	TCGA-LUAD		s11438	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Lung Adenocarcinoma Mixed Subtype	Stage IIB	1853-02	True	LUAD	C2	LUAD.5	0.326199535	0.76	0.45	4.438671787	0.3447	0.02	0.9873	0.9145	0.6653	0.3044	395.0	421.0	5.336188214	18.32482216	111.0	0.621672541	15.0	29.0	0.886579711	3.394395783	46.0	3.0981394960000004	23.0	0.9880864970000001	6.213827577000001	-503.66576619999995	203.2766107	1689.0684820000001	0.0	913.0	1.0	153.0	6.269930171134712	8.218042943434318	-0.8005915729812593	5.241161455833867	7.309784383257427	3.4438136838165745	-1.0287687153008456	-0.9082585601768911	4.244405256797833
13722.58cfa82ee4b0c9d6adf6b092	58cfa82ee4b0c9d6adf6b092	TCGA-05-4417-01A-22D-1853_111204_SN208_0256_C0562ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-05-4417-01A-22D-1853_111204_SN208_0256_C0562ACXX_s_6_rg.sorted	TCGA-05-4417-01A-22D-1853_111204_SN208_0256_C0562ACXX_s_6_rg.sorted.bam	184.7	1.9	0.16	58cfa82ee4b0c9d6adf6b092	TCGA-05-4417-01A-22D-1853_111204_SN208_0256_C0562ACXX_s_6_rg.sorted.bam	Alive	FEMALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4417-01A	A244A99A-D7CC-4FB1-BC76-B66886481621	Primary Tumor	Illumina HiSeq	f4f3791e-3b72-4f33-986c-dca1cf3ada94	Lung	51.0	9AB40E48-6979-43CB-9ACF-1D4F474CAD4D	B7C6B0BD-AB9E-4211-8B3A-786B45C43F3D	TCGA-05-4417-01A-22D-1853-02	HG19_Broad_variant	TCGA-05-4417	TCGA-LUAD		s11437	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1853-02	True	LUAD	C3	LUAD.6	0.35519708	0.6	0.36	8.617588161	-0.2947	-0.133	0.9571	1.8551	0.2404	0.5142	136.0	33.0	2.09507924	7.406547736	85.0	0.5519829070000001	15.0	22.0	0.883451916	4.371991409	141.0	3.738230895	43.0	0.993893114	2.149556115	643.8292002999999	-305.52112	2236.117859	0.0	455.0	0.0	455.0	7.29535809834138	6.663969092491479	-0.3119905129283226	6.273706850809399	6.8532110921300085	2.3566796549705336	-1.021651247531981	0.1892419996385284	2.6686701678988562
13722.58cfa82ee4b0c9d6adf6b0a5	58cfa82ee4b0c9d6adf6b0a5	TCGA-05-4249-01A-01D-1103_110729_SN208_0215_BD0CLPABXX_s_1_rg.sorted.filtered.	WGS	TCGA-05-4249-01A-01D-1103_110729_SN208_0215_BD0CLPABXX_s_1_rg.sorted	TCGA-05-4249-01A-01D-1103_110729_SN208_0215_BD0CLPABXX_s_1_rg.sorted.bam	64.93	1.9	0.15	58cfa82ee4b0c9d6adf6b0a5	TCGA-05-4249-01A-01D-1103_110729_SN208_0215_BD0CLPABXX_s_1_rg.sorted.bam	Alive	MALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4249-01A	4ADDF05F-3668-4B3F-A17F-C0227329CA52	Primary Tumor	Illumina HiSeq	94e6a5cd-7ba5-4f3e-bf83-7d07522963b4	Lung	67.0	80F196FE-1EAF-40CB-AB58-C84795ACC5C7	E3F50937-D6CF-423B-9DD3-31D715892FC7	TCGA-05-4249-01A-01D-1103-02	HG19_Broad_variant	TCGA-05-4249	TCGA-LUAD		s10642	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1103-02	True	LUAD	C3	LUAD.5	0.251680895	0.51	0.26	2.15188989	-0.8788	-0.1325	0.7904	0.9536	0.4666	0.2006	172.0	153.0	1.949942901	8.172554806	97.0	0.6430591489999999	22.0	10.0	0.6824665209999999	2.48253077	38.0	3.476845417	35.0	0.977919843	2.078720038	-420.27373279999995	-1082.674145	3999.4556759999996	0.0	1523.0	0.0	1523.0	7.381046766524051	7.253453924082027	0.03287884755708825	6.650159257981258	6.855770956415918	0.0	-0.7308875085427924	-0.3976829676661091	-0.03287884755708825
13722.58cfa82ee4b0c9d6adf6b197	58cfa82ee4b0c9d6adf6b197	TCGA-09-1666-01A-01D-A324-10_wgs_Illumina.filtered.	WGS	TCGA-09-1666-01A-01D-A324-10_wgs_Illumina	TCGA-09-1666-01A-01D-A324-10_wgs_Illumina.bam	788.97	1.9	0.08	58cfa82ee4b0c9d6adf6b197	TCGA-09-1666-01A-01D-A324-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Ovarian Serous Cystadenocarcinoma	Aligned reads	TCGA-09-1666-01A	4EAC2C98-86D2-4EE6-A1D3-157D013C78DC	Primary Tumor	Illumina HiSeq	6d2f46e9-b19b-431a-aa4e-c409eb1787dc	Ovary	57.0	77AB9685-021C-4D99-8980-79BEC534828E	127B0F7D-D24E-48B7-AC25-D3F14A43952D	TCGA-09-1666-01A-01D-A324-10	GRCh37-lite	TCGA-09-1666	TCGA-OV		s17490	Baylor College of Medicine	UCSF	None	NO			Serous Cystadenocarcinoma		A324-10	True	OV	C2	OVCA.Differentiated	0.084944091				0.4661	0.2685	0.2283	-0.3554	1.8776	-0.4095					335.0	0.98051996	3.0	64.0				3.8365870639999997	53.0	0.966323673	3.018458545	-1123.240243	-483.5727005	695.7985731000001	0.0	1752.0	1.0	480.0	6.5297107664499645	1.3598600001229073	0.30131278634765135	5.431098477781855	2.9032768114592136	2.4139398770131413	-1.0986122886681096	1.5434168113363063	2.11262709066549
13722.58cfa82fe4b0c9d6adf6b290	58cfa82fe4b0c9d6adf6b290	TCGA-09-2045-01A-01D-A324-10_wgs_Illumina.filtered.	WGS	TCGA-09-2045-01A-01D-A324-10_wgs_Illumina	TCGA-09-2045-01A-01D-A324-10_wgs_Illumina.bam	598.97	1.9	0.08	58cfa82fe4b0c9d6adf6b290	TCGA-09-2045-01A-01D-A324-10_wgs_Illumina.bam	Dead	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Ovarian Serous Cystadenocarcinoma	Aligned reads	TCGA-09-2045-01A	3768D34F-1527-40DB-B116-CD80CEE5EC3A	Primary Tumor	Illumina HiSeq	51ef343e-2d9c-48c4-9a6f-6c4f0dcac50d	Ovary	50.0	4D5AAF12-A500-4709-9C99-5B9FEF2C79B1	6797443C-EB4A-4654-B957-C0056E5A4206	TCGA-09-2045-01A-01D-A324-10	GRCh37-lite	TCGA-09-2045	TCGA-OV	1069.0	s17170	Baylor College of Medicine	UCSF	None	NO			Serous Cystadenocarcinoma		A324-10	True	OV	C4	OVCA.Differentiated	0.078582979				-0.6678	-0.1495	-0.2707	-1.1106	1.7729	-0.2658	13.0		0.318889886	1.211781565				49.0		0.0	1.0	2.599301927	14.0	0.9849357559999999	3.360733968	-1437.269566	-1753.445554	1706.7154460000002	1.0	1069.0	1.0	631.0	6.911747300251674	2.294770205009807	1.0811945126406952	4.386018655943419	1.3748930975044251	3.3923145080845782	-2.525728644308255	-0.919877107505382	2.311119995443883
13722.58cfa82fe4b0c9d6adf6b384	58cfa82fe4b0c9d6adf6b384	TCGA-24-2024-01A-02D-A324-10_wgs_Illumina.filtered.	WGS	TCGA-24-2024-01A-02D-A324-10_wgs_Illumina	TCGA-24-2024-01A-02D-A324-10_wgs_Illumina.bam	798.27	1.8	0.07	58cfa82fe4b0c9d6adf6b384	TCGA-24-2024-01A-02D-A324-10_wgs_Illumina.bam	Dead	FEMALE	BLACK OR AFRICAN AMERICAN		Ovarian Serous Cystadenocarcinoma	Aligned reads	TCGA-24-2024-01A	0A48873A-092A-4B25-822B-B0B3C18C08A8	Primary Tumor	Illumina HiSeq	03e36495-9e80-442c-bc07-456ee80a47ca	Ovary	72.0	A3F8DCAD-C42A-4070-80C4-782627BBACA2	46F19B5C-3EBA-4B23-A1AB-9748090CA4E5	TCGA-24-2024-01A-02D-A324-10	GRCh37-lite	TCGA-24-2024	TCGA-OV	1769.0	s17944	Baylor College of Medicine	Washington University	None	NO			Serous Cystadenocarcinoma		A324-10	True	OV	C1	OVCA.Differentiated	0.041457257000000004	0.09	0.0		0.0805	0.142	-0.2128	-0.8171	-0.2406	0.1921			0.9251359440000001	2.946729302	313.0	0.947136929	4.0	59.0	0.8433957940000001	3.5587150519999997	68.0	1.790171779	23.0	0.570937675	3.961961718	-1137.19001	-937.3506612	-107.99515009999999	1.0	1769.0	1.0	421.0	7.996317231796745	2.3227683826473147	-0.013492925737445982	5.598421958998374	2.0976849665152786	0.9958767596028953	-2.3978952727983707	-0.22508341613203608	1.0093696853403413
13722.58cfa82fe4b0c9d6adf6b3a2	58cfa82fe4b0c9d6adf6b3a2	TCGA-24-1419-01A-01D-A324-10_wgs_Illumina.filtered.	WGS	TCGA-24-1419-01A-01D-A324-10_wgs_Illumina	TCGA-24-1419-01A-01D-A324-10_wgs_Illumina.bam	589.97	1.9	0.09	58cfa82fe4b0c9d6adf6b3a2	TCGA-24-1419-01A-01D-A324-10_wgs_Illumina.bam	Alive	FEMALE	WHITE		Ovarian Serous Cystadenocarcinoma	Aligned reads	TCGA-24-1419-01A	5E18B17D-4626-4B6D-8AC6-E560CEE0376C	Primary Tumor	Illumina HiSeq	915b863a-f427-4e28-8809-4e9f244f9f4d	Ovary	62.0	92D562DF-4A58-43DA-8811-843D3D3C9438	2F2EAECC-6509-423F-B63A-8C3BEA1BA4A4	TCGA-24-1419-01A-01D-A324-10	GRCh37-lite	TCGA-24-1419	TCGA-OV		s17620	Baylor College of Medicine	Washington University	None	NO			Serous Cystadenocarcinoma		A324-10	True	OV	C2	OVCA.Proliferative	0.057877017	0.02	0.11		0.5539999999999999	0.2265	-1.2627	-2.7824	1.2183	-0.4038	20.0		0.23807232399999997	1.190361618	139.0	0.957207675	6.0	28.0					0.0		3.065815389	-1219.2846	286.74399589999996	-1587.257517	0.0	239.0	0.0	239.0	6.049733455231958	2.420827793103478	-0.24323290668661657	3.6073864198627534	1.5198257537444135	4.599700710183556	-2.4423470353692043	-0.9010020393590645	4.842933616870172
13722.58cfa82fe4b0c9d6adf6b3fa	58cfa82fe4b0c9d6adf6b3fa	TCGA-24-1552-01A-01D-A324-10_wgs_Illumina.filtered.	WGS	TCGA-24-1552-01A-01D-A324-10_wgs_Illumina	TCGA-24-1552-01A-01D-A324-10_wgs_Illumina.bam	719.67	1.9	0.08	58cfa82fe4b0c9d6adf6b3fa	TCGA-24-1552-01A-01D-A324-10_wgs_Illumina.bam	Dead	FEMALE	WHITE		Ovarian Serous Cystadenocarcinoma	Aligned reads	TCGA-24-1552-01A	62379BE5-13F0-474B-94D3-6F944EC4EE96	Primary Tumor	Illumina HiSeq	5549fe8c-2ced-4cb8-826b-b212f6ba24d5	Ovary	77.0	411B4C26-FCC4-438A-8731-D0CF5DD6C74F	14ED7388-41ED-43D4-AFB2-04CD6410D5D2	TCGA-24-1552-01A-01D-A324-10	GRCh37-lite	TCGA-24-1552	TCGA-OV	1259.0	s17300	Baylor College of Medicine	Washington University	None	NO			Serous Cystadenocarcinoma		A324-10	True	OV	C4	OVCA.Differentiated	0.029075361	0.09	0.04		1.0479	0.18100000000000002	-0.6196	-1.7569	0.6691	-0.2425	25.0		0.263025067	1.432025365	359.0	0.9457341090000001	14.0	27.0	0.990122631	0.68630071	2.0	2.2718685130000003	10.0	0.986659959	3.396691368	-1232.8673099999999	459.0098343	-2511.076994	1.0	1259.0	1.0	403.0	6.318476592478245	1.3157435358957308	-2.4227957351833727	5.420534999272286	2.3394383956788323	0.29640052349166224	-0.8979415932059585	1.0236948597831015	2.719196258675035
13722.58cfa82fe4b0c9d6adf6b408	58cfa82fe4b0c9d6adf6b408	TCGA-24-1558-01A-01D-A324-10_wgs_Illumina.filtered.	WGS	TCGA-24-1558-01A-01D-A324-10_wgs_Illumina	TCGA-24-1558-01A-01D-A324-10_wgs_Illumina.bam	326.97	1.9	0.08	58cfa82fe4b0c9d6adf6b408	TCGA-24-1558-01A-01D-A324-10_wgs_Illumina.bam	Dead	FEMALE	WHITE		Ovarian Serous Cystadenocarcinoma	Aligned reads	TCGA-24-1558-01A	BA68F2CF-9271-41FD-9655-1FAC7681F588	Primary Tumor	Illumina HiSeq	ff5c5c7d-21a4-4a46-b611-efb7750a4316	Ovary	73.0	3E8BD387-4FDA-4623-924E-314267C55EEA	9020B6A5-8325-4B0D-84D9-04371C857910	TCGA-24-1558-01A-01D-A324-10	GRCh37-lite	TCGA-24-1558	TCGA-OV	594.0	s18117	Baylor College of Medicine	Washington University	None	NO			Serous Cystadenocarcinoma		A324-10	True	OV	C4	OVCA.Proliferative	0.041680866000000004				0.6653	0.187	-0.62	-1.3858	0.2688	-0.1707					393.0	0.646788212	17.0	39.0				1.7478680969999998	6.0	0.9755037590000001	3.614860306	-1570.569172	-417.4057475	-573.3029836000001	1.0	594.0	1.0	273.0	6.640311468771347	1.722324217729465	-0.6240695489441077	4.520047932571256	1.283370439867257	2.299918819751042	-2.120263536200091	-0.4389537778622081	2.9239883686951496
13722.58cfa82fe4b0c9d6adf6b440	58cfa82fe4b0c9d6adf6b440	TCGA-24-2290-01A-01D-A324-10_wgs_Illumina.filtered.	WGS	TCGA-24-2290-01A-01D-A324-10_wgs_Illumina	TCGA-24-2290-01A-01D-A324-10_wgs_Illumina.bam	683.97	1.9	0.08	58cfa82fe4b0c9d6adf6b440	TCGA-24-2290-01A-01D-A324-10_wgs_Illumina.bam	Dead	FEMALE	WHITE		Ovarian Serous Cystadenocarcinoma	Aligned reads	TCGA-24-2290-01A	2B14123B-8FCD-402C-9399-4E7C47F20252	Primary Tumor	Illumina HiSeq	f1ffb755-85ec-4449-b604-8e9cd194d527	Ovary	56.0	BBFED693-79E1-4DC7-896E-15B98FC7DBAC	FEA5827B-251D-474B-8713-FC76DB995FE7	TCGA-24-2290-01A-01D-A324-10	GRCh37-lite	TCGA-24-2290	TCGA-OV	1102.0	s17878	Baylor College of Medicine	Washington University	None	NO			Serous Cystadenocarcinoma		A324-10	True	OV	C4	OVCA.Immunoreactive	0.128241729	0.19	0.17		0.8346	0.205	0.3945	-0.778	1.0362	-0.0725			0.670887636	1.661245575	362.0	0.960283343	7.0	72.0	0.834127587	1.832765634	9.0	2.924009467	26.0	0.897459432	2.182674706	-830.1681014999999	443.7782063	1466.949819	1.0	1102.0	1.0	324.0	7.12259780525696	2.6432940960774225	0.3011505004310816	5.130167640566754	1.955405472770944	2.062597089731448	-1.9924301646902063	-0.6878886233064785	1.7614465893003661
13722.58cfa82fe4b0c9d6adf6b524	58cfa82fe4b0c9d6adf6b524	TCGA-29-1705-01A-01D-0926-12_Illumina.filtered.	WGS	TCGA-29-1705-01A-01D-0926-12_Illumina	TCGA-29-1705-01A-01D-0926-12_Illumina.bam	135.7	1.9	0.15	58cfa82fe4b0c9d6adf6b524	TCGA-29-1705-01A-01D-0926-12_Illumina.bam	Dead	FEMALE	WHITE		Ovarian Serous Cystadenocarcinoma	Aligned reads	TCGA-29-1705-01A	F9C835DB-2AB6-4BF5-826F-48723493C0EC	Primary Tumor	Illumina HiSeq	862f409b-92fe-4bea-95cc-97f8beae4add	Ovary	47.0	FD3E7BA8-21A5-438B-82EE-482ED6905310	6730E18B-CC34-493E-AAE2-54E51D5D9CFF	TCGA-29-1705-01A-01D-0926-12	NCBI36_BCM_variant	TCGA-29-1705	TCGA-OV	555.0	s17530	Baylor College of Medicine	Duke	None	NO			Serous Cystadenocarcinoma		0926-12	True	OV	C4	OVCA.Mesenchymal	0.250474556	0.21	0.2		0.7368	0.2885	0.1289	-0.8574	-0.5206	0.4307	14.0		0.683732277	1.106995115	325.0	0.7941646290000001	6.0	57.0	0.9925403540000001	0.687976548	2.0	3.245427493	28.0	0.973958076	2.65702882	-1441.460592	-162.60049080000002	238.21805330000004	1.0	555.0	1.0	283.0	2.332998800895745	2.15903994698205	-0.7109805079370775	4.1199296755176045	4.928815727845216	4.288631287074328	1.7869308746218593	2.7697757808631662	4.999611795011406
13722.58cfa82fe4b0c9d6adf6b541	58cfa82fe4b0c9d6adf6b541	TCGA-25-2391-01A-01D-A324-10_wgs_Illumina.filtered.	WGS	TCGA-25-2391-01A-01D-A324-10_wgs_Illumina	TCGA-25-2391-01A-01D-A324-10_wgs_Illumina.bam	896.97	1.9	0.07	58cfa82fe4b0c9d6adf6b541	TCGA-25-2391-01A-01D-A324-10_wgs_Illumina.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Ovarian Serous Cystadenocarcinoma	Aligned reads	TCGA-25-2391-01A	F5033D52-EC36-4E67-88D8-B6D898B81B2F	Primary Tumor	Illumina HiSeq	4c0ed657-169e-4ee1-b8b9-4544a43ed2ee	Ovary	57.0	2179798C-4FD4-4434-B1D5-1453F6054FA2	58FAF969-BF37-4180-8807-2F44F2CC8EDA	TCGA-25-2391-01A-01D-A324-10	GRCh37-lite	TCGA-25-2391	TCGA-OV	1492.0	s17137	Baylor College of Medicine	Mayo Clinic - Rochester	None	NO			Serous Cystadenocarcinoma		A324-10	True	OV	C2	OVCA.Differentiated	0.122861755	0.12	0.1		0.6128	0.299	0.0102	-0.7492	1.2599	-0.2958	40.0		0.47890195799999996	2.171022211	280.0	0.9164875229999999	3.0	49.0				3.565537524	40.0	0.966563849	3.504118327	-515.5895779	262.448236	1519.820267	1.0	1492.0	0.0	1492.0	6.78260425716679	1.3883372627496904	1.888397188145528	5.922402991943679	2.752386014922262	2.3000850916919613	-0.8602012652231115	1.3640487521725717	0.41168790354643336
13722.58cfa82fe4b0c9d6adf6b5cc	58cfa82fe4b0c9d6adf6b5cc	TCGA-38-4628-01A-01D-1203_110804_SN208_0217_BC03EKABXX_s_8_rg.sorted.filtered.	WGS	TCGA-38-4628-01A-01D-1203_110804_SN208_0217_BC03EKABXX_s_8_rg.sorted	TCGA-38-4628-01A-01D-1203_110804_SN208_0217_BC03EKABXX_s_8_rg.sorted.bam	32.52	1.9	0.13	58cfa82fe4b0c9d6adf6b5cc	TCGA-38-4628-01A-01D-1203_110804_SN208_0217_BC03EKABXX_s_8_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-38-4628-01A	CC4BD56A-25C5-4C48-B583-AC3AEB778CA6	Primary Tumor	Illumina HiSeq	f215f323-8551-4bdc-bce7-17bc9bd45bf4	Lung	65.0	A74F6423-B5D3-4AE2-B61F-3EE04B1073BF	606E6830-C9FB-4107-8BD4-253C193D56B6	TCGA-38-4628-01A-01D-1203-02	HG19_Broad_variant	TCGA-38-4628	TCGA-LUAD	1492.0	s10652	Harvard Medical School	UNC	United States	NO	T2	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIB	1203-02	True	LUAD	C4	LUAD.3	0.152455206	0.5	0.32	0.49200492	-0.0921	0.209	0.5049	-0.1006	-0.2032	0.0916	62.0	12.0	0.9191171290000001	3.0538407839999997	329.0	0.757525928	20.0	46.0	0.973139192	1.743631362	6.0	2.138397246	9.0	0.973226528	2.804093675	253.9096423	-919.9677129	2630.39041	1.0	1492.0	1.0	1083.0	4.610898429083178	6.275138598162224	0.4183751763900734	3.8263170425636	5.5237225094783025	2.953372211568259	-0.7845813865195774	-0.7514160886839214	2.5349970351781854
13722.58cfa82fe4b0c9d6adf6b5dc	58cfa82fe4b0c9d6adf6b5dc	TCGA-50-5939-01A-11D-1623_120302_SN208_0271_BC0D91ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-50-5939-01A-11D-1623_120302_SN208_0271_BC0D91ACXX_s_3_rg.sorted	TCGA-50-5939-01A-11D-1623_120302_SN208_0271_BC0D91ACXX_s_3_rg.sorted.bam	111.7	1.9	0.15	58cfa82fe4b0c9d6adf6b5dc	TCGA-50-5939-01A-11D-1623_120302_SN208_0271_BC0D91ACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5939-01A	12B79B4F-C28C-418E-A1E7-E622F33FDCC2	Primary Tumor	Illumina HiSeq	7a3d6187-a909-4946-83bf-0d6fc6a753ee	Lung	85.0	6A27F5F8-F4EE-45C7-B953-DDD7D0291DBB	08D803D0-A294-4F70-9560-563357172BBB	TCGA-50-5939-01A-11D-1623-02	HG19_Broad_variant	TCGA-50-5939	TCGA-LUAD	460.0	s11007	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1623-02	True	LUAD	C1	LUAD.6	0.45048425700000005	0.62	0.17	13.626411	0.1158	0.0295	0.8781	1.237	0.0707	0.6289	35.0	4.0	0.550471526	2.048977348	119.0	0.238353433	7.0	35.0	0.8873604759999999	4.70151742	200.0	2.6156305769999997	14.0	0.99112306	3.1062414830000002	238.8044249	175.1137158	2558.210697	1.0	460.0	0.0	460.0	7.6335676411665965	9.043140822188024	-0.6898304279339513	7.113692181880689	7.944528533519914	1.1460788259070334	-0.5198754592859083	-1.0986122886681096	1.8359092538409847
13722.58cfa82fe4b0c9d6adf6b5f0	58cfa82fe4b0c9d6adf6b5f0	TCGA-50-5933-01A-11D-1751_110928_SN590_0108_BB01CWACXX_s_6_rg.sorted.filtered.	WGS	TCGA-50-5933-01A-11D-1751_110928_SN590_0108_BB01CWACXX_s_6_rg.sorted	TCGA-50-5933-01A-11D-1751_110928_SN590_0108_BB01CWACXX_s_6_rg.sorted.bam	168.4	2.0	0.15	58cfa82fe4b0c9d6adf6b5f0	TCGA-50-5933-01A-11D-1751_110928_SN590_0108_BB01CWACXX_s_6_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5933-01A	7A0EA814-F0DE-4BC4-A81A-DAA000559369	Primary Tumor	Illumina HiSeq	ca97b42b-d723-4c0a-8f71-819eca1bb805	Lung	72.0	D2355F3A-E2CE-4791-B1FB-B570850681DF	1D83B47D-66A8-4AE9-81BB-BDC03FA64AC6	TCGA-50-5933-01A-11D-1751-02	HG19_Broad_variant	TCGA-50-5933	TCGA-LUAD	2393.0	s11009	Harvard Medical School	University of Pittsburgh	United States	NO	T4	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIB	1751-02	True	LUAD	C6	LUAD.3	0.365416423	0.7	0.33		0.302	0.026000000000000002	1.0483	0.3428	0.149	0.6071	221.0	136.0	4.011924665	13.47516681	146.0	0.49247298100000003	19.0	25.0	0.926706756	2.678527035	18.0	2.890371758	18.0	1.0	2.7691128139999996	121.98713980000001	50.88663197	1901.2922760000001	1.0	2393.0	0.0	2393.0	7.031652915638374	7.488306233194237	-0.6149507347316775	6.002033498457216	8.137001651183349	1.916383350956853	-1.029619417181158	0.6486954179891113	2.5313340856885307
13722.58cfa82fe4b0c9d6adf6b5fe	58cfa82fe4b0c9d6adf6b5fe	TCGA-36-1574-01A-01D-A324-10_wgs_Illumina.filtered.	WGS	TCGA-36-1574-01A-01D-A324-10_wgs_Illumina	TCGA-36-1574-01A-01D-A324-10_wgs_Illumina.bam	475.97	1.9	0.08	58cfa82fe4b0c9d6adf6b5fe	TCGA-36-1574-01A-01D-A324-10_wgs_Illumina.bam	Alive	FEMALE	ASIAN		Ovarian Serous Cystadenocarcinoma	Aligned reads	TCGA-36-1574-01A	EEB9D147-608D-4692-8ADF-2F601D23A8FF	Primary Tumor	Illumina HiSeq	e3ba53fc-a70c-4bd4-8dc4-60969af737fa	Ovary	48.0	353B6C00-EBFE-4650-8379-F46C8FE3E9CF	80F02AEC-C07A-4BCB-B547-E60F8C33A7B1	TCGA-36-1574-01A-01D-A324-10	GRCh37-lite	TCGA-36-1574	TCGA-OV		s17538	Baylor College of Medicine	BC Cancer Agency	None	NO			Serous Cystadenocarcinoma		A324-10	True	OV	C2	OVCA.Immunoreactive	0.067604575				0.9089	0.3955	0.0811	-0.5961	1.4219	0.273					330.0	0.938823834	6.0	63.0	0.8141861090000001	1.9523330230000002	11.0	3.652629783	40.0	0.990173257	2.481495703	-827.7932281000001	755.1770176	-1844.181996	0.0	686.0	1.0	648.0	6.002033498457216	3.1205742758135004	-1.3461042848642495	3.832979798087693	2.2480209924197245	1.360619656096607	-2.169053700369523	-0.8725532833937759	2.7067239409608566
13722.58cfa82fe4b0c9d6adf6b60d	58cfa82fe4b0c9d6adf6b60d	TCGA-38-4631-01A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_5_rg.sorted.filtered.	WGS	TCGA-38-4631-01A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_5_rg.sorted	TCGA-38-4631-01A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_5_rg.sorted.bam	387.4	1.9	0.15	58cfa82fe4b0c9d6adf6b60d	TCGA-38-4631-01A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_5_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-38-4631-01A	2483621A-4DB3-41AB-AA33-B9427EA8A0AF	Primary Tumor	Illumina HiSeq	b1dd06d4-cd7d-4e62-8deb-12fed31731b5	Lung	72.0	13B0D336-205A-42AC-8A50-DB0EB065013D	B1FA802A-C88E-4B8D-88FF-4545DCF326DE	TCGA-38-4631-01A-01D-1751-02	HG19_Broad_variant	TCGA-38-4631	TCGA-LUAD	354.0	s11229	Harvard Medical School	UNC	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1751-02	True	LUAD	C2	LUAD.6	0.31096098899999997	0.51	0.65	4.265981368	0.8282	0.564	0.0869	0.5354	0.8751	-0.1696	314.0	229.0	5.860813514	19.61702347	316.0	0.6140737620000001	16.0	42.0	0.882721816	4.0198064769999995	95.0	1.791759469	6.0	1.0	6.82378843	-995.5703424000001	-278.5579141	-3579.417429	1.0	354.0	1.0	354.0	6.0369158100119	6.7325341685355875	-0.16422740432052296	5.033776315995209	4.719537726263905	1.1464169176683572	-1.0031394940166907	-2.0129964422716826	1.3106443219888804
13722.58cfa82fe4b0c9d6adf6b624	58cfa82fe4b0c9d6adf6b624	TCGA-75-5146-01A-01D-1623_110913_SN208_0238_BC008YACXX_s_5_rg.sorted.filtered.	WGS	TCGA-75-5146-01A-01D-1623_110913_SN208_0238_BC008YACXX_s_5_rg.sorted	TCGA-75-5146-01A-01D-1623_110913_SN208_0238_BC008YACXX_s_5_rg.sorted.bam	692.7	1.9	0.15	58cfa82fe4b0c9d6adf6b624	TCGA-75-5146-01A-01D-1623_110913_SN208_0238_BC008YACXX_s_5_rg.sorted.bam	Alive	MALE			Lung Adenocarcinoma	Aligned reads	TCGA-75-5146-01A	1D276B62-5E64-48FB-B2CE-5192B511FE37	Primary Tumor	Illumina HiSeq	926ac8ca-ff8f-4822-bf62-819bf5525a5d	Lung		373C5231-B6AE-49DB-AC0D-D674A0C9C100	2578C781-0BDF-4CA2-A8FA-8B624489818B	TCGA-75-5146-01A-01D-1623-02	HG19_Broad_variant	TCGA-75-5146	TCGA-LUAD		s10668	Harvard Medical School	Ontario Institute for Cancer Research (OICR)	Canada	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1623-02	True	LUAD	C2	LUAD.5	0.270856033	0.42	0.18	9.721115538	-0.7824	0.045	0.6121	1.7552	-0.0776	-0.4172	82.0	124.0	1.5851050359999999	5.090625789	191.0	0.793192646	8.0	18.0	0.954134413	2.0964475819999997	9.0	3.2331834839999996	26.0	0.9923534940000001	2.128916498	341.0651328	-733.6537860000001	1949.4133550000001	0.0	2368.0	1.0	1773.0	7.553361514773082	6.7007994412298215	-0.12960725416838825	6.454749226104973	6.372295374257785	3.2854471621551937	-1.0986122886681098	-0.32850406697203605	3.415054416323582
13722.58cfa82fe4b0c9d6adf6b62c	58cfa82fe4b0c9d6adf6b62c	TCGA-50-5941-01A-11D-1751_111007_SN590_0110_C003AACXX_s_3_rg.sorted.filtered.	WGS	TCGA-50-5941-01A-11D-1751_111007_SN590_0110_C003AACXX_s_3_rg.sorted	TCGA-50-5941-01A-11D-1751_111007_SN590_0110_C003AACXX_s_3_rg.sorted.bam	237.4	1.9	0.16	58cfa82fe4b0c9d6adf6b62c	TCGA-50-5941-01A-11D-1751_111007_SN590_0110_C003AACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE		Lung Adenocarcinoma	Aligned reads	TCGA-50-5941-01A	F3F024C2-52F1-400E-946C-398F5B72E6DC	Primary Tumor	Illumina HiSeq	f7c353bf-7be8-42d0-88d0-e89032718c2f	Lung	55.0	91719392-76CE-479F-BA05-E43BF0201CC4	666720AF-64D9-4A63-BE57-2B8E49E79413	TCGA-50-5941-01A-11D-1751-02	HG19_Broad_variant	TCGA-50-5941	TCGA-LUAD		s11128	Harvard Medical School	University of Pittsburgh	United States	NO	T2a	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1751-02	True	LUAD	C2	LUAD.5	0.44653042200000004	0.73	0.64		0.1331	0.039	1.298	2.1424	1.3185	0.3276	195.0	123.0	2.7801187080000003	9.894831099	164.0	0.5345951729999999	27.0	29.0	0.8838353390000001	3.804084833	74.0	4.0601572180000005	64.0	0.9762614470000001	1.912808281	88.09969435	-287.8586325	1567.101182	0.0	1474.0	0.0	1474.0	6.950814768442584	6.62168728781541	0.37841857554753655	6.257667587882638	6.859358939692529	2.2935175582024523	-0.6931471805599454	0.23767165187711958	1.9150989826549156
13722.58cfa82fe4b0c9d6adf6b62e	58cfa82fe4b0c9d6adf6b62e	TCGA-75-6206-01A-11D-1751_111116_SN208_0255_D09F1ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-75-6206-01A-11D-1751_111116_SN208_0255_D09F1ACXX_s_5_rg.sorted	TCGA-75-6206-01A-11D-1751_111116_SN208_0255_D09F1ACXX_s_5_rg.sorted.bam	304.4	1.9	0.16	58cfa82fe4b0c9d6adf6b62e	TCGA-75-6206-01A-11D-1751_111116_SN208_0255_D09F1ACXX_s_5_rg.sorted.bam	Alive	MALE			Lung Adenocarcinoma	Aligned reads	TCGA-75-6206-01A	C4C1469D-752F-42B6-8686-714AD4A8AC97	Primary Tumor	Illumina HiSeq	2b0c2142-3073-4443-9998-a7e909add85d	Lung		4AFC6152-819B-4E55-817D-DF8A42EB0D36	B6836DCC-F7D7-45BF-AE7C-DE6F2140779E	TCGA-75-6206-01A-11D-1751-02	HG19_Broad_variant	TCGA-75-6206	TCGA-LUAD		s11131	Harvard Medical School	Ontario Institute for Cancer Research (OICR)	Canada	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1751-02	True	LUAD	C3		0.122679154			1.09921242	-1.7797	-0.354	0.5161	-0.0099	0.0121	0.0636	53.0	1.0	0.5528639439999999	2.426458422	111.0	0.420275799	14.0	14.0	0.705637638	1.26433292	6.0	2.397895273	11.0	1.0	1.119200277	583.2810253	-1225.075131	4640.64801	0.0	2590.0	0.0	2590.0	7.161658944884925	7.169871115157978	-0.5933040553697557	6.804984000946192	7.443759865477423	1.9898798935679163	-0.35667494393873245	0.27388875031944515	2.583183948937672
13722.58cfa82fe4b0c9d6adf6b648	58cfa82fe4b0c9d6adf6b648	TCGA-86-6562-01A-11D-1751_120403_SN1222_0094_BD0UKBACXX_s_3_rg.sorted.filtered.	WGS	TCGA-86-6562-01A-11D-1751_120403_SN1222_0094_BD0UKBACXX_s_3_rg.sorted	TCGA-86-6562-01A-11D-1751_120403_SN1222_0094_BD0UKBACXX_s_3_rg.sorted.bam	237.4	1.9	0.13	58cfa82fe4b0c9d6adf6b648	TCGA-86-6562-01A-11D-1751_120403_SN1222_0094_BD0UKBACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-86-6562-01A	DCD066BA-5894-453E-B1DA-82092858C3DB	Primary Tumor	Illumina HiSeq	71d960e2-40e8-4084-bcc1-5ebbefc183af	Lung	52.0	DE4BB1D0-8BD9-4614-85CA-C39D8C636BCC	3AB9FD95-4329-4DD3-823D-F2E050CBA3C1	TCGA-86-6562-01A-11D-1751-02	HG19_Broad_variant	TCGA-86-6562	TCGA-LUAD		s11014	Harvard Medical School	Asterand	Russia	NO	T2a	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIA	1751-02	True	LUAD	C6	LUAD.3	0.19516963699999998	0.54	0.25	0.22734489100000002	-0.0838	-0.106	0.5357	0.4384	0.3181	0.5408	21.0		0.390818107	1.202517253	111.0	0.51425325	13.0	16.0	0.9626383409999999	2.115132621	9.0	2.540036304	13.0	0.990287117	2.1593990780000003	37.12008777	-112.39669209999998	2700.887691	1.0	376.0	1.0	274.0	6.728943345721927	8.693098373903576	-0.16322925689835976	5.784116306582837	6.933087602990101	2.5417599125426262	-0.9448270391390894	-1.7600107709134751	2.704989169440986
13722.58cfa82fe4b0c9d6adf6b64a	58cfa82fe4b0c9d6adf6b64a	TCGA-73-4662-01A-01D-1203_110629_SN208_0211_AB0BP8ABXX_s_5_rg.sorted.filtered.	WGS	TCGA-73-4662-01A-01D-1203_110629_SN208_0211_AB0BP8ABXX_s_5_rg.sorted	TCGA-73-4662-01A-01D-1203_110629_SN208_0211_AB0BP8ABXX_s_5_rg.sorted.bam	337.2	1.9	0.15	58cfa82fe4b0c9d6adf6b64a	TCGA-73-4662-01A-01D-1203_110629_SN208_0211_AB0BP8ABXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-73-4662-01A	294FF941-AEA1-4588-9A0E-E9F5393E2BB6	Primary Tumor	Illumina HiSeq	bb68d6e1-efca-4ccb-bbd6-45c4da207bb7	Lung	65.0	C7D727B6-47C6-4339-B9DD-5BAF41527BD4	DCC0A32E-EF17-4AA8-8321-A03137A61D72	TCGA-73-4662-01A-01D-1203-02	HG19_Broad_variant	TCGA-73-4662	TCGA-LUAD		s10663	Harvard Medical School	Roswell Park	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1203-02	True	LUAD	C3	LUAD.3	0.30101377100000004	0.52	0.26	5.680388579	-0.5629	-0.099	0.8098	1.6729	0.0622	0.0869	90.0	64.0	1.5342558259999999	5.745938486	190.0	0.675318042	10.0	36.0	0.87782023	4.141993766000001	112.0	4.55456403	99.0	0.9911741540000001	1.923729808	368.1024585	-645.5503152000001	3487.3238229999997	0.0	2515.0	1.0	21.0	8.054734361787952	7.151429483833626	-0.5530898054998569	6.668440000668062	6.494649947444556	1.9433198468442758	-1.3862943611198904	-0.6567795363890707	2.496409652344133
13722.58cfa82fe4b0c9d6adf6b64b	58cfa82fe4b0c9d6adf6b64b	TCGA-75-5126-01A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_5_rg.sorted.filtered.	WGS	TCGA-75-5126-01A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_5_rg.sorted	TCGA-75-5126-01A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_5_rg.sorted.bam	392.4	1.9	0.15	58cfa82fe4b0c9d6adf6b64b	TCGA-75-5126-01A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_5_rg.sorted.bam	Alive	FEMALE			Lung Adenocarcinoma	Aligned reads	TCGA-75-5126-01A	93766482-2F20-4C8F-BBD8-BDD203C37D5A	Primary Tumor	Illumina HiSeq	8c670948-9cf1-4db3-82d5-39ed824c61ff	Lung		39509EA1-E728-4350-B444-798C72ADE33A	7BCB1D5A-871F-472E-A964-9B68259D9716	TCGA-75-5126-01A-01D-1751-02	HG19_Broad_variant	TCGA-75-5126	TCGA-LUAD		s11251	Harvard Medical School	Ontario Institute for Cancer Research (OICR)	Canada	NO	T3	N2	Lung Papillary Adenocarcinoma	Stage IIIA	1751-02	True	LUAD	C4	LUAD.6	0.473820003	0.76	0.51	2.179409697	0.3646	0.1585	1.5019999999999998	1.0558	0.8612	0.3769	338.0	409.0	5.1435470180000005	16.09627655	94.0	0.201161587	7.0	17.0	0.846239739	0.586568689	2.0	2.83094043	18.0	0.979438172		531.6884364	-142.76156799999998	548.6406836	0.0		0.0		10.213093702837881	9.084478448346452	0.376051222901871	8.609555512530967	8.19288032906267	1.8562611382715017	-1.603538190306912	-0.8915981192837839	1.4802099153696306
13722.58cfa82fe4b0c9d6adf6b657	58cfa82fe4b0c9d6adf6b657	TCGA-64-5778-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-64-5778-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_3_rg.sorted	TCGA-64-5778-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_3_rg.sorted.bam	702.7	1.9	0.15	58cfa82fe4b0c9d6adf6b657	TCGA-64-5778-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-64-5778-01A	8FDBD88F-19AE-4AB8-BCD7-6BFA1BBDE742	Primary Tumor	Illumina HiSeq	bd5570f2-ed45-408a-a615-0a6808c31d84	Lung	60.0	92514FD2-A178-42E8-8929-0910558E7F87	BC8FFDB4-AB99-44B7-95B0-7BC2F8110B76	TCGA-64-5778-01A-01D-1623-02	HG19_Broad_variant	TCGA-64-5778	TCGA-LUAD		s10796	Harvard Medical School	Fox Chase	United States	NO	T2	N0	Lung Bronchioloalveolar Carcinoma Nonmucinous	Stage IB	1623-02	True	LUAD	C2	LUAD.5	0.316319533	0.41	0.15	9.708212037000001	0.0513	0.2185	0.9693	2.4054	1.4993	-0.2758	184.0	193.0	3.4024458760000003	12.80556902	116.0	0.8392103959999999	9.0	27.0	0.931258989	3.872997256	64.0	4.415035405	91.0	0.978757019	2.279322074	471.97672769999997	-737.069254	2159.740089	0.0	1305.0	1.0	962.0	6.091498401260084	7.030998130157643	0.5628667389918318	4.912843404918438	6.789836073340755	2.35345798378796	-1.178654996341646	-0.24116205681688863	1.7905912447961283
13722.58cfa82fe4b0c9d6adf6b668	58cfa82fe4b0c9d6adf6b668	TCGA-55-6642-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_1_rg.sorted.filtered.	WGS	TCGA-55-6642-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_1_rg.sorted	TCGA-55-6642-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_1_rg.sorted.bam	245.7	1.9	0.14	58cfa82fe4b0c9d6adf6b668	TCGA-55-6642-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE		Lung Adenocarcinoma	Aligned reads	TCGA-55-6642-01A	474B86D9-D897-467D-85D4-51DFA26EA107	Primary Tumor	Illumina HiSeq	9b12800d-6911-4d3f-a25e-4d1b686b63aa	Lung	63.0	08D8F333-08F9-4268-99B7-61F7B057F542	93AF51CC-26FF-4904-84BC-2DFFB317D86A	TCGA-55-6642-01A-11D-1853-02	HG19_Broad_variant	TCGA-55-6642	TCGA-LUAD		s11552	Harvard Medical School	International Genomics Consortium	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1853-02	True	LUAD	C3	LUAD.2	0.369819356	0.63	0.39	9.642930222999999	-0.1457	-0.0875	0.6363	1.5944	-0.0118	0.6706	45.0	141.0	1.063123112	3.248431731	98.0	0.39832252700000004	12.0	34.0	0.873926368	5.702395469	682.0	3.244461365	29.0	0.963521332	2.66409517	-64.11983347	399.4169027	1109.602027	0.0	2449.0	0.0	2449.0	6.446116566068028	8.839783808356207	-0.7297047762937428	6.105189979097435	7.109393285504445	0.7515579427163597	-0.3409265869705931	-1.730390522851763	1.4812627190101024
13722.58cfa82fe4b0c9d6adf6b66c	58cfa82fe4b0c9d6adf6b66c	TCGA-50-5946-01A-11D-1751_111111_SN208_0254_B0160ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-50-5946-01A-11D-1751_111111_SN208_0254_B0160ACXX_s_3_rg.sorted	TCGA-50-5946-01A-11D-1751_111111_SN208_0254_B0160ACXX_s_3_rg.sorted.bam	242.4	1.9	0.14	58cfa82fe4b0c9d6adf6b66c	TCGA-50-5946-01A-11D-1751_111111_SN208_0254_B0160ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE		Lung Adenocarcinoma	Aligned reads	TCGA-50-5946-01A	C95957A7-1A1A-4C8D-BB61-7C99B500F224	Primary Tumor	Illumina HiSeq	b7f024ff-9569-4d31-b652-ffc2ceaa2789	Lung	62.0	AD9A794F-52DD-4572-BF29-CD3D11BA6C24	F9F38A15-2964-4AE0-90AA-E5F3F7461AB3	TCGA-50-5946-01A-11D-1751-02	HG19_Broad_variant	TCGA-50-5946	TCGA-LUAD		s10790	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N0	Lung Adenocarcinoma Mixed Subtype	Stage IA	1751-02	True	LUAD	C2		0.068325795	0.25	0.48	18.16596489	0.9896	0.1055	-0.3455	-0.034	0.5532	-0.0503	190.0		2.7818640439999998	8.437301936	138.0	0.891684493	17.0	32.0	0.909725695	2.812000743	22.0	2.043191871	8.0	0.982567593	5.733293502	-235.8700952	483.04330880000003	1608.485871	0.0	1617.0	1.0	221.0	5.43580399508606	7.4109518755836366	0.3158979448064577	5.723486067537841	7.862936999326694	3.863357833446865	0.2876820724517808	0.4519851237430572	3.5474598886404074
13722.58cfa82fe4b0c9d6adf6b674	58cfa82fe4b0c9d6adf6b674	TCGA-71-6725-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_7_rg.sorted.filtered.	WGS	TCGA-71-6725-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_7_rg.sorted	TCGA-71-6725-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_7_rg.sorted.bam	406.7	1.9	0.14	58cfa82fe4b0c9d6adf6b674	TCGA-71-6725-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_7_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-71-6725-01A	4B7CD595-E7F9-45A8-B736-A8C7C42D9539	Primary Tumor	Illumina HiSeq	9c1abbc4-5f6b-486c-a6a3-17a01c8783cb	Lung	48.0	83973755-FA6A-460A-A042-385B34698C39	1AD7566E-B9DD-43A3-94DC-96F525007EAA	TCGA-71-6725-01A-11D-1853-02	HG19_Broad_variant	TCGA-71-6725	TCGA-LUAD		s11554	Harvard Medical School	ILSbio	Vietnam	NO	T2	N0	Lung Papillary Adenocarcinoma	Stage IB	1853-02	True	LUAD	C4	LUAD.3	0.24839929300000002	0.37	0.2	0.633252635	-0.5183	-0.114	-0.1407	-1.3718	0.1979	-0.2364	27.0	1.0	0.47144907399999997	1.2964849520000001	210.0	0.929285035	19.0	42.0					0.0		1.892587585	-354.3393788	-721.759596	193.0592178	0.0	256.0	1.0	164.0	2.245821620476102	5.434358627649226	0.16303341700941587	1.1579726451099805	3.52173445622738	1.982542799190373	-1.0878489753661214	-1.9126241714218462	1.8195093821809571
13722.58cfa82fe4b0c9d6adf6b676	58cfa82fe4b0c9d6adf6b676	TCGA-73-4666-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-73-4666-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-73-4666-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	375.23	1.9	0.16	58cfa82fe4b0c9d6adf6b676	TCGA-73-4666-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-73-4666-01A	4C31127E-D095-4978-9DAC-35153C27F6ED	Primary Tumor	Illumina HiSeq	7af89597-2a6c-4030-acf6-4bd33963a3f3	Lung	52.0	5BAE2E45-6DBC-458C-A66F-702EB1AF7357	AC0D75F8-B4C5-40A8-9044-0B74722424D8	TCGA-73-4666-01A-01D-1203-02	GRCh37	TCGA-73-4666	TCGA-LUAD		s11461	Harvard Medical School	Roswell Park	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IV	1203-02	True	LUAD	C2		0.334216293	0.55	0.28	5.457914017	0.9568	0.24	1.0713	1.1073	0.3996	-0.0069	169.0	123.0	3.05983989	9.44179166	104.0	0.638753848	20.0	17.0	0.91638359	3.0202508210000003	27.0	3.27304198	67.0	0.778425982	1.6077988669999999	-44.99235381	596.1566664	2470.544598	0.0	800.0	0.0	800.0	8.285064953974995	7.6599310371154194	0.5164833474858495	7.0645628476978475	6.599059076430157	1.7931709020664626	-1.2205021062771468	-1.060871960685263	1.2766875545806131
13722.58cfa82fe4b0c9d6adf6b678	58cfa82fe4b0c9d6adf6b678	TCGA-73-4670-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-73-4670-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-73-4670-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	343.9	1.9	0.16	58cfa82fe4b0c9d6adf6b678	TCGA-73-4670-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-73-4670-01A	1B354837-4925-4480-AC32-6B44D0957314	Primary Tumor	Illumina HiSeq	8e4449ab-641c-44ea-af17-a681182f7299	Lung	69.0	646402AF-BA5F-438C-AE63-213EBD58B16D	D2FFA731-14A2-4A83-964E-C9969080263C	TCGA-73-4670-01A-01D-1203-02	GRCh37	TCGA-73-4670	TCGA-LUAD		s11356	Harvard Medical School	Roswell Park	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IV	1203-02	True	LUAD	C1		0.181372195	0.38	0.26	6.593572332999999	0.6394	0.315	0.0377	0.0601	-0.3871	0.447	184.0	179.0	2.4586418119999998	8.851110524	272.0	0.7045332879999999	24.0	27.0	0.859831143	3.6153256610000004	67.0	2.3419942519999997	11.0	0.9766874640000001	4.3319466680000005	-1118.734862	-395.3038414	2915.962761	0.0	131.0	0.0	131.0	7.599267790865621	7.872073979866874	0.20814458790443469	6.696400079323608	6.154422482792541	2.127305136406095	-0.9028677115420143	-1.717651497074333	1.9191605485016603
13722.58cfa82fe4b0c9d6adf6b67d	58cfa82fe4b0c9d6adf6b67d	TCGA-49-4486-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-49-4486-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-49-4486-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	142.53	1.9	0.14	58cfa82fe4b0c9d6adf6b67d	TCGA-49-4486-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-49-4486-01A	61C655EC-52B5-453F-A6CC-B2ABA445B027	Primary Tumor	Illumina HiSeq	cb4d8cf1-9903-481c-8ba1-df0586b69916	Lung	72.0	5AE9B10F-347C-48C3-90CD-9290055CFE4B	EC0EE49C-D1D4-490D-BA82-CFAE6D451B8D	TCGA-49-4486-01A-01D-1203-02	GRCh37	TCGA-49-4486	TCGA-LUAD	2318.0	s10907	Harvard Medical School	Johns Hopkins	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1203-02	True	LUAD	C3	LUAD.1	0.091577638	0.27	0.1	0.644325322	-1.1296	0.0315	-0.6073	0.1189	-0.8323	-0.9281	74.0	35.0	1.575225004	3.6259896310000004	208.0	0.14684154800000002	1.0	9.0	0.956955345	1.989932697	8.0	2.5649493569999997	13.0	1.0	1.351237891	43.81513815	-1235.571391	3268.440929	1.0	2318.0	1.0	2045.0	9.9057765973396	6.896679240130541	0.27174473315292724	8.142188005078241	7.490453946877283	2.0560912699918568	-1.7635885922613586	0.5937747067467414	1.7843465368389295
13722.58cfa82fe4b0c9d6adf6b680	58cfa82fe4b0c9d6adf6b680	TCGA-49-4488-01A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_1_rg.sorted.filtered.	WGS	TCGA-49-4488-01A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_1_rg.sorted	TCGA-49-4488-01A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_1_rg.sorted.bam	195.4	1.9	0.14	58cfa82fe4b0c9d6adf6b680	TCGA-49-4488-01A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_1_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-49-4488-01A	D721BFE0-90E3-415E-B9F3-1A270EFA5FBB	Primary Tumor	Illumina HiSeq	26421230-2518-42aa-85ee-f9c83d47a6ba	Lung	74.0	1AEA8530-43FD-47EA-A2F1-377267DC9D33	DA0D3199-053B-4789-A217-CA2BFB83D57E	TCGA-49-4488-01A-01D-1751-02	HG19_Broad_variant	TCGA-49-4488	TCGA-LUAD	869.0	s11236	Harvard Medical School	Johns Hopkins	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1751-02	True	LUAD	C2	LUAD.3	0.23271017300000002	0.55	0.51		0.037000000000000005	0.073	0.4484	1.2728	0.2446	-0.0332	134.0	91.0	2.305942989	7.919093684	311.0	0.778496744	22.0	59.0	0.9166366159999999	2.7459978919999997	20.0	2.813355405	17.0	0.9929910190000001	2.5365069940000002	779.3671347999999	-891.9394091	2191.501933	1.0	869.0	1.0	634.0	8.00252686826431	7.250303489478392	-0.03358062005428508	7.012128164236433	6.353557353677207	1.354488364423974	-0.9903987040278763	-0.8967461358011848	1.3880689844782592
13722.58cfa82fe4b0c9d6adf6b687	58cfa82fe4b0c9d6adf6b687	TCGA-44-6148-01A-11D-1751_110927_SN208_0243_BC00TKACXX_s_6_rg.sorted.filtered.	WGS	TCGA-44-6148-01A-11D-1751_110927_SN208_0243_BC00TKACXX_s_6_rg.sorted	TCGA-44-6148-01A-11D-1751_110927_SN208_0243_BC00TKACXX_s_6_rg.sorted.bam	164.4	1.9	0.16	58cfa82fe4b0c9d6adf6b687	TCGA-44-6148-01A-11D-1751_110927_SN208_0243_BC00TKACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-6148-01A	8994C8C4-9EA0-46CB-B4A5-0055D7DA5BFA	Primary Tumor	Illumina HiSeq	e3f95d46-09ce-43a0-a2c7-581cb9fe8da9	Lung	60.0	C0FE5FFE-C0A3-4E62-AA55-2BC18788E505	F8A1C395-E730-48F9-BF82-E8931E4AF154	TCGA-44-6148-01A-11D-1751-02	HG19_Broad_variant	TCGA-44-6148	TCGA-LUAD		s10995	Harvard Medical School	Christiana Healthcare	United States	NO	T1b	N0	Lung Mucinous Adenocarcinoma	Stage IA	1751-02	True	LUAD	C3		0.177418319			14.65739562	-1.8732	-0.3625	0.6746	1.125	-0.2376	0.1702	2.0		0.061515039	0.12303007699999999	67.0	0.027558316	2.0	0.0	0.931206842	3.387345119	38.0	2.2718685130000003	10.0	0.986659959	2.9091360739999996	-29.48103552	-1189.900777	1324.908509	0.0	704.0	0.0	704.0	7.056276698836059	8.337066367290765	0.18263072359190347	6.392982481425795	8.301975047479495	2.313463211141229	-0.6632942174102641	-0.03509131981127034	2.130832487549325
13722.58cfa82fe4b0c9d6adf6b691	58cfa82fe4b0c9d6adf6b691	TCGA-36-1570-01A-01D-A324-10_wgs_Illumina.filtered.	WGS	TCGA-36-1570-01A-01D-A324-10_wgs_Illumina	TCGA-36-1570-01A-01D-A324-10_wgs_Illumina.bam	286.97	1.9	0.09	58cfa82fe4b0c9d6adf6b691	TCGA-36-1570-01A-01D-A324-10_wgs_Illumina.bam	Alive	FEMALE	WHITE		Ovarian Serous Cystadenocarcinoma	Aligned reads	TCGA-36-1570-01A	0F530B3E-5B6D-4892-9EBD-9138D76FDCA7	Primary Tumor	Illumina HiSeq	7bd2e9c4-4e02-4a02-83d2-c1da3a047b3a	Ovary	49.0	22B7E0E2-334C-419C-A243-358BA22E479A	A2F38E9E-48B2-4463-B2E3-61CC8475257F	TCGA-36-1570-01A-01D-A324-10	GRCh37-lite	TCGA-36-1570	TCGA-OV		s18070	Baylor College of Medicine	BC Cancer Agency	None	NO			Serous Cystadenocarcinoma		A324-10	True	OV	C4	OVCA.Differentiated	0.047691625999999994				0.7354	0.309	-0.3618	-1.5718	1.7838	-0.4803					392.0	0.495224712	5.0	59.0				2.7502140010000002	18.0	0.9515087440000001	3.801737661	-1687.7720379999998	-382.621334	170.9739279	0.0	655.0	1.0	375.0	7.215975002651466	2.7351521308800013	0.5229740585223221	4.773627967282262	2.1220476579935923	3.4573243358954415	-2.4423470353692043	-0.613104472886409	2.9343502773731194
13722.58cfa82fe4b0c9d6adf6b6aa	58cfa82fe4b0c9d6adf6b6aa	TCGA-44-6774-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-44-6774-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_7_rg.sorted	TCGA-44-6774-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_7_rg.sorted.bam	62.7	1.9	0.17	58cfa82fe4b0c9d6adf6b6aa	TCGA-44-6774-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-6774-01A	33C71EAD-4C2A-476D-85EF-885DBBFC2CBD	Primary Tumor	Illumina HiSeq	5ff8e7e5-3b91-49af-b384-9d870bd9e425	Lung	56.0	79CF84B5-84FF-42E5-B438-697B35D272FC	6B977266-994D-4440-BC09-59FD8737F2D0	TCGA-44-6774-01A-21D-1853-02	HG19_Broad_variant	TCGA-44-6774	TCGA-LUAD		s10996	Harvard Medical School	Christiana Healthcare	United States	NO	T1	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1853-02	True	LUAD	C1	LUAD.2	0.375200885	0.55	0.49	2.674586506	-0.2189	-0.111	0.7288	0.7294	0.3016	0.9725	81.0	7.0	2.19017705	7.319802247	136.0	0.32798056800000003	4.0	14.0	0.565158653	2.294794502	58.0	3.040727294	22.0	0.983722269	1.579929616	349.9317339	192.6167943	-564.3049782	0.0	658.0	0.0	658.0	6.463133455672779	7.03761326624035	-0.7770919200015685	5.952307831906788	6.6321481581321855	2.7677445338552533	-0.5108256237659905	-0.4054651081081646	3.544836453856822
13722.58cfa82fe4b0c9d6adf6b6b7	58cfa82fe4b0c9d6adf6b6b7	TCGA-64-5781-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-64-5781-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_7_rg.sorted	TCGA-64-5781-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_7_rg.sorted.bam	555.7	1.9	0.15	58cfa82fe4b0c9d6adf6b6b7	TCGA-64-5781-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-64-5781-01A	41C4C704-825E-49F5-9D54-DBD7D30725E0	Primary Tumor	Illumina HiSeq	901f4776-2659-4626-abec-5a9323e6f75e	Lung	55.0	B32F509D-91E5-4601-B8B3-4B0A5212C22B	69DEF564-A4D8-4820-9ED6-F17AF2CAB0A7	TCGA-64-5781-01A-01D-1623-02	HG19_Broad_variant	TCGA-64-5781	TCGA-LUAD		s11352	Harvard Medical School	Fox Chase	United States	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1623-02	True	LUAD	C1	LUAD.6	0.41173546899999997	0.62	0.34	28.48555229	0.1315	0.2315	0.3987	1.9334	0.3786	0.3925	385.0	406.0	9.386768661	30.41313046	37.0	0.37091669	9.0	15.0	0.7700695009999999	2.6925538319999998	33.0	3.042475876	23.0	0.970333755	2.660290329	11.24031264	-434.58440010000004	318.33122389999994	0.0	1559.0	1.0	96.0	5.8986980045138555	5.1258419142274585	0.21461051627626093	5.339082216578433	5.431223563778641	0.9404204398619908	-0.5596157879354227	0.30538164955118186	0.7258099235857298
13722.58cfa82fe4b0c9d6adf6b6be	58cfa82fe4b0c9d6adf6b6be	TCGA-55-6543-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_8.rg.sorted.filtered.	WGS	TCGA-55-6543-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_8.rg.sorted	TCGA-55-6543-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_8.rg.sorted.bam	127.4	1.9	0.15	58cfa82fe4b0c9d6adf6b6be	TCGA-55-6543-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_8.rg.sorted.bam	Alive	FEMALE	WHITE		Lung Adenocarcinoma	Aligned reads	TCGA-55-6543-01A	E68219B0-A9C2-49DF-8F0D-DB5EA97FD2DC	Primary Tumor	Illumina HiSeq	0715b83e-fcd8-41e9-88ac-cfeb5fabd3de	Lung	60.0	8D9491E7-9B14-4988-8FA7-E6AF041120BD	1D88DA12-E71A-4F44-8D71-DA8957BDFCD4	TCGA-55-6543-01A-11D-1751-02	HG19_Broad_variant	TCGA-55-6543	TCGA-LUAD		s10791	Harvard Medical School	International Genomics Consortium	United States	NO	T1b	N0	Lung Bronchioloalveolar Carcinoma Mucinous	Stage IA	1751-02	True	LUAD	C3	LUAD.5	0.18790563899999999	0.35	0.0	2.199477767	-1.1502	-0.153	0.8145	0.2996	0.1477	0.3165	13.0	38.0	0.12050144	0.632632561	70.0	0.356415372	9.0	4.0	0.908136924	2.572945651	17.0	2.3025850930000002	10.0	1.0	1.326564768	-768.0306126	-1067.60691	796.7847415	0.0	435.0	0.0	435.0	6.720642261452053	7.244975535086734	0.016317619105948866	6.027495080892107	7.031401434788675	2.7342036220098667	-0.6931471805599454	-0.21357410029805912	2.717886002903918
13722.58cfa82fe4b0c9d6adf6b6d2	58cfa82fe4b0c9d6adf6b6d2	TCGA-44-3396-01A-01D-1203_110804_SN208_0216_AD0CLLABXX_s_7_rg.sorted.filtered.	WGS	TCGA-44-3396-01A-01D-1203_110804_SN208_0216_AD0CLLABXX_s_7_rg.sorted	TCGA-44-3396-01A-01D-1203_110804_SN208_0216_AD0CLLABXX_s_7_rg.sorted.bam	472.3	1.9	0.15	58cfa82fe4b0c9d6adf6b6d2	TCGA-44-3396-01A-01D-1203_110804_SN208_0216_AD0CLLABXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-3396-01A	3BD6BADB-27FF-4D8D-B206-4D28DC264862	Primary Tumor	Illumina HiSeq	bf55243b-c7c6-46fc-9d54-e1916b0d7ea2	Lung	74.0	B560DF97-986B-4A88-A0F1-C38A30080EDB	ECCC6A5C-BB25-4591-996A-EE2A7507F771	TCGA-44-3396-01A-01D-1203-02	HG19_Broad_variant	TCGA-44-3396	TCGA-LUAD		s10653	Harvard Medical School	Christiana Healthcare	United States	NO	T2	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1203-02	True	LUAD	C2	LUAD.6	0.5650211589999999	0.76	0.16	6.3803451739999995	0.214	0.1555	1.227	1.7723	0.33799999999999997	0.6029	80.0	16.0	1.5610944830000002	4.967118809	111.0	0.160760972	6.0	10.0	0.8715762690000001	4.859864915	264.0	4.476237911	96.0	0.980695978	4.521725677	-110.0823496	-295.4203149	-75.55791497	0.0	1130.0	0.0	1130.0	5.280483223050919	6.0964782284321855	-0.40247881567575505	5.186454273402643	6.00410490830117	1.5347685829423436	-0.09402894964827624	-0.09237332013101529	1.9372473986180987
13722.58cfa82fe4b0c9d6adf6b6d8	58cfa82fe4b0c9d6adf6b6d8	TCGA-50-5942-01A-21D-1751_111007_SN590_0110_C003AACXX_s_5_rg.sorted.filtered.	WGS	TCGA-50-5942-01A-21D-1751_111007_SN590_0110_C003AACXX_s_5_rg.sorted	TCGA-50-5942-01A-21D-1751_111007_SN590_0110_C003AACXX_s_5_rg.sorted.bam	168.4	1.9	0.14	58cfa82fe4b0c9d6adf6b6d8	TCGA-50-5942-01A-21D-1751_111007_SN590_0110_C003AACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5942-01A	75DD635E-8E0C-4C0B-B21C-20F77770218D	Primary Tumor	Illumina HiSeq	915fe8ed-278a-43fb-90cd-986d5c65e9ad	Lung	67.0	AED669E8-23B6-4786-9398-6BB048815DFA	8DC8F884-F58B-4EFA-AE96-C87AB7F6D991	TCGA-50-5942-01A-21D-1751-02	HG19_Broad_variant	TCGA-50-5942	TCGA-LUAD		s10794	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1751-02	True	LUAD	C3	LUAD.4	0.14045702300000001	0.31	0.0	3.6842860219999998	-1.5752	-0.361	0.3612	1.04	0.0151	0.187	31.0	14.0	0.394405725	1.607961802	65.0	0.048331199000000005	2.0	4.0	0.869858875	3.811744758	80.0	3.17805383	24.0	1.0	2.044227592	-402.8065735	-933.2839436	4007.5601049999996	0.0	1847.0	1.0	1378.0	7.393746494390925	6.9127902015076135	-0.5282154702561763	6.700599313830979	7.0669408813348715	2.925914886423242	-0.6931471805599454	0.1541506798272585	3.4541303566794186
13722.58cfa82fe4b0c9d6adf6b6dc	58cfa82fe4b0c9d6adf6b6dc	TCGA-50-5935-01A-11D-1751_110928_SN590_0108_BB01CWACXX_s_8_rg.sorted.filtered.	WGS	TCGA-50-5935-01A-11D-1751_110928_SN590_0108_BB01CWACXX_s_8_rg.sorted	TCGA-50-5935-01A-11D-1751_110928_SN590_0108_BB01CWACXX_s_8_rg.sorted.bam	190.4	1.9	0.15	58cfa82fe4b0c9d6adf6b6dc	TCGA-50-5935-01A-11D-1751_110928_SN590_0108_BB01CWACXX_s_8_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5935-01A	100430C8-1446-45C8-AF36-B6DBB3DDD0C1	Primary Tumor	Illumina HiSeq	f4ad5c7d-a36e-4d9a-9c36-444e4b443953	Lung	86.0	98687ADB-F8E9-4E6E-BC1B-396A3DDFAC96	6F0D56B0-E246-4566-AFFB-B8DD5E88B5BA	TCGA-50-5935-01A-11D-1751-02	HG19_Broad_variant	TCGA-50-5935	TCGA-LUAD	653.0	s10908	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1751-02	True	LUAD	C3	LUAD.4	0.19445574699999998	0.61	0.22		-0.9375	-0.1845	0.5870000000000001	1.038	0.3166	0.0999	41.0	5.0	0.573643941	2.536110056	140.0	0.50264096	16.0	13.0	0.8031197240000001	2.05996142	13.0	3.528141868	35.0	0.992347812	2.91191553	-4.088510884	-915.9038224	1981.353559	1.0	653.0	0.0	653.0	7.004579463617677	6.158742965580797	-0.17823916107039894	6.055498908920531	7.034211702934696	3.6160421301616696	-0.9490805546971459	0.8754687373538999	3.7942812912320685
13722.58cfa82fe4b0c9d6adf6b6f8	58cfa82fe4b0c9d6adf6b6f8	TCGA-50-6593-01A-11D-1751_120105_SN1120_0107_AC054PACXX_s_3_rg.sorted.filtered.	WGS	TCGA-50-6593-01A-11D-1751_120105_SN1120_0107_AC054PACXX_s_3_rg.sorted	TCGA-50-6593-01A-11D-1751_120105_SN1120_0107_AC054PACXX_s_3_rg.sorted.bam	245.4	1.8	0.13	58cfa82fe4b0c9d6adf6b6f8	TCGA-50-6593-01A-11D-1751_120105_SN1120_0107_AC054PACXX_s_3_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-6593-01A	E10568FE-0436-43F2-9F0F-48F9903868C4	Primary Tumor	Illumina HiSeq	f552d49e-eaf1-4d8f-bd11-0f2017c95ba3	Lung	49.0	3B2ED302-D8F1-4078-95F0-3B5C5B322DEB	BC00F0B2-D91E-444A-91A4-08AC5F09CA1F	TCGA-50-6593-01A-11D-1751-02	HG19_Broad_variant	TCGA-50-6593	TCGA-LUAD	336.0	s11456	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N2	Lung Adenocarcinoma Mixed Subtype	Stage IIIA	1751-02	True	LUAD	C1	LUAD.3	0.288503946	0.69	0.26	2.8339611710000003	0.1201	0.07400000000000001	0.8365	0.5155	-0.1463	0.64	136.0	111.0	2.555572055	8.366456133	126.0	0.795681692	25.0	28.0	0.910786386	2.525236063	16.0	2.197224577	9.0	1.0	2.174245542	224.36018430000004	-461.779823	1810.910032	1.0	336.0	1.0	266.0	5.851282516508119	6.135781317876221	-0.8672165672883273	5.604422438576593	6.991447427933941	0.7830231883294905	-0.24686007793152598	0.8556661100577196	1.6502397556178177
13722.58cfa82fe4b0c9d6adf6b6fc	58cfa82fe4b0c9d6adf6b6fc	TCGA-55-6712-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_5_rg.sorted.filtered.	WGS	TCGA-55-6712-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_5_rg.sorted	TCGA-55-6712-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_5_rg.sorted.bam	218.7	1.9	0.15	58cfa82fe4b0c9d6adf6b6fc	TCGA-55-6712-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE		Lung Adenocarcinoma	Aligned reads	TCGA-55-6712-01A	F17D3463-AF6C-42C2-A8E9-FAE45F69286F	Primary Tumor	Illumina HiSeq	fb1682cf-0fca-4bf1-963d-67a3a177fe98	Lung	71.0	EA75499C-7BF0-47BE-9B09-3C12AAA22F12	61ADB041-60CE-4263-BEB3-33A4DBBA217B	TCGA-55-6712-01A-11D-1853-02	HG19_Broad_variant	TCGA-55-6712	TCGA-LUAD		s11345	Harvard Medical School	International Genomics Consortium	United States	NO	T2a	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIA	1853-02	True	LUAD	C3	LUAD.3	0.473691774	0.71	0.39	0.007646429000000001	0.0936	-0.061	1.0001	1.9617	0.4376	0.4685	56.0	16.0	1.60931879	3.33784638	137.0	0.440322279	18.0	27.0	0.952495807	2.986545094	23.0	3.6600032089999996	42.0	0.979220633	2.512057696	166.0181301	232.89654240000002	214.950132	1.0	171.0	1.0	171.0	2.8616404998556844	6.917528790809117	-0.16351269096640741	1.6197406436176873	4.92185713219474	3.447780526617482	-1.241899856237997	-1.9956716586143775	3.6112932175838894
13722.58cfa82fe4b0c9d6adf6b700	58cfa82fe4b0c9d6adf6b700	TCGA-64-5775-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-64-5775-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_1_rg.sorted	TCGA-64-5775-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_1_rg.sorted.bam	360.7	1.9	0.14	58cfa82fe4b0c9d6adf6b700	TCGA-64-5775-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-64-5775-01A	C8544FB3-B26E-4672-BB81-A271DB724B04	Primary Tumor	Illumina HiSeq	af9f3482-e78b-4fe4-ac01-64f69b84d78d	Lung	71.0	5449BCED-1356-4DE5-9352-349725656C5C	11AEF70D-D22B-4936-BD8C-863BDBD4940E	TCGA-64-5775-01A-01D-1623-02	HG19_Broad_variant	TCGA-64-5775	TCGA-LUAD	62.0	s10664	Harvard Medical School	Fox Chase	United States	NO	T4	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1623-02	True	LUAD	C4	LUAD.3	0.145016315	0.29	0.18	1.5853868690000001	0.5981	0.2215	0.1987	-0.7823	0.5844	0.3988	208.0	332.0	3.9107461789999998	12.77920996	158.0	0.525224163	12.0	16.0	0.846973755	1.517573246	6.0	1.5607104090000001	5.0	0.9697239	4.988163372	173.5022564	939.6675263000001	-2820.967332	1.0	62.0	1.0	62.0	6.405558981914201	5.446045348535768	0.40786524641105726	5.679621978531265	7.301520632149931	3.0520852101051226	-0.7259370033829362	1.8554752836141626	2.6442199636940655
13722.58cfa82fe4b0c9d6adf6b701	58cfa82fe4b0c9d6adf6b701	TCGA-44-6775-01A-11D-1853_111207_SN590_0112_D09CDACXX_s_4_rg.sorted.filtered.	WGS	TCGA-44-6775-01A-11D-1853_111207_SN590_0112_D09CDACXX_s_4_rg.sorted	TCGA-44-6775-01A-11D-1853_111207_SN590_0112_D09CDACXX_s_4_rg.sorted.bam	237.3	1.9	0.16	58cfa82fe4b0c9d6adf6b701	TCGA-44-6775-01A-11D-1853_111207_SN590_0112_D09CDACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-6775-01A	3C4FF061-D214-4D1C-8D2E-3034F207C252	Primary Tumor	Illumina HiSeq	c17b3c9b-e41f-48e2-9cde-facc8537afbc	Lung	72.0	7C606F64-69A1-465C-9F4E-2EB1EBEDA5D7	8B286297-0077-44ED-9093-6F13E2CA4EBA	TCGA-44-6775-01A-11D-1853-02	HG19_Broad_variant	TCGA-44-6775	TCGA-LUAD		s11454	Harvard Medical School	Christiana Healthcare	United States	NO	T2a	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1853-02	True	LUAD	C6	LUAD.5	0.465366124	0.73	0.46	9.580592908	0.1737	-0.005	1.1413	0.9586	0.7698	0.7537	31.0	11.0	0.5188742679999999	1.5566228030000002	94.0	0.616364508	24.0	27.0	0.9493378790000001	4.5449472580000005	120.0	3.535983082	35.0	0.994553282	2.438527763	128.2293964	256.6605864	862.5071525000001	0.0	705.0	1.0	684.0	7.528797608007126	7.83736491910229	-0.25617286641471937	6.77111190630961	7.500892682481078	2.273084428597348	-0.7576857016975165	-0.33647223662121295	2.5292572950120675
13722.58cfa82fe4b0c9d6adf6b704	58cfa82fe4b0c9d6adf6b704	TCGA-73-4659-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-73-4659-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-73-4659-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	665.52	1.9	0.15	58cfa82fe4b0c9d6adf6b704	TCGA-73-4659-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-73-4659-01A	CD0DC947-B708-464E-BEB7-954C9D4583E7	Primary Tumor	Illumina HiSeq	37276b21-3a00-4b58-b1df-cc2199584cb0	Lung	66.0	C35A5ED1-1821-4077-BA1E-B972DFA3233B	277D2F7F-1A7F-4D39-BD15-0334CC02840E	TCGA-73-4659-01A-01D-1203-02	GRCh37	TCGA-73-4659	TCGA-LUAD	711.0	s11246	Harvard Medical School	Roswell Park	United States	NO	T2	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1203-02	True	LUAD	C4	LUAD.2	0.24955424699999998	0.67	0.22	0.97933513	0.2275	0.1125	0.7764	0.2562	-0.5435	0.316	58.0	11.0	1.698423056	5.2740505419999995	132.0	0.338892363	19.0	16.0	0.897662995	4.029282769	89.0	2.163955657	9.0	0.984858662	1.722223017	-722.3360203999999	94.45023998	2796.060269	1.0	711.0	1.0	35.0	8.57385703853378	8.567696173589344	0.34915799548943327	7.219311375728469	7.779238813225074	2.8921338728895636	-1.3545456628053105	-0.7884573603642702	2.5429758774001305
13722.58cfa82fe4b0c9d6adf6b70a	58cfa82fe4b0c9d6adf6b70a	TCGA-67-6216-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_1.rg.sorted.filtered.	WGS	TCGA-67-6216-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_1.rg.sorted	TCGA-67-6216-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_1.rg.sorted.bam	355.4	1.9	0.14	58cfa82fe4b0c9d6adf6b70a	TCGA-67-6216-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_1.rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-67-6216-01A	CCECCE70-DD54-4C5B-BF9F-CA87D290CB00	Primary Tumor	Illumina HiSeq	ae4aaef1-8b47-476b-933a-ff69761aa0a9	Lung	57.0	4EAA4B4A-E9DB-4E65-97D6-7FA1A205DA95	1003F495-01FE-47ED-A717-B8769F0FA3A3	TCGA-67-6216-01A-11D-1751-02	HG19_Broad_variant	TCGA-67-6216	TCGA-LUAD		s11242	Harvard Medical School	St Joseph's Medical Center (MD)	United States	NO	T1a	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1751-02	True	LUAD	C3	LUAD.4	0.331484918	0.44	0.15	7.385021927	-0.5075	-0.0845	0.8636	1.4422	0.39399999999999996	0.1659	22.0	30.0	0.183621473	0.918107363	110.0	0.148905806	2.0	6.0	0.9506348240000001	3.059975454	25.0	2.833213344	17.0	1.0	1.853635731	440.6437244	-827.532046	2471.750881	0.0	141.0	0.0	141.0	6.490033546204934	5.178159938910257	0.08430195098371829	5.843406381279882	5.75504731335434	1.1768748445586852	-0.6466271649250523	0.576887374444083	1.092572893574967
13722.58cfa82fe4b0c9d6adf6b720	58cfa82fe4b0c9d6adf6b720	TCGA-67-6217-01A-11D-1751_120309_SN208_0274_AD0R6DACXX_s_3_rg.sorted.filtered.	WGS	TCGA-67-6217-01A-11D-1751_120309_SN208_0274_AD0R6DACXX_s_3_rg.sorted	TCGA-67-6217-01A-11D-1751_120309_SN208_0274_AD0R6DACXX_s_3_rg.sorted.bam	282.4	1.9	0.13	58cfa82fe4b0c9d6adf6b720	TCGA-67-6217-01A-11D-1751_120309_SN208_0274_AD0R6DACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-67-6217-01A	108A71CF-B9DB-47CD-AA74-C03EC989B41B	Primary Tumor	Illumina HiSeq	cb2962fe-7f6e-4a68-871a-11d696bb5279	Lung	73.0	BC0FE45C-3249-46D7-8991-C6888F0B9579	565E717D-310B-4FB1-B79A-5F40FF12BBB8	TCGA-67-6217-01A-11D-1751-02	HG19_Broad_variant	TCGA-67-6217	TCGA-LUAD		s11244	Harvard Medical School	St Joseph's Medical Center (MD)	United States	NO	T2a	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIA	1751-02	True	LUAD	C3	LUAD.5	0.348091875	0.75	0.32	18.40532159	-1.3492	-0.23	0.7276	1.6018	0.1587	-0.023	85.0	32.0	1.394699505	5.063365595	234.0	0.609049304	19.0	35.0	0.729339698	2.9227071760000003	55.0	3.6121358939999997	38.0	0.9930035290000001	2.82422526	659.7825311	-1272.441123	2770.2742670000002	0.0	422.0	1.0	296.0	5.89645083498068	6.75180297720825	-0.344915423531826	5.53051656562915	5.822267018584075	1.846683515158753	-0.3659342693515293	-0.9295359586241756	2.191598938690579
13722.58cfa82fe4b0c9d6adf6b726	58cfa82fe4b0c9d6adf6b726	TCGA-75-5147-01A-01D-1623_110913_SN208_0238_BC008YACXX_s_4_rg.sorted.filtered.	WGS	TCGA-75-5147-01A-01D-1623_110913_SN208_0238_BC008YACXX_s_4_rg.sorted	TCGA-75-5147-01A-01D-1623_110913_SN208_0238_BC008YACXX_s_4_rg.sorted.bam	817.7	1.9	0.15	58cfa82fe4b0c9d6adf6b726	TCGA-75-5147-01A-01D-1623_110913_SN208_0238_BC008YACXX_s_4_rg.sorted.bam	Alive	FEMALE			Lung Adenocarcinoma	Aligned reads	TCGA-75-5147-01A	D2824E6D-3784-45C2-9B0F-52B17356B5DA	Primary Tumor	Illumina HiSeq	ca549b28-f771-489d-93fe-90211aa22391	Lung		F9F9C1DD-8462-4560-82B8-AEA4309854C9	1291FD50-F1A9-4A2A-A2FD-2320ED01FB4E	TCGA-75-5147-01A-01D-1623-02	HG19_Broad_variant	TCGA-75-5147	TCGA-LUAD		s11466	Harvard Medical School	Ontario Institute for Cancer Research (OICR)	Canada	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1623-02	True	LUAD	C2	LUAD.5	0.306668646	0.6	0.35	4.76968311	0.5836	0.4005	0.8315	1.5269	1.4915	0.0667	12.0	3.0	0.213465391	1.128317065	157.0	0.5327707389999999	12.0	28.0	0.9331607909999999	4.840665041	179.0	3.997243179	56.0	0.993017129	7.4218279129999996	159.4412927	-47.29241937	-1343.586007	0.0	1333.0	0.0	1333.0	7.841885928984622	6.26985357264817	-0.04880012834820946	6.774045298983266	5.682066907746051	3.158780619536371	-1.0678406300013559	-0.5877866649021191	3.2075807478845806
13722.58cfa82fe4b0c9d6adf6b72a	58cfa82fe4b0c9d6adf6b72a	TCGA-49-6767-01A-11D-1853_120205_SN590_0136_BD0LRYACXX_s_7_rg.sorted.filtered.	WGS	TCGA-49-6767-01A-11D-1853_120205_SN590_0136_BD0LRYACXX_s_7_rg.sorted	TCGA-49-6767-01A-11D-1853_120205_SN590_0136_BD0LRYACXX_s_7_rg.sorted.bam	291.7	1.9	0.14	58cfa82fe4b0c9d6adf6b72a	TCGA-49-6767-01A-11D-1853_120205_SN590_0136_BD0LRYACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE		Lung Adenocarcinoma	Aligned reads	TCGA-49-6767-01A	6BFFE800-EC2B-4638-9333-97FE85DCD91C	Primary Tumor	Illumina HiSeq	759c1dd3-0f7d-4ba7-8c8e-c276faf0255b	Lung	46.0	708A8742-F6D6-411D-9340-2C6C25885D22	FBCE84D6-2880-45F5-BD6F-B079C33C353E	TCGA-49-6767-01A-11D-1853-02	HG19_Broad_variant	TCGA-49-6767	TCGA-LUAD		s11233	Harvard Medical School	Johns Hopkins	United States	NO	T3	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIB	1853-02	True	LUAD	C1	LUAD.3	0.34856916299999996	0.57	0.26	14.64443103	0.6171	0.2375	0.3779	0.6282	0.2599	0.2542	166.0	60.0	4.1612900569999995	11.80022966	172.0	0.581840343	21.0	30.0				2.6795438590000002	17.0	0.945761414	2.304205773	68.31754729	282.2270793	-2484.773402	0.0	677.0	0.0	677.0	6.87982333450776	6.919773676930337	-0.5969147142983608	6.142224391376981	6.427297191832543	2.2095922261448813	-0.737598943130779	-0.49247648509779385	2.806506940443242
13722.58cfa82fe4b0c9d6adf6b748	58cfa82fe4b0c9d6adf6b748	TCGA-44-6776-01A-11D-1853_111207_SN590_0112_D09CDACXX_s_7_rg.sorted.filtered.	WGS	TCGA-44-6776-01A-11D-1853_111207_SN590_0112_D09CDACXX_s_7_rg.sorted	TCGA-44-6776-01A-11D-1853_111207_SN590_0112_D09CDACXX_s_7_rg.sorted.bam	142.7	1.9	0.15	58cfa82fe4b0c9d6adf6b748	TCGA-44-6776-01A-11D-1853_111207_SN590_0112_D09CDACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE		Lung Adenocarcinoma	Aligned reads	TCGA-44-6776-01A	C2A1DE2E-6451-4C95-8CE6-263F2B7E6EFF	Primary Tumor	Illumina HiSeq	bb5d193c-cc97-466b-9b28-bdbf5cf255e8	Lung	60.0	64FB8EBA-A055-4128-92CA-695A3A6F8EBD	5BC01EC3-A1C2-41BB-A9C5-95946A066FA6	TCGA-44-6776-01A-11D-1853-02	HG19_Broad_variant	TCGA-44-6776	TCGA-LUAD		s10660	Harvard Medical School	Christiana Healthcare	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1853-02	True	LUAD	C3	LUAD.1	0.085246584	0.35	0.0	1.172910191	-1.3988	-0.259	-0.3545	0.1043	-1.2228	-0.2694	110.0	41.0	1.398990687	5.129632517	62.0	0.16653796	4.0	14.0	0.870619113	2.466649689	17.0	1.7478680969999998	6.0	0.9755037590000001	1.173365972	-279.1922951	-873.4740129	3444.2197439999995	0.0	2616.0	0.0	2616.0	7.312710453174531	7.94093976232779	-0.00853065527261776	6.813719287055543	7.1871679599514104	2.017369113037458	-0.49899116611898764	-0.7537718023763804	2.025899768310076
13722.58cfa82fe4b0c9d6adf6b756	58cfa82fe4b0c9d6adf6b756	TCGA-91-6835-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_5_rg.sorted.filtered.	WGS	TCGA-91-6835-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_5_rg.sorted	TCGA-91-6835-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_5_rg.sorted.bam	328.7	1.9	0.14	58cfa82fe4b0c9d6adf6b756	TCGA-91-6835-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-91-6835-01A	2F09479F-87FC-4C34-8E2C-333E970A3681	Primary Tumor	Illumina HiSeq	8c5e1a0f-e9a8-4ce4-b066-97b2040c5327	Lung	81.0	EFD3F14F-F785-4AEC-9EFD-6DD8E9C41EBA	A4DC40A6-EE0F-4637-937F-406F5FC8579F	TCGA-91-6835-01A-11D-1853-02	HG19_Broad_variant	TCGA-91-6835	TCGA-LUAD		s10913	Harvard Medical School	ABS - IUPUI	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1853-02	True	LUAD	C3	LUAD.5	0.506208099	0.79	0.45		-0.0573	-0.159	1.534	2.3644	0.8918	0.3818	36.0	0.0	0.701133637	2.191042615	63.0	0.423550975	10.0	23.0	0.89661571	1.744733609	7.0	4.720321087	125.0	0.977633465	3.260736693	469.5418047	41.10003208	2743.658696	0.0	79.0	0.0	79.0	7.7795715207544625	7.375271442047474	-0.6547793031369864	7.086424340194517	7.7683140301570806	1.5509559638671417	-0.6931471805599454	0.3930425881096071	2.205735267004128
13722.58cfa82fe4b0c9d6adf6b760	58cfa82fe4b0c9d6adf6b760	TCGA-75-5122-01A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_1_rg.sorted.filtered.	WGS	TCGA-75-5122-01A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_1_rg.sorted	TCGA-75-5122-01A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_1_rg.sorted.bam	466.4	1.9	0.15	58cfa82fe4b0c9d6adf6b760	TCGA-75-5122-01A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_1_rg.sorted.bam	Dead	MALE			Lung Adenocarcinoma	Aligned reads	TCGA-75-5122-01A	78AE716B-0CA5-4C01-A053-D41288385FCD	Primary Tumor	Illumina HiSeq	611aeb0f-3dbe-41c6-8b8e-b4a7c827ac1d	Lung		DD9C2F71-145A-4F7F-8B64-095B1FC75C3D	4ADD8465-F06A-4752-8B9F-A6F790F727B1	TCGA-75-5122-01A-01D-1751-02	HG19_Broad_variant	TCGA-75-5122	TCGA-LUAD		s11249	Harvard Medical School	Ontario Institute for Cancer Research (OICR)	Canada	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1751-02	True	LUAD	C2	LUAD.6	0.537361008	0.68	0.52	33.25353761	0.2048	0.028999999999999998	2.0633	2.2628	0.858	0.1389	64.0	213.0	1.3248155320000001	3.041053835	115.0	0.23291638399999998	8.0	17.0	0.84968202	2.996285135	34.0	3.614912439	60.0	0.8829038159999999		1101.938811	-394.6534537	346.3104605	1.0		1.0		9.654613002472974	9.208335422230554	0.7857182947671519	8.37573888997392	7.800222013716025	1.8474952863049106	-1.2788741124990537	-1.40811340851453	1.0617769915377586
13722.58cfa82fe4b0c9d6adf6b77c	58cfa82fe4b0c9d6adf6b77c	TCGA-44-5645-01A-01D-1623_110804_SN208_0216_AD0CLLABXX_s_5_rg.sorted.filtered.	WGS	TCGA-44-5645-01A-01D-1623_110804_SN208_0216_AD0CLLABXX_s_5_rg.sorted	TCGA-44-5645-01A-01D-1623_110804_SN208_0216_AD0CLLABXX_s_5_rg.sorted.bam	466.6	1.9	0.16	58cfa82fe4b0c9d6adf6b77c	TCGA-44-5645-01A-01D-1623_110804_SN208_0216_AD0CLLABXX_s_5_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-5645-01A	DDEACCCF-0953-4952-8A4E-C2617F2E7BCC	Primary Tumor	Illumina HiSeq	e1f13e42-abbc-4a28-91d2-65b2a95b0018	Lung	61.0	37A8D3A5-BAA0-427C-AB43-48AE4B93633B	A35054A5-9324-47AD-841E-E2ADCD97126D	TCGA-44-5645-01A-01D-1623-02	HG19_Broad_variant	TCGA-44-5645	TCGA-LUAD		s10993	Harvard Medical School	Christiana Healthcare	United States	NO	T1	NX	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1623-02	True	LUAD	C3	LUAD.5	0.357824851	0.46	0.0	8.21370393	-1.065	-0.255	1.0398	1.7929	-0.1896	-0.0088	11.0	0.0	0.260661052	1.013681867	176.0	0.9477171409999999	10.0	10.0	0.9164922670000001	2.649003366	18.0	4.189654742	66.0	1.0	2.301088498	-164.5811392	-1223.373722	1590.2777449999999	0.0	852.0	0.0	852.0	5.104597764801712	5.2225156531317545	-0.25886608327480265	4.210779888779616	4.229263880121471	1.4232351492830406	-0.8938178760220965	-0.9932517730102832	1.6821012325578433
13722.58cfa82fe4b0c9d6adf6b780	58cfa82fe4b0c9d6adf6b780	TCGA-50-5045-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_1_rg.sorted.filtered.	WGS	TCGA-50-5045-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_1_rg.sorted	TCGA-50-5045-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_1_rg.sorted.bam	1032.7	1.9	0.17	58cfa82fe4b0c9d6adf6b780	TCGA-50-5045-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_1_rg.sorted.bam	Dead	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5045-01A	9EE20C0D-A1C3-47F3-ABDA-131B3F190F52	Primary Tumor	Illumina HiSeq	e3bc7a3f-c296-412c-8974-8c21cf01dbfb	Lung	57.0	BDD75BCA-6224-4743-A367-CB1FF01E8121	42839A7D-81DB-428A-AB3B-072ACD26CA91	TCGA-50-5045-01A-01D-1623-02	HG19_Broad_variant	TCGA-50-5045	TCGA-LUAD	2174.0	s11004	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1623-02	True	LUAD	C2		0.467012991	0.78	0.44	3.675148442	-0.1355	0.251	1.4425	2.5693	0.922	0.5228	195.0	279.0	2.003592966	8.353441444	75.0	0.208533429	3.0	11.0	0.931909896	4.380424167	110.0	4.41954606	88.0	0.987092605	2.379315823	97.19337735	-741.8826917	55.81688557	1.0	2174.0	1.0	1433.0	7.062477224177687	5.23594703582158	0.5680815938227864	6.244166900663736	5.720002418522965	1.2872556099862402	-0.8183103235139515	0.4840553827013854	0.7191740161634537
13722.58cfa82fe4b0c9d6adf6b790	58cfa82fe4b0c9d6adf6b790	TCGA-44-6146-01A-11D-1751_110927_SN208_0243_BC00TKACXX_s_3_rg.sorted.filtered.	WGS	TCGA-44-6146-01A-11D-1751_110927_SN208_0243_BC00TKACXX_s_3_rg.sorted	TCGA-44-6146-01A-11D-1751_110927_SN208_0243_BC00TKACXX_s_3_rg.sorted.bam	72.0	1.9	0.16	58cfa82fe4b0c9d6adf6b790	TCGA-44-6146-01A-11D-1751_110927_SN208_0243_BC00TKACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-6146-01A	0C0B610E-FE4C-406D-A5ED-5CC3B11DABF5	Primary Tumor	Illumina HiSeq	99148000-be38-4da1-aeaa-4b0271725662	Lung	64.0	AD66185F-983D-4416-B705-25D3D4D8B5A5	2D5C6425-E3F4-4389-9DDF-FDE694B4227E	TCGA-44-6146-01A-11D-1751-02	HG19_Broad_variant	TCGA-44-6146	TCGA-LUAD		s11337	Harvard Medical School	Christiana Healthcare	United States	NO	T3	N0	Lung Mucinous Adenocarcinoma	Stage IIB	1751-02	True	LUAD	C3	LUAD.1	0.165765212	0.3	0.0	0.529289518	-1.0419	-0.387	-0.4049	-0.3729	0.3009	0.0007	7.0	2.0	0.319427354	1.016359762	74.0	0.322302393	4.0	11.0	0.962040682	1.548344746	5.0	2.197224577	9.0	1.0	1.356616267	-1148.8301470000001	96.57722816	2608.442684	0.0	728.0	1.0	631.0	7.189658184169879	7.966056063722527	-1.105992395965732	6.4241903420303075	8.234320050317207	0.34826729394118794	-0.7654678421395715	0.2682639865946794	1.45425968990692
13722.58cfa82fe4b0c9d6adf6b7b0	58cfa82fe4b0c9d6adf6b7b0	TCGA-49-4494-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-49-4494-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-49-4494-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	245.2	1.9	0.16	58cfa82fe4b0c9d6adf6b7b0	TCGA-49-4494-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-49-4494-01A	C6D78E27-E510-4F57-ABAE-19EFA6105A8D	Primary Tumor	Illumina HiSeq	3cb48d09-95ac-452f-9c92-19d7f966aec0	Lung	77.0	7CA68089-C61F-4D31-8CC8-FB11AE70910A	8DF0AEB4-1455-4760-A230-54FE1551D08C	TCGA-49-4494-01A-01D-1203-02	GRCh37	TCGA-49-4494	TCGA-LUAD	1081.0	s10783	Harvard Medical School	Johns Hopkins	United States	NO	T3	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1203-02	True	LUAD	C2	LUAD.3	0.304768286	0.54	0.32	9.317909018	0.2416	0.304	0.3948	0.8196	1.1194	0.0655	72.0	5.0	1.449654391	4.67439579	139.0	0.331858502	3.0	15.0	0.932007329	2.837517224	21.0	2.819170195	23.0	0.8991151	2.8484947810000003	-736.099831	-629.7702863	2234.0196309999997	1.0	1081.0	1.0	1081.0	9.402467859759202	7.370537776549505	0.43230208425267425	7.76833733473473	7.788272977249484	1.0081834794651874	-1.6341305250244722	0.4177352006999788	0.575881395212513
13722.58cfa82fe4b0c9d6adf6b7b4	58cfa82fe4b0c9d6adf6b7b4	TCGA-50-5930-01A-11D-1751_111007_SN590_0110_C003AACXX_s_1_rg.sorted.filtered.	WGS	TCGA-50-5930-01A-11D-1751_111007_SN590_0110_C003AACXX_s_1_rg.sorted	TCGA-50-5930-01A-11D-1751_111007_SN590_0110_C003AACXX_s_1_rg.sorted.bam	181.4	2.0	0.16	58cfa82fe4b0c9d6adf6b7b4	TCGA-50-5930-01A-11D-1751_111007_SN590_0110_C003AACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5930-01A	368E23F0-E573-4547-BF5A-14080BAF737B	Primary Tumor	Illumina HiSeq	09c8fefe-47f0-44eb-b4f4-160944e2991a	Lung	47.0	3E30DBD1-10BF-4450-8D19-6F44D3284E02	31047F3B-8F9D-47D9-87D3-BB2F8CF7E1EF	TCGA-50-5930-01A-11D-1751-02	HG19_Broad_variant	TCGA-50-5930	TCGA-LUAD	282.0	s11347	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N2	Lung Adenocarcinoma Mixed Subtype	Stage IIIA	1751-02	True	LUAD	C3		0.438795901	0.05	0.18		-0.158	-0.0745	0.7107	1.6898	-0.3308	0.5071	259.0	79.0	8.329810076000001	28.68483688	235.0	0.230143367	2.0	24.0	0.88811506	3.8104216419999997	73.0	2.3025850930000002	10.0	1.0	5.1439943239999995	-833.6280845	-592.8086931	2664.996825	1.0	282.0	1.0	177.0	7.616596837780669	7.3223420565725235	-0.10777140024213683	6.682287600403836	8.25843541574286	3.1849742731925197	-0.9343092373768331	0.9360933591703349	3.2927456734346565
13722.58cfa82fe4b0c9d6adf6b7d4	58cfa82fe4b0c9d6adf6b7d4	TCGA-44-3919-01A-02D-1103_110804_SN208_0217_BC03EKABXX_s_7_rg.sorted.filtered.	WGS	TCGA-44-3919-01A-02D-1103_110804_SN208_0217_BC03EKABXX_s_7_rg.sorted	TCGA-44-3919-01A-02D-1103_110804_SN208_0217_BC03EKABXX_s_7_rg.sorted.bam	427.33	1.9	0.15	58cfa82fe4b0c9d6adf6b7d4	TCGA-44-3919-01A-02D-1103_110804_SN208_0217_BC03EKABXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-3919-01A	66ED89F6-8BA2-49D0-AF0F-4B6EBF2381BF	Primary Tumor	Illumina HiSeq	14d2cfc2-f4ac-4ab1-93d3-0e178305e26f	Lung	71.0	9DE8D353-3442-41D8-8BFE-A08C4975EACA	9C982400-B6C3-4D00-9981-BA06775FEF4F	TCGA-44-3919-01A-02D-1103-02	HG19_Broad_variant	TCGA-44-3919	TCGA-LUAD		s10994	Harvard Medical School	Christiana Healthcare	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1103-02	True	LUAD	C2	LUAD.3	0.33970977	0.49	0.25	13.45053148	-0.055999999999999994	0.013000000000000001	1.1213	1.8246	1.2168	0.4013	24.0	33.0	0.334584148	1.031634457	121.0	0.31090371	5.0	16.0	0.773997948	3.129313385	57.0	4.489323947	96.0	0.983562988	2.43602751	-11.43671092	-417.96540739999995	1854.2984350000002	1.0	1026.0	1.0	921.0	5.604207658648486	6.810730296410263	-0.03834730827462374	4.815750298284216	5.855218851382827	2.7704892043574985	-0.7884573603642697	-0.9555114450274362	2.808836512632122
13722.58cfa82fe4b0c9d6adf6b7de	58cfa82fe4b0c9d6adf6b7de	TCGA-50-5931-01A-11D-1751_110928_SN590_0108_BB01CWACXX_s_2_rg.sorted.filtered.	WGS	TCGA-50-5931-01A-11D-1751_110928_SN590_0108_BB01CWACXX_s_2_rg.sorted	TCGA-50-5931-01A-11D-1751_110928_SN590_0108_BB01CWACXX_s_2_rg.sorted.bam	345.4	1.9	0.15	58cfa82fe4b0c9d6adf6b7de	TCGA-50-5931-01A-11D-1751_110928_SN590_0108_BB01CWACXX_s_2_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5931-01A	12CCD581-A921-41BC-BCEE-4E9BE54532CC	Primary Tumor	Illumina HiSeq	ba1d7028-7d97-4a0b-917e-b861a8656748	Lung	75.0	16A2D381-75A0-423B-AAC2-D5710AFB183B	5EA8E18D-2D34-4C6E-A89D-36DE5E91E80C	TCGA-50-5931-01A-11D-1751-02	HG19_Broad_variant	TCGA-50-5931	TCGA-LUAD	434.0	s11458	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1751-02	True	LUAD	C1	LUAD.2	0.083668491	0.14	0.43	1.4559812	0.8005	0.3175	-0.6178	-1.0374	-0.5597	0.4122	113.0	85.0	2.427148893	8.37055195	219.0	0.734883451	9.0	18.0	0.906519527	0.628351454	2.0	0.693147181	2.0	1.0	5.1565317969999995	-558.9678293	1015.30296	-3124.417919	1.0	434.0	1.0	425.0	6.565405805188048	6.22646691563409	-0.17988404185109574	5.9502201660978145	7.00555652599476	1.6205143560414967	-0.6151856390902335	0.7790896103606704	1.8003983978925924
13722.58cfa82fe4b0c9d6adf6b7ee	58cfa82fe4b0c9d6adf6b7ee	TCGA-91-6829-01A-21D-1853_120305_SN1120_0119_BD0REAACXX_s_2_rg.sorted.filtered.	WGS	TCGA-91-6829-01A-21D-1853_120305_SN1120_0119_BD0REAACXX_s_2_rg.sorted	TCGA-91-6829-01A-21D-1853_120305_SN1120_0119_BD0REAACXX_s_2_rg.sorted.bam	62.7	1.9	0.15	58cfa82fe4b0c9d6adf6b7ee	TCGA-91-6829-01A-21D-1853_120305_SN1120_0119_BD0REAACXX_s_2_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-91-6829-01A	1427CD18-5AD3-491A-9981-908E31AE49DB	Primary Tumor	Illumina HiSeq	be9bb40c-b149-4b91-b271-b8881bb90d6f	Lung	78.0	9B416640-9AEC-4B0D-AA88-B94287375950	E6E4F55E-8C3A-45E9-8F3B-9FDFE9D2965D	TCGA-91-6829-01A-21D-1853-02	HG19_Broad_variant	TCGA-91-6829	TCGA-LUAD	1258.0	s11361	Harvard Medical School	ABS - IUPUI	United States	NO	T2	N0	Lung Bronchioloalveolar Carcinoma Nonmucinous	Stage IB	1853-02	True	LUAD	C1	LUAD.2	0.22654524	0.51	0.52		0.2526	0.006999999999999999	0.4816	0.2086	0.3683	0.7769	209.0	79.0	4.530250573	16.19199237	179.0	0.63593399	15.0	59.0	0.8635561359999999	2.7444278860000004	24.0	2.079441542	8.0	1.0	5.2757994539999995	30.70129277	1027.155679	-2458.074889	1.0	1258.0	0.0	1258.0	5.190991958790487	8.413892281708254	0.04903534032973056	3.99909173569882	6.922237404930538	4.70815832456606	-1.1919002230916673	-1.4916548767777167	4.65912298423633
13722.58cfa82fe4b0c9d6adf6b7f6	58cfa82fe4b0c9d6adf6b7f6	TCGA-73-4677-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-73-4677-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-73-4677-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	153.0	1.9	0.15	58cfa82fe4b0c9d6adf6b7f6	TCGA-73-4677-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-73-4677-01A	03C3409A-9D16-41D0-9E26-F9FC2547A4C8	Primary Tumor	Illumina HiSeq	5dd207d7-c666-46ae-8154-cb0c0cd6467f	Lung	74.0	EF88B85A-61EE-44E1-BB63-1B4CE9154BFB	2E41BAD5-941E-4EE8-A1DC-5BBA14E89141	TCGA-73-4677-01A-01D-1203-02	GRCh37	TCGA-73-4677	TCGA-LUAD	38.0	s10914	Harvard Medical School	Roswell Park	United States	NO	T2a	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1203-02	True	LUAD	C3		0.17573580600000002	0.53	0.04	17.48283415	-1.2486	-0.207	0.3393	1.0607	-0.802	-0.2105	109.0	106.0	1.710531061	6.2622832079999995	67.0	0.383026084	11.0	9.0	0.8139544790000001	3.3326100939999996	60.0	3.69076133	45.0	0.969553077	1.774423595	-396.2511131	-1093.164894	4121.630802000001	1.0	38.0	1.0	38.0	8.065202353371138	6.94162261954631	0.0006283380665415006	6.966590064703029	7.113472876472969	2.35989131556976	-1.0986122886681096	0.17185025692665912	2.359262977503218
13722.58cfa82fe4b0c9d6adf6b7fc	58cfa82fe4b0c9d6adf6b7fc	TCGA-38-6178-01A-11D-1751_120301_SN208_0270_AD0KLRACXX_s_3_rg.sorted.filtered.	WGS	TCGA-38-6178-01A-11D-1751_120301_SN208_0270_AD0KLRACXX_s_3_rg.sorted	TCGA-38-6178-01A-11D-1751_120301_SN208_0270_AD0KLRACXX_s_3_rg.sorted.bam	240.4	1.9	0.14	58cfa82fe4b0c9d6adf6b7fc	TCGA-38-6178-01A-11D-1751_120301_SN208_0270_AD0KLRACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-38-6178-01A	EDF80622-AEA2-4B50-BB69-691D6708AA83	Primary Tumor	Illumina HiSeq	f309d501-6d91-40ce-839c-bef9a434bae1	Lung	70.0	81FB5FA9-D901-4FAA-B909-376B8676D2BC	DE9A3263-6ACD-4BBB-9F91-D4E7FCBEFA04	TCGA-38-6178-01A-11D-1751-02	HG19_Broad_variant	TCGA-38-6178	TCGA-LUAD		s11119	Harvard Medical School	UNC	United States	NO	T2b	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1751-02	True	LUAD	C2	LUAD.5	0.309406366	0.68	0.48	5.478592658999999	-0.4793	-0.0735	0.2338	0.4771	0.9779	0.5333	32.0	3.0	0.707632322	1.753697494	206.0	0.763148877	18.0	30.0	0.8496711859999999	2.626369707	22.0	2.079441542	8.0	1.0	2.313485629	30.99919751	-628.6276232000001	-235.264132	0.0	448.0	0.0	448.0	5.4359030295006	6.998158333622362	-0.07552272603640808	4.407249329439401	5.4359733060388065	4.811350153029985	-1.0286537000611986	-1.562185027583555	4.886872879066393
13722.58cfa82fe4b0c9d6adf6b800	58cfa82fe4b0c9d6adf6b800	TCGA-38-4632-01A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_7_rg.sorted.filtered.	WGS	TCGA-38-4632-01A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_7_rg.sorted	TCGA-38-4632-01A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_7_rg.sorted.bam	465.4	1.9	0.15	58cfa82fe4b0c9d6adf6b800	TCGA-38-4632-01A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_7_rg.sorted.bam	Dead	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-38-4632-01A	875333AB-9048-462D-AAA2-693AD127E3CC	Primary Tumor	Illumina HiSeq	ee38fc59-2812-43a0-b6c0-ab684daab63d	Lung	42.0	D994817A-474E-4F92-8A78-7586CAA85D52	77D4D914-9C77-401B-BD71-9CF71A58DCE7	TCGA-38-4632-01A-01D-1751-02	HG19_Broad_variant	TCGA-38-4632	TCGA-LUAD	1357.0	s11449	Harvard Medical School	UNC	United States	NO	T2	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IV	1751-02	True	LUAD	C2	LUAD.3	0.314434928	0.63	0.55	7.387088165	0.7092	0.425	0.9484	1.2436	0.5239	0.0138	279.0	201.0	3.60897261	13.88999542	229.0	0.644232908	20.0	40.0	0.9259453129999999	1.017254899	3.0	3.2163581339999996	26.0	0.9871893279999999	2.392948102	303.4150981	-28.033561	760.7620294	1.0	1357.0	1.0	680.0	4.01129638928762	6.891208417352946	0.6747032789006868	3.1360876961427007	5.340611004941779	1.0435658080313044	-0.875208693144919	-1.5505974124111663	0.36886252913061757
13722.58cfa82fe4b0c9d6adf6b80a	58cfa82fe4b0c9d6adf6b80a	TCGA-36-1571-01A-01D-A324-10_wgs_Illumina.filtered.	WGS	TCGA-36-1571-01A-01D-A324-10_wgs_Illumina	TCGA-36-1571-01A-01D-A324-10_wgs_Illumina.bam	740.97	1.9	0.07	58cfa82fe4b0c9d6adf6b80a	TCGA-36-1571-01A-01D-A324-10_wgs_Illumina.bam	Dead	FEMALE	WHITE		Ovarian Serous Cystadenocarcinoma	Aligned reads	TCGA-36-1571-01A	12581634-EEBB-4841-8498-71DC9D78C546	Primary Tumor	Illumina HiSeq	9c491361-7721-46fe-ae77-f268796b5b9a	Ovary	53.0	A1D026C2-4D7A-4454-A8E3-30E5C243ABA0	BA577913-356C-4488-8F9D-C45778E7B9E1	TCGA-36-1571-01A-01D-A324-10	GRCh37-lite	TCGA-36-1571	TCGA-OV	695.0	s17463	Baylor College of Medicine	BC Cancer Agency	None	NO			Serous Cystadenocarcinoma		A324-10	True	OV	C2	OVCA.Proliferative	0.034988652				0.8228	0.2615	-0.9471	-2.1126	1.4275	-0.2586					322.0	0.584637404	15.0	25.0				2.5649493569999997	13.0	1.0	4.517199416	-1485.918423	11.02307873	-1443.955041	1.0	695.0	1.0	375.0	6.44022132484945	1.922631399898198	0.42999081360578906	2.1610331364006843	2.9418866168469533	1.357339527675596	-4.2791881884487655	1.0192552169487552	0.9273487140698069
13722.58cfa82fe4b0c9d6adf6b80c	58cfa82fe4b0c9d6adf6b80c	TCGA-44-4112-01A-01D-1103_120318_SN1120_0124_AC0HNPACXX_s_1_rg.sorted.filtered.	WGS	TCGA-44-4112-01A-01D-1103_120318_SN1120_0124_AC0HNPACXX_s_1_rg.sorted	TCGA-44-4112-01A-01D-1103_120318_SN1120_0124_AC0HNPACXX_s_1_rg.sorted.bam	452.63	1.9	0.15	58cfa82fe4b0c9d6adf6b80c	TCGA-44-4112-01A-01D-1103_120318_SN1120_0124_AC0HNPACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-4112-01A	68B86559-38B2-41F2-B66E-C3C2B628B14D	Primary Tumor	Illumina HiSeq	7c0e7b16-7643-4891-96de-63f2106bfb1a	Lung	60.0	6C206676-E511-4281-91F5-BFE91B3279A4	68185A4B-CC12-494D-99F5-84F5888A24F9	TCGA-44-4112-01A-01D-1103-02	HG19_Broad_variant	TCGA-44-4112	TCGA-LUAD		s10651	Harvard Medical School	Christiana Healthcare	None	NO	T2a	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1103-02	True	LUAD	C1	LUAD.3	0.39141854	0.43	0.21	8.916229806	0.081	0.19	0.5206	0.8395	-0.0931	0.423	195.0	298.0	3.7506184160000005	12.00779384	99.0	0.293012063	5.0	20.0	0.8885911129999999	3.2554083210000004	39.0	3.091042453	22.0	1.0	2.970278956	-105.9005324	-65.15646952	985.139718	1.0	808.0	1.0	619.0	6.322069853205901	6.122777732741892	0.41592735389999425	5.299040245703798	5.320041700414599	2.804220892103254	-1.023029607502103	-0.8027360323272932	2.3882935382032597
13722.58cfa82fe4b0c9d6adf6b81e	58cfa82fe4b0c9d6adf6b81e	TCGA-A5-A0GE-01A-11D-A043_120214_SN590_0139_BC0DYEACXX_s_1_rg.sorted.filtered.	WGS	TCGA-A5-A0GE-01A-11D-A043_120214_SN590_0139_BC0DYEACXX_s_1_rg.sorted	TCGA-A5-A0GE-01A-11D-A043_120214_SN590_0139_BC0DYEACXX_s_1_rg.sorted.bam	82.92	2.0	0.17	58cfa82fe4b0c9d6adf6b81e	TCGA-A5-A0GE-01A-11D-A043_120214_SN590_0139_BC0DYEACXX_s_1_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GE-01A	A587E62E-430E-4F1B-82B7-6FBE856FDAF1	Primary Tumor	Illumina HiSeq	d3918efd-f063-4ea7-b839-9c0c143fd07c	Uterus	38.0	20C3F64D-ACF6-45B3-9ACE-2F93B3A951C8	3E23FB82-C875-460A-B19D-5EF9DCC58B9A	TCGA-A5-A0GE-01A-11D-A043-02	HG19_Broad_variant	TCGA-A5-A0GE	TCGA-UCEC		s4995	Harvard Medical School	Cedars Sinai	None	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C1	UCEC.CN_LOW	0.188361712	0.4	0.01	0.356920615	0.3762	0.237	-0.588	0.3759	-0.826	0.062	10.0		0.20871703100000003	0.8348681240000001	89.0	0.142074192	6.0	0.0							2.180944181	-1629.775838	-193.8883169	-2341.4638379999997	0.0	3205.0	0.0	3205.0	6.181474277044542	3.7187628589134167	-0.8226567349566476	6.033838278238477	5.433915206669274	7.330405211844403	-0.1476359988060647	1.7151523477558577	8.153061946801051
13722.58cfa82fe4b0c9d6adf6b82d	58cfa82fe4b0c9d6adf6b82d	TCGA-44-6779-01A-11D-1853_120312_SN1120_0120_AD0PYGACXX_s_8_rg.sorted.filtered.	WGS	TCGA-44-6779-01A-11D-1853_120312_SN1120_0120_AD0PYGACXX_s_8_rg.sorted	TCGA-44-6779-01A-11D-1853_120312_SN1120_0120_AD0PYGACXX_s_8_rg.sorted.bam	62.7	1.9	0.15	58cfa82fe4b0c9d6adf6b82d	TCGA-44-6779-01A-11D-1853_120312_SN1120_0120_AD0PYGACXX_s_8_rg.sorted.bam	Dead	FEMALE	WHITE		Lung Adenocarcinoma	Aligned reads	TCGA-44-6779-01A	CBBEA9F1-396A-4BF3-B67C-2CAC3394DCEB	Primary Tumor	Illumina HiSeq	ab458a7b-afac-4c72-8db7-45994af6ceb8	Lung	50.0	5E04D394-7A40-4E89-BA20-892774DCB469	DB5F07FE-8DC0-4259-A6B1-E75B6F1188C5	TCGA-44-6779-01A-11D-1853-02	HG19_Broad_variant	TCGA-44-6779	TCGA-LUAD	500.0	s11344	Harvard Medical School	Christiana Healthcare	United States	NO	T2	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIB	1853-02	True	LUAD	C6	LUAD.6	0.390883573	0.4	0.37	1.133794615	0.3987	-0.08800000000000001	1.0667	1.2662	0.8311	0.4513	48.0	156.0	0.79330451	2.468058475	154.0	0.6733319879999999	15.0	33.0	0.965534014	2.3152494480000003	11.0	3.5106997210000004	35.0	0.987441921	1.5684602909999998	-649.2524945	451.61798780000004	2663.2510620000003	1.0	500.0	1.0	232.0	6.648761889227338	7.972494751193889	-0.24636565472428051	5.797009678490754	6.9916654981821615	3.067820349948245	-0.851752210736584	-0.9808292530117262	3.3141860046725253
13722.58cfa82fe4b0c9d6adf6b834	58cfa82fe4b0c9d6adf6b834	TCGA-A5-A0RA-01A-21D-A101_120403_SN1222_0093_AC0L7VACXX_s_6_rg.sorted.filtered.	WGS	TCGA-A5-A0RA-01A-21D-A101_120403_SN1222_0093_AC0L7VACXX_s_6_rg.sorted	TCGA-A5-A0RA-01A-21D-A101_120403_SN1222_0093_AC0L7VACXX_s_6_rg.sorted.bam	85.83	2.23	0.16	58cfa82fe4b0c9d6adf6b834	TCGA-A5-A0RA-01A-21D-A101_120403_SN1222_0093_AC0L7VACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0RA-01A	AFD710B8-D172-4AC4-9973-E969DB1ED231	Primary Tumor	Illumina HiSeq	d644ff0f-6dc7-4922-a46d-3223823e8118	Uterus	68.0	4ED231EE-0E54-4AC5-8278-1061AD3972A2	01EFCC42-CCFA-4D41-87BE-CA8F1C551823	TCGA-A5-A0RA-01A-21D-A101-02	HG19_Broad_variant	TCGA-A5-A0RA	TCGA-UCEC		s5195	Harvard Medical School	Cedars Sinai	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C2	UCEC.CN_LOW	0.268427226	0.45	0.0	3.877849822	0.3344	0.159	-0.5121	0.1294	1.1248	-0.3693	39.0		0.42842585200000005	1.901139717	47.0	0.001793066	0.0	0.0							2.667313627	-1487.516763	-218.69863790000002	-1550.051056	0.0	884.0	0.0	884.0	5.499308258675647	6.747083382164613	-0.07794465323883804	4.512813268128244	5.557499315290777	1.7679514696497307	-0.9864949905474041	-1.1895840668738367	1.8458961228885689
13722.58cfa82fe4b0c9d6adf6b842	58cfa82fe4b0c9d6adf6b842	TCGA-A6-2674-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-2674-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-2674-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	260.29	1.9	0.14	58cfa82fe4b0c9d6adf6b842	TCGA-A6-2674-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2674-01A	57CDAA1C-4E94-4A28-AB3B-300C0457555F	Primary Tumor	Illumina HiSeq	92b3a16b-1a9e-47a3-9146-1a297c51c5a3	Colorectal	71.0	8ACA008C-F55A-420A-82C7-ACD2CCA77D85	9FDFC199-B878-4049-994E-B5CA384678FB	TCGA-A6-2674-01A-02D-1167-02	HG18	TCGA-A6-2674	TCGA-COAD		s13013	Harvard Medical School	Christiana Healthcare	None	NO	T3	N2	Colon Mucinous Adenocarcinoma	Stage IV	1167-02	True	COAD	C1		0.5082223220000001	0.75	0.25	5.217337993	0.6114	0.228	0.8464	0.9229999999999999	-0.1235	0.5433	62.0		1.007965713	2.423917548	155.0	0.486147528	20.0	19.0							2.229933405	-113.5524416	172.3277077	-2287.723603	0.0	1331.0	1.0	735.0	6.055465814575642	2.842163185575691	-0.7056223335225396	4.551388417799369	1.7429221637840717	-0.537653423303853	-1.5040773967762742	-1.0992410217916193	0.16796891021868654
13722.58cfa82fe4b0c9d6adf6b84e	58cfa82fe4b0c9d6adf6b84e	TCGA-A5-A0R8-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_4_rg.sorted.filtered.	WGS	TCGA-A5-A0R8-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_4_rg.sorted	TCGA-A5-A0R8-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_4_rg.sorted.bam	80.74	2.11	0.16	58cfa82fe4b0c9d6adf6b84e	TCGA-A5-A0R8-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0R8-01A	06D16B6B-9CA6-4CEC-A785-F27AA4323CEC	Primary Tumor	Illumina HiSeq	ed11d53d-5cbb-44e2-b4d2-1603cef4ec13	Uterus	81.0	5B5CC2BA-6A10-4279-A0AA-8DDAE94D56EA	289CE7E4-AF92-4857-9D07-7CF334C40542	TCGA-A5-A0R8-01A-11D-A101-02	HG19_Broad_variant	TCGA-A5-A0R8	TCGA-UCEC		s4420	Harvard Medical School	Cedars Sinai	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C2	UCEC.CN_LOW	0.29069162	0.55	0.0	15.49728752	0.1164	0.127	0.1119	0.9225	0.3237	-0.0522	15.0		0.546313732	2.070241512	55.0	2.13e-05	0.0	0.0							3.1330027310000004	-1459.41749	-640.1692079	-1113.199096	0.0	596.0	1.0	42.0	6.355890623256082	6.842392175545765	-0.7209013508610305	5.285449211554668	5.872991618357661	1.156901419443478	-1.0704414117014136	-0.9694005571881035	1.8778027703045084
13722.58cfa82fe4b0c9d6adf6b852	58cfa82fe4b0c9d6adf6b852	TCGA-A5-A0R9-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_5_rg.sorted.filtered.	WGS	TCGA-A5-A0R9-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_5_rg.sorted	TCGA-A5-A0R9-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_5_rg.sorted.bam	112.95	1.93	0.17	58cfa82fe4b0c9d6adf6b852	TCGA-A5-A0R9-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0R9-01A	284174FD-1320-4617-9E99-75BD75DF9BF3	Primary Tumor	Illumina HiSeq	4139f46d-ae94-47a2-a3ae-0b96262c6a89	Uterus	51.0	986AC6AC-087F-412B-BB0C-9BE10D104989	6BBEF031-7106-4D36-86A9-F8A2333448BB	TCGA-A5-A0R9-01A-11D-A101-02	HG19_Broad_variant	TCGA-A5-A0R9	TCGA-UCEC		s4419	Harvard Medical School	Cedars Sinai	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C1	UCEC.CN_LOW	0.07409809099999999	0.18	0.0	1.6979521080000002	-0.1699	0.11800000000000001	-0.2173	0.2125	-0.2456	0.0075	21.0	13.0	0.26450758	1.058030318	47.0	0.046539529	2.0	0.0							2.352061152	-761.9058734	-188.7275438	-2651.136444	0.0	749.0	0.0	749.0	7.4286726663149185	8.0409944117933	-0.21604984328684107	5.973385433708076	5.8776713861327625	2.6759983609365756	-1.4552872326068422	-2.163323025660538	2.892048204223417
13722.58cfa82fe4b0c9d6adf6b858	58cfa82fe4b0c9d6adf6b858	TCGA-29-1710-01A-02D-0926-12_Illumina.filtered.	WGS	TCGA-29-1710-01A-02D-0926-12_Illumina	TCGA-29-1710-01A-02D-0926-12_Illumina.bam	265.0	1.9	0.15	58cfa82fe4b0c9d6adf6b858	TCGA-29-1710-01A-02D-0926-12_Illumina.bam	Dead	FEMALE	WHITE		Ovarian Serous Cystadenocarcinoma	Aligned reads	TCGA-29-1710-01A	4261267C-7042-4C6E-83ED-12FB401003FC	Primary Tumor	Illumina HiSeq	3d865220-b0b8-4ca4-b4a1-56e05dc83e6f	Ovary	54.0	61513DA0-4EB3-4CAE-BFFF-7B05F3362488	6BA4DE87-C332-42B8-AF95-EB14A4C7F229	TCGA-29-1710-01A-02D-0926-12	NCBI36_BCM_variant	TCGA-29-1710	TCGA-OV	951.0	s17882	Baylor College of Medicine	Duke	None	NO			Serous Cystadenocarcinoma		0926-12	True	OV	C2	OVCA.Immunoreactive	0.146755266	0.53	0.22		-0.2323	0.004	0.8975	1.2541	0.9255	0.2604	30.0		0.442837476	1.121854939	176.0	0.482236184	9.0	21.0	0.8166074659999999	5.008578633	461.0	3.8636203080000002	205.0	0.725833753	4.401627059	-207.51186030000002	-668.6932776000001	1608.150509	1.0	951.0	1.0	315.0	5.425413624351089	0.6233483990226585	0.5655436827847147	4.814504542028116	3.494359909634282	2.60754466309423	-0.6109090823229733	2.8710115106116234	2.042000980309515
13722.58cfa82fe4b0c9d6adf6b85e	58cfa82fe4b0c9d6adf6b85e	TCGA-A6-2680-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-2680-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-2680-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	38.0	1.9	0.16	58cfa82fe4b0c9d6adf6b85e	TCGA-A6-2680-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2680-01A	FF1407C6-9174-4BAE-A19B-D34CA71B898C	Primary Tumor	Illumina HiSeq	b2bf326b-6022-44c8-87fd-c3777c1ab858	Colorectal	72.0	D664F620-CFEE-4700-B00E-68B65387883C	22A3FC8C-A661-4B3D-A4BA-B35DFDBE24BC	TCGA-A6-2680-01A-01D-1405-02	HG18	TCGA-A6-2680	TCGA-COAD		s13356	Harvard Medical School	Christiana Healthcare	None	NO	T3	N0	Colon Adenocarcinoma	Stage II	1405-02	True	COAD	C1		0.120522879			13.89243895	0.4341	0.203	-0.3673	-0.0889	-0.2521	0.22					92.0	0.510387334	15.0	6.0							1.254761391	-898.1483911	-319.54133260000003	-1017.8321890000001	0.0	1068.0	0.0	1068.0	6.71430536440034	6.6703617409965235	-0.8261228632507451	4.88617825100141	6.923197082118136	0.8683827909644142	-1.8281271133989296	0.2528353411216129	1.6945056542151593
13722.58cfa82fe4b0c9d6adf6b864	58cfa82fe4b0c9d6adf6b864	TCGA-A5-A0GU-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_5_rg.sorted.filtered.	WGS	TCGA-A5-A0GU-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_5_rg.sorted	TCGA-A5-A0GU-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_5_rg.sorted.bam	101.03	2.18	0.17	58cfa82fe4b0c9d6adf6b864	TCGA-A5-A0GU-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GU-01A	ADC22472-E31D-419F-AEAE-CB01B9423343	Primary Tumor	Illumina HiSeq	7666f932-cff3-4ea2-8650-8d4bdae72cac	Uterus	58.0	074D4466-E072-42CD-9A6C-A595DC9363E7	BB726D7A-6861-48AA-9BFD-5DF8DAAA1538	TCGA-A5-A0GU-01A-11D-A043-02	HG19_Broad_variant	TCGA-A5-A0GU	TCGA-UCEC		s4241	Harvard Medical School	Cedars Sinai	None	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C2	UCEC.CN_LOW	0.12776543099999998	0.23	0.0	2.365703749	-0.0124	0.048	-0.1463	0.0748	0.5667	-0.1303	22.0	67.0	0.34177936200000003	1.435473321	73.0	0.11245947	4.0	2.0							2.530530299	-254.6873884	-137.4246874	-263.71701129999997	0.0	860.0	0.0	860.0	4.433678661005729	6.274134077736219	0.25021218908596343	3.6733921776081555	5.293304824724493	4.081855550651325	-0.7602864833975733	-0.9808292530117257	3.8316433615653622
13722.58cfa82fe4b0c9d6adf6b866	58cfa82fe4b0c9d6adf6b866	TCGA-A6-2682-01A-01D-1405_110114_SN177_0133_A809KVABXX_s_8_rg.sorted.filtered.	WGS	TCGA-A6-2682-01A-01D-1405_110114_SN177_0133_A809KVABXX_s_8_rg.sorted	TCGA-A6-2682-01A-01D-1405_110114_SN177_0133_A809KVABXX_s_8_rg.sorted.bam	618.0	1.9	0.16	58cfa82fe4b0c9d6adf6b866	TCGA-A6-2682-01A-01D-1405_110114_SN177_0133_A809KVABXX_s_8_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2682-01A	77A44132-AF22-4115-9FA2-78F2F74BF687	Primary Tumor	Illumina HiSeq	dd9a1c6d-4344-4fed-a29f-b60afcfaa5eb	Colorectal	70.0	F10F139D-1D7F-4923-8129-F103F5D3163B	F8B17713-D431-4418-A6F7-DC6DE3077212	TCGA-A6-2682-01A-01D-1405-02	HG18_Broad_variant	TCGA-A6-2682	TCGA-COAD	424.0	s13651	Harvard Medical School	Christiana Healthcare	United States	NO	T4b	N1	Colon Adenocarcinoma	Stage IV	1405-02	True	COAD	C1		0.342627178			0.234126241	0.5489	0.3445	-0.0893	-0.1592	-0.8502	0.4234					69.0	0.382922954			0.790677435	2.285351728	18.0	1.609437912	5.0	1.0	1.286925519	-433.7188187	-242.4913358	-2016.2461469999998	1.0	424.0	1.0	381.0	6.367485240371508	4.842331309535598	-3.506506875610233	5.089079841262802	7.238290473307102	-2.81504203849212	-1.2784053991087054	2.3959591637715043	0.6914648371181129
13722.58cfa82fe4b0c9d6adf6b868	58cfa82fe4b0c9d6adf6b868	TCGA-A5-A0R7-01A-31D-A101_120403_SN1222_0093_AC0L7VACXX_s_3_rg.sorted.filtered.	WGS	TCGA-A5-A0R7-01A-31D-A101_120403_SN1222_0093_AC0L7VACXX_s_3_rg.sorted	TCGA-A5-A0R7-01A-31D-A101_120403_SN1222_0093_AC0L7VACXX_s_3_rg.sorted.bam	88.28	1.87	0.17	58cfa82fe4b0c9d6adf6b868	TCGA-A5-A0R7-01A-31D-A101_120403_SN1222_0093_AC0L7VACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0R7-01A	02B25675-094D-4098-96DA-51D121380FEC	Primary Tumor	Illumina HiSeq	daa92f08-7339-46a6-8a74-e6756c170ed5	Uterus	55.0	550C6341-260A-4156-B00C-0AE9031D647F	4C9B54D0-A58E-44CF-8937-913A34F0788C	TCGA-A5-A0R7-01A-31D-A101-02	HG19_Broad_variant	TCGA-A5-A0R7	TCGA-UCEC		s4777	Harvard Medical School	Cedars Sinai	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C2	UCEC.CN_LOW	0.178070617	0.28	0.43	1.188192443	0.442	0.115	-0.1412	1.1273	0.5392	0.3646	20.0	10.0	0.590061376	1.6092582990000002	107.0	0.53239216	7.0	5.0							2.275530496	-1313.281454	228.9044071	-2752.814725	0.0	535.0	0.0	535.0	7.619417493539796	7.779780594558277	-0.5264902797404621	6.035297389089986	7.129193028417127	2.071298860160053	-1.5841201044498106	-0.6505875661411493	2.5977891399005153
13722.58cfa82fe4b0c9d6adf6b86a	58cfa82fe4b0c9d6adf6b86a	TCGA-A6-2680-01A-01D-1554-10_wgs_Illumina.filtered.	WGS	TCGA-A6-2680-01A-01D-1554-10_wgs_Illumina	TCGA-A6-2680-01A-01D-1554-10_wgs_Illumina.bam	38.0	1.9	0.05	58cfa82fe4b0c9d6adf6b86a	TCGA-A6-2680-01A-01D-1554-10_wgs_Illumina.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2680-01A	FF1407C6-9174-4BAE-A19B-D34CA71B898C	Primary Tumor	Illumina HiSeq	d43e0ed3-ab1d-486a-bbf5-91dabacf8220	Colorectal	72.0	D664F620-CFEE-4700-B00E-68B65387883C	2CDC4CCE-0877-4EC1-85F5-20C909912E65	TCGA-A6-2680-01A-01D-1554-10	GRCh37-lite	TCGA-A6-2680	TCGA-COAD		s13172	Baylor College of Medicine	Christiana Healthcare	None	NO	T3	N0	Colon Adenocarcinoma	Stage II	1554-10	False	COAD	C1		0.120522879			13.89243895	0.4341	0.203	-0.3673	-0.0889	-0.2521	0.22					92.0	0.510387334	15.0	6.0							1.254761391	-898.1483911	-319.54133260000003	-1017.8321890000001	0.0	1068.0	0.0	1068.0	6.734353819562741	6.988324566552595	-0.8261228632507451	5.299269294273419	7.927166123948646	0.8683827909644142	-1.4350845252893227	0.9388415573960511	1.6945056542151593
13722.58cfa82fe4b0c9d6adf6b86c	58cfa82fe4b0c9d6adf6b86c	TCGA-A5-A0VP-01A-21D-A101_120407_SN590_0151_BC0KKJACXX_s_6_rg.sorted.filtered.	WGS	TCGA-A5-A0VP-01A-21D-A101_120407_SN590_0151_BC0KKJACXX_s_6_rg.sorted	TCGA-A5-A0VP-01A-21D-A101_120407_SN590_0151_BC0KKJACXX_s_6_rg.sorted.bam	77.93	2.03	0.16	58cfa82fe4b0c9d6adf6b86c	TCGA-A5-A0VP-01A-21D-A101_120407_SN590_0151_BC0KKJACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0VP-01A	2DB0FB62-64CE-457C-9E22-DD05EF59F684	Primary Tumor	Illumina HiSeq	26cc510d-e8a9-4782-9488-478373dbc1df	Uterus	74.0	F1FBE4AC-F3FD-4609-9A2B-507820ABE77E	E23FE404-0449-453D-971C-6E940B546119	TCGA-A5-A0VP-01A-21D-A101-02	HG19_Broad_variant	TCGA-A5-A0VP	TCGA-UCEC		s4992	Harvard Medical School	Cedars Sinai	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C1	UCEC.POLE	0.157312652	0.15	0.04	0.34627037899999996	0.2954	0.114	-0.545	0.2528	-0.059000000000000004	-0.0943	520.0		15.76493612	39.78361597	57.0	0.081252318	2.0	0.0							2.064174894	-663.8111048	-2.605393555	-1424.31621	0.0	1288.0	0.0	1288.0	7.682828008940755	8.241000419012213	0.36530778626110016	5.157099364632499	7.142388130344103	1.8857416275888603	-2.5257286443082556	-1.0986122886681096	1.52043384132776
13722.58cfa82fe4b0c9d6adf6b86e	58cfa82fe4b0c9d6adf6b86e	TCGA-A6-2671-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-2671-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-2671-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	243.0	1.9	0.15	58cfa82fe4b0c9d6adf6b86e	TCGA-A6-2671-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2671-01A	565E2726-4942-4726-89D3-C5E3797F7204	Primary Tumor	Illumina HiSeq	866dc7b9-86cd-4842-ad2f-1d5e7c714ccb	Colorectal	85.0	81505915-6C01-4299-AE89-964DC20D93CB	82E23BAF-DA11-4175-BEE0-81C0C0137D72	TCGA-A6-2671-01A-01D-1405-02	HG18	TCGA-A6-2671	TCGA-COAD		s13649	Harvard Medical School	Christiana Healthcare	None	NO	T3	N2	Colon Adenocarcinoma	Stage IV	1405-02	True	COAD	C2	GI.CIN	0.090780355	0.27	0.29	0.196756182	0.5382	0.252	-0.2334	-0.6621	0.4517	0.4229	20.0	52.0	0.9301965520000001	1.550327587	182.0	0.860899243	21.0	27.0	0.9589012809999999	3.436240901	36.0				0.851149314	-1067.174364	-723.8012668	-636.3894188999999	1.0	1331.0	1.0	535.0	7.015156567987615	5.891741475790522	-0.7013336242643542	5.042399168896114	6.283220341923947	1.9324070391914638	-1.9727573990915013	0.39147886613342475	2.633740663455818
13722.58cfa82fe4b0c9d6adf6b874	58cfa82fe4b0c9d6adf6b874	TCGA-A5-A0VQ-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_2_rg.sorted.filtered.	WGS	TCGA-A5-A0VQ-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_2_rg.sorted	TCGA-A5-A0VQ-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_2_rg.sorted.bam	105.24	2.0	0.15	58cfa82fe4b0c9d6adf6b874	TCGA-A5-A0VQ-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_2_rg.sorted.bam	Alive	FEMALE		HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0VQ-01A	23489245-48D7-4F19-8A42-E23B1181412B	Primary Tumor	Illumina HiSeq	b4dd6449-2e78-432b-86c6-348339f37763	Uterus	62.0	952CB6A5-7527-470A-978E-EDD44E3A368F	97FE43D0-30DF-45A1-83F0-B4ED5EDF76AE	TCGA-A5-A0VQ-01A-11D-A101-02	HG19_Broad_variant	TCGA-A5-A0VQ	TCGA-UCEC		s5381	Harvard Medical School	Cedars Sinai	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C1	UCEC.MSI	0.080162556	0.16	0.0	12.52508666	-0.2633	-0.027000000000000003	-0.5309	0.1054	-0.7547	0.1601	173.0	1085.0	3.114912074	10.40263089	47.0	7.099999999999999e-05	0.0	0.0							1.852927351	-946.1753448999999	-757.1435478	255.21428930000002	0.0	485.0	0.0	485.0	7.31183848031586	7.550818959374095	-0.11044311872129209	6.367376871475009	6.7179098364389915	1.417685461424079	-0.9444616088408515	-0.8329091229351038	1.528128580145371
13722.58cfa82fe4b0c9d6adf6b882	58cfa82fe4b0c9d6adf6b882	TCGA-A6-2678-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-2678-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-2678-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	493.29	1.9	0.15	58cfa82fe4b0c9d6adf6b882	TCGA-A6-2678-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2678-01A	3A785E32-7960-4C72-84C4-FB42C4DD86F1	Primary Tumor	Illumina HiSeq	31675676-aba0-4d34-a2dc-0356129ceaa2	Colorectal	43.0	20ECCD8A-DFAF-40E4-8128-D77AA41680C4	83E77250-E68B-4ECA-9592-4424151E0D79	TCGA-A6-2678-01A-01D-1167-02	HG18	TCGA-A6-2678	TCGA-COAD		s12856	Harvard Medical School	Christiana Healthcare	None	NO	T3	N1	Colon Adenocarcinoma	Stage IIIB	1167-02	True	COAD	C1		0.08780803300000001	0.18	0.15	3.850381374	0.8639	0.35	-0.1362	-0.1358	0.0303	-0.0352			0.510069885	4.250582372	175.0	0.889683412	5.0	31.0	0.8953732	3.62003975	57.0				3.2931244410000002	-578.1910761	824.7166388999999	-9.411211377999999	0.0	1286.0	0.0	1286.0	7.133960804332165	5.7549507612306	-0.36491160600461126	5.531211880048862	6.042632833682381	1.4069136483226266	-1.6027489242833037	0.2876820724517808	1.7718252543272377
13722.58cfa82fe4b0c9d6adf6b88f	58cfa82fe4b0c9d6adf6b88f	TCGA-73-4676-01A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_7_rg.sorted.filtered.	WGS	TCGA-73-4676-01A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_7_rg.sorted	TCGA-73-4676-01A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_7_rg.sorted.bam	216.0	1.9	0.15	58cfa82fe4b0c9d6adf6b88f	TCGA-73-4676-01A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-73-4676-01A	195A5AFB-B79F-44D2-9D12-884487630C2B	Primary Tumor	Illumina HiSeq	a2b68d59-a4d4-4793-9e6c-72ccaf7c242b	Lung	45.0	22434A49-EB8A-43AC-8C08-AE6DCBE6FBB8	A79111BF-CB9D-4790-AE9F-6CB13C9334E2	TCGA-73-4676-01A-01D-1751-02	HG19_Broad_variant	TCGA-73-4676	TCGA-LUAD		s11465	Harvard Medical School	Roswell Park	United States	NO	T2a	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIA	1751-02	True	LUAD	C4	LUAD.3	0.18810130100000003	0.23	0.51	15.70444452	0.6599	0.2985	0.5375	-0.2732	-0.3892	0.0533	38.0	34.0	0.8429175659999999	2.46631436	166.0	0.91212221	9.0	20.0				1.5607104090000001	5.0	0.9697239	3.969147928	-287.6476414	570.0622929	1275.454745	1.0	281.0	1.0	281.0	8.419638389067373	7.707307883638347	0.21553859712586987	7.780558429777702	7.3119951469941995	2.6965022985143143	-0.6390799592896697	-0.3953127366441471	2.4809637013884442
13722.58cfa82fe4b0c9d6adf6b892	58cfa82fe4b0c9d6adf6b892	TCGA-A6-2681-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-2681-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-2681-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	308.0	1.9	0.15	58cfa82fe4b0c9d6adf6b892	TCGA-A6-2681-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2681-01A	7D8EAB0A-E6C8-4449-9EBF-50C41DB94A06	Primary Tumor	Illumina HiSeq	eda754a1-3a13-47a5-8e0e-49ef1384646d	Colorectal	73.0	0537BAD8-0E85-4B05-91B3-FD965E96D0D7	BFF8CDA3-3C4B-416F-AF46-6811B139D670	TCGA-A6-2681-01A-01D-1405-02	HG18	TCGA-A6-2681	TCGA-COAD		s12860	Harvard Medical School	Christiana Healthcare	United States	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1405-02	True	COAD	C1	GI.CIN	0.158554139	0.28	0.52	6.232465795	0.2784	0.18	-0.0352	0.1826	-0.1314	0.44799999999999995	49.0	13.0			147.0	0.491324508	10.0	21.0							1.190940728	-574.9617732999999	-447.9774324	-353.9483236	0.0	1387.0	1.0	1150.0	6.875920555462118	6.391770958119229	-1.024922050423966	4.540545639645082	6.841840372464147	0.6914333840822104	-2.3353749158170363	0.45006941434491843	1.7163554345061764
13722.58cfa82fe4b0c9d6adf6b896	58cfa82fe4b0c9d6adf6b896	TCGA-49-6742-01A-11D-1853_111218_SN208_0258_C054RACXX_s_1_rg.sorted.filtered.	WGS	TCGA-49-6742-01A-11D-1853_111218_SN208_0258_C054RACXX_s_1_rg.sorted	TCGA-49-6742-01A-11D-1853_111218_SN208_0258_C054RACXX_s_1_rg.sorted.bam	39.7	2.0	0.13	58cfa82fe4b0c9d6adf6b896	TCGA-49-6742-01A-11D-1853_111218_SN208_0258_C054RACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-49-6742-01A	21FB46F9-4BBB-441C-AF19-A687E9138344	Primary Tumor	Illumina HiSeq	eeeb9a6f-97a9-4db9-aeb9-c5afaf9d0153	Lung	70.0	F0A4AE58-D5BC-4AB0-B1CF-0D951EA91FC7	04467FAB-BB2F-4F26-AF9E-39C09D920A63	TCGA-49-6742-01A-11D-1853-02	HG19_Broad_variant	TCGA-49-6742	TCGA-LUAD		s10655	Harvard Medical School	Johns Hopkins	United States	NO	T2a	N1	Mucinous (Colloid) Carcinoma	Stage IIA	1853-02	True	LUAD	C2	LUAD.1	0.184550443	0.51	0.16	6.488996263	0.5312	0.1055	-0.1611	-0.4244	0.9717	-0.0655	101.0	39.0	2.454418741	6.486678102000001	120.0	0.79654434	18.0	9.0	0.977603771	1.074007516	3.0	1.609437912	5.0	1.0	6.85347966	104.9344666	692.3114479	3032.317442	1.0	488.0	1.0	214.0	7.129831594335924	9.129593249594183	0.4957728756653238	5.20801899685967	9.02039395762919	2.9666024115624876	-1.921812597476253	-0.109199291964992	2.4708295358971637
13722.58cfa82fe4b0c9d6adf6b898	58cfa82fe4b0c9d6adf6b898	TCGA-A6-2676-01A-01D-1167-02_101203_SN177_0125_B802RYABXX_s_1.rg.sorted.filtered.	WGS	TCGA-A6-2676-01A-01D-1167-02_101203_SN177_0125_B802RYABXX_s_1.rg.sorted	TCGA-A6-2676-01A-01D-1167-02_101203_SN177_0125_B802RYABXX_s_1.rg.sorted.bam	296.29	1.9	0.17	58cfa82fe4b0c9d6adf6b898	TCGA-A6-2676-01A-01D-1167-02_101203_SN177_0125_B802RYABXX_s_1.rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2676-01A	89A6384E-1CEA-440B-9F17-D57CB0805174	Primary Tumor	Illumina HiSeq	c175a01b-eba5-4c4d-b786-fc9f54a2fa60	Colorectal	75.0	CBBD1187-E8F7-4E63-A8E2-3C19863E89F5	D02407DB-AECE-475A-AA3F-00653B1E7BEE	TCGA-A6-2676-01A-01D-1167-02	HG18_Broad_variant	TCGA-A6-2676	TCGA-COAD		s13022	Harvard Medical School	Christiana Healthcare	None	NO	T4	N0	Colon Adenocarcinoma	Stage IIB	1167-02	True	COAD	C2		0.25463716			9.319250578	1.1417	0.39	0.4016	0.0904	0.0309	-0.2207					181.0	0.04364106	1.0	5.0							0.259663365	496.3994431	955.0996397	-1534.821392	1.0	1305.0	0.0	1305.0	6.1132482838736735	6.017223663951191	0.28813498566194307	5.082229286338093	6.244281114586538	1.655708451275971	-1.0310189975355812	0.22705745063534621	1.367573465614028
13722.58cfa82fe4b0c9d6adf6b89a	58cfa82fe4b0c9d6adf6b89a	TCGA-A6-2683-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-2683-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-2683-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	467.29	1.9	0.16	58cfa82fe4b0c9d6adf6b89a	TCGA-A6-2683-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2683-01A	FAFD4576-0709-49E1-926F-AD1EE09907EC	Primary Tumor	Illumina HiSeq	06c41745-bee7-471d-9c51-8886c6c8dd9c	Colorectal	57.0	C24759F8-566B-42DA-A26D-BB0BF51EE15F	B22E3766-3FC6-4E77-86D0-0A10A810D313	TCGA-A6-2683-01A-01D-1167-02	HG18	TCGA-A6-2683	TCGA-COAD		s12852	Harvard Medical School	Christiana Healthcare	None	NO	T4	N0	Colon Adenocarcinoma	Stage IV	1167-02	True	COAD	C4		0.012108988999999999	0.15	0.25	5.610129489	-0.3185	-0.239	-1.2731	-1.1308	-2.0227	-0.1281			1.812045573	5.617341276	200.0	0.6207420539999999	16.0	15.0	0.889716753	3.137462036	34.0				0.702937452	-867.4073686	-1378.026545	3408.0083590000004	1.0	504.0	1.0	300.0	6.425821949458725	7.39608030152888	-0.6212050080639286	5.963198427510612	7.596750996991031	1.9831777482891788	-0.46262352194811296	0.20067069546215155	2.6043827563531075
13722.58cfa82fe4b0c9d6adf6b89b	58cfa82fe4b0c9d6adf6b89b	TCGA-A6-A566-01A-11D-A28G-10_wgs_Illumina.filtered.	WGS	TCGA-A6-A566-01A-11D-A28G-10_wgs_Illumina	TCGA-A6-A566-01A-11D-A28G-10_wgs_Illumina.bam	17.81		0.08	58cfa82fe4b0c9d6adf6b89b	TCGA-A6-A566-01A-11D-A28G-10_wgs_Illumina.bam	Dead	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-A566-01A	790266BC-C252-43F4-85D1-1B06EE529CF8	Primary Tumor	Illumina HiSeq	dd970455-c925-43f6-b58d-24982c846bdd	Colorectal	55.0	615FDEE9-637E-45C6-8909-36B9201A8EB7	492B4E58-12E2-47B2-BD47-28F8607072FA	TCGA-A6-A566-01A-11D-A28G-10	GRCh37-lite	TCGA-A6-A566	TCGA-COAD	758.0	s13351	Baylor College of Medicine	Christiana Healthcare	United States	NO	T4	N1	Colon Mucinous Adenocarcinoma	Stage IIIB	A28G-10	True	COAD	C1	GI.GS	0.46814417799999997	0.61	0.0	0.09889999	0.4912	0.161	0.8537	0.3945	0.1403	0.8095	87.0	54.0	1.572779259	3.853309185	79.0	0.12085626199999999	4.0	4.0				2.6156305769999997	14.0	0.99112306	1.52474475	-212.9376332	460.1294871	-1704.622527	1.0	758.0	1.0	257.0	7.1383377593933455	3.9139637803223106	-1.3696734798838504	5.145907594703139	5.637422659157176	2.797880915141909	-1.9924301646902063	1.7234588788348653	4.16755439502576
13722.58cfa82fe4b0c9d6adf6b8a5	58cfa82fe4b0c9d6adf6b8a5	TCGA-A6-2683-01A-01D-1554-10_wgs_Illumina.filtered.	WGS	TCGA-A6-2683-01A-01D-1554-10_wgs_Illumina	TCGA-A6-2683-01A-01D-1554-10_wgs_Illumina.bam	467.29	1.9	0.05	58cfa82fe4b0c9d6adf6b8a5	TCGA-A6-2683-01A-01D-1554-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2683-01A	FAFD4576-0709-49E1-926F-AD1EE09907EC	Primary Tumor	Illumina HiSeq	9e91b702-c4fb-4c6e-9060-987e5ff14421	Colorectal	57.0	C24759F8-566B-42DA-A26D-BB0BF51EE15F	FC453F67-6623-4E8C-B519-0BD79E4D4651	TCGA-A6-2683-01A-01D-1554-10	GRCh37-lite	TCGA-A6-2683	TCGA-COAD		s13015	Baylor College of Medicine	Christiana Healthcare	None	NO	T4	N0	Colon Adenocarcinoma	Stage IV	1554-10	False	COAD	C4		0.012108988999999999	0.15	0.25	5.610129489	-0.3185	-0.239	-1.2731	-1.1308	-2.0227	-0.1281			1.812045573	5.617341276	200.0	0.6207420539999999	16.0	15.0	0.889716753	3.137462036	34.0				0.702937452	-867.4073686	-1378.026545	3408.0083590000004	1.0	504.0	1.0	300.0	4.901204378948056	6.880719536308507	-0.6212050080639286	5.339459309879212	8.439832364855093	1.9831777482891788	0.4382549309311554	1.559112828546585	2.6043827563531075
13722.58cfa82fe4b0c9d6adf6b8b3	58cfa82fe4b0c9d6adf6b8b3	TCGA-50-5051-01A-21D-1853_120322_SN208_0277_AD0PL1ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-50-5051-01A-21D-1853_120322_SN208_0277_AD0PL1ACXX_s_7_rg.sorted	TCGA-50-5051-01A-21D-1853_120322_SN208_0277_AD0PL1ACXX_s_7_rg.sorted.bam	416.7	1.9	0.15	58cfa82fe4b0c9d6adf6b8b3	TCGA-50-5051-01A-21D-1853_120322_SN208_0277_AD0PL1ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5051-01A	E1C55BAC-BB41-4964-ADD5-ECD6BA04B58D	Primary Tumor	Illumina HiSeq	fd2a1c20-3ed6-4057-8fb5-4027ce0eec74	Lung	42.0	180EB213-0DDC-4F10-AB0E-B3AF92CDE3C3	80170E98-4886-4A34-BC88-F2B2F84743B2	TCGA-50-5051-01A-21D-1853-02	HG19_Broad_variant	TCGA-50-5051	TCGA-LUAD		s10789	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1853-02	True	LUAD	C1	LUAD.3	0.20476021100000003	0.41	0.26		0.1488	0.049	-0.2444	0.7024	-1.0188	0.0887	43.0	4.0	1.12645884	2.83058888	99.0	0.589783362	18.0	7.0	0.934572491	3.11418667	28.0	2.163955657	9.0	0.984858662	2.551435376	-637.1228579	-50.48416948	1639.712896	1.0	478.0	1.0	184.0	7.168856418627073	7.608684599984137	-0.07602255187577867	6.389766808266403	6.743687162497533	2.697163125908543	-0.7790896103606704	-0.8649974374866045	2.773185677784322
13722.58cfa82fe4b0c9d6adf6b8b8	58cfa82fe4b0c9d6adf6b8b8	TCGA-73-4675-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-73-4675-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-73-4675-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	482.2	1.9	0.16	58cfa82fe4b0c9d6adf6b8b8	TCGA-73-4675-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-73-4675-01A	AE39E358-08D7-4367-AE68-82B469E791E4	Primary Tumor	Illumina HiSeq	14b3ad66-64c9-4b39-a34e-5cb29788735a	Lung	59.0	1F5FA8FD-1DE8-4456-8935-71B5A8B54BD2	356D01E0-DF80-40C6-BA06-8CD4EDFBD1EC	TCGA-73-4675-01A-01D-1203-02	GRCh37	TCGA-73-4675	TCGA-LUAD		s11013	Harvard Medical School	Roswell Park	United States	NO	T3	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1203-02	True	LUAD	C3	LUAD.4	0.133261342	0.43	0.07	1.252497564	-0.7634	-0.113	0.3031	0.3204	-0.6313	0.28300000000000003	24.0	237.0	0.714646015	1.727061203	123.0	0.774866155	22.0	13.0	0.954739862	1.710664189	6.0	2.2718685130000003	10.0	0.986659959	2.115296481	-911.7271651000001	-1104.928668	4040.9521	1.0	922.0	1.0	361.0	9.584250925749025	7.21644559359611	-0.42553332601058924	7.81658900810003	7.141222172358522	0.8306275390601834	-1.767661917648995	-0.07522342123758818	1.2561608650707727
13722.58cfa82fe4b0c9d6adf6b8bc	58cfa82fe4b0c9d6adf6b8bc	TCGA-73-4668-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-73-4668-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-73-4668-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	311.9	1.9	0.15	58cfa82fe4b0c9d6adf6b8bc	TCGA-73-4668-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	AMERICAN INDIAN OR ALASKA NATIVE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-73-4668-01A	B2285924-9813-4F46-BB8F-91A0EFD8A9B6	Primary Tumor	Illumina HiSeq	c3c82aae-4b64-4f65-b4ed-048053aef739	Lung	66.0	FDBFDF52-C0CD-4FBB-A910-B747516DFEF4	DC227D17-FED3-489A-B5C6-3D4C910310FF	TCGA-73-4668-01A-01D-1203-02	GRCh37	TCGA-73-4668	TCGA-LUAD		s10795	Harvard Medical School	Roswell Park	United States	NO	T2	N1	Lung Micropapillary Adenocarcinoma	Stage IIB	1203-02	True	LUAD	C1		0.220254454	0.47	0.35	3.804938998	0.0276	0.161	0.0142	0.2742	-1.0243	0.6224	277.0	152.0	3.192446972	13.14707708	226.0	0.637350441	20.0	35.0	0.868664078	4.749907422	237.0	1.7478680969999998	6.0	0.9755037590000001	2.483417596	-244.45323530000002	-219.54078379999999	1963.312032	0.0	467.0	1.0	236.0	8.642784050373342	6.3592755304142505	0.0008121827857625608	7.351799869057777	6.808800628316446	3.4918502684477075	-1.2909841813155656	0.44952509790219475	3.491038085661945
13722.58cfa82fe4b0c9d6adf6b8c4	58cfa82fe4b0c9d6adf6b8c4	TCGA-49-4510-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-49-4510-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-49-4510-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	177.53	1.9	0.14	58cfa82fe4b0c9d6adf6b8c4	TCGA-49-4510-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-49-4510-01A	F77B6930-A1CE-446E-A15D-C018CBBECFEE	Primary Tumor	Illumina HiSeq	abe8920d-80b9-4fc8-a249-5bf0a4a06ac7	Lung	51.0	9A479D32-13A4-46C2-B26D-34CB6051A891	3324FA3E-B195-4974-A15B-0C8D8AC2EFA9	TCGA-49-4510-01A-01D-1203-02	GRCh37	TCGA-49-4510	TCGA-LUAD	896.0	s11338	Harvard Medical School	Johns Hopkins	United States	NO	T2	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIB	1203-02	True	LUAD	C3	LUAD.1	0.131528736	0.36	0.48	3.81020079	-1.5092	-0.028999999999999998	0.1	0.7584	-0.7169	0.0766	19.0	2.0	0.36054473600000003	1.2919519720000001	184.0	0.653190021	21.0	21.0	0.843413837	3.424633821	58.0	1.906154747	7.0	0.979569765	2.535424891	-630.0956186000001	-1516.006852	1527.6532650000001	1.0	896.0	1.0	502.0	8.732696199405904	7.749244091683318	0.007790117296414545	7.311310518474743	7.0560969111233725	3.0074403255456312	-1.421385680931161	-0.6931471805599454	2.9996502082492165
13722.58cfa82fe4b0c9d6adf6b8c6	58cfa82fe4b0c9d6adf6b8c6	TCGA-A5-A0GX-01A-11D-A043_120504_SN590_0156_BC0H68ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-A5-A0GX-01A-11D-A043_120504_SN590_0156_BC0H68ACXX_s_2_rg.sorted	TCGA-A5-A0GX-01A-11D-A043_120504_SN590_0156_BC0H68ACXX_s_2_rg.sorted.bam	89.76	2.06	0.14	58cfa82fe4b0c9d6adf6b8c6	TCGA-A5-A0GX-01A-11D-A043_120504_SN590_0156_BC0H68ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GX-01A	553F0CCD-4E6F-4AE2-9B39-97529EB3D826	Primary Tumor	Illumina HiSeq	cae767f1-aaee-4821-aa36-3ceb0b1756e8	Uterus	53.0	983A35A9-C825-4961-86C0-4C6133B5C9C1	FE0654FE-39AA-4993-8F36-768C7D829092	TCGA-A5-A0GX-01A-11D-A043-02	HG19_Broad_variant	TCGA-A5-A0GX	TCGA-UCEC		s4989	Harvard Medical School	Cedars Sinai	None	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C3	UCEC.CN_LOW	0.141398764	0.69	0.0	1.072099621	-1.1378	-0.348	-0.2959	0.5406	-0.8162	0.3931	16.0	1.0	0.241602917	0.936211303	61.0	0.029858481	0.0	3.0							2.6930270530000002	-215.3142048	-2173.227207	1384.770059	0.0	2088.0	0.0	2088.0	5.505992498758907	6.865891074883439	0.008457651127819932	4.809837797135007	6.2017314311967455	1.491851901702007	-0.6961547016239003	-0.6641596436866934	1.4833942505741873
13722.58cfa82fe4b0c9d6adf6b8c8	58cfa82fe4b0c9d6adf6b8c8	TCGA-A6-2681-01A-01D-1554-10_wgs_Illumina.filtered.	WGS	TCGA-A6-2681-01A-01D-1554-10_wgs_Illumina	TCGA-A6-2681-01A-01D-1554-10_wgs_Illumina.bam	308.0	1.9	0.05	58cfa82fe4b0c9d6adf6b8c8	TCGA-A6-2681-01A-01D-1554-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2681-01A	7D8EAB0A-E6C8-4449-9EBF-50C41DB94A06	Primary Tumor	Illumina HiSeq	11d59d80-a10a-4e78-b8a8-64a9569a9e32	Colorectal	73.0	0537BAD8-0E85-4B05-91B3-FD965E96D0D7	D3DAF373-1485-455E-A0A1-8E33D215D623	TCGA-A6-2681-01A-01D-1554-10	GRCh37-lite	TCGA-A6-2681	TCGA-COAD		s13650	Baylor College of Medicine	Christiana Healthcare	United States	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1554-10	False	COAD	C1	GI.CIN	0.158554139	0.28	0.52	6.232465795	0.2784	0.18	-0.0352	0.1826	-0.1314	0.44799999999999995	49.0	13.0			147.0	0.491324508	10.0	21.0							1.190940728	-574.9617732999999	-447.9774324	-353.9483236	0.0	1387.0	1.0	1150.0	6.993703591118502	7.018816547394226	-1.024922050423966	5.288955498880076	6.95668476628722	0.6914333840822104	-1.7047480922384255	-0.06213178110700568	1.7163554345061764
13722.58cfa82fe4b0c9d6adf6b8ca	58cfa82fe4b0c9d6adf6b8ca	TCGA-A4-A4ZT-01A-11D-A26P-10_wgs_Illumina.filtered.	WGS	TCGA-A4-A4ZT-01A-11D-A26P-10_wgs_Illumina	TCGA-A4-A4ZT-01A-11D-A26P-10_wgs_Illumina.bam	55.16		0.09	58cfa82fe4b0c9d6adf6b8ca	TCGA-A4-A4ZT-01A-11D-A26P-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-A4-A4ZT-01A	8B3C068D-5090-4030-8E7E-39DA005DEE79	Primary Tumor	Illumina HiSeq	90b348f5-ec38-4672-a60b-2bf4add19464	Kidney	71.0	460188E7-2A1E-4C3F-9C96-48C59A3FA9A0	483BB781-0179-42E1-BF9C-487B240769B8	TCGA-A4-A4ZT-01A-11D-A26P-10	GRCh37-lite	TCGA-A4-A4ZT	TCGA-KIRP		s11635	Baylor College of Medicine	International Genomics Consortium	United States	NO	T1b	NX	Kidney Papillary Renal Cell Carcinoma	Stage I	A26P-10	True	KIRP	C3	KIRP.C1	0.15759088599999999	0.18	0.06		-2.4867	-0.2655	0.0052	-0.2944	-0.3365	-0.3358	24.0	2.0	0.29425704199999997	1.177028166	45.0	0.947731338	12.0	0.0				2.094729048	9.0	0.9533522740000001	2.366762694	-1279.4877880000001	-1988.653079	323.98747599999996	0.0	516.0	0.0	516.0	6.961296045910166	2.945836425878011	-0.2006706954621511	5.203438128357792	2.2858414526349655	4.670155036077504	-1.7578579175523739	-0.6599949732430455	4.8708257315396555
13722.58cfa82fe4b0c9d6adf6b8d2	58cfa82fe4b0c9d6adf6b8d2	TCGA-61-2000-01A-01D-A324-10_wgs_Illumina.filtered.	WGS	TCGA-61-2000-01A-01D-A324-10_wgs_Illumina	TCGA-61-2000-01A-01D-A324-10_wgs_Illumina.bam	730.97	1.9	0.08	58cfa82fe4b0c9d6adf6b8d2	TCGA-61-2000-01A-01D-A324-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Ovarian Serous Cystadenocarcinoma	Aligned reads	TCGA-61-2000-01A	29949B65-2913-4C86-BBD7-B85C5DF6F15E	Primary Tumor	Illumina HiSeq	19381aa5-278b-49eb-87b8-c53fac7ee2e4	Ovary	67.0	FDB8966D-55C9-49BE-80DD-369246604AAD	B243ADB4-B3E7-4E0E-BC0D-625AA8DBB1BE	TCGA-61-2000-01A-01D-A324-10	GRCh37-lite	TCGA-61-2000	TCGA-OV		s17798	Baylor College of Medicine	University of Pittsburgh	None	NO			Serous Cystadenocarcinoma		A324-10	True	OV	C2	OVCA.Immunoreactive	0.051726456	0.08	0.09		0.7873	0.3435	-0.0031	-0.5024	0.9411	0.0567			0.666748566	2.000245697	846.0	0.382055729	5.0	43.0		0.0	1.0	3.5317065469999998	37.0	0.978063371	2.800464204	-1826.1052550000002	95.38785886	-2234.181873	0.0	441.0	1.0	339.0	5.969985515430857	3.310754564061198	0.423027778005469	2.8344912995017078	1.9861043660525146	1.9036963758988266	-3.1354942159291497	-1.3246501980086833	1.4806685978933576
13722.58cfa82fe4b0c9d6adf6b8d4	58cfa82fe4b0c9d6adf6b8d4	TCGA-50-5049-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_3_rg.sorted.filtered.	WGS	TCGA-50-5049-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_3_rg.sorted	TCGA-50-5049-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_3_rg.sorted.bam	743.7	1.9	0.16	58cfa82fe4b0c9d6adf6b8d4	TCGA-50-5049-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5049-01A	9944F46F-9FA8-4E2C-A806-776BEC7F8803	Primary Tumor	Illumina HiSeq	16ea05eb-f830-4b36-83bb-989c8de99568	Lung	70.0	21B2F32E-CCEA-4B20-86D3-6647E99825CF	26ED24EC-1AD1-492D-B2CB-46314B47919E	TCGA-50-5049-01A-01D-1623-02	HG19_Broad_variant	TCGA-50-5049	TCGA-LUAD		s11457	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1623-02	True	LUAD	C2	LUAD.6	0.568415873	0.74	0.49		0.017	0.1185	1.7417	2.8005	0.6184	0.3579	465.0	779.0	6.1515208260000005	21.92064782	132.0	0.469644302	14.0	26.0	0.718684765	4.0648751469999995	286.0	4.654619886	112.0	0.986462011	4.7147008360000005	543.5997721	-376.5524606	-463.12968600000005	0.0	3094.0	1.0	1568.0	7.517928376248827	7.991789601345416	-0.256449127375883	6.506327464570346	7.93772238007514	2.821755250734318	-1.0116009116784803	-0.054067221270275745	3.0782043781102013
13722.58cfa82fe4b0c9d6adf6b8d8	58cfa82fe4b0c9d6adf6b8d8	TCGA-A6-6781-01A-22D-1924-10_wgs_Illumina.filtered.	WGS	TCGA-A6-6781-01A-22D-1924-10_wgs_Illumina	TCGA-A6-6781-01A-22D-1924-10_wgs_Illumina.bam	190.3	1.9	0.05	58cfa82fe4b0c9d6adf6b8d8	TCGA-A6-6781-01A-22D-1924-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-6781-01A	B54865B6-824E-4163-B759-21A6EACC98CE	Primary Tumor	Illumina HiSeq	bee0f5f3-5654-4349-b3dd-afe0b89cc488	Colorectal	43.0	F1B2CA40-F20A-42DE-ABA2-4F730D7CCC09	2182CE2C-5941-4B65-9419-FC7966D5E6D5	TCGA-A6-6781-01A-22D-1924-10	GRCh37-lite	TCGA-A6-6781	TCGA-COAD		s13354	Baylor College of Medicine	Christiana Healthcare	United States	NO	T4b	N1b	Colon Mucinous Adenocarcinoma	Stage IIIC	1924-10	False	COAD	C1		0.44507442399999997	0.5	0.02		0.33799999999999997	0.1065	0.7452	0.6659999999999999	0.1932	0.884	437.0	1516.0	15.64698589	45.66164436	39.0	0.000147524	0.0	0.0	0.877555715	3.258866392	41.0	3.193148395	25.0	0.992007324	1.690261411	-831.2414569	213.2778568	2422.823532	0.0	598.0	0.0	598.0	6.978912473298465	4.454896869587362	-1.2672296474552571	5.750247056382157	7.267707951561516	2.2381047943245416	-1.2286654169163076	2.8128110819741545	3.5053344417797985
13722.58cfa82fe4b0c9d6adf6b8d9	58cfa82fe4b0c9d6adf6b8d9	TCGA-50-5055-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_5_rg.sorted.filtered.	WGS	TCGA-50-5055-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_5_rg.sorted	TCGA-50-5055-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_5_rg.sorted.bam	853.7	1.9	0.17	58cfa82fe4b0c9d6adf6b8d9	TCGA-50-5055-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5055-01A	CC3D9750-7CE0-489F-86D4-8017B7EBED29	Primary Tumor	Illumina HiSeq	97723d64-755b-4f00-b641-95ad083c397e	Lung	79.0	68D19E88-7FBD-48CC-A09F-55C47BFAF6E7	323E338B-1BA7-49E2-811B-C1FEE673A926	TCGA-50-5055-01A-01D-1623-02	HG19_Broad_variant	TCGA-50-5055	TCGA-LUAD		s11008	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N1	Lung Adenocarcinoma Mixed Subtype	Stage IIA	1623-02	True	LUAD	C2	LUAD.6	0.6179358939999999	0.87	0.18	15.64200601	-0.4041	0.0665	1.4269	3.1334	0.8607	0.441	17.0	5.0	0.030094961	0.57180426	96.0	0.037694366	1.0	2.0	0.967225452	3.4660707239999997	36.0	4.438814863	88.0	0.991396235	3.383425111	129.2780956	-968.7327696000001	45.44032255	1.0	1830.0	1.0	771.0	6.823772803059816	8.070755215338025	-0.16205382522851863	7.20326242476472	8.004063840839354	0.8986228801598237	0.3794896217049035	-0.06669137449867213	1.0606767053883424
13722.58cfa82fe4b0c9d6adf6b8de	58cfa82fe4b0c9d6adf6b8de	TCGA-A7-A0D9-01A-31D-A060_130807_SN590_0235_AC29RAACXX_s_5_rg.sorted.filtered.	WGS	TCGA-A7-A0D9-01A-31D-A060_130807_SN590_0235_AC29RAACXX_s_5_rg.sorted	TCGA-A7-A0D9-01A-31D-A060_130807_SN590_0235_AC29RAACXX_s_5_rg.sorted.bam	59.5	2.02	0.17	58cfa82fe4b0c9d6adf6b8de	TCGA-A7-A0D9-01A-31D-A060_130807_SN590_0235_AC29RAACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-A7-A0D9-01A	17BAEF7C-D97D-4B98-AB53-503EF856523D	Primary Tumor	Illumina HiSeq	43dc32db-2202-486d-82f4-388e37224379	Breast	37.0	C144AE50-ED29-4E27-BBEE-FA81E79AC7DB	7CD9AC40-F6B5-4C68-9D9A-D57845B812DB	TCGA-A7-A0D9-01A-31D-A060-02	HG19_Broad_variant	TCGA-A7-A0D9	TCGA-BRCA		s5638	Harvard Medical School	Christiana Healthcare	None	NO	T2	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IIA	A060-02	True	BRCA	C1	BRCA.Normal	0.061319279000000004	0.2	0.01	2.399320084	-0.6477	-0.086	-0.7559	-1.2619	-0.9596	0.3222	9.0		0.23806566399999998	0.565405952	251.0	0.187991722	7.0	16.0				1.609437912	5.0	1.0	1.81523756	-515.8217777	623.8602628	347.3096347	0.0	1139.0	0.0	1139.0	6.542471960506805	6.69346134294491	-0.31949017964800674	4.29118016190031	6.25162859066587		-2.251291798606495	-0.4418327522790393	
13722.58cfa82fe4b0c9d6adf6b8e1	58cfa82fe4b0c9d6adf6b8e1	TCGA-A6-A56B-01A-31D-A28G-10_wgs_Illumina.filtered.	WGS	TCGA-A6-A56B-01A-31D-A28G-10_wgs_Illumina	TCGA-A6-A56B-01A-31D-A28G-10_wgs_Illumina.bam	38.26		0.08	58cfa82fe4b0c9d6adf6b8e1	TCGA-A6-A56B-01A-31D-A28G-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-A56B-01A	74A0264D-1D31-430D-9A88-E7334C8AA96C	Primary Tumor	Illumina HiSeq	319d9aec-3e76-4b48-b4a8-9ffcb0f3acc4	Colorectal	57.0	4425892C-8C35-4F6C-B531-1EC510AD19D2	D3D65DB3-36F9-41C7-8E5E-1683CE94DFCB	TCGA-A6-A56B-01A-31D-A28G-10	GRCh37-lite	TCGA-A6-A56B	TCGA-COAD		s13353	Baylor College of Medicine	Christiana Healthcare	United States	NO	T3	N1	Colon Adenocarcinoma	Stage IIIB	A28G-10	True	COAD	C1	GI.CIN	0.091189779	0.28	0.08	6.5417064179999995	0.5549	0.0865	-0.8104	-1.7011	-1.3032	0.1542	53.0	90.0	0.824496109	2.207521841	289.0	0.458034024	10.0	36.0				0.0	1.0		0.84389422	-1505.85931	-110.5615	-2877.532127	1.0	1711.0	1.0	1678.0	7.838080399820094	3.8702820851509	-1.429969424622552	5.8921702507647815	4.052202920641156	0.7126097296348572	-1.9459101490553132	0.1819208354902555	2.1425791542574095
13722.58cfa82fe4b0c9d6adf6b8e2	58cfa82fe4b0c9d6adf6b8e2	TCGA-A7-A26F-01B-04D-A22S_120816_SN1222_0144_AD16PUACXX_s_1_rg.sorted.filtered.	WGS	TCGA-A7-A26F-01B-04D-A22S_120816_SN1222_0144_AD16PUACXX_s_1_rg.sorted	TCGA-A7-A26F-01B-04D-A22S_120816_SN1222_0144_AD16PUACXX_s_1_rg.sorted.bam	8.32		0.14	58cfa82fe4b0c9d6adf6b8e2	TCGA-A7-A26F-01B-04D-A22S_120816_SN1222_0144_AD16PUACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-A7-A26F-01B	3B7B9C1E-A84C-47ED-983C-9E4B00CBF01A	Primary Tumor	Illumina HiSeq	4925c013-4605-47d0-9c97-2e8a69233aa4	Breast	55.0	29619D1E-E8B4-411E-BBBA-07F2CFB69E8A	A723DE1E-A9E0-487D-8D86-7AA4A062A1C2	TCGA-A7-A26F-01B-04D-A22S-26	HG19_Broad_variant	TCGA-A7-A26F	TCGA-BRCA		s6916	MD Anderson - Institute for Applied Cancer Science	Christiana Healthcare	United States	YES	T1	N0	Other  specify	Stage IA	A22S-26	False	BRCA	C2	BRCA.Basal	0.27558046199999997	0.54	0.57	3.895528995	0.5988	0.0945	0.5889	0.5332	1.6194	0.6404	10.0	8.0	0.340757222	0.908685924	80.0	0.428884304	7.0	25.0	0.897735897	3.911173905	78.0	3.8971255460000003	51.0	0.9911745609999999	2.500544692	-174.078723	1020.309576	247.5168622	0.0	738.0	0.0	738.0	5.702823110503951	7.7409361041332865	-0.05254146555951489	4.747215875448184	5.993912528746622	3.093564522791026	-0.9556072350557674	-1.747023575386664	3.1461059883505404
13722.58cfa82fe4b0c9d6adf6b8e8	58cfa82fe4b0c9d6adf6b8e8	TCGA-AA-3510-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3510-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3510-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	346.0	1.9	0.13	58cfa82fe4b0c9d6adf6b8e8	TCGA-AA-3510-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3510-01A	35C295C2-37D1-44B2-87A3-1039645E5BAE	Primary Tumor	Illumina HiSeq	0bb810fb-0134-4ea2-a821-41bbbdbd9155	Colorectal	70.0	C71C031C-3089-44E5-A49F-5284D7D300CE	DA2A173C-BBD3-4A90-8D1D-CD35CBE750F3	TCGA-AA-3510-01A-01D-1405-02	HG18	TCGA-AA-3510	TCGA-COAD		s13666	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage II	1405-02	True	COAD	C1	GI.HM-SNV	0.21661485600000002	0.42	0.0		0.7233	0.313	-0.0243	0.4139	-0.6395	-0.0585	1721.0	13.0	20.0772658	79.28818528	79.0	0.00017837599999999997	0.0	0.0							0.629773488	-1006.8835359999999	139.53815480000003	1417.00891	0.0	1946.0	0.0	1946.0	6.114992366721257	6.600201754510521	-0.1149964096493179	5.299955368552275	9.010145365825066	2.169221424631231	-0.8150369981689822	2.409943611314545	2.2842178342805486
13722.58cfa82fe4b0c9d6adf6b8f2	58cfa82fe4b0c9d6adf6b8f2	TCGA-50-5932-01A-11D-1751_111007_SN590_0110_C003AACXX_s_6_rg.sorted.filtered.	WGS	TCGA-50-5932-01A-11D-1751_111007_SN590_0110_C003AACXX_s_6_rg.sorted	TCGA-50-5932-01A-11D-1751_111007_SN590_0110_C003AACXX_s_6_rg.sorted.bam	289.4	1.9	0.15	58cfa82fe4b0c9d6adf6b8f2	TCGA-50-5932-01A-11D-1751_111007_SN590_0110_C003AACXX_s_6_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5932-01A	EBCBA7F2-CE13-4BAE-97CD-91A6B1DCD465	Primary Tumor	Illumina HiSeq	a1be116a-f392-49b3-97c6-b674ac8dee93	Lung	75.0	7ECB9621-7A1F-4876-9DFB-9B77CC4CB7B4	B9ACEF1D-8029-47AB-9830-06B2FF147CDB	TCGA-50-5932-01A-11D-1751-02	HG19_Broad_variant	TCGA-50-5932	TCGA-LUAD	1235.0	s10661	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIB	1751-02	True	LUAD	C3	LUAD.1	0.080095786	0.16	0.08		-0.5204	-0.203	-0.1375	-0.2734	0.0707	-0.1919	45.0	257.0	0.493176974	2.0960021380000002	175.0	0.9471979620000001	9.0	25.0	0.850339445	2.628435323	22.0	2.397895273	11.0	1.0	1.932722085	-537.3001275	-833.4665190000001	4168.601715999999	1.0	1235.0	1.0	1090.0	7.628656583012436	6.356904246797758	-0.367151418490437	6.07805917060127	7.209681572949588	3.206778405392974	-1.550597412411167	0.8527773261518292	3.5739298238834114
13722.58cfa82fe4b0c9d6adf6b8fa	58cfa82fe4b0c9d6adf6b8fa	TCGA-AA-3518-01A-02D-1525-10_hg19_wgs_Illumina.filtered.	WGS	TCGA-AA-3518-01A-02D-1525-10_hg19_wgs_Illumina	TCGA-AA-3518-01A-02D-1525-10_hg19_wgs_Illumina.bam	3.86	1.9	0.05	58cfa82fe4b0c9d6adf6b8fa	TCGA-AA-3518-01A-02D-1525-10_hg19_wgs_Illumina.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3518-01A	C5C4A0A5-900D-483D-9282-475654D63265	Primary Tumor	Illumina HiSeq	e3929c47-b19b-4c57-9990-6448eb979647	Colorectal	81.0	BC08B757-ED0A-44C0-88CD-85496BB72A75	F4B9D98F-7B76-4EAA-9595-10B0973D5FF7	TCGA-AA-3518-01A-02D-1525-10	GRCh37-lite	TCGA-AA-3518	TCGA-COAD		s13663	Baylor College of Medicine	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1525-10	True	COAD	C1		0.13858648099999998			9.680869515	0.9129999999999999	0.317	-0.0384	0.5628	-0.0086	-0.0856					126.0	0.002637618	0.0	0.0	0.944506849	2.557771962	15.0				0.9818750759999999	-627.3481011	572.3954312000001	121.26900570000001	0.0	31.0	0.0	31.0	4.1566077695225365	-0.3163693811493662	-0.7162443371628529	4.292739943847117	2.903272433798416	2.2026068920551802	0.13613217432458002	3.2196418149477823	2.918851229218033
13722.58cfa82fe4b0c9d6adf6b8fb	58cfa82fe4b0c9d6adf6b8fb	TCGA-AA-3518-01A-02D-1525-10_Illumina.filtered.	WGS	TCGA-AA-3518-01A-02D-1525-10_Illumina	TCGA-AA-3518-01A-02D-1525-10_Illumina.bam	3.86	1.9	0.05	58cfa82fe4b0c9d6adf6b8fb	TCGA-AA-3518-01A-02D-1525-10_Illumina.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3518-01A	C5C4A0A5-900D-483D-9282-475654D63265	Primary Tumor	Illumina HiSeq	7d2638fc-9574-4f2a-baf2-495e6ba99e93	Colorectal	81.0	BC08B757-ED0A-44C0-88CD-85496BB72A75	F4B9D98F-7B76-4EAA-9595-10B0973D5FF7	TCGA-AA-3518-01A-02D-1525-10	NCBI36_BCM_variant	TCGA-AA-3518	TCGA-COAD		s13027	Baylor College of Medicine	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1525-10	True	COAD	C1		0.13858648099999998			9.680869515	0.9129999999999999	0.317	-0.0384	0.5628	-0.0086	-0.0856					126.0	0.002637618	0.0	0.0	0.944506849	2.557771962	15.0				0.9818750759999999	-627.3481011	572.3954312000001	121.26900570000001	0.0	31.0	0.0	31.0	5.000584958242754	-0.706593641780028	-0.7162443371628529	4.425220813339193	2.451708580378404	2.2026068920551802	-0.575364144903562	3.158302222158432	2.918851229218033
13722.58cfa82fe4b0c9d6adf6b8fe	58cfa82fe4b0c9d6adf6b8fe	TCGA-49-6744-01A-11D-1853_111218_SN208_0258_C054RACXX_s_5_rg.sorted.filtered.	WGS	TCGA-49-6744-01A-11D-1853_111218_SN208_0258_C054RACXX_s_5_rg.sorted	TCGA-49-6744-01A-11D-1853_111218_SN208_0258_C054RACXX_s_5_rg.sorted.bam	62.7	1.9	0.15	58cfa82fe4b0c9d6adf6b8fe	TCGA-49-6744-01A-11D-1853_111218_SN208_0258_C054RACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE		Lung Adenocarcinoma	Aligned reads	TCGA-49-6744-01A	15340DD3-84AE-49FB-989A-EB212F3E73DA	Primary Tumor	Illumina HiSeq	8290093a-0193-41fa-8e87-71960e0e640e	Lung	64.0	A9D69D7E-298C-4AB6-B64F-1EDC58832CCD	7455D0A5-45DB-461F-9026-5A0FE3D55A6A	TCGA-49-6744-01A-11D-1853-02	HG19_Broad_variant	TCGA-49-6744	TCGA-LUAD		s10656	Harvard Medical School	Johns Hopkins	United States	NO	T2a	N1	Lung Adenocarcinoma Mixed Subtype	Stage IIA	1853-02	True	LUAD	C2	LUAD.5	0.44227676899999996	0.63	0.57	12.88451397	-0.4994	-0.0635	1.176	1.9612	1.1316	0.5446	121.0	92.0	1.7370548780000001	6.006088054	145.0	0.43959410600000004	4.0	26.0							2.595987015	447.69177069999995	-440.64682410000006	3430.434145	0.0	1683.0	0.0	1683.0	6.69601702749594	6.922788766521415	-0.07320340402329495	5.891644211825771	6.642486801367257	1.6903851882380638	-0.8043728156701695	-0.28030196515415806	1.7635885922613588
13722.58cfa82fe4b0c9d6adf6b904	58cfa82fe4b0c9d6adf6b904	TCGA-49-4512-01A-21D-1853_120123_SN590_0134_AC0DJKACXX_s_6_rg.sorted.filtered.	WGS	TCGA-49-4512-01A-21D-1853_120123_SN590_0134_AC0DJKACXX_s_6_rg.sorted	TCGA-49-4512-01A-21D-1853_120123_SN590_0134_AC0DJKACXX_s_6_rg.sorted.bam	180.7	1.9	0.15	58cfa82fe4b0c9d6adf6b904	TCGA-49-4512-01A-21D-1853_120123_SN590_0134_AC0DJKACXX_s_6_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-49-4512-01A	A1E65587-24C1-4B41-92A7-4E1F15FFFD78	Primary Tumor	Illumina HiSeq	bfba789d-2b84-4c34-89f9-7a38586facf6	Lung	69.0	D809A778-D1AC-4406-AB09-67CC70F1F0C2	6D2569C8-4E18-423B-852D-315DDC3AE2F7	TCGA-49-4512-01A-21D-1853-02	HG19_Broad_variant	TCGA-49-4512	TCGA-LUAD	905.0	s10780	Harvard Medical School	Johns Hopkins	United States	NO	T2	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1853-02	True	LUAD	C6	LUAD.5	0.26382911600000003	0.68	0.24	3.1995179410000003	-0.5056	-0.057999999999999996	0.6702	0.5388	0.21100000000000002	0.4196	19.0	8.0	0.40609450399999997	0.928216009	172.0	0.459929696	27.0	25.0	0.597828221	0.41438294600000003	2.0	2.13833306	9.0	0.973197315	2.64112082	-64.61513789	-1483.7952089999999	-1293.443142	1.0	905.0	1.0	905.0	6.113336434228399	7.743351007150615	0.2669986225626447	5.468198472854815	7.148643899403922	2.479557563898971	-0.6451379613735848	-0.594707107746693	2.2125589413363262
13722.58cfa82fe4b0c9d6adf6b909	58cfa82fe4b0c9d6adf6b909	TCGA-A3-3387-01A-01D-2102-10_Illumina.filtered.	WGS	TCGA-A3-3387-01A-01D-2102-10_Illumina	TCGA-A3-3387-01A-01D-2102-10_Illumina.bam	180.4	1.9	0.14	58cfa82fe4b0c9d6adf6b909	TCGA-A3-3387-01A-01D-2102-10_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-A3-3387-01A	9DC7812B-C7A2-4DE4-BF6D-4C7261384A62	Primary Tumor	Illumina HiSeq	1abe0bf3-83d3-40d9-8e12-5729d760aeed	Kidney	49.0	413ED4FA-013A-4751-8F74-D54F6CF992C9	00BF0350-8C7C-4B9E-8143-13EA2DC1122F	TCGA-A3-3387-01A-01D-2102-10	GRCh37-lite	TCGA-A3-3387	TCGA-KIRC		s9302	Baylor College of Medicine	International Genomics Consortium	United States	NO	T1a	N0	Kidney Clear Cell Renal Carcinoma	Stage I	2102-10	False	KIRC	C3	KIRC.3	0.302846475	0.47	0.29		-0.5883	-0.1615	1.1199	0.6511	0.1999	0.3415	44.0	43.0	0.541467051	2.1057051980000003	69.0	0.302369691	2.0	4.0	0.7894477940000001	1.0944070259999998	4.0	3.536954686	37.0	0.97951678	2.199461683	237.7434518	-591.0429382	589.3058363	0.0	617.0	0.0	617.0	5.825672292265237	3.3893042781482032	-0.05621516585301922	4.887402653672307	4.326753235529704	3.2889467667138117	-0.9382696385929301	0.937448957381501	3.345161932566831
13722.58cfa82fe4b0c9d6adf6b90e	58cfa82fe4b0c9d6adf6b90e	TCGA-49-4507-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-49-4507-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-49-4507-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	289.2	1.9	0.14	58cfa82fe4b0c9d6adf6b90e	TCGA-49-4507-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-49-4507-01A	50B2C647-AECD-4C81-AF22-0D8116593552	Primary Tumor	Illumina HiSeq	557606c6-d245-45ba-b9f0-adc05c6a5f4f	Lung	73.0	962F85FF-1F27-49E4-8C3D-798FACEA122F	EF299B98-6A9F-4022-8683-A9C830E7263C	TCGA-49-4507-01A-01D-1203-02	GRCh37	TCGA-49-4507	TCGA-LUAD	268.0	s11453	Harvard Medical School	Johns Hopkins	United States	NO	T3	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1203-02	True	LUAD	C2	LUAD.6	0.438484992	0.65	0.25	11.45848763	0.5781	0.466	0.6189	1.9869999999999999	0.4011	0.1309	68.0	11.0	1.422722768	5.009169745	280.0	0.554587909	8.0	42.0	0.8463634109999999	3.258624058	47.0	3.2231488710000002	36.0	0.899436818	2.500579986	-568.9986852999999	-238.06379180000002	1373.038225	1.0	268.0	1.0	158.0	7.841127853337296	7.466139539668314	0.52148403187595	6.6959955490342935	6.772992359108368	1.283444009191347	-1.1451323043030026	-0.6931471805599454	0.7619599773153969
13722.58cfa82fe4b0c9d6adf6b912	58cfa82fe4b0c9d6adf6b912	TCGA-49-4506-01A-01D-1203_110729_SN208_0215_BD0CLPABXX_s_7_rg.sorted.filtered.	WGS	TCGA-49-4506-01A-01D-1203_110729_SN208_0215_BD0CLPABXX_s_7_rg.sorted	TCGA-49-4506-01A-01D-1203_110729_SN208_0215_BD0CLPABXX_s_7_rg.sorted.bam	258.2	1.9	0.13	58cfa82fe4b0c9d6adf6b912	TCGA-49-4506-01A-01D-1203_110729_SN208_0215_BD0CLPABXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-49-4506-01A	B61ABDFD-B7A0-4E1A-B570-D1EAECAD3A9E	Primary Tumor	Illumina HiSeq	b07f7ea8-c74b-4559-97d3-987f1985f2e9	Lung	68.0	9EDEA53D-AD06-4B5D-BFF0-48E834C3684F	2270ABD6-565B-46B6-8154-505C5659A7C3	TCGA-49-4506-01A-01D-1203-02	HG19_Broad_variant	TCGA-49-4506	TCGA-LUAD	999.0	s11234	Harvard Medical School	Johns Hopkins	United States	NO	T2	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIB	1203-02	True	LUAD	C2	LUAD.6	0.587712484	0.75	0.02	6.709587989	0.3451	0.3275	0.528	1.9721	0.1606	-0.2181	36.0	6.0	0.881189173	3.1905125219999997	117.0	0.310806578	16.0	9.0	0.827197443	3.071857317	41.0	2.7303695119999998	32.0	0.787818111	1.661637878	-969.5455636	-172.5153813	2715.791879	1.0	999.0	1.0	692.0	8.612543774444745	6.9447006782982825	1.1128441715763342	7.048568236087403	6.251553497738337	1.7464975562124077	-1.5639755383573428	-0.693147180559945	0.6336533846360735
13722.58cfa82fe4b0c9d6adf6b914	58cfa82fe4b0c9d6adf6b914	TCGA-49-4505-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-49-4505-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-49-4505-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	129.53	1.9	0.14	58cfa82fe4b0c9d6adf6b914	TCGA-49-4505-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-49-4505-01A	088EDF89-D2B5-40C7-B066-DF3BD383F7EA	Primary Tumor	Illumina HiSeq	af550be6-0986-458b-8206-9c7cf928c215	Lung	61.0	D1FB0862-8D9C-4BC4-AAC6-81DC4EED66C9	30B77A0C-3439-44E2-A586-5DF68C0D0002	TCGA-49-4505-01A-01D-1203-02	GRCh37	TCGA-49-4505	TCGA-LUAD	428.0	s11125	Harvard Medical School	Johns Hopkins	United States	NO	T2	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIB	1203-02	True	LUAD	C2	LUAD.3	0.288164733	0.55	0.51	4.537675568	-0.9028	0.1075	0.9440000000000001	1.5631	0.8547	0.4168	93.0	140.0	1.860869603	5.103293911000001	207.0	0.589915074	20.0	30.0	0.9265155190000001	3.5061104210000003	44.0	3.786768215	50.0	0.9679820920000001	2.903570849	393.9044915	-1625.359227	1529.769771	1.0	428.0	1.0	417.0	7.994564855531094	8.153493632540542	0.3431475052037266	6.559480330241772	6.767199271420651	1.9035209016229053	-1.4350845252893227	-1.3862943611198908	1.5603733964191786
13722.58cfa82fe4b0c9d6adf6b920	58cfa82fe4b0c9d6adf6b920	TCGA-A4-A48D-01A-11D-A25F-10_wgs_Illumina.filtered.	WGS	TCGA-A4-A48D-01A-11D-A25F-10_wgs_Illumina	TCGA-A4-A48D-01A-11D-A25F-10_wgs_Illumina.bam	21.0		0.08	58cfa82fe4b0c9d6adf6b920	TCGA-A4-A48D-01A-11D-A25F-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-A4-A48D-01A	925AE8FF-3200-4564-BE76-94DB0984B027	Primary Tumor	Illumina HiSeq	ca65f407-1de9-4171-8ae5-67e4d85f5beb	Kidney	84.0	4DDC37D4-35B8-4A5D-BBF1-6DBF0548852B	5ECC88F7-8391-4168-AF11-07A6BF9B3652	TCGA-A4-A48D-01A-11D-A25F-10	GRCh37-lite	TCGA-A4-A48D	TCGA-KIRP		s11850	Baylor College of Medicine	International Genomics Consortium	United States	NO	T1b	NX	Kidney Papillary Renal Cell Carcinoma	Stage I	A25F-10	True	KIRP	C3	KIRP.C2a	0.417446693	0.07	0.1		-2.1533	-0.272	0.7165	-0.1989	-0.1516	-0.6146	29.0	75.0	0.905868053	2.0781678869999998	69.0	0.15974746199999998	6.0	0.0				2.48490665	12.0	1.0	1.370946067	-886.7344701999999	-2311.0859809999997	1316.386322	0.0	379.0	0.0	379.0	7.428399211685465	0.4739550879576644	0.37224941880425644	4.478129312208232	4.243987744029163	5.639370929583813	-2.9502698994772336	3.770032656071499	5.267121510779556
13722.58cfa82fe4b0c9d6adf6b92a	58cfa82fe4b0c9d6adf6b92a	TCGA-91-6828-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_3_rg.sorted.filtered.	WGS	TCGA-91-6828-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_3_rg.sorted	TCGA-91-6828-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_3_rg.sorted.bam	349.7	1.9	0.14	58cfa82fe4b0c9d6adf6b92a	TCGA-91-6828-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-91-6828-01A	9536E32D-2707-48D2-A36D-08C521665BB9	Primary Tumor	Illumina HiSeq	94e2b6af-1f25-4698-9414-f3d916d26aee	Lung	70.0	CFE0F0E4-D8BF-40CE-99F1-2BF99CECA18B	2C0D4A9F-857D-4C6F-B616-304AB5922A2F	TCGA-91-6828-01A-11D-1853-02	HG19_Broad_variant	TCGA-91-6828	TCGA-LUAD		s10802	Harvard Medical School	ABS - IUPUI	United States	NO	T1a	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1853-02	True	LUAD	C3	LUAD.3	0.295857012	0.63	0.5		-0.172	-0.209	1.0955	1.3453	-0.2616	0.0634	81.0	129.0	1.5688076869999998	7.379206529	127.0	0.522942636	26.0	22.0	0.8521463979999999	3.834496604	90.0	3.065964512	23.0	0.977824962	1.298475289	-98.20389184	-187.4588777	1640.948658	0.0	323.0	0.0	323.0	7.122098314343074	8.51299391057468	0.22950725232635505	5.876161310918105	7.946598435653879	2.3161207109535664	-1.245937003424968	-0.5663954749208013	2.086613458627211
13722.58cfa82fe4b0c9d6adf6b92e	58cfa82fe4b0c9d6adf6b92e	TCGA-A4-A57E-01A-11D-A26P-10_wgs_Illumina.filtered.	WGS	TCGA-A4-A57E-01A-11D-A26P-10_wgs_Illumina	TCGA-A4-A57E-01A-11D-A26P-10_wgs_Illumina.bam	37.08		0.08	58cfa82fe4b0c9d6adf6b92e	TCGA-A4-A57E-01A-11D-A26P-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-A4-A57E-01A	D80F601B-1064-4FF0-9C51-7F6AFB22D1F5	Primary Tumor	Illumina HiSeq	8e29468f-f3dd-48a6-9c1a-3bd0083bae2d	Kidney	59.0	341EA198-C8A2-4675-8077-2C450E9925E1	2DEB8F9A-9E0A-46D1-BCB5-902DB3B5C8AC	TCGA-A4-A57E-01A-11D-A26P-10	GRCh37-lite	TCGA-A4-A57E	TCGA-KIRP		s11637	Baylor College of Medicine	International Genomics Consortium	United States	NO	T2a	N0	Kidney Papillary Renal Cell Carcinoma	Stage IV	A26P-10	True	KIRP	C4	KIRP.C2a	0.10822426800000001	0.17	0.07		-0.0827	0.095	-0.0461	-1.4089	-0.3763	-0.4503	35.0	24.0	0.58020551	1.74061653	98.0	0.41656350299999995	15.0	16.0		0.0	1.0	0.0	1.0		1.975459813	-653.4441404	-1175.54226	-679.4684484	1.0	258.0	1.0	258.0	7.750471229864229	4.39989446909521	-1.0521545670735661	5.671029688184394	3.9681351204543596	2.793208009442517	-2.079441541679836	-0.43175934864085086	3.845362576516083
13722.58cfa82fe4b0c9d6adf6b940	58cfa82fe4b0c9d6adf6b940	TCGA-A6-3808-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-3808-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-3808-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	236.0	1.9	0.14	58cfa82fe4b0c9d6adf6b940	TCGA-A6-3808-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-3808-01A	4F9775F2-B663-4DAF-AA9E-50915CAE9407	Primary Tumor	Illumina HiSeq	58504a37-4eb0-44ec-bb5d-83e955521de2	Colorectal	73.0	037BA047-2228-43DE-8DF8-32920A689ECA	2B2625B5-FBDD-41C3-9BB3-71566C5FBBA4	TCGA-A6-3808-01A-01D-1167-02	HG18	TCGA-A6-3808	TCGA-COAD		s13173	Harvard Medical School	Christiana Healthcare	None	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1167-02	True	COAD	C1		0.291840623			4.309410234	0.7144	0.335	0.3421	0.5654	-0.018000000000000002	0.3559	72.0	14.0													1.4630763969999998	-87.16627546	525.9417179999999	-1321.568276	0.0	1014.0	0.0	1014.0	6.315874530459439	6.7424762413670365	0.009452519949087579	5.894661065383135	6.385801297428303	1.1906007770842426	-0.42121346507630353	-0.35667494393873245	1.1811482571351548
13722.58cfa82fe4b0c9d6adf6b942	58cfa82fe4b0c9d6adf6b942	TCGA-A5-A0GN-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-A5-A0GN-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_3_rg.sorted	TCGA-A5-A0GN-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_3_rg.sorted.bam	65.96	1.81	0.16	58cfa82fe4b0c9d6adf6b942	TCGA-A5-A0GN-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GN-01A	A2A2DBDA-D10C-49C4-86A8-61BAF6160CDA	Primary Tumor	Illumina HiSeq	7270b44f-635f-48bf-b3c4-8042b4557613	Uterus	65.0	F6F9C40B-1E58-47A3-B518-9694FB5FF2CF	41896FDE-677E-419C-B8B9-0171D6669A4A	TCGA-A5-A0GN-01A-11D-A043-02	HG19_Broad_variant	TCGA-A5-A0GN	TCGA-UCEC		s4589	Harvard Medical School	Cedars Sinai	None	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C3	UCEC.CN_HIGH	0.130554428	0.13	0.3	6.88849788	-0.3402	-0.106	0.1014	1.0135	-0.4287	0.07400000000000001	33.0	2.0	0.366305566	1.52627319	76.0	0.947197958	20.0	1.0							2.550379603	-815.8845193	-551.7319511	3039.056584	0.0	1841.0	0.0	1841.0	5.783956106655665	6.789572163304413	-1.4403045893433024	5.191452451875406	5.668980967917529	1.6520210670654654	-0.5925036547802582	-1.120591195386885	3.092325656408768
13722.58cfa82fe4b0c9d6adf6b952	58cfa82fe4b0c9d6adf6b952	TCGA-AA-3534-01A-01D-1525-10_hg19_wgs_Illumina.filtered.	WGS	TCGA-AA-3534-01A-01D-1525-10_hg19_wgs_Illumina	TCGA-AA-3534-01A-01D-1525-10_hg19_wgs_Illumina.bam	84.63	1.9	0.05	58cfa82fe4b0c9d6adf6b952	TCGA-AA-3534-01A-01D-1525-10_hg19_wgs_Illumina.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3534-01A	DF228C56-89AC-4122-93B3-6C0740C4EC09	Primary Tumor	Illumina HiSeq	6e533853-5822-49cf-95a8-d75c517521cc	Colorectal	78.0	ECADE2C1-9DE2-4B05-B30C-4C8B81C65AE1	66701395-5A53-41BB-866B-3BBF08BC33AB	TCGA-AA-3534-01A-01D-1525-10	GRCh37-lite	TCGA-AA-3534	TCGA-COAD		s12861	Baylor College of Medicine	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1525-10	True	COAD	C1		0.08197274	0.22	0.0	23.41939986	0.9011	0.22399999999999998	-0.5037	-0.115	-1.0331	0.0745			1.795578307	3.2646878310000003	99.0	0.9477267359999999	14.0	4.0	0.940405191	4.2824894680000005	95.0				0.464430175	-1340.0334599999999	801.9235239	-1860.630959	0.0	882.0	0.0	882.0	2.951867459907052	3.1250064572787615	-0.6931471805599452	3.932696712918778	5.175226149745926	0.8985612678965857	0.9808292530117262	2.0502196924671647	1.591708448456531
13722.58cfa82fe4b0c9d6adf6b958	58cfa82fe4b0c9d6adf6b958	TCGA-AA-3534-01A-01D-1525-10_Illumina.filtered.	WGS	TCGA-AA-3534-01A-01D-1525-10_Illumina	TCGA-AA-3534-01A-01D-1525-10_Illumina.bam	84.63	1.9	0.05	58cfa82fe4b0c9d6adf6b958	TCGA-AA-3534-01A-01D-1525-10_Illumina.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3534-01A	DF228C56-89AC-4122-93B3-6C0740C4EC09	Primary Tumor	Illumina HiSeq	a3cf0d96-684b-4e42-ac5f-e1e6813123de	Colorectal	78.0	ECADE2C1-9DE2-4B05-B30C-4C8B81C65AE1	66701395-5A53-41BB-866B-3BBF08BC33AB	TCGA-AA-3534-01A-01D-1525-10	NCBI36_BCM_variant	TCGA-AA-3534	TCGA-COAD		s13509	Baylor College of Medicine	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1525-10	True	COAD	C1		0.08197274	0.22	0.0	23.41939986	0.9011	0.22399999999999998	-0.5037	-0.115	-1.0331	0.0745			1.795578307	3.2646878310000003	99.0	0.9477267359999999	14.0	4.0	0.940405191	4.2824894680000005	95.0				0.464430175	-1340.0334599999999	801.9235239	-1860.630959	0.0	882.0	0.0	882.0	2.766625501892668	2.9362839900371345	-0.6931471805599452	3.883973701618247	5.216637977452268	0.8985612678965857	1.117348199725579	2.2803539874151335	1.591708448456531
13722.58cfa82fe4b0c9d6adf6b95e	58cfa82fe4b0c9d6adf6b95e	TCGA-AA-3548-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3548-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3548-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	628.56	1.9	0.16	58cfa82fe4b0c9d6adf6b95e	TCGA-AA-3548-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3548-01A	2DCED66C-1F0D-4039-A5E5-54CCA77C16E9	Primary Tumor	Illumina HiSeq	362e7b19-891a-4eba-9cba-97d157a94152	Colorectal	71.0	633AFC4C-4A35-420E-9CE6-FF4670E28395	B5E87744-9963-4DBA-84C8-B61048169517	TCGA-AA-3548-01A-01D-1167-02	HG18	TCGA-AA-3548	TCGA-COAD		s13669	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Colon Adenocarcinoma	Stage IIIC	1167-02	True	COAD	C1		0.13228705699999999	0.38	0.19	35.63125032	0.5993	0.294	-0.2031	0.8792	0.068	-0.0578			1.328452819	2.8229622410000004	67.0	0.435416588	12.0	9.0							0.727827566	-1375.781526	-117.2580268	83.02855327	0.0	1034.0	0.0	1034.0	6.753029433778982	4.60065619645575	0.11849771746857907	5.17405072882959	4.831462620515529	2.4940138202370896	-1.578978704949392	0.2308064240597787	2.3755161027685103
13722.58cfa82fe4b0c9d6adf6b961	58cfa82fe4b0c9d6adf6b961	TCGA-AA-3529-01A-02D-1554-10_wgs_Illumina.filtered.	WGS	TCGA-AA-3529-01A-02D-1554-10_wgs_Illumina	TCGA-AA-3529-01A-02D-1554-10_wgs_Illumina.bam	109.29	1.9	0.05	58cfa82fe4b0c9d6adf6b961	TCGA-AA-3529-01A-02D-1554-10_wgs_Illumina.bam	Dead	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3529-01A	BFB07784-693B-4C25-874E-4AD6E04A5D46	Primary Tumor	Illumina HiSeq	510f1886-9023-432a-bc19-46aee37ea8a4	Colorectal	78.0	B083E3CB-0AF1-44EA-854D-85FD99B75AD5	9E5F0A23-E184-4611-B42B-E882DCF23ACD	TCGA-AA-3529-01A-02D-1554-10	GRCh37-lite	TCGA-AA-3529	TCGA-COAD	0.0	s12863	Baylor College of Medicine	Indivumed	Germany	NO	T3	N2	Colon Adenocarcinoma	Stage IIIC	1554-10	False	COAD	C1		0.148324781	0.4	0.0	1.87309572	0.7472	0.306	-0.5797	-0.5943	-0.929	-0.0647			1.6150755019999998	1.292060402	203.0	0.18646310300000002	7.0	7.0								-1170.272449	241.5566556	-979.8185432	1.0	0.0	1.0	0.0	6.614893146488814	2.157558191307265	-0.32706777859323455	5.327038858182176	4.5930885676973725	1.5479265895459782	-1.2878542883066384	2.4355303763901075	1.8749943681392125
13722.58cfa82fe4b0c9d6adf6b965	58cfa82fe4b0c9d6adf6b965	TCGA-AA-3529-01A-02D-1547-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3529-01A-02D-1547-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3529-01A-02D-1547-02_IlluminaHiSeq-DNASeq_whole.bam	109.29	1.9	0.13	58cfa82fe4b0c9d6adf6b965	TCGA-AA-3529-01A-02D-1547-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3529-01A	BFB07784-693B-4C25-874E-4AD6E04A5D46	Primary Tumor	Illumina HiSeq	8d96c289-9e08-45f8-a5dc-8c089ca7eb93	Colorectal	78.0	B083E3CB-0AF1-44EA-854D-85FD99B75AD5	B8C9B915-BD7E-41FA-B5E1-4A28478EDC6E	TCGA-AA-3529-01A-02D-1547-02	HG18	TCGA-AA-3529	TCGA-COAD	0.0	s13364	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Colon Adenocarcinoma	Stage IIIC	1547-02	False	COAD	C1		0.148324781	0.4	0.0	1.87309572	0.7472	0.306	-0.5797	-0.5943	-0.929	-0.0647			1.6150755019999998	1.292060402	203.0	0.18646310300000002	7.0	7.0								-1170.272449	241.5566556	-979.8185432	1.0	0.0	1.0	0.0	6.9784799833138464	3.6491404858843204	-0.32706777859323455	5.78889591644001	5.868075549591441	1.5479265895459782	-1.1895840668738364	2.2189350637071206	1.8749943681392125
13722.58cfa82fe4b0c9d6adf6b96f	58cfa82fe4b0c9d6adf6b96f	TCGA-AA-3666-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3666-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3666-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	554.96	1.9	0.17	58cfa82fe4b0c9d6adf6b96f	TCGA-AA-3666-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3666-01A	A512701F-88BB-4B05-8C94-FD285B9DD13E	Primary Tumor	Illumina HiSeq	0bc29a5e-10c6-4c45-8cb6-2284ab7be445	Colorectal	68.0	F1064663-1462-4901-8BF7-9F50DA5EE7B1	CAD86B88-04E5-400F-B3EB-43D31A2D8358	TCGA-AA-3666-01A-02D-1167-02	HG18	TCGA-AA-3666	TCGA-COAD	61.0	s13363	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Colon Adenocarcinoma	Stage III	1167-02	True	COAD	C1	GI.CIN	0.077716677	0.18	0.2	0.700538586	0.9818	0.335	-0.1802	0.0178	-0.5187	-0.1893	90.0	111.0	1.036041823	4.403177748	292.0	0.80576293	20.0	17.0							0.800179761	-184.46656430000002	716.4667903	-729.7130003999999	1.0	61.0	1.0	61.0	6.6584492854069675	4.903129841198114	-0.15313301090290543	4.978393805758913	5.604575824572754	1.238865390188702	-1.680055479648054	0.70144598337464	1.3919984010916076
13722.58cfa82fe4b0c9d6adf6b974	58cfa82fe4b0c9d6adf6b974	TCGA-AA-3675-01A-02D-1109-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3675-01A-02D-1109-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3675-01A-02D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	570.96	1.9	0.14	58cfa82fe4b0c9d6adf6b974	TCGA-AA-3675-01A-02D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3675-01A	41658CF8-0DE1-4A97-BB60-0F0107C84E00	Primary Tumor	Illumina HiSeq	f57af06a-9d5a-4a69-888a-8d611982b88e	Colorectal	84.0	A4CE3727-4506-493B-95F4-2F11CEB09CEB	D611373E-EF0A-46E4-8D3E-0722F221E828	TCGA-AA-3675-01A-02D-1109-02	HG18	TCGA-AA-3675	TCGA-COAD		s13672	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage II	1109-02	True	COAD	C1			0.23	0.0	0.034848062	0.6518	0.2555	-0.6545	-0.4516	-0.7135	0.0163	49.0	59.0	1.01544533	2.030890659	74.0	0.055575908	3.0	1.0	0.9010371859999999	1.753337405	7.0	2.45831133	12.0	0.989297256	1.659074035	-1349.7967210000002	232.6718272	1657.915514	0.0	1431.0	0.0	1431.0	6.702267444156343	5.106274800430809	-0.55415659415657	5.255348461220017	6.422610572943788	0.8937128946561921	-1.4469189829363258	1.3163357725129794	1.4478694888127621
13722.58cfa82fe4b0c9d6adf6b976	58cfa82fe4b0c9d6adf6b976	TCGA-AA-3666-01A-02D-1981-10_wgs_Illumina.filtered.	WGS	TCGA-AA-3666-01A-02D-1981-10_wgs_Illumina	TCGA-AA-3666-01A-02D-1981-10_wgs_Illumina.bam	554.96	1.9	0.17	58cfa82fe4b0c9d6adf6b976	TCGA-AA-3666-01A-02D-1981-10_wgs_Illumina.bam	Dead	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3666-01A	A512701F-88BB-4B05-8C94-FD285B9DD13E	Primary Tumor	Illumina HiSeq	6788c172-0c9d-4042-a664-c53d8e8a5cf9	Colorectal	68.0	F1064663-1462-4901-8BF7-9F50DA5EE7B1	6051F40A-99E5-4461-9255-0E70D757B4D5	TCGA-AA-3666-01A-02D-1981-10	GRCh37-lite	TCGA-AA-3666	TCGA-COAD	61.0	s13025	Baylor College of Medicine	Indivumed	Germany	NO	T3	N1	Colon Adenocarcinoma	Stage III	1981-10	False	COAD	C1	GI.CIN	0.077716677	0.18	0.2	0.700538586	0.9818	0.335	-0.1802	0.0178	-0.5187	-0.1893	90.0	111.0	1.036041823	4.403177748	292.0	0.80576293	20.0	17.0							0.800179761	-184.46656430000002	716.4667903	-729.7130003999999	1.0	61.0	1.0	61.0	6.704107935473429	3.9735353237306423	-0.15313301090290543	4.95490808066417	5.9101587872177515	1.238865390188702	-1.749199854809259	1.9366234634871091	1.3919984010916076
13722.58cfa82fe4b0c9d6adf6b97e	58cfa82fe4b0c9d6adf6b97e	TCGA-AA-3681-01A-01D-1637-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3681-01A-01D-1637-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3681-01A-01D-1637-02_IlluminaHiSeq-DNASeq_whole.bam	353.96	1.9	0.15	58cfa82fe4b0c9d6adf6b97e	TCGA-AA-3681-01A-01D-1637-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3681-01A	ABB0D53F-F74E-45DC-8FBB-40863016F3C6	Primary Tumor	Illumina HiSeq	4a7f8872-1280-4a05-8448-a62ee6de1108	Colorectal	77.0	190FECAB-1EF1-43FA-87A2-104014EB2CE2	85305E56-627C-4471-BD16-6818AD3751C2	TCGA-AA-3681-01A-01D-1637-02	HG18	TCGA-AA-3681	TCGA-COAD		s13029	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Colon Adenocarcinoma	Stage III	1637-02	False	COAD	C1	GI.CIN	0.21425759100000002	0.43	0.12	2.944777764	0.7662	0.312	-0.0106	0.7538	-0.1451	-0.0225	43.0	2.0	0.856908056	2.777564043	273.0	0.33481594600000003	12.0	15.0							0.998962556	-295.970644	769.0661261	-864.9019687000001	0.0	182.0	0.0	182.0	7.093555626246554	4.633819766217051	0.11775653611349923	6.195614033040595	6.398550563057187	1.4649953080610725	-0.8979415932059585	1.7647307968401362	1.3472387719475734
13722.58cfa82fe4b0c9d6adf6b982	58cfa82fe4b0c9d6adf6b982	TCGA-AA-3861-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3861-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3861-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	294.0	1.9	0.15	58cfa82fe4b0c9d6adf6b982	TCGA-AA-3861-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3861-01A	5DA56982-6DE7-4994-AA9E-3B01200B2959	Primary Tumor	Illumina HiSeq	041d683a-798a-4869-a98d-b7abfe977709	Colorectal	72.0	390070D8-EF9B-46FE-93EE-9CF01A642A92	3FF478FA-97AF-4122-AC93-1BF1DD21BCB3	TCGA-AA-3861-01A-01D-1167-02	HG18	TCGA-AA-3861	TCGA-COAD		s13186	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1167-02	True	COAD	C2		0.258206498			10.65966822	0.5268	0.187	-0.2323	0.8422	-0.231	-0.5671	60.0	2.0													0.804051593	-1011.166692	319.09353230000005	-22.556652399999997	0.0	914.0	0.0	914.0	7.240968241681907	6.476972362889683	0.01935474139623672	5.9118322944019654	4.762173934797756	1.753516718840955	-1.329135947279942	-1.7147984280919264	1.7341619774447183
13722.58cfa82fe4b0c9d6adf6b98e	58cfa82fe4b0c9d6adf6b98e	TCGA-50-5944-01A-11D-1751_111221_SN1120_0106_BD0M7HACXX_s_1_rg.sorted.filtered.	WGS	TCGA-50-5944-01A-11D-1751_111221_SN1120_0106_BD0M7HACXX_s_1_rg.sorted	TCGA-50-5944-01A-11D-1751_111221_SN1120_0106_BD0M7HACXX_s_1_rg.sorted.bam	115.4	1.9	0.14	58cfa82fe4b0c9d6adf6b98e	TCGA-50-5944-01A-11D-1751_111221_SN1120_0106_BD0M7HACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE		Lung Adenocarcinoma	Aligned reads	TCGA-50-5944-01A	1C339545-C08A-4A77-B8E9-A7E49E53853F	Primary Tumor	Illumina HiSeq	c76f3861-5117-4ed7-9ca6-eecc10e949f3	Lung	69.0	BF8FDF82-62B4-4B5D-93E7-CE153576FE49	71CD46A8-30B0-4452-860D-3ED173C461A7	TCGA-50-5944-01A-11D-1751-02	HG19_Broad_variant	TCGA-50-5944	TCGA-LUAD		s11348	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N0	Lung Acinar Adenocarcinoma	Stage IA	1751-02	True	LUAD	C3	LUAD.1	0.10243614699999999	0.43	0.15		-0.6587	-0.212	0.5383	-0.0123	0.1624	0.3992	32.0	19.0	0.545640989	1.515669415	315.0	0.61800592	15.0	23.0	0.422073762	0.463695421	3.0	1.9459101490000001	7.0	1.0	2.317136526	162.2438574	-461.8834396000001	1536.593854	0.0	1750.0	0.0	1750.0	6.597924973307345	6.35388296567378	-0.2700890531577623	5.408340906433509	6.57702651698799	4.843492078901367	-1.1895840668738364	0.2231435513142097	5.113581132059129
13722.58cfa82fe4b0c9d6adf6b991	58cfa82fe4b0c9d6adf6b991	TCGA-50-6597-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_3_rg.sorted.filtered.	WGS	TCGA-50-6597-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_3_rg.sorted	TCGA-50-6597-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_3_rg.sorted.bam	12.7	1.9	0.15	58cfa82fe4b0c9d6adf6b991	TCGA-50-6597-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-6597-01A	0D66BF6C-EED0-4726-BD5B-3BF6D610B4E0	Primary Tumor	Illumina HiSeq	e7110ba5-6000-459a-8128-32b420e21194	Lung	79.0	C5363830-3DB9-4C0C-AA47-B32FDC888C60	84D15DBA-6689-4A93-B2CA-999BF7F97E96	TCGA-50-6597-01A-11D-1853-02	HG19_Broad_variant	TCGA-50-6597	TCGA-LUAD		s11553	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1853-02	True	LUAD	C2	LUAD.5	0.274501606			4.136944194	-0.8757	-0.0845	0.5097	1.7853	1.2749	-0.309	15.0		0.38251287700000003	1.3535071019999998	301.0	0.728395692	11.0	22.0	0.929116948	1.932044378	8.0	3.3638820189999996	31.0	0.979584902	2.4943273440000002	661.8589728999999	-809.3682149	924.4797825999999	1.0	1268.0	0.0	1268.0	3.6322168133910164	7.561092684036747	-0.14371793714991965	3.014520187419625	5.760116559703768	1.5148186386076867	-0.6176966259713916	-1.800976124332979	1.6585365757576063
13722.58cfa82fe4b0c9d6adf6b99a	58cfa82fe4b0c9d6adf6b99a	TCGA-64-5774-01A-01D-1623_120228_SN1120_0117_BC0DKWACXX_s_1_rg.sorted.filtered.	WGS	TCGA-64-5774-01A-01D-1623_120228_SN1120_0117_BC0DKWACXX_s_1_rg.sorted	TCGA-64-5774-01A-01D-1623_120228_SN1120_0117_BC0DKWACXX_s_1_rg.sorted.bam	877.7	1.9	0.15	58cfa82fe4b0c9d6adf6b99a	TCGA-64-5774-01A-01D-1623_120228_SN1120_0117_BC0DKWACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-64-5774-01A	FD3FC273-C035-40EA-A459-FF4806F5D592	Primary Tumor	Illumina HiSeq	b5b4f9c8-7044-4c76-ae48-241c8c4dd953	Lung	60.0	252C5D60-7033-44C3-8AB5-4604670A80F4	83902D13-5FD4-4640-B20F-3A8110F6D5EC	TCGA-64-5774-01A-01D-1623-02	HG19_Broad_variant	TCGA-64-5774	TCGA-LUAD		s10910	Harvard Medical School	Fox Chase	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1623-02	True	LUAD	C1	LUAD.2	0.150211297	0.24	0.09	6.1467746960000005	0.7054	0.141	-0.4666	0.5766	-0.2956	0.0864	32.0	4.0	1.1659603040000002	3.74334624	223.0	0.7998623690000001	15.0	42.0	0.807947645	3.9138495460000002	127.0	2.36938212	11.0	0.9881090920000001	5.054270572	-1184.814253	240.95402280000002	2057.424352	0.0	2676.0	1.0	246.0	2.729027249451657	6.84825022252615	-0.4760423350112498	1.770548443196418	4.356953774639378	2.9327924737801165	-0.958478806255239	-2.4912964478867714	3.4088348087913665
13722.58cfa82fe4b0c9d6adf6b9a8	58cfa82fe4b0c9d6adf6b9a8	TCGA-67-6215-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_7.rg.sorted.filtered.	WGS	TCGA-67-6215-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_7.rg.sorted	TCGA-67-6215-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_7.rg.sorted.bam	292.4	1.9	0.14	58cfa82fe4b0c9d6adf6b9a8	TCGA-67-6215-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_7.rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-67-6215-01A	DBD5B0DE-94C9-45DD-AFB3-6820A7ECACA2	Primary Tumor	Illumina HiSeq	502bd59b-5e8d-4170-9a24-b18fa50a5dc1	Lung	52.0	3BA5F6B9-6458-44E2-A0AA-B5C7E5FCD632	483EF1DC-150E-4623-BA11-772ADE84E4E4	TCGA-67-6215-01A-11D-1751-02	HG19_Broad_variant	TCGA-67-6215	TCGA-LUAD		s11555	Harvard Medical School	St Joseph's Medical Center (MD)	United States	NO	T2a	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1751-02	True	LUAD	C4	LUAD.4	0.149603136	0.31	0.07	2.8585998810000004	-0.1852	-0.059000000000000004	0.5328	-0.3554	-0.4948	-0.1715	52.0	2.0	0.79319052	2.959210788	93.0	0.633681817	7.0	10.0		0.0	1.0	2.163955657	9.0	0.984858662	1.5657511119999998	-818.1547337000001	-75.47417311	3199.572014	0.0	174.0	0.0	174.0	6.657240530871796	6.9770239744951095	-0.14298305107324816	6.251775422763631	7.048482938477255	0.9928480180840354	-0.4054651081081646	0.07145896398214502	1.1358310691572835
13722.58cfa82fe4b0c9d6adf6b9ab	58cfa82fe4b0c9d6adf6b9ab	TCGA-44-6777-01A-11D-1853_120123_SN590_0134_AC0DJKACXX_s_2_rg.sorted.filtered.	WGS	TCGA-44-6777-01A-11D-1853_120123_SN590_0134_AC0DJKACXX_s_2_rg.sorted	TCGA-44-6777-01A-11D-1853_120123_SN590_0134_AC0DJKACXX_s_2_rg.sorted.bam	36.7	1.9	0.15	58cfa82fe4b0c9d6adf6b9ab	TCGA-44-6777-01A-11D-1853_120123_SN590_0134_AC0DJKACXX_s_2_rg.sorted.bam	Dead	FEMALE	WHITE		Lung Adenocarcinoma	Aligned reads	TCGA-44-6777-01A	349E6F38-2C67-4A69-A777-B9173A2A27CF	Primary Tumor	Illumina HiSeq	8f0fdfb5-6a7c-4e9a-9a4f-d32f9aca542d	Lung	85.0	174E4405-4848-4E5E-93CC-0CDF2795C91A	AAAAE42F-88A5-4E99-8057-A92D6759BE19	TCGA-44-6777-01A-11D-1853-02	HG19_Broad_variant	TCGA-44-6777	TCGA-LUAD	987.0	s11550	Harvard Medical School	Christiana Healthcare	United States	NO	T2	NX	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1853-02	True	LUAD	C3	LUAD.5	0.43516623200000004	0.66	0.55	4.162335541	-0.5198	-0.1915	1.6439	1.5747	0.2782	0.7154	120.0	137.0	2.821193375	9.452452029	72.0	0.438026171	17.0	12.0	0.893255067	4.592817027	171.0	3.871265198	49.0	0.994718384	2.0016224769999997	140.0493521	-419.3192523	1850.88813	1.0	987.0	0.0	987.0	6.7133979455765775	7.31168587699835	0.129507946280217	5.892417393506747	7.31168587699835	1.7917594692280547	-0.8209805520698299	0.0	1.6622515229478378
13722.58cfa82fe4b0c9d6adf6b9c6	58cfa82fe4b0c9d6adf6b9c6	TCGA-73-4658-01A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_5_rg.sorted.filtered.	WGS	TCGA-73-4658-01A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_5_rg.sorted	TCGA-73-4658-01A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_5_rg.sorted.bam	150.4	1.9	0.15	58cfa82fe4b0c9d6adf6b9c6	TCGA-73-4658-01A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_5_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-73-4658-01A	AFB91740-2668-46D7-BA01-BB26153AD1C7	Primary Tumor	Illumina HiSeq	9ee6d96c-98e7-4829-94dc-f41e5f078854	Lung	80.0	BFDE37F2-AB6F-4426-A33D-EF9D21772F02	6A3AFDA7-56BB-4120-AB92-6EDA217BC214	TCGA-73-4658-01A-01D-1751-02	HG19_Broad_variant	TCGA-73-4658	TCGA-LUAD	1600.0	s11130	Harvard Medical School	Roswell Park	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1751-02	True	LUAD	C6	LUAD.4	0.388598726	0.71	0.4	8.816077884	-0.4784	-0.019	1.3083	1.2308	-0.1552	0.6292	189.0	14.0	2.695768245	8.798276581	73.0	0.209710636	7.0	17.0	0.8679355559999999	3.060653682	34.0	3.4448137969999997	32.0	0.993963156	1.22232147	559.8120552	-428.96005180000003	1947.129476	1.0	1600.0	0.0	1600.0	7.066429464276663	5.958440073740833	0.2312154607840099	6.230181440076044	5.085951964525071	1.2689724737308448	-0.8362480242006187	-0.8724881092157624	1.0377570129468348
13722.58cfa82fe4b0c9d6adf6b9c8	58cfa82fe4b0c9d6adf6b9c8	TCGA-AA-A00Q-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A00Q-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A00Q-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	212.1	1.72	0.15	58cfa82fe4b0c9d6adf6b9c8	TCGA-AA-A00Q-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A00Q-01A	62D39BE5-F029-4EB8-8B00-46470E06A755	Primary Tumor	Illumina HiSeq	5ccd68f8-a32c-47e2-805b-e3721dbb395d	Colorectal	66.0	89FC5DB9-EDFF-480F-8FC4-ADDD28C6D615	D458CE34-22B1-41F7-9CE7-659107AD6F77	TCGA-AA-A00Q-01A-01D-A077-02	HG18	TCGA-AA-A00Q	TCGA-COAD		s13523	Harvard Medical School	Indivumed	Germany	NO	T4	N1	Colon Adenocarcinoma	Stage IIIB	A077-02	True	COAD	C1		0.150263944			4.506765605	0.4191	0.09300000000000001	-0.632	-0.3651	-0.6123	-0.0361					65.0	0.8288944859999999	17.0	4.0							0.6503794589999999	-1422.853088	43.86977234	-1168.525586	0.0	1278.0	0.0	1278.0	6.7439719338900375	6.736221832330919	0.04100164355185831	6.278608684200805	6.220755829008426		-0.46536324968923326	-0.5154660033224929	
13722.58cfa82fe4b0c9d6adf6b9ca	58cfa82fe4b0c9d6adf6b9ca	TCGA-AA-A00U-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A00U-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A00U-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	232.95	1.72	0.15	58cfa82fe4b0c9d6adf6b9ca	TCGA-AA-A00U-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A00U-01A	091E3084-04EE-4497-893C-D46226DEC78F	Primary Tumor	Illumina HiSeq	95f8b5f7-db6e-4a69-959f-dde28a98d4ed	Colorectal	50.0	2FC854D7-4F80-4C39-BD92-397E94FEE4A0	6765593B-17DC-4B0F-A20B-7F0FF67DFF64	TCGA-AA-A00U-01A-01D-A077-02	HG18	TCGA-AA-A00U	TCGA-COAD		s13682	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Colon Adenocarcinoma	Stage IIIB	A077-02	True	COAD	C1		0.135984752			19.64158436	0.9188	0.375	-0.9838	-0.4878	-0.4769	-0.1415					189.0	0.14820813	5.0	9.0							0.132611962	-1039.403677	791.2569815	-65.85221425	0.0	518.0	0.0	518.0	8.28614346853093	7.073201918551247	-1.1392774081390193	5.9835583755368855	5.738200851818907	0.2517346846434687	-2.3025850929940455	-1.3350010667323402	1.3910120927824883
13722.58cfa82fe4b0c9d6adf6b9cc	58cfa82fe4b0c9d6adf6b9cc	TCGA-AA-A00Z-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A00Z-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A00Z-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	264.6	1.73	0.15	58cfa82fe4b0c9d6adf6b9cc	TCGA-AA-A00Z-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A00Z-01A	AF3A0634-4292-45BD-B948-6B6BD2D58090	Primary Tumor	Illumina HiSeq	9701e2c0-3702-4d55-9816-940f128d19e0	Colorectal	70.0	75A6A64E-11F0-41C8-9CBA-179AE3333621	DF16D4D9-DD5E-4614-AE58-465EC09F2992	TCGA-AA-A00Z-01A-01D-A077-02	HG18	TCGA-AA-A00Z	TCGA-COAD		s13198	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	A077-02	True	COAD	C1		0.135171254	0.37	0.08	24.82030059	1.041	0.34	-0.6709	-0.2894	-0.0991	-0.0518	9.0	75.0	0.35562269700000004	2.48935888	205.0	0.20065555100000002	9.0	14.0							1.7956814540000001	-1944.923693	1142.249288	528.879267	0.0	669.0	0.0	669.0	5.410069178992159	5.113900593063954	-0.08280746155565066	5.1987600853249525	5.560914704084991	1.324936616652404	-0.21130909366720685	0.44701411102103705	1.4077440782080544
13722.58cfa82fe4b0c9d6adf6b9d8	58cfa82fe4b0c9d6adf6b9d8	TCGA-AA-3947-01A-01D-1167-02_101023_SN208_0167_B80L4DABXX_s_1.rg.sorted.filtered.	WGS	TCGA-AA-3947-01A-01D-1167-02_101023_SN208_0167_B80L4DABXX_s_1.rg.sorted	TCGA-AA-3947-01A-01D-1167-02_101023_SN208_0167_B80L4DABXX_s_1.rg.sorted.bam	880.86	1.9	0.14	58cfa82fe4b0c9d6adf6b9d8	TCGA-AA-3947-01A-01D-1167-02_101023_SN208_0167_B80L4DABXX_s_1.rg.sorted.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3947-01A	654C6F5C-3E5C-49F0-B53F-87CD9797D7C9	Primary Tumor	Illumina HiSeq	2d1ad0b4-c460-4a5b-ae6d-2926bfe40052	Colorectal	60.0	5241539D-65AC-434D-8EAA-AE57F702C8CE	EE2FCBCE-108F-46EC-8C7A-12D34142820A	TCGA-AA-3947-01A-01D-1167-02	HG18_Broad_variant	TCGA-AA-3947	TCGA-COAD		s13679	Harvard Medical School	Indivumed	Germany	NO	T4	N0	Colon Mucinous Adenocarcinoma	Stage IIB	1167-02	True	COAD	C4	GI.HM-indel	0.135055043	0.22	0.03	15.2110802	1.1349	0.415	-0.0287	-0.9578	0.45399999999999996	-0.8001	710.0		18.47130928	57.60675088	136.0	0.02742049	0.0	0.0							0.521717388	-158.8274011	2057.929295	-1640.845208	0.0	1004.0	0.0	1004.0	4.841643850092864	4.247875855222497	-0.08274877034929695	5.056755229709809	4.452424027431069	1.171670101819695	0.2151113796169457	0.2045481722085718	1.254418872168992
13722.58cfa82fe4b0c9d6adf6b9e0	58cfa82fe4b0c9d6adf6b9e0	TCGA-AA-3977-01A-01D-1024-10_wgs_Illumina.filtered.	WGS	TCGA-AA-3977-01A-01D-1024-10_wgs_Illumina	TCGA-AA-3977-01A-01D-1024-10_wgs_Illumina.bam	540.0	1.9	0.15	58cfa82fe4b0c9d6adf6b9e0	TCGA-AA-3977-01A-01D-1024-10_wgs_Illumina.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3977-01A	33E989B9-FAC4-47D8-B429-269044AC772A	Primary Tumor	Illumina HiSeq	34a6b8b6-5a24-4e03-9f20-8b51e27033c5	Colorectal	65.0	56DD63CB-CF0A-48C3-BCCC-C5094F8D8AC0	93FF786E-0165-4B02-8D27-806D422E93FC	TCGA-AA-3977-01A-01D-1024-10	GRCh37-lite	TCGA-AA-3977	TCGA-COAD		s13028	Baylor College of Medicine	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma		1024-10	False	COAD	C1		0.180402148	0.27	0.21	12.10294459	1.1527	0.444	-0.0522	-0.2114	-0.2985	-0.1233	1864.0	41.0			176.0	0.0007730139999999999	0.0	5.0							1.8251727930000001	-1325.770384	1242.777155	-1989.8723699999998	0.0	761.0	0.0	761.0	6.8322232163697	3.616004475630776	-0.12522062825934066	5.8912398719051735	6.4004661518507895	1.1710490087780154	-0.9409833444645268	2.7844616762200136	1.296269637037356
13722.58cfa82fe4b0c9d6adf6b9e8	58cfa82fe4b0c9d6adf6b9e8	TCGA-A5-A0G9-01A-11D-A043_120318_SN590_0146_AC0KH7ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-A5-A0G9-01A-11D-A043_120318_SN590_0146_AC0KH7ACXX_s_3_rg.sorted	TCGA-A5-A0G9-01A-11D-A043_120318_SN590_0146_AC0KH7ACXX_s_3_rg.sorted.bam	54.22	1.93	0.16	58cfa82fe4b0c9d6adf6b9e8	TCGA-A5-A0G9-01A-11D-A043_120318_SN590_0146_AC0KH7ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0G9-01A	45D58088-D3F4-4EB0-B75C-BCB98C0981DC	Primary Tumor	Illumina HiSeq	daffebdf-d935-425e-8576-3401ef583860	Uterus	79.0	117A5B33-42C5-4A52-BABE-D9712F3E7472	0DE57B60-95AF-48E2-85CA-58135A314355	TCGA-A5-A0G9-01A-11D-A043-02	HG19_Broad_variant	TCGA-A5-A0G9	TCGA-UCEC		s4778	Harvard Medical School	Cedars Sinai	None	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C1	UCEC.MSI	0.112810754	0.1	0.04	2.849274522	-0.0804	0.067	-0.2616	-0.6313	-0.4057	-0.0724	149.0	181.0	2.9151461089999997	12.17680823	68.0	0.034102007999999996	1.0	4.0							2.95754294	-1410.981992	-1155.1329660000001	2112.313488	0.0	2540.0	0.0	2540.0	6.224747001782047	7.517955538721156	0.4111563530302771	5.440628043016375	6.419343250053046	3.468280217631704	-0.7841189587656721	-1.0986122886681096	3.0571238646014267
13722.58cfa82fe4b0c9d6adf6b9fe	58cfa82fe4b0c9d6adf6b9fe	TCGA-AA-3968-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3968-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3968-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	756.0	1.9	0.15	58cfa82fe4b0c9d6adf6b9fe	TCGA-AA-3968-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3968-01A	CAB7BDBC-0A11-4901-97C3-26B884F79CB5	Primary Tumor	Illumina HiSeq	7c5f1648-b5c0-4e96-a5ca-38b2630f40ee	Colorectal	55.0	E950BC59-116F-4366-8524-F0731B1C9A3D	193F15A1-6BE4-4992-AC6E-EF34CBB3B57A	TCGA-AA-3968-01A-01D-1167-02	HG18	TCGA-AA-3968	TCGA-COAD		s13030	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	1167-02	True	COAD	C1	GI.CIN	0.087793218	0.29	0.13	0.5097340779999999	0.9567	0.256	-0.0881	0.4383	-0.4791	0.1324	42.0	0.0	0.743706546	3.966434912	185.0	0.8187453490000001	12.0	20.0							0.410578571	-1752.068898	682.9193541	-1891.150321	0.0	669.0	0.0	669.0	6.698352121874075	6.533179124714164	-0.3427888142901059	6.063701147995738	5.959833143966839	0.8329944265449201	-0.6346509738783372	-0.5733459807473249	1.175783240835026
13722.58cfa82fe4b0c9d6adf6ba00	58cfa82fe4b0c9d6adf6ba00	TCGA-AA-3555-01A-01D-1637-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3555-01A-01D-1637-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3555-01A-01D-1637-02_IlluminaHiSeq-DNASeq_whole.bam	949.56	1.9	0.13	58cfa82fe4b0c9d6adf6ba00	TCGA-AA-3555-01A-01D-1637-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3555-01A	36EAF209-C332-4321-B6AA-51A3368ECD79	Primary Tumor	Illumina HiSeq	4abf3b47-09b2-46e1-8bca-eb46790b3930	Colorectal	81.0	9F9961F0-4EE2-4471-AE4A-A0122D630A28	099EA705-3D94-4746-AF72-E21B31D0425A	TCGA-AA-3555-01A-01D-1637-02	HG18	TCGA-AA-3555	TCGA-COAD		s13513	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Mucinous Adenocarcinoma	Stage IIA	1637-02	False	COAD	C4		0.21071610300000002			2.260490556	1.0172	0.278	-0.2441	-1.1601	0.1498	0.1609					79.0	0.000350537	0.0	3.0							1.47107021	-1319.415918	1205.436214	-2602.9519649999997	0.0	911.0	1.0	91.0	7.291603807885378	4.989177198908291	-2.4344917898915663	6.812030727623492	7.052358219716347	-1.8152899666382492	-0.4795730802618863	2.063181020808056	0.6192018232533172
13722.58cfa82fe4b0c9d6adf6ba02	58cfa82fe4b0c9d6adf6ba02	TCGA-AA-A01I-01A-02D-A077-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A01I-01A-02D-A077-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A01I-01A-02D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	237.83	1.78	0.15	58cfa82fe4b0c9d6adf6ba02	TCGA-AA-A01I-01A-02D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01I-01A	86D18004-9478-4E46-83B4-4FBE445CCB70	Primary Tumor	Illumina HiSeq	397e6c0b-1bf2-43ff-b659-15147ee8be30	Colorectal	76.0	FBA03796-B9C8-4042-9720-F21660CFEC28	DAED1A71-909A-42D8-87B4-6760B54D91AF	TCGA-AA-A01I-01A-02D-A077-02	HG18	TCGA-AA-A01I	TCGA-COAD		s13201	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	A077-02	True	COAD	C1		0.15376109699999999	0.28	0.13	6.805528892000001	0.8765	0.29	-0.6814	-0.5725	-0.1513	-0.4438	55.0	0.0	0.754645652	3.0185826060000003	73.0	0.632541182	8.0	0.0							1.112224422	-102.6721458	1095.850858	-80.71735995	0.0	943.0	0.0	943.0	7.627165653841205	6.625189724429682	-0.1802723757490189	6.160828585047779	6.1311712189800724	1.0173106304781458	-1.4663370687934267	-0.4940185054496098	1.1975830062271648
13722.58cfa82fe4b0c9d6adf6ba06	58cfa82fe4b0c9d6adf6ba06	TCGA-AA-3956-01A-02D-1981-10_wgs_Illumina.filtered.	WGS	TCGA-AA-3956-01A-02D-1981-10_wgs_Illumina	TCGA-AA-3956-01A-02D-1981-10_wgs_Illumina.bam	282.86	1.9	0.14	58cfa82fe4b0c9d6adf6ba06	TCGA-AA-3956-01A-02D-1981-10_wgs_Illumina.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3956-01A	7B47489F-C3CC-4388-B5D7-C7C02790A5F6	Primary Tumor	Illumina HiSeq	72141594-ac11-437d-896e-d1ae66162764	Colorectal	65.0	DC1FFDA5-5B8F-4227-BE04-321643F73731	3C019B2F-52EC-40A8-99B5-98C1423CE627	TCGA-AA-3956-01A-02D-1981-10	GRCh37-lite	TCGA-AA-3956	TCGA-COAD		s12870	Baylor College of Medicine	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1981-10	False	COAD	C1	GI.CIN	0.204002341	0.65	0.2	50.50431578	0.4451	0.145	-0.363	0.3629	-0.3046	0.0118	84.0	13.0	1.069191462	4.276765848	149.0	0.232664444	10.0	17.0							0.524541495	-1499.029365	200.83480830000002	326.11250010000003	0.0	1035.0	0.0	1035.0	6.292915034781675	5.0740783248923895	-0.39885569872049054	5.2568231030948995	6.548617167260602	1.9333412483202	-1.0360919316867756	1.4745388423682124	2.3321969470406905
13722.58cfa82fe4b0c9d6adf6ba08	58cfa82fe4b0c9d6adf6ba08	TCGA-A5-A0G2-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_1_rg.sorted.filtered.	WGS	TCGA-A5-A0G2-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_1_rg.sorted	TCGA-A5-A0G2-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_1_rg.sorted.bam	104.46	2.03	0.15	58cfa82fe4b0c9d6adf6ba08	TCGA-A5-A0G2-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_1_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0G2-01A	4ABBD258-0F0C-4428-901D-625D47AD363A	Primary Tumor	Illumina HiSeq	f5289cfe-4208-4623-896c-ec78fb5f7dc5	Uterus	57.0	771811E3-740E-42FE-BE9C-FD485997EAAE	579C21E4-83BD-4DAE-B030-53E0930DEACA	TCGA-A5-A0G2-01A-11D-A043-02	HG19_Broad_variant	TCGA-A5-A0G2	TCGA-UCEC		s4773	Harvard Medical School	Cedars Sinai	None	NO			Serous endometrial adenocarcinoma		A043-02	True	UCEC	C1	UCEC.POLE	0.09886014300000001			8.137703979	0.757	0.188	-0.2096	0.4842	-0.8059	-0.434	11244.0		247.23629280000003	733.234354	113.0	0.43029177399999996	11.0	11.0							1.222715413	-771.8033002999999	-100.03404920000001	-1845.3733690000001	0.0	4549.0	0.0	4549.0	6.021427798293362	5.6644324602145755	0.07136785611036167	5.692923731321326	5.9222615695166745	2.1277398219239543	-0.32850406697203605	0.25782910930209946	2.0563719658135926
13722.58cfa82fe4b0c9d6adf6ba0c	58cfa82fe4b0c9d6adf6ba0c	TCGA-AA-3970-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3970-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3970-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	686.66	1.9	0.15	58cfa82fe4b0c9d6adf6ba0c	TCGA-AA-3970-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3970-01A	733D8B6A-CA9D-4A69-8C9C-1F88733E8B68	Primary Tumor	Illumina HiSeq	9a7a59e0-b435-4e8b-b503-c49ce6f819e4	Colorectal	65.0	767A5260-34F4-4BED-9CDA-305BC431A402	0F57E6B4-FE51-4ACF-B65B-1FDB2CF9C6CB	TCGA-AA-3970-01A-01D-1109-02	HG18	TCGA-AA-3970	TCGA-COAD		s13190	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1109-02	True	COAD	C2					2.646720368	0.7692	0.256	-0.1113	0.6971	0.7562	-0.2725															0.9879346520000001	-1164.025809	220.3010748	868.3948221	0.0	1096.0	0.0	1096.0	6.491734656934456	5.652489180268651	-0.3864956895682874	4.757133601546349	6.368625879053296	1.607569501374073	-1.7346010553881066	0.7161366987846445	1.9940651909423603
13722.58cfa82fe4b0c9d6adf6ba10	58cfa82fe4b0c9d6adf6ba10	TCGA-AA-A01G-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A01G-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A01G-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	233.25	1.69	0.15	58cfa82fe4b0c9d6adf6ba10	TCGA-AA-A01G-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01G-01A	6F2B5A14-569C-4084-8C67-B1A44D787897	Primary Tumor	Illumina HiSeq	efd511ca-ff06-4cbe-afe2-2c025120233e	Colorectal	63.0	A09ABC20-4F93-4130-A23A-8413E6C32FE5	D7D83B15-9EE5-4206-805D-AC3E5914BCC6	TCGA-AA-A01G-01A-01D-A077-02	HG18	TCGA-AA-A01G	TCGA-COAD		s13205	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Mucinous Adenocarcinoma	Stage IIA	A077-02	True	COAD	C1		0.164296924			30.00620925	0.9306	0.342	-1.08	-0.552	-0.4392	-0.2244					131.0	0.36773683	11.0	11.0							1.820252243	-959.7498947999999	795.1278087000001	-625.2645711	0.0	365.0	0.0	365.0	7.43901681364081	7.254206134599544	-0.4317824164255377	5.926428727196627	6.298694689572108	1.812513900697501	-1.512588086444183	-0.9555114450274362	2.244296317123039
13722.58cfa82fe4b0c9d6adf6ba16	58cfa82fe4b0c9d6adf6ba16	TCGA-AA-3549-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3549-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3549-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	431.56	1.9	0.17	58cfa82fe4b0c9d6adf6ba16	TCGA-AA-3549-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3549-01A	E6EC5A68-7555-4F26-BD7E-9CDB4C5F7004	Primary Tumor	Illumina HiSeq	cff80dc2-c080-4905-afce-cfd06a84f6c9	Colorectal	69.0	86158696-60A3-45B7-8351-D800F57EF23B	C5D50597-F0E1-4C34-AB95-3718566AF540	TCGA-AA-3549-01A-02D-1167-02	HG18	TCGA-AA-3549	TCGA-COAD		s13358	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	1167-02	True	COAD	C1		0.199749387	0.25	0.09	12.90898275	0.5201	0.228	-0.441	0.2332	-0.6795	0.1639			0.498035664	2.822202098	199.0	0.296680205	6.0	16.0							0.416165026	-894.1997094000001	227.426418	271.3260903	0.0	639.0	0.0	639.0	6.499486243541238	7.892525417209248	-1.1455187865239476	5.957161952715877	7.807003243771086	0.15148623195619937	-0.5423242908253618	-0.08552217343816171	1.297005018480147
13722.58cfa82fe4b0c9d6adf6ba1c	58cfa82fe4b0c9d6adf6ba1c	TCGA-AA-3664-01A-01D-1981-10_wgs_Illumina.filtered.	WGS	TCGA-AA-3664-01A-01D-1981-10_wgs_Illumina	TCGA-AA-3664-01A-01D-1981-10_wgs_Illumina.bam	338.96	1.9	0.16	58cfa82fe4b0c9d6adf6ba1c	TCGA-AA-3664-01A-01D-1981-10_wgs_Illumina.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3664-01A	A06C09A8-0951-49F4-A765-5147BBCAE109	Primary Tumor	Illumina HiSeq	c35bd7d9-ece5-492b-9d5f-dcc047684dc0	Colorectal	74.0	D448668C-90F3-40FA-9961-88407090DA31	B6B6E1D3-C592-4836-BDAD-D53AF2DBCC9A	TCGA-AA-3664-01A-01D-1981-10	GRCh37-lite	TCGA-AA-3664	TCGA-COAD		s13365	Baylor College of Medicine	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage II	1981-10	False	COAD	C2	GI.CIN	0.064330626	0.13	0.04	0.989274532	1.0507	0.223	-0.4502	-0.3308	0.1882	-0.255	56.0		1.180274663	3.88627023	220.0	0.255809367	4.0	35.0							1.651622201	-583.4668197000001	1323.512658	-989.4090712999999	0.0	1643.0	0.0	1643.0	6.4499436905017635	4.785005489631369	-0.6403725263426161	4.50403354144645	6.8444463646045355	1.4792323567791597	-1.9459101490553132	2.0594408749731663	2.1196048831217755
13722.58cfa82fe4b0c9d6adf6ba1e	58cfa82fe4b0c9d6adf6ba1e	TCGA-AA-3664-01A-01D-1167_101023_SN208_0166_A808PFABXX_s_5_rg.sorted.filtered.	WGS	TCGA-AA-3664-01A-01D-1167_101023_SN208_0166_A808PFABXX_s_5_rg.sorted	TCGA-AA-3664-01A-01D-1167_101023_SN208_0166_A808PFABXX_s_5_rg.sorted.bam	338.96	1.9	0.16	58cfa82fe4b0c9d6adf6ba1e	TCGA-AA-3664-01A-01D-1167_101023_SN208_0166_A808PFABXX_s_5_rg.sorted.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3664-01A	A06C09A8-0951-49F4-A765-5147BBCAE109	Primary Tumor	Illumina HiSeq	1eb3d869-c9bd-4087-80cd-7fb426eb7997	Colorectal	74.0	D448668C-90F3-40FA-9961-88407090DA31	4B4C0EDF-1012-4A6A-B01E-CDEB130FF2E6	TCGA-AA-3664-01A-01D-1167-02	HG18_Broad_variant	TCGA-AA-3664	TCGA-COAD		s12864	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage II	1167-02	True	COAD	C2	GI.CIN	0.064330626	0.13	0.04	0.989274532	1.0507	0.223	-0.4502	-0.3308	0.1882	-0.255	56.0		1.180274663	3.88627023	220.0	0.255809367	4.0	35.0							1.651622201	-583.4668197000001	1323.512658	-989.4090712999999	0.0	1643.0	0.0	1643.0	4.064882529491784	6.026380611314157	-0.6403725263426161	4.300196616426248	6.129921290254997	1.4792323567791597	0.2353140869344652	0.10354067894084018	2.1196048831217755
13722.58cfa82fe4b0c9d6adf6ba20	58cfa82fe4b0c9d6adf6ba20	TCGA-AA-3664-01A-01D-1167_110111_SN208_0178_B818TTABXX_s_5.rg.sorted.filtered.	WGS	TCGA-AA-3664-01A-01D-1167_110111_SN208_0178_B818TTABXX_s_5.rg.sorted	TCGA-AA-3664-01A-01D-1167_110111_SN208_0178_B818TTABXX_s_5.rg.sorted.bam	338.96	1.9	0.16	58cfa82fe4b0c9d6adf6ba20	TCGA-AA-3664-01A-01D-1167_110111_SN208_0178_B818TTABXX_s_5.rg.sorted.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3664-01A	A06C09A8-0951-49F4-A765-5147BBCAE109	Primary Tumor	Illumina HiSeq	9caec406-c1d9-43df-a730-7226fd5880b0	Colorectal	74.0	D448668C-90F3-40FA-9961-88407090DA31	4B4C0EDF-1012-4A6A-B01E-CDEB130FF2E6	TCGA-AA-3664-01A-01D-1167-02	HG18_Broad_variant	TCGA-AA-3664	TCGA-COAD		s13024	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage II	1167-02	True	COAD	C2	GI.CIN	0.064330626	0.13	0.04	0.989274532	1.0507	0.223	-0.4502	-0.3308	0.1882	-0.255	56.0		1.180274663	3.88627023	220.0	0.255809367	4.0	35.0							1.651622201	-583.4668197000001	1323.512658	-989.4090712999999	0.0	1643.0	0.0	1643.0	5.215286327288299	3.033716296500277	-0.6403725263426161	2.4346654333512543	3.768300666924395	1.4792323567791597	-2.780620893937045	0.734584370424118	2.1196048831217755
13722.58cfa82fe4b0c9d6adf6ba25	58cfa82fe4b0c9d6adf6ba25	TCGA-A3-3363-01A-01D-2094-10_wgs_Illumina.filtered.	WGS	TCGA-A3-3363-01A-01D-2094-10_wgs_Illumina	TCGA-A3-3363-01A-01D-2094-10_wgs_Illumina.bam	864.57	1.9	0.14	58cfa82fe4b0c9d6adf6ba25	TCGA-A3-3363-01A-01D-2094-10_wgs_Illumina.bam	Alive	MALE	ASIAN		Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-A3-3363-01A	659294B9-DED9-498A-BC00-C1D4D456AA4A	Primary Tumor	Illumina HiSeq	cbce285a-a226-46dc-9f92-dfe98700c750	Kidney	50.0	605E86AC-58F6-47D4-8BDE-15EB23C857CC	0F53E757-1823-409F-A0EA-249270728E15	TCGA-A3-3363-01A-01D-2094-10	GRCh37-lite	TCGA-A3-3363	TCGA-KIRC		s9301	Baylor College of Medicine	International Genomics Consortium	None	NO	T2	N0	Kidney Clear Cell Renal Carcinoma	Stage II	2094-10	False	KIRC	C4	KIRC.4	0.09918913	0.21	0.0		-1.4183	-0.081	0.6372	-0.4259	-0.2855	-0.2793	23.0	19.0	0.25405254	1.1855785209999998	186.0	0.050961985999999994	2.0	3.0				2.67011989	15.0	0.985993498	2.1377220059999997	-480.0969987	-1462.193217	931.8942347999999	0.0	319.0	0.0	319.0	7.029360062277924	1.3065063861846564	-0.3808583803462906	6.262104909564256	4.63081927880442	2.1793487182937348	-0.7672551527136671	3.324312892619764	2.560207098640025
13722.58cfa82fe4b0c9d6adf6ba26	58cfa82fe4b0c9d6adf6ba26	TCGA-A3-3370-01A-02D-2099-10_Illumina.filtered.	WGS	TCGA-A3-3370-01A-02D-2099-10_Illumina	TCGA-A3-3370-01A-02D-2099-10_Illumina.bam	152.4	1.9	0.14	58cfa82fe4b0c9d6adf6ba26	TCGA-A3-3370-01A-02D-2099-10_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-A3-3370-01A	9F632FC3-2241-469A-A14A-CD537350155F	Primary Tumor	Illumina HiSeq	2bf569a0-5698-4304-b006-f61284e72aef	Kidney	48.0	1B2DF3FD-183C-4099-A387-5908C8B44F57	D7F1DB09-8BA0-4B76-BCD2-01C14165F0D5	TCGA-A3-3370-01A-02D-2099-10	GRCh37-lite	TCGA-A3-3370	TCGA-KIRC		s9563	Baylor College of Medicine	International Genomics Consortium	United States	NO	T1b	N0	Kidney Clear Cell Renal Carcinoma	Stage I	2099-10	False	KIRC	C3	KIRC.1	0.283636542	0.57	0.01		-1.0158	-0.3465	1.0092	0.8426	0.46799999999999997	0.0048	19.0	5.0	0.23867341	0.924859465	71.0	0.100528771	1.0	9.0	0.98380246	0.681919901	2.0	3.71098902	62.0	0.899168448	1.267297594	187.63099069999998	-482.7723393	2994.358325	0.0	2274.0	0.0	2274.0	8.60066736749939	0.15033533754160544	-0.2307234468369791	5.406865180183305	2.7765283202438606	5.301947134598615	-3.1938021873160847	2.626192982702255	5.532670581435594
13722.58cfa82fe4b0c9d6adf6ba42	58cfa82fe4b0c9d6adf6ba42	TCGA-AA-A01R-01A-21D-A079-02_110402_SN208_0200_BB02BTABXX_s_3.rg.sorted.filtered.	WGS	TCGA-AA-A01R-01A-21D-A079-02_110402_SN208_0200_BB02BTABXX_s_3.rg.sorted	TCGA-AA-A01R-01A-21D-A079-02_110402_SN208_0200_BB02BTABXX_s_3.rg.sorted.bam	75.21	1.8	0.14	58cfa82fe4b0c9d6adf6ba42	TCGA-AA-A01R-01A-21D-A079-02_110402_SN208_0200_BB02BTABXX_s_3.rg.sorted.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01R-01A	97F6C8D3-09A0-4128-8F10-41E736648A5F	Primary Tumor	Illumina HiSeq	dc5cfaa9-514c-4e4d-b882-21df489668aa	Colorectal	47.0	73EE34E8-422D-4AB1-B0F0-DA8A5A2DD9AB	F8021A03-B35B-4E6C-B196-2948789AFCF3	TCGA-AA-A01R-01A-21D-A079-02	HG18_Broad_variant	TCGA-AA-A01R	TCGA-COAD		s12876	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Colon Mucinous Adenocarcinoma	Stage III	A079-02	True	COAD	C2	GI.HM-indel	0.291125137	0.37	0.02	11.59946136	0.5872	0.10800000000000001	0.0093	1.104	1.0544	-0.0428	804.0	431.0			150.0	0.083186977	2.0	11.0							0.813182066	-4.98278952	215.13846940000002	1202.565619	0.0	1065.0	1.0	608.0	6.877884999665216	7.29957520213326	0.40840589354528045	5.990581804664314	7.135687347028144	2.1646586743164256	-0.8873031950009032	-0.1638878551051164	1.7562527807711452
13722.58cfa82fe4b0c9d6adf6ba48	58cfa82fe4b0c9d6adf6ba48	TCGA-A5-A0G5-01A-11D-A043_120327_SN590_0148_BC0LM8ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-A5-A0G5-01A-11D-A043_120327_SN590_0148_BC0LM8ACXX_s_3_rg.sorted	TCGA-A5-A0G5-01A-11D-A043_120327_SN590_0148_BC0LM8ACXX_s_3_rg.sorted.bam	83.98	2.0	0.17	58cfa82fe4b0c9d6adf6ba48	TCGA-A5-A0G5-01A-11D-A043_120327_SN590_0148_BC0LM8ACXX_s_3_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0G5-01A	4806D9A6-E65D-4A82-B422-1B287980A0C6	Primary Tumor	Illumina HiSeq	db20abab-2eed-4958-a741-e31199adb617	Uterus	73.0	FA7392E8-335E-4465-9272-4A19DC99412E	EDFD99A3-38A2-4E43-A3D1-B1D19EA818E5	TCGA-A5-A0G5-01A-11D-A043-02	HG19_Broad_variant	TCGA-A5-A0G5	TCGA-UCEC		s5382	Harvard Medical School	Cedars Sinai	None	NO			Serous endometrial adenocarcinoma		A043-02	True	UCEC	C2	UCEC.CN_HIGH	0.41108211	0.5	0.08	2.598140259	0.2865	0.032	0.9574	1.9628	0.1528	0.0681	48.0		0.820350184	3.3662645469999997	880.0	0.9695646170000001	11.0	62.0							0.991224452	-183.12110019999997	91.86171874	3143.508792	0.0	1126.0	0.0	1126.0	5.200319616195064	7.353140156546081	0.41053774983626057	5.99255769939924	6.49293889132297	1.733681515093428	0.7922380832041758	-0.8602012652231115	1.3231437652571674
13722.58cfa830e4b0c9d6adf6ba4a	58cfa830e4b0c9d6adf6ba4a	TCGA-A6-3807-01A-01D-1459-10_wgs_Illumina.filtered.	WGS	TCGA-A6-3807-01A-01D-1459-10_wgs_Illumina	TCGA-A6-3807-01A-01D-1459-10_wgs_Illumina.bam	380.0	1.9	0.05	58cfa830e4b0c9d6adf6ba4a	TCGA-A6-3807-01A-01D-1459-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-3807-01A	5116E3B4-2BAC-40F5-8046-B9C1783FAAA5	Primary Tumor	Illumina HiSeq	b5897ed2-6c9b-4c6e-b131-41b62e60ecb9	Colorectal	53.0	1EB2A255-6EDD-4ADB-B52D-99DCEC590C5D	F38B5D2E-5CAB-45C7-BB0A-38B2EFC5C156	TCGA-A6-3807-01A-01D-1459-10	GRCh37-lite	TCGA-A6-3807	TCGA-COAD		s13652	Baylor College of Medicine	Christiana Healthcare	None	NO	T3	N2	Colon Adenocarcinoma	Stage IIIC	1459-10	False	COAD	C1	GI.CIN	0.22782604899999997	0.48	0.19	5.297474787	0.5989	0.245	-0.0674	-0.1753	0.0759	0.1453	44.0				221.0	0.48063888	12.0	20.0							1.323846415	-1247.546682	-120.7776531	-1586.448282	0.0	1054.0	0.0	1054.0	6.5018900908526325	4.8410171719339	-0.3807326103869644	5.020285549928417	6.470063555756377	0.638151505256193	-1.4816045409242158	1.6290463838224767	1.0188841156431574
13722.58cfa830e4b0c9d6adf6ba50	58cfa830e4b0c9d6adf6ba50	TCGA-AA-A02K-01A-21D-A079_110401_SN177_0152_A819RJABXX_s_2.rg.sorted.filtered.	WGS	TCGA-AA-A02K-01A-21D-A079_110401_SN177_0152_A819RJABXX_s_2.rg.sorted	TCGA-AA-A02K-01A-21D-A079_110401_SN177_0152_A819RJABXX_s_2.rg.sorted.bam	28.83	1.9	0.15	58cfa830e4b0c9d6adf6ba50	TCGA-AA-A02K-01A-21D-A079_110401_SN177_0152_A819RJABXX_s_2.rg.sorted.bam	Dead	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A02K-01A	10881458-55B2-41D1-8358-4EE6CCB8EC85	Primary Tumor	Illumina HiSeq	7942eab9-d80a-496e-b3cb-50b42bd23334	Colorectal	50.0	685DF015-1B7B-4993-BF05-E3206619DFBA	7CC17F3D-27F5-484A-8E22-C9D0B5B27836	TCGA-AA-A02K-01A-21D-A079-02	HG18_Broad_variant	TCGA-AA-A02K	TCGA-COAD	426.0	s13842	Harvard Medical School	Indivumed	Germany	NO	T4	N2	Colon Adenocarcinoma	Stage IV	A079-02	True	COAD	C2		0.232144845			5.161204723	0.8159	0.2825	-0.9163	-0.9282	0.6135	-0.3814	69.0	152.0										1.098612289	3.0	1.0	4.4440588	-1690.528792	-424.5005227	989.5328553999999	1.0	426.0	1.0	306.0	5.81166920850091	5.567648116541676	0.073829051574548	4.6195308618219775	5.723897433025855	1.0855519814338885	-1.1921383466789326	0.15624931648417917	1.0117229298593404
13722.58cfa830e4b0c9d6adf6ba54	58cfa830e4b0c9d6adf6ba54	TCGA-AA-A01Q-01A-01D-A077_110402_SN208_0200_BB02BTABXX_s_4_rg.sorted.filtered.	WGS	TCGA-AA-A01Q-01A-01D-A077_110402_SN208_0200_BB02BTABXX_s_4_rg.sorted	TCGA-AA-A01Q-01A-01D-A077_110402_SN208_0200_BB02BTABXX_s_4_rg.sorted.bam	237.45	1.73	0.15	58cfa830e4b0c9d6adf6ba54	TCGA-AA-A01Q-01A-01D-A077_110402_SN208_0200_BB02BTABXX_s_4_rg.sorted.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01Q-01A	4BE66108-E72A-406B-BB4B-F58FF2877336	Primary Tumor	Illumina HiSeq	f50b391c-a832-4938-86aa-0ae2e8261a9e	Colorectal	48.0	5D1D7C40-F636-46C6-9540-4DF11A466B15	D84E59D4-7777-4922-990F-622BD246A9F1	TCGA-AA-A01Q-01A-01D-A077-02	HG18_Broad_variant	TCGA-AA-A01Q	TCGA-COAD		s13032	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage II	A077-02	True	COAD	C1		0.13444883400000002			0.293062724	0.7121	0.151	-0.4613	-0.1074	-0.053	-0.4264					199.0	0.046231833	1.0	6.0							2.229676121	-1517.981223	547.5150168	1597.7563710000002	0.0	31.0	0.0	31.0	7.468449849901262	7.5991287751104935	-0.11100722296564092	6.333469917062278	7.689456590445669	1.128088106801063	-1.1349799328389842	0.09032781533517564	1.239095329766704
13722.58cfa830e4b0c9d6adf6ba56	58cfa830e4b0c9d6adf6ba56	TCGA-AA-3966-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3966-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3966-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	526.89	1.9	0.15	58cfa830e4b0c9d6adf6ba56	TCGA-AA-3966-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3966-01A	BC42FE2D-1A33-428D-A601-B1871F4C8D9B	Primary Tumor	Illumina HiSeq	3a88f23b-5740-4937-be5d-a5aed2c4e962	Colorectal	89.0	8C5799BF-DB65-40F6-9A67-ABD4DA4025F2	F1E05BF6-0B98-45F8-9F97-10ABE5957C99	TCGA-AA-3966-01A-01D-1109-02	HG18	TCGA-AA-3966	TCGA-COAD		s13674	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Mucinous Adenocarcinoma	Stage IIA	1109-02	True	COAD	C1	GI.HM-indel	0.240714614	0.49	0.11	0.28408082100000004	0.7255	0.223	0.6312	0.752	0.0513	0.3406	356.0	1383.0	9.528103079	31.92374086	142.0	0.8709884790000001	15.0	16.0							1.5918306969999998	-297.87618310000005	353.1275463	-746.5919637000001	0.0	61.0	0.0	61.0	6.252866810539282	5.723711596165439	-0.9357239124126461	5.223247393358124	6.278500343352546	0.9771729418086152	-1.029619417181158	0.5547887471871071	1.9128968542212612
13722.58cfa830e4b0c9d6adf6ba5d	58cfa830e4b0c9d6adf6ba5d	TCGA-AA-A00R-01A-01D-A126-10_hg19_wgs_Illumina.filtered.	WGS	TCGA-AA-A00R-01A-01D-A126-10_hg19_wgs_Illumina	TCGA-AA-A00R-01A-01D-A126-10_hg19_wgs_Illumina.bam	205.35	1.73	0.08	58cfa830e4b0c9d6adf6ba5d	TCGA-AA-A00R-01A-01D-A126-10_hg19_wgs_Illumina.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A00R-01A	CA22EDD4-EB7C-4677-84AA-6F0354459A19	Primary Tumor	Illumina HiSeq	6182870d-a572-4538-aaa5-06b4adad7bbe	Colorectal	64.0	F72EEAE9-F7F5-4576-A072-5021119117D6	05780D48-80E7-4D70-B00C-081F8A9519F2	TCGA-AA-A00R-01A-01D-A126-10	GRCh37-lite	TCGA-AA-A00R	TCGA-COAD		s13677	Baylor College of Medicine	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	A126-10	False	COAD	C2		0.40054602100000003			2.6955994339999996	1.125	0.41700000000000004	0.5398	1.5323	0.4167	-0.2405					96.0	0.103863096	2.0	0.0							0.457954507	-442.0228687	1637.762706	-434.6143528	0.0	30.0	0.0	30.0	3.1733338044212847	3.3933311400343102	-0.31280627762545954	4.1866485125774995	5.630444491939984	1.4469189829363254	1.0133147081562148	2.2371133519056734	1.759725260561785
13722.58cfa830e4b0c9d6adf6ba60	58cfa830e4b0c9d6adf6ba60	TCGA-A3-3372-01A-01D-2094-10_Illumina.filtered.	WGS	TCGA-A3-3372-01A-01D-2094-10_Illumina	TCGA-A3-3372-01A-01D-2094-10_Illumina.bam	595.87	1.9	0.15	58cfa830e4b0c9d6adf6ba60	TCGA-A3-3372-01A-01D-2094-10_Illumina.bam	Alive	MALE	WHITE		Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-A3-3372-01A	11AB53C8-6366-4BC9-B60D-23E6ED2D1CAE	Primary Tumor	Illumina HiSeq	0dc73f18-4553-49e0-b22e-8bc863c7b907	Kidney	64.0	D3280297-5674-4AE6-AB57-8D820543901E	F64E9609-D75D-400C-A92D-D77FD54D6C29	TCGA-A3-3372-01A-01D-2094-10	GRCh37-lite	TCGA-A3-3372	TCGA-KIRC		s9155	Baylor College of Medicine	International Genomics Consortium	United States	NO	T3	NX	Kidney Clear Cell Renal Carcinoma	Stage III	2094-10	False	KIRC	C3	KIRC.2	0.257411748	0.5	0.0		-1.1013	-0.36	0.6646	0.2419	0.4225	0.0352			0.0	0.0	74.0	0.640642597	22.0	1.0				3.272249183	37.0	0.906209795	1.012621589	-357.09681969999997	-873.2838305	2696.273389	0.0	735.0	0.0	735.0	8.571556368887157	0.8514772708127065	0.2726921193030897	5.473267507008074	3.992554681913359	3.7953108247732557	-3.0982888618790834	3.1410774111006523	3.522618705470166
13722.58cfa830e4b0c9d6adf6ba6c	58cfa830e4b0c9d6adf6ba6c	TCGA-AA-A010-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A010-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A010-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	113.85	1.65	0.15	58cfa830e4b0c9d6adf6ba6c	TCGA-AA-A010-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A010-01A	0712566E-3371-4715-95F1-5B792E72D758	Primary Tumor	Illumina HiSeq	ea0e92bb-7617-4183-82be-773e8cc15dca	Colorectal	46.0	46FB1711-E385-49A4-BF15-7990123CBE6B	30FCD977-8C62-4925-BC84-5894A12BABDB	TCGA-AA-A010-01A-01D-A077-02	HG18	TCGA-AA-A010	TCGA-COAD		s13200	Harvard Medical School	Indivumed	Germany	NO	T4	N0	Colon Adenocarcinoma	Stage IIB	A077-02	True	COAD	C1	GI.HM-SNV	0.143919894	0.23	0.0	30.57691389	0.9199	0.256	-0.5678	-0.2652	-0.628	-0.2932	3289.0	165.0			66.0	0.005584009	0.0	2.0							0.305366795	-751.3864624	1188.086608	-645.9534123	0.0	1064.0	0.0	1064.0	7.393519472152757	4.453096609160157	0.08904313729932112	6.6203295839192755	7.159519470602992	3.13099982634131	-0.7731898882334818	2.7064228614428343	3.041956689041989
13722.58cfa830e4b0c9d6adf6ba6e	58cfa830e4b0c9d6adf6ba6e	TCGA-AA-A01D-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A01D-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A01D-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	119.82	1.79	0.15	58cfa830e4b0c9d6adf6ba6e	TCGA-AA-A01D-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01D-01A	E2EDBF3F-25D8-49AA-B656-2A59C3B99AEB	Primary Tumor	Illumina HiSeq	dc156fb1-9b36-4d02-a6f0-54027775ed04	Colorectal	47.0	082DEF2F-4D99-4270-83E7-5A9A5C049C23	5BF3D0AB-D301-4EE7-84A1-83F596C29E6E	TCGA-AA-A01D-01A-01D-A077-02	HG18	TCGA-AA-A01D	TCGA-COAD		s13525	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Colon Mucinous Adenocarcinoma	Stage IIIC	A077-02	True	COAD	C1		0.253386927	0.6	0.2	7.504092739	0.5786	0.08199999999999999	-0.0151	-0.6064	-0.8963	0.40399999999999997			0.0	0.0	98.0	0.410368732	18.0	12.0							0.960176044	-283.1576697	104.4606462	-846.4965762	1.0	334.0	1.0	183.0	6.969085534133743	6.146049915053364	-1.6688808811450713	5.75269020980925	6.213491195848897	3.0573103357731783	-1.2163953243244934	0.06744128079553269	4.72619121691825
13722.58cfa830e4b0c9d6adf6ba74	58cfa830e4b0c9d6adf6ba74	TCGA-AA-3555-01A-01D-0959-10_wgs_Illumina.filtered.	WGS	TCGA-AA-3555-01A-01D-0959-10_wgs_Illumina	TCGA-AA-3555-01A-01D-0959-10_wgs_Illumina.bam	949.56	1.9	0.13	58cfa830e4b0c9d6adf6ba74	TCGA-AA-3555-01A-01D-0959-10_wgs_Illumina.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3555-01A	36EAF209-C332-4321-B6AA-51A3368ECD79	Primary Tumor	Illumina HiSeq	6843fb20-8f01-4121-9e2c-823e5ce9da98	Colorectal	81.0	9F9961F0-4EE2-4471-AE4A-A0122D630A28	154F80BD-984C-4792-BB89-20C4DA0C08E0	TCGA-AA-3555-01A-01D-0959-10	GRCh37-lite	TCGA-AA-3555	TCGA-COAD		s13182	Baylor College of Medicine	Indivumed	Germany	NO	T3	N0	Colon Mucinous Adenocarcinoma	Stage IIA	0959-10	False	COAD	C4		0.21071610300000002			2.260490556	1.0172	0.278	-0.2441	-1.1601	0.1498	0.1609					79.0	0.000350537	0.0	3.0							1.47107021	-1319.415918	1205.436214	-2602.9519649999997	0.0	911.0	1.0	91.0	7.2543707042887515	3.500575729554578	-2.4344917898915663	5.89106586139356	5.967120761810457	-1.8152899666382492	-1.3633048428951917	2.466545032255879	0.6192018232533172
13722.58cfa830e4b0c9d6adf6ba75	58cfa830e4b0c9d6adf6ba75	TCGA-AA-3812-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3812-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3812-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	270.96	1.9	0.15	58cfa830e4b0c9d6adf6ba75	TCGA-AA-3812-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3812-01A	4563E4E0-A661-46DE-AD25-9C86A621E147	Primary Tumor	Illumina HiSeq	92316171-5ae2-4812-b824-183f14adf90a	Colorectal	82.0	98AD41D5-FD77-4F30-94B5-03BF7B9C69B9	B4AA0837-42E8-41B7-B44B-F84D48155C3E	TCGA-AA-3812-01A-01D-1167-02	HG18	TCGA-AA-3812	TCGA-COAD		s13188	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1167-02	True	COAD	C3	GI.CIN	0.173636016	0.58	0.0	7.73243178	-0.5463	-0.175	-0.1145	0.1661	-0.9984	0.5213	53.0	18.0	0.901842948	3.05462934	130.0	0.699529697	12.0	4.0							3.124387505	-669.4354475	-1372.2858199999998	1964.565568	0.0	1066.0	1.0	762.0	5.761942940552666	6.301075467817396	-1.790688996333683	5.632731209072661	5.167977003078117	1.9726555090307885	-0.1292117314800061	-1.1330984647392794	3.7633445053644716
13722.58cfa830e4b0c9d6adf6ba78	58cfa830e4b0c9d6adf6ba78	TCGA-AA-A03F-01A-11D-A17O-10_wgs_Illumina.filtered.	WGS	TCGA-AA-A03F-01A-11D-A17O-10_wgs_Illumina	TCGA-AA-A03F-01A-11D-A17O-10_wgs_Illumina.bam	124.44	1.85	0.09	58cfa830e4b0c9d6adf6ba78	TCGA-AA-A03F-01A-11D-A17O-10_wgs_Illumina.bam	Dead	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A03F-01A	2A971E32-B0E7-4A3F-8C40-62D69C0307D8	Primary Tumor	Illumina HiSeq	d227eb87-8290-4223-b1d2-c241162935c9	Colorectal	90.0	8ABA8350-B5EE-4CA2-BC99-5C7922A886C4	18DD42D7-2D84-400E-9ADB-A38FAA916A9E	TCGA-AA-A03F-01A-11D-A17O-10	GRCh37-lite	TCGA-AA-A03F	TCGA-COAD	549.0	s12884	Baylor College of Medicine	Indivumed	Germany	NO	T3	N2	Colon Mucinous Adenocarcinoma	Stage III	A17O-10	True	COAD	C3	GI.GS	0.209805915	0.22	0.0	1.355866356	-0.1685	-0.23	-0.9335	0.1368	-1.4081	-0.2469	48.0	13.0	1.055323209	3.422669866	73.0	3.6e-05	0.0	3.0							0.81414896	-1225.2459099999999	-593.878884	3866.731188	1.0	549.0	1.0	549.0	7.230201031370209	3.5349409851162132	-2.064543449869165	5.3976195676218985	5.61481797204569	-0.20662773090340014	-1.83258146374831	2.0798769869294764	1.8579157189657647
13722.58cfa830e4b0c9d6adf6ba7c	58cfa830e4b0c9d6adf6ba7c	TCGA-AA-3509-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3509-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3509-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	496.0	1.9	0.14	58cfa830e4b0c9d6adf6ba7c	TCGA-AA-3509-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3509-01A	80E677B1-5EBE-4069-A1A5-1538FFEE6642	Primary Tumor	Illumina HiSeq	41b8f6a5-58f8-4e97-bbd3-a2587a70e30d	Colorectal	54.0	BA6E3333-3651-450E-A6EA-4E47CF0D18BF	ACCC21A8-D026-40E4-AA2C-C0F998A1D370	TCGA-AA-3509-01A-01D-1405-02	HG18	TCGA-AA-3509	TCGA-COAD		s13183	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage II	1405-02	True	COAD	C1		0.078997844				0.7642	0.2945	-0.1853	0.0409	0.0806	-0.0562															1.497895995	-862.0724802000001	50.27770687	-75.60246444	0.0	1915.0	0.0	1915.0	5.6284772048310145	6.196104626857632	-1.6757894413413945	4.612556632008018	5.719180554767322	0.8919440232083005	-1.015920572822996	-0.4769240720903096	2.567733464549695
13722.58cfa830e4b0c9d6adf6ba9b	58cfa830e4b0c9d6adf6ba9b	TCGA-A5-A0GJ-01A-11D-A043_120318_SN590_0146_AC0KH7ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-A5-A0GJ-01A-11D-A043_120318_SN590_0146_AC0KH7ACXX_s_7_rg.sorted	TCGA-A5-A0GJ-01A-11D-A043_120318_SN590_0146_AC0KH7ACXX_s_7_rg.sorted.bam	92.8	2.11	0.16	58cfa830e4b0c9d6adf6ba9b	TCGA-A5-A0GJ-01A-11D-A043_120318_SN590_0146_AC0KH7ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GJ-01A	94817E78-78F5-4556-9394-610DF65605E2	Primary Tumor	Illumina HiSeq	d5b73d0f-c14a-4a54-a8e1-14bc027cfef5	Uterus	44.0	48FA5B7D-E488-4743-A7CE-ACEB9945F00B	A5D63CC4-892C-4357-B8A1-2BF50CF425DC	TCGA-A5-A0GJ-01A-11D-A043-02	HG19_Broad_variant	TCGA-A5-A0GJ	TCGA-UCEC		s5384	Harvard Medical School	Cedars Sinai	None	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C3	UCEC.CN_HIGH	0.093266818	0.19	0.05	1.46415926	-0.2373	-0.071	-0.2789	0.7546	-0.0376	-0.0322	21.0	20.0	0.652056886	2.059127008	466.0	0.849487344	8.0	54.0							2.47967074	-1248.614695	-482.8791813	1972.8658920000003	0.0	2000.0	1.0	12.0	5.487599933315026	6.9183654580941525	-0.6234553964702839	5.646664627944713	5.619082473963891	4.464758032271346	0.15906469462968742	-1.299282984130261	5.08821342874163
13722.58cfa830e4b0c9d6adf6ba9e	58cfa830e4b0c9d6adf6ba9e	TCGA-AA-A01X-01A-21D-A17O-10_wgs_Illumina.filtered.	WGS	TCGA-AA-A01X-01A-21D-A17O-10_wgs_Illumina	TCGA-AA-A01X-01A-21D-A17O-10_wgs_Illumina.bam	71.0	1.92	0.07	58cfa830e4b0c9d6adf6ba9e	TCGA-AA-A01X-01A-21D-A17O-10_wgs_Illumina.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01X-01A	2E386E48-B99B-4806-A3E3-081D72A606E7	Primary Tumor	Illumina HiSeq	4b96a6ce-adbd-45b8-9c53-ea1850f0731c	Colorectal	80.0	0225A318-9BB2-4340-A34A-99FCBC563E0A	B7F2E85A-3C6A-48B7-8A4F-2DEC1D85359D	TCGA-AA-A01X-01A-21D-A17O-10	GRCh37-lite	TCGA-AA-A01X	TCGA-COAD		s12880	Baylor College of Medicine	Indivumed	Germany	NO	T2	N1	Colon Adenocarcinoma	Stage III	A17O-10	True	COAD	C1	GI.CIN	0.087045586	0.38	0.09	4.113525645	0.0492	0.040999999999999995	-0.8186	-0.1248	-0.5646	-0.0108	33.0	0.0	0.869170742	1.798284293	50.0	0.52213547	18.0	1.0				1.386294361	4.0	1.0	2.5460106330000003	-1112.5126699999998	-626.5077416	2251.569675	0.0	791.0	1.0	791.0	6.568604458155164	1.284902104637685	-0.4967054508381319	5.512551783905851	3.6239284767939868	3.1471112586388905	-1.056052674249314	2.339026372156302	3.643816709477022
13722.58cfa830e4b0c9d6adf6baa2	58cfa830e4b0c9d6adf6baa2	TCGA-AA-3514-01A-02D-1554-10_wgs_Illumina.filtered.	WGS	TCGA-AA-3514-01A-02D-1554-10_wgs_Illumina	TCGA-AA-3514-01A-02D-1554-10_wgs_Illumina.bam	263.29	1.9	0.05	58cfa830e4b0c9d6adf6baa2	TCGA-AA-3514-01A-02D-1554-10_wgs_Illumina.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3514-01A	DDF69ED9-4C53-48B8-9F01-495BD60C3425	Primary Tumor	Illumina HiSeq	2c81df5f-0948-463a-a303-3beb5bd5205b	Colorectal	81.0	A657AFDB-5322-454F-8DD7-8397291401C5	A0F94565-9169-49EE-8E6A-21BDC43D9DE6	TCGA-AA-3514-01A-02D-1554-10	GRCh37-lite	TCGA-AA-3514	TCGA-COAD		s13667	Baylor College of Medicine	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	1554-10	False	COAD	C1		0.076714682	0.21	0.02	6.348599292	0.0514	-0.045	-0.5979	-0.1347	-1.6094	0.3792			1.2691667979999999	4.442083794	67.0	0.078219128	4.0	3.0	0.934308253	3.238065655	32.0				0.7245671779999999	-958.6218389000001	-473.7177384	751.1534154	0.0	31.0	0.0	31.0	7.108880416624341	1.0695932352298705	-1.2952220214458814	5.938809163974087	4.331157698450985	3.1984385134440334	-1.1700712526502546	3.2615644632211147	4.493660534889915
13722.58cfa830e4b0c9d6adf6baa6	58cfa830e4b0c9d6adf6baa6	TCGA-AA-A03F-01A-11D-A079-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A03F-01A-11D-A079-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A03F-01A-11D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	124.44	1.85	0.17	58cfa830e4b0c9d6adf6baa6	TCGA-AA-A03F-01A-11D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A03F-01A	2A971E32-B0E7-4A3F-8C40-62D69C0307D8	Primary Tumor	Illumina HiSeq	93e089c5-c259-445d-9ffa-10073ad2d336	Colorectal	90.0	8ABA8350-B5EE-4CA2-BC99-5C7922A886C4	F445E8E6-6A82-4400-8307-1DE92AC03539	TCGA-AA-A03F-01A-11D-A079-02	HG18	TCGA-AA-A03F	TCGA-COAD	549.0	s13207	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Colon Mucinous Adenocarcinoma	Stage III	A079-02	True	COAD	C3	GI.GS	0.209805915	0.22	0.0	1.355866356	-0.1685	-0.23	-0.9335	0.1368	-1.4081	-0.2469	48.0	13.0	1.055323209	3.422669866	73.0	3.6e-05	0.0	3.0							0.81414896	-1225.2459099999999	-593.878884	3866.731188	1.0	549.0	1.0	549.0	2.1400661634962708	1.2729656758128873	-2.064543449869165	-0.05715841383994835	0.3856624808119844	-0.20662773090340014	-2.197224577336219	-0.8873031950009029	1.8579157189657647
13722.58cfa830e4b0c9d6adf6baaa	58cfa830e4b0c9d6adf6baaa	TCGA-A5-A0GD-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_3_rg.sorted.filtered.	WGS	TCGA-A5-A0GD-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_3_rg.sorted	TCGA-A5-A0GD-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_3_rg.sorted.bam	96.48	1.95	0.14	58cfa830e4b0c9d6adf6baaa	TCGA-A5-A0GD-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GD-01A	1486A031-B74D-4976-8B0B-4569E6978F49	Primary Tumor	Illumina HiSeq	98b5ea92-9e57-4d1f-937d-8bb0dd2a3cf2	Uterus	75.0	F449F50A-7664-4DDC-87AA-6A061EE7190C	069406A8-56D7-4E93-8570-7880A99D6C2D	TCGA-A5-A0GD-01A-11D-A043-02	HG19_Broad_variant	TCGA-A5-A0GD	TCGA-UCEC		s4771	Harvard Medical School	Cedars Sinai	None	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C2	UCEC.	0.177499805	0.33	0.03	1.859444104	0.7051	0.266	-0.1463	-0.1217	0.6639	-0.5657			0.0	0.0	1404.0	0.005285336999999999	0.0	0.0							1.942574094	-1305.275997	-93.33641558	-1225.783306	1.0	3423.0	0.0	3423.0	4.90416304958574	5.82578157591105	0.6263042695894018	4.108158483586086	5.189792809191053	1.9440662125677162	-0.7960045659996533	-0.6359887667199966	1.3177619429783145
13722.58cfa830e4b0c9d6adf6baba	58cfa830e4b0c9d6adf6baba	TCGA-AA-A01S-01A-21D-A17O-10_wgs_Illumina.filtered.	WGS	TCGA-AA-A01S-01A-21D-A17O-10_wgs_Illumina	TCGA-AA-A01S-01A-21D-A17O-10_wgs_Illumina.bam	89.57	1.8	0.07	58cfa830e4b0c9d6adf6baba	TCGA-AA-A01S-01A-21D-A17O-10_wgs_Illumina.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01S-01A	84E34CF2-B3BB-4A1A-8FB7-6C2C604C4008	Primary Tumor	Illumina HiSeq	02f49f2b-40ad-427b-bb81-6ef0c6efc46d	Colorectal	47.0	5743700C-CBD3-4F87-8109-6349A96EB605	A64000DF-16E5-4B88-865F-5C680ADF60EB	TCGA-AA-A01S-01A-21D-A17O-10	GRCh37-lite	TCGA-AA-A01S	TCGA-COAD		s12877	Baylor College of Medicine	Indivumed	Germany	NO	T3	N1	Colon Adenocarcinoma	Stage III	A17O-10	True	COAD	C1	GI.CIN	0.036294006000000004	0.1	0.03	1.01622772	0.4655	0.147	-1.8764	-1.5879	-1.9286	-0.5577	23.0	2.0	0.697744447	1.425825609	237.0	0.22491224199999998	7.0	19.0							0.445006699	-1982.0952280000001	-293.49188660000004	1436.6879	0.0	31.0	0.0	31.0	7.078341579557671	1.912842315766568	-0.16276103093946115	5.861946255233178	5.3238677863649855	0.6652902260569789	-1.2163953243244934	3.4110254705984175	0.82805125699644
13722.58cfa830e4b0c9d6adf6babc	58cfa830e4b0c9d6adf6babc	TCGA-AA-A01T-01A-21D-A079-02_110402_SN208_0200_BB02BTABXX_s_5.rg.sorted.filtered.	WGS	TCGA-AA-A01T-01A-21D-A079-02_110402_SN208_0200_BB02BTABXX_s_5.rg.sorted	TCGA-AA-A01T-01A-21D-A079-02_110402_SN208_0200_BB02BTABXX_s_5.rg.sorted.bam	80.04	2.03	0.14	58cfa830e4b0c9d6adf6babc	TCGA-AA-A01T-01A-21D-A079-02_110402_SN208_0200_BB02BTABXX_s_5.rg.sorted.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01T-01A	F87C6DCC-1A9E-4DF5-962C-1F946E2611F8	Primary Tumor	Illumina HiSeq	0dd44906-041d-4af2-8f42-a1bed185e1c6	Colorectal	63.0	BFC99C6D-7791-4037-9C74-A74BE68E616A	8F61B113-0E19-403E-9637-48E9D9733692	TCGA-AA-A01T-01A-21D-A079-02	HG18_Broad_variant	TCGA-AA-A01T	TCGA-COAD		s13839	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Colon Adenocarcinoma	Stage III	A079-02	True	COAD	C1	GI.CIN	0.045102565	0.29	0.11	0.154091685	0.2623	0.095	-1.6469	-1.2234	-0.3763	-0.3073	41.0		0.6833065070000001	2.525263179	141.0	0.910212919	18.0	16.0							0.20091035399999999	-648.3558958	-530.4368972	214.07018259999998	0.0	1005.0	0.0	1005.0	6.9644191260996795	4.1890997003840535	-0.9853958305089713	6.271271945539734	6.890054078504795	0.6351006464381883	-0.6931471805599454	2.7009543781207412	1.6204964769471597
13722.58cfa830e4b0c9d6adf6bac2	58cfa830e4b0c9d6adf6bac2	TCGA-49-4501-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-49-4501-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-49-4501-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	133.2	1.9	0.14	58cfa830e4b0c9d6adf6bac2	TCGA-49-4501-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-49-4501-01A	0780EB43-D5B5-4C3D-9825-BEACBA5CC723	Primary Tumor	Illumina HiSeq	2df919ad-215d-40a5-8e9d-e22862898cd7	Lung	67.0	FC511A67-5383-4877-AEEF-36C0B7934B77	FA521F2B-4BB1-4A15-9101-422B2B65489A	TCGA-49-4501-01A-01D-1203-02	GRCh37	TCGA-49-4501	TCGA-LUAD	1421.0	s11003	Harvard Medical School	Johns Hopkins	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1203-02	True	LUAD	C2	LUAD.5	0.293295016	0.57	0.46	7.937631349	-0.853	0.124	0.7525	1.7852	0.882	0.2617	18.0	6.0	0.6787629909999999	1.15094594	255.0	0.5956938079999999	15.0	28.0	0.91545844	2.982651975	26.0	4.257531193	74.0	0.9891883840000001	2.3967407780000003	499.82790769999997	-1137.957224	1953.079211	1.0	1421.0	1.0	545.0	9.669125053514565	8.514031054269022	0.6184800180991957	8.369842069384303	5.272555397483581	3.579923218174555	-1.2992829841302607	-3.241475656785442	2.961443200075359
13722.58cfa830e4b0c9d6adf6bad4	58cfa830e4b0c9d6adf6bad4	TCGA-AA-A01V-01A-23D-A079-02_110402_SN208_0200_BB02BTABXX_s_7.rg.sorted.filtered.	WGS	TCGA-AA-A01V-01A-23D-A079-02_110402_SN208_0200_BB02BTABXX_s_7.rg.sorted	TCGA-AA-A01V-01A-23D-A079-02_110402_SN208_0200_BB02BTABXX_s_7.rg.sorted.bam	86.94	2.0	0.15	58cfa830e4b0c9d6adf6bad4	TCGA-AA-A01V-01A-23D-A079-02_110402_SN208_0200_BB02BTABXX_s_7.rg.sorted.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01V-01A	0CB0DAC8-4CE2-444A-B1AE-1550E065B4D9	Primary Tumor	Illumina HiSeq	f9fde040-dea2-4d98-8a28-05cb13efa1c2	Colorectal	59.0	8816F14D-9FBB-4033-9CA4-6CA0DB66161A	D13F4522-90DC-41C8-A274-FBD9C0CD2E60	TCGA-AA-A01V-01A-23D-A079-02	HG18_Broad_variant	TCGA-AA-A01V	TCGA-COAD		s13683	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	A079-02	True	COAD	C1	GI.GS	0.10136753300000001	0.2	0.0	1.123851717	0.3243	0.084	-0.8204	-0.1163	-0.958	-0.3022	53.0		1.132780887	3.1078860230000003	55.0	0.000149704	0.0	0.0							1.842443271	-1133.990693	104.2096103	1434.598508	0.0	31.0	0.0	31.0	6.78469518622491	6.78152682519625	-1.4809090730284553	6.145615226935241	6.743786497213403	-0.6338872498528201	-0.6390799592896697	-0.03774032798284743	0.8470218231756351
13722.58cfa830e4b0c9d6adf6bad6	58cfa830e4b0c9d6adf6bad6	TCGA-A6-6141-01A-11D-1771-10_wgs_Illumina.filtered.	WGS	TCGA-A6-6141-01A-11D-1771-10_wgs_Illumina	TCGA-A6-6141-01A-11D-1771-10_wgs_Illumina.bam	315.4	1.9	0.05	58cfa830e4b0c9d6adf6bad6	TCGA-A6-6141-01A-11D-1771-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-6141-01A	58FACEDB-FCB8-4ECF-8338-2BFA4947ACEF	Primary Tumor	Illumina HiSeq	6fd83764-dbd4-43ec-bab9-c2950c46cf59	Colorectal	31.0	D67FC406-7974-433E-896D-57197ECED52B	00AA769D-622C-433E-8A8A-63FB5C41EA42	TCGA-A6-6141-01A-11D-1771-10	GRCh37-lite	TCGA-A6-6141	TCGA-COAD		s13355	Baylor College of Medicine	Christiana Healthcare	United States	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1771-10	False	COAD	C1		0.308890561	0.52	0.0	21.80153829	0.4722	0.1025	-0.0996	1.2934	0.0644	0.03			0.0	0.0	69.0	0.00020983099999999998	0.0	0.0	0.921015577	2.7118741660000003	19.0	3.258096538	26.0	1.0	1.340149077	-705.4844901	424.0472761	1052.875313	0.0	255.0	0.0	255.0	6.665319684287306	4.105490942566742	-0.0820743785247533	5.47573561741347	5.749050768070099	1.993689937356721	-1.1895840668738364	1.643559825503357	2.0757643158814743
13722.58cfa830e4b0c9d6adf6bada	58cfa830e4b0c9d6adf6bada	TCGA-49-6745-01A-11D-1853_111218_SN208_0258_C054RACXX_s_7_rg.sorted.filtered.	WGS	TCGA-49-6745-01A-11D-1853_111218_SN208_0258_C054RACXX_s_7_rg.sorted	TCGA-49-6745-01A-11D-1853_111218_SN208_0258_C054RACXX_s_7_rg.sorted.bam	88.7	1.9	0.15	58cfa830e4b0c9d6adf6bada	TCGA-49-6745-01A-11D-1853_111218_SN208_0258_C054RACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE		Lung Adenocarcinoma	Aligned reads	TCGA-49-6745-01A	9C7875AD-AB71-4D48-B2E3-E4C7A46393E9	Primary Tumor	Illumina HiSeq	b4eee7d7-a56c-4927-929e-ac66abe41408	Lung	82.0	357F3EFE-E2C9-432A-A2B6-75A5FDBAE3BE	A88D69EF-BE3C-4341-AD6C-0F035685862F	TCGA-49-6745-01A-11D-1853-02	HG19_Broad_variant	TCGA-49-6745	TCGA-LUAD		s11451	Harvard Medical School	Johns Hopkins	United States	NO	T2a	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1853-02	True	LUAD	C2	LUAD.4	0.33045954	0.76	0.33	7.710816212	0.2358	0.0405	0.9866	1.0438	0.9075	0.5605	52.0	5.0	0.8216590979999999	3.345326328	118.0	0.305232457	9.0	11.0	0.522689036	1.340670906	13.0	3.5956292160000003	43.0	0.955979237	1.499184444	443.0162012	153.5269825	1947.875216	0.0	522.0	0.0	522.0	7.396279519797057	9.260506877929863	-0.9744198678265424	6.1832568799512035	8.780933797667977	2.9242733095718463	-1.2130226398458537	-0.4795730802618863	3.8986931773983886
13722.58cfa830e4b0c9d6adf6baf8	58cfa830e4b0c9d6adf6baf8	TCGA-AA-3514-01A-02D-1547_110525_SN590_0091_AC02W2ABXX_s_1.rg.sorted.filtered.	WGS	TCGA-AA-3514-01A-02D-1547_110525_SN590_0091_AC02W2ABXX_s_1.rg.sorted	TCGA-AA-3514-01A-02D-1547_110525_SN590_0091_AC02W2ABXX_s_1.rg.sorted.bam	263.29	1.9	0.15	58cfa830e4b0c9d6adf6baf8	TCGA-AA-3514-01A-02D-1547_110525_SN590_0091_AC02W2ABXX_s_1.rg.sorted.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3514-01A	DDF69ED9-4C53-48B8-9F01-495BD60C3425	Primary Tumor	Illumina HiSeq	3737ce68-bbb0-4ecc-849f-0fd049fe4d85	Colorectal	81.0	A657AFDB-5322-454F-8DD7-8397291401C5	C0486DD0-5BE4-4B64-8A8F-3CF47BD5A330	TCGA-AA-3514-01A-02D-1547-02	HG18_Broad_variant	TCGA-AA-3514	TCGA-COAD		s13361	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	1547-02	False	COAD	C1		0.076714682	0.21	0.02	6.348599292	0.0514	-0.045	-0.5979	-0.1347	-1.6094	0.3792			1.2691667979999999	4.442083794	67.0	0.078219128	4.0	3.0	0.934308253	3.238065655	32.0				0.7245671779999999	-958.6218389000001	-473.7177384	751.1534154	0.0	31.0	0.0	31.0	7.451314272364764	4.500128380920983	-1.2952220214458814	6.0967686095594535	6.441948544724772	3.1984385134440334	-1.3545456628053105	1.9418201638037886	4.493660534889915
13722.58cfa830e4b0c9d6adf6bb02	58cfa830e4b0c9d6adf6bb02	TCGA-A6-A567-01A-31D-A28G-10_wgs_Illumina.filtered.	WGS	TCGA-A6-A567-01A-31D-A28G-10_wgs_Illumina	TCGA-A6-A567-01A-31D-A28G-10_wgs_Illumina.bam	29.22		0.08	58cfa830e4b0c9d6adf6bb02	TCGA-A6-A567-01A-31D-A28G-10_wgs_Illumina.bam	Dead	MALE	BLACK OR AFRICAN AMERICAN		Colon Adenocarcinoma	Aligned reads	TCGA-A6-A567-01A	857A5889-19E7-4208-8362-F1377C408037	Primary Tumor	Illumina HiSeq	062aa65c-624a-4bc6-97bc-6c35e7dc0ba3	Colorectal	56.0	ED37A5C0-341C-4ECC-8FB8-4B705E76E2AF	05486349-24A4-4931-BF5F-C9FEFE369AF2	TCGA-A6-A567-01A-31D-A28G-10	GRCh37-lite	TCGA-A6-A567	TCGA-COAD	1881.0	s12854	Baylor College of Medicine	Christiana Healthcare	United States	NO	T3	N1	Colon Adenocarcinoma	Stage IV	A28G-10	True	COAD	C1	GI.CIN	0.123899325	0.27	0.19	1.5379137280000001	0.294	0.1725	-0.9876	-0.6853	-1.1172	-0.0045	26.0	13.0	0.44376482899999997	1.252983046	153.0	0.8339306409999999	9.0	10.0				0.0	1.0		2.4998936169999997	-1589.618577	-32.54659161	1334.546032	1.0	1881.0	1.0	612.0	7.539913187915652	3.95933227851416	-0.24005402346252647	5.419649651715561	3.9461394750295966	4.722611282848187	-2.120263536200091	-0.01319280348456342	4.962665306310713
13722.58cfa830e4b0c9d6adf6bb0a	58cfa830e4b0c9d6adf6bb0a	TCGA-A5-A0R6-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_2_rg.sorted.filtered.	WGS	TCGA-A5-A0R6-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_2_rg.sorted	TCGA-A5-A0R6-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_2_rg.sorted.bam	55.64	2.08	0.15	58cfa830e4b0c9d6adf6bb0a	TCGA-A5-A0R6-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0R6-01A	39609D3C-F5D3-4BC4-B356-1403C6DD1CB5	Primary Tumor	Illumina HiSeq	7485f99f-a7fe-456f-873d-eb1be9fa04b1	Uterus	64.0	836BD487-091B-4728-BCD7-8065E5B76465	FBE6A365-A19A-42F1-9198-63549F77CD9B	TCGA-A5-A0R6-01A-11D-A101-02	HG19_Broad_variant	TCGA-A5-A0R6	TCGA-UCEC		s4991	Harvard Medical School	Cedars Sinai	None	NO			Serous endometrial adenocarcinoma		A101-02	True	UCEC	C2	UCEC.CN_HIGH	0.129028115	0.54	0.08	2.6213641180000002	0.3246	0.205	-0.7291	0.1002	0.5006	0.2284	29.0		0.35577869	1.204174028	293.0	0.8505981979999999	14.0	20.0							2.901907739	-742.6539784	-543.6751709	497.92909389999994	0.0	1153.0	1.0	961.0	6.301611142043766	6.592359367962841	-0.624604861006725	4.7123759369271845	5.360215686670209		-1.5892352051165815	-1.2321436812926327	
13722.58cfa830e4b0c9d6adf6bb0d	58cfa830e4b0c9d6adf6bb0d	TCGA-A6-A565-01A-31D-A28G-10_wgs_Illumina.filtered.	WGS	TCGA-A6-A565-01A-31D-A28G-10_wgs_Illumina	TCGA-A6-A565-01A-31D-A28G-10_wgs_Illumina.bam	27.34		0.08	58cfa830e4b0c9d6adf6bb0d	TCGA-A6-A565-01A-31D-A28G-10_wgs_Illumina.bam	Dead	FEMALE	BLACK OR AFRICAN AMERICAN		Colon Adenocarcinoma	Aligned reads	TCGA-A6-A565-01A	DD7A53EE-CB08-40C4-9935-51D1CA17E9E8	Primary Tumor	Illumina HiSeq	94ddbe0f-9753-4acc-abe8-2bfda86dd8b2	Colorectal	34.0	87A57810-8B62-4AF1-ADB9-4715A71ED632	63BC376E-5A3D-44FD-8D77-686DFC41E458	TCGA-A6-A565-01A-31D-A28G-10	GRCh37-lite	TCGA-A6-A565	TCGA-COAD	494.0	s13657	Baylor College of Medicine	Christiana Healthcare	United States	NO	T3	N2	Colon Mucinous Adenocarcinoma	Stage IIIC	A28G-10	True	COAD	C3	GI.HM-indel	0.463961634	0.81	0.24	17.39195529	0.2679	-0.0015	0.573	1.9444	-0.3474	0.5221	167.0	363.0	3.42506234	8.987569599	55.0	0.008224893	0.0	9.0	0.9040213429999999	3.2395776030000003	36.0	3.573450497	36.0	0.997190348	1.6987148109999999	-474.3061303	-17.46786283	56.98616124	1.0	494.0	1.0	301.0	6.303565855845951	1.8477427528406771	0.029443751331389767	5.340128345546095	3.605740834385151	0.6339065604956629	-0.9634375102998569	1.757998081544474	0.6044628091642731
13722.58cfa830e4b0c9d6adf6bb32	58cfa830e4b0c9d6adf6bb32	TCGA-AA-A00R-01A-01D-A126-10_Illumina.filtered.	WGS	TCGA-AA-A00R-01A-01D-A126-10_Illumina	TCGA-AA-A00R-01A-01D-A126-10_Illumina.bam	205.35	1.73	0.08	58cfa830e4b0c9d6adf6bb32	TCGA-AA-A00R-01A-01D-A126-10_Illumina.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A00R-01A	CA22EDD4-EB7C-4677-84AA-6F0354459A19	Primary Tumor	Illumina HiSeq	a3f8272c-4b21-47f7-be7c-d4fc4cbb70b0	Colorectal	64.0	F72EEAE9-F7F5-4576-A072-5021119117D6	05780D48-80E7-4D70-B00C-081F8A9519F2	TCGA-AA-A00R-01A-01D-A126-10	NCBI36_BCM_variant	TCGA-AA-A00R	TCGA-COAD		s13370	Baylor College of Medicine	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	A126-10	False	COAD	C2		0.40054602100000003			2.6955994339999996	1.125	0.41700000000000004	0.5398	1.5323	0.4167	-0.2405					96.0	0.103863096	2.0	0.0							0.457954507	-442.0228687	1637.762706	-434.6143528	0.0	30.0	0.0	30.0	2.818224403538684	2.9826190454582466	-0.31280627762545954	3.9036133590321045	5.625440356047864	1.4469189829363254	1.0853889554934204	2.6428213105896177	1.759725260561785
13722.58cfa830e4b0c9d6adf6bb3e	58cfa830e4b0c9d6adf6bb3e	TCGA-AA-A01S-01A-21D-A079_110402_SN208_0200_BB02BTABXX_s_6_rg.sorted.filtered.	WGS	TCGA-AA-A01S-01A-21D-A079_110402_SN208_0200_BB02BTABXX_s_6_rg.sorted	TCGA-AA-A01S-01A-21D-A079_110402_SN208_0200_BB02BTABXX_s_6_rg.sorted.bam	89.57	1.8	0.13	58cfa830e4b0c9d6adf6bb3e	TCGA-AA-A01S-01A-21D-A079_110402_SN208_0200_BB02BTABXX_s_6_rg.sorted.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01S-01A	84E34CF2-B3BB-4A1A-8FB7-6C2C604C4008	Primary Tumor	Illumina HiSeq	fe7c227a-1329-4956-b9bf-08bbb6fe161d	Colorectal	47.0	5743700C-CBD3-4F87-8109-6349A96EB605	DC9E606A-12D6-4AA6-9780-1D999EB72C5A	TCGA-AA-A01S-01A-21D-A079-02	HG18_Broad_variant	TCGA-AA-A01S	TCGA-COAD		s13206	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Colon Adenocarcinoma	Stage III	A079-02	True	COAD	C1	GI.CIN	0.036294006000000004	0.1	0.03	1.01622772	0.4655	0.147	-1.8764	-1.5879	-1.9286	-0.5577	23.0	2.0	0.697744447	1.425825609	237.0	0.22491224199999998	7.0	19.0							0.445006699	-1982.0952280000001	-293.49188660000004	1436.6879	0.0	31.0	0.0	31.0	6.92450313628336	6.547309498102019	-0.16276103093946115	6.3808876896943785	6.547309498102019	0.6652902260569789	-0.5436154465889818	0.0	0.82805125699644
13722.58cfa830e4b0c9d6adf6bb40	58cfa830e4b0c9d6adf6bb40	TCGA-AA-A02R-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A02R-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A02R-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	146.73	1.77	0.15	58cfa830e4b0c9d6adf6bb40	TCGA-AA-A02R-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A02R-01A	764C97C9-01D3-45CB-86BD-F8A52B5468DA	Primary Tumor	Illumina HiSeq	5affe933-9b26-4971-81d9-e380618fbfa0	Colorectal	84.0	197245F6-A310-4AF4-9231-0AFEFC547ECD	A803F2CD-F90D-4E51-8D90-1E6AF6897413	TCGA-AA-A02R-01A-01D-A077-02	HG18	TCGA-AA-A02R	TCGA-COAD	670.0	s13204	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	A077-02	True	COAD	C2		0.144991299	0.34	0.08	1.498947368	0.7503	0.19899999999999998	0.4541	0.5984	1.3442	0.0221	532.0	3209.0	11.1116826	36.19818075	93.0	0.046571972	2.0	0.0							0.436724998	-62.74812668	668.4003255	-839.7556804	1.0	670.0	1.0	670.0	6.43689795210692	5.078482728675974	-0.29175539783941695	4.762921518535249	5.260804285469928	1.5476135304257612	-1.6739764335716711	0.182321556793954	1.8393689282651782
13722.58cfa830e4b0c9d6adf6bb48	58cfa830e4b0c9d6adf6bb48	TCGA-AA-A02Y-01A-43D-A079-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A02Y-01A-43D-A079-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A02Y-01A-43D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	84.8	1.91	0.16	58cfa830e4b0c9d6adf6bb48	TCGA-AA-A02Y-01A-43D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A02Y-01A	A435FDF4-A89A-499E-9006-CBB5693EAB26	Primary Tumor	Illumina HiSeq	faa460a7-9c39-4da6-93c1-22d5d99742f0	Colorectal	73.0	8537633B-6426-4B66-A2A3-FA942EEDF01B	CD188DB1-ED81-42A6-B550-07D4008143EE	TCGA-AA-A02Y-01A-43D-A079-02	HG18	TCGA-AA-A02Y	TCGA-COAD		s13195	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	A079-02	True	COAD	C1	GI.GS	0.10199928300000001	0.25	0.0	5.554698349	0.3644	0.153	-0.9653	-0.4082	-0.4011	-0.8168	46.0	77.0	0.751741433	3.320191327	74.0	0.535476205	7.0	6.0				2.415052122	13.0	0.941559378	1.156491395	88.69404423	190.8700614	1028.7073369999998	0.0	1216.0	0.0	1216.0	6.130724691362717	5.136929019420548	-0.0033057881344992213	4.584800184650942	5.230957969068824	1.017115141061066	-1.5459245067117746	0.09402894964827624	1.0204209291955653
13722.58cfa830e4b0c9d6adf6bb4c	58cfa830e4b0c9d6adf6bb4c	TCGA-AA-A01T-01A-21D-A17O-10_wgs_Illumina.filtered.	WGS	TCGA-AA-A01T-01A-21D-A17O-10_wgs_Illumina	TCGA-AA-A01T-01A-21D-A17O-10_wgs_Illumina.bam	80.04	2.03	0.07	58cfa830e4b0c9d6adf6bb4c	TCGA-AA-A01T-01A-21D-A17O-10_wgs_Illumina.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01T-01A	F87C6DCC-1A9E-4DF5-962C-1F946E2611F8	Primary Tumor	Illumina HiSeq	abefb6f0-6456-48a1-b9d2-3789849aaea6	Colorectal	63.0	BFC99C6D-7791-4037-9C74-A74BE68E616A	75AD15B9-8F9C-40C1-9CA6-1E8454FBD310	TCGA-AA-A01T-01A-21D-A17O-10	GRCh37-lite	TCGA-AA-A01T	TCGA-COAD		s13681	Baylor College of Medicine	Indivumed	Germany	NO	T3	N1	Colon Adenocarcinoma	Stage III	A17O-10	True	COAD	C1	GI.CIN	0.045102565	0.29	0.11	0.154091685	0.2623	0.095	-1.6469	-1.2234	-0.3763	-0.3073	41.0		0.6833065070000001	2.525263179	141.0	0.910212919	18.0	16.0							0.20091035399999999	-648.3558958	-530.4368972	214.07018259999998	0.0	1005.0	0.0	1005.0	6.929761359244752	3.3504920387245356	-0.9853958305089713	5.2715332826412205	6.425845434785616	0.6351006464381883	-1.6582280766035324	3.0753533960610806	1.6204964769471597
13722.58cfa830e4b0c9d6adf6bb5a	58cfa830e4b0c9d6adf6bb5a	TCGA-AA-3553-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3553-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3553-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	1010.56	1.9	0.17	58cfa830e4b0c9d6adf6bb5a	TCGA-AA-3553-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3553-01A	D181C72B-843C-4B2D-B014-2A6DD1C3C1EC	Primary Tumor	Illumina HiSeq	b8e8f766-3a6f-4c2c-aeb0-ba7b926a3b99	Colorectal	61.0	B1DCD03C-3CDD-4C23-9391-C5ADEEBFF489	2159EE82-6427-4E1F-9C6F-28B48562DF0C	TCGA-AA-3553-01A-01D-1167-02	HG18	TCGA-AA-3553	TCGA-COAD		s13362	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	1167-02	True	COAD	C1		0.199844655			4.3303929430000005	0.7874	0.41600000000000004	-0.0008	0.5221	0.0662	0.0137					96.0	0.529025464	19.0	17.0							0.630509373	-858.6087825999999	167.7008251	-936.4799969000001	0.0	730.0	0.0	730.0	6.534031056658035	2.597530352704931	-0.2677274579222363	4.182655799494557	3.7713049098816684	1.487498267973363	-2.3513752571634776	1.1737745571767375	1.7552257258955992
13722.58cfa830e4b0c9d6adf6bb5c	58cfa830e4b0c9d6adf6bb5c	TCGA-AA-3675-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3675-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3675-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	570.96	1.9	0.14	58cfa830e4b0c9d6adf6bb5c	TCGA-AA-3675-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3675-01A	41658CF8-0DE1-4A97-BB60-0F0107C84E00	Primary Tumor	Illumina HiSeq	971987d4-bd49-45d8-949e-4c2108a7cbc7	Colorectal	84.0	A4CE3727-4506-493B-95F4-2F11CEB09CEB	42AD4E5A-8E58-47EC-9D1F-F65D5C22DA49	TCGA-AA-3675-01A-02D-1167-02	HG18	TCGA-AA-3675	TCGA-COAD		s13372	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage II	1167-02	True	COAD	C1			0.23	0.0	0.034848062	0.6518	0.2555	-0.6545	-0.4516	-0.7135	0.0163	49.0	59.0	1.01544533	2.030890659	74.0	0.055575908	3.0	1.0	0.9010371859999999	1.753337405	7.0	2.45831133	12.0	0.989297256	1.659074035	-1349.7967210000002	232.6718272	1657.915514	0.0	1431.0	0.0	1431.0	7.917087885735313	5.651035447834829	-0.55415659415657	6.610836232288959	6.646838242636718	0.8937128946561921	-1.3062516534463544	0.9958027948018886	1.4478694888127621
13722.58cfa830e4b0c9d6adf6bb68	58cfa830e4b0c9d6adf6bb68	TCGA-AA-A02Y-01A-43D-A17O-10_wgs_Illumina.filtered.	WGS	TCGA-AA-A02Y-01A-43D-A17O-10_wgs_Illumina	TCGA-AA-A02Y-01A-43D-A17O-10_wgs_Illumina.bam	84.8	1.91	0.08	58cfa830e4b0c9d6adf6bb68	TCGA-AA-A02Y-01A-43D-A17O-10_wgs_Illumina.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A02Y-01A	A435FDF4-A89A-499E-9006-CBB5693EAB26	Primary Tumor	Illumina HiSeq	258e501e-d510-4eda-b9fb-9d4bf0226c16	Colorectal	73.0	8537633B-6426-4B66-A2A3-FA942EEDF01B	B2AFBCBA-D67D-43F1-BE3B-05F3A5836EC0	TCGA-AA-A02Y-01A-43D-A17O-10	GRCh37-lite	TCGA-AA-A02Y	TCGA-COAD		s13685	Baylor College of Medicine	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	A17O-10	True	COAD	C1	GI.GS	0.10199928300000001	0.25	0.0	5.554698349	0.3644	0.153	-0.9653	-0.4082	-0.4011	-0.8168	46.0	77.0	0.751741433	3.320191327	74.0	0.535476205	7.0	6.0				2.415052122	13.0	0.941559378	1.156491395	88.69404423	190.8700614	1028.7073369999998	0.0	1216.0	0.0	1216.0	7.168708291691894	3.4477362814334294	-0.0033057881344992213	5.66463089491562	6.328597940778072	1.017115141061066	-1.5040773967762742	2.8808616593446423	1.0204209291955653
13722.58cfa830e4b0c9d6adf6bb6a	58cfa830e4b0c9d6adf6bb6a	TCGA-75-6205-01A-11D-1751_111116_SN208_0255_D09F1ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-75-6205-01A-11D-1751_111116_SN208_0255_D09F1ACXX_s_4_rg.sorted	TCGA-75-6205-01A-11D-1751_111116_SN208_0255_D09F1ACXX_s_4_rg.sorted.bam	267.4	1.9	0.15	58cfa830e4b0c9d6adf6bb6a	TCGA-75-6205-01A-11D-1751_111116_SN208_0255_D09F1ACXX_s_4_rg.sorted.bam	Dead	FEMALE			Lung Adenocarcinoma	Aligned reads	TCGA-75-6205-01A	9A63F744-4ED4-4B4D-AAC6-F9BDA66AA563	Primary Tumor	Illumina HiSeq	ccc090ad-afab-4e7d-b71b-dcd39a87e359	Lung		D845174B-1A04-4D22-B34F-C48D7AE35233	A5D194B2-0A92-49A1-9AC3-FC4C1B6ADE92	TCGA-75-6205-01A-11D-1751-02	HG19_Broad_variant	TCGA-75-6205	TCGA-LUAD		s10666	Harvard Medical School	Ontario Institute for Cancer Research (OICR)	Canada	NO	T2a	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1751-02	True	LUAD	C2	LUAD.6	0.587876208	0.73	0.68	10.97720295	0.1197	-0.0075	1.6492	1.9619	1.4706	0.5938	24.0	1.0	0.30738627399999996	1.2910223509999998	130.0	0.18343631	20.0	10.0	0.86539583	3.483522569	56.0	3.573151553	41.0	0.962187212		136.7035957	-393.0832802	516.9971435	1.0		1.0		7.449498005382849	5.627047956534364	-0.2490654064325415	6.456246232372566	6.260091213024604	3.1965837378004474	-0.9932517730102832	0.6330432564902404	3.4456491442329886
13722.58cfa830e4b0c9d6adf6bb72	58cfa830e4b0c9d6adf6bb72	TCGA-AA-A01V-01A-23D-A17O-10_wgs_Illumina.filtered.	WGS	TCGA-AA-A01V-01A-23D-A17O-10_wgs_Illumina	TCGA-AA-A01V-01A-23D-A17O-10_wgs_Illumina.bam	86.94	2.0	0.08	58cfa830e4b0c9d6adf6bb72	TCGA-AA-A01V-01A-23D-A17O-10_wgs_Illumina.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01V-01A	0CB0DAC8-4CE2-444A-B1AE-1550E065B4D9	Primary Tumor	Illumina HiSeq	12678e03-e8e4-4074-91b0-68bb57767c2d	Colorectal	59.0	8816F14D-9FBB-4033-9CA4-6CA0DB66161A	31F02F48-44A4-445E-AC3D-E9BF3D8D25A2	TCGA-AA-A01V-01A-23D-A17O-10	GRCh37-lite	TCGA-AA-A01V	TCGA-COAD		s13379	Baylor College of Medicine	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	A17O-10	True	COAD	C1	GI.GS	0.10136753300000001	0.2	0.0	1.123851717	0.3243	0.084	-0.8204	-0.1163	-0.958	-0.3022	53.0		1.132780887	3.1078860230000003	55.0	0.000149704	0.0	0.0							1.842443271	-1133.990693	104.2096103	1434.598508	0.0	31.0	0.0	31.0	6.424058322604399	2.8769441936688604	-1.4809090730284553	5.458977426560812	5.5180210460169485	-0.6338872498528201	-0.9650808960435873	2.641076852348088	0.8470218231756351
13722.58cfa830e4b0c9d6adf6bb79	58cfa830e4b0c9d6adf6bb79	TCGA-AA-3685-01A-02D-1981-10_wgs_Illumina.filtered.	WGS	TCGA-AA-3685-01A-02D-1981-10_wgs_Illumina	TCGA-AA-3685-01A-02D-1981-10_wgs_Illumina.bam	417.96	1.9	0.15	58cfa830e4b0c9d6adf6bb79	TCGA-AA-3685-01A-02D-1981-10_wgs_Illumina.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3685-01A	DCA004BF-9C14-45A1-B186-AB3759F6C7FE	Primary Tumor	Illumina HiSeq	e8516b3d-fcff-4f10-94a4-993b059ac4aa	Colorectal	69.0	A2DD99BF-3A02-42CD-9AA8-80A018584EE6	85E29049-A5E8-49FA-A576-E113C7B2C2E3	TCGA-AA-3685-01A-02D-1981-10	GRCh37-lite	TCGA-AA-3685	TCGA-COAD		s13515	Baylor College of Medicine	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage II	1981-10	False	COAD	C2	GI.CIN	0.17789671399999998	0.4	0.16	8.467384716	0.8318	0.512	0.1531	1.0584	-0.0363	-0.1191	40.0	56.0	0.461921915	2.194129094	256.0	0.8285352990000001	21.0	17.0	0.869703068	3.186210804	39.0	2.582306344	15.0	0.953566645	0.91097017	-957.4611468	110.5719303	-964.7731279999999	0.0	1127.0	0.0	1127.0	6.508998389609092	3.09446287862397	-0.03471213924013439	5.577440185604148	5.789298740530022	1.1927301970544169	-0.9315582040049435	2.6948358619060517	1.2274423362945512
13722.58cfa830e4b0c9d6adf6bb7c	58cfa830e4b0c9d6adf6bb7c	TCGA-AA-A01R-01A-21D-A17O-10_wgs_Illumina.filtered.	WGS	TCGA-AA-A01R-01A-21D-A17O-10_wgs_Illumina	TCGA-AA-A01R-01A-21D-A17O-10_wgs_Illumina.bam	75.21	1.8	0.07	58cfa830e4b0c9d6adf6bb7c	TCGA-AA-A01R-01A-21D-A17O-10_wgs_Illumina.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01R-01A	97F6C8D3-09A0-4128-8F10-41E736648A5F	Primary Tumor	Illumina HiSeq	5b6c9797-7cfe-4bd0-a656-74dd069d72d9	Colorectal	47.0	73EE34E8-422D-4AB1-B0F0-DA8A5A2DD9AB	303ABBE5-4155-4A0D-BC3B-F8995261CA52	TCGA-AA-A01R-01A-21D-A17O-10	GRCh37-lite	TCGA-AA-A01R	TCGA-COAD		s13194	Baylor College of Medicine	Indivumed	Germany	NO	T3	N2	Colon Mucinous Adenocarcinoma	Stage III	A17O-10	True	COAD	C2	GI.HM-indel	0.291125137	0.37	0.02	11.59946136	0.5872	0.10800000000000001	0.0093	1.104	1.0544	-0.0428	804.0	431.0			150.0	0.083186977	2.0	11.0							0.813182066	-4.98278952	215.13846940000002	1202.565619	0.0	1065.0	1.0	608.0	7.211064607319617	4.273904331872574	0.40840589354528045	5.419305138091562	7.0902044872027705	2.1646586743164256	-1.791759469228055	2.8163001553301967	1.7562527807711452
13722.58cfa830e4b0c9d6adf6bb7e	58cfa830e4b0c9d6adf6bb7e	TCGA-A5-A0GB-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-A5-A0GB-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_2_rg.sorted	TCGA-A5-A0GB-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_2_rg.sorted.bam	52.54	2.0	0.16	58cfa830e4b0c9d6adf6bb7e	TCGA-A5-A0GB-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GB-01A	2F4458B6-3CAF-4E33-890E-A04722BADD1B	Primary Tumor	Illumina HiSeq	c4dd9407-812c-41b2-9953-baec8808ddbd	Uterus	65.0	130744CA-A9A2-4C99-8ABB-20FE76E0A955	A025733C-E300-4C47-B2EF-D9C978B58BFD	TCGA-A5-A0GB-01A-11D-A043-02	HG19_Broad_variant	TCGA-A5-A0GB	TCGA-UCEC		s4585	Harvard Medical School	Cedars Sinai	None	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C1	UCEC.POLE	0.110943666	0.19	0.0	11.86279283	1.104	0.428	-1.1936	-0.5834	-1.2668	-0.5078	311.0		5.909763157	17.98017564	63.0	0.034585255	1.0	3.0							1.787827192	-1690.632859	732.7996147000001	-2268.636418	0.0	997.0	0.0	997.0	6.835410932911509	6.895371219782415	0.651004394086566	6.168931999433726	5.93396005262779	1.3291954834928612	-0.6664789334777841	-0.9614111671546248	0.6781910894062952
13722.58cfa830e4b0c9d6adf6bb82	58cfa830e4b0c9d6adf6bb82	TCGA-A3-3308-01A-01D-2094-10_Illumina.filtered.	WGS	TCGA-A3-3308-01A-01D-2094-10_Illumina	TCGA-A3-3308-01A-01D-2094-10_Illumina.bam	591.9	1.9	0.17	58cfa830e4b0c9d6adf6bb82	TCGA-A3-3308-01A-01D-2094-10_Illumina.bam	Alive	FEMALE	WHITE		Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-A3-3308-01A	3CBCA837-F5A7-4A87-8F02-C59EAC232D5A	Primary Tumor	Illumina HiSeq	ff863b55-b221-4580-b322-d2f1c9137279	Kidney	77.0	0B935ADB-0E19-4FCC-9BB0-B9D95872BCEF	68B7FDB1-22B5-4152-9E69-A41151640CD8	TCGA-A3-3308-01A-01D-2094-10	GRCh37-lite	TCGA-A3-3308	TCGA-KIRC		s9000	Baylor College of Medicine	International Genomics Consortium	None	NO	T3b	N0	Kidney Clear Cell Renal Carcinoma	Stage III	2094-10	False	KIRC	C3	KIRC.3	0.238993978	0.62	0.04		-0.752	-0.19699999999999998	0.634	0.1361	0.0912	0.4318	32.0	102.0	0.638632549	1.915897647	114.0	0.08464829	3.0	6.0				2.912494403	19.0	0.9891508790000001	2.061128763	2.95382005	-528.275159	568.1584542	0.0	16.0	0.0	16.0	8.622968914980977	0.4985240197276415	0.26491212670428654	5.452295191930654	2.944343280807595		-3.170673723050323	2.4458192610799534	
13722.58cfa830e4b0c9d6adf6bb88	58cfa830e4b0c9d6adf6bb88	TCGA-AA-3956-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3956-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3956-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	282.86	1.9	0.14	58cfa830e4b0c9d6adf6bb88	TCGA-AA-3956-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3956-01A	7B47489F-C3CC-4388-B5D7-C7C02790A5F6	Primary Tumor	Illumina HiSeq	edcd6fc2-ca83-409b-957a-ff0199cedf0d	Colorectal	65.0	DC1FFDA5-5B8F-4227-BE04-321643F73731	63EEF7A5-A1CC-4BB6-BA02-464D2DE89E2A	TCGA-AA-3956-01A-02D-1167-02	HG18	TCGA-AA-3956	TCGA-COAD		s13519	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1167-02	True	COAD	C1	GI.CIN	0.204002341	0.65	0.2	50.50431578	0.4451	0.145	-0.363	0.3629	-0.3046	0.0118	84.0	13.0	1.069191462	4.276765848	149.0	0.232664444	10.0	17.0							0.524541495	-1499.029365	200.83480830000002	326.11250010000003	0.0	1035.0	0.0	1035.0	7.56429034104535	5.265163997891438	-0.39885569872049054	5.868674732370197	5.825425989403468	1.9333412483202	-1.6956156086751526	0.5602619915120295	2.3321969470406905
13722.58cfa830e4b0c9d6adf6bba5	58cfa830e4b0c9d6adf6bba5	TCGA-AA-A02W-01A-01D-A077_110406_SN177_0153_A818P3ABXX_s_1_rg.sorted.filtered.	WGS	TCGA-AA-A02W-01A-01D-A077_110406_SN177_0153_A818P3ABXX_s_1_rg.sorted	TCGA-AA-A02W-01A-01D-A077_110406_SN177_0153_A818P3ABXX_s_1_rg.sorted.bam	226.38	1.78	0.15	58cfa830e4b0c9d6adf6bba5	TCGA-AA-A02W-01A-01D-A077_110406_SN177_0153_A818P3ABXX_s_1_rg.sorted.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A02W-01A	73448B56-A6C6-4C98-A153-AB704261E073	Primary Tumor	Illumina HiSeq	faf93a8d-56fb-4e28-97fa-1fcee234250c	Colorectal	73.0	B0F0EA02-B1DA-4613-A9B0-D18A07910010	4D2B2573-105C-4770-B8CF-9243B6D709EC	TCGA-AA-A02W-01A-01D-A077-02	HG18_Broad_variant	TCGA-AA-A02W	TCGA-COAD		s13532	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	A077-02	True	COAD	C1		0.097505232	0.28	0.12	0.255084916	0.7017	0.228	-0.8562	-0.1844	-0.7453	-0.1142	43.0		1.0585093	2.7124300810000004	154.0	0.783444019	17.0	9.0							1.0625609109999998	-1495.676645	575.9210607000001	-1053.949427	0.0	1247.0	1.0	1005.0	7.089555866761964	4.018236098714826	-0.019527103254964207	5.091459964536081	4.682395742401519	0.8082225222543254	-1.998095902225884	0.664159643686693	0.8277496255092897
13722.58cfa830e4b0c9d6adf6bbac	58cfa830e4b0c9d6adf6bbac	TCGA-AA-A02O-01A-21D-A079-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A02O-01A-21D-A079-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A02O-01A-21D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	107.64	2.11	0.16	58cfa830e4b0c9d6adf6bbac	TCGA-AA-A02O-01A-21D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A02O-01A	6FA41234-9077-4D05-A295-6820F3BEDF5B	Primary Tumor	Illumina HiSeq	e53db54a-bb1b-4c60-8214-aaa269abd153	Colorectal	82.0	2151DC9E-F76A-4CFF-8A20-B7C107D59C27	519A6BBF-68D8-4275-854A-5216FC4DFD15	TCGA-AA-A02O-01A-21D-A079-02	HG18	TCGA-AA-A02O	TCGA-COAD		s12873	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage II	A079-02	True	COAD	C1	GI.GS	0.068459152	0.2	0.03	0.077413761	0.4564	0.19899999999999998	-0.8117	-0.2658	-0.9057	-0.0822	86.0	3.0	1.0758405979999999	4.477823029	132.0	0.7627879809999999	11.0	6.0							1.234214295	-652.0974513	-117.4625793	-363.8310284	0.0	28.0	0.0	28.0	6.903077689431026	5.1731768222087355	-0.812470978745272	5.097524898070635	5.009387513543709	0.18903793882769881	-1.8055527913603906	-0.1637893086650264	1.0015089175729708
13722.58cfa830e4b0c9d6adf6bbb2	58cfa830e4b0c9d6adf6bbb2	TCGA-AA-A02O-01A-21D-A17O-10_wgs_Illumina.filtered.	WGS	TCGA-AA-A02O-01A-21D-A17O-10_wgs_Illumina	TCGA-AA-A02O-01A-21D-A17O-10_wgs_Illumina.bam	107.64	2.11	0.08	58cfa830e4b0c9d6adf6bbb2	TCGA-AA-A02O-01A-21D-A17O-10_wgs_Illumina.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A02O-01A	6FA41234-9077-4D05-A295-6820F3BEDF5B	Primary Tumor	Illumina HiSeq	22eeeeaf-8aa8-45e6-ace6-b84917c3b402	Colorectal	82.0	2151DC9E-F76A-4CFF-8A20-B7C107D59C27	4019C219-C51E-479F-8A9D-CFA6816ED696	TCGA-AA-A02O-01A-21D-A17O-10	GRCh37-lite	TCGA-AA-A02O	TCGA-COAD		s12872	Baylor College of Medicine	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage II	A17O-10	True	COAD	C1	GI.GS	0.068459152	0.2	0.03	0.077413761	0.4564	0.19899999999999998	-0.8117	-0.2658	-0.9057	-0.0822	86.0	3.0	1.0758405979999999	4.477823029	132.0	0.7627879809999999	11.0	6.0							1.234214295	-652.0974513	-117.4625793	-363.8310284	0.0	28.0	0.0	28.0	6.613085889021738	2.3687734266105656	-0.812470978745272	5.443014636371483	5.309306150809941	0.18903793882769881	-1.1700712526502546	2.9405327241993753	1.0015089175729708
13722.58cfa830e4b0c9d6adf6bbbc	58cfa830e4b0c9d6adf6bbbc	TCGA-A2-A0EU-01A-22D-A060_130807_SN590_0235_AC29RAACXX_s_1_rg.sorted.filtered.	WGS	TCGA-A2-A0EU-01A-22D-A060_130807_SN590_0235_AC29RAACXX_s_1_rg.sorted	TCGA-A2-A0EU-01A-22D-A060_130807_SN590_0235_AC29RAACXX_s_1_rg.sorted.bam	40.68	1.8	0.14	58cfa830e4b0c9d6adf6bbbc	TCGA-A2-A0EU-01A-22D-A060_130807_SN590_0235_AC29RAACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-A2-A0EU-01A	C0427237-B476-4AF4-B664-7BD479922EA5	Primary Tumor	Illumina HiSeq	f8f8a691-8930-46b3-9cd7-1b8ac6895baf	Breast	79.0	69DBB2AE-3F19-4C29-9C24-810AE60312F3	7F0FA628-7A18-4E52-81CC-3E213C431D3E	TCGA-A2-A0EU-01A-22D-A060-02	HG19_Broad_variant	TCGA-A2-A0EU	TCGA-BRCA		s5489	Harvard Medical School	Walter Reed	None	NO	T1c	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IA	A060-02	True	BRCA	C1	BRCA.LumA	0.078253339	0.34	0.17	1.29563199	0.0983	0.0595	-0.5454	-0.6947	0.3564	0.2129	24.0	28.0	0.30227416	1.209096639	99.0	0.54533454	22.0	3.0				1.7351264569999998	6.0	0.968392514	2.7565118539999998	-750.46262	592.6762102999999	-2379.686581	0.0	1043.0	0.0	1043.0	6.524296251136588	6.471766528323679	-0.8020091475090889	4.273004452530093	5.66083631210735	1.9472601323855478	-2.251291798606495	-0.8109302162163288	2.7492692798946368
13722.58cfa830e4b0c9d6adf6bbc0	58cfa830e4b0c9d6adf6bbc0	TCGA-AG-A002-01A-01D-A183-10_wgs_Illumina.filtered.	WGS	TCGA-AG-A002-01A-01D-A183-10_wgs_Illumina	TCGA-AG-A002-01A-01D-A183-10_wgs_Illumina.bam	228.5	1.72	0.08	58cfa830e4b0c9d6adf6bbc0	TCGA-AG-A002-01A-01D-A183-10_wgs_Illumina.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A002-01A	CB005C69-7301-41CE-B534-C9751F1436C5	Primary Tumor	Illumina HiSeq	23b2dbcf-d83f-448a-8e6a-e3395344bc03	Colorectal	35.0	B918B56C-5C78-4CEE-85A7-7C88501E88AD	567C8810-DAEF-4FE7-AA45-E70DB20B9F01	TCGA-AG-A002-01A-01D-A183-10	GRCh37-lite	TCGA-AG-A002	TCGA-READ		s2313	Baylor College of Medicine	Indivumed	Germany	NO	T2	N0	Rectal Adenocarcinoma	Stage I	A183-10	True	READ	C1	GI.HM-SNV	0.071644943	0.18	0.0	4.549724321	0.7217	0.171	-1.3902	-1.8246	-1.0054	-0.1468	6378.0	245.0	81.22102652	353.4896639	123.0	0.000454971	0.0	0.0							1.4268232019999998	-1488.259894	792.7846897000001	2548.476898	0.0	638.0	0.0	638.0	7.609614400144103	4.101182817368741	-0.3043445471221514	6.356851431648735	7.901048643522015	2.243322652036582	-1.252762968495368	3.7998658261532734	2.5476671991587336
13722.58cfa830e4b0c9d6adf6bbc2	58cfa830e4b0c9d6adf6bbc2	TCGA-AG-4008-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-4008-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-4008-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	624.89	1.9	0.14	58cfa830e4b0c9d6adf6bbc2	TCGA-AG-4008-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-4008-01A	72802851-9340-4C5F-A90B-23B7AFD7577A	Primary Tumor	Illumina HiSeq	95360a98-f3fd-40d4-b451-5973fe934b51	Colorectal	63.0	D803F092-3340-485D-9964-D6554D210E2E	CD36B70F-6819-4136-ADB5-8024E27B05A6	TCGA-AG-4008-01A-01D-1115-02	HG18	TCGA-AG-4008	TCGA-READ		s2312	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage IIA	1115-02	True	READ	C1	GI.CIN	0.12986034400000002	0.5	0.28	16.23753451	0.623	0.25	-0.1572	0.0054	-0.003	0.3494	42.0	56.0			131.0	0.312662294	10.0	18.0							1.899820099	-1245.514177	-17.50748492	236.4009461	0.0	518.0	0.0	518.0	6.3014146925404795	4.584856902013192	-0.5468609868239894	3.847949568587298	4.8095496403142315	1.9450491933413483	-2.453465123953181	0.22469273830103909	2.4919101801653376
13722.58cfa830e4b0c9d6adf6bbc4	58cfa830e4b0c9d6adf6bbc4	TCGA-AG-A008-01A-01D-A077-02_110217_SN208_0190_B81CLKABXX_s_7.rg.sorted.filtered.	WGS	TCGA-AG-A008-01A-01D-A077-02_110217_SN208_0190_B81CLKABXX_s_7.rg.sorted	TCGA-AG-A008-01A-01D-A077-02_110217_SN208_0190_B81CLKABXX_s_7.rg.sorted.bam	174.93	1.72	0.15	58cfa830e4b0c9d6adf6bbc4	TCGA-AG-A008-01A-01D-A077-02_110217_SN208_0190_B81CLKABXX_s_7.rg.sorted.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A008-01A	E7503A51-6647-4CC2-80DD-645D0DF4DB43	Primary Tumor	Illumina HiSeq	e31d4ba3-4d48-4e50-9932-05a2978a90df	Colorectal	50.0	AC02CD55-BC05-4329-8845-E09D088E3CB4	999D82E8-B92F-4397-A9F9-9AFBFD8A249C	TCGA-AG-A008-01A-01D-A077-02	HG18_Broad_variant	TCGA-AG-A008	TCGA-READ		s1995	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Rectal Mucinous Adenocarcinoma	Stage I	A077-02	True	READ	C1	GI.CIN	0.00882538	0.11	0.05	6.134869492000001	0.9087	0.275	-1.1452	-1.0824	-0.8195	-0.5186	36.0	3.0			71.0	0.947890338	16.0	4.0							0.9857982479999999	-1196.3004449999999	775.793386	322.89567289999997	0.0	424.0	0.0	424.0	7.674446071794437	4.457161382326197	-1.5688579802864315	7.108050596873635	6.835935613677788	0.4237066562657401	-0.5663954749208013	2.378774231351591	1.9925646365521716
13722.58cfa830e4b0c9d6adf6bbc8	58cfa830e4b0c9d6adf6bbc8	TCGA-AG-4015-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-4015-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-4015-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	610.89	1.9	0.14	58cfa830e4b0c9d6adf6bbc8	TCGA-AG-4015-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-4015-01A	1388BBA1-02BA-40DF-93E5-C3D58B7BBAE0	Primary Tumor	Illumina HiSeq	70efc59a-8909-43e4-961b-76a7a3633927	Colorectal	85.0	3C910093-DF83-485B-86EF-26A0991D9A0B	2E183A8C-5755-4DC7-AEAB-6F7E9A9A5D1A	TCGA-AG-4015-01A-01D-1115-02	HG18	TCGA-AG-4015	TCGA-READ		s1986	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage IIA	1115-02	True	READ	C1	GI.CIN	0.05714771	0.2	0.07	11.74949326	0.7624	0.228	-0.6086	0.0398	-0.3724	-0.0693	53.0	92.0	0.848539155	2.817149995	359.0	0.669283361	19.0	25.0								-1445.9612220000001	19.50401733	1111.815253	0.0	0.0	0.0	0.0	6.559115195812683	3.901235618458883	-0.5257884964427029	5.217941269973262	4.578046379699135	2.300354194132378	-1.3411739258394206	0.6768107612402519	2.826142690575081
13722.58cfa830e4b0c9d6adf6bbdd	58cfa830e4b0c9d6adf6bbdd	TCGA-AG-4015-01A-01D-1989-10_wgs_Illumina.filtered.	WGS	TCGA-AG-4015-01A-01D-1989-10_wgs_Illumina	TCGA-AG-4015-01A-01D-1989-10_wgs_Illumina.bam	610.89	1.9	0.14	58cfa830e4b0c9d6adf6bbdd	TCGA-AG-4015-01A-01D-1989-10_wgs_Illumina.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-4015-01A	1388BBA1-02BA-40DF-93E5-C3D58B7BBAE0	Primary Tumor	Illumina HiSeq	ba539625-e278-4166-9667-ec8f68d0b5a0	Colorectal	85.0	3C910093-DF83-485B-86EF-26A0991D9A0B	AA06AE46-2336-4666-A3AF-FC790DAF8DA4	TCGA-AG-4015-01A-01D-1989-10	GRCh37-lite	TCGA-AG-4015	TCGA-READ		s2169	Baylor College of Medicine	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage IIA	1989-10	True	READ	C1	GI.CIN	0.05714771	0.2	0.07	11.74949326	0.7624	0.228	-0.6086	0.0398	-0.3724	-0.0693	53.0	92.0	0.848539155	2.817149995	359.0	0.669283361	19.0	25.0								-1445.9612220000001	19.50401733	1111.815253	0.0	0.0	0.0	0.0	6.4682420567344	1.712012596376434	-0.5257884964427029	5.908626268798978	4.965524837975974	2.300354194132378	-0.5596157879354227	3.25351224159954	2.826142690575081
13722.58cfa830e4b0c9d6adf6bbe4	58cfa830e4b0c9d6adf6bbe4	TCGA-AG-A002-01A-01D-A077-02_110217_SN208_0190_B81CLKABXX_s_1.rg.sorted.filtered.	WGS	TCGA-AG-A002-01A-01D-A077-02_110217_SN208_0190_B81CLKABXX_s_1.rg.sorted	TCGA-AG-A002-01A-01D-A077-02_110217_SN208_0190_B81CLKABXX_s_1.rg.sorted.bam	228.5	1.72	0.15	58cfa830e4b0c9d6adf6bbe4	TCGA-AG-A002-01A-01D-A077-02_110217_SN208_0190_B81CLKABXX_s_1.rg.sorted.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A002-01A	CB005C69-7301-41CE-B534-C9751F1436C5	Primary Tumor	Illumina HiSeq	90021059-77d3-4362-9cc9-f14fcfba46c9	Colorectal	35.0	B918B56C-5C78-4CEE-85A7-7C88501E88AD	901C5D59-CE0A-44AE-91AE-9C253E99B68E	TCGA-AG-A002-01A-01D-A077-02	HG18_Broad_variant	TCGA-AG-A002	TCGA-READ		s1991	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Rectal Adenocarcinoma	Stage I	A077-02	True	READ	C1	GI.HM-SNV	0.071644943	0.18	0.0	4.549724321	0.7217	0.171	-1.3902	-1.8246	-1.0054	-0.1468	6378.0	245.0	81.22102652	353.4896639	123.0	0.000454971	0.0	0.0							1.4268232019999998	-1488.259894	792.7846897000001	2548.476898	0.0	638.0	0.0	638.0	7.81630705130011	4.797348157395015	-0.3043445471221514	7.301851659483541	4.862284228186351	2.243322652036582	-0.5144553918165693	0.06493607079133668	2.5476671991587336
13722.58cfa830e4b0c9d6adf6bbf4	58cfa830e4b0c9d6adf6bbf4	TCGA-A5-A0GW-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_5_rg.sorted.filtered.	WGS	TCGA-A5-A0GW-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_5_rg.sorted	TCGA-A5-A0GW-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_5_rg.sorted.bam	88.42	2.12	0.14	58cfa830e4b0c9d6adf6bbf4	TCGA-A5-A0GW-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_5_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GW-01A	5B6B9D0F-787C-4AE9-AFD4-DE7CE6C57A42	Primary Tumor	Illumina HiSeq	84e2e6bd-f438-45e9-9d44-2af82246e341	Uterus	46.0	E84D0533-E892-4C1E-9415-99F92AA9A360	3DCC9DC1-990D-4053-967E-B8E4EE752C4E	TCGA-A5-A0GW-01A-11D-A043-02	HG19_Broad_variant	TCGA-A5-A0GW	TCGA-UCEC		s4421	Harvard Medical School	Cedars Sinai	None	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C1	UCEC.MSI	0.327124191	0.48	0.0	19.39594454	0.7474	0.355	0.3424	1.5916	0.2222	0.4807	134.0	711.0	3.441808954	8.266224923	89.0	0.050215112	2.0	0.0							1.3788076009999999	-1118.8566640000001	588.4369717999999	-2375.911927	0.0	706.0	0.0	706.0	6.208438160042196	6.73389438138191	0.1634468461302796	5.989075331567893	6.339990095674823	0.9907233266569246	-0.21936282847430322	-0.39390428570708824	0.827276480526645
13722.58cfa830e4b0c9d6adf6bbfa	58cfa830e4b0c9d6adf6bbfa	TCGA-AG-3593-01A-01D-1525-10_hg19_wgs_Illumina.filtered.	WGS	TCGA-AG-3593-01A-01D-1525-10_hg19_wgs_Illumina	TCGA-AG-3593-01A-01D-1525-10_hg19_wgs_Illumina.bam	495.85	1.9	0.05	58cfa830e4b0c9d6adf6bbfa	TCGA-AG-3593-01A-01D-1525-10_hg19_wgs_Illumina.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3593-01A	10290E91-9784-4F94-8DAA-B5D9A8B0EFB9	Primary Tumor	Illumina HiSeq	9275573a-23ac-40aa-b792-cff9ee5bca8c	Colorectal	72.0	EFFCA0F1-E81D-47CD-8287-392A2B6AB786	FAFF4626-615B-416A-B7A6-9D177DCC94A9	TCGA-AG-3593-01A-01D-1525-10	GRCh37-lite	TCGA-AG-3593	TCGA-READ		s1953	Baylor College of Medicine	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage IIA	1525-10	True	READ	C1		0.09435855900000001			21.47919761	0.8963	0.24600000000000002	-0.0354	0.4447	-0.5132	-0.1155					240.0	0.8847177009999999	20.0	13.0							1.3550179180000002	-1925.126791	598.2607267000001	913.2091785	0.0	1035.0	0.0	1035.0	3.590709797743652	1.1527444450033446	-0.4448740742740499	4.734442521692231	3.0341546301110425	1.3326880138830612	1.1437327239485793	1.8814101851076979	1.777562088157111
13722.58cfa830e4b0c9d6adf6bbfe	58cfa830e4b0c9d6adf6bbfe	TCGA-A6-2684-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-2684-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-2684-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	463.6	1.9	0.15	58cfa830e4b0c9d6adf6bbfe	TCGA-A6-2684-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2684-01A	49929108-023E-4D35-B26D-50AB4D3AE581	Primary Tumor	Illumina HiSeq	1d127721-dd08-4127-af3b-0dfd623ea7bf	Colorectal	75.0	73B6994E-C9BF-41A8-A455-17D7BE309A9F	5A35E547-72DB-4B4E-8459-1264D0845506	TCGA-A6-2684-01A-01D-1405-02	HG18	TCGA-A6-2684	TCGA-COAD		s13174	Harvard Medical School	Christiana Healthcare	None	NO	T2	N0	Colon Adenocarcinoma	Stage I	1405-02	True	COAD	C1		0.23007724300000001	0.37	0.01	6.343803187000001	0.6759999999999999	0.324	0.3452	0.4289	0.1098	0.3204	62.0	66.0	0.8775503109999999	2.315757764	69.0	0.130577254	6.0	7.0	0.927437925	3.184809969	31.0				1.323700665	-794.9475332000001	161.8819914	400.01001	0.0	1127.0	1.0	976.0	5.824313055103472	4.646540766469642	0.175875217079708	4.273715642692306	5.61184731974086	1.7724649870359594	-1.5505974124111668	0.9653065532712173	1.5965897699562515
13722.58cfa830e4b0c9d6adf6bc00	58cfa830e4b0c9d6adf6bc00	TCGA-A6-3807-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-3807-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-3807-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	380.0	1.9	0.15	58cfa830e4b0c9d6adf6bc00	TCGA-A6-3807-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-3807-01A	5116E3B4-2BAC-40F5-8046-B9C1783FAAA5	Primary Tumor	Illumina HiSeq	d5f643a5-b69b-499a-8aab-7fc6520f2e55	Colorectal	53.0	1EB2A255-6EDD-4ADB-B52D-99DCEC590C5D	3A4293C1-0860-42F9-9D64-26B7298C2CDB	TCGA-A6-3807-01A-01D-1167-02	HG18	TCGA-A6-3807	TCGA-COAD		s13505	Harvard Medical School	Christiana Healthcare	None	NO	T3	N2	Colon Adenocarcinoma	Stage IIIC	1167-02	True	COAD	C1	GI.CIN	0.22782604899999997	0.48	0.19	5.297474787	0.5989	0.245	-0.0674	-0.1753	0.0759	0.1453	44.0				221.0	0.48063888	12.0	20.0							1.323846415	-1247.546682	-120.7776531	-1586.448282	0.0	1054.0	0.0	1054.0	5.654927090968718	5.502530168434587	-0.3807326103869644	4.395972152225428	5.7043963213015125	0.638151505256193	-1.2589549387432895	0.20186615286692522	1.0188841156431574
13722.58cfa830e4b0c9d6adf6bc0a	58cfa830e4b0c9d6adf6bc0a	TCGA-A5-A0GV-01A-31D-A043_120214_SN590_0139_BC0DYEACXX_s_3_rg.sorted.filtered.	WGS	TCGA-A5-A0GV-01A-31D-A043_120214_SN590_0139_BC0DYEACXX_s_3_rg.sorted	TCGA-A5-A0GV-01A-31D-A043_120214_SN590_0139_BC0DYEACXX_s_3_rg.sorted.bam	42.49	2.13	0.16	58cfa830e4b0c9d6adf6bc0a	TCGA-A5-A0GV-01A-31D-A043_120214_SN590_0139_BC0DYEACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GV-01A	5E3B981E-73FE-4CC9-8C89-B420E8E2F426	Primary Tumor	Illumina HiSeq	c99f6cb7-44cc-4045-a0f6-4fec580e964c	Uterus	67.0	339926E1-61E6-4256-A808-F931AA2C17D2	721D7961-15F0-4A52-8D2C-885278D3B579	TCGA-A5-A0GV-01A-31D-A043-02	HG19_Broad_variant	TCGA-A5-A0GV	TCGA-UCEC		s4987	Harvard Medical School	Cedars Sinai	None	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C1	UCEC.CN_LOW	0.05033908	0.12	0.01	2.094585882	0.4133	0.095	-1.3333	-1.4509	-1.1665	-0.3211	24.0	1.0	0.362080974	1.2069365779999999	74.0	0.895066398	7.0	1.0							3.038575967	-1238.235458	-12.19220339	1676.677375	0.0	1643.0	1.0	304.0	6.856892513913108	7.016929940101921	-0.18191792409422636	6.186734851577862	6.52049305378803	1.5060163212809483	-0.6701576623352463	-0.49643688631389127	1.6879342453751747
13722.58cfa830e4b0c9d6adf6bc0e	58cfa830e4b0c9d6adf6bc0e	TCGA-AG-4008-01A-01D-1989-10_wgs_Illumina.filtered.	WGS	TCGA-AG-4008-01A-01D-1989-10_wgs_Illumina	TCGA-AG-4008-01A-01D-1989-10_wgs_Illumina.bam	624.89	1.9	0.14	58cfa830e4b0c9d6adf6bc0e	TCGA-AG-4008-01A-01D-1989-10_wgs_Illumina.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-4008-01A	72802851-9340-4C5F-A90B-23B7AFD7577A	Primary Tumor	Illumina HiSeq	673cc168-5c3a-4eec-b299-8de319725cc6	Colorectal	63.0	D803F092-3340-485D-9964-D6554D210E2E	428C100F-D7D0-4860-A8FC-2BAE6A4BBA95	TCGA-AG-4008-01A-01D-1989-10	GRCh37-lite	TCGA-AG-4008	TCGA-READ		s1990	Baylor College of Medicine	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage IIA	1989-10	True	READ	C1	GI.CIN	0.12986034400000002	0.5	0.28	16.23753451	0.623	0.25	-0.1572	0.0054	-0.003	0.3494	42.0	56.0			131.0	0.312662294	10.0	18.0							1.899820099	-1245.514177	-17.50748492	236.4009461	0.0	518.0	0.0	518.0	6.031486221457467	3.662347611744769	-0.5468609868239894	5.050656968445741	4.6719788556602015	1.9450491933413483	-0.9808292530117262	1.0096312439154325	2.4919101801653376
13722.58cfa830e4b0c9d6adf6bc11	58cfa830e4b0c9d6adf6bc11	TCGA-AG-3727-01A-01D-1989-10_wgs_Illumina.filtered.	WGS	TCGA-AG-3727-01A-01D-1989-10_wgs_Illumina	TCGA-AG-3727-01A-01D-1989-10_wgs_Illumina.bam	489.31	1.9	0.15	58cfa830e4b0c9d6adf6bc11	TCGA-AG-3727-01A-01D-1989-10_wgs_Illumina.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3727-01A	E6827400-0D95-46B0-8874-6CE9E9D5011B	Primary Tumor	Illumina HiSeq	70d6fce9-139d-448e-8f5f-14b10832d66b	Colorectal	78.0	DA1CA84F-6C55-4536-9449-3C87E51EF85A	786FC3E4-E2BF-4914-9251-41C800EBB2FA	TCGA-AG-3727-01A-01D-1989-10	GRCh37-lite	TCGA-AG-3727	TCGA-READ		s2142	Baylor College of Medicine	Indivumed	Germany	NO	T3	N1	Rectal Adenocarcinoma	Stage III	1989-10	True	READ	C1	GI.CIN	0.04641623	0.11	0.0	0.430606161	-0.075	-0.27399999999999997	-0.9151	-0.5606	-1.8986	0.3263	58.0		0.547627348	2.403475584	163.0	0.201099754	4.0	28.0							0.399174065	-1346.321798	-1190.190994	1527.0203720000002	0.0	30.0	0.0	30.0	2.4871976015345556	2.881642322948319	-0.6447119382925427	5.232635334708386	5.350648188361437	2.1566684791904622	2.7454377331738304	2.469005865413118	2.801380417483005
13722.58cfa830e4b0c9d6adf6bc1c	58cfa830e4b0c9d6adf6bc1c	TCGA-AG-A020-01A-21D-A079-02_110409_SN590_0077_BB04EHABXX_s_1.rg.sorted.filtered.	WGS	TCGA-AG-A020-01A-21D-A079-02_110409_SN590_0077_BB04EHABXX_s_1.rg.sorted	TCGA-AG-A020-01A-21D-A079-02_110409_SN590_0077_BB04EHABXX_s_1.rg.sorted.bam	125.63	1.96	0.17	58cfa830e4b0c9d6adf6bc1c	TCGA-AG-A020-01A-21D-A079-02_110409_SN590_0077_BB04EHABXX_s_1.rg.sorted.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A020-01A	19E46A3D-18C5-4927-8501-2265E2D617B8	Primary Tumor	Illumina HiSeq	1aa43549-776a-4daf-b60e-f0b8c3287077	Colorectal	57.0	EEC9C9E3-6CB3-4589-B3A8-EA2337878599	140B186D-B7EC-4A31-8FE0-A490BBDAE19B	TCGA-AG-A020-01A-21D-A079-02	HG18_Broad_variant	TCGA-AG-A020	TCGA-READ		s2003	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Rectal Mucinous Adenocarcinoma	Stage III	A079-02	True	READ	C1	GI.CIN	0.07388470400000001	0.13	0.3	4.726256426	1.1226	0.33799999999999997	-1.2969	-0.9555	-0.4903	-0.4645	32.0	4.0	0.703804695	2.026957522	161.0	0.381263736	6.0	15.0							1.423678019	-1696.5399129999998	955.4673720000001	-905.9929235	0.0	31.0	0.0	31.0	7.168719963095205	5.013855908796298	-0.6501144237232168	6.347739411025374	6.446363113071321	1.6464850491998893	-0.8209805520698299	1.4325072042750224	2.296599472923106
13722.58cfa830e4b0c9d6adf6bc1e	58cfa830e4b0c9d6adf6bc1e	TCGA-AG-A01Y-01A-41D-A079-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-A01Y-01A-41D-A079-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-A01Y-01A-41D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	100.13	2.07	0.17	58cfa830e4b0c9d6adf6bc1e	TCGA-AG-A01Y-01A-41D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A01Y-01A	A91F7A8C-E0FE-403A-9EF0-F7679B2761CC	Primary Tumor	Illumina HiSeq	9b6deb45-fcab-4b6f-8c5d-225444c42154	Colorectal	49.0	28B76ABF-6A5F-4D3B-87FE-18EA7139DEDF	D295156A-3A31-4540-B295-0B620340E4DB	TCGA-AG-A01Y-01A-41D-A079-02	HG18	TCGA-AG-A01Y	TCGA-READ		s2172	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage II	A079-02	True	READ	C1	GI.CIN	0.139867272	0.21	0.06	7.284400486	0.9743	0.293	-0.1239	0.2842	-0.32799999999999996	0.0604	33.0	1.0	0.707354169	2.206945007	187.0	0.366270879	9.0	30.0								-1003.977082	596.9967002000001	-1210.392061	0.0	0.0	0.0	0.0	6.328356863550538	4.907795002527541	-0.7073726262334232	4.7189189511164376	4.952746390389807	1.6542116843459875	-1.6094379124341005	0.044951387862266046	2.3615843105794108
13722.58cfa830e4b0c9d6adf6bc22	58cfa830e4b0c9d6adf6bc22	TCGA-AG-3727-01A-01D-1167_101105_SN208_0168_A80A3BABXX_s_3.rg.sorted.filtered.	WGS	TCGA-AG-3727-01A-01D-1167_101105_SN208_0168_A80A3BABXX_s_3.rg.sorted	TCGA-AG-3727-01A-01D-1167_101105_SN208_0168_A80A3BABXX_s_3.rg.sorted.bam	489.31	1.9	0.15	58cfa830e4b0c9d6adf6bc22	TCGA-AG-3727-01A-01D-1167_101105_SN208_0168_A80A3BABXX_s_3.rg.sorted.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3727-01A	E6827400-0D95-46B0-8874-6CE9E9D5011B	Primary Tumor	Illumina HiSeq	c29d4836-8104-479e-98ce-a8c435a242d7	Colorectal	78.0	DA1CA84F-6C55-4536-9449-3C87E51EF85A	D8361FC2-8AB1-4D36-9009-237D905CF899	TCGA-AG-3727-01A-01D-1167-02	HG18_Broad_variant	TCGA-AG-3727	TCGA-READ		s2141	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Rectal Adenocarcinoma	Stage III	1167-02	True	READ	C1	GI.CIN	0.04641623	0.11	0.0	0.430606161	-0.075	-0.27399999999999997	-0.9151	-0.5606	-1.8986	0.3263	58.0		0.547627348	2.403475584	163.0	0.201099754	4.0	28.0							0.399174065	-1346.321798	-1190.190994	1527.0203720000002	0.0	30.0	0.0	30.0	4.148975534329445	5.068157734576931	-0.6447119382925427	3.9548195198884875	4.6913478822291435	2.1566684791904622	-0.19415601444095731	-0.37680985234778763	2.801380417483005
13722.58cfa830e4b0c9d6adf6bc26	58cfa830e4b0c9d6adf6bc26	TCGA-A6-3810-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-3810-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-3810-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	420.6	1.9	0.16	58cfa830e4b0c9d6adf6bc26	TCGA-A6-3810-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-3810-01A	B728E6E8-A0E4-496B-904C-6F07C12E901F	Primary Tumor	Illumina HiSeq	54687a8d-c693-4ae5-8451-4f4c80adca53	Colorectal	62.0	F2BD44D3-A53C-4A10-9AE1-A93E762F174C	AD4275F1-789D-471C-88DD-B6E76069D856	TCGA-A6-3810-01A-01D-1167-02	HG18	TCGA-A6-3810	TCGA-COAD		s13016	Harvard Medical School	Christiana Healthcare	None	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1167-02	True	COAD	C1		0.24937186	0.4	0.36	4.075723831	0.5404	0.213	0.2462	0.1809	-0.1997	0.3302	70.0	24.0			97.0	0.705043912	18.0	15.0							1.037395766	-742.7106805	334.0869488	-875.2312210000001	0.0	1111.0	0.0	1111.0	7.357266270201761	5.800627195632509	-0.34370862425804605	5.926520146511036	6.854984475296577	1.3791334765220904	-1.4307461236907244	1.0543572796640683	1.7228421007801364
13722.58cfa830e4b0c9d6adf6bc2a	58cfa830e4b0c9d6adf6bc2a	TCGA-AA-3994-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3994-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3994-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	631.89	1.9	0.16	58cfa830e4b0c9d6adf6bc2a	TCGA-AA-3994-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3994-01A	750770DB-53CF-4021-A8C2-5E0DDB97FEF5	Primary Tumor	Illumina HiSeq	dadc0f63-410b-4eb6-b287-c05bbc274608	Colorectal	69.0	41933A62-1325-4089-80B5-06E3EBB238DA	FED1DBB6-D332-4239-A878-8587A7CE4D05	TCGA-AA-3994-01A-01D-1109-02	HG18	TCGA-AA-3994	TCGA-COAD		s13518	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Colon Mucinous Adenocarcinoma	Stage IIIB	1109-02	True	COAD	C1	GI.CIN	0.10895039599999999	0.24	0.02	2.566144589	0.4976	0.23	-0.2875	-0.4736	-0.2791	0.1195	93.0	47.0	1.8422406709999999	4.813596592	100.0	0.21440938199999998	6.0	9.0							1.7897410630000001	-1144.988405	257.72687790000003	-2104.8989070000002	0.0	822.0	0.0	822.0	6.729425743457719	6.1762869805117475	-0.5586374448147403	5.289064161067554	6.869434161071693	1.0139371793870204	-1.440361582390166	0.693147180559945	1.5725746242017609
13722.58cfa830e4b0c9d6adf6bc31	58cfa830e4b0c9d6adf6bc31	TCGA-AA-3994-01A-01D-1981-10_wgs_Illumina.filtered.	WGS	TCGA-AA-3994-01A-01D-1981-10_wgs_Illumina	TCGA-AA-3994-01A-01D-1981-10_wgs_Illumina.bam	631.89	1.9	0.16	58cfa830e4b0c9d6adf6bc31	TCGA-AA-3994-01A-01D-1981-10_wgs_Illumina.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3994-01A	750770DB-53CF-4021-A8C2-5E0DDB97FEF5	Primary Tumor	Illumina HiSeq	6cc193d6-40f0-46ba-aa41-4240fe42a46c	Colorectal	69.0	41933A62-1325-4089-80B5-06E3EBB238DA	D9690A27-BB02-498E-B15C-EE76E31D16EE	TCGA-AA-3994-01A-01D-1981-10	GRCh37-lite	TCGA-AA-3994	TCGA-COAD		s12867	Baylor College of Medicine	Indivumed	Germany	NO	T3	N1	Colon Mucinous Adenocarcinoma	Stage IIIB	1981-10	False	COAD	C1	GI.CIN	0.10895039599999999	0.24	0.02	2.566144589	0.4976	0.23	-0.2875	-0.4736	-0.2791	0.1195	93.0	47.0	1.8422406709999999	4.813596592	100.0	0.21440938199999998	6.0	9.0							1.7897410630000001	-1144.988405	257.72687790000003	-2104.8989070000002	0.0	822.0	0.0	822.0	6.708694398183884	5.376929811752605	-0.5586374448147403	5.003946305945458	7.013090794327459	1.0139371793870204	-1.7047480922384255	1.6361609825748538	1.5725746242017609
13722.58cfa830e4b0c9d6adf6bc38	58cfa830e4b0c9d6adf6bc38	TCGA-AA-A01C-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A01C-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A01C-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	91.92	1.64	0.15	58cfa830e4b0c9d6adf6bc38	TCGA-AA-A01C-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01C-01A	80809D79-92E1-4D6C-BA2E-0A9589997792	Primary Tumor	Illumina HiSeq	a7b8c819-1f82-43d2-93aa-5c85e2710e7e	Colorectal	75.0	1E191EED-2238-450E-A384-26DF9C569FD0	77F9EF43-7202-4C9B-9556-F00F0A66D2D4	TCGA-AA-A01C-01A-01D-A077-02	HG18	TCGA-AA-A01C	TCGA-COAD		s13199	Harvard Medical School	Indivumed	Germany	NO	T2	N1	Colon Adenocarcinoma	Stage IIIA	A077-02	True	COAD	C1		0.12431349300000001	0.4	0.33	0.7577510409999999	0.6822	0.26899999999999996	-0.7408	-0.7117	-0.3535	0.1969	37.0	103.0	0.5982889570000001	2.2672002559999997	103.0	0.428688216	13.0	10.0							1.003630686	-1511.048855	162.35327980000002	-1681.590334	0.0	457.0	0.0	457.0	7.33726238157054	5.777311870092468	-0.1177830356563837	6.158607385228894	7.200943901650003	1.2115921975953636	-1.1786549963416464	1.4236320315575348	1.3293752332517474
13722.58cfa830e4b0c9d6adf6bc3e	58cfa830e4b0c9d6adf6bc3e	TCGA-AG-3582-01A-01D-1989-10_wgs_Illumina.filtered.	WGS	TCGA-AG-3582-01A-01D-1989-10_wgs_Illumina	TCGA-AG-3582-01A-01D-1989-10_wgs_Illumina.bam	747.21	1.9	0.15	58cfa830e4b0c9d6adf6bc3e	TCGA-AG-3582-01A-01D-1989-10_wgs_Illumina.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3582-01A	DB1E3104-8BFD-4353-854A-C478BA1F7D07	Primary Tumor	Illumina HiSeq	f968a6d9-8eb8-436a-92a3-b7080bdf5a3e	Colorectal	75.0	1B1EF856-EA45-4857-8B4B-C4330FA930D8	D452293A-6148-4FCF-9FBC-446815016751	TCGA-AG-3582-01A-01D-1989-10	GRCh37-lite	TCGA-AG-3582	TCGA-READ		s2135	Baylor College of Medicine	Indivumed	Germany	NO	T3	N1	Rectal Adenocarcinoma	Stage IV	1989-10	True	READ	C1		0.065837927			23.52186738	0.7997	0.262	-0.3103	-0.1201	-0.6781	0.0982					206.0	0.420046801	13.0	20.0							0.292375495	-1884.930789	296.879728	-287.956525	1.0	1096.0	1.0	1096.0	6.5197370844776925	3.5053026929193063	-0.6208387140279106	5.490117667296534	6.848164497568499	0.9376555543718521	-1.029619417181158	3.3428618046491927	1.5584942683997627
13722.58cfa830e4b0c9d6adf6bc46	58cfa830e4b0c9d6adf6bc46	TCGA-AO-A0JF-01A-11D-A060_130719_SN1120_0270_AC2CVRACXX_s_1_rg.sorted.filtered.	WGS	TCGA-AO-A0JF-01A-11D-A060_130719_SN1120_0270_AC2CVRACXX_s_1_rg.sorted	TCGA-AO-A0JF-01A-11D-A060_130719_SN1120_0270_AC2CVRACXX_s_1_rg.sorted.bam	16.97	1.91	0.13	58cfa830e4b0c9d6adf6bc46	TCGA-AO-A0JF-01A-11D-A060_130719_SN1120_0270_AC2CVRACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-AO-A0JF-01A	F357FE19-5359-4662-8CE9-AA996132283B	Primary Tumor	Illumina HiSeq	031ab51d-07d0-4afe-a9dd-222889f5c32b	Breast	68.0	DDEE0B07-2771-40C7-BDDA-C1100958F0D8	BDAA1600-1B4F-4BBA-B4D6-A4D169B029D6	TCGA-AO-A0JF-01A-11D-A060-02	HG19_Broad_variant	TCGA-AO-A0JF	TCGA-BRCA		s5491	Harvard Medical School	MSKCC	None	NO	T1c	N1a	Infiltrating Ductal Carcinoma	Stage IIA	A060-02	True	BRCA	C3	BRCA.LumA	0.262502852	0.58	0.01	0.176035677	-0.5981	-0.1075	0.4684	0.3551	-0.1303	0.5901	10.0	1.0	0.289704644	0.666320682	79.0	0.053613315999999994	2.0	4.0				3.538454027	40.0	0.959221918	2.019538273	-975.1847267	747.2890054999999	118.13165320000002	0.0	1980.0	0.0	1980.0	8.045428011550841	6.407763612529566	-0.6367831196349767	5.848203434214622	6.648925669346454	1.7152420156992207	-2.197224577336219	0.24116205681688774	2.3520251353341974
13722.58cfa830e4b0c9d6adf6bc4c	58cfa830e4b0c9d6adf6bc4c	TCGA-AL-3473-01A-01D-1253-10_wgs_Illumina.filtered.	WGS	TCGA-AL-3473-01A-01D-1253-10_wgs_Illumina	TCGA-AL-3473-01A-01D-1253-10_wgs_Illumina.bam	543.0	1.9	0.14	58cfa830e4b0c9d6adf6bc4c	TCGA-AL-3473-01A-01D-1253-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-AL-3473-01A	A7BF785F-0539-4899-AC21-47D1FC347EE8	Primary Tumor	Illumina HiSeq	7f8267f9-4d48-48c6-aebb-a596aaf7755c	Kidney	55.0	DE88A41B-8A32-40D6-9C0B-1FE2303D8AD2	14DD86C1-DFB3-4124-A453-4D64223BC048	TCGA-AL-3473-01A-01D-1253-10	GRCh37-lite	TCGA-AL-3473	TCGA-KIRP		s11638	Baylor College of Medicine	Fox Chase	None	NO	T2	N0	Kidney Papillary Renal Cell Carcinoma	Stage II	1253-10	False	KIRP	C2	KIRP.C2a	0.51923392	0.68	0.0		-1.1451	-0.0765	1.2326	1.6986	0.8261	-0.541	16.0	24.0	0.292588297	1.199612016	110.0	0.121685396	1.0	4.0		0.0	1.0	3.7898783660000004	118.0	0.794409747	1.5418626309999999	550.6204992	-1115.555723	1001.141108	0.0	1906.0	0.0	1906.0	6.616734305264842	4.122563330762284	2.7060347486228604	4.911986213026417	3.349904087274605	2.9162587620356373	-1.7047480922384255	-0.7726592434876789	0.21022401341277686
13722.58cfa830e4b0c9d6adf6bc4e	58cfa830e4b0c9d6adf6bc4e	TCGA-AP-A05P-01A-11D-A043_120214_SN590_0139_BC0DYEACXX_s_5_rg.sorted.filtered.	WGS	TCGA-AP-A05P-01A-11D-A043_120214_SN590_0139_BC0DYEACXX_s_5_rg.sorted	TCGA-AP-A05P-01A-11D-A043_120214_SN590_0139_BC0DYEACXX_s_5_rg.sorted.bam	55.61	2.3	0.14	58cfa830e4b0c9d6adf6bc4e	TCGA-AP-A05P-01A-11D-A043_120214_SN590_0139_BC0DYEACXX_s_5_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A05P-01A	3CB83517-78A4-47B8-8B1E-57E765DBDD2E	Primary Tumor	Illumina HiSeq	a12cb33f-6f29-4068-a6c8-3e20520bc2e0	Uterus	54.0	F51F7B0E-3EA6-4232-9DE4-A4DD63B23BB5	E08A6886-B019-4920-ACC3-73A4CAF18E3F	TCGA-AP-A05P-01A-11D-A043-02	HG19_Broad_variant	TCGA-AP-A05P	TCGA-UCEC		s5385	Harvard Medical School	MSKCC	None	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C1	UCEC.CN_LOW	0.079815593	0.54	0.03	1.4425406719999998	-0.1288	0.040999999999999995	-0.4466	0.11699999999999999	-0.23	0.0745	28.0	3.0	0.434935946	1.2758121070000001	36.0	0.168812772	5.0	0.0							2.531444479	-397.94670069999995	-10.67422583	-1995.401832	0.0	636.0	0.0	636.0	7.23409700978949	4.0658700677397	0.4378503592658818	6.7922642575104515	1.7219631051837485	3.2073091884967355	-0.4418327522790393	-2.343906962555952	2.769458829230854
13722.58cfa830e4b0c9d6adf6bc52	58cfa830e4b0c9d6adf6bc52	TCGA-AG-A011-01A-01D-A077-02_110409_SN590_0076_AB04G5ABXX_s_1.rg.sorted.filtered.	WGS	TCGA-AG-A011-01A-01D-A077-02_110409_SN590_0076_AB04G5ABXX_s_1.rg.sorted	TCGA-AG-A011-01A-01D-A077-02_110409_SN590_0076_AB04G5ABXX_s_1.rg.sorted.bam	217.29	1.72	0.15	58cfa830e4b0c9d6adf6bc52	TCGA-AG-A011-01A-01D-A077-02_110409_SN590_0076_AB04G5ABXX_s_1.rg.sorted.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A011-01A	3BE106BC-BA42-4C70-9B50-697D89DB617D	Primary Tumor	Illumina HiSeq	af371ab1-77bf-4408-860e-ccc4386c99aa	Colorectal	80.0	B5DD8F49-26FC-48D9-A964-D8EBDCCA9E19	8C282A6C-3D47-4F9E-96C4-2C0852E7785B	TCGA-AG-A011-01A-01D-A077-02	HG18_Broad_variant	TCGA-AG-A011	TCGA-READ		s2001	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage IIA	A077-02	True	READ	C1	GI.CIN	0.152210219	0.45	0.06	22.12477452	0.4651	0.046	-0.6202	0.1451	-0.5705	-0.0721	54.0	8.0			232.0	0.331239833	10.0	25.0							0.6920289040000001	-477.80809450000004	5.005204953	3006.622796	0.0	1126.0	0.0	1126.0	6.5422839964700366	5.753705783422801	-0.5446989344329014	5.401112093383131	7.022217108886308	2.308533276513807	-1.1411719030869056	1.268511325463507	2.8532322109467083
13722.58cfa830e4b0c9d6adf6bc5a	58cfa830e4b0c9d6adf6bc5a	TCGA-AP-A0LH-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_1_rg.sorted.filtered.	WGS	TCGA-AP-A0LH-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_1_rg.sorted	TCGA-AP-A0LH-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_1_rg.sorted.bam	94.43	2.0	0.16	58cfa830e4b0c9d6adf6bc5a	TCGA-AP-A0LH-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_1_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0LH-01A	7DCE4215-01F6-43E9-9378-9E22C26C23A2	Primary Tumor	Illumina HiSeq	4334c333-7627-4949-90aa-55897232ec49	Uterus	60.0	4C657AD4-2C53-4EA9-82B5-52996E74E3FF	FCA1C7F5-E456-4574-9716-79770E6DAE8C	TCGA-AP-A0LH-01A-11D-A043-02	HG19_Broad_variant	TCGA-AP-A0LH	TCGA-UCEC	1106.0	s5203	Harvard Medical School	MSKCC	None	NO			Mixed serous and endometrioid		A043-02	True	UCEC	C2	UCEC.CN_HIGH	0.073323567	0.07	0.98	17.1613425	0.838	0.28	-0.6707	-0.8716	0.4548	-0.4072	15.0	0.0	0.164682567	0.741071549	275.0	0.113158878	5.0	6.0							2.882589186	-656.4614351	222.0111136	-580.3885031000001	1.0	1106.0	1.0	302.0	5.678191124989292	7.5458049457979826	-0.3585098822163302	5.7190131195095475	6.96598645054504	1.1693100901662161	0.04082199452025481	-0.5798184952529422	1.5278199723825463
13722.58cfa830e4b0c9d6adf6bc5e	58cfa830e4b0c9d6adf6bc5e	TCGA-AL-3472-01A-01D-1253-10_wgs_Illumina.filtered.	WGS	TCGA-AL-3472-01A-01D-1253-10_wgs_Illumina	TCGA-AL-3472-01A-01D-1253-10_wgs_Illumina.bam	543.0	1.9	0.13	58cfa830e4b0c9d6adf6bc5e	TCGA-AL-3472-01A-01D-1253-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-AL-3472-01A	42D044AE-1416-477D-AC80-779C49BC8D35	Primary Tumor	Illumina HiSeq	8f19974d-a670-4221-82fc-60d3918c19e0	Kidney	57.0	7EEA5C2A-F1A2-432E-88A2-E96B809E15D9	63D0C49D-918D-41FB-808A-1F8001981917	TCGA-AL-3472-01A-01D-1253-10	GRCh37-lite	TCGA-AL-3472	TCGA-KIRP		s11852	Baylor College of Medicine	Fox Chase	None	NO	T2	N0	Kidney Papillary Renal Cell Carcinoma		1253-10	False	KIRP	C3	KIRP.C1	0.024497567999999997	0.11	0.0		-2.4245	-0.265	-0.5862	-0.3704	-0.7353	-0.3654	20.0	4.0	0.284075011	1.306745049	143.0	0.082042158	4.0	0.0		0.0	1.0	1.732867951	6.0	0.9671320179999999	2.301625202	-549.9041202000001	-2276.620436	2829.1656940000003	0.0	2029.0	0.0	2029.0	6.9865664594064265	1.639979395015132	-0.12054576188499022	5.357325919676146	2.070132461964258		-1.6292405397302798	0.43015306694912603	
13722.58cfa830e4b0c9d6adf6bc62	58cfa830e4b0c9d6adf6bc62	TCGA-AG-A00Y-01A-02D-A077-02_110405_SN590_0074_AB04EUABXX_s_7.rg.sorted.filtered.	WGS	TCGA-AG-A00Y-01A-02D-A077-02_110405_SN590_0074_AB04EUABXX_s_7.rg.sorted	TCGA-AG-A00Y-01A-02D-A077-02_110405_SN590_0074_AB04EUABXX_s_7.rg.sorted.bam	150.39	1.72	0.15	58cfa830e4b0c9d6adf6bc62	TCGA-AG-A00Y-01A-02D-A077-02_110405_SN590_0074_AB04EUABXX_s_7.rg.sorted.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A00Y-01A	C7E09161-60D6-4DFF-A840-7CEC3BB7A30A	Primary Tumor	Illumina HiSeq	2c284389-2d4d-4e3b-9b5b-a37212874f6e	Colorectal	68.0	8EC6ADED-026E-47F5-91F1-2A75F07BD8D0	27B036A3-5277-4C0F-93EE-593FDA1441DC	TCGA-AG-A00Y-01A-02D-A077-02	HG18_Broad_variant	TCGA-AG-A00Y	TCGA-READ		s1983	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage IIA	A077-02	True	READ	C2		0.16793866300000002	0.3	0.7	19.84232675	0.7965	0.196	-0.6124	0.2012	0.9409	-0.3247	142.0				1336.0	0.440865526	6.0	27.0							0.513894086	-1042.093279	340.41857830000004	-565.0084509	0.0	700.0	1.0	123.0	5.723911845951367	7.292979886163677	0.05329479344522181	4.891002723016262	6.559010711083477	2.056659643096701	-0.8329091229351042	-0.7339691750802002	2.0033648496514793
13722.58cfa830e4b0c9d6adf6bc6c	58cfa830e4b0c9d6adf6bc6c	TCGA-AG-4007-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-4007-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-4007-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	915.89	1.9	0.16	58cfa830e4b0c9d6adf6bc6c	TCGA-AG-4007-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-4007-01A	8E00E7E7-FFAF-44F0-91A7-172671F18E08	Primary Tumor	Illumina HiSeq	5f015b15-7286-4700-88d4-e7c460f68336	Colorectal	87.0	E6FC3F28-1DE1-4587-9E0E-0861323E6772	E9D7A5C4-3E98-4C98-A953-B75EA555DD7D	TCGA-AG-4007-01A-01D-1115-02	HG18	TCGA-AG-4007	TCGA-READ		s1985	Harvard Medical School	Indivumed	Germany	NO	T4	N2	Rectal Adenocarcinoma	Stage IV	1115-02	True	READ	C1		0.085002955	0.31	0.06	13.90430149	0.2916	0.138	-0.0642	0.7799	-0.4136	0.1805					420.0	0.997270488	21.0	23.0							1.557623971	-1257.6077289999998	-596.9351227999999	435.28805520000003	0.0	31.0	0.0	31.0	6.071613349948983	4.269559872886024	-0.3234562428015064	3.578122956469592	4.722013490430108	2.07244501139	-2.4934903934793913	0.45245361754408364	2.3959012541915063
13722.58cfa830e4b0c9d6adf6bc7a	58cfa830e4b0c9d6adf6bc7a	TCGA-AO-A0JL-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_1_rg.sorted.filtered.	WGS	TCGA-AO-A0JL-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_1_rg.sorted	TCGA-AO-A0JL-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_1_rg.sorted.bam	48.13	1.89	0.13	58cfa830e4b0c9d6adf6bc7a	TCGA-AO-A0JL-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-AO-A0JL-01A	D5D8E76E-2F2A-49BC-BA0A-D51283611B16	Primary Tumor	Illumina HiSeq	b39a31b9-dd85-403d-ac11-d7b6dd2703a6	Breast	59.0	834D2E25-DA72-413B-BB0E-3BEB24D46472	A34C3F47-AD37-4777-A733-07AE8F4B4BFF	TCGA-AO-A0JL-01A-11D-A060-02	HG19_Broad_variant	TCGA-AO-A0JL	TCGA-BRCA		s5639	Harvard Medical School	MSKCC	None	NO	T2	N2a	Infiltrating Ductal Carcinoma	Stage IIIA	A060-02	True	BRCA	C1	BRCA.Basal	0.06545793			1.520725499	0.6154	0.059000000000000004	-0.5355	-0.3576	-1.0403	0.1153					247.0	0.707262463	20.0	45.0	0.969703445	1.0653281209999999	3.0	0.0	1.0		3.52642544	-1279.713357	339.12283130000003	-440.7004632	0.0	1683.0	0.0	1683.0	8.301273485191349	6.278052270978726	-0.09461753202875645	5.965898569374311	6.862000159573679	1.9580806846755685	-2.3353749158170363	0.5839478885949534	2.052698216704325
13722.58cfa830e4b0c9d6adf6bc82	58cfa830e4b0c9d6adf6bc82	TCGA-AP-A0LI-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_7_rg.sorted.filtered.	WGS	TCGA-AP-A0LI-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_7_rg.sorted	TCGA-AP-A0LI-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_7_rg.sorted.bam	85.32	1.85	0.15	58cfa830e4b0c9d6adf6bc82	TCGA-AP-A0LI-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_7_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0LI-01A	E1E8DC66-467C-48A5-BE56-3DB4F665B9F1	Primary Tumor	Illumina HiSeq	9fe530df-5c54-45fa-a25d-65e1a7d0110b	Uterus	67.0	981D9E3B-63C5-41E9-827F-7F1D268D62F4	D80E9147-7A64-4AB0-891A-2D97D0634EAB	TCGA-AP-A0LI-01A-11D-A043-02	HG19_Broad_variant	TCGA-AP-A0LI	TCGA-UCEC		s5387	Harvard Medical School	MSKCC	None	NO			Serous endometrial adenocarcinoma		A043-02	True	UCEC	C2	UCEC.CN_HIGH	0.29465461	0.57	0.14	14.41569867	0.6177	0.05	0.1909	1.7989	0.3881	-0.0891	33.0	65.0	0.7632011759999999	2.968004572	410.0	0.707326421	18.0	43.0							1.3062935359999999	316.7068643	-530.7196472	1566.45729	0.0	2972.0	0.0	2972.0	5.255269828235686	7.976064549154533	0.8707873703272615	5.2311722766566255	6.636290203669535	2.865452435671282	-0.024097551579060017	-1.3397743454849977	1.9946650653440203
13722.58cfa830e4b0c9d6adf6bc84	58cfa830e4b0c9d6adf6bc84	TCGA-AG-A032-01A-01D-A183-10_wgs_Illumina.filtered.	WGS	TCGA-AG-A032-01A-01D-A183-10_wgs_Illumina	TCGA-AG-A032-01A-01D-A183-10_wgs_Illumina.bam	237.12	1.85	0.08	58cfa830e4b0c9d6adf6bc84	TCGA-AG-A032-01A-01D-A183-10_wgs_Illumina.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A032-01A	0BB786EE-07CF-4853-9B49-EC95CD14E282	Primary Tumor	Illumina HiSeq	3d3bf209-70e8-4882-99c7-6e20c03cccea	Colorectal	68.0	AE3C8931-C06F-466A-B6BF-440007E13387	CD3D7559-B583-4474-81DF-4BF9232DE3C2	TCGA-AG-A032-01A-01D-A183-10	GRCh37-lite	TCGA-AG-A032	TCGA-READ		s2170	Baylor College of Medicine	Indivumed	Germany	NO	T3	N1	Rectal Adenocarcinoma	Stage IIIB	A183-10	True	READ	C1		0.072361592			18.9495052	0.6692	0.174	-0.8102	0.0028	-0.4896	-0.0127	36.0	2.0	0.6996234859999999	2.4653399030000003	129.0	0.92073294	19.0	13.0							1.092164521	-1574.3863210000002	288.6084835	-608.016343	0.0	1157.0	1.0	792.0	6.364750756851911	2.4518853186875544	-0.8023841991203053	5.2333486453608105	5.0749423069563715	0.8750311963274489	-1.1314021114911004	2.623056988268817	1.6774153954477542
13722.58cfa830e4b0c9d6adf6bc8a	58cfa830e4b0c9d6adf6bc8a	TCGA-AP-A0L8-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-AP-A0L8-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_5_rg.sorted	TCGA-AP-A0L8-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_5_rg.sorted.bam	128.45	2.03	0.16	58cfa830e4b0c9d6adf6bc8a	TCGA-AP-A0L8-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_5_rg.sorted.bam	Dead	FEMALE	BLACK OR AFRICAN AMERICAN		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0L8-01A	9AA8C2B4-DB32-4899-BF0C-D578CB175E90	Primary Tumor	Illumina HiSeq	41360e8e-e9e9-402a-bd9e-a987e56c920e	Uterus	70.0	D1A7A58F-7A35-4A94-A337-051AE56DED00	2BE44D5B-CCD6-4DD5-B0C7-C7813B526B94	TCGA-AP-A0L8-01A-11D-A043-02	HG19_Broad_variant	TCGA-AP-A0L8	TCGA-UCEC	1484.0	s4244	Harvard Medical School	MSKCC	None	NO			Serous endometrial adenocarcinoma		A043-02	True	UCEC	C1	UCEC.CN_HIGH	0.04822512	0.12	0.29	0.587124083	0.9387	0.27	-1.2204	-0.7864	-1.7436	0.0664	33.0	8.0	0.48673382600000004	1.7339892559999999	351.0	0.834495291	19.0	45.0							3.3876409919999997	-1443.727041	183.8589938	-376.4867799	1.0	1484.0	1.0	1453.0	4.962345004968474	6.561280239542891	0.09455141330539907	4.854131420328241	5.544345981889049	1.3494620976961285	-0.10821358464023234	-1.0169342576538423	1.2549106843907292
13722.58cfa830e4b0c9d6adf6bc8c	58cfa830e4b0c9d6adf6bc8c	TCGA-AG-3896-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3896-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3896-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	913.89	1.9	0.15	58cfa830e4b0c9d6adf6bc8c	TCGA-AG-3896-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3896-01A	9AF35239-FFB9-4D4F-889E-F743DA271EEF	Primary Tumor	Illumina HiSeq	5666993b-483e-4cb2-ac08-c5f26b31b9cd	Colorectal	85.0	03B40342-3CCE-4A45-B2EC-8855AEB85100	D33D46C5-F3FD-4FD5-9CE2-06839BF33A37	TCGA-AG-3896-01A-01D-1115-02	HG18	TCGA-AG-3896	TCGA-READ		s1988	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Rectal Adenocarcinoma	Stage I	1115-02	True	READ	C1	GI.CIN	0.07508369	0.36	0.11	8.506290998999999	0.7562	0.316	-0.376	0.0429	-1.037	0.0707	53.0	0.0			145.0	0.9009666759999999	16.0	12.0							0.809726519	-1902.6506980000001	-44.13456392	149.7527415	0.0	31.0	0.0	31.0	6.793185824239002	4.635490168095123	-0.17583592400735648	5.070419226497898	5.514888183588912	1.461017907315827	-1.7227665977411033	0.8793980154937895	1.6368538313231835
13722.58cfa830e4b0c9d6adf6bc8e	58cfa830e4b0c9d6adf6bc8e	TCGA-AG-3901-01A-01D-1989-10_wgs_Illumina.filtered.	WGS	TCGA-AG-3901-01A-01D-1989-10_wgs_Illumina	TCGA-AG-3901-01A-01D-1989-10_wgs_Illumina.bam	510.89	1.9	0.15	58cfa830e4b0c9d6adf6bc8e	TCGA-AG-3901-01A-01D-1989-10_wgs_Illumina.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3901-01A	1586CB0A-081A-4364-9470-46F9D0F0167D	Primary Tumor	Illumina HiSeq	51acbe73-78d9-48e4-b937-42a159dfb5a5	Colorectal	67.0	93B755E6-5D6E-4542-8BAE-2121F44F590C	7D59205A-65EC-4341-9748-28639D82ED29	TCGA-AG-3901-01A-01D-1989-10	GRCh37-lite	TCGA-AG-3901	TCGA-READ		s2160	Baylor College of Medicine	Indivumed	Germany	NO	T3	N1	Rectal Mucinous Adenocarcinoma	Stage IIIB	1989-10	True	READ	C1	GI.CIN	0.24371406199999998	0.56	0.04	13.32631333	0.47200000000000003	0.213	0.5434	0.6764	-0.1118	0.5886	29.0	34.0			57.0	0.102987179	2.0	5.0							0.9081042559999999	-640.2876447000001	182.4189459	-575.8737787	0.0	761.0	0.0	761.0	7.067319848653476	3.729225811061048	-1.4141711910481087	5.318119993844217	5.535070020170842	1.4025021713467443	-1.749199854809259	1.805844209109794	2.816673362394853
13722.58cfa830e4b0c9d6adf6bc90	58cfa830e4b0c9d6adf6bc90	TCGA-AZ-4308-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AZ-4308-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-AZ-4308-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	414.02	1.9	0.15	58cfa830e4b0c9d6adf6bc90	TCGA-AZ-4308-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AZ-4308-01A	3D8FD9B2-9AA2-4C81-8843-535AE66D6140	Primary Tumor	Illumina HiSeq	562ea734-bcd1-499a-8054-f710f2de3e41	Colorectal	47.0	6F0E65B2-7CA0-4F10-8952-B64900009001	1C7E82B6-A8EB-4593-B329-5299BC05140E	TCGA-AZ-4308-01A-01D-1405-02	HG18	TCGA-AZ-4308	TCGA-COAD		s13540	Harvard Medical School	University of Pittsburgh	None	NO	T3	N1	Colon Adenocarcinoma	Stage IIIB	1405-02	True	COAD	C1	GI.CIN	0.121125232	0.31	0.01	4.645367874	-0.0609	0.054000000000000006	-0.7556	-0.4715	-0.2222	0.3507	31.0				229.0	0.19738980399999997	6.0	14.0							0.845681896	-770.2988232999999	-1147.4909710000002	282.41545460000003	0.0	3324.0	0.0	3324.0	4.337154565983774	5.825619899478191	-1.0679179147312199	3.2667131542823604	5.911694508249434	1.5478923240224327	-1.0704414117014132	0.08607460877124318	2.6158102387536526
13722.58cfa830e4b0c9d6adf6bc92	58cfa830e4b0c9d6adf6bc92	TCGA-AG-3902-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3902-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3902-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	500.89	1.9	0.14	58cfa830e4b0c9d6adf6bc92	TCGA-AG-3902-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3902-01A	BCFE4FE9-D090-49F9-85A7-2B472E0F7453	Primary Tumor	Illumina HiSeq	66b629b3-3801-4c84-966b-4b01243390f0	Colorectal	61.0	F52423C2-7780-4470-8E27-5982201CCB83	A8A88775-9775-4087-8C03-9B5BC771F983	TCGA-AG-3902-01A-01D-1115-02	HG18	TCGA-AG-3902	TCGA-READ		s2159	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage IIA	1115-02	True	READ	C2	GI.CIN	0.271548453	0.47	0.24	30.79631182	0.6799	0.203	0.3141	1.1204	0.7188	-0.1775	53.0	0.0			139.0	0.268984715	11.0	25.0	0.847924608	3.08439882	38.0	3.4641255139999996	35.0	0.9743421609999999	1.403379951	-133.2516396	-31.06620621	-714.3013561	0.0	974.0	0.0	974.0	6.3607569238224215	6.075404974238033	0.3901377052401669	4.43766145253328	6.488592128440108	1.5777363050757105	-1.923095471289142	0.41318715420207486	1.1875985998355436
13722.58cfa830e4b0c9d6adf6bca2	58cfa830e4b0c9d6adf6bca2	TCGA-AZ-4315-01A-01W-1461-10_wgs_Illumina.filtered.	WGS	TCGA-AZ-4315-01A-01W-1461-10_wgs_Illumina	TCGA-AZ-4315-01A-01W-1461-10_wgs_Illumina.bam	171.0		0.5	58cfa830e4b0c9d6adf6bca2	TCGA-AZ-4315-01A-01W-1461-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AZ-4315-01A	DE287A25-981D-49F8-81AF-FE0300E4CD31	Primary Tumor	Illumina HiSeq	707a2d43-0ea1-4012-8f29-4202690c6608	Colorectal	61.0	BA9E5603-BB1D-4AA8-93E4-40043164F143	A9D1B074-7F36-4A04-B270-A2061249FF20	TCGA-AZ-4315-01A-01W-1461-10	GRCh37-lite	TCGA-AZ-4315	TCGA-COAD		s13211	Baylor College of Medicine	University of Pittsburgh	None	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1461-10	False	COAD	C2	GI.HM-SNV	0.250854138	0.34	0.0	7.89640673	1.0292	0.5105	-0.4433	-0.0336	0.2078	-0.1211	2786.0	240.0	45.27527495	158.5655486	125.0	0.0012725219999999999	0.0	1.0		0.0	1.0	1.386294361	4.0	1.0	0.6837562909999999	-1241.59736	903.4220772	-250.25309860000002	0.0	1776.0	0.0	1776.0	2.2971439602539645	3.82239422425988	0.07488955294056965	2.8131509427619523	6.200725291411886	1.6707372222329484	0.5160069825079878	2.378331067152006	1.5958476692923789
13722.58cfa830e4b0c9d6adf6bca6	58cfa830e4b0c9d6adf6bca6	TCGA-AZ-4315-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AZ-4315-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-AZ-4315-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	524.02	1.9	0.15	58cfa830e4b0c9d6adf6bca6	TCGA-AZ-4315-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AZ-4315-01A	DE287A25-981D-49F8-81AF-FE0300E4CD31	Primary Tumor	Illumina HiSeq	8b6a06d6-c15c-4491-996c-2a012440f8a2	Colorectal	61.0	BA9E5603-BB1D-4AA8-93E4-40043164F143	FBEA9F07-A969-4396-8A17-A269BF1F8A2A	TCGA-AZ-4315-01A-01D-1405-02	HG18	TCGA-AZ-4315	TCGA-COAD		s13389	Harvard Medical School	University of Pittsburgh	None	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1405-02	True	COAD	C2	GI.HM-SNV	0.250854138	0.34	0.0	7.89640673	1.0292	0.5105	-0.4433	-0.0336	0.2078	-0.1211	2786.0	240.0	45.27527495	158.5655486	125.0	0.0012725219999999999	0.0	1.0		0.0	1.0	1.386294361	4.0	1.0	0.6837562909999999	-1241.59736	903.4220772	-250.25309860000002	0.0	1776.0	0.0	1776.0	5.176789118784869	4.363837205473672	0.07488955294056965	3.658143306180305	4.898272694878796	1.6707372222329484	-1.5186458126045648	0.5344354894051238	1.5958476692923789
13722.58cfa830e4b0c9d6adf6bcae	58cfa830e4b0c9d6adf6bcae	TCGA-AZ-4614-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AZ-4614-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-AZ-4614-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	449.02	1.9	0.16	58cfa830e4b0c9d6adf6bcae	TCGA-AZ-4614-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AZ-4614-01A	3334201D-A3C0-45EC-A9ED-CF48CC8C38E8	Primary Tumor	Illumina HiSeq	50679ea1-6443-43b4-ab23-0f7542f4cb98	Colorectal	71.0	0C4DAF52-CC9F-4099-8825-33C484CED5B1	29DA0D99-6FD9-4CC0-84BE-E1670FC253E7	TCGA-AZ-4614-01A-01D-1405-02	HG18	TCGA-AZ-4614	TCGA-COAD	172.0	s12888	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N1	Colon Adenocarcinoma	Stage IVA	1405-02	True	COAD	C1	GI.CIN	0.090730596	0.14	0.22	7.866044934	0.725	0.256	-1.3626	-0.5779	-0.7127	-0.386	92.0	29.0			293.0	0.574136785	6.0	23.0							2.006480019	-1064.525141	147.28631940000002	-3049.025169	1.0	172.0	1.0	172.0	4.35272211044577	2.2143788576071373	0.0346365755970498	2.1142158741362467	2.9914604896522325	0.7277837561569951	-2.2385062363095236	0.7770816320450953	0.6931471805599453
13722.58cfa830e4b0c9d6adf6bcb2	58cfa830e4b0c9d6adf6bcb2	TCGA-AZ-4684-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AZ-4684-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-AZ-4684-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	275.02	1.9	0.15	58cfa830e4b0c9d6adf6bcb2	TCGA-AZ-4684-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AZ-4684-01A	CAC80259-3A26-4A99-B0D3-13454068E6ED	Primary Tumor	Illumina HiSeq	bab439b0-f1d3-41c2-98dd-a660818851fe	Colorectal	49.0	37AD61EA-96D1-40F1-B77A-56408E4243EA	6731F782-4435-497F-9626-C0199DAE8A8A	TCGA-AZ-4684-01A-01D-1405-02	HG18	TCGA-AZ-4684	TCGA-COAD		s13391	Harvard Medical School	University of Pittsburgh	None	NO	T3	N2	Colon Adenocarcinoma	Stage IVA	1405-02	True	COAD	C1		0.249031673			0.389557186	0.7134	0.2885	-0.1128	0.5572	-0.1254	0.2528					188.0	0.558182214	18.0	20.0							0.9236013740000001	25.06041059	219.06750950000003	377.2856388	0.0	1977.0	1.0	411.0	6.144350691483453	7.438401912228295	-0.6634851178244613	5.197754610113969	7.438401912228295	0.5816452540157608	-0.9465960813694836	0.0	1.2451303718402222
13722.58cfa830e4b0c9d6adf6bcb3	58cfa830e4b0c9d6adf6bcb3	TCGA-B0-5695-01A-11D-2103-10_wgs_Illumina.filtered.	WGS	TCGA-B0-5695-01A-11D-2103-10_wgs_Illumina	TCGA-B0-5695-01A-11D-2103-10_wgs_Illumina.bam	239.4	1.9	0.15	58cfa830e4b0c9d6adf6bcb3	TCGA-B0-5695-01A-11D-2103-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-B0-5695-01A	FB9BAFA5-7133-4955-8156-4EB6763DC8E1	Primary Tumor	Illumina HiSeq	a8ffeac5-01c4-4dac-92b8-413f4009f4fa	Kidney	61.0	86E4862C-7405-40B5-B73F-BE0C6C52EA6D	B6365BDB-E6D5-4615-95B3-DB12A0C2F3D9	TCGA-B0-5695-01A-11D-2103-10	GRCh37-lite	TCGA-B0-5695	TCGA-KIRC		s8833	Baylor College of Medicine	University of Pittsburgh	None	NO	T1b	N0	Kidney Clear Cell Renal Carcinoma	Stage I	2103-10	False	KIRC	C3	KIRC.1	0.084807997	0.22	0.03		-1.5962	-0.267	0.1019	0.3791	-0.0986	0.0543	33.0	3.0	0.439992657	1.730637786	63.0	0.061866729	1.0	5.0		0.0	1.0	3.271732977	31.0	0.9527504859999999	1.21244138	74.11152539	-1465.0599300000001	3121.023634	0.0	2150.0	0.0	2150.0	6.995242733105252	1.4276088451846984	-0.008025725262303829	6.1079395381043495	4.774701967853653	5.044231243524771	-0.8873031950009032	3.347093122668954	5.052256968787074
13722.58cfa830e4b0c9d6adf6bcbd	58cfa830e4b0c9d6adf6bcbd	TCGA-B0-5693-01A-11D-2103-10_Illumina.filtered.	WGS	TCGA-B0-5693-01A-11D-2103-10_Illumina	TCGA-B0-5693-01A-11D-2103-10_Illumina.bam	344.4	1.9	0.14	58cfa830e4b0c9d6adf6bcbd	TCGA-B0-5693-01A-11D-2103-10_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-B0-5693-01A	DB058EB4-9C5E-4226-92D1-DE24AEA83630	Primary Tumor	Illumina HiSeq	4a0c2db0-f10b-41b1-8aca-fcd712b7f672	Kidney	47.0	20A21A6F-F615-47F7-9935-B330B116D51B	FB194CA3-10AA-4DC5-8D08-619DDBD6D1B6	TCGA-B0-5693-01A-11D-2103-10	GRCh37-lite	TCGA-B0-5693	TCGA-KIRC		s9937	Baylor College of Medicine	University of Pittsburgh	None	NO	T1b	NX	Kidney Clear Cell Renal Carcinoma	Stage I	2103-10	False	KIRC	C3	KIRC.1	0.08923067400000001	0.27	0.02		-1.0398	-0.1835	0.0229	-0.6792	0.2442	0.1862	24.0	250.0	0.245459242	1.043201778	57.0	0.087256134	3.0	4.0		0.0	1.0	1.9459101490000001	7.0	1.0	1.055445845	-10.00308467	-903.2738593	2560.413159	0.0	4074.0	0.0	4074.0	8.8698199525084	-0.4763372902184635	0.4066488403847145	5.4854296891626255	2.601051347990066	3.7297577850754333	-3.3843902633457743	3.0773886382085296	3.323108944690719
13722.58cfa830e4b0c9d6adf6bcc0	58cfa830e4b0c9d6adf6bcc0	TCGA-B0-5094-01A-01D-2099-10_wgs_Illumina.filtered.	WGS	TCGA-B0-5094-01A-01D-2099-10_wgs_Illumina	TCGA-B0-5094-01A-01D-2099-10_wgs_Illumina.bam	167.4	1.9	0.15	58cfa830e4b0c9d6adf6bcc0	TCGA-B0-5094-01A-01D-2099-10_wgs_Illumina.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-B0-5094-01A	8AAA4E25-5C12-4ACE-96DC-91AAA0C4457C	Primary Tumor	Illumina HiSeq	22151e7f-a939-414f-9658-14262a84253f	Kidney	62.0	B05A7F4B-BC56-4DA6-B810-79E7C3A5395E	D429C27A-5963-42FE-B3A0-7252C20669D8	TCGA-B0-5094-01A-01D-2099-10	GRCh37-lite	TCGA-B0-5094	TCGA-KIRC	333.0	s9445	Baylor College of Medicine	University of Pittsburgh	None	NO	T3b	N0	Kidney Clear Cell Renal Carcinoma	Stage IV	2099-10	False	KIRC	C3	KIRC.3	0.188036665	0.31	0.05		-1.1135	-0.3575	0.2397	0.0979	-0.2277	-0.0849	40.0	98.0	0.37382684200000005	2.127937406	105.0	0.411574285	12.0	12.0				3.1282795610000003	24.0	0.9843381290000001	1.981572866	-260.7056223	-1611.360971	1331.48215	1.0	333.0	1.0	75.0	5.267858159063328	2.580265862419812	-0.20443873694736225	4.374040283041231	4.1239523972911325	1.7485399669662427	-0.8938178760220965	1.5436865348713207	1.9529787039136048
13722.58cfa830e4b0c9d6adf6bcc4	58cfa830e4b0c9d6adf6bcc4	TCGA-AZ-4313-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AZ-4313-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-AZ-4313-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	397.02	1.9	0.15	58cfa830e4b0c9d6adf6bcc4	TCGA-AZ-4313-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AZ-4313-01A	1FD75C4D-E74C-410C-A150-814722C6C1CC	Primary Tumor	Illumina HiSeq	b8e9093c-1570-45c6-8278-f686c276ee91	Colorectal	51.0	475F161C-2F7F-43A2-B187-DE6038752F39	F64D4985-D460-435C-8EC0-477D313A895A	TCGA-AZ-4313-01A-01D-1405-02	HG18	TCGA-AZ-4313	TCGA-COAD		s13212	Harvard Medical School	University of Pittsburgh	None	NO	T1	N0	Colon Adenocarcinoma	Stage I	1405-02	True	COAD	C1		0.415139966			8.805547342	1.1106	0.5485	-1.4878	-1.0082	-1.0329	-0.307					61.0	0.138133862	4.0	0.0				0.0	1.0		1.219649252	-1836.873485	916.2242054999999	1455.000147	0.0	2310.0	0.0	2310.0	5.204006687076795	3.3571063043973055	-0.8573044698802615	3.7869406672901516	4.487266950800341	-0.015618538747627975	-1.417066019786644	1.1301606464030352	0.8416859311326336
13722.58cfa830e4b0c9d6adf6bcc6	58cfa830e4b0c9d6adf6bcc6	TCGA-AP-A0L9-01A-11D-A043_120318_SN590_0147_BD0U3RACXX_s_3_rg.sorted.filtered.	WGS	TCGA-AP-A0L9-01A-11D-A043_120318_SN590_0147_BD0U3RACXX_s_3_rg.sorted	TCGA-AP-A0L9-01A-11D-A043_120318_SN590_0147_BD0U3RACXX_s_3_rg.sorted.bam	93.54	2.18	0.15	58cfa830e4b0c9d6adf6bcc6	TCGA-AP-A0L9-01A-11D-A043_120318_SN590_0147_BD0U3RACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0L9-01A	7B9947D5-E86B-4006-8890-EA5209584A88	Primary Tumor	Illumina HiSeq	df10c3ed-7978-4d58-b4f6-52a76db0994a	Uterus	71.0	53D0521F-10D6-4F70-9277-D99025A6B963	DAA573AF-564D-456D-8181-DF4C07B77672	TCGA-AP-A0L9-01A-11D-A043-02	HG19_Broad_variant	TCGA-AP-A0L9	TCGA-UCEC		s4423	Harvard Medical School	MSKCC	None	NO			Serous endometrial adenocarcinoma		A043-02	True	UCEC	C2	UCEC.CN_HIGH	0.088082971	0.16	0.38	11.09997891	0.7817	0.301	-0.7752	-0.9558	1.5029	-0.193	28.0	0.0	0.600819239	1.8340797830000002	465.0	0.7109751129999999	12.0	55.0							4.085954012	-1643.4935480000001	-376.9021529	-1954.864734	0.0	3815.0	0.0	3815.0	4.1195451758393995	7.811310714675637	-1.4496805209236812	4.449786862709976	6.877001477298803	0.612345798299087	0.3302416868705764	-0.9343092373768331	2.062026319222768
13722.58cfa830e4b0c9d6adf6bcc8	58cfa830e4b0c9d6adf6bcc8	TCGA-AG-3582-01A-01D-1167_101105_SN208_0168_A80A3BABXX_s_1_rg.sorted.filtered.	WGS	TCGA-AG-3582-01A-01D-1167_101105_SN208_0168_A80A3BABXX_s_1_rg.sorted	TCGA-AG-3582-01A-01D-1167_101105_SN208_0168_A80A3BABXX_s_1_rg.sorted.bam	747.21	1.9	0.15	58cfa830e4b0c9d6adf6bcc8	TCGA-AG-3582-01A-01D-1167_101105_SN208_0168_A80A3BABXX_s_1_rg.sorted.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3582-01A	DB1E3104-8BFD-4353-854A-C478BA1F7D07	Primary Tumor	Illumina HiSeq	85a5fdbc-5a9a-4ddf-aac9-84a213ee17fd	Colorectal	75.0	1B1EF856-EA45-4857-8B4B-C4330FA930D8	CA0DD61C-D4F2-4ED9-91EF-11F7B1BE15AF	TCGA-AG-3582-01A-01D-1167-02	HG18_Broad_variant	TCGA-AG-3582	TCGA-READ		s1973	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Rectal Adenocarcinoma	Stage IV	1167-02	True	READ	C1		0.065837927			23.52186738	0.7997	0.262	-0.3103	-0.1201	-0.6781	0.0982					206.0	0.420046801	13.0	20.0							0.292375495	-1884.930789	296.879728	-287.956525	1.0	1096.0	1.0	1096.0	5.262219046375558	5.675274698840197	-0.6208387140279106	4.676960827826798	4.707690672578492	0.9376555543718521	-0.5852582185487605	-0.9675840262617053	1.5584942683997627
13722.58cfa830e4b0c9d6adf6bcda	58cfa830e4b0c9d6adf6bcda	TCGA-AG-3574-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3574-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3574-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	750.21	1.9	0.14	58cfa830e4b0c9d6adf6bcda	TCGA-AG-3574-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3574-01A	0EDA7373-8335-455F-B90A-8C3540F28088	Primary Tumor	Illumina HiSeq	44e4b931-5188-44b9-aea5-fdff70c4c058	Colorectal	89.0	DA897A5D-B2CC-419F-ACD7-473B4928C5D5	5DAA6B90-B302-4B0E-A44B-0A6D3159DACE	TCGA-AG-3574-01A-01D-1167-02	HG18	TCGA-AG-3574	TCGA-READ		s1955	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage II	1167-02	True	READ	C1		0.04333499			3.175417593	0.4391	0.207	-0.5073	-0.2912	-1.0001	-0.1569			0.648191481	1.6204787019999998	93.0	0.24083651399999997	10.0	2.0							1.177134779	-702.2939719999999	-730.6651832	-32.8054185	1.0	1096.0	1.0	1096.0	6.61616080113901	5.568132437171394	-0.14078480933874382	5.887922300767794	5.162667329063229	1.2885825320577209	-0.7282385003712157	-0.4054651081081646	1.4293673413964647
13722.58cfa830e4b0c9d6adf6bcfc	58cfa830e4b0c9d6adf6bcfc	TCGA-AD-6964-01A-11D-1924-10_wgs_Illumina.filtered.	WGS	TCGA-AD-6964-01A-11D-1924-10_wgs_Illumina	TCGA-AD-6964-01A-11D-1924-10_wgs_Illumina.bam	177.7		0.05	58cfa830e4b0c9d6adf6bcfc	TCGA-AD-6964-01A-11D-1924-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AD-6964-01A	5E7074A6-5011-4DC5-950C-41365DBC6D09	Primary Tumor	Illumina HiSeq	67abf892-45e8-4468-a1fd-8446401b3f55	Colorectal	58.0	4D16E41A-B100-4080-A759-1F62E54C1C91	42D20028-0DDC-4DAC-9F05-D674F8915F21	TCGA-AD-6964-01A-11D-1924-10	GRCh37-lite	TCGA-AD-6964	TCGA-COAD		s13536	Baylor College of Medicine	International Genomics Consortium	United States	NO	T4a	N2b	Colon Adenocarcinoma		1924-10	False	COAD	C2	GI.HM-indel	0.399593254	0.5	0.0	18.93444682	0.40299999999999997	0.146	0.8749	1.5414	0.4724	0.3776	615.0	1497.0	12.004934	35.2693136	75.0	0.011102788	0.0	3.0	0.83092974	3.50611444	68.0	3.3791935719999997	32.0	0.975029162	4.609349627	-700.2847767999999	305.5953205	1377.272535	1.0	331.0	1.0	325.0	6.349676770365601	3.814555236543703	0.29598700161005975	5.736572297479192	5.3602773345916965	2.363393521446418	-0.613104472886409	1.5457220980479933	2.067406519836358
13722.58cfa830e4b0c9d6adf6bd00	58cfa830e4b0c9d6adf6bd00	TCGA-AF-2692-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AF-2692-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AF-2692-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	2.0	1.9	0.15	58cfa830e4b0c9d6adf6bd00	TCGA-AF-2692-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Rectum Adenocarcinoma	Aligned reads	TCGA-AF-2692-01A	71A32FCA-D48F-4EA3-8DF7-69F9DDA8FA91	Primary Tumor	Illumina HiSeq	f19d4bca-a876-4c65-a830-4d5f12eb5803	Colorectal	54.0	3CA7589A-E887-4DA2-8D59-19FE5963AC21	CC1B3C2A-43B7-43CB-85F8-383A3C255D4B	TCGA-AF-2692-01A-01D-1167-02	HG18	TCGA-AF-2692	TCGA-READ		s1972	Harvard Medical School	Christiana Healthcare	United States	NO	T3	N0		Stage IIA	1167-02	True	READ	C1		0.060004599000000006	0.26	0.1	39.93574471	0.7895	0.209	-0.4874	-0.08	-1.0094	0.2925			1.919397156	1.759447393	180.0	0.917432852	12.0	20.0	0.9575917690000001	3.082368994	25.0				1.247680761	-847.5226018	473.1060596	-277.2420522	0.0	412.0	1.0	327.0	7.448649283870163	4.513359737619827	-1.8268714991904065	5.609423277403184	6.109486305415688	-0.5847791438381638	-1.8392260064669785	1.596126567795861	1.2420923553522427
13722.58cfa830e4b0c9d6adf6bd2e	58cfa830e4b0c9d6adf6bd2e	TCGA-AA-A01P-01A-21D-A079-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A01P-01A-21D-A079-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A01P-01A-21D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	76.48	1.86	0.16	58cfa830e4b0c9d6adf6bd2e	TCGA-AA-A01P-01A-21D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01P-01A	13AE9D83-A22F-451F-88BB-686051725CF3	Primary Tumor	Illumina HiSeq	bd44a9e2-a1a2-43a2-bfca-3a7d028fd86c	Colorectal	80.0	133C13DE-6C6B-45E2-A611-A5C5A4AEBAA6	7788130D-F341-4900-B7E0-95EAD3063A9F	TCGA-AA-A01P-01A-21D-A079-02	HG18	TCGA-AA-A01P	TCGA-COAD	1158.0	s13527	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Colon Adenocarcinoma	Stage III	A079-02	True	COAD	C2	GI.HM-indel	0.413161486	0.62	0.09	6.065449651000001	0.7284	0.2765	0.6258	1.5382	1.3757	0.3784	310.0	908.0			57.0	0.00032910800000000005	0.0	3.0							1.294181349	-174.70693319999998	604.6832397999999	-1055.053441	1.0	1158.0	1.0	762.0	6.861082870783706	6.112953127047765	-0.3088345949818251	6.13514586740077	5.930631570253811	1.739603821577334	-0.7259370033829362	-0.182321556793954	2.048438416559159
13722.58cfa830e4b0c9d6adf6bd38	58cfa830e4b0c9d6adf6bd38	TCGA-AA-A00N-01A-02D-A17O-10_wgs_Illumina.filtered.	WGS	TCGA-AA-A00N-01A-02D-A17O-10_wgs_Illumina	TCGA-AA-A00N-01A-02D-A17O-10_wgs_Illumina.bam	149.57	1.79	0.08	58cfa830e4b0c9d6adf6bd38	TCGA-AA-A00N-01A-02D-A17O-10_wgs_Illumina.bam	Dead	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A00N-01A	E457344D-76FB-46BF-B362-61A6E811D131	Primary Tumor	Illumina HiSeq	d83f0731-9567-4d26-83ed-42e1c4e01ef0	Colorectal	75.0	D52F3D05-1850-473E-8E1E-AB2B4F88AF2A	6CA5C1BB-275B-4D05-948A-3C6C7D03FAB9	TCGA-AA-A00N-01A-02D-A17O-10	GRCh37-lite	TCGA-AA-A00N	TCGA-COAD	122.0	s13516	Baylor College of Medicine	Indivumed	Germany	NO	T4	N0	Colon Mucinous Adenocarcinoma	Stage IIB	A17O-10	True	COAD	C1		0.31785041399999997	0.57	0.15	9.974271525	0.5514	0.22	-0.0674	-0.4751	0.3596	0.4667	2350.0	73.0			57.0	0.000717678	0.0	0.0							1.516019446	-555.4849303999999	247.166095	-224.2835437	1.0	122.0	1.0	122.0	7.283173465738004	3.424973270187193	-1.5798506971885398	6.00223962027594	6.606040198190793	1.1318963657949965	-1.2809338454620645	3.1810669280035997	2.7117470629835365
13722.58cfa830e4b0c9d6adf6bd3c	58cfa830e4b0c9d6adf6bd3c	TCGA-AG-3892-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3892-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3892-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	728.89	1.9	0.15	58cfa830e4b0c9d6adf6bd3c	TCGA-AG-3892-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3892-01A	DED3FEB2-1079-4520-A7CA-F5B5FC73D7C5	Primary Tumor	Illumina HiSeq	adde3886-c16e-4d0c-8186-1a253ffca559	Colorectal	57.0	D5B6919D-5654-486F-95B0-D89CB1893614	8B81AA70-5B77-4BE9-8438-AE0928339E21	TCGA-AG-3892-01A-01D-1115-02	HG18	TCGA-AG-3892	TCGA-READ		s1998	Harvard Medical School	Indivumed	Germany	NO	T1	N0	Rectal Adenocarcinoma	Stage I	1115-02	True	READ	C2	GI.HM-SNV	0.262819833	0.6	0.0	10.02739726	0.7882	0.442	0.063	1.1271	0.3399	-0.1562	978.0	2.0			49.0	0.00031827900000000003	0.0	0.0							2.250650269	-436.4104398	382.5767088	159.74328880000002	0.0	396.0	0.0	396.0	5.680804440718127	5.882610142195899	0.0621257479427022	4.817758223362785	6.246356796736771	0.8833111737313653	-0.8630462173553424	0.36374665454087207	0.821185425788663
13722.58cfa830e4b0c9d6adf6bd41	58cfa830e4b0c9d6adf6bd41	TCGA-AG-3593-01A-01D-1525-10_Illumina.filtered.	WGS	TCGA-AG-3593-01A-01D-1525-10_Illumina	TCGA-AG-3593-01A-01D-1525-10_Illumina.bam	495.85	1.9	0.05	58cfa830e4b0c9d6adf6bd41	TCGA-AG-3593-01A-01D-1525-10_Illumina.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3593-01A	10290E91-9784-4F94-8DAA-B5D9A8B0EFB9	Primary Tumor	Illumina HiSeq	d2b54a0a-394a-4174-afce-c86c43e4524d	Colorectal	72.0	EFFCA0F1-E81D-47CD-8287-392A2B6AB786	FAFF4626-615B-416A-B7A6-9D177DCC94A9	TCGA-AG-3593-01A-01D-1525-10	NCBI36_BCM_variant	TCGA-AG-3593	TCGA-READ		s2130	Baylor College of Medicine	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage IIA	1525-10	True	READ	C1		0.09435855900000001			21.47919761	0.8963	0.24600000000000002	-0.0354	0.4447	-0.5132	-0.1155					240.0	0.8847177009999999	20.0	13.0							1.3550179180000002	-1925.126791	598.2607267000001	913.2091785	0.0	1035.0	0.0	1035.0	3.9072805951603105	1.1055274141880416	-0.4448740742740499	4.856361149857457	2.252313249154959	1.3326880138830612	0.9490805546971464	1.1467858349669173	1.777562088157111
13722.58cfa830e4b0c9d6adf6bd44	58cfa830e4b0c9d6adf6bd44	TCGA-AP-A054-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_1_rg.sorted.filtered.	WGS	TCGA-AP-A054-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_1_rg.sorted	TCGA-AP-A054-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_1_rg.sorted.bam	117.13	2.03	0.16	58cfa830e4b0c9d6adf6bd44	TCGA-AP-A054-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_1_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A054-01A	D77E4DBC-B239-4742-8CB7-EFD427010D13	Primary Tumor	Illumina HiSeq	a8fe0928-3d0c-4d16-be11-a5dd077bdb2c	Uterus	64.0	DDFFB9C7-185F-402F-99B8-8058B40086D9	F5A9F85D-4E8E-4400-A109-C227D6B4C0A4	TCGA-AP-A054-01A-11D-A043-02	HG19_Broad_variant	TCGA-AP-A054	TCGA-UCEC	709.0	s4590	Harvard Medical School	MSKCC	None	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C1	UCEC.POLE	0.060366710999999997	0.05	0.0	10.76817441	1.5477	0.344	-1.2537	-0.9931	-0.9224	-0.24100000000000002	560.0	1599.0	9.695997284	30.43955511	145.0	0.054539425999999995	2.0	3.0							2.658615998	-1225.725913	1558.6568220000001	-2369.203234	1.0	709.0	1.0	566.0	5.271810851142943	6.5161680030177775	-0.07048748049796516	4.507870618591898	5.506109111691114	1.5308755899309983	-0.7639402325510449	-1.010058891326664	1.6013630704289636
13722.58cfa830e4b0c9d6adf6bd64	58cfa830e4b0c9d6adf6bd64	TCGA-AA-A00R-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A00R-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A00R-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	205.35	1.73	0.15	58cfa830e4b0c9d6adf6bd64	TCGA-AA-A00R-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A00R-01A	CA22EDD4-EB7C-4677-84AA-6F0354459A19	Primary Tumor	Illumina HiSeq	f8afa471-fd74-43ef-8cc5-58a4f3788e31	Colorectal	64.0	F72EEAE9-F7F5-4576-A072-5021119117D6	AC9F45EC-C004-475F-8537-8977F20B0DE8	TCGA-AA-A00R-01A-01D-A077-02	HG18	TCGA-AA-A00R	TCGA-COAD		s13517	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	A077-02	True	COAD	C2		0.40054602100000003			2.6955994339999996	1.125	0.41700000000000004	0.5398	1.5323	0.4167	-0.2405					96.0	0.103863096	2.0	0.0							0.457954507	-442.0228687	1637.762706	-434.6143528	0.0	30.0	0.0	30.0	7.155070982267333	5.998647024584	-0.31280627762545954	5.878777516361771	6.067639896070951	1.4469189829363254	-1.276293465905562	0.06899287148695166	1.759725260561785
13722.58cfa830e4b0c9d6adf6bd78	58cfa830e4b0c9d6adf6bd78	TCGA-AO-A0JJ-01A-11D-A060_130725_SN590_0233_AD2B3HACXX_s_3_rg.sorted.filtered.	WGS	TCGA-AO-A0JJ-01A-11D-A060_130725_SN590_0233_AD2B3HACXX_s_3_rg.sorted	TCGA-AO-A0JJ-01A-11D-A060_130725_SN590_0233_AD2B3HACXX_s_3_rg.sorted.bam	29.04	1.87	0.14	58cfa830e4b0c9d6adf6bd78	TCGA-AO-A0JJ-01A-11D-A060_130725_SN590_0233_AD2B3HACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-AO-A0JJ-01A	BEF7B135-A727-45E8-850A-CC4CD56C49AA	Primary Tumor	Illumina HiSeq	6d955c96-b34d-4aea-961b-378e856ae8cb	Breast	54.0	008DAFDD-A3D1-4801-8C0A-8714E2B58E48	ED24B69D-599E-42ED-BBE3-5C4F59FABED4	TCGA-AO-A0JJ-01A-11D-A060-02	HG19_Broad_variant	TCGA-AO-A0JJ	TCGA-BRCA		s6271	Harvard Medical School	MSKCC	None	NO	T2	N1a	Infiltrating Lobular Carcinoma	Stage IIB	A060-02	True	BRCA	C6	BRCA.LumA	0.239506131	0.49	0.02	0.546225747	-0.0779	-0.071	0.7165	1.7016	0.5772	0.4762	6.0	62.0	0.123591887	0.432571604	65.0	0.20893381100000002	3.0	10.0	0.9575708959999999	2.9153460780000002	21.0	4.28566588	85.0	0.9646640329999999	1.0630364490000002	-345.7518472	533.5787058	1567.923703	0.0	1887.0	0.0	1887.0	9.173728253479451	5.8743533747419985	0.31428638365692685	6.5346709238641925	6.232987183166063	7.052201883347165	-2.6390573296152584	0.3586338084240652	6.737915499690239
13722.58cfa830e4b0c9d6adf6bd7c	58cfa830e4b0c9d6adf6bd7c	TCGA-BF-A1PV-01A-11D-A18Z_120517_SN208_0300_BC0VYMACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BF-A1PV-01A-11D-A18Z_120517_SN208_0300_BC0VYMACXX_s_1_rg.sorted	TCGA-BF-A1PV-01A-11D-A18Z_120517_SN208_0300_BC0VYMACXX_s_1_rg.sorted.bam	78.67		0.17	58cfa830e4b0c9d6adf6bd7c	TCGA-BF-A1PV-01A-11D-A18Z_120517_SN208_0300_BC0VYMACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE		Skin Cutaneous Melanoma	Aligned reads	TCGA-BF-A1PV-01A	EFF78AF6-0F68-49B9-866B-0D511606F2B1	Primary Tumor	Illumina HiSeq	a219d21e-e657-407a-8e8f-aba8b0190425	Skin	74.0	090DEBB2-290D-49DD-B642-7F01C99A795C	BC0B690D-7C05-4B68-B2F2-5D38EA621A02	TCGA-BF-A1PV-01A-11D-A18Z-02	HG19_Broad_variant	TCGA-BF-A1PV	TCGA-SKCM		s7491	Harvard Medical School	Cureline	Russia	NO	T4b	N0		Stage IIC	A18Z-02	True	SKCM	C1	SKCM.RAS_Hotspot_Mutants	0.07230895799999999	0.08	0.03		0.4448	0.1065	-1.3462	-1.871	-0.8773	0.0167	177.0	0.0	3.59345787	7.985461934			6.0	3.0	0.952548174	1.533067144	5.0	0.693147181	2.0	1.0	2.573604574	-944.9283423	876.6266404999999	-2396.149474	0.0	14.0	0.0	14.0	5.893713891764296	4.94023297910607	-0.16279972035316315	5.537038947825565	6.158390418423963	1.3291088142875784	-0.35667494393873245	1.2181574393178924	1.4919085346407415
13722.58cfa830e4b0c9d6adf6bd86	58cfa830e4b0c9d6adf6bd86	TCGA-BG-A0LX-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BG-A0LX-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_7_rg.sorted	TCGA-BG-A0LX-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_7_rg.sorted.bam	65.42	2.11	0.15	58cfa830e4b0c9d6adf6bd86	TCGA-BG-A0LX-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0LX-01A	AC1D3946-FE6C-4BD8-B02C-638799CB0F67	Primary Tumor	Illumina HiSeq	182220ca-d437-40a2-adeb-d4cb1ce2f284	Uterus	57.0	99CDF3A0-90DC-4992-B75A-11DD41928D43	B294F25A-93D9-49A6-8FD3-6D2B0BBEF27C	TCGA-BG-A0LX-01A-11D-A043-02	HG19_Broad_variant	TCGA-BG-A0LX	TCGA-UCEC		s5218	Harvard Medical School	University of Pittsburgh	None	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C1	UCEC.POLE	0.134058108			8.91983712	0.6407	0.177	-0.341	0.5736	-0.9367	0.2646	211.0	1234.0	4.91634819	12.47996079	44.0	0.081141159	3.0	4.0							2.359876464	-1142.560326	298.5413017	-1976.4896899999999	0.0	614.0	0.0	614.0	6.04276855572385	7.588468332333305	-0.23223406893739806	5.860446998929895	6.238541615384289	1.3958734613392587	-0.1823215567939549	-1.349926716949016	1.6281075302766568
13722.58cfa830e4b0c9d6adf6bd8c	58cfa830e4b0c9d6adf6bd8c	TCGA-BG-A0M0-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BG-A0M0-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_6_rg.sorted	TCGA-BG-A0M0-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_6_rg.sorted.bam	94.25	2.11	0.15	58cfa830e4b0c9d6adf6bd8c	TCGA-BG-A0M0-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0M0-01A	8BF0B156-6EB4-45E8-9CBB-0979EFBEA898	Primary Tumor	Illumina HiSeq	bedca351-a4f7-4fbd-af8e-d49f3d9b2c37	Uterus	66.0	E3F599DB-19CF-4086-8E5D-D3527119120F	78D21C64-205B-4C9C-A862-8A70348D2602	TCGA-BG-A0M0-01A-11D-A101-02	HG19_Broad_variant	TCGA-BG-A0M0	TCGA-UCEC		s5216	Harvard Medical School	University of Pittsburgh	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C1	UCEC.MSI	0.027935897			1.136934556	0.3454	0.162	-1.4571	-1.3493	-1.1585	-0.4579	49.0	193.0	1.173556592	4.092402476	84.0	0.17323638600000002	4.0	2.0							1.811412765	-814.4981841	-153.3638985	127.5674267	0.0	588.0	0.0	588.0	6.18877733838767	7.534562316457883	-0.7137790730959978	6.049015396012511	6.435950027789774	3.052273212845145	-0.13976194237515882	-1.09861228866811	3.766052285941143
13722.58cfa830e4b0c9d6adf6bd8f	58cfa830e4b0c9d6adf6bd8f	TCGA-BB-4223-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BB-4223-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_7_rg.sorted	TCGA-BB-4223-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_7_rg.sorted.bam	11.7	2.0	0.14	58cfa830e4b0c9d6adf6bd8f	TCGA-BB-4223-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BB-4223-01A	05F01280-BF77-4682-A7A8-20DD0EAC77BD	Primary Tumor	Illumina HiSeq	e8bc6546-004a-4702-9289-b5c90582298e	Head and Neck	48.0	82DB742D-885D-4788-B509-474715AE183B	007F0F41-C370-45F9-8053-2C774ADDED49	TCGA-BB-4223-01A-01D-1431-02	HG19_Broad_variant	TCGA-BB-4223	TCGA-HNSC		s15490	Harvard Medical School	Johns Hopkins	United States	NO	T2	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	True	HNSC	C2	HNSC.Atypical	0.21168147699999998	0.26	0.17		1.1246	0.237	0.4689	1.8611	0.3363	0.0978	96.0		1.276922488	3.525416434	195.0	0.39787309600000004	11.0	10.0	0.9090664829999999	3.9369245260000003	76.0	3.841264545	59.0	0.942055002	2.065141229	-789.7089089	1145.252594	-1510.127175	0.0	3221.0	0.0	3221.0	6.903824486607304	9.488369756774663	-0.07973206827160795	5.684584210150579	8.754400581694462	1.83157255160623	-1.2192402764567243	-0.7339691750802002	1.9113046198778378
13722.58cfa830e4b0c9d6adf6bd92	58cfa830e4b0c9d6adf6bd92	TCGA-BG-A0LW-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BG-A0LW-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_5_rg.sorted	TCGA-BG-A0LW-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_5_rg.sorted.bam	100.95	1.92	0.15	58cfa830e4b0c9d6adf6bd92	TCGA-BG-A0LW-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0LW-01A	68181BC9-AA8B-44EC-8601-564B30EA0561	Primary Tumor	Illumina HiSeq	89430da6-f21d-4534-8b48-c645836813b5	Uterus	47.0	6527EC31-1D41-49C2-93FF-11615A6CBA8B	5D88ADF5-468B-4377-B3E3-DF986C613D24	TCGA-BG-A0LW-01A-11D-A043-02	HG19_Broad_variant	TCGA-BG-A0LW	TCGA-UCEC		s5003	Harvard Medical School	University of Pittsburgh	None	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C3	UCEC.CN_LOW	0.059149774	0.06	0.0	2.175036955	-0.8166	-0.10400000000000001	-0.4872	-0.5873	-0.3895	-0.0202	20.0	25.0	0.20399321399999998	0.845114743	63.0	5.03e-05	0.0	0.0							2.538470225	-1038.815055	-1258.0891199999999	102.3033658	0.0	566.0	0.0	566.0	5.425209118402661	4.432760562118595	-0.09925160459067728	5.080368632110932	4.624545033946071	3.683781737042267	-0.34484048629172914	0.19178447182747593	3.7830333416329447
13722.58cfa830e4b0c9d6adf6bd9a	58cfa830e4b0c9d6adf6bd9a	TCGA-BG-A0M6-01A-31D-A101_120330_SN1120_0129_BD0UCLACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BG-A0M6-01A-31D-A101_120330_SN1120_0129_BD0UCLACXX_s_2_rg.sorted	TCGA-BG-A0M6-01A-31D-A101_120330_SN1120_0129_BD0UCLACXX_s_2_rg.sorted.bam	71.62	1.94	0.14	58cfa830e4b0c9d6adf6bd9a	TCGA-BG-A0M6-01A-31D-A101_120330_SN1120_0129_BD0UCLACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0M6-01A	002724FA-7051-49FA-9C58-4BCB7EBA4AC6	Primary Tumor	Illumina HiSeq	0db41cb8-f118-4d04-a002-22df953a0dec	Uterus	73.0	66E4B080-E6EF-4531-9B69-1B27F15C5669	61C058D9-E5DC-4D74-B378-28B8F0A2BF78	TCGA-BG-A0M6-01A-31D-A101-02	HG19_Broad_variant	TCGA-BG-A0M6	TCGA-UCEC		s4249	Harvard Medical School	University of Pittsburgh	None	NO			Serous endometrial adenocarcinoma		A101-02	True	UCEC	C1	UCEC.CN_HIGH	0.042892953	0.31	0.18	4.843023072	0.6525	0.052000000000000005	-1.6021	-1.8642	-1.0292	0.2725	17.0		0.35589972700000005	1.326535347	265.0	0.7062789070000001	18.0	42.0							2.923706328	-1484.450728	-16.11459132	-754.4244173999999	1.0	671.0	0.0	671.0	6.815340902289838	7.5182969468779195	0.10048446508873721	6.2954654430039305	6.41968465820981		-0.5198754592859083	-1.0986122886681098	
13722.58cfa830e4b0c9d6adf6bd9b	58cfa830e4b0c9d6adf6bd9b	TCGA-BG-A0M3-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BG-A0M3-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_8_rg.sorted	TCGA-BG-A0M3-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_8_rg.sorted.bam	101.93	1.88	0.15	58cfa830e4b0c9d6adf6bd9b	TCGA-BG-A0M3-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0M3-01A	8BDD4E0E-5BEC-43F2-B9FA-D6E94A72FE05	Primary Tumor	Illumina HiSeq	d3fa774f-c50e-499c-ad6e-1a5f67dd2be3	Uterus	74.0	1802CD6B-4D4A-45FA-B839-7450071E41EE	04E49830-378E-4EB2-B77C-70D6955627F7	TCGA-BG-A0M3-01A-11D-A101-02	HG19_Broad_variant	TCGA-BG-A0M3	TCGA-UCEC		s5394	Harvard Medical School	University of Pittsburgh	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C1	UCEC.CN_LOW	0.064079732	0.12	0.0	0.180187216	0.4007	0.147	-0.7103	-0.5798	-0.8506	-0.4059	30.0	19.0	0.539648031	1.708885431	63.0	0.160502924	6.0	2.0							3.286932222	-1527.2159609999999	64.37580557	-1099.18695	0.0	1071.0	0.0	1071.0	7.105427164322677	6.766729204595354	0.0489861081300863	6.444028682077312	6.383736952339248	4.926861912380401	-0.6613984822453651	-0.382992252256106	4.877875804250315
13722.58cfa830e4b0c9d6adf6bda2	58cfa830e4b0c9d6adf6bda2	TCGA-BF-A1PX-01A-12D-A18Z_120518_SN1120_0142_AC0VG4ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BF-A1PX-01A-12D-A18Z_120518_SN1120_0142_AC0VG4ACXX_s_2_rg.sorted	TCGA-BF-A1PX-01A-12D-A18Z_120518_SN1120_0142_AC0VG4ACXX_s_2_rg.sorted.bam	42.01		0.16	58cfa830e4b0c9d6adf6bda2	TCGA-BF-A1PX-01A-12D-A18Z_120518_SN1120_0142_AC0VG4ACXX_s_2_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-BF-A1PX-01A	197AC33E-D5DF-40DE-92F2-6EF7FE2AD6DD	Primary Tumor	Illumina HiSeq	4a62234d-e7fe-4cd1-a319-baafc27c9db8	Skin	56.0	EE2F9863-0DAE-4830-A780-E7745414BC3D	98B49A52-61EC-4A87-B2DD-EEFD6E0E028F	TCGA-BF-A1PX-01A-12D-A18Z-02	HG19_Broad_variant	TCGA-BF-A1PX	TCGA-SKCM	282.0	s7825	Harvard Medical School	Cureline	Russia	NO	T4b	N2a		Stage IIIB	A18Z-02	True	SKCM	C2	SKCM.BRAF_Hotspot_Mutants	0.538046201	0.75	0.06		0.3343	0.1005	0.8836	1.7737	0.8158	0.5997	115.0		4.9298358780000004	8.247398387999999			8.0	6.0	0.909331863	4.050479927	86.0	4.028032069	78.0	0.924558475	2.546182904	613.6556135	758.0904780000001	-2127.8766	1.0	282.0	0.0	282.0	6.4790087495846045	5.728338629019635	0.43930975916076864	6.556970291054316	8.858601795531232	1.6648506173640256	0.0779615414697119	3.130263166511597	1.225540858203257
13722.58cfa830e4b0c9d6adf6bda8	58cfa830e4b0c9d6adf6bda8	TCGA-BF-A1Q0-01A-21D-A18Z_120520_SN590_0158_AC0J99ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BF-A1Q0-01A-21D-A18Z_120520_SN590_0158_AC0J99ACXX_s_5_rg.sorted	TCGA-BF-A1Q0-01A-21D-A18Z_120520_SN590_0158_AC0J99ACXX_s_5_rg.sorted.bam	66.95		0.16	58cfa830e4b0c9d6adf6bda8	TCGA-BF-A1Q0-01A-21D-A18Z_120520_SN590_0158_AC0J99ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-BF-A1Q0-01A	633DDC04-C424-42C8-8E54-673968B130A7	Primary Tumor	Illumina HiSeq	44801af7-d042-441d-afc9-4c0d7b493b01	Skin	80.0	B68CFB6B-4249-4855-8278-B18C0F561EFD	C94F7E24-8073-4786-BFC0-C45A37D85B2F	TCGA-BF-A1Q0-01A-21D-A18Z-02	HG19_Broad_variant	TCGA-BF-A1Q0	TCGA-SKCM		s7320	Harvard Medical School	Cureline	Russia	NO	T4b	N0		Stage IIC	A18Z-02	True	SKCM	C1	SKCM.Triple_WT	0.318470044	0.6	0.33		1.0546	0.373	0.0017	0.3759	0.0528	0.2309	386.0	18.0	9.500260447	17.31850757			18.0	44.0	0.885353435	2.45472095	16.0	2.8647385119999997	19.0	0.972931867	5.519405872	272.47218010000006	926.7188249	-2578.082887	0.0	831.0	0.0	831.0	5.760340869551376	6.990919264242873	0.7208251045040441	5.014271287537088	6.59887717646685	2.4927819464359193	-0.7460695820142877	-0.3920420877760238	1.7719568419318752
13722.58cfa830e4b0c9d6adf6bdad	58cfa830e4b0c9d6adf6bdad	TCGA-AG-3574-01A-01D-1989-10_wgs_Illumina.filtered.	WGS	TCGA-AG-3574-01A-01D-1989-10_wgs_Illumina	TCGA-AG-3574-01A-01D-1989-10_wgs_Illumina.bam	750.21	1.9	0.14	58cfa830e4b0c9d6adf6bdad	TCGA-AG-3574-01A-01D-1989-10_wgs_Illumina.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3574-01A	0EDA7373-8335-455F-B90A-8C3540F28088	Primary Tumor	Illumina HiSeq	b41b6882-7cf8-49c6-aa56-8418d77c24cb	Colorectal	89.0	DA897A5D-B2CC-419F-ACD7-473B4928C5D5	ECF4E05A-0912-4B93-AD66-323002F0C845	TCGA-AG-3574-01A-01D-1989-10	GRCh37-lite	TCGA-AG-3574	TCGA-READ		s2309	Baylor College of Medicine	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage II	1989-10	True	READ	C1		0.04333499			3.175417593	0.4391	0.207	-0.5073	-0.2912	-1.0001	-0.1569			0.648191481	1.6204787019999998	93.0	0.24083651399999997	10.0	2.0							1.177134779	-702.2939719999999	-730.6651832	-32.8054185	1.0	1096.0	1.0	1096.0	7.75505313936934	1.3818793429107732	-0.14078480933874382	5.634789603169249	4.526717123250188	1.2885825320577209	-2.120263536200091	3.144837780339415	1.4293673413964647
13722.58cfa830e4b0c9d6adf6bdb3	58cfa830e4b0c9d6adf6bdb3	TCGA-BG-A0MG-01A-21D-A101_120330_SN1120_0129_BD0UCLACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BG-A0MG-01A-21D-A101_120330_SN1120_0129_BD0UCLACXX_s_5_rg.sorted	TCGA-BG-A0MG-01A-21D-A101_120330_SN1120_0129_BD0UCLACXX_s_5_rg.sorted.bam	57.94	1.87	0.14	58cfa830e4b0c9d6adf6bdb3	TCGA-BG-A0MG-01A-21D-A101_120330_SN1120_0129_BD0UCLACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0MG-01A	9CDE90C8-2BE0-4328-A032-FF1DC19E66FD	Primary Tumor	Illumina HiSeq	30b3e5f5-4066-401d-9cf3-5ee64b9014ef	Uterus	73.0	96B6826D-8A4C-45F5-8CD3-B5988AA5FD0E	755BD772-9331-402B-832B-2933AAECFC71	TCGA-BG-A0MG-01A-21D-A101-02	HG19_Broad_variant	TCGA-BG-A0MG	TCGA-UCEC		s4248	Harvard Medical School	University of Pittsburgh	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C1	UCEC.CN_LOW	0.134104119	0.24	0.0	12.12363915	0.7344	0.221	-0.5229	-1.1506	-0.1201	-0.2003	48.0		1.037517085	2.412227222	84.0	0.093795957	4.0	6.0							2.510679504	-1056.6364839999999	131.2332118	38.05707878	0.0	1477.0	0.0	1477.0	7.929414526482119	7.678634808082434	-0.05603078686244156	6.40335822298707	6.7848169320603375	1.3969549487561213	-1.5260563034950492	-0.8938178760220965	1.452985735618563
13722.58cfa830e4b0c9d6adf6bdc0	58cfa830e4b0c9d6adf6bdc0	TCGA-BG-A186-01A-11D-A12F_120413_SN1120_0132_AD0T6RACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BG-A186-01A-11D-A12F_120413_SN1120_0132_AD0T6RACXX_s_1_rg.sorted	TCGA-BG-A186-01A-11D-A12F_120413_SN1120_0132_AD0T6RACXX_s_1_rg.sorted.bam	79.77	1.93	0.17	58cfa830e4b0c9d6adf6bdc0	TCGA-BG-A186-01A-11D-A12F_120413_SN1120_0132_AD0T6RACXX_s_1_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A186-01A	FE4DB898-3A9F-4DFF-ADCB-7B8C30137350	Primary Tumor	Illumina HiSeq	f65268ef-b937-4d49-922e-a5e3ebc0eab8	Uterus	61.0	B1645A83-57B7-4357-B977-63A5B6AEE39E	ECF410AD-B160-4F00-A165-38529FAE974B	TCGA-BG-A186-01A-11D-A12F-02	HG19_Broad_variant	TCGA-BG-A186	TCGA-UCEC		s4792	Harvard Medical School	University of Pittsburgh	None	NO			Endometrioid endometrial adenocarcinoma		A12F-02	True	UCEC	C3	UCEC.CN_LOW	0.145743423	0.18	0.0	6.600332262999999	-0.18600000000000003	-0.11800000000000001	-0.113	0.5196	-0.4062	0.0142	17.0	8.0	0.24228122300000002	0.807604077	69.0	0.049554182	2.0	3.0							2.297214664	-1080.09172	-179.07782759999998	-171.5410928	0.0	419.0	0.0	419.0	5.9909209211092715	7.532049884335596	-0.3504288274417797	5.388745518755053	6.482227759836919	2.6453034461122114	-0.6021754023542183	-1.0498221244986778	2.9957322735539913
13722.58cfa830e4b0c9d6adf6bdc4	58cfa830e4b0c9d6adf6bdc4	TCGA-BG-A18A-01A-21D-A12F_120626_SN590_0163_AC0VU5ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BG-A18A-01A-21D-A12F_120626_SN590_0163_AC0VU5ACXX_s_7_rg.sorted	TCGA-BG-A18A-01A-21D-A12F_120626_SN590_0163_AC0VU5ACXX_s_7_rg.sorted.bam	21.93	1.96	0.17	58cfa830e4b0c9d6adf6bdc4	TCGA-BG-A18A-01A-21D-A12F_120626_SN590_0163_AC0VU5ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A18A-01A	FEB3E930-3638-44B4-AC0F-A5DCB01FED76	Primary Tumor	Illumina HiSeq	cf06b397-1811-4a38-93b4-05f1457e9882	Uterus	74.0	8FD0971D-40BA-46C2-B3C4-8E48A3E6C122	518AFA21-9E19-49DE-A2A6-387828A10837	TCGA-BG-A18A-01A-21D-A12F-02	HG19_Broad_variant	TCGA-BG-A18A	TCGA-UCEC		s4789	Harvard Medical School	University of Pittsburgh	None	NO			Endometrioid endometrial adenocarcinoma		A12F-02	True	UCEC	C3	UCEC.POLE	0.132474538			0.654568547	-0.3674	-0.18100000000000002	-0.4874	0.1368	0.042	0.2705	33.0		0.648015156	1.408728601	49.0	0.046416655999999994	2.0	0.0							2.398418193	-892.6312488	-1308.594014	-940.4675377	0.0	426.0	0.0	426.0	7.3658760863161	8.83859322726383	-1.0345652138329755	6.26726379764799	7.6064495459711985		-1.0986122886681096	-1.2321436812926325	
13722.58cfa830e4b0c9d6adf6bdcc	58cfa830e4b0c9d6adf6bdcc	TCGA-BH-A0H6-01A-21D-A060_130725_SN590_0233_AD2B3HACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BH-A0H6-01A-21D-A060_130725_SN590_0233_AD2B3HACXX_s_1_rg.sorted	TCGA-BH-A0H6-01A-21D-A060_130725_SN590_0233_AD2B3HACXX_s_1_rg.sorted.bam	71.16	2.03	0.15	58cfa830e4b0c9d6adf6bdcc	TCGA-BH-A0H6-01A-21D-A060_130725_SN590_0233_AD2B3HACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE		Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0H6-01A	AEB6A3A6-B57A-4C53-90E6-E833777DD2A1	Primary Tumor	Illumina HiSeq	9c69c17b-33de-4bb8-be9f-7e0dcde9db0a	Breast	82.0	B2921C9D-C655-46F3-86E5-2FC2BED1ED33	57D73BC9-950E-42A3-B9FB-6045117112B7	TCGA-BH-A0H6-01A-21D-A060-02	HG19_Broad_variant	TCGA-BH-A0H6	TCGA-BRCA		s5963	Harvard Medical School	University of Pittsburgh	None	NO	T1b	NX	Infiltrating Ductal Carcinoma	Stage I	A060-02	True	BRCA	C1	BRCA.LumA	0.064488516	0.29	0.96	1.066692816	-0.5622	-0.1035	-0.5143	-1.5154	-0.29100000000000004	0.512	6.0	56.0	0.172825082	0.460866885	94.0	0.098181046	3.0	9.0				0.693147181	2.0	1.0	1.109805256	-555.7239907000001	340.5538874	1101.190057	0.0	747.0	0.0	747.0	8.891786635857315	6.955416057840587	0.30740001737736833	6.58920154286327	6.81726571935977	3.5366461269099907	-2.3025850929940455	-0.13815033848081715	3.2292461095326224
13722.58cfa830e4b0c9d6adf6bdd4	58cfa830e4b0c9d6adf6bdd4	TCGA-BH-A0BM-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BH-A0BM-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_3_rg.sorted	TCGA-BH-A0BM-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_3_rg.sorted.bam	18.62	1.9	0.15	58cfa830e4b0c9d6adf6bdd4	TCGA-BH-A0BM-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE		Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0BM-01A	C2AEEE6C-BA10-4CF9-B560-C739580F7BF3	Primary Tumor	Illumina HiSeq	46f039c4-a705-4933-bf85-0e96e80e5024	Breast	54.0	5423B7F8-D2BB-47C8-9AF8-3D3E1276888C	FA99DD38-37F1-4B24-960E-617F92CDADD0	TCGA-BH-A0BM-01A-11D-A060-02	HG19_Broad_variant	TCGA-BH-A0BM	TCGA-BRCA		s6772	Harvard Medical School	University of Pittsburgh	None	NO	T2	N1a	Infiltrating Ductal Carcinoma	Stage IIB	A060-02	True	BRCA	C3	BRCA.Normal	0.101749361	0.4	0.01	0.69456749	-1.595	-0.147	-0.3096	0.2591	-0.5683	0.2428	15.0	16.0	0.283521405	0.56704281	53.0	0.09363184599999999	4.0	8.0				2.022808529	8.0	0.972765278	1.669469976	-774.8854727	-514.3070882000001	1499.309232	0.0	1876.0	0.0	1876.0	8.628108251987392	6.2751043697560664	-0.350927083555725	6.325523158993347	7.030771907297345	2.6378121545072957	-2.3025850929940455	0.7556675375412789	2.9887392380630207
13722.58cfa830e4b0c9d6adf6bdd6	58cfa830e4b0c9d6adf6bdd6	TCGA-BG-A0MC-01A-21D-A043_120530_SN1222_0110_AC0VLAACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BG-A0MC-01A-21D-A043_120530_SN1222_0110_AC0VLAACXX_s_1_rg.sorted	TCGA-BG-A0MC-01A-21D-A043_120530_SN1222_0110_AC0VLAACXX_s_1_rg.sorted.bam	84.24	2.08	0.16	58cfa830e4b0c9d6adf6bdd6	TCGA-BG-A0MC-01A-21D-A043_120530_SN1222_0110_AC0VLAACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0MC-01A	884FD57D-BD8E-40E7-82F6-0BA1C71101A9	Primary Tumor	Illumina HiSeq	db9c9c51-2c42-4a56-a87d-9c01038c4e6f	Uterus	74.0	46B48BF8-346B-4F25-916E-26A3CDDFA00D	9376C8CD-BD9D-4576-BBE3-7D771914AFA3	TCGA-BG-A0MC-01A-21D-A043-02	HG19_Broad_variant	TCGA-BG-A0MC	TCGA-UCEC		s4601	Harvard Medical School	University of Pittsburgh	None	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C3	UCEC.CN_LOW	0.188808925	0.36	0.0	4.438969912	-0.6959	-0.233	-0.1293	1.0501	-0.8668	-0.0834	28.0	10.0	0.436254252	1.4250972240000002	59.0	0.029636922000000003	0.0	7.0							2.607272996	-1125.632233	-1739.3831109999999	-34.8488741	0.0	1263.0	0.0	1263.0	7.287332616138174	7.73300227238953	-0.5453240954637477	6.869597415438196	6.752173019377805	2.7374974024285113	-0.4177352006999788	-0.9808292530117262	3.2828214978922587
13722.58cfa830e4b0c9d6adf6bde2	58cfa830e4b0c9d6adf6bde2	TCGA-AG-A01N-01A-01D-A077_110406_SN177_0154_B818URABXX_s_3.rg.sorted.filtered.	WGS	TCGA-AG-A01N-01A-01D-A077_110406_SN177_0154_B818URABXX_s_3.rg.sorted	TCGA-AG-A01N-01A-01D-A077_110406_SN177_0154_B818URABXX_s_3.rg.sorted.bam	237.59	1.78	0.15	58cfa830e4b0c9d6adf6bde2	TCGA-AG-A01N-01A-01D-A077_110406_SN177_0154_B818URABXX_s_3.rg.sorted.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A01N-01A	1118490D-75AA-43CC-B2A2-C2AF61829FFC	Primary Tumor	Illumina HiSeq	1e5467f7-e974-4244-b9fb-2afff5ed40b4	Colorectal	68.0	0350E0DE-7B86-485A-A057-50E77D899ED9	49977602-A81B-4DDD-9354-8949BC3208CF	TCGA-AG-A01N-01A-01D-A077-02	HG18_Broad_variant	TCGA-AG-A01N	TCGA-READ		s2007	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Rectal Adenocarcinoma	Stage IV	A077-02	True	READ	C1	GI.CIN	0.12512737	0.41	0.28	17.296726500000002	0.7508	0.237	-1.1971	-1.2203	-0.048	-0.1425	51.0		0.784290832	3.375860538	75.0	0.927395676	21.0	13.0							1.39153088	-1954.639823	1.230471514	-345.2454112	0.0	943.0	0.0	943.0	6.23793392372569	4.784892739882774	-1.9681258947641562	4.889860775425996	5.014202806112648	-0.22952615229470696	-1.3480731482996933	0.22931006622987393	1.7385997424694493
13722.58cfa830e4b0c9d6adf6bded	58cfa830e4b0c9d6adf6bded	TCGA-BH-A0DK-01A-21D-A060_130807_SN590_0236_BC291KACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BH-A0DK-01A-21D-A060_130807_SN590_0236_BC291KACXX_s_5_rg.sorted	TCGA-BH-A0DK-01A-21D-A060_130807_SN590_0236_BC291KACXX_s_5_rg.sorted.bam	43.73	2.05	0.16	58cfa830e4b0c9d6adf6bded	TCGA-BH-A0DK-01A-21D-A060_130807_SN590_0236_BC291KACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE		Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0DK-01A	F2BBFA9D-9A9D-4F46-9FDE-378E4C44E2AD	Primary Tumor	Illumina HiSeq	71acb20b-f186-44d4-a92e-a2751f845fe3	Breast	49.0	1ACAE6E0-3100-4DE8-A436-E15CDBE1322B	92245807-8B1B-4E96-8567-6CFE5E70ADE4	TCGA-BH-A0DK-01A-21D-A060-02	HG19_Broad_variant	TCGA-BH-A0DK	TCGA-BRCA		s5493	Harvard Medical School	University of Pittsburgh	None	NO	T2	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IIA	A060-02	True	BRCA	C2	BRCA.LumA	0.314561435	0.48	0.01	0.8058527190000001	0.21	0.0655	0.7502	1.8828	1.6852	0.6667	41.0	56.0	0.49974637899999996	2.38114451	180.0	0.22289701399999998	6.0	16.0	0.7232843659999999	2.9368549489999998	58.0	4.725641556	123.0	0.9820159009999999	2.56356427	214.0376674	474.5170661	1063.839284	0.0	423.0	0.0	423.0	7.328218462667736	6.276480023873361	-0.10763513279706594	5.431098477781855	6.276480023873361	2.580173038127275	-1.897119984885881	0.0	2.687808170924341
13722.58cfa830e4b0c9d6adf6bdf1	58cfa830e4b0c9d6adf6bdf1	TCGA-AK-3428-01A-02D-2096-10_Illumina.filtered.	WGS	TCGA-AK-3428-01A-02D-2096-10_Illumina	TCGA-AK-3428-01A-02D-2096-10_Illumina.bam	23.4	1.9	0.14	58cfa830e4b0c9d6adf6bdf1	TCGA-AK-3428-01A-02D-2096-10_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-AK-3428-01A	9DA334ED-314C-4445-BA29-FFD9BB42403C	Primary Tumor	Illumina HiSeq	46d21c8f-8493-4886-82f4-91fd488b4364	Kidney	62.0	0B96A41E-6A0C-4FC6-8F21-8E5F992CE5D1	D01710F9-EFC8-4B5F-9E53-300B30F9219F	TCGA-AK-3428-01A-02D-2096-10	GRCh37-lite	TCGA-AK-3428	TCGA-KIRC		s9303	Baylor College of Medicine	Fox Chase	None	NO	T3b	N0	Kidney Clear Cell Renal Carcinoma	Stage III	2096-10	False	KIRC	C3	KIRC.4	0.11381819900000001				-1.5454	-0.2025	0.4208	-0.3233	0.1646	-0.0196					49.0	0.072729068	0.0	2.0				0.0	1.0		1.812582766	-289.3513585	-731.0425541000001	2331.118498	0.0	3728.0	0.0	3728.0	8.10605921540729	0.856552162639538	1.7399223397285144	5.462966910579853	3.9242311401755883	1.8887959624549289	-2.6430923048274377	3.0676789775360502	0.14887362272641447
13722.58cfa830e4b0c9d6adf6bdf5	58cfa830e4b0c9d6adf6bdf5	TCGA-AG-A01W-01A-21D-A079-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-A01W-01A-21D-A079-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-A01W-01A-21D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	140.75	2.0	0.15	58cfa830e4b0c9d6adf6bdf5	TCGA-AG-A01W-01A-21D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A01W-01A	74543FA4-CE73-46E4-9C59-224E8242B4A2	Primary Tumor	Illumina HiSeq	66ffc729-68c6-4bd6-b4d2-e68e3989e252	Colorectal	67.0	C481ABBB-21EB-4393-AB8D-C27E3DA1B8F7	BC3C3340-5E36-4754-AF22-F08EF550BD07	TCGA-AG-A01W-01A-21D-A079-02	HG18	TCGA-AG-A01W	TCGA-READ		s2171	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage II	A079-02	True	READ	C2	GI.CIN	0.187136672	0.39	0.12	14.97478291	1.1471	0.426	-0.5799	0.1669	0.2249	-0.2872	74.0	34.0	1.088335558	3.5227703569999997	199.0	0.542209834	15.0	28.0								-1632.03746	713.4304784	660.567984	0.0	0.0	0.0	0.0	6.395556163388334	5.045295131588768	-0.1222979489643391	4.4496460143330205	5.517770949979892	1.6263357564178216	-1.9459101490553135	0.47247581839112396	1.7486337053821606
13722.58cfa830e4b0c9d6adf6bdf8	58cfa830e4b0c9d6adf6bdf8	TCGA-AK-3454-01A-02D-2096-10_wgs_Illumina.filtered.	WGS	TCGA-AK-3454-01A-02D-2096-10_wgs_Illumina	TCGA-AK-3454-01A-02D-2096-10_wgs_Illumina.bam	28.07	1.9	0.15	58cfa830e4b0c9d6adf6bdf8	TCGA-AK-3454-01A-02D-2096-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-AK-3454-01A	28E9B6F9-AB6A-400B-A6A9-79095A443591	Primary Tumor	Illumina HiSeq	54d1e202-1017-4494-af06-5b5747b7201c	Kidney	84.0	74741322-3B24-43E6-9CE1-F267B0555F62	FD74DE4D-6973-4597-A541-E8A13D80AD55	TCGA-AK-3454-01A-02D-2096-10	GRCh37-lite	TCGA-AK-3454	TCGA-KIRC		s9731	Baylor College of Medicine	Fox Chase	United States	NO	T1b	NX	Kidney Clear Cell Renal Carcinoma	Stage I	2096-10	False	KIRC	C3	KIRC.1	0.169385125				-1.2809	-0.2385	0.3106	0.1118	0.1941	-0.0387					95.0	0.120049713	1.0	11.0				1.71049323	6.0	0.9546444479999999	1.2612456140000001	927.5326691	-1207.295069	3127.4585260000003	0.0	874.0	0.0	874.0	8.665068377301067	-0.2593691651613721	0.7634394067439164	5.4461925524328665	2.7228944332564433		-3.2188758248682006	2.9822635984178154	
13722.58cfa830e4b0c9d6adf6be04	58cfa830e4b0c9d6adf6be04	TCGA-BG-A0M9-01A-21D-A101_120330_SN1120_0129_BD0UCLACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BG-A0M9-01A-21D-A101_120330_SN1120_0129_BD0UCLACXX_s_4_rg.sorted	TCGA-BG-A0M9-01A-21D-A101_120330_SN1120_0129_BD0UCLACXX_s_4_rg.sorted.bam	133.79	2.0	0.17	58cfa830e4b0c9d6adf6be04	TCGA-BG-A0M9-01A-21D-A101_120330_SN1120_0129_BD0UCLACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0M9-01A	4FD1CB59-6C50-4355-9D37-A341E1F4FAD9	Primary Tumor	Illumina HiSeq	633f3cff-14c3-45f7-b568-caa86760d863	Uterus	73.0	DC487BBF-555B-423B-B7C0-3E92DEFA5A79	3D712314-6FDC-41C7-9CE1-5F9BB85929EE	TCGA-BG-A0M9-01A-21D-A101-02	HG19_Broad_variant	TCGA-BG-A0M9	TCGA-UCEC		s4603	Harvard Medical School	University of Pittsburgh	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C1	UCEC.CN_LOW	0.072580584			0.917571885	-0.1953	0.063	-0.8322	-1.1941	-1.1606	-0.113	26.0		0.362567142	1.63155214	119.0	0.049821577									4.183850517	-990.4722621	-1035.578023	-889.9575833999999	0.0	2270.0	0.0	2270.0	7.037261916468042	7.4025023325354375	-1.0668860758560026	6.941951736663718	6.629312444301956	1.2887434329558176	-0.09531017980432477	-0.7731898882334818	2.35562950881182
13722.58cfa830e4b0c9d6adf6be06	58cfa830e4b0c9d6adf6be06	TCGA-BG-A0MQ-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BG-A0MQ-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_6_rg.sorted	TCGA-BG-A0MQ-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_6_rg.sorted.bam	87.16	2.0	0.14	58cfa830e4b0c9d6adf6be06	TCGA-BG-A0MQ-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0MQ-01A	12D36A1D-9922-4311-BBDA-71F32AC2C03B	Primary Tumor	Illumina HiSeq	d1e9cdb8-f8a6-43da-9afb-28a6e6d72b6a	Uterus	71.0	3D1FA321-D2E8-4460-AE87-356AB1CA6281	08F01B17-0386-4C7E-B926-1736CEC043D2	TCGA-BG-A0MQ-01A-11D-A101-02	HG19_Broad_variant	TCGA-BG-A0MQ	TCGA-UCEC		s4253	Harvard Medical School	University of Pittsburgh	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C1	UCEC.MSI	0.056270479000000005	0.15	0.0	10.25845071	0.2858	0.098	-0.9543	-1.4031	-1.1404	-0.2984	143.0		5.108797837	15.4328268	69.0	0.049252434000000005	2.0	2.0							1.7620417000000002	-1110.6693599999999	-58.79649531	2396.1888989999998	0.0	1817.0	0.0	1817.0	7.321655301205362	7.726212650507528	-1.6717718913236395	6.41719902697821	7.033065469947584	2.4702799979290617	-0.9044562742271522	-0.693147180559945	4.142051889252701
13722.58cfa830e4b0c9d6adf6be10	58cfa830e4b0c9d6adf6be10	TCGA-BH-A0HX-01A-21D-A060_130807_SN590_0236_BC291KACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BH-A0HX-01A-21D-A060_130807_SN590_0236_BC291KACXX_s_7_rg.sorted	TCGA-BH-A0HX-01A-21D-A060_130807_SN590_0236_BC291KACXX_s_7_rg.sorted.bam	19.84	1.95	0.16	58cfa830e4b0c9d6adf6be10	TCGA-BH-A0HX-01A-21D-A060_130807_SN590_0236_BC291KACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE		Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0HX-01A	3B01D064-8C00-4972-9F07-407EAC8E7534	Primary Tumor	Illumina HiSeq	06f7db86-540c-401d-bbd9-0b88698c5f36	Breast	54.0	989C2DF5-5183-4DAA-A8DA-FC9AB18A437C	11821020-0E93-4479-85F8-306976DE6722	TCGA-BH-A0HX-01A-21D-A060-02	HG19_Broad_variant	TCGA-BH-A0HX	TCGA-BRCA		s6126	Harvard Medical School	University of Pittsburgh	None	NO	T2	N1a	Infiltrating Ductal Carcinoma	Stage IIB	A060-02	True	BRCA	C1	BRCA.LumA	0.147624926	0.4	0.44		0.1575	0.069	-0.1506	-0.2522	-0.1606	0.4108	26.0	0.0	0.5878101689999999	1.70464949	278.0	0.605404901	16.0	44.0		0.0	1.0	2.94700477	20.0	0.98373436	3.9100396660000003	-467.21010650000005	793.4465865	-37.15866052	0.0	829.0	0.0	829.0	8.22817689595132	7.026109580006812	-0.4785270550619065	5.830281623152949	6.774795151725907		-2.3978952727983707	-0.2513144282809061	
13722.58cfa830e4b0c9d6adf6be13	58cfa830e4b0c9d6adf6be13	TCGA-BH-A0W5-01A-11D-A106_130719_SN1120_0270_AC2CVRACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BH-A0W5-01A-11D-A106_130719_SN1120_0270_AC2CVRACXX_s_3_rg.sorted	TCGA-BH-A0W5-01A-11D-A106_130719_SN1120_0270_AC2CVRACXX_s_3_rg.sorted.bam	55.92	1.91	0.16	58cfa830e4b0c9d6adf6be13	TCGA-BH-A0W5-01A-11D-A106_130719_SN1120_0270_AC2CVRACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0W5-01A	DA9C10EA-C13F-4D88-8B94-A0CBC106D036	Primary Tumor	Illumina HiSeq	eeccc516-2d3d-4f41-a324-c90f92a6f944	Breast	77.0	050E66BB-438A-49D5-A005-7967A006B3F0	6C8B3A70-CD58-4BFC-9418-54182588CFCB	TCGA-BH-A0W5-01A-11D-A106-02	HG19_Broad_variant	TCGA-BH-A0W5	TCGA-BRCA		s5803	Harvard Medical School	University of Pittsburgh	None	NO	T1c	N1a	Infiltrating Ductal Carcinoma	Stage IIA	A106-02	False	BRCA	C3	BRCA.LumA	0.46683243700000004	0.67	0.05	2.232300791	-0.4587	-0.1205	0.7806	2.2521	-0.1723	0.4202	2.0	0.0	0.082612459	0.633362188	47.0	0.10814992699999999	5.0	5.0	0.874063502	3.6486795539999997	65.0	4.759145088	136.0	0.968752171	1.4578462859999999	-564.1030262	305.634995	94.70566613	0.0	1288.0	0.0	1288.0	8.08193875449732	6.403101049120689	-0.283805740879026	5.830646955890826	6.097719399569508	2.0539763606203403	-2.251291798606495	-0.30538164955118186	2.337782101499366
13722.58cfa830e4b0c9d6adf6be18	58cfa830e4b0c9d6adf6be18	TCGA-AZ-4615-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AZ-4615-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-AZ-4615-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	361.02	1.9	0.15	58cfa830e4b0c9d6adf6be18	TCGA-AZ-4615-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AZ-4615-01A	BF69A4CE-EC7E-4752-A86D-DCC80E3C9A57	Primary Tumor	Illumina HiSeq	82dc215a-4234-4f8b-a4c0-50c8103dda6e	Colorectal	84.0	89811300-8202-4A82-8353-5B2B2B2ECFD4	90D11094-F492-4B05-81AB-E637AEC8F953	TCGA-AZ-4615-01A-01D-1405-02	HG18	TCGA-AZ-4615	TCGA-COAD		s13216	Harvard Medical School	University of Pittsburgh	None	NO	T3	N1	Colon Adenocarcinoma	Stage IIIB	1405-02	True	COAD	C2	GI.HM-indel	0.22896406100000002	0.35	0.0	16.07671708	0.6597	0.2075	0.2953	0.4828	1.4096	0.0864	217.0	1371.0	8.163128215	24.52054162	100.0	0.058709582999999996	2.0	1.0							0.8662784579999999	-588.1257283	408.7878023	-2058.379225	0.0	1002.0	1.0	688.0	4.925238774139026	4.720135800781582	0.41422320005343616	3.8082773468027193	5.20679106361976	1.636708055506746	-1.1169614273363067	0.4866552628381777	1.2224848554533096
13722.58cfa830e4b0c9d6adf6be22	58cfa830e4b0c9d6adf6be22	TCGA-B9-4113-01A-01D-1253-10_wgs_Illumina.filtered.	WGS	TCGA-B9-4113-01A-01D-1253-10_wgs_Illumina	TCGA-B9-4113-01A-01D-1253-10_wgs_Illumina.bam	0.0	1.9	0.15	58cfa830e4b0c9d6adf6be22	TCGA-B9-4113-01A-01D-1253-10_wgs_Illumina.bam	Dead	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-B9-4113-01A	5C9A6C40-982E-45C7-98D3-AEB6CAD16986	Primary Tumor	Illumina HiSeq	946b3469-d936-4438-8fc4-3075da99cd4d	Kidney	64.0	DDDC5575-D88F-4F4E-B591-96F11403184B	F03330DD-C616-4AD5-ABC3-6D6B0445E9E9	TCGA-B9-4113-01A-01D-1253-10	GRCh37-lite	TCGA-B9-4113	TCGA-KIRP	1536.0	s11585	Baylor College of Medicine	UNC	None	NO	T1	NX	Kidney Papillary Renal Cell Carcinoma	Stage I	1253-10	False	KIRP	C3	KIRP.C1	0.149588568	0.3	0.0		-2.0969	-0.313	0.7138	0.1198	-0.2456	-0.3152	24.0	209.0	0.536051948	1.4953028030000002	255.0	0.132563989	6.0	0.0	0.946290698	1.0396065890000001	3.0	3.39691442	31.0	0.989204158	2.361942134	-691.0374095	-1670.987957	1306.36679	1.0	1536.0	0.0	1536.0	6.14173013872367	2.487284772192967	0.5719479600355871	5.043117850055561	2.6622862475004156	4.997212273764115	-1.0986122886681098	0.17500147530744847	4.425264313728528
13722.58cfa830e4b0c9d6adf6be2a	58cfa830e4b0c9d6adf6be2a	TCGA-B6-A0X4-01A-11D-A106_130719_SN1120_0270_AC2CVRACXX_s_7_rg.sorted.filtered.	WGS	TCGA-B6-A0X4-01A-11D-A106_130719_SN1120_0270_AC2CVRACXX_s_7_rg.sorted	TCGA-B6-A0X4-01A-11D-A106_130719_SN1120_0270_AC2CVRACXX_s_7_rg.sorted.bam	65.55	2.08	0.15	58cfa830e4b0c9d6adf6be2a	TCGA-B6-A0X4-01A-11D-A106_130719_SN1120_0270_AC2CVRACXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-B6-A0X4-01A	4E42FDC5-2A8B-49E9-87EF-6DB7A6692D08	Primary Tumor	Illumina HiSeq	1973be6c-c5a9-40d1-bdd2-a752dd33d6d1	Breast	62.0	45C3BD72-D260-4663-9091-5058E58F352D	062A41CC-4B23-49E2-AFF8-3CFE34DE9A36	TCGA-B6-A0X4-01A-11D-A106-02	HG19_Broad_variant	TCGA-B6-A0X4	TCGA-BRCA	860.0	s6462	Harvard Medical School	Duke	United States	NO	T2	N1b	Infiltrating Ductal Carcinoma	Stage IIB	A106-02	False	BRCA	C4	BRCA.LumA	0.053161753			1.2612446290000001	-0.9085	-0.1465	-1.4458	-2.5987	0.08800000000000001	-0.326	7.0	15.0	0.122748814	0.5523696610000001	53.0	0.030510977999999998	0.0	1.0					0.0		1.95250742	-1039.717813	447.67878360000003	2729.8853059999997	1.0	860.0	1.0	716.0	7.734704648831211	6.61565319625069	0.2300513398553713	5.788794499775898	6.136080115988804	1.4705302306251218	-1.9459101490553132	-0.4795730802618863	1.2404788907697506
13722.58cfa830e4b0c9d6adf6be38	58cfa830e4b0c9d6adf6be38	TCGA-B5-A0JY-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_6_rg.sorted.filtered.	WGS	TCGA-B5-A0JY-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_6_rg.sorted	TCGA-B5-A0JY-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_6_rg.sorted.bam	80.24	1.95	0.16	58cfa830e4b0c9d6adf6be38	TCGA-B5-A0JY-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0JY-01A	61935424-44D0-4211-81C1-C925E436EAC5	Primary Tumor	Illumina HiSeq	e463dbb2-091a-4183-98b6-a90c2e55ffae	Uterus	50.0	95F418CE-FCD9-4402-BC24-1520F45CB6B7	88CE0037-F3F9-4F45-BF14-36A58FF61A3D	TCGA-B5-A0JY-01A-11D-A101-02	HG19_Broad_variant	TCGA-B5-A0JY	TCGA-UCEC		s4784	Harvard Medical School	Duke	United States	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C1	UCEC.POLE	0.1447737	0.4	0.0	8.243563297	0.5635	0.247	-0.3913	0.1238	-0.9981	0.1752	4625.0	61.0	62.32319203	253.5817898	65.0	0.00030883099999999997	0.0	0.0							2.75032741	-2227.999312	385.1045972	-2786.977451	0.0	2107.0	0.0	2107.0	6.642949326341339	5.951675418468969	-0.1218754120196679	5.9660626666531735	6.8759343199923	2.6964742282189693	-0.6768866596881651	0.924258901523332	2.8183496402386377
13722.58cfa830e4b0c9d6adf6be3a	58cfa830e4b0c9d6adf6be3a	TCGA-BJ-A18Z-01A-21D-A13U_120712_SN1222_0125_BD13TPACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BJ-A18Z-01A-21D-A13U_120712_SN1222_0125_BD13TPACXX_s_1_rg.sorted	TCGA-BJ-A18Z-01A-21D-A13U_120712_SN1222_0125_BD13TPACXX_s_1_rg.sorted.bam	45.3	1.98	0.17	58cfa830e4b0c9d6adf6be3a	TCGA-BJ-A18Z-01A-21D-A13U_120712_SN1222_0125_BD13TPACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A18Z-01A	0D497FAF-2C1C-4173-A5FE-770CCA73323C	Primary Tumor	Illumina HiSeq	a740c90f-9cbc-4ff1-8cad-c78d4dbb92cf	Thyroid	58.0	19DEE039-9C98-4D4A-8BAF-EEA1B6DDA8EB	815C53C3-8ADD-4612-B93C-3ED4BFA530AA	TCGA-BJ-A18Z-01A-21D-A13U-02	HG19_Broad_variant	TCGA-BJ-A18Z	TCGA-THCA		s12354	Harvard Medical School	University of Pittsburgh	United States	NO	T3	N1b	Thyroid Papillary Carcinoma - Classical/usual	Stage IVA	A13U-02	True	THCA	C3	THCA.4	0.190872515	0.67	0.0		-1.6356	-0.253	-0.0298	-0.4102	-0.0701	0.5091	16.0		0.029045427000000002	0.464726827	37.0	1.4400000000000001e-05	0.0	0.0				1.9459101490000001	7.0	1.0	1.6103323840000001	281.16050989999997	-1225.680656	1857.156645	0.0	1263.0	0.0	1263.0	5.694853843911899	8.545132560105479	-0.4545297232590616	4.665234426730741	7.158838198985589	0.9011994556736966	-1.029619417181158	-1.3862943611198904	1.3557291789327581
13722.58cfa830e4b0c9d6adf6be3c	58cfa830e4b0c9d6adf6be3c	TCGA-BJ-A18Y-01A-11D-A13U_120706_SN1222_0122_AC0WPYACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BJ-A18Y-01A-11D-A13U_120706_SN1222_0122_AC0WPYACXX_s_1_rg.sorted	TCGA-BJ-A18Y-01A-11D-A13U_120706_SN1222_0122_AC0WPYACXX_s_1_rg.sorted.bam	77.56	2.0	0.18	58cfa830e4b0c9d6adf6be3c	TCGA-BJ-A18Y-01A-11D-A13U_120706_SN1222_0122_AC0WPYACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A18Y-01A	ACB3B9DB-16E9-40F5-87A9-9DF9D4CEEE54	Primary Tumor	Illumina HiSeq	0074a697-0800-4872-9a48-48945f46d18d	Thyroid	29.0	5D1D84D0-9A03-4381-9CF1-E460B3617AAA	56D2A069-7969-40F1-A237-E4FE7E62C84C	TCGA-BJ-A18Y-01A-11D-A13U-02	HG19_Broad_variant	TCGA-BJ-A18Y	TCGA-THCA		s12351	Harvard Medical School	University of Pittsburgh	United States	NO	T1b	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A13U-02	True	THCA	C3	THCA.1	0.061199582	0.4	0.0		-2.1359	-0.3495	-0.5921	-1.5621	-0.8101	-0.2703	6.0		0.060061802000000004	0.150154506	53.0	0.011083262	0.0	0.0				0.693147181	2.0	1.0	1.818513285	-1063.0899960000002	-1055.9526779999999	2119.803652	0.0	1563.0	0.0	1563.0	6.568545966651039	7.267001913288688	-1.0853595922356625	5.339880549734731	6.861536805180522	1.4204857258681696	-1.2286654169163076	-0.4054651081081646	2.505845318103832
13722.58cfa830e4b0c9d6adf6be44	58cfa830e4b0c9d6adf6be44	TCGA-AF-2691-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AF-2691-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AF-2691-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	406.94	1.9	0.15	58cfa830e4b0c9d6adf6be44	TCGA-AF-2691-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Rectum Adenocarcinoma	Aligned reads	TCGA-AF-2691-01A	830FD359-ABD4-4C99-89E4-2D6BB9CE5637	Primary Tumor	Illumina HiSeq	92f1a7a8-08ff-487e-bd7d-8146bc0109c6	Colorectal	48.0	CE252C3D-5CF3-46BC-A181-3714D1C65E4E	64EDFE90-619C-42A0-BBE1-EB78B4D5C26D	TCGA-AF-2691-01A-01D-1167-02	HG18	TCGA-AF-2691	TCGA-READ		s2131	Harvard Medical School	Christiana Healthcare	None	NO	T1	N0	Rectal Adenocarcinoma	Stage I	1167-02	True	READ	C1		0.121589793	0.57	0.26	11.192712599999998	0.3274	0.177	-0.0041	0.6225	0.0057	-0.0484			1.171023851	5.353251891	129.0	0.458679751	9.0	17.0	0.9350018659999999	3.449109172	40.0				1.345116664	-403.68021380000005	-99.26833894	1850.7353649999998	0.0	1309.0	0.0	1309.0	7.753103872361171	4.569342160767492	-0.3977332369495312	5.979043980232517	5.034705410456725	0.829901074874563	-1.774059892128654	0.4653632496892337	1.2276343118240942
13722.58cfa830e4b0c9d6adf6be46	58cfa830e4b0c9d6adf6be46	TCGA-AF-2691-01A-01D-1989-10_wgs_Illumina.filtered.	WGS	TCGA-AF-2691-01A-01D-1989-10_wgs_Illumina	TCGA-AF-2691-01A-01D-1989-10_wgs_Illumina.bam	406.94	1.9	0.15	58cfa830e4b0c9d6adf6be46	TCGA-AF-2691-01A-01D-1989-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Rectum Adenocarcinoma	Aligned reads	TCGA-AF-2691-01A	830FD359-ABD4-4C99-89E4-2D6BB9CE5637	Primary Tumor	Illumina HiSeq	51fe9202-95ee-418b-a143-fe84f4b20380	Colorectal	48.0	CE252C3D-5CF3-46BC-A181-3714D1C65E4E	81B1E78C-6032-4FF4-B52A-83456B9450EA	TCGA-AF-2691-01A-01D-1989-10	GRCh37-lite	TCGA-AF-2691	TCGA-READ		s1956	Baylor College of Medicine	Christiana Healthcare	None	NO	T1	N0	Rectal Adenocarcinoma	Stage I	1989-10	True	READ	C1		0.121589793	0.57	0.26	11.192712599999998	0.3274	0.177	-0.0041	0.6225	0.0057	-0.0484			1.171023851	5.353251891	129.0	0.458679751	9.0	17.0	0.9350018659999999	3.449109172	40.0				1.345116664	-403.68021380000005	-99.26833894	1850.7353649999998	0.0	1309.0	0.0	1309.0	7.138708257187829	0.5985851615619548	-0.3977332369495312	6.183196812160393	3.845928907807175	0.829901074874563	-0.9555114450274362	3.24734374624522	1.2276343118240942
13722.58cfa830e4b0c9d6adf6be4c	58cfa830e4b0c9d6adf6be4c	TCGA-AG-3890-01A-01D-1989-10_wgs_Illumina.filtered.	WGS	TCGA-AG-3890-01A-01D-1989-10_wgs_Illumina	TCGA-AG-3890-01A-01D-1989-10_wgs_Illumina.bam	614.89	1.9	0.15	58cfa830e4b0c9d6adf6be4c	TCGA-AG-3890-01A-01D-1989-10_wgs_Illumina.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3890-01A	E2D395F8-BF13-4FE4-8031-683B0EEDD875	Primary Tumor	Illumina HiSeq	8df564e5-cdec-4714-b522-5f7356be8d5d	Colorectal	62.0	DB70A6DD-DE09-4ED7-916C-708B21734500	03CFF38D-7E29-4409-A508-749BDDB1B3DF	TCGA-AG-3890-01A-01D-1989-10	GRCh37-lite	TCGA-AG-3890	TCGA-READ		s1975	Baylor College of Medicine	Indivumed	Germany	NO	T2	N0	Rectal Adenocarcinoma	Stage I	1989-10	True	READ	C1	GI.CIN	0.184366589	0.29	0.54	14.40303525	0.3755	0.023	-0.1392	1.0402	-0.5787	0.0309	55.0	63.0			185.0	0.501152942	7.0	26.0							0.995981417	-1458.486919	-396.9077121	-441.5665663	0.0	518.0	0.0	518.0	6.831818712892197	3.23320615104367	-0.5216039371399058	5.692384429703832	4.696264528375399	2.098144268754017	-1.1394342831883648	1.4630583773317287	2.6197482058939223
13722.58cfa830e4b0c9d6adf6be55	58cfa830e4b0c9d6adf6be55	TCGA-AP-A0LT-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-AP-A0LT-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_1_rg.sorted	TCGA-AP-A0LT-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_1_rg.sorted.bam	118.49	2.07	0.17	58cfa830e4b0c9d6adf6be55	TCGA-AP-A0LT-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0LT-01A	43714E9A-E9C4-4206-AF92-1D00D2A8AE35	Primary Tumor	Illumina HiSeq	42ca121f-f3b0-4b47-acb4-f1294f88eb39	Uterus	57.0	C94DD7A5-DD58-4702-A7D1-8199D3F8C9CC	B057AD28-5D99-48BC-B642-7E548914F1B1	TCGA-AP-A0LT-01A-11D-A043-02	HG19_Broad_variant	TCGA-AP-A0LT	TCGA-UCEC		s4242	Harvard Medical School	MSKCC	None	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C1	UCEC.MSI	0.123158925	0.11	0.0	9.665798896	1.0328	0.395	-1.2906	-0.5331	-1.6369999999999998	-0.511	200.0		5.50002095	17.97856311	47.0	3.37e-06	0.0	0.0							1.919688869	-1530.135765	561.6855283	-705.4964139	0.0	1497.0	0.0	1497.0	5.6958724851327105	6.618643613720762	-0.7257771145668184	5.478807979894882	5.823713738850874	0.2923951567764178	-0.21706450523782772	-0.7949298748698879	1.0181722713432362
13722.58cfa830e4b0c9d6adf6be66	58cfa830e4b0c9d6adf6be66	TCGA-BJ-A3PT-01A-12D-A221_120530_SN1222_0111_BD12L1ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BJ-A3PT-01A-12D-A221_120530_SN1222_0111_BD12L1ACXX_s_1_rg.sorted	TCGA-BJ-A3PT-01A-12D-A221_120530_SN1222_0111_BD12L1ACXX_s_1_rg.sorted.bam	17.47		0.15	58cfa830e4b0c9d6adf6be66	TCGA-BJ-A3PT-01A-12D-A221_120530_SN1222_0111_BD12L1ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A3PT-01A	29C4319C-3EAD-42B1-810D-418DA8D515C4	Primary Tumor	Illumina HiSeq	0d7263bd-8ffa-4ba1-93c4-0444afd9b56e	Thyroid	51.0	8C112A5F-AE83-4B13-8E00-802382729344	EC6A8D75-A25A-4179-BAF4-53607841AC09	TCGA-BJ-A3PT-01A-12D-A221-26	HG19_Broad_variant	TCGA-BJ-A3PT	TCGA-THCA		s12747	MD Anderson - Institute for Applied Cancer Science	University of Pittsburgh	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A221-26	True	THCA	C3	THCA.1	0.194264176	0.33	0.01		-1.9385	-0.1485	0.1039	0.4766	-0.627	-0.1797	11.0		0.029047051	0.319517559	57.0	0.011020303	0.0	0.0				2.404244448	17.0	0.8485928009999999	1.835905792	-245.367993	-1279.9870640000001	1487.1961119999999	0.0	709.0	0.0	709.0	6.61463911371722	8.246007633492919	-0.2355366903980195	6.411040158475981	7.14739534482481	2.17161528399403	-0.2035989552412394	-1.09861228866811	2.40715197439205
13722.58cfa830e4b0c9d6adf6be68	58cfa830e4b0c9d6adf6be68	TCGA-BJ-A28Z-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BJ-A28Z-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_2_rg.sorted	TCGA-BJ-A28Z-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_2_rg.sorted.bam	46.06	1.81	0.15	58cfa830e4b0c9d6adf6be68	TCGA-BJ-A28Z-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A28Z-01A	6BA76174-620E-4851-857A-D0ADBFD6F3E6	Primary Tumor	Illumina HiSeq	3d2be877-3825-44b4-99b1-b3c314e68c0c	Thyroid	46.0	D9689254-AFE2-4544-AF54-E02670BD5EBD	F353E9F5-A869-4BE1-ACC4-A832D77285D4	TCGA-BJ-A28Z-01A-11D-A16N-02	HG19_Broad_variant	TCGA-BJ-A28Z	TCGA-THCA		s12508	Harvard Medical School	University of Pittsburgh	United States	NO	T3	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A16N-02	True	THCA	C3	THCA.2	0.43958029600000004				-1.2609	-0.3135	1.2212	2.3451	0.6455	0.2293	6.0		0.31345745199999997	0.37044971600000004	61.0	0.005854447			0.729885363	2.728070348	42.0	4.123460637	68.0	0.9772373759999999	1.7612990990000001	1348.67525	-575.8263492000001	1107.6120210000001	0.0	337.0	0.0	337.0	6.732267461766748	8.264019893650332	0.6464640726960358	6.342802695005024	7.325750255057402	2.231908216437371	-0.38946476676172326	-0.9382696385929301	1.585444143741335
13722.58cfa830e4b0c9d6adf6be6c	58cfa830e4b0c9d6adf6be6c	TCGA-BL-A13J-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BL-A13J-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_8_rg.sorted	TCGA-BL-A13J-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_8_rg.sorted.bam	57.46	1.9	0.15	58cfa830e4b0c9d6adf6be6c	TCGA-BL-A13J-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_8_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BL-A13J-01A	556FCBC8-172A-4AF1-8822-AE036E8D68E8	Primary Tumor	Illumina HiSeq	58daf5d5-0c54-4a8c-b756-35565cdc9671	Bladder	65.0	CF23846D-A7D2-40A9-8B51-49A27967D101	782CEFE1-C28F-40BA-93A2-66279184EEF6	TCGA-BL-A13J-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BL-A13J	TCGA-BLCA	81.0	s3080	Harvard Medical School	Christiana Healthcare	United States	NO	T4	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A10R-02	True	BLCA	C1	BLCA.2	0.157691052	0.44	0.21	2.3099850969999998	0.5812	0.0015	-0.6311	-0.9139	-0.6015	0.3095	25.0	32.0	0.9475945659999999	2.628810732	209.0	0.736032885	17.0	43.0	0.9269905629999999	1.2850817909999999	4.0	0.693147181	2.0	1.0	1.7907422419999999	-1295.047718	636.5785716	-3493.2627409999996	1.0	81.0	1.0	81.0	5.533866409193041	6.39892765787882	-0.3153379245472394	4.624496120163459	5.795392636008562	1.0628656178929559	-0.9093702890295816	-0.603535021870258	1.378203542440195
13722.58cfa830e4b0c9d6adf6be6e	58cfa830e4b0c9d6adf6be6e	TCGA-BJ-A190-01A-11D-A13U_120711_SN1120_0173_AC0WN6ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BJ-A190-01A-11D-A13U_120711_SN1120_0173_AC0WN6ACXX_s_6_rg.sorted	TCGA-BJ-A190-01A-11D-A13U_120711_SN1120_0173_AC0WN6ACXX_s_6_rg.sorted.bam	53.09	1.95	0.16	58cfa830e4b0c9d6adf6be6e	TCGA-BJ-A190-01A-11D-A13U_120711_SN1120_0173_AC0WN6ACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A190-01A	04FFF86A-B6F5-4900-9E37-C1F0B881B160	Primary Tumor	Illumina HiSeq	a9f1f6de-8f02-48c6-a9e2-6cef21cd8438	Thyroid	55.0	2EB89D79-861E-41C2-BDD5-6F16D2A84B25	42FE4D84-B54D-42B8-81F8-92191723D057	TCGA-BJ-A190-01A-11D-A13U-02	HG19_Broad_variant	TCGA-BJ-A190	TCGA-THCA		s12234	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage II	A13U-02	True	THCA	C3	THCA.1	0.036559572				-2.1637	-0.315	-1.7482	-2.63	-1.0206	-0.6747					69.0	0.9230235940000001						0.693147181	2.0	1.0	1.502920667	-842.5599526000001	-687.8511679999999	2503.5107329999996	0.0	626.0	0.0	626.0	6.226371965342435	8.823229474293688	-0.6924820658031346	4.983178447863217	7.463603360255958	1.1214781134051126	-1.2431935174792175	-1.35962611403773	1.8139601792082471
13722.58cfa830e4b0c9d6adf6be70	58cfa830e4b0c9d6adf6be70	TCGA-BJ-A28R-01A-11D-A16N_121204_SN208_0442_BC1F7YACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BJ-A28R-01A-11D-A16N_121204_SN208_0442_BC1F7YACXX_s_7_rg.sorted	TCGA-BJ-A28R-01A-11D-A16N_121204_SN208_0442_BC1F7YACXX_s_7_rg.sorted.bam	82.3	2.03	0.16	58cfa830e4b0c9d6adf6be70	TCGA-BJ-A28R-01A-11D-A16N_121204_SN208_0442_BC1F7YACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A28R-01A	524A39EE-8FA3-418E-98A2-A6A90E9C8064	Primary Tumor	Illumina HiSeq	122e0c7e-da24-4121-907e-8b913b4e4147	Thyroid	38.0	F4906B86-3971-4ED3-AC3C-69635311FB45	A5170F7D-F298-4330-8272-8DACFF7775A1	TCGA-BJ-A28R-01A-11D-A16N-02	HG19_Broad_variant	TCGA-BJ-A28R	TCGA-THCA		s11987	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	True	THCA	C3	THCA.4	0.164744426	0.25	0.0		-1.756	-0.2855	0.1764	0.9106	-0.2336	-0.1075	1.0		0.057967849	0.144919622	35.0	2.68e-05	0.0	0.0	0.614723117	2.84907505	103.0	3.717941795	44.0	0.98249352	1.263738211	40.45623521	-986.6245582	2590.319727	0.0	1282.0	0.0	1282.0	7.418480897747795	5.853638230200578	-0.29031599024048294	0.5881467657342432	5.020729107265474	2.1474535401111954	-6.830334132013552	-0.8329091229351038	2.4377695303516784
13722.58cfa830e4b0c9d6adf6be71	58cfa830e4b0c9d6adf6be71	TCGA-BP-4326-01A-01D-2097-10_wgs_Illumina.filtered.	WGS	TCGA-BP-4326-01A-01D-2097-10_wgs_Illumina	TCGA-BP-4326-01A-01D-2097-10_wgs_Illumina.bam	109.0	1.9	0.14	58cfa830e4b0c9d6adf6be71	TCGA-BP-4326-01A-01D-2097-10_wgs_Illumina.bam	Alive	FEMALE	WHITE		Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-BP-4326-01A	7664C241-B369-4D76-9CD1-7F2BDC1D267F	Primary Tumor	Illumina HiSeq	8d64ee9c-1973-46e9-8ad7-1d9c3a96a47c	Kidney	53.0	068BFE4D-341C-49F7-B7A9-5D070DE00AB3	54842328-9432-4820-8976-7964BF9BF147	TCGA-BP-4326-01A-01D-2097-10	GRCh37-lite	TCGA-BP-4326	TCGA-KIRC		s9163	Baylor College of Medicine	MSKCC	None	NO	T1b	N0	Kidney Clear Cell Renal Carcinoma	Stage I	2097-10	False	KIRC	C3	KIRC.3	0.09398661800000001				-1.1505	-0.19	0.3015	-0.1892	-0.0506	0.5279					87.0	0.035486317999999996	1.0	10.0				2.397895273	11.0	1.0	1.830947681	39.18644695	-431.26181349999996	1387.235129	1.0	1625.0	1.0	958.0	7.5011323490156645	1.5529519684517492	-0.7083861630680768	6.161358003530667	5.085686000940004	2.2720318755128717	-1.3397743454849977	3.5327340324882543	2.9804180385809484
13722.58cfa830e4b0c9d6adf6be78	58cfa830e4b0c9d6adf6be78	TCGA-BL-A3JM-01A-12D-A21C_120914_SN590_0180_BC19KDACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BL-A3JM-01A-12D-A21C_120914_SN590_0180_BC19KDACXX_s_3_rg.sorted	TCGA-BL-A3JM-01A-12D-A21C_120914_SN590_0180_BC19KDACXX_s_3_rg.sorted.bam	24.07		0.16	58cfa830e4b0c9d6adf6be78	TCGA-BL-A3JM-01A-12D-A21C_120914_SN590_0180_BC19KDACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BL-A3JM-01A	0F4FB205-B13C-4A85-97B3-779429E6CCDD	Primary Tumor	Illumina HiSeq	5cd881b7-caa0-43ad-9ba8-f9696fdf7403	Bladder	62.0	110ACEE1-915F-43A2-B382-5D0AF1FC167F	6ABBBA00-C322-4EDE-91A4-85D0D3E886F9	TCGA-BL-A3JM-01A-12D-A21C-26	HG19_Broad_variant	TCGA-BL-A3JM	TCGA-BLCA	205.0	s2691	MD Anderson - Institute for Applied Cancer Science	Christiana Healthcare	United States	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A21C-26	True	BLCA	C2	BLCA.4	0.150053419	0.24	0.12	6.926086497000001	1.2142	0.45	-0.5119	-0.5683	0.1278	-0.2622	57.0	74.0	2.067980416	5.200362517	110.0	0.940040412	17.0	7.0				1.992798144	9.0	0.9069615209999999	2.639992611	-1492.3495619999999	1121.514171	-3705.0976299999998	1.0	205.0	1.0	111.0	6.805353345364056	9.73116133008312	-1.1502779939825576	5.576687928447748	8.833219736877162	1.4983968047036498	-1.2286654169163076	-0.8979415932059585	2.6486747986862076
13722.58cfa830e4b0c9d6adf6be7e	58cfa830e4b0c9d6adf6be7e	TCGA-BJ-A192-01A-31D-A13U_120706_SN1120_0170_BD1422ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BJ-A192-01A-31D-A13U_120706_SN1120_0170_BD1422ACXX_s_4_rg.sorted	TCGA-BJ-A192-01A-31D-A13U_120706_SN1120_0170_BD1422ACXX_s_4_rg.sorted.bam	32.81	2.02	0.17	58cfa830e4b0c9d6adf6be7e	TCGA-BJ-A192-01A-31D-A13U_120706_SN1120_0170_BD1422ACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE		Thyroid Carcinoma	Aligned reads	TCGA-BJ-A192-01A	B55375C3-9EF2-4D2F-9C29-224E746931C4	Primary Tumor	Illumina HiSeq	9218178e-761c-40ac-b3ca-044bf37f8686	Thyroid	54.0	582C3030-1F23-4535-9C8B-6B594E656AF4	6D770754-E14D-4E47-AE33-BE0FC9B40CE9	TCGA-BJ-A192-01A-31D-A13U-02	HG19_Broad_variant	TCGA-BJ-A192	TCGA-THCA		s12235	Harvard Medical School	University of Pittsburgh	United States	NO	T3	NX	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A13U-02	True	THCA	C4	THCA.1	0.106448866				-2.4739	-0.209	-0.4268	-1.9371	-0.4196	-0.6	3.0	0.0	0.059633705999999995	0.208717971	70.0	0.076602723						0.0	1.0		1.836146488	-1469.982573	-1348.646028	3257.970522	0.0	1349.0	0.0	1349.0	7.2832519771614574	8.421948009499504	-1.0121246455638127	6.115646817006397	7.323335720831395	2.409098789636864	-1.1676051601550612	-1.09861228866811	3.4212234352006767
13722.58cfa830e4b0c9d6adf6be84	58cfa830e4b0c9d6adf6be84	TCGA-BJ-A191-01A-11D-A13U_120706_SN1120_0170_BD1422ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BJ-A191-01A-11D-A13U_120706_SN1120_0170_BD1422ACXX_s_1_rg.sorted	TCGA-BJ-A191-01A-11D-A13U_120706_SN1120_0170_BD1422ACXX_s_1_rg.sorted.bam	110.16	1.93	0.17	58cfa830e4b0c9d6adf6be84	TCGA-BJ-A191-01A-11D-A13U_120706_SN1120_0170_BD1422ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A191-01A	2501EE46-8D38-448B-8765-E9C9706CBBE8	Primary Tumor	Illumina HiSeq	fb73296b-b8ef-4ff9-a954-fab7d29ab101	Thyroid	49.0	C92FC4E3-7A96-4000-A969-AA894CA58A33	B3EDF2BC-5E8F-435A-ADA1-F292722EDD9C	TCGA-BJ-A191-01A-11D-A13U-02	HG19_Broad_variant	TCGA-BJ-A191	TCGA-THCA		s12237	Harvard Medical School	University of Pittsburgh	United States	NO	T1b	N0	Other  specify	Stage I	A13U-02	True	THCA	C3	THCA.1	0.048944620999999994	0.64	0.0		-1.6826	-0.3945	-0.5602	0.6797	-0.5778	-0.5002	6.0	1.0	0.232515124	0.465030249	55.0	2.24e-05	0.0	0.0	0.855526282	3.820701769	87.0	2.599301927	14.0	0.9849357559999999	1.96319774	-1508.9667949999998	-1187.604247	1847.246869	0.0	147.0	0.0	147.0	6.400465064950385	7.443013318888712	0.4947617461648748	5.666495889870184	6.899397872299731	1.5599202109462915	-0.7339691750802002	-0.5436154465889818	1.0651584647814167
13722.58cfa830e4b0c9d6adf6be88	58cfa830e4b0c9d6adf6be88	TCGA-BJ-A291-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BJ-A291-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_8_rg.sorted	TCGA-BJ-A291-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_8_rg.sorted.bam	30.94	1.89	0.15	58cfa830e4b0c9d6adf6be88	TCGA-BJ-A291-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A291-01A	D4C68C1C-A3F3-4E0C-B555-D457378A1D24	Primary Tumor	Illumina HiSeq	bb0bf0e4-e29d-422a-879e-b8dc7f5c720b	Thyroid	56.0	D1612961-A709-487B-A4D1-CE42F0B9AA54	E28A1E8B-41A3-44C0-ADBC-6A203C92DDF5	TCGA-BJ-A291-01A-11D-A16N-02	HG19_Broad_variant	TCGA-BJ-A291	TCGA-THCA		s11990	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	True	THCA	C3	THCA.1	0.066797418				-2.6085	-0.2605	-1.035	-1.3556	-0.1485	-0.2704					35.0	0.000227875	0.0	0.0				0.0	1.0		1.6136904090000002	-531.4698621	-862.5013011	2018.660925	0.0	696.0	0.0	696.0	7.206711063657295	8.657515363306961	-1.0624897629642163	6.591525424567061	7.487444110656707	2.548016485866304	-0.6151856390902335	-1.1700712526502546	3.6105062488305206
13722.58cfa830e4b0c9d6adf6be8d	58cfa830e4b0c9d6adf6be8d	TCGA-BK-A0CB-01A-32D-A101_120330_SN208_0280_AD0UKLACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BK-A0CB-01A-32D-A101_120330_SN208_0280_AD0UKLACXX_s_1_rg.sorted	TCGA-BK-A0CB-01A-32D-A101_120330_SN208_0280_AD0UKLACXX_s_1_rg.sorted.bam	79.7	1.9	0.16	58cfa830e4b0c9d6adf6be8d	TCGA-BK-A0CB-01A-32D-A101_120330_SN208_0280_AD0UKLACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BK-A0CB-01A	59E9029A-8DDD-4447-B35A-72BC39F82A30	Primary Tumor	Illumina HiSeq	2c466122-c49e-4866-b9d4-faf31dde999c	Uterus	60.0	7678C70D-A298-4472-89A0-427AF1E93D28	F186159C-DCE6-467C-AAAF-BB08FBAE6827	TCGA-BK-A0CB-01A-32D-A101-02	HG19_Broad_variant	TCGA-BK-A0CB	TCGA-UCEC		s5006	Harvard Medical School	Christiana Healthcare	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C1	UCEC.CN_LOW	0.120724741	0.33	0.05	1.4426516180000002	-0.4308	-0.113	-0.0945	-0.1206	-0.7479	0.6436	21.0	41.0	0.581325258	1.328743448	53.0	0.049984144	0.0	0.0							2.45743179	-899.1807367999999	-754.3778766	-705.3037774000001	0.0	1092.0	0.0	1092.0	5.978366318100272	6.567453496780385	-0.6306268235786113	5.564390520324198	6.056627873014394	3.3534067178258073	-0.4139757977760734	-0.5108256237659909	3.9840335414044183
13722.58cfa830e4b0c9d6adf6be90	58cfa830e4b0c9d6adf6be90	TCGA-BL-A13I-01A-11D-A13U_121005_SN1120_0195_AC13RHACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BL-A13I-01A-11D-A13U_121005_SN1120_0195_AC13RHACXX_s_4_rg.sorted	TCGA-BL-A13I-01A-11D-A13U_121005_SN1120_0195_AC13RHACXX_s_4_rg.sorted.bam	92.87	2.0	0.15	58cfa830e4b0c9d6adf6be90	TCGA-BL-A13I-01A-11D-A13U_121005_SN1120_0195_AC13RHACXX_s_4_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BL-A13I-01A	EBC094A6-CDC9-4C02-B8EC-A181B25A364D	Primary Tumor	Illumina HiSeq	b7cfe609-703a-4750-b9e7-5bda8e948cc4	Bladder	57.0	62C2BA8F-02E3-4100-86BC-5958038B4983	7C09CFF3-3162-4952-93AD-8A7D89F07266	TCGA-BL-A13I-01A-11D-A13U-02	HG19_Broad_variant	TCGA-BL-A13I	TCGA-BLCA	223.0	s2689	Harvard Medical School	Christiana Healthcare	United States	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A13U-02	True	BLCA	C4	BLCA.4	0.494772514	0.67	0.13	12.79047019	0.7346	0.3435	1.192	0.3819	0.0129	0.2083	48.0	66.0			86.0	0.070601795	2.0	5.0				3.3988230710000003	34.0	0.963833121	5.851954332999999	-301.1959584	881.7584521	-1246.029291	1.0	223.0	1.0	216.0	5.579876837967964	6.2032713523940455	0.6884103698084436	5.934698213257374	5.674427223125376	3.5317356431400033	0.3548213752894096	-0.5288441292686694	2.8433252733315597
13722.58cfa830e4b0c9d6adf6be92	58cfa830e4b0c9d6adf6be92	TCGA-AG-4007-01A-01D-1989-10_wgs_Illumina.filtered.	WGS	TCGA-AG-4007-01A-01D-1989-10_wgs_Illumina	TCGA-AG-4007-01A-01D-1989-10_wgs_Illumina.bam	915.89	1.9	0.16	58cfa830e4b0c9d6adf6be92	TCGA-AG-4007-01A-01D-1989-10_wgs_Illumina.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-4007-01A	8E00E7E7-FFAF-44F0-91A7-172671F18E08	Primary Tumor	Illumina HiSeq	16ef1919-094b-44db-a49b-966c6bf84f33	Colorectal	87.0	E6FC3F28-1DE1-4587-9E0E-0861323E6772	8DA641E4-9B12-4163-BD1E-9D5AF91E5186	TCGA-AG-4007-01A-01D-1989-10	GRCh37-lite	TCGA-AG-4007	TCGA-READ		s1981	Baylor College of Medicine	Indivumed	Germany	NO	T4	N2	Rectal Adenocarcinoma	Stage IV	1989-10	True	READ	C1		0.085002955	0.31	0.06	13.90430149	0.2916	0.138	-0.0642	0.7799	-0.4136	0.1805					420.0	0.997270488	21.0	23.0							1.557623971	-1257.6077289999998	-596.9351227999999	435.28805520000003	0.0	31.0	0.0	31.0	7.35171968624091	1.8205671338101492	-0.3234562428015064	5.96542532512102	4.942662310510049	2.07244501139	-1.3862943611198908	3.1220951766999	2.3959012541915063
13722.58cfa830e4b0c9d6adf6be9f	58cfa830e4b0c9d6adf6be9f	TCGA-AG-3896-01A-01D-1989-10_wgs_Illumina.filtered.	WGS	TCGA-AG-3896-01A-01D-1989-10_wgs_Illumina	TCGA-AG-3896-01A-01D-1989-10_wgs_Illumina.bam	913.89	1.9	0.15	58cfa830e4b0c9d6adf6be9f	TCGA-AG-3896-01A-01D-1989-10_wgs_Illumina.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3896-01A	9AF35239-FFB9-4D4F-889E-F743DA271EEF	Primary Tumor	Illumina HiSeq	a9406c81-5dd3-4c50-8984-c81a85f67723	Colorectal	85.0	03B40342-3CCE-4A45-B2EC-8855AEB85100	14334AEA-2DAE-428C-9D4A-1A37878DFC3F	TCGA-AG-3896-01A-01D-1989-10	GRCh37-lite	TCGA-AG-3896	TCGA-READ		s1992	Baylor College of Medicine	Indivumed	Germany	NO	T2	N0	Rectal Adenocarcinoma	Stage I	1989-10	True	READ	C1	GI.CIN	0.07508369	0.36	0.11	8.506290998999999	0.7562	0.316	-0.376	0.0429	-1.037	0.0707	53.0	0.0			145.0	0.9009666759999999	16.0	12.0							0.809726519	-1902.6506980000001	-44.13456392	149.7527415	0.0	31.0	0.0	31.0	8.033442164909529	1.4958276246781352	-0.17583592400735648	6.018539144367264	4.678087900316064	1.461017907315827	-2.0149030205422647	3.182260275637929	1.6368538313231835
13722.58cfa830e4b0c9d6adf6bea4	58cfa830e4b0c9d6adf6bea4	TCGA-AG-3898-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3898-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3898-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	722.89	1.9	0.15	58cfa830e4b0c9d6adf6bea4	TCGA-AG-3898-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3898-01A	5A7D19F9-6BE2-45AC-9FFC-11E28594EEEE	Primary Tumor	Illumina HiSeq	846bcf47-2650-4479-be12-96589e587f3a	Colorectal	61.0	C782D6BF-AA57-4184-8276-E08D6B64E6B2	AA49029D-0F51-4836-BD7B-74CC0C2F9576	TCGA-AG-3898-01A-01D-1115-02	HG18	TCGA-AG-3898	TCGA-READ		s2314	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage IIA	1115-02	True	READ	C1	GI.CIN	0.22200247	0.47	0.29	12.67047392	1.0628	0.39	-0.1724	-0.3199	0.1193	0.0561	41.0	20.0			216.0	0.43219339799999995	16.0	17.0							1.3474514709999998	-1446.706422	534.5420848	-1070.1509740000001	0.0	1461.0	0.0	1461.0	4.674074164635302	4.966159043928388	-0.2746244563632865	3.8267763042480984	5.327172389465718	0.48602099346240313	-0.8472978603872039	0.3610133455373301	0.7606454498256896
13722.58cfa830e4b0c9d6adf6bea9	58cfa830e4b0c9d6adf6bea9	TCGA-AG-3909-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3909-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3909-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	208.89	1.9	0.14	58cfa830e4b0c9d6adf6bea9	TCGA-AG-3909-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3909-01A	769880AE-34D9-405E-8EA7-33BA47CF2DD2	Primary Tumor	Illumina HiSeq	f11e5abe-82c7-4b53-bc65-7bde2dbc2bb1	Colorectal	69.0	12A43BEB-EDB6-4ABC-8322-CA8246D64B3F	F168205F-B2ED-4563-A211-DA59223830AB	TCGA-AG-3909-01A-01D-1115-02	HG18	TCGA-AG-3909	TCGA-READ		s1987	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Rectal Adenocarcinoma	Stage IIIB	1115-02	True	READ	C1	GI.CIN	0.081166317	0.44	0.0	16.96628451	0.1611	0.077	-0.4147	0.3462	-0.9587	-0.0405	30.0	25.0	0.543188308	2.4103981180000003	131.0	0.457828859	16.0	12.0							0.652135798	-1365.976745	-547.4250194	1593.212357	0.0	608.0	0.0	608.0	5.907455651164566	5.013712990402457	-0.25341317644444605	4.447053317890954	5.4191780985106215	2.2530885290413396	-1.460402333273612	0.4054651081081646	2.506501705485786
13722.58cfa830e4b0c9d6adf6bead	58cfa830e4b0c9d6adf6bead	TCGA-AG-3901-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3901-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3901-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	510.89	1.9	0.15	58cfa830e4b0c9d6adf6bead	TCGA-AG-3901-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3901-01A	1586CB0A-081A-4364-9470-46F9D0F0167D	Primary Tumor	Illumina HiSeq	c8ff4c94-25ea-4468-8ae0-06cb92ffa025	Colorectal	67.0	93B755E6-5D6E-4542-8BAE-2121F44F590C	F5D4395A-5E00-4616-A402-CDCAD8702E1B	TCGA-AG-3901-01A-01D-1115-02	HG18	TCGA-AG-3901	TCGA-READ		s2148	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Rectal Mucinous Adenocarcinoma	Stage IIIB	1115-02	True	READ	C1	GI.CIN	0.24371406199999998	0.56	0.04	13.32631333	0.47200000000000003	0.213	0.5434	0.6764	-0.1118	0.5886	29.0	34.0			57.0	0.102987179	2.0	5.0							0.9081042559999999	-640.2876447000001	182.4189459	-575.8737787	0.0	761.0	0.0	761.0	6.254941552573401	5.181497242939189	-1.4141711910481087	4.699570861409576	5.546395166058353	1.4025021713467443	-1.5553706911638248	0.36489792311916425	2.816673362394853
13722.58cfa830e4b0c9d6adf6bec0	58cfa830e4b0c9d6adf6bec0	TCGA-AR-A0TU-01A-31D-A106_130719_SN1120_0270_AC2CVRACXX_s_5_rg.sorted.filtered.	WGS	TCGA-AR-A0TU-01A-31D-A106_130719_SN1120_0270_AC2CVRACXX_s_5_rg.sorted	TCGA-AR-A0TU-01A-31D-A106_130719_SN1120_0270_AC2CVRACXX_s_5_rg.sorted.bam	73.2	1.9	0.15	58cfa830e4b0c9d6adf6bec0	TCGA-AR-A0TU-01A-31D-A106_130719_SN1120_0270_AC2CVRACXX_s_5_rg.sorted.bam	Alive	FEMALE			Breast Invasive Carcinoma	Aligned reads	TCGA-AR-A0TU-01A	DFE6DB17-CF45-488E-BD3C-B8433D7343CA	Primary Tumor	Illumina HiSeq	fb34c291-904a-4613-80cd-9788ff446157	Breast	35.0	1E629A73-68CD-449D-A1C0-B856BE4143E6	E00819A1-4A65-4289-9DDE-0800FC6C69F6	TCGA-AR-A0TU-01A-31D-A106-02	HG19_Broad_variant	TCGA-AR-A0TU	TCGA-BRCA		s6630	Harvard Medical School	Mayo	None	NO	T2	N0	Infiltrating Ductal Carcinoma	Stage IIA	A106-02	False	BRCA	C2	BRCA.Basal	0.246029035			6.1658864179999995	1.4047	0.4095	0.3189	0.4111	1.1035	-0.4503	25.0	34.0	0.722646442	1.759486989					0.823042045	1.4746933780000002	6.0	3.340656682	35.0	0.939614525	2.554081988	-362.6219135	1995.743352	-3296.2924359999997	0.0	709.0	0.0	709.0	8.301521654940728	6.79802626093824	0.29693800668648096	6.050229856334234	6.472603860503612	1.4041501871098871	-2.251291798606495	-0.3254224004346278	1.1072121804234063
13722.58cfa830e4b0c9d6adf6bec5	58cfa830e4b0c9d6adf6bec5	TCGA-AG-A032-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-A032-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-A032-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	237.12	1.85	0.15	58cfa830e4b0c9d6adf6bec5	TCGA-AG-A032-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A032-01A	0BB786EE-07CF-4853-9B49-EC95CD14E282	Primary Tumor	Illumina HiSeq	16a2716c-9563-4403-9a4b-8d4856022741	Colorectal	68.0	AE3C8931-C06F-466A-B6BF-440007E13387	AF7D94D6-C414-4812-A329-8856C086087E	TCGA-AG-A032-01A-01D-A077-02	HG18	TCGA-AG-A032	TCGA-READ		s2175	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Rectal Adenocarcinoma	Stage IIIB	A077-02	True	READ	C1		0.072361592			18.9495052	0.6692	0.174	-0.8102	0.0028	-0.4896	-0.0127	36.0	2.0	0.6996234859999999	2.4653399030000003	129.0	0.92073294	19.0	13.0							1.092164521	-1574.3863210000002	288.6084835	-608.016343	0.0	1157.0	1.0	792.0	7.570052133988066	5.63864317248524	-0.8023841991203053	7.015374627693226	5.932781045279892	0.8750311963274489	-0.5546775062948406	0.29413787279465176	1.6774153954477542
13722.58cfa830e4b0c9d6adf6bec7	58cfa830e4b0c9d6adf6bec7	TCGA-AP-A0LJ-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-AP-A0LJ-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_7_rg.sorted	TCGA-AP-A0LJ-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_7_rg.sorted.bam	83.32	2.09	0.15	58cfa830e4b0c9d6adf6bec7	TCGA-AP-A0LJ-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0LJ-01A	B4A520AE-F259-48C8-823E-C10B9B8A133A	Primary Tumor	Illumina HiSeq	c3705d55-9194-4d83-9162-41aae551e016	Uterus	42.0	BE3ED392-4D9F-4EAF-8A56-D251846DF4DA	2A88E054-E64F-4C5F-97F0-53F95D64FC04	TCGA-AP-A0LJ-01A-11D-A043-02	HG19_Broad_variant	TCGA-AP-A0LJ	TCGA-UCEC		s4996	Harvard Medical School	MSKCC	None	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C3	UCEC.CN_LOW	0.209274364	0.39	0.02	24.15658012	-0.4587	-0.08800000000000001	-0.2316	0.21100000000000002	-0.18	-0.0791	12.0	26.0	0.34863861700000004	1.074969069	81.0	0.046862077	2.0	0.0							2.536446741	-431.33559	-1401.252785	-804.8210573	0.0	1421.0	0.0	1421.0	7.110139381756317	7.080867896690782	-0.39018535767742935	6.537620188984987	6.554774800794002	1.6981194056308344	-0.5725191927713302	-0.5260930958967793	2.0883047633082636
13722.58cfa830e4b0c9d6adf6bec9	58cfa830e4b0c9d6adf6bec9	TCGA-AP-A0LP-01A-12D-A101_120330_SN208_0279_BC0L73ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-AP-A0LP-01A-12D-A101_120330_SN208_0279_BC0L73ACXX_s_4_rg.sorted	TCGA-AP-A0LP-01A-12D-A101_120330_SN208_0279_BC0L73ACXX_s_4_rg.sorted.bam	109.58	1.91	0.16	58cfa830e4b0c9d6adf6bec9	TCGA-AP-A0LP-01A-12D-A101_120330_SN208_0279_BC0L73ACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0LP-01A	EFAE3940-D3CC-4988-BDB4-FA05D977AFF5	Primary Tumor	Illumina HiSeq	369f32c0-ebb9-490e-baa4-0735e0efa092	Uterus	76.0	D67450C1-8848-4B28-9C16-83AA7132E8C8	C7A70C11-A05E-473D-929E-59A260FFBD97	TCGA-AP-A0LP-01A-12D-A101-02	HG19_Broad_variant	TCGA-AP-A0LP	TCGA-UCEC		s5202	Harvard Medical School	MSKCC	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C2	UCEC.MSI	0.106223321	0.19	0.0	9.414800176	-0.0138	0.035	0.0388	0.1119	0.4161	-0.318	117.0		2.28887839	8.35291984	69.0	2.59e-05	0.0	0.0							3.110740171	-1901.3367239999998	-1072.474661	-1269.463368	0.0	1875.0	0.0	1875.0	6.55208512108209	7.209710010720637	-0.21644999446039936	5.935898981658273	6.46777266599126	3.57876510946957	-0.6161861394238168	-0.7419373447293771	3.7952151039299693
13722.58cfa830e4b0c9d6adf6bed5	58cfa830e4b0c9d6adf6bed5	TCGA-BP-4756-01A-01D-2097-10_wgs_Illumina.filtered.	WGS	TCGA-BP-4756-01A-01D-2097-10_wgs_Illumina	TCGA-BP-4756-01A-01D-2097-10_wgs_Illumina.bam	133.0	1.9	0.14	58cfa830e4b0c9d6adf6bed5	TCGA-BP-4756-01A-01D-2097-10_wgs_Illumina.bam	Alive	FEMALE	ASIAN		Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-BP-4756-01A	9ECDDE9C-2179-4830-BD10-C4FA40F26066	Primary Tumor	Illumina HiSeq	21f5c572-343f-4923-af48-99ee2a4ccbdf	Kidney	62.0	98D425BE-4D70-4260-8C4F-B0EB89E0E4A6	DB4592FB-13C2-4D61-9DC3-A5D43DEF8D4B	TCGA-BP-4756-01A-01D-2097-10	GRCh37-lite	TCGA-BP-4756	TCGA-KIRC		s9164	Baylor College of Medicine	MSKCC	None	NO	T1b	N0	Kidney Clear Cell Renal Carcinoma	Stage I	2097-10	False	KIRC	C3	KIRC.1	0.09510768800000001				-1.3715	-0.3105	0.3629	0.4091	-0.23600000000000002	-0.6222					101.0	0.328981946	9.0	2.0	0.88624812	0.9736430759999999	3.0	3.340439622	32.0	0.9638471359999999	2.191520408	-753.6733227999999	-2046.4290239999998	3893.019923	0.0	374.0	0.0	374.0	5.497782790507669	1.9491801808963896	0.3125692220888092	4.7799429973573515	3.153741047573879	3.29796113658541	-0.7178397931503171	1.2045608666774896	2.9853919144966006
13722.58cfa830e4b0c9d6adf6bee2	58cfa830e4b0c9d6adf6bee2	TCGA-AP-A0LO-01A-11D-A043_120318_SN590_0147_BD0U3RACXX_s_7_rg.sorted.filtered.	WGS	TCGA-AP-A0LO-01A-11D-A043_120318_SN590_0147_BD0U3RACXX_s_7_rg.sorted	TCGA-AP-A0LO-01A-11D-A043_120318_SN590_0147_BD0U3RACXX_s_7_rg.sorted.bam	90.97	2.13	0.17	58cfa830e4b0c9d6adf6bee2	TCGA-AP-A0LO-01A-11D-A043_120318_SN590_0147_BD0U3RACXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0LO-01A	A081DA6F-51F3-4555-A6B8-736F8C6CDA39	Primary Tumor	Illumina HiSeq	4726575a-1ad0-471a-8a8e-26eb668681f2	Uterus	45.0	9846D8F3-5B22-48E9-B972-A0FE9F509FB4	A91FCC79-7AE0-4BD1-BCAE-543E49E2D62E	TCGA-AP-A0LO-01A-11D-A043-02	HG19_Broad_variant	TCGA-AP-A0LO	TCGA-UCEC	1016.0	s4243	Harvard Medical School	MSKCC	None	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C1	UCEC.CN_LOW	0.12904304800000002	0.4	0.24	2.326440467	0.3136	0.266	-0.8159	-0.5296	-1.196	-0.33399999999999996	22.0		0.236823924	0.799280742	62.0	0.738030608	11.0	1.0							1.617192314	-1509.9898699999999	89.43753034	658.1189293	1.0	1016.0	1.0	516.0	7.1521039823666115	7.67028858702709	-0.2941561107193228	6.600035400066572	6.640669169845932	3.920085652851497	-0.55206858230004	-1.029619417181158	4.21424176357082
13722.58cfa830e4b0c9d6adf6bee6	58cfa830e4b0c9d6adf6bee6	TCGA-AX-A0IU-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_2_rg.sorted.filtered.	WGS	TCGA-AX-A0IU-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_2_rg.sorted	TCGA-AX-A0IU-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_2_rg.sorted.bam	117.75	2.28	0.16	58cfa830e4b0c9d6adf6bee6	TCGA-AX-A0IU-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_2_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AX-A0IU-01A	7E64EA6C-A3DB-48EB-91BE-131361510A92	Primary Tumor	Illumina HiSeq	927c6e80-e2e3-4198-98a4-77a79159fb8a	Uterus	79.0	DC4B3695-CE62-48D5-9F1D-7DD70D049C97	24746F36-88BC-44B0-955A-55A2CC98E17C	TCGA-AX-A0IU-01A-11D-A101-02	HG19_Broad_variant	TCGA-AX-A0IU	TCGA-UCEC		s4999	Harvard Medical School	Gynecologic Oncology Group	None	NO			Serous endometrial adenocarcinoma		A101-02	True	UCEC	C4	UCEC.CN_HIGH	0.080913256	0.21	0.06	3.3678039089999996	0.5502	0.049	-1.2027	-0.2842	0.5097	-0.2693	20.0	7.0	0.416791785	1.305947594	336.0	0.222581009	9.0	24.0							2.7475192410000004	-954.1049666000001	-326.7745966	-3021.829863	0.0	1087.0	0.0	1087.0	6.281189985011348	6.64600847090803	0.11036751639691844	5.202986567974445	5.8416356552378605	2.9916542020706123	-1.0782034170369026	-0.8043728156701695	2.881286685673694
13722.58cfa830e4b0c9d6adf6beea	58cfa830e4b0c9d6adf6beea	TCGA-AP-A0LL-01A-12D-A101_120330_SN208_0279_BC0L73ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-AP-A0LL-01A-12D-A101_120330_SN208_0279_BC0L73ACXX_s_3_rg.sorted	TCGA-AP-A0LL-01A-12D-A101_120330_SN208_0279_BC0L73ACXX_s_3_rg.sorted.bam	106.84	1.77	0.15	58cfa830e4b0c9d6adf6beea	TCGA-AP-A0LL-01A-12D-A101_120330_SN208_0279_BC0L73ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0LL-01A	D17668C4-5D66-4E16-8B70-B54616581AAE	Primary Tumor	Illumina HiSeq	0ea2fbb0-cc11-44d9-9706-2523b9d268be	Uterus	56.0	488A7462-8348-422C-91D3-7D9F0C39D25E	0D29C555-7C7C-4BBB-A4C6-E554CC758CA7	TCGA-AP-A0LL-01A-12D-A101-02	HG19_Broad_variant	TCGA-AP-A0LL	TCGA-UCEC		s4595	Harvard Medical School	MSKCC	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C3	UCEC.CN_LOW	0.0307981	0.06	0.02	2.834476004	-0.5135	-0.18600000000000003	-0.6288	-0.0071	-0.6733	-0.129	18.0	7.0	0.25674124800000003	1.255179434	74.0	0.034401083	1.0	1.0							2.7695412910000003	-1632.699827	-1273.1567890000001	2125.34047	0.0	2554.0	1.0	790.0	6.697587521572453	7.579751781176068	-0.2565036529868774	6.214735749848869	6.3901677143022315	1.6169379475906474	-0.4828517717235843	-1.1895840668738364	1.8734416005775247
13722.58cfa830e4b0c9d6adf6bef0	58cfa830e4b0c9d6adf6bef0	TCGA-BP-4327-01A-01D-1995-10_Illumina.filtered.	WGS	TCGA-BP-4327-01A-01D-1995-10_Illumina	TCGA-BP-4327-01A-01D-1995-10_Illumina.bam	119.0	1.9	0.14	58cfa830e4b0c9d6adf6bef0	TCGA-BP-4327-01A-01D-1995-10_Illumina.bam	Dead	FEMALE	WHITE		Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-BP-4327-01A	9B84D013-713B-4571-888C-12863FDD4A52	Primary Tumor	Illumina HiSeq	02674510-9972-4120-8940-18449f4623e8	Kidney	75.0	45CC1D31-9B81-4268-B83A-5D4C740BD2B6	85448D11-9F84-44B7-8AE3-A115F24BDB76	TCGA-BP-4327-01A-01D-1995-10	GRCh37-lite	TCGA-BP-4327	TCGA-KIRC	109.0	s9565	Baylor College of Medicine	MSKCC	None	NO	T2	N0	Kidney Clear Cell Renal Carcinoma	Stage II	1995-10	False	KIRC	C3	KIRC.2	0.113321639				-1.5557	-0.268	0.3237	0.2879	0.1435	0.1264					73.0	0.29177806100000003	4.0	4.0	0.829584813	1.335165249	5.0	2.7759755530000003	17.0	0.979797571	1.213678098	350.4260198	-1771.9378609999999	2591.3309289999997	1.0	109.0	0.0	109.0	8.859333855911183	-0.5884907007127822	0.23136189019681908	5.433443861658656	2.3452419789464036	3.0795217992836745	-3.4258899942525267	2.933732679659186	2.8481599090868555
13722.58cfa830e4b0c9d6adf6bef8	58cfa830e4b0c9d6adf6bef8	TCGA-BJ-A28W-01A-11D-A16N_120805_SN208_0421_AC11HPACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BJ-A28W-01A-11D-A16N_120805_SN208_0421_AC11HPACXX_s_2_rg.sorted	TCGA-BJ-A28W-01A-11D-A16N_120805_SN208_0421_AC11HPACXX_s_2_rg.sorted.bam	59.66	1.88	0.17	58cfa830e4b0c9d6adf6bef8	TCGA-BJ-A28W-01A-11D-A16N_120805_SN208_0421_AC11HPACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A28W-01A	A6D37F61-BECA-46EA-A59A-62257475AC77	Primary Tumor	Illumina HiSeq	32effbdc-7d3b-4ad8-9245-1a253cbe1ff3	Thyroid	32.0	32AEF736-82A4-4813-A272-86EF160E7D56	229AD821-4BB0-4046-B5E6-6193005D3C8A	TCGA-BJ-A28W-01A-11D-A16N-02	HG19_Broad_variant	TCGA-BJ-A28W	TCGA-THCA		s12507	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	True	THCA	C2	THCA.	0.620685803				-0.3754	-0.016	1.3434	3.705	0.2004	-0.5439					55.0	2.18e-05			0.9680495929999999	3.153999029	26.0	4.85149484	130.0	0.996704777	1.61696903	-0.993661027	-941.9068273	1159.888053	0.0	344.0	0.0	344.0	7.265954061289213	7.942273392220942	0.6227451395208221	6.7353258102270415	6.495354409284617	1.2488501376239272	-0.5306282510621707	-1.4469189829363258	0.626104998103105
13722.58cfa830e4b0c9d6adf6bf00	58cfa830e4b0c9d6adf6bf00	TCGA-BP-5168-01A-01D-2099-10_Illumina.filtered.	WGS	TCGA-BP-5168-01A-01D-2099-10_Illumina	TCGA-BP-5168-01A-01D-2099-10_Illumina.bam	129.4	1.9	0.15	58cfa830e4b0c9d6adf6bf00	TCGA-BP-5168-01A-01D-2099-10_Illumina.bam	Dead	MALE	WHITE		Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-BP-5168-01A	781ACAFA-A58B-4180-BBCA-C5B675D51B17	Primary Tumor	Illumina HiSeq	a353f21b-796e-4d66-a273-83755c9b0525	Kidney	75.0	233C6672-A850-48E0-99FD-024CF1A76B4C	D991F23A-DC1B-427A-B798-BD4187D3AA02	TCGA-BP-5168-01A-01D-2099-10	GRCh37-lite	TCGA-BP-5168	TCGA-KIRC	1463.0	s8837	Baylor College of Medicine	MSKCC	None	NO	T1a	NX	Kidney Clear Cell Renal Carcinoma	Stage I	2099-10	False	KIRC	C3	KIRC.1	0.119398155				-1.4226	-0.262	0.2711	0.23199999999999998	0.4094	0.0341	33.0	122.0	1.015461165	2.470040671	54.0	0.09893382	3.0	2.0				3.260918854	28.0	0.9786070590000001	1.2626867309999998	180.6152017	-1153.277531	3244.770802	1.0	1463.0	0.0	1463.0	8.579312121035041	0.96448244714054	0.0801253994565011	5.4365976571324035	3.748339856149432	2.7851700165013638	-3.142714463902637	2.783857409008892	2.7050446170448628
13722.58cfa830e4b0c9d6adf6bf02	58cfa830e4b0c9d6adf6bf02	TCGA-BP-4968-01A-01D-2100-10_wgs_Illumina.filtered.	WGS	TCGA-BP-4968-01A-01D-2100-10_wgs_Illumina	TCGA-BP-4968-01A-01D-2100-10_wgs_Illumina.bam	68.77	1.9	0.14	58cfa830e4b0c9d6adf6bf02	TCGA-BP-4968-01A-01D-2100-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-BP-4968-01A	1E417B93-837D-4110-9090-239EB82C3E20	Primary Tumor	Illumina HiSeq	e2ce6973-54d1-4e7b-88f1-cb684419ff11	Kidney	40.0	8CD2BBCD-3CE9-4B57-99DA-895B82300AF8	AAD8C8D6-D828-4AAC-9CFB-CEE893E36850	TCGA-BP-4968-01A-01D-2100-10	GRCh37-lite	TCGA-BP-4968	TCGA-KIRC		s9162	Baylor College of Medicine	MSKCC	None	NO	T1b	N0	Kidney Clear Cell Renal Carcinoma	Stage I	2100-10	False	KIRC	C3	KIRC.4	0.22849461199999999	0.36	0.23		-0.8249	-0.0585	0.8049	1.3419	0.4518	0.1935	18.0	3.0	0.373889641	1.06414744	77.0	0.270653949	0.0	5.0				3.420374752	69.0	0.8078150009999999	1.816854978	680.2056943	-987.6559996	193.3231144	0.0	1746.0	0.0	1746.0	8.866762953224923	0.3440697644117261	0.8723065188468163	5.445762944266587	3.441108191949345	3.356170959056373	-3.4210000089583352	3.097038427537619	2.4838644402095564
13722.58cfa830e4b0c9d6adf6bf14	58cfa830e4b0c9d6adf6bf14	TCGA-BR-4267-01A-01D-1128_120805_SN1120_0181_AD16WCACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BR-4267-01A-01D-1128_120805_SN1120_0181_AD16WCACXX_s_3_rg.sorted	TCGA-BR-4267-01A-01D-1128_120805_SN1120_0181_AD16WCACXX_s_3_rg.sorted.bam	265.9	1.9	0.13	58cfa830e4b0c9d6adf6bf14	TCGA-BR-4267-01A-01D-1128_120805_SN1120_0181_AD16WCACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4267-01A	0D0F0200-25B8-483B-B04A-82A7833B4D30	Primary Tumor	Illumina HiSeq	cd48e485-3a3f-4eec-92e7-f1c52c0866f1	Stomach	51.0	32D28ED3-2E33-4D83-8DE6-82E156B33211	F0DB5AF5-091F-4CDC-9917-BEFD658BF454	TCGA-BR-4267-01A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4267	TCGA-STAD		s15044	Harvard Medical School	Asterand	None	NO	T2a	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1128-02	True	STAD	C1	GI.CIN	0.131743479	0.25	0.11		0.2313	0.122	0.2592	0.3188	0.0	0.1069			0.65404763	2.1999783930000003	188.0	0.314047427	5.0	53.0	0.867851921	4.30092403	142.0	4.390203436	90.0	0.9756420290000001	0.47408961	200.51691830000001	255.40767689999998	1270.458936	1.0	188.0	0.0	188.0	6.9825209295548305	4.523167979161409	-0.3549795997794174	6.9825209295548305	8.374378845192798	0.6063834815901574	0.0	3.8512108660313884	0.9613630813695748
13722.58cfa830e4b0c9d6adf6bf16	58cfa830e4b0c9d6adf6bf16	TCGA-BR-4257-01A-01D-1128_130110_SN1222_0167_AC1JPDACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BR-4257-01A-01D-1128_130110_SN1222_0167_AC1JPDACXX_s_3_rg.sorted	TCGA-BR-4257-01A-01D-1128_130110_SN1222_0167_AC1JPDACXX_s_3_rg.sorted.bam	106.9	1.9	0.16	58cfa830e4b0c9d6adf6bf16	TCGA-BR-4257-01A-01D-1128_130110_SN1222_0167_AC1JPDACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4257-01A	DA112431-5579-4FD1-A230-9144B359B0E9	Primary Tumor	Illumina HiSeq	5e38d8b4-97fb-407a-ab06-2f002456472d	Stomach	79.0	97B44B05-97EB-486C-94DB-42838831DE0B	465E5E4D-A801-4BBC-9E1C-004C7718571F	TCGA-BR-4257-01A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4257	TCGA-STAD		s15048	Harvard Medical School	Asterand	Russia	NO	TX	NX	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)		1128-02	True	STAD	C4	GI.HM-indel	0.234499542	0.46	0.08		0.8403	0.265	0.8042	0.2381	0.111	0.4142			11.88986578	29.01505708	169.0	0.858750955	20.0	2.0	0.9021383690000001	2.903871386	25.0	4.334255996	152.0	0.862730707	0.7464722509999999	-494.1063647	752.6595844999999	1572.1452060000001	1.0	294.0	0.0	294.0	8.966356154790121	7.209833231717651	0.07469371726485385	6.663771061796076	6.6990076079516605	0.9708065992022686	-2.3025850929940455	-0.5108256237659905	0.8961128819374148
13722.58cfa830e4b0c9d6adf6bf19	58cfa830e4b0c9d6adf6bf19	TCGA-AY-A54L-01A-11D-A28G-10_wgs_Illumina.filtered.	WGS	TCGA-AY-A54L-01A-11D-A28G-10_wgs_Illumina	TCGA-AY-A54L-01A-11D-A28G-10_wgs_Illumina.bam	62.42		0.07	58cfa830e4b0c9d6adf6bf19	TCGA-AY-A54L-01A-11D-A28G-10_wgs_Illumina.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN		Colon Adenocarcinoma	Aligned reads	TCGA-AY-A54L-01A	D8E9EA52-FF28-4626-BAA3-71350FD53DDF	Primary Tumor	Illumina HiSeq	709d8bea-f505-4558-b12a-7bd4322e75ea	Colorectal	74.0	52EFBEB4-7B23-4C49-92F9-931A3EB99055	080ECC31-756A-4A1B-A51E-D632AC8219F7	TCGA-AY-A54L-01A-11D-A28G-10	GRCh37-lite	TCGA-AY-A54L	TCGA-COAD		s13542	Baylor College of Medicine	UNC	United States	NO	T2	N0	Colon Adenocarcinoma	Stage I	A28G-10	True	COAD	C1	GI.CIN	0.12693058599999998	0.56	0.49	7.774961837	0.8727	0.433	-1.6172	-1.1304	-1.1903	-0.5731	68.0	30.0	1.011558692	3.4756119169999997	70.0	0.692071697	23.0	24.0	0.9999585999999999	0.6931184840000001	2.0	0.693147181	2.0	1.0	3.663768449	-805.5525665	398.5673332	-1185.241019	0.0	525.0	1.0	396.0	6.42722982227682	4.049864689609175	-1.9529869341692216	5.867614034341397	6.504348688968896	-0.4124514813961444	-0.5596157879354227	2.454483999359722	1.5405354527730772
13722.58cfa830e4b0c9d6adf6bf21	58cfa830e4b0c9d6adf6bf21	TCGA-BR-4279-01A-01D-1128_121127_SN208_0441_BC1F8CACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BR-4279-01A-01D-1128_121127_SN208_0441_BC1F8CACXX_s_1_rg.sorted	TCGA-BR-4279-01A-01D-1128_121127_SN208_0441_BC1F8CACXX_s_1_rg.sorted.bam	7.9	1.9	0.16	58cfa830e4b0c9d6adf6bf21	TCGA-BR-4279-01A-01D-1128_121127_SN208_0441_BC1F8CACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4279-01A	117EB38B-0C62-4336-A866-FA5BD013256A	Primary Tumor	Illumina HiSeq	0fa8a7d6-6636-4135-82f6-21c9df279b16	Stomach	43.0	84AD647D-76B8-4EDA-8603-40220089BE34	01DC88B7-45FC-464C-A613-9793CD0C068B	TCGA-BR-4279-01A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4279	TCGA-STAD		s14814	Harvard Medical School	Asterand	Russia	NO	T2a	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage II	1128-02	True	STAD	C2	GI.CIN	0.240371117	0.66	0.03		-0.0561	0.06	0.9621	1.3563	0.7199	0.3548			0.691316405	1.08206046	72.0	0.194011452	5.0	14.0	0.9317356170000001	4.271977504	98.0	2.998822118	22.0	0.9701652959999999	0.803881022	561.6231215	238.18675180000002	-2681.2273210000003	1.0	291.0	0.0	291.0	8.188633567345379	8.353396134537173	-0.23374229653948053	6.753549042056056	7.02216155060031	1.2517438601269113	-1.4350845252893227	-1.3312345839368631	1.4854861566663917
13722.58cfa830e4b0c9d6adf6bf30	58cfa830e4b0c9d6adf6bf30	TCGA-BR-4191-01A-02D-1128_120805_SN1222_0143_BD172BACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BR-4191-01A-02D-1128_120805_SN1222_0143_BD172BACXX_s_3_rg.sorted	TCGA-BR-4191-01A-02D-1128_120805_SN1222_0143_BD172BACXX_s_3_rg.sorted.bam	266.9	1.9	0.15	58cfa830e4b0c9d6adf6bf30	TCGA-BR-4191-01A-02D-1128_120805_SN1222_0143_BD172BACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4191-01A	74F859CF-6DF5-4E96-AE6B-CFAAB691D5FD	Primary Tumor	Illumina HiSeq	d71fa3ea-a7fb-40af-a7b9-64ceca39e135	Stomach	72.0	E5A1A598-5896-46F9-8DCA-BA19AC138D14	125C563B-A1CE-4FFC-8D8D-19C7CA2E1049	TCGA-BR-4191-01A-02D-1128-02	HG19_Broad_variant	TCGA-BR-4191	TCGA-STAD		s14608	Harvard Medical School	Asterand	Russia	NO	TX	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)		1128-02	True	STAD	C2	GI.CIN	0.26734475	0.49	0.19		0.4411	0.184	1.2678	1.6027	0.6105	0.2261			1.692164553	5.651191056	319.0	0.44107908100000004	4.0	66.0	0.612564648	2.9576543039999996	125.0	3.540255555	39.0	0.9663425640000001	1.121097636	474.4271181	382.8697204	-718.0618772999999	1.0	558.0	0.0	558.0	6.789604988395917	6.162382730345451	0.11583181552512167	5.484656266729979	7.683851869833594	1.3862943611198904	-1.3049487216659386	1.5214691394881434	1.2704625455947687
13722.58cfa830e4b0c9d6adf6bf3c	58cfa830e4b0c9d6adf6bf3c	TCGA-BR-4256-01A-01D-1128_130110_SN1222_0167_AC1JPDACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BR-4256-01A-01D-1128_130110_SN1222_0167_AC1JPDACXX_s_1_rg.sorted	TCGA-BR-4256-01A-01D-1128_130110_SN1222_0167_AC1JPDACXX_s_1_rg.sorted.bam	67.9	1.9	0.15	58cfa830e4b0c9d6adf6bf3c	TCGA-BR-4256-01A-01D-1128_130110_SN1222_0167_AC1JPDACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4256-01A	7B0D69CA-13A6-46E0-839C-E433BBEDE3AD	Primary Tumor	Illumina HiSeq	6e990147-2463-4d38-a785-6c76ae1dbc25	Stomach	80.0	61C7AAB0-51D9-4706-A37C-D5058007DAF1	30AF7950-11F7-43BF-9A1D-98A57F416397	TCGA-BR-4256-01A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4256	TCGA-STAD		s14396	Harvard Medical School	Asterand	Russia	NO	TX	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)		1128-02	True	STAD	C2	GI.HM-indel	0.42206694200000006	0.65	0.63		0.5927	0.22399999999999998	1.2664	1.1592	1.7793	0.4906			9.724516057999999	26.94315458	91.0	0.049847394	4.0	3.0	0.81753726	4.398266543	217.0	5.09476292	264.0	0.913703268	1.041331683	491.4392056	665.8963431	-95.54220466	1.0	284.0	0.0	284.0	7.461257177028564	7.556602200645502	0.2880666138908591	6.208494208533196	7.674385236301886	1.7566283777063973	-1.252762968495368	0.11778303565638337	1.4685617638155382
13722.58cfa830e4b0c9d6adf6bf3d	58cfa830e4b0c9d6adf6bf3d	TCGA-BR-4187-01A-01D-1128_120805_SN1222_0142_AD16TGACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BR-4187-01A-01D-1128_120805_SN1222_0142_AD16TGACXX_s_5_rg.sorted	TCGA-BR-4187-01A-01D-1128_120805_SN1222_0142_AD16TGACXX_s_5_rg.sorted.bam	138.9	1.9	0.15	58cfa830e4b0c9d6adf6bf3d	TCGA-BR-4187-01A-01D-1128_120805_SN1222_0142_AD16TGACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4187-01A	12071070-D06B-4C7B-A7B1-77C84963ABE6	Primary Tumor	Illumina HiSeq	1da3a244-39ae-4b4d-baed-e4d9b312f777	Stomach	56.0	144FB4ED-63BB-4908-B678-6026E09566A3	57CF858D-FF3F-4528-96DB-5A820C9B78DE	TCGA-BR-4187-01A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4187	TCGA-STAD		s15046	Harvard Medical School	Asterand	Russia	NO	TX	NX	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)		1128-02	True	STAD	C2	GI.GS	0.43923428	0.7	0.22		-0.0943	-0.006	1.1346	1.2958	1.5778	0.6093			0.298779611	0.7170710659999999	66.0	0.004903066	4.0	0.0	0.7927208990000001	2.245947429	17.0	4.670585234	131.0	0.9580299879999999	2.2592292869999997	166.27277769999998	541.212935	-1487.747203	1.0	141.0	0.0	141.0	7.123715194924921	8.055732018888312	-0.12018733925052894	6.3069540583978	7.149010738030308	1.8816567312696377	-0.8167611365271221	-0.9067212808580045	2.0018440705201668
13722.58cfa830e4b0c9d6adf6bf40	58cfa830e4b0c9d6adf6bf40	TCGA-AX-A1CJ-01A-11D-A133_120511_SN1120_0141_BC0VK9ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-AX-A1CJ-01A-11D-A133_120511_SN1120_0141_BC0VK9ACXX_s_5_rg.sorted	TCGA-AX-A1CJ-01A-11D-A133_120511_SN1120_0141_BC0VK9ACXX_s_5_rg.sorted.bam	100.97	1.91	0.17	58cfa830e4b0c9d6adf6bf40	TCGA-AX-A1CJ-01A-11D-A133_120511_SN1120_0141_BC0VK9ACXX_s_5_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AX-A1CJ-01A	ABAF757B-F79F-40BD-96E3-E2C0F63061F0	Primary Tumor	Illumina HiSeq	f42806a5-e473-4ae8-bb1a-aa11fe2dde53	Uterus	59.0	72D06DDF-9FB2-4577-BFDB-B0E463105B4A	A4EE1BB7-59FF-4034-ABA1-9AF4F62B42B0	TCGA-AX-A1CJ-01A-11D-A133-02	HG19_Broad_variant	TCGA-AX-A1CJ	TCGA-UCEC		s5388	Harvard Medical School	Gynecologic Oncology Group	None	NO			Endometrioid endometrial adenocarcinoma		A133-02	False	UCEC	C2	UCEC.CN_LOW	0.172377804	0.27	0.01	5.23783572	-0.0155	0.036000000000000004	0.0386	0.8479	-0.2263	-0.4439	13.0		0.52382935	1.0476587	114.0	0.08111581400000001	3.0	1.0							2.984653867	-641.8685085	-179.73680369999997	-789.4798668	0.0	2233.0	0.0	2233.0	4.394646350547741	6.754147929784926	0.010396587376933275	3.1579867896189517	4.663895472000874	3.25627301406364	-1.2366595609287891	-2.090252457784052	3.2458764266867064
13722.58cfa830e4b0c9d6adf6bf44	58cfa830e4b0c9d6adf6bf44	TCGA-AX-A2HD-01A-21D-A17E_120511_SN1120_0141_BC0VK9ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-AX-A2HD-01A-21D-A17E_120511_SN1120_0141_BC0VK9ACXX_s_1_rg.sorted	TCGA-AX-A2HD-01A-21D-A17E_120511_SN1120_0141_BC0VK9ACXX_s_1_rg.sorted.bam	115.02	1.84	0.16	58cfa830e4b0c9d6adf6bf44	TCGA-AX-A2HD-01A-21D-A17E_120511_SN1120_0141_BC0VK9ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AX-A2HD-01A	A8DEF1A0-A136-47F4-9AD9-60EBCF9B726B	Primary Tumor	Illumina HiSeq	b9d10df5-eb11-4976-b3dd-10e970fc715d	Uterus	69.0	5A2EDE97-0CF7-44D7-A789-92EE9BDA3D6C	C24E7F27-2155-4727-B6D8-8E5BC16D9197	TCGA-AX-A2HD-01A-21D-A17E-02	HG19_Broad_variant	TCGA-AX-A2HD	TCGA-UCEC		s4428	Harvard Medical School	Gynecologic Oncology Group	United States	NO			Endometrioid endometrial adenocarcinoma		A17E-02	True	UCEC	C1	UCEC.POLE	0.11195608	0.13	0.01		0.7555	0.126	-0.5729	-0.3078	-0.3808	-0.0276	4043.0	1835.0	64.12421966	164.39742230000002	99.0	0.029972197000000003	0.0	7.0		0.0	1.0				2.698888119	-1405.109501	829.990518	439.1317302	0.0	1414.0	0.0	1414.0	5.57916873030469	8.603268945662196	0.21228043905683858	4.322552192493332	6.626106253102779	2.0144177014354323	-1.2566165378113574	-1.9771626925594172	1.802137262378594
13722.58cfa830e4b0c9d6adf6bf52	58cfa830e4b0c9d6adf6bf52	TCGA-BR-4280-01A-01D-1128_121127_SN208_0440_AC1F4LACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BR-4280-01A-01D-1128_121127_SN208_0440_AC1F4LACXX_s_1_rg.sorted	TCGA-BR-4280-01A-01D-1128_121127_SN208_0440_AC1F4LACXX_s_1_rg.sorted.bam	252.9	1.9	0.14	58cfa830e4b0c9d6adf6bf52	TCGA-BR-4280-01A-01D-1128_121127_SN208_0440_AC1F4LACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4280-01A	E0916597-E489-45EF-A8F7-653A3C6591EF	Primary Tumor	Illumina HiSeq	418e722c-d444-43fe-87b1-6d8ce0ce5359	Stomach	78.0	797D2D3A-F01C-4985-B27C-4E4C2838D34D	7F073E1B-E936-44FF-B3C0-8F4C26ECC3A9	TCGA-BR-4280-01A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4280	TCGA-STAD		s14880	Harvard Medical School	Asterand	Russia	NO	T2b	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage III	1128-02	True	STAD	C2	GI.HM-indel	0.107561025	0.24	0.02		0.71	0.259	0.2414	0.6074	-0.0506	-0.27399999999999997			5.515588298	19.89763305	77.0	0.05854168	2.0	0.0	0.7354327709999999	4.005709157	232.0	3.9849217169999998	132.0	0.8161137359999999	0.9888676270000001	-70.23232587	746.3912173	-34.97269652	1.0	201.0	0.0	201.0	7.5508114496396015	7.271053402454714	-0.04154019575995427	6.894031913250531	5.829843283738709	2.1104296271410714	-0.6567795363890707	-1.441210118716005	2.151969822901026
13722.58cfa830e4b0c9d6adf6bf60	58cfa830e4b0c9d6adf6bf60	TCGA-BR-4357-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_5_rg.sorted.filtered.	WGS	TCGA-BR-4357-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_5_rg.sorted	TCGA-BR-4357-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_5_rg.sorted.bam	197.2	1.9	0.16	58cfa830e4b0c9d6adf6bf60	TCGA-BR-4357-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4357-01A	BEC83DFF-2BBA-4467-92AA-5DC3DB9E0EAF	Primary Tumor	Illumina HiSeq	4bc9f55b-1edb-49c9-be1a-1d00a108b99b	Stomach	58.0	81C87C27-47C7-4DC7-BF92-E0037433DF30	93F60FA6-0D34-441E-8F61-80306E10D046	TCGA-BR-4357-01A-01D-1154-02	HG19_Broad_variant	TCGA-BR-4357	TCGA-STAD		s15301	Harvard Medical School	Asterand	Russia	NO	T3	NX	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)		1154-02	True	STAD	C2	GI.CIN	0.28910268699999997	0.56	0.13		1.0819	0.249	1.0296	1.2819	0.87	0.2841			1.7191263719999998	5.974668701000001	1032.0	0.8756358909999999	19.0	45.0	0.693673867	3.956564846	300.0	3.0897556539999997	24.0	0.9722162740000001		647.066367	544.0487472	512.7046729	0.0	0.0	0.0	0.0	9.156587915976937	6.88681018113312	-0.08247714508254622	7.16415775128673	6.079252649395429	2.0413976102499887	-1.9924301646902063	-0.80755753173769	2.123874755332535
13722.58cfa830e4b0c9d6adf6bf6a	58cfa830e4b0c9d6adf6bf6a	TCGA-BR-6452-01A-12D-1798_130115_SN1222_0169_BD1K2PACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BR-6452-01A-12D-1798_130115_SN1222_0169_BD1K2PACXX_s_2_rg.sorted	TCGA-BR-6452-01A-12D-1798_130115_SN1222_0169_BD1K2PACXX_s_2_rg.sorted.bam	409.4	1.9	0.16	58cfa830e4b0c9d6adf6bf6a	TCGA-BR-6452-01A-12D-1798_130115_SN1222_0169_BD1K2PACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6452-01A	27988B3E-CDE1-4F4B-82A1-6D8AD08DB8E9	Primary Tumor	Illumina HiSeq	cfd9aa7a-7f3d-4b70-9359-2c93f0238361	Stomach	78.0	76144F2F-2498-430D-B33C-F000394C427E	460DE564-5AAB-46B0-8174-36AF18D2DF4C	TCGA-BR-6452-01A-12D-1798-02	HG19_Broad_variant	TCGA-BR-6452	TCGA-STAD		s14744	Harvard Medical School	Asterand	Russia	NO	T3	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIA	1798-02	True	STAD	C1	GI.HM-indel	0.240214782	0.53	0.12	17.57870195	0.8142	0.19899999999999998	0.3409	0.8682	-0.0851	0.28600000000000003			45.55028334	136.38805990000003	51.0	0.050651244000000005	2.0	0.0	0.6849360409999999	4.023951798	356.0	3.5846819180000002	144.0	0.721291063	2.298592501	-689.4325947000001	807.3589946000001	-117.00123959999999	0.0	1055.0	0.0	1055.0	7.786274913169293	7.418695181932298	-0.46416384347593953	5.84036476411398	6.368873057433621	1.7995071560188807	-1.9459101490553132	-1.0498221244986776	2.26367099949482
13722.58cfa830e4b0c9d6adf6bf72	58cfa830e4b0c9d6adf6bf72	TCGA-BR-4363-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_7_rg.sorted.filtered.	WGS	TCGA-BR-4363-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_7_rg.sorted	TCGA-BR-4363-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_7_rg.sorted.bam	264.2	1.9	0.15	58cfa830e4b0c9d6adf6bf72	TCGA-BR-4363-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4363-01A	66BCA2F8-F269-454D-ABE2-CE51A0704645	Primary Tumor	Illumina HiSeq	ab5af808-6239-48fa-ba17-b80aa3fc5e14	Stomach	60.0	06EC6231-EE0E-4C15-AF9F-5B9E5BF557B8	D62228AE-B0AB-4C31-9FD7-F9D48B140CDC	TCGA-BR-4363-01A-01D-1154-02	HG19_Broad_variant	TCGA-BR-4363	TCGA-STAD		s14528	Harvard Medical School	Asterand	Russia	NO	T3	NX	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)		1154-02	True	STAD	C2	GI.HM-indel	0.200073652	0.37	0.01		0.8644	0.18	0.7488	0.9848	0.47100000000000003	0.358			4.4749399489999995	14.94515201	175.0	0.09018887699999999	2.0	5.0	0.90488552	5.007084026	253.0	3.4698571410000003	36.0	0.968282072		-679.5446234	1242.129007	-2332.696856	0.0	0.0	0.0	0.0	8.152198015861787	5.5737738472840315	0.029531781197345897	5.849612922867742	7.342543798287387	2.2286849994399707	-2.3025850929940455	1.7687699510033559	2.1991532182426248
13722.58cfa830e4b0c9d6adf6bf74	58cfa830e4b0c9d6adf6bf74	TCGA-AP-A0LD-01A-11D-A043_120330_SN1120_0128_AC0L52ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-AP-A0LD-01A-11D-A043_120330_SN1120_0128_AC0L52ACXX_s_6_rg.sorted	TCGA-AP-A0LD-01A-11D-A043_120330_SN1120_0128_AC0L52ACXX_s_6_rg.sorted.bam	84.77	1.86	0.16	58cfa830e4b0c9d6adf6bf74	TCGA-AP-A0LD-01A-11D-A043_120330_SN1120_0128_AC0L52ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0LD-01A	1200C8B7-A058-4C01-BBE2-04EC09A65245	Primary Tumor	Illumina HiSeq	aa90984a-1483-43a2-8b20-f1654e3f601e	Uterus	63.0	649DADDA-5823-4B0D-B5A2-49F501ADC029	3D587F43-D9C5-4E3B-B245-60BB0AE92808	TCGA-AP-A0LD-01A-11D-A043-02	HG19_Broad_variant	TCGA-AP-A0LD	TCGA-UCEC		s5199	Harvard Medical School	MSKCC	None	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C2	UCEC.MSI	0.07119687	0.2	0.03	6.02712248	0.6286	0.152	-1.3244	-0.9166	0.5964	-0.0495	176.0	594.0	4.288222192	12.51697289	38.0	0.130012084	5.0	2.0							2.875513958	-1339.176737	452.51787249999995	-1216.62567	0.0	3589.0	0.0	3589.0	5.139204394890964	7.424364147503855	-1.0897635839509348	5.080935486766988	6.2542928948536005	-0.7759754711116351	-0.058268908123976004	-1.1700712526502546	0.31378811283929964
13722.58cfa830e4b0c9d6adf6bf7e	58cfa830e4b0c9d6adf6bf7e	TCGA-B5-A0JV-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_5_rg.sorted.filtered.	WGS	TCGA-B5-A0JV-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_5_rg.sorted	TCGA-B5-A0JV-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_5_rg.sorted.bam	90.33	1.92	0.15	58cfa830e4b0c9d6adf6bf7e	TCGA-B5-A0JV-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_5_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0JV-01A	233E947A-D5E2-48E5-A8CE-5DA1ABB20681	Primary Tumor	Illumina HiSeq	2c99d5d5-1f92-452e-9370-59486a6d7bce	Uterus	63.0	42199E5A-9F4F-4445-9E6E-114D47BA67FA	7132C5C6-9DC5-42A8-863F-D82280266427	TCGA-B5-A0JV-01A-11D-A101-02	HG19_Broad_variant	TCGA-B5-A0JV	TCGA-UCEC		s4783	Harvard Medical School	Duke	United States	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C2	UCEC.MSI	0.069220966	0.15	0.01	11.29573551	0.6032	0.212	-0.9676	-0.6899	0.2586	-0.5503	174.0	743.0	2.730732118	8.437962245	172.0	0.035947175	1.0	2.0							1.747964104	-953.4197849	-253.3427955	1090.632869	0.0	2616.0	1.0	698.0	6.912168602848917	7.544385016706911	0.23562013851831654	6.532678981144013	6.902531130534516	2.0230096080752533	-0.3794896217049035	-0.6418538861723944	1.7873894695569368
13722.58cfa830e4b0c9d6adf6bf80	58cfa830e4b0c9d6adf6bf80	TCGA-BR-6455-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BR-6455-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_8_rg.sorted	TCGA-BR-6455-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_8_rg.sorted.bam	324.7	1.9	0.15	58cfa830e4b0c9d6adf6bf80	TCGA-BR-6455-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6455-01A	75A29059-4705-4A55-BC3D-F5923B24B358	Primary Tumor	Illumina HiSeq	719ee3a5-cfe9-48cb-9e48-e11e49bd217c	Stomach	59.0	59BD0192-A50B-4672-A17F-4DF138F58988	6C038E7C-8B03-4AB6-A31A-00C3C6CE6204	TCGA-BR-6455-01A-11D-1798-02	HG19_Broad_variant	TCGA-BR-6455	TCGA-STAD		s14470	Harvard Medical School	Asterand	Russia	NO	T3	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIB	1798-02	True	STAD	C1	GI.EBV	0.196753383	0.34	0.0	15.85250697	0.9551	0.3135	0.4286	1.1679	-0.0988	0.0972			1.100960098	2.028084391	75.0	0.11804980400000001	6.0	0.0	0.7294279220000001	3.711034821	162.0	4.295376223	139.0	0.870483111	2.6978569080000003	-642.3476883999999	1018.210641	-2450.565048	1.0	422.0	1.0	385.0	7.813187267521416	8.511946116229248	0.49665969995595904	5.561895468914921	7.470492241401087	2.0855248141113463	-2.251291798606495	-1.0414538748281612	1.5888651141553871
13722.58cfa830e4b0c9d6adf6bf83	58cfa830e4b0c9d6adf6bf83	TCGA-BR-6453-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BR-6453-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_4_rg.sorted	TCGA-BR-6453-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_4_rg.sorted.bam	93.7	1.9	0.15	58cfa830e4b0c9d6adf6bf83	TCGA-BR-6453-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6453-01A	AE633E83-303F-4A90-AC3B-34458FD9BEEF	Primary Tumor	Illumina HiSeq	e92977c9-6880-4f84-842a-9152e558d0b1	Stomach	54.0	A8F3B148-5929-4025-81A1-6595D49F2279	EE3446DC-7278-47AF-8F65-F63A1D423644	TCGA-BR-6453-01A-11D-1798-02	HG19_Broad_variant	TCGA-BR-6453	TCGA-STAD		s15305	Harvard Medical School	Asterand	Russia	NO	T2	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIA	1798-02	True	STAD	C2	GI.GS	0.568008509	0.81	0.08	25.76105777	0.131	0.0695	1.146	2.9802	0.0837	0.1698			1.5066073130000002	4.345982635	50.0	0.09672275300000001	4.0	3.0	0.82873913	4.524572147	235.0	5.801951814	434.0	0.955361315	1.522569199	588.1166622999999	-194.20330719999998	-535.0120747	0.0	485.0	0.0	485.0	8.460199469896118	7.872154238299068	0.9631429970789931	6.157614376902073	6.373941960975191	3.173508367976271	-2.3025850929940455	-1.4982122773238764	2.2103653708972777
13722.58cfa830e4b0c9d6adf6bf87	58cfa830e4b0c9d6adf6bf87	TCGA-BJ-A3PR-01A-11D-A221_120524_SN1120_0144_AC0VNCACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BJ-A3PR-01A-11D-A221_120524_SN1120_0144_AC0VNCACXX_s_7_rg.sorted	TCGA-BJ-A3PR-01A-11D-A221_120524_SN1120_0144_AC0VNCACXX_s_7_rg.sorted.bam	45.84		0.15	58cfa830e4b0c9d6adf6bf87	TCGA-BJ-A3PR-01A-11D-A221_120524_SN1120_0144_AC0VNCACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A3PR-01A	FD036EC5-3FFB-40B1-8002-943BE0E2532E	Primary Tumor	Illumina HiSeq	c8c8646f-54e4-4440-bf91-d2cd90083c44	Thyroid	69.0	E058A8E1-ED00-48A5-A46B-77538D7B73F1	57FD6BDA-C7B4-4B74-B21A-B7FF5D1C87EE	TCGA-BJ-A3PR-01A-11D-A221-26	HG19_Broad_variant	TCGA-BJ-A3PR	TCGA-THCA		s12358	MD Anderson - Institute for Applied Cancer Science	University of Pittsburgh	United States	NO	T1a	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A221-26	True	THCA	C2	THCA.4	0.620774311	0.54	0.0		-0.1548	-0.076	1.2973	3.2449	0.4329	-0.0634	5.0		0.05814382	0.145359549	35.0	6.64e-05	0.0	0.0	0.8883753059999999	4.8349095	231.0	5.221741509	211.0	0.97568758	1.622303111	1004.923635	-662.6023018999999	-668.4881095	0.0	1107.0	0.0	1107.0	6.342601457133442	8.402511591332622	0.3627516812101407	6.312748493983761	7.486220859458468	1.622203637856305	-0.029852963149681333	-0.9162907318741551	1.2594519566461642
13722.58cfa830e4b0c9d6adf6bf8f	58cfa830e4b0c9d6adf6bf8f	TCGA-B5-A0K0-01A-11D-A043_120209_SN1120_0113_AC0DKVACXX_s_7_rg.sorted.filtered.	WGS	TCGA-B5-A0K0-01A-11D-A043_120209_SN1120_0113_AC0DKVACXX_s_7_rg.sorted	TCGA-B5-A0K0-01A-11D-A043_120209_SN1120_0113_AC0DKVACXX_s_7_rg.sorted.bam	106.93	1.95	0.16	58cfa830e4b0c9d6adf6bf8f	TCGA-B5-A0K0-01A-11D-A043_120209_SN1120_0113_AC0DKVACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0K0-01A	29C8F468-5AC1-4D6C-8376-E36E6D246926	Primary Tumor	Illumina HiSeq	5de016ca-e694-4ebc-b06f-5d07f7523fda	Uterus	48.0	11C43948-E7C9-4436-A654-82FA8033B625	3296C785-7C20-487D-BAEC-C66022E77E53	TCGA-B5-A0K0-01A-11D-A043-02	HG19_Broad_variant	TCGA-B5-A0K0	TCGA-UCEC		s5204	Harvard Medical School	Duke	United States	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C1	UCEC.CN_LOW	0.190545054			22.46429525	-0.1344	-0.054000000000000006	0.2164	0.2847	-0.1471	0.3718	9.0	0.0	0.14607725300000002	0.525878111	58.0	0.088807446	3.0	1.0							2.269278766	-791.8938086	-472.3800669	-1945.3798370000002	0.0	1478.0	0.0	1478.0	5.840515259092246	6.5061864167940975	-0.7488803103501094	5.643804964846192	6.153365042171355	1.8934255332209804	-0.19671029424605457	-0.3528213746227422	2.6423058435710898
13722.58cfa830e4b0c9d6adf6bf95	58cfa830e4b0c9d6adf6bf95	TCGA-BR-6564-01A-12D-1880_121220_SN1222_0163_AC1HA2ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BR-6564-01A-12D-1880_121220_SN1222_0163_AC1HA2ACXX_s_1_rg.sorted	TCGA-BR-6564-01A-12D-1880_121220_SN1222_0163_AC1HA2ACXX_s_1_rg.sorted.bam	29.7	1.9	0.13	58cfa830e4b0c9d6adf6bf95	TCGA-BR-6564-01A-12D-1880_121220_SN1222_0163_AC1HA2ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6564-01A	AF1086CC-B330-4AD6-AE1C-3B5C7259949A	Primary Tumor	Illumina HiSeq	6ee5a220-be0b-4909-bd37-5a6d8c53177d	Stomach	46.0	B8355E52-D7A7-4711-BBA7-BC4D201741F2	62E2C436-03DA-4B32-B43A-DF7AC992DD7C	TCGA-BR-6564-01A-12D-1880-02	HG19_Broad_variant	TCGA-BR-6564	TCGA-STAD		s15051	Harvard Medical School	Asterand	Russia	NO	T3	N2	Stomach  Adenocarcinoma  Diffuse Type	Stage IIIA	1880-02	True	STAD	C2	GI.CIN	0.274202253	0.78	0.14	12.61669024	-1.0592	-0.237	0.4319	1.2336	1.5673	0.5685			0.34231179100000003	0.798727513	84.0	0.290098573	8.0	21.0	0.969895556	1.7378195459999999	6.0	4.845365714	140.0	0.980517265	1.762194441	-249.8457508	-713.95088	-1297.425989	1.0	794.0	0.0	794.0	7.693253720606268	7.241963048870852	0.4861450399725593	5.496029143270049	6.200509174042691	3.5314697240286206	-2.197224577336219	-1.0414538748281612	3.045324684056061
13722.58cfa830e4b0c9d6adf6bf9f	58cfa830e4b0c9d6adf6bf9f	TCGA-BR-6458-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BR-6458-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_5_rg.sorted	TCGA-BR-6458-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_5_rg.sorted.bam	306.4	1.9	0.15	58cfa830e4b0c9d6adf6bf9f	TCGA-BR-6458-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6458-01A	E516880B-C4E5-43CD-A358-BE0DB88564D7	Primary Tumor	Illumina HiSeq	545acf44-8e16-46b9-b35a-c860c08b416b	Stomach	57.0	A30B45F5-C6E4-4975-A912-8313D93DFD27	2DD3E59B-4DBB-49B4-9DC4-A949FE48AA17	TCGA-BR-6458-01A-11D-1798-02	HG19_Broad_variant	TCGA-BR-6458	TCGA-STAD		s14613	Harvard Medical School	Asterand	Ukraine	NO	T3	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIB	1798-02	True	STAD	C2	GI.CIN	0.287551892	0.55	0.16	9.686403627	0.6554	0.129	0.7929	1.1067	0.5419	0.4094			2.416486025	7.278572362999999	249.0	0.58492169	10.0	53.0	0.8027486859999999	4.774777275	383.0	5.3958935839999995	291.0	0.9510992640000001	4.459754351	-696.8968999	510.26480639999994	-832.6829815000001	1.0	588.0	1.0	574.0	8.28488275227721	7.816457289207617	-0.06653684973225926	6.675444839843111	7.174603403035222	2.2196825885742744	-1.6094379124341003	-0.6418538861723944	2.2862194383065337
13722.58cfa830e4b0c9d6adf6bfa4	58cfa830e4b0c9d6adf6bfa4	TCGA-BR-6457-01A-21D-1798_130116_SN208_0448_AC1J58ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BR-6457-01A-21D-1798_130116_SN208_0448_AC1J58ACXX_s_3_rg.sorted	TCGA-BR-6457-01A-21D-1798_130116_SN208_0448_AC1J58ACXX_s_3_rg.sorted.bam	77.4	1.9	0.15	58cfa830e4b0c9d6adf6bfa4	TCGA-BR-6457-01A-21D-1798_130116_SN208_0448_AC1J58ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6457-01A	05CE16D4-A999-491A-91AD-9449A57228FF	Primary Tumor	Illumina HiSeq	695f7145-7735-48f7-98e8-99b86bb936f4	Stomach	69.0	BADB9AE0-9C44-41D4-848B-EE03B6FCA503	85EEEBBE-BDBB-4FE7-8CCD-401E818EEB29	TCGA-BR-6457-01A-21D-1798-02	HG19_Broad_variant	TCGA-BR-6457	TCGA-STAD		s14618	Harvard Medical School	Asterand	Ukraine	NO	T3	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIA	1798-02	True	STAD	C3	GI.GS	0.42500251899999997	0.77	0.45	9.694220652	-0.3455	-0.0985	0.5359	1.7006	-0.1518	0.762			0.924417782	2.773253347	90.0	0.166781705	8.0	14.0	0.7980269190000001	4.850122117	436.0	4.422367536	119.0	0.9253511740000001	2.119165064	-217.6824353	-269.2042361	328.8282373	0.0	416.0	0.0	416.0	8.1084727905874	9.266121912434944	0.3563000610852324	6.1989302857029625	7.839005556794797	3.0054026785856736	-1.9095425048844386	-1.4271163556401456	2.649102617500441
13722.58cfa830e4b0c9d6adf6bfa8	58cfa830e4b0c9d6adf6bfa8	TCGA-BR-6454-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BR-6454-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_6_rg.sorted	TCGA-BR-6454-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_6_rg.sorted.bam	478.4	1.9	0.14	58cfa830e4b0c9d6adf6bfa8	TCGA-BR-6454-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6454-01A	AC2CBCE4-4BA8-42C9-AC61-70F42995588E	Primary Tumor	Illumina HiSeq	e344c34d-da8c-4145-8a02-b9ae248ca3a3	Stomach	58.0	E7D94421-7A3B-4100-9CBF-1B1F2EC07737	6F5506E4-8375-4F62-8B85-64FD729C6136	TCGA-BR-6454-01A-11D-1798-02	HG19_Broad_variant	TCGA-BR-6454	TCGA-STAD		s14619	Harvard Medical School	Asterand	Russia	NO	T3	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIA	1798-02	True	STAD	C2	GI.CIN	0.38438392	0.63	0.18	50.97562736	0.5009	0.0465	0.5864	2.0149	0.8170000000000001	0.0163			1.2473432309999999	3.5099658369999998	113.0	0.540212271	20.0	34.0	0.795346695	4.807874996000001	422.0	4.741883045	273.0	0.845335037		336.29564980000004	546.0980927999999	1923.091708	0.0	0.0	0.0	0.0	7.49517150490984	7.7798154359428775	0.32474860271689265	5.59805152002396	6.627135926004492	2.275215721683333	-1.897119984885881	-1.1526795099383853	1.95046711896644
13722.58cfa830e4b0c9d6adf6bfa9	58cfa830e4b0c9d6adf6bfa9	TCGA-BR-6456-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BR-6456-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_1_rg.sorted	TCGA-BR-6456-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_1_rg.sorted.bam	282.7	1.9	0.15	58cfa830e4b0c9d6adf6bfa9	TCGA-BR-6456-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6456-01A	1CA3C5E0-32B0-4467-8EC0-CA212E35D2B3	Primary Tumor	Illumina HiSeq	a772744a-8f77-4f03-adaf-cbd5db4ba399	Stomach	74.0	53369A25-3BC4-48CB-9004-DA3507C4D478	B2D5157F-5D0A-451C-8E78-AFFFC67B2F68	TCGA-BR-6456-01A-11D-1798-02	HG19_Broad_variant	TCGA-BR-6456	TCGA-STAD		s14399	Harvard Medical School	Asterand	Russia	NO	T3	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIB	1798-02	True	STAD	C2	GI.CIN	0.218351293	0.7	0.15	9.410818419	0.5509	0.005	0.4635	0.8189	0.8378	0.7137			0.352767449	0.91131591	257.0	0.549682656	20.0	43.0	0.83278864	4.205462719	156.0	5.08687235	206.0	0.9547654990000001	4.737923747	-103.1117772	523.6502498	-2155.092206	1.0	526.0	0.0	526.0	7.187405179736653	7.358512376282009	-0.4121362469251866	5.341578489238323	6.317058501453848	7.5968944381445445	-1.8458266904983305	-1.0414538748281612	8.009030685069732
13722.58cfa830e4b0c9d6adf6bfc0	58cfa830e4b0c9d6adf6bfc0	TCGA-B5-A0JS-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_4_rg.sorted.filtered.	WGS	TCGA-B5-A0JS-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_4_rg.sorted	TCGA-B5-A0JS-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_4_rg.sorted.bam	61.49	1.87	0.17	58cfa830e4b0c9d6adf6bfc0	TCGA-B5-A0JS-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0JS-01A	0DA7BBD4-ED8D-474B-B494-CB93C5FA811E	Primary Tumor	Illumina HiSeq	06607d3e-b9f0-4332-aee8-7001d26e7d12	Uterus	54.0	D0B88B1C-150D-4ABC-9F9E-8C51CB208EFA	D2DD7ED4-03F6-463E-94BD-6CF98D80E8FD	TCGA-B5-A0JS-01A-11D-A101-02	HG19_Broad_variant	TCGA-B5-A0JS	TCGA-UCEC		s5208	Harvard Medical School	Duke	United States	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C3	UCEC.CN_LOW	0.13496497	0.35	0.0	8.16971582	-0.4385	-0.035	-0.0746	0.5732	-0.6277	0.1189	10.0	0.0	0.17085335199999999	0.768840085	88.0	0.019541054	1.0	1.0							2.606778053	-864.1903812999999	-881.8012197999999	-966.7605751	0.0	2627.0	0.0	2627.0	6.170371188801868	7.325514869628581	-0.3463586924862505	5.547841575455876	6.226902580960472	7.230080294877457	-0.6225296133459919	-1.0986122886681096	7.576438987363708
13722.58cfa830e4b0c9d6adf6bfd6	58cfa830e4b0c9d6adf6bfd6	TCGA-AG-3728-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3728-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3728-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	650.31	1.9	0.14	58cfa830e4b0c9d6adf6bfd6	TCGA-AG-3728-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3728-01A	856A490C-C6DA-48FE-88B5-9FDE0F481365	Primary Tumor	Illumina HiSeq	d36f782a-483a-478d-a9a6-22f626b032bb	Colorectal	73.0	019EB82B-4A2D-4E67-99A6-FE10B0ABCB70	DF699DEA-C800-47D0-A526-A6C7A610041A	TCGA-AG-3728-01A-01D-1115-02	HG18	TCGA-AG-3728	TCGA-READ		s2137	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Rectal Adenocarcinoma	Stage IIIB	1115-02	True	READ	C3					25.21544635	-0.3585	-0.14400000000000002	0.0299	1.3328	-0.5501	0.3684					130.0	0.504954669	16.0	14.0							0.962070918	-1225.494557	-1056.0460970000001	2841.575206	0.0	912.0	0.0	912.0	5.131541021089544	6.15859188916102	-0.06117559613660439	4.540672689650017	6.369900982828226	3.955207424615784	-0.5908683314395269	0.2113090936672064	4.0163830207523885
13722.58cfa830e4b0c9d6adf6bfdf	58cfa830e4b0c9d6adf6bfdf	TCGA-BR-6801-01A-11D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BR-6801-01A-11D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_5_rg.sorted	TCGA-BR-6801-01A-11D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_5_rg.sorted.bam	172.7	1.9	0.15	58cfa830e4b0c9d6adf6bfdf	TCGA-BR-6801-01A-11D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6801-01A	24FED326-BDCF-4C20-A06E-7C1C3D6C9CC5	Primary Tumor	Illumina HiSeq	48843aff-35a1-472b-a298-6489ad1b7de7	Stomach	70.0	713F11EE-D285-4A3B-B421-1D416E5F8E52	FDD2EE8C-C74B-49B8-A530-8CC171C34804	TCGA-BR-6801-01A-11D-1880-02	HG19_Broad_variant	TCGA-BR-6801	TCGA-STAD		s15450	Harvard Medical School	Asterand	Russia	NO	T3	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIA	1880-02	True	STAD	C1	GI.CIN	0.181032759	0.32	0.55	3.9912430939999997	0.0997	0.0375	-0.4268	-1.0729	-0.3676	0.4925			0.52116369	1.013373842	156.0	0.853433784	6.0	9.0				2.479955521	13.0	0.966863347	1.883567325	-1040.254543	-511.3075627	-751.8282264	0.0	1223.0	0.0	1223.0	7.974532844130229	7.235750125414308	-0.8666067459239402	5.77730826679401	6.266349568226204	1.9762642023530659	-2.197224577336219	-0.9694005571881035	2.842870948277006
13722.58cfa830e4b0c9d6adf6bfe8	58cfa830e4b0c9d6adf6bfe8	TCGA-BR-6565-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BR-6565-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_7_rg.sorted	TCGA-BR-6565-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_7_rg.sorted.bam	338.7	1.9	0.14	58cfa830e4b0c9d6adf6bfe8	TCGA-BR-6565-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6565-01A	DAECEA36-B379-46CE-8AE9-A38D22556CE2	Primary Tumor	Illumina HiSeq	8cfafa49-f561-4e59-98c5-b9a816534417	Stomach	67.0	1D7AAE07-2453-4DC3-A26D-D67161172648	E5F188AD-28C2-4AD0-89DD-C13493CE4B03	TCGA-BR-6565-01A-11D-1798-02	HG19_Broad_variant	TCGA-BR-6565	TCGA-STAD		s14881	Harvard Medical School	Asterand	Russia	NO	T4a	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIB	1798-02	True	STAD	C2	GI.CIN	0.28470665100000003	0.68	0.42	8.727746417999999	0.8485	0.156	0.5588	1.1911	0.6176	0.2743			0.989183655	3.6076109769999998	214.0	0.663876794	23.0	33.0	0.8724122059999999	5.149529369	366.0	4.359274736000001	202.0	0.821223605	3.171869879	-46.83260304	628.7790457000001	-2314.7882050000003	1.0	279.0	1.0	279.0	7.483806687665835	8.184188270037334	-0.9657298624918946	5.085911414867464	6.3383615795390025	0.9599317857592513	-2.3978952727983707	-1.8458266904983307	1.925661648251146
13722.58cfa830e4b0c9d6adf6bfea	58cfa830e4b0c9d6adf6bfea	TCGA-AG-3885-01A-01D-0967-10_wgs_Illumina.filtered.	WGS	TCGA-AG-3885-01A-01D-0967-10_wgs_Illumina	TCGA-AG-3885-01A-01D-0967-10_wgs_Illumina.bam	688.31	1.9	0.15	58cfa830e4b0c9d6adf6bfea	TCGA-AG-3885-01A-01D-0967-10_wgs_Illumina.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3885-01A	E5E4AA9F-6015-4D62-A088-69920D7F2500	Primary Tumor	Illumina HiSeq	f75ec564-baa7-4aeb-8c4e-21e77d60669d	Colorectal	71.0	7764DB67-5D9E-4421-86C6-7151ACA688D1	BB6150F7-23E4-40F2-B466-6B6EDD19C502	TCGA-AG-3885-01A-01D-0967-10	GRCh37-lite	TCGA-AG-3885	TCGA-READ		s1964	Baylor College of Medicine	Indivumed	Germany	NO	T3	N1	Rectal Adenocarcinoma	Stage IIIB	0967-10	False	READ	C3	GI.CIN	0.06986483	0.24	0.21	7.907829275	-0.0273	-0.066	-0.569	0.3689	-1.2481	0.0306	48.0	39.0	0.7157878240000001	2.614181618	228.0	0.47968001299999996	13.0	12.0							0.64494896	-1168.0736650000001	-1027.482191	2265.873325	0.0	546.0	0.0	546.0	7.087740775978543	4.359775458588267	-0.4512104303537641	5.606136235054327	7.164952370421199	4.500842728273378	-1.4816045409242158	2.805176911832932	4.952053158627143
13722.58cfa830e4b0c9d6adf6bff8	58cfa830e4b0c9d6adf6bff8	TCGA-AG-3887-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3887-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3887-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	745.89	1.9	0.15	58cfa830e4b0c9d6adf6bff8	TCGA-AG-3887-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3887-01A	8C7CCDB0-7653-4A8D-86B6-DE39AFC40765	Primary Tumor	Illumina HiSeq	0041b462-7ad7-4a4d-8fea-1942532341ed	Colorectal	68.0	7F10DD13-E2C3-4F27-8673-FF5CD1632B2B	5986038D-2696-4F89-A5F5-C8173BA7D70F	TCGA-AG-3887-01A-01D-1115-02	HG18	TCGA-AG-3887	TCGA-READ		s2136	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Mucinous Adenocarcinoma	Stage IIA	1115-02	True	READ	C1	GI.CIN	0.055162540999999995	0.17	0.0	7.242231179	0.986	0.331	-0.5292	0.4802	-0.8756	0.0352	43.0		0.6137172470000001	1.84115174	98.0	0.18545603	8.0	8.0							0.8071641409999999	-1376.54102	191.0762671	-518.8277003000001	0.0	1124.0	1.0	1064.0	6.153498358955215	4.952687267181801	0.2895594431830354	4.977925029150977	5.192260761313552	0.689328238481744	-1.1755733298042386	0.23957349413175066	0.39976879529870857
13722.58cfa830e4b0c9d6adf6bffa	58cfa830e4b0c9d6adf6bffa	TCGA-AG-3878-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3878-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3878-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	360.61	1.9	0.15	58cfa830e4b0c9d6adf6bffa	TCGA-AG-3878-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3878-01A	FDEEFF8E-1328-42A4-ACA0-A03B97421F1E	Primary Tumor	Illumina HiSeq	df3192f9-1041-4ef9-80aa-2f3e263fa968	Colorectal	64.0	D2F28259-87A7-4BD8-84BC-832E551C1ACE	8F233F73-550A-4708-9C2C-BEA9347969F7	TCGA-AG-3878-01A-02D-1167-02	HG18	TCGA-AG-3878	TCGA-READ		s2127	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Rectal Adenocarcinoma	Stage I	1167-02	True	READ	C3	GI.GS	0.23450769300000002	0.58	0.09	11.25956674	-0.2171	-0.217	-0.0127	1.0186	-0.544	0.5987	50.0	13.0	0.512378322	2.682451214	43.0	0.144047023	8.0	0.0							0.682635164	-1239.611365	-1140.246106	1878.909323	0.0	30.0	0.0	30.0	8.422314585137327	6.261930003759791	0.012312500288817807	6.070939327973849	5.123577386442168	1.8369922072769058	-2.3513752571634776	-1.138352617317623	1.8246797069880882
13722.58cfa830e4b0c9d6adf6bffc	58cfa830e4b0c9d6adf6bffc	TCGA-AG-3890-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3890-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3890-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	614.89	1.9	0.15	58cfa830e4b0c9d6adf6bffc	TCGA-AG-3890-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3890-01A	E2D395F8-BF13-4FE4-8031-683B0EEDD875	Primary Tumor	Illumina HiSeq	b4bf7544-0816-4940-aa9f-d770f09f35f3	Colorectal	62.0	DB70A6DD-DE09-4ED7-916C-708B21734500	12064771-AE96-441D-BE8B-EE49B63F1E4E	TCGA-AG-3890-01A-01D-1115-02	HG18	TCGA-AG-3890	TCGA-READ		s2145	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Rectal Adenocarcinoma	Stage I	1115-02	True	READ	C1	GI.CIN	0.184366589	0.29	0.54	14.40303525	0.3755	0.023	-0.1392	1.0402	-0.5787	0.0309	55.0	63.0			185.0	0.501152942	7.0	26.0							0.995981417	-1458.486919	-396.9077121	-441.5665663	0.0	518.0	0.0	518.0	6.519080243590533	5.95507838424712	-0.5216039371399058	5.420467954922424	6.364121313703167	2.098144268754017	-1.0986122886681091	0.4090429294560476	2.6197482058939223
13722.58cfa830e4b0c9d6adf6c005	58cfa830e4b0c9d6adf6c005	TCGA-B3-4103-01A-02D-1402-10_wgs_Illumina.filtered.	WGS	TCGA-B3-4103-01A-02D-1402-10_wgs_Illumina	TCGA-B3-4103-01A-02D-1402-10_wgs_Illumina.bam	216.07	1.9	0.05	58cfa830e4b0c9d6adf6c005	TCGA-B3-4103-01A-02D-1402-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-B3-4103-01A	1A726069-0B44-42AD-9A20-0EE90B31796B	Primary Tumor	Illumina HiSeq	e00b0cfe-8b23-4f21-998f-957efbc26955	Kidney	56.0	3829FA12-FDD5-4829-8F00-BDFBB057F23E	1DA96C26-20A5-435A-8CA3-9F698B8652A2	TCGA-B3-4103-01A-02D-1402-10	GRCh37-lite	TCGA-B3-4103	TCGA-KIRP		s11853	Baylor College of Medicine	Christiana Healthcare	None	NO	T1a	NX	Kidney Papillary Renal Cell Carcinoma	Stage I	1402-10	False	KIRP	C3	KIRP.C1	0.224020351				-1.6363	-0.2765	0.1917	-0.6742	-0.5046	-0.2577	25.0	1.0	0.388620762	1.138103661	61.0	0.8488251520000001	12.0	0.0				2.441015278	12.0	0.982336813	2.231070046	-561.4163442	-1538.168111	-505.5333297	0.0	930.0	0.0	930.0	6.827629234502852	3.1616349595556548	0.026828435891713576	4.370893461681549	2.5528073643196274	6.226931848111024	-2.456735772821304	-0.6088275952360274	6.20010341221931
13722.58cfa830e4b0c9d6adf6c00e	58cfa830e4b0c9d6adf6c00e	TCGA-B3-3926-01A-02D-1402-10_wgs_Illumina.filtered.	WGS	TCGA-B3-3926-01A-02D-1402-10_wgs_Illumina	TCGA-B3-3926-01A-02D-1402-10_wgs_Illumina.bam	191.07	1.9	0.05	58cfa830e4b0c9d6adf6c00e	TCGA-B3-3926-01A-02D-1402-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-B3-3926-01A	2666AB3E-F2B9-4B3D-BFCE-AAC2A4BAFE62	Primary Tumor	Illumina HiSeq	7825c6ac-6e33-4e1d-82cc-35cf60c16253	Kidney	59.0	3BB75DF9-E710-4F3D-B1B1-A4D459EB376F	72293A70-9DC8-4E4A-ACDC-C74587A90420	TCGA-B3-3926-01A-02D-1402-10	GRCh37-lite	TCGA-B3-3926	TCGA-KIRP		s11582	Baylor College of Medicine	Christiana Healthcare	None	NO	T1	NX	Kidney Papillary Renal Cell Carcinoma	Stage I	1402-10	False	KIRP	C3	KIRP.C1	0.07384742400000001	0.06	0.77		-1.4903	-0.2605	0.1008	-1.0384	-0.4803	-0.2944	4.0	15.0	0.0	0.31248711	83.0	0.947733499	12.0	0.0				2.25385759	10.0	0.9788379140000001	2.018040699	-1149.997538	-1125.382524	-43.57368885	0.0	883.0	0.0	883.0	5.786432502924047	1.9288133915091308	0.05367583183279423	5.786432502924047	3.4139627783998856	4.68861136762074	0.0	1.4851493868907548	4.634935535787945
13722.58cfa830e4b0c9d6adf6c010	58cfa830e4b0c9d6adf6c010	TCGA-B5-A0K0-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_7_rg.sorted.filtered.	WGS	TCGA-B5-A0K0-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_7_rg.sorted	TCGA-B5-A0K0-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_7_rg.sorted.bam	106.93	1.95	0.16	58cfa830e4b0c9d6adf6c010	TCGA-B5-A0K0-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0K0-01A	29C8F468-5AC1-4D6C-8376-E36E6D246926	Primary Tumor	Illumina HiSeq	e5550bf6-3edf-480e-9dc5-6d590e837e5e	Uterus	48.0	11C43948-E7C9-4436-A654-82FA8033B625	3296C785-7C20-487D-BAEC-C66022E77E53	TCGA-B5-A0K0-01A-11D-A043-02	HG19_Broad_variant	TCGA-B5-A0K0	TCGA-UCEC		s4598	Harvard Medical School	Duke	United States	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C1	UCEC.CN_LOW	0.190545054			22.46429525	-0.1344	-0.054000000000000006	0.2164	0.2847	-0.1471	0.3718	9.0	0.0	0.14607725300000002	0.525878111	58.0	0.088807446	3.0	1.0							2.269278766	-791.8938086	-472.3800669	-1945.3798370000002	0.0	1478.0	0.0	1478.0	4.46497210200538	6.578880773035685	-0.7488803103501094	3.8888814768664517	5.176057109964584	1.8934255332209804	-0.576090625138928	-1.4028236630711013	2.6423058435710898
13722.58cfa830e4b0c9d6adf6c01c	58cfa830e4b0c9d6adf6c01c	TCGA-B5-A0K7-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_8_rg.sorted.filtered.	WGS	TCGA-B5-A0K7-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_8_rg.sorted	TCGA-B5-A0K7-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_8_rg.sorted.bam	106.4	2.0	0.15	58cfa830e4b0c9d6adf6c01c	TCGA-B5-A0K7-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0K7-01A	2F0640BC-598C-4714-9E9B-7E0F2CA4567F	Primary Tumor	Illumina HiSeq	b1ac8e27-775c-4d91-8a4d-9d096cde589d	Uterus	64.0	51E8577D-6849-422E-8F37-2EA8C400BBE5	ED30E619-1EBE-4CCE-B7FD-93B552953B65	TCGA-B5-A0K7-01A-11D-A101-02	HG19_Broad_variant	TCGA-B5-A0K7	TCGA-UCEC		s5390	Harvard Medical School	Duke	United States	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C3	UCEC.CN_LOW	0.164332805	0.27	0.0	10.72851227	-0.1906	-0.015	0.1754	1.0059	-0.0122	-0.1316	24.0	1.0	0.450079925	1.200213134	56.0	0.118320219	3.0	1.0							2.732431762	-1086.596179	89.98286378	934.8215256000001	0.0	1933.0	1.0	322.0	6.344359629087981	7.646353722445999	0.18273728650005006	5.889623471973033	6.358499434139361	2.877046985352583	-0.4547361571149473	-1.2878542883066384	2.694309698852533
13722.58cfa830e4b0c9d6adf6c01e	58cfa830e4b0c9d6adf6c01e	TCGA-BJ-A0Z2-01A-11D-A10R_120711_SN208_0414_BD13L5ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BJ-A0Z2-01A-11D-A10R_120711_SN208_0414_BD13L5ACXX_s_1_rg.sorted	TCGA-BJ-A0Z2-01A-11D-A10R_120711_SN208_0414_BD13L5ACXX_s_1_rg.sorted.bam	89.84	1.92	0.14	58cfa830e4b0c9d6adf6c01e	TCGA-BJ-A0Z2-01A-11D-A10R_120711_SN208_0414_BD13L5ACXX_s_1_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0Z2-01A	F9CEFFC0-D544-418D-B4A9-BD3C84E37026	Primary Tumor	Illumina HiSeq	9493c81d-440a-4066-975b-c6265b7641a6	Thyroid	57.0	B06B7493-F38A-493F-8B47-61E0FA4D111F	D8B6F131-76CA-45D3-8934-A6CDEA8153AD	TCGA-BJ-A0Z2-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0Z2	TCGA-THCA		s12353	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage IVC	A10R-02	True	THCA	C3	THCA.1	0.019618853999999998	0.03	0.0		-0.8832	-0.3535	-0.922	-1.1556	-0.925	-0.4405	8.0	3.0	0.169364602	0.39518407200000005	61.0	0.011035305	0.0	0.0				1.791759469	6.0	1.0	1.45546468	-1399.837385	-631.9459477	1818.829332	0.0	1514.0	1.0	158.0	7.4353537347624545	8.42836197770962	-1.3008881966934387	6.410849418248067	7.1755990092142525	0.6454466108720429	-1.024504316514388	-1.252762968495368	1.9463348075654816
13722.58cfa830e4b0c9d6adf6c022	58cfa830e4b0c9d6adf6c022	TCGA-BJ-A0ZE-01A-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BJ-A0ZE-01A-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_4_rg.sorted	TCGA-BJ-A0ZE-01A-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_4_rg.sorted.bam	36.9	2.03	0.15	58cfa830e4b0c9d6adf6c022	TCGA-BJ-A0ZE-01A-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0ZE-01A	AB8C9101-ADEB-4C43-A8BB-B089EBD711F6	Primary Tumor	Illumina HiSeq	b215d9c2-6a64-45cf-8e4b-0e2b87207119	Thyroid	63.0	695C5627-F442-4A86-9702-EF35DEFD8C8C	ED0B1C86-A516-422F-92C4-7C535E709989	TCGA-BJ-A0ZE-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0ZE	TCGA-THCA		s12231	Harvard Medical School	University of Pittsburgh	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A10R-02	True	THCA	C3	THCA.1	0.04604256	0.27	0.0		-1.6713	-0.244	-1.1628	-1.4041	-1.0973	-0.9057	8.0	0.0	0.084361534	0.337446136	37.0	2.46e-05	0.0	0.0				0.0	1.0		0.921170597	-573.37163	-1265.5602939999999	796.3313831	0.0	509.0	0.0	509.0	7.628335216943322	8.082772898852653	-0.06787596891365733	6.1814162340069965	7.089521125842369	1.3633048428951917	-1.4469189829363258	-0.9932517730102832	1.4311808118088492
13722.58cfa830e4b0c9d6adf6c024	58cfa830e4b0c9d6adf6c024	TCGA-AX-A0J1-01A-11D-A043_120403_SN1222_0094_BD0UKBACXX_s_4_rg.sorted.filtered.	WGS	TCGA-AX-A0J1-01A-11D-A043_120403_SN1222_0094_BD0UKBACXX_s_4_rg.sorted	TCGA-AX-A0J1-01A-11D-A043_120403_SN1222_0094_BD0UKBACXX_s_4_rg.sorted.bam	87.89	1.88	0.15	58cfa830e4b0c9d6adf6c024	TCGA-AX-A0J1-01A-11D-A043_120403_SN1222_0094_BD0UKBACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AX-A0J1-01A	EC7A9D74-8B3F-4747-8926-1739A016AB2B	Primary Tumor	Illumina HiSeq	7bce686e-1ac7-49b4-9b2f-c76eec80a77c	Uterus	80.0	AC14E378-2DE1-458A-B8CD-7C60131AA927	3612DB54-D93C-47FB-A5E7-3BA3CE404A3C	TCGA-AX-A0J1-01A-11D-A043-02	HG19_Broad_variant	TCGA-AX-A0J1	TCGA-UCEC		s4594	Harvard Medical School	Gynecologic Oncology Group	None	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C1	UCEC.POLE	0.165305218	0.22	0.02	2.831382365	0.7809999999999999	0.304	-0.3665	0.2969	-1.0899	-0.2345	2620.0	2991.0	54.62686897	149.3293449	56.0	0.034093745	1.0	2.0							2.785401515	-1246.3692	447.9276438999999	2811.601453	0.0	2354.0	0.0	2354.0	5.233919186439395	5.389868686931677	0.3248590201380367	4.056614629195621	5.72634092355289	1.162906639373507	-1.1773045572437741	0.33647223662121295	0.8380476192354702
13722.58cfa830e4b0c9d6adf6c026	58cfa830e4b0c9d6adf6c026	TCGA-BJ-A0ZB-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BJ-A0ZB-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_4_rg.sorted	TCGA-BJ-A0ZB-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_4_rg.sorted.bam	79.63	2.0	0.16	58cfa830e4b0c9d6adf6c026	TCGA-BJ-A0ZB-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0ZB-01A	DC4D8468-6F34-40CB-A826-8D582CD86FDE	Primary Tumor	Illumina HiSeq	72ce31c8-5889-450a-ac21-159c97d9b125	Thyroid	66.0	145A474E-D262-468A-8DB7-EE9F1B7CE0A7	EBAA6AE4-66C0-49A7-938C-620E24564846	TCGA-BJ-A0ZB-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0ZB	TCGA-THCA		s12097	Harvard Medical School	University of Pittsburgh	United States	NO	T3	N1b	Thyroid Papillary Carcinoma - Classical/usual	Stage IVA	A10R-02	True	THCA	C3	THCA.4	0.051433805	0.33	0.01		-1.535	-0.29	-0.5715	-0.6734	-0.6039	-0.0314	18.0	1.0	0.226859308	0.9074372340000001	57.0	0.018293262	0.0	0.0				2.582306344	14.0	0.978495736	0.8373336570000001	-292.7745836	-929.1002110999999	2210.018689	0.0	122.0	0.0	122.0	6.732841510763575	8.330368880845837	-0.2910428255928812	5.828385236536423	7.637221700285892	3.7159372522912877	-0.9044562742271518	-0.6931471805599454	4.006980077884169
13722.58cfa830e4b0c9d6adf6c02a	58cfa830e4b0c9d6adf6c02a	TCGA-AX-A0IW-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-AX-A0IW-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_3_rg.sorted	TCGA-AX-A0IW-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_3_rg.sorted.bam	112.67	1.79	0.14	58cfa830e4b0c9d6adf6c02a	TCGA-AX-A0IW-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AX-A0IW-01A	DB21FCCF-40CB-4235-A34D-336A03B8C8F4	Primary Tumor	Illumina HiSeq	26dfa889-ba7c-4cc0-8adc-59d5eb4e4026	Uterus	67.0	874A1C5C-229B-4BCE-B612-55EFF238D533	CFB35E8C-470B-4F9E-B7C1-63FCAA162F3C	TCGA-AX-A0IW-01A-11D-A043-02	HG19_Broad_variant	TCGA-AX-A0IW	TCGA-UCEC		s4422	Harvard Medical School	Gynecologic Oncology Group	None	NO			Serous endometrial adenocarcinoma		A043-02	True	UCEC	C2	UCEC.CN_HIGH	0.089105368	0.18	0.29	0.08194242	0.5402	0.20800000000000002	-0.8825	-0.4751	1.4811	0.0287	31.0		0.486116734	1.519114794	402.0	0.9176000959999999	14.0	41.0							3.2213989389999997	-1759.447177	-294.2454894	480.5656004	0.0	1149.0	0.0	1149.0	4.353406677293833	6.129050210060544	0.3741305096298281	3.848311728236827	3.9160772757561864	3.420655952529687	-0.5050949490570056	-2.212972934304358	3.046525442899859
13722.58cfa830e4b0c9d6adf6c02c	58cfa830e4b0c9d6adf6c02c	TCGA-BJ-A0ZC-01A-12D-A13U_120706_SN1222_0123_BD1488ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BJ-A0ZC-01A-12D-A13U_120706_SN1222_0123_BD1488ACXX_s_1_rg.sorted	TCGA-BJ-A0ZC-01A-12D-A13U_120706_SN1222_0123_BD1488ACXX_s_1_rg.sorted.bam	26.88	1.91	0.16	58cfa830e4b0c9d6adf6c02c	TCGA-BJ-A0ZC-01A-12D-A13U_120706_SN1222_0123_BD1488ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0ZC-01A	6675C581-297D-44CD-B80F-AE7E53D48228	Primary Tumor	Illumina HiSeq	a470b305-96a5-43a8-b1f4-db15c7b0b4d5	Thyroid	55.0	1F945AFF-7BC2-40F5-87DB-92313E541243	0E4A0528-883D-47A5-B399-57B1B15EC412	TCGA-BJ-A0ZC-01A-12D-A13U-02	HG19_Broad_variant	TCGA-BJ-A0ZC	TCGA-THCA		s12232	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A13U-02	True	THCA	C3	THCA.1	0.078934457	0.24	0.0		-2.4381	-0.396	-0.986	-0.8714	-0.3386	-0.622	6.0		0.057987612	0.086981419	41.0	0.014757171000000001	0.0	2.0		0.0	1.0	1.098612289	3.0	1.0	1.4129880769999998	-1286.6066759999999	-780.5237093999999	2631.941823	0.0	352.0	0.0	352.0	6.750772467453286	9.522193344965276	0.22252209182053695	6.089373985207922	8.590635140960332	2.1850571268454857	-0.6613984822453651	-0.9315582040049435	1.9625350350249489
13722.58cfa830e4b0c9d6adf6c032	58cfa830e4b0c9d6adf6c032	TCGA-BR-6852-01A-11D-1880_130115_SN590_0207_AC1H8PACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BR-6852-01A-11D-1880_130115_SN590_0207_AC1H8PACXX_s_7_rg.sorted	TCGA-BR-6852-01A-11D-1880_130115_SN590_0207_AC1H8PACXX_s_7_rg.sorted.bam	385.7	1.9	0.15	58cfa830e4b0c9d6adf6c032	TCGA-BR-6852-01A-11D-1880_130115_SN590_0207_AC1H8PACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6852-01A	44799C67-61CD-4F3E-BDBC-423E2E0FD2E8	Primary Tumor	Illumina HiSeq	bff2f642-516a-4072-95aa-f213a4555f79	Stomach	64.0	F230ED0B-8D08-4546-9762-923097B4BF02	20F8131D-3F7E-47C5-AE84-A3886A387514	TCGA-BR-6852-01A-11D-1880-02	HG19_Broad_variant	TCGA-BR-6852	TCGA-STAD		s15387	Harvard Medical School	Asterand	Ukraine	NO	T3	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIA	1880-02	True	STAD	C2	GI.HM-indel	0.480599899	0.65	0.07	24.31713101	0.72	0.2155	1.0306	2.0896	1.6480000000000001	0.4021			8.842388897000001	25.92427654	91.0	0.057290959	2.0	2.0	0.771513608	4.4527453669999995	321.0	5.074082466	251.0	0.918310684	1.800259655	265.4824338	669.3868249	-132.14565430000002	0.0	1367.0	0.0	1367.0	6.124683390894204	5.575949103146316	0.018174259100801615	3.927458813557985	4.534495228318155	1.5400790489216898	-2.197224577336219	-1.0414538748281612	1.521904789820888
13722.58cfa830e4b0c9d6adf6c03c	58cfa830e4b0c9d6adf6c03c	TCGA-AG-4001-01A-02D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-4001-01A-02D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-4001-01A-02D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	420.89	1.9	0.15	58cfa830e4b0c9d6adf6c03c	TCGA-AG-4001-01A-02D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-4001-01A	D846228F-67AF-4B3B-9796-DBC263C2054C	Primary Tumor	Illumina HiSeq	53c6af7e-4876-4559-b1b1-d7dc58c2b702	Colorectal	74.0	6160C363-B050-4B3B-9909-4EBC33ED3A1A	05B6BA78-DDE8-4E68-9622-7B618A083CC8	TCGA-AG-4001-01A-02D-1115-02	HG18	TCGA-AG-4001	TCGA-READ		s2164	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage IIA	1115-02	True	READ	C1	GI.CIN	0.167939737	0.52	0.24	27.79547868	0.4129	0.084	0.0615	-0.1642	-0.154	0.4604	52.0	28.0	1.095867381	3.190907962	126.0	0.695696236	17.0	20.0							2.612913858	-1522.091483	-438.30870130000005	142.1427802	0.0	1096.0	0.0	1096.0	5.946153324397979	5.265277512469836	-0.6888767114364929	4.665219478935915	5.5077029933334956	1.8012742888693938	-1.2809338454620645	0.2424254808636599	2.490151000305887
13722.58cfa830e4b0c9d6adf6c044	58cfa830e4b0c9d6adf6c044	TCGA-AG-3893-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3893-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3893-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	551.89	1.9	0.15	58cfa830e4b0c9d6adf6c044	TCGA-AG-3893-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3893-01A	ADD567B7-29EF-4122-8A54-57D36F735E78	Primary Tumor	Illumina HiSeq	d98305fc-80c0-4336-b35c-0c47d8c297b8	Colorectal	74.0	7E16AFE9-DA05-451B-BD8C-86D75C8E475C	5815181B-A53B-4AAF-9817-168AC41DAD2A	TCGA-AG-3893-01A-01D-1115-02	HG18	TCGA-AG-3893	TCGA-READ		s2152	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Rectal Adenocarcinoma	Stage IIIB	1115-02	True	READ	C1	GI.CIN	0.08262618599999999	0.28	0.13	12.68272163	0.4622	0.11199999999999999	-0.2597	-0.5781	-0.5741	0.2672	60.0	12.0			156.0	0.326965353	9.0	23.0							2.803122058	-1123.424109	-277.5146727	1347.814058	0.0	1065.0	0.0	1065.0	5.89057431158106	5.342137110515183	-0.18012874520184463	4.06187132716132	5.57279949424342	1.8973546991223773	-1.8287029844197393	0.23066238372823733	2.077483444324222
13722.58cfa830e4b0c9d6adf6c046	58cfa830e4b0c9d6adf6c046	TCGA-B2-4102-01A-02D-2095-10_wgs_Illumina.filtered.	WGS	TCGA-B2-4102-01A-02D-2095-10_wgs_Illumina	TCGA-B2-4102-01A-02D-2095-10_wgs_Illumina.bam	142.77	1.9	0.16	58cfa830e4b0c9d6adf6c046	TCGA-B2-4102-01A-02D-2095-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-B2-4102-01A	BBBCE1BA-C739-43BA-B9CF-A4F746491AE3	Primary Tumor	Illumina HiSeq	08200438-3da7-446b-99d7-c23e7cbfb2b5	Kidney	61.0	0A187E9E-FAE3-4B9F-B6ED-23CF0FFCB39E	39C55051-E1BC-4081-962A-17205645DE45	TCGA-B2-4102-01A-02D-2095-10	GRCh37-lite	TCGA-B2-4102	TCGA-KIRC		s9734	Baylor College of Medicine	Christiana Healthcare	None	NO	T1b	NX	Kidney Clear Cell Renal Carcinoma	Stage I	2095-10	False	KIRC	C3	KIRC.1	0.293631595	0.51	0.03		-1.4223	-0.3405	1.0291	0.594	0.7401	-0.0678	25.0	103.0	0.551147144	1.405425217	121.0	0.081844032	0.0	4.0	0.9171479379999999	1.9071555230000001	8.0	3.626656184	40.0	0.9831322029999999	1.7170155580000002	314.5913329	-831.4660703	3783.7470049999997	0.0	952.0	0.0	952.0	8.310628833894864	1.8703410200177668	0.34859276000807315	5.386415912619785	4.7399970354422525	4.559383702969763	-2.924212921275079	2.8696560154244857	4.210790942961689
13722.58cfa830e4b0c9d6adf6c048	58cfa830e4b0c9d6adf6c048	TCGA-B3-3925-01A-02D-1402-10_wgs_Illumina.filtered.	WGS	TCGA-B3-3925-01A-02D-1402-10_wgs_Illumina	TCGA-B3-3925-01A-02D-1402-10_wgs_Illumina.bam	241.07	1.9	0.05	58cfa830e4b0c9d6adf6c048	TCGA-B3-3925-01A-02D-1402-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-B3-3925-01A	75A53BFF-BF0F-4AD8-9B8E-14A27914D4F2	Primary Tumor	Illumina HiSeq	9130f58c-9250-4f4f-a60d-028366b76852	Kidney	52.0	16223531-33C3-4D2C-8715-FA9899CEE168	42F88B95-FA12-47C7-93F1-CF72F207291C	TCGA-B3-3925-01A-02D-1402-10	GRCh37-lite	TCGA-B3-3925	TCGA-KIRP		s11770	Baylor College of Medicine	Christiana Healthcare	None	NO	T3a	NX	Kidney Papillary Renal Cell Carcinoma	Stage III	1402-10	False	KIRP	C3	KIRP.C1	0.17334782899999998	0.28	0.01		-1.8408	-0.3535	0.627	-0.0354	-0.0395	-0.2442	25.0	17.0	0.5795256089999999	1.655787453	59.0	0.17085177699999998	8.0	0.0				3.193148395	25.0	0.992007324	1.8829260419999998	-330.2548045	-1405.8251599999999	1187.468567	0.0	1029.0	0.0	1029.0	5.375187626512117	2.138462971683362	0.2166948877876762	5.780652734620282	3.6234085319764144	3.140683256482826	0.40546510810816416	1.4849455602930526	2.9239883686951496
13722.58cfa830e4b0c9d6adf6c050	58cfa830e4b0c9d6adf6c050	TCGA-B5-A0K6-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-B5-A0K6-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_5_rg.sorted	TCGA-B5-A0K6-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_5_rg.sorted.bam	110.74	2.06	0.14	58cfa830e4b0c9d6adf6c050	TCGA-B5-A0K6-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0K6-01A	5CBA9441-6812-49C0-A0F6-7928ED4E5B81	Primary Tumor	Illumina HiSeq	06cd1c7f-2531-4a07-bf4f-c086f7a954a0	Uterus	58.0	69BF0D3A-B7AE-4EE1-B7D1-18A32FCFA67C	A4364F57-81A8-4B96-BA31-1D8B1CC78C5D	TCGA-B5-A0K6-01A-11D-A043-02	HG19_Broad_variant	TCGA-B5-A0K6	TCGA-UCEC		s4247	Harvard Medical School	Duke	United States	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C3	UCEC.MSI	0.10440606	0.23	0.01	4.447968886	-0.3936	-0.157	-0.1888	0.0578	0.0771	-0.127	141.0	404.0	2.7718146530000003	9.777500041	49.0	0.048752067999999996	2.0	4.0							2.250419995	-616.2231332	-1157.638374	1835.411832	0.0	1953.0	0.0	1953.0	4.425781823171579	6.8371181993826955	-0.2632442557243668	4.253931566244919	5.63314539505676	2.486338289259438	-0.17185025692665956	-1.203972804325936	2.749582544983805
13722.58cfa830e4b0c9d6adf6c052	58cfa830e4b0c9d6adf6c052	TCGA-B2-4101-01A-02D-2096-10_Illumina.filtered.	WGS	TCGA-B2-4101-01A-02D-2096-10_Illumina	TCGA-B2-4101-01A-02D-2096-10_Illumina.bam	138.47	1.9	0.15	58cfa830e4b0c9d6adf6c052	TCGA-B2-4101-01A-02D-2096-10_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-B2-4101-01A	CFC999AA-802E-4A0D-8B14-BE2B19FA2A17	Primary Tumor	Illumina HiSeq	06203d35-b4db-4e6b-9c54-14edb4129481	Kidney	52.0	A9947B6C-DBC7-4BA5-AF61-7647E11E2973	F3C1A125-06E9-41C4-9558-275A3E346CC5	TCGA-B2-4101-01A-02D-2096-10	GRCh37-lite	TCGA-B2-4101	TCGA-KIRC		s9564	Baylor College of Medicine	Christiana Healthcare	None	NO	T2a	NX	Kidney Clear Cell Renal Carcinoma	Stage II	2096-10	False	KIRC	C3	KIRC.2	0.295856371				-1.3241	-0.33299999999999996	0.9608	1.3917	0.3853	0.2498	18.0	61.0	0.307153933	1.2286157340000001	77.0	0.049202357	0.0	5.0	0.8386601570000001	2.011019226	11.0	4.057029200000001	63.0	0.9792173000000001	1.77745219	187.33762430000002	-745.7840012	2712.5034170000004	0.0	648.0	0.0	648.0	8.481003309222544	1.9362083941558517	0.437294013678336	5.4881322679495845	5.01941948218822	4.442319801399447	-2.992871041272959	3.0832110880323684	4.00502578772111
13722.58cfa830e4b0c9d6adf6c05e	58cfa830e4b0c9d6adf6c05e	TCGA-AG-3999-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3999-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3999-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	651.89	1.9	0.14	58cfa830e4b0c9d6adf6c05e	TCGA-AG-3999-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3999-01A	60778DA8-D99E-4E51-96A2-3E900B3978D9	Primary Tumor	Illumina HiSeq	3d30dbe4-9c61-402a-afcd-c869123af4c6	Colorectal	61.0	022BA0B0-F8CC-474C-9FB9-7928B45FD756	1C65913D-665D-455E-9F40-8464E5EA0D55	TCGA-AG-3999-01A-01D-1115-02	HG18	TCGA-AG-3999	TCGA-READ		s2161	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Rectal Adenocarcinoma	Stage IIIC	1115-02	True	READ	C1		0.063095816	0.28	0.08	9.446913045	0.5798	0.165	-0.6864	-0.8558	-1.4936	0.1187					210.0	0.589356263	13.0	24.0							0.889801105	-1388.628728	-391.0536314	-510.7394856000001	0.0	853.0	1.0	791.0	6.373604163245928	6.910177448644558	-1.6779677768178778	4.742187344093052	8.577146145058824	0.7910475056334878	-1.631416819152876	1.6669686964142665	2.4690152824513656
13722.58cfa830e4b0c9d6adf6c062	58cfa830e4b0c9d6adf6c062	TCGA-B6-A0RI-01A-11D-A060_130807_SN590_0236_BC291KACXX_s_3_rg.sorted.filtered.	WGS	TCGA-B6-A0RI-01A-11D-A060_130807_SN590_0236_BC291KACXX_s_3_rg.sorted	TCGA-B6-A0RI-01A-11D-A060_130807_SN590_0236_BC291KACXX_s_3_rg.sorted.bam	78.5	1.92	0.14	58cfa830e4b0c9d6adf6c062	TCGA-B6-A0RI-01A-11D-A060_130807_SN590_0236_BC291KACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-B6-A0RI-01A	BFD55808-DDDD-44C3-97D7-41600497B992	Primary Tumor	Illumina HiSeq	9283f68e-d261-4afd-b0eb-0a29fdda83ca	Breast	44.0	973EE776-E287-4568-A43D-7B16CC0094A9	71542129-1393-4608-B81C-1767A5051763	TCGA-B6-A0RI-01A-11D-A060-02	HG19_Broad_variant	TCGA-B6-A0RI	TCGA-BRCA		s6273	Harvard Medical School	Duke	United States	NO	T4b	N1b	Infiltrating Ductal Carcinoma	Stage IIIB	A060-02	True	BRCA	C1	BRCA.LumA	0.092150144	0.25	0.07	0.312540172	0.3981	0.03	-0.0455	-1.3031	-0.2505	0.6483	7.0	2.0	0.117022335	0.526600508	82.0	0.104391729	3.0	13.0				1.098612289	3.0	1.0	1.58094652	-1076.205933	1394.288322	1472.065626	0.0	7126.0	1.0	1100.0	9.20230820027892	7.13801629806521	-0.31791387341191113	6.850932943115442	7.292166977892469	7.652308247601983	-2.3513752571634776	0.15415067982725805	7.970222121013895
13722.58cfa830e4b0c9d6adf6c064	58cfa830e4b0c9d6adf6c064	TCGA-AG-4005-01A-01D-1115_101122_SN177_0123_B20APUABXX_s_3_rg.sorted.filtered.	WGS	TCGA-AG-4005-01A-01D-1115_101122_SN177_0123_B20APUABXX_s_3_rg.sorted	TCGA-AG-4005-01A-01D-1115_101122_SN177_0123_B20APUABXX_s_3_rg.sorted.bam	618.89	1.9	0.15	58cfa830e4b0c9d6adf6c064	TCGA-AG-4005-01A-01D-1115_101122_SN177_0123_B20APUABXX_s_3_rg.sorted.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-4005-01A	866DE12B-E4DF-4F19-B62E-E3FD85D4EC08	Primary Tumor	Illumina HiSeq	06bb3e36-d2de-48c4-a23d-89eae00ec7e5	Colorectal	64.0	5B98C136-7BC3-411C-B07D-F0CF657F834D	284653D0-67A2-4ABF-9F75-1F045D0DAA70	TCGA-AG-4005-01A-01D-1115-02	HG18_Broad_variant	TCGA-AG-4005	TCGA-READ		s1999	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Rectal Adenocarcinoma	Stage IV	1115-02	True	READ	C1		0.09400395199999999	0.33	0.11	15.59285328	0.6697	0.225	-0.5347	-0.2662	-0.4582	0.1992					135.0	0.41019497899999996	12.0	16.0							0.562578335	-1261.0950300000002	105.5172238	-175.1604093	0.0	427.0	0.0	427.0	6.295349862398226	4.421377032497562	-0.5482550587537981	3.575251322779841	5.213353752954896	2.0814418281018963	-2.7200985396183848	0.7919767204573347	2.6296968868556947
13722.58cfa830e4b0c9d6adf6c066	58cfa830e4b0c9d6adf6c066	TCGA-AG-3894-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3894-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3894-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	710.89	1.9	0.15	58cfa830e4b0c9d6adf6c066	TCGA-AG-3894-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3894-01A	065B26FC-6827-44D5-83D8-1100C63FCDA6	Primary Tumor	Illumina HiSeq	8db01c5c-36a6-4060-ada7-3d57682daaf6	Colorectal	65.0	D6B7E2F3-01AD-4E77-87BB-9CBAEF03A5FB	339E9078-1166-45F6-A6BD-A2818B8918A1	TCGA-AG-3894-01A-01D-1115-02	HG18	TCGA-AG-3894	TCGA-READ		s2163	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage IIA	1115-02	True	READ	C1	GI.GS	0.069722048	0.19	0.0	6.000751032999999	0.6211	0.258	-0.6401	-0.3583	-1.3179	-0.0159	45.0	101.0	0.9341105540000001	2.591403471	79.0	0.054762327	2.0	0.0							1.4018160219999998	-1847.1786309999998	25.67308902	-1304.233214	0.0	426.0	0.0	426.0	6.720534785447278	5.749116648396586	-1.400657014764716	5.155548635584011	6.247839249991333	0.5796178733242927	-1.564986149863267	0.49872260159474724	1.9802748880890086
13722.58cfa830e4b0c9d6adf6c070	58cfa830e4b0c9d6adf6c070	TCGA-AY-4070-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AY-4070-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole	TCGA-AY-4070-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	458.59	1.9	0.13	58cfa830e4b0c9d6adf6c070	TCGA-AY-4070-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AY-4070-01A	6BAF61B6-AE5B-42F0-ADC9-0D26FDA231F7	Primary Tumor	Illumina HiSeq	c0679a4e-afc6-4b64-80a5-35bf5e446cb1	Colorectal	50.0	C35CB7B2-7A85-4320-89AC-3A395EF8C1BE	B9EFEB1A-FA1D-4917-8FC5-149ECAF26989	TCGA-AY-4070-01A-01D-1109-02	HG18	TCGA-AY-4070	TCGA-COAD	496.0	s13388	Harvard Medical School	UNC	None	NO	T3	N2	Colon Adenocarcinoma	Stage IIIC	1109-02	True	COAD	C1	GI.CIN	0.249834657	0.69	0.43	24.39052047	0.46399999999999997	0.162	-0.3455	0.7954	-0.1937	0.1939	79.0	7.0	1.412638186	4.268624084	292.0	0.591922476	15.0	47.0							2.96111719	-307.9169203	-160.5005279	-1967.208202	1.0	496.0	1.0	186.0	4.992414747982728	4.752410597929186	-0.6200032962128808	3.7884419436567924	5.403710668553631	1.288991298093713	-1.2039728043259355	0.651300070624445	1.9089945943065938
13722.58cfa830e4b0c9d6adf6c07c	58cfa830e4b0c9d6adf6c07c	TCGA-BJ-A0ZH-01A-11D-A10R_120711_SN208_0414_BD13L5ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BJ-A0ZH-01A-11D-A10R_120711_SN208_0414_BD13L5ACXX_s_2_rg.sorted	TCGA-BJ-A0ZH-01A-11D-A10R_120711_SN208_0414_BD13L5ACXX_s_2_rg.sorted.bam	57.81	1.95	0.16	58cfa830e4b0c9d6adf6c07c	TCGA-BJ-A0ZH-01A-11D-A10R_120711_SN208_0414_BD13L5ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0ZH-01A	866CA8AD-ADC9-45D4-AD92-9F8F1A161DDF	Primary Tumor	Illumina HiSeq	488591c3-7ba4-421a-9fc0-36d0604c8175	Thyroid	52.0	01EE736B-F907-465B-9142-C50BE0A3461B	8B8B2852-9D53-4654-A37C-2749C0F264ED	TCGA-BJ-A0ZH-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0ZH	TCGA-THCA		s12096	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N1b	Thyroid Papillary Carcinoma - Tall Cell (>= 50% tall cell features)	Stage IVA	A10R-02	True	THCA	C3	THCA.3	0.190365007	0.38	0.01		-1.4694	-0.1655	-0.0702	0.0688	-0.0596	-0.0693	10.0		0.056756102	0.34053661	53.0	0.011004141	0.0	0.0	0.9158981359999999	1.474081183	5.0	2.3025850930000002	10.0	1.0	1.20076956	69.31354019	-1099.364167	1285.5281300000001	0.0	460.0	0.0	460.0	6.818924065275521	8.287821954930623	-1.103658556735734	6.439434443570617	7.553852779850422	1.6039722692292746	-0.3794896217049035	-0.7339691750802002	2.7076308259650084
13722.58cfa830e4b0c9d6adf6c07e	58cfa830e4b0c9d6adf6c07e	TCGA-B1-A47M-01A-11D-A25F-10_wgs_Illumina.filtered.	WGS	TCGA-B1-A47M-01A-11D-A25F-10_wgs_Illumina	TCGA-B1-A47M-01A-11D-A25F-10_wgs_Illumina.bam	27.53		0.08	58cfa830e4b0c9d6adf6c07e	TCGA-B1-A47M-01A-11D-A25F-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-B1-A47M-01A	072507CF-1249-4B28-86D4-3AB97822A74C	Primary Tumor	Illumina HiSeq	aa347261-ddce-4395-b3f2-84e8210d4d8a	Kidney	79.0	75658EDD-12F1-4BB3-BEA2-01C154CB6AE9	8FB7FCAC-6C1D-40C2-9309-B53821CBEF30	TCGA-B1-A47M-01A-11D-A25F-10	GRCh37-lite	TCGA-B1-A47M	TCGA-KIRP		s11581	Baylor College of Medicine	University of Pittsburgh	United States	NO	T3a	NX	Kidney Papillary Renal Cell Carcinoma	Stage III	A25F-10	True	KIRP	C3	KIRP.C1	0.238623173	0.04	0.13		-1.278	-0.1105	-0.079	-0.6169	-0.4547	-0.2523	45.0	263.0	0.7262073659999999	2.31827736	60.0	0.148500872	7.0	5.0				1.098612289	3.0	1.0	2.101022978	-823.6249101	-2292.080963	-193.32316840000001	0.0	659.0	1.0	408.0	7.068023852239623	0.530860921693451	0.16845979677056566	6.353370466458714	4.195672567985858	0.3138608949228159	-0.7146533857809088	3.6648116462924074	0.14540109815225022
13722.58cfa830e4b0c9d6adf6c0fe	58cfa830e4b0c9d6adf6c0fe	TCGA-B5-A0K4-01A-11D-A043_120504_SN590_0156_BC0H68ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-B5-A0K4-01A-11D-A043_120504_SN590_0156_BC0H68ACXX_s_3_rg.sorted	TCGA-B5-A0K4-01A-11D-A043_120504_SN590_0156_BC0H68ACXX_s_3_rg.sorted.bam	31.24	2.03	0.14	58cfa830e4b0c9d6adf6c0fe	TCGA-B5-A0K4-01A-11D-A043_120504_SN590_0156_BC0H68ACXX_s_3_rg.sorted.bam	Alive	FEMALE			Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0K4-01A	A8F38E37-978B-4435-B676-E8D4C34DA909	Primary Tumor	Illumina HiSeq	a95ec772-f010-453f-b4a3-20abf1f681e3	Uterus	51.0	A4AC1F6E-3411-47AE-9592-513B3D32223F	4612DB59-3A8E-4F32-968A-76BCE0D4F042	TCGA-B5-A0K4-01A-11D-A043-02	HG19_Broad_variant	TCGA-B5-A0K4	TCGA-UCEC		s5389	Harvard Medical School	Duke	United States	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C4	UCEC.CN_LOW	0.067636772	0.18	0.0	4.890772944	-0.419	-0.129	-1.2074	-1.3366	0.0725	-0.1837	29.0	169.0	0.231589047	1.447431544	63.0	0.9798162990000001	9.0	1.0							1.432101464	-1365.09015	-1250.726217	-1937.809272	0.0	1757.0	0.0	1757.0	6.138424601074376	7.006944618126702	-1.2758918616540136	5.2988487867810825	6.36585379952281	2.471464964207752	-0.8395758142932932	-0.6410908186038915	3.747356825861765
13722.58cfa830e4b0c9d6adf6c102	58cfa830e4b0c9d6adf6c102	TCGA-B5-A0K9-01A-21D-A101_120330_SN208_0279_BC0L73ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-B5-A0K9-01A-21D-A101_120330_SN208_0279_BC0L73ACXX_s_1_rg.sorted	TCGA-B5-A0K9-01A-21D-A101_120330_SN208_0279_BC0L73ACXX_s_1_rg.sorted.bam	97.15	2.16	0.13	58cfa830e4b0c9d6adf6c102	TCGA-B5-A0K9-01A-21D-A101_120330_SN208_0279_BC0L73ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0K9-01A	4485CC98-5D58-4EB4-8325-7D1A617B6461	Primary Tumor	Illumina HiSeq	71c016d1-ab89-4d8f-acb9-92767959d603	Uterus	88.0	52A96216-708F-43F2-A923-130A1C35922D	30D94271-91F3-4CF5-83C0-4708662115D0	TCGA-B5-A0K9-01A-21D-A101-02	HG19_Broad_variant	TCGA-B5-A0K9	TCGA-UCEC		s5210	Harvard Medical School	Duke	United States	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C1	UCEC.MSI	0.34675396700000005	0.44	0.05	8.376547824	0.5194	0.177	-0.2334	0.0498	-0.1504	-0.0565	309.0	1474.0	6.190675072	18.28709875	40.0	0.118362497	3.0	1.0	0.627021528	1.12347176	6.0	2.5649493569999997	13.0	1.0	3.282726134	-1285.503236	-186.2598324	1903.895227	1.0	409.0	0.0	409.0	5.889639441184395	5.799614984062373	-0.9307314160289495	4.402369162724502	4.918415571999488	2.306228084272547	-1.4872702784598926	-0.8811994120628852	3.2369595003014964
13722.58cfa830e4b0c9d6adf6c106	58cfa830e4b0c9d6adf6c106	TCGA-BS-A0TJ-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BS-A0TJ-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_6_rg.sorted	TCGA-BS-A0TJ-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_6_rg.sorted.bam	96.9	1.86	0.16	58cfa830e4b0c9d6adf6c106	TCGA-BS-A0TJ-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_6_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0TJ-01A	F74DA4C6-4291-46D2-ABD4-7D7F6EF03B00	Primary Tumor	Illumina HiSeq	d9625d1c-df48-4532-994d-9ab3a3c8f8b6	Uterus	59.0	AC35307B-AC7F-49FC-A237-5E03AB2E2276	C20AA17E-3866-4864-A4AE-44ACFD746221	TCGA-BS-A0TJ-01A-11D-A101-02	HG19_Broad_variant	TCGA-BS-A0TJ	TCGA-UCEC		s5012	Harvard Medical School	University of Hawaii	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C1	UCEC.MSI	0.07152868700000001	0.21	0.0	3.766897375	0.7705	0.23199999999999998	-0.6883	0.0703	-1.2307	0.2515	318.0	2016.0	5.589081737000001	17.5282	105.0	0.00018462	0.0	0.0							1.767094245	-435.8294692	574.7496423	-1441.4838539999998	0.0	2068.0	0.0	2068.0	7.902733955098282	7.467207788282206	0.06561311184531804	5.74324970574491	6.579904593281303	0.92167527022611	-2.1594842493533726	-0.8873031950009029	0.8560621583807919
13722.58cfa830e4b0c9d6adf6c107	58cfa830e4b0c9d6adf6c107	TCGA-BS-A0TA-01A-11D-A101_120403_SN1222_0094_BD0UKBACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BS-A0TA-01A-11D-A101_120403_SN1222_0094_BD0UKBACXX_s_1_rg.sorted	TCGA-BS-A0TA-01A-11D-A101_120403_SN1222_0094_BD0UKBACXX_s_1_rg.sorted.bam	95.02	2.03	0.15	58cfa830e4b0c9d6adf6c107	TCGA-BS-A0TA-01A-11D-A101_120403_SN1222_0094_BD0UKBACXX_s_1_rg.sorted.bam	Alive	FEMALE	NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER	HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0TA-01A	AD3D8420-F562-4CBE-AC82-C968BD4F782D	Primary Tumor	Illumina HiSeq	ee69554a-eb4c-482a-b37e-a643758f27e5	Uterus	58.0	B6A042B6-F94A-4ACC-98CB-A1A2FE72B9AD	896590DE-B00E-40A3-912D-D625F3581AD8	TCGA-BS-A0TA-01A-11D-A101-02	HG19_Broad_variant	TCGA-BS-A0TA	TCGA-UCEC		s4437	Harvard Medical School	University of Hawaii	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C2	UCEC.MSI	0.5270991389999999	0.69	0.01	22.71104562	0.644	0.32899999999999996	0.9442	2.3057	1.2481	-0.0697	249.0	1559.0	4.446074483	12.77184453	59.0	0.00047263	0.0	2.0							2.5397056940000002	81.11156194	348.2583042	-2689.982629	1.0	740.0	1.0	394.0	7.203974336867755	7.482006304598227	0.8383749203690103	5.878304597564299	6.201072459136163	0.9240028523604937	-1.3256697393034553	-1.280933845462064	0.08562793199148344
13722.58cfa830e4b0c9d6adf6c11a	58cfa830e4b0c9d6adf6c11a	TCGA-BS-A0TE-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BS-A0TE-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_3_rg.sorted	TCGA-BS-A0TE-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_3_rg.sorted.bam	53.44	1.91	0.17	58cfa830e4b0c9d6adf6c11a	TCGA-BS-A0TE-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_3_rg.sorted.bam	Dead	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0TE-01A	09066FBF-6A1D-46C9-A4C5-C53340C3D1BA	Primary Tumor	Illumina HiSeq	a687b0ac-0eda-43c1-ab2f-cf8b3d6ffb94	Uterus	35.0	2D1226A1-1C88-422B-9A8D-316BEBEB65FD	250BF272-4CCD-41DB-ABD1-4FE2E304AB21	TCGA-BS-A0TE-01A-11D-A101-02	HG19_Broad_variant	TCGA-BS-A0TE	TCGA-UCEC	146.0	s4607	Harvard Medical School	University of Hawaii	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C2	UCEC.MSI	0.23199868699999998	0.24	0.43	6.129520438999999	0.9992	0.39799999999999996	-0.5509	0.0059	0.2777	-0.1802	163.0	846.0	3.186107241	8.12313828	248.0	0.9479735159999999	13.0	13.0							2.9468693760000004	-890.9193263000001	945.3760341	-2259.9083809999997	1.0	146.0	1.0	58.0	7.173651759361996	7.473977765968415	-0.138105689643912	5.524993133774615	3.3598305764501344	1.837785291623337	-1.6486586255873819	-4.11414718951828	1.975890981267249
13722.58cfa830e4b0c9d6adf6c11c	58cfa830e4b0c9d6adf6c11c	TCGA-BS-A0TD-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BS-A0TD-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_2_rg.sorted	TCGA-BS-A0TD-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_2_rg.sorted.bam	96.72	1.83	0.13	58cfa830e4b0c9d6adf6c11c	TCGA-BS-A0TD-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_2_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0TD-01A	FFAA98A0-2B69-46DC-AEE5-C5C3F2ABBC38	Primary Tumor	Illumina HiSeq	8f5ee5b5-1b1c-4af7-a179-4b71cc7c9f12	Uterus	65.0	8BB3A057-8958-4F62-AF81-976DA2E92DF7	3EF9C5ED-860A-4FF2-AA76-C53E9EB2453E	TCGA-BS-A0TD-01A-11D-A101-02	HG19_Broad_variant	TCGA-BS-A0TD	TCGA-UCEC		s5219	Harvard Medical School	University of Hawaii	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C1	UCEC.CN_LOW	0.279078817	0.39	0.0	7.274906934	0.2583	0.08900000000000001	-0.6274	-0.2434	0.0135	-0.0307	12.0	1.0	0.358638358	0.866709365	45.0	0.000127184	0.0	0.0							3.121731625	-1451.14176	-459.61542189999994	-1944.74945	0.0	2379.0	0.0	2379.0	7.142629753172045	6.889523417387332	-0.9474633959399157	6.086577078922732	6.4195197881415975	2.5573004401840693	-1.056052674249314	-0.4700036292457357	3.504763836123985
13722.58cfa830e4b0c9d6adf6c120	58cfa830e4b0c9d6adf6c120	TCGA-BJ-A0ZG-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BJ-A0ZG-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_5_rg.sorted	TCGA-BJ-A0ZG-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_5_rg.sorted.bam	37.3	1.98	0.16	58cfa830e4b0c9d6adf6c120	TCGA-BJ-A0ZG-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0ZG-01A	A3810F36-D2B4-4A45-AD08-A4DBFB9D27AA	Primary Tumor	Illumina HiSeq	44c5a52a-3434-4e05-a510-33799f327c93	Thyroid	80.0	3AC025C9-FEC6-4997-8630-085750DC84E0	D030DC18-6E50-4679-8BF9-26A1DAEC8F79	TCGA-BJ-A0ZG-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0ZG	TCGA-THCA		s12101	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A10R-02	True	THCA	C3	THCA.1	0.123152778	0.37	0.0		-2.4512	-0.3045	-0.7608	-0.3708	-0.4909	-0.3666	5.0		0.055840935	0.167522806	45.0	0.000188612	0.0	0.0	0.722687179	0.50092858	2.0	2.197224577	9.0	1.0	1.502791456	-450.0748456	-1083.4566320000001	1197.947717	0.0	775.0	0.0	775.0	5.892164063679703	9.361386236849961	0.3916969398546838	6.240470757947919	4.491656395830944	1.8307011173941028	0.34830669426821625	-4.8697298410190175	1.4390041775394191
13722.58cfa830e4b0c9d6adf6c124	58cfa830e4b0c9d6adf6c124	TCGA-BS-A0TC-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BS-A0TC-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_1_rg.sorted	TCGA-BS-A0TC-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_1_rg.sorted.bam	60.12	1.87	0.14	58cfa830e4b0c9d6adf6c124	TCGA-BS-A0TC-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_1_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0TC-01A	7B7D2D2B-ABE6-4F32-ADD0-3715096995D1	Primary Tumor	Illumina HiSeq	402004c3-b5d0-41ad-990c-203cbf02ec5d	Uterus	69.0	C4C99327-B778-4E29-A111-75569AD38696	99E19D8C-EC6E-45D7-89E5-091D101BF466	TCGA-BS-A0TC-01A-11D-A101-02	HG19_Broad_variant	TCGA-BS-A0TC	TCGA-UCEC		s5015	Harvard Medical School	University of Hawaii	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C3	UCEC.POLE	0.154124383	0.21	0.0	2.4361557819999997	-0.4655	-0.08	-0.7104	-0.08800000000000001	-0.5756	-0.1333	642.0	5.0	7.0831562539999995	36.52075365	71.0	0.000531873	0.0	3.0							2.400207497	-1261.5413429999999	-1270.236631	1033.041262	0.0	2602.0	0.0	2602.0	7.50292205118188	7.64627408876091	0.09487737304578325	5.7111625819538245	6.142196691984635	2.8397280250774095	-1.791759469228055	-1.5040773967762742	2.7448506520316265
13722.58cfa830e4b0c9d6adf6c128	58cfa830e4b0c9d6adf6c128	TCGA-B6-A0RE-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_7_rg.sorted.filtered.	WGS	TCGA-B6-A0RE-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_7_rg.sorted	TCGA-B6-A0RE-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_7_rg.sorted.bam	49.61	2.14	0.16	58cfa830e4b0c9d6adf6c128	TCGA-B6-A0RE-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_7_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-B6-A0RE-01A	08DA7C4C-3067-4BCF-9D7A-78566DF72E69	Primary Tumor	Illumina HiSeq	f7dd44eb-562f-4d27-8c45-5ec7fbf49448	Breast	61.0	270BE245-2239-4E96-A917-79CCA40868BA	D5CE279A-3A7F-43E7-894C-265E9504C3FD	TCGA-B6-A0RE-01A-11D-A060-02	HG19_Broad_variant	TCGA-B6-A0RE	TCGA-BRCA		s6769	Harvard Medical School	Duke	United States	NO	TX	N0 (i-)	Infiltrating Ductal Carcinoma	Stage X	A060-02	True	BRCA	C1	BRCA.Basal	0.149228887	0.36	0.4	2.8217284510000002	0.8333	0.273	-0.2232	-0.5676	-0.0488	0.3611	82.0	14.0	1.1390208179999999	3.836701703	288.0	0.7091048329999999	17.0	39.0	0.894199251	3.3422213710000004	42.0	1.285293024	6.0	0.717335695	3.298748757	-753.4718547	817.6360206	-2681.477654	0.0	7777.0	0.0	7777.0	7.628355486323383	6.4240844845205	-0.5029245177362625	5.591473559062344	6.967699931109482	1.618604404575386	-2.0368819272610397	0.5436154465889818	2.1215289223116485
13722.58cfa830e4b0c9d6adf6c12e	58cfa830e4b0c9d6adf6c12e	TCGA-BS-A0UM-01A-11D-A101_120622_SN1120_0155_AC0WVLACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BS-A0UM-01A-11D-A101_120622_SN1120_0155_AC0WVLACXX_s_1_rg.sorted	TCGA-BS-A0UM-01A-11D-A101_120622_SN1120_0155_AC0WVLACXX_s_1_rg.sorted.bam	107.99	2.0	0.17	58cfa830e4b0c9d6adf6c12e	TCGA-BS-A0UM-01A-11D-A101_120622_SN1120_0155_AC0WVLACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0UM-01A	A7C565FC-C711-4B63-9549-4CD74D1F57C2	Primary Tumor	Illumina HiSeq	942f9e1e-4e57-4325-a7d0-0a464cda140a	Uterus	64.0	6F70F18E-5C53-4F1F-A63D-62BD27039B8D	6CD1B997-3123-4934-A06C-14A5CF1BEBFC	TCGA-BS-A0UM-01A-11D-A101-02	HG19_Broad_variant	TCGA-BS-A0UM	TCGA-UCEC		s5009	Harvard Medical School	University of Hawaii	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C2	UCEC.	0.32566897100000003			7.749655946	0.465	0.07400000000000001	0.3358	1.6382	0.8292	-0.4396	151.0	537.0	4.933660847	14.49685276											2.627933036	-887.7987085000001	38.69053015	2864.984665	0.0	2644.0	1.0	1454.0	6.00223962027594	8.036249942132116	0.018107490627390588	5.502587297108075	7.509550969209835	2.8594518082823015	-0.4996523231678651	-0.5266989729222811	2.841344317654911
13722.58cfa830e4b0c9d6adf6c12f	58cfa830e4b0c9d6adf6c12f	TCGA-BG-A0MU-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BG-A0MU-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_1_rg.sorted	TCGA-BG-A0MU-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_1_rg.sorted.bam	74.26	2.08	0.16	58cfa830e4b0c9d6adf6c12f	TCGA-BG-A0MU-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0MU-01A	A7329910-B1C7-4A18-B28E-8FAD79121339	Primary Tumor	Illumina HiSeq	c676fa46-db3a-402d-804d-9717141fdae6	Uterus	78.0	F0AF3F30-3D64-4BD8-9A8F-7FF7AB9BB7B0	0BB10C9F-C337-4E2E-A661-9CE12C8BEB35	TCGA-BG-A0MU-01A-11D-A101-02	HG19_Broad_variant	TCGA-BG-A0MU	TCGA-UCEC		s5393	Harvard Medical School	University of Pittsburgh	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C3	UCEC.CN_LOW	0.10618328199999999	0.14	0.01	6.147435517000001	-0.0954	0.003	-0.0688	0.6334	-0.5379	-0.2625	28.0	8.0	0.5855970070000001	1.410756427	89.0	0.049513386	2.0	6.0							1.96470931	-1585.604873	85.67797702	1022.460292	0.0	617.0	0.0	617.0	6.401978616129593	7.3013164825874775	-0.43858404069223006	5.4073560409855315	5.825409962777901		-0.9946225751440618	-1.4759065198095778	
13722.58cfa830e4b0c9d6adf6c134	58cfa830e4b0c9d6adf6c134	TCGA-B6-A0RG-01A-11D-A060_130807_SN590_0235_AC29RAACXX_s_3_rg.sorted.filtered.	WGS	TCGA-B6-A0RG-01A-11D-A060_130807_SN590_0235_AC29RAACXX_s_3_rg.sorted	TCGA-B6-A0RG-01A-11D-A060_130807_SN590_0235_AC29RAACXX_s_3_rg.sorted.bam	40.26	2.11	0.15	58cfa830e4b0c9d6adf6c134	TCGA-B6-A0RG-01A-11D-A060_130807_SN590_0235_AC29RAACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-B6-A0RG-01A	9B13927C-7357-44FD-8385-92AE6A656B7D	Primary Tumor	Illumina HiSeq	b38ff19d-a769-4388-81e2-03263bba7985	Breast	26.0	B98AA84F-5144-4062-BADC-32E89368D684	E71ED8ED-7371-4423-83C8-6075A6FC7C39	TCGA-B6-A0RG-01A-11D-A060-02	HG19_Broad_variant	TCGA-B6-A0RG	TCGA-BRCA		s5640	Harvard Medical School	Duke	United States	NO	T3	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IIB	A060-02	True	BRCA	C2	BRCA.LumA	0.047395989000000006	0.1	0.16	0.18420608600000002	0.2191	0.027000000000000003	-0.9403	-1.1075	0.4398	0.3648	41.0	52.0	0.331711305	1.779178819	192.0	0.484761299	6.0	30.0		0.0	1.0	0.0	1.0		4.198980786	-121.82593190000001	656.2521141	-1333.6149050000001	0.0	2082.0	0.0	2082.0	8.577409886904785	7.152479664483728	-0.27093749517797916	6.731583196406454	7.2325223721572645	1.9065948240470958	-1.8458266904983305	0.08004270767353638	2.177532319225075
13722.58cfa830e4b0c9d6adf6c136	58cfa830e4b0c9d6adf6c136	TCGA-BS-A0UJ-01A-12D-A101_120407_SN590_0151_BC0KKJACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BS-A0UJ-01A-12D-A101_120407_SN590_0151_BC0KKJACXX_s_3_rg.sorted	TCGA-BS-A0UJ-01A-12D-A101_120407_SN590_0151_BC0KKJACXX_s_3_rg.sorted.bam	125.71	2.0	0.17	58cfa830e4b0c9d6adf6c136	TCGA-BS-A0UJ-01A-12D-A101_120407_SN590_0151_BC0KKJACXX_s_3_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0UJ-01A	FF82548A-F1BB-4DAA-A8F7-B3831B5843AD	Primary Tumor	Illumina HiSeq	094adbd4-f2af-42bb-9509-0dcfa2c6672f	Uterus	68.0	2EA1339F-A5EB-4552-AC13-858FA70E606E	15FDA615-0A79-4211-B5DE-F61741E8937A	TCGA-BS-A0UJ-01A-12D-A101-02	HG19_Broad_variant	TCGA-BS-A0UJ	TCGA-UCEC		s5221	Harvard Medical School	University of Hawaii	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C3	UCEC.MSI	0.085062536	0.13	0.0	5.2914570780000005	-1.0114	-0.258	-0.2316	0.5293	0.2804	-0.3906	433.0	109.0	15.94382023	45.41483728	111.0	0.000146605	0.0	0.0							2.132239131	-280.80558030000003	-2144.3429170000004	1706.555961	0.0	2506.0	0.0	2506.0	6.490815496981881	8.337519554357893	0.30903032368521577	6.5533358539632145	6.916133873426732	2.1781938108607664	0.06252035698133396	-1.421385680931161	1.8691634871755505
13722.58cfa830e4b0c9d6adf6c138	58cfa830e4b0c9d6adf6c138	TCGA-BS-A0UF-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BS-A0UF-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_1_rg.sorted	TCGA-BS-A0UF-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_1_rg.sorted.bam	110.21	1.89	0.17	58cfa830e4b0c9d6adf6c138	TCGA-BS-A0UF-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_1_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0UF-01A	F77D7256-2CCF-42A7-9B30-332AC24CA812	Primary Tumor	Illumina HiSeq	33e84ef1-730b-4f0b-9967-bca62c9f631c	Uterus	65.0	C805F55A-322F-4A11-AE0C-4BBC365D1BD6	D1F78FB2-7BB7-4BF7-8EC7-E2E08F579A38	TCGA-BS-A0UF-01A-11D-A101-02	HG19_Broad_variant	TCGA-BS-A0UF	TCGA-UCEC		s5220	Harvard Medical School	University of Hawaii	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C2	UCEC.POLE	0.304054455	0.43	0.0	8.18109162	0.7737	0.141	0.3937	1.4788	0.366	0.0298	2950.0	205.0	49.16358748	221.0362917	43.0	0.0018056329999999998	0.0	0.0							1.9916199140000002	-968.8552356	-145.1185618	-1528.7345189999999	0.0	2611.0	0.0	2611.0	7.0915231577690605	7.580359558310752	-0.5185352490186715	6.634764755273345	6.833145156480532	2.264886009778275	-0.4567584024957152	-0.7472144018302207	2.7834212587969462
13722.58cfa830e4b0c9d6adf6c13a	58cfa830e4b0c9d6adf6c13a	TCGA-BS-A0U8-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BS-A0U8-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_8_rg.sorted	TCGA-BS-A0U8-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_8_rg.sorted.bam	116.56	1.88	0.15	58cfa830e4b0c9d6adf6c13a	TCGA-BS-A0U8-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0U8-01A	FB7475DF-30CC-4316-B9AC-37CBEEB6BA2B	Primary Tumor	Illumina HiSeq	44c78212-4860-4cf3-bd54-0e8e150cd0b1	Uterus	55.0	E3E23393-8597-4091-A343-CD544111C63B	89AB037F-B001-486F-A7EB-37AF8FBD0677	TCGA-BS-A0U8-01A-11D-A101-02	HG19_Broad_variant	TCGA-BS-A0U8	TCGA-UCEC		s4261	Harvard Medical School	University of Hawaii	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C1	UCEC.MSI	0.069198447	0.14	0.0	5.831079655	0.5119	0.27899999999999997	-0.8487	-0.0104	-0.9113	0.0587	187.0	856.0	3.9599017689999996	10.31169051	79.0	0.0034286	0.0	0.0							2.9557330389999996	-870.1259506000001	118.77559529999999	-1081.408362	0.0	2963.0	0.0	2963.0	6.509294991497383	6.78123223742606	-0.9458419903903815	6.0466714695492705	6.401742615721156	1.1698554423897973	-0.46262352194811296	-0.3794896217049035	2.1156974327801787
13722.58cfa830e4b0c9d6adf6c13e	58cfa830e4b0c9d6adf6c13e	TCGA-B9-A44B-01A-11D-A25F-10_wgs_Illumina.filtered.	WGS	TCGA-B9-A44B-01A-11D-A25F-10_wgs_Illumina	TCGA-B9-A44B-01A-11D-A25F-10_wgs_Illumina.bam	19.16		0.08	58cfa830e4b0c9d6adf6c13e	TCGA-B9-A44B-01A-11D-A25F-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-B9-A44B-01A	B809C2F2-185C-496A-A1D4-589294443A1D	Primary Tumor	Illumina HiSeq	148c4a68-bab6-4ff6-bcd7-fc69c33bea94	Kidney	70.0	07C08E8F-4DCA-42E4-9954-C62C32FED225	88E35D25-D98D-4576-8EBE-1CD74010ECD8	TCGA-B9-A44B-01A-11D-A25F-10	GRCh37-lite	TCGA-B9-A44B	TCGA-KIRP		s11860	Baylor College of Medicine	UNC	United States	NO	T3b	NX	Kidney Papillary Renal Cell Carcinoma	Stage III	A25F-10	True	KIRP	C3	KIRP.C2b	0.060410659000000005	0.2	0.2		-0.9014	-0.342	-1.004	-1.6708	-0.9668	-0.1279	44.0	260.0	0.92941447	3.170943486	139.0	0.662950582	12.0	21.0				0.0	1.0		2.282502386	-927.9435083999999	-1644.809002	1962.40715	0.0	361.0	0.0	361.0	7.461394056451693	0.30394785894051957	-0.3031021029011075	6.2292503751590615	3.8502958596791954	2.022891080990953	-1.2321436812926327	3.546348000738676	2.3259931838920602
13722.58cfa830e4b0c9d6adf6c140	58cfa830e4b0c9d6adf6c140	TCGA-BA-6872-01A-11D-A32X-10_wgs_Illumina.filtered.	WGS	TCGA-BA-6872-01A-11D-A32X-10_wgs_Illumina	TCGA-BA-6872-01A-11D-A32X-10_wgs_Illumina.bam	89.7	1.9	0.07	58cfa830e4b0c9d6adf6c140	TCGA-BA-6872-01A-11D-A32X-10_wgs_Illumina.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-6872-01A	3E5F451A-5882-4914-AE1A-95C898C2BCCA	Primary Tumor	Illumina HiSeq	28a6e3a3-207f-4df1-bdb3-c63373ce9ba2	Head and Neck	47.0	04107A58-667D-4712-B972-61837EFF6029	C76F7FCC-2748-4B6D-805E-D21652DD5E3A	TCGA-BA-6872-01A-11D-A32X-10	GRCh37-lite	TCGA-BA-6872	TCGA-HNSC	384.0	s16028	Baylor College of Medicine	UNC	United States	NO	TX	NX	Head and Neck Squamous Cell Carcinoma		A32X-10	True	HNSC	C2	HNSC.Basal	0.191836898	0.42	0.25		0.6939	0.285	-0.3928	-0.1778	1.4231	0.7076			0.9729562390000001	4.30459427	290.0	0.6123593079999999	13.0	29.0	0.938805034	1.510948415	5.0	1.098612289	3.0	1.0	2.538754102	58.36163002	565.092791	-70.19127055	1.0	384.0	1.0	384.0	6.590667281491385	3.2969507152310786	-1.0295330775497749	5.743369421104182	3.907268788999758	1.4729395316382217	-0.8472978603872034	0.6103180737686795	2.5024726091879965
13722.58cfa830e4b0c9d6adf6c147	58cfa830e4b0c9d6adf6c147	TCGA-B7-5818-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_2_rg.sorted.filtered.	WGS	TCGA-B7-5818-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_2_rg.sorted	TCGA-B7-5818-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_2_rg.sorted.bam	411.0	1.9	0.14	58cfa830e4b0c9d6adf6c147	TCGA-B7-5818-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-B7-5818-01A	6E03B415-84A1-4B91-8717-1A41EDD4A255	Primary Tumor	Illumina HiSeq	e2875187-aeca-43f4-85d8-13ecd0452ec3	Stomach	62.0	FD97CDF5-0F7F-48A2-B5DA-5C5F56A89166	0EBF1A63-C6E4-49FE-B21B-AE46FF14261D	TCGA-B7-5818-01A-11D-1598-02	HG19_Broad_variant	TCGA-B7-5818	TCGA-STAD		s15372	Harvard Medical School	Cureline	Russia	NO	T2	N0	Stomach  Adenocarcinoma  Diffuse Type	Stage IB	1598-02	True	STAD	C2	GI.EBV	0.209524916	0.29	0.01		0.456	0.2935	0.5016	0.6304	-0.3767	0.0536			2.8936743710000004	9.339978661	106.0	0.24794421600000002	6.0	9.0	0.84995006	3.325024187	50.0	4.553101348	107.0	0.974377943	1.038937985	-707.1105459	71.76064057	1624.563314	0.0	356.0	0.0	356.0	7.994294986415978	6.578361927825217	0.45982683681688163	5.691709893421933	6.6191839223454725	1.4767437681025906	-2.3025850929940455	0.04082199452025481	1.016916931285709
13722.58cfa830e4b0c9d6adf6c149	58cfa830e4b0c9d6adf6c149	TCGA-BA-4076-01A-01D-2266-10_Illumina.filtered.	WGS	TCGA-BA-4076-01A-01D-2266-10_Illumina	TCGA-BA-4076-01A-01D-2266-10_Illumina.bam	333.33	1.9	0.05	58cfa830e4b0c9d6adf6c149	TCGA-BA-4076-01A-01D-2266-10_Illumina.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-4076-01A	7DE19081-D5FD-468C-AD0D-F6E3E8B2AD70	Primary Tumor	Illumina HiSeq	62857418-5247-4ae1-8064-d900ef856428	Head and Neck	39.0	FD99FD83-4040-4738-8A5A-E42D36ECFE0E	E2B5C926-491D-430D-8D9C-5C73D7752D1B	TCGA-BA-4076-01A-01D-2266-10	GRCh37-lite	TCGA-BA-4076	TCGA-HNSC	415.0	s16171	Baylor College of Medicine	UNC	None	NO	TX	NX	Head and Neck Squamous Cell Carcinoma		2266-10	True	HNSC	C1	HNSC.Basal	0.077182429	0.15	0.04		0.5787	0.3035	-0.9717	-0.9716	-1.0844	0.2782	71.0	53.0	2.357735115	8.152650339	254.0	0.6594124920000001	9.0	32.0		0.0	1.0	1.039720771	3.0	0.94639463	4.900389623	-579.1640716	443.16475959999997	528.3904353999999	1.0	415.0	1.0	286.0	-1.414868816487168	4.156708281382318	-1.8094635551478357	5.169100975224929	7.47088026759253	0.5059544437711327	6.5839697917120965	3.3141719862102113	2.3154179989189685
13722.58cfa830e4b0c9d6adf6c14d	58cfa830e4b0c9d6adf6c14d	TCGA-BA-5556-01A-01D-A32X-10_wgs_Illumina.filtered.	WGS	TCGA-BA-5556-01A-01D-A32X-10_wgs_Illumina	TCGA-BA-5556-01A-01D-A32X-10_wgs_Illumina.bam	116.7	1.9	0.08	58cfa830e4b0c9d6adf6c14d	TCGA-BA-5556-01A-01D-A32X-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-5556-01A	70741B73-9683-42BD-87FC-6A021A70103B	Primary Tumor	Illumina HiSeq	e855f092-899d-469a-981c-5094b07c31ac	Head and Neck	58.0	C00EEDDB-6AE2-48BA-8677-C174E579A724	8294A969-59A1-4D3B-895B-F07E96BF9F7A	TCGA-BA-5556-01A-01D-A32X-10	GRCh37-lite	TCGA-BA-5556	TCGA-HNSC		s16319	Baylor College of Medicine	UNC	None	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	A32X-10	True	HNSC	C2	HNSC.Basal	0.5222371029999999	0.7	0.25		0.4597	0.092	0.6394	1.5490000000000002	2.4389	0.4684	83.0	2.0	0.904196228	3.390735854	43.0	0.100843956	4.0	0.0	0.8120616620000001	3.224121851	53.0	4.182994321000001	71.0	0.98130623	1.3266321159999999	84.86100472	444.31670599999995	-223.8461371	0.0	725.0	0.0	725.0	6.907755278982138	4.059331131862488	0.17982912182019595	5.2590966533947565	3.544217838304216	1.931164968897604	-1.6486586255873819	-0.5151132935582723	1.751335847077408
13722.58cfa830e4b0c9d6adf6c156	58cfa830e4b0c9d6adf6c156	TCGA-B9-4117-01A-02D-1402-10_wgs_Illumina.filtered.	WGS	TCGA-B9-4117-01A-02D-1402-10_wgs_Illumina	TCGA-B9-4117-01A-02D-1402-10_wgs_Illumina.bam	155.07	1.9	0.05	58cfa830e4b0c9d6adf6c156	TCGA-B9-4117-01A-02D-1402-10_wgs_Illumina.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-B9-4117-01A	71B35CD8-ECEE-4599-BB24-B1EF78118423	Primary Tumor	Illumina HiSeq	4d9a1f84-a989-4caa-84d2-36d42c950675	Kidney	48.0	F3871637-192D-4324-9C59-CECFFF436356	6BA5F81A-B7A0-4C18-A112-2E11094EEC85	TCGA-B9-4117-01A-02D-1402-10	GRCh37-lite	TCGA-B9-4117	TCGA-KIRP		s11776	Baylor College of Medicine	UNC	None	NO	T2	NX	Kidney Papillary Renal Cell Carcinoma		1402-10	False	KIRP	C3	KIRP.C1	0.161521491	0.52	0.11		-1.8522	-0.35	0.7154	-0.0457	0.0813	-0.1617	23.0	8.0	0.364204191	1.031911875	111.0	0.9365382459999999	34.0	8.0				3.1079722760000004	23.0	0.9912224559999999	1.7992260180000001	-224.686884	-1539.976279	1697.4752469999999	0.0	14.0	0.0	14.0	6.19915599386327	1.843572533443532	0.10626391637745924	4.772039638223125	1.9388827132478568	3.3298852203841127	-1.4271163556401456	0.09531017980432477	3.2236213040066533
13722.58cfa830e4b0c9d6adf6c15e	58cfa830e4b0c9d6adf6c15e	TCGA-BA-6869-01A-11D-A32X-10_wgs_Illumina.filtered.	WGS	TCGA-BA-6869-01A-11D-A32X-10_wgs_Illumina	TCGA-BA-6869-01A-11D-A32X-10_wgs_Illumina.bam	379.7	1.9	0.07	58cfa830e4b0c9d6adf6c15e	TCGA-BA-6869-01A-11D-A32X-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-6869-01A	FAFD6F5B-1D76-4537-BD1C-E0BD7B4E2166	Primary Tumor	Illumina HiSeq	e35c380b-a1ee-47e3-b382-139ed8640d98	Head and Neck	62.0	F4ED2C84-39F8-4AB3-8762-A9920ACC2432	3E604A1C-B95F-44FF-9723-E2FAC845DA3B	TCGA-BA-6869-01A-11D-A32X-10	GRCh37-lite	TCGA-BA-6869	TCGA-HNSC		s15615	Baylor College of Medicine	UNC	United States	NO	T3	N0	Head and Neck Squamous Cell Carcinoma	Stage III	A32X-10	True	HNSC	C1	HNSC.Atypical	0.19658439100000002	0.36	0.05		0.2455	0.16899999999999998	-0.6898	0.2055	0.0787	0.2117	190.0	148.0	3.8824355	12.2355543	141.0	0.218232387	4.0	23.0	0.954407067	3.807114566	54.0	2.3025850930000002	10.0	1.0	2.6100083	-218.9219411	-360.02720889999995	-731.0775426	0.0	644.0	0.0	644.0	3.632219420548445	6.08453445714309	0.3706489114971795	4.618714411095849	4.918982685799871	0.42154870930486144	0.9864949905474036	-1.1655517713432193	0.050899797807681946
13722.58cfa830e4b0c9d6adf6c164	58cfa830e4b0c9d6adf6c164	TCGA-BA-5151-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BA-5151-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_3_rg.sorted	TCGA-BA-5151-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_3_rg.sorted.bam	227.7	1.9	0.15	58cfa830e4b0c9d6adf6c164	TCGA-BA-5151-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-5151-01A	A55FB87D-F606-48A5-82F5-09EACBACF41B	Primary Tumor	Illumina HiSeq	d1067ce4-863a-49f4-9061-d2e677695382	Head and Neck	72.0	63384A6A-9686-44EE-8C8F-22923968C9DE	5B29B8E2-23E6-4E6E-815C-B8D0EF534B14	TCGA-BA-5151-01A-01D-1431-02	HG19_Broad_variant	TCGA-BA-5151	TCGA-HNSC		s15488	Harvard Medical School	UNC	None	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	True	HNSC	C2	HNSC.Basal	0.43253796	0.38	0.41		0.41700000000000004	0.047	0.19899999999999998	0.2544	1.7321	0.5981	23.0	4.0	0.779458963	1.781620486	83.0	0.150123222	4.0	8.0	0.772382731	3.270350745	69.0	3.842319878	47.0	0.997966903	1.7401504769999998	374.59051989999995	619.688821	-670.8065947000001	0.0	722.0	1.0	517.0	1.433402758495717	5.393741767022882	-0.36990153327040765	5.884340960538451	8.088022387401335	0.9538131711972448	4.450938202042734	2.6942806203784535	1.3237147044676525
13722.58cfa830e4b0c9d6adf6c167	58cfa830e4b0c9d6adf6c167	TCGA-BJ-A0Z9-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BJ-A0Z9-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_7_rg.sorted	TCGA-BJ-A0Z9-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_7_rg.sorted.bam	75.83	2.17	0.13	58cfa830e4b0c9d6adf6c167	TCGA-BJ-A0Z9-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0Z9-01A	86F9ECA0-D1EA-4375-A6BC-055E44B3198A	Primary Tumor	Illumina HiSeq	2fcaeaf0-3a03-4b60-975a-31ac8afe58aa	Thyroid	57.0	AA8578FE-EDB2-4137-B363-FEB2C27D475A	B761F912-BDF6-4F1F-8CD0-0AE9DFC57A59	TCGA-BJ-A0Z9-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0Z9	TCGA-THCA		s12099	Harvard Medical School	University of Pittsburgh	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Tall Cell (>= 50% tall cell features)	Stage III	A10R-02	True	THCA	C4	THCA.4	0.217871907	0.39	0.0		-1.2172	-0.2425	-0.0544	-0.4204	1.2547	0.0277	7.0		0.089773368	0.418942384	79.0	5.73e-05	0.0	0.0	0.9209394479999999	0.638346582	2.0	2.079441542	8.0	1.0	1.230053531	462.43845639999995	-853.0020982000001	1838.2938649999999	0.0	1257.0	0.0	1257.0	6.548714902249186	7.684477383127986	-0.6518536448340781	5.763760172436117	7.30148513087188	1.7108110723346617	-0.7849547298130681	-0.382992252256106	2.36266471716874
13722.58cfa830e4b0c9d6adf6c16a	58cfa830e4b0c9d6adf6c16a	TCGA-BH-A0HK-01A-11D-A060_130807_SN590_0236_BC291KACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BH-A0HK-01A-11D-A060_130807_SN590_0236_BC291KACXX_s_1_rg.sorted	TCGA-BH-A0HK-01A-11D-A060_130807_SN590_0236_BC291KACXX_s_1_rg.sorted.bam	22.97	1.94	0.13	58cfa830e4b0c9d6adf6c16a	TCGA-BH-A0HK-01A-11D-A060_130807_SN590_0236_BC291KACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE		Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0HK-01A	24334AC1-28A3-4B61-B590-3F51E375B247	Primary Tumor	Illumina HiSeq	c4f3a9e0-4b45-4e06-9320-171c27d9e28d	Breast	81.0	8835B20E-9343-4266-A356-E0343C657130	B96AE5EC-0139-4B8D-8136-B5BFA7AF8987	TCGA-BH-A0HK-01A-11D-A060-02	HG19_Broad_variant	TCGA-BH-A0HK	TCGA-BRCA		s5642	Harvard Medical School	University of Pittsburgh	None	NO	T2	N1	Infiltrating Ductal Carcinoma	Stage IIB	A060-02	True	BRCA	C1	BRCA.Normal	0.092307582	0.22	0.02	0.9565014409999999	-0.4276	-0.08	-0.1629	0.0348	-0.2125	0.3257	31.0	9.0	1.0689954609999999	2.316156833	121.0	0.092431989	5.0	10.0	0.980986813	1.578837368	5.0	2.033662344	9.0	0.9255596190000001	2.603010823	-618.5340169	616.3151684999999	2112.084886	0.0	178.0	0.0	178.0	7.746300662231439	6.312007004409326	0.21063737580898034	5.54907608489522	6.1722450620341665	2.07115073934517	-2.197224577336219	-0.13976194237515882	1.8605133635361895
13722.58cfa830e4b0c9d6adf6c16c	58cfa830e4b0c9d6adf6c16c	TCGA-BA-5557-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BA-5557-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_4_rg.sorted	TCGA-BA-5557-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_4_rg.sorted.bam	52.7	1.9	0.16	58cfa830e4b0c9d6adf6c16c	TCGA-BA-5557-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_4_rg.sorted.bam	Alive	FEMALE		HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-5557-01A	7E0575CE-670B-4035-8A90-4D35279707B2	Primary Tumor	Illumina HiSeq	bb531fb4-064f-47dd-8231-bd6131866968	Head and Neck	41.0	67D75889-E868-41F2-8255-5D5D1AA0A854	0DDC26B3-2D83-4539-A934-4B0FEF8D1F69	TCGA-BA-5557-01A-01D-1509-02	HG19_Broad_variant	TCGA-BA-5557	TCGA-HNSC		s15617	Harvard Medical School	UNC	None	NO	T1	N1	Head and Neck Squamous Cell Carcinoma	Stage III	1509-02	True	HNSC	C1	HNSC.Basal	0.6095925670000001	0.72	0.34		0.0426	0.001	1.1183	0.3594	0.8341	1.1797	19.0	0.0	0.49394068399999996	1.016936703	85.0	0.234781762	4.0	15.0				2.557507739	15.0	0.944409279	1.5197382469999998	418.1035657	-120.5935979	-39.51172328	0.0	623.0	0.0	623.0	7.202485980788416	3.361032642627519	-1.6110401267452452	6.509338800228471	5.365377453127647	-0.24676896590923136	-0.6931471805599454	2.004344810500128	1.3642711608360139
13722.58cfa830e4b0c9d6adf6c170	58cfa830e4b0c9d6adf6c170	TCGA-BS-A0TG-01A-32D-A101_120407_SN590_0152_AC0C7LACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BS-A0TG-01A-32D-A101_120407_SN590_0152_AC0C7LACXX_s_4_rg.sorted	TCGA-BS-A0TG-01A-32D-A101_120407_SN590_0152_AC0C7LACXX_s_4_rg.sorted.bam	31.82	1.93	0.16	58cfa830e4b0c9d6adf6c170	TCGA-BS-A0TG-01A-32D-A101_120407_SN590_0152_AC0C7LACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0TG-01A	13F31BCB-BEFD-4ED2-ADC0-DC9E9CE52B75	Primary Tumor	Illumina HiSeq	bbb0de46-a395-47cf-938b-3a6a6c59b9ec	Uterus	60.0	36E44603-A1EE-4A5B-9506-49A9358BF8D0	FABEC5F4-2EF2-41CB-A728-E21D6C49F3F7	TCGA-BS-A0TG-01A-32D-A101-02	HG19_Broad_variant	TCGA-BS-A0TG	TCGA-UCEC		s4795	Harvard Medical School	University of Hawaii	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C2	UCEC.CN_LOW	0.15695473699999998	0.26	0.02	3.678266568	-0.23	0.069	-0.1408	0.385	1.0116	0.6185	21.0	63.0	0.40294985299999997	1.022872705	29.0	0.049828066	2.0	3.0							2.6991662730000003	-502.559104	-351.96308239999996	-3097.313944	0.0	2371.0	0.0	2371.0	7.335373191731434	7.7463727161277856	-0.8472475927118217	5.809316888236385	6.5936932061894	1.6850627601156836	-1.5260563034950494	-1.1526795099383853	2.5323103528275053
13722.58cfa830e4b0c9d6adf6c172	58cfa830e4b0c9d6adf6c172	TCGA-BS-A0U7-01A-21D-A101_120407_SN590_0152_AC0C7LACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BS-A0U7-01A-21D-A101_120407_SN590_0152_AC0C7LACXX_s_7_rg.sorted	TCGA-BS-A0U7-01A-21D-A101_120407_SN590_0152_AC0C7LACXX_s_7_rg.sorted.bam	86.95	1.93	0.17	58cfa830e4b0c9d6adf6c172	TCGA-BS-A0U7-01A-21D-A101_120407_SN590_0152_AC0C7LACXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0U7-01A	282DDC43-922D-4F1F-80C7-6BA2DE23B7BC	Primary Tumor	Illumina HiSeq	1d76b3a6-ff5e-4092-b273-cc2380e0810c	Uterus	63.0	803C6D51-0EBA-475A-9C3C-7B3401787907	652088F1-AB84-40C7-8B24-FD92A32DFA44	TCGA-BS-A0U7-01A-21D-A101-02	HG19_Broad_variant	TCGA-BS-A0U7	TCGA-UCEC	935.0	s4436	Harvard Medical School	University of Hawaii	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C1	UCEC.CN_LOW	0.19479126100000002	0.4	0.0	0.9654238909999999	0.2997	0.03	-0.1024	0.7726	-0.5823	0.0847	90.0	226.0	1.8571367319999998	4.3510060589999995	66.0	0.090791527	3.0	0.0							2.2683422	-1075.330733	-9.066913768	2869.679393	1.0	935.0	0.0	935.0	6.8544717012003655	7.216499689163319	-0.1168493169911432	5.9606538251782695	6.329196494162416	1.9227968122659265	-0.8938178760220965	-0.8873031950009029	2.0396461292570693
13722.58cfa830e4b0c9d6adf6c178	58cfa830e4b0c9d6adf6c178	TCGA-B9-4115-01A-01D-1554-10_wgs_Illumina.filtered.	WGS	TCGA-B9-4115-01A-01D-1554-10_wgs_Illumina	TCGA-B9-4115-01A-01D-1554-10_wgs_Illumina.bam	374.67	1.9	0.05	58cfa830e4b0c9d6adf6c178	TCGA-B9-4115-01A-01D-1554-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-B9-4115-01A	A121406A-30B2-4717-AE96-EDCB17D911E2	Primary Tumor	Illumina HiSeq	4971043f-212e-4a2c-a9db-7e10c9203ce1	Kidney	53.0	31769C98-8882-44E9-B61B-417903B3E4F5	0ED63D84-D3FE-4289-9255-35F4A03B703B	TCGA-B9-4115-01A-01D-1554-10	GRCh37-lite	TCGA-B9-4115	TCGA-KIRP		s11858	Baylor College of Medicine	UNC	None	NO	T1a	NX	Kidney Papillary Renal Cell Carcinoma	Stage I	1554-10	False	KIRP	C4	KIRP.C1	0.17224545100000002	0.26	0.0		-0.9269	0.06	0.4987	-0.5494	-0.3537	-0.38799999999999996	14.0	15.0	0.645425991	1.3788646169999998	91.0	0.082005147	4.0	0.0				1.557113098	5.0	0.967488765	2.4011893769999997	-946.2701302000002	-1331.202172	-1204.50506	0.0	803.0	0.0	803.0	7.575698605178792	1.1002236328775332	0.2904533823418495	6.276415621048532	3.0757570919798587	3.9969649348952876	-1.2992829841302607	1.9755334591023255	3.706511552553438
13722.58cfa830e4b0c9d6adf6c17e	58cfa830e4b0c9d6adf6c17e	TCGA-BA-4074-01A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BA-4074-01A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_1_rg.sorted	TCGA-BA-4074-01A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_1_rg.sorted.bam	598.33	1.9	0.16	58cfa830e4b0c9d6adf6c17e	TCGA-BA-4074-01A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-4074-01A	A63CA97D-EF31-4118-9547-A6730967290F	Primary Tumor	Illumina HiSeq	da78e5e3-ea94-4ac2-8b21-69809cabb0c7	Head and Neck	69.0	7BC6B159-19B4-4711-961D-830BC9E56493	4786A24C-D127-43FB-9D9C-FF59622B7B24	TCGA-BA-4074-01A-01D-1431-02	HG19_Broad_variant	TCGA-BA-4074	TCGA-HNSC	462.0	s16168	Harvard Medical School	UNC	None	NO	T2	N2c	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	True	HNSC	C2	HNSC.Mesenchymal	0.217916472	0.39	0.06		1.4033	0.912	-0.1023	-0.2615	1.0226	0.3959	79.0	71.0	1.093732144	3.4214185010000002	168.0	0.648295559	12.0	27.0				1.5607104090000001	5.0	0.9697239	3.5184408510000003	-109.80266850000001	1332.256111	-990.9211207999999	1.0	462.0	1.0	396.0	6.832384971957361	5.0280499161018755	-0.5226585836771958	5.767674234964932	6.551266653088846	0.7014565923848728	-1.0647107369924282	1.5232167369869707	1.2241151760620685
13722.58cfa830e4b0c9d6adf6c196	58cfa830e4b0c9d6adf6c196	TCGA-AK-3455-01A-01D-2233-10_wgs_Illumina.filtered.	WGS	TCGA-AK-3455-01A-01D-2233-10_wgs_Illumina	TCGA-AK-3455-01A-01D-2233-10_wgs_Illumina.bam	612.57	1.9	0.05	58cfa830e4b0c9d6adf6c196	TCGA-AK-3455-01A-01D-2233-10_wgs_Illumina.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-AK-3455-01A	2ED3296A-5B10-40D8-8AF4-90DC031657CD	Primary Tumor	Illumina HiSeq	77412ddb-2013-4e9c-aa60-2ce76f5269a8	Kidney	71.0	2D970196-BEEE-4783-90A1-E313A789DD92	A56CD282-F6C5-4373-B3D8-676562894598	TCGA-AK-3455-01A-01D-2233-10	GRCh37-lite	TCGA-AK-3455	TCGA-KIRC	683.0	s9730	Baylor College of Medicine	Fox Chase	United States	NO	T3b	NX	Kidney Clear Cell Renal Carcinoma	Stage III	2233-10	False	KIRC	C2	KIRC.4	0.282271221	0.44	0.0		-1.4021	-0.1195	0.5638	1.8656	0.4907	-0.4608	32.0	32.0	0.307238025	1.508259396	95.0	0.100649239	2.0	3.0	0.786630167	2.130233981	15.0	4.086051756	132.0	0.836825212	2.153205793	856.153091	-1036.220207	2669.7582239999997	1.0	683.0	0.0	683.0	7.547457729669015	0.18212187628210863	1.298533210129935	5.437244529322425	2.331969172607317	2.9819298855261938	-2.1102132003465894	2.149847296325208	1.683396675396259
13722.58cfa830e4b0c9d6adf6c198	58cfa830e4b0c9d6adf6c198	TCGA-B9-4116-01A-02D-1402-10_wgs_Illumina.filtered.	WGS	TCGA-B9-4116-01A-02D-1402-10_wgs_Illumina	TCGA-B9-4116-01A-02D-1402-10_wgs_Illumina.bam	149.07	1.8	0.05	58cfa830e4b0c9d6adf6c198	TCGA-B9-4116-01A-02D-1402-10_wgs_Illumina.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-B9-4116-01A	4EDD92E1-5DA5-49A3-80E4-FA456AA425B8	Primary Tumor	Illumina HiSeq	23059106-498b-44b7-a1a9-72b42dcd751c	Kidney	75.0	DAC245C0-39A0-40D3-8FE1-E33F97B95D27	E6801359-D1D7-4871-B2FB-180674A2E469	TCGA-B9-4116-01A-02D-1402-10	GRCh37-lite	TCGA-B9-4116	TCGA-KIRP		s11772	Baylor College of Medicine	UNC	None	NO	T2a	NX	Kidney Papillary Renal Cell Carcinoma		1402-10	False	KIRP	C3	KIRP.C1	0.18051490899999997	0.18	0.03		-0.9429	-0.111	-0.0745	-0.4141	-0.0478	-0.0193	26.0	6.0	0.7436136740000001	1.9448357630000002	137.0	0.167568289	4.0	7.0				2.25385759	10.0	0.9788379140000001	2.4704324580000003	49.34449847	-1523.8356449999999	-1543.987715	0.0	627.0	0.0	627.0	7.599401333415814	2.5120705787288227	0.09404515749773801	4.737200452486347	2.291829787072575	0.9389859160275602	-2.862200880929468	-0.22024079165624766	0.8449407585298222
13722.58cfa830e4b0c9d6adf6c1a0	58cfa830e4b0c9d6adf6c1a0	TCGA-B7-5818-01A-11D-1598_121130_SN1222_0160_AC1F13ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-B7-5818-01A-11D-1598_121130_SN1222_0160_AC1F13ACXX_s_8_rg.sorted	TCGA-B7-5818-01A-11D-1598_121130_SN1222_0160_AC1F13ACXX_s_8_rg.sorted.bam	411.0	1.9	0.14	58cfa830e4b0c9d6adf6c1a0	TCGA-B7-5818-01A-11D-1598_121130_SN1222_0160_AC1F13ACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-B7-5818-01A	6E03B415-84A1-4B91-8717-1A41EDD4A255	Primary Tumor	Illumina HiSeq	9924779b-8261-4ea6-9925-28dd5a0aed8a	Stomach	62.0	FD97CDF5-0F7F-48A2-B5DA-5C5F56A89166	0EBF1A63-C6E4-49FE-B21B-AE46FF14261D	TCGA-B7-5818-01A-11D-1598-02	HG19_Broad_variant	TCGA-B7-5818	TCGA-STAD		s14963	Harvard Medical School	Cureline	Russia	NO	T2	N0	Stomach  Adenocarcinoma  Diffuse Type	Stage IB	1598-02	True	STAD	C2	GI.EBV	0.209524916	0.29	0.01		0.456	0.2935	0.5016	0.6304	-0.3767	0.0536			2.8936743710000004	9.339978661	106.0	0.24794421600000002	6.0	9.0	0.84995006	3.325024187	50.0	4.553101348	107.0	0.974377943	1.038937985	-707.1105459	71.76064057	1624.563314	0.0	356.0	0.0	356.0	8.79346036105272	6.3270435277519805	0.45982683681688163	6.8963403761668385	7.3982568422319765	1.4767437681025906	-1.897119984885881	1.0712133144799956	1.016916931285709
13722.58cfa830e4b0c9d6adf6c1a6	58cfa830e4b0c9d6adf6c1a6	TCGA-BH-A0HB-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BH-A0HB-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_5_rg.sorted	TCGA-BH-A0HB-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_5_rg.sorted.bam	58.9	2.0	0.14	58cfa830e4b0c9d6adf6c1a6	TCGA-BH-A0HB-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE		Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0HB-01A	0C1023C0-D2CE-4940-8047-7642F1DC3965	Primary Tumor	Illumina HiSeq	c9a434dc-8ce3-485f-88aa-a2373f6cdfac	Breast	55.0	19193B8F-1E1B-448C-B934-93F25E60D45B	49556237-D73F-4DE9-B5D9-7169DB7A53C5	TCGA-BH-A0HB-01A-11D-A060-02	HG19_Broad_variant	TCGA-BH-A0HB	TCGA-BRCA		s6275	Harvard Medical School	University of Pittsburgh	None	NO	T1c	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IA	A060-02	True	BRCA	C2	BRCA.LumA	0.21892633600000003	0.35	0.09	5.581433027	0.4531	0.27399999999999997	0.2835	0.9109	0.7308	0.1735	15.0	49.0	0.269580525	0.92855514	523.0	0.299922647	6.0	27.0	0.9672912379999999	1.5567951919999998	5.0	3.641219045	44.0	0.962218968	2.88687138	-411.2400019	751.3770423	-608.1403228999999	0.0	806.0	0.0	806.0	8.89802401856604	6.475362676430905	-0.8068036889425579	6.455676983196836	7.040676485480965	1.8380366426363484	-2.4423470353692043	0.5653138090500605	2.6448403315789064
13722.58cfa830e4b0c9d6adf6c1aa	58cfa830e4b0c9d6adf6c1aa	TCGA-BA-5555-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BA-5555-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_2_rg.sorted	TCGA-BA-5555-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_2_rg.sorted.bam	213.7	1.9	0.16	58cfa830e4b0c9d6adf6c1aa	TCGA-BA-5555-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_2_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-5555-01A	8970F713-4A7A-4125-892C-6A34139371D8	Primary Tumor	Illumina HiSeq	cd7725ec-bc8e-4c93-aba5-19dbdeb78b0d	Head and Neck	54.0	2920CA1C-6035-4350-ADA4-C60D485DBFFF	4AB42DF9-A215-4965-A125-CC0C4122FF06	TCGA-BA-5555-01A-01D-1509-02	HG19_Broad_variant	TCGA-BA-5555	TCGA-HNSC		s15609	Harvard Medical School	UNC	None	NO	T3	N2c	Head and Neck Squamous Cell Carcinoma	Stage IVA	1509-02	True	HNSC	C2	HNSC.Atypical	0.260293503	0.54	0.21		0.807	0.14400000000000002	-0.2171	0.3124	1.0483	0.4242	55.0	0.0	0.815427391	3.5147732389999997	183.0	0.6962147679999999	21.0	32.0	0.917140707	2.9881329610000003	26.0	2.625048159	15.0	0.969349888	2.156071433	-156.5966621	740.8779882	676.6692367	0.0	520.0	1.0	248.0	7.126991205465329	7.977157189550445	-0.028551236691811033	6.316060989249	7.079215596344486	1.5325433971516065	-0.8109302162163288	-0.8979415932059585	1.5610946338434175
13722.58cfa830e4b0c9d6adf6c1ae	58cfa830e4b0c9d6adf6c1ae	TCGA-B9-4617-01A-01D-1253-10_wgs_Illumina.filtered.	WGS	TCGA-B9-4617-01A-01D-1253-10_wgs_Illumina	TCGA-B9-4617-01A-01D-1253-10_wgs_Illumina.bam	45.94	1.9	0.15	58cfa830e4b0c9d6adf6c1ae	TCGA-B9-4617-01A-01D-1253-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-B9-4617-01A	A6E960AF-3CA5-42FB-B546-451C2583282D	Primary Tumor	Illumina HiSeq	dbbf365c-a7c9-4093-8ffb-acf0b6eabf20	Kidney	41.0	605B6DD3-552B-403C-98D9-C8B441B37A90	BEF23192-57CD-4301-B7A7-5E82CA62482D	TCGA-B9-4617-01A-01D-1253-10	GRCh37-lite	TCGA-B9-4617	TCGA-KIRP		s11586	Baylor College of Medicine	UNC	None	NO	T1a	NX	Kidney Papillary Renal Cell Carcinoma		1253-10	False	KIRP	C3	KIRP.C1	0.062399486	0.17	0.01		-1.8209	-0.19399999999999998	-0.1618	-0.986	-0.6626	-0.5113	25.0	66.0	0.24929011199999998	1.135654954	285.0	0.947764665	14.0	0.0				1.4270610430000001	5.0	0.88668288	1.913686215	-1233.624022	-1964.5944780000002	-188.5024181	0.0	35.0	0.0	35.0	6.843749949006225	0.7718519760685165	-0.4230490828971689	5.80576228215455	2.0769455517942434	4.879260304920406	-1.037987666851675	1.305093575725727	5.302309387817575
13722.58cfa830e4b0c9d6adf6c1b2	58cfa830e4b0c9d6adf6c1b2	TCGA-BG-A0MO-01A-11D-A043_120327_SN590_0148_BC0LM8ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BG-A0MO-01A-11D-A043_120327_SN590_0148_BC0LM8ACXX_s_1_rg.sorted	TCGA-BG-A0MO-01A-11D-A043_120327_SN590_0148_BC0LM8ACXX_s_1_rg.sorted.bam	37.97	2.0	0.16	58cfa830e4b0c9d6adf6c1b2	TCGA-BG-A0MO-01A-11D-A043_120327_SN590_0148_BC0LM8ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0MO-01A	734EF97F-807C-480E-8DF9-FEAF041032D2	Primary Tumor	Illumina HiSeq	e165d17d-a860-4111-9ae9-3fb19605cd21	Uterus	63.0	7582CBB9-42D3-496C-991D-D76BEA4C434C	9AD06738-F4A2-47A8-972E-BF8C817326A6	TCGA-BG-A0MO-01A-11D-A043-02	HG19_Broad_variant	TCGA-BG-A0MO	TCGA-UCEC		s5215	Harvard Medical School	University of Pittsburgh	None	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C2	UCEC.CN_LOW	0.06061735	0.78	0.05	9.959492093	-0.59	-0.011000000000000001	-0.2003	0.1056	0.1268	-0.3421	23.0	2.0	0.37797614399999996	1.133928433	41.0	0.043301803	2.0	4.0							2.55841676	-1144.6391310000001	-1238.05468	2878.004304	0.0	1309.0	0.0	1309.0	5.581525158604897	6.164436981175827	-0.19893380280698336	4.3775523542789605	4.960464176849891	2.5310324731833758	-1.2039728043259363	-1.203972804325936	2.729966275990359
13722.58cfa830e4b0c9d6adf6c1b6	58cfa830e4b0c9d6adf6c1b6	TCGA-BA-4076-01A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BA-4076-01A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_5_rg.sorted	TCGA-BA-4076-01A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_5_rg.sorted.bam	333.33	1.9	0.15	58cfa830e4b0c9d6adf6c1b6	TCGA-BA-4076-01A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_5_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-4076-01A	7DE19081-D5FD-468C-AD0D-F6E3E8B2AD70	Primary Tumor	Illumina HiSeq	f67d413c-c33d-4d97-9853-0b00f93f2304	Head and Neck	39.0	FD99FD83-4040-4738-8A5A-E42D36ECFE0E	54F77A3E-290A-4073-8012-4873579E95E9	TCGA-BA-4076-01A-01D-1431-02	HG19_Broad_variant	TCGA-BA-4076	TCGA-HNSC	415.0	s15749	Harvard Medical School	UNC	None	NO	TX	NX	Head and Neck Squamous Cell Carcinoma		1431-02	True	HNSC	C1	HNSC.Basal	0.077182429	0.15	0.04		0.5787	0.3035	-0.9717	-0.9716	-1.0844	0.2782	71.0	53.0	2.357735115	8.152650339	254.0	0.6594124920000001	9.0	32.0		0.0	1.0	1.039720771	3.0	0.94639463	4.900389623	-579.1640716	443.16475959999997	528.3904353999999	1.0	415.0	1.0	286.0	-0.7675321983744094	4.336103349837051	-1.8094635551478357	5.169140117232135	7.479458192077377	0.5059544437711327	5.936672315606544	3.143354842240326	2.3154179989189685
13722.58cfa830e4b0c9d6adf6c1b8	58cfa830e4b0c9d6adf6c1b8	TCGA-BF-A1PZ-01A-11D-A18Z_120612_SN590_0162_BC0VNGACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BF-A1PZ-01A-11D-A18Z_120612_SN590_0162_BC0VNGACXX_s_5_rg.sorted	TCGA-BF-A1PZ-01A-11D-A18Z_120612_SN590_0162_BC0VNGACXX_s_5_rg.sorted.bam	64.32		0.18	58cfa830e4b0c9d6adf6c1b8	TCGA-BF-A1PZ-01A-11D-A18Z_120612_SN590_0162_BC0VNGACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-BF-A1PZ-01A	455F982C-A067-46AC-BF89-3E535D0FFCA0	Primary Tumor	Illumina HiSeq	61217185-aa8a-467c-ba89-48231f6a81cc	Skin	71.0	2A5EE782-122E-432B-98E0-0849B6F9A3D9	25D65D8B-ED75-47D6-B7F6-95CF26CCBE06	TCGA-BF-A1PZ-01A-11D-A18Z-02	HG19_Broad_variant	TCGA-BF-A1PZ	TCGA-SKCM		s7319	Harvard Medical School	Cureline	Russia	NO	T4a	N0		Stage IIB	A18Z-02	True	SKCM	C2	SKCM.RAS_Hotspot_Mutants	0.1190901	0.1	0.16		0.23800000000000002	0.114	-0.612	-0.7079	0.8755	-0.1944	90.0	1.0	3.0853450660000004	6.42515158			8.0	10.0	0.976344993	2.030252337	8.0	2.3419942519999997	11.0	0.9766874640000001	4.884418477	-602.9931837	71.85575881	-928.5924656	0.0	853.0	0.0	853.0	6.282733927469792	5.950034729011508	0.1120358151302352	5.977352277918611	6.355499837119673	1.2341436819592992	-0.30538164955118186	0.4054651081081646	1.1221078668290638
13722.58cfa830e4b0c9d6adf6c1ba	58cfa830e4b0c9d6adf6c1ba	TCGA-BS-A0UT-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BS-A0UT-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_4_rg.sorted	TCGA-BS-A0UT-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_4_rg.sorted.bam	65.26	1.97	0.13	58cfa830e4b0c9d6adf6c1ba	TCGA-BS-A0UT-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_4_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0UT-01A	E2B1D0DE-5221-44A1-8FAD-9708A3CADA14	Primary Tumor	Illumina HiSeq	ca5a88b7-6801-435a-aeef-b9ca9d963c17	Uterus	62.0	824D0DBC-293F-4893-A68C-24DEDD437EA5	12674687-D555-40DB-ACC9-7638F85D0661	TCGA-BS-A0UT-01A-11D-A101-02	HG19_Broad_variant	TCGA-BS-A0UT	TCGA-UCEC		s4608	Harvard Medical School	University of Hawaii	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C1	UCEC.CN_LOW	0.035815087			0.081570901	-0.0888	-0.094	-1.1244	-1.6898	-0.7071	0.2666	2.0	0.0	0.256639565	0.969527245	63.0	0.7857368779999999	7.0	1.0							2.201572126	-1600.193687	-886.9294057	1637.9586470000002	0.0	2212.0	0.0	2212.0	6.688794145622208	7.52321115182621	-0.6408194288007696	6.15471165969195	6.51161024014773	1.513475962199913	-0.534082485930258	-1.0116009116784803	2.1542953910006823
13722.58cfa830e4b0c9d6adf6c1bc	58cfa830e4b0c9d6adf6c1bc	TCGA-AG-A01L-01A-01D-A077_110406_SN177_0154_B818URABXX_s_1_rg.sorted.filtered.	WGS	TCGA-AG-A01L-01A-01D-A077_110406_SN177_0154_B818URABXX_s_1_rg.sorted	TCGA-AG-A01L-01A-01D-A077_110406_SN177_0154_B818URABXX_s_1_rg.sorted.bam	251.75	1.72	0.15	58cfa830e4b0c9d6adf6c1bc	TCGA-AG-A01L-01A-01D-A077_110406_SN177_0154_B818URABXX_s_1_rg.sorted.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A01L-01A	848A5838-8A06-45A9-A3D6-E4ED47B824AB	Primary Tumor	Illumina HiSeq	f1b7cb66-3e14-4411-b17a-0ad856d8c686	Colorectal	58.0	B034C90B-D0BD-466A-88BA-B61EFD36C6E4	337F94D6-ECFB-4653-A63C-49F0D1893BF0	TCGA-AG-A01L-01A-01D-A077-02	HG18_Broad_variant	TCGA-AG-A01L	TCGA-READ		s2002	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Rectal Adenocarcinoma	Stage IIIB	A077-02	True	READ	C1	GI.CIN	0.054700874000000003	0.22	0.25	11.35399254	0.5942	0.133	-1.12	-0.3961	-1.1479	-0.2256	32.0	4.0	0.46673369600000003	1.835819204	120.0	0.900046233	17.0	5.0								-1560.29285	105.1593271	-254.377135	0.0	0.0	0.0	0.0	6.592907538457587	5.3255768366728695	-0.40454733239817164	4.6613861268543735	5.263056479691536	5.895404085912952	-1.9315214116032138	-0.06252035698133351	6.2999514183111245
13722.58cfa830e4b0c9d6adf6c1c0	58cfa830e4b0c9d6adf6c1c0	TCGA-BB-4225-01A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BB-4225-01A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_3_rg.sorted	TCGA-BB-4225-01A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_3_rg.sorted.bam	56.7	1.9	0.15	58cfa830e4b0c9d6adf6c1c0	TCGA-BB-4225-01A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BB-4225-01A	C1F50A22-38DF-41CC-A1F4-F7985504A7AC	Primary Tumor	Illumina HiSeq	4903ac5e-6fa0-41de-b272-c4139a3c0632	Head and Neck	73.0	AC42070B-F4D6-47BE-96AA-A713D66A0072	F7E6BD4D-3E7C-427E-8618-FAFB3731E597	TCGA-BB-4225-01A-01D-1431-02	HG19_Broad_variant	TCGA-BB-4225	TCGA-HNSC		s16024	Harvard Medical School	Johns Hopkins	United States	NO	TX	NX	Head and Neck Squamous Cell Carcinoma		1431-02	True	HNSC	C2	HNSC.Atypical	0.19049693899999998	0.35	0.25		0.9704	0.233	0.447	1.8278	1.3726	0.0134	33.0		0.7415959	1.4831918	127.0	0.860108675	22.0	11.0	0.853089199	4.410884048	176.0	4.756702113999999	125.0	0.9851683990000001	2.761468795	-242.00409759999997	753.5966581	-3679.009725	0.0	146.0	0.0	146.0	7.249136083767851	8.87140009224059	-0.5347411751625486	6.150523795099742	7.731965809052225	1.6718555420025338	-1.0986122886681096	-1.1394342831883648	2.206596717165082
13722.58cfa830e4b0c9d6adf6c1c8	58cfa830e4b0c9d6adf6c1c8	TCGA-BC-A217-01A-11D-A152-10_wgs_Illumina.filtered.	WGS	TCGA-BC-A217-01A-11D-A152-10_wgs_Illumina	TCGA-BC-A217-01A-11D-A152-10_wgs_Illumina.bam	102.31	1.74	0.09	58cfa830e4b0c9d6adf6c1c8	TCGA-BC-A217-01A-11D-A152-10_wgs_Illumina.bam	Alive	FEMALE	WHITE		Liver Hepatocellular Carcinoma	Aligned reads	TCGA-BC-A217-01A	6DCFC418-AB28-4365-95EA-C1AE254F2341	Primary Tumor	Illumina HiSeq	a8b86f30-113b-4e02-98d3-b1dae29380d3	Liver	75.0	C827A8B9-359C-4A6F-B950-839B3FB0C097	2BFF30D5-BE79-4686-8164-7A7D9619D3C0	TCGA-BC-A217-01A-11D-A152-10	GRCh37-lite	TCGA-BC-A217	TCGA-LIHC		s17057	Baylor College of Medicine	UNC	United States	NO	T2	NX	Hepatocellular Carcinoma	Stage II	A152-10	True	LIHC	C2	LIHC.iCluster:3	0.080023226	0.08	0.27		0.3042	0.07200000000000001	-0.2665	0.2111	0.3903	-1.0167	45.0	10.0	0.8081864390000001	2.320277194	574.0	0.79188261	21.0	34.0	0.46681164399999997	0.970707524	8.0	1.791759469	6.0	1.0	4.254714142	-1392.1493560000001	-80.58747347	3891.861006	1.0	1397.0	0.0	1397.0	6.814699698514689	1.736104362947228	0.3199889201386025	5.464772981565673	1.9570125628596182	3.6054978451748854	-1.349926716949016	0.2209081999123903	3.285508925036283
13722.58cfa830e4b0c9d6adf6c1cc	58cfa830e4b0c9d6adf6c1cc	TCGA-BF-A1PU-01A-11D-A18Z_120517_SN208_0300_BC0VYMACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BF-A1PU-01A-11D-A18Z_120517_SN208_0300_BC0VYMACXX_s_5_rg.sorted	TCGA-BF-A1PU-01A-11D-A18Z_120517_SN208_0300_BC0VYMACXX_s_5_rg.sorted.bam	55.01		0.18	58cfa830e4b0c9d6adf6c1cc	TCGA-BF-A1PU-01A-11D-A18Z_120517_SN208_0300_BC0VYMACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE		Skin Cutaneous Melanoma	Aligned reads	TCGA-BF-A1PU-01A	3DD5A206-D7F3-42F1-B9CC-4B31C76D495D	Primary Tumor	Illumina HiSeq	26c2ab51-9411-4718-8733-1c3c5ba19602	Skin	46.0	D9C8128A-5990-43C8-AC08-CBDF035213D6	AAC0230D-759F-4B2E-9904-3F7822E6B13C	TCGA-BF-A1PU-01A-11D-A18Z-02	HG19_Broad_variant	TCGA-BF-A1PU	TCGA-SKCM		s7667	Harvard Medical School	Cureline	Russia	NO	T4b	N0		Stage IIC	A18Z-02	True	SKCM	C1	SKCM.BRAF_Hotspot_Mutants	0.07290150299999999	0.08	0.03		0.1199	-0.05	-1.4077	-2.2016	-1.6979	0.2661	36.0		1.012714415	2.2095587230000002			8.0	19.0		0.0	1.0		0.0		1.9015404269999998	-1368.553211	1014.950693	-2119.084451	0.0	387.0	1.0	484.0	7.053091717056422	5.976484483064246	-0.16047772298405705	5.82094803576379	5.588718952055482	-0.1321212476436382	-1.2321436812926327	-0.38776553100876354	0.028356475340418852
13722.58cfa830e4b0c9d6adf6c1d6	58cfa830e4b0c9d6adf6c1d6	TCGA-BC-A216-01A-11D-A152-10_wgs_Illumina.filtered.	WGS	TCGA-BC-A216-01A-11D-A152-10_wgs_Illumina	TCGA-BC-A216-01A-11D-A152-10_wgs_Illumina.bam	85.26	1.85	0.09	58cfa830e4b0c9d6adf6c1d6	TCGA-BC-A216-01A-11D-A152-10_wgs_Illumina.bam	Alive	FEMALE	WHITE		Liver Hepatocellular Carcinoma	Aligned reads	TCGA-BC-A216-01A	4BBDBE77-F3CB-4B64-9826-72DEBB734784	Primary Tumor	Illumina HiSeq	b808f3c9-f5be-4c4d-af62-4389365badbb	Liver	62.0	F8B5247F-5276-4189-9041-2D914482D539	C1D9ED06-7498-4C6C-A0DE-DBF28E868109	TCGA-BC-A216-01A-11D-A152-10	GRCh37-lite	TCGA-BC-A216	TCGA-LIHC		s16672	Baylor College of Medicine	UNC	United States	NO	T3	NX	Hepatocellular Carcinoma	Stage IIIA	A152-10	True	LIHC	C1	LIHC.iCluster:3	0.168912273	0.16	0.07		0.7013	0.0315	-0.2795	0.4947	-0.4007	-0.4818	28.0	1.0	0.434042131	1.600530356	567.0	0.20920491800000002	5.0	20.0	0.90929609	1.7694084890000001	7.0	2.8676876389999997	21.0	0.941917065	2.230385874	-1257.712443	611.6685476	3403.995571	0.0	1351.0	0.0	1351.0	6.641008090185794	1.5880970807388035	0.7465819907419503	5.542395801517685	3.3314151621771755	2.229856259888461	-1.0986122886681096	1.743318081438372	1.4832742691465106
13722.58cfa830e4b0c9d6adf6c1db	58cfa830e4b0c9d6adf6c1db	TCGA-BB-4224-01A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BB-4224-01A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_1_rg.sorted	TCGA-BB-4224-01A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_1_rg.sorted.bam	16.7	1.9	0.13	58cfa830e4b0c9d6adf6c1db	TCGA-BB-4224-01A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BB-4224-01A	58574E35-8A30-4207-B127-59FFF7C87A43	Primary Tumor	Illumina HiSeq	44a7ef3f-57df-49e2-80b9-1f0dca51067f	Head and Neck	52.0	077ACD68-8C30-41A6-BB7E-5B014866B807	E2FF93EB-AE22-4C6B-B4D5-181B9393BC64	TCGA-BB-4224-01A-01D-1431-02	HG19_Broad_variant	TCGA-BB-4224	TCGA-HNSC		s15876	Harvard Medical School	Johns Hopkins	United States	NO	T2	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	True	HNSC	C2	HNSC.Basal	0.083494882	0.26	0.19		1.3074	0.3855	-0.5595	-1.4027	0.738	-0.1906	33.0	15.0	0.509826928	1.8693654030000002	208.0	0.461543518	15.0	37.0				0.410116318	2.0	0.591672779	1.485900205	-679.6364129	1183.5314349999999	-3659.574743	0.0	278.0	1.0	175.0	7.140905736635371	8.02852380418292	-0.5745717214523746	6.345975861765484	7.881920329991043	-0.27150532486273904	-0.7949298748698879	-0.1466034741918758	0.3030663965896355
13722.58cfa830e4b0c9d6adf6c1de	58cfa830e4b0c9d6adf6c1de	TCGA-BT-A0YX-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BT-A0YX-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_6_rg.sorted	TCGA-BT-A0YX-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_6_rg.sorted.bam	62.34	1.97	0.15	58cfa830e4b0c9d6adf6c1de	TCGA-BT-A0YX-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A0YX-01A	22473AD4-DF39-4716-B558-3C1409D5FA0E	Primary Tumor	Illumina HiSeq	71886c7b-a73b-4c00-9555-5fd61b5e1347	Bladder	70.0	DA614214-F84C-43AB-983C-D9D76CF2D6AE	DC052DFC-26A8-4393-8849-FA954913C622	TCGA-BT-A0YX-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BT-A0YX	TCGA-BLCA		s2867	Harvard Medical School	University of Pittsburgh	None	NO	T3b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A10R-02	True	BLCA	C1	BLCA.3	0.456947714	0.51	0.04	24.85415126	0.6325	0.2625	0.1189	0.54	-0.3435	0.187	255.0	47.0	5.245224957	16.19178139	91.0	0.10102124800000001	1.0	16.0	0.8128249940000001	2.548608067	23.0	2.500138026	14.0	0.947360256	3.956993026	-487.7126665	247.977994	-2479.3929550000003	1.0	400.0	1.0	326.0	6.634332956072036	7.323350719743974	0.18661286717850523	5.498333135332306	5.89260459605325	1.3126662929945754	-1.13599982073973	-1.4307461236907244	1.1260534258160702
13722.58cfa830e4b0c9d6adf6c1e1	58cfa830e4b0c9d6adf6c1e1	TCGA-BG-A0MT-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BG-A0MT-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_8_rg.sorted	TCGA-BG-A0MT-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_8_rg.sorted.bam	93.28	1.98	0.17	58cfa830e4b0c9d6adf6c1e1	TCGA-BG-A0MT-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0MT-01A	082E32C5-7F82-466A-B52D-A3293A8F8E57	Primary Tumor	Illumina HiSeq	3499ad67-e5ed-4030-9fba-fac9fa52f9c5	Uterus	64.0	91F629F5-6938-4F5C-BA2E-1F519CE6B255	23FB2C48-BE95-4169-BB10-00EA361C5687	TCGA-BG-A0MT-01A-11D-A101-02	HG19_Broad_variant	TCGA-BG-A0MT	TCGA-UCEC		s5217	Harvard Medical School	University of Pittsburgh	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C4	UCEC.CN_LOW	0.14203947	0.19	0.02	5.039507432	0.2185	0.154	0.1154	-0.3731	0.674	-0.3874	14.0	4.0	0.379741038	0.788692924	139.0	0.155629562	3.0	16.0							2.29435229	-854.1064969	-716.326146	-3268.930664	0.0	644.0	1.0	565.0	6.992674963735178	7.518804611209893	0.49185704346035947	6.854524625254361	6.920967610454273	4.477661437107254	-0.13815033848081715	-0.5978370007556202	3.9858043936468945
13722.58cfa830e4b0c9d6adf6c1e6	58cfa830e4b0c9d6adf6c1e6	TCGA-AL-3466-01A-02D-1402-10_wgs_Illumina.filtered.	WGS	TCGA-AL-3466-01A-02D-1402-10_wgs_Illumina	TCGA-AL-3466-01A-02D-1402-10_wgs_Illumina.bam	151.07	1.9	0.05	58cfa830e4b0c9d6adf6c1e6	TCGA-AL-3466-01A-02D-1402-10_wgs_Illumina.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-AL-3466-01A	9FC40B03-0B56-4B1F-93ED-DBC455AE3FD9	Primary Tumor	Illumina HiSeq	e3c3f7d5-b1b3-4a59-be19-a675fd939ad5	Kidney	41.0	D74C7152-798F-4913-95D3-67AC834204F0	642E1379-1061-40BC-9A4C-F7C191E84D9D	TCGA-AL-3466-01A-02D-1402-10	GRCh37-lite	TCGA-AL-3466	TCGA-KIRP	293.0	s11766	Baylor College of Medicine	Fox Chase	None	NO	T3b	N1	Kidney Papillary Renal Cell Carcinoma	Stage IV	1402-10	False	KIRP	C3	KIRP.C2b	0.16010785800000002	0.36	0.09		0.1059	0.0285	-0.3576	-0.4269	-0.6993	-0.3185	14.0	3.0	0.280575521	0.7856114590000001	470.0	0.974378915	23.0	29.0				0.9839614459999999	3.0	0.8956403059999999	3.732598437	146.8806564	420.1718153	-1421.316635	1.0	293.0	1.0	138.0	6.843749949006225	3.9735759887533124	0.016400367593497056	4.764308407326389	3.2322654068147445		-2.079441541679836	-0.7413105819385679	
13722.58cfa830e4b0c9d6adf6c1f2	58cfa830e4b0c9d6adf6c1f2	TCGA-BT-A20N-01A-11D-A14U_120921_SN208_0431_BD1D5FACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BT-A20N-01A-11D-A14U_120921_SN208_0431_BD1D5FACXX_s_1_rg.sorted	TCGA-BT-A20N-01A-11D-A14U_120921_SN208_0431_BD1D5FACXX_s_1_rg.sorted.bam	70.31	1.91	0.17	58cfa830e4b0c9d6adf6c1f2	TCGA-BT-A20N-01A-11D-A14U_120921_SN208_0431_BD1D5FACXX_s_1_rg.sorted.bam	Dead	MALE			Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A20N-01A	EBEDAB7C-DD7C-448E-8324-78C86F13BE8B	Primary Tumor	Illumina HiSeq	c7de2a6f-d24f-4be6-98af-307070063116	Bladder	72.0	89EC2DFD-7A0C-4631-958D-D5492BC89F8D	CE801D11-240F-4510-8010-E3D7DA8247FC	TCGA-BT-A20N-01A-11D-A14U-02	HG19_Broad_variant	TCGA-BT-A20N	TCGA-BLCA	795.0	s2697	Harvard Medical School	University of Pittsburgh	None	NO	T3a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A14U-02	True	BLCA	C1	BLCA.1	0.18273757899999998	0.28	0.64	4.155600154	0.9077	0.2925	-1.3335	-1.7928	-1.0122	0.0371	133.0	42.0	2.5769137509999998	6.639342488	274.0	0.7609570240000001	12.0	63.0	0.999495093	0.6927972059999999	2.0	0.6365141679999999	2.0	0.918295834	1.85374376	-1616.745447	1290.213786	-1642.787583	1.0	795.0	1.0	795.0	7.028774901301882	9.436461304670013	0.11491029596169988	5.891696331805976	8.433159195806228	3.6246286613627556	-1.1370785694959058	-1.0033021088637848	3.5097183654010555
13722.58cfa830e4b0c9d6adf6c1f6	58cfa830e4b0c9d6adf6c1f6	TCGA-BG-A0M4-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BG-A0M4-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_1_rg.sorted	TCGA-BG-A0M4-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_1_rg.sorted.bam	66.56	2.03	0.15	58cfa830e4b0c9d6adf6c1f6	TCGA-BG-A0M4-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0M4-01A	73E5310D-BA8C-4CBC-AA4F-E06206F898F4	Primary Tumor	Illumina HiSeq	6f34976e-c9a0-4b3f-afb6-d476e4d9f22d	Uterus	60.0	E6E7E411-45CF-47A1-BCF0-7AE800A61A8D	238A1E43-B716-479B-82C8-0E62A30F9BE9	TCGA-BG-A0M4-01A-11D-A101-02	HG19_Broad_variant	TCGA-BG-A0M4	TCGA-UCEC		s4429	Harvard Medical School	University of Pittsburgh	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C3	UCEC.MSI	0.158953021	0.28	0.0	4.438949876000001	-0.4234	-0.13699999999999998	-0.135	-1.1634	-0.7969	0.1408	213.0	721.0	4.57777271	15.5930383	53.0	0.193923555	8.0	4.0							2.509075648	-1106.318189	-649.7675167	1579.9849609999999	0.0	2167.0	0.0	2167.0	7.342081908697956	8.001019961323651	0.5047223050453975	6.473044061674346	6.902407672655542	2.1793624030168726	-0.8690378470236095	-1.0986122886681098	1.6746400979714753
13722.58cfa830e4b0c9d6adf6c1fa	58cfa830e4b0c9d6adf6c1fa	TCGA-BA-5559-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BA-5559-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_6_rg.sorted	TCGA-BA-5559-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_6_rg.sorted.bam	476.7	1.9	0.16	58cfa830e4b0c9d6adf6c1fa	TCGA-BA-5559-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-5559-01A	17B17D91-C3DF-4B89-9C10-4DB069AFF656	Primary Tumor	Illumina HiSeq	a6749339-8b87-4219-84dd-8045857cbe79	Head and Neck	71.0	FBEA64F9-B46B-4AF1-BFB2-1791D93977B6	61532C84-EDD9-492D-AF89-99086F87381E	TCGA-BA-5559-01A-01D-1509-02	HG19_Broad_variant	TCGA-BA-5559	TCGA-HNSC		s16320	Harvard Medical School	UNC	None	NO	TX	NX	Head and Neck Squamous Cell Carcinoma		1509-02	True	HNSC	C2	HNSC.Atypical	0.26018771	0.38	0.53		1.0432	0.113	1.101	1.9565	0.8305	0.3911	18.0	0.0	0.629736279	1.63158945	107.0	0.621634606	13.0	16.0	0.746758376	4.241716472	293.0	4.543870013	120.0	0.9491128670000001	1.743283208	-351.369621	1004.2528599999999	-347.4020362	1.0	2083.0	1.0	1614.0	6.132458695612006	8.797884216679163	0.1072899835090717	6.132458695612006	7.43976073252597	1.4125517012204007	0.0	-1.358123484153194	1.305261717711329
13722.58cfa830e4b0c9d6adf6c1fc	58cfa830e4b0c9d6adf6c1fc	TCGA-BG-A0M2-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BG-A0M2-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_7_rg.sorted	TCGA-BG-A0M2-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_7_rg.sorted.bam	63.57	1.97	0.15	58cfa830e4b0c9d6adf6c1fc	TCGA-BG-A0M2-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0M2-01A	9731E0B3-C62D-43CB-8AE7-8F973D69AB19	Primary Tumor	Illumina HiSeq	9dcd7360-a8dc-49cb-bf13-8fb36c436e30	Uterus	62.0	2AF18345-2A71-4574-AC8E-83DDEED3AD57	E59EB8B5-DA68-44B3-BB18-8C42F583B2BA	TCGA-BG-A0M2-01A-11D-A101-02	HG19_Broad_variant	TCGA-BG-A0M2	TCGA-UCEC		s4604	Harvard Medical School	University of Pittsburgh	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C1	UCEC.CN_LOW	0.132626262			17.30347159	0.23199999999999998	0.177	-0.4691	0.2702	-0.0038	-0.1347	11.0	7.0	0.315592628	0.774636452	88.0	0.9193151359999999	10.0	13.0							2.82288144	-762.2666582	-29.23871254	566.0926182	0.0	637.0	0.0	637.0	6.682287600403836	7.089756271580367	-2.446201877964183	6.51798454911256	6.563663175683587	1.9245659614946287	-0.16430305129127643	-0.5260930958967793	4.370767839458812
13722.58cfa830e4b0c9d6adf6c206	58cfa830e4b0c9d6adf6c206	TCGA-BT-A20W-01A-21D-A14U_120921_SN208_0431_BD1D5FACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BT-A20W-01A-21D-A14U_120921_SN208_0431_BD1D5FACXX_s_5_rg.sorted	TCGA-BT-A20W-01A-21D-A14U_120921_SN208_0431_BD1D5FACXX_s_5_rg.sorted.bam	77.69	1.98	0.17	58cfa830e4b0c9d6adf6c206	TCGA-BT-A20W-01A-21D-A14U_120921_SN208_0431_BD1D5FACXX_s_5_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A20W-01A	4DC5CFFE-ED8C-47AB-B5FC-F9615B5414F7	Primary Tumor	Illumina HiSeq	a817f2b5-a06a-422e-869a-694baf6bb127	Bladder	71.0	CA14F475-1BE4-450C-80C3-7094D23D0B3D	A32E59E0-242F-465D-8277-E0FE26124091	TCGA-BT-A20W-01A-21D-A14U-02	HG19_Broad_variant	TCGA-BT-A20W	TCGA-BLCA	254.0	s3085	Harvard Medical School	University of Pittsburgh	United States	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A14U-02	True	BLCA	C1	BLCA.2	0.27540437100000004	0.28	0.74	4.888273648999999	0.7563	0.1835	-0.3294	0.7284	-0.2163	0.1506	36.0	7.0	0.570086545	2.160327959	330.0	0.491498975	3.0	18.0		0.0	1.0	2.725550396	16.0	0.98303451	3.427676378	-1080.505764	635.2688836	-1955.8732989999999	1.0	254.0	0.0	254.0	6.897517869888917	7.545999418986694	0.6270490022307276	5.55862574766361	5.983814391403139	1.6061481510046713	-1.3388921222253067	-1.562185027583555	0.9790991487739438
13722.58cfa830e4b0c9d6adf6c208	58cfa830e4b0c9d6adf6c208	TCGA-BA-5558-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BA-5558-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_5_rg.sorted	TCGA-BA-5558-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_5_rg.sorted.bam	252.7	1.9	0.15	58cfa830e4b0c9d6adf6c208	TCGA-BA-5558-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-5558-01A	6A1AA50C-097C-4E04-8DDD-12D50F8A5AC2	Primary Tumor	Illumina HiSeq	4116c10d-23f4-49f2-bd5a-9b9466f08bfb	Head and Neck	65.0	EB749281-B3DC-43E4-812E-F5F5004A21ED	41737268-345A-4F87-B2DB-E184247E1396	TCGA-BA-5558-01A-01D-1509-02	HG19_Broad_variant	TCGA-BA-5558	TCGA-HNSC		s15610	Harvard Medical School	UNC	None	NO	TX	NX	Head and Neck Squamous Cell Carcinoma		1509-02	True	HNSC	C2	HNSC.Basal	0.419550483	0.55	0.06		0.5506	0.209	0.4158	0.3275	1.5721	0.474	62.0	114.0	1.78434563	3.2571388480000003	107.0	0.255821786	7.0	23.0	0.794482055	2.7282412089999997	31.0	2.841460038	19.0	0.965025955	4.298240253	-287.9255068	44.82522319	-968.57247	0.0	1995.0	0.0	1995.0	6.53233429222235	3.914895614705573	-0.7449337743079882	5.999529761737584	4.172782361891917	1.0329490539976065	-0.532804530484766	0.25788674718634397	1.7778828283055947
13722.58cfa830e4b0c9d6adf6c20b	58cfa830e4b0c9d6adf6c20b	TCGA-BA-4078-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BA-4078-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_1_rg.sorted	TCGA-BA-4078-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_1_rg.sorted.bam	747.33	1.9	0.16	58cfa830e4b0c9d6adf6c20b	TCGA-BA-4078-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-4078-01A	C7353D6A-82A2-4A0D-8CD4-8C8957943EDB	Primary Tumor	Illumina HiSeq	aaa9123e-a827-4226-9b51-0b04709fadb2	Head and Neck	83.0	2027EDE3-13F5-40F6-BEF6-16704981D676	66A9CFF2-397E-415E-BF54-9A75CCC80BDE	TCGA-BA-4078-01A-01D-1431-02	HG19_Broad_variant	TCGA-BA-4078	TCGA-HNSC	276.0	s15493	Harvard Medical School	UNC	None	NO			Head and Neck Squamous Cell Carcinoma		1431-02	True	HNSC	C1	HNSC.Classical	0.058146823	0.14	0.02		0.9576	0.18899999999999997	0.1094	-0.1404	-0.0517	0.7533	206.0	13.0	3.6177075710000004	10.59875265	123.0	0.946944778	13.0	24.0	0.939010785	1.511279557	5.0	3.548582422	37.0	0.982736941	4.201370432	-1943.585812	886.3957972000001	-1467.064857	1.0	276.0	1.0	276.0	7.243370005189221	6.6353339446317365	0.02426292283791276	5.356300356156842	6.602544121808745	0.8085118353520472	-1.8870696490323793	-0.032789822822991255	0.7842489125141344
13722.58cfa830e4b0c9d6adf6c21a	58cfa830e4b0c9d6adf6c21a	TCGA-BA-5153-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BA-5153-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_5_rg.sorted	TCGA-BA-5153-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_5_rg.sorted.bam	422.7	1.9	0.15	58cfa830e4b0c9d6adf6c21a	TCGA-BA-5153-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_5_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-5153-01A	B3631718-9E0A-454C-BEE1-8F36EBC509D8	Primary Tumor	Illumina HiSeq	3bd56918-8f2b-4486-86ea-e479c2cab413	Head and Neck	51.0	2DC7070A-9C70-4BB1-9634-8C934BB9C8D1	F14D0AA8-E7BB-4E0E-B887-DA7B6FA0BC86	TCGA-BA-5153-01A-01D-1431-02	HG19_Broad_variant	TCGA-BA-5153	TCGA-HNSC	1762.0	s16316	Harvard Medical School	UNC	None	NO	T2	NX	Head and Neck Squamous Cell Carcinoma		1431-02	True	HNSC	C1	HNSC.Atypical	0.19296574600000002	0.21	0.0		1.0455	0.008	0.3007	1.5749	0.3267	0.1753	26.0	9.0	0.224900708	1.0120531879999999	70.0	0.177316565	4.0	21.0	0.8830786979999999	4.256687971	124.0	3.859637123	57.0	0.954634722	2.032251551	-479.9166973999999	986.7012609	-2167.6783969999997	1.0	1762.0	1.0	1522.0	6.229882158146566	7.044199093053695	-0.5063350184088836	5.3580431888432445	5.757988190490787	1.9580246795230796	-0.8718389693033215	-1.286210902562908	2.4643596979319633
13722.58cfa830e4b0c9d6adf6c224	58cfa830e4b0c9d6adf6c224	TCGA-C5-A2LS-01A-22D-A232_140124_SN1120_0291_AC2PHAACXX_s_1_rg.sorted.filtered.	WGS	TCGA-C5-A2LS-01A-22D-A232_140124_SN1120_0291_AC2PHAACXX_s_1_rg.sorted	TCGA-C5-A2LS-01A-22D-A232_140124_SN1120_0291_AC2PHAACXX_s_1_rg.sorted.bam	49.75		0.15	58cfa830e4b0c9d6adf6c224	TCGA-C5-A2LS-01A-22D-A232_140124_SN1120_0291_AC2PHAACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-C5-A2LS-01A	185E1520-92EE-4AF5-AF15-FBEEFB352C99	Primary Tumor	Illumina HiSeq	3c012d75-0d17-4b4d-834f-cd4767f6b023	Cervix	37.0	79248694-77E1-4FBE-8C94-64A308FC982D	DE7180EF-3E7E-43D5-8ACE-C7ED57992345	TCGA-C5-A2LS-01A-22D-A232-26	HG19_Broad_variant	TCGA-C5-A2LS	TCGA-CESC		s1356	MD Anderson - Institute for Applied Cancer Science	Medical College of Wisconsin	United States	NO	T1b2	N0	Endocervical Adenocarcinoma of the Usual Type		A232-26	True	CESC	C1		0.186497605	0.29	0.0	21.07986872	1.0935	0.177	-1.2337	-0.6318	-0.371	-0.5744	26.0	7.0	0.52311665	0.9780006929999999	46.0	0.095367947	4.0	7.0				1.098612289	3.0	1.0	3.0596232210000003	-561.5375481000001	804.8836209	-1568.471044	0.0	1345.0	0.0	1345.0	7.410347097821024	6.747586526829316	0.6184169308503621	5.159055299214529	5.706132652001155	1.987137230919335	-2.251291798606495	-1.0414538748281612	1.3687203000689727
13722.58cfa830e4b0c9d6adf6c226	58cfa830e4b0c9d6adf6c226	TCGA-BS-A0UV-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BS-A0UV-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_5_rg.sorted	TCGA-BS-A0UV-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_5_rg.sorted.bam	96.07	1.92	0.15	58cfa830e4b0c9d6adf6c226	TCGA-BS-A0UV-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_5_rg.sorted.bam	Alive	FEMALE	NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0UV-01A	B19425AB-A82F-4C2A-BF58-D1BD30511D74	Primary Tumor	Illumina HiSeq	91fbcf9b-f514-49ff-925b-08d6244293f7	Uterus	55.0	30945527-528A-448E-8DB4-2E0C31C9016D	A0F51177-4C00-4F97-8CD4-2E05B63B00DE	TCGA-BS-A0UV-01A-11D-A101-02	HG19_Broad_variant	TCGA-BS-A0UV	TCGA-UCEC		s5222	Harvard Medical School	University of Hawaii	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C1	UCEC.POLE	0.23965756100000002	0.3	0.03	5.503024184	1.1051	0.376	-0.5525	-0.0092	-0.9237	-0.0587	4486.0	68.0	62.56139746	234.4795886	142.0	0.12549843800000002	4.0	2.0							3.9565936560000003	-1650.764849	859.9955373	-1785.246516	0.0	2228.0	0.0	2228.0	6.892797817964535	4.726569457620653	-0.5322881277070463	5.961239613959592	6.4146504973738665	0.6810258200276005	-0.9315582040049435	1.6880810397532136	1.2133139477346466
13722.58cfa830e4b0c9d6adf6c22c	58cfa830e4b0c9d6adf6c22c	TCGA-BT-A0S7-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BT-A0S7-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_4_rg.sorted	TCGA-BT-A0S7-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_4_rg.sorted.bam	12.85	1.87	0.15	58cfa830e4b0c9d6adf6c22c	TCGA-BT-A0S7-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_4_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A0S7-01A	68BC786E-07C7-4964-BC88-5E2A8633626A	Primary Tumor	Illumina HiSeq	55a63ec5-a803-44ee-905f-c7bfff9162d6	Bladder	75.0	A9B73851-4609-4DF7-8EB8-45A56F4B2DD6	F415813D-F975-492B-9E4E-55CE47C967B9	TCGA-BT-A0S7-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BT-A0S7	TCGA-BLCA	200.0	s3269	Harvard Medical School	University of Pittsburgh	United States	NO	T4a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A10R-02	True	BLCA	C1	BLCA.3	0.34405746299999995	0.71	0.27	0.7058478909999999	0.8849	0.3105	-0.6301	-0.0411	-1.5973	-0.0241	23.0	56.0	0.33965670299999995	1.01897011	130.0	0.287154934	19.0	22.0		0.0	1.0	0.0	1.0		5.829662532	-1345.333632	983.9912744999999	-2842.560902	1.0	200.0	1.0	200.0	6.770180006600592	6.652550174945414	0.3380578165244592	5.353113986813948	5.779609883944873	0.9902543934713093	-1.417066019786644	-0.8729402910005413	0.6521965769468501
13722.58cfa830e4b0c9d6adf6c236	58cfa830e4b0c9d6adf6c236	TCGA-BJ-A0Z3-01A-11D-A13U_120706_SN1120_0170_BD1422ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BJ-A0Z3-01A-11D-A13U_120706_SN1120_0170_BD1422ACXX_s_7_rg.sorted	TCGA-BJ-A0Z3-01A-11D-A13U_120706_SN1120_0170_BD1422ACXX_s_7_rg.sorted.bam	64.48	1.98	0.16	58cfa830e4b0c9d6adf6c236	TCGA-BJ-A0Z3-01A-11D-A13U_120706_SN1120_0170_BD1422ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0Z3-01A	331CAE6E-2868-4C58-9302-709A9FF7D025	Primary Tumor	Illumina HiSeq	ddae4f5a-aed4-4466-9434-23f6ed312d19	Thyroid	33.0	6BF032C1-B7D5-4B1C-BF41-C9BFEAFA5E7A	3D0982B1-944E-4C03-AAA4-F8FD4602D4C9	TCGA-BJ-A0Z3-01A-11D-A13U-02	HG19_Broad_variant	TCGA-BJ-A0Z3	TCGA-THCA		s12628	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A13U-02	True	THCA	C3	THCA.2	0.34470090700000006	0.46	0.0		-0.9094	-0.1525	0.5793	2.2328	-0.1904	-0.0528	2.0		0.02901066	0.1450533	59.0	2.7000000000000002e-05	0.0	0.0	0.922860782	4.221821351	97.0	4.52809852	96.0	0.9920580840000001	2.167110398	364.70817139999997	-897.1891097000001	2692.235347	0.0	497.0	0.0	497.0	6.678866086371848	7.854472511923798	0.505553203819418	5.682532646824156	7.221949953180287	1.83921132228698	-0.996333439547691	-0.6325225587435104	1.3336581184675618
13722.58cfa830e4b0c9d6adf6c23a	58cfa830e4b0c9d6adf6c23a	TCGA-BT-A20R-01A-12D-A16N_120920_SN1222_0151_BD1D5CACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BT-A20R-01A-12D-A16N_120920_SN1222_0151_BD1D5CACXX_s_3_rg.sorted	TCGA-BT-A20R-01A-12D-A16N_120920_SN1222_0151_BD1D5CACXX_s_3_rg.sorted.bam	26.04	1.91	0.17	58cfa830e4b0c9d6adf6c23a	TCGA-BT-A20R-01A-12D-A16N_120920_SN1222_0151_BD1D5CACXX_s_3_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A20R-01A	F8780A4B-7F55-41D1-BF92-8513955D150E	Primary Tumor	Illumina HiSeq	e997f623-927f-4dae-8fe9-590eef9a9f59	Bladder	79.0	20231B7F-CB6A-4CD0-9C46-10D4E959D483	78460059-E3A1-40F1-89B5-2F69C6E2E0F1	TCGA-BT-A20R-01A-12D-A16N-02	HG19_Broad_variant	TCGA-BT-A20R	TCGA-BLCA	154.0	s2696	Harvard Medical School	University of Pittsburgh	United States	NO	T3b	N1	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A16N-02	True	BLCA	C2	BLCA.2	0.215896957	0.54	0.27	2.366813163	0.4369	0.201	0.1604	-0.6882	0.6785	0.5707	130.0	42.0	2.274320035	6.852496728999999	122.0	0.430756429	13.0	27.0				0.47413931299999995	2.0	0.6840384359999999	5.759216547	-930.7162933000001	1005.8694	-1965.275898	1.0	154.0	0.0	154.0	7.002889490225724	7.063326378107526	-2.178169900791021	5.82175617786961	6.9235644357323665	1.2690732179320752	-1.1811333123561134	-0.13976194237515882	3.447243118723096
13722.58cfa830e4b0c9d6adf6c23c	58cfa830e4b0c9d6adf6c23c	TCGA-BT-A2LB-01A-11D-A18D_120904_SN1120_0186_BC1911ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BT-A2LB-01A-11D-A18D_120904_SN1120_0186_BC1911ACXX_s_6_rg.sorted	TCGA-BT-A2LB-01A-11D-A18D_120904_SN1120_0186_BC1911ACXX_s_6_rg.sorted.bam	51.24		0.18	58cfa830e4b0c9d6adf6c23c	TCGA-BT-A2LB-01A-11D-A18D_120904_SN1120_0186_BC1911ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A2LB-01A	D17A5AB1-3789-4652-AFF5-D8F4F2291F9C	Primary Tumor	Illumina HiSeq	de67212f-594e-409c-bd19-3d40f013b89a	Bladder	73.0	7C6178A6-6D4C-4DEF-B4AC-A064AB4A6C8A	FAD087E0-3752-4144-960B-659B59312C92	TCGA-BT-A2LB-01A-11D-A18D-02	HG19_Broad_variant	TCGA-BT-A2LB	TCGA-BLCA		s3087	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A18D-02	True	BLCA	C2	BLCA.2	0.286018042	0.5	0.13	4.931538417	0.3173	0.19899999999999998	-0.0126	0.4329	1.1926	0.4914	225.0	59.0	6.4367728820000005	14.75966991	170.0	0.7070564690000001	22.0	23.0	0.957965554	3.0444660989999996	24.0	2.9785084210000004	20.0	0.994250537	4.889354961	-968.8577431	314.4240093	-1355.669694	1.0	492.0	0.0	492.0	6.486330151295243	7.2274549867959745	0.9704291592715386	5.765783996547183	5.739377931366142	2.0485602278783706	-0.7205461547480598	-1.488077055429833	1.078131068606832
13722.58cfa830e4b0c9d6adf6c23e	58cfa830e4b0c9d6adf6c23e	TCGA-BW-A5NQ-01A-11D-A27I-10_wgs_Illumina.filtered.	WGS	TCGA-BW-A5NQ-01A-11D-A27I-10_wgs_Illumina	TCGA-BW-A5NQ-01A-11D-A27I-10_wgs_Illumina.bam	66.53		0.07	58cfa830e4b0c9d6adf6c23e	TCGA-BW-A5NQ-01A-11D-A27I-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-BW-A5NQ-01A	C7F1B389-AEC7-4993-8AFB-B7A56064F8FC	Primary Tumor	Illumina HiSeq	4bbd34a1-0024-44aa-9e51-9ac4c51c7f1d	Liver	63.0	C8FFE03A-62C3-4B47-9DEA-CB3377F59ABB	E30C64D5-E796-4CFC-8DC8-6E62BF97822F	TCGA-BW-A5NQ-01A-11D-A27I-10	GRCh37-lite	TCGA-BW-A5NQ	TCGA-LIHC		s16848	Baylor College of Medicine	St Joseph's Medical Center (MD)	United States	NO	T1	NX	Hepatocellular Carcinoma	Stage I	A27I-10	True	LIHC	C2	LIHC.iCluster:3	0.373025868	0.63	0.01		0.701	0.3385	0.3662	1.3426	0.2133	-0.8604	42.0	53.0	0.824635604	2.391443251	57.0	0.880727287	29.0	3.0	0.7687681209999999	2.8548758210000003	41.0	2.913089005	27.0	0.883869294		-920.1274331000001	840.1991373999999	2666.560234	0.0	0.0	0.0	0.0	6.0127366823835215	3.1562579387499596	1.3975740529678449	4.531132141459306	2.8788023980820094	1.5624876113147035	-1.4816045409242158	-0.2774555406679502	0.1649135583468586
13722.58cfa830e4b0c9d6adf6c246	58cfa830e4b0c9d6adf6c246	TCGA-BA-4078-01A-01D-1431_120612_SN590_0161_AC0VUTACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BA-4078-01A-01D-1431_120612_SN590_0161_AC0VUTACXX_s_5_rg.sorted	TCGA-BA-4078-01A-01D-1431_120612_SN590_0161_AC0VUTACXX_s_5_rg.sorted.bam	747.33	1.9	0.16	58cfa830e4b0c9d6adf6c246	TCGA-BA-4078-01A-01D-1431_120612_SN590_0161_AC0VUTACXX_s_5_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-4078-01A	C7353D6A-82A2-4A0D-8CD4-8C8957943EDB	Primary Tumor	Illumina HiSeq	cf3b040a-b4be-41ce-a172-1a295ebd79b2	Head and Neck	83.0	2027EDE3-13F5-40F6-BEF6-16704981D676	66A9CFF2-397E-415E-BF54-9A75CCC80BDE	TCGA-BA-4078-01A-01D-1431-02	HG19_Broad_variant	TCGA-BA-4078	TCGA-HNSC	276.0	s15877	Harvard Medical School	UNC	None	NO			Head and Neck Squamous Cell Carcinoma		1431-02	True	HNSC	C1	HNSC.Classical	0.058146823	0.14	0.02		0.9576	0.18899999999999997	0.1094	-0.1404	-0.0517	0.7533	206.0	13.0	3.6177075710000004	10.59875265	123.0	0.946944778	13.0	24.0	0.939010785	1.511279557	5.0	3.548582422	37.0	0.982736941	4.201370432	-1943.585812	886.3957972000001	-1467.064857	1.0	276.0	1.0	276.0	7.518314849683589	6.957638595442828	0.02426292283791276	6.345594588861758	7.666534132970912	0.8085118353520472	-1.1727202608218317	0.7088955375280843	0.7842489125141344
13722.58cfa830e4b0c9d6adf6c258	58cfa830e4b0c9d6adf6c258	TCGA-BJ-A0Z5-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BJ-A0Z5-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_1_rg.sorted	TCGA-BJ-A0Z5-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_1_rg.sorted.bam	95.63	2.11	0.16	58cfa830e4b0c9d6adf6c258	TCGA-BJ-A0Z5-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0Z5-01A	0FE3B19A-F5E4-497E-92DA-32FF6C77B066	Primary Tumor	Illumina HiSeq	84ec4e2b-c502-4348-b6ce-ae4a912e603c	Thyroid	58.0	D17746B4-EDEA-45DB-9AD1-5EE4973F007C	0AB5F114-C3CC-4DB4-87DF-1B339DDC54C2	TCGA-BJ-A0Z5-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0Z5	TCGA-THCA		s12352	Harvard Medical School	University of Pittsburgh	United States	NO	T3	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A10R-02	True	THCA	C3	THCA.3	0.057257191				-1.5336	-0.287	-0.409	-0.5658	-0.5021	-0.3649					60.0	0.011003603999999998						1.609437912	5.0	1.0	1.087547775	-376.80425049999997	-967.6922521	203.392084	0.0	448.0	0.0	448.0	5.982446735868669	6.750711529372451	-0.9738842885231219	4.8613615913485	5.885714091885846	2.1348069477677862	-1.1210851445201686	-0.8649974374866045	3.108691236290908
13722.58cfa830e4b0c9d6adf6c260	58cfa830e4b0c9d6adf6c260	TCGA-C5-A3HL-01A-11D-A20X_140117_SN590_0246_BC37BDACXX_s_7_rg.sorted.filtered.	WGS	TCGA-C5-A3HL-01A-11D-A20X_140117_SN590_0246_BC37BDACXX_s_7_rg.sorted	TCGA-C5-A3HL-01A-11D-A20X_140117_SN590_0246_BC37BDACXX_s_7_rg.sorted.bam	48.29		0.14	58cfa830e4b0c9d6adf6c260	TCGA-C5-A3HL-01A-11D-A20X_140117_SN590_0246_BC37BDACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-C5-A3HL-01A	09329A53-D58D-4480-95D8-32043E40DE6E	Primary Tumor	Illumina HiSeq	84c6e022-f737-4fae-a2c7-812ef4f00adf	Cervix	76.0	2A3CC87B-B120-49EC-93E6-8BDDBAE5C97C	04FC6219-3EAC-4BB8-82CA-CD0AA6B0ACE3	TCGA-C5-A3HL-01A-11D-A20X-26	HG19_Broad_variant	TCGA-C5-A3HL	TCGA-CESC		s1516	MD Anderson - Institute for Applied Cancer Science	Medical College of Wisconsin	United States	NO	T1b2	N0	Cervical Squamous Cell Carcinoma		A20X-26	True	CESC	C1		0.208800137	0.34	0.01	4.210388125	1.1024	0.2785	-0.6925	-0.3161	-0.1299	0.1155			0.0	0.0	41.0	0.044891821	0.0	7.0	0.907011542	3.1434624639999997	32.0	1.5607104090000001	5.0	0.9697239	1.955469528	-587.0025987	331.313221	-1991.080905	0.0	621.0	0.0	621.0	5.957455231005234	7.129755319594267	0.21010592517875915	5.146525014788906	6.185293710753416	2.4707940813856037	-0.8109302162163288	-0.9444616088408513	2.2606881562068444
13722.58cfa830e4b0c9d6adf6c266	58cfa830e4b0c9d6adf6c266	TCGA-C5-A1BQ-01C-11D-A20X_140106_SN590_0243_AC371BACXX_s_2_rg.sorted.filtered.	WGS	TCGA-C5-A1BQ-01C-11D-A20X_140106_SN590_0243_AC371BACXX_s_2_rg.sorted	TCGA-C5-A1BQ-01C-11D-A20X_140106_SN590_0243_AC371BACXX_s_2_rg.sorted.bam	43.3		0.15	58cfa830e4b0c9d6adf6c266	TCGA-C5-A1BQ-01C-11D-A20X_140106_SN590_0243_AC371BACXX_s_2_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-C5-A1BQ-01C	E77C3F70-08D1-40D3-B038-F09A519423CC	Primary Tumor	Illumina HiSeq	58d97d84-99da-4b08-ae63-7e49f4b861b7	Cervix	65.0	6EF38E19-07AC-4032-8FB4-59129A126D3F	359691B6-9EB5-40F2-8F9E-16AA5A1D32F4	TCGA-C5-A1BQ-01C-11D-A20X-26	HG19_Broad_variant	TCGA-C5-A1BQ	TCGA-CESC	604.0	s1170	MD Anderson - Institute for Applied Cancer Science	Medical College of Wisconsin	United States	NO			Cervical Squamous Cell Carcinoma		A20X-26	True	CESC	C2		0.266807141	0.29	0.04	18.641328299999998	1.0443	0.371	0.2206	0.7818	0.9508	-0.1752			0.0	0.0	84.0	0.203097319	5.0	15.0	0.9113545809999999	2.730174332	20.0	3.76697443	48.0	0.973076422	1.81783096	-466.406818	687.0667317000001	-522.4802152	1.0	604.0	0.0	604.0	8.262494471446471	5.537334267018537	0.8766602962418644	6.60426639484294	7.2684691144301565	1.8932623978678962	-1.6582280766035324	1.73113484741162	1.0166021016260318
13722.58cfa830e4b0c9d6adf6c272	58cfa830e4b0c9d6adf6c272	TCGA-BJ-A0ZA-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BJ-A0ZA-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_5_rg.sorted	TCGA-BJ-A0ZA-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_5_rg.sorted.bam	34.66	1.95	0.15	58cfa830e4b0c9d6adf6c272	TCGA-BJ-A0ZA-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0ZA-01A	4C513413-263E-4C7B-B997-7B688C47B698	Primary Tumor	Illumina HiSeq	787aed3e-08d4-4fa8-93e1-c04216a9875f	Thyroid	67.0	A61A9EC7-B893-44A5-AB6F-A390C168BE88	F3A353BB-07C3-49D1-BED2-2F8F5A328E1C	TCGA-BJ-A0ZA-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0ZA	TCGA-THCA		s12744	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage II	A10R-02	True	THCA	C3	THCA.1	0.113151734	0.14	0.0		-1.8529	-0.32299999999999995	-0.3753	-0.0727	-0.8744	-0.5342	6.0		0.05663453	0.22653812	49.0	8.94e-05	0.0	0.0	0.903801926	4.288478795	115.0	1.609437912	5.0	1.0	1.3794134530000002	-773.7804901000001	-821.6784187000001	1766.8488730000001	0.0	574.0	0.0	574.0	6.328508049097486	8.108623268354593	-0.5578980085002435	5.615558241241361	7.170353629761664	0.2405197960369425	-0.7129498078561252	-0.9382696385929301	0.798417804537186
13722.58cfa830e4b0c9d6adf6c278	58cfa830e4b0c9d6adf6c278	TCGA-B5-A0K1-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_3_rg.sorted.filtered.	WGS	TCGA-B5-A0K1-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_3_rg.sorted	TCGA-B5-A0K1-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_3_rg.sorted.bam	82.72	2.05	0.16	58cfa830e4b0c9d6adf6c278	TCGA-B5-A0K1-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0K1-01A	40A3ED98-3892-449C-B07E-7B7612BD997E	Primary Tumor	Illumina HiSeq	fb29a0da-eb80-43a5-be71-85cf2d58268c	Uterus	69.0	B514F636-DEE3-45F3-BB31-197CA6A171F1	D4814366-AEF2-453B-8DC7-A731B5E53FE8	TCGA-B5-A0K1-01A-11D-A043-02	HG19_Broad_variant	TCGA-B5-A0K1	TCGA-UCEC		s5211	Harvard Medical School	Duke	United States	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C1	UCEC.CN_LOW	0.093312268	0.18	0.0	3.445768343	0.4276	0.162	-1.0289	-1.1532	-0.9183	-0.1832	18.0	2.0	0.431058129	1.149488344	57.0	1.47e-05	0.0	0.0							2.5984348390000003	-1536.678423	-567.7149147999999	-1368.432288	0.0	1110.0	0.0	1110.0	4.921037503119445	8.238074349624945	-1.4078928550075638	5.455119989049702	7.167632937923532	0.36272476970861156	0.5340824859302575	-1.0704414117014132	1.7706176247161753
13722.58cfa830e4b0c9d6adf6c28c	58cfa830e4b0c9d6adf6c28c	TCGA-AD-A5EJ-01A-11D-A28G-10_wgs_Illumina.filtered.	WGS	TCGA-AD-A5EJ-01A-11D-A28G-10_wgs_Illumina	TCGA-AD-A5EJ-01A-11D-A28G-10_wgs_Illumina.bam	40.09		0.07	58cfa830e4b0c9d6adf6c28c	TCGA-AD-A5EJ-01A-11D-A28G-10_wgs_Illumina.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AD-A5EJ-01A	613AA3E8-A70B-45A9-9C08-0C2346C8BF00	Primary Tumor	Illumina HiSeq	ce0bf9ea-efa0-4c54-8970-a703051d667e	Colorectal	74.0	F675116A-BFEC-47AE-AC24-9B61DD3CC6C1	711C8A16-3CF8-42D8-B29E-FD1E9EF1C82B	TCGA-AD-A5EJ-01A-11D-A28G-10	GRCh37-lite	TCGA-AD-A5EJ	TCGA-COAD		s13538	Baylor College of Medicine	International Genomics Consortium	United States	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	A28G-10	True	COAD	C1	GI.HM-indel	0.24285841	0.32	0.0	10.02232405	0.9002	0.4025	-0.6945	-0.6096	-0.7535	0.1247	663.0	4125.0	12.22771395	37.38963198	66.0	0.011378296000000001	0.0	1.0	0.96889586	2.485168814	13.0	0.0	1.0			-1012.9114210000001	770.8239391	-300.3128526	0.0	0.0	0.0	0.0	7.7929680552854315	3.815689045926229	-1.2345446428301707	5.441592798121954	3.738414844214457	1.9523410393856038	-2.3513752571634776	-0.0772742017117718	3.1868856822157743
13722.58cfa830e4b0c9d6adf6c290	58cfa830e4b0c9d6adf6c290	TCGA-BR-4294-01A-01D-1128_121204_SN590_0204_BC1H5VACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BR-4294-01A-01D-1128_121204_SN590_0204_BC1H5VACXX_s_2_rg.sorted	TCGA-BR-4294-01A-01D-1128_121204_SN590_0204_BC1H5VACXX_s_2_rg.sorted.bam	42.9	1.9	0.14	58cfa830e4b0c9d6adf6c290	TCGA-BR-4294-01A-01D-1128_121204_SN590_0204_BC1H5VACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4294-01A	ACAB1362-C8A0-448B-8533-0CD84D97959C	Primary Tumor	Illumina HiSeq	23c036ca-ac6a-45dc-9100-558b2249f3bc	Stomach	65.0	CB5D3EDE-205D-43F6-A3E3-DB287FB1783B	97DB8928-FACC-4095-984F-07C52A759DB4	TCGA-BR-4294-01A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4294	TCGA-STAD		s15374	Harvard Medical School	Asterand	Russia	NO	T2a	NX	Stomach  Intestinal Adenocarcinoma  Tubular Type		1128-02	True	STAD	C3	GI.CIN	0.025715177999999998	0.06	0.15		-1.6556	-0.191	-0.4333	-0.7799	-1.3092	-0.5503			0.24866263800000002	0.870319233	117.0	0.9082675440000001	16.0	5.0	0.831647303	0.576453983	2.0	1.695742534	6.0	0.946411928		-2304.804164	-1009.140458	4263.08412	0.0	0.0	0.0	0.0	8.572627898304338	8.743956848898602	-0.40329026918180755	7.31986492980897	8.95526594256581	1.0879019269844883	-1.252762968495368	0.21130909366720685	1.491192196166296
13722.58cfa830e4b0c9d6adf6c292	58cfa830e4b0c9d6adf6c292	TCGA-AY-4071-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AY-4071-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole	TCGA-AY-4071-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	504.59	1.9	0.15	58cfa830e4b0c9d6adf6c292	TCGA-AY-4071-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AY-4071-01A	315EF7F6-CA21-4D87-8F19-40BD455885EC	Primary Tumor	Illumina HiSeq	0335df8b-3dec-4304-95e5-47210ed06ba3	Colorectal	63.0	7D09112D-53F5-4B72-993A-337C55A0C902	8DE6361C-E9B5-45FF-A328-67B0DED836B9	TCGA-AY-4071-01A-01D-1109-02	HG18	TCGA-AY-4071	TCGA-COAD	29.0	s12887	Harvard Medical School	UNC	None	NO	T1	N0		Stage I	1109-02	True	COAD	C1	GI.CIN	0.163318772	0.4	0.34	0.494969166	0.069	0.046	0.0694	1.1627	0.23199999999999998	0.054000000000000006	71.0	62.0	0.9605915009999999	3.172862836	130.0	0.420760133	14.0	19.0							0.849620011	-904.5439912999999	-496.5165693	946.3406602	1.0	29.0	0.0	29.0	4.655601039614982	4.021577837629493	-0.49169951508304677	3.7462307505854016	4.504160249082088	1.5246877681842337	-0.9093702890295812	0.4825824114525954	2.0163872832672807
13722.58cfa830e4b0c9d6adf6c294	58cfa830e4b0c9d6adf6c294	TCGA-BP-4781-01A-01D-2098-10_Illumina.filtered.	WGS	TCGA-BP-4781-01A-01D-2098-10_Illumina	TCGA-BP-4781-01A-01D-2098-10_Illumina.bam	69.07	1.9	0.16	58cfa830e4b0c9d6adf6c294	TCGA-BP-4781-01A-01D-2098-10_Illumina.bam	Alive	MALE	WHITE		Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-BP-4781-01A	80C4FC5B-DC7D-4308-8C81-6E83625963B5	Primary Tumor	Illumina HiSeq	d6c662c6-17e1-4d7c-ab4b-9a002c00648b	Kidney	78.0	15423D9C-91C3-4FE5-9880-A28840ACB75A	FBF937F1-5F30-470C-8A77-46CD1C41E073	TCGA-BP-4781-01A-01D-2098-10	GRCh37-lite	TCGA-BP-4781	TCGA-KIRC		s8836	Baylor College of Medicine	MSKCC	None	NO	T1a	NX	Kidney Clear Cell Renal Carcinoma	Stage I	2098-10	True	KIRC	C3	KIRC.3	0.13015091				-0.9953	-0.2275	0.8461	-0.2389	0.3376	0.27					111.0	0.457283909						3.376443384	31.0	0.983242855	1.78626717	1090.835458	-1265.507251	2696.981065	0.0	2080.0	0.0	2080.0	8.56389250132178	1.2340608805993352	1.0488011953645706	5.403230413685704	4.12726087925815	2.217716191382063	-3.160662087636076	2.8931999986588153	1.1689149960174923
13722.58cfa830e4b0c9d6adf6c298	58cfa830e4b0c9d6adf6c298	TCGA-BH-A0GY-01A-11D-A060_130807_SN590_0235_AC29RAACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BH-A0GY-01A-11D-A060_130807_SN590_0235_AC29RAACXX_s_7_rg.sorted	TCGA-BH-A0GY-01A-11D-A060_130807_SN590_0235_AC29RAACXX_s_7_rg.sorted.bam	48.65	2.08	0.16	58cfa830e4b0c9d6adf6c298	TCGA-BH-A0GY-01A-11D-A060_130807_SN590_0235_AC29RAACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE		Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0GY-01A	7D9D3522-EC3B-4EFE-8C8E-C0E675276EF5	Primary Tumor	Illumina HiSeq	bcac7e1b-ddeb-43d6-ba44-db40336bf564	Breast	67.0	A7E71EAC-1768-4FC2-8EBA-1576D22E0F43	F5C72179-9BDA-4BC6-B006-93EB616804BC	TCGA-BH-A0GY-01A-11D-A060-02	HG19_Broad_variant	TCGA-BH-A0GY	TCGA-BRCA		s6771	Harvard Medical School	University of Pittsburgh	None	NO	T2	N1	Infiltrating Ductal Carcinoma	Stage IIA	A060-02	True	BRCA	C2	BRCA.LumA	0.19402960600000002	0.52	0.02	1.39549361	0.2656	0.07400000000000001	0.1374	0.2782	0.8335	0.4471	11.0	2.0	0.184626735	0.9539047970000001	195.0	0.810152835	26.0	22.0	0.599458419	0.964791106	5.0	2.630253356	15.0	0.971272008	3.093846287	37.4274489	963.5508025	-2200.503779	0.0	923.0	0.0	923.0	8.067149039910106	6.563228468979052	-1.0914801777884628	6.074718875219899	6.732304799022986	2.10898394389186	-1.9924301646902063	0.16907633004393396	3.2004641216803225
13722.58cfa830e4b0c9d6adf6c29a	58cfa830e4b0c9d6adf6c29a	TCGA-B5-A0JR-01A-13D-A043_120403_SN1222_0094_BD0UKBACXX_s_6_rg.sorted.filtered.	WGS	TCGA-B5-A0JR-01A-13D-A043_120403_SN1222_0094_BD0UKBACXX_s_6_rg.sorted	TCGA-B5-A0JR-01A-13D-A043_120403_SN1222_0094_BD0UKBACXX_s_6_rg.sorted.bam	91.47	2.12	0.14	58cfa830e4b0c9d6adf6c29a	TCGA-B5-A0JR-01A-13D-A043_120403_SN1222_0094_BD0UKBACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0JR-01A	A766D113-BC3F-4448-A4E5-F391FB0C0E22	Primary Tumor	Illumina HiSeq	1e3ae5a0-6439-4dba-a151-f107d43c65cf	Uterus	73.0	07381A09-5CBD-4744-86EC-41A81E470204	E4F782AB-1668-4730-95D9-CB28E3CF61FD	TCGA-B5-A0JR-01A-13D-A043-02	HG19_Broad_variant	TCGA-B5-A0JR	TCGA-UCEC		s4786	Harvard Medical School	Duke	United States	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C1	UCEC.MSI	0.145675061	0.26	0.0	24.13367512	0.725	0.239	-0.2897	0.6839	-0.8973	-0.3142	109.0	252.0	5.470589902	15.99777912	60.0	0.118704335	3.0	1.0	0.942157538	1.9591615230000001	8.0	3.0146300139999997	22.0	0.975279395	2.3534116000000003	-1468.9604880000002	-72.32840259	2391.5585730000003	0.0	1731.0	0.0	1731.0	6.126956516545139	7.029161373058431	0.4512213326686184	4.771121362909957	4.181349229581062	1.5735709996049745	-1.3558351536351823	-2.8478121434773684	1.1223496669363562
13722.58cfa830e4b0c9d6adf6c29c	58cfa830e4b0c9d6adf6c29c	TCGA-BS-A0T9-01A-11D-A12F_120523_SN1222_0109_BD12MPACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BS-A0T9-01A-11D-A12F_120523_SN1222_0109_BD12MPACXX_s_3_rg.sorted	TCGA-BS-A0T9-01A-11D-A12F_120523_SN1222_0109_BD12MPACXX_s_3_rg.sorted.bam	66.31	1.98	0.16	58cfa830e4b0c9d6adf6c29c	TCGA-BS-A0T9-01A-11D-A12F_120523_SN1222_0109_BD12MPACXX_s_3_rg.sorted.bam	Dead	FEMALE	NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0T9-01A	4EB95566-0E73-4260-853E-F7DF650667A0	Primary Tumor	Illumina HiSeq	2c61f255-688e-4a53-83fd-bea3b66d5a15	Uterus	39.0	3C9FF865-013F-427A-8D4D-C8E60EA346A1	CB5B905D-7287-41B3-9B49-B2F7FF7D2173	TCGA-BS-A0T9-01A-11D-A12F-02	HG19_Broad_variant	TCGA-BS-A0T9	TCGA-UCEC	1428.0	s4260	Harvard Medical School	University of Hawaii	None	NO			Endometrioid endometrial adenocarcinoma		A12F-02	True	UCEC	C1	UCEC.CN_LOW	0.19985227600000002	0.52	0.02	5.146875606	-0.6304	-0.033	-0.4129	0.0008	-0.0573	0.6564	25.0		0.465195331	1.4503148540000002	51.0	0.09686555	4.0	0.0							3.873432345	-1044.2009679999999	-969.1321989	-1423.2404060000001	1.0	1428.0	1.0	634.0	5.834524031593167	7.659584018363104	0.1506194058296748	5.854326658889347	6.743293286488949	6.509327848225623	0.019802627296179764	-0.9162907318741551	6.358708442395948
13722.58cfa830e4b0c9d6adf6c29e	58cfa830e4b0c9d6adf6c29e	TCGA-BR-4366-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_1_rg.sorted.filtered.	WGS	TCGA-BR-4366-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_1_rg.sorted	TCGA-BR-4366-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_1_rg.sorted.bam	194.2	1.9	0.15	58cfa830e4b0c9d6adf6c29e	TCGA-BR-4366-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4366-01A	525A6978-2D7B-4F3A-AC68-13FE8CBBBDCC	Primary Tumor	Illumina HiSeq	c4b9424f-d0da-48ae-8723-69cbccfdefc6	Stomach	87.0	8C2D2CCE-E071-42E8-89B2-77C56B4F3472	5AF4101A-F7F6-4014-BC9C-02446DA9CBDC	TCGA-BR-4366-01A-01D-1154-02	HG19_Broad_variant	TCGA-BR-4366	TCGA-STAD		s15235	Harvard Medical School	Asterand	Russia	NO	TX	NX	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)		1154-02	True	STAD	C4	GI.CIN	0.09180486800000001	0.2	0.26		0.6706	0.10800000000000001	0.2457	-0.3931	0.7791	0.0035			1.041534158	3.34979905	704.0	0.47111474	7.0	43.0	0.597023573	2.122626604	35.0	1.906154747	7.0	0.979569765		565.4768322000001	580.9634718	382.7098045	0.0	0.0	0.0	0.0	7.549959980804508	6.52983585244675	-1.7689862078262482	5.704133290306178	5.642532657445847	0.7381998445008884	-1.8458266904983305	-0.8873031950009029	2.5071860523271363
13722.58cfa830e4b0c9d6adf6c2a2	58cfa830e4b0c9d6adf6c2a2	TCGA-BP-4807-01A-01D-2098-10_wgs_Illumina.filtered.	WGS	TCGA-BP-4807-01A-01D-2098-10_wgs_Illumina	TCGA-BP-4807-01A-01D-2098-10_wgs_Illumina.bam	91.4	1.9	0.16	58cfa830e4b0c9d6adf6c2a2	TCGA-BP-4807-01A-01D-2098-10_wgs_Illumina.bam	Alive	MALE	WHITE		Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-BP-4807-01A	33CF0893-0411-4758-AA90-602BFEDF0850	Primary Tumor	Illumina HiSeq	929b4e29-102f-48e2-a919-ff967127437e	Kidney	42.0	26307437-2F30-4647-81AC-F6BAE5BE6113	A54AAC0E-4108-49CF-BF50-687031C7CDA6	TCGA-BP-4807-01A-01D-2098-10	GRCh37-lite	TCGA-BP-4807	TCGA-KIRC		s9447	Baylor College of Medicine	MSKCC	None	NO	T1a	NX	Kidney Clear Cell Renal Carcinoma	Stage I	2098-10	True	KIRC	C3	KIRC.1	0.117910664				-1.1557	-0.2725	0.8326	-0.0778	0.2673	0.2932					91.0	0.050384751	2.0	5.0				2.890371758	18.0	1.0	1.602125196	560.1990047	-640.0605377	3296.084737	0.0	211.0	0.0	211.0	6.408894823274419	3.7464688095679666	0.27241280010694713	5.140383497810912	5.46964116913245	3.8703103009532156	-1.268511325463507	1.723172359564483	3.5978975008462686
13722.58cfa830e4b0c9d6adf6c2a3	58cfa830e4b0c9d6adf6c2a3	TCGA-B1-A47N-01A-11D-A25F-10_wgs_Illumina.filtered.	WGS	TCGA-B1-A47N-01A-11D-A25F-10_wgs_Illumina	TCGA-B1-A47N-01A-11D-A25F-10_wgs_Illumina.bam	32.02		0.08	58cfa830e4b0c9d6adf6c2a3	TCGA-B1-A47N-01A-11D-A25F-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-B1-A47N-01A	F1EC5A7B-0973-4C38-9908-862196DF9541	Primary Tumor	Illumina HiSeq	57987e56-d118-4f55-98c4-340866fcf3e8	Kidney	62.0	C5EDE5F5-35D2-4059-9F0C-6736ABC6F899	BD2CC59D-F5CE-46ED-BEB0-4C80B24CBE71	TCGA-B1-A47N-01A-11D-A25F-10	GRCh37-lite	TCGA-B1-A47N	TCGA-KIRP		s11855	Baylor College of Medicine	University of Pittsburgh	United States	NO	T1a	NX	Kidney Papillary Renal Cell Carcinoma	Stage I	A25F-10	True	KIRP	C3	KIRP.C1	0.09216739199999999	0.17	0.1		-2.056	-0.3415	-0.1113	0.1998	-0.3185	-0.4507	12.0	149.0	0.189867504	0.732346086	59.0	0.18266139	8.0	0.0				1.5607104090000001	5.0	0.9697239	2.394762226	-1140.007433	-1875.1469359999999	-342.4053659	0.0	1110.0	0.0	1110.0	7.728132792117677	0.27047840411533386	-0.20200730540194234	6.475369823622309	3.9587082966604745	3.2286564100565482	-1.252762968495368	3.6882298925451407	3.4306637154584907
13722.58cfa830e4b0c9d6adf6c2aa	58cfa830e4b0c9d6adf6c2aa	TCGA-BR-4201-01A-01D-1128_120816_SN590_0175_AD16M6ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BR-4201-01A-01D-1128_120816_SN590_0175_AD16M6ACXX_s_5_rg.sorted	TCGA-BR-4201-01A-01D-1128_120816_SN590_0175_AD16M6ACXX_s_5_rg.sorted.bam	204.9	1.9	0.15	58cfa830e4b0c9d6adf6c2aa	TCGA-BR-4201-01A-01D-1128_120816_SN590_0175_AD16M6ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4201-01A	8520654B-2192-46CF-9D72-1DDB885A7C55	Primary Tumor	Illumina HiSeq	359db0d8-a78f-4d9d-9a3e-9f1a04472df0	Stomach	66.0	B42CC87B-4BB0-433D-8AFB-CB314B8CBA30	FE12C75F-5A26-40A8-BEF0-742FAD4CD0E5	TCGA-BR-4201-01A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4201	TCGA-STAD		s14529	Harvard Medical School	Asterand	Russia	NO	T2a	NX	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)		1128-02	True	STAD	C2	GI.HM-indel	0.398502426	0.64	0.02		0.6782	0.252	0.8198	0.7311	0.5379	0.4906			12.57900682	38.15732141	96.0	0.07328246	4.0	4.0	0.9220403509999999	3.980898254	75.0	3.2578093989999997	31.0	0.948695847	1.01586962	1016.8346970000001	769.8424	-2515.656477	1.0	940.0	0.0	940.0	7.66262451817008	6.073443598119196	-0.08544412594005824	6.780235337971606	6.823286122355687	0.876621995435439	-0.8823891801984738	0.7498425242364908	0.9620661213754972
13722.58cfa830e4b0c9d6adf6c2c4	58cfa830e4b0c9d6adf6c2c4	TCGA-AD-A5EK-01A-11D-A28G-10_wgs_Illumina.filtered.	WGS	TCGA-AD-A5EK-01A-11D-A28G-10_wgs_Illumina	TCGA-AD-A5EK-01A-11D-A28G-10_wgs_Illumina.bam	58.87		0.08	58cfa830e4b0c9d6adf6c2c4	TCGA-AD-A5EK-01A-11D-A28G-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AD-A5EK-01A	E8EC26BD-C88D-42B9-AC8A-AB121B8140F8	Primary Tumor	Illumina HiSeq	e84aec8b-4304-43e0-96c7-d605fc64dd11	Colorectal	51.0	C48314EE-C778-4B82-8E5A-4923DF4C8413	D0A0D845-32E2-4590-B909-29BD27B92900	TCGA-AD-A5EK-01A-11D-A28G-10	GRCh37-lite	TCGA-AD-A5EK	TCGA-COAD		s13537	Baylor College of Medicine	International Genomics Consortium	United States	NO	T2	N0	Colon Adenocarcinoma	Stage I	A28G-10	True	COAD	C1	GI.CIN	0.039024043	0.16	0.03	14.60143944	0.7377	0.1815	-1.0194	-1.3206	0.1196	-0.0457	48.0	1.0	0.924155792	1.848311584	218.0	0.947589232	21.0	11.0				1.386294361	4.0	1.0	0.9141735990000001	-1183.228917	226.0330866	-2254.79805	0.0	500.0	0.0	500.0	6.3532099478598205	3.0541195218723516	-0.7347393236559314	6.183310911064423	5.249878897481243	2.61380267487233	-0.16989903679539742	2.1957593756088913	3.3485419985282614
13722.58cfa830e4b0c9d6adf6c2c6	58cfa830e4b0c9d6adf6c2c6	TCGA-CF-A1HS-01A-11D-A13U_121011_SN590_0184_BC192GACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CF-A1HS-01A-11D-A13U_121011_SN590_0184_BC192GACXX_s_5_rg.sorted	TCGA-CF-A1HS-01A-11D-A13U_121011_SN590_0184_BC192GACXX_s_5_rg.sorted.bam	42.45	1.95	0.16	58cfa830e4b0c9d6adf6c2c6	TCGA-CF-A1HS-01A-11D-A13U_121011_SN590_0184_BC192GACXX_s_5_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CF-A1HS-01A	A73C0842-39C5-4C2C-AA6A-F31341A4F36E	Primary Tumor	Illumina HiSeq	ed90abf4-1d04-41ce-9de3-9dcf24c1e375	Bladder	75.0	0A01E5BA-5549-4027-9E84-1BBB163A8F07	B8F18CDA-053F-4E40-8978-7524A4C0B49A	TCGA-CF-A1HS-01A-11D-A13U-02	HG19_Broad_variant	TCGA-CF-A1HS	TCGA-BLCA		s2875	Harvard Medical School	ILSbio	Vietnam	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A13U-02	True	BLCA	C2	BLCA.3	0.298075798	0.46	0.5	2.489487476	1.0639	0.38	-0.037000000000000005	-0.5607	0.9484	0.2588	159.0	20.0	2.168840682	6.447101752999999	298.0	0.741083246	14.0	45.0		0.0	1.0	0.693147181	2.0	1.0	1.583941789	-519.6362673	1051.646384	-1024.578941	0.0	382.0	1.0	133.0	7.01204021641303	6.788345921581169	0.16186746800735108	5.941598804711617	6.543223463548184	0.8901819187070881	-1.0704414117014132	-0.24512245803298516	0.728314450699737
13722.58cfa830e4b0c9d6adf6c2ca	58cfa830e4b0c9d6adf6c2ca	TCGA-BG-A0RY-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BG-A0RY-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_7_rg.sorted	TCGA-BG-A0RY-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_7_rg.sorted.bam	73.32	1.95	0.16	58cfa830e4b0c9d6adf6c2ca	TCGA-BG-A0RY-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0RY-01A	F299AD43-BB16-46CE-9617-48CC6C6F29E7	Primary Tumor	Illumina HiSeq	5464e1b6-9efc-49a0-bd5b-4fcd152a7718	Uterus	68.0	260692E1-9B2C-4F8B-952D-1B95C042E659	8DB9ED84-C708-4075-B93D-CC58E84E6D99	TCGA-BG-A0RY-01A-11D-A101-02	HG19_Broad_variant	TCGA-BG-A0RY	TCGA-UCEC		s4258	Harvard Medical School	University of Pittsburgh	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C4	UCEC.CN_LOW	0.156545297			4.503569111	-0.2976	-0.002	-0.166	-1.1196	-0.5660000000000001	0.0425	18.0	9.0	0.47739112899999997	1.3426625509999999	78.0	0.94719405	9.0	4.0							3.174542457	-1445.560606	-681.1824278	1641.8062730000001	0.0	469.0	0.0	469.0	5.569202913847668	6.862757913051401	-1.6607793487164564	4.421800461010126	5.2533200006173	0.4874870772169655	-1.1474024528375417	-1.6094379124341	2.148266425933422
13722.58cfa830e4b0c9d6adf6c2ce	58cfa830e4b0c9d6adf6c2ce	TCGA-B5-A0JN-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_3_rg.sorted.filtered.	WGS	TCGA-B5-A0JN-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_3_rg.sorted	TCGA-B5-A0JN-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_3_rg.sorted.bam	73.22	2.09	0.15	58cfa830e4b0c9d6adf6c2ce	TCGA-B5-A0JN-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_3_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0JN-01A	B60F22AC-A659-4F33-B01D-820E86A9A5C9	Primary Tumor	Illumina HiSeq	19c2a28e-bdeb-46af-b33e-e9849fc553ed	Uterus	84.0	684C6894-FD49-4934-8962-9628ECE734FB	EB2131FF-4AE0-4814-81F3-A480A0DEBB2E	TCGA-B5-A0JN-01A-11D-A101-02	HG19_Broad_variant	TCGA-B5-A0JN	TCGA-UCEC		s4245	Harvard Medical School	Duke	United States	NO			Serous endometrial adenocarcinoma		A101-02	True	UCEC	C2	UCEC.CN_HIGH	0.08281237799999999	0.26	0.48	7.39572064	0.7825	0.3195	-1.1829	-1.4482	0.2663	-0.1462	91.0	52.0	1.1724863890000001	3.68904254	578.0	0.735750646	9.0	58.0		0.0	1.0	1.33217904	4.0	0.960964047	4.906354498	-1489.7448539999998	-316.0421873	-2144.600779	0.0	2445.0	0.0	2445.0	6.421309523472461	6.785935259506955	0.436756144487884	5.248589262650629	6.018680106793287	1.8959829750988062	-1.1727202608218312	-0.7672551527136671	1.4592268306109222
13722.58cfa830e4b0c9d6adf6c2d0	58cfa830e4b0c9d6adf6c2d0	TCGA-CE-A27D-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CE-A27D-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_1_rg.sorted	TCGA-CE-A27D-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_1_rg.sorted.bam	52.72	1.93	0.17	58cfa830e4b0c9d6adf6c2d0	TCGA-CE-A27D-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_1_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-CE-A27D-01A	75A93F0E-CD41-43C6-A303-FF37E31395E9	Primary Tumor	Illumina HiSeq	c2d55126-05aa-44ef-97c3-ae2ac400c1b9	Thyroid	28.0	1807CEEE-28E1-4E8D-A1C4-6F6AD60EE310	CE991BB3-A63D-40C1-BFAF-3C4498D2C6EE	TCGA-CE-A27D-01A-11D-A16N-02	HG19_Broad_variant	TCGA-CE-A27D	TCGA-THCA		s12362	Harvard Medical School	ILSbio	Vietnam	NO	T2	N1	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	True	THCA	C3	THCA.2	0.264828555	0.46	0.01		-0.7718	-0.157	0.8038	2.1947	0.6432	0.0236	2.0		0.029877725	0.119510898	57.0	1.55e-05	0.0	0.0	0.8939771809999999	3.835572838	73.0	4.397995081	88.0	0.9822792570000001	2.019350659	791.4958429999999	-774.8244218	1573.066973	0.0	374.0	0.0	374.0	7.325187707882924	7.514981397034443	0.06762925875139847	6.28720004103125	6.598690665160287	0.6644185904745754	-1.037987666851675	-0.9162907318741551	0.5967893317231769
13722.58cfa830e4b0c9d6adf6c2d1	58cfa830e4b0c9d6adf6c2d1	TCGA-B2-4099-01A-02D-2095-10_wgs_Illumina.filtered.	WGS	TCGA-B2-4099-01A-02D-2095-10_wgs_Illumina	TCGA-B2-4099-01A-02D-2095-10_wgs_Illumina.bam	660.34	1.9	0.16	58cfa830e4b0c9d6adf6c2d1	TCGA-B2-4099-01A-02D-2095-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-B2-4099-01A	1ADB05D4-E1CA-4EDE-81C7-FF24A243ABAE	Primary Tumor	Illumina HiSeq	5a0ccacd-ed1b-47b2-818a-592a0cf426ad	Kidney	83.0	E242ADB8-DB67-475E-A0E4-52A622666B12	252A1C43-F954-44D7-8E31-6BCD0157A05C	TCGA-B2-4099-01A-02D-2095-10	GRCh37-lite	TCGA-B2-4099	TCGA-KIRC		s9732	Baylor College of Medicine	Christiana Healthcare	None	NO	T1a	NX	Kidney Clear Cell Renal Carcinoma	Stage I	2095-10	False	KIRC	C4	KIRC.4	0.155410087	0.36	0.18		-0.9849	0.023	1.0439	0.5281	0.6087	-0.2182	33.0	32.0	0.5053564970000001	1.5160694890000002	61.0	0.071146652	1.0	5.0				3.044820482	22.0	0.985046478	1.7894693019999999	69.65365538	-1368.3409	1567.896688	0.0	972.0	0.0	972.0	6.642114223121515	1.7197109649151372	0.6895174125093664	4.749507513346776	4.47602999080674	4.31748811353631	-1.8926067097747392	2.756319025891603	3.6279707010269435
13722.58cfa830e4b0c9d6adf6c2d6	58cfa830e4b0c9d6adf6c2d6	TCGA-BR-6707-01A-11D-1880_121220_SN1222_0163_AC1HA2ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BR-6707-01A-11D-1880_121220_SN1222_0163_AC1HA2ACXX_s_7_rg.sorted	TCGA-BR-6707-01A-11D-1880_121220_SN1222_0163_AC1HA2ACXX_s_7_rg.sorted.bam	333.7	1.9	0.15	58cfa830e4b0c9d6adf6c2d6	TCGA-BR-6707-01A-11D-1880_121220_SN1222_0163_AC1HA2ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6707-01A	DF3DF249-86C2-43D4-ABE1-796CD7DF653F	Primary Tumor	Illumina HiSeq	e2babdbd-1849-48ed-8726-1e3788be6064	Stomach	75.0	36F691AA-B737-4369-AD62-84F987F697A6	AA430360-2BE7-4C92-A10C-52588D8A6061	TCGA-BR-6707-01A-11D-1880-02	HG19_Broad_variant	TCGA-BR-6707	TCGA-STAD		s14890	Harvard Medical School	Asterand	Ukraine	NO	T3	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIA	1880-02	True	STAD	C2	GI.EBV	0.314321927	0.47	0.05	12.99713931	0.8012	0.3605	0.5224	1.8079	0.455	-0.1421			0.48856874200000006	1.6668815890000002	69.0	0.119751038	8.0	3.0	0.6957997490000001	3.313519428	117.0	4.375688112	109.0	0.9327144820000001	1.006561378	-459.3748624	1008.204753	-2892.1372260000003	0.0	491.0	1.0	426.0	8.300031711779575	7.47911140248816	0.541486276160776	5.9974466187855295	6.326431892549774	1.637355078883135	-2.3025850929940455	-1.1526795099383853	1.095868802722359
13722.58cfa830e4b0c9d6adf6c2d8	58cfa830e4b0c9d6adf6c2d8	TCGA-BT-A3PH-01A-11D-A221_120902_SN1222_0147_AC195DACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BT-A3PH-01A-11D-A221_120902_SN1222_0147_AC195DACXX_s_7_rg.sorted	TCGA-BT-A3PH-01A-11D-A221_120902_SN1222_0147_AC195DACXX_s_7_rg.sorted.bam	56.18		0.16	58cfa830e4b0c9d6adf6c2d8	TCGA-BT-A3PH-01A-11D-A221_120902_SN1222_0147_AC195DACXX_s_7_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A3PH-01A	932BCDD4-5145-49E8-9A95-8A546396F572	Primary Tumor	Illumina HiSeq	9096dde9-2391-4c22-b816-2057b8adb483	Bladder	76.0	33A83E54-3BE5-4A68-8AB0-D31D0BCD3B67	4C010558-360B-44AF-A980-A1CCDF3AB9C7	TCGA-BT-A3PH-01A-11D-A221-26	HG19_Broad_variant	TCGA-BT-A3PH	TCGA-BLCA	142.0	s2699	MD Anderson - Institute for Applied Cancer Science	University of Pittsburgh	United States	NO	T3b	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A221-26	True	BLCA	C1	BLCA.1	0.070766964	0.17	0.11	9.476114699	0.8282	0.2305	-1.4121	-1.4625	-1.7947	-0.1876	77.0	1.0	3.767455255	11.94487752	138.0	0.754187811	13.0	19.0		0.0	1.0		0.0		2.464404271	-1679.360189	1249.80197	-2682.494776	1.0	142.0	1.0	142.0	6.621938133139869	5.038669996214236	-2.44797063295605	6.463714127924974	6.517337677465142	-0.32262910252901555	-0.15822400521489444	1.478667681250906	2.1253415304270344
13722.58cfa830e4b0c9d6adf6c2da	58cfa830e4b0c9d6adf6c2da	TCGA-BR-4370-01A-01D-1154_130815_VM001_0003_VMR0003CXX_s_1_rg.sorted.filtered.	WGS	TCGA-BR-4370-01A-01D-1154_130815_VM001_0003_VMR0003CXX_s_1_rg.sorted	TCGA-BR-4370-01A-01D-1154_130815_VM001_0003_VMR0003CXX_s_1_rg.sorted.bam	179.2	1.9	0.15	58cfa830e4b0c9d6adf6c2da	TCGA-BR-4370-01A-01D-1154_130815_VM001_0003_VMR0003CXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4370-01A	A2A71CB0-9DBD-45CC-8867-DA84500515E7	Primary Tumor	Illumina HiSeq	a1feb789-c851-4608-a5c1-382bb432c4c7	Stomach	74.0	CFB7901B-E4E1-42FE-802D-DCD34F8C4912	B27FAC46-97C3-4262-B8CB-6E15AA75483A	TCGA-BR-4370-01A-01D-1154-02	HG19_Broad_variant	TCGA-BR-4370	TCGA-STAD		s14883	Harvard Medical School	Asterand	Russia	NO	TX	NX	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)		1154-02	True	STAD	C1	GI.HM-indel	0.301009814	0.58	0.07		0.2392	-0.042	0.8189	1.0212	0.8959	0.6018			9.04912713	25.95743501	89.0	0.104253006	4.0	0.0	0.8598084859999999	4.589260536	208.0	3.5538613580000002	40.0	0.963398615		-90.80946252	408.9638104	-1945.6151510000002	0.0	0.0	0.0	0.0	7.048820719260739	6.129050210060544	-0.2905143624292933	5.390592642657207	5.318119993844216	1.0095096369256868	-1.6582280766035324	-0.8109302162163288	1.3000239993549803
13722.58cfa830e4b0c9d6adf6c2db	58cfa830e4b0c9d6adf6c2db	TCGA-C4-A0F0-01A-12D-A10R_120926_SN590_0181_AC19HCACXX_s_5_rg.sorted.filtered.	WGS	TCGA-C4-A0F0-01A-12D-A10R_120926_SN590_0181_AC19HCACXX_s_5_rg.sorted	TCGA-C4-A0F0-01A-12D-A10R_120926_SN590_0181_AC19HCACXX_s_5_rg.sorted.bam	13.51	1.77	0.15	58cfa830e4b0c9d6adf6c2db	TCGA-C4-A0F0-01A-12D-A10R_120926_SN590_0181_AC19HCACXX_s_5_rg.sorted.bam	Alive	MALE			Bladder Urothelial Carcinoma	Aligned reads	TCGA-C4-A0F0-01A	40398C03-A9CC-476B-9EE9-AECF161BE43F	Primary Tumor	Illumina HiSeq	38f56daa-7d69-4fe0-8895-10e22397ee2a	Bladder	60.0	54234A11-8674-4B01-B2EF-A4C6D772AA43	5584A4A7-2EA1-46D8-8960-8905689D5720	TCGA-C4-A0F0-01A-12D-A10R-02	HG19_Broad_variant	TCGA-C4-A0F0	TCGA-BLCA		s2862	Harvard Medical School	Indivumed	Germany	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A10R-02	True	BLCA	C2	BLCA.3	0.254038091	0.61	0.35	3.57439734	1.0972	0.6865	-0.3964	-0.3531	0.8806	0.0325	49.0	90.0	0.940982196	2.309683571	145.0	0.525021365	22.0	27.0				1.732867951	6.0	0.9671320179999999	2.167773619	-1353.133053	1148.315152	-3044.810834	0.0	59.0	0.0	59.0	6.972879566025357	4.026860669443088	0.06870833598922876	6.685197493573575	7.729220285113717	1.2737881223211458	-0.2876820724517808	3.702359615670629	1.2050797863319171
13722.58cfa830e4b0c9d6adf6c2e0	58cfa830e4b0c9d6adf6c2e0	TCGA-BT-A20P-01A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BT-A20P-01A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_3_rg.sorted	TCGA-BT-A20P-01A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_3_rg.sorted.bam	75.72	2.03	0.15	58cfa830e4b0c9d6adf6c2e0	TCGA-BT-A20P-01A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_3_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A20P-01A	F48937ED-E294-41F0-8872-7010391167A9	Primary Tumor	Illumina HiSeq	814688fe-5071-40b6-bb89-643389543580	Bladder	81.0	6B43EEEC-4FEB-4062-827A-E63ED8CE3820	022AEFEC-CBAC-46C1-9F17-AC087BD7164E	TCGA-BT-A20P-01A-11D-A14U-02	HG19_Broad_variant	TCGA-BT-A20P	TCGA-BLCA	544.0	s3272	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A14U-02	True	BLCA	C1	BLCA.1	0.03720472	0.07	0.0	6.055585302999999	0.3534	0.0335	-1.3219	-1.5618	-0.124	-0.1013	22.0	11.0	0.73101978	2.589028386	249.0	0.236864784	7.0	11.0					0.0		2.115935769	-1894.8219210000002	515.8377843999999	-528.2095919	1.0	544.0	0.0	544.0	7.113793362393407	7.852050207265888	0.2001825674234503	5.909820558067471	6.681978954615634	1.294204182382961	-1.203972804325936	-1.1700712526502546	1.0940216149595108
13722.58cfa830e4b0c9d6adf6c2e4	58cfa830e4b0c9d6adf6c2e4	TCGA-BR-6802-01A-11D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BR-6802-01A-11D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_7_rg.sorted	TCGA-BR-6802-01A-11D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_7_rg.sorted.bam	487.7	1.9	0.14	58cfa830e4b0c9d6adf6c2e4	TCGA-BR-6802-01A-11D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6802-01A	7C831A1D-3253-4AF4-A0FF-7FE9FF9AF1CE	Primary Tumor	Illumina HiSeq	73cec875-41a5-40bd-9d13-9e1ed4dd64d0	Stomach	65.0	E3BF04C2-961F-4511-AF63-5A0E8AE6377B	0B4F4B0B-EF5C-4717-875A-7B8C5342DBC4	TCGA-BR-6802-01A-11D-1880-02	HG19_Broad_variant	TCGA-BR-6802	TCGA-STAD		s14885	Harvard Medical School	Asterand	Russia	NO	T3	N2	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIIA	1880-02	True	STAD	C2	GI.HM-indel	0.518376717	0.67	0.03	10.87630018	0.6916	0.2055	0.4411	1.5288	1.5454	0.3521			4.237968953999999	11.29176963	75.0	0.11765751099999999	4.0	0.0	0.799493178	4.469955951	268.0	4.286752553	133.0	0.87657393	1.283661188	-12.21485429	444.2357221	-676.4832679	0.0	940.0	1.0	807.0	8.08717921038666	8.18706743985389	1.0184299844284217	5.889954633050441	7.1456135650257275	1.2422590150337252	-2.197224577336219	-1.0414538748281612	0.22382903060530346
13722.58cfa830e4b0c9d6adf6c2ec	58cfa830e4b0c9d6adf6c2ec	TCGA-BR-6566-01A-11D-1798_130116_SN208_0449_BD1RNWACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BR-6566-01A-11D-1798_130116_SN208_0449_BD1RNWACXX_s_2_rg.sorted	TCGA-BR-6566-01A-11D-1798_130116_SN208_0449_BD1RNWACXX_s_2_rg.sorted.bam	118.7	1.9	0.15	58cfa830e4b0c9d6adf6c2ec	TCGA-BR-6566-01A-11D-1798_130116_SN208_0449_BD1RNWACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6566-01A	43F0421C-6578-4D77-9314-EF0305C7EFBD	Primary Tumor	Illumina HiSeq	ae711b74-3be9-4959-addd-03427c07f35b	Stomach	64.0	EEB8703E-5F0A-429D-9A5C-7C5227EB7A01	7BAAEED3-AA68-4825-84F1-0516B543C762	TCGA-BR-6566-01A-11D-1798-02	HG19_Broad_variant	TCGA-BR-6566	TCGA-STAD		s14884	Harvard Medical School	Asterand	Russia	NO	T3	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIA	1798-02	True	STAD	C2	GI.HM-indel	0.365471172	0.53	0.14	9.637525033	0.5982	0.392	0.4579	1.2399	0.4469	0.4414			7.930490425	22.61764417	59.0	0.17096611899999997	4.0	1.0	0.718527813	4.011897391000001	266.0	4.079541565	83.0	0.92321537	2.572225478	-280.8308963	318.1332846	1740.5796879999998	0.0	997.0	0.0	997.0	7.8046592970561015	7.263399692106344	-0.13418194019164886	5.5020742040620565	6.474942331742074	3.6652985115250294	-2.3025850929940455	-0.7884573603642702	3.7994804517166783
13722.58cfa830e4b0c9d6adf6c2f5	58cfa830e4b0c9d6adf6c2f5	TCGA-BR-6803-01A-11D-1880_130329_SN590_0221_BD1WHDACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BR-6803-01A-11D-1880_130329_SN590_0221_BD1WHDACXX_s_7_rg.sorted	TCGA-BR-6803-01A-11D-1880_130329_SN590_0221_BD1WHDACXX_s_7_rg.sorted.bam	91.7	1.9	0.14	58cfa830e4b0c9d6adf6c2f5	TCGA-BR-6803-01A-11D-1880_130329_SN590_0221_BD1WHDACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6803-01A	2F90209B-7464-4D7E-83D1-67850C263DED	Primary Tumor	Illumina HiSeq	af361f62-8dd0-4336-9fa9-41cdc800b18e	Stomach	54.0	E56FE72A-760A-4A60-9013-EA611080BA3F	D2F16739-9EAA-465D-95BA-D13C3AEB9A40	TCGA-BR-6803-01A-11D-1880-02	HG19_Broad_variant	TCGA-BR-6803	TCGA-STAD		s15308	Harvard Medical School	Asterand	Russia	NO	T3	N0	Stomach  Adenocarcinoma  Diffuse Type	Stage IIA	1880-02	True	STAD	C3	GI.GS	0.392919894	0.7	0.23	18.7364255	-0.1669	-0.078	0.5354	1.8066	0.1459	0.4335			0.170342308	0.312294232	81.0	0.196924806	3.0	5.0	0.882452344	5.20879262	366.0	5.335718202	265.0	0.956268201	2.0003593619999998	-686.6269583	-245.8217583	629.8116093	0.0	949.0	0.0	949.0	6.340359303727752	5.73925686284986	0.3427244278802629	4.143134726391533	4.697802988021699	3.8331529432703606	-2.197224577336219	-1.0414538748281612	3.490428515390098
13722.58cfa830e4b0c9d6adf6c319	58cfa830e4b0c9d6adf6c319	TCGA-BR-6705-01A-12D-1880_121220_SN1222_0163_AC1HA2ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BR-6705-01A-12D-1880_121220_SN1222_0163_AC1HA2ACXX_s_3_rg.sorted	TCGA-BR-6705-01A-12D-1880_121220_SN1222_0163_AC1HA2ACXX_s_3_rg.sorted.bam	27.7	1.9	0.15	58cfa830e4b0c9d6adf6c319	TCGA-BR-6705-01A-12D-1880_121220_SN1222_0163_AC1HA2ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6705-01A	B14F2FCB-E869-475E-BC7C-ADAF6E7E636F	Primary Tumor	Illumina HiSeq	cf5ffdf8-e424-4a51-862f-816cba0c92e0	Stomach	68.0	DB8D0AC1-23B7-49AB-8BB3-44782156F038	F55A158B-F7DB-4786-9553-65DEBCAE80BA	TCGA-BR-6705-01A-12D-1880-02	HG19_Broad_variant	TCGA-BR-6705	TCGA-STAD		s15239	Harvard Medical School	Asterand	Ukraine	NO	T3	N3a	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIIB	1880-02	True	STAD	C1	GI.CIN	0.40756388299999996	0.83	0.38	10.30912604	0.1472	0.0155	0.3162	1.0090000000000001	0.045	0.8693			0.749152831	2.276272062	140.0	0.160026413	4.0	10.0	0.79970664	3.666628938	98.0	3.5737655630000003	59.0	0.87645193	2.600981364	-344.21308650000003	92.57776419	-1211.81859	1.0	779.0	1.0	779.0	7.8595418465411315	7.759045160638879	-0.485729937040628	6.013715156042801	6.506282192143511		-1.8458266904983305	-1.252762968495368	
13722.58cfa830e4b0c9d6adf6c31b	58cfa830e4b0c9d6adf6c31b	TCGA-BS-A0TI-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BS-A0TI-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_5_rg.sorted	TCGA-BS-A0TI-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_5_rg.sorted.bam	82.74	1.89	0.17	58cfa830e4b0c9d6adf6c31b	TCGA-BS-A0TI-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0TI-01A	DF857BC6-FD6A-4713-BEF9-6EE1301E5FB1	Primary Tumor	Illumina HiSeq	ea49ec05-391f-4ccc-8dbf-11ec80154839	Uterus	64.0	2F52C850-8E70-4EAB-88F3-D35DC55E385B	E1707EDD-FAC5-4213-BA50-2538F9F90EE5	TCGA-BS-A0TI-01A-11D-A101-02	HG19_Broad_variant	TCGA-BS-A0TI	TCGA-UCEC		s5010	Harvard Medical School	University of Hawaii	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C2	UCEC.CN_HIGH	0.195157742	0.47	0.29	6.070962051	0.5393	0.24100000000000002	-0.0244	0.7521	1.2955	-0.0298	35.0	68.0	0.502615028	2.513075137	317.0	0.510198085	6.0	54.0							2.919436305	-955.3098369999999	17.75719914	-507.7634915	0.0	1882.0	0.0	1882.0	6.700238983553626	7.64126434822988	0.012636333718904824	6.058385097381231	6.8874925458535	1.7310711738278581	-0.6418538861723944	-0.7537718023763804	1.7184348401089533
13722.58cfa830e4b0c9d6adf6c31e	58cfa830e4b0c9d6adf6c31e	TCGA-CF-A27C-01A-11D-A16N_120920_SN1222_0151_BD1D5CACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CF-A27C-01A-11D-A16N_120920_SN1222_0151_BD1D5CACXX_s_7_rg.sorted	TCGA-CF-A27C-01A-11D-A16N_120920_SN1222_0151_BD1D5CACXX_s_7_rg.sorted.bam	67.64	2.28	0.18	58cfa830e4b0c9d6adf6c31e	TCGA-CF-A27C-01A-11D-A16N_120920_SN1222_0151_BD1D5CACXX_s_7_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CF-A27C-01A	7FEE9D6F-C0EA-43C2-89C2-66D965A077A8	Primary Tumor	Illumina HiSeq	ecc65751-9b59-49c3-a142-7a4c61174649	Bladder	52.0	EAD6792B-4E52-4C28-891C-6D8696873A13	1E553EB3-8C42-48A1-87A7-BFA8541CE568	TCGA-CF-A27C-01A-11D-A16N-02	HG19_Broad_variant	TCGA-CF-A27C	TCGA-BLCA		s2873	Harvard Medical School	ILSbio	Vietnam	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A16N-02	True	BLCA	C4	BLCA.1	0.032224743	0.02	0.08	0.9883168609999999	-0.2654	-0.0175	-1.7876	-1.7772	-0.6781	-0.6954	70.0	21.0	1.51435714	3.815015102	160.0	0.19036567399999998	3.0	13.0				1.039720771	3.0	0.94639463	2.4224402990000002	-1631.279844	-441.5982327	1007.6502720000001	0.0	425.0	0.0	425.0	6.0777378045321555	8.6638228016302	0.3608056047970265	5.266807588315826	7.825493611225758	1.9605359767453339	-0.8109302162163288	-0.8383291904044432	1.5997303719483074
13722.58cfa831e4b0c9d6adf6c338	58cfa831e4b0c9d6adf6c338	TCGA-CG-4476-01A-01D-1154_130815_VM001_0006_VMR0006CXX_s_7_rg.sorted.filtered.	WGS	TCGA-CG-4476-01A-01D-1154_130815_VM001_0006_VMR0006CXX_s_7_rg.sorted	TCGA-CG-4476-01A-01D-1154_130815_VM001_0006_VMR0006CXX_s_7_rg.sorted.bam	127.2	1.9	0.14	58cfa831e4b0c9d6adf6c338	TCGA-CG-4476-01A-01D-1154_130815_VM001_0006_VMR0006CXX_s_7_rg.sorted.bam	Alive	MALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4476-01A	442D7415-D095-4962-8296-A14390BAD40A	Primary Tumor	Illumina HiSeq	87a698be-8fb0-4ced-842b-fdc852b98aa8	Stomach	69.0	37F5444F-A58D-4899-A11B-9C09ECD357FC	0C5818D8-5C20-4E4B-99CF-6F378CA6EBE7	TCGA-CG-4476-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4476	TCGA-STAD		s14983	Harvard Medical School	Indivumed	Germany	NO	T4b	N3a	Stomach  Adenocarcinoma  Diffuse Type	Stage IIIC	1154-02	True	STAD	C2	GI.CIN	0.280260254	0.72	0.25	7.341158127000001	0.2374	0.031	0.8505	1.3030000000000002	0.0439	0.2885			0.715104836	3.175065473	195.0	0.577159466	15.0	24.0	0.901499353	4.005047233	85.0	3.749769882	49.0	0.963500263		114.6021004	685.5125836	613.0811003	0.0	0.0	0.0	0.0	8.990483081653124	7.923867737441883	-0.6171338118861833	6.953601154392084	7.763525087366704	2.0541237336955467	-2.0368819272610397	-0.16034265007517945	2.67125754558173
13722.58cfa831e4b0c9d6adf6c33c	58cfa831e4b0c9d6adf6c33c	TCGA-CG-4475-01A-01D-1154_121026_SN1120_0198_BC188JACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CG-4475-01A-01D-1154_121026_SN1120_0198_BC188JACXX_s_7_rg.sorted	TCGA-CG-4475-01A-01D-1154_121026_SN1120_0198_BC188JACXX_s_7_rg.sorted.bam	128.2	1.9	0.14	58cfa831e4b0c9d6adf6c33c	TCGA-CG-4475-01A-01D-1154_121026_SN1120_0198_BC188JACXX_s_7_rg.sorted.bam	Alive	MALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4475-01A	CAD2ADC1-0F41-4651-9C80-AE9961E2DC8D	Primary Tumor	Illumina HiSeq	8d322c4d-bfdb-40cc-a222-87ff33a87718	Stomach	76.0	3E5D09C6-8F98-4701-BD24-FCA581343DE8	86D8A371-57BB-4DC7-9872-0EB4542208DC	TCGA-CG-4475-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4475	TCGA-STAD		s14706	Harvard Medical School	Indivumed	Germany	NO	T3	N1		Stage IIB	1154-02	True	STAD	C4	GI.CIN	0.174603171	0.57	0.13	19.30040088	0.5432	0.157	0.2667	-0.6874	-0.6055	0.4199			0.562206505	1.264964637	351.0	0.565153096	13.0	60.0	0.911486881	2.582436795	17.0	2.338371705	11.0	0.9751767440000001	1.275797392	611.0768866000001	195.6476907	785.2994304	0.0	699.0	0.0	699.0	8.804175018753625	7.905585034388117	-0.43933711834089173	7.012415549525571	6.945809190574223	0.2591789143722085	-1.7917594692280552	-0.9597758438138939	0.6985160327131003
13722.58cfa831e4b0c9d6adf6c342	58cfa831e4b0c9d6adf6c342	TCGA-CG-4475-01A-01D-1154_130815_VM001_0006_VMR0006CXX_s_5_rg.sorted.filtered.	WGS	TCGA-CG-4475-01A-01D-1154_130815_VM001_0006_VMR0006CXX_s_5_rg.sorted	TCGA-CG-4475-01A-01D-1154_130815_VM001_0006_VMR0006CXX_s_5_rg.sorted.bam	128.2	1.9	0.14	58cfa831e4b0c9d6adf6c342	TCGA-CG-4475-01A-01D-1154_130815_VM001_0006_VMR0006CXX_s_5_rg.sorted.bam	Alive	MALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4475-01A	CAD2ADC1-0F41-4651-9C80-AE9961E2DC8D	Primary Tumor	Illumina HiSeq	77dce8cf-5642-43d4-8111-4f72d2ef30ef	Stomach	76.0	3E5D09C6-8F98-4701-BD24-FCA581343DE8	86D8A371-57BB-4DC7-9872-0EB4542208DC	TCGA-CG-4475-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4475	TCGA-STAD		s14639	Harvard Medical School	Indivumed	Germany	NO	T3	N1		Stage IIB	1154-02	True	STAD	C4	GI.CIN	0.174603171	0.57	0.13	19.30040088	0.5432	0.157	0.2667	-0.6874	-0.6055	0.4199			0.562206505	1.264964637	351.0	0.565153096	13.0	60.0	0.911486881	2.582436795	17.0	2.338371705	11.0	0.9751767440000001	1.275797392	611.0768866000001	195.6476907	785.2994304	0.0	699.0	0.0	699.0	8.804175018753625	7.905585034388117	-0.43933711834089173	7.012415549525571	6.945809190574223	0.2591789143722085	-1.7917594692280552	-0.9597758438138939	0.6985160327131003
13722.58cfa831e4b0c9d6adf6c34a	58cfa831e4b0c9d6adf6c34a	TCGA-CG-5718-01A-11D-1598_121029_SN208_0438_AC18NJACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CG-5718-01A-11D-1598_121029_SN208_0438_AC18NJACXX_s_6_rg.sorted	TCGA-CG-5718-01A-11D-1598_121029_SN208_0438_AC18NJACXX_s_6_rg.sorted.bam	563.0	1.9	0.15	58cfa831e4b0c9d6adf6c34a	TCGA-CG-5718-01A-11D-1598_121029_SN208_0438_AC18NJACXX_s_6_rg.sorted.bam	Alive	FEMALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5718-01A	D5C58161-05ED-4472-81ED-176216F49929	Primary Tumor	Illumina HiSeq	98032563-24e7-466c-9f90-1ba67975f2f9	Stomach	78.0	5865A287-63C4-44F7-92D5-C4F3C323AF89	1A108108-EEAC-4EE8-AFD7-871AFA69054B	TCGA-CG-5718-01A-11D-1598-02	HG19_Broad_variant	TCGA-CG-5718	TCGA-STAD		s14903	Harvard Medical School	Indivumed	Germany	NO	T2b	N1	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage II	1598-02	True	STAD	C2	GI.CIN	0.267027506	0.42	0.1		0.5251	0.0645	0.4309	0.9792	0.5435	0.0623			0.694528186	2.112523232	278.0	0.524285718	11.0	38.0	0.811923403	5.2942448980000005	679.0	4.70416155	130.0	0.966436211	3.892365355	-239.98426780000003	-530.3815371999999	3503.6101049999997	1.0	1095.0	0.0	1095.0	7.6817909632754215	6.348639366088365	-0.40685728430406154	5.484566385939202	5.943174257980202	1.2580709848692901	-2.197224577336219	-0.4054651081081646	1.6649282691733518
13722.58cfa831e4b0c9d6adf6c350	58cfa831e4b0c9d6adf6c350	TCGA-CG-5717-01A-11D-1598_121029_SN208_0438_AC18NJACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CG-5717-01A-11D-1598_121029_SN208_0438_AC18NJACXX_s_5_rg.sorted	TCGA-CG-5717-01A-11D-1598_121029_SN208_0438_AC18NJACXX_s_5_rg.sorted.bam	152.0	1.9	0.15	58cfa831e4b0c9d6adf6c350	TCGA-CG-5717-01A-11D-1598_121029_SN208_0438_AC18NJACXX_s_5_rg.sorted.bam	Dead	MALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5717-01A	BDC3899E-15AE-421F-829B-0E07FBD27C60	Primary Tumor	Illumina HiSeq	34ec4e75-2398-4904-adf0-34500892e1a5	Stomach	58.0	CEA37BBD-1BCC-4205-BE3D-DAFAC2E30256	64826993-D765-4895-BE39-BE5ECC72807B	TCGA-CG-5717-01A-11D-1598-02	HG19_Broad_variant	TCGA-CG-5717	TCGA-STAD	212.0	s14488	Harvard Medical School	Indivumed	Germany	NO	T2b	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage II	1598-02	True	STAD	C2	GI.GS	0.34702931	0.77	0.37		-0.1245	-0.062	0.3252	1.3188	1.3838	0.1066			0.769065825	2.563552751	103.0	0.043015412999999995	4.0	8.0	0.847844094	4.051951628	119.0	4.820342447	142.0	0.9726615540000001	2.503709475	-353.14706689999997	-760.2152597	1206.262271	1.0	212.0	1.0	120.0	7.499976540952122	6.8719686625631375	-0.5249396468224238	5.302751963615903	6.345875566666358	1.3523731497534557	-2.197224577336219	-0.5260930958967793	1.8773127965758794
13722.58cfa831e4b0c9d6adf6c356	58cfa831e4b0c9d6adf6c356	TCGA-CG-4477-01A-01D-1154_130815_VM001_0007_VMR0007CXX_s_2_rg.sorted.filtered.	WGS	TCGA-CG-4477-01A-01D-1154_130815_VM001_0007_VMR0007CXX_s_2_rg.sorted	TCGA-CG-4477-01A-01D-1154_130815_VM001_0007_VMR0007CXX_s_2_rg.sorted.bam	281.2	1.9	0.14	58cfa831e4b0c9d6adf6c356	TCGA-CG-4477-01A-01D-1154_130815_VM001_0007_VMR0007CXX_s_2_rg.sorted.bam	Alive	FEMALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4477-01A	18D0AAE7-9694-4252-B8FE-16E62DADAB07	Primary Tumor	Illumina HiSeq	6fb461b5-4d42-4cba-bc62-bb8f68c3deed	Stomach	58.0	6D7C7B4E-6913-487D-9DC3-DDA901434192	3AE56504-30EE-4C03-9F69-C5B415DE6738	TCGA-CG-4477-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4477	TCGA-STAD		s14637	Harvard Medical School	Indivumed	Germany	NO	T2a	N0	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1154-02	True	STAD	C2	GI.CIN	0.30151113	0.51	0.14	31.11498554	0.8605	0.28800000000000003	0.9962	1.3133	1.2385	0.1422			0.9621760090000001	3.0239817419999997	141.0	0.693291047	4.0	34.0	0.828144186	4.774409491	319.0	3.3654988789999996	32.0	0.9710777079999999	0.944525932	752.3872243	413.015928	-2252.340252	0.0	942.0	1.0	365.0	7.793999089503995	5.5855185541624675	0.042078838380462336	5.596774512167776	5.2060289324575635	1.5620015367534115	-2.197224577336219	-0.3794896217049035	1.519922698372949
13722.58cfa831e4b0c9d6adf6c366	58cfa831e4b0c9d6adf6c366	TCGA-CG-5720-01A-11D-1598_121029_SN208_0439_BD1KHKACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CG-5720-01A-11D-1598_121029_SN208_0439_BD1KHKACXX_s_2_rg.sorted	TCGA-CG-5720-01A-11D-1598_121029_SN208_0439_BD1KHKACXX_s_2_rg.sorted.bam	135.0	1.9	0.14	58cfa831e4b0c9d6adf6c366	TCGA-CG-5720-01A-11D-1598_121029_SN208_0439_BD1KHKACXX_s_2_rg.sorted.bam	Dead	MALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5720-01A	7C9EA4FA-4CBC-4941-945A-E531E1D48304	Primary Tumor	Illumina HiSeq	6cf7bbf9-63f5-40e8-b595-c9012a1825ba	Stomach	71.0	1B2E1B50-8D4E-4E62-9B1B-B484936BD6EB	98CE6D0E-465C-40FA-9408-33AA7A25FBB2	TCGA-CG-5720-01A-11D-1598-02	HG19_Broad_variant	TCGA-CG-5720	TCGA-STAD	30.0	s14984	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1598-02	True	STAD	C1	GI.CIN	0.265836527	0.37	0.1		0.4981	0.21100000000000002	0.5672	1.1759	-0.0714	0.2953			0.832098599	1.750276364	68.0	0.080261268	0.0	13.0	0.705954393	4.224386106	397.0	5.228332571	260.0	0.9402323159999999	1.26877527	333.24582960000004	354.64869980000003	1518.026574	1.0	30.0	0.0	30.0	8.241703159729818	8.673182995344051	-0.2374560140246531	6.583475083126286	8.36780134579287	0.9118957058210576	-1.6582280766035324	-0.30538164955118186	1.1493517198457108
13722.58cfa831e4b0c9d6adf6c36c	58cfa831e4b0c9d6adf6c36c	TCGA-CD-5803-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CD-5803-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_8_rg.sorted	TCGA-CD-5803-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_8_rg.sorted.bam	193.3	1.9	0.14	58cfa831e4b0c9d6adf6c36c	TCGA-CD-5803-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_8_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-CD-5803-01A	33901C6F-9180-4A19-866C-F4AC6BEC76DA	Primary Tumor	Illumina HiSeq	1002025d-03b9-46ab-988a-576f59957cac	Stomach	78.0	EB71264D-C896-4910-BF46-D6F129B83941	EABD49CE-0F0C-443D-9BF4-0ADD2C2532B2	TCGA-CD-5803-01A-11D-1598-02	HG19_Broad_variant	TCGA-CD-5803	TCGA-STAD		s15118	Harvard Medical School	ILSbio	Vietnam	NO	T3	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage II	1598-02	True	STAD	C2	GI.CIN	0.453905874	0.73	0.39	15.41677368	0.1141	-0.025	1.163	2.4366	1.8413	0.7149			0.255432982	0.8798247140000001	53.0	0.169324008	9.0	2.0	0.571994553	2.292172756	55.0	6.329508715	687.0	0.9689505209999999	2.019566044	303.98998839999996	437.3332568	-550.9052582	1.0	341.0	1.0	300.0	8.799887847356972	8.15641460093048	0.4706691866746301	6.497302754362927	6.812679854229385	3.246191635515164	-2.3025850929940455	-1.3437347467010947	2.775522448840534
13722.58cfa831e4b0c9d6adf6c375	58cfa831e4b0c9d6adf6c375	TCGA-CG-4477-01A-01D-1154_121212_SN1120_0205_AC1F18ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CG-4477-01A-01D-1154_121212_SN1120_0205_AC1F18ACXX_s_2_rg.sorted	TCGA-CG-4477-01A-01D-1154_121212_SN1120_0205_AC1F18ACXX_s_2_rg.sorted.bam	281.2	1.9	0.14	58cfa831e4b0c9d6adf6c375	TCGA-CG-4477-01A-01D-1154_121212_SN1120_0205_AC1F18ACXX_s_2_rg.sorted.bam	Alive	FEMALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4477-01A	18D0AAE7-9694-4252-B8FE-16E62DADAB07	Primary Tumor	Illumina HiSeq	854ac518-e119-4ce6-97c4-b123e75a99ee	Stomach	58.0	6D7C7B4E-6913-487D-9DC3-DDA901434192	3AE56504-30EE-4C03-9F69-C5B415DE6738	TCGA-CG-4477-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4477	TCGA-STAD		s14907	Harvard Medical School	Indivumed	Germany	NO	T2a	N0	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1154-02	True	STAD	C2	GI.CIN	0.30151113	0.51	0.14	31.11498554	0.8605	0.28800000000000003	0.9962	1.3133	1.2385	0.1422			0.9621760090000001	3.0239817419999997	141.0	0.693291047	4.0	34.0	0.828144186	4.774409491	319.0	3.3654988789999996	32.0	0.9710777079999999	0.944525932	752.3872243	413.015928	-2252.340252	0.0	942.0	1.0	365.0	7.793999089503995	5.58522991222079	0.042078838380462336	5.596774512167776	5.205740290515886	1.5620015367534115	-2.197224577336219	-0.3794896217049035	1.519922698372949
13722.58cfa831e4b0c9d6adf6c37a	58cfa831e4b0c9d6adf6c37a	TCGA-CD-5813-01A-11D-1598_121026_SN1120_0198_BC188JACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CD-5813-01A-11D-1598_121026_SN1120_0198_BC188JACXX_s_5_rg.sorted	TCGA-CD-5813-01A-11D-1598_121026_SN1120_0198_BC188JACXX_s_5_rg.sorted.bam	46.0	1.9	0.17	58cfa831e4b0c9d6adf6c37a	TCGA-CD-5813-01A-11D-1598_121026_SN1120_0198_BC188JACXX_s_5_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-CD-5813-01A	152B9D8A-19FD-4665-B9E4-4FEDFB1608CD	Primary Tumor	Illumina HiSeq	ccc0d204-3529-43aa-b108-62d12f6465bd	Stomach	60.0	09E42E33-D2EC-406C-9A42-36D9D2EBD6C6	2118F0C5-3178-40EA-850D-C3F6F8752DD9	TCGA-CD-5813-01A-11D-1598-02	HG19_Broad_variant	TCGA-CD-5813	TCGA-STAD		s14408	Harvard Medical School	ILSbio	Vietnam	NO	T3	N0	Stomach Intestinal Adenocarcinoma Mucinous Type	Stage II	1598-02	True	STAD	C3		0.322316763			6.047253347000001	0.0134	-0.0695	1.0436	2.1695	0.1578	0.5749			1.3116049440000002	4.105893737					0.798243825	4.581754248	311.0	4.940591888	197.0	0.935150742	1.220384747	35.32646395	-84.71289643	-2106.2404539999998	1.0	377.0	1.0	315.0	8.430981494597171	8.770790936869256	0.9663069527278101	6.639222025369117	8.483108864417476	2.0589915417626443	-1.7917594692280552	-0.2876820724517808	1.0926845890348342
13722.58cfa831e4b0c9d6adf6c37e	58cfa831e4b0c9d6adf6c37e	TCGA-CG-5719-01A-11D-1598_121029_SN208_0439_BD1KHKACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CG-5719-01A-11D-1598_121029_SN208_0439_BD1KHKACXX_s_1_rg.sorted	TCGA-CG-5719-01A-11D-1598_121029_SN208_0439_BD1KHKACXX_s_1_rg.sorted.bam	46.0	1.9	0.16	58cfa831e4b0c9d6adf6c37e	TCGA-CG-5719-01A-11D-1598_121029_SN208_0439_BD1KHKACXX_s_1_rg.sorted.bam	Alive	FEMALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5719-01A	263F67E0-0A28-42E6-B3F3-1DDD0D397220	Primary Tumor	Illumina HiSeq	e6237df3-92e8-4e8b-92a4-b09d3515f16f	Stomach	54.0	606573EE-ED11-4DB5-ABAF-E842EC575EEE	9008E364-B8F3-4923-B0CC-6ED34AA7BAC3	TCGA-CG-5719-01A-11D-1598-02	HG19_Broad_variant	TCGA-CG-5719	TCGA-STAD		s15247	Harvard Medical School	Indivumed	Germany	NO	T4	N0	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IV	1598-02	True	STAD	C1	GI.CIN	0.294667472	0.57	0.19		0.0545	0.08900000000000001	0.4566	0.596	0.2409	0.7006			0.651560399	1.5580792159999999	144.0	0.38063041799999997	9.0	24.0	0.291458557	1.1933317559999999	60.0	4.00825267	64.0	0.963781042	2.316582537	78.44067564	128.7960113	391.8895318	0.0	31.0	0.0	31.0	8.726427117538877	8.630633477638483	-1.0759859803611875	6.606163581338786	7.819703261422155	3.25650923610091	-2.120263536200091	-0.8109302162163288	4.332495216462098
13722.58cfa831e4b0c9d6adf6c384	58cfa831e4b0c9d6adf6c384	TCGA-CD-5801-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CD-5801-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_6_rg.sorted	TCGA-CD-5801-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_6_rg.sorted.bam	374.0	2.0	0.17	58cfa831e4b0c9d6adf6c384	TCGA-CD-5801-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_6_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-CD-5801-01A	DF822EA3-E0E6-4AD3-A228-E20E3A737DAC	Primary Tumor	Illumina HiSeq	5196b0dd-1d41-47f4-84a8-999f211443f4	Stomach	69.0	9D0DF8D7-8D59-4983-9BBF-C6C106BDEFEC	F32CB4AA-D842-427A-8B7E-371764308512	TCGA-CD-5801-01A-11D-1598-02	HG19_Broad_variant	TCGA-CD-5801	TCGA-STAD		s15317	Harvard Medical School	ILSbio	Vietnam	NO	T3	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIIA	1598-02	True	STAD	C2	GI.EBV	0.39567483	0.69	0.09		0.3505	0.1805	0.805	1.8621	0.8053	0.0434			3.0439897769999997	9.700939384	75.0	0.526165904	24.0	7.0	0.8811665959999999	4.882776336	255.0	4.401351149	175.0	0.852184615	1.270254223	-284.9064459	-61.31462862	-2470.859664	1.0	401.0	1.0	401.0	9.058062936530606	8.09883822197971	0.5990622273274254	6.615715901161401	7.847523793698804	1.3055518339712102	-2.4423470353692043	-0.2513144282809061	0.7064896066437849
13722.58cfa831e4b0c9d6adf6c388	58cfa831e4b0c9d6adf6c388	TCGA-CG-5723-01A-11D-1598_121011_SN208_0434_AC18MYACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CG-5723-01A-11D-1598_121011_SN208_0434_AC18MYACXX_s_3_rg.sorted	TCGA-CG-5723-01A-11D-1598_121011_SN208_0434_AC18MYACXX_s_3_rg.sorted.bam	224.0	1.9	0.14	58cfa831e4b0c9d6adf6c388	TCGA-CG-5723-01A-11D-1598_121011_SN208_0434_AC18MYACXX_s_3_rg.sorted.bam	Alive	MALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5723-01A	0F00AD32-E4BE-49D4-A02A-D233BFC913C5	Primary Tumor	Illumina HiSeq	9e55e0ac-b9dd-42dd-afe7-d6f93c1dcc88	Stomach	83.0	4CCD9CCB-BF50-44EB-AA55-133D8824C433	9A2DC75A-E7BE-4226-9D8C-940946F75958	TCGA-CG-5723-01A-11D-1598-02	HG19_Broad_variant	TCGA-CG-5723	TCGA-STAD		s14417	Harvard Medical School	Indivumed	Germany	NO	T2	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage II	1598-02	True	STAD	C2	GI.HM-indel	0.391660484	0.53	0.0		0.7412	0.4165	0.7443	1.1943	1.1394	0.1693			14.48462175	44.46174152	145.0	0.015855661	0.0	4.0	0.721444272	4.24247684	358.0	3.631674155	87.0	0.8131994790000001	2.661783724	595.5217062	278.06865919999996	-2796.756231	0.0	3196.0	0.0	3196.0	8.279189777195004	6.564704839593388	-0.6382881058361968	5.976604684200959	1.636039026321848	0.09854488912276627	-2.3025850929940455	-4.9286658132715395	0.736832994958963
13722.58cfa831e4b0c9d6adf6c392	58cfa831e4b0c9d6adf6c392	TCGA-CD-5799-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CD-5799-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_4_rg.sorted	TCGA-CD-5799-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_4_rg.sorted.bam	177.7	2.0	0.17	58cfa831e4b0c9d6adf6c392	TCGA-CD-5799-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_4_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-CD-5799-01A	C991697F-77F9-412A-9BD1-0E47F7387CB2	Primary Tumor	Illumina HiSeq	a59236bd-649f-4f2d-a702-4fb190d7f92c	Stomach	45.0	A3180E0E-EB99-49DD-8252-5FEA05A9885F	74F06FDA-C4D0-4542-AC92-68677B595800	TCGA-CD-5799-01A-11D-1598-02	HG19_Broad_variant	TCGA-CD-5799	TCGA-STAD		s14633	Harvard Medical School	ILSbio	Vietnam	NO	T2	N1	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage II	1598-02	True	STAD	C1	GI.CIN	0.202172532	0.37	0.5	12.02986635	0.7307	0.4855	-0.4904	-0.4492	0.1006	0.3028			0.373071065	0.803537678	205.0	0.573794512	19.0	25.0	0.847097606	2.987171557	34.0	1.80474849	7.0	0.927457257	1.567188995	10.90137971	581.9242166	1114.3195130000001	0.0	396.0	0.0	396.0	7.753623546559745	8.86246587596351	0.2591974951684467	5.761193381869539	7.897384979919924	1.6185414781745935	-1.9924301646902063	-0.9650808960435873	1.3593439830061467
13722.58cfa831e4b0c9d6adf6c39a	58cfa831e4b0c9d6adf6c39a	TCGA-CG-5721-01A-11D-1598_121011_SN208_0434_AC18MYACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CG-5721-01A-11D-1598_121011_SN208_0434_AC18MYACXX_s_1_rg.sorted	TCGA-CG-5721-01A-11D-1598_121011_SN208_0434_AC18MYACXX_s_1_rg.sorted.bam	211.0	1.9	0.16	58cfa831e4b0c9d6adf6c39a	TCGA-CG-5721-01A-11D-1598_121011_SN208_0434_AC18MYACXX_s_1_rg.sorted.bam	Alive	MALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5721-01A	588ABAEA-AB16-42F4-9457-5901EE791B5F	Primary Tumor	Illumina HiSeq	450e30b5-bcb4-4169-a48f-bbf3db7feda2	Stomach	58.0	B79123B9-5094-426D-8267-FD4A1C9F2778	8DE4E4AE-4C98-4D4E-BC77-2C205D817E01	TCGA-CG-5721-01A-11D-1598-02	HG19_Broad_variant	TCGA-CG-5721	TCGA-STAD		s14555	Harvard Medical School	Indivumed	Germany	NO	T4	N1	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IV	1598-02	True	STAD	C2	GI.HM-indel	0.45173348	0.51	0.0		0.7074	0.2275	1.1306	1.9369	1.358	0.0661			35.53772402	102.94681059999999	72.0	0.001549965	0.0	0.0	0.839268791	4.471520192	206.0	5.127564712	369.0	0.867491308	2.1810783959999998	658.8358914	634.5276371	-450.31793550000003	0.0	183.0	0.0	183.0	8.29014201527101	6.3327582164540495	0.3938482291460036	6.680704102836909	5.60227336545646	1.0281979528337808	-1.6094379124341003	-0.7304848509975894	0.6343497236877771
13722.58cfa831e4b0c9d6adf6c39e	58cfa831e4b0c9d6adf6c39e	TCGA-C5-A2M1-01A-11D-A18I_140206_SN1222_0239_BC2RAKACXX_s_6_rg.sorted.filtered.	WGS	TCGA-C5-A2M1-01A-11D-A18I_140206_SN1222_0239_BC2RAKACXX_s_6_rg.sorted	TCGA-C5-A2M1-01A-11D-A18I_140206_SN1222_0239_BC2RAKACXX_s_6_rg.sorted.bam	54.44		0.16	58cfa831e4b0c9d6adf6c39e	TCGA-C5-A2M1-01A-11D-A18I_140206_SN1222_0239_BC2RAKACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-C5-A2M1-01A	8911C80C-C903-48E4-AF5B-FFEDEF9ABC47	Primary Tumor	Illumina HiSeq	374c6310-126e-48e8-8b83-145f75714a4b	Cervix	37.0	065BB06F-5BB7-4F79-B374-97A3011F22AE	E2DAD681-2B26-43A0-804B-0F2DD17B1EFE	TCGA-C5-A2M1-01A-11D-A18I-02	HG19_Broad_variant	TCGA-C5-A2M1	TCGA-CESC		s1518	Harvard Medical School	Medical College of Wisconsin	United States	NO	T1b1	N0	Endocervical Type of Adenocarcinoma		A18I-02	True	CESC	C2		0.23361153399999998	0.29	0.01	8.995685493	1.0752	0.4275	0.3207	0.8992	0.6322	-0.5182	36.0	13.0	0.747644732	1.744504375	148.0	0.140327834	4.0	18.0	0.8605685959999999	2.063553368	11.0	2.847365157	64.0	0.684646599	1.919008557	-349.04305800000003	915.5139426000001	-1115.315069	0.0	1169.0	0.0	1169.0	8.483274398212611	8.23542691939376	0.09268984221843424	6.8738364857785115	7.22382600771528	0.9940734657434509	-1.6094379124341003	-1.0116009116784803	0.9013836235250167
13722.58cfa831e4b0c9d6adf6c3a0	58cfa831e4b0c9d6adf6c3a0	TCGA-BT-A20U-01A-11D-A14U_120927_SN208_0433_BD1D5JACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BT-A20U-01A-11D-A14U_120927_SN208_0433_BD1D5JACXX_s_7_rg.sorted	TCGA-BT-A20U-01A-11D-A14U_120927_SN208_0433_BD1D5JACXX_s_7_rg.sorted.bam	68.38	1.71	0.17	58cfa831e4b0c9d6adf6c3a0	TCGA-BT-A20U-01A-11D-A14U_120927_SN208_0433_BD1D5JACXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A20U-01A	83B41D35-69B1-4218-BE1A-8821D8A6899C	Primary Tumor	Illumina HiSeq	9947c8cb-fa3d-4cc2-942e-b013f7a47faa	Bladder	70.0	D29E555F-8467-45C8-9124-0E6A757B1ADF	8D4442E9-3312-4607-A59F-49538B19FA71	TCGA-BT-A20U-01A-11D-A14U-02	HG19_Broad_variant	TCGA-BT-A20U	TCGA-BLCA	455.0	s3270	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A14U-02	True	BLCA	C1	BLCA.3	0.360535795	0.5	0.11	5.903938247	0.7393	0.233	-0.5251	-0.7592	-0.5692	0.2691	37.0	0.0	0.6330737820000001	2.200685052	73.0	0.048607334	0.0	9.0		0.0	1.0	1.039720771	3.0	0.94639463	3.5634266439999998	-887.7752449999999	1184.980475	-1495.61126	1.0	455.0	0.0	455.0	6.8065527734729745	5.977214560436578	-0.7911558970828094	6.305777485560485	5.564682285105321	1.1007376879804232	-0.5007752879124894	-0.412532275331257	1.8918935850632326
13722.58cfa831e4b0c9d6adf6c3a6	58cfa831e4b0c9d6adf6c3a6	TCGA-CC-A1HT-01A-11D-A12Z-10_wgs_Illumina.filtered.	WGS	TCGA-CC-A1HT-01A-11D-A12Z-10_wgs_Illumina	TCGA-CC-A1HT-01A-11D-A12Z-10_wgs_Illumina.bam	75.65	1.95	0.08	58cfa831e4b0c9d6adf6c3a6	TCGA-CC-A1HT-01A-11D-A12Z-10_wgs_Illumina.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-CC-A1HT-01A	670C1CBC-4494-45F1-BB8B-18DB82D4F7E0	Primary Tumor	Illumina HiSeq	f7c13bc4-5edc-4964-8267-e7956bf2fdd0	Liver	50.0	96F911ED-2064-4745-AD07-6C47B0A0C7CD	6B25A78F-20DC-4CCC-B4C0-F9885D16725D	TCGA-CC-A1HT-01A-11D-A12Z-10	GRCh37-lite	TCGA-CC-A1HT	TCGA-LIHC		s16850	Baylor College of Medicine	ILSbio	Vietnam	NO	T3	N0	Hepatocellular Carcinoma	Stage IIIA	A12Z-10	True	LIHC	C2	LIHC.iCluster:1	0.668101555	0.79	0.2		0.6898	0.289	1.0362	1.1936	1.2695	-0.1039	52.0	49.0	0.5623452210000001	2.172697444	120.0	0.210070667	11.0	26.0	0.558488589	1.2859675	10.0	4.201724105	72.0	0.982476534	5.444076292	312.43575939999994	289.39738189999997	462.2118454	1.0	101.0	0.0	101.0	6.625657584824256	2.5292099969055446	0.7069893458856588	5.290656518091916	4.1336865683587325	2.2520913508998297	-1.3350010667323398	1.604476571453188	1.5451020050141708
13722.58cfa831e4b0c9d6adf6c3a8	58cfa831e4b0c9d6adf6c3a8	TCGA-CD-5798-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CD-5798-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_3_rg.sorted	TCGA-CD-5798-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_3_rg.sorted.bam	44.0	1.9	0.13	58cfa831e4b0c9d6adf6c3a8	TCGA-CD-5798-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_3_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-CD-5798-01A	E42F45C6-FD00-44CF-A210-C8803DA326A1	Primary Tumor	Illumina HiSeq	5b2c6e2f-0b61-49e1-bef5-6d7408918d47	Stomach	82.0	72855D36-60BE-498F-96E9-0F10DC05B3A0	F9D13E07-70F4-48F3-B49E-06984C9E39EE	TCGA-CD-5798-01A-11D-1598-02	HG19_Broad_variant	TCGA-CD-5798	TCGA-STAD		s15455	Harvard Medical School	ILSbio	Vietnam	NO	T3	N0	Stomach Intestinal Adenocarcinoma Mucinous Type	Stage II	1598-02	True	STAD	C1	GI.GS	0.21468515	0.81	0.12	7.397488205	-0.4826	0.0385	0.44799999999999995	0.4746	0.5479	0.758			0.686125196	2.201318338	81.0	0.014317638	1.0	4.0	0.913639758	2.411147701	14.0	3.412538102	34.0	0.9677224090000001	2.024380551	569.085339	-465.1901313999999	-2561.064676	0.0	408.0	0.0	408.0	8.532081803909989	9.30301070681749	0.6929872701094566	6.740322334681934	8.358549097976638	2.3110971495281607	-1.7917594692280547	-0.9444616088408513	1.618109879418704
13722.58cfa831e4b0c9d6adf6c3ac	58cfa831e4b0c9d6adf6c3ac	TCGA-CG-5722-01A-21D-1598_121011_SN208_0434_AC18MYACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CG-5722-01A-21D-1598_121011_SN208_0434_AC18MYACXX_s_2_rg.sorted	TCGA-CG-5722-01A-21D-1598_121011_SN208_0434_AC18MYACXX_s_2_rg.sorted.bam	195.0	1.9	0.15	58cfa831e4b0c9d6adf6c3ac	TCGA-CG-5722-01A-21D-1598_121011_SN208_0434_AC18MYACXX_s_2_rg.sorted.bam	Alive	FEMALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5722-01A	F35E8FEF-F61D-4614-B73F-F7E1D0F21F52	Primary Tumor	Illumina HiSeq	05762233-5294-478d-b462-14b931579f63	Stomach	67.0	30D63C9D-E36A-4654-86B5-5D7A622089C2	F262DDED-846F-4DEB-8FC3-EF0DF814ECA4	TCGA-CG-5722-01A-21D-1598-02	HG19_Broad_variant	TCGA-CG-5722	TCGA-STAD		s14642	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IV	1598-02	True	STAD	C2	GI.EBV	0.366538762	0.75	0.09		0.445	0.257	0.8255	2.6049	0.1242	0.0007			0.7237039559999999	2.055319236	68.0	0.19183515899999998	17.0	1.0	0.8399254840000001	5.136893655	453.0	4.323003662	266.0	0.7742467129999999	1.479281039	-828.7715582000001	116.04166229999998	-1558.793817	0.0	30.0	0.0	30.0	7.402451520818245	5.4186368652003285	0.5049559375316967	5.2052269434820255	4.531333670199426	1.6173988736032214	-2.197224577336219	-0.8873031950009029	1.1124429360715247
13722.58cfa831e4b0c9d6adf6c3b0	58cfa831e4b0c9d6adf6c3b0	TCGA-BH-A0H7-01A-13D-A060_130725_SN590_0233_AD2B3HACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BH-A0H7-01A-13D-A060_130725_SN590_0233_AD2B3HACXX_s_7_rg.sorted	TCGA-BH-A0H7-01A-13D-A060_130725_SN590_0233_AD2B3HACXX_s_7_rg.sorted.bam	20.53	2.0	0.15	58cfa831e4b0c9d6adf6c3b0	TCGA-BH-A0H7-01A-13D-A060_130725_SN590_0233_AD2B3HACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE		Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0H7-01A	2021ED1F-DC75-4701-B8B8-1386466E4802	Primary Tumor	Illumina HiSeq	d5ab471a-88d1-4966-865a-f7fa29214fe4	Breast	65.0	69BFA6CE-ED46-4321-A107-347C49D68951	E0E60B71-1EFA-4896-B89F-D05974CDCF48	TCGA-BH-A0H7-01A-13D-A060-02	HG19_Broad_variant	TCGA-BH-A0H7	TCGA-BRCA		s5801	Harvard Medical School	University of Pittsburgh	None	NO	T1c	N2a	Infiltrating Ductal Carcinoma	Stage IIIA	A060-02	True	BRCA	C2	BRCA.Normal	0.08777341	0.37	0.19	0.856940202	0.0691	0.064	-0.3336	-0.0182	0.6323	0.6474	22.0	0.0	0.47185223	1.445047455	595.0	0.826884862	17.0	39.0	0.9993375040000001	0.692687973	2.0	3.170148321	25.0	0.98486195	1.1604242390000001	19.37608477	770.8091352999999	989.3475957999999	0.0	702.0	0.0	702.0	6.902742737158593	6.208955790548401	-0.4063834201483214	5.0569160466602625	5.387975238478571	5.458583760992518	-1.8458266904983305	-0.8209805520698299	5.864967181140839
13722.58cfa831e4b0c9d6adf6c3b2	58cfa831e4b0c9d6adf6c3b2	TCGA-CG-4476-01A-01D-1154_121029_SN208_0438_AC18NJACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CG-4476-01A-01D-1154_121029_SN208_0438_AC18NJACXX_s_1_rg.sorted	TCGA-CG-4476-01A-01D-1154_121029_SN208_0438_AC18NJACXX_s_1_rg.sorted.bam	127.2	1.9	0.14	58cfa831e4b0c9d6adf6c3b2	TCGA-CG-4476-01A-01D-1154_121029_SN208_0438_AC18NJACXX_s_1_rg.sorted.bam	Alive	MALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4476-01A	442D7415-D095-4962-8296-A14390BAD40A	Primary Tumor	Illumina HiSeq	fa01457a-1a83-47ed-b744-7494b9756706	Stomach	69.0	37F5444F-A58D-4899-A11B-9C09ECD357FC	0C5818D8-5C20-4E4B-99CF-6F378CA6EBE7	TCGA-CG-4476-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4476	TCGA-STAD		s14554	Harvard Medical School	Indivumed	Germany	NO	T4b	N3a	Stomach  Adenocarcinoma  Diffuse Type	Stage IIIC	1154-02	True	STAD	C2	GI.CIN	0.280260254	0.72	0.25	7.341158127000001	0.2374	0.031	0.8505	1.3030000000000002	0.0439	0.2885			0.715104836	3.175065473	195.0	0.577159466	15.0	24.0	0.901499353	4.005047233	85.0	3.749769882	49.0	0.963500263		114.6021004	685.5125836	613.0811003	0.0	0.0	0.0	0.0	8.990483081653124	7.923867737441883	-0.6171338118861833	6.953601154392084	7.763525087366704	2.0541237336955467	-2.0368819272610397	-0.16034265007517945	2.67125754558173
13722.58cfa831e4b0c9d6adf6c3b6	58cfa831e4b0c9d6adf6c3b6	TCGA-CC-5262-01A-01D-A21X-10_wgs_Illumina.filtered.	WGS	TCGA-CC-5262-01A-01D-A21X-10_wgs_Illumina	TCGA-CC-5262-01A-01D-A21X-10_wgs_Illumina.bam	73.73	1.92	0.07	58cfa831e4b0c9d6adf6c3b6	TCGA-CC-5262-01A-01D-A21X-10_wgs_Illumina.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-CC-5262-01A	1B428ADA-EB3F-40C2-B4BF-1BBF6B61729D	Primary Tumor	Illumina HiSeq	c98a5543-b4b7-42ad-807e-73cdbbf77345	Liver	67.0	DC595EED-D459-40FD-8417-6A1C56759EC8	47E5FF56-9534-4FCF-A593-33027E877F93	TCGA-CC-5262-01A-01D-A21X-10	GRCh37-lite	TCGA-CC-5262	TCGA-LIHC		s16851	Baylor College of Medicine	ILSbio	None	NO	T4	N0	Hepatocellular Carcinoma	Stage IIIC	A21X-10	False	LIHC	C2	LIHC.iCluster:2	0.44429405200000005	0.61	0.0		-0.2111	0.0845	0.1395	0.4733	0.6602	-0.1476	59.0	9.0	0.846660517	3.062918929	79.0	0.145817735	3.0	14.0				2.51265853	13.0	0.97961331	2.747798436	-886.3167735	-230.9388195	1218.4804900000001	1.0	103.0	0.0	103.0	5.580964055435275	2.6088404000280114	-0.24711587503156152	5.738149638957688	4.112917796804286	1.608446094847217	0.15718558352241274	1.5040773967762746	1.8555619698787784
13722.58cfa831e4b0c9d6adf6c3b8	58cfa831e4b0c9d6adf6c3b8	TCGA-CG-5724-01A-11D-1598_121011_SN208_0434_AC18MYACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CG-5724-01A-11D-1598_121011_SN208_0434_AC18MYACXX_s_7_rg.sorted	TCGA-CG-5724-01A-11D-1598_121011_SN208_0434_AC18MYACXX_s_7_rg.sorted.bam	362.0	1.9	0.15	58cfa831e4b0c9d6adf6c3b8	TCGA-CG-5724-01A-11D-1598_121011_SN208_0434_AC18MYACXX_s_7_rg.sorted.bam	Dead	MALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5724-01A	0B4E8D73-459D-4930-9D1A-ABB8D53E1844	Primary Tumor	Illumina HiSeq	b1cebb86-fe73-4b53-899d-9e6a4caa800b	Stomach	59.0	4D624B21-5AEE-42B8-B192-8AFECB51434D	8611C0AC-38E4-4BFD-A1C4-56CABFCF6374	TCGA-CG-5724-01A-11D-1598-02	HG19_Broad_variant	TCGA-CG-5724	TCGA-STAD	366.0	s15248	Harvard Medical School	Indivumed	Germany	NO	T3	N3	Stomach  Adenocarcinoma  Diffuse Type	Stage IV	1598-02	True	STAD	C2	GI.CIN	0.22508269399999997	0.35	0.31		1.0065	0.6	0.113	0.2401	0.4614	0.4247			0.918516955	2.583328935	263.0	0.563571818	13.0	50.0	0.8955782259999999	3.368448929	43.0	3.714567725	50.0	0.949526043	3.262347147	-1283.3829449999998	480.58703219999995	-2088.0920530000003	1.0	366.0	1.0	122.0	8.279595683131879	7.724021659864164	0.3180029974826164	6.797991142207662	6.904580753979926	1.767011299538861	-1.4816045409242158	-0.8194409058842376	1.4490083020562445
13722.58cfa831e4b0c9d6adf6c3be	58cfa831e4b0c9d6adf6c3be	TCGA-CC-5261-01A-01D-A12Z-10_wgs_Illumina.filtered.	WGS	TCGA-CC-5261-01A-01D-A12Z-10_wgs_Illumina	TCGA-CC-5261-01A-01D-A12Z-10_wgs_Illumina.bam	125.45	1.93	0.08	58cfa831e4b0c9d6adf6c3be	TCGA-CC-5261-01A-01D-A12Z-10_wgs_Illumina.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-CC-5261-01A	1AD7F17E-B3B8-40E9-AAB8-5A17E0AEC408	Primary Tumor	Illumina HiSeq	43047cdb-fea6-4e20-9248-30ae5624c5a7	Liver	44.0	538998F3-5230-4963-8B67-D34DE695E97D	A2F143D6-BA07-4FF0-960D-B29C3C716665	TCGA-CC-5261-01A-01D-A12Z-10	GRCh37-lite	TCGA-CC-5261	TCGA-LIHC		s16582	Baylor College of Medicine	ILSbio	None	NO	T2	N0	Hepatocellular Carcinoma	Stage II	A12Z-10	True	LIHC	C3	LIHC.iCluster:1	0.283040301	0.51	0.18		-0.0582	-0.242	0.2377	1.3255	-0.3599	-0.0193			0.0	0.0	122.0	0.456123944	14.0	28.0				3.165672167	25.0	0.9834713540000001	0.55379582	-1042.245853	240.13481349999998	4214.054039	1.0	97.0	0.0	97.0	6.659293919683638	3.525736444000356	-0.18457127652797023	4.787491742782047	3.225631851550018	2.0618891280056837	-1.8718021769015916	-0.3001045924503378	2.246460404533654
13722.58cfa831e4b0c9d6adf6c3c2	58cfa831e4b0c9d6adf6c3c2	TCGA-BT-A20Q-01A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BT-A20Q-01A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_5_rg.sorted	TCGA-BT-A20Q-01A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_5_rg.sorted.bam	56.34	2.11	0.15	58cfa831e4b0c9d6adf6c3c2	TCGA-BT-A20Q-01A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_5_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A20Q-01A	419DEAAC-EA45-4BDD-9FA0-B5CD8429B44F	Primary Tumor	Illumina HiSeq	9d2dc2d3-8995-42b8-9bee-010c8bce06e0	Bladder	73.0	F3906CD4-31C7-48A8-935B-5B7FAFEC1AE7	72AF980B-98A8-4572-8AF9-EFD4294700F9	TCGA-BT-A20Q-01A-11D-A14U-02	HG19_Broad_variant	TCGA-BT-A20Q	TCGA-BLCA	593.0	s3083	Harvard Medical School	University of Pittsburgh	United States	NO	T3b	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A14U-02	True	BLCA	C1	BLCA.2	0.21912309800000002	0.32	0.0	5.160367415	-0.4592	-0.032	0.1466	0.7527	0.5972	0.5919	35.0	87.0	0.798330115	2.702040388	185.0	0.154824566	5.0	11.0	0.8047555340000001	3.506085536	78.0	3.2509410410000004	28.0	0.9756127	1.577130567	-1416.637424	448.12771039999996	-2342.717158	1.0	593.0	1.0	593.0	6.845015139785945	9.431905535434254	0.08835174258556466	5.856403746332164	8.119719146468086	1.5143801279598605	-0.9886113934537812	-1.312186388966169	1.4260283853742957
13722.58cfa831e4b0c9d6adf6c3c4	58cfa831e4b0c9d6adf6c3c4	TCGA-BT-A20O-01A-21D-A14U_120921_SN208_0431_BD1D5FACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BT-A20O-01A-21D-A14U_120921_SN208_0431_BD1D5FACXX_s_3_rg.sorted	TCGA-BT-A20O-01A-21D-A14U_120921_SN208_0431_BD1D5FACXX_s_3_rg.sorted.bam	63.78	1.88	0.16	58cfa831e4b0c9d6adf6c3c4	TCGA-BT-A20O-01A-21D-A14U_120921_SN208_0431_BD1D5FACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A20O-01A	C0E7FBE7-B9CB-4E65-941B-CD7D581C54EC	Primary Tumor	Illumina HiSeq	c345a912-f3c8-4622-9793-88cf795fc964	Bladder	75.0	5ECD84AD-44FD-4599-BF3D-AB725E0404EC	13596E86-7CD8-4A07-941F-E936D0004F6B	TCGA-BT-A20O-01A-21D-A14U-02	HG19_Broad_variant	TCGA-BT-A20O	TCGA-BLCA	370.0	s3090	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A14U-02	True	BLCA	C2	BLCA.4	0.661803895	0.84	0.25	24.097056100000003	0.8088	0.2475	1.7066	2.5309	1.2793	0.1693	95.0	48.0	1.211451647	4.603516257	69.0	0.02359439	0.0	4.0	0.868756234	4.358793134	151.0	3.793747872	66.0	0.9055037	4.742483084	1055.44674	680.1730132	-1606.84168	1.0	370.0	1.0	315.0	7.667704043021286	9.498563207280283	0.4992200776456831	6.587783887365328	8.182886413374344	1.8222879667993857	-1.0799201556559574	-1.3156767939059373	1.3230678891537027
13722.58cfa831e4b0c9d6adf6c3cb	58cfa831e4b0c9d6adf6c3cb	TCGA-C5-A3HD-01B-11D-A20X_140117_SN590_0245_AC371LACXX_s_1_rg.sorted.filtered.	WGS	TCGA-C5-A3HD-01B-11D-A20X_140117_SN590_0245_AC371LACXX_s_1_rg.sorted	TCGA-C5-A3HD-01B-11D-A20X_140117_SN590_0245_AC371LACXX_s_1_rg.sorted.bam	60.19		0.16	58cfa831e4b0c9d6adf6c3cb	TCGA-C5-A3HD-01B-11D-A20X_140117_SN590_0245_AC371LACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-C5-A3HD-01B	12427B02-6E3F-461C-B271-6AB230F628E7	Primary Tumor	Illumina HiSeq	475d850b-49e8-4f15-9f59-8d65bf9cf22d	Cervix	51.0	56AA88C8-AF6D-42BE-8672-074476F6575A	03576AE9-4222-48C3-A428-D85AEC400BD6	TCGA-C5-A3HD-01B-11D-A20X-26	HG19_Broad_variant	TCGA-C5-A3HD	TCGA-CESC		s1171	MD Anderson - Institute for Applied Cancer Science	Medical College of Wisconsin	United States	NO			Cervical Squamous Cell Carcinoma		A20X-26	True	CESC	C2		0.06828218900000001	0.09	0.13		1.2589	0.33	-1.4469	-1.3889	0.47100000000000003	-0.2935			0.0	0.0	238.0	0.707417429	1.0	64.0				1.098612289	3.0	1.0	1.997623226	-743.0523991	1093.3989390000002	-2189.912148	0.0	1582.0	0.0	1582.0	8.553042844309935	8.141314624415932	-0.5391415438832784	6.155147571511565	7.091492499917255	1.6791148422792463	-2.3978952727983707	-1.0498221244986776	2.218256386162525
13722.58cfa831e4b0c9d6adf6c3d4	58cfa831e4b0c9d6adf6c3d4	TCGA-C5-A3HF-01A-11D-A20X_140117_SN590_0246_BC37BDACXX_s_1_rg.sorted.filtered.	WGS	TCGA-C5-A3HF-01A-11D-A20X_140117_SN590_0246_BC37BDACXX_s_1_rg.sorted	TCGA-C5-A3HF-01A-11D-A20X_140117_SN590_0246_BC37BDACXX_s_1_rg.sorted.bam	62.13		0.16	58cfa831e4b0c9d6adf6c3d4	TCGA-C5-A3HF-01A-11D-A20X_140117_SN590_0246_BC37BDACXX_s_1_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-C5-A3HF-01A	085DF27C-9BC2-425A-9A49-547D692EA028	Primary Tumor	Illumina HiSeq	4b4bea19-4db4-4996-8037-4129a4494419	Cervix	24.0	79C43439-BC01-4033-85FA-3191A79277C6	0C08A31F-1414-42E3-986A-00BAF9C926F8	TCGA-C5-A3HF-01A-11D-A20X-26	HG19_Broad_variant	TCGA-C5-A3HF	TCGA-CESC	543.0	s1358	MD Anderson - Institute for Applied Cancer Science	Medical College of Wisconsin	United States	NO			Mucinous Adenocarcinoma of Endocervical Type		A20X-26	True	CESC	C2		0.302954648	0.58	0.11		0.5454	0.256	-0.2496	1.0316	0.4902	0.005	19.0	0.0	0.272755905	0.608455479	61.0	0.195178695	2.0	8.0	0.8798916090000001	3.572749735	58.0	3.1949847680000003	28.0	0.958820132	2.1005895359999998	-717.4222272999999	246.55177769999997	521.1805948	1.0	543.0	1.0	450.0	8.278377470707733	7.573993642984864	-0.11989903144446035	6.709761552793887	6.93213975681247	3.2498980023471806	-1.5686159179138455	-0.6418538861723944	3.3697970337916408
13722.58cfa831e4b0c9d6adf6c3d6	58cfa831e4b0c9d6adf6c3d6	TCGA-CG-5734-01A-11D-1598_121023_SN208_0436_AC1CMBACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CG-5734-01A-11D-1598_121023_SN208_0436_AC1CMBACXX_s_7_rg.sorted	TCGA-CG-5734-01A-11D-1598_121023_SN208_0436_AC1CMBACXX_s_7_rg.sorted.bam	206.0	1.9	0.15	58cfa831e4b0c9d6adf6c3d6	TCGA-CG-5734-01A-11D-1598_121023_SN208_0436_AC1CMBACXX_s_7_rg.sorted.bam	Dead	MALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5734-01A	2A227292-C73D-45FC-AB68-CDFAF7AEF9E7	Primary Tumor	Illumina HiSeq	4cac9679-5c5e-4b51-b7a0-0d82ab2c2237	Stomach	68.0	A0237637-3859-47D9-A60E-0AF8C6884B4A	12BCC59A-0A89-4087-B976-A22F66D8190C	TCGA-CG-5734-01A-11D-1598-02	HG19_Broad_variant	TCGA-CG-5734	TCGA-STAD	243.0	s14990	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIIA	1598-02	True	STAD	C2	GI.CIN	0.409986464	0.81	0.51		-0.0504	0.0365	0.9166	2.0598	0.7695	0.2745			0.546533093	1.927248276	72.0	0.11387276699999999	16.0	11.0	0.752017413	4.471059824	382.0	2.705276697	119.0	0.566061267	1.191334305	926.9822498	-653.8509246	1236.098164	1.0	243.0	0.0	243.0	8.466478676871736	8.145346594931699	-1.0245803997494836	6.761730584633311	7.452199414371753	0.7915141683826299	-1.7047480922384255	-0.693147180559945	1.8160945681321135
13722.58cfa831e4b0c9d6adf6c3dc	58cfa831e4b0c9d6adf6c3dc	TCGA-CG-5726-01A-11D-1598_121011_SN208_0435_BD1E43ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CG-5726-01A-11D-1598_121011_SN208_0435_BD1E43ACXX_s_2_rg.sorted	TCGA-CG-5726-01A-11D-1598_121011_SN208_0435_BD1E43ACXX_s_2_rg.sorted.bam	217.0	1.9	0.16	58cfa831e4b0c9d6adf6c3dc	TCGA-CG-5726-01A-11D-1598_121011_SN208_0435_BD1E43ACXX_s_2_rg.sorted.bam	Dead	MALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5726-01A	863AD936-E2A0-471C-8D95-3A548BB94AFA	Primary Tumor	Illumina HiSeq	87491384-bbcf-4127-8cf0-59e692b8e37b	Stomach	73.0	C881739A-982C-436F-9BE2-4638DB792C53	D472F361-BC94-44A5-9158-5BD999C96C27	TCGA-CG-5726-01A-11D-1598-02	HG19_Broad_variant	TCGA-CG-5726	TCGA-STAD	881.0	s15130	Harvard Medical School	Indivumed	Germany	NO	T1	N0	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IA	1598-02	True	STAD	C1	GI.HM-indel	0.07220496700000001	0.1	0.0		0.9811	0.36700000000000005	-0.9091	-0.7891	-0.2366	-0.3072			11.59449101	31.83475062	91.0	0.331502366	6.0	0.0	0.90289022	3.183916429	34.0	3.050638616	29.0	0.9059609759999999	1.3059124340000001	-1137.8271619999998	481.19601789999996	1955.8351480000001	1.0	881.0	0.0	881.0	7.85748078694253	7.126087273299124	-0.6250670417564085	5.6602562096063105	6.127558443187997	1.247411153423421	-2.197224577336219	-0.998528830111127	1.8724781951798293
13722.58cfa831e4b0c9d6adf6c3dd	58cfa831e4b0c9d6adf6c3dd	TCGA-CH-5744-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CH-5744-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_5_rg.sorted	TCGA-CH-5744-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_5_rg.sorted.bam	249.7	1.9	0.15	58cfa831e4b0c9d6adf6c3dd	TCGA-CH-5744-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5744-01A	4E76DE8E-CB0D-4B83-8AB4-53BC67A7A9D3	Primary Tumor	Illumina HiSeq	b48809ce-93ac-45d2-b127-bf6ee8bd6870	Prostate	64.0	DCCEAF54-0BCE-4650-9980-9843ABCE0C41	B3198EFA-5613-4B16-BA05-4F0AACCCC00F	TCGA-CH-5744-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5744	TCGA-PRAD		s3771	Harvard Medical School	Indivumed	Germany	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.1-ERG	0.15276103300000002	0.41	0.0	1.588894464	-1.3137	-0.1455	-0.7112	-0.486	-0.9857	-0.3405	9.0	31.0	0.277900301	0.528010572	136.0	0.050484465	1.0	12.0	0.9262895309999999	1.284109953	4.0	2.813355405	17.0	0.9929910190000001	2.118788579	391.02456889999996	-792.738995	3679.1758950000003	0.0	60.0	0.0	60.0	8.698792265059861	8.71425556653169	-0.5591812371947864	6.85296557456153	8.021108385971745	4.150348964117548	-1.8458266904983305	-0.693147180559945	4.709530201312334
13722.58cfa831e4b0c9d6adf6c3e2	58cfa831e4b0c9d6adf6c3e2	TCGA-CH-5743-01A-21D-1572_130104_SN1120_0209_BD1KP6ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CH-5743-01A-21D-1572_130104_SN1120_0209_BD1KP6ACXX_s_3_rg.sorted	TCGA-CH-5743-01A-21D-1572_130104_SN1120_0209_BD1KP6ACXX_s_3_rg.sorted.bam	245.7	1.9	0.15	58cfa831e4b0c9d6adf6c3e2	TCGA-CH-5743-01A-21D-1572_130104_SN1120_0209_BD1KP6ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5743-01A	2DEE4BD8-B00E-4F8A-BFEA-5D8D1A068202	Primary Tumor	Illumina HiSeq	1c58f516-3239-499a-bbcd-f5a8d619d796	Prostate	66.0	6BD8573D-535F-4F6D-8EAF-60918B5DA578	EE5F51E6-F989-4380-A86F-29CBF50BA03A	TCGA-CH-5743-01A-21D-1572-02	HG19_Broad_variant	TCGA-CH-5743	TCGA-PRAD		s3588	Harvard Medical School	Indivumed	Germany	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.1-ERG	0.139631628			0.402481972	-1.5765	-0.21600000000000003	0.0632	0.4329	-0.2874	-0.1027			0.0	0.0	45.0	4.1200000000000005e-05						3.4040404339999997	31.0	0.9912793	1.9919464269999998	725.7720073	-699.7186323	2359.219608	0.0	425.0	1.0	425.0	7.495541943884256	7.570378816991788	-0.11332059963118213	5.703782474656202	6.705381379505184	1.9380174482564048	-1.7917594692280547	-0.8649974374866045	2.0513380478875867
13722.58cfa831e4b0c9d6adf6c3e3	58cfa831e4b0c9d6adf6c3e3	TCGA-CC-5260-01A-01D-A12Z-10_wgs_Illumina.filtered.	WGS	TCGA-CC-5260-01A-01D-A12Z-10_wgs_Illumina	TCGA-CC-5260-01A-01D-A12Z-10_wgs_Illumina.bam	91.26	1.95	0.08	58cfa831e4b0c9d6adf6c3e3	TCGA-CC-5260-01A-01D-A12Z-10_wgs_Illumina.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-CC-5260-01A	CA8AFB2C-BE3D-41E8-8DBC-19FE7AB6154B	Primary Tumor	Illumina HiSeq	94aaf939-2195-4c49-b867-778f3670e7ff	Liver	61.0	7F347680-CD4D-4289-8F8F-3B0541381A42	3BACC189-01B8-46CC-A442-F393C0F428C6	TCGA-CC-5260-01A-01D-A12Z-10	GRCh37-lite	TCGA-CC-5260	TCGA-LIHC		s16581	Baylor College of Medicine	ILSbio	None	NO	T4	N0	Hepatocellular Carcinoma	Stage IIIC	A12Z-10	True	LIHC	C3	LIHC.iCluster:1	0.23558531600000002	0.39	0.1		-0.0936	-0.1475	0.0961	-0.3008	-0.0268	0.2028	31.0	9.0	0.306861453	1.304161174	164.0	0.317378982	5.0	17.0				2.45831133	12.0	0.989297256	2.10814455	-947.4802195	147.41710790000002	-415.5950245	1.0	87.0	0.0	87.0	6.1508396510720456	1.8100661756817074	0.3981302173900042	4.980768398421791	1.7677983191059736	2.805875232858506	-1.1700712526502546	-0.04226785657573373	2.4077450154685023
13722.58cfa831e4b0c9d6adf6c3e6	58cfa831e4b0c9d6adf6c3e6	TCGA-CH-5745-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CH-5745-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_7_rg.sorted	TCGA-CH-5745-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_7_rg.sorted.bam	146.7	1.9	0.15	58cfa831e4b0c9d6adf6c3e6	TCGA-CH-5745-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5745-01A	AC67D0DF-7DC0-4A1A-8B47-BEEC9B94DE86	Primary Tumor	Illumina HiSeq	c1d27dca-0355-41e5-a53b-0af94a125c6a	Prostate	68.0	BDA91E83-643B-4FAE-BFE9-B4660F3BDF02	780758FF-58EE-4B4B-AC71-DE15C89C4625	TCGA-CH-5745-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5745	TCGA-PRAD		s3770	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3		0.10142666800000001			1.6447573359999998	-2.0801	-0.299	-0.3197	0.2856	-0.2293	-0.0248	15.0	3.0	0.111037336	0.610705348						0.0	1.0	2.949012331	21.0	0.968628871	1.3737098580000002	121.15763909999998	-775.334911	3723.552304	0.0	91.0	0.0	91.0	8.108623268354593	8.185814626660772	0.1568611564808905	5.911398691018374	7.14436075183261	2.0717469195187936	-2.197224577336219	-1.0414538748281612	1.9148857630379035
13722.58cfa831e4b0c9d6adf6c3ec	58cfa831e4b0c9d6adf6c3ec	TCGA-CH-5748-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CH-5748-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_3_rg.sorted	TCGA-CH-5748-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_3_rg.sorted.bam	196.7	1.9	0.14	58cfa831e4b0c9d6adf6c3ec	TCGA-CH-5748-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5748-01A	0AF98331-9305-41E9-AF55-30390016D65E	Primary Tumor	Illumina HiSeq	02aa8440-93b8-43d7-a58b-6c4421e05321	Prostate	64.0	A499BF51-B137-4DA9-87A3-D1B1A0F04695	24A0496A-CA69-4AE3-BF8A-92289C738E9F	TCGA-CH-5748-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5748	TCGA-PRAD		s3413	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.2-ETV1	0.048943579	0.76	0.06	0.748612864	-0.9824	-0.1535	-1.1101	-0.6391	-0.7165	-0.6567	20.0		0.391501925	0.810968273	81.0	0.031112121	0.0	7.0		0.0	1.0	2.2718685130000003	10.0	0.986659959	2.130368743	-612.0510049	-428.15209680000004	2965.545576	0.0	31.0	0.0	31.0	8.16961956172385	8.721462598546102	-0.4458003157744804	5.818244304560373	7.8341594035452	3.6148084635249087	-2.3513752571634776	-0.8873031950009029	4.060608779299389
13722.58cfa831e4b0c9d6adf6c3f0	58cfa831e4b0c9d6adf6c3f0	TCGA-C5-A2LX-01A-11D-A18I_140206_SN1222_0239_BC2RAKACXX_s_5_rg.sorted.filtered.	WGS	TCGA-C5-A2LX-01A-11D-A18I_140206_SN1222_0239_BC2RAKACXX_s_5_rg.sorted	TCGA-C5-A2LX-01A-11D-A18I_140206_SN1222_0239_BC2RAKACXX_s_5_rg.sorted.bam	82.12		0.18	58cfa831e4b0c9d6adf6c3f0	TCGA-C5-A2LX-01A-11D-A18I_140206_SN1222_0239_BC2RAKACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-C5-A2LX-01A	B82F4C6D-530F-4B0E-8F33-995633CB254A	Primary Tumor	Illumina HiSeq	ef574f7b-2b69-4be8-83f3-cc02df579a0a	Cervix	54.0	41BEBEA3-11C2-4748-8E60-082CFB8E0251	F4772B1E-699C-4C3D-9E0B-1BD4634A7F36	TCGA-C5-A2LX-01A-11D-A18I-02	HG19_Broad_variant	TCGA-C5-A2LX	TCGA-CESC		s1175	Harvard Medical School	Medical College of Wisconsin	United States	NO	T2	N1	Cervical Squamous Cell Carcinoma		A18I-02	True	CESC	C2		0.299283268	0.39	0.07	3.4304676	0.9555	0.377	0.5925	2.2697	1.2308	-0.1178	84.0	2.0	1.254918854	3.7875732689999997	148.0	0.7895593240000001	11.0	30.0	0.930830142	3.30942514	35.0	4.034722266	60.0	0.98543789	3.308192413	-169.13628359999998	555.579796	-2834.348181	0.0	2526.0	0.0	2526.0	8.11237787214957	7.590700597057485	0.1192395369502246	5.809792779155526	6.948846710885091	1.0454175340577492	-2.3025850929940455	-0.6418538861723944	0.9261779971075247
13722.58cfa831e4b0c9d6adf6c3f8	58cfa831e4b0c9d6adf6c3f8	TCGA-CH-5771-01A-21D-1572_130104_SN208_0446_BD1KR5ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CH-5771-01A-21D-1572_130104_SN208_0446_BD1KR5ACXX_s_7_rg.sorted	TCGA-CH-5771-01A-21D-1572_130104_SN208_0446_BD1KR5ACXX_s_7_rg.sorted.bam	30.7	1.9	0.14	58cfa831e4b0c9d6adf6c3f8	TCGA-CH-5771-01A-21D-1572_130104_SN208_0446_BD1KR5ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5771-01A	3ACD8328-76F7-4F43-9660-394B95748C3D	Primary Tumor	Illumina HiSeq	93b110cf-3f4b-4f72-8025-320b77838b0a	Prostate	63.0	19C87DE2-7936-4277-8AA8-3942D36E7579	83F4BDB9-ED8B-4472-87BB-74C901B1A350	TCGA-CH-5771-01A-21D-1572-02	HG19_Broad_variant	TCGA-CH-5771	TCGA-PRAD		s3931	Harvard Medical School	Indivumed	Germany	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.3-ETV4	0.16307887599999998				-1.4851	-0.2755	0.1044	0.2457	-0.3672	0.1944	7.0	1.0	0.139540037	0.613976163	86.0	0.035652174						3.271689322	27.0	0.99267332	2.347212763	50.37008824	-637.8268699	2520.329834	0.0	396.0	0.0	396.0	7.4460014983241205	7.8317661338714295	0.20007887682708014	5.248776920987901	7.0779943314950495	3.9869651415929406	-2.197224577336219	-0.7537718023763804	3.7868862647658603
13722.58cfa831e4b0c9d6adf6c3fc	58cfa831e4b0c9d6adf6c3fc	TCGA-CH-5788-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CH-5788-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_3_rg.sorted	TCGA-CH-5788-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_3_rg.sorted.bam	257.7	1.9	0.16	58cfa831e4b0c9d6adf6c3fc	TCGA-CH-5788-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5788-01A	C039014F-821C-43D6-9D3C-914F9C8D98FA	Primary Tumor	Illumina HiSeq	8bd51d54-e1be-4a0a-bad5-3b8013692b90	Prostate	69.0	144E0265-C04E-4538-A721-94DEF2570486	ADB6611D-7A44-4FFE-A48B-FF8E24696B38	TCGA-CH-5788-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5788	TCGA-PRAD		s3595	Harvard Medical School	Indivumed	Germany	NO	T3b	N1	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C4	PRAD.5-SPOP	0.055470449000000005	0.16	0.03		-0.132	-0.0765	-1.15	-2.0049	-1.5590000000000002	-0.5298	19.0	1.0	0.391231616	0.754518117	417.0	0.267051013	5.0	28.0				0.693147181	2.0	1.0	1.9382210690000001	-600.2635485000001	776.2387974	714.4105002	0.0	821.0	0.0	821.0	8.895766604056087	8.544313011165261	-0.3956677324419461	6.662174382548992	8.108994939907415	3.3296862514784804	-2.2335922215070942	-0.4353180712578455	3.725353983920426
13722.58cfa831e4b0c9d6adf6c3fe	58cfa831e4b0c9d6adf6c3fe	TCGA-CH-5792-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CH-5792-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_3_rg.sorted	TCGA-CH-5792-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_3_rg.sorted.bam	61.7	1.9	0.17	58cfa831e4b0c9d6adf6c3fe	TCGA-CH-5792-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5792-01A	8A5F2D7F-835C-4726-B238-F82D6A7F25BD	Primary Tumor	Illumina HiSeq	1c4a46f6-fc5f-44b1-b30a-5baaa806e78b	Prostate	57.0	DA5F8107-7B69-45B5-8BEB-21D17B066CB4	5975F57F-2918-46C2-B59F-38FAA67A49BA	TCGA-CH-5792-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5792	TCGA-PRAD		s3933	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.8-other	0.174723	0.62	0.0		-1.1889	-0.22	0.193	0.7568	-0.5953	0.1478	16.0	6.0	0.225333902	0.87316887	207.0	0.08729621300000001	0.0	19.0	0.9168603609999999	1.642793234	6.0	3.727905199	44.0	0.985126423	3.102187971	-310.9007167	-592.4889886	3156.803307	0.0	91.0	0.0	91.0	9.128479345495863	9.647974142285081	-0.10217453128228027	7.091597418234823	8.837043926068752	2.2865882579528183	-2.0368819272610397	-0.8109302162163288	2.3887627892350984
13722.58cfa831e4b0c9d6adf6c401	58cfa831e4b0c9d6adf6c401	TCGA-CH-5791-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CH-5791-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_1_rg.sorted	TCGA-CH-5791-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_1_rg.sorted.bam	145.7	2.0	0.17	58cfa831e4b0c9d6adf6c401	TCGA-CH-5791-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5791-01A	829BED0C-C40D-44FD-AEE8-6C7589DB60F9	Primary Tumor	Illumina HiSeq	e2778c71-6feb-40df-8b1e-8d8f0e889beb	Prostate	72.0	C14B5C15-994B-4739-870B-A50984D274A1	500F071A-6697-4880-BBD0-9054CCAE108A	TCGA-CH-5791-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5791	TCGA-PRAD		s3417	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.1-ERG	0.10619253199999999	0.34	0.15		-1.2021	-0.2585	-0.7354	-0.6425	-0.8978	-0.3591	10.0	1.0	0.337991504	0.84497876	155.0	0.24700748100000003	1.0	12.0				1.791759469	6.0	1.0	2.0746855440000003	-864.6951375	-694.7305992	2926.528282	0.0	1004.0	1.0	396.0	7.922623574217287	8.467337459731334	0.13123165991299135	5.620038481223242	7.314657949792949	3.1788215847042762	-2.3025850929940455	-1.1526795099383853	3.0475899247912848
13722.58cfa831e4b0c9d6adf6c404	58cfa831e4b0c9d6adf6c404	TCGA-CH-5790-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CH-5790-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_7_rg.sorted	TCGA-CH-5790-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_7_rg.sorted.bam	285.7	1.9	0.15	58cfa831e4b0c9d6adf6c404	TCGA-CH-5790-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5790-01A	2B5EF82D-E137-43F6-BFEF-B202F20EE187	Primary Tumor	Illumina HiSeq	22e486a4-e20b-4211-b3fd-35f37d14e718	Prostate	64.0	5C8782C0-0B0D-4AFF-B996-423D214FF5FF	9BA30DBB-2730-48A1-94E5-10CCA134728F	TCGA-CH-5790-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5790	TCGA-PRAD		s3936	Harvard Medical School	Indivumed	Germany	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.1-ERG	0.033826769	0.19	0.05		-1.9479	-0.264	-0.8332	-0.9014	-1.4325	-0.4314	11.0		0.11241436199999999	0.505864629	97.0	0.033568356	1.0	8.0				1.386294361	4.0	1.0	1.853984531	-791.394034	-333.49798210000006	3818.813539	0.0	974.0	0.0	974.0	7.08114820503179	7.316658913022744	-0.16054546103577882	5.23532151453346	6.275205038194582	4.108685679492758	-1.8458266904983305	-1.0414538748281612	4.269231140528538
13722.58cfa831e4b0c9d6adf6c406	58cfa831e4b0c9d6adf6c406	TCGA-C5-A3HE-01A-21D-A232_140124_SN1120_0292_BD2F1HACXX_s_8_rg.sorted.filtered.	WGS	TCGA-C5-A3HE-01A-21D-A232_140124_SN1120_0292_BD2F1HACXX_s_8_rg.sorted	TCGA-C5-A3HE-01A-21D-A232_140124_SN1120_0292_BD2F1HACXX_s_8_rg.sorted.bam	43.33		0.15	58cfa831e4b0c9d6adf6c406	TCGA-C5-A3HE-01A-21D-A232_140124_SN1120_0292_BD2F1HACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-C5-A3HE-01A	BC63DD2A-B8F6-4B30-A8D7-CE193BCD17F1	Primary Tumor	Illumina HiSeq	1d64c1f3-438b-4576-b2bc-74c1a26a2aca	Cervix	44.0	506D8B22-EE8D-4FB3-BB57-5CA79D6F5637	D0321E82-FF46-450C-AAF2-9FDCA2FF2590	TCGA-C5-A3HE-01A-21D-A232-26	HG19_Broad_variant	TCGA-C5-A3HE	TCGA-CESC		s1514	MD Anderson - Institute for Applied Cancer Science	Medical College of Wisconsin	United States	NO	T1b2	N0	Cervical Squamous Cell Carcinoma		A232-26	True	CESC	C2		0.389414644	0.61	0.25	1.176315789	0.9735	0.4055	0.3297	1.4680000000000002	0.5328	-0.3135					97.0	0.42811877299999995	10.0	13.0	0.898096263	3.218344969	36.0	2.9909852000000003	38.0	0.8222444959999999	1.8083055419999998	-1157.212406	780.4349786	347.97803439999996	0.0	548.0	1.0	252.0	7.267990544115626	7.388482454924095	0.24023215877547888	5.422163853617295	6.634710652547715	1.9349642884494143	-1.8458266904983305	-0.7537718023763804	1.6947321296739353
13722.58cfa831e4b0c9d6adf6c412	58cfa831e4b0c9d6adf6c412	TCGA-CH-5794-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CH-5794-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_5_rg.sorted	TCGA-CH-5794-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_5_rg.sorted.bam	52.7	2.0	0.15	58cfa831e4b0c9d6adf6c412	TCGA-CH-5794-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5794-01A	A80D3EE7-60DD-49BB-B049-9335AFC035F5	Primary Tumor	Illumina HiSeq	2cf518ee-af91-4cf0-a277-263170f71791	Prostate	65.0	D1A1CCFE-1215-4B34-94A9-C9765264F617	9D7EACBC-B476-4813-9215-AC0073382A25	TCGA-CH-5794-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5794	TCGA-PRAD		s3775	Harvard Medical School	Indivumed	Germany	NO	T2b	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.1-ERG	0.045833265	0.43	0.0		-0.7472	-0.0795	-0.905	-1.0639	-1.2930000000000001	-0.2759	6.0	1.0	0.344010926	0.573351543	139.0	0.044033416	0.0	4.0				1.9459101490000001	7.0	1.0	2.8038356369999997	-854.4936916000001	-547.6555221	3380.179363	0.0	882.0	0.0	882.0	8.051978078902298	8.13531032356563	0.2023348522347832	5.854753501566079	7.38153852118925	2.5577768087808144	-2.197224577336219	-0.7537718023763804	2.3554419565460316
13722.58cfa831e4b0c9d6adf6c414	58cfa831e4b0c9d6adf6c414	TCGA-CJ-4639-01A-01D-2095-10_Illumina.filtered.	WGS	TCGA-CJ-4639-01A-01D-2095-10_Illumina	TCGA-CJ-4639-01A-01D-2095-10_Illumina.bam	90.64	1.9	0.15	58cfa831e4b0c9d6adf6c414	TCGA-CJ-4639-01A-01D-2095-10_Illumina.bam	Alive	FEMALE	WHITE	HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-CJ-4639-01A	3E976301-4042-4AC0-8F01-EF2F1A8161A6	Primary Tumor	Illumina HiSeq	d3739e9e-1149-4ec1-bb8d-f3b495ed1b4d	Kidney	49.0	11B1DCA7-6FCE-41C0-9580-A28CCF83E55C	063CFACF-9933-4A2D-8921-0AEB76E12779	TCGA-CJ-4639-01A-01D-2095-10	GRCh37-lite	TCGA-CJ-4639	TCGA-KIRC		s9168	Baylor College of Medicine	MD Anderson Cancer Center	None	NO	T2	N0	Kidney Clear Cell Renal Carcinoma	Stage II	2095-10	False	KIRC	C3	KIRC.1	0.202343988	0.41	0.0		-1.2446	-0.39799999999999996	0.6041	1.0174	0.494	-0.055999999999999994	30.0	85.0	0.28058607	1.6273992069999998	63.0	0.094538334	2.0	5.0				3.85655168	54.0	0.966800477	1.12049332	757.7907458	-1002.820827	2897.532013	0.0	3229.0	0.0	3229.0	8.831809265108099	-0.48630105030084714	0.5400594636645061	5.43339352640782	2.359058608808101	2.6582453713903638	-3.3984157387002782	2.845359659108948	2.1181859077258576
13722.58cfa831e4b0c9d6adf6c418	58cfa831e4b0c9d6adf6c418	TCGA-CJ-4878-01A-01D-2098-10_wgs_Illumina.filtered.	WGS	TCGA-CJ-4878-01A-01D-2098-10_wgs_Illumina	TCGA-CJ-4878-01A-01D-2098-10_wgs_Illumina.bam	215.7	1.9	0.15	58cfa831e4b0c9d6adf6c418	TCGA-CJ-4878-01A-01D-2098-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-CJ-4878-01A	7CA06DBE-F073-4AEE-86FF-A545FAD5EA93	Primary Tumor	Illumina HiSeq	cb7f204c-4503-4691-b1c7-fe363b44f4de	Kidney	71.0	24814EED-FDDB-475A-822E-EFFF92202954	DE4C3F91-D164-47DF-9971-FEBA840D247C	TCGA-CJ-4878-01A-01D-2098-10	GRCh37-lite	TCGA-CJ-4878	TCGA-KIRC		s9567	Baylor College of Medicine	MD Anderson Cancer Center	None	NO	T3a	NX	Kidney Clear Cell Renal Carcinoma	Stage III	2098-10	True	KIRC	C3	KIRC.2	0.08285034299999999				-1.1293	-0.1955	0.019	-0.6419	0.1866	-0.0787					79.0	0.108271854	3.0	14.0				1.559581156	5.0	0.9690222559999999	1.262587466	-244.0617296	-708.3513118	1691.190132	0.0	2186.0	0.0	2186.0	7.661432959282114	1.1845657754621062	0.14017740733956408	6.092817041368269	4.076819001457976	2.7648904548140285	-1.5686159179138455	2.89225322599587	2.6247130474744647
13722.58cfa831e4b0c9d6adf6c41a	58cfa831e4b0c9d6adf6c41a	TCGA-CJ-4899-01A-01D-2100-10_Illumina.filtered.	WGS	TCGA-CJ-4899-01A-01D-2100-10_Illumina	TCGA-CJ-4899-01A-01D-2100-10_Illumina.bam	109.4	1.9	0.16	58cfa831e4b0c9d6adf6c41a	TCGA-CJ-4899-01A-01D-2100-10_Illumina.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-CJ-4899-01A	900B5F21-E8FB-4A3F-B8E3-EF098716E508	Primary Tumor	Illumina HiSeq	ad992cd4-c4d5-4f87-b721-a2cbdf70f57d	Kidney	42.0	E2D40747-F751-4CCB-A45C-A60B06046DB1	9C181313-5B4C-41C5-9AD5-A5A86FE609AA	TCGA-CJ-4899-01A-01D-2100-10	GRCh37-lite	TCGA-CJ-4899	TCGA-KIRC		s9568	Baylor College of Medicine	MD Anderson Cancer Center	None	NO	T1b	NX	Kidney Clear Cell Renal Carcinoma	Stage I	2100-10	False	KIRC	C3	KIRC.1	0.17577852800000002	0.6	0.0		-1.046	-0.2925	0.8107	0.5729	0.3484	0.3516	19.0	42.0	0.257562227	0.829922733	99.0	0.144677886	3.0	2.0	0.96067689	1.055411437	3.0	3.0903647010000004	28.0	0.92742348	1.29500969	353.362116	-342.24683450000003	1992.7619300000001	0.0	1528.0	0.0	1528.0	7.0289512872347615	1.9271201457285674	0.5375266936911411	5.662075011971972	4.748024085560342		-1.366876275262789	2.8209039398317746	
13722.58cfa831e4b0c9d6adf6c420	58cfa831e4b0c9d6adf6c420	TCGA-BT-A20T-01A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BT-A20T-01A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_7_rg.sorted	TCGA-BT-A20T-01A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_7_rg.sorted.bam	59.68	2.07	0.17	58cfa831e4b0c9d6adf6c420	TCGA-BT-A20T-01A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_7_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A20T-01A	096B4F32-10C1-4737-A0DD-CAE04C54EE33	Primary Tumor	Illumina HiSeq	e605a62d-c633-415e-bba0-2174fd3ad94e	Bladder	63.0	52F538EF-B05D-4C76-9976-CE6D49158016	3929BC99-B4FC-4EB9-BDEA-1986EA49AF2A	TCGA-BT-A20T-01A-11D-A14U-02	HG19_Broad_variant	TCGA-BT-A20T	TCGA-BLCA	453.0	s2871	Harvard Medical School	University of Pittsburgh	United States	NO	T3b	N1	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A14U-02	True	BLCA	C1	BLCA.2	0.144387136	0.25	0.26	4.116488949	0.1913	0.07	-0.2393	0.0539	0.33899999999999997	0.3351	112.0	75.0	2.442283931	6.723818724	222.0	0.71242855	5.0	25.0		0.0	1.0	2.2008276490000003	12.0	0.8856782	3.578491575	-755.8021294	150.1353221	-3769.9904539999998	1.0	453.0	1.0	314.0	5.266974115982325	7.182110303154788	0.2041036700703096	4.130974295242595	6.024657514463745	0.947392914424268	-1.13599982073973	-1.1574527886910433	0.7432892443539584
13722.58cfa831e4b0c9d6adf6c422	58cfa831e4b0c9d6adf6c422	TCGA-BW-A5NP-01A-11D-A27I-10_wgs_Illumina.filtered.	WGS	TCGA-BW-A5NP-01A-11D-A27I-10_wgs_Illumina	TCGA-BW-A5NP-01A-11D-A27I-10_wgs_Illumina.bam	62.92		0.08	58cfa831e4b0c9d6adf6c422	TCGA-BW-A5NP-01A-11D-A27I-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-BW-A5NP-01A	56A82A56-0241-4D3D-9DE2-696B0C36DF91	Primary Tumor	Illumina HiSeq	ce91806d-fb1a-452a-ad2e-51c7bdfbeb15	Liver	26.0	C13884B6-EAEF-4E1C-8FA7-5FE76548D32F	1C00925B-7328-4DB0-B930-04AAB2D80719	TCGA-BW-A5NP-01A-11D-A27I-10	GRCh37-lite	TCGA-BW-A5NP	TCGA-LIHC		s16972	Baylor College of Medicine	St Joseph's Medical Center (MD)	United States	NO	T2	N0	Hepatocellular Carcinoma	Stage IV	A27I-10	True	LIHC	C3	LIHC.iCluster:1	0.024179361				-0.2198	-0.08199999999999999	-1.2363	-1.1464	-1.3942	-0.8924	37.0	7.0	0.5837873579999999	1.806960869	154.0	0.738237832						0.0	1.0			-1567.623726	-713.5864589	3595.7864670000004	0.0	0.0	1.0	102.0	4.0098378828474806	2.2957481469975134	-0.6077275996346716	5.5853742436059	2.472872810224276	3.303044623891822	1.5755363607584187	0.17712466322676246	3.910772223526494
13722.58cfa831e4b0c9d6adf6c424	58cfa831e4b0c9d6adf6c424	TCGA-CN-4725-01A-01D-1431_120504_SN590_0155_AC0KTHACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CN-4725-01A-01D-1431_120504_SN590_0155_AC0KTHACXX_s_3_rg.sorted	TCGA-CN-4725-01A-01D-1431_120504_SN590_0155_AC0KTHACXX_s_3_rg.sorted.bam	52.7	1.9	0.17	58cfa831e4b0c9d6adf6c424	TCGA-CN-4725-01A-01D-1431_120504_SN590_0155_AC0KTHACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4725-01A	3BE2ACE5-1C2A-49E9-8DA9-CEED6119530B	Primary Tumor	Illumina HiSeq	7ddc2537-f164-4a40-befe-6e0a3deed186	Head and Neck	60.0	DD42AB2F-E936-4ACE-93D8-60375E03F2FE	C8B71532-685F-47AC-B019-B898A8D1670D	TCGA-CN-4725-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4725	TCGA-HNSC		s15755	Harvard Medical School	University of Pittsburgh	None	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	1431-02	True	HNSC	C1	HNSC.Basal	0.16235240199999998	0.41	0.18		0.8290000000000001	0.22699999999999998	-0.8343	-1.4368	0.0268	0.5405	24.0	7.0	0.5584038339999999	1.31224901	175.0	0.8773077420000001	25.0	17.0				2.163955657	9.0	0.984858662	1.511701835	-1029.887249	1065.9952349999999	-1593.5612039999999	0.0	1157.0	0.0	1157.0	7.791316186233374	3.663182660034595	-0.3391328645165663	6.215779825474954	5.868438315723215	2.152619425408115	-1.5755363607584192	2.20525565568862	2.491752289924681
13722.58cfa831e4b0c9d6adf6c426	58cfa831e4b0c9d6adf6c426	TCGA-CN-4727-01A-01D-1431_120504_SN590_0155_AC0KTHACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CN-4727-01A-01D-1431_120504_SN590_0155_AC0KTHACXX_s_7_rg.sorted	TCGA-CN-4727-01A-01D-1431_120504_SN590_0155_AC0KTHACXX_s_7_rg.sorted.bam	81.7	1.9	0.14	58cfa831e4b0c9d6adf6c426	TCGA-CN-4727-01A-01D-1431_120504_SN590_0155_AC0KTHACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4727-01A	12D05E8F-8D13-47C1-B713-2250F6ABCEF9	Primary Tumor	Illumina HiSeq	f26c4909-b285-4ca0-ac40-fe65ad4a6a1a	Head and Neck	56.0	F102AEF0-94B8-4D26-8055-35B76DA9DD5F	E42C764C-98DB-4E55-A625-B1443E6C4B3A	TCGA-CN-4727-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4727	TCGA-HNSC		s15495	Harvard Medical School	University of Pittsburgh	United States	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	True	HNSC	C1	HNSC.Classical	0.351785659	0.53	0.06		0.6938	0.317	-0.982	-1.6592	-0.268	0.4339	159.0	63.0	3.0809316489999996	10.50317608	165.0	0.5232932220000001	14.0	29.0					0.0		2.361847533	412.7812816	-108.8066041	-911.8087935000001	0.0	1560.0	0.0	1560.0	6.573755658599984	5.789786929958654	-0.6178521123205915	6.6293255097547945	6.720340108753374	-0.27235046897998405	0.055569851154810834	0.9305531787947192	0.3455016433406074
13722.58cfa831e4b0c9d6adf6c42c	58cfa831e4b0c9d6adf6c42c	TCGA-BT-A2LD-01A-12D-A210_120914_SN590_0180_BC19KDACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BT-A2LD-01A-12D-A210_120914_SN590_0180_BC19KDACXX_s_5_rg.sorted	TCGA-BT-A2LD-01A-12D-A210_120914_SN590_0180_BC19KDACXX_s_5_rg.sorted.bam	16.84		0.18	58cfa831e4b0c9d6adf6c42c	TCGA-BT-A2LD-01A-12D-A210_120914_SN590_0180_BC19KDACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A2LD-01A	9DD97821-7AFD-4982-8B1D-F14F845B79F7	Primary Tumor	Illumina HiSeq	205bfe9f-2bc9-4236-930c-a862874ad8e0	Bladder	78.0	AEB379D5-B157-4BCE-82C5-0CD0077DB01F	BF6A16B2-9DC9-4E9A-A810-2EBA7E9B56A1	TCGA-BT-A2LD-01A-12D-A210-26	HG19_Broad_variant	TCGA-BT-A2LD	TCGA-BLCA		s3089	MD Anderson - Institute for Applied Cancer Science	University of Pittsburgh	United States	NO	T3a	N1	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A210-26	True	BLCA	C2	BLCA.4	0.292105701	0.41	0.75	1.999907497	0.7155	0.1475	-0.7559	-0.1286	1.1728	0.2105	49.0	63.0	0.9173697540000001	2.6041463990000002	261.0	0.6252822920000001	5.0	33.0	0.334704658	0.23199959	2.0		0.0		4.006658251	-806.322723	1097.789291	-2456.274492	1.0	623.0	1.0	555.0	5.591495670644759	6.543836113806643	0.3255713717877122	4.00970928954117	5.596454794862456	1.540057819257896	-1.5817863811035897	-0.9473813189441862	1.2144864474701837
13722.58cfa831e4b0c9d6adf6c430	58cfa831e4b0c9d6adf6c430	TCGA-CJ-4918-01A-01D-2101-10_Illumina.filtered.	WGS	TCGA-CJ-4918-01A-01D-2101-10_Illumina	TCGA-CJ-4918-01A-01D-2101-10_Illumina.bam	41.4	1.9	0.16	58cfa831e4b0c9d6adf6c430	TCGA-CJ-4918-01A-01D-2101-10_Illumina.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-CJ-4918-01A	267FF78B-BCEB-466E-8582-C560FE227FF0	Primary Tumor	Illumina HiSeq	6b97d11a-5289-440f-a2df-5c10c9cb91fc	Kidney	64.0	8262BF2A-F944-4101-8E43-51658B580747	81D0D6BB-7319-4B67-BCF7-36DF24E76B43	TCGA-CJ-4918-01A-01D-2101-10	GRCh37-lite	TCGA-CJ-4918	TCGA-KIRC	93.0	s9305	Baylor College of Medicine	MD Anderson Cancer Center	None	NO	T3a	N0	Kidney Clear Cell Renal Carcinoma	Stage IV	2101-10	False	KIRC	C3	KIRC.3	0.356268701	0.64	0.0		-0.9248	-0.249	0.9591	1.1361	0.0914	0.6065	29.0	31.0	0.503856758	1.735506609	68.0	0.053517630999999996	0.0	4.0	0.837636343	2.4663691	19.0	3.587834535	38.0	0.986322901	2.112607261	102.45205759999999	-337.81510610000004	-1809.041254	1.0	93.0	1.0	33.0	8.689348664917473	1.2215063698195472	0.7785547079676007	5.427652842866345	4.262296551689234		-3.2616958220511285	3.0407901818696867	
13722.58cfa831e4b0c9d6adf6c438	58cfa831e4b0c9d6adf6c438	TCGA-CH-5772-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CH-5772-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_1_rg.sorted	TCGA-CH-5772-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_1_rg.sorted.bam	85.7	1.9	0.16	58cfa831e4b0c9d6adf6c438	TCGA-CH-5772-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5772-01A	ECF9F8BE-7830-4626-8617-694C68EF4074	Primary Tumor	Illumina HiSeq	97cf547a-bc4b-4b08-9f8e-c1986b18aa30	Prostate	63.0	068AC08D-1A9E-4C71-B436-4ED861A9DCF8	5C9AAB80-29D2-4D85-A9FE-99FA22222CA4	TCGA-CH-5772-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5772	TCGA-PRAD		s4128	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.7-IDH1	0.061299062	0.2	0.13		-1.2313	-0.073	-0.8168	-0.9456	-0.5278	-0.5087	29.0	8.0	0.523824821	0.96494046	75.0	0.090232248	0.0	4.0				0.0	1.0		2.219805964	-670.1813279	-749.7539230000001	688.5234012	0.0	486.0	0.0	486.0	8.467267382646511	9.278707492166067	-0.027504132188106212	6.762519290408086	8.819175162787626	2.0097283647522475	-1.7047480922384255	-0.4595323293784399	2.0372324969403537
13722.58cfa831e4b0c9d6adf6c43a	58cfa831e4b0c9d6adf6c43a	TCGA-CJ-4870-01A-01D-2098-10_wgs_Illumina.filtered.	WGS	TCGA-CJ-4870-01A-01D-2098-10_wgs_Illumina	TCGA-CJ-4870-01A-01D-2098-10_wgs_Illumina.bam	85.7	1.9	0.15	58cfa831e4b0c9d6adf6c43a	TCGA-CJ-4870-01A-01D-2098-10_wgs_Illumina.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-CJ-4870-01A	78048432-2DE1-498C-9CF1-9C5BD43DAA39	Primary Tumor	Illumina HiSeq	22d3d6f1-5686-493f-b205-6ecc2602d2b8	Kidney	58.0	F7D03CD3-2D55-400A-BB29-F86CCAE475EC	267A9862-17BD-4056-BA4A-1F373736FFBB	TCGA-CJ-4870-01A-01D-2098-10	GRCh37-lite	TCGA-CJ-4870	TCGA-KIRC		s9566	Baylor College of Medicine	MD Anderson Cancer Center	None	NO	T3a	NX	Kidney Clear Cell Renal Carcinoma	Stage III	2098-10	True	KIRC	C3		0.086769389				-1.6735	-0.17	0.2714	-0.2071	0.0836	0.0865					109.0	0.099344895						2.043191871	8.0	0.982567593	0.731779347	-18.40242855	-1626.537237	1990.332873	0.0	1498.0	0.0	1498.0	7.230770021428235	-0.4665564743904813	0.060011944273957285	6.085637717125232	3.0563103934754654	3.941679870920566	-1.1451323043030028	3.5228668678659467	3.8816679266466085
13722.58cfa831e4b0c9d6adf6c440	58cfa831e4b0c9d6adf6c440	TCGA-CH-5789-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CH-5789-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_5_rg.sorted	TCGA-CH-5789-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_5_rg.sorted.bam	148.7	1.9	0.15	58cfa831e4b0c9d6adf6c440	TCGA-CH-5789-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5789-01A	BE5411DC-3CAA-4B25-9B94-CE463E8E52B4	Primary Tumor	Illumina HiSeq	fc8da645-2fde-4ef8-9ee7-8b8101580793	Prostate	61.0	3C42EB4B-DB63-4F81-8D28-A439E932C716	1D569000-EA8E-4D54-A581-AEE36E66688E	TCGA-CH-5789-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5789	TCGA-PRAD		s3779	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.1-ERG	0.15498187800000002	0.0	0.0		-1.8892	-0.2645	-0.3817	-0.5184	-1.2029	-0.2155	1.0		0.055569922	0.0	53.0	5.89e-06	0.0	0.0				2.163955657	9.0	0.984858662	1.6564678380000002	290.41445120000003	-299.2372084	2630.824642	0.0	304.0	0.0	304.0	7.578656850594763	8.556670281958437	0.3311452041956754	5.327365051988268	7.515216407130276	3.59705046906027	-2.251291798606495	-1.0414538748281612	3.2659052648645948
13722.58cfa831e4b0c9d6adf6c442	58cfa831e4b0c9d6adf6c442	TCGA-CJ-4885-01A-01D-2098-10_Illumina.filtered.	WGS	TCGA-CJ-4885-01A-01D-2098-10_Illumina	TCGA-CJ-4885-01A-01D-2098-10_Illumina.bam	75.7	1.9	0.15	58cfa831e4b0c9d6adf6c442	TCGA-CJ-4885-01A-01D-2098-10_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-CJ-4885-01A	5338D435-68FB-4F0D-A3E6-C843F703F75F	Primary Tumor	Illumina HiSeq	e9c31511-6628-44c2-a7cf-b25609056ad9	Kidney	64.0	A30B3254-3963-48D1-9710-7C3CAC0B1993	72C0603B-AD49-4E53-8164-2B69614BB743	TCGA-CJ-4885-01A-01D-2098-10	GRCh37-lite	TCGA-CJ-4885	TCGA-KIRC		s9171	Baylor College of Medicine	MD Anderson Cancer Center	None	NO	T3a	NX	Kidney Clear Cell Renal Carcinoma	Stage IV	2098-10	True	KIRC	C3	KIRC.4	0.08265120299999999				-1.7912	-0.2005	0.196	-0.0134	-0.106	-0.02					68.0	0.307313627	11.0	5.0				2.232694477	12.0	0.898502355	1.7675131519999998	-15.11905698	-1317.110344	1592.152478	0.0	3451.0	1.0	2041.0	8.839257105591374	-0.608320701339677	0.31849708215354755	5.438059723929218	2.5745188084776878	4.971027839501476	-3.4011973816621555	3.1828395098173647	4.652530757347929
13722.58cfa831e4b0c9d6adf6c446	58cfa831e4b0c9d6adf6c446	TCGA-CH-5750-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CH-5750-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_5_rg.sorted	TCGA-CH-5750-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_5_rg.sorted.bam	300.7	1.9	0.16	58cfa831e4b0c9d6adf6c446	TCGA-CH-5750-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5750-01A	DC40CF49-B208-4F59-B5F0-CFBDD02970B2	Primary Tumor	Illumina HiSeq	d0338227-feec-4f2e-bcfa-89c723bb89b5	Prostate	72.0	0386D0E9-7BD8-467F-BA97-A379C1D67A83	E1FEA0C9-E1D6-49C2-9DFF-9DC87F7776E9	TCGA-CH-5750-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5750	TCGA-PRAD		s3591	Harvard Medical School	Indivumed	Germany	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.2-ETV1	0.042993464	0.25	0.0	16.55266082	-0.5526	-0.122	-0.2742	0.8982	-0.1178	-0.4385	16.0	52.0	0.27698147100000003	0.8863407090000001	59.0	0.011795693000000001	0.0	2.0	0.852745725	2.250444855	14.0	3.35498757	29.0	0.996344764	2.414363699	-437.24486490000004	-664.2839357999999	2503.886187	0.0	396.0	0.0	396.0	8.241966560231802	8.413470223134432	0.20147133601733014	5.990674761625307	7.659698420758052	1.6967767467207673	-2.251291798606495	-0.7537718023763804	1.4953054107034371
13722.58cfa831e4b0c9d6adf6c44a	58cfa831e4b0c9d6adf6c44a	TCGA-CH-5741-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CH-5741-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_1_rg.sorted	TCGA-CH-5741-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_1_rg.sorted.bam	214.7	1.9	0.15	58cfa831e4b0c9d6adf6c44a	TCGA-CH-5741-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5741-01A	B3BF57D4-E31A-4740-B438-FA826FB79550	Primary Tumor	Illumina HiSeq	ae88c859-e075-4e3a-ba86-e6018e71fa98	Prostate	56.0	B22CBB75-E6E5-443D-AB4E-1CFD0079C69A	6AC2CA6C-FC79-4E5D-B08F-029A4AC2577B	TCGA-CH-5741-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5741	TCGA-PRAD		s3589	Harvard Medical School	Indivumed	Germany	NO	T3b	N1	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.1-ERG	0.025867155	0.18	0.0	4.53780023	-1.5619999999999998	-0.065	-1.4103	-1.1748	-1.3965	-0.8754	9.0	0.0	0.11168859099999999	0.474676511	103.0	0.057592752000000004	0.0	12.0							2.598125973	-1098.007791	-1395.8343300000001	2516.3066519999998	0.0	395.0	0.0	395.0	7.861341795599989	8.289099910376114	-0.3571120599514235	5.610049996993494	7.478169694159786		-2.251291798606495	-0.8109302162163288	
13722.58cfa831e4b0c9d6adf6c450	58cfa831e4b0c9d6adf6c450	TCGA-BW-A5NO-01A-11D-A27I-10_wgs_Illumina.filtered.	WGS	TCGA-BW-A5NO-01A-11D-A27I-10_wgs_Illumina	TCGA-BW-A5NO-01A-11D-A27I-10_wgs_Illumina.bam	61.1		0.08	58cfa831e4b0c9d6adf6c450	TCGA-BW-A5NO-01A-11D-A27I-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-BW-A5NO-01A	EE63C44B-91F4-4004-8DEA-192EAB527036	Primary Tumor	Illumina HiSeq	b36db6ae-5ff9-4608-9db1-8dd5dc62fd82	Liver	50.0	3CBD785D-CAD5-4299-8FE8-695CA8DB726D	81A8B064-E735-455F-B2DB-AF7AE11DAAC4	TCGA-BW-A5NO-01A-11D-A27I-10	GRCh37-lite	TCGA-BW-A5NO	TCGA-LIHC		s16580	Baylor College of Medicine	St Joseph's Medical Center (MD)	United States	NO	T3a	NX	Hepatocellular Carcinoma	Stage IIIA	A27I-10	True	LIHC	C4	LIHC.iCluster:3	0.126662267	0.29	0.55		-0.5409	-0.1495	-0.2647	0.1404	0.3126	-0.7988	52.0	16.0	1.05496663	3.428641546	469.0	0.671669915	17.0	25.0	0.908934062	1.768704016	7.0	0.693147181	2.0	1.0	3.982604753	-1043.963988	-232.5235787	3524.79635	0.0	20.0	0.0	20.0	7.271472037709915	5.234421373987497	-0.14450445632632836	5.19203049603008	7.4471501378596825	2.7754760090873383	-2.079441541679836	2.2127287638721853	2.9199804654136665
13722.58cfa831e4b0c9d6adf6c456	58cfa831e4b0c9d6adf6c456	TCGA-CA-6717-01A-11D-1835-10_wgs_Illumina.filtered.	WGS	TCGA-CA-6717-01A-11D-1835-10_wgs_Illumina	TCGA-CA-6717-01A-11D-1835-10_wgs_Illumina.bam	201.0	1.9	0.05	58cfa831e4b0c9d6adf6c456	TCGA-CA-6717-01A-11D-1835-10_wgs_Illumina.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-CA-6717-01A	268C01B3-D2CE-44C0-A2FE-EA846A1253CC	Primary Tumor	Illumina HiSeq	da552d40-23e1-469c-9fe7-ff2904a35ebe	Colorectal	57.0	D412011F-061C-43D6-8FA7-F917DA658AFF	2DF02F2B-9F1C-4249-B3B4-B03079CD97D9	TCGA-CA-6717-01A-11D-1835-10	GRCh37-lite	TCGA-CA-6717	TCGA-COAD		s13038	Baylor College of Medicine	ILSbio	Vietnam	NO	T3	N0	Colon Mucinous Adenocarcinoma	Stage IIA	1835-10	False	COAD	C1	GI.HM-SNV	0.419474585			1.208664021	0.6997	0.313	0.5702	1.4572	-0.5039	0.4487	4533.0	159.0	58.89418386	246.32682909999997	37.0	9.54e-07			0.928894041	4.169467578	89.0	3.975841178	54.0	0.996705209	1.528041309	-647.1946347	847.6181852	-279.10888389999997	0.0	388.0	0.0	388.0	7.115920547115634	2.710211963470897	-0.4950451995849705	5.5934940116711624	6.227524323688739	1.8002126049391134	-1.5224265354444708	3.5173123602178418	2.295257804524084
13722.58cfa831e4b0c9d6adf6c45e	58cfa831e4b0c9d6adf6c45e	TCGA-CJ-5681-01A-11D-1534-10_wgs_Illumina.filtered.	WGS	TCGA-CJ-5681-01A-11D-1534-10_wgs_Illumina	TCGA-CJ-5681-01A-11D-1534-10_wgs_Illumina.bam	253.4	1.9	0.05	58cfa831e4b0c9d6adf6c45e	TCGA-CJ-5681-01A-11D-1534-10_wgs_Illumina.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-CJ-5681-01A	2939C03A-6F3F-4F7B-B246-34361BAADEB9	Primary Tumor	Illumina HiSeq	7efcb420-d7ac-41f1-847f-17a9ec6d10d5	Kidney	44.0	252836BE-AFF6-4967-8887-D93B178A4FF9	9AE0744A-9BC1-4CD7-B7CF-C6569ED9E4AA	TCGA-CJ-5681-01A-11D-1534-10	GRCh37-lite	TCGA-CJ-5681	TCGA-KIRC	552.0	s9170	Baylor College of Medicine	MD Anderson Cancer Center	None	NO	T3a	NX	Kidney Clear Cell Renal Carcinoma	Stage IV	1534-10	False	KIRC	C4	KIRC.1	0.119581514	0.16	0.0		-0.3298	-0.242	0.0757	-0.8254	-1.2397	-0.3068	11.0	78.0	0.166031963	0.5534398779999999	1155.0	0.078057579	0.0	7.0				2.48490665	12.0	1.0	1.826729934	-688.4120095	-732.5050011	3778.520072	1.0	552.0	1.0	17.0	6.908062923962259	1.4564404383563616	0.8336730973366782	5.917664219934382	4.776153193897996	0.37558094925849583	-0.9903987040278768	3.3197127555416346	-0.4580921480781823
13722.58cfa831e4b0c9d6adf6c467	58cfa831e4b0c9d6adf6c467	TCGA-CH-5751-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CH-5751-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_7_rg.sorted	TCGA-CH-5751-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_7_rg.sorted.bam	226.7	1.9	0.15	58cfa831e4b0c9d6adf6c467	TCGA-CH-5751-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5751-01A	721E76D0-4B1D-4E78-ADB8-1344B8030062	Primary Tumor	Illumina HiSeq	c152f07f-eb7f-464d-ba51-ce1b55777952	Prostate	68.0	6D8CE214-3A06-4F7C-858B-709A40EBBE25	FC06702A-2C27-42FD-A925-D0DB20C358E7	TCGA-CH-5751-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5751	TCGA-PRAD		s3425	Harvard Medical School	Indivumed	Germany	NO	T4	N1	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C2	PRAD.8-other	0.40694659200000005	0.46	0.6	0.395976875	0.1766	-0.086	0.5309	2.0208	0.6948	-0.2433	14.0	2.0	0.165538207	0.689742527	270.0	0.5297939389999999	3.0	26.0	0.827026237	3.283535581	53.0	4.400051461	85.0	0.990411177	2.410729385	-504.34006469999997	-30.91046005	-2658.6387050000003	0.0	1065.0	1.0	365.0	8.57772369115627	8.242041804776608	0.45532179684209695	6.7318970006579395	7.662223309523666	3.45843417769371	-1.8458266904983305	-0.5798184952529422	3.003112380851613
13722.58cfa831e4b0c9d6adf6c46a	58cfa831e4b0c9d6adf6c46a	TCGA-CA-5256-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-CA-5256-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-CA-5256-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	806.02	1.9	0.13	58cfa831e4b0c9d6adf6c46a	TCGA-CA-5256-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	ASIAN		Colon Adenocarcinoma	Aligned reads	TCGA-CA-5256-01A	17633A60-E12B-4A7C-BD8A-C16341DDC606	Primary Tumor	Illumina HiSeq	21c81645-36f0-4e4a-8f23-b589998bcb76	Colorectal	54.0	D4D5DEB6-6CFB-4E25-9824-8F7DC8D5B451	A8F8AAD6-F8C5-4133-A651-454C047A19D0	TCGA-CA-5256-01A-01D-1405-02	HG18	TCGA-CA-5256	TCGA-COAD		s13544	Harvard Medical School	ILSbio	None	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1405-02	True	COAD	C1	GI.CIN	0.12083937199999999	0.34	0.16	11.0202603	0.7662	0.4525	-0.5942	0.1866	-0.9041	-0.3918	32.0	74.0			97.0	0.8444377740000001	19.0	6.0							1.087828799	-1984.152909	175.85601359999998	-1532.095135	0.0	379.0	0.0	379.0	6.210600077024653	5.05139178939546	-0.5247758020633689	5.494980040612649	5.87556723236181	0.44761954786219826	-0.7156200364120036	0.8241754429663501	0.9723953499255672
13722.58cfa831e4b0c9d6adf6c470	58cfa831e4b0c9d6adf6c470	TCGA-CA-6718-01A-11D-1835-10_wgs_Illumina.filtered.	WGS	TCGA-CA-6718-01A-11D-1835-10_wgs_Illumina	TCGA-CA-6718-01A-11D-1835-10_wgs_Illumina.bam	376.7	1.9	0.05	58cfa831e4b0c9d6adf6c470	TCGA-CA-6718-01A-11D-1835-10_wgs_Illumina.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-CA-6718-01A	DF5AB6CC-6F68-4B6B-95E2-954C6B57BA9C	Primary Tumor	Illumina HiSeq	3f12f1a7-45cc-4500-b7e1-8ac12465fbfe	Colorectal	46.0	F235AFBB-DC2A-41DD-B373-77C0AACEFB37	0980E7FD-051D-45E9-9CA6-2BAF073DA4E8	TCGA-CA-6718-01A-11D-1835-10	GRCh37-lite	TCGA-CA-6718	TCGA-COAD		s13037	Baylor College of Medicine	ILSbio	Vietnam	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1835-10	False	COAD	C2	GI.HM-SNV	0.328323077	0.52	0.04	13.01722267	1.1573	0.39299999999999996	0.5123	0.9631	1.3165	0.187	1803.0	74.0	17.42767715	89.14486172	91.0	0.114100442	2.0	11.0	0.81480432	3.203668511	51.0	3.176082815	25.0	0.9867056040000001	1.489660811	181.99409550000001	914.7297297	-1306.384417	1.0	306.0	1.0	207.0	5.962550536943339	5.399653710285451	0.1869797930653574	4.89783979995091	6.657793035817199	1.6546982459000077	-1.0647107369924282	1.2581393255317481	1.4677184528346503
13722.58cfa831e4b0c9d6adf6c47a	58cfa831e4b0c9d6adf6c47a	TCGA-BT-A3PK-01A-21D-A221_120906_SN208_0426_BC194HACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BT-A3PK-01A-21D-A221_120906_SN208_0426_BC194HACXX_s_3_rg.sorted	TCGA-BT-A3PK-01A-21D-A221_120906_SN208_0426_BC194HACXX_s_3_rg.sorted.bam	57.66		0.17	58cfa831e4b0c9d6adf6c47a	TCGA-BT-A3PK-01A-21D-A221_120906_SN208_0426_BC194HACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A3PK-01A	73041FCF-F3B6-4851-B34D-1D62A1FCF6FE	Primary Tumor	Illumina HiSeq	637e8bd5-61ee-4d45-8cc5-e3b89950d020	Bladder	80.0	F09E1EEB-BCD5-4DBA-92F0-7D4B34B81CE7	EE975BE9-76BF-4B5A-BF4C-155750C168CD	TCGA-BT-A3PK-01A-21D-A221-26	HG19_Broad_variant	TCGA-BT-A3PK	TCGA-BLCA		s2858	MD Anderson - Institute for Applied Cancer Science	University of Pittsburgh	United States	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A221-26	True	BLCA	C2	BLCA.3	0.62102208	0.72	0.5	13.79950575	0.7279	0.3465	0.1167	-0.1509	1.1436	0.7091	166.0	50.0	2.94139647	9.059501127	94.0	0.170668748	5.0	21.0	0.7951365640000001	2.5906316869999997	26.0	2.150060224	10.0	0.933759291	4.5431766819999995	-28.21567467	170.7700676	-0.19093361399999997	1.0	303.0	1.0	303.0	6.638256097613956	8.002907041475801	-0.54806446670695	6.045192375610993	7.356279876550749	0.8042793603464189	-0.5930637220029626	-0.6466271649250523	1.3523438270533688
13722.58cfa831e4b0c9d6adf6c480	58cfa831e4b0c9d6adf6c480	TCGA-CJ-5682-01A-11D-2103-10_Illumina.filtered.	WGS	TCGA-CJ-5682-01A-11D-2103-10_Illumina	TCGA-CJ-5682-01A-11D-2103-10_Illumina.bam	155.4	1.9	0.15	58cfa831e4b0c9d6adf6c480	TCGA-CJ-5682-01A-11D-2103-10_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-CJ-5682-01A	4C325EE1-9B8E-45D4-A0A7-E47EC1EAC402	Primary Tumor	Illumina HiSeq	5586870f-0a22-4bd6-b331-defce06a0f46	Kidney	60.0	3D38F604-E571-422D-B645-BF73A0348243	DACD4CC2-FC2B-4FBD-ADF6-C8A46AE69C91	TCGA-CJ-5682-01A-11D-2103-10	GRCh37-lite	TCGA-CJ-5682	TCGA-KIRC		s9450	Baylor College of Medicine	MD Anderson Cancer Center	None	NO	T3a	NX	Kidney Clear Cell Renal Carcinoma	Stage IV	2103-10	False	KIRC	C3	KIRC.2	0.10784948400000001				-1.0155	-0.2725	0.33399999999999996	0.6292	0.2475	0.4236	29.0	172.0	0.447154686	1.8445130809999999	61.0	0.55203888	20.0	0.0		0.0	1.0	2.323396823	13.0	0.905825613	1.695250278	726.6743931	-148.9007823	1265.828693	0.0	3736.0	1.0	55.0	7.757550019567928	1.8996045804494752	0.15097102690987851	5.164162726785857	4.300459894876322	4.33411108791511	-2.59338729278207	2.400855314426847	4.183140061005232
13722.58cfa831e4b0c9d6adf6c485	58cfa831e4b0c9d6adf6c485	TCGA-CM-4752-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-CM-4752-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-CM-4752-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	846.02	1.9	0.15	58cfa831e4b0c9d6adf6c485	TCGA-CM-4752-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-CM-4752-01A	7EA546CE-F48A-4D9C-96B4-A0124C692870	Primary Tumor	Illumina HiSeq	ad469933-d84b-4305-85e2-a7d919298b71	Colorectal	58.0	5703F0D8-DB96-40CE-8009-51D2EC188ABF	43756C1F-6ED2-468B-B0AD-D44A447C7709	TCGA-CM-4752-01A-01D-1405-02	HG18	TCGA-CM-4752	TCGA-COAD		s13219	Harvard Medical School	MSKCC	None	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1405-02	True	COAD	C2	GI.CIN	0.308599578	0.62	0.3	7.589066376	0.5182	0.285	0.0511	0.5818	0.2403	-0.0208	68.0	41.0	1.073164555	2.6585212830000002	226.0	0.56907469	24.0	22.0							2.551347725	-1528.910574	-117.2054122	-1554.912814	0.0	396.0	0.0	396.0	6.06998552508716	7.401285130663129	0.16783578900901874	5.1037978220683815	6.995820022554964	1.3825278783244137	-0.9661877030187784	-0.40546510810816416	1.214692089315395
13722.58cfa831e4b0c9d6adf6c48e	58cfa831e4b0c9d6adf6c48e	TCGA-C4-A0F6-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-C4-A0F6-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_1_rg.sorted	TCGA-C4-A0F6-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_1_rg.sorted.bam	74.36	1.93	0.16	58cfa831e4b0c9d6adf6c48e	TCGA-C4-A0F6-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_1_rg.sorted.bam	Alive	FEMALE			Bladder Urothelial Carcinoma	Aligned reads	TCGA-C4-A0F6-01A	4FF9B4F2-6D04-4FED-8796-155902A8BF28	Primary Tumor	Illumina HiSeq	2332be3a-c2a5-446a-ae60-b8f873fe1866	Bladder	82.0	905D2BF1-08CB-4260-8188-00B60D881CF2	1765E178-12BD-4682-AB4A-368C4DCB5AEE	TCGA-C4-A0F6-01A-11D-A10R-02	HG19_Broad_variant	TCGA-C4-A0F6	TCGA-BLCA		s3084	Harvard Medical School	Indivumed	Germany	NO	T3b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A10R-02	True	BLCA	C1	BLCA.2	0.139500614	0.32	0.11	6.058318392	0.512	0.0755	-0.6683	-0.4519	-1.7269	0.1368	70.0	2.0	1.5400499840000001	5.190538834	210.0	0.521822637	16.0	17.0	0.7559764370000001	2.301587224	21.0	1.098612289	3.0	1.0	3.1767441539999997	-1307.6133929999999	271.9004378	-2078.0125940000003	0.0	700.0	0.0	700.0	5.827165648632004	6.000331370386686	0.25825185291439823	5.231656937635974	5.000159154531829	1.0762521469730684	-0.5955087109960293	-1.0001722158548572	0.8180002940586701
13722.58cfa831e4b0c9d6adf6c490	58cfa831e4b0c9d6adf6c490	TCGA-CJ-6033-01A-11D-2104-10_Illumina.filtered.	WGS	TCGA-CJ-6033-01A-11D-2104-10_Illumina	TCGA-CJ-6033-01A-11D-2104-10_Illumina.bam	13.66	1.9	0.17	58cfa831e4b0c9d6adf6c490	TCGA-CJ-6033-01A-11D-2104-10_Illumina.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-CJ-6033-01A	4EDFF57F-4B0E-4770-BEAC-590DA7D7232C	Primary Tumor	Illumina HiSeq	42a6262a-a044-4cac-b1dd-a97139e7859b	Kidney	54.0	840633A2-9565-4096-AA67-584952FBD6AB	10D15B7A-16D1-4953-AAEF-F193FFA97F42	TCGA-CJ-6033-01A-11D-2104-10	GRCh37-lite	TCGA-CJ-6033	TCGA-KIRC	224.0	s9169	Baylor College of Medicine	MD Anderson Cancer Center	United States	NO	T3a	N0	Kidney Clear Cell Renal Carcinoma	Stage IV	2104-10	False	KIRC	C6	KIRC.3	0.328989558	0.41	0.22		-0.6412	0.0	0.5291	0.1615	0.1145	0.4288	40.0	0.0	0.615430189	1.846290566	99.0	0.255367964	4.0	6.0	0.9634762440000001	1.335661684	4.0	3.115475025	24.0	0.9803090790000001	2.04359818	450.3931108	-405.6753986	1174.698303	1.0	224.0	1.0	144.0	8.711941717092191	-0.8517952359852403	0.7195804376281008	5.4455635582389865	2.213126611020077	4.386534531113071	-3.2663781588532044	3.0649218470053174	3.6669540934849705
13722.58cfa831e4b0c9d6adf6c498	58cfa831e4b0c9d6adf6c498	TCGA-CN-4722-01A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CN-4722-01A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_7_rg.sorted	TCGA-CN-4722-01A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_7_rg.sorted.bam	52.7	1.9	0.16	58cfa831e4b0c9d6adf6c498	TCGA-CN-4722-01A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4722-01A	B64BFCA1-033C-4501-A900-103AC105C084	Primary Tumor	Illumina HiSeq	3723e20c-1e27-4158-8bc5-1768c49ee5e5	Head and Neck	61.0	6E767FC9-0F5A-49EC-999A-CDA2DAEBA6FF	0CA196A7-5A71-4E70-8FA6-9506E1883032	TCGA-CN-4722-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4722	TCGA-HNSC		s15758	Harvard Medical School	University of Pittsburgh	None	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	1431-02	True	HNSC	C1		0.39299807700000006				0.0244	0.086	-0.2292	0.7081	-0.61	0.5273					90.0	0.074216056	2.0	3.0	0.960889112	4.109401908	72.0	3.578323836	37.0	0.990973465	4.793216792	-1031.292261	607.4924133999999	-784.4890199	0.0	1483.0	0.0	1483.0	2.2081642419304375	0.9528162667859714	-0.09471322425978401	6.182222638278036	5.929127682178377	2.4160013094840886	3.974058396347599	4.976311415392406	2.5107145337438723
13722.58cfa831e4b0c9d6adf6c4a2	58cfa831e4b0c9d6adf6c4a2	TCGA-CG-5732-01A-11D-1598_121023_SN208_0436_AC1CMBACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CG-5732-01A-11D-1598_121023_SN208_0436_AC1CMBACXX_s_2_rg.sorted	TCGA-CG-5732-01A-11D-1598_121023_SN208_0436_AC1CMBACXX_s_2_rg.sorted.bam	180.0	1.9	0.16	58cfa831e4b0c9d6adf6c4a2	TCGA-CG-5732-01A-11D-1598_121023_SN208_0436_AC1CMBACXX_s_2_rg.sorted.bam	Alive	MALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5732-01A	E62D5F3C-0A99-4932-A589-BFF4FA02B1D3	Primary Tumor	Illumina HiSeq	3bc07391-1ef5-4bbf-9614-e3f31b8448c9	Stomach	66.0	5295412B-3D28-4774-85D8-3D38C682C343	E09E88E6-7697-4A1F-BF79-6DE9BE6E0960	TCGA-CG-5732-01A-11D-1598-02	HG19_Broad_variant	TCGA-CG-5732	TCGA-STAD		s14491	Harvard Medical School	Indivumed	Germany	NO	T2	N3	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IV	1598-02	True	STAD	C2	GI.CIN	0.33460322600000003	0.42	0.4		0.1198	0.094	0.4228	2.0474	0.0692	-0.1555			0.577496059	1.2416165259999998	219.0	0.38729659299999997	5.0	30.0	0.743458965	5.207167362	1101.0	3.217489167	282.0	0.5702839710000001	4.396879715	626.4458373	-479.49717530000004	1449.184602	1.0	2100.0	1.0	1949.0	7.778839418018213	4.37260741275739	-0.2795333639411238	5.527547619411719	5.698277152060846	1.1489475889386171	-2.251291798606495	1.3256697393034553	1.428480952879741
13722.58cfa831e4b0c9d6adf6c4a4	58cfa831e4b0c9d6adf6c4a4	TCGA-CF-A1HR-01A-11D-A13U_121011_SN590_0184_BC192GACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CF-A1HR-01A-11D-A13U_121011_SN590_0184_BC192GACXX_s_3_rg.sorted	TCGA-CF-A1HR-01A-11D-A13U_121011_SN590_0184_BC192GACXX_s_3_rg.sorted.bam	37.6	2.0	0.16	58cfa831e4b0c9d6adf6c4a4	TCGA-CF-A1HR-01A-11D-A13U_121011_SN590_0184_BC192GACXX_s_3_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CF-A1HR-01A	39EA19E1-4959-4F1B-9934-54BDAF766842	Primary Tumor	Illumina HiSeq	65dee943-f41b-4f59-a5bb-2477053d1079	Bladder	62.0	6E77AB45-9C53-4A74-9581-043005C3E685	B048E28D-38FC-4E37-9C54-9C56526AD0E3	TCGA-CF-A1HR-01A-11D-A13U-02	HG19_Broad_variant	TCGA-CF-A1HR	TCGA-BLCA		s2872	Harvard Medical School	ILSbio	Vietnam	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A13U-02	True	BLCA	C1	BLCA.2	0.27292611	0.6	0.27	7.487180972999999	-0.0014	0.031	-0.5339	0.2312	0.162	-0.1492	106.0	6.0	2.5222645569999997	6.892234546	137.0	0.453636007	16.0	14.0	0.950566853	0.658882734	2.0	1.9459101490000001	7.0	1.0	2.486260054	-1317.223335	328.60895389999996	319.23432189999994	0.0	389.0	1.0	294.0	7.449672510225802	9.58350609253387	0.7564074673572121	6.494161065198366	8.444071809345505	2.401019787135346	-0.9555114450274362	-1.1394342831883648	1.644612319778134
13722.58cfa831e4b0c9d6adf6c4a6	58cfa831e4b0c9d6adf6c4a6	TCGA-BJ-A0ZJ-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BJ-A0ZJ-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_2_rg.sorted	TCGA-BJ-A0ZJ-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_2_rg.sorted.bam	59.26	1.9	0.16	58cfa831e4b0c9d6adf6c4a6	TCGA-BJ-A0ZJ-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0ZJ-01A	8877B479-B62A-4794-B71E-418DE96DFF23	Primary Tumor	Illumina HiSeq	649e17cb-1adf-40a9-a837-4980acc1a108	Thyroid	36.0	C6D64D80-C8AA-494A-8C0E-8640BEEBDFC9	D54FCA2A-0B8E-4A33-8B52-3FBF0E47D799	TCGA-BJ-A0ZJ-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0ZJ	TCGA-THCA		s12629	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A10R-02	True	THCA	C3	THCA.2	0.276441427	0.44	0.0		-1.2289	-0.2755	0.6785	2.0142	-0.0875	-0.1119	1.0		0.028381697999999997	0.028381697999999997	47.0	2.8300000000000003e-05	0.0	0.0	0.9386632290000001	3.093680875	27.0	4.2466116430000005	72.0	0.9929724520000001	1.622704685	334.68956180000004	-1096.561528	2171.0648920000003	0.0	1280.0	0.0	1280.0	5.236555129807946	7.580465881341485	0.11226115347965382	3.7539839382526354	6.4277863714031	1.7363966359810326	-1.4825711915553104	-1.1526795099383853	1.6241354825013787
13722.58cfa831e4b0c9d6adf6c4ac	58cfa831e4b0c9d6adf6c4ac	TCGA-CF-A3MH-01A-11D-A210_120906_SN208_0425_AD1CU2ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CF-A3MH-01A-11D-A210_120906_SN208_0425_AD1CU2ACXX_s_1_rg.sorted	TCGA-CF-A3MH-01A-11D-A210_120906_SN208_0425_AD1CU2ACXX_s_1_rg.sorted.bam	63.16		0.15	58cfa831e4b0c9d6adf6c4ac	TCGA-CF-A3MH-01A-11D-A210_120906_SN208_0425_AD1CU2ACXX_s_1_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CF-A3MH-01A	B8A8D2FC-421B-4393-8D5A-946CF72CB496	Primary Tumor	Illumina HiSeq	f82c1606-fe81-428d-9889-58cafa1f29e4	Bladder	75.0	8CF68BB1-5966-40CD-A038-E9E91E608766	463978F0-D37A-4035-9D1C-8C0E7B0F721C	TCGA-CF-A3MH-01A-11D-A210-26	HG19_Broad_variant	TCGA-CF-A3MH	TCGA-BLCA		s2874	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T2	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A210-26	True	BLCA	C1	BLCA.1	0.043360925	0.13	0.08	0.83719579	-0.0046	0.0035	-1.4542	-1.2937	-0.9745	-0.2245	22.0	46.0	0.331871239	1.206804507	104.0	0.258675861	9.0	10.0		0.0	1.0		0.0		1.9548106930000002	-744.8492438999999	-397.7246752	487.71876960000003	0.0	398.0	0.0	398.0	6.349231000396747	9.395203567862165	1.5643852484931573	5.443522377853129	8.824658709394551	-1.2237754316221157	-0.9057086225436182	-0.5705448584676129	-2.788160680115273
13722.58cfa831e4b0c9d6adf6c4b4	58cfa831e4b0c9d6adf6c4b4	TCGA-CE-A13K-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CE-A13K-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_1_rg.sorted	TCGA-CE-A13K-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_1_rg.sorted.bam	88.59	2.02	0.17	58cfa831e4b0c9d6adf6c4b4	TCGA-CE-A13K-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_1_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-CE-A13K-01A	A1227FFA-2733-4A43-BA82-834755453870	Primary Tumor	Illumina HiSeq	7f979498-38e3-4b28-b84a-c3eede43fa06	Thyroid	30.0	DAF2A444-AB89-48D4-9DA7-888AC3099AB7	7CEF35A1-E530-47C9-9A86-3EA2C970FCD3	TCGA-CE-A13K-01A-11D-A10R-02	HG19_Broad_variant	TCGA-CE-A13K	TCGA-THCA		s12632	Harvard Medical School	ILSbio	Vietnam	NO	T3	N1	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A10R-02	True	THCA	C3	THCA.5	0.093608218	0.2	0.03		-1.8378	-0.284	-0.4182	-0.259	-0.3843	0.1693	4.0		0.08495372400000001	0.16990744800000002	55.0	0.024486067	0.0	0.0	0.835209353	0.917571259	3.0	1.609437912	5.0	1.0	1.684603995	-100.52686240000001	-437.2099271000001	1522.935824	0.0	385.0	0.0	385.0	5.492628167770511	6.983368611019397	-0.6989118921308553	4.764994811139396	6.58805587437525	0.7101087179343208	-0.7276333566311148	-0.39531273664414623	1.409020610065176
13722.58cfa831e4b0c9d6adf6c4b7	58cfa831e4b0c9d6adf6c4b7	TCGA-BR-4253-01A-01D-1128_120816_SN590_0175_AD16M6ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BR-4253-01A-01D-1128_120816_SN590_0175_AD16M6ACXX_s_7_rg.sorted	TCGA-BR-4253-01A-01D-1128_120816_SN590_0175_AD16M6ACXX_s_7_rg.sorted.bam	201.9	1.9	0.14	58cfa831e4b0c9d6adf6c4b7	TCGA-BR-4253-01A-01D-1128_120816_SN590_0175_AD16M6ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4253-01A	411257A4-A148-4606-8C8B-F9F1240E40ED	Primary Tumor	Illumina HiSeq	90590609-4f3e-48b4-98e5-963c1c97f057	Stomach	80.0	C536B8DF-6FE3-425E-82E8-36299A6BA2B9	B7CE561B-B51B-4C85-822D-58DF663DE8EA	TCGA-BR-4253-01A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4253	TCGA-STAD		s15104	Harvard Medical School	Asterand	Russia	NO	T3	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIIA	1128-02	True	STAD	C2	GI.EBV	0.38760031	0.75	0.01		0.982	0.287	1.4372	1.7529	1.4573	-0.2724			0.853707963	2.256228188	76.0	0.023514389	2.0	3.0	0.8841582840000001	4.381735549	142.0	4.207481656000001	99.0	0.9156413309999999	0.330316215	155.6998927	1167.3661630000001	-2087.945058	1.0	124.0	0.0	124.0	3.897757700215333	3.9656612848134687	0.8060016700151796	6.766287716196449	6.2754740809289675	1.0509006793398856	2.868530015981116	2.309812796115499	0.2448990093247061
13722.58cfa831e4b0c9d6adf6c4be	58cfa831e4b0c9d6adf6c4be	TCGA-BR-4367-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_3_rg.sorted.filtered.	WGS	TCGA-BR-4367-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_3_rg.sorted	TCGA-BR-4367-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_3_rg.sorted.bam	65.9	1.9	0.14	58cfa831e4b0c9d6adf6c4be	TCGA-BR-4367-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4367-01A	D139BD0C-2EEB-44EC-856B-E77CB03D294E	Primary Tumor	Illumina HiSeq	98785371-4af3-4d04-acc8-5c53c8076618	Stomach	78.0	1506E790-C21C-4419-B11B-14250C947FB5	174658D3-1933-47FD-A883-5F4AFA169778	TCGA-BR-4367-01A-01D-1154-02	HG19_Broad_variant	TCGA-BR-4367	TCGA-STAD		s14611	Harvard Medical School	Asterand	Russia	NO	TX	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)		1154-02	True	STAD	C2		0.26788943600000004				0.4295	0.115	0.8072	0.9621	1.1092	0.2607					324.0	0.621130975	13.0	46.0	0.896627611	5.102133405	296.0	3.182564674	29.0	0.9451396120000001		-386.31311439999996	444.6538234	-2134.0198570000002	0.0	0.0	0.0	0.0	8.620561724393271	6.62011918248494	0.18561364048414297	6.317976631399226	6.19567817291777	1.618404754662595	-2.3025850929940455	-0.42444100956717	1.432791114178452
13722.58cfa831e4b0c9d6adf6c4d0	58cfa831e4b0c9d6adf6c4d0	TCGA-BT-A3PJ-01A-21D-A221_120906_SN208_0426_BC194HACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BT-A3PJ-01A-21D-A221_120906_SN208_0426_BC194HACXX_s_1_rg.sorted	TCGA-BT-A3PJ-01A-21D-A221_120906_SN208_0426_BC194HACXX_s_1_rg.sorted.bam	55.89		0.15	58cfa831e4b0c9d6adf6c4d0	TCGA-BT-A3PJ-01A-21D-A221_120906_SN208_0426_BC194HACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A3PJ-01A	CB664EEF-BE6F-44EF-AA90-6F6DA0E6440A	Primary Tumor	Illumina HiSeq	cac436d2-b3cb-4351-953e-084c7a431f0f	Bladder	76.0	29D79B83-FA80-490E-A8A1-C51C9AD061FE	4BAD319F-9A5F-4257-863A-BCD8ED983EFE	TCGA-BT-A3PJ-01A-21D-A221-26	HG19_Broad_variant	TCGA-BT-A3PJ	TCGA-BLCA		s2698	MD Anderson - Institute for Applied Cancer Science	University of Pittsburgh	United States	NO	T3a	N3	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A221-26	True	BLCA	C2	BLCA.3	0.29280263100000004	0.49	0.06	9.074967467999999	0.9937	0.32799999999999996	-0.0419	-0.2495	0.8149	0.289	256.0	104.0	5.003309395	12.27282363	271.0	0.902918763	20.0	43.0	0.904315924	1.4554403319999998	5.0	2.7080502010000003	15.0	1.0	3.3024049339999997	-724.0858691000001	759.2801667	794.9469956	0.0	789.0	0.0	789.0	6.847385832938929	8.449461429158564	0.18342106212737141	6.287770045003507	7.5111917905656345	1.269921166385032	-0.5596157879354227	-0.9382696385929301	1.0865001042576607
13722.58cfa831e4b0c9d6adf6c4d2	58cfa831e4b0c9d6adf6c4d2	TCGA-CF-A3MG-01A-11D-A210_120914_SN590_0180_BC19KDACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CF-A3MG-01A-11D-A210_120914_SN590_0180_BC19KDACXX_s_7_rg.sorted	TCGA-CF-A3MG-01A-11D-A210_120914_SN590_0180_BC19KDACXX_s_7_rg.sorted.bam	66.73		0.14	58cfa831e4b0c9d6adf6c4d2	TCGA-CF-A3MG-01A-11D-A210_120914_SN590_0180_BC19KDACXX_s_7_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CF-A3MG-01A	39EFA06A-FFE5-40B3-8F8A-A2D7071BC9E3	Primary Tumor	Illumina HiSeq	695ed631-423c-4381-ae8f-4a70fd6266b9	Bladder	48.0	1ACF91C8-4971-4893-AC27-64EA4A4C3023	99993BCD-8555-407A-A918-3F51D57BA720	TCGA-CF-A3MG-01A-11D-A210-26	HG19_Broad_variant	TCGA-CF-A3MG	TCGA-BLCA		s3095	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T2	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A210-26	True	BLCA	C1	BLCA.1	0.026223181	0.2	0.38	1.1943616670000001	0.5379	0.102	-2.1063	-2.7932	-1.8235	-0.6947	68.0	31.0	1.455144805	3.6533422769999997	114.0	0.738382141	18.0	16.0					0.0		1.680485921	-1513.438729	59.468592099999995	2290.398944	0.0	369.0	0.0	369.0	6.9830946355279515	9.200376612461422	0.40149899510322073	5.373656723093852	7.888190223495254	0.3022383702259882	-1.6094379124341005	-1.312186388966169	-0.09926062487723253
13722.58cfa831e4b0c9d6adf6c4d6	58cfa831e4b0c9d6adf6c4d6	TCGA-CF-A3MF-01A-12D-A21C_120914_SN590_0180_BC19KDACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CF-A3MF-01A-12D-A21C_120914_SN590_0180_BC19KDACXX_s_1_rg.sorted	TCGA-CF-A3MF-01A-12D-A21C_120914_SN590_0180_BC19KDACXX_s_1_rg.sorted.bam	55.07		0.16	58cfa831e4b0c9d6adf6c4d6	TCGA-CF-A3MF-01A-12D-A21C_120914_SN590_0180_BC19KDACXX_s_1_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CF-A3MF-01A	1E308B12-0590-4DAE-94D0-A539FCF25DF7	Primary Tumor	Illumina HiSeq	57be2848-15e4-489c-b122-a660f03c68dd	Bladder	34.0	E9889071-4C6E-4761-9D65-06C6B5989FB7	6646401F-5235-4847-A4E6-006F98CAFE85	TCGA-CF-A3MF-01A-12D-A21C-26	HG19_Broad_variant	TCGA-CF-A3MF	TCGA-BLCA		s3092	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A21C-26	True	BLCA	C3	BLCA.1	0.04219946	0.22	0.02	0.12999290900000002	-0.4224	-0.34600000000000003	-1.6586	-1.2031	-1.6255	-0.4836	13.0		0.211333763	0.603810752	95.0	0.45397687600000003	18.0	2.0					0.0		1.8773611019999998	-2006.205373	-441.36154239999996	894.4169985	0.0	383.0	0.0	383.0	6.101887228358073	7.309714247761013	1.0658855951655526	4.597809831581799	6.275640480230475	1.250482465796643	-1.5040773967762742	-1.0340737675305385	0.18459687063109032
13722.58cfa831e4b0c9d6adf6c4da	58cfa831e4b0c9d6adf6c4da	TCGA-CG-4477-01A-01D-1154_121029_SN208_0438_AC18NJACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CG-4477-01A-01D-1154_121029_SN208_0438_AC18NJACXX_s_2_rg.sorted	TCGA-CG-4477-01A-01D-1154_121029_SN208_0438_AC18NJACXX_s_2_rg.sorted.bam	281.2	1.9	0.14	58cfa831e4b0c9d6adf6c4da	TCGA-CG-4477-01A-01D-1154_121029_SN208_0438_AC18NJACXX_s_2_rg.sorted.bam	Alive	FEMALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4477-01A	18D0AAE7-9694-4252-B8FE-16E62DADAB07	Primary Tumor	Illumina HiSeq	a2b4b066-6bb7-401c-9ff9-e88bee42884b	Stomach	58.0	6D7C7B4E-6913-487D-9DC3-DDA901434192	3AE56504-30EE-4C03-9F69-C5B415DE6738	TCGA-CG-4477-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4477	TCGA-STAD		s14764	Harvard Medical School	Indivumed	Germany	NO	T2a	N0	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1154-02	True	STAD	C2	GI.CIN	0.30151113	0.51	0.14	31.11498554	0.8605	0.28800000000000003	0.9962	1.3133	1.2385	0.1422			0.9621760090000001	3.0239817419999997	141.0	0.693291047	4.0	34.0	0.828144186	4.774409491	319.0	3.3654988789999996	32.0	0.9710777079999999	0.944525932	752.3872243	413.015928	-2252.340252	0.0	942.0	1.0	365.0	3.3141860046725258	2.6625878270254524	0.042078838380462336	1.1169614273363067	1.6211339521972912	1.5620015367534115	-2.197224577336219	-1.0414538748281612	1.519922698372949
13722.58cfa831e4b0c9d6adf6c4e4	58cfa831e4b0c9d6adf6c4e4	TCGA-C5-A2LZ-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_2_rg.sorted.filtered.	WGS	TCGA-C5-A2LZ-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_2_rg.sorted	TCGA-C5-A2LZ-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_2_rg.sorted.bam	58.89		0.17	58cfa831e4b0c9d6adf6c4e4	TCGA-C5-A2LZ-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_2_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-C5-A2LZ-01A	BE8FA67D-C2D3-4FFF-82FE-A46BA1FA8DF0	Primary Tumor	Illumina HiSeq	19f84215-7f5d-4cf8-a6f5-e135327ccd50	Cervix	65.0	6B9F4254-DBD3-4D82-BAE8-D43A4915A7CD	837B293C-0843-4002-A8AB-3A945E040C75	TCGA-C5-A2LZ-01A-11D-A20X-26	HG19_Broad_variant	TCGA-C5-A2LZ	TCGA-CESC	3046.0	s1173	MD Anderson - Institute for Applied Cancer Science	Medical College of Wisconsin	United States	NO			Cervical Squamous Cell Carcinoma		A20X-26	True	CESC	C2		0.26652133699999997	0.32	0.42	2.534955891	1.1643	0.297	-0.1641	0.8129	1.3103	-0.4357			0.0	0.0	77.0	0.34333829899999996	8.0	11.0	0.8904488009999999	2.710991354	21.0	2.995732274	20.0	1.0	3.029967066	-417.6383103	169.99353119999998	-437.2571307	1.0	3046.0	1.0	2893.0	7.953494078043178	7.57695123871957	-0.048953043883123826	5.756269500706959	6.535497363891408	1.4672496857858124	-2.197224577336219	-1.0414538748281612	1.5162027296689362
13722.58cfa831e4b0c9d6adf6c4e9	58cfa831e4b0c9d6adf6c4e9	TCGA-AZ-4682-01B-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AZ-4682-01B-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-AZ-4682-01B-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	752.02	1.9	0.15	58cfa831e4b0c9d6adf6c4e9	TCGA-AZ-4682-01B-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AZ-4682-01B	E588714A-7753-4C3C-ABB6-EAF1AAB53AB3	Primary Tumor	Illumina HiSeq	fb93cdea-2ff1-454c-9fac-523a4bb11d62	Colorectal	61.0	A2412F6F-324E-4EF2-BD46-0D33596A033B	2007180A-F4AC-4300-A560-903ACEAC4F71	TCGA-AZ-4682-01B-01D-1405-02	HG18	TCGA-AZ-4682	TCGA-COAD	680.0	s13390	Harvard Medical School	University of Pittsburgh	None	NO	T3	N0	Colon Adenocarcinoma	Stage IVA	1405-02	True	COAD	C1	GI.CIN	0.086722304	0.22	0.09	0.276618688	0.6915	0.498	-0.9586	-0.57	-1.2907	-0.1507	38.0	0.0	0.676565532	1.795500834	126.0	0.443323054	9.0	7.0	0.9778838559999999	1.573843352	5.0	1.609437912	5.0	1.0	1.434519334	-561.4735106	23.53487216	-764.2564378	1.0	680.0	1.0	680.0	5.977225723455728	7.223116304147028	-0.415586286138948	5.412695920717876	7.620418101616031	1.562855971542972	-0.5645298027378516	0.3973017974690034	1.97844225768192
13722.58cfa831e4b0c9d6adf6c4f9	58cfa831e4b0c9d6adf6c4f9	TCGA-BR-4369-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_7_rg.sorted.filtered.	WGS	TCGA-BR-4369-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_7_rg.sorted	TCGA-BR-4369-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_7_rg.sorted.bam	161.2	1.9	0.14	58cfa831e4b0c9d6adf6c4f9	TCGA-BR-4369-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4369-01A	FE9A5FCF-FF99-4DD1-8CC7-ED9F4B9D952B	Primary Tumor	Illumina HiSeq	cbba5183-9ada-4363-8f98-bf406b64f6d6	Stomach	75.0	39B440B3-F888-488A-A0CC-D7410DC73093	7220D8C0-DF8F-4A72-8338-795181BD8A47	TCGA-BR-4369-01A-01D-1154-02	HG19_Broad_variant	TCGA-BR-4369	TCGA-STAD		s14966	Harvard Medical School	Asterand	Russia	NO	TX	NX	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)		1154-02	True	STAD	C1	GI.CIN	0.202171827	0.6	0.43		0.7864	0.172	0.4628	1.0395	-0.4121	0.1616			1.4167815830000001	4.028104502	329.0	0.669958779	17.0	39.0	0.7053354140000001	3.370885047	119.0	3.97563229	64.0	0.9559374979999999		-719.5079728	716.722892	-2427.483077	0.0	0.0	0.0	0.0	8.701928499434127	8.430414514622544	-0.28581945590120206	6.450636700827632	7.299012403131443	1.4444195424067385	-2.251291798606495	-1.1314021114911004	1.7302389983079405
13722.58cfa831e4b0c9d6adf6c4fd	58cfa831e4b0c9d6adf6c4fd	TCGA-CD-5800-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CD-5800-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_5_rg.sorted	TCGA-CD-5800-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_5_rg.sorted.bam	389.0	2.0	0.17	58cfa831e4b0c9d6adf6c4fd	TCGA-CD-5800-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_5_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-CD-5800-01A	EEB114EA-ECEE-49EE-A162-B3B7BC0A60CD	Primary Tumor	Illumina HiSeq	e62fc018-7ddb-4d26-b187-0781aa2ba772	Stomach	51.0	B23E2D58-E61B-4B94-B4D8-407418351167	5EF4C8F7-B17A-48DA-AAF2-EF2FA32619A9	TCGA-CD-5800-01A-11D-1598-02	HG19_Broad_variant	TCGA-CD-5800	TCGA-STAD		s14753	Harvard Medical School	ILSbio	Vietnam	NO	T3	N0	Stomach Intestinal Adenocarcinoma Papillary Type	Stage II	1598-02	True	STAD	C2	GI.CIN	0.303505357	0.53	0.44	5.679343515	1.1562	0.34700000000000003	-0.2058	0.6496	0.9415	0.0465			1.227963537	4.151686243	336.0	0.522428476	14.0	45.0	0.852142011	3.224666963	44.0	3.7743904269999997	49.0	0.969826492	6.441484495	-700.6742141	555.7509092	-1092.751851	0.0	400.0	0.0	400.0	7.859606186254842	6.897031315619161	-0.45293529009364164	6.2501682738207425	5.223054882047489	1.719579606747547	-1.6094379124341003	-1.6739764335716716	2.1725148968411885
13722.58cfa831e4b0c9d6adf6c50c	58cfa831e4b0c9d6adf6c50c	TCGA-CF-A3MI-01A-11D-A210_120913_SN208_0428_BC188KACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CF-A3MI-01A-11D-A210_120913_SN208_0428_BC188KACXX_s_1_rg.sorted	TCGA-CF-A3MI-01A-11D-A210_120913_SN208_0428_BC188KACXX_s_1_rg.sorted.bam	46.48		0.14	58cfa831e4b0c9d6adf6c50c	TCGA-CF-A3MI-01A-11D-A210_120913_SN208_0428_BC188KACXX_s_1_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CF-A3MI-01A	F1EBF96B-8DF9-4E59-ACEF-7AD433E40214	Primary Tumor	Illumina HiSeq	6559c325-d368-4f95-a2c0-df5efa895e3d	Bladder	62.0	A373568A-BBD3-4D67-92D6-96E8378065CF	86D4A4FB-47BB-4CD4-B481-CE9F815D38E6	TCGA-CF-A3MI-01A-11D-A210-26	HG19_Broad_variant	TCGA-CF-A3MI	TCGA-BLCA		s3273	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T2	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A210-26	True	BLCA	C3	BLCA.1	0.09146680900000001	0.21	0.3	1.003533678	-0.1339	-0.043	-0.8679	-0.7534	-0.9189	-0.3686	41.0	3.0	0.686446326	1.840924239	195.0	0.612000739	15.0	18.0					0.0		1.7762620530000002	-1853.307473	-674.2333592	-2787.436771	0.0	370.0	0.0	370.0	6.279970144006764	9.009480769783389	0.5540365633617703	6.192958767017135	8.41164376902777	2.2238246111290416	-0.08701137698962969	-0.5978370007556202	1.6697880477672713
13722.58cfa831e4b0c9d6adf6c514	58cfa831e4b0c9d6adf6c514	TCGA-CN-4735-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CN-4735-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_2_rg.sorted	TCGA-CN-4735-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_2_rg.sorted.bam	52.7	1.9	0.13	58cfa831e4b0c9d6adf6c514	TCGA-CN-4735-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4735-01A	FE844945-3EA9-449E-993C-DF392FABCFD0	Primary Tumor	Illumina HiSeq	b8913a67-9dd4-41f9-8888-c998df0a0a23	Head and Neck	52.0	FBB300FA-8793-42DA-A68E-4570AE2E5186	F759672A-62CA-49DC-BC4F-643E8A885787	TCGA-CN-4735-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4735	TCGA-HNSC		s16032	Harvard Medical School	University of Pittsburgh	None	NO	T3	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	True	HNSC	C2	HNSC.Mesenchymal	0.22891892	0.28	0.01		0.7941	0.1625	0.7067	1.1642	0.6108	0.4278	58.0	5.0	1.095155291	3.3697085889999996	185.0	0.5702755420000001	8.0	28.0	0.838143462	3.59602053	73.0	3.5951494939999997	38.0	0.988333839	5.838389707	-588.9144501000001	766.1755019	-2093.427679	0.0	1737.0	0.0	1737.0	6.9487227174703605	6.937188799339277	-1.1910933857698769	6.0885214522472495	8.323483160459169	2.240357948153795	-0.8602012652231115	1.3862943611198908	3.4314513339236723
13722.58cfa831e4b0c9d6adf6c522	58cfa831e4b0c9d6adf6c522	TCGA-CN-4731-01A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CN-4731-01A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_7_rg.sorted	TCGA-CN-4731-01A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_7_rg.sorted.bam	31.7	1.9	0.14	58cfa831e4b0c9d6adf6c522	TCGA-CN-4731-01A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4731-01A	50E25A4B-2EB2-4770-9A2D-8922A1E0AB56	Primary Tumor	Illumina HiSeq	50e66965-d2d5-49dd-a113-8b1751d6f7b7	Head and Neck	63.0	CD4E9D8C-B1F9-486A-ADCD-BD4B77A50326	981D992B-B92F-4E42-AA43-FC48068648A8	TCGA-CN-4731-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4731	TCGA-HNSC		s15753	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N2c	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	True	HNSC	C2	HNSC.Classical	0.21403546699999998	0.37	0.08		0.5715	0.139	-0.4663	-0.2215	0.4597	0.6417	39.0	111.0	1.175134917	2.546125654	177.0	0.31450812699999997	9.0	22.0	0.553448309	0.383621135	2.0	0.0	1.0		3.7403648730000003	318.7855505	405.73675910000003	-631.3749746	1.0	998.0	1.0	243.0	6.685111602709577	4.27019258255422	-0.8656060297209413	5.959174599326642	4.603271150759996	2.0507645031589297	-0.7259370033829362	0.3330785682057762	2.916370532879871
13722.58cfa831e4b0c9d6adf6c524	58cfa831e4b0c9d6adf6c524	TCGA-CM-4744-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-CM-4744-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-CM-4744-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	471.0	1.9	0.14	58cfa831e4b0c9d6adf6c524	TCGA-CM-4744-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-CM-4744-01A	CC15469C-7BAD-4E86-9DA3-AE0C72E9D380	Primary Tumor	Illumina HiSeq	e1403b52-6792-4d08-acad-95659ceeca82	Colorectal	69.0	A545FB9A-C386-4A80-9A25-660DC4F62904	6D073A6F-FB7B-4ED2-BD24-5233E019D64A	TCGA-CM-4744-01A-01D-1405-02	HG18	TCGA-CM-4744	TCGA-COAD		s13689	Harvard Medical School	MSKCC	None	NO	T2	N0	Colon Adenocarcinoma	Stage I	1405-02	True	COAD	C1	GI.CIN	0.258616587	0.4	0.06	7.78099867	0.8154	0.5915	-0.5622	0.5304	-0.1041	-0.4746	58.0	54.0	1.174564369	3.344955052	109.0	0.21350877399999998	9.0	4.0		0.0	1.0	1.5244259880000002	8.0	0.733093938	1.371800505	88.93723311	790.5811862	-2214.035809	0.0	609.0	0.0	609.0	5.741021587727219	7.662770006086445	0.552421876774656	5.278398065779106	7.627678686275176	0.7808798781523585	-0.46262352194811296	-0.03509131981126945	0.22845800137770245
13722.58cfa831e4b0c9d6adf6c526	58cfa831e4b0c9d6adf6c526	TCGA-CM-4746-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-CM-4746-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-CM-4746-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	516.0	1.9	0.15	58cfa831e4b0c9d6adf6c526	TCGA-CM-4746-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-CM-4746-01A	C0B8C55C-B993-481D-AEEA-9EBFA64EE20E	Primary Tumor	Illumina HiSeq	cba07266-002c-406e-bfb3-5fc3483bb04b	Colorectal	61.0	85991716-6807-4F31-BE63-BF80CEC40CC2	32AAA8D7-1ABF-4AEF-8067-BE801C95D30B	TCGA-CM-4746-01A-01D-1405-02	HG18	TCGA-CM-4746	TCGA-COAD		s12892	Harvard Medical School	MSKCC	None	NO	T2	N0	Colon Adenocarcinoma	Stage I	1405-02	True	COAD	C1	GI.HM-indel	0.129985144	0.19	0.01	13.03047141	0.6266	0.355	-1.2548	-0.8202	-0.5032	-0.3586	317.0	1146.0	6.162197141	17.8105698	110.0	0.13588191	5.0	8.0							1.213155675	-1572.244163	136.20747	-571.4069218	0.0	1126.0	0.0	1126.0	5.845454401900841	3.690035578942174	-1.085363480570464	5.706617957046625	7.585398839129145	2.6810215287142904	-0.1388364448542161	3.895363260186971	3.7663850092847544
13722.58cfa831e4b0c9d6adf6c52c	58cfa831e4b0c9d6adf6c52c	TCGA-CK-4951-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-CK-4951-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-CK-4951-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	36.02	1.9	0.17	58cfa831e4b0c9d6adf6c52c	TCGA-CK-4951-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-CK-4951-01A	2DB3C23D-C591-4EA0-B0A8-ED9C4343C80E	Primary Tumor	Illumina HiSeq	7dcee63f-adaa-46d6-a48c-750143760f41	Colorectal	79.0	EA9E7E8C-4151-4CFC-8631-5880C6F1A21F	C501681C-26B5-4385-AE24-BEC8FB230C51	TCGA-CK-4951-01A-01D-1405-02	HG18	TCGA-CK-4951	TCGA-COAD		s13040	Harvard Medical School	Harvard	None	NO	T3	N0	Colon Mucinous Adenocarcinoma	Stage IIA	1405-02	True	COAD	C2	GI.HM-indel	0.278074594	0.4	0.03	15.39199361	0.7461	0.2405	0.2659	0.3778	1.3117	0.3707	2186.0	2711.0	44.50485879	106.0945212	111.0	0.0026217209999999996	0.0	0.0	0.9150289229999999	1.6395117369999999	6.0	2.588573163	14.0	0.9808703790000001	1.0748248009999999	-331.6839593	532.9294272	-1560.247941	1.0	2134.0	1.0	480.0	5.819120080241868	6.858565034791365	-1.032389773362482	5.538217694775465	6.5401113036728304	2.1564810480362957	-0.2809023854664021	-0.3184537311185345	3.1888708213987775
13722.58cfa831e4b0c9d6adf6c52e	58cfa831e4b0c9d6adf6c52e	TCGA-CH-5769-01A-11D-1572_130104_SN208_0446_BD1KR5ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CH-5769-01A-11D-1572_130104_SN208_0446_BD1KR5ACXX_s_5_rg.sorted	TCGA-CH-5769-01A-11D-1572_130104_SN208_0446_BD1KR5ACXX_s_5_rg.sorted.bam	75.7	1.9	0.15	58cfa831e4b0c9d6adf6c52e	TCGA-CH-5769-01A-11D-1572_130104_SN208_0446_BD1KR5ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5769-01A	A7B76662-8380-4F35-9307-99C0ACACB904	Primary Tumor	Illumina HiSeq	2fe51267-827f-4ffb-8aa8-42352e2352d5	Prostate	48.0	18606532-21D5-40BF-92CF-A42B027449A1	5488DCD8-EC8B-4E14-8F62-5F9931580B87	TCGA-CH-5769-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5769	TCGA-PRAD		s3424	Harvard Medical School	Indivumed	Germany	NO	T3b	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C1	PRAD.1-ERG	0.166072479	0.39	0.0	4.719297516	-0.0396	0.009000000000000001	-0.6899	-0.7186	-0.9038	-0.0097	50.0	99.0	0.916647697	2.666611483	175.0	0.028362799999999997	0.0	6.0				1.386294361	4.0	1.0	1.9975109430000002	-362.45589	-149.8099504	1969.515209	0.0	62.0	0.0	62.0	7.3702306418070815	7.92948652331429	-0.2522681985506944	5.018855384643604	6.7255137189883545	1.432561819612388	-2.3513752571634776	-1.203972804325936	1.6848300181630824
13722.58cfa831e4b0c9d6adf6c530	58cfa831e4b0c9d6adf6c530	TCGA-CH-5753-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CH-5753-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_3_rg.sorted	TCGA-CH-5753-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_3_rg.sorted.bam	339.7	1.9	0.16	58cfa831e4b0c9d6adf6c530	TCGA-CH-5753-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5753-01A	928C48A0-68EE-4E28-AE83-9832E52850CA	Primary Tumor	Illumina HiSeq	971890ca-4817-4b12-b817-51caf2239fa3	Prostate	70.0	2BEEEBA8-47FE-4857-8704-E4C63E38C926	302AE7E6-2ADD-4556-8173-21EA12412058	TCGA-CH-5753-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5753	TCGA-PRAD		s3592	Harvard Medical School	Indivumed	Germany	NO	T3b	N1	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C4	PRAD.2-ETV1	0.050519198	0.17	0.1	6.027893783	-1.3145	-0.218	-0.6303	-0.4134	1.5258	-0.5531	9.0	5.0	0.19633646800000001	1.149970742	72.0	0.22259341600000002	4.0	17.0	0.990349197	0.6864577540000001	2.0	1.791759469	6.0	1.0	1.993896247	-486.54486529999997	-995.172434	1999.6354629999998	0.0	31.0	0.0	31.0	7.387502947177267	8.244563921590748	-0.19127720178827445	5.395072782487061	7.379566484104144	1.5117655181152876	-1.9924301646902063	-0.8649974374866045	1.703042719903562
13722.58cfa831e4b0c9d6adf6c531	58cfa831e4b0c9d6adf6c531	TCGA-CH-5768-01A-11D-1572_130104_SN208_0446_BD1KR5ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CH-5768-01A-11D-1572_130104_SN208_0446_BD1KR5ACXX_s_3_rg.sorted	TCGA-CH-5768-01A-11D-1572_130104_SN208_0446_BD1KR5ACXX_s_3_rg.sorted.bam	131.7	1.9	0.15	58cfa831e4b0c9d6adf6c531	TCGA-CH-5768-01A-11D-1572_130104_SN208_0446_BD1KR5ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5768-01A	F6C61A22-A711-416D-9E65-6A1B957E5B2E	Primary Tumor	Illumina HiSeq	98aa2eb7-52a4-424c-aa01-a574d0215ee6	Prostate	72.0	C4FF48C4-E953-4267-AB9C-3A09A97A88C4	9813DF8A-57D6-4D59-8534-3942B7FE672E	TCGA-CH-5768-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5768	TCGA-PRAD		s3420	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.1-ERG	0.039544817999999995	0.28	0.05	0.5267056210000001	-0.8791	-0.131	-0.8779	-0.784	-0.8167	-0.5693	26.0		0.342159197	0.912424525	158.0	0.101492319	0.0	7.0				1.098612289	3.0	1.0	1.899739366	-444.7776515	-287.82749680000006	2745.58322	0.0	731.0	0.0	731.0	8.697554494835005	9.803266584525154	-0.19763089270002454	6.864973031086695	8.838185688481568	2.47642327895233	-1.83258146374831	-0.9650808960435873	2.674054171652355
13722.58cfa831e4b0c9d6adf6c534	58cfa831e4b0c9d6adf6c534	TCGA-CH-5766-01A-11D-1572_130104_SN208_0446_BD1KR5ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CH-5766-01A-11D-1572_130104_SN208_0446_BD1KR5ACXX_s_1_rg.sorted	TCGA-CH-5766-01A-11D-1572_130104_SN208_0446_BD1KR5ACXX_s_1_rg.sorted.bam	273.7	1.9	0.15	58cfa831e4b0c9d6adf6c534	TCGA-CH-5766-01A-11D-1572_130104_SN208_0446_BD1KR5ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5766-01A	A5C77AB6-6E98-4A3D-81C8-F3D5FABD31D2	Primary Tumor	Illumina HiSeq	f778efd0-d2ed-48bc-ab57-e2bd12130169	Prostate	55.0	8477DA86-95BD-4B6D-A3E8-C16C9D61EA1F	ACAE8359-C2D0-4EB8-836B-D0BDF815F065	TCGA-CH-5766-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5766	TCGA-PRAD		s3421	Harvard Medical School	Indivumed	Germany	NO	T3a	N1	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.1-ERG	0.180924488	0.45	0.11	0.312417262	-1.2326	-0.163	-0.5066	0.3329	-0.2512	-0.4556	15.0	0.0	0.302794032	0.688168254	125.0	0.17780001	2.0	19.0		0.0	1.0	3.123938509	25.0	0.970506065	3.3985233	168.2932608	-928.8019283	2934.896368	0.0	31.0	0.0	31.0	7.255591274253665	7.585534982410961	-0.33488940449423543	5.058366696917446	6.544081107582799	1.730831991477872	-2.197224577336219	-1.0414538748281612	2.0657213959721075
13722.58cfa831e4b0c9d6adf6c536	58cfa831e4b0c9d6adf6c536	TCGA-CH-5763-01A-11D-1572_130104_SN208_0445_AC1JWAACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CH-5763-01A-11D-1572_130104_SN208_0445_AC1JWAACXX_s_3_rg.sorted	TCGA-CH-5763-01A-11D-1572_130104_SN208_0445_AC1JWAACXX_s_3_rg.sorted.bam	172.7	1.9	0.17	58cfa831e4b0c9d6adf6c536	TCGA-CH-5763-01A-11D-1572_130104_SN208_0445_AC1JWAACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5763-01A	18E79A01-07A2-4CD5-B700-71D41724E041	Primary Tumor	Illumina HiSeq	25246d22-8217-4900-8b3c-c63126974b5c	Prostate	66.0	F4192448-E5B3-4A9F-8354-9FE28503017A	0B812175-D56C-4407-9745-8DA5B8E531B4	TCGA-CH-5763-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5763	TCGA-PRAD		s4126	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.3-ETV4	0.161994036			4.27769986	-1.8013	-0.2045	-0.532	-0.3504	-0.649	0.0749	7.0		0.141403071	0.282806142	49.0	3.69e-05			0.895127316	0.620454975	2.0	2.145841753	9.0	0.976614669	1.92753874	897.3673815999999	-786.6208231	1118.5433130000001	0.0	365.0	0.0	365.0	7.270660772671506	7.654976259738085	-0.5684593001974622	4.919285515508028	6.901204457361705	2.445203364074958	-2.3513752571634776	-0.7537718023763804	3.01366266427242
13722.58cfa831e4b0c9d6adf6c540	58cfa831e4b0c9d6adf6c540	TCGA-CH-5764-01A-21D-1572_130104_SN208_0445_AC1JWAACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CH-5764-01A-21D-1572_130104_SN208_0445_AC1JWAACXX_s_5_rg.sorted	TCGA-CH-5764-01A-21D-1572_130104_SN208_0445_AC1JWAACXX_s_5_rg.sorted.bam	157.7	1.9	0.17	58cfa831e4b0c9d6adf6c540	TCGA-CH-5764-01A-21D-1572_130104_SN208_0445_AC1JWAACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5764-01A	ED73F136-42E8-4100-B432-D10370D07E8B	Primary Tumor	Illumina HiSeq	036937fb-20a8-45df-a234-f7396aefb2d1	Prostate	66.0	48726D56-93A1-4730-A660-FCEEE0321084	F57D0D07-21B0-4901-9D81-C371C4673D4A	TCGA-CH-5764-01A-21D-1572-02	HG19_Broad_variant	TCGA-CH-5764	TCGA-PRAD		s3777	Harvard Medical School	Indivumed	Germany	NO	T3b	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.1-ERG	0.10571549699999999	0.49	0.03	0.029355644	-1.3657	-0.222	-0.7145	-0.419	-0.8539	-0.3993	18.0	2.0	0.055888237	0.9221559020000001	102.0	0.057768531	2.0	10.0				1.7478680969999998	6.0	0.9755037590000001	1.792909021	48.3524518	-87.38266369	3771.53861	0.0	31.0	0.0	31.0	7.22983877815125	8.207856110402293	0.03263983748036814	4.831943505352879	7.109243821734183	2.5572068574962192	-2.3978952727983707	-1.0986122886681096	2.524567020015851
13722.58cfa831e4b0c9d6adf6c542	58cfa831e4b0c9d6adf6c542	TCGA-CH-5754-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CH-5754-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_5_rg.sorted	TCGA-CH-5754-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_5_rg.sorted.bam	197.7	1.9	0.16	58cfa831e4b0c9d6adf6c542	TCGA-CH-5754-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5754-01A	0AAD0ABD-750A-400D-A34F-491DA996D46C	Primary Tumor	Illumina HiSeq	9b3dfe47-a8c3-4a73-8aa3-66af9d5001a2	Prostate	65.0	BE645D37-B3E1-4D09-91CB-6231E25ACEB8	2C0EF4A5-DC20-45E7-B8EE-7525D77128B6	TCGA-CH-5754-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5754	TCGA-PRAD		s3596	Harvard Medical School	Indivumed	Germany	NO	T3b	N1	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C2	PRAD.1-ERG	0.248505648	0.37	0.11	1.110024731	-0.1164	-0.013000000000000001	0.0734	1.0509	1.5311	0.0478	30.0	4.0	0.909865172	2.040303719	148.0	0.213693608	3.0	35.0	0.8154739559999999	3.795183459	105.0	3.823661828	50.0	0.97741292	2.3968053019999997	298.93697480000003	-319.88395310000004	1427.071097	0.0	62.0	0.0	62.0	9.606596540999037	9.373564053078198	0.04356444683336658	7.041647183537501	8.680416872518252	1.9463302288766555	-2.5649493574615367	-0.6931471805599454	1.9027657820432888
13722.58cfa831e4b0c9d6adf6c548	58cfa831e4b0c9d6adf6c548	TCGA-CM-4747-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-CM-4747-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-CM-4747-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	541.0	1.9	0.15	58cfa831e4b0c9d6adf6c548	TCGA-CM-4747-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-CM-4747-01A	56EB96A4-D2C2-42FB-B26C-1A80012BCB8E	Primary Tumor	Illumina HiSeq	e66cdfc9-e0b0-4ca4-bbcc-9ae23d9d663f	Colorectal	47.0	D3DAA95A-19B5-4822-BCBE-35CEEC12FDF1	7E2021D4-E528-4EB1-A7A0-71D6BE77A71D	TCGA-CM-4747-01A-01D-1405-02	HG18	TCGA-CM-4747	TCGA-COAD		s13217	Harvard Medical School	MSKCC	None	NO	T4a	N1b	Colon Adenocarcinoma	Stage IVA	1405-02	True	COAD	C1	GI.CIN	0.153784198	0.41	0.1	3.6002529869999997	0.1683	0.0555	-0.7554	-0.5529	-0.6886	0.0668	45.0	26.0	1.153160714	1.930873754	115.0	0.446203156	12.0	21.0							1.17466624	-1265.007578	-356.1437509	-1132.917176	0.0	761.0	0.0	761.0	5.583059073848409	7.880412341533855	-1.578373607954483	5.4124335568176445	7.369586717767865	0.9269591731910789	-0.17062551703076334	-0.5108256237659905	2.5053327811455617
13722.58cfa831e4b0c9d6adf6c54a	58cfa831e4b0c9d6adf6c54a	TCGA-CN-4730-01A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CN-4730-01A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_5_rg.sorted	TCGA-CN-4730-01A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_5_rg.sorted.bam	23.7	1.9	0.14	58cfa831e4b0c9d6adf6c54a	TCGA-CN-4730-01A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4730-01A	35C1F2C6-771C-4533-82DF-F8E2EC7107D7	Primary Tumor	Illumina HiSeq	56942e06-fb67-4bf4-993e-16cb67f52239	Head and Neck	62.0	8270C53E-F2CF-4F57-A1AC-A8BA978CC1C8	094C2014-ABA2-4C11-B076-27EA61C7A48E	TCGA-CN-4730-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4730	TCGA-HNSC		s15496	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N1	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	True	HNSC	C1	HNSC.Basal	0.33579155299999996	0.52	0.16		1.0438	0.502	-1.0897	-1.1409	-0.5772	0.1072	82.0	43.0	1.152472765	3.82283649	102.0	0.43697671899999996	15.0	14.0				1.33217904	4.0	0.960964047	3.7192801510000004	-1053.271338	1275.646343	-2633.997065	0.0	817.0	0.0	817.0	7.38193766504929	6.243002368012311	-0.6255549699285319	6.317226928056861	7.798588785635822	1.5098107354843748	-1.0647107369924282	1.5555864176235108	2.135365705412907
13722.58cfa831e4b0c9d6adf6c552	58cfa831e4b0c9d6adf6c552	TCGA-CH-5762-01A-11D-1572_130104_SN208_0445_AC1JWAACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CH-5762-01A-11D-1572_130104_SN208_0445_AC1JWAACXX_s_1_rg.sorted	TCGA-CH-5762-01A-11D-1572_130104_SN208_0445_AC1JWAACXX_s_1_rg.sorted.bam	211.7	1.9	0.15	58cfa831e4b0c9d6adf6c552	TCGA-CH-5762-01A-11D-1572_130104_SN208_0445_AC1JWAACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5762-01A	D4FFAFDC-EE83-43DF-AA3B-7326503C6438	Primary Tumor	Illumina HiSeq	70b297c6-c1f6-4651-93c3-17888cf0b118	Prostate	60.0	6D1A2D44-72F3-4333-8506-E53CDC4E5185	25189A34-4C05-4D77-9A3B-212A475F66B1	TCGA-CH-5762-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5762	TCGA-PRAD		s3594	Harvard Medical School	Indivumed	Germany	NO	T3b	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.3-ETV4	0.21660396699999998	0.66	0.04	0.608082282	-1.0826	-0.20600000000000002	-0.218	0.6515	-0.7278	-0.1608	16.0	5.0	0.39312362799999995	1.404012955	129.0	0.138839573	1.0	26.0	0.9241921129999999	2.1280309809999998	10.0	2.45831133	12.0	0.989297256	1.68372936	457.57729850000004	-441.19810930000006	2301.072629	0.0	1339.0	0.0	1339.0	7.4175804024145435	7.586875975308942	-0.41711606553460734	5.220355825078324	6.588347145197815	2.0728547704016096	-2.197224577336219	-0.998528830111127	2.4899708359362167
13722.58cfa831e4b0c9d6adf6c556	58cfa831e4b0c9d6adf6c556	TCGA-CH-5752-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CH-5752-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_1_rg.sorted	TCGA-CH-5752-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_1_rg.sorted.bam	191.7	1.9	0.16	58cfa831e4b0c9d6adf6c556	TCGA-CH-5752-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5752-01A	D8F56D75-51AB-4A86-A502-C86E1DCD1EFF	Primary Tumor	Illumina HiSeq	d1bae4e7-eb79-4ede-abb5-19a328e4ad0c	Prostate	66.0	94A01526-7771-4A05-A9CE-9694B73DF3A7	490FC467-7E7E-40A1-98D0-ABA46EC71F53	TCGA-CH-5752-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5752	TCGA-PRAD		s3427	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.1-ERG	0.084140051	0.21	0.0	9.464212679	-0.3948	-0.0885	-0.9036	-1.2625	-1.4411	-0.3891	12.0	10.0	0.36596823100000003	0.92899628	141.0	0.031904095	0.0	3.0				1.5607104090000001	5.0	0.9697239	2.948514887	-1140.048493	-30.00478956	1473.6056740000001	0.0	943.0	0.0	943.0	9.121873390653853	5.0466980610037036	-0.11419545916015561	6.962389141300481	4.2219992944449265	3.585669939500565	-2.1594842493533726	-0.824698766558777	3.6998653986607204
13722.58cfa831e4b0c9d6adf6c558	58cfa831e4b0c9d6adf6c558	TCGA-CN-4733-01A-02D-1868_120427_SN208_0287_AC0J25ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CN-4733-01A-02D-1868_120427_SN208_0287_AC0J25ACXX_s_5_rg.sorted	TCGA-CN-4733-01A-02D-1868_120427_SN208_0287_AC0J25ACXX_s_5_rg.sorted.bam	7.7	1.9	0.14	58cfa831e4b0c9d6adf6c558	TCGA-CN-4733-01A-02D-1868_120427_SN208_0287_AC0J25ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4733-01A	DEDD71B4-8537-4947-839E-90ACEDDD0893	Primary Tumor	Illumina HiSeq	c1887d1c-970a-4e8d-80df-a16844daef9f	Head and Neck	61.0	A1FD1C9D-C763-488A-8649-FF069F56D2BE	1CB41C9B-FB04-438D-A9FB-89D6186E0D37	TCGA-CN-4733-01A-02D-1868-02	HG19_Broad_variant	TCGA-CN-4733	TCGA-HNSC		s15880	Harvard Medical School	University of Pittsburgh	None	NO	T1	N1	Head and Neck Squamous Cell Carcinoma	Stage III	1868-02	True	HNSC	C2	HNSC.Mesenchymal	0.677924548	0.86	0.22		0.4222	0.11699999999999999	1.1721	2.4666	1.8776	0.8619	10.0	34.0	0.23506708399999998	0.499517554	39.0	8.13e-06	1.0	1.0	0.672920772	4.048397119	410.0	4.67833445	114.0	0.987782607	1.520798172	752.1273669	510.64626910000004	-602.393781	0.0	1586.0	0.0	1586.0	6.284880151407524	7.942136070083185	-0.4631520470704408	6.336173445795074	6.626459276177248	1.8602034932808116	0.05129329438755059	-1.3156767939059373	2.3233555403512525
13722.58cfa831e4b0c9d6adf6c560	58cfa831e4b0c9d6adf6c560	TCGA-CH-5767-01A-11D-1784_130329_SN590_0221_BD1WHDACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CH-5767-01A-11D-1784_130329_SN590_0221_BD1WHDACXX_s_6_rg.sorted	TCGA-CH-5767-01A-11D-1784_130329_SN590_0221_BD1WHDACXX_s_6_rg.sorted.bam	200.4	1.9	0.16	58cfa831e4b0c9d6adf6c560	TCGA-CH-5767-01A-11D-1784_130329_SN590_0221_BD1WHDACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5767-01A	8DC53431-44AB-485E-B4E6-C3D06509506D	Primary Tumor	Illumina HiSeq	4ec6dbff-5194-4938-949c-d5ae0ec6a882	Prostate	66.0	A87E6352-C469-484D-87FC-FABDBA237D01	02D28407-4AE4-4DA6-ABB5-6D6A4BB3D8D3	TCGA-CH-5767-01A-11D-1784-02	HG19_Broad_variant	TCGA-CH-5767	TCGA-PRAD		s4129	Harvard Medical School	Indivumed	Germany	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1784-02	True	PRAD	C3	PRAD.8-other	0.045803007	0.17	0.01	0.9218436870000001	-1.4857	-0.1335	-1.3277	-1.5103	-1.4969	-0.6064	23.0	1.0	0.17624992899999997	0.9399996190000001	230.0	0.083904675	1.0	8.0				1.098612289	3.0	1.0	1.666303115	373.45776739999997	-711.6706381	2853.4741940000004	0.0	458.0	0.0	458.0	7.917050504304535	8.895720947167595	0.22044581822499265	6.0712238138062045	7.642957978672227	1.8160199551593088	-1.8458266904983305	-1.252762968495368	1.5955741369343162
13722.58cfa831e4b0c9d6adf6c562	58cfa831e4b0c9d6adf6c562	TCGA-CH-5761-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CH-5761-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_7_rg.sorted	TCGA-CH-5761-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_7_rg.sorted.bam	197.7	1.9	0.15	58cfa831e4b0c9d6adf6c562	TCGA-CH-5761-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5761-01A	854A481B-71A2-4F23-80AA-E91E9F4069B1	Primary Tumor	Illumina HiSeq	4d316299-7958-45e8-93ab-2150e05d3210	Prostate	61.0	332A54B1-2DF4-4BAA-84AC-2D95ABEF4064	F2F787DA-691C-4E73-A8B1-8D662781953E	TCGA-CH-5761-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5761	TCGA-PRAD		s3593	Harvard Medical School	Indivumed	Germany	NO	T3b	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C4	PRAD.8-other	0.09491113300000001	0.3	0.04	1.007239534	0.452	0.0605	-0.5789	-1.4093	0.8954	-0.168	26.0	16.0	0.42109020799999997	1.235197942	230.0	0.339434358	7.0	32.0				1.33217904	4.0	0.960964047	3.506259586	-685.8928348999999	-332.6343892	607.5028741	0.0	28.0	0.0	28.0	7.316548177182976	8.342601680684194	-2.3537784999018214	5.370638028127663	7.301147805856032	1.4889167565455925	-1.9459101490553132	-1.0414538748281612	3.8426952564474135
13722.58cfa831e4b0c9d6adf6c56a	58cfa831e4b0c9d6adf6c56a	TCGA-CH-5765-01A-11D-1572_130104_SN208_0445_AC1JWAACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CH-5765-01A-11D-1572_130104_SN208_0445_AC1JWAACXX_s_7_rg.sorted	TCGA-CH-5765-01A-11D-1572_130104_SN208_0445_AC1JWAACXX_s_7_rg.sorted.bam	256.7	1.9	0.16	58cfa831e4b0c9d6adf6c56a	TCGA-CH-5765-01A-11D-1572_130104_SN208_0445_AC1JWAACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5765-01A	716EB429-D7AF-4D4F-BD8D-AFCFF1A323EE	Primary Tumor	Illumina HiSeq	265ff01e-199b-4908-acaa-62aa8986967a	Prostate	55.0	E2359111-B056-4676-A8B6-C5CEA259B478	B7EFFFED-73EC-4139-A359-41B239F2978D	TCGA-CH-5765-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5765	TCGA-PRAD		s3428	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.1-ERG	0.032880561	0.25	0.0	2.9155148580000003	-1.359	-0.158	-1.2502	-1.1101	-1.7053	-0.598	11.0	0.0	0.36871619	0.680706812	130.0	0.054432765999999994	1.0	9.0		0.0	1.0	1.791759469	6.0	1.0	1.4586090409999999	-464.53158229999997	-400.250094	3025.701229	0.0	700.0	0.0	700.0	8.632038583085277	9.295157677082827	-0.011401263615465562	6.882838728276019	8.648530512157775		-1.749199854809259	-0.6466271649250523	
13722.58cfa831e4b0c9d6adf6c56b	58cfa831e4b0c9d6adf6c56b	TCGA-CH-5746-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CH-5746-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_1_rg.sorted	TCGA-CH-5746-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_1_rg.sorted.bam	299.7	1.9	0.15	58cfa831e4b0c9d6adf6c56b	TCGA-CH-5746-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5746-01A	618272C0-C2ED-4BFB-BB4B-404F0987F822	Primary Tumor	Illumina HiSeq	c4373feb-ceca-4bb3-9db2-6f9e94d29605	Prostate	57.0	54AD063E-68D9-4104-856A-2BD3905FA971	ABAFDCA6-6109-4686-A058-BDBEB9ADD1E7	TCGA-CH-5746-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5746	TCGA-PRAD		s3930	Harvard Medical School	Indivumed	Germany	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.1-ERG	0.038000326	0.69	0.0	0.022990267	-1.2341	-0.1435	-1.1633	-0.9234	-1.1975	-0.4662	4.0		0.056625308	0.226501233	71.0	0.012522738	0.0	3.0				2.197224577	9.0	1.0	2.2377222999999997	-469.81129969999995	-302.24383	2807.264668	0.0	731.0	0.0	731.0	8.79674228063783	9.023069085456314	-1.6331011265261106	6.637258031284457	7.220946829192712	2.472576037330521	-2.1594842493533726	-1.8021222562636017	4.105677163856632
13722.58cfa831e4b0c9d6adf6c57e	58cfa831e4b0c9d6adf6c57e	TCGA-CN-4729-01A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CN-4729-01A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_3_rg.sorted	TCGA-CN-4729-01A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_3_rg.sorted.bam	99.7	1.9	0.15	58cfa831e4b0c9d6adf6c57e	TCGA-CN-4729-01A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4729-01A	2FC960BD-01B0-422D-AD33-34520FA3DF0E	Primary Tumor	Illumina HiSeq	8b48a937-18eb-4e54-95d1-680ce9284b60	Head and Neck	73.0	1DA8FE25-AEE2-45FD-A1F3-3239A42E54B2	A49670C2-95A6-4DEB-BFC5-59B0FF37389E	TCGA-CN-4729-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4729	TCGA-HNSC		s15620	Harvard Medical School	University of Pittsburgh	None	NO	T2	N1	Head and Neck Squamous Cell Carcinoma	Stage III	1431-02	True	HNSC	C1	HNSC.Basal	0.38830522700000003	0.71	0.25		0.5223	0.16699999999999998	-0.1837	0.2653	-0.2729	0.7535	46.0	55.0	1.44751194	3.17884975	239.0	0.5184071020000001	18.0	39.0	0.902589663	4.1383442530000005	98.0	3.01494688	21.0	0.99028565	3.7403595739999997	-81.09376949	601.8685562000001	-1558.815707	0.0	392.0	0.0	392.0	7.06548197481813	4.616230383967583	-0.5341227217119443	6.133923770813187	6.389794121285761	1.5521822648928743	-0.9315582040049435	1.7735637373181783	2.0863049866048184
13722.58cfa831e4b0c9d6adf6c580	58cfa831e4b0c9d6adf6c580	TCGA-BR-4368-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_5_rg.sorted.filtered.	WGS	TCGA-BR-4368-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_5_rg.sorted	TCGA-BR-4368-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_5_rg.sorted.bam	215.2	1.9	0.15	58cfa831e4b0c9d6adf6c580	TCGA-BR-4368-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4368-01A	449BF2BE-B20E-4AD0-9FFB-910D83114018	Primary Tumor	Illumina HiSeq	138fe28f-1055-4872-99b0-71ca92e3494a	Stomach	78.0	87239062-9EA0-4987-AD13-5A2DDED4FF82	1AED45C5-BB15-43D4-9C04-291B7C5B4428	TCGA-BR-4368-01A-01D-1154-02	HG19_Broad_variant	TCGA-BR-4368	TCGA-STAD		s14469	Harvard Medical School	Asterand	Russia	NO	T4	N2	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IV	1154-02	True	STAD	C2	GI.HM-indel	0.347871317	0.58	0.0		0.4377	0.207	0.6736	1.2188	0.6835	0.1964			11.57200703	31.393365600000003	101.0	0.582418146	15.0	1.0	0.894175598	3.704689971	63.0	4.04286865	66.0	0.964964633		-87.01005986	940.5629123	-1326.058734	0.0	0.0	0.0	0.0	6.770024605516058	6.45467431693231	0.1999889857077526	5.426289858814963	5.201911348436942	1.4833245135010644	-1.3437347467010947	-1.252762968495368	1.2833355277933118
13722.58cfa831e4b0c9d6adf6c59a	58cfa831e4b0c9d6adf6c59a	TCGA-CN-4737-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CN-4737-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_4_rg.sorted	TCGA-CN-4737-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_4_rg.sorted.bam	142.0	1.9	0.15	58cfa831e4b0c9d6adf6c59a	TCGA-CN-4737-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4737-01A	1F744ADA-6DE1-446D-B62C-76A7FC8B40AF	Primary Tumor	Illumina HiSeq	db7d0f46-b4eb-4cad-8324-08d0a5781624	Head and Neck	19.0	BA5D40F5-56A2-438B-92B8-6EB7DB6D6AFA	43003723-9C58-4B5E-8F47-56B4BDA476A0	TCGA-CN-4737-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4737	TCGA-HNSC		s15754	Harvard Medical School	University of Pittsburgh	None	NO	T2	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	True	HNSC	C1	HNSC.Mesenchymal	0.20508900300000002	0.49	0.42		0.1664	-0.0165	0.0119	-0.5283	0.3549	0.8768	20.0	84.0	0.41991868	0.923821097	167.0	0.68952435	21.0	19.0		0.0	1.0	2.3025850930000002	10.0	1.0	5.715736014	-476.41956849999997	-155.2280138	-931.122955	0.0	625.0	0.0	625.0	6.022322782113475	8.683421023895887	-1.0671645108990984	5.7991792307992664	8.536817549704011	1.0973408326799132	-0.2231435513142097	-0.1466034741918758	2.1645053435790116
13722.58cfa831e4b0c9d6adf6c59e	58cfa831e4b0c9d6adf6c59e	TCGA-CG-4465-01A-01D-1154_130815_VM001_0005_VMR0005CXX_s_1_rg.sorted.filtered.	WGS	TCGA-CG-4465-01A-01D-1154_130815_VM001_0005_VMR0005CXX_s_1_rg.sorted	TCGA-CG-4465-01A-01D-1154_130815_VM001_0005_VMR0005CXX_s_1_rg.sorted.bam	122.2	1.9	0.13	58cfa831e4b0c9d6adf6c59e	TCGA-CG-4465-01A-01D-1154_130815_VM001_0005_VMR0005CXX_s_1_rg.sorted.bam	Dead	FEMALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4465-01A	C9AB5BF4-092A-420F-9B90-87DEEA58104C	Primary Tumor	Illumina HiSeq	543d167f-2418-4dea-b387-5baa5dc4309f	Stomach	69.0	89DAB798-0B26-470C-82AF-1B23C83FE4F5	2CCE681F-F5C6-496E-96C3-21046ECEAA56	TCGA-CG-4465-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4465	TCGA-STAD	274.0	s14411	Harvard Medical School	Indivumed	Germany	NO	T4	N3	Stomach  Adenocarcinoma  Diffuse Type	Stage IV	1154-02	True	STAD	C2	GI.HM-indel	0.17623664100000003	0.33	0.0	29.27605032	0.7589	0.29600000000000004	0.6851	0.18100000000000002	1.1152	0.0617			4.9842404369999995	16.19157876	141.0	0.003835233	0.0	6.0	0.687502669	2.26589664	27.0	2.7804663689999995	17.0	0.981382632	0.667552416	-227.4378038	874.7101558	191.46167859999997	1.0	274.0	0.0	274.0	8.720827672342221	7.595146797014657	-0.41746045385783914	6.929068203114166	7.264905110144079	1.8087984210072257	-1.7917594692280552	-0.33024168687057687	2.226258874865065
13722.58cfa831e4b0c9d6adf6c5a0	58cfa831e4b0c9d6adf6c5a0	TCGA-CG-4465-01A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CG-4465-01A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_1_rg.sorted	TCGA-CG-4465-01A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_1_rg.sorted.bam	122.2	1.9	0.13	58cfa831e4b0c9d6adf6c5a0	TCGA-CG-4465-01A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_1_rg.sorted.bam	Dead	FEMALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4465-01A	C9AB5BF4-092A-420F-9B90-87DEEA58104C	Primary Tumor	Illumina HiSeq	cb9d270d-5328-46d7-b7ff-cb564fad9175	Stomach	69.0	89DAB798-0B26-470C-82AF-1B23C83FE4F5	2CCE681F-F5C6-496E-96C3-21046ECEAA56	TCGA-CG-4465-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4465	TCGA-STAD	274.0	s14826	Harvard Medical School	Indivumed	Germany	NO	T4	N3	Stomach  Adenocarcinoma  Diffuse Type	Stage IV	1154-02	True	STAD	C2	GI.HM-indel	0.17623664100000003	0.33	0.0	29.27605032	0.7589	0.29600000000000004	0.6851	0.18100000000000002	1.1152	0.0617			4.9842404369999995	16.19157876	141.0	0.003835233	0.0	6.0	0.687502669	2.26589664	27.0	2.7804663689999995	17.0	0.981382632	0.667552416	-227.4378038	874.7101558	191.46167859999997	1.0	274.0	0.0	274.0	8.720827672342221	7.595146797014657	-0.41746045385783914	6.929068203114166	7.264905110144079	1.8087984210072257	-1.7917594692280552	-0.33024168687057687	2.226258874865065
13722.58cfa831e4b0c9d6adf6c5ab	58cfa831e4b0c9d6adf6c5ab	TCGA-CG-4462-01A-01D-1154_130815_VM001_0004_VMR0004CXX_s_7_rg.sorted.filtered.	WGS	TCGA-CG-4462-01A-01D-1154_130815_VM001_0004_VMR0004CXX_s_7_rg.sorted	TCGA-CG-4462-01A-01D-1154_130815_VM001_0004_VMR0004CXX_s_7_rg.sorted.bam	57.2	1.9	0.14	58cfa831e4b0c9d6adf6c5ab	TCGA-CG-4462-01A-01D-1154_130815_VM001_0004_VMR0004CXX_s_7_rg.sorted.bam	Dead	FEMALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4462-01A	E9EA3687-0DB3-47F3-8099-B4FC054397F1	Primary Tumor	Illumina HiSeq	bd5f9f37-7032-427b-a031-8789066620ac	Stomach	72.0	D4F28131-D917-449B-95DC-DC6BA2EEE81B	8CB261D0-2AF0-4D1B-895C-9D7F2404DBDC	TCGA-CG-4462-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4462	TCGA-STAD	0.0	s14700	Harvard Medical School	Indivumed	Germany	NO	T3	N3	Stomach  Adenocarcinoma  Diffuse Type	Stage IV	1154-02	True	STAD	C6	GI.GS	0.5143942539999999	0.78	0.01	5.61534862	-0.4328	-0.209	1.2555	0.4082	-0.4238	0.7675			0.8014774159999999	1.520043375	89.0	0.084762152	4.0	4.0	0.81090806	3.421632807	68.0	3.176082815	26.0	0.974827718		183.57024019999997	-61.86321906	905.9051136	1.0	0.0	1.0	0.0	8.010912778069258	6.921190930813447	0.11992765860528831	6.113792793183377	6.058967420209568	0.5160553704632677	-1.897119984885881	-0.8622235106038794	0.39612771185797935
13722.58cfa831e4b0c9d6adf6c5c2	58cfa831e4b0c9d6adf6c5c2	TCGA-CG-4462-01A-01D-1154_121023_SN208_0437_BD1H3FACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CG-4462-01A-01D-1154_121023_SN208_0437_BD1H3FACXX_s_7_rg.sorted	TCGA-CG-4462-01A-01D-1154_121023_SN208_0437_BD1H3FACXX_s_7_rg.sorted.bam	57.2	1.9	0.14	58cfa831e4b0c9d6adf6c5c2	TCGA-CG-4462-01A-01D-1154_121023_SN208_0437_BD1H3FACXX_s_7_rg.sorted.bam	Dead	FEMALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4462-01A	E9EA3687-0DB3-47F3-8099-B4FC054397F1	Primary Tumor	Illumina HiSeq	1bcd6b3d-eeca-4c1e-bf6f-52c0a6b151ca	Stomach	72.0	D4F28131-D917-449B-95DC-DC6BA2EEE81B	8CB261D0-2AF0-4D1B-895C-9D7F2404DBDC	TCGA-CG-4462-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4462	TCGA-STAD	0.0	s15124	Harvard Medical School	Indivumed	Germany	NO	T3	N3	Stomach  Adenocarcinoma  Diffuse Type	Stage IV	1154-02	True	STAD	C6	GI.GS	0.5143942539999999	0.78	0.01	5.61534862	-0.4328	-0.209	1.2555	0.4082	-0.4238	0.7675			0.8014774159999999	1.520043375	89.0	0.084762152	4.0	4.0	0.81090806	3.421632807	68.0	3.176082815	26.0	0.974827718		183.57024019999997	-61.86321906	905.9051136	1.0	0.0	1.0	0.0	8.010912778069258	6.921190930813447	0.11992765860528831	6.113792793183377	6.058967420209568	0.5160553704632677	-1.897119984885881	-0.8622235106038794	0.39612771185797935
13722.58cfa831e4b0c9d6adf6c5c8	58cfa831e4b0c9d6adf6c5c8	TCGA-CG-4469-01A-01D-1154_130815_VM001_0005_VMR0005CXX_s_7_rg.sorted.filtered.	WGS	TCGA-CG-4469-01A-01D-1154_130815_VM001_0005_VMR0005CXX_s_7_rg.sorted	TCGA-CG-4469-01A-01D-1154_130815_VM001_0005_VMR0005CXX_s_7_rg.sorted.bam	298.2	1.9	0.14	58cfa831e4b0c9d6adf6c5c8	TCGA-CG-4469-01A-01D-1154_130815_VM001_0005_VMR0005CXX_s_7_rg.sorted.bam	Dead	MALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4469-01A	2AC986F6-CD6F-4CA5-90CC-7A105CFE85EA	Primary Tumor	Illumina HiSeq	ed99ca3f-0ae6-43ab-a171-dc2774cf52e2	Stomach	70.0	2A3D7538-D377-4D94-BB61-BF77BA56BE1B	9BAFEA4B-CCC4-4F5D-8BFE-BD13D56741F6	TCGA-CG-4469-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4469	TCGA-STAD	215.0	s14988	Harvard Medical School	Indivumed	Germany	NO	T3	N3	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IV	1154-02	True	STAD	C4	GI.CIN	0.10261728699999999	0.18	0.06	6.545082194	0.7725	0.125	0.428	-0.4999	0.4252	-0.2709			2.212938153	7.6752538470000005	239.0	0.333764723	9.0	16.0				2.547531366	14.0	0.9653186909999999	1.202464902	-434.40125430000006	1168.578851	-309.6982715	1.0	215.0	0.0	215.0	7.525460264375224	6.888277335812466	0.20912463013487903	5.6796335738768935	7.434821042180536	0.6131406726366346	-1.8458266904983305	0.5465437063680696	0.4040160425017556
13722.58cfa831e4b0c9d6adf6c5d8	58cfa831e4b0c9d6adf6c5d8	TCGA-CN-5363-01A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CN-5363-01A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_3_rg.sorted	TCGA-CN-5363-01A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_3_rg.sorted.bam	197.7	1.9	0.15	58cfa831e4b0c9d6adf6c5d8	TCGA-CN-5363-01A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_3_rg.sorted.bam	Dead	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-5363-01A	291B069C-9DDE-4E1E-8430-85146BC94338	Primary Tumor	Illumina HiSeq	624b1e50-b5bd-4a3f-98fd-4514bff3244d	Head and Neck	48.0	5E4E1E21-8016-4E27-8F72-2411714203E8	BEB17091-BD47-4666-8E3A-7A397977EA41	TCGA-CN-5363-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-5363	TCGA-HNSC	253.0	s15891	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N3	Head and Neck Squamous Cell Carcinoma	Stage IVB	1431-02	True	HNSC	C2	HNSC.Mesenchymal	0.35689477299999994	0.49	0.44		1.0687	0.267	0.2578	0.6048	1.6030000000000002	0.7138	86.0	80.0	1.6281356669999998	4.322980908	172.0	0.594092301	10.0	24.0	0.848325897	3.5541926189999997	66.0	2.9412316869999997	20.0	0.981807257	1.7784939240000002	-482.5442933	884.3113896	-1105.547912	1.0	253.0	1.0	53.0	5.799408261217131	6.379384866692961	0.48469359996954087	4.5001252770868705	3.764266722990109	1.930183807123445	-1.2992829841302602	-2.615118143702852	1.4454902071539042
13722.58cfa831e4b0c9d6adf6c5de	58cfa831e4b0c9d6adf6c5de	TCGA-CN-5364-01A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CN-5364-01A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_4_rg.sorted	TCGA-CN-5364-01A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_4_rg.sorted.bam	172.7	1.9	0.14	58cfa831e4b0c9d6adf6c5de	TCGA-CN-5364-01A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_4_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-5364-01A	13F63218-0949-41E6-A661-C844414C45B5	Primary Tumor	Illumina HiSeq	c408c80c-a712-46f0-8945-22511233d2bf	Head and Neck	55.0	38A4AC42-BE08-4187-98C2-AF861218C3DB	6CE3D597-51F1-4807-A28F-271F25F95ED4	TCGA-CN-5364-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-5364	TCGA-HNSC	493.0	s15767	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N2c	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	True	HNSC	C2	HNSC.Atypical	0.319922322	0.57	0.02		1.1440000000000001	0.355	0.1168	-0.4352	1.2543	0.5228	61.0	11.0	0.781836468	3.474828746	144.0	0.18620212600000002	5.0	34.0				2.242973226	11.0	0.935392489	2.9244027160000003	-486.2194165	1513.400816	-1636.989132	1.0	493.0	0.0	493.0	6.261904225581018	8.334646994007855	-1.1942619405965467	5.068801093491985	6.919914697567431	1.001267002590291	-1.1931031320890324	-1.4147322964404236	2.195528943186838
13722.58cfa831e4b0c9d6adf6c5e4	58cfa831e4b0c9d6adf6c5e4	TCGA-CG-4437-01A-01D-1798_130116_SN208_0449_BD1RNWACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CG-4437-01A-01D-1798_130116_SN208_0449_BD1RNWACXX_s_4_rg.sorted	TCGA-CG-4437-01A-01D-1798_130116_SN208_0449_BD1RNWACXX_s_4_rg.sorted.bam	215.4	1.9	0.14	58cfa831e4b0c9d6adf6c5e4	TCGA-CG-4437-01A-01D-1798_130116_SN208_0449_BD1RNWACXX_s_4_rg.sorted.bam	Alive	MALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4437-01A	6244E506-D163-4D34-8FEC-6158191679CB	Primary Tumor	Illumina HiSeq	ff02c427-3a7b-4e29-9ddc-0b8034807ad6	Stomach	83.0	A882F6C0-D12D-4D49-9A2A-3850EA736C37	B6D1C576-6AB8-4759-B1B0-6E18DC162962	TCGA-CG-4437-01A-01D-1798-02	HG19_Broad_variant	TCGA-CG-4437	TCGA-STAD		s14553	Harvard Medical School	Indivumed	Germany	NO	T2	N1	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage II	1798-02	True	STAD	C2	GI.HM-SNV	0.306603055	0.63	0.34		0.5782	0.321	0.6049	1.5435	0.7206	0.3746			4.354794266	13.09360961	233.0	0.400927191	7.0	59.0	0.8643849109999999	5.092648355	362.0	4.434572103	119.0	0.9279048990000001	1.8830313580000002	-660.239071	63.50465782	-1088.103305	0.0	245.0	0.0	245.0	8.02300615324727	8.841857897465554	0.17405550212619147	6.030575988557063	7.414741541825407	1.4063055607392791	-1.9924301646902063	-1.4271163556401456	1.2322500586130878
13722.58cfa831e4b0c9d6adf6c5e7	58cfa831e4b0c9d6adf6c5e7	TCGA-CN-5367-01A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CN-5367-01A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_2_rg.sorted	TCGA-CN-5367-01A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_2_rg.sorted.bam	214.7	1.9	0.15	58cfa831e4b0c9d6adf6c5e7	TCGA-CN-5367-01A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_2_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-5367-01A	61D0709C-D148-413B-A7B5-C0C82ED2F32F	Primary Tumor	Illumina HiSeq	9ab4b634-5191-4a97-b9df-f75528b90bae	Head and Neck	60.0	379F9E65-54F3-4566-B018-3F3EEE6A4DF4	1380173D-316F-4821-8B98-654AD1050A38	TCGA-CN-5367-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-5367	TCGA-HNSC	352.0	s15762	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	True	HNSC	C2	HNSC.Basal	0.280664529	0.45	0.28		0.875	0.29600000000000004	0.1134	-0.5351	1.923	0.5709	28.0	3.0	0.693835973	2.4573357369999997	162.0	0.389412146	8.0	26.0		0.0	1.0	1.791759469	6.0	1.0	3.608180388	-754.1597184	884.5238119999999	-413.4501625	1.0	352.0	0.0	352.0	5.926065440719364	7.0471258404299455	-0.5293871648508433	5.531411248715415	6.214216717494841	0.2761119794668634	-0.3946541920039488	-0.8329091229351042	0.8054991443177066
13722.58cfa831e4b0c9d6adf6c5ed	58cfa831e4b0c9d6adf6c5ed	TCGA-CG-4306-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_3_rg.sorted.filtered.	WGS	TCGA-CG-4306-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_3_rg.sorted	TCGA-CG-4306-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_3_rg.sorted.bam	213.2	1.9	0.14	58cfa831e4b0c9d6adf6c5ed	TCGA-CG-4306-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_3_rg.sorted.bam	Dead	MALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4306-01A	73D177F7-8C0A-42F6-A73D-8073C0E6142B	Primary Tumor	Illumina HiSeq	97a524b1-432a-4c20-adcf-5e45ee168834	Stomach	90.0	78785DB9-C3D5-4C26-BBEF-E741C4AAE429	42E4D7EE-860D-498E-AA00-D2AB42EB4ECA	TCGA-CG-4306-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4306	TCGA-STAD	31.0	s14827	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IV	1154-02	True	STAD	C2	GI.HM-indel	0.269627151	0.49	0.01	20.97238692	0.7353	0.23600000000000002	0.4688	0.8335	0.8201	0.2018			9.276987513	28.05723053	127.0	0.0020943470000000003	0.0	1.0	0.830907391	4.3055822489999995	178.0	2.435829711	18.0	0.8427392440000001	0.496872088	257.196656	706.4809777	500.4917858	1.0	31.0	0.0	31.0	4.488976795267343	6.346074861164498	-0.42305184408191376	5.6828992637397775	6.9785974199080085	0.22264467377829567	1.1939224684724343	0.6325225587435104	0.6456965178602094
13722.58cfa831e4b0c9d6adf6c5f0	58cfa831e4b0c9d6adf6c5f0	TCGA-CG-4440-01A-01D-A326_131002_SN208_0497_AC2CLVACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CG-4440-01A-01D-A326_131002_SN208_0497_AC2CLVACXX_s_5_rg.sorted	TCGA-CG-4440-01A-01D-A326_131002_SN208_0497_AC2CLVACXX_s_5_rg.sorted.bam	126.2	1.9	0.14	58cfa831e4b0c9d6adf6c5f0	TCGA-CG-4440-01A-01D-A326_131002_SN208_0497_AC2CLVACXX_s_5_rg.sorted.bam	Dead	FEMALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4440-01A	8CA597DB-AC21-43D1-9329-586B2EAF6982	Primary Tumor	Illumina HiSeq	d72343ff-91f0-4705-a398-914c5d2344d9	Stomach	68.0	C7B05D36-0386-4B2C-9E8B-2C7502CC4F21	8743D838-FD82-47D4-9BD0-0BAC137FE644	TCGA-CG-4440-01A-01D-A326-26	HG19_Broad_variant	TCGA-CG-4440	TCGA-STAD	122.0	s15397	MD Anderson - Institute for Applied Cancer Science	Indivumed	Germany	NO	T3	N3	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IV	A326-26	True	STAD	C2	GI.CIN	0.297754132	0.5	0.23	3.435134161	1.0257	0.483	0.0147	-0.652	0.8106	0.033			0.708768237	3.28868462	304.0	0.542629137	13.0	30.0	0.958411578	1.052922738	3.0	2.163955657	9.0	0.984858662	0.8790306259999999	-591.4482977000001	379.36925279999997	-1158.553444	1.0	122.0	0.0	122.0	8.654953131120722	7.388637026375055	-0.05110175102633663	6.2570578583223515	6.513168289021156	1.0733184215976457	-2.3978952727983707	-0.8754687373538999	1.1244201726239822
13722.58cfa831e4b0c9d6adf6c5f5	58cfa831e4b0c9d6adf6c5f5	TCGA-CN-5355-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CN-5355-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_7_rg.sorted	TCGA-CN-5355-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_7_rg.sorted.bam	322.7	1.9	0.16	58cfa831e4b0c9d6adf6c5f5	TCGA-CN-5355-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_7_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-5355-01A	45A10908-19E6-421A-8903-1440BFA57C9D	Primary Tumor	Illumina HiSeq	083daa5f-0e79-4402-94b2-48a892a5a4f1	Head and Neck	64.0	63535469-D402-4BA2-9AB5-986E6ED80F55	180BC055-9C10-4B84-80C4-3DF00742719D	TCGA-CN-5355-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-5355	TCGA-HNSC		s15501	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	True	HNSC	C1	HNSC.Basal	0.340318127	0.54	0.23		0.6827	0.242	-0.1836	0.0646	-0.9334	0.8969	63.0	44.0	0.759766011	2.532553371	143.0	0.45597022600000003	7.0	20.0	0.768425245	3.264650997	70.0	2.397895273	11.0	1.0	2.247449994	-399.76467139999994	1193.504864	-1711.745371	0.0	1278.0	0.0	1278.0	7.046688720895656	4.0257230793251075	-0.8907353095368405	6.37763909191477	3.5920776988004626	2.0645845298103755	-0.6690496289808849	-0.43364538052464496	2.955319839347216
13722.58cfa831e4b0c9d6adf6c5fc	58cfa831e4b0c9d6adf6c5fc	TCGA-CN-5369-01A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CN-5369-01A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_3_rg.sorted	TCGA-CN-5369-01A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_3_rg.sorted.bam	345.7	1.9	0.15	58cfa831e4b0c9d6adf6c5fc	TCGA-CN-5369-01A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_3_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-5369-01A	B98867D7-7D5A-4C58-8878-37BEE6F2F4FA	Primary Tumor	Illumina HiSeq	bd85b141-d240-412f-9b74-379c4e3797d2	Head and Neck	90.0	B4C02606-0F86-46E4-9DAF-DC7DBCD60D78	1A532CA9-E72F-4906-867B-272A18CFEC79	TCGA-CN-5369-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-5369	TCGA-HNSC	380.0	s16323	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	True	HNSC	C2	HNSC.Basal	0.614190321	0.82	0.04		0.6046	0.2045	0.7818	1.4788	1.7651	0.6654			3.887193753	10.84933182	39.0	0.000533355	0.0	6.0	0.778906439	4.018421391	174.0	3.5520489860000004	42.0	0.9503378709999999	5.032450141	847.6455707999999	568.1850944	-492.3948618	1.0	380.0	0.0	380.0	2.098759402603468	4.816558467170504	-0.15930400223416363	6.3466592293330635	5.374893024949878	2.433794203578897	4.247899826729595	0.5583345577793741	2.5930982058130607
13722.58cfa831e4b0c9d6adf6c600	58cfa831e4b0c9d6adf6c600	TCGA-CG-4466-01A-01D-1154_130815_VM001_0005_VMR0005CXX_s_4_rg.sorted.filtered.	WGS	TCGA-CG-4466-01A-01D-1154_130815_VM001_0005_VMR0005CXX_s_4_rg.sorted	TCGA-CG-4466-01A-01D-1154_130815_VM001_0005_VMR0005CXX_s_4_rg.sorted.bam	143.3	1.9	0.14	58cfa831e4b0c9d6adf6c600	TCGA-CG-4466-01A-01D-1154_130815_VM001_0005_VMR0005CXX_s_4_rg.sorted.bam	Alive	FEMALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4466-01A	2F1B96B2-7031-4F7D-9490-14728D320F3E	Primary Tumor	Illumina HiSeq	ca26b1dd-13f3-4f26-9cb8-922cb4b53a59	Stomach	81.0	0BC4ABB4-047B-4C8D-9F79-5B9EB32969E9	623D5E6A-A5D3-4580-BEF7-04673D42A1D0	TCGA-CG-4466-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4466	TCGA-STAD		s14760	Harvard Medical School	Indivumed	Germany	NO	T2a	N0	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1154-02	True	STAD	C1	GI.CIN	0.050863472	0.21	0.18	2.1445793330000003	1.1401	0.326	-0.4742	-0.8054	-0.2431	-0.1598			1.627411752	4.882235255	397.0	0.757757846	13.0	25.0	0.81003232	1.45138308	6.0	1.7351264569999998	6.0	0.968392514	0.882634356	-454.39976210000003	964.1836619999999	-2351.812276	0.0	577.0	0.0	577.0	7.042359013109605	3.701853746331694	-0.9554120134445694	6.3917714469684555	5.903795313546053	0.3436500250374219	-0.6505875661411493	2.2019415672143587	1.2990620384819913
13722.58cfa831e4b0c9d6adf6c602	58cfa831e4b0c9d6adf6c602	TCGA-CQ-6225-01A-11D-1911_120504_SN208_0296_AC0V09ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CQ-6225-01A-11D-1911_120504_SN208_0296_AC0V09ACXX_s_1_rg.sorted	TCGA-CQ-6225-01A-11D-1911_120504_SN208_0296_AC0V09ACXX_s_1_rg.sorted.bam	191.7	1.9	0.15	58cfa831e4b0c9d6adf6c602	TCGA-CQ-6225-01A-11D-1911_120504_SN208_0296_AC0V09ACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-6225-01A	90F44998-3C05-44B2-9501-BBD0F43C5147	Primary Tumor	Illumina HiSeq	a96392ab-a0d3-4c22-a2e2-08b58bb3e61b	Head and Neck	65.0	E907D8D4-C4C6-441F-9F19-FF3746E5D13E	40BFD664-E699-4F0D-9670-30D0F5CC8728	TCGA-CQ-6225-01A-11D-1911-02	HG19_Broad_variant	TCGA-CQ-6225	TCGA-HNSC	403.0	s16186	Harvard Medical School	University Health Network, Toronto	Canada	NO	T3	N0	Head and Neck Squamous Cell Carcinoma	Stage III	1911-02	True	HNSC	C1	HNSC.Atypical	0.036727829	0.19	0.27		0.7371	0.266	-1.0462	-1.2668	-1.3824	-0.1584	57.0	26.0	1.390242865	3.656943187	134.0	0.780240258	23.0	39.0				0.0	1.0		6.253781545	-1182.453222	67.22277986	-1844.892143	1.0	403.0	1.0	180.0	6.95316978866555	7.666136761295444	-1.1223825080020216	6.714758765220552	7.119593054927375	0.1779130265091886	-0.2384110234449981	-0.5465437063680696	1.3002955345112102
13722.58cfa831e4b0c9d6adf6c604	58cfa831e4b0c9d6adf6c604	TCGA-CQ-5330-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CQ-5330-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_4_rg.sorted	TCGA-CQ-5330-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_4_rg.sorted.bam	258.0	1.9	0.14	58cfa831e4b0c9d6adf6c604	TCGA-CQ-5330-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-5330-01A	9FFA79FA-D2D8-48E1-8FD6-4B020ECF357C	Primary Tumor	Illumina HiSeq	a37f15ec-e0df-4bcd-8275-88312d0a1566	Head and Neck	69.0	A70301B0-F66D-49B7-B420-C1F56B90002D	AB6DC814-ECE0-497C-BC58-5FECE5D3DCE6	TCGA-CQ-5330-01A-01D-1681-02	HG19_Broad_variant	TCGA-CQ-5330	TCGA-HNSC		s15640	Harvard Medical School	University Health Network, Toronto	Canada	NO	T3	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	True	HNSC	C2	HNSC.Mesenchymal	0.247757229	0.47	0.3		0.669	0.185	0.7777	0.4934	1.8386	0.9057	22.0	1.0	0.515102549	1.5150074980000001	81.0	0.296895208	10.0	13.0		0.0	1.0	3.312615877	29.0	0.9837614640000001	1.941172942	-208.3115908	258.03212909999996	-1107.1596220000001	0.0	1897.0	0.0	1897.0	6.0744172179123765	6.753671263599422	0.024975283576077256	5.777165694444444	7.159136371707586	2.5236752554964133	-0.2972515234679318	0.40546510810816416	2.498699971920336
13722.58cfa831e4b0c9d6adf6c605	58cfa831e4b0c9d6adf6c605	TCGA-CQ-5329-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CQ-5329-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_3_rg.sorted	TCGA-CQ-5329-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_3_rg.sorted.bam	687.0	1.9	0.14	58cfa831e4b0c9d6adf6c605	TCGA-CQ-5329-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-5329-01A	02DCC11F-4F0E-4C9E-8D96-D22D47BEEF5D	Primary Tumor	Illumina HiSeq	b54a3eac-9c58-453d-9db1-395601ae82ea	Head and Neck	46.0	D22E9B65-495B-4D42-926A-01BF2C436D76	63CE8A9C-2CC5-41D9-B24D-3FB88343B693	TCGA-CQ-5329-01A-01D-1681-02	HG19_Broad_variant	TCGA-CQ-5329	TCGA-HNSC		s15772	Harvard Medical School	University Health Network, Toronto	Canada	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	1681-02	True	HNSC	C2	HNSC.Mesenchymal	0.25039570699999997	0.42	0.02		0.8445	0.2985	0.4236	0.3291	1.4689	0.6177	18.0	101.0	0.2116683	0.846673199	131.0	0.922496238	13.0	20.0	0.929709535	2.634065459	17.0	2.912494403	19.0	0.9891508790000001	1.125776214	-879.5536225999999	659.5954802	-2251.450566	0.0	2143.0	0.0	2143.0	5.747631462154516	4.006949036836712	-0.48091778942641406	5.122537744839586	7.458824444282424	2.0742424603285734	-0.6250937173149298	3.451875407445712	2.5551602497549877
13722.58cfa831e4b0c9d6adf6c608	58cfa831e4b0c9d6adf6c608	TCGA-CN-5365-01A-01D-2276-10_Illumina.filtered.	WGS	TCGA-CN-5365-01A-01D-2276-10_Illumina	TCGA-CN-5365-01A-01D-2276-10_Illumina.bam	305.73	1.9	0.05	58cfa831e4b0c9d6adf6c608	TCGA-CN-5365-01A-01D-2276-10_Illumina.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-5365-01A	4CFFEA0B-90A7-4C86-A73F-BB8FECA3ADA7	Primary Tumor	Illumina HiSeq	84352351-1bc3-4c62-93be-29c899ff9811	Head and Neck	38.0	665D4BFF-603C-497B-816F-C98784665D0F	A0FE80E0-E3AC-485B-8A1A-4C80C101B874	TCGA-CN-5365-01A-01D-2276-10	GRCh37-lite	TCGA-CN-5365	TCGA-HNSC	351.0	s16033	Baylor College of Medicine	University of Pittsburgh	None	NO	T2	N3	Head and Neck Squamous Cell Carcinoma	Stage IVB	2276-10	True	HNSC	C2	HNSC.Basal	0.368644003	0.0	0.38		0.9458	0.34299999999999997	0.1343	-0.0721	1.5569	0.263	42.0	71.0	0.515183665	1.8317641409999998	120.0	0.27227104399999996	5.0	18.0				2.425479708	13.0	0.9456247940000001	4.978064847	-561.860665	525.4380316	-1522.440727	1.0	351.0	1.0	351.0	1.236675384974662	2.8755155085293627	0.8518763495239075	5.802480847440476	5.041350298343437	0.5807410372762902	4.565805462465814	2.165834789814074	-0.2711353122476172
13722.58cfa831e4b0c9d6adf6c60a	58cfa831e4b0c9d6adf6c60a	TCGA-CQ-6220-01A-11D-1911_120504_SN1222_0102_BC0VHDACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CQ-6220-01A-11D-1911_120504_SN1222_0102_BC0VHDACXX_s_1_rg.sorted	TCGA-CQ-6220-01A-11D-1911_120504_SN1222_0102_BC0VHDACXX_s_1_rg.sorted.bam	342.7	1.9	0.15	58cfa831e4b0c9d6adf6c60a	TCGA-CQ-6220-01A-11D-1911_120504_SN1222_0102_BC0VHDACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-6220-01A	96D0CEFE-7949-4736-A7DC-1E4FA94765EC	Primary Tumor	Illumina HiSeq	d86390d3-24c6-4e56-9b8a-d6b3ec75c989	Head and Neck	69.0	E0E75203-3982-40B2-A057-FAA8433DFB7A	C7EABDCF-81F2-4C87-946A-B5BA42056B04	TCGA-CQ-6220-01A-11D-1911-02	HG19_Broad_variant	TCGA-CQ-6220	TCGA-HNSC	985.0	s16037	Harvard Medical School	University Health Network, Toronto	Canada	NO	T3	N0	Head and Neck Squamous Cell Carcinoma	Stage III	1911-02	True	HNSC	C2	HNSC.Basal	0.37243429100000003	0.61	0.22		0.5965	0.2075	-0.3718	-0.2304	1.6865	0.2997	42.0		0.9361710120000001	2.69149166	83.0	0.556715454	12.0	14.0				1.5607104090000001	5.0	0.9697239	3.3095722039999997	36.72960458	576.7089665	-1223.533999	1.0	985.0	0.0	985.0	6.290491901492283	4.514218024483562	0.014367138946715263	5.908557290794312	5.839412726962732	1.9444209455038455	-0.3819346106979702	1.3251947024791697	1.93005380655713
13722.58cfa831e4b0c9d6adf6c60c	58cfa831e4b0c9d6adf6c60c	TCGA-CN-5360-01A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CN-5360-01A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_1_rg.sorted	TCGA-CN-5360-01A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_1_rg.sorted.bam	449.7	1.9	0.15	58cfa831e4b0c9d6adf6c60c	TCGA-CN-5360-01A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-5360-01A	5793879B-F663-4A10-9BD9-1ACD2E189650	Primary Tumor	Illumina HiSeq	56414402-7420-42b7-a93d-3d1f88308155	Head and Neck	68.0	0C00768E-8B13-4B8E-80FC-B344740845F1	7EE362C2-86AD-462C-B478-21255D96ED90	TCGA-CN-5360-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-5360	TCGA-HNSC		s15883	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	True	HNSC	C2	HNSC.Atypical	0.33935715299999997	0.47	0.08		0.1374	-0.081	0.8711	1.6744	0.895	0.5654	241.0	91.0	4.012999093	13.26034483	92.0	0.944428505	17.0	25.0	0.83552836	4.443440075	204.0	2.9383714110000003	47.0	0.7631840940000001	3.361173743	-179.3283607	149.3161219	811.7028737	0.0	2169.0	0.0	2169.0	6.025133748560117	4.835951581577984	-0.3149578352316601	4.812111108714263	7.253800817208929	3.5476998406511573	-1.2130226398458537	2.4178492356309453	3.8626576758828173
13722.58cfa831e4b0c9d6adf6c60e	58cfa831e4b0c9d6adf6c60e	TCGA-CQ-6219-01A-11D-1911_120504_SN1222_0101_AC0UMDACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CQ-6219-01A-11D-1911_120504_SN1222_0101_AC0UMDACXX_s_7_rg.sorted	TCGA-CQ-6219-01A-11D-1911_120504_SN1222_0101_AC0UMDACXX_s_7_rg.sorted.bam	187.7	1.9	0.16	58cfa831e4b0c9d6adf6c60e	TCGA-CQ-6219-01A-11D-1911_120504_SN1222_0101_AC0UMDACXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-6219-01A	0CA3D25A-22E9-4E40-834B-65F402535005	Primary Tumor	Illumina HiSeq	e1a5a3ec-64d9-4348-8104-4f08021e914e	Head and Neck	50.0	2AAD293C-B3ED-4BD7-971D-EA8A5EFC66AD	215B7B8C-E4D0-4CD2-B2B8-9CDC222EBF25	TCGA-CQ-6219-01A-11D-1911-02	HG19_Broad_variant	TCGA-CQ-6219	TCGA-HNSC	479.0	s15632	Harvard Medical School	University Health Network, Toronto	Canada	NO	T3	N2a	Head and Neck Squamous Cell Carcinoma	Stage IVA	1911-02	True	HNSC	C2		0.47804413799999995				0.8381	0.3355	0.6667	0.6431	1.9937	0.5355	31.0	0.0	0.561006488	1.7420727790000001								3.675417957	47.0	0.954617417	2.201964095	-45.54292834	527.6820526	-1949.994316	1.0	479.0	1.0	195.0	6.184835940088521	7.3792161792258515	-0.0794067776044105	5.424549456690947	6.33776230439769	1.2770217908887926	-0.7602864833975742	-1.0414538748281612	1.356428568493203
13722.58cfa831e4b0c9d6adf6c612	58cfa831e4b0c9d6adf6c612	TCGA-CQ-6228-01A-11D-A32X-10_wgs_Illumina.filtered.	WGS	TCGA-CQ-6228-01A-11D-A32X-10_wgs_Illumina	TCGA-CQ-6228-01A-11D-A32X-10_wgs_Illumina.bam	338.7	1.9	0.07	58cfa831e4b0c9d6adf6c612	TCGA-CQ-6228-01A-11D-A32X-10_wgs_Illumina.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-6228-01A	E303B8C4-6428-4134-BB9D-A95DC1D8E35E	Primary Tumor	Illumina HiSeq	c8e6d97c-8cc3-45f6-99a2-d20b8bc3b2d6	Head and Neck	71.0	62E8F535-CF5E-4F90-AFCD-1E0136066820	C2124BB2-30E1-4093-9A8A-3A188A6DC0A9	TCGA-CQ-6228-01A-11D-A32X-10	GRCh37-lite	TCGA-CQ-6228	TCGA-HNSC	456.0	s15634	Baylor College of Medicine	University Health Network, Toronto	Canada	NO	T1	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	A32X-10	True	HNSC	C2	HNSC.Classical	0.073580566	0.15	0.16		0.5296	0.2125	-0.3498	-0.1851	0.5828	0.3404	56.0	3.0	0.50841453	2.871046756	187.0	0.466418382	8.0	37.0	0.927822488	3.467893925	42.0	1.609437912	5.0	1.0	2.48430608	-1279.8906279999999	-160.47259119999998	-3010.610088	1.0	456.0	1.0	273.0	7.551011689928617	2.8454564297849094	-0.7061589757670688	5.317419468421523	2.048479316075869	1.2397511732882442	-2.2335922215070942	-0.7969771137090405	1.945910149055313
13722.58cfa831e4b0c9d6adf6c619	58cfa831e4b0c9d6adf6c619	TCGA-CN-5356-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CN-5356-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_8_rg.sorted	TCGA-CN-5356-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_8_rg.sorted.bam	301.7	1.9	0.15	58cfa831e4b0c9d6adf6c619	TCGA-CN-5356-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-5356-01A	E1FED7AA-2BCE-45AE-B0C6-7F50EF97E425	Primary Tumor	Illumina HiSeq	c8e59618-fd16-4e8e-abe2-e3d5d674390c	Head and Neck	56.0	BCB5DA85-78D6-4519-9740-378587B1BD37	199B42E1-301A-49AD-A364-BBF4FAD8B049	TCGA-CN-5356-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-5356	TCGA-HNSC		s15885	Harvard Medical School	University of Pittsburgh	None	NO	T3	N0	Head and Neck Squamous Cell Carcinoma	Stage III	1431-02	True	HNSC	C1	HNSC.Mesenchymal	0.306051461	0.63	0.23		0.5482	0.15	-0.1873	0.4618	-0.42200000000000004	0.6687	141.0	16.0	2.7572088580000003	8.783273577000001	148.0	0.66696024	20.0	26.0	0.9122445570000001	4.191873072	99.0	2.63905733	14.0	1.0	6.011473725	-523.0508267	618.0313357000001	-1392.2674880000002	0.0	1409.0	0.0	1409.0	6.596842487815196	4.869224800020816	0.32406146776633615	5.823652599581714	2.350346599734358	1.7132555277678834	-0.7731898882334818	-2.5188782002864576	1.3891940600015473
13722.58cfa831e4b0c9d6adf6c61a	58cfa831e4b0c9d6adf6c61a	TCGA-CG-4305-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_1_rg.sorted.filtered.	WGS	TCGA-CG-4305-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_1_rg.sorted	TCGA-CG-4305-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_1_rg.sorted.bam	264.2	1.9	0.13	58cfa831e4b0c9d6adf6c61a	TCGA-CG-4305-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_1_rg.sorted.bam	Alive	MALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4305-01A	E0E35051-FBB4-4389-AEDB-87BDE84D21AD	Primary Tumor	Illumina HiSeq	dad3a237-d784-4731-bbef-c4d3dce49fa2	Stomach	69.0	6B64B4A0-EDC8-4DC3-B527-D320DED81351	A01B1633-2A30-4379-80AC-72799C14B5C7	TCGA-CG-4305-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4305	TCGA-STAD		s14981	Harvard Medical School	Indivumed	Germany	NO	T2a	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage II	1154-02	True	STAD	C2	GI.HM-indel	0.302141155	0.61	0.0	9.458509142	0.6168	0.165	0.8824	1.3376	-0.1459	0.3689			9.951876226	30.05638699	101.0	0.19794267399999999	7.0	1.0	0.922208308	3.304750936	36.0	2.9678674689999998	22.0	0.9601509890000001	0.992447937	-399.1775165	703.9467761	-2030.7608649999997	0.0	485.0	1.0	457.0	8.629628620746026	8.756255085250224	0.05993234072267373	6.637198456055819	7.566671018376388	1.6671103651893364	-1.9924301646902063	-1.1895840668738364	1.6071780244666627
13722.58cfa831e4b0c9d6adf6c61f	58cfa831e4b0c9d6adf6c61f	TCGA-CG-4436-01A-01D-1154_130815_VM001_0003_VMR0003CXX_s_5_rg.sorted.filtered.	WGS	TCGA-CG-4436-01A-01D-1154_130815_VM001_0003_VMR0003CXX_s_5_rg.sorted	TCGA-CG-4436-01A-01D-1154_130815_VM001_0003_VMR0003CXX_s_5_rg.sorted.bam	336.2	1.9	0.13	58cfa831e4b0c9d6adf6c61f	TCGA-CG-4436-01A-01D-1154_130815_VM001_0003_VMR0003CXX_s_5_rg.sorted.bam	Alive	MALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4436-01A	7938CA55-766E-4277-9E7E-603FFA02E570	Primary Tumor	Illumina HiSeq	0b869c68-28bb-4675-ba6c-6d20a89a1a49	Stomach	57.0	21F40CF9-D89F-4FEC-BE65-1740AB39DAE4	9215C180-AC30-4585-9AF3-4EF1D718E187	TCGA-CG-4436-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4436	TCGA-STAD		s14980	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1154-02	True	STAD	C2	GI.CIN	0.26261597	0.36	0.69	0.563454682	0.997	0.375	0.0467	-0.2086	-0.1851	-0.4196			1.412282785	4.179204159	120.0	0.820934718	14.0	31.0	0.839581008	2.426701233	18.0	2.5245459219999997	14.0	0.9566089729999999	0.294201369	-145.26003909999997	607.2352043	-75.46478674	0.0	243.0	0.0	243.0	7.697575346802343	6.256330739869792	-0.6985275873844206	5.705145182112137	5.624219449896216	-0.26597647034708194	-1.9924301646902063	-0.6321112899735759	0.4325511170373386
13722.58cfa831e4b0c9d6adf6c62c	58cfa831e4b0c9d6adf6c62c	TCGA-CG-4301-01A-01D-A326_131002_SN208_0497_AC2CLVACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CG-4301-01A-01D-A326_131002_SN208_0497_AC2CLVACXX_s_1_rg.sorted	TCGA-CG-4301-01A-01D-A326_131002_SN208_0497_AC2CLVACXX_s_1_rg.sorted.bam	84.9	1.9	0.15	58cfa831e4b0c9d6adf6c62c	TCGA-CG-4301-01A-01D-A326_131002_SN208_0497_AC2CLVACXX_s_1_rg.sorted.bam	Alive	FEMALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4301-01A	7E13FE2A-3D6E-487F-900D-F5891D986AA2	Primary Tumor	Illumina HiSeq	7d1cd13f-5ac5-457f-8e7b-89cabb2463c6	Stomach	75.0	F8CCC777-65A2-41FA-95AC-AB33C3E9AD9A	55F814EC-D386-4277-8CF1-245313CF373D	TCGA-CG-4301-01A-01D-A326-26	HG19_Broad_variant	TCGA-CG-4301	TCGA-STAD		s15456	MD Anderson - Institute for Applied Cancer Science	Indivumed	Germany	NO	T4	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IV	A326-26	True	STAD	C2	GI.CIN	0.146443257	0.58	0.03	0.241050982	0.0209	0.11699999999999999	0.6248	0.2101	0.5342	0.299			0.43669370700000004	1.2809682070000001	285.0	0.423045736	7.0	52.0	0.956940305	2.1026127580000002	9.0	3.19669541	27.0	0.9699191859999999	1.005165179	38.6344386	103.64299609999999	-1645.1530890000001	0.0	92.0	0.0	92.0	6.299080540757529	6.870053411798126	0.07499075561162627	6.047766112476624	6.282266746896007	2.4659685775663087	-0.2513144282809061	-0.5877866649021186	2.3909778219546824
13722.58cfa831e4b0c9d6adf6c630	58cfa831e4b0c9d6adf6c630	TCGA-CN-4737-01A-01D-2266-10_Illumina.filtered.	WGS	TCGA-CN-4737-01A-01D-2266-10_Illumina	TCGA-CN-4737-01A-01D-2266-10_Illumina.bam	142.0	1.9	0.05	58cfa831e4b0c9d6adf6c630	TCGA-CN-4737-01A-01D-2266-10_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4737-01A	1F744ADA-6DE1-446D-B62C-76A7FC8B40AF	Primary Tumor	Illumina HiSeq	cd1138ab-45a7-4da9-a78d-142e2e75f255	Head and Neck	19.0	BA5D40F5-56A2-438B-92B8-6EB7DB6D6AFA	878A7FE7-20FF-4651-9587-B4D6FD42E929	TCGA-CN-4737-01A-01D-2266-10	GRCh37-lite	TCGA-CN-4737	TCGA-HNSC		s16030	Baylor College of Medicine	University of Pittsburgh	None	NO	T2	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	2266-10	True	HNSC	C1	HNSC.Mesenchymal	0.20508900300000002	0.49	0.42		0.1664	-0.0165	0.0119	-0.5283	0.3549	0.8768	20.0	84.0	0.41991868	0.923821097	167.0	0.68952435	21.0	19.0		0.0	1.0	2.3025850930000002	10.0	1.0	5.715736014	-476.41956849999997	-155.2280138	-931.122955	0.0	625.0	0.0	625.0	7.411103012892168	2.4635042172197625	-1.0671645108990984	5.907025616115894	5.587653475731959	1.0973408326799132	-1.5040773967762742	3.1241492585121966	2.1645053435790116
13722.58cfa831e4b0c9d6adf6c632	58cfa831e4b0c9d6adf6c632	TCGA-CG-4441-01A-01D-1798_130214_SN1120_0236_AC1RPCACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CG-4441-01A-01D-1798_130214_SN1120_0236_AC1RPCACXX_s_1_rg.sorted	TCGA-CG-4441-01A-01D-1798_130214_SN1120_0236_AC1RPCACXX_s_1_rg.sorted.bam	250.0	1.9	0.15	58cfa831e4b0c9d6adf6c632	TCGA-CG-4441-01A-01D-1798_130214_SN1120_0236_AC1RPCACXX_s_1_rg.sorted.bam	Dead	MALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4441-01A	37E22429-EFD7-4D6A-B79A-9D8C7BE2170C	Primary Tumor	Illumina HiSeq	d3542e45-2b25-406d-976d-5d4c63e4839e	Stomach	83.0	60937697-57BA-4D03-9545-B0E321215448	DE856FF9-FEF4-4AA8-9418-F29EB79932B0	TCGA-CG-4441-01A-01D-1798-02	HG19_Broad_variant	TCGA-CG-4441	TCGA-STAD	426.0	s14699	Harvard Medical School	Indivumed	Germany	NO	T2	N2	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIIA	1798-02	True	STAD	C1	GI.GS	0.25542149199999997	0.37	0.06	0.260570887	0.7077	0.1675	0.2619	0.2193	0.0917	0.6079			1.063878423	2.571039521	1321.0	0.136878126	4.0	3.0	0.889018814	5.857679602999999	727.0	3.7372821519999997	114.0	0.789089011	2.162531634	-760.0618736	551.1479312000001	352.6052188	1.0	426.0	0.0	426.0	7.949973567454082	7.5985839844809835	-0.27798827683513416	5.552078294655711	7.652651205751259	0.87711212309763	-2.3978952727983707	0.054067221270275745	1.1551003999327643
13722.58cfa831e4b0c9d6adf6c634	58cfa831e4b0c9d6adf6c634	TCGA-CN-5361-01A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CN-5361-01A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_2_rg.sorted	TCGA-CN-5361-01A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_2_rg.sorted.bam	225.7	1.9	0.15	58cfa831e4b0c9d6adf6c634	TCGA-CN-5361-01A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-5361-01A	044579EF-16A6-4F00-B951-EDC423D8A14F	Primary Tumor	Illumina HiSeq	490cddf8-816a-45f5-acbf-3fd898eb3479	Head and Neck	80.0	C807171A-4433-4246-A454-C5CF768DA8AA	A4E6D494-865F-4F60-B9C6-13C9C0CEA6AB	TCGA-CN-5361-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-5361	TCGA-HNSC		s16184	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N2a	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	True	HNSC	C2		0.22212588800000002				0.4995	0.0775	-0.0477	-0.4154	1.2968	0.8824	41.0	21.0	1.352118504	2.4225456519999997								2.397895273	11.0	1.0	4.904462271	-365.48560739999994	239.88489330000002	-397.1555517	1.0	2120.0	1.0	2062.0	5.846596408455313	5.087070849145673	-0.47625101132116854	4.724030878764711	5.834876442243482	2.302585092994046	-1.1225655296906023	0.7478055930978096	2.7788361043152143
13722.58cfa831e4b0c9d6adf6c63a	58cfa831e4b0c9d6adf6c63a	TCGA-CG-4304-01A-01D-A326_131002_SN208_0497_AC2CLVACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CG-4304-01A-01D-A326_131002_SN208_0497_AC2CLVACXX_s_3_rg.sorted	TCGA-CG-4304-01A-01D-A326_131002_SN208_0497_AC2CLVACXX_s_3_rg.sorted.bam	286.2	1.9	0.16	58cfa831e4b0c9d6adf6c63a	TCGA-CG-4304-01A-01D-A326_131002_SN208_0497_AC2CLVACXX_s_3_rg.sorted.bam	Alive	MALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4304-01A	8E005891-D6FE-4FEE-A699-971FEE4E70F1	Primary Tumor	Illumina HiSeq	4fbdbad3-32cb-45de-990a-1337f32a25fa	Stomach	84.0	CC852701-8996-4C8B-828D-5C4AC1F4CFD4	46FB2601-D210-4528-B7D9-BE054DD54BFD	TCGA-CG-4304-01A-01D-A326-26	HG19_Broad_variant	TCGA-CG-4304	TCGA-STAD		s14549	MD Anderson - Institute for Applied Cancer Science	Indivumed	Germany	NO	T2a	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	A326-26	True	STAD	C6	GI.CIN	0.227014845	0.42	0.04	4.324852861	0.18899999999999997	0.003	0.7487	1.1934	-0.2548	0.2424			0.7834237609999999	1.454929841	304.0	0.228357318	5.0	28.0	0.806873026	4.813922873	390.0	3.464739808	36.0	0.9668540529999999		-88.83905495	-178.760548	1882.9499219999998	0.0		0.0		8.93971205409023	8.713779192223896	0.040747225369971884	6.637126961096184	8.020632011663952	1.261210391595323	-2.3025850929940455	-0.693147180559945	1.2204631662253511
13722.58cfa831e4b0c9d6adf6c640	58cfa831e4b0c9d6adf6c640	TCGA-CG-4466-01A-01D-1154_121212_SN1120_0205_AC1F18ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CG-4466-01A-01D-1154_121212_SN1120_0205_AC1F18ACXX_s_1_rg.sorted	TCGA-CG-4466-01A-01D-1154_121212_SN1120_0205_AC1F18ACXX_s_1_rg.sorted.bam	143.3	1.9	0.14	58cfa831e4b0c9d6adf6c640	TCGA-CG-4466-01A-01D-1154_121212_SN1120_0205_AC1F18ACXX_s_1_rg.sorted.bam	Alive	FEMALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4466-01A	2F1B96B2-7031-4F7D-9490-14728D320F3E	Primary Tumor	Illumina HiSeq	a8cb52d3-64c6-4fca-a59c-b177968a7489	Stomach	81.0	0BC4ABB4-047B-4C8D-9F79-5B9EB32969E9	623D5E6A-A5D3-4580-BEF7-04673D42A1D0	TCGA-CG-4466-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4466	TCGA-STAD		s14987	Harvard Medical School	Indivumed	Germany	NO	T2a	N0	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1154-02	True	STAD	C1	GI.CIN	0.050863472	0.21	0.18	2.1445793330000003	1.1401	0.326	-0.4742	-0.8054	-0.2431	-0.1598			1.627411752	4.882235255	397.0	0.757757846	13.0	25.0	0.81003232	1.45138308	6.0	1.7351264569999998	6.0	0.968392514	0.882634356	-454.39976210000003	964.1836619999999	-2351.812276	0.0	577.0	0.0	577.0	7.042359013109605	3.701853746331694	-0.9554120134445694	6.3917714469684555	5.903795313546053	0.3436500250374219	-0.6505875661411493	2.2019415672143587	1.2990620384819913
13722.58cfa831e4b0c9d6adf6c642	58cfa831e4b0c9d6adf6c642	TCGA-CN-4734-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CN-4734-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_1_rg.sorted	TCGA-CN-4734-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_1_rg.sorted.bam	72.7	1.9	0.15	58cfa831e4b0c9d6adf6c642	TCGA-CN-4734-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4734-01A	B80FDC9A-341D-4277-9664-8E8F770D9DDD	Primary Tumor	Illumina HiSeq	4b3be461-622d-492e-8465-1d0d1167701c	Head and Neck	70.0	20614787-1E55-40F0-88DE-080640EB8A03	EA9125C8-3F3B-47CE-AD79-802692B1FB4A	TCGA-CN-4734-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4734	TCGA-HNSC		s15759	Harvard Medical School	University of Pittsburgh	None	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	1431-02	True	HNSC	C2		0.33608055200000003				0.6733	0.1655	0.409	0.5403	1.9942	0.5966	64.0	34.0	1.359190036	3.39797509					0.840891843	2.219161783	14.0	3.3866416480000003	43.0	0.900415172	1.6863142919999998	121.5823997	572.5046332000001	-986.6573591	0.0	1690.0	0.0	1690.0	2.0661269955038346	4.061071063793209	-0.3107845990731237	6.064327697173033	3.723106188316944	2.1030904425380763	3.9982007016691985	-0.3379648754762652	2.4138750416112003
13722.58cfa831e4b0c9d6adf6c646	58cfa831e4b0c9d6adf6c646	TCGA-CQ-5327-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CQ-5327-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_2_rg.sorted	TCGA-CQ-5327-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_2_rg.sorted.bam	234.0	1.9	0.15	58cfa831e4b0c9d6adf6c646	TCGA-CQ-5327-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_2_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-5327-01A	5A03E2B6-4C8B-479A-9036-9859AF031DA4	Primary Tumor	Illumina HiSeq	3482a15d-acdc-4fcf-86a5-b015e57faefd	Head and Neck	61.0	93D283A7-E866-4F23-81F7-942DEE5009B8	55F0F300-E472-4254-9BDA-76AD94EA8C13	TCGA-CQ-5327-01A-01D-1681-02	HG19_Broad_variant	TCGA-CQ-5327	TCGA-HNSC		s15638	Harvard Medical School	University Health Network, Toronto	Canada	NO	T3	N2c	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	True	HNSC	C2		0.413350968	0.55	0.08		0.7015	0.2575	0.6098	0.9505	1.6079	0.2013	115.0	14.0	1.938046555	5.784323565	89.0	0.026534598	0.0	3.0	0.447064654	0.309881604	2.0	2.397698626	14.0	0.908543592	2.24019488	121.89861029999999	483.1813996	-1347.199833	0.0	1660.0	0.0	1660.0	6.052738045579513	4.277372497152577	0.5425256195959232	5.089300535279657	6.157100739326589	2.3403641349003603	-0.9634375102998569	1.8797282421740125	1.7978385153044372
13722.58cfa831e4b0c9d6adf6c64e	58cfa831e4b0c9d6adf6c64e	TCGA-CN-4741-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CN-4741-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_6_rg.sorted	TCGA-CN-4741-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_6_rg.sorted.bam	215.7	1.9	0.14	58cfa831e4b0c9d6adf6c64e	TCGA-CN-4741-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4741-01A	277B02E9-DED5-4980-845D-AF53690000AC	Primary Tumor	Illumina HiSeq	cd19ee2f-be9d-446a-9045-e7bfcafb49aa	Head and Neck	75.0	03C9108A-5139-4BAC-9641-C7DBBEDEF420	FAA30C0B-E008-4313-A2AB-1D641F98E2B9	TCGA-CN-4741-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4741	TCGA-HNSC		s15760	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	True	HNSC	C2	HNSC.Atypical	0.111519301	0.36	0.08		0.9954	0.20199999999999999	-0.3067	0.2232	0.43799999999999994	0.309	63.0		1.053424809	2.704739375	93.0	0.154349113	4.0	11.0	0.8551368970000001	2.256755296	14.0	3.3071040560000005	29.0	0.9821245959999999	2.755704251	-397.27783230000006	836.6668997	-2034.4044800000001	0.0	2239.0	1.0	1716.0	6.617402977974477	3.9925290151296497	-0.351258033468539	6.115311034177241	7.831513710225545	0.7265180609239799	-0.502091943797236	3.8389846950958955	1.0777760943925188
13722.58cfa831e4b0c9d6adf6c651	58cfa831e4b0c9d6adf6c651	TCGA-CN-4736-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CN-4736-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_3_rg.sorted	TCGA-CN-4736-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_3_rg.sorted.bam	52.7	1.9	0.15	58cfa831e4b0c9d6adf6c651	TCGA-CN-4736-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_3_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4736-01A	0FB3E5FF-54F0-43C5-9322-541BB7825E7F	Primary Tumor	Illumina HiSeq	45c5cea2-56a4-43af-9c53-19302867f2d9	Head and Neck	70.0	6DB0B6EE-23B3-43BF-8AA9-FDF641AFC673	8141905F-DE66-4DB2-A9F9-5819C953A465	TCGA-CN-4736-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4736	TCGA-HNSC	395.0	s15881	Harvard Medical School	University of Pittsburgh	None	NO	T1	NX	Head and Neck Squamous Cell Carcinoma		1431-02	True	HNSC	C2	HNSC.Mesenchymal	0.41785554799999997	0.66	0.26		0.1974	0.0755	0.8266	0.8635	2.2061	0.7094	31.0	21.0	0.495578839	2.419590803	143.0	0.346544355	4.0	19.0	0.9172972220000001	1.4763329269999999	5.0	3.148097385	30.0	0.9255850309999999	5.283482093	652.2827401000001	0.8340079	-719.698704	1.0	395.0	1.0	209.0	7.781068918001152	7.824300523919639	-0.31149346915551246	6.076320825762727	7.331824038821845	1.7301180705065335	-1.7047480922384253	-0.49247648509779385	2.041611539662046
13722.58cfa831e4b0c9d6adf6c655	58cfa831e4b0c9d6adf6c655	TCGA-CG-4444-01A-01D-A326_131002_SN208_0497_AC2CLVACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CG-4444-01A-01D-A326_131002_SN208_0497_AC2CLVACXX_s_7_rg.sorted	TCGA-CG-4444-01A-01D-A326_131002_SN208_0497_AC2CLVACXX_s_7_rg.sorted.bam	51.2	1.9	0.14	58cfa831e4b0c9d6adf6c655	TCGA-CG-4444-01A-01D-A326_131002_SN208_0497_AC2CLVACXX_s_7_rg.sorted.bam	Alive	MALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4444-01A	5C087D33-0BD3-407D-8350-FABBA6AEC597	Primary Tumor	Illumina HiSeq	37421315-54a7-4a59-9939-4706dcd66019	Stomach	76.0	8563E95B-8E50-4E23-95D1-25AE8437B1DB	37738374-DDCD-4710-A1CC-BF86868C252A	TCGA-CG-4444-01A-01D-A326-26	HG19_Broad_variant	TCGA-CG-4444	TCGA-STAD		s15192	MD Anderson - Institute for Applied Cancer Science	Indivumed	Germany	NO	T2b	N2	Stomach  Adenocarcinoma  Diffuse Type	Stage IIIA	A326-26	True	STAD	C2	GI.CIN	0.202649805	0.51	0.38	0.885019949	0.8748	0.243	0.5529999999999999	1.0083	0.6663	-0.0328			1.667621697	4.008143377	443.0	0.713789804	16.0	43.0	0.651944607	3.3891321039999998	181.0	3.401322962	32.0	0.9814143540000001	1.317595245	-564.24973	864.4607001	-1.9857788159999998	0.0	1431.0	0.0	1431.0	8.035926369891792	8.195412503538014	-0.7652910373235904	5.684551112728315	7.196883673426887	1.1836779565863482	-2.3513752571634776	-0.998528830111127	1.9489689939099386
13722.58cfa831e4b0c9d6adf6c661	58cfa831e4b0c9d6adf6c661	TCGA-CG-4443-01A-01D-1154_130815_VM001_0004_VMR0004CXX_s_3_rg.sorted.filtered.	WGS	TCGA-CG-4443-01A-01D-1154_130815_VM001_0004_VMR0004CXX_s_3_rg.sorted	TCGA-CG-4443-01A-01D-1154_130815_VM001_0004_VMR0004CXX_s_3_rg.sorted.bam	261.2	1.9	0.15	58cfa831e4b0c9d6adf6c661	TCGA-CG-4443-01A-01D-1154_130815_VM001_0004_VMR0004CXX_s_3_rg.sorted.bam	Alive	MALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4443-01A	8CB0144B-BE6B-40A1-86A2-708F96D9B615	Primary Tumor	Illumina HiSeq	d15f98aa-3849-4230-aea5-46a959ece810	Stomach	68.0	F4FB736A-42C9-4367-A327-D0D1C4CBA359	0FCF9057-D05B-480B-A17F-5FE35BFEB0CA	TCGA-CG-4443-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4443	TCGA-STAD		s15245	Harvard Medical School	Indivumed	Germany	NO	T1	N0	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IA	1154-02	True	STAD	C4	GI.CIN	0.033317891	0.13	0.04	1.678531775	0.1682	-0.021	-0.4097	-1.8439	-1.4484	-0.1149			0.9077517759999999	2.196173651	613.0	0.7111092720000001	3.0	53.0	0.873937705	0.605767456	2.0	1.039720771	3.0	0.94639463	0.64663915	-487.48640539999997	286.7348622	2057.8575149999997	0.0	912.0	0.0	912.0	8.473310963599388	7.7417779121693115	-0.2896073377703702	6.4808807989091815	7.336312804061148		-1.9924301646902063	-0.4054651081081646	
13722.58cfa831e4b0c9d6adf6c662	58cfa831e4b0c9d6adf6c662	TCGA-CM-4750-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-CM-4750-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-CM-4750-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	450.02	1.9	0.14	58cfa831e4b0c9d6adf6c662	TCGA-CM-4750-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-CM-4750-01A	C777A777-373A-4773-9566-6C373261F00A	Primary Tumor	Illumina HiSeq	eae74e76-b630-469d-9ad7-549fbfe64297	Colorectal	34.0	463D4B1E-2068-45DD-9631-FB9C7268FE6C	EE814BA4-311A-4ABC-B7A6-F32C68C50F2A	TCGA-CM-4750-01A-01D-1405-02	HG18	TCGA-CM-4750	TCGA-COAD		s12891	Harvard Medical School	MSKCC	United States	NO	T1	N1b	Colon Adenocarcinoma	Stage IIIA	1405-02	True	COAD	C2	GI.CIN	0.157168502	0.33	0.29	9.287956737	0.6805	0.41200000000000003	-0.8444	0.1453	0.1394	-0.051	48.0	20.0	0.633675714	2.085849224	132.0	0.879545927	19.0	7.0							0.370752191	-1538.977702	59.12023719	-1382.235019	0.0	244.0	0.0	244.0	5.774316245889214	5.6319171391328	0.25862057048100073	5.300531893803572	7.653813195166036	2.1022416480278436	-0.47378435208564174	2.0218960560332357	1.843621077546843
13722.58cfa831e4b0c9d6adf6c667	58cfa831e4b0c9d6adf6c667	TCGA-CG-4466-01A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CG-4466-01A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_2_rg.sorted	TCGA-CG-4466-01A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_2_rg.sorted.bam	143.3	1.9	0.14	58cfa831e4b0c9d6adf6c667	TCGA-CG-4466-01A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_2_rg.sorted.bam	Alive	FEMALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4466-01A	2F1B96B2-7031-4F7D-9490-14728D320F3E	Primary Tumor	Illumina HiSeq	cea9fe91-10d4-464c-80a6-24b7ed98ba9c	Stomach	81.0	0BC4ABB4-047B-4C8D-9F79-5B9EB32969E9	623D5E6A-A5D3-4580-BEF7-04673D42A1D0	TCGA-CG-4466-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4466	TCGA-STAD		s14757	Harvard Medical School	Indivumed	Germany	NO	T2a	N0	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1154-02	True	STAD	C1	GI.CIN	0.050863472	0.21	0.18	2.1445793330000003	1.1401	0.326	-0.4742	-0.8054	-0.2431	-0.1598			1.627411752	4.882235255	397.0	0.757757846	13.0	25.0	0.81003232	1.45138308	6.0	1.7351264569999998	6.0	0.968392514	0.882634356	-454.39976210000003	964.1836619999999	-2351.812276	0.0	577.0	0.0	577.0	6.89719976504262	4.571048507371652	-0.9554120134445694	6.032202327556016	6.02330083628334	0.3436500250374219	-0.8649974374866045	1.4522523289116882	1.2990620384819913
13722.58cfa831e4b0c9d6adf6c66a	58cfa831e4b0c9d6adf6c66a	TCGA-CR-7382-01A-11D-A32X-10_wgs_Illumina.filtered.	WGS	TCGA-CR-7382-01A-11D-A32X-10_wgs_Illumina	TCGA-CR-7382-01A-11D-A32X-10_wgs_Illumina.bam	170.7		0.08	58cfa831e4b0c9d6adf6c66a	TCGA-CR-7382-01A-11D-A32X-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CR-7382-01A	F030E410-2585-461E-AD23-9FDF026AC06C	Primary Tumor	Illumina HiSeq	ab5f1c0e-d07d-49b4-9fc2-b74f3c4928a6	Head and Neck	49.0	A8D8886B-B422-4C66-B0B4-4C9F0546B1B3	B86E88E7-0D5F-4B32-A35F-DC97251AB990	TCGA-CR-7382-01A-11D-A32X-10	GRCh37-lite	TCGA-CR-7382	TCGA-HNSC		s16328	Baylor College of Medicine	Vanderbilt University	United States	NO	T2	N2c	Head and Neck Squamous Cell Carcinoma	Stage IVA	A32X-10	True	HNSC	C2	HNSC.Mesenchymal	0.5073379339999999	0.79	0.05		0.6671	0.1665	1.0587	0.9856	2.1538	1.1	34.0	0.0	0.644710163	2.139265542	59.0	0.11903888300000001	4.0	5.0	0.944149254	3.111761918	27.0	3.93261022	54.0	0.985867623	1.10843258	408.7055606	807.4455741	382.45027989999994	0.0	796.0	1.0	614.0	7.438089369136172	3.990715177672234	-0.0042236363777349295	5.56628719223458	5.3799097081422405	1.4986344508199965	-1.8718021769015913	1.3891945304700064	1.5028580871977315
13722.58cfa831e4b0c9d6adf6c66d	58cfa831e4b0c9d6adf6c66d	TCGA-CU-A0YN-01A-21D-A10R_120926_SN590_0182_BD1EAGACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CU-A0YN-01A-21D-A10R_120926_SN590_0182_BD1EAGACXX_s_3_rg.sorted	TCGA-CU-A0YN-01A-21D-A10R_120926_SN590_0182_BD1EAGACXX_s_3_rg.sorted.bam	82.02	2.0	0.16	58cfa831e4b0c9d6adf6c66d	TCGA-CU-A0YN-01A-21D-A10R_120926_SN590_0182_BD1EAGACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CU-A0YN-01A	679A6869-2CE9-4472-8DB1-8869E2C1A440	Primary Tumor	Illumina HiSeq	89fcc222-6a37-406f-a641-b3d857104f9f	Bladder	60.0	DBCC2FCB-A103-46DA-9893-6EC689D2F98E	98E994A3-9823-472B-AED1-38876DEA7F24	TCGA-CU-A0YN-01A-21D-A10R-02	HG19_Broad_variant	TCGA-CU-A0YN	TCGA-BLCA	393.0	s3276	Harvard Medical School	UNC	United States	NO	T3a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A10R-02	True	BLCA	C2	BLCA.3	0.374169624	0.6	0.39	3.719984615	0.9509	0.257	-0.0574	0.7592	0.43	0.5132	81.0	122.0	1.308602603	3.982703574	179.0	0.621650322	19.0	31.0	0.520612474	2.122816856	59.0	3.319492576	28.0	0.9961851279999999	0.654600279	-598.0317703	1502.191094	-2637.7798989999997	1.0	393.0	0.0	393.0	6.930379757325853	8.313460033621851	-1.3240109314732487	6.002392985688507	7.725673368719732	1.5068201986453797	-0.9279867716373462	-0.5877866649021186	2.830831130118628
13722.58cfa831e4b0c9d6adf6c670	58cfa831e4b0c9d6adf6c670	TCGA-CS-4944-01A-01D-1465_130808_SN208_0487_AC28U7ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CS-4944-01A-01D-1465_130808_SN208_0487_AC28U7ACXX_s_3_rg.sorted	TCGA-CS-4944-01A-01D-1465_130808_SN208_0487_AC28U7ACXX_s_3_rg.sorted.bam	18.0	1.9	0.14	58cfa831e4b0c9d6adf6c670	TCGA-CS-4944-01A-01D-1465_130808_SN208_0487_AC28U7ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE		Brain Lower Grade Glioma	Aligned reads	TCGA-CS-4944-01A	64CD17EB-C778-45E9-B994-02B68182E51B	Primary Tumor	Illumina HiSeq	c266d33e-c72f-4059-b287-2f1bbd6fd48b	Brain	50.0	F1AA24E4-BC7F-427F-9CEB-8CAAFABFE535	63B56E68-639B-483B-B777-EAD4BDDC112C	TCGA-CS-4944-01A-01D-1465-02	HG19_Broad_variant	TCGA-CS-4944	TCGA-LGG		s8127	Harvard Medical School	Thomas Jefferson University	United States	NO			Astrocytoma		1465-02	True	LGG	C5	GBM_LGG.G-CIMP-high	0.100240244	0.26	0.0		-2.707	-0.242	-0.0093	-1.7452	-0.7338	-0.9799	12.0	21.0	0.086389795	0.547135366	65.0	0.060307015	1.0	7.0				0.0	1.0		3.2593463060000003	-142.59718	-1058.0436109999998	-3803.707141	0.0	1828.0	0.0	1828.0	8.481289637069883	8.591372589590488	0.7063903910813417	6.3610261008697915	8.289091717717556	3.976511122069625	-2.120263536200091	-0.3022808718729335	3.2701207309882836
13722.58cfa831e4b0c9d6adf6c678	58cfa831e4b0c9d6adf6c678	TCGA-CQ-5325-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CQ-5325-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_1_rg.sorted	TCGA-CQ-5325-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_1_rg.sorted.bam	166.0	1.9	0.14	58cfa831e4b0c9d6adf6c678	TCGA-CQ-5325-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-5325-01A	408C5D54-7888-4955-8386-BF8819B48A6C	Primary Tumor	Illumina HiSeq	a7440672-d797-4ad6-979a-c0835f0c2768	Head and Neck	65.0	8394A7F6-1BF6-473E-A155-3DA1A3DE244F	FFB4F8E1-B683-4A35-A5E7-15DBF610AE47	TCGA-CQ-5325-01A-01D-1681-02	HG19_Broad_variant	TCGA-CQ-5325	TCGA-HNSC	654.0	s16331	Harvard Medical School	University Health Network, Toronto	Canada	NO	T1	N0	Head and Neck Squamous Cell Carcinoma	Stage I	1681-02	True	HNSC	C2	HNSC.Mesenchymal	0.581116445	0.78	0.16		0.4699	0.16699999999999998	1.0372	2.2111	2.3336	0.5905	25.0	0.0	0.301649771	1.4479189	47.0	0.117704216	3.0	10.0	0.8788598240000001	4.568750188	181.0	3.5517508	37.0	0.983614385	2.269403351	284.94744069999996	456.57370599999996	-996.8160474	1.0	654.0	1.0	204.0	6.696712134602015	6.441400741271779	-0.035714308098473646	6.003564954042069	7.1906373884827675	2.1581942040228825	-0.6931471805599454	0.7492366472109886	2.1939085121213564
13722.58cfa831e4b0c9d6adf6c67c	58cfa831e4b0c9d6adf6c67c	TCGA-CN-4739-01A-02D-1509_120420_SN1120_0135_BD0T5FACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CN-4739-01A-02D-1509_120420_SN1120_0135_BD0T5FACXX_s_8_rg.sorted	TCGA-CN-4739-01A-02D-1509_120420_SN1120_0135_BD0T5FACXX_s_8_rg.sorted.bam	187.7	1.9	0.14	58cfa831e4b0c9d6adf6c67c	TCGA-CN-4739-01A-02D-1509_120420_SN1120_0135_BD0T5FACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4739-01A	7E3B90C1-8772-4E12-8050-A156558BEB82	Primary Tumor	Illumina HiSeq	796943be-2aa7-419f-801f-22c78459cc72	Head and Neck	71.0	F450DBE6-4972-4C49-AF97-963BCD0D0DA0	3B0BED92-ED76-451D-B605-A79FAE296DDE	TCGA-CN-4739-01A-02D-1509-02	HG19_Broad_variant	TCGA-CN-4739	TCGA-HNSC		s15888	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	1509-02	True	HNSC	C1	HNSC.Atypical	0.418240406	0.51	0.49		0.8568	0.1405	0.1878	1.4214	-0.239	0.2948	109.0	13.0	1.749634277	5.079583385	105.0	0.482915218	12.0	15.0	0.884916046	4.796718397	226.0	3.4561627980000003	35.0	0.972102517	4.23509332	27.29557079	231.7211511	-640.9919610000001	1.0	1394.0	1.0	1302.0	6.966803210905736	9.445089049830193	0.30495474381082066	6.70110004517273	8.51077981245336	2.032904543358791	-0.2657031657330058	-0.9343092373768331	1.7279497995479707
13722.58cfa831e4b0c9d6adf6c67d	58cfa831e4b0c9d6adf6c67d	TCGA-CG-4469-01A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CG-4469-01A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_3_rg.sorted	TCGA-CG-4469-01A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_3_rg.sorted.bam	298.2	1.9	0.14	58cfa831e4b0c9d6adf6c67d	TCGA-CG-4469-01A-01D-1154_121026_SN1120_0197_AC1878ACXX_s_3_rg.sorted.bam	Dead	MALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4469-01A	2AC986F6-CD6F-4CA5-90CC-7A105CFE85EA	Primary Tumor	Illumina HiSeq	dcd0352b-a451-4eaa-840e-14884d08bd89	Stomach	70.0	2A3D7538-D377-4D94-BB61-BF77BA56BE1B	9BAFEA4B-CCC4-4F5D-8BFE-BD13D56741F6	TCGA-CG-4469-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4469	TCGA-STAD	215.0	s14831	Harvard Medical School	Indivumed	Germany	NO	T3	N3	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IV	1154-02	True	STAD	C4	GI.CIN	0.10261728699999999	0.18	0.06	6.545082194	0.7725	0.125	0.428	-0.4999	0.4252	-0.2709			2.212938153	7.6752538470000005	239.0	0.333764723	9.0	16.0				2.547531366	14.0	0.9653186909999999	1.202464902	-434.40125430000006	1168.578851	-309.6982715	1.0	215.0	0.0	215.0	7.525639975041535	6.888357832746918	0.20912463013487903	5.679813284543204	7.434901539114987	0.6131406726366346	-1.8458266904983305	0.5465437063680696	0.4040160425017556
13722.58cfa831e4b0c9d6adf6c682	58cfa831e4b0c9d6adf6c682	TCGA-CR-5250-01A-01D-2276-10_Illumina.filtered.	WGS	TCGA-CR-5250-01A-01D-2276-10_Illumina	TCGA-CR-5250-01A-01D-2276-10_Illumina.bam	261.73	1.9	0.05	58cfa831e4b0c9d6adf6c682	TCGA-CR-5250-01A-01D-2276-10_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CR-5250-01A	9E178D80-FE90-4998-9DAE-726C4BECEEF7	Primary Tumor	Illumina HiSeq	486d7653-48d6-47cc-b04b-362d1b0e485b	Head and Neck	71.0	13AE9411-E63F-4093-A80E-8B64837C001D	29FC38AA-F367-46A3-A14D-A5F657AD0CAA	TCGA-CR-5250-01A-01D-2276-10	GRCh37-lite	TCGA-CR-5250	TCGA-HNSC		s16039	Baylor College of Medicine	Vanderbilt University	None	NO	TX	NX	Head and Neck Squamous Cell Carcinoma		2276-10	True	HNSC	C3	HNSC.Atypical	0.236998084	0.3	0.0		0.6801	-0.0445	-0.0029	1.4743	-0.3329	0.4575	13.0	24.0	0.23069387800000002	0.8651020429999999	66.0	0.063401851	0.0	9.0	0.920967208	4.468560767	128.0	3.9119676930000002	51.0	0.994949435	1.743086093	-564.5236143	618.8080053	-2594.618151	0.0	799.0	0.0	799.0	7.1364832085902465	3.477548470531115	-1.3721574713593883	5.487824583002865	5.02025135845235	0.9083013418406765	-1.6486586255873819	1.5427028879212346	2.280458813200065
13722.58cfa831e4b0c9d6adf6c684	58cfa831e4b0c9d6adf6c684	TCGA-CN-4738-01A-02D-1509_120420_SN1120_0135_BD0T5FACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CN-4738-01A-02D-1509_120420_SN1120_0135_BD0T5FACXX_s_7_rg.sorted	TCGA-CN-4738-01A-02D-1509_120420_SN1120_0135_BD0T5FACXX_s_7_rg.sorted.bam	122.7	1.9	0.15	58cfa831e4b0c9d6adf6c684	TCGA-CN-4738-01A-02D-1509_120420_SN1120_0135_BD0T5FACXX_s_7_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4738-01A	97640EF0-0259-4244-95BA-48D28C60B372	Primary Tumor	Illumina HiSeq	142fc981-c09b-4d94-96d3-b0d48b4d59f2	Head and Neck	53.0	8277E744-0508-47D5-9CEA-11DCF7F56D35	0EABE3ED-367B-4055-8700-0036E6A0FB1D	TCGA-CN-4738-01A-02D-1509-02	HG19_Broad_variant	TCGA-CN-4738	TCGA-HNSC	436.0	s16176	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	1509-02	True	HNSC	C2	HNSC.Atypical	0.341420988	0.77	0.44		0.067	0.057	0.4651	0.9044	0.8017	0.5601	48.0	88.0	0.8873951390000001	2.2328006719999998	88.0	0.17878691300000002	7.0	21.0	0.902109589	3.9185885239999996	77.0	3.371890775	36.0	0.940944036	3.659574011	235.81697000000003	-108.0934321	244.13669879999998	1.0	436.0	0.0	436.0	6.637913124658688	7.659758197544155	-0.6005520616398486	6.199658193727532	8.247544862446274	1.1967075933345237	-0.4382549309311554	0.5877866649021191	1.7972596549743725
13722.58cfa831e4b0c9d6adf6c688	58cfa831e4b0c9d6adf6c688	TCGA-CU-A0YO-01A-11D-A10R_120926_SN590_0182_BD1EAGACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CU-A0YO-01A-11D-A10R_120926_SN590_0182_BD1EAGACXX_s_5_rg.sorted	TCGA-CU-A0YO-01A-11D-A10R_120926_SN590_0182_BD1EAGACXX_s_5_rg.sorted.bam	30.08	1.91	0.16	58cfa831e4b0c9d6adf6c688	TCGA-CU-A0YO-01A-11D-A10R_120926_SN590_0182_BD1EAGACXX_s_5_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CU-A0YO-01A	4A9EF220-922C-49CF-BBED-D173B214ED31	Primary Tumor	Illumina HiSeq	98d555c2-93ae-4db5-9b19-43655d10609d	Bladder	84.0	9E190462-39FC-41B2-B1D6-2DA150412FCF	A407711E-26FF-4C0C-9391-326A51614BB7	TCGA-CU-A0YO-01A-11D-A10R-02	HG19_Broad_variant	TCGA-CU-A0YO	TCGA-BLCA	149.0	s3097	Harvard Medical School	UNC	United States	NO	T3a	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A10R-02	True	BLCA	C1	BLCA.2	0.44068313	0.67	0.45	5.711255528	-0.3418	-0.028999999999999998	-0.051	0.2088	0.2962	0.2809	29.0	11.0	0.765695503	2.438881972	63.0	0.362835446	14.0	12.0		0.0	1.0	2.48490665	12.0	1.0	2.101129907	-848.2403287000001	346.4024241	-848.2976405999999	1.0	149.0	1.0	118.0	6.9591062640132435	9.186662244621607	0.19743726396698036	5.652854610566889	8.452693069541406	1.5274841466749092	-1.3062516534463544	-0.7339691750802002	1.3300468827079288
13722.58cfa831e4b0c9d6adf6c68a	58cfa831e4b0c9d6adf6c68a	TCGA-CU-A0YR-01A-12D-A10R_120926_SN590_0182_BD1EAGACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CU-A0YR-01A-12D-A10R_120926_SN590_0182_BD1EAGACXX_s_7_rg.sorted	TCGA-CU-A0YR-01A-12D-A10R_120926_SN590_0182_BD1EAGACXX_s_7_rg.sorted.bam	36.74	1.82	0.16	58cfa831e4b0c9d6adf6c68a	TCGA-CU-A0YR-01A-12D-A10R_120926_SN590_0182_BD1EAGACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CU-A0YR-01A	811B3950-36E7-485F-BC48-ACA1EEE2DDEF	Primary Tumor	Illumina HiSeq	197d19a7-07c1-4cd3-b41d-a8233c9d8a42	Bladder	83.0	B362FCFA-4E31-4321-9E17-11A8BAE839C3	0CB51232-CFEA-4F4F-A26A-173B1094A64B	TCGA-CU-A0YR-01A-12D-A10R-02	HG19_Broad_variant	TCGA-CU-A0YR	TCGA-BLCA		s3096	Harvard Medical School	UNC	United States	NO	T2	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A10R-02	True	BLCA	C1	BLCA.2	0.382613415	0.53	0.09	2.233759961	0.8631	0.275	0.4262	0.4665	-0.1268	0.2213	66.0	109.0	1.3246497190000002	3.776660901	262.0	0.598722823	11.0	54.0	0.922333471	3.073403753	28.0	2.397895273	11.0	1.0	1.7142009180000002	-1382.0162	528.6149793000001	-3262.369673	1.0	460.0	1.0	219.0	5.951781226968587	-1.7734669704494905	-0.19217308897711938	4.812346943780222	7.067445210636365	2.06550727070529	-1.1394342831883648	8.840912181085855	2.2576803596824093
13722.58cfa831e4b0c9d6adf6c68f	58cfa831e4b0c9d6adf6c68f	TCGA-CU-A3YL-01A-11D-A233_120829_SN1120_0183_AC18U8ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CU-A3YL-01A-11D-A233_120829_SN1120_0183_AC18U8ACXX_s_3_rg.sorted	TCGA-CU-A3YL-01A-11D-A233_120829_SN1120_0183_AC18U8ACXX_s_3_rg.sorted.bam	42.41		0.15	58cfa831e4b0c9d6adf6c68f	TCGA-CU-A3YL-01A-11D-A233_120829_SN1120_0183_AC18U8ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CU-A3YL-01A	087A7F70-2FA8-4A16-B130-4DF10A70C662	Primary Tumor	Illumina HiSeq	8753d7f5-4d92-4781-8d19-d44710fa4f45	Bladder	67.0	F66AD788-E2D8-4688-820F-49A609701533	CAD008C4-3B53-4E9D-8730-9807E4753DDD	TCGA-CU-A3YL-01A-11D-A233-26	HG19_Broad_variant	TCGA-CU-A3YL	TCGA-BLCA		s3274	MD Anderson - Institute for Applied Cancer Science	UNC	United States	NO	T4a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A233-26	True	BLCA	C3	BLCA.1	0.14442986	0.27	0.03	1.79328591	0.0064	-0.107	-0.915	-0.4494	-0.2877	-0.0976	102.0	23.0	1.701142341	6.136263446	71.0	0.20522837600000002	4.0	13.0				2.441015278	12.0	0.982336813	2.9186441010000004	-2607.84265	-43.80648929	-2649.132951	0.0	906.0	1.0	370.0	6.272373735272334	8.20631072579402	0.21243912465514347	5.684587070370215	7.061178421491018	1.548290340214723	-0.5877866649021191	-1.1451323043030028	1.3358512155595794
13722.58cfa831e4b0c9d6adf6c696	58cfa831e4b0c9d6adf6c696	TCGA-CS-6186-01A-12D-2022_130910_SN208_0494_AC2A1DACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CS-6186-01A-12D-2022_130910_SN208_0494_AC2A1DACXX_s_3_rg.sorted	TCGA-CS-6186-01A-12D-2022_130910_SN208_0494_AC2A1DACXX_s_3_rg.sorted.bam	324.7		0.15	58cfa831e4b0c9d6adf6c696	TCGA-CS-6186-01A-12D-2022_130910_SN208_0494_AC2A1DACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-CS-6186-01A	9EE6E821-3AF2-42D7-9D14-F0CA455F338C	Primary Tumor	Illumina HiSeq	5660aee8-60eb-40d1-9083-d4fc781e8ddc	Brain	58.0	5F73FA4E-FC7D-4FC0-8436-2241E57B9B69	4143FB11-BA46-4129-8543-F72C015AE5C4	TCGA-CS-6186-01A-12D-2022-02	HG19_Broad_variant	TCGA-CS-6186	TCGA-LGG	538.0	s8556	Harvard Medical School	Thomas Jefferson University	United States	NO			Oligoastrocytoma		2022-02	True	LGG	C4	GBM_LGG.Classic-like	0.074330115	0.11	0.01		-0.9676	-0.2745	-0.2962	-2.7708	0.8318	-0.8211	25.0	0.0	0.5009585529999999	1.37763602	94.0	0.151773257	7.0	5.0				0.0	1.0		2.8435788189999998	-536.6218325	-1037.415606	-4088.9947049999996	1.0	538.0	1.0	188.0	8.028944121829152	8.192451877670724	0.9314612468437733	5.831719544492933	7.305148682669821	5.044826658844535	-2.197224577336219	-0.8873031950009029	4.1133654120007614
13722.58cfa831e4b0c9d6adf6c698	58cfa831e4b0c9d6adf6c698	TCGA-CN-5366-01A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CN-5366-01A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_1_rg.sorted	TCGA-CN-5366-01A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_1_rg.sorted.bam	313.7	1.9	0.16	58cfa831e4b0c9d6adf6c698	TCGA-CN-5366-01A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-5366-01A	30EB06A5-8E88-4C46-BEBB-FB93CA07F108	Primary Tumor	Illumina HiSeq	0a7fb0ab-3302-4187-a567-58bc19979dc5	Head and Neck	51.0	62FDF8F3-A028-453F-B27C-C2506BE68CBE	AE791AB1-78E2-4E8B-AB05-4435D9C67AA3	TCGA-CN-5366-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-5366	TCGA-HNSC	360.0	s15497	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N2c	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	True	HNSC	C2	HNSC.Basal	0.356199604	0.75	0.28		0.5541	0.2235	0.0554	-0.0004	1.2439	0.7519	33.0	25.0	0.727960125	2.407868107	113.0	0.27892971899999996	22.0	25.0	0.818980918	2.5315047859999997	22.0	2.8976082930000002	23.0	0.924131283	2.7557476000000003	-1283.732031	646.6002287	-2028.230162	1.0	360.0	1.0	276.0	6.490597072282927	7.2549616238424015	-0.70326531072553	5.3511627890945626	7.602362930995805	2.791565804413698	-1.1394342831883644	0.34740130715340367	3.494831115139228
13722.58cfa831e4b0c9d6adf6c69c	58cfa831e4b0c9d6adf6c69c	TCGA-CQ-6229-01A-11D-1911_120504_SN208_0296_AC0V09ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CQ-6229-01A-11D-1911_120504_SN208_0296_AC0V09ACXX_s_2_rg.sorted	TCGA-CQ-6229-01A-11D-1911_120504_SN208_0296_AC0V09ACXX_s_2_rg.sorted.bam	60.7	1.9	0.17	58cfa831e4b0c9d6adf6c69c	TCGA-CQ-6229-01A-11D-1911_120504_SN208_0296_AC0V09ACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-6229-01A	A091822C-447A-49A5-8C20-E329DF79599C	Primary Tumor	Illumina HiSeq	c3f7b43b-25d2-4df3-a85c-231a6708bf8c	Head and Neck	61.0	F01165B0-911A-45B0-BA7D-7CD0E723A2E4	4AF0777A-6FE3-49AE-B3B9-4AB077DDB007	TCGA-CQ-6229-01A-11D-1911-02	HG19_Broad_variant	TCGA-CQ-6229	TCGA-HNSC		s15631	Harvard Medical School	University Health Network, Toronto	Canada	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	1911-02	True	HNSC	C2	HNSC.Basal	0.44355480799999997	0.77	0.33		0.4567	0.1565	-0.1603	0.1982	2.0912	0.4734	12.0	5.0	0.296089735	0.6810063909999999	55.0	0.347059296	13.0	12.0	0.945310577	1.038529816	3.0	2.7519159689999997	17.0	0.971305594	1.4394580319999999	-157.83044619999998	616.957348	-1226.810363	0.0	1179.0	0.0	1179.0	6.740380287218822	7.002472397584933	0.18865034047840623	6.629154652108598	7.193527634347642	4.120698764782132	-0.1112256351102241	0.1910552367627094	3.932048424303725
13722.58cfa831e4b0c9d6adf6c6a0	58cfa831e4b0c9d6adf6c6a0	TCGA-CQ-6224-01A-11D-1911_120504_SN1222_0102_BC0VHDACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CQ-6224-01A-11D-1911_120504_SN1222_0102_BC0VHDACXX_s_4_rg.sorted	TCGA-CQ-6224-01A-11D-1911_120504_SN1222_0102_BC0VHDACXX_s_4_rg.sorted.bam	40.7	2.0	0.16	58cfa831e4b0c9d6adf6c6a0	TCGA-CQ-6224-01A-11D-1911_120504_SN1222_0102_BC0VHDACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-6224-01A	D86FD392-FA5C-4142-A647-440E6C32D478	Primary Tumor	Illumina HiSeq	e8b32a2c-944e-4b3e-a302-ffe9e9f8a3ea	Head and Neck	52.0	AD242EAC-A5AE-42B7-85CE-3E4D0DD308D6	3FAD44AE-89FC-4BB4-BA86-15A0EF7E2C3A	TCGA-CQ-6224-01A-11D-1911-02	HG19_Broad_variant	TCGA-CQ-6224	TCGA-HNSC		s15633	Harvard Medical School	University Health Network, Toronto	Canada	NO	T2	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1911-02	True	HNSC	C2	HNSC.Mesenchymal	0.252708588	0.73	0.24		0.1744	0.13	0.45399999999999996	0.3228	2.0115	1.0604	32.0	0.0	0.711199426	1.3334989240000001	132.0	0.44543056299999995	17.0	30.0	0.75253559	1.869980692	12.0	2.926417556	19.0	0.993879505	2.339672751	-485.94417469999996	-126.53014080000001	-440.24748289999997	0.0	1721.0	0.0	1721.0	6.444382250217759	8.816581477998055	-0.7989705520464467	5.73816298809046	8.024343394793878	1.5793731585933413	-0.7062192621272985	-0.7922380832041762	2.378343710639788
13722.58cfa831e4b0c9d6adf6c6a2	58cfa831e4b0c9d6adf6c6a2	TCGA-CQ-6223-01A-11D-1911_120504_SN1222_0102_BC0VHDACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CQ-6223-01A-11D-1911_120504_SN1222_0102_BC0VHDACXX_s_3_rg.sorted	TCGA-CQ-6223-01A-11D-1911_120504_SN1222_0102_BC0VHDACXX_s_3_rg.sorted.bam	325.7	1.9	0.15	58cfa831e4b0c9d6adf6c6a2	TCGA-CQ-6223-01A-11D-1911_120504_SN1222_0102_BC0VHDACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-6223-01A	D9E8C707-E61A-4813-8DC0-2472E9CCF12B	Primary Tumor	Illumina HiSeq	d12d744d-5a58-4e30-bcb7-b8c033a8255d	Head and Neck	69.0	775DB365-3533-41D9-B635-582292B22700	6CE8A7EC-2730-49E4-81F0-47B03A54EA1A	TCGA-CQ-6223-01A-11D-1911-02	HG19_Broad_variant	TCGA-CQ-6223	TCGA-HNSC		s16038	Harvard Medical School	University Health Network, Toronto	Canada	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	1911-02	True	HNSC	C2	HNSC.Basal	0.253616791	0.32	0.22		0.3849	0.07200000000000001	-0.152	0.2019	1.5941	0.1739	48.0	4.0	0.803853088	2.262697582	113.0	0.297335819	6.0	9.0	0.9593961440000001	3.125805255	26.0	2.043191871	8.0	0.982567593	5.552170723	-147.0407431	90.57013318	-725.7984443	0.0	1428.0	0.0	1428.0	4.5163672852530645	7.361446018043132	0.33192856646219504	5.409609621690929	6.504669413701385	1.8050197506642234	0.8932423364378641	-0.8567766043417473	1.4730911842020284
13722.58cfa831e4b0c9d6adf6c6ad	58cfa831e4b0c9d6adf6c6ad	TCGA-CV-5970-01A-11D-1681_120427_SN1120_0136_AC0JEMACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CV-5970-01A-11D-1681_120427_SN1120_0136_AC0JEMACXX_s_3_rg.sorted	TCGA-CV-5970-01A-11D-1681_120427_SN1120_0136_AC0JEMACXX_s_3_rg.sorted.bam	115.0	1.9	0.15	58cfa831e4b0c9d6adf6c6ad	TCGA-CV-5970-01A-11D-1681_120427_SN1120_0136_AC0JEMACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-5970-01A	1F6167D9-C99D-4873-8D6E-E62A1C964135	Primary Tumor	Illumina HiSeq	e7fcc1c5-e66d-4024-adb8-45def5252f1a	Head and Neck	59.0	4DF92618-5E63-46D7-8526-846932BCE3C2	7EBDEF16-0A0E-4DB2-AB6A-7B6115A7B739	TCGA-CV-5970-01A-11D-1681-02	HG19_Broad_variant	TCGA-CV-5970	TCGA-HNSC	406.0	s15509	Harvard Medical School	MD Anderson Cancer Center	None	NO	T4a	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	True	HNSC	C2	HNSC.Basal	0.266994172	0.6	0.12		0.1667	0.064	-0.111	-0.0408	0.9174	0.7857	81.0	0.0	1.7049113809999998	4.627616605	167.0	0.37472269399999997	10.0	27.0	0.91038122	3.880663705	71.0	2.197224577	9.0	1.0	2.7930916260000003	-2.157768981	324.042804	185.5995252	1.0	406.0	1.0	406.0	6.916374278462293	4.327276721787063	-1.240618961240569	6.718548535132373	6.645225177979719	1.6886298524318963	-0.19782574332991976	2.3179484561926555	2.9292488136724653
13722.58cfa831e4b0c9d6adf6c6b0	58cfa831e4b0c9d6adf6c6b0	TCGA-CR-6491-01A-11D-A32X-10_wgs_Illumina.filtered.	WGS	TCGA-CR-6491-01A-11D-A32X-10_wgs_Illumina	TCGA-CR-6491-01A-11D-A32X-10_wgs_Illumina.bam	78.7	1.9	0.08	58cfa831e4b0c9d6adf6c6b0	TCGA-CR-6491-01A-11D-A32X-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CR-6491-01A	5FCE954C-11B9-41F4-9471-4B5BDC0EFA7F	Primary Tumor	Illumina HiSeq	85a87fce-1144-4d78-8495-597c211a5312	Head and Neck	60.0	E23D2F8B-ACA4-43C2-876E-F8C6E1CA2D93	A315B798-F037-48D5-91ED-E733E3BBD6EE	TCGA-CR-6491-01A-11D-A32X-10	GRCh37-lite	TCGA-CR-6491	TCGA-HNSC		s15504	Baylor College of Medicine	Vanderbilt University	United States	NO	T4a	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	A32X-10	True	HNSC	C2	HNSC.Basal	0.170832331	0.25	0.25		0.6572	0.193	-0.7756	0.08	0.6705	0.5062	66.0	22.0	1.38939776	3.103973719	122.0	0.365657823	3.0	19.0	0.8747686659999999	3.1347500810000004	36.0	2.48490665	12.0	1.0	1.8412896140000001	-328.04888769999997	691.3523052999999	-1268.129995	0.0	693.0	1.0	499.0	5.155312672131034	3.8499392421868706	-0.8050773729034122	4.749847564022868	6.227377467995721	1.4242219976137813	-0.4054651081081646	2.3774382258088504	2.2292993705171935
13722.58cfa831e4b0c9d6adf6c6b2	58cfa831e4b0c9d6adf6c6b2	TCGA-CR-5249-01A-01D-2276-10_wgs_Illumina.filtered.	WGS	TCGA-CR-5249-01A-01D-2276-10_wgs_Illumina	TCGA-CR-5249-01A-01D-2276-10_wgs_Illumina.bam	213.73	1.9	0.05	58cfa831e4b0c9d6adf6c6b2	TCGA-CR-5249-01A-01D-2276-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CR-5249-01A	C7DF3466-B9A7-4818-883B-D0CD08483570	Primary Tumor	Illumina HiSeq	cef48339-6b24-4da9-b25d-55a64c71d0dc	Head and Neck	35.0	6697DD71-5A58-4862-B26E-EA16DCC383F2	C0812962-A345-48B7-AEC0-01336C2D1EED	TCGA-CR-5249-01A-01D-2276-10	GRCh37-lite	TCGA-CR-5249	TCGA-HNSC		s15894	Baylor College of Medicine	Vanderbilt University	None	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	2276-10	True	HNSC	C6	HNSC.Atypical	0.373320008	0.46	0.05		0.8411	0.0155	0.5974	2.1586	0.3267	0.4479	10.0	4.0	0.45161053799999995	0.592738831	68.0	0.087868054	1.0	8.0	0.9155417840000001	4.3361875780000005	114.0	4.573001243999999	101.0	0.990873635	2.542526863	-558.7245781	490.0060198	-420.2084843	0.0	1152.0	0.0	1152.0	7.43799129626795	3.4103705556704798	0.2369982245025961	5.445561131577744	5.09015635334899	1.420167901198769	-1.9924301646902063	1.6797857976785107	1.1831696766961728
13722.58cfa831e4b0c9d6adf6c6b6	58cfa831e4b0c9d6adf6c6b6	TCGA-CQ-7065-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CQ-7065-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_1_rg.sorted	TCGA-CQ-7065-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_1_rg.sorted.bam	15.93		0.13	58cfa831e4b0c9d6adf6c6b6	TCGA-CQ-7065-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_1_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-7065-01A	20ECE2CA-8601-4CCA-AEC5-0A5C0B92594D	Primary Tumor	Illumina HiSeq	a7ab0507-8b7a-45aa-9e07-21bfc50fddd0	Head and Neck	40.0	65B44EBF-F817-4B29-8FB6-01B07BC2E7D1	DFB72780-B485-403B-997C-6F6FD0EF0E75	TCGA-CQ-7065-01A-11D-2317-26	HG19_Broad_variant	TCGA-CQ-7065	TCGA-HNSC		s16040	MD Anderson - Institute for Applied Cancer Science	University Health Network, Toronto	Canada	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	2317-26	True	HNSC	C2	HNSC.Basal	0.10689471199999999	0.25	0.03		0.3586	0.09300000000000001	-1.7038	-2.3755	1.3967	0.3496	18.0	4.0	0.214707487	0.9201749459999999	135.0	0.287650364	9.0	13.0					0.0		2.9378773910000002	-1226.919143	318.555927	-2537.007353	0.0	1628.0	1.0	230.0	7.910158945151442	7.278022643396748	-0.3908827903470451	7.054492835093722	7.110299886023946	1.1290512764221154	-0.8556661100577201	-0.16772275737280218	1.5199340667691605
13722.58cfa831e4b0c9d6adf6c6b9	58cfa831e4b0c9d6adf6c6b9	TCGA-CQ-6225-01A-11D-A32X-10_wgs_Illumina.filtered.	WGS	TCGA-CQ-6225-01A-11D-A32X-10_wgs_Illumina	TCGA-CQ-6225-01A-11D-A32X-10_wgs_Illumina.bam	191.7	1.9	0.08	58cfa831e4b0c9d6adf6c6b9	TCGA-CQ-6225-01A-11D-A32X-10_wgs_Illumina.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-6225-01A	90F44998-3C05-44B2-9501-BBD0F43C5147	Primary Tumor	Illumina HiSeq	4bedf81d-7024-4c95-8d97-32aa6de7578e	Head and Neck	65.0	E907D8D4-C4C6-441F-9F19-FF3746E5D13E	AFA4344E-2252-4EF9-8B8A-14AAE14ACC9C	TCGA-CQ-6225-01A-11D-A32X-10	GRCh37-lite	TCGA-CQ-6225	TCGA-HNSC	403.0	s15503	Baylor College of Medicine	University Health Network, Toronto	Canada	NO	T3	N0	Head and Neck Squamous Cell Carcinoma	Stage III	A32X-10	True	HNSC	C1	HNSC.Atypical	0.036727829	0.19	0.27		0.7371	0.266	-1.0462	-1.2668	-1.3824	-0.1584	57.0	26.0	1.390242865	3.656943187	134.0	0.780240258	23.0	39.0				0.0	1.0		6.253781545	-1182.453222	67.22277986	-1844.892143	1.0	403.0	1.0	180.0	5.084947327060808	3.8547910594730137	-1.1223825080020216	4.993975548855081	2.8837754279096117	0.1779130265091886	-0.09097177820572666	-0.971015631563402	1.3002955345112102
13722.58cfa831e4b0c9d6adf6c6be	58cfa831e4b0c9d6adf6c6be	TCGA-CN-4742-01A-02D-1509_120420_SN208_0285_AD0T5JACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CN-4742-01A-02D-1509_120420_SN208_0285_AD0T5JACXX_s_1_rg.sorted	TCGA-CN-4742-01A-02D-1509_120420_SN208_0285_AD0T5JACXX_s_1_rg.sorted.bam	52.7	1.9	0.16	58cfa831e4b0c9d6adf6c6be	TCGA-CN-4742-01A-02D-1509_120420_SN208_0285_AD0T5JACXX_s_1_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4742-01A	444E5BFC-D4E5-4B0D-B96D-88ECEA8873E9	Primary Tumor	Illumina HiSeq	e655fe0a-a859-4967-b69c-4c8d36a8a7e0	Head and Neck	48.0	507B9A1D-BFBF-43F8-86D2-665A488441AF	A9768535-FE1C-4B4F-B709-DED0809BA592	TCGA-CN-4742-01A-02D-1509-02	HG19_Broad_variant	TCGA-CN-4742	TCGA-HNSC	397.0	s15892	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1509-02	True	HNSC	C2	HNSC.Basal	0.34795869700000004	0.7	0.09		0.4291	0.171	0.0643	0.3249	1.463	0.9474	17.0	3.0	0.425925035	1.788885146	144.0	0.552625791	11.0	27.0	0.869156444	4.124088333	115.0	2.9444389789999996	19.0	1.0	5.613924856000001	342.3323639	251.56230290000002	742.5597677999999	1.0	397.0	1.0	397.0	6.202535517187924	6.551602176882243	-0.907209286295914	5.630749193632245	6.42530845155795		-0.5717863235556782	-0.12629372532429217	
13722.58cfa831e4b0c9d6adf6c6c2	58cfa831e4b0c9d6adf6c6c2	TCGA-CN-4740-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CN-4740-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_5_rg.sorted	TCGA-CN-4740-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_5_rg.sorted.bam	78.7	1.9	0.14	58cfa831e4b0c9d6adf6c6c2	TCGA-CN-4740-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE		Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4740-01A	E37C83DC-C2C4-4E5F-A57B-39FFCF9AA3CF	Primary Tumor	Illumina HiSeq	c1580763-a5d9-4753-b80c-f8d5498a7494	Head and Neck	79.0	2311DEEC-8DBC-4449-BE09-FCD4E3BAFD87	9DD678DF-BCE7-46C2-8454-3DE815FB85ED	TCGA-CN-4740-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4740	TCGA-HNSC		s15884	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	True	HNSC	C1	HNSC.Mesenchymal	0.43493723799999995	0.76	0.14		0.6819	0.1285	1.0457	0.8564	0.532	0.9402	78.0	1.0	1.010447068	3.480428791	156.0	0.46742436600000004	14.0	14.0	0.904998526	3.690165375	59.0	3.735992668	46.0	0.975801148	5.575689614	530.2010136	1029.43444	-776.4475742000001	1.0	839.0	1.0	224.0	6.660646281183744	8.020042863850463	-0.5531700567895115	6.054510477613428	7.44949800538285	3.2914047257849903	-0.6061358035703157	-0.5705448584676129	3.844574782574502
13722.58cfa831e4b0c9d6adf6c6c3	58cfa831e4b0c9d6adf6c6c3	TCGA-CU-A3QU-01A-11D-A233_120829_SN1120_0183_AC18U8ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CU-A3QU-01A-11D-A233_120829_SN1120_0183_AC18U8ACXX_s_1_rg.sorted	TCGA-CU-A3QU-01A-11D-A233_120829_SN1120_0183_AC18U8ACXX_s_1_rg.sorted.bam	73.31		0.15	58cfa831e4b0c9d6adf6c6c3	TCGA-CU-A3QU-01A-11D-A233_120829_SN1120_0183_AC18U8ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CU-A3QU-01A	AE6D853B-A7F0-4465-B7BF-5A45006AB3B3	Primary Tumor	Illumina HiSeq	c4c9ea17-be51-4e92-8cdc-0d5880def11c	Bladder	58.0	75448068-DED8-42F0-BB99-6D1C4B3FFA4E	98A4CFCF-34FE-433A-A598-4191742DC977	TCGA-CU-A3QU-01A-11D-A233-26	HG19_Broad_variant	TCGA-CU-A3QU	TCGA-BLCA		s3278	MD Anderson - Institute for Applied Cancer Science	UNC	United States	NO	T2b	N1	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A233-26	True	BLCA	C4	BLCA.1	0.046861964000000006	0.1	0.18	0.92973776	0.6951	0.13699999999999998	-1.4947	-2.4416	-1.1122	-0.8675	47.0	81.0	1.019589401	2.518985579	179.0	0.872264974	12.0	38.0				0.0	1.0		1.011924601	-2031.795796	211.5472835	1733.6211280000002	0.0	158.0	0.0	158.0	5.8041761304073045	7.85449207539749	-0.3945562141577501	4.85216731593107	6.366415019967657	3.935839687286169	-0.9520088144762342	-1.488077055429833	4.330395901443919
13722.58cfa831e4b0c9d6adf6c6c6	58cfa831e4b0c9d6adf6c6c6	TCGA-CV-5432-01A-02D-A32X-10_wgs_Illumina.filtered.	WGS	TCGA-CV-5432-01A-02D-A32X-10_wgs_Illumina	TCGA-CV-5432-01A-02D-A32X-10_wgs_Illumina.bam	341.0	1.9	0.08	58cfa831e4b0c9d6adf6c6c6	TCGA-CV-5432-01A-02D-A32X-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-5432-01A	D89B1FD6-BEF4-4803-8ED3-3B442BE600B6	Primary Tumor	Illumina HiSeq	6d564719-34a3-4b79-bf57-a5c8f73d7436	Head and Neck	68.0	B4A36114-80D3-4F28-B85A-077DC31EB485	9988EB07-01F6-4F83-8699-BB63E0525F08	TCGA-CV-5432-01A-02D-A32X-10	GRCh37-lite	TCGA-CV-5432	TCGA-HNSC		s16196	Baylor College of Medicine	MD Anderson Cancer Center	None	NO	T3	N0	Head and Neck Squamous Cell Carcinoma	Stage III	A32X-10	True	HNSC	C1	HNSC.Classical	0.179282512	0.53	0.12		0.9075	0.299	-0.5473	0.1389	-0.3163	0.3308	116.0	3.0	2.584292706	6.737620269	260.0	0.7025483440000001	19.0	56.0	0.960028245	1.720139699	6.0	0.693147181	2.0	1.0	3.11049607	-1120.341946	965.3346908	-300.9304264	0.0	3930.0	0.0	3930.0	4.401697950828122	4.06025261933779	0.19224030504281853	6.029154368764901	5.035730600264633	1.904914462553665	1.6274564179367785	0.9754779809268426	1.7126741575108464
13722.58cfa831e4b0c9d6adf6c6c8	58cfa831e4b0c9d6adf6c6c8	TCGA-CU-A3KJ-01A-11D-A21C_120914_SN590_0179_AD13PPACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CU-A3KJ-01A-11D-A21C_120914_SN590_0179_AD13PPACXX_s_7_rg.sorted	TCGA-CU-A3KJ-01A-11D-A21C_120914_SN590_0179_AD13PPACXX_s_7_rg.sorted.bam	49.18		0.15	58cfa831e4b0c9d6adf6c6c8	TCGA-CU-A3KJ-01A-11D-A21C_120914_SN590_0179_AD13PPACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CU-A3KJ-01A	A75584BC-BEF7-48F6-B4B3-C1472A3AF768	Primary Tumor	Illumina HiSeq	6b7a9ee7-ee89-4473-9170-7372313595f7	Bladder	75.0	3D92F5A6-949A-4176-9309-4294CCA6FC25	25847D62-9932-4A04-9B00-378794D2CE72	TCGA-CU-A3KJ-01A-11D-A21C-26	HG19_Broad_variant	TCGA-CU-A3KJ	TCGA-BLCA		s3098	MD Anderson - Institute for Applied Cancer Science	UNC	United States	NO	T3b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A21C-26	True	BLCA	C1	BLCA.3	0.129804324	0.25	0.14	9.415864587	0.8776	0.2375	-0.3803	-0.6201	0.2374	0.0721	82.0	1.0	2.272169063	6.007241496000001	317.0	0.6732910670000001	18.0	44.0		0.0	1.0	1.609437912	5.0	1.0	5.3239533539999995	275.2710961	625.7352283	-2161.397076	0.0	562.0	1.0	166.0	6.230166437338044	7.976995970107032	-1.0655013133637496	5.1052368403525605	6.773023165781096	0.3778677900903722	-1.1249295969854836	-1.203972804325936	1.4433691034541218
13722.58cfa831e4b0c9d6adf6c6ce	58cfa831e4b0c9d6adf6c6ce	TCGA-CS-6290-01A-11D-1703_130808_SN208_0487_AC28U7ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CS-6290-01A-11D-1703_130808_SN208_0487_AC28U7ACXX_s_7_rg.sorted	TCGA-CS-6290-01A-11D-1703_130808_SN208_0487_AC28U7ACXX_s_7_rg.sorted.bam	95.3	1.9	0.15	58cfa831e4b0c9d6adf6c6ce	TCGA-CS-6290-01A-11D-1703_130808_SN208_0487_AC28U7ACXX_s_7_rg.sorted.bam	Alive	MALE			Brain Lower Grade Glioma	Aligned reads	TCGA-CS-6290-01A	42FE260F-520B-4FAC-8C09-D2B31AED59FB	Primary Tumor	Illumina HiSeq	dd2c0db0-5e68-43b9-a591-4efa9a782af1	Brain	31.0	6148F31E-CDBA-481B-BCD7-B3AEE05925B1	D31BD4D8-DF61-4B6B-9304-17B22FDD023B	TCGA-CS-6290-01A-11D-1703-02	HG19_Broad_variant	TCGA-CS-6290	TCGA-LGG		s8555	Harvard Medical School	Thomas Jefferson University	United States	NO			Astrocytoma		1703-02	True	LGG	C4	GBM_LGG.G-CIMP-high	0.20687226	0.47	0.08		-1.9526	-0.28	0.9426	-1.4233	1.0218	-0.9031	11.0		0.151175506	0.574466923	64.0	0.057426925	0.0	3.0				0.0	1.0		3.2398720119999997	-152.0035468	-1371.1417900000001	-1836.7538809999999	1.0	1137.0	0.0	1137.0	8.781363516282045	9.044267623826611	0.5762323060193298	7.0321636614727865	8.613484707734157		-1.749199854809259	-0.4307829160924541	
13722.58cfa831e4b0c9d6adf6c6d0	58cfa831e4b0c9d6adf6c6d0	TCGA-CS-4941-01A-01D-1465_130808_SN208_0487_AC28U7ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CS-4941-01A-01D-1465_130808_SN208_0487_AC28U7ACXX_s_1_rg.sorted	TCGA-CS-4941-01A-01D-1465_130808_SN208_0487_AC28U7ACXX_s_1_rg.sorted.bam	157.0	1.9	0.15	58cfa831e4b0c9d6adf6c6d0	TCGA-CS-4941-01A-01D-1465_130808_SN208_0487_AC28U7ACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-CS-4941-01A	FC222F23-B3B2-4AC0-BC61-E8E8FA5CC160	Primary Tumor	Illumina HiSeq	7df56317-1eca-4fb0-af19-36a4bfc5df00	Brain	67.0	4E5AEE62-DF39-4A74-917C-C3AB154F8D0E	8CA32F59-BA52-49E8-BA72-D2761ED47099	TCGA-CS-4941-01A-01D-1465-02	HG19_Broad_variant	TCGA-CS-4941	TCGA-LGG	234.0	s8126	Harvard Medical School	Thomas Jefferson University	United States	NO			Astrocytoma		1465-02	True	LGG	C4	GBM_LGG.Mesenchymal-like	0.318987593	0.38	0.05		-0.7552	-0.204	0.6477	-0.2648	1.4874	-0.4556	23.0		0.200108179	1.2578228359999999	105.0	0.22414923899999997	6.0	2.0	0.990805075	0.686773744	2.0	2.7363390510000003	16.0	0.986925695	3.627120618	51.978573299999994	-765.9839997	-3220.831656	1.0	234.0	1.0	9.0	9.225819942824568	9.060350468545492	0.17919096389725397	6.783472907455364	8.549524844779501	3.4864796222803554	-2.4423470353692043	-0.5108256237659905	3.3072886583831016
13722.58cfa831e4b0c9d6adf6c6d2	58cfa831e4b0c9d6adf6c6d2	TCGA-CS-4938-01B-11D-1891_130919_SN590_0238_AC29TRACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CS-4938-01B-11D-1891_130919_SN590_0238_AC29TRACXX_s_1_rg.sorted	TCGA-CS-4938-01B-11D-1891_130919_SN590_0238_AC29TRACXX_s_1_rg.sorted.bam	19.7	1.9	0.15	58cfa831e4b0c9d6adf6c6d2	TCGA-CS-4938-01B-11D-1891_130919_SN590_0238_AC29TRACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-CS-4938-01B	334F715E-08DC-4A29-B8E4-B010B829C478	Primary Tumor	Illumina HiSeq	8b9dc3cd-2c99-405c-8306-3b388ad5bdf6	Brain	31.0	99104139-6CB5-44F7-8314-A4DDF02DE7D4	7FE72196-9DE8-4A43-87F2-D2E8F74B0007	TCGA-CS-4938-01B-11D-1891-02	HG19_Broad_variant	TCGA-CS-4938	TCGA-LGG		s8553	Harvard Medical School	Thomas Jefferson University	United States	NO			Astrocytoma		1891-02	True	LGG	C5	GBM_LGG.G-CIMP-high	0.081383854	0.21	0.03		-1.7923	-0.2715	-0.0634	-2.3298	-0.8686	-1.0856	5.0	0.0	0.14226136	0.36987953700000004	76.0	0.069411748	1.0	5.0					0.0		3.6530887069999998	115.4072696	-1067.433856	-3625.831065	0.0	3574.0	0.0	3574.0	8.568076401730806	8.397508348470257	2.9899685688372406	6.316784603124312	6.318066806790421	2.2474840284717748	-2.251291798606495	-2.079441541679836	-0.7424845403654659
13722.58cfa831e4b0c9d6adf6c6ea	58cfa831e4b0c9d6adf6c6ea	TCGA-CG-4442-01A-01D-1154_130815_VM001_0004_VMR0004CXX_s_1_rg.sorted.filtered.	WGS	TCGA-CG-4442-01A-01D-1154_130815_VM001_0004_VMR0004CXX_s_1_rg.sorted	TCGA-CG-4442-01A-01D-1154_130815_VM001_0004_VMR0004CXX_s_1_rg.sorted.bam	165.2	1.9	0.14	58cfa831e4b0c9d6adf6c6ea	TCGA-CG-4442-01A-01D-1154_130815_VM001_0004_VMR0004CXX_s_1_rg.sorted.bam	Alive	MALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4442-01A	8FCCFF71-3710-4CB9-B8AF-61707AEBE5D8	Primary Tumor	Illumina HiSeq	3a08f497-17a4-4b39-87b6-680e2fa13379	Stomach	85.0	51927F82-2585-465B-92ED-36EF46D44FAB	7597FC80-5A3C-4999-97B2-4DCB55609CC2	TCGA-CG-4442-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4442	TCGA-STAD		s14635	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1154-02	True	STAD	C1	GI.HM-indel	0.15698829	0.27	0.0	2.181793311	0.8897	0.38799999999999996	-0.226	-0.5212	0.1231	0.0356			11.56826036	36.39357823	165.0	0.050271660999999995	2.0	0.0	0.944777338	2.9203468619999997	22.0	1.329661349	4.0	0.959147917		-776.3995391	1118.675549	-334.90236969999995	0.0	0.0	0.0	0.0	1.3622448206794235	6.53233429222235	0.02718614030415678	5.800966799029851	7.339140791254817	0.8634720210662684	4.4387219783504275	0.8068064990324668	0.8362858807621116
13722.58cfa831e4b0c9d6adf6c6ee	58cfa831e4b0c9d6adf6c6ee	TCGA-CR-6467-01A-11D-2266-10_Illumina.filtered.	WGS	TCGA-CR-6467-01A-11D-2266-10_Illumina	TCGA-CR-6467-01A-11D-2266-10_Illumina.bam	319.7	1.9	0.05	58cfa831e4b0c9d6adf6c6ee	TCGA-CR-6467-01A-11D-2266-10_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CR-6467-01A	89F91E36-FED8-4DA3-8A35-C761D6F65285	Primary Tumor	Illumina HiSeq	27f00d9e-af52-4af4-b29b-a75a506754a8	Head and Neck	59.0	5EF4D047-5A84-4E03-ACF5-02029D8A4CF2	EE963667-56B1-49BD-8896-E07B536D3014	TCGA-CR-6467-01A-11D-2266-10	GRCh37-lite	TCGA-CR-6467	TCGA-HNSC		s15769	Baylor College of Medicine	Vanderbilt University	United States	NO	T2	N1	Head and Neck Squamous Cell Carcinoma	Stage III	2266-10	True	HNSC	C2	HNSC.Atypical	0.23461082	0.34	0.01		1.2095	0.1835	0.6464	2.2388	0.1834	-0.1266	20.0	20.0	0.528956986	0.940367975	135.0	0.64588027	17.0	17.0	0.898286866	4.679612988	183.0	4.2947169569999994	105.0	0.9228090990000001	1.616599615	-448.0391813	757.6711442000001	-2552.012851	0.0	1777.0	0.0	1777.0	7.8632026193908136	2.4981729626854765	0.20263390722325536	6.359125222614539	5.331386306741693	2.2858419316985685	-1.5040773967762742	2.833213344056216	2.083208024475313
13722.58cfa831e4b0c9d6adf6c6f4	58cfa831e4b0c9d6adf6c6f4	TCGA-CV-5977-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CV-5977-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_3_rg.sorted	TCGA-CV-5977-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_3_rg.sorted.bam	307.0	1.9	0.15	58cfa831e4b0c9d6adf6c6f4	TCGA-CV-5977-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-5977-01A	50239D1D-B3A4-4240-AB83-B24BA67B1299	Primary Tumor	Illumina HiSeq	ccdab134-2f40-4e7a-8b7c-ac1269321d3e	Head and Neck	66.0	84756AB5-9CB6-4DBD-848C-A85804F22AA1	140E6B2E-7EDD-417D-B720-58BEAB50AEA5	TCGA-CV-5977-01A-11D-1681-02	HG19_Broad_variant	TCGA-CV-5977	TCGA-HNSC		s15896	Harvard Medical School	MD Anderson Cancer Center	None	NO	T3	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	True	HNSC	C2	HNSC.Basal	0.11373448	0.34	0.12		0.8682	0.43	-0.9638	-1.0881	2.3803	0.1613	39.0	0.0	1.1603707140000001	1.9543085709999999	113.0	0.818440328	19.0	12.0				1.791759469	6.0	1.0	2.485806904	102.6940561	642.9804938999999	-824.1086921	0.0	1840.0	0.0	1840.0	7.310723445163317	6.024257179862959	-0.028477636292815633	7.140824408367919	7.443852528109821	2.352225235965182	-0.16989903679539742	1.4195953482468626	2.3807028722579977
13722.58cfa831e4b0c9d6adf6c6fc	58cfa831e4b0c9d6adf6c6fc	TCGA-CV-5431-01A-01D-1509_120420_SN208_0285_AD0T5JACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CV-5431-01A-01D-1509_120420_SN208_0285_AD0T5JACXX_s_3_rg.sorted	TCGA-CV-5431-01A-01D-1509_120420_SN208_0285_AD0T5JACXX_s_3_rg.sorted.bam	464.7	1.8	0.15	58cfa831e4b0c9d6adf6c6fc	TCGA-CV-5431-01A-01D-1509_120420_SN208_0285_AD0T5JACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-5431-01A	64BB5550-2735-4401-A0DB-58EC1020A32D	Primary Tumor	Illumina HiSeq	0cba1ad9-9899-40b0-9fa7-dc39030c04e7	Head and Neck	73.0	BE567C0A-3833-45D7-B846-D229A8E16E16	D751368D-5948-42EF-8C61-D24595CAC1E9	TCGA-CV-5431-01A-01D-1509-02	HG19_Broad_variant	TCGA-CV-5431	TCGA-HNSC	522.0	s16334	Harvard Medical School	MD Anderson Cancer Center	None	NO	T3	N2c	Head and Neck Squamous Cell Carcinoma	Stage IVA	1509-02	True	HNSC	C1	HNSC.Mesenchymal	0.42617500799999997				0.7121	0.2	0.75	1.8318	0.2216	0.8034					252.0	0.514787066	13.0	44.0	0.807468458	4.538296422	276.0	3.664523721	42.0	0.980430079	3.572421455	316.81177010000005	661.3135378	-2674.441298	1.0	522.0	0.0	522.0	6.00158363059831	7.095893221097532	-0.5970916128088158	5.725330253970152	5.8828705812516775	1.245493583765344	-0.2762533766281581	-1.2130226398458537	1.8425851965741598
13722.58cfa831e4b0c9d6adf6c702	58cfa831e4b0c9d6adf6c702	TCGA-CV-5966-01A-11D-1681_120427_SN1120_0136_AC0JEMACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CV-5966-01A-11D-1681_120427_SN1120_0136_AC0JEMACXX_s_2_rg.sorted	TCGA-CV-5966-01A-11D-1681_120427_SN1120_0136_AC0JEMACXX_s_2_rg.sorted.bam	99.0	1.9	0.14	58cfa831e4b0c9d6adf6c702	TCGA-CV-5966-01A-11D-1681_120427_SN1120_0136_AC0JEMACXX_s_2_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-5966-01A	0D0731E2-8D82-4B6D-9258-2896A770A868	Primary Tumor	Illumina HiSeq	a774b0c6-39f6-4601-9c2a-5a81369b9f87	Head and Neck	63.0	E71C33E9-1F74-4CF6-B6BF-985D0C96F71E	84D0CA61-132A-4B85-A343-0C55DE088B0C	TCGA-CV-5966-01A-11D-1681-02	HG19_Broad_variant	TCGA-CV-5966	TCGA-HNSC	545.0	s16335	Harvard Medical School	MD Anderson Cancer Center	None	NO	T4a	N1	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	True	HNSC	C2	HNSC.Mesenchymal	0.360564318	0.74	0.12		1.2874	0.6645	0.3452	-0.1736	2.3885	0.2211	44.0	5.0	0.846522865	2.872131149	180.0	0.422069517	12.0	38.0				2.751102289	17.0	0.9710184000000001	1.4078953019999998	-19.36702329	806.1623272	-1217.158197	1.0	545.0	0.0	545.0	6.924366544787334	6.772400796968151	0.6109423624081731	6.547072313645867	6.387989098057819	3.271784480523603	-0.37729423114146776	-0.38441169891033233	2.66084211811543
13722.58cfa831e4b0c9d6adf6c706	58cfa831e4b0c9d6adf6c706	TCGA-CV-5431-01A-01D-A32X-10_wgs_Illumina.filtered.	WGS	TCGA-CV-5431-01A-01D-A32X-10_wgs_Illumina	TCGA-CV-5431-01A-01D-A32X-10_wgs_Illumina.bam	464.7	1.8	0.08	58cfa831e4b0c9d6adf6c706	TCGA-CV-5431-01A-01D-A32X-10_wgs_Illumina.bam	Dead	MALE	WHITE	HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-5431-01A	64BB5550-2735-4401-A0DB-58EC1020A32D	Primary Tumor	Illumina HiSeq	cbfa9144-8087-42ab-9497-71bfeddc55ae	Head and Neck	73.0	BE567C0A-3833-45D7-B846-D229A8E16E16	DE8EF60B-4DBE-4AA8-ADEF-6F58CDFADA29	TCGA-CV-5431-01A-01D-A32X-10	GRCh37-lite	TCGA-CV-5431	TCGA-HNSC	522.0	s16192	Baylor College of Medicine	MD Anderson Cancer Center	None	NO	T3	N2c	Head and Neck Squamous Cell Carcinoma	Stage IVA	A32X-10	True	HNSC	C1	HNSC.Mesenchymal	0.42617500799999997				0.7121	0.2	0.75	1.8318	0.2216	0.8034					252.0	0.514787066	13.0	44.0	0.807468458	4.538296422	276.0	3.664523721	42.0	0.980430079	3.572421455	316.81177010000005	661.3135378	-2674.441298	1.0	522.0	0.0	522.0	6.97354301952014	5.045391872289424	-0.5970916128088158	4.622167762356662	4.644840778983689	1.245493583765344	-2.3513752571634776	-0.4005510933057348	1.8425851965741598
13722.58cfa831e4b0c9d6adf6c70c	58cfa831e4b0c9d6adf6c70c	TCGA-CV-5973-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CV-5973-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_1_rg.sorted	TCGA-CV-5973-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_1_rg.sorted.bam	115.0	1.9	0.15	58cfa831e4b0c9d6adf6c70c	TCGA-CV-5973-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-5973-01A	8FC1F1BE-D2D5-4B3A-9973-F4D964018BEB	Primary Tumor	Illumina HiSeq	4965236e-7173-4701-bd61-0550f3451b03	Head and Neck	62.0	5078222F-B257-4286-A29A-BC1E395149BC	55E8AEAC-4C0E-49DF-8F57-605E7C820B89	TCGA-CV-5973-01A-11D-1681-02	HG19_Broad_variant	TCGA-CV-5973	TCGA-HNSC		s16193	Harvard Medical School	MD Anderson Cancer Center	None	NO	T3	N1	Head and Neck Squamous Cell Carcinoma	Stage III	1681-02	True	HNSC	C2	HNSC.Basal	0.172602492	0.3	0.03		-0.5438	-0.0145	-0.862	-0.9047	0.8832	0.1434	18.0	23.0	0.731036435	1.3706933159999999	283.0	0.532755183	12.0	35.0					0.0		4.48805971	-648.0297784	-799.5250942000001	-1366.551138	0.0	2641.0	0.0	2641.0	6.542895671372853	6.968330733654857	-0.9329276436323098	5.942121810943923	5.688226419555168	2.2534823799863135	-0.6007738604289301	-1.280104314099689	3.1864100236186235
13722.58cfa831e4b0c9d6adf6c710	58cfa831e4b0c9d6adf6c710	TCGA-CV-7428-01A-11D-2317_120623_SN1222_0119_BC0WLLACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CV-7428-01A-11D-2317_120623_SN1222_0119_BC0WLLACXX_s_2_rg.sorted	TCGA-CV-7428-01A-11D-2317_120623_SN1222_0119_BC0WLLACXX_s_2_rg.sorted.bam	325.73		0.16	58cfa831e4b0c9d6adf6c710	TCGA-CV-7428-01A-11D-2317_120623_SN1222_0119_BC0WLLACXX_s_2_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-7428-01A	90D3C240-5CB6-4601-A852-B5CDFBCD6483	Primary Tumor	Illumina HiSeq	234197c5-8479-49c1-9f04-5e9171364a3d	Head and Neck	47.0	F3CFC60B-ADA9-4549-8CDB-6CEBABB1E6B3	BA021325-B1CC-4C81-99B7-7B7349CFFFB6	TCGA-CV-7428-01A-11D-2317-26	HG19_Broad_variant	TCGA-CV-7428	TCGA-HNSC	1671.0	s15784	MD Anderson - Institute for Applied Cancer Science	MD Anderson Cancer Center	United States	NO	T4a	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	2317-26	True	HNSC	C2		0.276841813				0.8791	0.253	0.2156	0.5529	1.9026	0.3749					212.0	0.20953302199999999			0.863987594	2.395482258	16.0	2.97137654	21.0	0.975974591	1.77670021	223.6112731	721.41161	-674.4484573	1.0	1671.0	1.0	1671.0	7.464939541726146	7.813245032590894	-0.1189667807101743	6.7717923611662005	7.120097852030948	1.952052814257839	-0.6931471805599454	-0.6931471805599454	2.0710195949680132
13722.58cfa831e4b0c9d6adf6c718	58cfa831e4b0c9d6adf6c718	TCGA-D7-6528-01A-11D-1798_130218_SN208_0453_AC1T26ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-D7-6528-01A-11D-1798_130218_SN208_0453_AC1T26ACXX_s_5_rg.sorted	TCGA-D7-6528-01A-11D-1798_130218_SN208_0453_AC1T26ACXX_s_5_rg.sorted.bam	303.4	1.9	0.15	58cfa831e4b0c9d6adf6c718	TCGA-D7-6528-01A-11D-1798_130218_SN208_0453_AC1T26ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6528-01A	35496E4E-598F-4FFC-B11E-8EDAEB676079	Primary Tumor	Illumina HiSeq	478ea84f-df8f-4d1b-a7da-ab1ac7751e97	Stomach	70.0	DF817250-9A2C-42E8-AD90-0D9E13FE37B3	7DA37A25-E2DE-4193-AD71-2182B6DA5C26	TCGA-D7-6528-01A-11D-1798-02	HG19_Broad_variant	TCGA-D7-6528	TCGA-STAD		s14562	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N0	Stomach  Intestinal Adenocarcinoma  Tubular Type	Stage IB	1798-02	True	STAD	C2	GI.HM-SNV	0.17527567800000002	0.38	0.28	9.362430677	1.0678	0.2945	-0.8282	-1.0521	0.5809	-0.21100000000000002			2.48051035	8.356957487999999	200.0	0.8328339790000001	20.0	35.0	0.9589547829999999	2.299473142	11.0	2.245035274	10.0	0.975006431	1.333063651	-538.075148	670.2818671	-510.43659469999994	0.0	463.0	0.0	463.0	3.0859330035903207	5.902438154323944	-1.3471064701850661	5.994653900154682	6.401429320442932	0.4721942106255541	2.908720896564361	0.49899116611898764	1.8193006808106202
13722.58cfa831e4b0c9d6adf6c720	58cfa831e4b0c9d6adf6c720	TCGA-D7-6527-01A-11D-1798_130218_SN208_0453_AC1T26ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-D7-6527-01A-11D-1798_130218_SN208_0453_AC1T26ACXX_s_3_rg.sorted	TCGA-D7-6527-01A-11D-1798_130218_SN208_0453_AC1T26ACXX_s_3_rg.sorted.bam	84.4	1.9	0.13	58cfa831e4b0c9d6adf6c720	TCGA-D7-6527-01A-11D-1798_130218_SN208_0453_AC1T26ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6527-01A	CB622CD6-776D-4681-8A67-4ADDD61C66B8	Primary Tumor	Illumina HiSeq	d1534b7a-a5b2-4083-9736-d1ad62a97ad2	Stomach	62.0	8461CE68-3A6F-4343-8977-78448123F373	F91DFFCE-5185-4555-92EA-919E94EB9569	TCGA-D7-6527-01A-11D-1798-02	HG19_Broad_variant	TCGA-D7-6527	TCGA-STAD		s14496	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N1	Stomach Intestinal Adenocarcinoma Papillary Type	Stage II	1798-02	True	STAD	C1	GI.CIN	0.182704621	0.54	0.2	7.647723244	0.5122	0.14800000000000002	-0.1169	0.5765	-0.1938	0.2204			1.623868558	5.563253394	764.0	0.752134851	22.0	51.0	0.783898757	5.017153857	602.0	4.165754078	90.0	0.925762284	4.89027948	-558.986689	277.7728765	3565.521236	1.0	312.0	1.0	75.0	7.562161631225651	6.710685499839274	-0.255564642569601	5.364937053889432	6.199859876073283	2.413250660881565	-2.197224577336219	-0.5108256237659905	2.668815303451166
13722.58cfa831e4b0c9d6adf6c726	58cfa831e4b0c9d6adf6c726	TCGA-D6-6825-01A-21D-1911_120518_SN1120_0143_BC0VN6ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-D6-6825-01A-21D-1911_120518_SN1120_0143_BC0VN6ACXX_s_2_rg.sorted	TCGA-D6-6825-01A-21D-1911_120518_SN1120_0143_BC0VN6ACXX_s_2_rg.sorted.bam	288.7	1.9	0.14	58cfa831e4b0c9d6adf6c726	TCGA-D6-6825-01A-21D-1911_120518_SN1120_0143_BC0VN6ACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-D6-6825-01A	42BC2336-2408-441A-83B9-AADC9700F750	Primary Tumor	Illumina HiSeq	e785062a-dcec-4a1d-aa67-6089980c9e35	Head and Neck	73.0	D9E2F5AA-A6E2-491A-9DBC-E5D10B4ABA58	8B36C904-50A1-4B17-94A2-F9331A5FED1E	TCGA-D6-6825-01A-21D-1911-02	HG19_Broad_variant	TCGA-D6-6825	TCGA-HNSC		s15529	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T1	N0	Head and Neck Squamous Cell Carcinoma	Stage I	1911-02	True	HNSC	C2	HNSC.Basal	0.44299443200000005	0.58	0.02		0.6588	0.1145	0.7874	1.1985	2.0484	0.5867	26.0	78.0	0.773341376	1.7548900459999999	115.0	0.268103352	6.0	20.0	0.783540775	2.172436317	16.0	4.146750945	75.0	0.960454513	3.55381665	328.0906352	767.7528719	-340.0549837	0.0	491.0	0.0	491.0	6.482937442358158	7.054084239974236	-0.0731953551613369	5.846948675638161	6.114978830333909	1.585774836504084	-0.635988766719997	-0.9391054096403262	1.658970191665421
13722.58cfa831e4b0c9d6adf6c730	58cfa831e4b0c9d6adf6c730	TCGA-D1-A17N-01A-11D-A12F_120413_SN1120_0132_AD0T6RACXX_s_6_rg.sorted.filtered.	WGS	TCGA-D1-A17N-01A-11D-A12F_120413_SN1120_0132_AD0T6RACXX_s_6_rg.sorted	TCGA-D1-A17N-01A-11D-A12F_120413_SN1120_0132_AD0T6RACXX_s_6_rg.sorted.bam	98.78	1.87	0.17	58cfa831e4b0c9d6adf6c730	TCGA-D1-A17N-01A-11D-A12F_120413_SN1120_0132_AD0T6RACXX_s_6_rg.sorted.bam	Alive	FEMALE		NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A17N-01A	001E0309-9C50-42B0-9E38-347883EE2CD3	Primary Tumor	Illumina HiSeq	610d595a-df00-4af9-9644-d750501c1737	Uterus	46.0	F93931BA-8333-4E22-A430-CA02D9DA3FFC	DB0F8EE9-33A0-46CC-8218-59E18B2F824F	TCGA-D1-A17N-01A-11D-A12F-02	HG19_Broad_variant	TCGA-D1-A17N	TCGA-UCEC		s5226	Harvard Medical School	Mayo Clinic	None	NO			Endometrioid endometrial adenocarcinoma		A12F-02	True	UCEC	C3	UCEC.CN_LOW	0.239525304	0.47	0.0	10.81341903	-0.8931	-0.312	-0.0947	0.9702	-0.5655	0.2835	7.0	2.0	0.163124256	0.652497023	45.0	1.7e-05	0.0	0.0							2.72337466	-537.5058562	-1688.513766	-286.6956034	0.0	46.0	0.0	46.0	4.687597316569061	8.628287238921825	-0.06051341803539145	5.202261716642218	6.741217589889445	3.2642063221177238	0.5146644000731566	-1.8870696490323793	3.324719740153115
13722.58cfa831e4b0c9d6adf6c737	58cfa831e4b0c9d6adf6c737	TCGA-CV-7263-01A-11D-2317_120623_SN1222_0118_AD13T1ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CV-7263-01A-11D-2317_120623_SN1222_0118_AD13T1ACXX_s_8_rg.sorted	TCGA-CV-7263-01A-11D-2317_120623_SN1222_0118_AD13T1ACXX_s_8_rg.sorted.bam	170.73		0.14	58cfa831e4b0c9d6adf6c737	TCGA-CV-7263-01A-11D-2317_120623_SN1222_0118_AD13T1ACXX_s_8_rg.sorted.bam	Dead	MALE	BLACK OR AFRICAN AMERICAN		Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-7263-01A	93B742EB-5FC3-4CE2-B7F6-C89F97E0DCC9	Primary Tumor	Illumina HiSeq	d8d79518-dd53-49b5-850c-3af45043e30c	Head and Neck	64.0	54DCB9AC-FD35-49C2-A790-B1F016160183	32435F1B-5D36-4335-B25E-43B89202F1B2	TCGA-CV-7263-01A-11D-2317-26	HG19_Broad_variant	TCGA-CV-7263	TCGA-HNSC	560.0	s15776	MD Anderson - Institute for Applied Cancer Science	MD Anderson Cancer Center	United States	NO	T2	NX	Head and Neck Squamous Cell Carcinoma	Stage II	2317-26	True	HNSC	C1	HNSC.Mesenchymal	0.279192477	0.59	0.15		0.5624	0.17300000000000001	0.3381	0.7753	0.5065	0.6773	59.0	20.0	0.6955554209999999	2.840184636	75.0	0.540127885	21.0	9.0	0.806284245	3.523016961	79.0	3.308777758	28.0	0.992969593	2.916952161	-1247.015775	80.53391384	-1515.372446	1.0	560.0	1.0	560.0	7.382435456111775	8.918449454750347	-0.8287211736819655	6.587505581241888	7.8198371660822374	2.5015708680912776	-0.7949298748698879	-1.09861228866811	3.330292041773243
13722.58cfa831e4b0c9d6adf6c73a	58cfa831e4b0c9d6adf6c73a	TCGA-D7-6524-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_5_rg.sorted.filtered.	WGS	TCGA-D7-6524-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_5_rg.sorted	TCGA-D7-6524-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_5_rg.sorted.bam	274.4	1.9	0.16	58cfa831e4b0c9d6adf6c73a	TCGA-D7-6524-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6524-01A	7EF3F065-1928-4A58-B5A6-76DDDB8488CF	Primary Tumor	Illumina HiSeq	67f702e7-84ad-4d23-90e7-03040d417e4d	Stomach	53.0	6F14723A-AF83-402D-AB98-B4ED29A93AAF	48540EAA-46FD-4C0A-9893-1FF69D205F79	TCGA-D7-6524-01A-11D-1798-02	HG19_Broad_variant	TCGA-D7-6524	TCGA-STAD		s14557	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N1	Stomach  Adenocarcinoma  Diffuse Type	Stage II	1798-02	True	STAD	C1	GI.GS	0.414271509	0.82	0.1	9.812028426	0.1335	-0.022000000000000002	0.5525	0.3587	-0.163	0.8605			0.849440458	2.489739272	57.0	0.050084027	2.0	2.0	0.823572602	3.18821509	48.0	4.590799638	111.0	0.9747892979999999	1.467434959	-458.4771108	452.96850020000005	-945.725387	0.0	543.0	1.0	543.0	8.469262657658687	6.415939732441121	-1.0790096413745962	6.166677564664642	6.128257659989339	-0.6629911411842737	-2.3025850929940455	-0.2876820724517808	0.4160185001903224
13722.58cfa831e4b0c9d6adf6c741	58cfa831e4b0c9d6adf6c741	TCGA-CV-7247-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CV-7247-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_7_rg.sorted	TCGA-CV-7247-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_7_rg.sorted.bam	52.73		0.13	58cfa831e4b0c9d6adf6c741	TCGA-CV-7247-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_7_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-7247-01A	5E25AB76-A8AB-4779-AA03-8DE658F18DA1	Primary Tumor	Illumina HiSeq	0b4ae8f3-7acd-4d37-a39f-cb4fc2b537b4	Head and Neck	55.0	F84AE44B-4BB7-4841-AEE0-139CD79B9680	A5BA905A-C959-4118-B1C9-F6466CB5541A	TCGA-CV-7247-01A-11D-2317-26	HG19_Broad_variant	TCGA-CV-7247	TCGA-HNSC	577.0	s15904	MD Anderson - Institute for Applied Cancer Science	MD Anderson Cancer Center	United States	NO	T3	N0	Head and Neck Squamous Cell Carcinoma	Stage III	2317-26	True	HNSC	C1	HNSC.Classical	0.168788405	0.54	0.39		1.0555	0.4205	-0.8544	-1.4336	-0.2445	0.5495	30.0	151.0	0.46758163	1.782654966	132.0	0.536800963	19.0	24.0				0.693147181	2.0	1.0	4.108086217	-1111.231414	1099.176601	-1297.182023	1.0	577.0	1.0	577.0	5.013343488033136	5.691301529037858	-1.9628653646584189	5.999838478580539	7.440501383847117	-0.2679312817008481	0.9864949905474041	1.7491998548092584	1.6949340829575705
13722.58cfa831e4b0c9d6adf6c748	58cfa831e4b0c9d6adf6c748	TCGA-CV-6959-01A-11D-1911_120505_SN1120_0138_AD11NHACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CV-6959-01A-11D-1911_120505_SN1120_0138_AD11NHACXX_s_4_rg.sorted	TCGA-CV-6959-01A-11D-1911_120505_SN1120_0138_AD11NHACXX_s_4_rg.sorted.bam	264.7	1.9	0.13	58cfa831e4b0c9d6adf6c748	TCGA-CV-6959-01A-11D-1911_120505_SN1120_0138_AD11NHACXX_s_4_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6959-01A	EF3CE0E5-D2E8-4616-8B1A-A78C591CF235	Primary Tumor	Illumina HiSeq	ff9553cc-07a7-497f-be70-1ad5b8e09130	Head and Neck	48.0	07FB167A-3F61-4517-A79E-BA2042F10A3A	E1D21CB1-4329-447E-AC5B-EC31BF045495	TCGA-CV-6959-01A-11D-1911-02	HG19_Broad_variant	TCGA-CV-6959	TCGA-HNSC	256.0	s15903	Harvard Medical School	MD Anderson Cancer Center	United States	NO	T3	N0	Head and Neck Squamous Cell Carcinoma	Stage III	1911-02	True	HNSC	C2	HNSC.Basal	0.286581762	0.6	0.04		0.7971	0.2125	0.2021	0.2954	1.1148	0.7071	26.0	182.0	0.553514785	1.4857502130000002	94.0	0.415896728	13.0	12.0	0.8344837509999999	3.959568758	115.0	2.523210953	13.0	0.9837273959999999	2.808667652	-307.9691003	701.1497559	-735.4051915	1.0	256.0	1.0	103.0	5.811249860213214	5.100368000070761	-0.47682469320824017	5.947382034537794	6.579444094641618	1.306029997676855	0.13613217432458002	1.479076094570857	1.7828546908850953
13722.58cfa831e4b0c9d6adf6c74d	58cfa831e4b0c9d6adf6c74d	TCGA-D1-A177-01A-21D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-D1-A177-01A-21D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_1_rg.sorted	TCGA-D1-A177-01A-21D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_1_rg.sorted.bam	86.4	1.36	0.15	58cfa831e4b0c9d6adf6c74d	TCGA-D1-A177-01A-21D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A177-01A	E8C58D8B-51D7-4599-AF79-469EE6F269DB	Primary Tumor	Illumina HiSeq	cf08e174-408a-4212-8caf-72692bcb55af	Uterus	70.0	97587FD4-0F6F-4AF5-AC0A-7328ABB40E9C	2F6D7D10-84AA-48A6-9B8E-9CBB257C653D	TCGA-D1-A177-01A-21D-A12F-02	HG19_Broad_variant	TCGA-D1-A177	TCGA-UCEC		s4800	Harvard Medical School	Mayo Clinic	None	NO			Endometrioid endometrial adenocarcinoma		A12F-02	True	UCEC	C1	UCEC.MSI	0.056257308	0.02	0.0	1.7941158019999999	1.0484	0.249	-1.7291	-1.5679	-2.085	-0.4834	314.0		6.16141988	20.01144918	93.0	0.03418231	1.0	1.0							1.5009521140000002	-1682.223611	490.9779551	2128.644548	0.0	548.0	1.0	347.0	6.797766011607182	7.767475659367897	-0.2278561169409551	6.502301798713347	6.9345665364327935	3.292860332610383	-0.29546421289383584	-0.8329091229351038	3.5207164495513377
13722.58cfa831e4b0c9d6adf6c752	58cfa831e4b0c9d6adf6c752	TCGA-CV-6939-01A-11D-1911_120504_SN208_0297_BC0VJEACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CV-6939-01A-11D-1911_120504_SN208_0297_BC0VJEACXX_s_1_rg.sorted	TCGA-CV-6939-01A-11D-1911_120504_SN208_0297_BC0VJEACXX_s_1_rg.sorted.bam	193.7	1.9	0.14	58cfa831e4b0c9d6adf6c752	TCGA-CV-6939-01A-11D-1911_120504_SN208_0297_BC0VJEACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE		Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6939-01A	E7D1F0DD-EEC0-4670-A2BA-00FFE38C6382	Primary Tumor	Illumina HiSeq	28dc7c63-6d80-4648-a356-07e8f846bc80	Head and Neck	60.0	1ED822F5-FEA5-46DE-9681-EC484DE734D8	8BB4510A-C148-4A9E-8ECF-6F8C8E9309CA	TCGA-CV-6939-01A-11D-1911-02	HG19_Broad_variant	TCGA-CV-6939	TCGA-HNSC	666.0	s15515	Harvard Medical School	MD Anderson Cancer Center	United States	NO	T4a	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1911-02	True	HNSC	C1	HNSC.Atypical	0.331799096	0.54	0.16		0.8296	0.0995	0.4311	1.2124	0.4015	0.4587	14.0	32.0	0.356145628	0.920042873	95.0	0.349235148	4.0	14.0	0.90502457	4.140225836	97.0	3.520805544	37.0	0.9750444709999999	2.626500791	2.70468024	786.7461528	-1897.1464839999999	1.0	666.0	1.0	666.0	6.255475806183295	8.88566351295447	-0.37312930666782107	6.142997822756604	8.88566351295447	1.4424251962398928	-0.11247798342669002	0.0	1.8155545029077138
13722.58cfa831e4b0c9d6adf6c757	58cfa831e4b0c9d6adf6c757	TCGA-CV-7183-01A-11D-2317_120710_SN590_0166_AC0VNFACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CV-7183-01A-11D-2317_120710_SN590_0166_AC0VNFACXX_s_7_rg.sorted	TCGA-CV-7183-01A-11D-2317_120710_SN590_0166_AC0VNFACXX_s_7_rg.sorted.bam	7.43		0.14	58cfa831e4b0c9d6adf6c757	TCGA-CV-7183-01A-11D-2317_120710_SN590_0166_AC0VNFACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-7183-01A	DE206681-3E27-4D4F-8669-AEFB12B5B1E3	Primary Tumor	Illumina HiSeq	f449ea84-f7cf-4a26-bc43-707ac56f0038	Head and Neck	53.0	0BFD11FD-B227-41EF-BD54-7BE877BCE5A2	C2030338-EFEF-48CD-B893-BBDB8D85456E	TCGA-CV-7183-01A-11D-2317-26	HG19_Broad_variant	TCGA-CV-7183	TCGA-HNSC		s15652	MD Anderson - Institute for Applied Cancer Science	MD Anderson Cancer Center	United States	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	2317-26	True	HNSC	C2	HNSC.Basal	0.23297405300000001	0.49	0.05		0.0187	0.08199999999999999	-1.2303	-1.2019	-0.0414	0.5065	29.0	20.0	0.521133437	1.447592882	53.0	0.000545393	0.0	0.0				1.609437912	5.0	1.0	1.158253598	-1118.715883	278.57212000000004	-993.5670980000001	0.0	3981.0	0.0	3981.0	5.1200933635673165	3.113178564017433	-0.9162129381053967	6.04302863816014	6.668860635653313	0.9422969256210796	0.9229352745928239	3.5556820716358795	1.8585098637264763
13722.58cfa831e4b0c9d6adf6c75a	58cfa831e4b0c9d6adf6c75a	TCGA-D6-6515-01A-21D-1868_120530_SN1222_0110_AC0VLAACXX_s_7_rg.sorted.filtered.	WGS	TCGA-D6-6515-01A-21D-1868_120530_SN1222_0110_AC0VLAACXX_s_7_rg.sorted	TCGA-D6-6515-01A-21D-1868_120530_SN1222_0110_AC0VLAACXX_s_7_rg.sorted.bam	127.7	1.9	0.15	58cfa831e4b0c9d6adf6c75a	TCGA-D6-6515-01A-21D-1868_120530_SN1222_0110_AC0VLAACXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-D6-6515-01A	8E0E456E-85EE-4DE5-8F0B-72393D6ACDE0	Primary Tumor	Illumina HiSeq	5a79073a-b6a0-41df-b26b-247649784d4d	Head and Neck	82.0	4453D224-F846-4CEE-972F-8438C964913B	D6E287D9-D7C4-496C-829F-F7D7980D77A2	TCGA-D6-6515-01A-21D-1868-02	HG19_Broad_variant	TCGA-D6-6515	TCGA-HNSC	403.0	s15914	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	1868-02	True	HNSC	C2	HNSC.Mesenchymal	0.540827807	0.83	0.09		0.618	0.1035	1.0726	1.3624	2.37	0.871	9.0	0.0	0.473518171	1.035820999	49.0	0.04561929	4.0	0.0	0.8956178379999999	3.15827139	34.0	3.822195432	52.0	0.967339831	1.982333722	324.10860499999995	773.8873292000001	-475.1118659	1.0	403.0	1.0	195.0	6.089340602197485	7.303380466808328	0.02447830273596885	5.986156365962254	7.158198456963831	1.5029788577225935	-0.10318423623523065	-0.1451820098444978	1.4785005549866246
13722.58cfa831e4b0c9d6adf6c768	58cfa831e4b0c9d6adf6c768	TCGA-D1-A1O0-01A-11D-A17E_120511_SN1120_0141_BC0VK9ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-D1-A1O0-01A-11D-A17E_120511_SN1120_0141_BC0VK9ACXX_s_3_rg.sorted	TCGA-D1-A1O0-01A-11D-A17E_120511_SN1120_0141_BC0VK9ACXX_s_3_rg.sorted.bam	86.58	1.84	0.16	58cfa831e4b0c9d6adf6c768	TCGA-D1-A1O0-01A-11D-A17E_120511_SN1120_0141_BC0VK9ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A1O0-01A	A98BBE29-8817-4380-A738-3C1BF9F8E0CC	Primary Tumor	Illumina HiSeq	30d286e0-9e60-48a1-81f4-b35d81af6da1	Uterus	77.0	E113E0F0-3AE5-48A3-A226-AD920F41259E	8DF3928E-65CE-4578-96A4-BA3AE51E764C	TCGA-D1-A1O0-01A-11D-A17E-02	HG19_Broad_variant	TCGA-D1-A1O0	TCGA-UCEC		s4619	Harvard Medical School	Mayo Clinic	United States	NO			Endometrioid endometrial adenocarcinoma		A17E-02	True	UCEC	C2	UCEC.CN_HIGH	0.069396083	0.15	0.2	1.7961499840000001	1.1851	0.23199999999999998	-0.8377	-0.7029	1.2615	-0.4801	31.0	4.0	0.403244731	1.052916798	461.0	0.818841398	10.0	50.0							2.508902146	-1491.270551	123.40067890000002	-2295.428121	0.0	63.0	0.0	63.0	6.258066614263576	8.206782031940888	-0.4289466447114745	5.939612883145042	6.029966326235876	0.7503940547476007	-0.3184537311185345	-2.176815705705012	1.1793406994590752
13722.58cfa831e4b0c9d6adf6c76c	58cfa831e4b0c9d6adf6c76c	TCGA-CV-7178-01A-21D-2317_120623_SN1222_0118_AD13T1ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CV-7178-01A-21D-2317_120623_SN1222_0118_AD13T1ACXX_s_7_rg.sorted	TCGA-CV-7178-01A-21D-2317_120623_SN1222_0118_AD13T1ACXX_s_7_rg.sorted.bam	199.73		0.16	58cfa831e4b0c9d6adf6c76c	TCGA-CV-7178-01A-21D-2317_120623_SN1222_0118_AD13T1ACXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-7178-01A	8F044599-3FBE-4B69-B67D-49AEE9168545	Primary Tumor	Illumina HiSeq	f76f830b-a361-4cf5-a60f-69d4d574723f	Head and Neck	64.0	CAAB8E84-3225-4543-949E-7B7EB11244A2	A139820A-0B76-4A95-A3EE-DDDDF514A9C3	TCGA-CV-7178-01A-21D-2317-26	HG19_Broad_variant	TCGA-CV-7178	TCGA-HNSC	2166.0	s15900	MD Anderson - Institute for Applied Cancer Science	MD Anderson Cancer Center	United States	NO	T4a	N2	Head and Neck Squamous Cell Carcinoma	Stage IVA	2317-26	True	HNSC	C2	HNSC.Mesenchymal	0.308919018	0.55	0.07		0.7119	0.1995	0.5028	0.523	0.8142	0.6678	48.0	2.0	1.074891746	2.788908314	187.0	0.989688707	23.0	41.0	0.886254743	3.043387446	31.0	3.422025735	37.0	0.9476885979999999	5.277619164	-590.8771188999999	434.8703352	1027.032698	1.0	2166.0	1.0	2166.0	6.633683863578615	8.11326536262696	-0.8135244409571505	5.997695096858618	7.212478817288769	3.291237646333408	-0.635988766719997	-0.9007865453381898	4.104762087290558
13722.58cfa831e4b0c9d6adf6c772	58cfa831e4b0c9d6adf6c772	TCGA-CQ-7068-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CQ-7068-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_6_rg.sorted	TCGA-CQ-7068-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_6_rg.sorted.bam	637.73		0.15	58cfa831e4b0c9d6adf6c772	TCGA-CQ-7068-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-7068-01A	8EBE8C25-5EF9-42D4-9414-8313227B673F	Primary Tumor	Illumina HiSeq	77b40e7d-41a7-4e5d-a3e9-ce1e2d077c98	Head and Neck	80.0	1C86E4AF-03CE-477C-BE08-0CFA565861B7	F0B87929-92F5-4AB9-849F-00F970E56577	TCGA-CQ-7068-01A-11D-2317-26	HG19_Broad_variant	TCGA-CQ-7068	TCGA-HNSC		s15506	MD Anderson - Institute for Applied Cancer Science	University Health Network, Toronto	Canada	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	2317-26	True	HNSC	C2	HNSC.Basal	0.296267152	0.37	0.0		0.61	0.1655	0.5303	0.8095	2.5661	0.062	58.0	132.0	1.181743212	2.6122744680000003	121.0	0.112385813	5.0	9.0	0.8454379540000001	1.3606798969999998	5.0	3.8008792010000003	66.0	0.9072058279999999	1.430765605	517.2069098000001	321.9770014	430.14935499999996	0.0	1309.0	1.0	1148.0	5.555891622441127	5.163578001157337	0.4532597520360948	6.344348982805396	4.395819956806217	1.3401365987039564	0.7884573603642697	-0.7677580443511198	0.8868768466678616
13722.58cfa831e4b0c9d6adf6c774	58cfa831e4b0c9d6adf6c774	TCGA-D1-A174-01A-11D-A12F_120522_SN208_0301_BC0VNWACXX_s_3_rg.sorted.filtered.	WGS	TCGA-D1-A174-01A-11D-A12F_120522_SN208_0301_BC0VNWACXX_s_3_rg.sorted	TCGA-D1-A174-01A-11D-A12F_120522_SN208_0301_BC0VNWACXX_s_3_rg.sorted.bam	124.95	1.37	0.15	58cfa831e4b0c9d6adf6c774	TCGA-D1-A174-01A-11D-A12F_120522_SN208_0301_BC0VNWACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A174-01A	FC7315B0-9F48-4206-B197-2268C0518EB4	Primary Tumor	Illumina HiSeq	6ec3f35d-55a7-439a-b179-8a4aebcab751	Uterus	51.0	AD5A9CB6-B3F9-4651-B6D1-13C78010BD88	D661CFB9-248A-49E6-B0DB-865CA257E8DC	TCGA-D1-A174-01A-11D-A12F-02	HG19_Broad_variant	TCGA-D1-A174	TCGA-UCEC		s4614	Harvard Medical School	Mayo Clinic	None	NO			Endometrioid endometrial adenocarcinoma		A12F-02	True	UCEC	C3	UCEC.MSI	0.30429977399999997	0.38	0.05	29.52018835	-0.1493	-0.231	0.0752	2.1086	-0.5205	0.0886	253.0		6.2873933189999995	20.6313599	53.0	0.0005856069999999999	0.0	0.0							2.2655938140000003	-373.8394247	-1080.718733	2072.646581	0.0	594.0	0.0	594.0	6.733151233858857	7.21081845347222	0.27333641384474405	5.806389202117407	6.181199036291062	2.0873886033723674	-0.9267620317414509	-1.029619417181158	1.8140521895276236
13722.58cfa831e4b0c9d6adf6c778	58cfa831e4b0c9d6adf6c778	TCGA-D1-A17D-01A-12D-A12F_120522_SN208_0301_BC0VNWACXX_s_4_rg.sorted.filtered.	WGS	TCGA-D1-A17D-01A-12D-A12F_120522_SN208_0301_BC0VNWACXX_s_4_rg.sorted	TCGA-D1-A17D-01A-12D-A12F_120522_SN208_0301_BC0VNWACXX_s_4_rg.sorted.bam	99.41	2.0	0.15	58cfa831e4b0c9d6adf6c778	TCGA-D1-A17D-01A-12D-A12F_120522_SN208_0301_BC0VNWACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A17D-01A	7DDEDDD1-B2AD-425F-94A2-9C476B959F2A	Primary Tumor	Illumina HiSeq	9d6f1593-568e-447d-b4f7-10048102ce8f	Uterus	58.0	9EC5A25B-9CE1-4FDE-9341-13DA39BC74B0	0F6ECDCA-5659-426A-8DAC-3211183597BD	TCGA-D1-A17D-01A-12D-A12F-02	HG19_Broad_variant	TCGA-D1-A17D	TCGA-UCEC		s4443	Harvard Medical School	Mayo Clinic	None	NO			Endometrioid endometrial adenocarcinoma		A12F-02	True	UCEC	C3	UCEC.MSI	0.234768476	0.33	0.0	1.7456330230000001	-0.1977	-0.166	-0.2639	0.3862	-0.5591	-0.0639	178.0	704.0	4.08415004	11.82812284	35.0	2.11e-05	0.0	0.0							2.1287772869999997	-1461.955937	-1437.444251	249.5525881	0.0	926.0	0.0	926.0	7.858215526626389	7.50341212715346	-1.564418144762997	6.497238973490789	6.656114266766258	1.7781698952474099	-1.3609765531356004	-0.8472978603872034	3.342588040010407
13722.58cfa831e4b0c9d6adf6c77e	58cfa831e4b0c9d6adf6c77e	TCGA-CS-5396-01A-02D-1465_130906_SN1440_0166_BC2A68ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CS-5396-01A-02D-1465_130906_SN1440_0166_BC2A68ACXX_s_4_rg.sorted	TCGA-CS-5396-01A-02D-1465_130906_SN1440_0166_BC2A68ACXX_s_4_rg.sorted.bam	152.7	1.9	0.15	58cfa831e4b0c9d6adf6c77e	TCGA-CS-5396-01A-02D-1465_130906_SN1440_0166_BC2A68ACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-CS-5396-01A	B6C2C9BD-625B-4A98-830C-49C344F6CB5F	Primary Tumor	Illumina HiSeq	3d26b7bb-4cc9-4d9b-8c42-6fbd2ea9b590	Brain	53.0	CE1ED4B3-AF89-4BBD-B9A6-EEFA007E4368	F2F5E5EE-B807-4CAF-99B3-68270C1F305E	TCGA-CS-5396-01A-02D-1465-02	HG19_Broad_variant	TCGA-CS-5396	TCGA-LGG		s8342	Harvard Medical School	Thomas Jefferson University	United States	NO			Oligodendroglioma		1465-02	True	LGG	C5	GBM_LGG.Codel	0.065778303	0.11	0.09		-1.0081	-0.47	-0.349	-2.4271	-0.6218	-0.6027	14.0	1.0	0.20382176300000002	0.698817473	71.0	0.21335420800000002	6.0	3.0					0.0		3.256866306	-67.91409237	-1010.451857	-2108.134728	0.0	1631.0	0.0	1631.0	8.135346948906706	6.750165358407366	-0.5142339058845101	5.832761855912661	6.219537107345196	2.513958972382502	-2.3025850929940455	-0.5306282510621703	3.0281928782670127
13722.58cfa831e4b0c9d6adf6c77f	58cfa831e4b0c9d6adf6c77f	TCGA-D7-6815-01A-11D-1880_130111_SN208_0447_AC1JP0ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-D7-6815-01A-11D-1880_130111_SN208_0447_AC1JP0ACXX_s_1_rg.sorted	TCGA-D7-6815-01A-11D-1880_130111_SN208_0447_AC1JP0ACXX_s_1_rg.sorted.bam	457.0	1.9	0.15	58cfa831e4b0c9d6adf6c77f	TCGA-D7-6815-01A-11D-1880_130111_SN208_0447_AC1JP0ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6815-01A	53086E20-A727-40D6-B42D-8030109B5130	Primary Tumor	Illumina HiSeq	aaa1a66d-814e-403e-bd88-38f4e3ea8c47	Stomach	70.0	B5F3D9A1-46B5-4A63-8F7D-9C993FE9340D	810C88A8-62F3-42C6-BBFD-A9D65E2A07A4	TCGA-D7-6815-01A-11D-1880-02	HG19_Broad_variant	TCGA-D7-6815	TCGA-STAD		s14497	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N2	Stomach  Intestinal Adenocarcinoma  Tubular Type	Stage IIB	1880-02	True	STAD	C1	GI.CIN	0.101428429	0.18	0.54	15.85788676	0.6565	0.109	-0.0771	-0.1138	-0.0044	0.3006			1.443324806	3.030982093	163.0	0.6571648520000001	4.0	19.0	0.52644113	2.455026145	106.0	3.604370634	52.0	0.9122116709999999	3.930281393	-231.2237176	301.79067139999995	1154.570203	0.0	486.0	0.0	486.0	7.3658128372094716	6.8870422373845965	-0.8247967903722841	5.014437580045994	5.845588362556435	2.799690652017573	-2.3513752571634776	-1.0414538748281612	3.624487442389857
13722.58cfa831e4b0c9d6adf6c78a	58cfa831e4b0c9d6adf6c78a	TCGA-CV-5439-01A-01D-1681_120427_SN1120_0136_AC0JEMACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CV-5439-01A-01D-1681_120427_SN1120_0136_AC0JEMACXX_s_1_rg.sorted	TCGA-CV-5439-01A-01D-1681_120427_SN1120_0136_AC0JEMACXX_s_1_rg.sorted.bam	262.0	1.9	0.17	58cfa831e4b0c9d6adf6c78a	TCGA-CV-5439-01A-01D-1681_120427_SN1120_0136_AC0JEMACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-5439-01A	3EE863DA-7991-414F-82D8-2B6502D4C061	Primary Tumor	Illumina HiSeq	e10c02de-cabd-4311-baab-3bb90e13717f	Head and Neck	62.0	C94D8E61-8A15-4702-90EF-37616F1C015B	A1170138-A1B1-4D13-B66B-0507D3DE897B	TCGA-CV-5439-01A-01D-1681-02	HG19_Broad_variant	TCGA-CV-5439	TCGA-HNSC	546.0	s16194	Harvard Medical School	MD Anderson Cancer Center	None	NO	T3	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	True	HNSC	C2	HNSC.Basal	0.296703881	0.53	0.24		0.171	0.034	-0.3138	0.4936	0.7227	0.0302	46.0	254.0	1.056266119	2.74629191	63.0	0.525269019	15.0	19.0				2.231606952	11.0	0.930652384	2.769952964	-250.45458530000002	-398.2459888	-316.4772925	1.0	546.0	1.0	211.0	6.669546897725718	5.205642432781798	0.3663867046413304	6.461907532947473	7.677367345867734	0.8652881774217823	-0.2076393647782444	2.471724913085936	0.49890147278045194
13722.58cfa831e4b0c9d6adf6c78f	58cfa831e4b0c9d6adf6c78f	TCGA-CZ-4856-01A-02D-2101-10_Illumina.filtered.	WGS	TCGA-CZ-4856-01A-02D-2101-10_Illumina	TCGA-CZ-4856-01A-02D-2101-10_Illumina.bam	34.73	1.9	0.15	58cfa831e4b0c9d6adf6c78f	TCGA-CZ-4856-01A-02D-2101-10_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-CZ-4856-01A	FCECAFA8-8B8B-4AE6-81BC-73ACF05B211A	Primary Tumor	Illumina HiSeq	5cf38428-0ee7-4a06-8f49-c41a19ad6f74	Kidney	62.0	6F6C9F00-D6E5-452F-BA04-F77B146B780B	9FB40473-74CB-43CB-9A54-C990B8BBDE17	TCGA-CZ-4856-01A-02D-2101-10	GRCh37-lite	TCGA-CZ-4856	TCGA-KIRC		s9453	Baylor College of Medicine	Harvard	None	NO	T1b	N0	Kidney Clear Cell Renal Carcinoma	Stage I	2101-10	False	KIRC	C3	KIRC.1	0.279851381	0.59	0.0		-1.4002	-0.253	0.7335	1.1554	0.5761	0.1505	33.0	48.0	0.336256071	1.569194999	89.0	0.113015571	3.0	6.0	0.942915636	3.501585168	41.0	4.061583975	71.0	0.9528240659999999	1.752435685	212.9016111	-738.8397838999999	2352.005529	0.0	18.0	0.0	18.0	8.713737682444014	-0.533285369076518	0.21647762615998922	5.448581105011807	2.5178931487843057	3.217953740893232	-3.265156577432207	3.0511785178608237	3.0014761147332427
13722.58cfa831e4b0c9d6adf6c794	58cfa831e4b0c9d6adf6c794	TCGA-CN-6017-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CN-6017-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_2_rg.sorted	TCGA-CN-6017-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_2_rg.sorted.bam	69.0	1.9	0.15	58cfa831e4b0c9d6adf6c794	TCGA-CN-6017-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-6017-01A	23C4E2EB-142B-4FCC-A974-9A248AEC3F37	Primary Tumor	Illumina HiSeq	e0dae8a5-f74f-4e25-98c2-238e28c54863	Head and Neck	55.0	6C07CD48-2269-4D42-9879-309EA4CD3A74	48A22F9A-2A18-4FCA-8271-44B3F7C3A628	TCGA-CN-6017-01A-11D-1681-02	HG19_Broad_variant	TCGA-CN-6017	TCGA-HNSC		s16181	Harvard Medical School	University of Pittsburgh	United States	NO	T3	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	True	HNSC	C2	HNSC.Mesenchymal	0.644661619	0.53	0.0		0.0764	-0.038	1.1239	2.3009	1.9328	0.7566	0.0		0.060977406	0.060977406	35.0	0.000136324	0.0	0.0	0.621809675	3.5059834839999997	281.0	4.129015218	69.0	0.97517982	1.847093352	874.9821193	122.5233735	483.31680199999994	1.0	853.0	0.0	853.0	6.080356870058502	9.654762625743235	0.005736762785183647	5.444368103338505	8.417999998594308	2.084539258751505	-0.6359887667199966	-1.2367626271489267	2.0788024959663214
13722.58cfa831e4b0c9d6adf6c79a	58cfa831e4b0c9d6adf6c79a	TCGA-CV-7255-01A-11D-2276-10_Illumina.filtered.	WGS	TCGA-CV-7255-01A-11D-2276-10_Illumina	TCGA-CV-7255-01A-11D-2276-10_Illumina.bam	143.73		0.05	58cfa831e4b0c9d6adf6c79a	TCGA-CV-7255-01A-11D-2276-10_Illumina.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-7255-01A	534F85F2-B9EB-45BE-87D5-C3DFFD13D541	Primary Tumor	Illumina HiSeq	7f307e2b-3164-4bb0-aa04-90c538b8bb46	Head and Neck	32.0	45A42060-1F1C-45FF-9717-9BE2F7FDF3F7	1AFF91A6-1B0F-4575-8F4B-4E064A50B886	TCGA-CV-7255-01A-11D-2276-10	GRCh37-lite	TCGA-CV-7255	TCGA-HNSC	64.0	s16051	Baylor College of Medicine	MD Anderson Cancer Center	United States	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	2276-10	True	HNSC	C2	HNSC.Basal	0.09529218800000001	0.35	0.11		0.6491	0.1935	-1.2279	-1.551	1.3714	0.3834	46.0	74.0	0.872010588	2.7322998419999998	112.0	0.8471523240000001	24.0	19.0		0.0	1.0	0.0	1.0		4.948430729	-600.8228426	333.96117819999995	-2212.853219	1.0	64.0	1.0	64.0	1.833501203040024	4.674419814633558	-1.5187670671226097	5.303304908059076	6.106176549830207	2.574589352726597	3.4698037050190518	1.4317567351966485	4.093356419849206
13722.58cfa831e4b0c9d6adf6c7a3	58cfa831e4b0c9d6adf6c7a3	TCGA-CV-6954-01A-11D-1911_120505_SN1120_0138_AD11NHACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CV-6954-01A-11D-1911_120505_SN1120_0138_AD11NHACXX_s_3_rg.sorted	TCGA-CV-6954-01A-11D-1911_120505_SN1120_0138_AD11NHACXX_s_3_rg.sorted.bam	62.7	1.9	0.15	58cfa831e4b0c9d6adf6c7a3	TCGA-CV-6954-01A-11D-1911_120505_SN1120_0138_AD11NHACXX_s_3_rg.sorted.bam	Dead	MALE	BLACK OR AFRICAN AMERICAN		Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6954-01A	402FD96C-76D3-4AC2-9F64-77BD34BE0ADB	Primary Tumor	Illumina HiSeq	115469a6-3c3e-4a3b-adf9-ed831266829c	Head and Neck	59.0	F72D39EA-7DB5-47C6-9428-3E26454C9A9A	7FA6660F-0B18-4F4D-AEA1-17C22A9DBAA6	TCGA-CV-6954-01A-11D-1911-02	HG19_Broad_variant	TCGA-CV-6954	TCGA-HNSC	2002.0	s16341	Harvard Medical School	MD Anderson Cancer Center	United States	NO	T4a	NX	Head and Neck Squamous Cell Carcinoma	Stage IVA	1911-02	True	HNSC	C2	HNSC.Basal	0.31117573	0.51	0.11		0.4419	0.1065	0.0392	-0.2648	1.6917	0.4721	73.0	37.0	0.969704435	3.232348118	158.0	0.477454626	15.0	22.0	0.593819664	0.9557158809999999	5.0	2.4282736380000003	13.0	0.946714067	3.542000699	213.96937230000003	699.2288735000001	-2470.5476329999997	1.0	2002.0	0.0	2002.0	7.156523257934692	8.297146402679335	-0.1768060914373205	6.955852562472542	8.818443326312622	1.457960056455379	-0.2006706954621511	0.5212969236332858	1.6347661478926994
13722.58cfa831e4b0c9d6adf6c7aa	58cfa831e4b0c9d6adf6c7aa	TCGA-D1-A17R-01A-11D-A12F_120523_SN1222_0109_BD12MPACXX_s_1_rg.sorted.filtered.	WGS	TCGA-D1-A17R-01A-11D-A12F_120523_SN1222_0109_BD12MPACXX_s_1_rg.sorted	TCGA-D1-A17R-01A-11D-A12F_120523_SN1222_0109_BD12MPACXX_s_1_rg.sorted.bam	76.31	1.88	0.16	58cfa831e4b0c9d6adf6c7aa	TCGA-D1-A17R-01A-11D-A12F_120523_SN1222_0109_BD12MPACXX_s_1_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A17R-01A	73A0DD38-115D-48FB-B683-04AA5D612F2A	Primary Tumor	Illumina HiSeq	5425360b-22c2-480d-aa90-d7b4b67dad49	Uterus	58.0	205DE3E7-B078-4904-82C3-3D0F757D94A8	DF3E4C9B-67D4-46FF-BFE0-4F55A72CA179	TCGA-D1-A17R-01A-11D-A12F-02	HG19_Broad_variant	TCGA-D1-A17R	TCGA-UCEC	339.0	s5227	Harvard Medical School	Mayo Clinic	None	NO			Endometrioid endometrial adenocarcinoma		A12F-02	True	UCEC	C1	UCEC.MSI	0.07060771	0.15	0.0	5.174288271	0.0499	-0.094	-0.7957	-1.1187	-1.0339	0.5472	97.0	251.0	1.7373133840000001	5.944869237000001	71.0	0.5817875370000001	8.0	3.0							3.027558892	-1330.3540560000001	-855.67846	1741.018533	1.0	339.0	0.0	339.0	5.974911633766914	7.637647583478913	-1.0001248423904483	6.262593706218695	6.448063516605076	3.54565372755084	0.2876820724517808	-1.1895840668738364	4.545778569941288
13722.58cfa831e4b0c9d6adf6c7ac	58cfa831e4b0c9d6adf6c7ac	TCGA-D6-6827-01A-11D-1911_120518_SN1120_0143_BC0VN6ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-D6-6827-01A-11D-1911_120518_SN1120_0143_BC0VN6ACXX_s_4_rg.sorted	TCGA-D6-6827-01A-11D-1911_120518_SN1120_0143_BC0VN6ACXX_s_4_rg.sorted.bam	262.7	1.9	0.14	58cfa831e4b0c9d6adf6c7ac	TCGA-D6-6827-01A-11D-1911_120518_SN1120_0143_BC0VN6ACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-D6-6827-01A	3C5BC678-41E9-46B3-9686-5CD95659AB71	Primary Tumor	Illumina HiSeq	849f41d7-0557-40ce-bca0-8a54c496fef2	Head and Neck	55.0	C53D6135-C614-45F4-8F41-49B20ED4A549	E2CDC496-8A62-4501-98C0-2AF2CCF48988	TCGA-D6-6827-01A-11D-1911-02	HG19_Broad_variant	TCGA-D6-6827	TCGA-HNSC		s16057	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T1	N0	Head and Neck Squamous Cell Carcinoma	Stage I	1911-02	True	HNSC	C1		0.060148365	0.25	0.03		0.6459	0.11900000000000001	-0.2226	-0.1734	-0.1828	0.2005	6.0	57.0	0.147539703	0.32458734699999997	316.0	0.222166492	6.0	6.0	0.863518839	1.795636945	8.0	2.3025850930000002	10.0	1.0	2.447951312	-909.5844792000001	1053.895949	-3137.7829070000003	0.0	568.0	0.0	568.0	6.606199634264485	7.1868405042084	-0.2322331902054785	5.650688189237049	5.0974486316753955	1.644152348369348	-0.9555114450274362	-2.0893918725330045	1.8763855385748265
13722.58cfa831e4b0c9d6adf6c7b1	58cfa831e4b0c9d6adf6c7b1	TCGA-CN-6996-01A-11D-1911_120504_SN1222_0101_AC0UMDACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CN-6996-01A-11D-1911_120504_SN1222_0101_AC0UMDACXX_s_5_rg.sorted	TCGA-CN-6996-01A-11D-1911_120504_SN1222_0101_AC0UMDACXX_s_5_rg.sorted.bam	155.7		0.15	58cfa831e4b0c9d6adf6c7b1	TCGA-CN-6996-01A-11D-1911_120504_SN1222_0101_AC0UMDACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-6996-01A	49B94421-FE82-4F24-8EF2-820674142418	Primary Tumor	Illumina HiSeq	533cea76-ea79-4b37-8e72-5626bc894990	Head and Neck	58.0	2C3790CE-A54D-431B-B76C-FA25441AA41C	5367CF72-E404-4203-AD7D-CF7663072EA7	TCGA-CN-6996-01A-11D-1911-02	HG19_Broad_variant	TCGA-CN-6996	TCGA-HNSC		s16180	Harvard Medical School	University of Pittsburgh	United States	NO	T3	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1911-02	True	HNSC	C2		0.366462711	0.54	0.51		0.7019	0.11199999999999999	0.7586	1.1654	2.4055	0.5969	20.0	55.0	0.415274077	1.3348095340000001	87.0	0.268366813	5.0	13.0	0.6516497370000001	2.994408642	99.0	3.889182954	52.0	0.984293359	2.413140384	272.5733749	580.991455	-206.10866130000002	1.0	530.0	1.0	350.0	5.684120746524176	5.556069362487367	-0.13078156963016752	5.137577040156106	6.445926837293366	2.8703623908845497	-0.54654370636807	0.8898574748059991	3.001143960514717
13722.58cfa831e4b0c9d6adf6c7ba	58cfa831e4b0c9d6adf6c7ba	TCGA-CN-6011-01A-11D-A32X-10_wgs_Illumina.filtered.	WGS	TCGA-CN-6011-01A-11D-A32X-10_wgs_Illumina	TCGA-CN-6011-01A-11D-A32X-10_wgs_Illumina.bam	193.0	1.9	0.08	58cfa831e4b0c9d6adf6c7ba	TCGA-CN-6011-01A-11D-A32X-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-6011-01A	E7D49212-E9CB-4CD7-923A-BDFC82A4A150	Primary Tumor	Illumina HiSeq	33680362-5ef1-477f-9dbc-64dc2ed0d5a8	Head and Neck	57.0	AFBF3020-1715-4E74-8224-05E316796999	21205681-A0C7-48D0-81D4-0B7EF31158CF	TCGA-CN-6011-01A-11D-A32X-10	GRCh37-lite	TCGA-CN-6011	TCGA-HNSC		s15500	Baylor College of Medicine	University of Pittsburgh	None	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	A32X-10	True	HNSC	C2	HNSC.Basal	0.15225140199999998	0.32	0.08		0.3037	-0.06	-0.2487	-0.7118	2.3035	0.3359	129.0	78.0	2.970644605	9.124122716	253.0	0.7584365	13.0	39.0				1.846220219	7.0	0.94876951	3.417198926	-296.0394216	36.46591997	349.0327862	0.0	933.0	0.0	933.0	6.682609724997254	4.645703766828095	-0.15028220304933781	5.113993807083409	3.7190022989361013		-1.5686159179138455	-0.926701467891994	
13722.58cfa831e4b0c9d6adf6c7bc	58cfa831e4b0c9d6adf6c7bc	TCGA-CN-6019-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CN-6019-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_4_rg.sorted	TCGA-CN-6019-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_4_rg.sorted.bam	172.0	1.9	0.15	58cfa831e4b0c9d6adf6c7bc	TCGA-CN-6019-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-6019-01A	EE3061EC-273C-4BEF-A325-35E9C469BF01	Primary Tumor	Illumina HiSeq	e7b9cb7d-0a1a-4461-ab89-108d02821762	Head and Neck	61.0	AC349695-2219-4A67-ADD5-A94FF85794E1	2C509E96-12D7-4DBB-A02F-DCDCC6F76952	TCGA-CN-6019-01A-11D-1681-02	HG19_Broad_variant	TCGA-CN-6019	TCGA-HNSC		s16178	Harvard Medical School	University of Pittsburgh	United States	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	True	HNSC	C6	HNSC.Mesenchymal	0.30541325199999997	0.64	0.2		-0.6997	-0.1695	1.0627	1.0336	-0.1719	1.195	55.0	5.0	0.814586702	3.499705829	50.0	0.28627031399999997	10.0	14.0	0.956403835	2.8651298360000004	20.0	3.308777758	28.0	0.992969593	3.1583158389999997	259.6072583	-669.1712305	-551.8647532000001	0.0	1038.0	0.0	1038.0	5.031339025305628	7.896960073304463	-0.921037917657562	4.224247585396465	6.214094692315545	2.3712175391752393	-0.8070914399091631	-1.6828653809889178	3.292255456832801
13722.58cfa831e4b0c9d6adf6c7be	58cfa831e4b0c9d6adf6c7be	TCGA-CV-6956-01A-21D-A32X-10_wgs_Illumina.filtered.	WGS	TCGA-CV-6956-01A-21D-A32X-10_wgs_Illumina	TCGA-CV-6956-01A-21D-A32X-10_wgs_Illumina.bam	124.43		0.07	58cfa831e4b0c9d6adf6c7be	TCGA-CV-6956-01A-21D-A32X-10_wgs_Illumina.bam	Dead	MALE	WHITE	HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6956-01A	8C238D30-DF8E-4E6B-98FC-21696269A294	Primary Tumor	Illumina HiSeq	f9762350-aee5-49d2-a5de-165317ff2bd3	Head and Neck	67.0	8B9F33FA-04EF-4767-93D1-98F6E420D037	5046F1B4-9D95-4841-BA30-691FA44719A2	TCGA-CV-6956-01A-21D-A32X-10	GRCh37-lite	TCGA-CV-6956	TCGA-HNSC	217.0	s16201	Baylor College of Medicine	MD Anderson Cancer Center	United States	NO	T3	N1	Head and Neck Squamous Cell Carcinoma	Stage III	A32X-10	True	HNSC	C2	HNSC.Basal	0.120084447	0.42	0.07		0.8449	0.21	-1.7512	-2.4474	0.6422	0.2037	72.0	15.0	2.020573479	4.421834715	258.0	0.47951392	10.0	24.0					0.0		4.565345882	-797.5375856	893.9493997999999	190.650041	1.0	217.0	1.0	217.0	4.30957155545846	3.1163747458568505	-1.9511244942233994	5.7511285952534	4.698505195850047	0.7428739534231603	1.4415570397949407	1.5821304499931967	2.6939984476465595
13722.58cfa831e4b0c9d6adf6c7c6	58cfa831e4b0c9d6adf6c7c6	TCGA-CW-6087-01A-11D-2279-10_wgs_Illumina.filtered.	WGS	TCGA-CW-6087-01A-11D-2279-10_wgs_Illumina	TCGA-CW-6087-01A-11D-2279-10_wgs_Illumina.bam	47.4	1.9	0.05	58cfa831e4b0c9d6adf6c7c6	TCGA-CW-6087-01A-11D-2279-10_wgs_Illumina.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-CW-6087-01A	BBDAA931-E922-49BE-BFBF-FA0C2AE27D7A	Primary Tumor	Illumina HiSeq	efcf45d7-17bb-4653-908f-773b5045531c	Kidney	61.0	B4F9B73B-94DB-4E0F-AF55-CF0583318A4A	2C581A74-7716-4C20-B366-A8E1D9A901F6	TCGA-CW-6087-01A-11D-2279-10	GRCh37-lite	TCGA-CW-6087	TCGA-KIRC	41.0	s9452	Baylor College of Medicine	Mayo Clinic - Rochester	United States	NO	T3a	N1	Kidney Clear Cell Renal Carcinoma	Stage IV	2279-10	False	KIRC	C3	KIRC.3	0.6097954879999999				0.2577	-0.015	1.9729	2.2025	1.0253	0.2337	38.0	36.0	0.584284653	1.5191400990000001	55.0	0.16291328300000002			0.946705578	3.392537369	36.0	3.9327734010000004	198.0	0.74367905	1.4198657419999998	1081.0249410000001	233.55268540000003	1178.470611	1.0	41.0	0.0	41.0	7.238109940240099	1.6933314574678526	0.09067827292511066	5.911238999591008	4.961522243158832	4.349989016436263	-1.3268709406490897	3.2681907856909795	4.259310743511152
13722.58cfa831e4b0c9d6adf6c7c8	58cfa831e4b0c9d6adf6c7c8	TCGA-D1-A17K-01A-11D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-D1-A17K-01A-11D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_2_rg.sorted	TCGA-D1-A17K-01A-11D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_2_rg.sorted.bam	56.36	1.95	0.15	58cfa831e4b0c9d6adf6c7c8	TCGA-D1-A17K-01A-11D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A17K-01A	5C22C8D6-5805-455C-8E1C-E6B8006738E4	Primary Tumor	Illumina HiSeq	312dd86a-5fc1-4446-bfd6-fe867e3617f2	Uterus	74.0	CA213835-EFC5-4216-A762-A6B320B516BF	3E67F5BD-C5A6-4CDD-8D71-78038D316447	TCGA-D1-A17K-01A-11D-A12F-02	HG19_Broad_variant	TCGA-D1-A17K	TCGA-UCEC		s4617	Harvard Medical School	Mayo Clinic	None	NO			Endometrioid endometrial adenocarcinoma		A12F-02	True	UCEC	C2	UCEC.CN_HIGH	0.11776962	0.08	0.07	6.323661921	0.8208	0.305	-0.6729	-0.4158	1.1474	-0.4195	30.0	99.0	0.6789078270000001	1.4992547859999998	293.0	0.7878455440000001	4.0	29.0							4.078911237	-997.4569122000001	-40.217575	-870.8901527999999	0.0	854.0	1.0	815.0	5.5268820941320795	6.333025853236666	-0.6905967328493299	5.383781250491406	5.604787352865451	6.321068009523319	-0.14310084364067333	-0.7282385003712157	7.011664742372649
13722.58cfa831e4b0c9d6adf6c7cb	58cfa831e4b0c9d6adf6c7cb	TCGA-CX-7085-01A-21D-2317_120710_SN590_0166_AC0VNFACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CX-7085-01A-21D-2317_120710_SN590_0166_AC0VNFACXX_s_3_rg.sorted	TCGA-CX-7085-01A-21D-2317_120710_SN590_0166_AC0VNFACXX_s_3_rg.sorted.bam	262.73		0.15	58cfa831e4b0c9d6adf6c7cb	TCGA-CX-7085-01A-21D-2317_120710_SN590_0166_AC0VNFACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CX-7085-01A	2A7B4613-F908-4E78-98ED-857DCD7ED774	Primary Tumor	Illumina HiSeq	2a118e3e-c8f9-43b4-b1d7-4659e37a96ce	Head and Neck	77.0	A07E086C-1D2D-4D92-A663-ECD7EA4DBD73	57FA3BBB-D571-475C-95A2-AAEDFF4835FC	TCGA-CX-7085-01A-21D-2317-26	HG19_Broad_variant	TCGA-CX-7085	TCGA-HNSC		s16056	MD Anderson - Institute for Applied Cancer Science	Medical College of Georgia	United States	NO	T1	N0	Head and Neck Squamous Cell Carcinoma	Stage I	2317-26	True	HNSC	C1	HNSC.Mesenchymal	0.571293705	0.81	0.0		-0.0442	-0.131	1.0704	1.8259	1.2392	1.0416	43.0	0.0	0.873975348	2.9132511589999996	43.0	6.05e-05	0.0	3.0	0.8758430490000001	5.314988371	432.0	3.9365583560000004	53.0	0.991503507	2.130509354	949.4335097999999	352.0906619	-474.5775307	0.0	321.0	1.0	92.0	1.8207277008956586	6.133133960989293	-0.6514397178757156	5.382855449370451	4.396269539463615	1.0479564523157279	3.5621277484747926	-1.736864421525678	1.6993961701914435
13722.58cfa831e4b0c9d6adf6c7ce	58cfa831e4b0c9d6adf6c7ce	TCGA-CV-7434-01A-11D-2317_120730_SN1222_0141_BC115GACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CV-7434-01A-11D-2317_120730_SN1222_0141_BC115GACXX_s_3_rg.sorted	TCGA-CV-7434-01A-11D-2317_120730_SN1222_0141_BC115GACXX_s_3_rg.sorted.bam	274.73		0.14	58cfa831e4b0c9d6adf6c7ce	TCGA-CV-7434-01A-11D-2317_120730_SN1222_0141_BC115GACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-7434-01A	63B50E1C-7948-464F-BFF1-8E0E5DAAFCC5	Primary Tumor	Illumina HiSeq	c645c62d-79d3-478c-a9c4-16294daad71c	Head and Neck	64.0	2CB75C6E-CA4F-4A88-9679-812A51C7B832	4A4BF5E3-272F-492C-9755-BBFE14D3BEE1	TCGA-CV-7434-01A-11D-2317-26	HG19_Broad_variant	TCGA-CV-7434	TCGA-HNSC	218.0	s15528	MD Anderson - Institute for Applied Cancer Science	MD Anderson Cancer Center	United States	NO	T4a	N1	Head and Neck Squamous Cell Carcinoma	Stage IVA	2317-26	True	HNSC	C2	HNSC.Basal	0.133889929	0.29	0.02		0.9266	0.2735	-0.2239	-0.9021	2.6235	0.2842	29.0	21.0	0.7543760829999999	2.3838284219999997	154.0	0.288939171	9.0	23.0	0.8889220529999999	3.3224969489999996	42.0	0.693147181	2.0	1.0	2.004282043	-51.63986164	547.5180922000001	-1537.622537	1.0	218.0	0.0	218.0	5.077978422946077	6.003228414028223	0.3784579066968531	5.404375007578548	5.8395989902464205	2.2603684729192053	0.32639658463247123	-0.16362942378180234	1.8819105662223523
13722.58cfa831e4b0c9d6adf6c7d0	58cfa831e4b0c9d6adf6c7d0	TCGA-CV-6945-01A-11D-1911_120504_SN208_0297_BC0VJEACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CV-6945-01A-11D-1911_120504_SN208_0297_BC0VJEACXX_s_2_rg.sorted	TCGA-CV-6945-01A-11D-1911_120504_SN208_0297_BC0VJEACXX_s_2_rg.sorted.bam	155.7	1.9	0.14	58cfa831e4b0c9d6adf6c7d0	TCGA-CV-6945-01A-11D-1911_120504_SN208_0297_BC0VJEACXX_s_2_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6945-01A	15714E69-E075-4688-8F51-C7102FE4CA07	Primary Tumor	Illumina HiSeq	50a2b9f7-d572-47c4-bf4b-3d6255512094	Head and Neck	41.0	55849997-67DE-4FC6-B7BF-9D02D15920C9	FC2ACD2E-751C-4252-85A1-6C5A8E980964	TCGA-CV-6945-01A-11D-1911-02	HG19_Broad_variant	TCGA-CV-6945	TCGA-HNSC	366.0	s15775	Harvard Medical School	MD Anderson Cancer Center	United States	NO	T4a	N2	Head and Neck Squamous Cell Carcinoma	Stage IVA	1911-02	True	HNSC	C2	HNSC.Basal	0.272472129	0.6	0.09		0.5806	0.3235	-0.9726	-1.3217	0.5581	0.5997	40.0	71.0	1.268673809	3.127428459	166.0	0.633899041	24.0	30.0				0.6365141679999999	2.0	0.918295834	5.01615798	-711.8540811	204.751226	-1732.714393	1.0	366.0	1.0	366.0	5.903268536370065	6.366376521706401	-2.1203491856369983	6.109120590574214	6.681219416404232	-0.3167001992517724	0.20585205420414887	0.314842894697831	1.8036489863852256
13722.58cfa831e4b0c9d6adf6c7da	58cfa831e4b0c9d6adf6c7da	TCGA-CV-7091-01A-11D-2317_120623_SN1222_0119_BC0WLLACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CV-7091-01A-11D-2317_120623_SN1222_0119_BC0WLLACXX_s_8_rg.sorted	TCGA-CV-7091-01A-11D-2317_120623_SN1222_0119_BC0WLLACXX_s_8_rg.sorted.bam	289.73		0.15	58cfa831e4b0c9d6adf6c7da	TCGA-CV-7091-01A-11D-2317_120623_SN1222_0119_BC0WLLACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-7091-01A	2A192049-6435-49AB-8444-DDEB2B9EE774	Primary Tumor	Illumina HiSeq	8a0170b3-9cda-4426-be4b-9e488f6244c2	Head and Neck	54.0	3AB78DC4-682E-4B5A-ADDA-223ACF0FBB6A	78998DCE-A468-416B-9F81-D64E43B52883	TCGA-CV-7091-01A-11D-2317-26	HG19_Broad_variant	TCGA-CV-7091	TCGA-HNSC		s16342	MD Anderson - Institute for Applied Cancer Science	MD Anderson Cancer Center	United States	NO	T1	N0	Head and Neck Squamous Cell Carcinoma	Stage I	2317-26	True	HNSC	C2	HNSC.Basal	0.239067068	0.55	0.12		0.6292	0.22699999999999998	-0.2356	0.2113	0.6304	0.7575	50.0	31.0	0.9668935359999999	3.281578062	184.0	0.694425168	18.0	36.0	0.96323122	0.667661004	2.0	2.96682676	21.0	0.9744801759999999	4.1047631860000005	-84.24774606	127.31792150000001	327.876396	0.0	3381.0	0.0	3381.0	7.059843683404582	6.788603660184107	-0.4874939137533303	6.538546759771295	4.515198356298837	1.5517747189512916	-0.5212969236332863	-2.2734053038852693	2.039268632704622
13722.58cfa831e4b0c9d6adf6c7dd	58cfa831e4b0c9d6adf6c7dd	TCGA-CV-6933-01A-11D-1911_120504_SN208_0296_AC0V09ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CV-6933-01A-11D-1911_120504_SN208_0296_AC0V09ACXX_s_3_rg.sorted	TCGA-CV-6933-01A-11D-1911_120504_SN208_0296_AC0V09ACXX_s_3_rg.sorted.bam	361.7	1.9	0.15	58cfa831e4b0c9d6adf6c7dd	TCGA-CV-6933-01A-11D-1911_120504_SN208_0296_AC0V09ACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6933-01A	2A749317-0156-4213-8482-B2C2D6E52E9B	Primary Tumor	Illumina HiSeq	76d94513-c228-445e-91f7-474a75422b69	Head and Neck	53.0	8C57C9E6-75BD-442C-984D-3709D2AC4CEC	662EA9EC-86E3-46EE-91C9-6972DA5B5CA1	TCGA-CV-6933-01A-11D-1911-02	HG19_Broad_variant	TCGA-CV-6933	TCGA-HNSC	2741.0	s15516	Harvard Medical School	MD Anderson Cancer Center	United States	NO	T3	N1	Head and Neck Squamous Cell Carcinoma	Stage III	1911-02	True	HNSC	C1	HNSC.Classical	0.28039262	0.52	0.22		0.6594	0.191	0.6561	-0.149	0.4381	0.7347	45.0	0.0	0.9414045120000001	2.853632427	226.0	0.816038402	23.0	47.0	0.981861298	1.361148781	4.0	1.609437912	5.0	1.0	5.0216464819999995	-250.5025453	137.1711649	-153.58048200000002	1.0	2741.0	0.0	2741.0	6.604917266641154	7.853766612305375	-2.3409093471002898	6.544292644824719	7.1197974372251736	0.5856384363638298	-0.06062462181643502	-0.7339691750802002	2.9265477834641196
13722.58cfa831e4b0c9d6adf6c7e1	58cfa831e4b0c9d6adf6c7e1	TCGA-CV-7090-01A-11D-2276-10_Illumina.filtered.	WGS	TCGA-CV-7090-01A-11D-2276-10_Illumina	TCGA-CV-7090-01A-11D-2276-10_Illumina.bam	158.73		0.05	58cfa831e4b0c9d6adf6c7e1	TCGA-CV-7090-01A-11D-2276-10_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-7090-01A	05FBD98C-28BD-41BC-AE60-16AC0C16C723	Primary Tumor	Illumina HiSeq	30e23a3f-f6eb-45e4-9d14-bddafc4fab6d	Head and Neck	39.0	E8BD9DCB-A9C7-4361-9724-24922A5E613B	A8041E86-071E-46CD-8FB5-7ECDC1AB0553	TCGA-CV-7090-01A-11D-2276-10	GRCh37-lite	TCGA-CV-7090	TCGA-HNSC		s15646	Baylor College of Medicine	MD Anderson Cancer Center	United States	NO	T2	NX	Head and Neck Squamous Cell Carcinoma	Stage II	2276-10	True	HNSC	C2	HNSC.Mesenchymal	0.351136554	0.62	0.1		0.7047	0.1845	0.6284	0.3539	2.2977	0.91	24.0	0.0	0.499379726	1.116260565	154.0	0.514147118	15.0	15.0	0.765921418	1.232702968	5.0	3.141804159	24.0	0.988593752	4.485473105	62.72253296	526.6845314	-239.31632779999998	0.0	5252.0	0.0	5252.0	6.994457084249861	2.8771398354928124	-0.687348293563802	5.644530367300845	2.102022942763986	2.9044694477070028	-1.349926716949016	-0.7751168927288266	3.591817741270805
13722.58cfa831e4b0c9d6adf6c7e5	58cfa831e4b0c9d6adf6c7e5	TCGA-D1-A169-01A-11D-A12F_120522_SN208_0301_BC0VNWACXX_s_1_rg.sorted.filtered.	WGS	TCGA-D1-A169-01A-11D-A12F_120522_SN208_0301_BC0VNWACXX_s_1_rg.sorted	TCGA-D1-A169-01A-11D-A12F_120522_SN208_0301_BC0VNWACXX_s_1_rg.sorted.bam	68.97	1.95	0.15	58cfa831e4b0c9d6adf6c7e5	TCGA-D1-A169-01A-11D-A12F_120522_SN208_0301_BC0VNWACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A169-01A	9A599F57-0E8D-4E1F-A181-791F5FDEADB7	Primary Tumor	Illumina HiSeq	43a5a914-7913-4e5e-9d2f-42fcec7bab2f	Uterus	63.0	9B36F264-55C3-4E08-A151-4B356871520C	B3A7C237-92C3-448A-A87E-8C8B1061A79F	TCGA-D1-A169-01A-11D-A12F-02	HG19_Broad_variant	TCGA-D1-A169	TCGA-UCEC		s4796	Harvard Medical School	Mayo Clinic	None	NO			Endometrioid endometrial adenocarcinoma		A12F-02	True	UCEC	C3	UCEC.CN_HIGH	0.292825932	0.33	0.29	1.183045489	-0.309	-0.141	0.1084	0.4861	0.1046	0.3278	25.0	2.0	0.452831017	1.305218814	101.0	0.48081636899999997	6.0	6.0							2.114153337	-672.8694485000001	-729.1846989000001	2872.858177	0.0	1135.0	1.0	519.0	6.296523177987073	7.456206938485579	0.06584656579758663	5.475542625917242	6.069912577365688	3.71671425310738	-0.8209805520698299	-1.3862943611198906	3.6508676873097934
13722.58cfa831e4b0c9d6adf6c7f3	58cfa831e4b0c9d6adf6c7f3	TCGA-D7-5577-01A-01D-1598_121023_SN208_0437_BD1H3FACXX_s_1_rg.sorted.filtered.	WGS	TCGA-D7-5577-01A-01D-1598_121023_SN208_0437_BD1H3FACXX_s_1_rg.sorted	TCGA-D7-5577-01A-01D-1598_121023_SN208_0437_BD1H3FACXX_s_1_rg.sorted.bam	414.0	1.87	0.14	58cfa831e4b0c9d6adf6c7f3	TCGA-D7-5577-01A-01D-1598_121023_SN208_0437_BD1H3FACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-5577-01A	2DC154AA-C478-404B-A92E-86ABCC8DBDB7	Primary Tumor	Illumina HiSeq	e417c8be-9c96-4e81-a2c9-ac3f23791347	Stomach	53.0	93BBD9FD-2385-46C3-AF21-E46C72A8A75D	8FCA6D2A-04D8-4A60-AEA3-298853E74752	TCGA-D7-5577-01A-01D-1598-02	HG19_Broad_variant	TCGA-D7-5577	TCGA-STAD		s14908	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N3	Stomach  Intestinal Adenocarcinoma  Tubular Type	Stage IIIA	1598-02	True	STAD	C2	GI.EBV	0.221285117	0.36	0.06		0.6095	0.3075	0.8138	1.2808	1.0189	-0.0205			0.8531153	3.0143407260000004	89.0	0.09389017300000001	3.0	10.0	0.905001473	4.176690863999999	101.0	5.107746767	219.0	0.9477971390000001	1.7157784669999998	-908.1620507000001	58.06764267	-1939.5837239999998	1.0	782.0	1.0	376.0	7.369443178186579	6.41308057537562	0.5281728193500286	5.536861714438269	5.54404272835201	1.954604343969915	-1.83258146374831	-0.8690378470236095	1.4264315246198864
13722.58cfa831e4b0c9d6adf6c7f4	58cfa831e4b0c9d6adf6c7f4	TCGA-CZ-5987-01A-11D-2104-10_Illumina.filtered.	WGS	TCGA-CZ-5987-01A-11D-2104-10_Illumina	TCGA-CZ-5987-01A-11D-2104-10_Illumina.bam	57.4	1.9	0.17	58cfa831e4b0c9d6adf6c7f4	TCGA-CZ-5987-01A-11D-2104-10_Illumina.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-CZ-5987-01A	F5759059-C0E3-4F1A-AF96-5C7197D3C33C	Primary Tumor	Illumina HiSeq	86bbaa26-53e2-4aa9-a257-0f86b5d2ca13	Kidney	60.0	6E67F804-5C82-4750-894A-0E85357F7E3D	FA5E2900-95E7-4700-9707-A329CD0C77FD	TCGA-CZ-5987-01A-11D-2104-10	GRCh37-lite	TCGA-CZ-5987	TCGA-KIRC	445.0	s9739	Baylor College of Medicine	Harvard	None	NO	T3b	NX	Kidney Clear Cell Renal Carcinoma	Stage IV	2104-10	False	KIRC	C3	KIRC.4	0.280510738				-0.5349	-0.19699999999999998	0.8107	0.7308	0.33399999999999996	0.0256	16.0	42.0	0.38097255399999996	1.230834406	77.0	0.704840899	8.0	0.0	0.570831055	1.418461884	12.0	3.39691442	31.0	0.989204158	1.888378291	1098.105142	-1062.8300769999998	1843.064041	1.0	445.0	1.0	377.0	8.194359293121053	1.9930434249790636	0.025246216139593103	5.429150678178893	4.399683834402793	3.9452783002148557	-2.765208614942159	2.406640409423729	3.9200320840752627
13722.58cfa831e4b0c9d6adf6c7f7	58cfa831e4b0c9d6adf6c7f7	TCGA-D1-A17C-01A-11D-A12F_120418_SN1222_0097_AC0M28ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-D1-A17C-01A-11D-A12F_120418_SN1222_0097_AC0M28ACXX_s_1_rg.sorted	TCGA-D1-A17C-01A-11D-A12F_120418_SN1222_0097_AC0M28ACXX_s_1_rg.sorted.bam	46.77	1.95	0.15	58cfa831e4b0c9d6adf6c7f7	TCGA-D1-A17C-01A-11D-A12F_120418_SN1222_0097_AC0M28ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A17C-01A	6F4F0CDD-8387-45D0-A9E8-EFCE6260159D	Primary Tumor	Illumina HiSeq	554e5953-4680-4681-a963-fcc940b3f448	Uterus	78.0	2D5AC7FC-BED4-4C7F-927D-9B44846324C4	99444E9D-219B-4653-9410-B258D28DEEB7	TCGA-D1-A17C-01A-11D-A12F-02	HG19_Broad_variant	TCGA-D1-A17C	TCGA-UCEC		s4801	Harvard Medical School	Mayo Clinic	None	NO			Endometrioid endometrial adenocarcinoma		A12F-02	True	UCEC	C3	UCEC.CN_LOW	0.182817746	0.48	0.06	9.585616406	-0.7938	-0.21899999999999997	-0.317	0.6598	-0.7884	0.6578	7.0	7.0	0.5578874220000001	1.222039114	55.0	0.054377568	0.0	0.0							2.311909908	-1075.406507	-1537.818282	-427.3373495	0.0	30.0	0.0	30.0	7.198898745196921	6.953456777905423	-0.6844574391650717	5.5222086057536535	6.008995169064571	2.935071936814071	-1.6766901394432674	-0.9444616088408515	3.6195293759791425
13722.58cfa831e4b0c9d6adf6c7fb	58cfa831e4b0c9d6adf6c7fb	TCGA-D7-6526-01A-11D-1798_130218_SN208_0453_AC1T26ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-D7-6526-01A-11D-1798_130218_SN208_0453_AC1T26ACXX_s_1_rg.sorted	TCGA-D7-6526-01A-11D-1798_130218_SN208_0453_AC1T26ACXX_s_1_rg.sorted.bam	423.4	1.9	0.15	58cfa831e4b0c9d6adf6c7fb	TCGA-D7-6526-01A-11D-1798_130218_SN208_0453_AC1T26ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6526-01A	A28E57E2-9071-4558-856A-162F7A837380	Primary Tumor	Illumina HiSeq	0a9e4a52-46b9-4c50-9dd3-9418ed5569e2	Stomach	67.0	DDCEA84E-3135-445C-BA0D-62F686463797	737041EA-9798-4D2E-9C0B-371F533E058F	TCGA-D7-6526-01A-11D-1798-02	HG19_Broad_variant	TCGA-D7-6526	TCGA-STAD		s15251	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T3	N2	Stomach  Intestinal Adenocarcinoma  Tubular Type	Stage IIIA	1798-02	True	STAD	C2	GI.CIN	0.127499107	0.4	0.4	5.047178303	0.8011	0.2285	-0.406	-0.4528	0.4327	0.0782			2.041855553	5.0010665	472.0	0.7488473109999999	18.0	58.0	0.9072917220000001	3.6191722060000004	54.0	3.526367118	39.0	0.962551598	5.3057490430000005	-379.08162289999996	529.1131713999999	-764.1858802999999	0.0	523.0	0.0	523.0	7.352227402198106	6.4628561016285655	-0.4516660002661581	5.455107417312226	4.516945952573253	1.0395545390245087	-1.897119984885881	-1.945910149055313	1.4912205392906668
13722.58cfa831e4b0c9d6adf6c7ff	58cfa831e4b0c9d6adf6c7ff	TCGA-D1-A16X-01A-11D-A12F_120413_SN1120_0132_AD0T6RACXX_s_4_rg.sorted.filtered.	WGS	TCGA-D1-A16X-01A-11D-A12F_120413_SN1120_0132_AD0T6RACXX_s_4_rg.sorted	TCGA-D1-A16X-01A-11D-A12F_120413_SN1120_0132_AD0T6RACXX_s_4_rg.sorted.bam	91.84	2.11	0.16	58cfa831e4b0c9d6adf6c7ff	TCGA-D1-A16X-01A-11D-A12F_120413_SN1120_0132_AD0T6RACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A16X-01A	22618073-4EF0-4C3A-97B9-90BA1CAA1D72	Primary Tumor	Illumina HiSeq	8f166eb0-a44e-4848-ae7a-4e174f470d5b	Uterus	54.0	6421D807-9BEC-4AD4-8B75-8F9DD594A977	E652FF84-B885-4245-86E5-70ADE972FD67	TCGA-D1-A16X-01A-11D-A12F-02	HG19_Broad_variant	TCGA-D1-A16X	TCGA-UCEC		s5023	Harvard Medical School	Mayo Clinic	None	NO			Endometrioid endometrial adenocarcinoma		A12F-02	True	UCEC	C2	UCEC.POLE	0.332009155	0.43	0.0	10.9355426	-0.1494	-0.174	0.3041	1.4569	0.7573	0.1683	1426.0	23.0	18.9085017	73.84385281	45.0	5.5799999999999994e-05	0.0	0.0							2.294191795	-746.5830649000001	-1186.689537	1442.924801	0.0	111.0	0.0	111.0	5.48120373555695	7.4548979961907875	0.10376383641074227	5.2546760862585	6.068603635070897	4.12847756859156	-0.22652764929845048	-1.3862943611198908	4.0247137321808175
13722.58cfa831e4b0c9d6adf6c801	58cfa831e4b0c9d6adf6c801	TCGA-CN-6018-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CN-6018-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_3_rg.sorted	TCGA-CN-6018-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_3_rg.sorted.bam	96.0	1.9	0.14	58cfa831e4b0c9d6adf6c801	TCGA-CN-6018-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-6018-01A	55838E1F-07E8-49CA-89D6-46216BABC6F7	Primary Tumor	Illumina HiSeq	ce9ca233-92c4-44b8-b97f-b56f1f73cb5a	Head and Neck	85.0	1A3E8C8B-9E99-499A-9BA7-4CDFC11B106D	7F0998E4-AF05-42C5-962C-5EA4D8993EB0	TCGA-CN-6018-01A-11D-1681-02	HG19_Broad_variant	TCGA-CN-6018	TCGA-HNSC		s15498	Harvard Medical School	University of Pittsburgh	United States	NO	T4a	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	True	HNSC	C2	HNSC.Mesenchymal	0.44295775	0.69	0.06		0.9528	0.3345	0.6246	0.8274	1.8326	0.8481	40.0	15.0	1.095140948	2.646590624	165.0	0.5896535629999999	14.0	23.0	0.860611773	4.444875615	175.0	3.1132312989999997	25.0	0.967179683	2.8435881530000002	-36.86716391	833.4901527000001	-1207.886802	1.0	580.0	0.0	580.0	5.847733531475839	4.935675242163953	-0.8888714520867708	5.010336742071348	7.751582839122577	1.502434011032544	-0.8373967894044916	2.8159075969586236	2.391305463119315
13722.58cfa831e4b0c9d6adf6c803	58cfa831e4b0c9d6adf6c803	TCGA-D1-A16N-01A-11D-A12F_120522_SN208_0301_BC0VNWACXX_s_2_rg.sorted.filtered.	WGS	TCGA-D1-A16N-01A-11D-A12F_120522_SN208_0301_BC0VNWACXX_s_2_rg.sorted	TCGA-D1-A16N-01A-11D-A12F_120522_SN208_0301_BC0VNWACXX_s_2_rg.sorted.bam	99.18	1.97	0.15	58cfa831e4b0c9d6adf6c803	TCGA-D1-A16N-01A-11D-A12F_120522_SN208_0301_BC0VNWACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A16N-01A	DBBBDDAE-D711-40F5-BD10-863735885B1F	Primary Tumor	Illumina HiSeq	0cea9a43-7170-4273-879f-084cb6e14196	Uterus	51.0	6D916A47-DCFF-4C98-9E88-348AAA353F98	133CBA56-19C9-47AE-AB5E-37FF35A7E71E	TCGA-D1-A16N-01A-11D-A12F-02	HG19_Broad_variant	TCGA-D1-A16N	TCGA-UCEC		s4263	Harvard Medical School	Mayo Clinic	None	NO			Endometrioid endometrial adenocarcinoma		A12F-02	True	UCEC	C2	UCEC.MSI	0.146685654	0.11	0.09	5.627943405	0.6581	-0.039	-0.3187	-0.3506	0.9209	0.2209	58.0	67.0	0.9090193790000001	3.181567825	224.0	0.855254312	12.0	20.0							2.350824027	-1190.550447	461.2380501	-1569.968508	0.0	945.0	0.0	945.0	6.685361446558474	6.971105594482899	0.28155728298411364	5.586749157890364	3.7683591515445825	7.261400638360504	-1.0986122886681096	-3.2027464429383166	6.979843355376391
13722.58cfa831e4b0c9d6adf6c804	58cfa831e4b0c9d6adf6c804	TCGA-D1-A2G6-01A-11D-A17E_120511_SN208_0299_BD12J9ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-D1-A2G6-01A-11D-A17E_120511_SN208_0299_BD12J9ACXX_s_7_rg.sorted	TCGA-D1-A2G6-01A-11D-A17E_120511_SN208_0299_BD12J9ACXX_s_7_rg.sorted.bam	60.54		0.18	58cfa831e4b0c9d6adf6c804	TCGA-D1-A2G6-01A-11D-A17E_120511_SN208_0299_BD12J9ACXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A2G6-01A	46CD8DED-F8A1-4F8C-A4C2-2D5B51C04F18	Primary Tumor	Illumina HiSeq	4ac2b259-f781-4a71-b271-2d326472c965	Uterus	53.0	2127E58B-BD7B-490E-B34B-4F626B2A4053	079C1D47-95AC-456B-8DD5-C89B4076E578	TCGA-D1-A2G6-01A-11D-A17E-02	HG19_Broad_variant	TCGA-D1-A2G6	TCGA-UCEC	258.0	s5230	Harvard Medical School	Mayo Clinic	United States	NO			Endometrioid endometrial adenocarcinoma		A17E-02	True	UCEC	C1	UCEC.MSI	0.12335736900000001	0.4	0.05	6.542112888999999	-0.2741	-0.024	-0.4771	-0.6697	-1.0276	0.4463	20.0		0.7069175	1.5050501619999999	60.0	0.783426944	9.0	1.0							1.9582797840000001	-1202.3517980000001	-65.86640779	1383.0500029999998	1.0	258.0	1.0	258.0	6.658011045870748	8.089329088364593	-0.17877754835922555	5.539980671345537	6.125719362209879	1.8170772772123445	-1.1180303745252114	-1.9636097261547145	1.9958548255715702
13722.58cfa831e4b0c9d6adf6c80b	58cfa831e4b0c9d6adf6c80b	TCGA-CZ-5454-01A-01D-2102-10_wgs_Illumina.filtered.	WGS	TCGA-CZ-5454-01A-01D-2102-10_wgs_Illumina	TCGA-CZ-5454-01A-01D-2102-10_wgs_Illumina.bam	99.4	1.9	0.15	58cfa831e4b0c9d6adf6c80b	TCGA-CZ-5454-01A-01D-2102-10_wgs_Illumina.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-CZ-5454-01A	F2801B21-5444-4CC3-A642-C60C6D82CD3D	Primary Tumor	Illumina HiSeq	c238e952-da1c-4af6-a799-62e9ff477374	Kidney	63.0	B8CCB09D-ACEB-4069-A911-89663575AB4B	B51FA117-2C0A-4E1D-8EC4-9F039073A486	TCGA-CZ-5454-01A-01D-2102-10	GRCh37-lite	TCGA-CZ-5454	TCGA-KIRC	722.0	s8843	Baylor College of Medicine	Harvard	None	NO	T2	N0	Kidney Clear Cell Renal Carcinoma	Stage IV	2102-10	False	KIRC	C4	KIRC.3	0.144335148	0.25	0.0		-1.3998	-0.121	1.4594	0.5225	0.2039	0.0676	11.0	5.0	0.28422489	0.511604803	75.0	0.139781827	4.0	8.0				3.711391435	43.0	0.9867572370000001	1.112124224	778.6663149	-1305.589377	3458.743536	1.0	722.0	1.0	423.0	6.938656835873303	2.140679163360698	0.734501047220784	5.370568483257898	5.125020272641031	5.414469443284062	-1.5680883526154048	2.984341109280333	4.679968396063278
13722.58cfa831e4b0c9d6adf6c80f	58cfa831e4b0c9d6adf6c80f	TCGA-CV-6938-01A-11D-1911_120504_SN208_0296_AC0V09ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CV-6938-01A-11D-1911_120504_SN208_0296_AC0V09ACXX_s_4_rg.sorted	TCGA-CV-6938-01A-11D-1911_120504_SN208_0296_AC0V09ACXX_s_4_rg.sorted.bam	62.7	2.0	0.16	58cfa831e4b0c9d6adf6c80f	TCGA-CV-6938-01A-11D-1911_120504_SN208_0296_AC0V09ACXX_s_4_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6938-01A	FF9DB03D-F81C-4079-8B05-F5A8C05B8CFE	Primary Tumor	Illumina HiSeq	a328ffc7-c5cd-4726-a75a-e625d33859a8	Head and Neck	87.0	9EB292E6-AE4D-4613-98EE-0197FD97B633	87E1BCCB-5B03-40AF-A262-0B2B5E6A08D2	TCGA-CV-6938-01A-11D-1911-02	HG19_Broad_variant	TCGA-CV-6938	TCGA-HNSC	144.0	s16050	Harvard Medical School	MD Anderson Cancer Center	United States	NO	T2	NX	Head and Neck Squamous Cell Carcinoma	Stage II	1911-02	True	HNSC	C2	HNSC.Basal	0.551343762	0.77	0.29		0.475	0.1745	0.7507	0.4322	2.5232	0.0501	46.0	53.0	0.9009336029999999	3.4874849130000003	55.0	0.005027462	3.0	5.0	0.89443036	2.4221623169999997	15.0	2.009709182	9.0	0.914658066	1.444029987	-126.94385279999999	604.9098474	399.5931422	1.0	144.0	0.0	144.0	6.418123229487515	7.499151241734329	0.5578252771616344	6.217452534025364	8.632249706473608	2.008777427115582	-0.2006706954621511	1.1330984647392794	1.4509521499539475
13722.58cfa831e4b0c9d6adf6c810	58cfa831e4b0c9d6adf6c810	TCGA-D1-A2G0-01A-11D-A17E_120511_SN1120_0140_AD12J0ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-D1-A2G0-01A-11D-A17E_120511_SN1120_0140_AD12J0ACXX_s_5_rg.sorted	TCGA-D1-A2G0-01A-11D-A17E_120511_SN1120_0140_AD12J0ACXX_s_5_rg.sorted.bam	59.69		0.17	58cfa831e4b0c9d6adf6c810	TCGA-D1-A2G0-01A-11D-A17E_120511_SN1120_0140_AD12J0ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A2G0-01A	6F661F0D-F08B-486E-8BD7-4306E1593EB9	Primary Tumor	Illumina HiSeq	675cc0ce-f2e1-4e4c-a337-4bc31fcb46c5	Uterus	70.0	134CD317-CBEB-4633-B540-B639454615F7	DF417E78-8258-40C2-8305-2FE14DCC8035	TCGA-D1-A2G0-01A-11D-A17E-02	HG19_Broad_variant	TCGA-D1-A2G0	TCGA-UCEC		s4803	Harvard Medical School	Mayo Clinic	United States	NO			Mixed serous and endometrioid		A17E-02	True	UCEC	C1	UCEC.MSI	0.21404127399999998	0.24	0.0	4.600552122	0.9427	0.5725	-0.5067	0.2679	-1.3004	-0.7916	250.0	1358.0	6.159283477000001	16.88183172	71.0	0.091626724	4.0	2.0		0.0	1.0	2.7555497910000004	17.0	0.972588173	1.6219998969999998	-1165.120127	1008.7574810000001	-3711.002357	0.0	1484.0	0.0	1484.0	6.362087222178911	7.864995997185247	1.3475629036639662	5.869610737081117	6.289459636426827	0.8831285208240433	-0.49247648509779385	-1.5755363607584192	-0.4644343828399229
13722.58cfa831e4b0c9d6adf6c819	58cfa831e4b0c9d6adf6c819	TCGA-CN-6998-01A-23D-2317_120623_SN1222_0118_AD13T1ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CN-6998-01A-23D-2317_120623_SN1222_0118_AD13T1ACXX_s_5_rg.sorted	TCGA-CN-6998-01A-23D-2317_120623_SN1222_0118_AD13T1ACXX_s_5_rg.sorted.bam	9.03		0.13	58cfa831e4b0c9d6adf6c819	TCGA-CN-6998-01A-23D-2317_120623_SN1222_0118_AD13T1ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-6998-01A	039788EC-1364-40C7-9E9D-13DC305674E9	Primary Tumor	Illumina HiSeq	d281a462-58dd-4303-9419-617fec3fcf35	Head and Neck	53.0	64C8DB8B-5D5C-4FBE-8996-4A7CB161D4A0	88B8B48D-51B8-4D46-9C36-E565A2582D94	TCGA-CN-6998-01A-23D-2317-26	HG19_Broad_variant	TCGA-CN-6998	TCGA-HNSC		s16333	MD Anderson - Institute for Applied Cancer Science	University of Pittsburgh	United States	NO	T3	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	2317-26	True	HNSC	C2	HNSC.Basal	0.21935595600000002	0.54	0.08		0.1388	0.0575	-0.5192	-0.8109	1.8766	0.2789	28.0	12.0	0.90300016	1.747742245	69.0	0.428243225	13.0	8.0		0.0	1.0	2.079441542	8.0	1.0	2.04178687	94.66880381	-80.89862414	338.889383	1.0	357.0	1.0	244.0	6.986206978082746	6.681149300986902	-0.5676318629236586	6.475381354316754	9.166055950774902	1.7691301310972951	-0.5108256237659909	2.4849066497880004	2.3367619940209536
13722.58cfa831e4b0c9d6adf6c81d	58cfa831e4b0c9d6adf6c81d	TCGA-CV-6433-01A-11D-2276-10_Illumina.filtered.	WGS	TCGA-CV-6433-01A-11D-2276-10_Illumina	TCGA-CV-6433-01A-11D-2276-10_Illumina.bam	207.03	1.9	0.05	58cfa831e4b0c9d6adf6c81d	TCGA-CV-6433-01A-11D-2276-10_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6433-01A	D5EEDFB5-4FA3-4A1E-AD0D-EA550B22A5BA	Primary Tumor	Illumina HiSeq	0fc542ae-619e-45f5-9496-dcf6f31f4c32	Head and Neck	57.0	47EC5010-4353-493B-AB28-C95BC2CB026C	0E6CA8DC-0F31-4675-95B1-5920576DAEFF	TCGA-CV-6433-01A-11D-2276-10	GRCh37-lite	TCGA-CV-6433	TCGA-HNSC		s15511	Baylor College of Medicine	MD Anderson Cancer Center	United States	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	2276-10	True	HNSC	C2	HNSC.Atypical	0.24958169100000002	0.27	0.02		1.27	0.368	0.6748	1.5882	0.8162	-0.2588	28.0	63.0	0.515115801	1.2423381070000001	129.0	0.245635797	9.0	11.0	0.705523735	2.21216559	23.0	3.270241892	37.0	0.9056539	1.6644741090000001	-77.42909094	1137.392907	-2916.907663	0.0	641.0	0.0	641.0	7.914861255072082	3.1231187463698244	0.14943149640785558	5.8354197133922465	6.389574630888286	1.5593365441846052	-2.079441541679836	3.2664558845184617	1.4099050477767496
13722.58cfa831e4b0c9d6adf6c826	58cfa831e4b0c9d6adf6c826	TCGA-D1-A17U-01A-21D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-D1-A17U-01A-21D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_3_rg.sorted	TCGA-D1-A17U-01A-21D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_3_rg.sorted.bam	73.35	1.96	0.17	58cfa831e4b0c9d6adf6c826	TCGA-D1-A17U-01A-21D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A17U-01A	6397C4A1-0A29-4C2C-B8CB-CE73AF93DD0B	Primary Tumor	Illumina HiSeq	8d00983f-b836-41a9-a4b9-51c75b4452a8	Uterus	53.0	1F1945EE-4CF3-43A3-9998-1C4528C7A511	1B9EB26F-48E0-4EBF-9094-5013E3DF2FBD	TCGA-D1-A17U-01A-21D-A12F-02	HG19_Broad_variant	TCGA-D1-A17U	TCGA-UCEC		s4616	Harvard Medical School	Mayo Clinic	None	NO			Endometrioid endometrial adenocarcinoma		A12F-02	True	UCEC	C1	UCEC.MSI	0.183137205	0.3	0.0	9.577143581	0.1731	0.059000000000000004	-0.318	-0.2102	-1.2987	0.1139	167.0		3.437595421	10.6401763	41.0	0.000942714	0.0	0.0							3.739336321	-411.1237318	-334.09597169999995	952.0042594	0.0	697.0	0.0	697.0	6.721954505997009	7.467215210616754	-0.34897735160886867	6.26113930280568	6.729616267485975	4.712933218694593	-0.46081520319132885	-0.737598943130779	5.0619105703034615
13722.58cfa831e4b0c9d6adf6c828	58cfa831e4b0c9d6adf6c828	TCGA-CV-7238-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CV-7238-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_4_rg.sorted	TCGA-CV-7238-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_4_rg.sorted.bam	143.73		0.14	58cfa831e4b0c9d6adf6c828	TCGA-CV-7238-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-7238-01A	78FCC813-D0A8-44AA-B004-62810DCA9D12	Primary Tumor	Illumina HiSeq	3eb627a6-bbcf-4699-ad23-e52a26cd4453	Head and Neck	69.0	831808D5-1883-4F6F-B252-1BB397FBD62A	D051D2CB-F8DE-4E42-B9CF-E7CBE43861A0	TCGA-CV-7238-01A-11D-2317-26	HG19_Broad_variant	TCGA-CV-7238	TCGA-HNSC		s15520	MD Anderson - Institute for Applied Cancer Science	MD Anderson Cancer Center	United States	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	2317-26	True	HNSC	C2	HNSC.Mesenchymal	0.5535224639999999	0.75	0.4		0.4763	0.2005	0.3034	1.2216	2.0348	0.6468	22.0	60.0	0.445804525	1.367133876	49.0	0.140530389	2.0	2.0	0.583647634	1.718514845	19.0	2.891424171	22.0	0.9354204009999999	4.750670008	-292.8314702	-176.8265942	-311.88948010000007	0.0	2727.0	0.0	2727.0	7.676664525113575	5.16640930546755	-0.5945407940885339	6.466826601335241	7.411835984621646	3.7017275965917853	-1.209837923778334	2.2454266791540967	4.29626839068032
13722.58cfa831e4b0c9d6adf6c82b	58cfa831e4b0c9d6adf6c82b	TCGA-D1-A17Q-01A-11D-A12F_120418_SN1222_0097_AC0M28ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-D1-A17Q-01A-11D-A12F_120418_SN1222_0097_AC0M28ACXX_s_2_rg.sorted	TCGA-D1-A17Q-01A-11D-A12F_120418_SN1222_0097_AC0M28ACXX_s_2_rg.sorted.bam	77.69	1.86	0.16	58cfa831e4b0c9d6adf6c82b	TCGA-D1-A17Q-01A-11D-A12F_120418_SN1222_0097_AC0M28ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A17Q-01A	CA8DBBFD-8928-4E25-94C6-B875DE631BBD	Primary Tumor	Illumina HiSeq	77e56615-42dd-4c50-a518-cc93c3b80107	Uterus	54.0	B6ABEB01-B6EA-4AB4-AA00-AE16CFC88B7C	59FB249D-4C77-40B1-A557-98281869AC91	TCGA-D1-A17Q-01A-11D-A12F-02	HG19_Broad_variant	TCGA-D1-A17Q	TCGA-UCEC		s4442	Harvard Medical School	Mayo Clinic	None	NO			Endometrioid endometrial adenocarcinoma		A12F-02	True	UCEC	C3	UCEC.POLE	0.043014910999999996	0.12	0.0	9.343219375	0.1206	-0.14	-1.2103	-1.107	-1.4444	0.2271	2945.0	106.0	40.482656299999995	157.6735743	37.0	1.82e-05	0.0	0.0							2.037207925	-1364.79383	-948.9481643999999	1121.874698	0.0	54.0	0.0	54.0	5.459835795712228	7.194780886007633	-1.8061217120519388	4.705569800096237	5.818957824755038	1.1038186968586836	-0.7542659956159907	-1.375823061252595	2.9099404089106224
13722.58cfa831e4b0c9d6adf6c830	58cfa831e4b0c9d6adf6c830	TCGA-CV-7407-01A-11D-2317_120710_SN590_0166_AC0VNFACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CV-7407-01A-11D-2317_120710_SN590_0166_AC0VNFACXX_s_8_rg.sorted	TCGA-CV-7407-01A-11D-2317_120710_SN590_0166_AC0VNFACXX_s_8_rg.sorted.bam	131.73		0.16	58cfa831e4b0c9d6adf6c830	TCGA-CV-7407-01A-11D-2317_120710_SN590_0166_AC0VNFACXX_s_8_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-7407-01A	8B63BE59-9CE6-45A0-80D9-4D20F4918CB9	Primary Tumor	Illumina HiSeq	e5709830-4141-4354-94f0-94f576fe84c9	Head and Neck	67.0	6ABAF81A-B228-4AFE-B931-BC1FC39CD265	4CC9AD85-2F84-4657-8F3E-6C5DD69F1B30	TCGA-CV-7407-01A-11D-2317-26	HG19_Broad_variant	TCGA-CV-7407	TCGA-HNSC	1081.0	s15909	MD Anderson - Institute for Applied Cancer Science	MD Anderson Cancer Center	United States	NO	T2	NX	Head and Neck Squamous Cell Carcinoma	Stage II	2317-26	True	HNSC	C2	HNSC.Atypical	0.320994314	0.61	0.4		0.4823	0.0805	0.3138	-0.0241	1.4439	0.3305	50.0	8.0	1.25675868	2.8200438660000002	297.0	0.715467163	20.0	30.0				2.811375957	18.0	0.972669329	1.838325719	-585.2943478	-242.20382709999998	406.1043371	1.0	1081.0	0.0	1081.0	6.479347163195548	5.414279207176576	0.7119415147296148	5.2799301754054735	7.017028131459879	1.5989983496987232	-1.1994169877900749	1.6027489242833037	0.8870568349691084
13722.58cfa831e4b0c9d6adf6c836	58cfa831e4b0c9d6adf6c836	TCGA-D7-6521-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_1_rg.sorted.filtered.	WGS	TCGA-D7-6521-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_1_rg.sorted	TCGA-D7-6521-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_1_rg.sorted.bam	131.4	1.9	0.14	58cfa831e4b0c9d6adf6c836	TCGA-D7-6521-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6521-01A	6DE6B8E2-03EB-4F32-B5A3-BEA73FC632B4	Primary Tumor	Illumina HiSeq	72a895e9-b1b0-4b79-a5e6-6bae340e8798	Stomach	65.0	C3D9FC3B-EF2A-4D02-B7A4-5D1463AD5EF3	0F49F6E2-C6C8-4F3E-8755-BAA962453E71	TCGA-D7-6521-01A-11D-1798-02	HG19_Broad_variant	TCGA-D7-6521	TCGA-STAD		s14838	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2b	N2	Stomach  Adenocarcinoma  Diffuse Type	Stage IIIA	1798-02	True	STAD	C1	GI.CIN	0.344638958	0.77	0.45	6.258098837	-0.1239	0.0375	0.8569	1.875	-0.0898	0.5431			0.385923047	1.959301624	129.0	0.632798083	27.0	17.0	0.838491502	5.353931239	593.0	5.005300247	299.0	0.87805452	2.3468959469999997	-603.2832884	-363.18195110000005	37.95024515	0.0	564.0	1.0	192.0	8.615106041938907	9.294064208063128	0.09668754924686163	6.769279351440575	7.98187781909696	2.444443786174819	-1.8458266904983305	-1.312186388966169	2.3477562369279577
13722.58cfa831e4b0c9d6adf6c837	58cfa831e4b0c9d6adf6c837	TCGA-CV-7095-01A-21D-2317_120730_SN1222_0140_AC11GKACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CV-7095-01A-21D-2317_120730_SN1222_0140_AC11GKACXX_s_2_rg.sorted	TCGA-CV-7095-01A-21D-2317_120730_SN1222_0140_AC11GKACXX_s_2_rg.sorted.bam	90.73		0.14	58cfa831e4b0c9d6adf6c837	TCGA-CV-7095-01A-21D-2317_120730_SN1222_0140_AC11GKACXX_s_2_rg.sorted.bam	Dead	FEMALE		HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-7095-01A	D7D49895-032F-4385-8B68-AE16F8675CA7	Primary Tumor	Illumina HiSeq	d944910b-a3cf-45e9-84be-5ea0e6cd6f03	Head and Neck	87.0	E7D35C82-8992-4CC0-AA65-DF5CAB5727EB	F85FA02B-0695-4F2E-957B-FF11F1E6FCE6	TCGA-CV-7095-01A-21D-2317-26	HG19_Broad_variant	TCGA-CV-7095	TCGA-HNSC	572.0	s16052	MD Anderson - Institute for Applied Cancer Science	MD Anderson Cancer Center	United States	NO	T2	NX	Head and Neck Squamous Cell Carcinoma	Stage II	2317-26	True	HNSC	C2	HNSC.Basal	0.28821155	0.44	0.36		0.5962	0.153	-0.4158	-0.4136	1.2014	0.424			1.938120055	5.667532888999999	155.0	0.455085536	7.0	28.0	0.964160375	3.103512522	25.0	1.906154747	7.0	0.979569765	3.041449047	-207.1765106	447.06111289999996	-635.1862041	1.0	572.0	0.0	572.0	7.394800374082725	8.269842326401765	-0.8848314272817508	6.296188085414615	7.610596697517501	1.6328650453292404	-1.09861228866811	-0.6592456288842641	2.517696472610991
13722.58cfa831e4b0c9d6adf6c83b	58cfa831e4b0c9d6adf6c83b	TCGA-CV-7180-01A-11D-2266-10_Illumina.filtered.	WGS	TCGA-CV-7180-01A-11D-2266-10_Illumina	TCGA-CV-7180-01A-11D-2266-10_Illumina.bam	52.7		0.05	58cfa831e4b0c9d6adf6c83b	TCGA-CV-7180-01A-11D-2266-10_Illumina.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-7180-01A	D2CA9A4D-C14C-40C0-871C-88794A02E4AA	Primary Tumor	Illumina HiSeq	b66083b7-e0ae-4f6e-ab6a-76caf55a13bc	Head and Neck	34.0	551B5AC7-41E8-42BC-B64D-20E7E156DBBC	1727E88B-DF0A-4AF2-9191-8C6061D98AD0	TCGA-CV-7180-01A-11D-2266-10	GRCh37-lite	TCGA-CV-7180	TCGA-HNSC	327.0	s15648	Baylor College of Medicine	MD Anderson Cancer Center	United States	NO	T2	NX	Head and Neck Squamous Cell Carcinoma	Stage II	2266-10	True	HNSC	C2	HNSC.Basal	0.333478679	0.58	0.34		0.7215	0.3125	-1.0155	-0.2419	0.3179	-0.0534	21.0	4.0	0.499485985	1.263405726	68.0	0.49695562200000004	7.0	15.0	0.9789987370000001	0.6785902140000001	2.0	1.386294361	4.0	1.0	1.7426641059999999	-650.2884566	726.9503555	-1214.7016800000001	1.0	327.0	1.0	327.0	7.071196005716487	5.126239043075639	-0.31178495291633157	5.834433378567561	5.119746725207749	0.4802619753015309	-1.2367626271489267	-0.006492317867889952	0.7920469282178625
13722.58cfa831e4b0c9d6adf6c845	58cfa831e4b0c9d6adf6c845	TCGA-CV-5442-01A-01D-2266-10_Illumina.filtered.	WGS	TCGA-CV-5442-01A-01D-2266-10_Illumina	TCGA-CV-5442-01A-01D-2266-10_Illumina.bam	323.7	1.9	0.05	58cfa831e4b0c9d6adf6c845	TCGA-CV-5442-01A-01D-2266-10_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-5442-01A	3C975B68-4A6E-4C97-A8D1-B9A427D4957C	Primary Tumor	Illumina HiSeq	53f0ce53-95fe-4d6c-930d-f8427c0c46ec	Head and Neck	76.0	698208BB-7272-4AD5-9CC0-909CB669BDAF	46D35B82-E1B7-4D35-BE5E-3A70FD47E421	TCGA-CV-5442-01A-01D-2266-10	GRCh37-lite	TCGA-CV-5442	TCGA-HNSC		s16336	Baylor College of Medicine	MD Anderson Cancer Center	None	NO	T4a	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	2266-10	True	HNSC	C1	HNSC.Basal	0.084086219	0.15	0.01		0.6071	0.11900000000000001	-1.5129	-1.3096	-2.6224	-0.5378	81.0	38.0	1.778337311	6.125384072	128.0	0.947713055	17.0	4.0		0.0	1.0	0.0	1.0		1.680073889	-1436.522042	583.4952252999999	2030.555245	0.0	2327.0	0.0	2327.0	2.1660788771464965	2.9966408580248434	-0.7653799145918141	5.808914392759027	1.7292599863969365	-0.45524497050044754	3.64283551561253	-1.267380871627907	0.31013494409136655
13722.58cfa831e4b0c9d6adf6c850	58cfa831e4b0c9d6adf6c850	TCGA-CV-6948-01A-11D-1911_120504_SN208_0297_BC0VJEACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CV-6948-01A-11D-1911_120504_SN208_0297_BC0VJEACXX_s_3_rg.sorted	TCGA-CV-6948-01A-11D-1911_120504_SN208_0297_BC0VJEACXX_s_3_rg.sorted.bam	263.7	1.9	0.15	58cfa831e4b0c9d6adf6c850	TCGA-CV-6948-01A-11D-1911_120504_SN208_0297_BC0VJEACXX_s_3_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6948-01A	FCF0DC48-B889-4593-A15B-AA715AAE7BF5	Primary Tumor	Illumina HiSeq	87c6cf32-e113-471b-86b3-cca360f47616	Head and Neck	79.0	21844F33-DD12-4940-B42D-2F9FABB2F7BA	8FEEA708-D971-4FD0-8542-1E31A9DFF8EA	TCGA-CV-6948-01A-11D-1911-02	HG19_Broad_variant	TCGA-CV-6948	TCGA-HNSC	1289.0	s15650	Harvard Medical School	MD Anderson Cancer Center	United States	NO	T4a	N3	Head and Neck Squamous Cell Carcinoma	Stage IVB	1911-02	True	HNSC	C1	HNSC.Atypical	0.12072280199999999	0.16	0.09		1.1235	0.386	0.0434	0.3678	-0.2012	0.0533	85.0	184.0	1.802578154	4.787174769	389.0	0.9150682090000001	10.0	52.0	0.7766223940000001	3.126178266	56.0	3.4365228310000004	32.0	0.991570889	4.503999021	-1772.278489	510.1888731000001	-2860.601798	1.0	1289.0	0.0	1289.0	6.613708164977481	6.451178348222697	-0.6290410651492215	6.722907456942474	6.352738275409445	1.5442624301585746	0.109199291964992	-0.0984400728132524	2.1733034953077963
13722.58cfa831e4b0c9d6adf6c858	58cfa831e4b0c9d6adf6c858	TCGA-D6-6517-01A-11D-1868_120427_SN208_0288_BD0RWBACXX_s_3_rg.sorted.filtered.	WGS	TCGA-D6-6517-01A-11D-1868_120427_SN208_0288_BD0RWBACXX_s_3_rg.sorted	TCGA-D6-6517-01A-11D-1868_120427_SN208_0288_BD0RWBACXX_s_3_rg.sorted.bam	209.7	1.9	0.15	58cfa831e4b0c9d6adf6c858	TCGA-D6-6517-01A-11D-1868_120427_SN208_0288_BD0RWBACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-D6-6517-01A	EBE99910-E9F2-43DC-AD57-AC2F610B60C8	Primary Tumor	Illumina HiSeq	e84f34a5-8df7-4824-92d7-4f53b4bace58	Head and Neck	59.0	8C099F45-3FD6-4966-8CDB-CA4B9288B1A2	97962F6C-B2FB-4618-A5A4-7B376714EC62	TCGA-D6-6517-01A-11D-1868-02	HG19_Broad_variant	TCGA-D6-6517	TCGA-HNSC		s15655	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T3	N0	Head and Neck Squamous Cell Carcinoma	Stage III	1868-02	True	HNSC	C1	HNSC.Basal	0.38239606299999995	0.56	0.01		0.6853	0.324	0.0711	0.5638	0.3793	0.6984	25.0	6.0	0.597945418	1.763938982	116.0	0.234894197	7.0	29.0	0.905120872	4.664351781000001	173.0	3.01494688	21.0	0.99028565	3.3642820469999997	-656.4030008999999	797.1493301	363.93476499999997	0.0	292.0	1.0	161.0	6.215548832263912	7.63029943639287	-0.3242973299990586	6.158390418423964	7.476148756565612	2.1568224610574447	-0.05715841383994835	-0.15415067982725805	2.481119791056503
13722.58cfa831e4b0c9d6adf6c862	58cfa831e4b0c9d6adf6c862	TCGA-CW-6093-01A-11D-2279-10_wgs_Illumina.filtered.	WGS	TCGA-CW-6093-01A-11D-2279-10_wgs_Illumina	TCGA-CW-6093-01A-11D-2279-10_wgs_Illumina.bam	112.4	1.9	0.05	58cfa831e4b0c9d6adf6c862	TCGA-CW-6093-01A-11D-2279-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-CW-6093-01A	3F93D1CF-A307-4E29-9E6F-239E9FFAA179	Primary Tumor	Illumina HiSeq	1e7df335-e096-49e1-8490-8be7151ec2db	Kidney	73.0	13BA18EB-C94B-4F6C-AB50-2A98A8044CED	51206157-94CC-4702-8247-C98283B487AA	TCGA-CW-6093-01A-11D-2279-10	GRCh37-lite	TCGA-CW-6093	TCGA-KIRC		s9571	Baylor College of Medicine	Mayo Clinic - Rochester	United States	NO	T1a	NX	Kidney Clear Cell Renal Carcinoma	Stage I	2279-10	False	KIRC	C3	KIRC.1	0.125863271	0.44	0.02		-1.14	-0.281	0.287	-0.348	0.3336	0.0532	37.0	30.0	0.794878135	2.885113231	72.0	0.073114393	2.0	2.0				1.33217904	4.0	0.960964047	0.802127548	285.7295351	-339.3670091	1459.135477	0.0	3146.0	0.0	3146.0	6.8301540329585855	2.587981704990052	0.5058691822498107	4.750712491278749	3.9243199682666416		-2.079441541679836	1.3363382632765894	
13722.58cfa831e4b0c9d6adf6c866	58cfa831e4b0c9d6adf6c866	TCGA-D6-6823-01A-11D-1911_120518_SN1120_0143_BC0VN6ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-D6-6823-01A-11D-1911_120518_SN1120_0143_BC0VN6ACXX_s_1_rg.sorted	TCGA-D6-6823-01A-11D-1911_120518_SN1120_0143_BC0VN6ACXX_s_1_rg.sorted.bam	384.7	1.9	0.14	58cfa831e4b0c9d6adf6c866	TCGA-D6-6823-01A-11D-1911_120518_SN1120_0143_BC0VN6ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-D6-6823-01A	FBDAB01C-191C-4AEF-9451-CA3AFEC55FA1	Primary Tumor	Illumina HiSeq	250e5855-f3af-4c16-9efe-918be02bf754	Head and Neck	50.0	2DA83450-04C2-44D0-AB8A-9CC876242D5A	FE15C318-C3B1-4541-A0DA-4E41D7E99FBB	TCGA-D6-6823-01A-11D-1911-02	HG19_Broad_variant	TCGA-D6-6823	TCGA-HNSC		s15531	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	1911-02	True	HNSC	C2	HNSC.Classical	0.260676483	0.55	0.11		1.094	0.45399999999999996	-0.527	-0.3431	1.4267	0.4793	56.0	41.0	0.537780676	2.8084101969999997	153.0	0.7260153709999999	16.0	28.0	0.84295544	2.388272601	17.0	2.043191871	8.0	0.982567593	1.8615073580000001	-638.3380214	1402.710619	-1137.734343	0.0	701.0	0.0	701.0	6.483325763601782	5.057091810735107	-0.9263494922920014	5.7211857115548845	3.824238557284697	0.3753829725485991	-0.762140052046897	-1.2328532534504104	1.3017324648406006
13722.58cfa831e4b0c9d6adf6c86a	58cfa831e4b0c9d6adf6c86a	TCGA-CV-6003-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CV-6003-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_4_rg.sorted	TCGA-CV-6003-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_4_rg.sorted.bam	223.0	1.9	0.14	58cfa831e4b0c9d6adf6c86a	TCGA-CV-6003-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6003-01A	417B357E-C90E-4B63-AE7A-4B782038FFD3	Primary Tumor	Illumina HiSeq	b314312e-2a3f-45dd-a813-870344654395	Head and Neck	50.0	6892F7E3-630E-45B5-8C30-139161461A85	9DF426C5-E45E-428B-A63C-11D4C1BEB4B2	TCGA-CV-6003-01A-11D-1681-02	HG19_Broad_variant	TCGA-CV-6003	TCGA-HNSC		s16197	Harvard Medical School	MD Anderson Cancer Center	None	NO	T2	N1	Head and Neck Squamous Cell Carcinoma	Stage III	1681-02	True	HNSC	C2	HNSC.Basal	0.171334845	0.44	0.08		1.0047	0.4795	-0.9012	-1.0871	1.6777	0.2797	41.0	143.0	0.6813590190000001	2.547690243	136.0	0.73247204	22.0	17.0				1.329661349	4.0	0.959147917	4.912580877	-423.9350545	848.172868	-789.8129048999999	0.0	1665.0	0.0	1665.0	7.295438217294503	6.57223009376614	-0.29078248734870804	6.07904289297001	6.7010108836320645	5.139790458319799	-1.2163953243244934	0.12878078986592456	5.430572945668507
13722.58cfa831e4b0c9d6adf6c876	58cfa831e4b0c9d6adf6c876	TCGA-D6-6826-01A-11D-1911_120518_SN1120_0143_BC0VN6ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-D6-6826-01A-11D-1911_120518_SN1120_0143_BC0VN6ACXX_s_3_rg.sorted	TCGA-D6-6826-01A-11D-1911_120518_SN1120_0143_BC0VN6ACXX_s_3_rg.sorted.bam	275.7	1.9	0.14	58cfa831e4b0c9d6adf6c876	TCGA-D6-6826-01A-11D-1911_120518_SN1120_0143_BC0VN6ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-D6-6826-01A	31243867-8E9F-46E9-A213-B83544EB8028	Primary Tumor	Illumina HiSeq	377f848a-3e59-4eee-bd9d-87fdc1a898bb	Head and Neck	64.0	1737989D-8463-4761-B111-53E4FD396375	07759CEA-B923-4D20-96DB-7952D50314C7	TCGA-D6-6826-01A-11D-1911-02	HG19_Broad_variant	TCGA-D6-6826	TCGA-HNSC		s15912	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T4a	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1911-02	True	HNSC	C1	HNSC.Mesenchymal	0.348830904	0.66	0.11		0.6188	0.066	0.858	0.6236	1.0914	0.8573	41.0	17.0	0.831619208	2.554258995	225.0	0.521612237	12.0	35.0	0.820217986	3.004919155	39.0	3.2684048939999997	31.0	0.951781326	5.638811725	199.9875915	875.6247175000001	-637.6408859000001	1.0	348.0	0.0	348.0	6.641182169740592	5.9056289492073635	-0.40476938676618246	5.622612588746018	5.8301213966992185	0.7311168137490254	-1.0185695809945732	-0.07550755250814545	1.1358862005152077
13722.58cfa831e4b0c9d6adf6c87c	58cfa831e4b0c9d6adf6c87c	TCGA-CV-7414-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CV-7414-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_8_rg.sorted	TCGA-CV-7414-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_8_rg.sorted.bam	79.73		0.16	58cfa831e4b0c9d6adf6c87c	TCGA-CV-7414-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_8_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-7414-01A	C3B2C38D-81A3-42FD-A41E-6F6DE3934007	Primary Tumor	Illumina HiSeq	d2264558-e25d-4169-9e22-8f3c23b50ad9	Head and Neck	78.0	7BE274D5-D5A0-4EF9-A65A-4127ED864F0C	A78CD28C-EDAF-4439-905B-44B4616DF078	TCGA-CV-7414-01A-11D-2317-26	HG19_Broad_variant	TCGA-CV-7414	TCGA-HNSC	14.0	s15523	MD Anderson - Institute for Applied Cancer Science	MD Anderson Cancer Center	United States	NO	T4a	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	2317-26	True	HNSC	C2	HNSC.Atypical	0.080038784	0.18	0.08		0.402	0.126	-0.6425	-0.6542	0.7912	0.6228	132.0	69.0	2.529818044	6.590019842999999	190.0	0.406737715	8.0	41.0				1.386294361	4.0	1.0	4.494848622	-1358.167573	-26.05857951	-3436.986548	1.0	14.0	0.0	14.0	6.979145275068811	8.138029157727445	-1.0194372600077957	6.3285577089276615	6.909363740811137	1.452543746661091	-0.6505875661411493	-1.2286654169163076	2.4719810066688868
13722.58cfa831e4b0c9d6adf6c889	58cfa831e4b0c9d6adf6c889	TCGA-D7-6525-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_7_rg.sorted.filtered.	WGS	TCGA-D7-6525-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_7_rg.sorted	TCGA-D7-6525-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_7_rg.sorted.bam	198.4	1.9	0.15	58cfa831e4b0c9d6adf6c889	TCGA-D7-6525-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6525-01A	82F9A197-040D-4C5E-89D9-D87A7AA0168D	Primary Tumor	Illumina HiSeq	03097d75-d0ad-4e1e-8a9b-5157a768cc05	Stomach	58.0	C1AC6717-828B-4289-9755-7C56A6FC1392	26A09728-CA75-4E29-A222-0826899E0800	TCGA-D7-6525-01A-11D-1798-02	HG19_Broad_variant	TCGA-D7-6525	TCGA-STAD		s14493	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N2	Stomach  Adenocarcinoma  Diffuse Type	Stage IIIA	1798-02	True	STAD	C2	GI.CIN	0.20797465199999998	0.37	0.19	22.11897828	0.5999	0.2895	-0.0376	-0.0978	1.3089	0.4007			1.670834055	4.057739848	242.0	0.602458225	6.0	23.0	0.7654258209999999	2.7429179269999997	36.0	3.427510678	39.0	0.935567901	3.3987340039999996	-1330.492534	260.4742926	-1398.691474	1.0	406.0	1.0	171.0	7.564682952546502	9.021658632029546	-0.009550006544699396	6.291717276733614	8.010057720351066	3.4403364321638055	-1.2729656758128873	-1.0116009116784803	3.449886438708505
13722.58cfa831e4b0c9d6adf6c88c	58cfa831e4b0c9d6adf6c88c	TCGA-D7-6822-01A-11D-1880_121220_SN1120_0207_BC1JALACXX_s_5_rg.sorted.filtered.	WGS	TCGA-D7-6822-01A-11D-1880_121220_SN1120_0207_BC1JALACXX_s_5_rg.sorted	TCGA-D7-6822-01A-11D-1880_121220_SN1120_0207_BC1JALACXX_s_5_rg.sorted.bam	442.7	1.9	0.14	58cfa831e4b0c9d6adf6c88c	TCGA-D7-6822-01A-11D-1880_121220_SN1120_0207_BC1JALACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6822-01A	E2AAABD9-F4BA-4763-A28A-C14D46A4BC5D	Primary Tumor	Illumina HiSeq	b8f8d06c-7bbf-4d0d-8f5a-e3012379df95	Stomach	77.0	C30AFDA8-FC63-4228-A9A9-42BCDB562ACE	586B20D4-917E-4344-BFBC-A21B12811C69	TCGA-D7-6822-01A-11D-1880-02	HG19_Broad_variant	TCGA-D7-6822	TCGA-STAD		s14769	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N0	Stomach  Intestinal Adenocarcinoma  Tubular Type	Stage IB	1880-02	True	STAD	C2	GI.CIN	0.179304472	0.27	0.13	6.026573267000001	0.8953	0.1275	-0.1706	-0.27699999999999997	0.5093	0.2265			1.389772255	6.485603856	637.0	0.507665047	13.0	55.0	0.8427878529999999	2.808341485	28.0	3.742839305	50.0	0.956752887	2.395142024	-1657.215541	612.7303336	-352.39421830000003	0.0	375.0	0.0	375.0	6.9541616517962925	5.763622475012218	0.18873025509023333	4.702869853189798	4.722168600184057	1.516438493599848	-2.251291798606495	-1.0414538748281612	1.3277082385096146
13722.58cfa831e4b0c9d6adf6c88e	58cfa831e4b0c9d6adf6c88e	TCGA-D5-6540-01A-11D-1719-10_wgs_Illumina.filtered.	WGS	TCGA-D5-6540-01A-11D-1719-10_wgs_Illumina	TCGA-D5-6540-01A-11D-1719-10_wgs_Illumina.bam	473.0	1.9	0.05	58cfa831e4b0c9d6adf6c88e	TCGA-D5-6540-01A-11D-1719-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-D5-6540-01A	B08B5F49-9434-4653-9772-097EC29B2CA3	Primary Tumor	Illumina HiSeq	ea4fb044-493b-4e48-ac28-28ba39b8be21	Colorectal	66.0	201B6B48-418F-48A3-A568-6E851F85C25E	EC43C4B5-FB72-4A4A-AF03-10C2D05FF159	TCGA-D5-6540-01A-11D-1719-10	GRCh37-lite	TCGA-D5-6540	TCGA-COAD		s13396	Baylor College of Medicine	Greater Poland Cancer Center	Poland	NO	T2	N0	Colon Mucinous Adenocarcinoma	Stage I	1719-10	False	COAD	C1	GI.HM-indel	0.202320202	0.24	0.01	6.181431475	0.9957	0.2815	-0.4448	-0.2781	-0.322	0.2491	501.0	3125.0	10.61335583	29.86608586	55.0	0.076547086	4.0	0.0				2.163955657	9.0	0.984858662	0.8109369270000001	-705.1833666	742.1567477000001	2337.331541	0.0	491.0	0.0	491.0	7.365295194199035	3.5613836177338474	-1.1802187183178288	6.09962882086776	6.3240938962078825	0.03936678537582128	-1.2656663733312756	2.762710278474035	1.21958550369365
13722.58cfa831e4b0c9d6adf6c896	58cfa831e4b0c9d6adf6c896	TCGA-DJ-A13V-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_2_rg.sorted.filtered.	WGS	TCGA-DJ-A13V-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_2_rg.sorted	TCGA-DJ-A13V-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_2_rg.sorted.bam	80.38	1.94	0.14	58cfa831e4b0c9d6adf6c896	TCGA-DJ-A13V-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_2_rg.sorted.bam	Alive	FEMALE		NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A13V-01A	99AC4F2E-2E63-4F1E-AF0F-8F23A2CAF999	Primary Tumor	Illumina HiSeq	a3620988-3968-488b-88e7-9ae555459dc7	Thyroid	21.0	A870F5CA-F049-48C1-AFAC-B788A3111086	DB0AC00C-ABED-4D02-B05B-A3CD87DCA75F	TCGA-DJ-A13V-01A-11D-A10R-02	HG19_Broad_variant	TCGA-DJ-A13V	TCGA-THCA		s12634	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A10R-02	True	THCA	C3	THCA.5	0.051920760999999996	0.0	0.0		-1.2972	-0.281	-0.5182	-0.2809	-0.5287	0.0501	3.0		0.056582157	0.19803755	49.0	3.0799999999999996e-05	0.0	0.0	0.9154666090000001	1.0057428659999998	3.0	2.48490665	12.0	1.0	1.4434251130000002	189.5407755	-1101.4716210000001	2374.051939	0.0	1313.0	0.0	1313.0	5.925700049543103	7.491273588141569	-0.43706087830783646	5.8730563160576805	6.191990604011307	0.948664708505319	-0.05264373348542195	-1.299282984130261	1.3857255868131555
13722.58cfa831e4b0c9d6adf6c898	58cfa831e4b0c9d6adf6c898	TCGA-DU-5854-01A-11D-1703_130806_SN1440_0159_BC29Y3ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DU-5854-01A-11D-1703_130806_SN1440_0159_BC29Y3ACXX_s_1_rg.sorted	TCGA-DU-5854-01A-11D-1703_130806_SN1440_0159_BC29Y3ACXX_s_1_rg.sorted.bam	66.3	1.9	0.16	58cfa831e4b0c9d6adf6c898	TCGA-DU-5854-01A-11D-1703_130806_SN1440_0159_BC29Y3ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-5854-01A	B95AFB1A-A1DF-4D85-AD34-191928E28A77	Primary Tumor	Illumina HiSeq	f499956c-7655-4be7-8a53-44403d30ea04	Brain	57.0	D5BAA53A-958C-4163-A388-D3C957C891F9	4716DB1C-94F8-40AE-B89B-EA41E6A7E8CE	TCGA-DU-5854-01A-11D-1703-02	HG19_Broad_variant	TCGA-DU-5854	TCGA-LGG		s8562	Harvard Medical School	Henry Ford Hospital	United States	NO			Astrocytoma		1703-02	True	LGG	C4	GBM_LGG.Mesenchymal-like	0.17013003899999998	0.48	0.0		-0.5188	-0.3365	0.5349	-1.2599	-0.2925	-0.23600000000000002	14.0	12.0	0.30361730600000003	1.184107492	118.0	0.165181725	7.0	6.0				1.7478680969999998	6.0	0.9755037590000001	3.16893291	43.41938928	-1138.347848	-2294.074012	0.0	257.0	1.0	202.0	9.113939597689829	7.692645679240725	-0.6289238185803562	6.439790948263299	7.181820055474734	2.5283917617277396	-2.6741486494265287	-0.5108256237659905	3.1573155803080954
13722.58cfa831e4b0c9d6adf6c89a	58cfa831e4b0c9d6adf6c89a	TCGA-DD-A1EH-01A-11D-A12Z-10_wgs_Illumina.filtered.	WGS	TCGA-DD-A1EH-01A-11D-A12Z-10_wgs_Illumina	TCGA-DD-A1EH-01A-11D-A12Z-10_wgs_Illumina.bam	38.71	1.93	0.08	58cfa831e4b0c9d6adf6c89a	TCGA-DD-A1EH-01A-11D-A12Z-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-DD-A1EH-01A	CAB5B264-ABAB-4BDB-816E-9D2C0AC30629	Primary Tumor	Illumina HiSeq	6126a7f9-c6d2-4361-9420-37af4bfafb5f	Liver	23.0	44C98B82-ADCB-4597-A9DB-83E7D2A0E2F9	B9F03936-1DE5-4330-8B0F-6D0AB533876E	TCGA-DD-A1EH-01A-11D-A12Z-10	GRCh37-lite	TCGA-DD-A1EH	TCGA-LIHC		s16776	Baylor College of Medicine	Mayo Clinic - Rochester	United States	NO	T3	N0	Hepatocellular Carcinoma	Stage III	A12Z-10	True	LIHC	C3	LIHC.iCluster:1	0.069814453	0.13	0.28		-0.3964	-0.2125	-0.6549	-0.3758	-0.8628	-0.3307	17.0	5.0	0.291903419	0.955320281	53.0	0.46399297	6.0	9.0	0.93763162	2.158976591	10.0	2.685945325	15.0	0.991837346	1.016812433	-1431.534985	-125.2466249	4001.4809200000004	0.0	1495.0	1.0	120.0	4.439332706832749	2.4963428101053307	-0.029937510849732063	5.628096092495156	4.32526020650105	3.7813190147643017	1.1887633856624071	1.8289173963957195	3.811256525614034
13722.58cfa831e4b0c9d6adf6c89e	58cfa831e4b0c9d6adf6c89e	TCGA-DD-A1EG-01A-11D-A20W-10_wgs_Illumina.filtered.	WGS	TCGA-DD-A1EG-01A-11D-A20W-10_wgs_Illumina	TCGA-DD-A1EG-01A-11D-A20W-10_wgs_Illumina.bam	24.35		0.08	58cfa831e4b0c9d6adf6c89e	TCGA-DD-A1EG-01A-11D-A20W-10_wgs_Illumina.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-DD-A1EG-01A	6C79F64B-63FE-46F5-BF7B-77208231B0F2	Primary Tumor	Illumina HiSeq	cf962035-7148-470e-a820-f252e162e9ef	Liver	76.0	E8B59658-06C6-46B7-B51F-ED52DE0C403E	50EE360C-E3DF-4888-9999-EBB88E271D08	TCGA-DD-A1EG-01A-11D-A20W-10	GRCh37-lite	TCGA-DD-A1EG	TCGA-LIHC	1372.0	s16585	Baylor College of Medicine	Mayo Clinic - Rochester	United States	NO	T1	N0	Hepatocellular Carcinoma	Stage I	A20W-10	False	LIHC	C2	LIHC.iCluster:3	0.300816225	0.67	0.31		-0.3529	0.01	0.4017	0.7782	0.2289	-0.2719			0.0	0.0	68.0	0.45891994	18.0	14.0	0.853483202	3.286036303	47.0	2.8943995439999997	20.0	0.966174304	2.63765503	-632.6162573	-666.7906002999999	3254.227547	1.0	1372.0	1.0	875.0	7.098375638590786	2.4736533203794604	-0.0212022076506031	5.953243334287784	4.032838812854426	3.9326422926308817	-1.1451323043030026	1.559185492474966	3.953844500281485
13722.58cfa831e4b0c9d6adf6c8a2	58cfa831e4b0c9d6adf6c8a2	TCGA-DQ-5631-01A-01D-1868_120504_SN1222_0101_AC0UMDACXX_s_2_rg.sorted.filtered.	WGS	TCGA-DQ-5631-01A-01D-1868_120504_SN1222_0101_AC0UMDACXX_s_2_rg.sorted	TCGA-DQ-5631-01A-01D-1868_120504_SN1222_0101_AC0UMDACXX_s_2_rg.sorted.bam	207.7	1.9	0.14	58cfa831e4b0c9d6adf6c8a2	TCGA-DQ-5631-01A-01D-1868_120504_SN1222_0101_AC0UMDACXX_s_2_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-DQ-5631-01A	10B3F56A-E61E-486B-8D3C-176668D5DC34	Primary Tumor	Illumina HiSeq	9aae2925-69ec-44f9-bc1d-bfefd16ce242	Head and Neck	52.0	2E4AA773-6094-46BD-A97F-9694E80C71CF	5B9E894B-444B-4DCF-9E6C-C1F398A52A81	TCGA-DQ-5631-01A-01D-1868-02	HG19_Broad_variant	TCGA-DQ-5631	TCGA-HNSC	548.0	s15916	Harvard Medical School	University of Michigan	United States	NO	TX	NX	Head and Neck Squamous Cell Carcinoma		1868-02	True	HNSC	C1	HNSC.Mesenchymal	0.12895457400000002	0.42	0.16		0.787	0.226	-0.6646	-0.9918	-0.434	0.7188	25.0	29.0	0.884268814	2.15172078	179.0	0.651912163	17.0	22.0	0.8080605809999999	3.3349746089999996	62.0	2.043191871	8.0	0.982567593	4.1739116130000005	-284.5762125	505.8376331	-1376.014219	1.0	548.0	1.0	447.0	5.849868376394252	4.264620363235849	-1.7612368357600063	5.389343491103061	5.423754177748262	-0.4508404786487945	-0.4605248852911914	1.1591338145124128	1.3103963571112118
13722.58cfa831e4b0c9d6adf6c8a6	58cfa831e4b0c9d6adf6c8a6	TCGA-D7-6519-01A-11D-1798_130214_SN1120_0236_AC1RPCACXX_s_5_rg.sorted.filtered.	WGS	TCGA-D7-6519-01A-11D-1798_130214_SN1120_0236_AC1RPCACXX_s_5_rg.sorted	TCGA-D7-6519-01A-11D-1798_130214_SN1120_0236_AC1RPCACXX_s_5_rg.sorted.bam	266.4	1.9	0.14	58cfa831e4b0c9d6adf6c8a6	TCGA-D7-6519-01A-11D-1798_130214_SN1120_0236_AC1RPCACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6519-01A	E37CAE9E-0656-4B89-B326-739A5CC859E0	Primary Tumor	Illumina HiSeq	66b2b99b-ac75-4068-9d05-34e6dbe9721d	Stomach	64.0	FA7426E1-FCFB-4B08-AD50-1D9E903A81FB	D7D0FD1C-F540-4BE1-A10B-160F59970FFF	TCGA-D7-6519-01A-11D-1798-02	HG19_Broad_variant	TCGA-D7-6519	TCGA-STAD		s15249	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N1	Stomach  Adenocarcinoma  Diffuse Type	Stage IIIB	1798-02	True	STAD	C2	GI.CIN	0.08130554799999999	0.26	0.11	10.62347111	0.5566	0.2225	-0.1703	-0.2358	0.6225	0.3756			0.32799084	1.371598057	319.0	0.928119192	23.0	46.0	0.9103480620000001	0.631005193	2.0	3.002484726	41.0	0.808516617	2.8339078580000003	-1194.012363	229.8071481	-2030.134825	0.0	625.0	1.0	429.0	8.7662383802531	8.043422475601258	-0.6778411618287212	6.2813317304651	7.232492259384929	1.820673318206353	-2.4849066497880004	-0.8109302162163288	2.498514480035074
13722.58cfa831e4b0c9d6adf6c8a8	58cfa831e4b0c9d6adf6c8a8	TCGA-CZ-5453-01A-01D-2102-10_wgs_Illumina.filtered.	WGS	TCGA-CZ-5453-01A-01D-2102-10_wgs_Illumina	TCGA-CZ-5453-01A-01D-2102-10_wgs_Illumina.bam	156.4	1.9	0.15	58cfa831e4b0c9d6adf6c8a8	TCGA-CZ-5453-01A-01D-2102-10_wgs_Illumina.bam	Alive	MALE	WHITE		Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-CZ-5453-01A	577847B9-F9B6-4954-868F-3D5AB2B4F694	Primary Tumor	Illumina HiSeq	28e40615-1ae0-420f-b7c0-ca99eaa91361	Kidney	67.0	5C1B955D-9D60-4975-A1E6-C4D531E79190	64446AEC-C125-4C81-B9CC-62482CB1AAED	TCGA-CZ-5453-01A-01D-2102-10	GRCh37-lite	TCGA-CZ-5453	TCGA-KIRC		s9307	Baylor College of Medicine	Harvard	None	NO	T2	NX	Kidney Clear Cell Renal Carcinoma	Stage II	2102-10	False	KIRC	C3	KIRC.1	0.033827899	0.22	0.01		-1.3333	-0.21	-0.0693	-1.1799	-0.1769	-0.0972	35.0	31.0	0.655124251	1.965372753	71.0	0.131555169	3.0	7.0				0.0	1.0		0.8089938990000001	443.2564246	-1397.2850210000001	2470.3576510000003	1.0	2419.0	0.0	2419.0	7.678662844417527	1.49070771564479	-0.3921633685006225	6.292368483297636	5.111293527092038	4.307811819205778	-1.3862943611198904	3.6205858114472482	4.699975187706401
13722.58cfa831e4b0c9d6adf6c8b0	58cfa831e4b0c9d6adf6c8b0	TCGA-CV-7432-01A-11D-2317_120730_SN1222_0141_BC115GACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CV-7432-01A-11D-2317_120730_SN1222_0141_BC115GACXX_s_1_rg.sorted	TCGA-CV-7432-01A-11D-2317_120730_SN1222_0141_BC115GACXX_s_1_rg.sorted.bam	222.73		0.15	58cfa831e4b0c9d6adf6c8b0	TCGA-CV-7432-01A-11D-2317_120730_SN1222_0141_BC115GACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-7432-01A	EAF674DD-9909-4879-B9A3-74253169EDDD	Primary Tumor	Illumina HiSeq	d1f8d81a-4553-4c26-9d59-534aa2475dca	Head and Neck	79.0	9213AB13-AFC6-40B9-B278-98DD05C92934	541FB07A-7568-4CFC-9FCD-C5B403C619BA	TCGA-CV-7432-01A-11D-2317-26	HG19_Broad_variant	TCGA-CV-7432	TCGA-HNSC	2570.0	s15783	MD Anderson - Institute for Applied Cancer Science	MD Anderson Cancer Center	United States	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	2317-26	True	HNSC	C2	HNSC.Basal	0.271878729	0.51	0.19		1.1121	0.4195	-0.9132	-1.5311	0.8996	0.0755	68.0	103.0	1.338749298	3.8377479880000003	91.0	0.547068341	11.0	16.0				0.693147181	2.0	1.0	1.520521175	-636.4867977000001	831.698028	-1227.966995	1.0	2570.0	1.0	2570.0	7.442687978091362	5.120978679775921	0.050889106117708804	6.077447026169303	2.427289496063162	2.0779894099030356	-1.365240951922058	-2.693689183712759	2.0271003037853266
13722.58cfa831e4b0c9d6adf6c8b2	58cfa831e4b0c9d6adf6c8b2	TCGA-DD-A3A7-01A-11D-A22F-10_wgs_Illumina.filtered.	WGS	TCGA-DD-A3A7-01A-11D-A22F-10_wgs_Illumina	TCGA-DD-A3A7-01A-11D-A22F-10_wgs_Illumina.bam	41.76		0.08	58cfa831e4b0c9d6adf6c8b2	TCGA-DD-A3A7-01A-11D-A22F-10_wgs_Illumina.bam	Dead	MALE			Liver Hepatocellular Carcinoma	Aligned reads	TCGA-DD-A3A7-01A	614C0ECF-6A84-4C86-8706-79BE5BB00991	Primary Tumor	Illumina HiSeq	48ae1497-c89f-4b1e-a0c4-1c6bd49c39b7	Liver	67.0	1EF290A3-D054-4E3A-9683-8F99A2010E3E	29B92B51-7BA3-42A9-97D3-6A9B5E43F928	TCGA-DD-A3A7-01A-11D-A22F-10	GRCh37-lite	TCGA-DD-A3A7	TCGA-LIHC	419.0	s16852	Baylor College of Medicine	Mayo Clinic - Rochester	United States	NO	T3b	N0	Hepatocellular Carcinoma	Stage IIIB	A22F-10	True	LIHC	C3	LIHC.iCluster:2	0.073627978	0.18	0.06		-0.6472	-0.1545	-1.2814	-0.7916	-0.9514	-1.0857	40.0	34.0	0.881590587	2.929992243	239.0	0.94638928	26.0	32.0					0.0		1.26666082	-1502.008196	-846.3081535	3975.6847880000005	1.0	419.0	1.0	144.0	6.083131735633805	2.1538163346649544	-0.8766379599541612	5.053512318452647	3.6888794541139367	1.625037720892308	-1.029619417181158	1.5350631194489823	2.501675680846469
13722.58cfa831e4b0c9d6adf6c8b8	58cfa831e4b0c9d6adf6c8b8	TCGA-DD-A4NG-01A-11D-A27I-10_wgs_Illumina.filtered.	WGS	TCGA-DD-A4NG-01A-11D-A27I-10_wgs_Illumina	TCGA-DD-A4NG-01A-11D-A27I-10_wgs_Illumina.bam	15.95		0.07	58cfa831e4b0c9d6adf6c8b8	TCGA-DD-A4NG-01A-11D-A27I-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-DD-A4NG-01A	89791F8F-DC06-4A04-B166-AFBFD6CF53DE	Primary Tumor	Illumina HiSeq	ef6dfbd5-d562-4452-9843-9c3db280717c	Liver	77.0	38507EDD-DFB4-4931-9895-2C0482BD4555	03C88506-D72E-4A44-A34E-A7F0564F1799	TCGA-DD-A4NG-01A-11D-A27I-10	GRCh37-lite	TCGA-DD-A4NG	TCGA-LIHC		s16856	Baylor College of Medicine	Mayo Clinic - Rochester	United States	NO	T3a	NX	Hepatocellular Carcinoma	Stage IIIA	A27I-10	True	LIHC	C3	LIHC.	0.199245599				-0.8091	-0.187	-0.4651	-0.2925	-0.8732	-0.624	33.0	14.0	0.43844759	1.7537903590000001						0.0	1.0	1.386294361	4.0	1.0	1.473086435	-1029.880949	-1042.173413	2957.149541	1.0	802.0	1.0	430.0	6.5959322935776	3.761790988630189	-0.5775079191171948	5.679641561703445	7.034130723367702	3.413373661223271	-0.9162907318741551	3.272339734737513	3.9908815803404654
13722.58cfa831e4b0c9d6adf6c8ba	58cfa831e4b0c9d6adf6c8ba	TCGA-DK-A3IM-01A-11D-A210_120906_SN208_0425_AD1CU2ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-DK-A3IM-01A-11D-A210_120906_SN208_0425_AD1CU2ACXX_s_7_rg.sorted	TCGA-DK-A3IM-01A-11D-A210_120906_SN208_0425_AD1CU2ACXX_s_7_rg.sorted.bam	26.41		0.15	58cfa831e4b0c9d6adf6c8ba	TCGA-DK-A3IM-01A-11D-A210_120906_SN208_0425_AD1CU2ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A3IM-01A	41B59716-116F-4942-8B63-409870A87E26	Primary Tumor	Illumina HiSeq	27ca0d22-3ef8-4c3c-814a-94dfb76c3289	Bladder	76.0	7A37AE7C-6B46-410D-AE2B-12FD868C25B3	CDAC6FE7-FB06-4F9A-86D0-DF0DF26FD558	TCGA-DK-A3IM-01A-11D-A210-26	HG19_Broad_variant	TCGA-DK-A3IM	TCGA-BLCA		s2882	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A210-26	True	BLCA	C1	BLCA.3	0.125308574	0.17	0.43		1.1261	0.4545	-1.4159	-2.0536	-0.6229	-0.0903	30.0	0.0	0.854238638	2.196613639	352.0	0.761652725	12.0	60.0				0.0	1.0		2.816599325	-915.4849034	1027.9131929999999	-2588.2866329999997	1.0	248.0	1.0	201.0	7.08249609106818	0.941282753896937	-1.9517999431113768	5.794641802761542	6.720774234969557	0.9205190679836761	-1.287854288306638	5.77949148107262	2.872319011095053
13722.58cfa831e4b0c9d6adf6c8bc	58cfa831e4b0c9d6adf6c8bc	TCGA-DK-A3IT-01A-31D-A210_120911_SN1120_0189_BD1D04ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DK-A3IT-01A-31D-A210_120911_SN1120_0189_BD1D04ACXX_s_5_rg.sorted	TCGA-DK-A3IT-01A-31D-A210_120911_SN1120_0189_BD1D04ACXX_s_5_rg.sorted.bam	24.31		0.16	58cfa831e4b0c9d6adf6c8bc	TCGA-DK-A3IT-01A-31D-A210_120911_SN1120_0189_BD1D04ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A3IT-01A	58520C66-7688-435A-B09F-653B18768C41	Primary Tumor	Illumina HiSeq	276fd52d-8d51-4e03-85a5-a7f02ee03b71	Bladder	62.0	6B48DAE5-B757-450A-8248-65C2434A7AFC	CDBAE634-52F3-4165-A214-BB60BEC5D6C4	TCGA-DK-A3IT-01A-31D-A210-26	HG19_Broad_variant	TCGA-DK-A3IT	TCGA-BLCA		s2715	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A210-26	True	BLCA	C1	BLCA.2	0.27691081300000003	0.54	0.01		0.9647	0.3365	-0.1881	0.4552	-0.0001	0.2411	173.0	102.0	2.6366912890000003	11.55851879	229.0	0.866253226	16.0	23.0	0.8545420359999999	3.359910282	51.0	2.143952201	9.0	0.9757546970000001	1.068336903	-899.1303197999999	1427.794601	-3202.223356	0.0	648.0	0.0	648.0	6.5514204132646725	9.072076921685362	-0.055660847105553746	6.012423912531985	8.545983825788582	3.054674809187441	-0.5389965007326869	-0.5260930958967793	3.1103356562929942
13722.58cfa831e4b0c9d6adf6c8c0	58cfa831e4b0c9d6adf6c8c0	TCGA-CV-5971-01A-11D-1681_120427_SN1120_0136_AC0JEMACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CV-5971-01A-11D-1681_120427_SN1120_0136_AC0JEMACXX_s_4_rg.sorted	TCGA-CV-5971-01A-11D-1681_120427_SN1120_0136_AC0JEMACXX_s_4_rg.sorted.bam	22.0	1.9	0.16	58cfa831e4b0c9d6adf6c8c0	TCGA-CV-5971-01A-11D-1681_120427_SN1120_0136_AC0JEMACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-5971-01A	1465B7EC-8D2B-47DD-8387-977EED44CC86	Primary Tumor	Illumina HiSeq	03c22e39-15a9-4b8a-8db1-cf41d618b7fc	Head and Neck	60.0	82589B3F-BD41-4ABE-9469-7DD48447DDDC	5739D7DE-98D4-4591-B8B1-E0E9AA9B05DF	TCGA-CV-5971-01A-11D-1681-02	HG19_Broad_variant	TCGA-CV-5971	TCGA-HNSC		s16198	Harvard Medical School	MD Anderson Cancer Center	None	NO	T4a	N2a	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	True	HNSC	C1	HNSC.Mesenchymal	0.5479269370000001	0.0	0.13		0.0839	0.0055	0.5962	1.2664	0.3749	0.6731	10.0		0.243908656	0.243908656	59.0	0.0006672189999999999	0.0	0.0	0.894810909	3.7073221530000002	63.0	3.52569573	36.0	0.983864126	2.8664907680000002	9.497963273	547.5827796	1726.928335	0.0	701.0	0.0	701.0	6.60345439440039	6.879577028716369	-0.18753535278454447	6.5234116867268535	7.112626109019982	2.48765768315989	-0.08004270767353638	0.23304908030361293	2.6751930359444347
13722.58cfa831e4b0c9d6adf6c8c2	58cfa831e4b0c9d6adf6c8c2	TCGA-DK-A3IL-01A-11D-A210_120913_SN208_0428_BC188KACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DK-A3IL-01A-11D-A210_120913_SN208_0428_BC188KACXX_s_3_rg.sorted	TCGA-DK-A3IL-01A-11D-A210_120913_SN208_0428_BC188KACXX_s_3_rg.sorted.bam	32.38		0.16	58cfa831e4b0c9d6adf6c8c2	TCGA-DK-A3IL-01A-11D-A210_120913_SN208_0428_BC188KACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A3IL-01A	178B28CD-99C3-48DC-8D09-1EF71B4CEE80	Primary Tumor	Illumina HiSeq	56a85daa-804e-4c68-b2be-c58cf3d5153e	Bladder	79.0	59D6683F-5EB7-493D-8E8E-78B88BE2CD70	F666A681-CA0D-4281-8E8A-156A24BBB63A	TCGA-DK-A3IL-01A-11D-A210-26	HG19_Broad_variant	TCGA-DK-A3IL	TCGA-BLCA		s3282	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T3	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A210-26	True	BLCA	C1	BLCA.2	0.110164055	0.26	0.1		0.3939	0.0905	-1.0923	-0.2932	-1.4522	-0.0687	55.0	4.0	1.161822099	5.3067009380000005	144.0	0.557781204	16.0	22.0					0.0		1.673955099	-2607.79839	633.3994022	-3438.649387	1.0	413.0	0.0	413.0	7.50103962441924	6.4884751818402435	0.3035325483886072	6.733784471705572	6.37514649653324	3.016679229397302	-0.7672551527136671	-0.11332868530700324	2.7131466810086944
13722.58cfa831e4b0c9d6adf6c8c4	58cfa831e4b0c9d6adf6c8c4	TCGA-CN-5373-01A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CN-5373-01A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_4_rg.sorted	TCGA-CN-5373-01A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_4_rg.sorted.bam	165.7	1.9	0.14	58cfa831e4b0c9d6adf6c8c4	TCGA-CN-5373-01A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-5373-01A	546F01D5-AED5-4FB8-91C0-0FD5E0FDE935	Primary Tumor	Illumina HiSeq	22213a76-97e9-4565-8074-c3046269b70a	Head and Neck	55.0	9D73D061-F1E1-47BA-929D-FEEB6C191279	3FE7F18F-8AA4-4AFE-8AF0-256876F7E86E	TCGA-CN-5373-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-5373	TCGA-HNSC		s16035	Harvard Medical School	University of Pittsburgh	None	NO	T1	N0	Head and Neck Squamous Cell Carcinoma	Stage I	1431-02	True	HNSC	C2	HNSC.Basal	0.312554199	0.53	0.07		0.1264	-0.125	0.5491	0.7440000000000001	2.6668	0.872	57.0	19.0	1.23313675	3.363100227	85.0	0.16964327899999998	4.0	10.0	0.8816869479999999	2.26148237	13.0	3.564623299	36.0	0.9947270709999999	3.877598859	123.67325179999999	-75.05292414	-273.10825510000006	0.0	1584.0	0.0	1584.0	6.563785002183568	4.8952628315578135	0.6740094469052816	5.534165585002409	6.973497857909309	1.6860261417172722	-1.0296194171811588	2.0782350263514955	1.0120166948119906
13722.58cfa831e4b0c9d6adf6c8c8	58cfa831e4b0c9d6adf6c8c8	TCGA-CV-6952-01A-11D-1911_120505_SN1120_0138_AD11NHACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CV-6952-01A-11D-1911_120505_SN1120_0138_AD11NHACXX_s_1_rg.sorted	TCGA-CV-6952-01A-11D-1911_120505_SN1120_0138_AD11NHACXX_s_1_rg.sorted.bam	111.7	1.9	0.15	58cfa831e4b0c9d6adf6c8c8	TCGA-CV-6952-01A-11D-1911_120505_SN1120_0138_AD11NHACXX_s_1_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6952-01A	7ED006E8-461F-4664-BFFF-55FA6812743C	Primary Tumor	Illumina HiSeq	7145e1a2-e609-45d9-a111-efe59656286d	Head and Neck	65.0	18E70193-5D78-41DD-9FCA-AF5E54594AD3	EAA6BAF6-1D90-471D-BBFF-2230B87339E4	TCGA-CV-6952-01A-11D-1911-02	HG19_Broad_variant	TCGA-CV-6952	TCGA-HNSC	185.0	s15647	Harvard Medical School	MD Anderson Cancer Center	United States	NO	T3	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1911-02	True	HNSC	C2	HNSC.Basal	0.31465829100000003	0.49	0.09		0.4396	0.2	-0.063	0.4041	2.4888	0.5173	42.0	5.0	1.444838499	4.157596496	80.0	0.163091105	5.0	12.0	0.9293400079999999	2.576677626	16.0	2.818411948	20.0	0.940809021	1.7753281109999999	9.38500806	163.73451430000003	-1491.338209	1.0	185.0	0.0	185.0	5.817111159963204	6.430872412812535	0.19718698237271293	6.034834643808075	6.787862764418289	1.2479264539681036	0.21772348384487072	0.356990351605754	1.0507394715953908
13722.58cfa831e4b0c9d6adf6c8ca	58cfa831e4b0c9d6adf6c8ca	TCGA-CV-5973-01A-11D-A32X-10_wgs_Illumina.filtered.	WGS	TCGA-CV-5973-01A-11D-A32X-10_wgs_Illumina	TCGA-CV-5973-01A-11D-A32X-10_wgs_Illumina.bam	115.0	1.9	0.08	58cfa831e4b0c9d6adf6c8ca	TCGA-CV-5973-01A-11D-A32X-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-5973-01A	8FC1F1BE-D2D5-4B3A-9973-F4D964018BEB	Primary Tumor	Illumina HiSeq	91b47661-f43d-4fb8-a616-e40ed72329d3	Head and Neck	62.0	5078222F-B257-4286-A29A-BC1E395149BC	7E584FF6-0B81-4F85-81DA-B8117AFEE326	TCGA-CV-5973-01A-11D-A32X-10	GRCh37-lite	TCGA-CV-5973	TCGA-HNSC		s16042	Baylor College of Medicine	MD Anderson Cancer Center	None	NO	T3	N1	Head and Neck Squamous Cell Carcinoma	Stage III	A32X-10	True	HNSC	C2	HNSC.Basal	0.172602492	0.3	0.03		-0.5438	-0.0145	-0.862	-0.9047	0.8832	0.1434	18.0	23.0	0.731036435	1.3706933159999999	283.0	0.532755183	12.0	35.0					0.0		4.48805971	-648.0297784	-799.5250942000001	-1366.551138	0.0	2641.0	0.0	2641.0	6.784457062637643	5.908377348991917	-0.9329276436323098	4.887337077751763	5.3067549522371475	2.2534823799863135	-1.897119984885881	-0.6016223967547694	3.1864100236186235
13722.58cfa831e4b0c9d6adf6c8ce	58cfa831e4b0c9d6adf6c8ce	TCGA-D1-A16Q-01A-12D-A12F_120511_SN208_0299_BD12J9ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-D1-A16Q-01A-12D-A12F_120511_SN208_0299_BD12J9ACXX_s_5_rg.sorted	TCGA-D1-A16Q-01A-12D-A12F_120511_SN208_0299_BD12J9ACXX_s_5_rg.sorted.bam	74.24	1.92	0.14	58cfa831e4b0c9d6adf6c8ce	TCGA-D1-A16Q-01A-12D-A12F_120511_SN208_0299_BD12J9ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A16Q-01A	7F4F3AED-69AF-421E-817B-B258DCC0BAC5	Primary Tumor	Illumina HiSeq	c23e5f4d-d7be-44b1-a19e-c949819d58c9	Uterus	54.0	BFE3DA05-506E-4837-AC72-A285FE079C58	23DF790A-0AB3-4EFB-AD9D-62AF1B79D941	TCGA-D1-A16Q-01A-12D-A12F-02	HG19_Broad_variant	TCGA-D1-A16Q	TCGA-UCEC		s5024	Harvard Medical School	Mayo Clinic	None	NO			Endometrioid endometrial adenocarcinoma		A12F-02	True	UCEC	C1	UCEC.CN_LOW	0.167810121	0.18	0.0	1.9827623419999998	0.0566	0.03	-0.1632	0.9614	-0.7809	0.1249	18.0	8.0	0.160232688	0.721047095	45.0	0.0060761619999999995	0.0	2.0							2.4253819930000002	-607.138245	-655.6169872	-1483.824714	0.0	324.0	0.0	324.0	6.8134445995108965	7.044992297287222	-0.4489614359026356	5.887675123682197	4.8257888132322275	2.676655743172266	-0.925769475828699	-2.2192034840549946	3.1256171790749017
13722.58cfa831e4b0c9d6adf6c8d6	58cfa831e4b0c9d6adf6c8d6	TCGA-D1-A16B-01A-11D-A12F_120511_SN208_0299_BD12J9ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-D1-A16B-01A-11D-A12F_120511_SN208_0299_BD12J9ACXX_s_1_rg.sorted	TCGA-D1-A16B-01A-11D-A12F_120511_SN208_0299_BD12J9ACXX_s_1_rg.sorted.bam	93.6	1.92	0.15	58cfa831e4b0c9d6adf6c8d6	TCGA-D1-A16B-01A-11D-A12F_120511_SN208_0299_BD12J9ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A16B-01A	BCA1057A-1E96-404D-8A37-5A8DC1944EE7	Primary Tumor	Illumina HiSeq	fee88e21-5479-4b67-8933-80c22e6fa222	Uterus	64.0	6A59FF6E-7CC6-4D46-8983-7D9E6A48CC19	D581BCAA-4EA7-4364-840B-E2D24F1916E4	TCGA-D1-A16B-01A-11D-A12F-02	HG19_Broad_variant	TCGA-D1-A16B	TCGA-UCEC		s5017	Harvard Medical School	Mayo Clinic	None	NO			Endometrioid endometrial adenocarcinoma		A12F-02	True	UCEC	C1	UCEC.CN_LOW	0.242021165	0.35	0.0	8.890820946	0.2402	0.126	-0.07	0.5169	-0.4105	0.32	18.0	21.0	0.275488408	1.294795517	53.0	0.000123714	0.0	0.0							2.723716282	-796.2964017	-210.9563929	-3585.398243	0.0	1106.0	0.0	1106.0	6.801788518989284	6.86056837435954	-0.7873893645347387	5.703176230321175	5.451801157387591	2.739862028737224	-1.0986122886681091	-1.408767216971949	3.527251393271963
13722.58cfa831e4b0c9d6adf6c8d8	58cfa831e4b0c9d6adf6c8d8	TCGA-CV-6951-01A-11D-1911_120504_SN208_0297_BC0VJEACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CV-6951-01A-11D-1911_120504_SN208_0297_BC0VJEACXX_s_4_rg.sorted	TCGA-CV-6951-01A-11D-1911_120504_SN208_0297_BC0VJEACXX_s_4_rg.sorted.bam	62.7	1.9	0.14	58cfa831e4b0c9d6adf6c8d8	TCGA-CV-6951-01A-11D-1911_120504_SN208_0297_BC0VJEACXX_s_4_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6951-01A	91728CD6-ED91-49DC-9279-FAEDBE211A9D	Primary Tumor	Illumina HiSeq	ec458668-da73-4d3e-8ac6-08a0e974b879	Head and Neck	57.0	9EE0F161-0976-4697-BF69-7E42E7149FEB	90F9C6C1-B7E9-48E4-9A02-C5FAB56AFD95	TCGA-CV-6951-01A-11D-1911-02	HG19_Broad_variant	TCGA-CV-6951	TCGA-HNSC	915.0	s15905	Harvard Medical School	MD Anderson Cancer Center	United States	NO	T4a	N2c	Head and Neck Squamous Cell Carcinoma	Stage IVA	1911-02	True	HNSC	C2	HNSC.Classical	0.098741139	0.37	0.02		-0.0178	0.011000000000000001	-0.9084	-1.103	0.9416	0.3368	33.0	4.0	1.110027584	3.2700812619999997	178.0	0.442712321	13.0	18.0	0.6858536470000001	0.753487245	3.0	1.589026915	7.0	0.816598298	2.516246509	-1310.129271	-271.2498422	-1302.615313	1.0	915.0	1.0	915.0	6.876129995211556	8.408449180410525	-0.09734404883456993	6.753527673119224	7.907673892498035	1.1039820843389911	-0.12260232209233246	-0.5007752879124894	1.2013261331735612
13722.58cfa831e4b0c9d6adf6c8da	58cfa831e4b0c9d6adf6c8da	TCGA-D1-A168-01A-31D-A12F_120413_SN1120_0133_BC0J8UACXX_s_6_rg.sorted.filtered.	WGS	TCGA-D1-A168-01A-31D-A12F_120413_SN1120_0133_BC0J8UACXX_s_6_rg.sorted	TCGA-D1-A168-01A-31D-A12F_120413_SN1120_0133_BC0J8UACXX_s_6_rg.sorted.bam	60.13	1.98	0.15	58cfa831e4b0c9d6adf6c8da	TCGA-D1-A168-01A-31D-A12F_120413_SN1120_0133_BC0J8UACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A168-01A	41893E97-7E90-4B03-B738-260F288ADE4C	Primary Tumor	Illumina HiSeq	f7d0c63d-0a01-4ff3-b721-3c10692581ca	Uterus	67.0	B44C673E-9560-4B59-9FF3-34CE230CAD1C	4593D11C-3A35-4269-80EC-D282497CF71C	TCGA-D1-A168-01A-31D-A12F-02	HG19_Broad_variant	TCGA-D1-A168	TCGA-UCEC		s4438	Harvard Medical School	Mayo Clinic	None	NO			Endometrioid endometrial adenocarcinoma		A12F-02	True	UCEC	C4	UCEC.CN_LOW	0.123486266			1.740063966	-0.6086	-0.239	-1.3688	-1.3401	-2.0204	0.7823	20.0	56.0	0.379828595	1.3565306959999999	64.0	0.876133655	7.0	3.0							2.374960208	-1951.8331420000002	-577.3280593999999	-1166.846389	0.0	1098.0	0.0	1098.0	5.567237574270165	7.788574261548039	-0.7870007842737665	5.8893210734392785	6.8234933655044525	1.9702192461377868	0.3220834991691137	-0.9650808960435873	2.7572200304115535
13722.58cfa831e4b0c9d6adf6c8de	58cfa831e4b0c9d6adf6c8de	TCGA-CV-7429-01A-11D-2317_120710_SN590_0165_BC0VU7ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CV-7429-01A-11D-2317_120710_SN590_0165_BC0VU7ACXX_s_4_rg.sorted	TCGA-CV-7429-01A-11D-2317_120710_SN590_0165_BC0VU7ACXX_s_4_rg.sorted.bam	262.73		0.15	58cfa831e4b0c9d6adf6c8de	TCGA-CV-7429-01A-11D-2317_120710_SN590_0165_BC0VU7ACXX_s_4_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-7429-01A	44D99F11-EF5B-45D7-B7DF-B5C5893D878F	Primary Tumor	Illumina HiSeq	4860e1b8-251e-4894-91f2-c9416a9b7f28	Head and Neck	55.0	A8A03639-FAD0-4B1B-9802-E3882BBFC7B8	18E1FCE0-D678-48D9-AD23-432E23C9077D	TCGA-CV-7429-01A-11D-2317-26	HG19_Broad_variant	TCGA-CV-7429	TCGA-HNSC	107.0	s15908	MD Anderson - Institute for Applied Cancer Science	MD Anderson Cancer Center	United States	NO	T4a	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	2317-26	True	HNSC	C2	HNSC.Mesenchymal	0.293210207	0.48	0.45		0.669	0.316	0.1244	-0.289	0.8519	0.6423	25.0	0.0	0.504306421	1.334928761	113.0	0.307136906	4.0	7.0	0.9015982640000001	0.9905069329999999	3.0	2.511630344	17.0	0.8864953109999999	6.117349732	-47.35635467	487.37170639999994	-909.8290337000001	1.0	107.0	1.0	107.0	7.716582274879396	8.68028945422506	-0.0028380315014849833	6.856381009656285	7.832991593837855	3.6119334504587295	-0.8602012652231115	-0.8472978603872034	3.6147714819602146
13722.58cfa831e4b0c9d6adf6c8e0	58cfa831e4b0c9d6adf6c8e0	TCGA-DK-A3IV-01A-22D-A21C_120830_SN590_0177_BD141PACXX_s_7_rg.sorted.filtered.	WGS	TCGA-DK-A3IV-01A-22D-A21C_120830_SN590_0177_BD141PACXX_s_7_rg.sorted	TCGA-DK-A3IV-01A-22D-A21C_120830_SN590_0177_BD141PACXX_s_7_rg.sorted.bam	71.23		0.16	58cfa831e4b0c9d6adf6c8e0	TCGA-DK-A3IV-01A-22D-A21C_120830_SN590_0177_BD141PACXX_s_7_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A3IV-01A	F953DC5D-58BF-4936-B9FE-74B45E8C00E5	Primary Tumor	Illumina HiSeq	5bf5cb9d-7592-4967-8440-fe80dfe9c2a6	Bladder	60.0	BC065247-1179-4FC2-B45C-8EFB13AADE65	62148C98-8E6F-4CA0-9EC6-C7FD7F96495D	TCGA-DK-A3IV-01A-22D-A21C-26	HG19_Broad_variant	TCGA-DK-A3IV	TCGA-BLCA	294.0	s3108	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO		NX	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A21C-26	True	BLCA	C2	BLCA.1	0.388598813	0.44	0.09		0.6899	0.1065	0.1583	1.3271	1.8259999999999998	-0.6702	25.0	4.0	0.6447233139999999	2.149077714	201.0	0.286900086	7.0	29.0	0.5849447839999999	1.4535331830000002	12.0	3.706083651	47.0	0.9625822270000001	1.368472051	-873.8951252999999	852.0137176000001	-178.25003519999999	1.0	294.0	1.0	212.0	6.607460668479511	7.932792786658184	0.056797598393133364	5.4034878641535755	6.868082049665755	2.3046321766157707	-1.203972804325936	-1.0647107369924282	2.2478345782226374
13722.58cfa831e4b0c9d6adf6c8e1	58cfa831e4b0c9d6adf6c8e1	TCGA-CW-5585-01A-01D-2103-10_wgs_Illumina.filtered.	WGS	TCGA-CW-5585-01A-01D-2103-10_wgs_Illumina	TCGA-CW-5585-01A-01D-2103-10_wgs_Illumina.bam	288.4	1.88	0.15	58cfa831e4b0c9d6adf6c8e1	TCGA-CW-5585-01A-01D-2103-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-CW-5585-01A	0487FC41-386C-4D76-9084-DAF959BF5E98	Primary Tumor	Illumina HiSeq	ff078c8b-f861-46f7-ac62-eb5ff21a805c	Kidney	51.0	B5040DA2-0D96-422A-9760-98A95C136FE8	3FEAC02A-C99F-4DD9-9EFF-E4F5E87F7DC5	TCGA-CW-5585-01A-01D-2103-10	GRCh37-lite	TCGA-CW-5585	TCGA-KIRC		s9306	Baylor College of Medicine	Mayo Clinic - Rochester	United States	NO	T3b	N0	Kidney Clear Cell Renal Carcinoma	Stage IV	2103-10	False	KIRC	C3	KIRC.1	0.047630904	0.2	0.0		-1.4293	-0.3745	-0.1941	-0.8681	-0.0865	-0.1256	14.0	10.0	0.281608316	1.0701116000000002	88.0	0.15027585599999999	3.0	10.0				1.791759469	6.0	1.0	1.149405941	-189.9573687	-1367.418352	3657.225664	0.0	2609.0	0.0	2609.0	6.826545223556593	3.794505297697687	0.0990909026442307	4.778852380191338	5.362004520911458		-2.0476928433652555	1.5674992232137708	
13722.58cfa831e4b0c9d6adf6c8e4	58cfa831e4b0c9d6adf6c8e4	TCGA-CX-7086-01A-11D-A32X-10_wgs_Illumina.filtered.	WGS	TCGA-CX-7086-01A-11D-A32X-10_wgs_Illumina	TCGA-CX-7086-01A-11D-A32X-10_wgs_Illumina.bam	464.7		0.08	58cfa831e4b0c9d6adf6c8e4	TCGA-CX-7086-01A-11D-A32X-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CX-7086-01A	AD6C9D09-2C03-4786-A72D-DD2AA5F603D4	Primary Tumor	Illumina HiSeq	2c64cb1b-6ae4-4191-9b2c-e5c13e267e83	Head and Neck	53.0	B293A736-9A82-4AD9-BF7E-9E2CEA09DDBC	E52FFA79-557A-4024-81F3-F3826C227EC5	TCGA-CX-7086-01A-11D-A32X-10	GRCh37-lite	TCGA-CX-7086	TCGA-HNSC		s16343	Baylor College of Medicine	Medical College of Georgia	United States	NO	T3	N1	Head and Neck Squamous Cell Carcinoma	Stage III	A32X-10	True	HNSC	C2	HNSC.Atypical	0.178878788	0.3	0.25		0.9787	0.2505	-0.5303	-0.0508	1.6215	-0.0253	92.0	77.0	1.750286883	6.251024582	333.0	0.643687625	17.0	42.0	0.8995107729999999	2.1569326319999997	11.0	2.245952081	11.0	0.936634767	6.763835358	-0.328718215	318.95215460000003	-2190.735892	0.0	573.0	0.0	573.0	6.703626229348638	4.014208657753825	-0.29814249134065873	5.87694765616417	4.287850216704694	0.8238969302225911	-0.8266785731844681	0.27364155895086917	1.1220394215632499
13722.58cfa831e4b0c9d6adf6c8e6	58cfa831e4b0c9d6adf6c8e6	TCGA-CV-6960-01A-41D-2317_120623_SN1222_0118_AD13T1ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CV-6960-01A-41D-2317_120623_SN1222_0118_AD13T1ACXX_s_6_rg.sorted	TCGA-CV-6960-01A-41D-2317_120623_SN1222_0118_AD13T1ACXX_s_6_rg.sorted.bam	52.73		0.13	58cfa831e4b0c9d6adf6c8e6	TCGA-CV-6960-01A-41D-2317_120623_SN1222_0118_AD13T1ACXX_s_6_rg.sorted.bam	Dead	MALE	BLACK OR AFRICAN AMERICAN		Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6960-01A	2C985B30-0F8F-4C8F-A924-CC6AAD7EBF0D	Primary Tumor	Illumina HiSeq	5fdfb781-64fd-48dd-9d26-3de7bfdf5908	Head and Neck	49.0	967F6CC9-95D2-4666-A20A-717D768613A4	F41864FE-49FA-4037-AF02-E3F8E2515614	TCGA-CV-6960-01A-41D-2317-26	HG19_Broad_variant	TCGA-CV-6960	TCGA-HNSC	862.0	s15902	MD Anderson - Institute for Applied Cancer Science	MD Anderson Cancer Center	United States	NO	T3	N0	Head and Neck Squamous Cell Carcinoma	Stage III	2317-26	True	HNSC	C1	HNSC.Classical	0.311791716	0.33	0.0		0.544	0.2115	-0.9337	-1.8374	0.0281	0.4286	72.0	174.0	1.41456713	4.449992429	161.0	0.8398919690000001	9.0	34.0				0.0	1.0		1.9032210019999998	783.282244	654.1896499	591.8782863	1.0	862.0	0.0	862.0	6.872185670205758	4.420419179434282	-1.8336356746070033	6.296821525302196	8.33175229176849	-1.059661991957796	-0.575364144903562	3.911333112334208	0.7739736826492073
13722.58cfa831e4b0c9d6adf6c8e8	58cfa831e4b0c9d6adf6c8e8	TCGA-CV-6441-01A-11D-1681_120427_SN208_0287_AC0J25ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CV-6441-01A-11D-1681_120427_SN208_0287_AC0J25ACXX_s_2_rg.sorted	TCGA-CV-6441-01A-11D-1681_120427_SN208_0287_AC0J25ACXX_s_2_rg.sorted.bam	46.0	1.9	0.14	58cfa831e4b0c9d6adf6c8e8	TCGA-CV-6441-01A-11D-1681_120427_SN208_0287_AC0J25ACXX_s_2_rg.sorted.bam	Dead	MALE	WHITE	HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6441-01A	59398D50-45CF-4812-A24E-0C00C0199971	Primary Tumor	Illumina HiSeq	4df6f8df-9255-4e46-8936-baeab0ed20c2	Head and Neck	60.0	192C9F36-08EC-4F7F-8137-1A9BD0282D98	FE879D88-4817-4ED8-9FB2-EE92AF1A582F	TCGA-CV-6441-01A-11D-1681-02	HG19_Broad_variant	TCGA-CV-6441	TCGA-HNSC	292.0	s15779	Harvard Medical School	MD Anderson Cancer Center	United States	NO	T3	N0	Head and Neck Squamous Cell Carcinoma	Stage III	1681-02	True	HNSC	C2	HNSC.Atypical	0.058163676	0.3	0.07		0.7201	0.228	-1.0324	-1.6573	0.9352	-0.4611	60.0	98.0	2.1600587730000003	5.537052066	328.0	0.924338529	14.0	35.0				0.693147181	2.0	1.0	2.0746047659999998	-931.6811482	668.7299366000001	-1047.28284	1.0	292.0	1.0	95.0	6.812024177269281	4.5404079839218285	1.072432783086339	6.161436611128131	9.073007477075084	2.92084679714962	-0.6505875661411493	4.532599493153256	1.8484140140632814
13722.58cfa831e4b0c9d6adf6c8ea	58cfa831e4b0c9d6adf6c8ea	TCGA-CV-7411-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CV-7411-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_5_rg.sorted	TCGA-CV-7411-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_5_rg.sorted.bam	80.73		0.16	58cfa831e4b0c9d6adf6c8ea	TCGA-CV-7411-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_5_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-7411-01A	600FC87B-A177-4BF9-9084-457F7E7E102C	Primary Tumor	Illumina HiSeq	7db9b308-952d-4c12-98c4-9de1f4b9fbd2	Head and Neck	64.0	24876E1A-E07E-4F74-86BF-3395A88CE4A1	221E7B51-6E05-45A9-99AC-EB705D3B2AD8	TCGA-CV-7411-01A-11D-2317-26	HG19_Broad_variant	TCGA-CV-7411	TCGA-HNSC	2717.0	s15526	MD Anderson - Institute for Applied Cancer Science	MD Anderson Cancer Center	United States	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	2317-26	True	HNSC	C2	HNSC.Basal	0.375647556	0.76	0.0		-0.2921	-0.121	-0.4827	0.1199	0.5042	0.6784	40.0	3.0	1.0698850770000001	2.934541924	45.0	0.000163209	0.0	9.0	0.9468015340000001	2.4986635280000002	14.0	1.9730014059999998	8.0	0.948813115	3.217928413	-477.4800476	-129.1982002	-826.0554641	1.0	2717.0	0.0	2717.0	7.491942882432932	3.159430626205234	-0.9045448144643209	6.393330593764823	5.210229392462162	1.3941346103532408	-1.0986122886681096	2.0507987662569285	2.2986794248175615
13722.58cfa831e4b0c9d6adf6c8f2	58cfa831e4b0c9d6adf6c8f2	TCGA-CV-5976-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CV-5976-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_2_rg.sorted	TCGA-CV-5976-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_2_rg.sorted.bam	135.0	1.9	0.15	58cfa831e4b0c9d6adf6c8f2	TCGA-CV-5976-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-5976-01A	23062172-7361-4E61-8EE6-B0A613D72A24	Primary Tumor	Illumina HiSeq	ef7745ae-17be-41bc-a3a5-c24eeda89075	Head and Neck	50.0	EEF68956-D624-4CD0-9C48-28FAF052C5F9	2581BC16-0DEF-40BC-8A97-54A1AE577E26	TCGA-CV-5976-01A-11D-1681-02	HG19_Broad_variant	TCGA-CV-5976	TCGA-HNSC		s16041	Harvard Medical School	MD Anderson Cancer Center	None	NO	T4a	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	True	HNSC	C2	HNSC.Basal	0.26021193	0.45	0.12		0.4662	0.174	-0.5086	-1.0956	1.1337	0.6588	30.0	2.0	0.7004394620000001	1.857687268	120.0	0.293736767	6.0	19.0		0.0	1.0	0.693147181	2.0	1.0	2.154555816	-709.6519675	188.5900683	-1159.7347220000001	0.0	1478.0	0.0	1478.0	6.862365576683327	8.492543142022605	-0.8857198913236166	6.574683504231546	7.4199063397577545	2.6917671460347865	-0.2876820724517808	-1.0726368022648494	3.5774870373584036
13722.58cfa831e4b0c9d6adf6c8f4	58cfa831e4b0c9d6adf6c8f4	TCGA-CV-7432-01A-11D-A32X-10_wgs_Illumina.filtered.	WGS	TCGA-CV-7432-01A-11D-A32X-10_wgs_Illumina	TCGA-CV-7432-01A-11D-A32X-10_wgs_Illumina.bam	222.73		0.08	58cfa831e4b0c9d6adf6c8f4	TCGA-CV-7432-01A-11D-A32X-10_wgs_Illumina.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-7432-01A	EAF674DD-9909-4879-B9A3-74253169EDDD	Primary Tumor	Illumina HiSeq	b0ae59a2-ff3b-4c06-a046-3138e659d051	Head and Neck	79.0	9213AB13-AFC6-40B9-B278-98DD05C92934	D25A4C65-9CB4-4611-909E-E68F93408D84	TCGA-CV-7432-01A-11D-A32X-10	GRCh37-lite	TCGA-CV-7432	TCGA-HNSC	2570.0	s15785	Baylor College of Medicine	MD Anderson Cancer Center	United States	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	A32X-10	True	HNSC	C2	HNSC.Basal	0.271878729	0.51	0.19		1.1121	0.4195	-0.9132	-1.5311	0.8996	0.0755	68.0	103.0	1.338749298	3.8377479880000003	91.0	0.547068341	11.0	16.0				0.693147181	2.0	1.0	1.520521175	-636.4867977000001	831.698028	-1227.966995	1.0	2570.0	1.0	2570.0	6.822415231815121	4.396936465534761	0.050889106117708804	6.163169602930857	2.046487107002287	2.0779894099030356	-0.6592456288842641	-2.350449358532474	2.0271003037853266
13722.58cfa831e4b0c9d6adf6c8fe	58cfa831e4b0c9d6adf6c8fe	TCGA-CN-6994-01A-11D-A32X-10_wgs_Illumina.filtered.	WGS	TCGA-CN-6994-01A-11D-A32X-10_wgs_Illumina	TCGA-CN-6994-01A-11D-A32X-10_wgs_Illumina.bam	267.7		0.07	58cfa831e4b0c9d6adf6c8fe	TCGA-CN-6994-01A-11D-A32X-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-6994-01A	6909302D-358A-46CD-8052-EEDB09C83C83	Primary Tumor	Illumina HiSeq	165171a0-a11e-4c82-b718-897ca9741478	Head and Neck	67.0	1A5AF8E2-61B4-4A04-B4B6-EA41FC34C89A	190EB791-383D-4E27-870D-E470630843E7	TCGA-CN-6994-01A-11D-A32X-10	GRCh37-lite	TCGA-CN-6994	TCGA-HNSC		s16325	Baylor College of Medicine	University of Pittsburgh	United States	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	A32X-10	True	HNSC	C1	HNSC.Classical	0.154506203	0.42	0.09		0.3826	-0.008	-0.0195	-0.3866	0.5315	0.777	39.0	0.0	1.104941655	2.896738932	149.0	0.6101057129999999	22.0	19.0		0.0	1.0	1.791759469	6.0	1.0	4.711617791	-972.1097973	212.2260457	-1634.739869	0.0	1183.0	0.0	1183.0	6.5722825426940075	4.175915008185715	-1.1358940932463717	4.675162557808127	3.385201583694762	1.8675432266820247	-1.897119984885881	-0.7907134244909528	3.003437319928396
13722.58cfa831e4b0c9d6adf6c900	58cfa831e4b0c9d6adf6c900	TCGA-DU-6399-01A-12D-1703_130813_SN1440_0160_AD2B87ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DU-6399-01A-12D-1703_130813_SN1440_0160_AD2B87ACXX_s_3_rg.sorted	TCGA-DU-6399-01A-12D-1703_130813_SN1440_0160_AD2B87ACXX_s_3_rg.sorted.bam	39.3	1.9	0.17	58cfa831e4b0c9d6adf6c900	TCGA-DU-6399-01A-12D-1703_130813_SN1440_0160_AD2B87ACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-6399-01A	4EF429BE-C345-4258-9B42-B56E215E1A2C	Primary Tumor	Illumina HiSeq	bcd63f96-cd75-4e38-826d-5304bd0d18db	Brain	54.0	41555F97-0269-4F3D-AB13-6B0AE08D1FF5	329097BC-E434-4EA7-B0AC-EFF202C58C6F	TCGA-DU-6399-01A-12D-1703-02	HG19_Broad_variant	TCGA-DU-6399	TCGA-LGG	2000.0	s8754	Harvard Medical School	Henry Ford Hospital	United States	NO			Oligodendroglioma		1703-02	True	LGG	C5	GBM_LGG.G-CIMP-high	0.070478606	0.31	0.29		-0.4712	-0.2395	0.1978	-2.2193	-0.2997	-0.8168	24.0	5.0	0.5180941170000001	1.310473355	123.0	0.147822324	0.0	11.0				0.0	1.0		3.590357415	35.57267048	-232.52019019999997	-2750.844502	1.0	2000.0	1.0	1629.0	7.938623915563728	8.233806641886614	-0.22799827298341468	5.741399338227509	7.1839845173879375	2.2414186577565585	-2.197224577336219	-1.0498221244986776	2.469416930739973
13722.58cfa831e4b0c9d6adf6c902	58cfa831e4b0c9d6adf6c902	TCGA-DB-5273-01A-01D-1465_130808_SN208_0488_BC294YACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DB-5273-01A-01D-1465_130808_SN208_0488_BC294YACXX_s_1_rg.sorted	TCGA-DB-5273-01A-01D-1465_130808_SN208_0488_BC294YACXX_s_1_rg.sorted.bam	64.0	1.9	0.15	58cfa831e4b0c9d6adf6c902	TCGA-DB-5273-01A-01D-1465_130808_SN208_0488_BC294YACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DB-5273-01A	AE2DB022-EB4F-4B65-89B6-9FD4439DDEEF	Primary Tumor	Illumina HiSeq	844bcbca-fe48-4dee-be69-4cef2ac59e27	Brain	33.0	4BA48810-3915-4567-9D35-615DF00006E4	6F0ACC8E-2A73-4B08-AAA3-A29EBE61E6B7	TCGA-DB-5273-01A-01D-1465-02	HG19_Broad_variant	TCGA-DB-5273	TCGA-LGG		s8751	Harvard Medical School	Mayo Clinic - Rochester	United States	NO			Astrocytoma		1465-02	True	LGG	C4	GBM_LGG.G-CIMP-high	0.23320862399999998	0.27	0.01		-0.8873	-0.2535	0.3396	-1.8932	0.3004	-0.711	7.0		0.226997325	0.312121322	58.0	0.017349201	1.0	5.0				0.0	1.0		3.253636458	141.12879630000003	-576.720175	-3920.308529	0.0	2493.0	0.0	2493.0	7.314774734022538	8.091321273530411	0.7677663624173361	5.523015264794483	7.04986739870225	4.366352102961397	-1.7917594692280547	-1.0414538748281612	3.59858574054406
13722.58cfa831e4b0c9d6adf6c90a	58cfa831e4b0c9d6adf6c90a	TCGA-DU-5849-01A-11D-1703_130806_SN1222_0209_AD2AW0ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DU-5849-01A-11D-1703_130806_SN1222_0209_AD2AW0ACXX_s_5_rg.sorted	TCGA-DU-5849-01A-11D-1703_130806_SN1222_0209_AD2AW0ACXX_s_5_rg.sorted.bam	97.3	1.8	0.14	58cfa831e4b0c9d6adf6c90a	TCGA-DU-5849-01A-11D-1703_130806_SN1222_0209_AD2AW0ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-5849-01A	5AF8ADA5-86B5-4832-8A8E-E975ECCA5515	Primary Tumor	Illumina HiSeq	d4f0a4e9-de7c-498f-89e7-aad71fb01915	Brain	48.0	9E0E239F-CED4-4CF3-BF3C-5EC8224D760B	7732E26C-3B82-4D03-A331-82D8088CEB44	TCGA-DU-5849-01A-11D-1703-02	HG19_Broad_variant	TCGA-DU-5849	TCGA-LGG		s8349	Harvard Medical School	Henry Ford Hospital	United States	NO			Oligodendroglioma		1703-02	True	LGG	C5	GBM_LGG.Codel	0.058897695	0.31	0.03		-1.2741	-0.3555	-0.4086	-1.8397	-0.8131	-0.9792	17.0		0.306226791	0.8268123359999999	79.0	0.104560736	3.0	12.0				0.693147181	2.0	1.0	3.3473290139999996	133.3584422	-492.0980978	-3714.197276	0.0	443.0	0.0	443.0	6.1268691841141845	6.353282493109951	1.1457124068040427	3.9296446067779653	5.599510690733571	1.686128354190956	-2.197224577336219	-0.7537718023763804	0.5404159473869132
13722.58cfa831e4b0c9d6adf6c90c	58cfa831e4b0c9d6adf6c90c	TCGA-DK-A2HX-01A-12D-A18D_120913_SN208_0429_AC187FACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DK-A2HX-01A-12D-A18D_120913_SN208_0429_AC187FACXX_s_1_rg.sorted	TCGA-DK-A2HX-01A-12D-A18D_120913_SN208_0429_AC187FACXX_s_1_rg.sorted.bam	16.46		0.14	58cfa831e4b0c9d6adf6c90c	TCGA-DK-A2HX-01A-12D-A18D_120913_SN208_0429_AC187FACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A2HX-01A	C728FAC9-5452-4759-A4ED-A366E0F757CB	Primary Tumor	Illumina HiSeq	17e4edb9-ac80-43de-a7c1-66edf1201ac0	Bladder	80.0	537F3FE6-4E8E-4570-827A-0F5CAB193BE0	4BAFEFB4-28D5-4126-B6B7-AE5B0D03F05D	TCGA-DK-A2HX-01A-12D-A18D-02	HG19_Broad_variant	TCGA-DK-A2HX	TCGA-BLCA		s2712	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A18D-02	True	BLCA	C1	BLCA.2	0.13744537699999998	0.51	0.13		-0.0804	-0.0955	-0.1986	-0.2985	0.2262	0.7287	37.0	11.0	0.815417162	2.562739653	196.0	0.598663316	18.0	24.0	0.534757916	1.1119978259999999	8.0	2.441015278	12.0	0.982336813	1.5118670769999998	-954.0533065	516.2772808999999	274.0812143	1.0	1420.0	0.0	1420.0	7.300521043065222	9.147649032636263	0.3045009692618108	6.572282542694007	8.049036743968152		-0.7282385003712157	-1.0986122886681096	
13722.58cfa831e4b0c9d6adf6c912	58cfa831e4b0c9d6adf6c912	TCGA-DK-A2I2-01A-11D-A17R_120927_SN208_0433_BD1D5JACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DK-A2I2-01A-11D-A17R_120927_SN208_0433_BD1D5JACXX_s_3_rg.sorted	TCGA-DK-A2I2-01A-11D-A17R_120927_SN208_0433_BD1D5JACXX_s_3_rg.sorted.bam	49.35		0.16	58cfa831e4b0c9d6adf6c912	TCGA-DK-A2I2-01A-11D-A17R_120927_SN208_0433_BD1D5JACXX_s_3_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A2I2-01A	234086DD-5A74-4FF1-94AB-BAD43EE69D5C	Primary Tumor	Illumina HiSeq	99517da2-f39e-4005-8efc-4487b92c0dcc	Bladder	63.0	45F8E4B6-5D36-47D7-A77D-E5E4C15848B3	767D7AA5-093D-48AB-BCDA-92729F4B95B7	TCGA-DK-A2I2-01A-11D-A17R-02	HG19_Broad_variant	TCGA-DK-A2I2	TCGA-BLCA	237.0	s2708	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N3	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A17R-02	True	BLCA	C4	BLCA.3	0.47293172200000005	0.7	0.3		0.4465	0.3945	0.5553	-0.1231	0.2292	0.4682	41.0	12.0	1.060223149	2.5033046569999997	156.0	0.611742979	16.0	32.0	0.7874172420000001	0.545796041	2.0	1.732867951	6.0	0.9671320179999999	5.603337649	-952.5394028	188.33909599999998	-2126.756234	1.0	237.0	1.0	163.0	6.662390856194171	6.961123691549174	-1.0019672572659473	5.906723318652892	6.063182098343216	0.015658682933196166	-0.7556675375412789	-0.8979415932059585	1.0176259401991437
13722.58cfa831e4b0c9d6adf6c914	58cfa831e4b0c9d6adf6c914	TCGA-DK-A1AA-01A-11D-A13U_121025_SN590_0188_AC190CACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DK-A1AA-01A-11D-A13U_121025_SN590_0188_AC190CACXX_s_3_rg.sorted	TCGA-DK-A1AA-01A-11D-A13U_121025_SN590_0188_AC190CACXX_s_3_rg.sorted.bam	72.54	1.95	0.16	58cfa831e4b0c9d6adf6c914	TCGA-DK-A1AA-01A-11D-A13U_121025_SN590_0188_AC190CACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A1AA-01A	56D8A1B8-1268-4362-A7F1-77B76FBF1B59	Primary Tumor	Illumina HiSeq	006c1498-f327-4fff-8936-7d7cb06639f4	Bladder	57.0	577700D1-C366-41EF-8A0D-E50DEEFB5E3C	6482BD80-A3F1-4169-A9F2-B45A9445035C	TCGA-DK-A1AA-01A-11D-A13U-02	HG19_Broad_variant	TCGA-DK-A1AA	TCGA-BLCA		s3107	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A13U-02	True	BLCA	C1	BLCA.1	0.07767367	0.07	0.0		-0.4195	-0.0065	-0.9123	-1.4949	-0.1161	-0.0111	35.0	0.0	0.44251517	2.1535738280000003	91.0	0.105723206	2.0	3.0				1.098612289	3.0	1.0	2.0944428619999997	-1602.378276	-266.5688378	780.4689696	0.0	578.0	0.0	578.0	7.181211644169936	7.498580800140768	-0.030627759280955846	5.677134247393663	7.589552578346495	1.0698282727073338	-1.504077396776274	0.09097177820572666	1.1004560319882897
13722.58cfa831e4b0c9d6adf6c91b	58cfa831e4b0c9d6adf6c91b	TCGA-DK-A2I1-01A-11D-A17R_120927_SN208_0433_BD1D5JACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DK-A2I1-01A-11D-A17R_120927_SN208_0433_BD1D5JACXX_s_1_rg.sorted	TCGA-DK-A2I1-01A-11D-A17R_120927_SN208_0433_BD1D5JACXX_s_1_rg.sorted.bam	37.09		0.15	58cfa831e4b0c9d6adf6c91b	TCGA-DK-A2I1-01A-11D-A17R_120927_SN208_0433_BD1D5JACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A2I1-01A	036B9681-AB58-4734-A8FD-E0D5D078BF5A	Primary Tumor	Illumina HiSeq	724308ea-3fa9-4762-9800-445a044e94f2	Bladder	73.0	F9BD70B2-6CDE-48E5-9F0D-55D86CCFEBA8	010259EE-2667-4B8E-BB20-0F75F53A64BA	TCGA-DK-A2I1-01A-11D-A17R-02	HG19_Broad_variant	TCGA-DK-A2I1	TCGA-BLCA		s2704	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A17R-02	True	BLCA	C1	BLCA.2	0.232329194	0.42	0.16		0.2554	0.198	0.3103	1.0441	-0.4411	0.32299999999999995	86.0	47.0	2.073907055	6.043957703999999	339.0	0.717737537	21.0	21.0	0.876264358	3.971755385	93.0	2.426984031	14.0	0.919640511	2.446372516	-1692.376723	61.85722866	-3185.565575	0.0	546.0	0.0	546.0	6.634195241753911	5.958804617809245	0.8848545357484674	5.167858172960485	6.01942923962568	2.531490623807326	-1.4663370687934267	0.06062462181643502	1.6466360880588586
13722.58cfa831e4b0c9d6adf6c91f	58cfa831e4b0c9d6adf6c91f	TCGA-DK-A1AB-01A-11D-A13U_121002_SN1222_0154_AC1A3DACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DK-A1AB-01A-11D-A13U_121002_SN1222_0154_AC1A3DACXX_s_3_rg.sorted	TCGA-DK-A1AB-01A-11D-A13U_121002_SN1222_0154_AC1A3DACXX_s_3_rg.sorted.bam	43.47	2.0	0.18	58cfa831e4b0c9d6adf6c91f	TCGA-DK-A1AB-01A-11D-A13U_121002_SN1222_0154_AC1A3DACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A1AB-01A	F027D254-EC01-4882-A8A7-964AE90B7D49	Primary Tumor	Illumina HiSeq	a5005e15-2ada-4bf4-9a61-0febc81a99ca	Bladder	74.0	253F84AB-FCE2-4E2D-955B-0B8D13A9E4F0	D1F85B58-EBF8-4A73-A5E0-8DFE62CF1164	TCGA-DK-A1AB-01A-11D-A13U-02	HG19_Broad_variant	TCGA-DK-A1AB	TCGA-BLCA		s2707	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T4a	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A13U-02	True	BLCA	C2	BLCA.3	0.258343356	0.44	0.0		0.2631	-0.0295	0.3041	0.0384	1.1679	0.7975	87.0		1.789765281	4.892025101000001	55.0	0.7241925770000001	11.0	9.0	0.895983961	2.9530169710000003	27.0	2.79129457	18.0	0.965721645	2.2442264080000003	-676.4018070000001	403.73931170000003	-2794.000005	1.0	508.0	1.0	364.0	5.833640461914415	7.371436882939311	-0.1519534016563746	4.367303393120988	6.369988342724849	2.771476003753992	-1.4663370687934272	-1.0014485402144624	2.9234294054103667
13722.58cfa831e4b0c9d6adf6c934	58cfa831e4b0c9d6adf6c934	TCGA-DD-A4ND-01A-11D-A25V-10_wgs_Illumina.filtered.	WGS	TCGA-DD-A4ND-01A-11D-A25V-10_wgs_Illumina	TCGA-DD-A4ND-01A-11D-A25V-10_wgs_Illumina.bam	24.52		0.07	58cfa831e4b0c9d6adf6c934	TCGA-DD-A4ND-01A-11D-A25V-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-DD-A4ND-01A	C0BF9278-9CBB-4361-B4D8-AB172B67E276	Primary Tumor	Illumina HiSeq	7b8d29e8-a5ac-4b38-9ac0-77398a23286f	Liver	56.0	4282039E-396B-44D8-B4EC-AC14C46DDEF6	D9C5493E-F969-4C04-A646-9A3134011021	TCGA-DD-A4ND-01A-11D-A25V-10	GRCh37-lite	TCGA-DD-A4ND	TCGA-LIHC		s16857	Baylor College of Medicine	Mayo Clinic - Rochester	United States	NO	T1	N0	Hepatocellular Carcinoma	Stage I	A25V-10	True	LIHC	C3	LIHC.iCluster:2	0.33976826299999996	0.6	0.01		-0.2276	-0.11599999999999999	0.3787	0.6371	-0.17600000000000002	0.172	26.0	13.0	0.404217868	1.3743407509999999	84.0	0.398497913	13.0	14.0	0.96389904	1.058951331	3.0	2.902002313	19.0	0.9855875209999999	1.510707319	-212.929601	375.98325550000004	2456.790671	0.0	2746.0	1.0	15.0	6.543911845564793	1.7529345706059107	0.1058120266146374	5.799471370617297	3.9328440608549045	3.3574776743058288	-0.744440474947496	2.1799094902489937	3.2516656476911914
13722.58cfa831e4b0c9d6adf6c936	58cfa831e4b0c9d6adf6c936	TCGA-D1-A16E-01A-22D-A12F_120523_SN1222_0109_BD12MPACXX_s_4_rg.sorted.filtered.	WGS	TCGA-D1-A16E-01A-22D-A12F_120523_SN1222_0109_BD12MPACXX_s_4_rg.sorted	TCGA-D1-A16E-01A-22D-A12F_120523_SN1222_0109_BD12MPACXX_s_4_rg.sorted.bam	37.7	1.95	0.15	58cfa831e4b0c9d6adf6c936	TCGA-D1-A16E-01A-22D-A12F_120523_SN1222_0109_BD12MPACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A16E-01A	E70465F6-1922-4EB7-B646-8B01AD3CE77B	Primary Tumor	Illumina HiSeq	d5fd8d77-e4f4-4b13-b244-0dbbc2f74021	Uterus	73.0	58FC1E66-39C4-44D1-BDD3-338E0D833792	0651FC75-DFFC-4271-8832-2DB47C642804	TCGA-D1-A16E-01A-22D-A12F-02	HG19_Broad_variant	TCGA-D1-A16E	TCGA-UCEC		s4439	Harvard Medical School	Mayo Clinic	None	NO			Endometrioid endometrial adenocarcinoma		A12F-02	True	UCEC	C2	UCEC.CN_LOW	0.23074725399999998	0.43	0.0	1.2788146459999998	0.0269	-0.019	0.0073	0.1699	0.4474	-0.0301	22.0	5.0	0.580609654	1.293176047	35.0	0.000137193	0.0	3.0							2.7487856589999997	-1763.0705079999998	-912.2162672000001	686.6425499	0.0	1119.0	0.0	1119.0	5.993577697447678	8.609658419088332	0.004859292817459782	6.333903503384882	7.431003422746686	3.6951604999890058	0.3403258059372032	-1.1786549963416464	3.690301207171546
13722.58cfa831e4b0c9d6adf6c93f	58cfa831e4b0c9d6adf6c93f	TCGA-DK-A1AC-01A-11D-A13U_121002_SN1222_0154_AC1A3DACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DK-A1AC-01A-11D-A13U_121002_SN1222_0154_AC1A3DACXX_s_5_rg.sorted	TCGA-DK-A1AC-01A-11D-A13U_121002_SN1222_0154_AC1A3DACXX_s_5_rg.sorted.bam	61.12	1.95	0.15	58cfa831e4b0c9d6adf6c93f	TCGA-DK-A1AC-01A-11D-A13U_121002_SN1222_0154_AC1A3DACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE		Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A1AC-01A	36C14E9D-1863-4C55-BBBB-F8C9DD418932	Primary Tumor	Illumina HiSeq	befc5d25-55df-4a22-b4e4-25508f3935c9	Bladder	72.0	CD2FB6B8-5DB9-42B4-A407-A5B6F7B8665F	221E5DDE-BAB0-456C-87BE-DB54998FE197	TCGA-DK-A1AC-01A-11D-A13U-02	HG19_Broad_variant	TCGA-DK-A1AC	TCGA-BLCA		s2884	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A13U-02	True	BLCA	C1	BLCA.2	0.205644429	0.31	0.15		0.9332	0.23800000000000002	0.2454	0.5508	-0.6663	-0.0256	547.0	176.0	16.73700927	37.47765564	340.0	0.633065298	12.0	44.0	0.512281471	2.033906984	53.0	3.019736127	22.0	0.976931302	3.805712002	-1756.133577	1144.105201	-1026.3407550000002	0.0	3981.0	0.0	3981.0	6.28293941779846	6.708816416364744	0.5733459807473245	4.942688995179976	6.238812787119009	1.9993073409041622	-1.340250422618484	-0.47000362924573524	1.4259613601568377
13722.58cfa831e4b0c9d6adf6c945	58cfa831e4b0c9d6adf6c945	TCGA-D7-6818-01A-11D-1880_121220_SN1120_0207_BC1JALACXX_s_1_rg.sorted.filtered.	WGS	TCGA-D7-6818-01A-11D-1880_121220_SN1120_0207_BC1JALACXX_s_1_rg.sorted	TCGA-D7-6818-01A-11D-1880_121220_SN1120_0207_BC1JALACXX_s_1_rg.sorted.bam	113.7	1.9	0.14	58cfa831e4b0c9d6adf6c945	TCGA-D7-6818-01A-11D-1880_121220_SN1120_0207_BC1JALACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6818-01A	AA2934F9-8783-428E-88A6-1D04B93FA1FD	Primary Tumor	Illumina HiSeq	5a217dfc-ada8-4dec-8f7c-06be0123b9ef	Stomach	53.0	953E155F-D9E1-41C8-BA12-351A38195D22	21E75BA4-E4C1-4D8A-BFA2-E4698B4FB46B	TCGA-D7-6818-01A-11D-1880-02	HG19_Broad_variant	TCGA-D7-6818	TCGA-STAD		s15464	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N3	Stomach  Adenocarcinoma  Diffuse Type	Stage IIIA	1880-02	True	STAD	C1	GI.CIN	0.43899446200000003	0.57	0.25	0.011277772	0.8432	0.069	0.7408	0.2795	0.8064	0.6893			0.8581072959999999	4.004500716	178.0	0.412315382	13.0	28.0	0.757012674	3.53739065	107.0	3.8893988339999996	53.0	0.979625408	5.246982747	1.4805503709999999	1439.472308	991.6424152000001	1.0	376.0	1.0	247.0	6.99773660029215	8.397615124602334	0.41102141291750105	6.343810132885485	7.9747582737822995	2.342967430439731	-0.6539264674066638	-0.4228568508200339	1.9319460175222303
13722.58cfa831e4b0c9d6adf6c949	58cfa831e4b0c9d6adf6c949	TCGA-DJ-A13O-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DJ-A13O-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_5_rg.sorted	TCGA-DJ-A13O-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_5_rg.sorted.bam	21.24	1.93	0.16	58cfa831e4b0c9d6adf6c949	TCGA-DJ-A13O-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A13O-01A	77D5B246-33BA-4A96-9D73-06ACA797653E	Primary Tumor	Illumina HiSeq	ae4a78d9-4c9a-40f7-9612-17d11799ea67	Thyroid	56.0	457B11C0-3C36-4907-8C76-60E3861EBABB	EC713290-9998-489B-9D1E-CC9D33CF5428	TCGA-DJ-A13O-01A-11D-A10R-02	HG19_Broad_variant	TCGA-DJ-A13O	TCGA-THCA		s12241	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T1b	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A10R-02	True	THCA	C3	THCA.2	0.27603558100000003	0.64	0.0		-1.7644	-0.1535	0.3353	1.5766	-0.2563	-0.2053	2.0		0.0	0.113586041	69.0	6.7e-05	0.0	0.0	0.925246737	4.142641278999999	88.0	3.8519770560000004	52.0	0.97487711	1.8678018230000002	726.6949941	-1495.928759	2062.3290420000003	0.0	1161.0	0.0	1161.0	5.848383326508683	7.990292384793571	-0.39155430891309007	4.749771037840574	7.337967198753882	1.0771360762788618	-1.0986122886681096	-0.6523251860396906	1.4686903851919517
13722.58cfa831e4b0c9d6adf6c94b	58cfa831e4b0c9d6adf6c94b	TCGA-DJ-A1QO-01A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-DJ-A1QO-01A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_6_rg.sorted	TCGA-DJ-A1QO-01A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_6_rg.sorted.bam	43.74	1.8	0.18	58cfa831e4b0c9d6adf6c94b	TCGA-DJ-A1QO-01A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A1QO-01A	F2AD720E-579F-4E2C-A3F0-17877CA91067	Primary Tumor	Illumina HiSeq	1ac10023-1615-4727-ac8d-23b842c19d3c	Thyroid	69.0	03811796-0ECE-4408-82F7-B449A631D2FB	9E0C97ED-7482-4400-B66A-72AB48BA11A2	TCGA-DJ-A1QO-01A-11D-A14U-02	HG19_Broad_variant	TCGA-DJ-A1QO	TCGA-THCA		s12372	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Tall Cell (>= 50% tall cell features)	Stage III	A14U-02	True	THCA	C3	THCA.3	0.149485733	0.32	0.04		-1.2711	-0.2825	0.2959	-0.2631	-0.3289	0.19699999999999998	6.0	0.0	0.12030590099999999	0.39099417700000005	39.0	4.1e-06	0.0	0.0	0.876752923	2.786367985	24.0	2.025326221	8.0	0.973976032	1.4509298609999999	114.88948959999999	-915.9865880000001	1357.481376	0.0	1442.0	1.0	1062.0	6.234541436129641	7.702985108861023	-0.7891048191113946	5.401632313194537	7.957877358489813	3.2903467827814166	-0.8329091229351042	0.25489224962879	4.079451601892811
13722.58cfa831e4b0c9d6adf6c94f	58cfa831e4b0c9d6adf6c94f	TCGA-D7-5578-01A-01D-1598_121023_SN208_0437_BD1H3FACXX_s_2_rg.sorted.filtered.	WGS	TCGA-D7-5578-01A-01D-1598_121023_SN208_0437_BD1H3FACXX_s_2_rg.sorted	TCGA-D7-5578-01A-01D-1598_121023_SN208_0437_BD1H3FACXX_s_2_rg.sorted.bam	331.0	1.88	0.15	58cfa831e4b0c9d6adf6c94f	TCGA-D7-5578-01A-01D-1598_121023_SN208_0437_BD1H3FACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-5578-01A	A3C1F9A2-9174-48CF-81DC-2AFCFDC4BA9C	Primary Tumor	Illumina HiSeq	306aee2b-5fac-4825-952b-d838746530a5	Stomach	80.0	E88D8673-C0BE-4549-8DAF-100187608F17	A00E8607-F965-421B-B0ED-57C09488F514	TCGA-D7-5578-01A-01D-1598-02	HG19_Broad_variant	TCGA-D7-5578	TCGA-STAD		s15401	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T3	N2	Stomach  Intestinal Adenocarcinoma  Tubular Type	Stage IIIA	1598-02	True	STAD	C1	GI.CIN	0.306313096	0.4	0.54		0.6808	0.287	0.4525	1.3921	-0.1237	0.2981			2.119125434	5.269176754	133.0	0.5255789329999999	2.0	19.0	0.845795448	6.100125834	1356.0	4.3082156739999995	239.0	0.786678416	4.088818548	-496.7200075	-40.11906449	-2749.715765	0.0	385.0	0.0	385.0	8.911260254572033	7.856125904319704	-0.02802399094998076	6.659968455965538	6.844524992641224	1.7433785412093301	-2.251291798606495	-1.0116009116784803	1.771402532159311
13722.58cfa831e4b0c9d6adf6c954	58cfa831e4b0c9d6adf6c954	TCGA-DQ-5629-01A-01D-A32X-10_wgs_Illumina.filtered.	WGS	TCGA-DQ-5629-01A-01D-A32X-10_wgs_Illumina	TCGA-DQ-5629-01A-01D-A32X-10_wgs_Illumina.bam	233.7	1.9	0.08	58cfa831e4b0c9d6adf6c954	TCGA-DQ-5629-01A-01D-A32X-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-DQ-5629-01A	E95E9E7D-A1ED-46EB-9CF8-1D355BF0577F	Primary Tumor	Illumina HiSeq	3fb0505f-e847-4658-93f1-0af7d8617e66	Head and Neck	64.0	57EA3EED-F8E2-4310-90C0-50D89F818A12	2AFB198A-D4AA-4544-BDCE-85695E185869	TCGA-DQ-5629-01A-01D-A32X-10	GRCh37-lite	TCGA-DQ-5629	TCGA-HNSC		s16345	Baylor College of Medicine	University of Michigan	United States	NO	TX	NX	Head and Neck Squamous Cell Carcinoma		A32X-10	True	HNSC	C2	HNSC.Classical	0.185600911	0.41	0.35		0.8954	0.2585	-0.9032	-0.8918	0.141	0.4672	172.0	105.0	2.9100295369999998	8.190083129	224.0	0.750159992	18.0	41.0	0.674941462	1.61843894	11.0	0.693147181	2.0	1.0	6.419372527	-1304.24127	823.8509897000001	-1364.590256	1.0	941.0	0.0	941.0	5.748524050299633	3.2319958921192473	0.41439680609720586	5.010925107168854	4.69447133101334	3.0074283133171824	-0.737598943130779	1.462475438894093	2.5930315072199766
13722.58cfa831e4b0c9d6adf6c958	58cfa831e4b0c9d6adf6c958	TCGA-DK-A3IK-01A-32D-A21C_120914_SN590_0179_AD13PPACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DK-A3IK-01A-32D-A21C_120914_SN590_0179_AD13PPACXX_s_3_rg.sorted	TCGA-DK-A3IK-01A-32D-A21C_120914_SN590_0179_AD13PPACXX_s_3_rg.sorted.bam	35.88		0.16	58cfa831e4b0c9d6adf6c958	TCGA-DK-A3IK-01A-32D-A21C_120914_SN590_0179_AD13PPACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A3IK-01A	3F0A0748-9ACC-4D0B-BA18-7C08BD183F86	Primary Tumor	Illumina HiSeq	6c286798-955c-487f-b541-72f253866ada	Bladder	87.0	4FF20C48-29EE-4101-B409-C4573E38CF92	B13B80DE-1722-44D3-888D-EEE8677F205C	TCGA-DK-A3IK-01A-32D-A21C-26	HG19_Broad_variant	TCGA-DK-A3IK	TCGA-BLCA		s2887	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T3	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A21C-26	True	BLCA	C3	BLCA.2	0.21328967899999998	0.5	0.14		-0.2907	-0.0125	-0.8566	0.2206	-1.1587	0.1682	88.0	3.0	1.43838581	5.539315567999999	276.0	0.546183564	13.0	47.0	0.9322344909999999	2.923015855	23.0	0.6365141679999999	2.0	0.918295834	4.734868888	-1966.2477800000001	-568.8025727999999	-2183.8772910000002	1.0	146.0	0.0	146.0	6.993321167311784	8.17611034223734	0.5937833017994294	5.481863663237887	6.982187873764907	3.2827255495178935	-1.511457504073897	-1.1939224684724343	2.688942247718464
13722.58cfa831e4b0c9d6adf6c95a	58cfa831e4b0c9d6adf6c95a	TCGA-DJ-A1QF-01A-12D-A14U_120629_SN1120_0167_AC0WMBACXX_s_4_rg.sorted.filtered.	WGS	TCGA-DJ-A1QF-01A-12D-A14U_120629_SN1120_0167_AC0WMBACXX_s_4_rg.sorted	TCGA-DJ-A1QF-01A-12D-A14U_120629_SN1120_0167_AC0WMBACXX_s_4_rg.sorted.bam	14.32	1.97	0.15	58cfa831e4b0c9d6adf6c95a	TCGA-DJ-A1QF-01A-12D-A14U_120629_SN1120_0167_AC0WMBACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE		Thyroid Carcinoma	Aligned reads	TCGA-DJ-A1QF-01A	FCA0C7D9-5E6F-4AA7-BA04-5DF2EB8BA398	Primary Tumor	Illumina HiSeq	267d7caa-22fc-41bc-8ea9-ee910a0ac510	Thyroid	61.0	E4B53CA1-D395-4FEA-A962-DFBD2B373A6B	FA0BE982-CE22-449F-9D2B-E688196BA8AE	TCGA-DJ-A1QF-01A-12D-A14U-02	HG19_Broad_variant	TCGA-DJ-A1QF	TCGA-THCA		s11991	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage II	A14U-02	True	THCA	C3	THCA.5	0.08756330300000001	0.22	0.0		-2.0176	-0.3715	-0.2509	-1.381	-0.4151	0.1386	1.0		0.269201572	0.11964514300000001	53.0	2.4299999999999998e-05	0.0	0.0				1.098612289	3.0	1.0	1.137212696	42.58429279999999	-558.7272717999999	3255.293581	0.0	931.0	0.0	931.0	6.59329356913314	5.914853444736142	-1.4891038549861115	5.327627195801864	6.659293919683638	1.0308941146131587	-1.2656663733312756	0.7444404749474955	2.5199979695992702
13722.58cfa831e4b0c9d6adf6c95b	58cfa831e4b0c9d6adf6c95b	TCGA-DU-5847-01A-11D-1703_130806_SN1222_0209_AD2AW0ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DU-5847-01A-11D-1703_130806_SN1222_0209_AD2AW0ACXX_s_3_rg.sorted	TCGA-DU-5847-01A-11D-1703_130806_SN1222_0209_AD2AW0ACXX_s_3_rg.sorted.bam	173.3	1.9	0.14	58cfa831e4b0c9d6adf6c95b	TCGA-DU-5847-01A-11D-1703_130806_SN1222_0209_AD2AW0ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-5847-01A	92A7C445-2217-400A-BDCD-DF41502416B6	Primary Tumor	Illumina HiSeq	a76674c6-34c4-4c06-b7e4-eb602b3bc5fa	Brain	34.0	C68FC12C-C538-4A89-9F6E-C0800A5A6B53	F83FB674-A46C-47DE-BAD8-36605068D2E2	TCGA-DU-5847-01A-11D-1703-02	HG19_Broad_variant	TCGA-DU-5847	TCGA-LGG		s8136	Harvard Medical School	Henry Ford Hospital	United States	NO			Astrocytoma		1703-02	True	LGG	C4	GBM_LGG.Mesenchymal-like	0.122215965	0.24	0.0		-0.0629	-0.0295	0.652	-0.6579999999999999	0.3411	-0.4381	15.0	0.0	0.306273948	1.041331424	95.0	0.93007767	4.0	11.0				2.3419942519999997	11.0	0.9766874640000001	3.045520414	-412.28258839999995	-65.83985429	-2336.1746239999998	0.0	548.0	0.0	548.0	9.060447282401565	7.61253454377179	1.2743074325971793	6.6625520096031945	7.229542291515685	3.7248464388809714	-2.3978952727983707	-0.382992252256106	2.450539006283792
13722.58cfa831e4b0c9d6adf6c966	58cfa831e4b0c9d6adf6c966	TCGA-CN-5374-01A-01D-2266-10_Illumina.filtered.	WGS	TCGA-CN-5374-01A-01D-2266-10_Illumina	TCGA-CN-5374-01A-01D-2266-10_Illumina.bam	384.7	1.9	0.05	58cfa831e4b0c9d6adf6c966	TCGA-CN-5374-01A-01D-2266-10_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-5374-01A	D7641CA1-A062-4DD2-9414-447AF7311A84	Primary Tumor	Illumina HiSeq	3713f8c9-23d7-490a-bec2-99cb7ab55eac	Head and Neck	56.0	617DF1E0-B075-4610-B6D5-8850786FEA70	AB923DB7-54E8-4A50-B7FD-C2B4B300041E	TCGA-CN-5374-01A-01D-2266-10	GRCh37-lite	TCGA-CN-5374	TCGA-HNSC		s15768	Baylor College of Medicine	University of Pittsburgh	None	NO	T2	N2	Head and Neck Squamous Cell Carcinoma	Stage IVA	2266-10	True	HNSC	C2	HNSC.Atypical	0.347879025	0.6	0.07		1.1692	0.272	0.2871	2.0181	0.2786	-0.1209	51.0		1.4282569719999998	3.4446197560000003	81.0	0.442330412	22.0	7.0	0.7920236140000001	1.899189679	11.0	4.153874254	66.0	0.9914598	4.870274489	-260.5779185	-31.969440600000002	-11.99619182	1.0	1732.0	1.0	1369.0	6.9665631254107225	1.8715499382825218	-0.12768532206109873	5.942058808896335	4.241957627615329	1.1052963090966816	-1.024504316514388	2.370407689332807	1.2329816311577804
13722.58cfa831e4b0c9d6adf6c96a	58cfa831e4b0c9d6adf6c96a	TCGA-DJ-A1QI-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DJ-A1QI-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_5_rg.sorted	TCGA-DJ-A1QI-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_5_rg.sorted.bam	97.61	1.98	0.17	58cfa831e4b0c9d6adf6c96a	TCGA-DJ-A1QI-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A1QI-01A	3B1E2BD6-3D32-40F7-9B32-0DF32DFCBC72	Primary Tumor	Illumina HiSeq	e0052e53-2d8c-45ba-8d2c-db4eab61a141	Thyroid	63.0	C58506A1-8C6B-4CE8-99E0-F2D1234F95F5	3C049586-BD3C-490D-93DB-E344BD6A1AE8	TCGA-DJ-A1QI-01A-11D-A14U-02	HG19_Broad_variant	TCGA-DJ-A1QI	TCGA-THCA		s12641	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage II	A14U-02	True	THCA	C3	THCA.5	0.098862188	0.09	0.0		-1.8408	-0.3015	-0.16899999999999998	-0.3845	-0.5521	0.087	5.0	0.0	0.030263829	0.181582971	67.0	0.00012083299999999999	0.0	0.0	0.944492427	1.037630987	3.0	2.47622065	13.0	0.965407228	1.37685114	1047.500086	-556.2982225	1962.2148079999997	0.0	455.0	0.0	455.0	7.162024186225276	8.26227943617986	0.10701889083060234	6.931500527613443	7.702663648244437	1.7583551413962133	-0.23052365861183244	-0.5596157879354227	1.651336250565611
13722.58cfa831e4b0c9d6adf6c976	58cfa831e4b0c9d6adf6c976	TCGA-DK-A1A6-01A-11D-A13U_121011_SN590_0184_BC192GACXX_s_7_rg.sorted.filtered.	WGS	TCGA-DK-A1A6-01A-11D-A13U_121011_SN590_0184_BC192GACXX_s_7_rg.sorted	TCGA-DK-A1A6-01A-11D-A13U_121011_SN590_0184_BC192GACXX_s_7_rg.sorted.bam	85.12	1.95	0.15	58cfa831e4b0c9d6adf6c976	TCGA-DK-A1A6-01A-11D-A13U_121011_SN590_0184_BC192GACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE		Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A1A6-01A	9C274536-3CA1-4F0E-93A8-1688074D862F	Primary Tumor	Illumina HiSeq	66e30a9a-052c-40b8-ac7c-a241a6b87d6e	Bladder	53.0	7AD1CD01-0EA2-4FA4-9B05-C280BD256546	CACE3242-E727-4E1F-9427-B952E10C9B12	TCGA-DK-A1A6-01A-11D-A13U-02	HG19_Broad_variant	TCGA-DK-A1A6	TCGA-BLCA		s2892	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T2a	N1	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A13U-02	True	BLCA	C2	BLCA.1	0.31894306899999997	0.47	0.16		0.9217	0.34600000000000003	-0.2122	-0.2521	1.2929	-0.14800000000000002	151.0	84.0			341.0	0.89056003	14.0	29.0		0.0	1.0	2.582306344	14.0	0.978495736	1.190366213	-978.7534856000001	630.037529	-1826.717325	0.0	2020.0	0.0	2020.0	8.031060180240619	6.928945831553165	2.973109884991373	6.296459124852512	5.750290835211518	1.758665780798142	-1.7346010553881066	-1.178654996341646	-1.2144441041932312
13722.58cfa831e4b0c9d6adf6c977	58cfa831e4b0c9d6adf6c977	TCGA-DD-A1EL-01A-11D-A152-10_wgs_Illumina.filtered.	WGS	TCGA-DD-A1EL-01A-11D-A152-10_wgs_Illumina	TCGA-DD-A1EL-01A-11D-A152-10_wgs_Illumina.bam	63.8	1.71	0.08	58cfa831e4b0c9d6adf6c977	TCGA-DD-A1EL-01A-11D-A152-10_wgs_Illumina.bam	Dead	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-DD-A1EL-01A	2854FFE8-1F77-497A-BF49-11E0189FEE35	Primary Tumor	Illumina HiSeq	a4594690-fa54-40f6-bd78-08ffa730aa84	Liver	23.0	5A756B40-6C08-47E8-9B25-9B3FFFF39606	D252F328-4583-4E97-9A71-BB2885F06F73	TCGA-DD-A1EL-01A-11D-A152-10	GRCh37-lite	TCGA-DD-A1EL	TCGA-LIHC	415.0	s16676	Baylor College of Medicine	Mayo Clinic - Rochester	United States	NO	T2	N0	Hepatocellular Carcinoma	Stage II	A152-10	True	LIHC	C4	LIHC.iCluster:3	0.191134058	0.18	0.21		0.3341	0.32299999999999995	-0.336	-1.1281	-0.7144	-0.8322	29.0	9.0	0.7008603090000001	2.076623137	136.0	0.684494886	8.0	33.0		0.0	1.0	0.0	1.0		4.4165954030000005	-858.7807321	-214.25399590000004	2523.639485	1.0	415.0	1.0	415.0	7.770026195869727	0.30735420628790067	-0.5320201298373848	6.489092350407663	4.122850744831206	2.971792066007983	-1.2809338454620645	3.8154965385433055	3.5038121958453674
13722.58cfa831e4b0c9d6adf6c97a	58cfa831e4b0c9d6adf6c97a	TCGA-DJ-A1QN-01A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DJ-A1QN-01A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_1_rg.sorted	TCGA-DJ-A1QN-01A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_1_rg.sorted.bam	94.75	1.91	0.17	58cfa831e4b0c9d6adf6c97a	TCGA-DJ-A1QN-01A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_1_rg.sorted.bam	Alive	FEMALE		NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A1QN-01A	2012869D-C169-4CEA-AA09-C892FB79BBAA	Primary Tumor	Illumina HiSeq	5cfa9ea5-2e72-4f40-96be-d6accc8482a8	Thyroid	42.0	884C1978-00CF-4E48-BEF8-F03CA67D6C02	F5D0FC17-824D-42F7-931B-E23CD68B9E2F	TCGA-DJ-A1QN-01A-11D-A14U-02	HG19_Broad_variant	TCGA-DJ-A1QN	TCGA-THCA		s12640	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T1b	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A14U-02	True	THCA	C3	THCA.5	0.068054662	0.4	0.02		-1.6442	-0.303	0.0538	-0.4844	-0.3166	-0.0281	3.0	8.0	0.0	0.149002362	77.0	0.034789859	0.0	5.0				2.7080502010000003	15.0	1.0	1.488023962	-410.62629560000005	-1209.488226	1773.6377079999997	0.0	1295.0	0.0	1295.0	6.349782876790444	7.00416874604508	-0.18277312600460827	5.167087470911793	7.00416874604508	2.850525849348965	-1.1826954058786514	0.0	3.0332989753535733
13722.58cfa831e4b0c9d6adf6c985	58cfa831e4b0c9d6adf6c985	TCGA-DJ-A13W-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DJ-A13W-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_1_rg.sorted	TCGA-DJ-A13W-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_1_rg.sorted.bam	50.62	1.95	0.15	58cfa831e4b0c9d6adf6c985	TCGA-DJ-A13W-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A13W-01A	3B48CC5E-3396-4DD5-893D-54B75B98B016	Primary Tumor	Illumina HiSeq	ab5fa454-36a6-4d10-bfda-443dd6709cd8	Thyroid	45.0	4DCA97A5-B0E5-4383-8CC5-B6FF07741647	8A15A4FE-F286-422D-9D50-33ABBD885250	TCGA-DJ-A13W-01A-11D-A10R-02	HG19_Broad_variant	TCGA-DJ-A13W	TCGA-THCA		s11992	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T1b	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A10R-02	True	THCA	C4	THCA.1	0.026939797999999997	0.13	0.0		-1.8619	-0.5355	-0.677	-0.3007	-0.7896	-0.4361	10.0		0.0	0.282481782	51.0	3.68e-05	0.0	0.0					0.0		1.4827784259999999	-969.3807669	-2005.0200300000001	2744.4337600000003	0.0	1593.0	0.0	1593.0	6.604621101971436	7.943427767876374	-0.2181067332267813	5.558652546788747	6.794805058633602	1.7617786370161195	-1.045968555182688	-1.1486227092427712	1.9798853702429007
13722.58cfa831e4b0c9d6adf6c988	58cfa831e4b0c9d6adf6c988	TCGA-DJ-A1QE-01A-21D-A14U_120711_SN1120_0173_AC0WN6ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-DJ-A1QE-01A-21D-A14U_120711_SN1120_0173_AC0WN6ACXX_s_2_rg.sorted	TCGA-DJ-A1QE-01A-21D-A14U_120711_SN1120_0173_AC0WN6ACXX_s_2_rg.sorted.bam	36.64	2.05	0.17	58cfa831e4b0c9d6adf6c988	TCGA-DJ-A1QE-01A-21D-A14U_120711_SN1120_0173_AC0WN6ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE		Thyroid Carcinoma	Aligned reads	TCGA-DJ-A1QE-01A	DCCBA97D-4E81-42FB-93B3-90BE68A034FB	Primary Tumor	Illumina HiSeq	b2380599-45dd-48d5-840c-f6e358db7169	Thyroid	62.0	E8BF40C4-8F4D-4032-B18B-D61A87A2DD1A	FB93D33F-510B-45BD-8E70-8FD3A0EA5DBE	TCGA-DJ-A1QE-01A-21D-A14U-02	HG19_Broad_variant	TCGA-DJ-A1QE	TCGA-THCA		s12635	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A14U-02	True	THCA	C3	THCA.4	0.112966821	0.05	0.02		-1.4533	-0.257	-0.3626	-0.2421	0.0214	0.3415	8.0	0.0	0.120827436	0.453102885	55.0	0.018548211000000002	0.0	0.0	0.321182109	0.22262647300000002	2.0	2.63905733	14.0	1.0	1.880477225	539.7569734	-489.07591030000003	922.6299018999999	0.0	4134.0	0.0	4134.0	5.760693944427725	8.168051704361016	0.23177476493596028	4.779864691415999	6.850750214728077	1.3259846122063998	-0.9808292530117266	-1.3173014896329396	1.0942098472704398
13722.58cfa831e4b0c9d6adf6c98e	58cfa831e4b0c9d6adf6c98e	TCGA-D7-6520-01A-11D-1798_130214_SN1120_0236_AC1RPCACXX_s_7_rg.sorted.filtered.	WGS	TCGA-D7-6520-01A-11D-1798_130214_SN1120_0236_AC1RPCACXX_s_7_rg.sorted	TCGA-D7-6520-01A-11D-1798_130214_SN1120_0236_AC1RPCACXX_s_7_rg.sorted.bam	94.4	1.9	0.14	58cfa831e4b0c9d6adf6c98e	TCGA-D7-6520-01A-11D-1798_130214_SN1120_0236_AC1RPCACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6520-01A	3C573AF6-6298-49DE-8DE0-6A7F9CE9B000	Primary Tumor	Illumina HiSeq	46b79d94-56c0-4b23-955d-2395a50ecaf9	Stomach	53.0	7C162352-903E-4723-AF91-6FDD8E8EAD3B	F1CB7996-BD0E-4123-84E9-D359E5DB7700	TCGA-D7-6520-01A-11D-1798-02	HG19_Broad_variant	TCGA-D7-6520	TCGA-STAD		s14494	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2b	N2	Stomach  Intestinal Adenocarcinoma  Tubular Type	Stage IIIA	1798-02	True	STAD	C2	GI.CIN	0.144192212	0.48	0.06	9.972543338	-0.0671	-0.0905	-0.0577	-0.1691	1.4380000000000002	0.3522			0.592385775	1.45134515	238.0	0.41598715799999997	10.0	32.0	0.890674372	5.535192162	500.0	4.263276725	84.0	0.962187542	6.971879174	135.4012759	-191.72811240000001	-10.79750809	0.0	573.0	1.0	46.0	7.8234458307842605	8.173237019885281	-0.024824728694195497	5.5208607377902155	7.585450354983162	1.9539597954797538	-2.3025850929940455	-0.5877866649021186	1.9787845241739492
13722.58cfa831e4b0c9d6adf6c998	58cfa831e4b0c9d6adf6c998	TCGA-DK-A1A7-01A-11D-A13U_121025_SN590_0188_AC190CACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DK-A1A7-01A-11D-A13U_121025_SN590_0188_AC190CACXX_s_1_rg.sorted	TCGA-DK-A1A7-01A-11D-A13U_121025_SN590_0188_AC190CACXX_s_1_rg.sorted.bam	35.04	2.0	0.15	58cfa831e4b0c9d6adf6c998	TCGA-DK-A1A7-01A-11D-A13U_121025_SN590_0188_AC190CACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A1A7-01A	3ED614E7-F356-4D87-985B-D3BBBAE3BB40	Primary Tumor	Illumina HiSeq	4c14028a-f15d-42f9-ad5f-19f0dca3984e	Bladder	67.0	D68D16F7-6117-4D3D-8347-CF5CD3F23AE4	2DDD46A0-5304-4CA3-9AE3-AC3787D3C86A	TCGA-DK-A1A7-01A-11D-A13U-02	HG19_Broad_variant	TCGA-DK-A1A7	TCGA-BLCA		s3280	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A13U-02	True	BLCA	C1	BLCA.1	0.126227483	0.26	0.22		0.3758	0.1935	-0.7249	0.6948	-1.2726	-0.1282	59.0	49.0	1.675212943	6.030766595	484.0	0.654559199	12.0	49.0		0.0	1.0	1.098612289	3.0	1.0	4.211337341	-1672.61066	-18.94527717	-3531.29868	0.0	560.0	1.0	112.0	9.329411466617197	8.4255821613135	0.419202968661495	7.026826373623152	7.83779549641138	5.037618381399607	-2.3025850929940455	-0.5877866649021186	4.618415412738112
13722.58cfa831e4b0c9d6adf6c99c	58cfa831e4b0c9d6adf6c99c	TCGA-DK-A3WX-01A-22D-A233_120829_SN1120_0183_AC18U8ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DK-A3WX-01A-22D-A233_120829_SN1120_0183_AC18U8ACXX_s_5_rg.sorted	TCGA-DK-A3WX-01A-22D-A233_120829_SN1120_0183_AC18U8ACXX_s_5_rg.sorted.bam	36.57		0.16	58cfa831e4b0c9d6adf6c99c	TCGA-DK-A3WX-01A-22D-A233_120829_SN1120_0183_AC18U8ACXX_s_5_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A3WX-01A	D63C186D-ADD6-492E-8250-E83F46D39D00	Primary Tumor	Illumina HiSeq	12365344-0a7a-4ef2-a651-2f1f3a15f6a1	Bladder	67.0	FED73C89-75F1-45C9-B14B-7840C52C305F	A6D2A8FB-6A01-4625-AEB9-FFA9476B658E	TCGA-DK-A3WX-01A-22D-A233-26	HG19_Broad_variant	TCGA-DK-A3WX	TCGA-BLCA	321.0	s2899	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A233-26	True	BLCA	C1	BLCA.3	0.573854055	0.63	0.49		0.9105	0.36	0.1854	0.4267	0.0798	0.5075	15.0	36.0	0.37539334700000004	0.9529215740000001	62.0	0.274738768	12.0	14.0	0.9292240709999999	2.516385431	15.0	2.294122382	12.0	0.923222762	4.724142048	-1738.7905329999999	584.0358112	403.74646989999997	1.0	321.0	1.0	167.0	6.641345341805895	6.520989248306458	-0.47615601007328934	5.542733053137786	5.914853444736142	0.4829296641764016	-1.09861228866811	-0.6061358035703157	0.9590856742496909
13722.58cfa831e4b0c9d6adf6c9a0	58cfa831e4b0c9d6adf6c9a0	TCGA-DO-A1K0-01A-11D-A13U_120706_SN1222_0123_BD1488ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DO-A1K0-01A-11D-A13U_120706_SN1222_0123_BD1488ACXX_s_3_rg.sorted	TCGA-DO-A1K0-01A-11D-A13U_120706_SN1222_0123_BD1488ACXX_s_3_rg.sorted.bam	80.19	1.78	0.16	58cfa831e4b0c9d6adf6c9a0	TCGA-DO-A1K0-01A-11D-A13U_120706_SN1222_0123_BD1488ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DO-A1K0-01A	B7A01148-5BAB-4268-986A-A9CF7BCA967F	Primary Tumor	Illumina HiSeq	52d6a725-e64a-4e5b-88cb-c4845dc97057	Thyroid	30.0	C25AED9B-A1B7-48A9-8587-8D218F6A9562	7BC99883-45C3-4ADF-8761-40B4836552F2	TCGA-DO-A1K0-01A-11D-A13U-02	HG19_Broad_variant	TCGA-DO-A1K0	TCGA-THCA		s12245	Harvard Medical School	Medical College of Georgia	United States	NO	T3	N1b	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A13U-02	True	THCA	C3	THCA.3	0.065956192	0.08	0.0		-1.36	-0.3575	-0.3813	-1.1849	-0.7752	-0.0314	4.0	0.0	0.029882877000000002	0.17929726199999999	37.0	0.00017901	0.0	0.0				2.210253578	10.0	0.959900932	1.0727652570000001	8.125152652	-620.3845072	2004.765972	0.0	655.0	1.0	577.0	6.558040185978465	8.941937914256357	-0.35795743807199876	5.649184432591828	7.620182074274037	3.2896860285536498	-0.9088557533866366	-1.3217558399823197	3.6476434666256488
13722.58cfa831e4b0c9d6adf6c9a2	58cfa831e4b0c9d6adf6c9a2	TCGA-DD-A3A8-01A-11D-A22F-10_wgs_Illumina.filtered.	WGS	TCGA-DD-A3A8-01A-11D-A22F-10_wgs_Illumina	TCGA-DD-A3A8-01A-11D-A22F-10_wgs_Illumina.bam	34.18		0.07	58cfa831e4b0c9d6adf6c9a2	TCGA-DD-A3A8-01A-11D-A22F-10_wgs_Illumina.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-DD-A3A8-01A	69D6881B-9E9A-407B-8B02-BAD5FC2455BF	Primary Tumor	Illumina HiSeq	772bc588-a4c5-4f9a-a1d8-be943b521c76	Liver	75.0	93D007F8-84D9-427D-A1E9-54919605F7B3	4CFF8590-559E-4204-8635-96E11BFEDA68	TCGA-DD-A3A8-01A-11D-A22F-10	GRCh37-lite	TCGA-DD-A3A8	TCGA-LIHC	11.0	s16976	Baylor College of Medicine	Mayo Clinic - Rochester	United States	NO	T2	N0	Hepatocellular Carcinoma	Stage II	A22F-10	True	LIHC	C4	LIHC.iCluster:2	0.066796707	0.21	0.11		-1.4535	-0.3115	-1.3012	-1.3921	-0.6467	-1.1474	77.0	19.0	1.030190585	2.78151458	88.0	0.224231448	5.0	14.0				0.0	1.0		0.99751525	-102.19139840000001	-1362.026552	3667.9796420000002	1.0	11.0	0.0	11.0	6.707626103538217	0.6881640904077955	-0.6427795264729819	5.290560083751574	3.9317510754083544	3.4805072201200393	-1.4170660197866445	3.243586985000559	4.123286746593021
13722.58cfa831e4b0c9d6adf6c9a4	58cfa831e4b0c9d6adf6c9a4	TCGA-DD-A1ED-01A-11D-A152-10_wgs_Illumina.filtered.	WGS	TCGA-DD-A1ED-01A-11D-A152-10_wgs_Illumina	TCGA-DD-A1ED-01A-11D-A152-10_wgs_Illumina.bam	38.22	1.7	0.08	58cfa831e4b0c9d6adf6c9a4	TCGA-DD-A1ED-01A-11D-A152-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-DD-A1ED-01A	0FF6364A-E6F4-47CA-A7E7-14705BF0A8DF	Primary Tumor	Illumina HiSeq	baa8f20c-66ac-448e-9ca3-b1302905fa30	Liver	68.0	1CF84C3E-E7E2-43A6-B9AF-E0042312F02F	4C3EDA94-56F4-46D3-8C88-50D476E773F6	TCGA-DD-A1ED-01A-11D-A152-10	GRCh37-lite	TCGA-DD-A1ED	TCGA-LIHC		s16977	Baylor College of Medicine	Mayo Clinic - Rochester	United States	NO	T1	N0	Hepatocellular Carcinoma	Stage I	A152-10	True	LIHC	C3	LIHC.iCluster:1	0.327251538	0.64	0.0		-2.3556	-0.314	0.2434	0.3297	-0.22899999999999998	-0.5515	8.0	99.0	0.186919052	0.587459879	41.0	3.54e-05	0.0	0.0				1.69878299	7.0	0.873001762	1.4104126069999998	-330.7620559	-1162.60016	3633.5666920000003	0.0	2301.0	0.0	2301.0	7.02921409037239	2.6184716548410574	0.22891931378340014	5.954699353283341	4.8658183575535	3.999743701748424	-1.0745147370890495	2.2473467027124423	3.770824387965024
13722.58cfa831e4b0c9d6adf6c9a8	58cfa831e4b0c9d6adf6c9a8	TCGA-DK-A1AG-01A-11D-A13U_121025_SN590_0188_AC190CACXX_s_7_rg.sorted.filtered.	WGS	TCGA-DK-A1AG-01A-11D-A13U_121025_SN590_0188_AC190CACXX_s_7_rg.sorted	TCGA-DK-A1AG-01A-11D-A13U_121025_SN590_0188_AC190CACXX_s_7_rg.sorted.bam	70.38	1.89	0.17	58cfa831e4b0c9d6adf6c9a8	TCGA-DK-A1AG-01A-11D-A13U_121025_SN590_0188_AC190CACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A1AG-01A	F8C0A69C-DF53-4A0A-A30E-4424C0CE3DD5	Primary Tumor	Illumina HiSeq	4043eef2-fcc6-411c-a6a3-ddd71f3852d8	Bladder	65.0	64668AA0-DDE5-4534-8CD0-378881E4A4E4	69A3B1DB-3463-456C-B3D1-6BE1FD7EE1D9	TCGA-DK-A1AG-01A-11D-A13U-02	HG19_Broad_variant	TCGA-DK-A1AG	TCGA-BLCA		s2885	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A13U-02	True	BLCA	C1	BLCA.1	0.101322606	0.08	0.01		-0.2613	0.001	-0.8695	-0.6484	-0.3239	-0.1204	53.0	18.0	1.046197923	3.08204253	121.0	0.065010026	2.0	0.0		0.0	1.0	1.7351264569999998	6.0	0.968392514	2.3557526319999997	-2278.080306	-116.2052419	-608.6977909	0.0	475.0	0.0	475.0	7.831120924528253	7.600078590843684	-0.25276191459094277	6.172892847924722	7.43755966134591	1.3143066602777567	-1.6582280766035324	-0.1625189294977747	1.5670685748686997
13722.58cfa831e4b0c9d6adf6c9b0	58cfa831e4b0c9d6adf6c9b0	TCGA-DJ-A13M-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_6_rg.sorted.filtered.	WGS	TCGA-DJ-A13M-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_6_rg.sorted	TCGA-DJ-A13M-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_6_rg.sorted.bam	24.89	1.93	0.14	58cfa831e4b0c9d6adf6c9b0	TCGA-DJ-A13M-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A13M-01A	BA9DEC81-FFC0-453A-9621-94BEBA45FAB1	Primary Tumor	Illumina HiSeq	6d7b5f3b-5fba-469e-a651-31a4569d7877	Thyroid	28.0	28913C64-8637-4537-AF8C-7315097A5AD1	8C708D3B-B312-4C27-898B-A0FE87110474	TCGA-DJ-A13M-01A-11D-A10R-02	HG19_Broad_variant	TCGA-DJ-A13M	TCGA-THCA		s12369	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T1b	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A10R-02	True	THCA	C3	THCA.1	0.041077116000000004	0.12	0.0		-2.1737	-0.1	-1.0608	-1.3038	-0.9817	-0.7121	2.0		0.0	0.141932602	59.0	0.01147292	0.0	0.0					0.0		1.6756679819999998	-344.4353376	-1452.268035	-503.1420497	0.0	1484.0	0.0	1484.0	5.754201513119513	7.601612733553555	1.187434683993692	5.1907321558681	7.287955174698514	3.223728894517274	-0.5634693572514125	-0.3136575588550419	2.0362942105235824
13722.58cfa831e4b0c9d6adf6c9b4	58cfa831e4b0c9d6adf6c9b4	TCGA-DJ-A13S-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-DJ-A13S-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_6_rg.sorted	TCGA-DJ-A13S-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_6_rg.sorted.bam	58.89	1.97	0.13	58cfa831e4b0c9d6adf6c9b4	TCGA-DJ-A13S-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A13S-01A	8AA99F35-C644-4F91-9EFF-A5D3FAE758B0	Primary Tumor	Illumina HiSeq	a19c2149-887d-4a36-992f-2a0ebb46072c	Thyroid	19.0	17952842-3447-4A38-90F4-D25B90C3233A	3C630C3D-343D-4F9F-8067-43B66466D382	TCGA-DJ-A13S-01A-11D-A10R-02	HG19_Broad_variant	TCGA-DJ-A13S	TCGA-THCA		s12239	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T1b	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A10R-02	True	THCA	C3	THCA.1	0.053773216	0.33	0.0		-1.6006	-0.3375	-0.8816	-2.1546	-0.6787	-0.5164	5.0	4.0	0.05633189	0.33799134200000003	49.0	3.13e-05	0.0	0.0				0.0	1.0		1.135956862	-253.74728849999997	-480.89256730000005	2714.323931	0.0	265.0	0.0	265.0	5.151886036908826	8.42350170082737	0.0358018206694537	5.520649778166562	7.4541011436392655	2.054835730877636	0.3687637412577356	-0.9694005571881035	2.019033910208182
13722.58cfa831e4b0c9d6adf6c9b5	58cfa831e4b0c9d6adf6c9b5	TCGA-DK-A3IU-01A-11D-A210_120911_SN1120_0189_BD1D04ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-DK-A3IU-01A-11D-A210_120911_SN1120_0189_BD1D04ACXX_s_7_rg.sorted	TCGA-DK-A3IU-01A-11D-A210_120911_SN1120_0189_BD1D04ACXX_s_7_rg.sorted.bam	34.01		0.15	58cfa831e4b0c9d6adf6c9b5	TCGA-DK-A3IU-01A-11D-A210_120911_SN1120_0189_BD1D04ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A3IU-01A	F093F043-EFD4-4CBA-A87F-8CBB5C1ACD9E	Primary Tumor	Illumina HiSeq	346b87a3-0c3a-455c-b3c1-0fb96acd0f2f	Bladder	58.0	B9C39E8B-D689-499A-BC06-CE3BFFC9996C	8E8E8966-582A-45FF-96C2-EC0C1718C4F2	TCGA-DK-A3IU-01A-11D-A210-26	HG19_Broad_variant	TCGA-DK-A3IU	TCGA-BLCA		s3285	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A210-26	True	BLCA	C2	BLCA.4	0.566870028	0.73	0.39		0.37200000000000005	0.1185	1.311	2.7609	1.1396	0.5464	171.0	4.0	4.477262712	9.721179998	64.0	0.296653295	7.0	11.0	0.834899319	3.648049038	79.0	3.788125533	92.0	0.83774937	4.064206789	25.87219885	579.1635754	-2705.309423	1.0	706.0	1.0	462.0	6.946879833666188	9.123736184800801	0.5912496954560988	6.279050461090532	8.33527882443653	1.9614514062665251	-0.6678293725756554	-0.7884573603642702	1.3702017108104263
13722.58cfa831e4b0c9d6adf6c9bf	58cfa831e4b0c9d6adf6c9bf	TCGA-DD-A1EJ-01A-11D-A152-10_wgs_Illumina.filtered.	WGS	TCGA-DD-A1EJ-01A-11D-A152-10_wgs_Illumina	TCGA-DD-A1EJ-01A-11D-A152-10_wgs_Illumina.bam	51.74	1.45	0.08	58cfa831e4b0c9d6adf6c9bf	TCGA-DD-A1EJ-01A-11D-A152-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-DD-A1EJ-01A	52292FFC-0902-4D97-B461-20723987A177	Primary Tumor	Illumina HiSeq	65b1f0b7-fec9-4ee4-8634-583e00af7202	Liver	71.0	2D549BB0-9E98-40C7-8B33-545C481DD105	9C681CD9-25FB-42AC-AA6B-BB962882FA22	TCGA-DD-A1EJ-01A-11D-A152-10	GRCh37-lite	TCGA-DD-A1EJ	TCGA-LIHC		s16586	Baylor College of Medicine	Mayo Clinic - Rochester	United States	NO	T1	N1	Hepatocellular Carcinoma	Stage IIIC	A152-10	True	LIHC	C4	LIHC.iCluster:3	0.15733450400000001	0.25	0.56		-0.1343	0.1045	-0.2849	-1.0046	-1.5793	-0.7267	38.0	54.0	0.42402118200000005	1.4045701640000001	145.0	0.541367944	11.0	16.0	0.9930002440000001	1.376590639	4.0	1.386294361	4.0	1.0	4.175529439	-1587.99674	-331.124868	3384.270455	1.0	1005.0	1.0	263.0	6.954459936660548	1.2765867662230548	0.08106169042256572	5.92038616913001	3.1386172665624628	3.0142347411019825	-1.0340737675305385	1.862030500339408	2.9331730506794167
13722.58cfa831e4b0c9d6adf6c9c7	58cfa831e4b0c9d6adf6c9c7	TCGA-DQ-5630-01A-01D-1868_120504_SN1222_0101_AC0UMDACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DQ-5630-01A-01D-1868_120504_SN1222_0101_AC0UMDACXX_s_1_rg.sorted	TCGA-DQ-5630-01A-01D-1868_120504_SN1222_0101_AC0UMDACXX_s_1_rg.sorted.bam	374.7	1.9	0.15	58cfa831e4b0c9d6adf6c9c7	TCGA-DQ-5630-01A-01D-1868_120504_SN1222_0101_AC0UMDACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-DQ-5630-01A	91A712B5-A724-48D0-BA06-4F6857683463	Primary Tumor	Illumina HiSeq	865b23ff-32b6-41bf-8316-cde4e80d7873	Head and Neck	73.0	A0CDB208-E66F-4AD7-86FA-5077145A4A68	4C2960DA-103B-4620-ABCD-0EE586F39E0D	TCGA-DQ-5630-01A-01D-1868-02	HG19_Broad_variant	TCGA-DQ-5630	TCGA-HNSC		s16346	Harvard Medical School	University of Michigan	United States	NO	TX	NX	Head and Neck Squamous Cell Carcinoma		1868-02	True	HNSC	C2	HNSC.Mesenchymal	0.39592850399999996	0.73	0.23		0.1557	0.1555	0.6244	1.0696	1.9749	0.7587	21.0	51.0	0.620089281	1.624043354	54.0	0.138809971	7.0	9.0	0.913842355	2.270812944	12.0	2.723254331	20.0	0.909044628	2.70405948	257.7141849	-357.0311501	-1115.347926	0.0	1030.0	0.0	1030.0	6.974617487155529	7.661609430908877	-0.2477397551313083	6.55688228645555	6.755369034888223	1.6661023771407657	-0.4177352006999788	-0.9062403960206535	1.913842132272074
13722.58cfa831e4b0c9d6adf6c9c9	58cfa831e4b0c9d6adf6c9c9	TCGA-DJ-A1QH-01A-21D-A14U_120629_SN1222_0121_BD143UACXX_s_7_rg.sorted.filtered.	WGS	TCGA-DJ-A1QH-01A-21D-A14U_120629_SN1222_0121_BD143UACXX_s_7_rg.sorted	TCGA-DJ-A1QH-01A-21D-A14U_120629_SN1222_0121_BD143UACXX_s_7_rg.sorted.bam	51.98	1.61	0.16	58cfa831e4b0c9d6adf6c9c9	TCGA-DJ-A1QH-01A-21D-A14U_120629_SN1222_0121_BD143UACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A1QH-01A	F3C73DC9-6280-4619-A629-B575FDBDB0CA	Primary Tumor	Illumina HiSeq	0e84405e-6687-4f5d-89c9-c507d3c0bba0	Thyroid	58.0	B1775A45-D30D-42C3-91D8-53C662B4A974	31F3AA22-9E90-4FF7-872C-0EED3DB18545	TCGA-DJ-A1QH-01A-21D-A14U-02	HG19_Broad_variant	TCGA-DJ-A1QH	TCGA-THCA		s12376	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N1a	Thyroid Papillary Carcinoma - Tall Cell (>= 50% tall cell features)	Stage III	A14U-02	True	THCA	C3	THCA.4	0.10319790000000001	0.17	0.0		-1.6403	-0.2985	-0.2294	-0.2904	-0.5082	0.3215	10.0	4.0	0.182018275	0.45504568799999995	33.0	2.42e-06	0.0	0.0				2.582306344	14.0	0.978495736	1.274090121	90.23264405	-491.9503714	1033.585853	0.0	1293.0	0.0	1293.0	5.712848397562804	6.890299460990946	-0.18691223050255346	4.62621229994141	5.906756502107624	1.8718021769015918	-1.086636097621394	-0.983542958883322	2.0587144074041452
13722.58cfa831e4b0c9d6adf6c9ca	58cfa831e4b0c9d6adf6c9ca	TCGA-DD-A1EB-01A-11D-A12Z-10_wgs_Illumina.filtered.	WGS	TCGA-DD-A1EB-01A-11D-A12Z-10_wgs_Illumina	TCGA-DD-A1EB-01A-11D-A12Z-10_wgs_Illumina.bam	45.15	1.98	0.08	58cfa831e4b0c9d6adf6c9ca	TCGA-DD-A1EB-01A-11D-A12Z-10_wgs_Illumina.bam	Alive	FEMALE			Liver Hepatocellular Carcinoma	Aligned reads	TCGA-DD-A1EB-01A	68015CC7-D3A1-4C90-B8FB-5D14143D9960	Primary Tumor	Illumina HiSeq	df20c59b-843a-4f42-babb-7205e75d0a32	Liver	72.0	FEE48A64-CF2F-4AE9-B3CF-315410D8E8AE	90611290-E44C-438E-91AA-F3B83DAE3B71	TCGA-DD-A1EB-01A-11D-A12Z-10	GRCh37-lite	TCGA-DD-A1EB	TCGA-LIHC		s16675	Baylor College of Medicine	Mayo Clinic - Rochester	United States	NO	T1	N0	Hepatocellular Carcinoma	Stage I	A12Z-10	True	LIHC	C4	LIHC.iCluster:2	0.099418239	0.18	0.01		-1.5302	-0.35700000000000004	-0.9033	-0.8598	0.226	-0.8759	91.0	78.0	1.266384142	3.9838334460000002	394.0	0.111754884	3.0	22.0				1.609437912	5.0	1.0	0.90801145	-1412.9152490000001	-619.7079143999999	4554.955295000001	0.0	2017.0	1.0	505.0	6.224118288423183	1.4905396054122164	-0.09563093679356305	5.125505999755074	1.9387621557900268	2.247659233656559	-1.0986122886681096	0.44822255037781034	2.343290170450122
13722.58cfa831e4b0c9d6adf6c9ce	58cfa831e4b0c9d6adf6c9ce	TCGA-DK-A3WY-01A-11D-A233_120829_SN1120_0183_AC18U8ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-DK-A3WY-01A-11D-A233_120829_SN1120_0183_AC18U8ACXX_s_7_rg.sorted	TCGA-DK-A3WY-01A-11D-A233_120829_SN1120_0183_AC18U8ACXX_s_7_rg.sorted.bam	13.9		0.15	58cfa831e4b0c9d6adf6c9ce	TCGA-DK-A3WY-01A-11D-A233_120829_SN1120_0183_AC18U8ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A3WY-01A	9BB5D187-033E-4E86-A76E-E1A6D20488F7	Primary Tumor	Illumina HiSeq	ae1b3911-b342-4886-b75a-3e9be21dae41	Bladder	67.0	33D579B3-198D-46CA-B2CF-574A0673E26F	ABA3AF01-2CBD-4450-9CCB-698DF8982E91	TCGA-DK-A3WY-01A-11D-A233-26	HG19_Broad_variant	TCGA-DK-A3WY	TCGA-BLCA		s2895	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A233-26	True	BLCA	C2	BLCA.4	0.876875025				0.9598	0.2845	1.4784	3.4348	0.42100000000000004	0.0787	6.0		0.089069897	0.32658962399999997	43.0	3.56e-06			0.8710796390000001	4.4317015810000004	162.0	5.1419370110000004	187.0	0.982953593	2.491106828	89.53029906	816.3444996000001	-3447.187825	0.0	4967.0	0.0	4967.0	6.604356135017152	8.2482674474469	0.7384422606170737	6.128932438302078	7.058683380573063	2.1130950467214786	-0.4754236967150747	-1.1895840668738364	1.374652786104405
13722.58cfa831e4b0c9d6adf6c9d3	58cfa831e4b0c9d6adf6c9d3	TCGA-DK-A1A3-01A-11D-A13U_120921_SN208_0431_BD1D5FACXX_s_7_rg.sorted.filtered.	WGS	TCGA-DK-A1A3-01A-11D-A13U_120921_SN208_0431_BD1D5FACXX_s_7_rg.sorted	TCGA-DK-A1A3-01A-11D-A13U_120921_SN208_0431_BD1D5FACXX_s_7_rg.sorted.bam	16.46	1.91	0.17	58cfa831e4b0c9d6adf6c9d3	TCGA-DK-A1A3-01A-11D-A13U_120921_SN208_0431_BD1D5FACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A1A3-01A	C5B20CCC-523D-491C-8536-008E05C57212	Primary Tumor	Illumina HiSeq	0e78dec3-7b8b-425e-9cc5-489bf825e0ea	Bladder	60.0	954E46BA-514F-4708-AD3C-ECBF8CEF005A	DC0A234A-9177-4E2A-B218-212F1278B4A1	TCGA-DK-A1A3-01A-11D-A13U-02	HG19_Broad_variant	TCGA-DK-A1A3	TCGA-BLCA		s3102	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A13U-02	True	BLCA	C1	BLCA.2	0.303847635	0.57	0.09		0.2631	0.063	0.0764	0.3751	-0.0465	0.2224	214.0	7.0	5.818344582000001	16.10329713	261.0	0.644181356	18.0	26.0	0.921929908	2.433025882	14.0	2.303488495	11.0	0.9606293159999999	2.570798816	-1355.526729	286.66869239999994	-2946.132968	1.0	665.0	1.0	665.0	7.068834283396307	9.596404200808703	0.49011799343850126	6.088005030384581	8.97736499240248	2.9511212626350227	-0.9808292530117266	-0.6190392084062237	2.4610032691965213
13722.58cfa831e4b0c9d6adf6c9d5	58cfa831e4b0c9d6adf6c9d5	TCGA-DK-A3IQ-01A-31D-A210_120911_SN1120_0189_BD1D04ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DK-A3IQ-01A-31D-A210_120911_SN1120_0189_BD1D04ACXX_s_3_rg.sorted	TCGA-DK-A3IQ-01A-31D-A210_120911_SN1120_0189_BD1D04ACXX_s_3_rg.sorted.bam	22.29		0.16	58cfa831e4b0c9d6adf6c9d5	TCGA-DK-A3IQ-01A-31D-A210_120911_SN1120_0189_BD1D04ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A3IQ-01A	E44F60EC-66C4-45A2-A003-0A1FAF1D6E03	Primary Tumor	Illumina HiSeq	edc43d06-7118-46e7-894e-d40138b6d69c	Bladder	74.0	1E375786-DB8F-4A8C-BA1C-C6DD7DE1A9BE	DB940CE0-2357-4E83-AA19-AEA672A121D9	TCGA-DK-A3IQ-01A-31D-A210-26	HG19_Broad_variant	TCGA-DK-A3IQ	TCGA-BLCA		s2894	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A210-26	True	BLCA	C1		0.11098221300000001	0.65	0.29		-0.4474	-0.1715	-0.1961	-1.2354	-0.8389	1.1512	27.0	18.0	1.81618902	4.790981382	290.0	0.358417175	7.0	26.0		0.0	1.0	0.0	1.0		2.61889269	-1468.74786	447.67846449999996	-2738.8991309999997	1.0	539.0	1.0	250.0	6.8171009107140055	8.964660688014591	-0.11269590176265654	6.529418838262225	8.271513507454646	4.218228114470481	-0.2876820724517808	-0.6931471805599454	4.330924016233138
13722.58cfa831e4b0c9d6adf6c9da	58cfa831e4b0c9d6adf6c9da	TCGA-DJ-A13T-01A-11D-A10R_120629_SN1120_0167_AC0WMBACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DJ-A13T-01A-11D-A10R_120629_SN1120_0167_AC0WMBACXX_s_1_rg.sorted	TCGA-DJ-A13T-01A-11D-A10R_120629_SN1120_0167_AC0WMBACXX_s_1_rg.sorted.bam	48.83	2.0	0.16	58cfa831e4b0c9d6adf6c9da	TCGA-DJ-A13T-01A-11D-A10R_120629_SN1120_0167_AC0WMBACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE		Thyroid Carcinoma	Aligned reads	TCGA-DJ-A13T-01A	0B170ED4-D919-466B-B765-47878B865AED	Primary Tumor	Illumina HiSeq	f42aa2a6-4acd-4650-aea7-c83fbddf27d2	Thyroid	37.0	6883BA87-9184-40D7-840B-603B15D73F7A	76DCBA6C-0992-44BB-9492-3023A2430CC4	TCGA-DJ-A13T-01A-11D-A10R-02	HG19_Broad_variant	TCGA-DJ-A13T	TCGA-THCA		s12513	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A10R-02	True	THCA	C3	THCA.5	0.03841165	0.1	0.0		-1.7797	-0.3265	-0.4325	-0.7359	-0.461	-0.1379	2.0		0.028045683	0.168274096	41.0	0.011174611000000001	0.0	0.0				1.386294361	4.0	1.0	1.555827609	398.4490337	-965.1968691	1420.779462	0.0	1709.0	0.0	1709.0	6.820218511473824	5.41292907530042	-0.09339328233513211	6.021710815256053	7.185270458671374	0.9658246669964318	-0.7985076962177713	1.7723413833709531	1.0592179493315639
13722.58cfa831e4b0c9d6adf6c9db	58cfa831e4b0c9d6adf6c9db	TCGA-DD-A3A9-01A-11D-A25V-10_wgs_Illumina.filtered.	WGS	TCGA-DD-A3A9-01A-11D-A25V-10_wgs_Illumina	TCGA-DD-A3A9-01A-11D-A25V-10_wgs_Illumina.bam	36.73		0.08	58cfa831e4b0c9d6adf6c9db	TCGA-DD-A3A9-01A-11D-A25V-10_wgs_Illumina.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-DD-A3A9-01A	457CCA7C-A8B4-414E-A3C0-7FCCF0EE2034	Primary Tumor	Illumina HiSeq	f40faf20-3443-4f29-85be-0107c0d838aa	Liver	64.0	9BFBC85E-86E0-4AC5-9304-84B1EB32B9CC	96517058-18D2-4847-8085-768CA8AA1565	TCGA-DD-A3A9-01A-11D-A25V-10	GRCh37-lite	TCGA-DD-A3A9	TCGA-LIHC	931.0	s16587	Baylor College of Medicine	Mayo Clinic - Rochester	United States	NO	T4	N0	Hepatocellular Carcinoma	Stage IVB	A25V-10	True	LIHC	C3	LIHC.iCluster:1	0.156016909	0.51	0.11		-1.1846	-0.1125	-0.5363	0.2361	-0.9602	-0.1237	170.0	242.0	3.106693219	8.725755738	166.0	0.633520634	19.0	20.0				1.351783994	4.0	0.975106032	0.55456373	-2192.484916	-1238.736908	3055.554049	1.0	931.0	1.0	289.0	6.330611774178498	3.955078018923408	-0.4368425909060407	5.008855934196179	4.327225858165385	2.6340919463571595	-1.3217558399823197	0.37214783924197725	3.0709345372632004
13722.58cfa831e4b0c9d6adf6c9dc	58cfa831e4b0c9d6adf6c9dc	TCGA-DU-6392-01A-11D-1703_130906_SN1440_0166_BC2A68ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-DU-6392-01A-11D-1703_130906_SN1440_0166_BC2A68ACXX_s_6_rg.sorted	TCGA-DU-6392-01A-11D-1703_130906_SN1440_0166_BC2A68ACXX_s_6_rg.sorted.bam	16.0	2.0	0.13	58cfa831e4b0c9d6adf6c9dc	TCGA-DU-6392-01A-11D-1703_130906_SN1440_0166_BC2A68ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-6392-01A	FCD9E1C4-BDDB-4856-844C-03DF48FBA499	Primary Tumor	Illumina HiSeq	8f4eff17-77e1-4e7d-9fc7-83ae4db50b3a	Brain	35.0	14780BB2-67A9-4ACA-BCE4-12793FB1808E	E7B36F2D-9AB1-4A46-B669-65367B841752	TCGA-DU-6392-01A-11D-1703-02	HG19_Broad_variant	TCGA-DU-6392	TCGA-LGG		s8561	Harvard Medical School	Henry Ford Hospital	United States	NO			Astrocytoma		1703-02	True	LGG	C4	GBM_LGG.PA-like	0.131003405	0.17	0.1		0.0745	-0.0785	0.1536	-1.3751	-0.8091	-0.2265	5122.0	843.0	110.7029232	321.7246775	85.0	0.146773125	2.0	3.0				1.098612289	3.0	1.0	3.610708343	534.702682	707.9441917	-2472.1924280000003	0.0	6423.0	1.0	950.0	8.842965530615153	7.534877119350945	0.42587397973937136	5.822540644470791	6.955058624098003	3.4909673810908655	-3.0204248861443626	-0.5798184952529422	3.065093401351494
13722.58cfa831e4b0c9d6adf6c9e6	58cfa831e4b0c9d6adf6c9e6	TCGA-DK-A3X1-01A-12D-A233_120829_SN1120_0184_BD1DRAACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DK-A3X1-01A-12D-A233_120829_SN1120_0184_BD1DRAACXX_s_1_rg.sorted	TCGA-DK-A3X1-01A-12D-A233_120829_SN1120_0184_BD1DRAACXX_s_1_rg.sorted.bam	47.57		0.16	58cfa831e4b0c9d6adf6c9e6	TCGA-DK-A3X1-01A-12D-A233_120829_SN1120_0184_BD1DRAACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A3X1-01A	6BDDAFDE-7004-49B6-80CF-8081CD4B7D44	Primary Tumor	Illumina HiSeq	4c8de054-fd6d-4ebd-8a6e-b5061ef5913b	Bladder	78.0	3D440A83-214E-432F-89D2-B523BFE7C6EF	4A8B5117-AF70-40AB-9698-B736EF20F3DE	TCGA-DK-A3X1-01A-12D-A233-26	HG19_Broad_variant	TCGA-DK-A3X1	TCGA-BLCA		s3286	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A233-26	True	BLCA	C1	BLCA.2	0.276971885	0.53	0.11		0.5948	0.2995	-0.7734	-0.7248	-0.6133	0.1207	439.0	5.0	8.204908397	21.4835234	287.0	0.540607994	16.0	40.0		0.0	1.0	1.098612289	3.0	1.0	5.312220363	-2636.67173	362.5478312	-3525.00229	0.0	2009.0	0.0	2009.0	6.646848774994754	6.284258531445939	0.01675524206346557	5.742392500767602	5.734212194526668	1.5961898090168716	-0.9044562742271522	-0.5500463369192721	1.579434566953406
13722.58cfa831e4b0c9d6adf6c9e7	58cfa831e4b0c9d6adf6c9e7	TCGA-DJ-A1QQ-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_4_rg.sorted.filtered.	WGS	TCGA-DJ-A1QQ-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_4_rg.sorted	TCGA-DJ-A1QQ-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_4_rg.sorted.bam	48.48	1.91	0.16	58cfa831e4b0c9d6adf6c9e7	TCGA-DJ-A1QQ-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_4_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A1QQ-01A	99EF2FEC-5A3C-4E42-8F78-7EAF9877E26D	Primary Tumor	Illumina HiSeq	091bb28f-4fe0-41e6-b7c5-b952dc370506	Thyroid	43.0	64D1F58A-986F-4D4B-962E-DA59A48C988B	DDE34A05-A208-4F86-9803-0FB1EB858947	TCGA-DJ-A1QQ-01A-11D-A14U-02	HG19_Broad_variant	TCGA-DJ-A1QQ	TCGA-THCA		s12639	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A14U-02	True	THCA	C3	THCA.3	0.07652558400000001	0.07	0.0		-1.4839	-0.373	-0.2639	-0.3954	-0.6065	0.2731	7.0	0.0	0.148895542	0.297791084	75.0	6.850000000000001e-05	0.0	3.0	0.855874362	2.7885212960000003	26.0	2.163955657	9.0	0.984858662	1.215459888	567.7231032000001	-660.2306374	1901.909258	0.0	534.0	0.0	534.0	6.569531509322118	7.381789237068906	0.18954012347493143	5.247775669339799	7.421009950222187	2.2429162983822177	-1.3217558399823193	0.03922071315328157	2.053376174907286
13722.58cfa831e4b0c9d6adf6c9ed	58cfa831e4b0c9d6adf6c9ed	TCGA-DJ-A13P-01A-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DJ-A13P-01A-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_5_rg.sorted	TCGA-DJ-A13P-01A-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_5_rg.sorted.bam	104.83	1.95	0.16	58cfa831e4b0c9d6adf6c9ed	TCGA-DJ-A13P-01A-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A13P-01A	CA95A11C-B54C-409E-B9A0-DA850945033D	Primary Tumor	Illumina HiSeq	5d993dc5-0dfb-4f12-bd8b-c21a2c64577d	Thyroid	52.0	EFAD8B07-B295-468F-A836-F94029AEC777	528EC19A-8218-4E8F-B1E7-8A149F54A6BE	TCGA-DJ-A13P-01A-11D-A10R-02	HG19_Broad_variant	TCGA-DJ-A13P	TCGA-THCA		s11995	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage II	A10R-02	True	THCA	C3	THCA.5	0.039187032000000004	0.18	0.0		-1.9894	-0.3655	-0.3834	-1.0762	-0.27899999999999997	-0.2357	1.0		0.08420867800000001	0.16841735600000002	75.0	0.032935956	0.0	0.0				1.329661349	4.0	0.959147917	1.273012314	-443.4396437	-831.4128321000001	1628.396793	0.0	5150.0	0.0	5150.0	5.0501764687167885	8.192016914536875	0.2546774716389182	5.450654035313915	6.879830525570707	1.6965561213238372	0.4004775665971261	-1.312186388966169	1.441878649684919
13722.58cfa831e4b0c9d6adf6c9f6	58cfa831e4b0c9d6adf6c9f6	TCGA-DD-A4NB-01A-12D-A25V-10_wgs_Illumina.filtered.	WGS	TCGA-DD-A4NB-01A-12D-A25V-10_wgs_Illumina	TCGA-DD-A4NB-01A-12D-A25V-10_wgs_Illumina.bam	9.12		0.07	58cfa831e4b0c9d6adf6c9f6	TCGA-DD-A4NB-01A-12D-A25V-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-DD-A4NB-01A	1983FADE-44F1-41E0-8983-F2CE8D649655	Primary Tumor	Illumina HiSeq	a3509f59-4d19-4a9b-afd1-dc57f8f871dd	Liver	25.0	0A79C3EE-9DD0-4FF7-B079-C9A0AEB08E1F	5D58B984-E0B8-4237-A576-0E9D4079599E	TCGA-DD-A4NB-01A-12D-A25V-10	GRCh37-lite	TCGA-DD-A4NB	TCGA-LIHC		s16855	Baylor College of Medicine	Mayo Clinic - Rochester	United States	NO	T1	N0	Fibrolamellar Carcinoma	Stage I	A25V-10	True	LIHC	C3	LIHC.iCluster:1	0.30391370100000004	0.08	0.13		-1.4333	-0.1875	0.1108	-0.1033	-0.7601	0.2525	15.0	64.0	0.266541691	0.6130458879999999	85.0	0.16607032	0.0	0.0				2.540036304	13.0	0.990287117	0.6780275659999999	-985.0261367999999	-435.8024757	2377.366115	0.0	989.0	1.0	912.0	6.586998898800927	3.160897697992671	-0.1380379836641885	5.631487453773492	4.053931567702559	3.5497044606626726	-0.9555114450274362	0.8930338697098881	3.6877424443268616
13722.58cfa831e4b0c9d6adf6ca01	58cfa831e4b0c9d6adf6ca01	TCGA-DQ-5625-01A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DQ-5625-01A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_1_rg.sorted	TCGA-DQ-5625-01A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_1_rg.sorted.bam	154.7	1.9	0.15	58cfa831e4b0c9d6adf6ca01	TCGA-DQ-5625-01A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-DQ-5625-01A	53D9A130-4A3A-4491-85CD-9A44415A1632	Primary Tumor	Illumina HiSeq	33b84364-a81e-48fd-89d6-552802c7ff18	Head and Neck	52.0	74856E66-109F-4A68-A496-8FA66729FE1F	9641D13E-BE95-46BB-8330-6128EE15D47C	TCGA-DQ-5625-01A-01D-1868-02	HG19_Broad_variant	TCGA-DQ-5625	TCGA-HNSC		s16058	Harvard Medical School	University of Michigan	United States	NO	TX	NX	Head and Neck Squamous Cell Carcinoma		1868-02	True	HNSC	C2	HNSC.Basal	0.326881209	0.54	0.05		0.26	-0.017	0.5041	0.8195	2.1622	0.4357	79.0	20.0	1.384991431	4.714864447	70.0	0.9369280320000001	12.0	11.0	0.822759055	2.464765854	20.0	2.346648317	29.0	0.696894017	1.9503564930000001	464.5705984	268.507839	-254.8324949	1.0	1133.0	1.0	1058.0	6.96856087989598	6.491462532221909	0.6178066315091598	6.166214407371042	7.3516637974450205	1.2120879355449268	-0.8023464725249374	0.8602012652231115	0.5942813040357671
13722.58cfa831e4b0c9d6adf6ca05	58cfa831e4b0c9d6adf6ca05	TCGA-DE-A0Y3-01B-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DE-A0Y3-01B-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_3_rg.sorted	TCGA-DE-A0Y3-01B-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_3_rg.sorted.bam	60.48	2.03	0.14	58cfa831e4b0c9d6adf6ca05	TCGA-DE-A0Y3-01B-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_3_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DE-A0Y3-01B	C31B3ADF-3FC6-4A72-83B0-BBC0F295B5E7	Primary Tumor	Illumina HiSeq	e17f6c8d-d069-4561-8371-8138731e3dd2	Thyroid	60.0	3AE03B86-1473-409C-8118-A91A73A36F60	F3099D9B-DBBE-46CB-BA22-DAD7F9428C4F	TCGA-DE-A0Y3-01B-11D-A10R-02	HG19_Broad_variant	TCGA-DE-A0Y3	TCGA-THCA		s12848	Harvard Medical School	University of North Carolina	United States	NO	T4a	N1b	Thyroid Papillary Carcinoma - Classical/usual	Stage IVC	A10R-02	True	THCA	C3	THCA.3	0.039938527	0.0	0.0		-1.932	-0.4105	-0.7004	-0.7714	-0.6116	-0.1976	4.0	3.0	0.11292268300000001	0.310537377	63.0	4.05e-05	0.0	0.0	0.835344882	0.57901695	2.0	1.986731649	9.0	0.90420054	1.071507147	-9.214488767	-916.4587287999999	1810.1635010000002	0.0	1526.0	1.0	30.0	6.628135853953706	8.420324297447916	-0.3165042598832385	5.4605306937986455	7.408723385769436	2.4065511942849316	-1.1676051601550612	-1.0116009116784803	2.72305545416817
13722.58cfa831e4b0c9d6adf6ca0c	58cfa831e4b0c9d6adf6ca0c	TCGA-DK-A1AE-01A-11D-A13U_121002_SN1222_0154_AC1A3DACXX_s_7_rg.sorted.filtered.	WGS	TCGA-DK-A1AE-01A-11D-A13U_121002_SN1222_0154_AC1A3DACXX_s_7_rg.sorted	TCGA-DK-A1AE-01A-11D-A13U_121002_SN1222_0154_AC1A3DACXX_s_7_rg.sorted.bam	76.27	1.91	0.17	58cfa831e4b0c9d6adf6ca0c	TCGA-DK-A1AE-01A-11D-A13U_121002_SN1222_0154_AC1A3DACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A1AE-01A	493A4FF2-37A5-4B79-928D-83DBFE534556	Primary Tumor	Illumina HiSeq	31314a75-c671-479c-aff0-437d0965f1fc	Bladder	84.0	67865453-D515-4D63-84E8-CFB2686A211D	885B8E06-182F-437B-9183-B454643A64EC	TCGA-DK-A1AE-01A-11D-A13U-02	HG19_Broad_variant	TCGA-DK-A1AE	TCGA-BLCA		s2710	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A13U-02	True	BLCA	C1	BLCA.3	0.107029803	0.17	0.0		0.8968	0.36700000000000005	-1.1451	-1.4559	-0.2229	-0.1863	60.0	2.0	0.886653021	2.937038132	196.0	0.101745388	0.0	16.0				1.7986522059999999	7.0	0.9243243870000001	2.716533122	-1276.721082	1331.479442	-2762.511872	0.0	491.0	1.0	211.0	6.323927434267198	7.008392935338877	0.2698377856555084	5.171247924328812	7.3216875836473845	0.9462154284624095	-1.1526795099383857	0.3132946483085073	0.676377642806901
13722.58cfa831e4b0c9d6adf6ca0d	58cfa831e4b0c9d6adf6ca0d	TCGA-DK-A1AD-01A-11D-A13U_121025_SN590_0188_AC190CACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DK-A1AD-01A-11D-A13U_121025_SN590_0188_AC190CACXX_s_5_rg.sorted	TCGA-DK-A1AD-01A-11D-A13U_121025_SN590_0188_AC190CACXX_s_5_rg.sorted.bam	55.51	1.93	0.17	58cfa831e4b0c9d6adf6ca0d	TCGA-DK-A1AD-01A-11D-A13U_121025_SN590_0188_AC190CACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE		Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A1AD-01A	88A521CE-A5E9-4C6F-83D4-EC36A62FEDB6	Primary Tumor	Illumina HiSeq	26694fc3-c6e4-45f9-82f0-57b6f4955b4b	Bladder	69.0	C79F4327-675D-4651-994D-E683096DF9C3	86DF29FD-B5F6-4316-BC89-DC9386D177C6	TCGA-DK-A1AD-01A-11D-A13U-02	HG19_Broad_variant	TCGA-DK-A1AD	TCGA-BLCA		s2711	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3b	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A13U-02	True	BLCA	C2	BLCA.2	0.143604651	0.27	0.31		0.5012	0.1835	-0.483	0.0326	0.5184	0.0153	97.0	78.0	2.278949248	6.067332414	267.0	0.6900448159999999	14.0	38.0	0.935013558	1.675319397	6.0	2.025326221	8.0	0.973976032	4.852045576	-2235.5198809999997	530.2730753999999	-3098.15853	0.0	3420.0	0.0	3420.0	7.028201432058004	6.6692865615651815	1.6115633117464139	4.830976854721785	5.516607051626796	0.8356075178019154	-2.197224577336219	-1.1526795099383853	-0.7759557939444985
13722.58cfa831e4b0c9d6adf6ca0f	58cfa831e4b0c9d6adf6ca0f	TCGA-DK-A3X2-01A-11D-A233_120829_SN1120_0184_BD1DRAACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DK-A3X2-01A-11D-A233_120829_SN1120_0184_BD1DRAACXX_s_3_rg.sorted	TCGA-DK-A3X2-01A-11D-A233_120829_SN1120_0184_BD1DRAACXX_s_3_rg.sorted.bam	51.32		0.15	58cfa831e4b0c9d6adf6ca0f	TCGA-DK-A3X2-01A-11D-A233_120829_SN1120_0184_BD1DRAACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A3X2-01A	40551D53-388B-4067-9341-76E94D023703	Primary Tumor	Illumina HiSeq	a8b7a158-32d0-421e-82bd-edb6a44d69e0	Bladder	85.0	3B816277-91CB-413E-BC7C-BA33CD72B67D	5D13DEBC-82D6-45EA-A9EA-A85B85CF659F	TCGA-DK-A3X2-01A-11D-A233-26	HG19_Broad_variant	TCGA-DK-A3X2	TCGA-BLCA	547.0	s2716	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T3	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A233-26	True	BLCA	C2	BLCA.1	0.044056824	0.08	0.16		1.3572	0.389	-1.619	-2.1591	0.11900000000000001	-0.6087	58.0	66.0	0.8564251	3.2829628810000004	244.0	0.70290079	20.0	29.0	0.910806992	0.631323299	2.0		0.0		3.7168458810000002	-1303.682501	1190.598278	-3151.540084	1.0	547.0	1.0	533.0	6.260673465265439	8.500686270166957	0.8816071494856372	5.721676964532752	7.188499881200789	1.1257505179935936	-0.5389965007326869	-1.312186388966169	0.24414336850795637
13722.58cfa831e4b0c9d6adf6ca17	58cfa831e4b0c9d6adf6ca17	TCGA-DD-A4NE-01A-11D-A27I-10_wgs_Illumina.filtered.	WGS	TCGA-DD-A4NE-01A-11D-A27I-10_wgs_Illumina	TCGA-DD-A4NE-01A-11D-A27I-10_wgs_Illumina.bam	36.93		0.07	58cfa831e4b0c9d6adf6ca17	TCGA-DD-A4NE-01A-11D-A27I-10_wgs_Illumina.bam	Dead	FEMALE	WHITE	HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-DD-A4NE-01A	BCE25281-502E-4599-9679-32DC8462FFB1	Primary Tumor	Illumina HiSeq	fde02df3-c43e-4d99-bb67-57c883818892	Liver	75.0	C8CB1326-7AB9-4E3D-BDC9-9CE42715DAC7	343FCBC2-F30C-4FFA-A0B3-F5BB21E5E70B	TCGA-DD-A4NE-01A-11D-A27I-10	GRCh37-lite	TCGA-DD-A4NE	TCGA-LIHC	660.0	s16588	Baylor College of Medicine	Mayo Clinic - Rochester	United States	NO	T3a	N0	Hepatocellular Carcinoma	Stage IIIA	A27I-10	True	LIHC	C4	LIHC.	0.033590722999999996				0.5037	-0.0525	-1.1079999999999999	-1.9379	-0.8948	-0.5676	24.0	7.0	0.52368463	1.3781174459999999									0.0		0.359997461	-895.1328927999999	302.070025	2558.983227	1.0	660.0	1.0	190.0	5.142195047346954	2.319826899428552	0.3337171737615313	4.362036489797379	2.0806632889301584	3.511283555891197	-0.7801585575495751	-0.23916361049839363	3.177566382129666
13722.58cfa831e4b0c9d6adf6ca1b	58cfa831e4b0c9d6adf6ca1b	TCGA-DK-A2I6-01A-12D-A18D_120913_SN208_0429_AC187FACXX_s_6_rg.sorted.filtered.	WGS	TCGA-DK-A2I6-01A-12D-A18D_120913_SN208_0429_AC187FACXX_s_6_rg.sorted	TCGA-DK-A2I6-01A-12D-A18D_120913_SN208_0429_AC187FACXX_s_6_rg.sorted.bam	57.02		0.16	58cfa831e4b0c9d6adf6ca1b	TCGA-DK-A2I6-01A-12D-A18D_120913_SN208_0429_AC187FACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A2I6-01A	DE810AF0-4C18-4E8F-9836-F8ABC425E3EB	Primary Tumor	Illumina HiSeq	6567cd2d-a1e5-4226-9239-77c48c09c55e	Bladder	81.0	A536F8F9-3A68-4792-880D-387D78FD0C66	B791021D-173E-4B08-8769-A9F289818D11	TCGA-DK-A2I6-01A-12D-A18D-02	HG19_Broad_variant	TCGA-DK-A2I6	TCGA-BLCA		s2703	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T2b	N1	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A18D-02	True	BLCA	C1	BLCA.3	0.149994575	0.46	0.22		0.9861	0.3745	-1.1644	-1.4892	-0.986	0.023	145.0	95.0	3.05791328	6.8353355670000004	369.0	0.781410707	17.0	54.0				1.5607104090000001	5.0	0.9697239	4.914244966	-1440.6249460000001	557.8935352999999	126.1305439	0.0	2656.0	0.0	2656.0	7.1005347808533585	7.794127894069007	0.4408646792494577	6.168976576848415	7.308620078287307	2.30188798595989	-0.9315582040049435	-0.485507815781701	1.861023306710432
13722.58cfa831e4b0c9d6adf6ca21	58cfa831e4b0c9d6adf6ca21	TCGA-DJ-A1QD-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-DJ-A1QD-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_6_rg.sorted	TCGA-DJ-A1QD-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_6_rg.sorted.bam	61.38	2.0	0.18	58cfa831e4b0c9d6adf6ca21	TCGA-DJ-A1QD-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A1QD-01A	DA201150-748E-4B74-BB35-10C995E26079	Primary Tumor	Illumina HiSeq	df7bafb3-c992-479d-be29-dae220124025	Thyroid	20.0	A8307181-67CE-4A79-8D23-76CEEE1D2761	781162AA-AAFA-4C44-B9AF-727917E8C9F4	TCGA-DJ-A1QD-01A-11D-A14U-02	HG19_Broad_variant	TCGA-DJ-A1QD	TCGA-THCA		s12367	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T2	N1b	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A14U-02	True	THCA	C3	THCA.3	0.106073344	0.51	0.0		-1.9209	-0.3325	-0.2682	-0.4122	-0.9333	0.0087	3.0		0.0	0.24046229600000002	49.0	1.7e-05	0.0	0.0	0.989129782	1.086670134	3.0	2.079441542	8.0	1.0	1.329224425	736.2659865	-408.2691691	919.5272244999999	0.0	1462.0	0.0	1462.0	5.889689549812753	8.090300135894452	-0.04204823624349929	6.18893244466561	7.802618063442672	1.9053335834232703	0.2992428948528567	-0.2876820724517808	1.9473818196667696
13722.58cfa831e4b0c9d6adf6ca23	58cfa831e4b0c9d6adf6ca23	TCGA-DD-A1EI-01A-11D-A12Z-10_wgs_Illumina.filtered.	WGS	TCGA-DD-A1EI-01A-11D-A12Z-10_wgs_Illumina	TCGA-DD-A1EI-01A-11D-A12Z-10_wgs_Illumina.bam	51.84	1.86	0.08	58cfa831e4b0c9d6adf6ca23	TCGA-DD-A1EI-01A-11D-A12Z-10_wgs_Illumina.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-DD-A1EI-01A	3ACF7438-FD65-442C-8A30-68B6714537F3	Primary Tumor	Illumina HiSeq	3578b4d9-a65f-4096-bb30-1b3509f8a918	Liver	46.0	65FB618A-9296-47AD-BBA9-A93FC3F88E68	C016D025-3C92-41C5-B846-493B1FCCE79E	TCGA-DD-A1EI-01A-11D-A12Z-10	GRCh37-lite	TCGA-DD-A1EI	TCGA-LIHC		s16975	Baylor College of Medicine	Mayo Clinic - Rochester	United States	NO	T1	N0	Hepatocellular Carcinoma	Stage I	A12Z-10	True	LIHC	C1	LIHC.iCluster:1	0.29882165899999996	0.67	0.13		-0.2703	-0.0055	-0.1236	-0.1163	-0.3551	-0.0693	27.0	198.0	0.326372068	1.230171642	155.0	0.401671215	11.0	18.0				2.63905733	14.0	1.0	1.017196608	-12.27143129	-311.70039289999994	2007.773197	0.0	183.0	0.0	183.0	6.456769655572163	3.1491856756510774	-0.07081347278809336	4.216059966296204	5.202852594642297	3.5399085726534674	-2.2407096892759584	2.05366691899122	3.6107220454415607
13722.58cfa831e4b0c9d6adf6ca25	58cfa831e4b0c9d6adf6ca25	TCGA-DE-A0Y2-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DE-A0Y2-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_3_rg.sorted	TCGA-DE-A0Y2-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_3_rg.sorted.bam	63.0	2.03	0.14	58cfa831e4b0c9d6adf6ca25	TCGA-DE-A0Y2-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DE-A0Y2-01A	6AD260AD-769A-4F3C-BD07-927ADF6B2338	Primary Tumor	Illumina HiSeq	eaf940db-08d0-4dc4-b390-0576523fb2f5	Thyroid	30.0	EB4FEEBB-293E-43E3-A2ED-344B17D180B3	E86091EB-6DCC-479B-BAFD-3DABA65787EC	TCGA-DE-A0Y2-01A-11D-A10R-02	HG19_Broad_variant	TCGA-DE-A0Y2	TCGA-THCA		s12514	Harvard Medical School	University of North Carolina	United States	NO	T2	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A10R-02	True	THCA	C3	THCA.3	0.063421694	0.15	0.0		-1.6202	-0.41100000000000003	-0.4324	-1.2397	0.0208	0.0463	10.0	7.0	0.197527598	0.451491652	41.0	5.38e-06	0.0	0.0				1.33217904	4.0	0.960964047	1.107703436	358.3738647	-884.1104780999999	671.7688077	0.0	658.0	0.0	658.0	6.246851866477216	7.654324736038076	-0.6809037110743268	5.131290019495332	5.984262201787541	2.2532962707910196	-1.1155618469818833	-1.6700625342505355	2.934199981865346
13722.58cfa831e4b0c9d6adf6ca37	58cfa831e4b0c9d6adf6ca37	TCGA-DB-5279-01A-01D-1465_130806_SN1440_0159_BC29Y3ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-DB-5279-01A-01D-1465_130806_SN1440_0159_BC29Y3ACXX_s_7_rg.sorted	TCGA-DB-5279-01A-01D-1465_130806_SN1440_0159_BC29Y3ACXX_s_7_rg.sorted.bam	81.0	1.9	0.14	58cfa831e4b0c9d6adf6ca37	TCGA-DB-5279-01A-01D-1465_130806_SN1440_0159_BC29Y3ACXX_s_7_rg.sorted.bam	Alive	MALE			Brain Lower Grade Glioma	Aligned reads	TCGA-DB-5279-01A	85F77526-791E-47CD-904D-D1DBB49EAEAB	Primary Tumor	Illumina HiSeq	1c15ff7e-3cbc-41b1-b814-1cf03f1f5a27	Brain	59.0	0096C7FB-34E3-4D0F-BA81-3559CC00080A	109052DB-CACF-4E14-8258-500E90B6B476	TCGA-DB-5279-01A-01D-1465-02	HG19_Broad_variant	TCGA-DB-5279	TCGA-LGG		s8559	Harvard Medical School	Mayo Clinic - Rochester	United States	NO			Oligodendroglioma		1465-02	True	LGG	C5	GBM_LGG.Codel	0.032743943				-2.3656	-0.2545	-0.4693	-1.6262	-1.1231	-0.9759	17.0	2.0	0.525020325	0.991705058	73.0	0.9471219479999999	12.0	4.0				0.0	1.0		3.375284513	-76.54313719	-728.1619637	-4309.780947	0.0	1354.0	1.0	695.0	7.595219676406583	8.449128460502108	-0.7791365607642844	5.649309527351271	7.350516171833998	-0.9249193049361983	-1.9459101490553132	-1.0986122886681098	-0.14578274417191395
13722.58cfa831e4b0c9d6adf6ca3c	58cfa831e4b0c9d6adf6ca3c	TCGA-DH-5143-01A-01D-1465_130808_SN208_0488_BC294YACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DH-5143-01A-01D-1465_130808_SN208_0488_BC294YACXX_s_5_rg.sorted	TCGA-DH-5143-01A-01D-1465_130808_SN208_0488_BC294YACXX_s_5_rg.sorted.bam	48.0	1.9	0.16	58cfa831e4b0c9d6adf6ca3c	TCGA-DH-5143-01A-01D-1465_130808_SN208_0488_BC294YACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DH-5143-01A	DCD0856D-423A-40D7-8070-4C0988D61416	Primary Tumor	Illumina HiSeq	9e2bca97-d504-4863-b306-8f559a2cc8a1	Brain	30.0	570101B6-3670-4D1A-A94D-0DDC8DF42061	55952783-8C2C-4528-A544-B4C962AB634A	TCGA-DH-5143-01A-01D-1465-02	HG19_Broad_variant	TCGA-DH-5143	TCGA-LGG		s8753	Harvard Medical School	University of Florida	United States	NO			Oligoastrocytoma		1465-02	True	LGG	C5	GBM_LGG.G-CIMP-high	0.08887767	0.71	0.09		-1.2745	-0.2505	0.0602	-2.3699	-0.2944	-1.0258	19.0	1.0	0.110219667	0.633763084	39.0	0.029462767999999997	0.0	0.0					0.0		3.530621167	544.5152879	-477.40540989999994	-3355.053441	0.0	1401.0	0.0	1401.0	6.59235936796284	6.963347652405842	1.9861493893635558	4.341067569356345	5.92189377757768	1.0467015335124747	-2.251291798606495	-1.0414538748281612	-0.939447855851081
13722.58cfa831e4b0c9d6adf6ca43	58cfa831e4b0c9d6adf6ca43	TCGA-DJ-A1QL-01A-11D-A14U_120711_SN1120_0173_AC0WN6ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DJ-A1QL-01A-11D-A14U_120711_SN1120_0173_AC0WN6ACXX_s_1_rg.sorted	TCGA-DJ-A1QL-01A-11D-A14U_120711_SN1120_0173_AC0WN6ACXX_s_1_rg.sorted.bam	77.76	1.96	0.18	58cfa831e4b0c9d6adf6ca43	TCGA-DJ-A1QL-01A-11D-A14U_120711_SN1120_0173_AC0WN6ACXX_s_1_rg.sorted.bam	Alive	MALE		NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A1QL-01A	E4B08E66-0772-4956-8670-E5C6553EECBE	Primary Tumor	Illumina HiSeq	115df95b-61fb-4fef-a23f-df0ade71c646	Thyroid	70.0	62B6D426-E1E4-48E8-BC8F-6B07C67CC0D0	C5B8FBAE-98B5-437B-A8BD-D695C5E8CB4F	TCGA-DJ-A1QL-01A-11D-A14U-02	HG19_Broad_variant	TCGA-DJ-A1QL	TCGA-THCA		s12373	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage II	A14U-02	True	THCA	C3	THCA.1	0.032541777	0.16	0.0		-1.4853	-0.301	-0.8959999999999999	-1.5622	-0.9158	-0.3905	4.0		0.09017982599999999	0.33065936100000004	73.0	5.28e-05	0.0	0.0				0.693147181	2.0	1.0	1.7726232869999998	-827.1073306	-1436.067759	2948.992761	0.0	535.0	0.0	535.0	6.427382283731845	8.884425542626028	0.31658476109724965	5.480000964787658	7.842971667797866	2.5973846332146904	-0.9473813189441866	-1.0414538748281612	2.280799872117441
13722.58cfa831e4b0c9d6adf6ca54	58cfa831e4b0c9d6adf6ca54	TCGA-DB-5280-01A-01D-1465_130906_SN1440_0166_BC2A68ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DB-5280-01A-01D-1465_130906_SN1440_0166_BC2A68ACXX_s_5_rg.sorted	TCGA-DB-5280-01A-01D-1465_130906_SN1440_0166_BC2A68ACXX_s_5_rg.sorted.bam	325.7	1.9	0.15	58cfa831e4b0c9d6adf6ca54	TCGA-DB-5280-01A-01D-1465_130906_SN1440_0166_BC2A68ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DB-5280-01A	4797C600-F024-42FE-B287-D919B24DCB79	Primary Tumor	Illumina HiSeq	47363648-94bb-4221-a905-4832396ef90e	Brain	43.0	D9B929FD-335C-46B1-B60D-B846C372AA6A	677B8F71-325E-49F9-B3D7-B6ADB6831ED5	TCGA-DB-5280-01A-01D-1465-02	HG19_Broad_variant	TCGA-DB-5280	TCGA-LGG		s8130	Harvard Medical School	Mayo Clinic - Rochester	United States	NO			Oligoastrocytoma		1465-02	True	LGG	C5	GBM_LGG.G-CIMP-high	0.046843752	0.13	0.0		-1.9466	-0.4235	-0.3093	-2.4643	-0.7599	-0.9812	10.0	18.0	0.11370353	0.5116658829999999	46.0	0.028538355	0.0	3.0					0.0		3.19755776	-303.8471053	-1158.577726	-3297.222153	0.0	1112.0	0.0	1112.0	8.05721909780768	8.19375563306548	0.06918446636753273	5.086804632237979	7.143933508566803	2.0435750693771775	-2.970414465569701	-1.0498221244986776	1.9743906030096448
13722.58cfa831e4b0c9d6adf6ca56	58cfa831e4b0c9d6adf6ca56	TCGA-DU-5852-01A-11D-1703_130806_SN1222_0209_AD2AW0ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-DU-5852-01A-11D-1703_130806_SN1222_0209_AD2AW0ACXX_s_7_rg.sorted	TCGA-DU-5852-01A-11D-1703_130806_SN1222_0209_AD2AW0ACXX_s_7_rg.sorted.bam	172.3	1.9	0.16	58cfa831e4b0c9d6adf6ca56	TCGA-DU-5852-01A-11D-1703_130806_SN1222_0209_AD2AW0ACXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-5852-01A	9ED5AF0E-C87F-46FF-81E7-9D3041B4034E	Primary Tumor	Illumina HiSeq	9dd03595-2a2f-4fc1-9cd1-52a490696f01	Brain	61.0	101AAA90-FE0A-42B7-BCC7-4F44E29883EC	E5AF958A-0014-4259-970D-5E0EA3CAE376	TCGA-DU-5852-01A-11D-1703-02	HG19_Broad_variant	TCGA-DU-5852	TCGA-LGG	205.0	s8347	Harvard Medical School	Henry Ford Hospital	United States	NO			Oligoastrocytoma		1703-02	True	LGG	C4	GBM_LGG.Mesenchymal-like	0.13806314	0.19	0.03		0.0648	-0.0625	0.5073	-1.5676	-0.4635	-0.1577	29.0	0.0	0.707308577	1.7528951680000002	130.0	0.244986005	4.0	7.0				0.693147181	2.0	1.0	3.02621593	74.44480044	338.28941160000005	-3295.65978	1.0	205.0	1.0	24.0	6.014529820038978	5.697093486505404	-0.30166831442652076	4.222770350810923	4.655639611677243	2.5737299016794815	-1.7917594692280547	-1.0414538748281612	2.8753982161060025
13722.58cfa831e4b0c9d6adf6ca58	58cfa831e4b0c9d6adf6ca58	TCGA-DD-A4NA-01A-11D-A25V-10_wgs_Illumina.filtered.	WGS	TCGA-DD-A4NA-01A-11D-A25V-10_wgs_Illumina	TCGA-DD-A4NA-01A-11D-A25V-10_wgs_Illumina.bam	38.33		0.08	58cfa831e4b0c9d6adf6ca58	TCGA-DD-A4NA-01A-11D-A25V-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-DD-A4NA-01A	BEE9D6C8-948F-4B76-97CA-B985064249EF	Primary Tumor	Illumina HiSeq	9011fbab-0082-4675-98d0-33225253f93c	Liver	67.0	1E7C53F1-DFB6-4A50-BD83-F8062B1306F2	5EAD73FE-1C34-48ED-B20D-89FC3C82DBD6	TCGA-DD-A4NA-01A-11D-A25V-10	GRCh37-lite	TCGA-DD-A4NA	TCGA-LIHC		s17059	Baylor College of Medicine	Mayo Clinic - Rochester	United States	NO	T2	N1	Hepatocellular Carcinoma	Stage IIIC	A25V-10	True	LIHC	C3		0.169933193				-0.6153	-0.2115	-0.0859	-0.2348	-0.6562	-0.0875	13.0	53.0	0.273806076	0.766657013	240.0	0.8041460359999999	11.0	24.0	0.7132827820000001	2.42601553	30.0	1.329661349	4.0	0.959147917	2.6815339959999998	-1354.2765880000002	-919.6405457000001	1421.7937140000001	0.0	1008.0	0.0	1008.0	7.127817163758939	1.6858654691619943	0.11498522903203601	5.9315664055269135	4.0028048756077235	3.7160655944180934	-1.1962507582320256	2.316939406445729	3.601080365386057
13722.58cfa831e4b0c9d6adf6ca5a	58cfa831e4b0c9d6adf6ca5a	TCGA-DK-A3IN-01A-11D-A210_120911_SN1120_0189_BD1D04ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DK-A3IN-01A-11D-A210_120911_SN1120_0189_BD1D04ACXX_s_1_rg.sorted	TCGA-DK-A3IN-01A-11D-A210_120911_SN1120_0189_BD1D04ACXX_s_1_rg.sorted.bam	36.12		0.15	58cfa831e4b0c9d6adf6ca5a	TCGA-DK-A3IN-01A-11D-A210_120911_SN1120_0189_BD1D04ACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A3IN-01A	FC0032DB-B6D8-4DA3-BD1B-BEEC4196ABF0	Primary Tumor	Illumina HiSeq	ff3d1235-2aed-4091-a8a2-72340b403e05	Bladder	72.0	F8C14183-3982-44E5-967E-03967EAA8123	11901B8B-BE4C-4914-8D50-06EA0128EB39	TCGA-DK-A3IN-01A-11D-A210-26	HG19_Broad_variant	TCGA-DK-A3IN	TCGA-BLCA	250.0	s2890	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T4a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A210-26	True	BLCA	C1	BLCA.2	0.296699036	0.61	0.14		0.7155	0.226	0.39799999999999996	0.2974	0.2156	0.6325	169.0	110.0	3.790718585	9.843640195	151.0	0.583717351	20.0	25.0	0.600104202	2.11618377	34.0	2.997068727	21.0	0.984413414	5.508520923	-837.567661	1005.847963	42.24264352	1.0	250.0	0.0	250.0	7.410498326554773	8.570275717506991	1.3738539466353563	6.909723038642284	7.964139913936675	2.742092619929041	-0.5007752879124894	-0.6061358035703157	1.3682386732936846
13722.58cfa831e4b0c9d6adf6ca5e	58cfa831e4b0c9d6adf6ca5e	TCGA-DJ-A1QG-01A-11D-A14U_120629_SN1222_0121_BD143UACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DJ-A1QG-01A-11D-A14U_120629_SN1222_0121_BD143UACXX_s_1_rg.sorted	TCGA-DJ-A1QG-01A-11D-A14U_120629_SN1222_0121_BD143UACXX_s_1_rg.sorted.bam	73.27	1.98	0.17	58cfa831e4b0c9d6adf6ca5e	TCGA-DJ-A1QG-01A-11D-A14U_120629_SN1222_0121_BD143UACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A1QG-01A	CB29E795-7618-4882-A7E0-69D39787B80C	Primary Tumor	Illumina HiSeq	cd7d52cc-20ac-4fa7-a821-231d15f926fc	Thyroid	62.0	D0A669AF-1A0A-451D-9D6F-9EEE15F7264C	EF88FE61-36C4-43CF-BD57-D15F7E264DF0	TCGA-DJ-A1QG-01A-11D-A14U-02	HG19_Broad_variant	TCGA-DJ-A1QG	TCGA-THCA		s12240	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T1b	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A14U-02	True	THCA	C3	THCA.1	0.097458571	0.24	0.0		-1.4414	-0.2785	-0.2329	-0.7578	-0.6625	-0.5024	9.0		0.08999614800000001	0.389983309	73.0	0.011146607	0.0	0.0				0.693147181	2.0	1.0	1.133816177	-1082.294793	-623.0500165	83.62780615	0.0	1368.0	0.0	1368.0	6.014631606389517	8.695662894894445	-0.2629261182371765	5.298317366548037	7.4718874632723296	2.8891940401767147	-0.7163142398414797	-1.2237754316221157	3.1521201584138914
13722.58cfa831e4b0c9d6adf6ca60	58cfa831e4b0c9d6adf6ca60	TCGA-CN-6013-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CN-6013-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_1_rg.sorted	TCGA-CN-6013-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_1_rg.sorted.bam	354.0	1.9	0.15	58cfa831e4b0c9d6adf6ca60	TCGA-CN-6013-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-6013-01A	714496C5-D221-4397-9C5A-CD2D22603E6F	Primary Tumor	Illumina HiSeq	2ca5ef3f-76f6-4db9-85e7-d32249cd642f	Head and Neck	56.0	D018CD44-6B01-44F2-9181-81153225AAB8	2DE7DBC6-2A3E-4E67-BB96-552E27137618	TCGA-CN-6013-01A-11D-1681-02	HG19_Broad_variant	TCGA-CN-6013	TCGA-HNSC		s15629	Harvard Medical School	University of Pittsburgh	United States	NO	T4a	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	True	HNSC	C2	HNSC.Atypical	0.38711583	0.49	0.13		0.2919	-0.059000000000000004	0.9499	1.3204	1.6177	0.3572	67.0	47.0	1.516466567	4.822363684	114.0	0.374681759	12.0	20.0	0.851663878	4.033649137	114.0	3.835069313	51.0	0.975391503	5.139661043	632.3112143999999	-387.39895930000006	-511.72527410000004	1.0	727.0	1.0	323.0	6.037136300972664	7.0009143865580015	-0.33323960916362216	4.817896024515939	6.277914242848374	2.4373940782403554	-1.2192402764567247	-0.7230001437096267	2.7706336874039774
13722.58cfa831e4b0c9d6adf6ca63	58cfa831e4b0c9d6adf6ca63	TCGA-CN-6989-01A-11D-A32X-10_wgs_Illumina.filtered.	WGS	TCGA-CN-6989-01A-11D-A32X-10_wgs_Illumina	TCGA-CN-6989-01A-11D-A32X-10_wgs_Illumina.bam	182.7		0.08	58cfa831e4b0c9d6adf6ca63	TCGA-CN-6989-01A-11D-A32X-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-6989-01A	F33AA93F-B32D-4C4F-9A71-1E5AB69C6899	Primary Tumor	Illumina HiSeq	190e57a0-694b-46ca-a944-0bf0e9d732c2	Head and Neck	64.0	7AC8FB22-0A09-4B16-AF8C-B5C2E90A968A	08227616-02A5-46E8-9DB1-F2D1D691AB23	TCGA-CN-6989-01A-11D-A32X-10	GRCh37-lite	TCGA-CN-6989	TCGA-HNSC		s16177	Baylor College of Medicine	University of Pittsburgh	United States	NO	T3	N2c	Head and Neck Squamous Cell Carcinoma	Stage IVA	A32X-10	True	HNSC	C1	HNSC.Mesenchymal	0.23116340800000001	0.69	0.29		0.7075	0.2325	0.7683	0.2376	0.3816	1.0906	38.0	2.0	0.8764325359999999	2.454011102	168.0	0.513712529	14.0	43.0	0.863361442	2.845498468	27.0	3.424730339	36.0	0.955689198	3.0954187660000003	-158.8226301	1108.097242	-316.3514515	1.0	980.0	1.0	436.0	6.539482729811127	3.144055486454283	-1.480517488120394	5.34989866293729	4.542415197377339	1.8114064666118512	-1.1895840668738367	1.3983597109230557	3.291923954732245
13722.58cfa831e4b0c9d6adf6ca71	58cfa831e4b0c9d6adf6ca71	TCGA-DO-A1JZ-01A-11D-A13U_120706_SN1222_0123_BD1488ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-DO-A1JZ-01A-11D-A13U_120706_SN1222_0123_BD1488ACXX_s_6_rg.sorted	TCGA-DO-A1JZ-01A-11D-A13U_120706_SN1222_0123_BD1488ACXX_s_6_rg.sorted.bam	91.81	1.77	0.15	58cfa831e4b0c9d6adf6ca71	TCGA-DO-A1JZ-01A-11D-A13U_120706_SN1222_0123_BD1488ACXX_s_6_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DO-A1JZ-01A	169F045F-1739-4B0B-9BDC-028AACA420F8	Primary Tumor	Illumina HiSeq	a349224e-f179-4a21-ae6f-5807917a484d	Thyroid	23.0	2EEB72CD-8A11-4ED1-87B0-3CF0C1BF1FB5	C69C86EC-D4E4-422B-88F8-AF3CE8B14148	TCGA-DO-A1JZ-01A-11D-A13U-02	HG19_Broad_variant	TCGA-DO-A1JZ	TCGA-THCA		s12377	Harvard Medical School	Medical College of Georgia	United States	NO	T2	NX	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A13U-02	True	THCA	C3	THCA.5	0.045534009	0.0	0.0		-1.6026	-0.3235	-0.8405	-1.5526	-0.8887	0.1354	1.0		0.0	0.14700327400000002	53.0	4.91e-05	0.0	0.0				0.0	1.0		1.386505446	390.19782999999995	-844.9542991000001	557.4285868	0.0	1670.0	0.0	1670.0	7.099417137005965	7.439986522639764	0.7766827314631798	6.076028269575443	6.311521270821973	1.9036858553068132	-1.0233888674305218	-1.128465251817791	1.1270031238436333
13722.58cfa831e4b0c9d6adf6ca7c	58cfa831e4b0c9d6adf6ca7c	TCGA-DJ-A13X-01A-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DJ-A13X-01A-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_1_rg.sorted	TCGA-DJ-A13X-01A-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_1_rg.sorted.bam	52.8	1.95	0.16	58cfa831e4b0c9d6adf6ca7c	TCGA-DJ-A13X-01A-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_1_rg.sorted.bam	Alive	FEMALE		NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A13X-01A	3B3C99AB-5336-4433-B682-E1A590221611	Primary Tumor	Illumina HiSeq	a3b0754a-92ca-4ef2-b612-4e5bf2f74048	Thyroid	51.0	AC52BED3-FDD6-4281-89DE-D2F125BA038E	3E92A45C-FFFB-4C07-BD81-DB3EBF41841F	TCGA-DJ-A13X-01A-11D-A10R-02	HG19_Broad_variant	TCGA-DJ-A13X	TCGA-THCA		s12748	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage III	A10R-02	True	THCA	C3	THCA.5	0.062839047	0.28	0.0		-1.9284	-0.379	-0.2351	-0.5206	-0.1326	-0.0641	6.0		0.0	0.20076921600000003	51.0	1.3800000000000002e-05	0.0	0.0				2.106577333	9.0	0.9587446609999999	1.315150448	368.4722868	-969.4107377999999	2280.562042	0.0	253.0	0.0	253.0	7.289982776077627	8.24996712753184	-0.8074416057340195	6.222142146076271	7.333676395657685	2.8691534002443504	-1.0678406300013559	-0.9162907318741551	3.6765950059783696
13722.58cfa831e4b0c9d6adf6ca7f	58cfa831e4b0c9d6adf6ca7f	TCGA-DK-A1A5-01A-11D-A13U_121002_SN1222_0154_AC1A3DACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DK-A1A5-01A-11D-A13U_121002_SN1222_0154_AC1A3DACXX_s_1_rg.sorted	TCGA-DK-A1A5-01A-11D-A13U_121002_SN1222_0154_AC1A3DACXX_s_1_rg.sorted.bam	59.04	1.91	0.16	58cfa831e4b0c9d6adf6ca7f	TCGA-DK-A1A5-01A-11D-A13U_121002_SN1222_0154_AC1A3DACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A1A5-01A	904A8757-E0C5-41EF-B583-C8F170CAAAC1	Primary Tumor	Illumina HiSeq	3aa26bad-446a-4391-a584-27b78fc638e8	Bladder	79.0	A9EF3EC5-B1C1-481F-89CF-1729FAB50173	C4A751AF-E8CC-452A-9B5B-99D4B0AC585D	TCGA-DK-A1A5-01A-11D-A13U-02	HG19_Broad_variant	TCGA-DK-A1A5	TCGA-BLCA	65.0	s2889	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A13U-02	True	BLCA	C1	BLCA.2	0.122964325	0.41	0.06		0.7193	0.2455	-0.3939	-0.7679	0.1374	0.5338	150.0	45.0	2.642278595	6.575670595	260.0	0.628056055	15.0	37.0	0.902201692	0.625358559	2.0	1.386294361	4.0	1.0	2.575847758	-1384.912307	962.1234795	-253.8190488	1.0	65.0	0.0	65.0	5.733097002087369	7.604776524599451	0.02506513211613537	4.30976136928713	6.742553013995572	1.1496281687959944	-1.42333563280024	-0.8622235106038794	1.124563036679859
13722.58cfa831e4b0c9d6adf6ca90	58cfa831e4b0c9d6adf6ca90	TCGA-DU-5872-01A-11D-1703_130808_SN208_0488_BC294YACXX_s_6_rg.sorted.filtered.	WGS	TCGA-DU-5872-01A-11D-1703_130808_SN208_0488_BC294YACXX_s_6_rg.sorted	TCGA-DU-5872-01A-11D-1703_130808_SN208_0488_BC294YACXX_s_6_rg.sorted.bam	31.7	1.8	0.17	58cfa831e4b0c9d6adf6ca90	TCGA-DU-5872-01A-11D-1703_130808_SN208_0488_BC294YACXX_s_6_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-5872-01A	48607130-C09A-491D-882F-7D2591D13182	Primary Tumor	Illumina HiSeq	ed7bb33a-0d4e-4215-b4c5-2dc1250d882b	Brain	43.0	048550EE-189D-483D-B07F-B77F10278420	CF245938-DD0C-42FE-9A39-09F29FF12F23	TCGA-DU-5872-01A-11D-1703-02	HG19_Broad_variant	TCGA-DU-5872	TCGA-LGG		s8350	Harvard Medical School	Henry Ford Hospital	United States	NO			Oligoastrocytoma		1703-02	True	LGG	C4	GBM_LGG.G-CIMP-high	0.575829339	0.13	0.02		-1.3664	-0.28300000000000003	0.1991	-1.1581	0.7716	-0.7459	14.0		0.12124115699999999	0.348568325	74.0	0.10067973699999999	0.0	0.0		0.0	1.0		0.0		3.397358268	31.33006207	-1144.696486	-3029.357672	0.0	532.0	1.0	265.0	8.07355881719057	6.229457301272397	0.5248900765615931	5.8763342398543505	6.190236588119117	2.3984001958083407	-2.197224577336219	-0.03922071315328157	1.8735101192467476
13722.58cfa831e4b0c9d6adf6ca92	58cfa831e4b0c9d6adf6ca92	TCGA-DQ-5624-01A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DQ-5624-01A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_5_rg.sorted	TCGA-DQ-5624-01A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_5_rg.sorted.bam	98.7	1.9	0.15	58cfa831e4b0c9d6adf6ca92	TCGA-DQ-5624-01A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-DQ-5624-01A	B4A41682-4ACA-4F1D-BACD-66F5E6EC7466	Primary Tumor	Illumina HiSeq	72ea153a-e312-4f8e-8fa6-bd705df2b106	Head and Neck	43.0	39A74037-6C20-4713-A6AA-E972218EFF90	45F819EB-F6B5-4B82-9E47-060B2E111851	TCGA-DQ-5624-01A-01D-1868-02	HG19_Broad_variant	TCGA-DQ-5624	TCGA-HNSC		s15532	Harvard Medical School	University of Michigan	United States	NO	TX	NX	Head and Neck Squamous Cell Carcinoma		1868-02	True	HNSC	C2	HNSC.Basal	0.344363349	0.73	0.32		0.0133	-0.0005	-0.1505	-0.0171	0.8845	1.0431	42.0	0.0	0.7446323770000001	2.025400066	145.0	0.30668493	18.0	26.0	0.91605019	4.025535983999999	81.0	2.941616953	20.0	0.981935862	6.294998265	431.12092879999994	-356.3159723	286.70498	0.0	1778.0	0.0	1778.0	7.527847778636171	3.5627265060707067	-0.5982784044264374	6.534596005625888	3.9993405204884356	1.0948351359243642	-0.9932517730102832	0.43661401441772885	1.6931135403508017
13722.58cfa831e4b0c9d6adf6ca93	58cfa831e4b0c9d6adf6ca93	TCGA-D1-A16R-01A-11D-A12F_120523_SN1222_0109_BD12MPACXX_s_5_rg.sorted.filtered.	WGS	TCGA-D1-A16R-01A-11D-A12F_120523_SN1222_0109_BD12MPACXX_s_5_rg.sorted	TCGA-D1-A16R-01A-11D-A12F_120523_SN1222_0109_BD12MPACXX_s_5_rg.sorted.bam	93.33	1.39	0.17	58cfa831e4b0c9d6adf6ca93	TCGA-D1-A16R-01A-11D-A12F_120523_SN1222_0109_BD12MPACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A16R-01A	40F43483-B504-4EA7-AD24-40682B10CAAC	Primary Tumor	Illumina HiSeq	3574ade8-f6bc-44dc-94ce-8ea657978707	Uterus	39.0	F57EB4ED-4393-4DC3-9362-A4757EF8B21D	93FEF054-0782-4A27-A27B-22176874E805	TCGA-D1-A16R-01A-11D-A12F-02	HG19_Broad_variant	TCGA-D1-A16R	TCGA-UCEC		s4618	Harvard Medical School	Mayo Clinic	None	NO			Endometrioid endometrial adenocarcinoma		A12F-02	True	UCEC	C1	UCEC.CN_LOW	0.114665211	0.22	0.33	5.641611524	-0.0184	0.002	-0.2387	0.0141	0.1029	0.2985	25.0	0.0	0.269338737	1.131222694	1966.0	0.066648683	2.0	3.0							2.497186129	-1088.461177	-529.8180480000001	682.7179854	0.0	21.0	0.0	21.0	5.876190380835941	7.3796321526095525	0.1903537284912189	6.382751605815474	4.965343070035506	2.007576980450192	0.5065612249795333	-2.4142890825740464	1.817223251958973
13722.58cfa831e4b0c9d6adf6caa0	58cfa831e4b0c9d6adf6caa0	TCGA-DJ-A1QM-01A-11D-A14U_120629_SN1120_0167_AC0WMBACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DJ-A1QM-01A-11D-A14U_120629_SN1120_0167_AC0WMBACXX_s_3_rg.sorted	TCGA-DJ-A1QM-01A-11D-A14U_120629_SN1120_0167_AC0WMBACXX_s_3_rg.sorted.bam	41.49	1.86	0.16	58cfa831e4b0c9d6adf6caa0	TCGA-DJ-A1QM-01A-11D-A14U_120629_SN1120_0167_AC0WMBACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A1QM-01A	3597AF5E-65FF-40A7-95FC-DACC26CBCA14	Primary Tumor	Illumina HiSeq	e98815fd-cd95-4af1-af17-129186e4a00a	Thyroid	42.0	B4215B1F-3918-43D6-8862-380C35F891EC	A070BCA4-DDFA-4BE7-A635-69A2BA97FFE9	TCGA-DJ-A1QM-01A-11D-A14U-02	HG19_Broad_variant	TCGA-DJ-A1QM	TCGA-THCA		s12243	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T1a	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A14U-02	True	THCA	C3	THCA.2	0.115197337	0.81	0.0		-1.5168	-0.2945	-0.2201	-0.4919	-0.503	0.3939	1.0		0.120624679	0.241249358	47.0	1.9e-05	0.0	0.0	0.966620149	1.061940774	3.0	2.36938212	11.0	0.9881090920000001	1.749393746	602.6866782000001	-880.4928152999998	2759.206139	0.0	183.0	0.0	183.0	6.876596268518647	7.674992574393507	-0.5588126599201517	6.183449087958701	7.4365815509485085	1.5648961368113132	-0.6931471805599458	-0.2384110234449981	2.123708796731465
13722.58cfa831e4b0c9d6adf6caaa	58cfa831e4b0c9d6adf6caaa	TCGA-D1-A16D-01A-11D-A12F_120511_SN208_0299_BD12J9ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-D1-A16D-01A-11D-A12F_120511_SN208_0299_BD12J9ACXX_s_3_rg.sorted	TCGA-D1-A16D-01A-11D-A12F_120511_SN208_0299_BD12J9ACXX_s_3_rg.sorted.bam	64.8	1.88	0.16	58cfa831e4b0c9d6adf6caaa	TCGA-D1-A16D-01A-11D-A12F_120511_SN208_0299_BD12J9ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A16D-01A	5693302A-4548-4C0B-8725-0CB7C67BC4F8	Primary Tumor	Illumina HiSeq	c72febd1-cbf3-4ba1-9e3e-35d65e99aa5e	Uterus	49.0	007BDFD3-81B6-42C3-A4A6-C4DDAF1BE0AE	DCA0D1DE-E9A0-45CF-B709-A492D513C1C4	TCGA-D1-A16D-01A-11D-A12F-02	HG19_Broad_variant	TCGA-D1-A16D	TCGA-UCEC		s4613	Harvard Medical School	Mayo Clinic	None	NO			Endometrioid endometrial adenocarcinoma		A12F-02	True	UCEC	C1	UCEC.CN_LOW	0.303452425			0.91141816	-0.5756	-0.02	-0.003	0.1175	-0.4001	0.1188	16.0	41.0	0.15809432699999998	1.053962179	45.0	0.00028746	0.0	0.0							2.74063431	-676.0683661	-909.9101954	-253.230571	0.0	1141.0	0.0	1141.0	6.632061663014117	6.583606792049755	0.034193250599585556	5.127984266237843	5.179612853830464	1.5988672175211145	-1.5040773967762737	-1.4039939382192919	1.564673966921529
13722.58cfa831e4b0c9d6adf6cab0	58cfa831e4b0c9d6adf6cab0	TCGA-DJ-A13U-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DJ-A13U-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_3_rg.sorted	TCGA-DJ-A13U-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_3_rg.sorted.bam	76.6	1.95	0.16	58cfa831e4b0c9d6adf6cab0	TCGA-DJ-A13U-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A13U-01A	8C5AEF43-341E-4A37-84EB-FD730EB957C7	Primary Tumor	Illumina HiSeq	c717fac6-b3b3-4335-8ee8-5862d742ea16	Thyroid	60.0	CD19D6BB-21A4-409A-A7BA-A4521A03ABD3	B80A7146-1AB2-49BD-A3B2-7F6650840195	TCGA-DJ-A13U-01A-11D-A10R-02	HG19_Broad_variant	TCGA-DJ-A13U	TCGA-THCA		s12104	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A10R-02	True	THCA	C3	THCA.3	0.039428117	0.7	0.0		-1.7789	-0.36	-0.6413	-0.9879	-0.5018	-0.26899999999999996	5.0		0.115040177	0.258840399	70.0	0.034092211000000004	1.0	0.0				1.791759469	6.0	1.0	1.218803361	32.25251806	-712.2337858	2343.610263	0.0	1590.0	0.0	1590.0	6.103638008750757	8.703008637464448	-0.2820403085451131	5.040117039893918	7.712609933436571	4.027698558744965	-1.0635209688568392	-0.9903987040278768	4.309738867290077
13722.58cfa831e4b0c9d6adf6cac2	58cfa831e4b0c9d6adf6cac2	TCGA-DJ-A13R-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-DJ-A13R-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_2_rg.sorted	TCGA-DJ-A13R-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_2_rg.sorted.bam	78.88	1.95	0.16	58cfa831e4b0c9d6adf6cac2	TCGA-DJ-A13R-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A13R-01A	3E787A0E-B5D2-401E-B1E5-077376090B3A	Primary Tumor	Illumina HiSeq	84cf379b-0f45-44d0-b5e3-00a439bab300	Thyroid	50.0	27B0FF79-4213-4B57-B6E0-A393B8983D20	7B0104C8-1264-4580-94D1-C7C39D79C6E6	TCGA-DJ-A13R-01A-11D-A10R-02	HG19_Broad_variant	TCGA-DJ-A13R	TCGA-THCA		s12368	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage III	A10R-02	True	THCA	C3	THCA.1	0.314872781	0.42	0.0		-1.4102	-0.2865	1.0081	2.1431	0.2437	-0.6138	4.0		0.08548378	0.284945933	59.0	1.24e-05	0.0	0.0		0.0	1.0	2.951865634	27.0	0.895634631	1.295474727	-137.4669415	-1324.303281	1548.426685	0.0	565.0	0.0	565.0	6.590301048196686	9.543250717031034	0.3441456195913133	6.325608493969604	8.604981078438104	1.9837285962125515	-0.26469255422708216	-0.9382696385929301	1.6395829766212384
13722.58cfa831e4b0c9d6adf6cad2	58cfa831e4b0c9d6adf6cad2	TCGA-DI-A1BU-01A-11D-A133_120511_SN1120_0141_BC0VK9ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-DI-A1BU-01A-11D-A133_120511_SN1120_0141_BC0VK9ACXX_s_7_rg.sorted	TCGA-DI-A1BU-01A-11D-A133_120511_SN1120_0141_BC0VK9ACXX_s_7_rg.sorted.bam	88.64	1.98	0.17	58cfa831e4b0c9d6adf6cad2	TCGA-DI-A1BU-01A-11D-A133_120511_SN1120_0141_BC0VK9ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-DI-A1BU-01A	53245616-E095-4616-89BB-6062669122DA	Primary Tumor	Illumina HiSeq	1a6e5cca-d65a-40c4-b8ce-b7b282493459	Uterus	55.0	241BFB1F-5CF8-458D-B335-18BABF507E85	085C72D3-C295-4D9B-A5CC-08F76CFF2284	TCGA-DI-A1BU-01A-11D-A133-02	HG19_Broad_variant	TCGA-DI-A1BU	TCGA-UCEC		s4805	Harvard Medical School	MD Anderson	United States	NO			Mixed serous and endometrioid		A133-02	False	UCEC	C1	UCEC.POLE	0.16519708	0.39	0.0	9.982244709	0.5998	0.273	-0.5653	0.2826	-1.1247	-0.3138	3587.0	6324.0	58.56079598	162.2826985	46.0	0.000144865	0.0	0.0				2.813355405	17.0	0.9929910190000001	2.285385207	-1428.330726	-281.024743	-2737.954033	0.0	1195.0	0.0	1195.0	5.873490944514384	6.446972167702045	0.6078892671091888	6.185865629556537	6.752353817253226	1.57381511461834	0.31237468504215293	0.30538164955118186	0.9659258475091512
13722.58cfa831e4b0c9d6adf6cad6	58cfa831e4b0c9d6adf6cad6	TCGA-DU-6408-01A-11D-1703_130813_SN1440_0160_AD2B87ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-DU-6408-01A-11D-1703_130813_SN1440_0160_AD2B87ACXX_s_8_rg.sorted	TCGA-DU-6408-01A-11D-1703_130813_SN1440_0160_AD2B87ACXX_s_8_rg.sorted.bam	157.3	1.9	0.15	58cfa831e4b0c9d6adf6cad6	TCGA-DU-6408-01A-11D-1703_130813_SN1440_0160_AD2B87ACXX_s_8_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-6408-01A	14375753-A69F-41E0-B910-2BB8E84CC43A	Primary Tumor	Illumina HiSeq	f441e949-5e27-4235-a0db-39c77aacdb5c	Brain	23.0	F68159AD-A0E9-4F9F-AD68-A29D53772982	57952871-E6FE-4C1F-87FE-404FADFC67C1	TCGA-DU-6408-01A-11D-1703-02	HG19_Broad_variant	TCGA-DU-6408	TCGA-LGG	3470.0	s8757	Harvard Medical School	Henry Ford Hospital	United States	NO			Oligodendroglioma		1703-02	True	LGG	C5	GBM_LGG.G-CIMP-high	0.09105190699999999	0.11	0.17		-0.7705	-0.1865	-0.0316	-2.4822	-0.49200000000000005	-0.8126	11.0	0.0	0.129313415	0.7435521340000001	66.0	0.229582562	1.0	13.0				0.0	1.0		3.38921846	416.2513326	-124.17872220000001	-2452.945792	1.0	3470.0	1.0	2097.0	7.110696122978827	6.701960366002541	1.8454479743415604	5.724401761858937	6.171332114940371	0.7648105906441958	-1.3862943611198906	-0.5306282510621703	-1.0806373836973646
13722.58cfa831e4b0c9d6adf6cada	58cfa831e4b0c9d6adf6cada	TCGA-DU-6542-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_2_rg.sorted.filtered.	WGS	TCGA-DU-6542-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_2_rg.sorted	TCGA-DU-6542-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_2_rg.sorted.bam	424.7	1.9	0.14	58cfa831e4b0c9d6adf6cada	TCGA-DU-6542-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-6542-01A	CD69D509-A652-4257-A8D3-767296BBB4EC	Primary Tumor	Illumina HiSeq	4b6cb752-5ed6-42e5-aed5-c8bdc6b95945	Brain	25.0	D00791AB-AA9D-406B-934C-E6946A430BB2	6EF0AE20-9197-4162-9A35-E235071A83B5	TCGA-DU-6542-01A-11D-1891-02	HG19_Broad_variant	TCGA-DU-6542	TCGA-LGG		s8143	Harvard Medical School	Henry Ford Hospital	United States	NO			Oligoastrocytoma		1891-02	True	LGG	C5	GBM_LGG.G-CIMP-high	0.103864703	0.18	0.15		-1.0788	-0.3065	0.3515	-2.2229	-0.2771	-0.7161	8.0	0.0	0.20412040399999998	0.612361211	287.0	0.160135135	1.0	15.0				0.693147181	2.0	1.0	3.166070716	-57.24068832	-64.93522735	-2021.2592300000001	0.0	73.0	0.0	73.0	8.678886780414224	8.450091387875501	0.43452326395676455	6.481662203078005	6.597707296831011	2.6971341793528945	-2.197224577336219	-1.85238409104449	2.26261091539613
13722.58cfa831e4b0c9d6adf6cadd	58cfa831e4b0c9d6adf6cadd	TCGA-E1-5305-01A-01D-1891_130919_SN590_0238_AC29TRACXX_s_3_rg.sorted.filtered.	WGS	TCGA-E1-5305-01A-01D-1891_130919_SN590_0238_AC29TRACXX_s_3_rg.sorted	TCGA-E1-5305-01A-01D-1891_130919_SN590_0238_AC29TRACXX_s_3_rg.sorted.bam	57.7	1.9	0.14	58cfa831e4b0c9d6adf6cadd	TCGA-E1-5305-01A-01D-1891_130919_SN590_0238_AC29TRACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-E1-5305-01A	A0BC5147-D9B4-41FD-8DF3-A241D23722E8	Primary Tumor	Illumina HiSeq	0f660d53-1dae-499d-8a76-f591e1110acb	Brain	34.0	1B3185BF-9DEF-4B13-93F8-02CF3171464A	036EF90A-EACA-4105-9B7B-74C20BFA0BB9	TCGA-E1-5305-01A-01D-1891-02	HG19_Broad_variant	TCGA-E1-5305	TCGA-LGG	2433.0	s8354	Harvard Medical School	Duke	United States	NO			Astrocytoma		1891-02	True	LGG	C5	GBM_LGG.G-CIMP-high	0.037839072	0.23	0.03		-0.6416	-0.2595	-0.1642	-2.2824	-0.3015	-0.9003	14.0	2.0	0.202132673	0.664150211	92.0	0.164352857	2.0	18.0				0.0	1.0		3.3271399280000002	-12.8127144	-12.81734475	-3499.97046	1.0	2433.0	1.0	1604.0	6.994849985833071	7.9605417554448294	-1.6477995078223966	4.5969547130347	6.326411230420358	0.5614781435062917	-2.3978952727983707	-1.6341305250244722	2.209277651328688
13722.58cfa831e4b0c9d6adf6cae0	58cfa831e4b0c9d6adf6cae0	TCGA-DJ-A13L-01A-11D-A221_120610_SN1120_0151_AC0WN0ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DJ-A13L-01A-11D-A221_120610_SN1120_0151_AC0WN0ACXX_s_5_rg.sorted	TCGA-DJ-A13L-01A-11D-A221_120610_SN1120_0151_AC0WN0ACXX_s_5_rg.sorted.bam	32.87		0.15	58cfa831e4b0c9d6adf6cae0	TCGA-DJ-A13L-01A-11D-A221_120610_SN1120_0151_AC0WN0ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A13L-01A	C7A2F394-3E3F-4C90-9F1E-F2BE3E5B0D6B	Primary Tumor	Illumina HiSeq	9424534d-10ae-4669-9a13-75ab8e7a7432	Thyroid	85.0	AB13FB1A-8B7F-4D84-84A9-C4F7EE59CAF8	417BD826-C151-459E-AAEA-DFA2CB4182DF	TCGA-DJ-A13L-01A-11D-A221-26	HG19_Broad_variant	TCGA-DJ-A13L	TCGA-THCA		s12105	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T1b	N0	Thyroid Papillary Carcinoma - Tall Cell (>= 50% tall cell features)	Stage I	A221-26	True	THCA	C3	THCA.4	0.393602755				-1.133	-0.1515	0.8079999999999999	1.5391	0.2113	0.2926	19.0	25.0	0.21142234	0.936298932	84.0	0.035222459	1.0	1.0	0.8649781809999999	3.49715113	57.0	3.58610832	39.0	0.978858463	1.4835624459999999	927.9203428	-799.1216457	903.9351642000001	0.0	303.0	0.0	303.0	5.900810178839851	9.410983259565068	0.4133310149451237	5.447142968913809	8.580634957491636	0.9147455345540889	-0.45366720992604215	-0.8303483020734301	0.5014145196089652
13722.58cfa831e4b0c9d6adf6cae4	58cfa831e4b0c9d6adf6cae4	TCGA-DQ-5625-01A-01D-A32X-10_wgs_Illumina.filtered.	WGS	TCGA-DQ-5625-01A-01D-A32X-10_wgs_Illumina	TCGA-DQ-5625-01A-01D-A32X-10_wgs_Illumina.bam	154.7	1.9	0.08	58cfa831e4b0c9d6adf6cae4	TCGA-DQ-5625-01A-01D-A32X-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-DQ-5625-01A	53D9A130-4A3A-4491-85CD-9A44415A1632	Primary Tumor	Illumina HiSeq	cb931cae-83da-428c-86f1-59df36c9af80	Head and Neck	52.0	74856E66-109F-4A68-A496-8FA66729FE1F	D3709EEA-CA2A-49AC-B79C-871A5473D450	TCGA-DQ-5625-01A-01D-A32X-10	GRCh37-lite	TCGA-DQ-5625	TCGA-HNSC		s16061	Baylor College of Medicine	University of Michigan	United States	NO	TX	NX	Head and Neck Squamous Cell Carcinoma		A32X-10	True	HNSC	C2	HNSC.Basal	0.326881209	0.54	0.05		0.26	-0.017	0.5041	0.8195	2.1622	0.4357	79.0	20.0	1.384991431	4.714864447	70.0	0.9369280320000001	12.0	11.0	0.822759055	2.464765854	20.0	2.346648317	29.0	0.696894017	1.9503564930000001	464.5705984	268.507839	-254.8324949	1.0	1133.0	1.0	1058.0	6.0330862217988015	4.884758366602279	0.6178066315091598	4.551481680874586	4.271228814007025	1.2120879355449268	-1.4816045409242158	-0.6135295525952538	0.5942813040357671
13722.58cfa831e4b0c9d6adf6cae8	58cfa831e4b0c9d6adf6cae8	TCGA-D7-6522-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_3_rg.sorted.filtered.	WGS	TCGA-D7-6522-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_3_rg.sorted	TCGA-D7-6522-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_3_rg.sorted.bam	52.7	1.9	0.14	58cfa831e4b0c9d6adf6cae8	TCGA-D7-6522-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6522-01A	8BB3FACB-1933-4350-9F78-74537559E000	Primary Tumor	Illumina HiSeq	ac3cc7c3-e03a-4218-b297-d6c525338753	Stomach	58.0	825AE87A-69C0-44AC-A1AF-D1FAD7746C05	030D9DF5-48AB-46F4-AC23-F299A069191C	TCGA-D7-6522-01A-11D-1798-02	HG19_Broad_variant	TCGA-D7-6522	TCGA-STAD		s15197	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N0	Stomach  Adenocarcinoma  Diffuse Type	Stage IB	1798-02	True	STAD	C3	GI.GS	0.632937744	0.92	0.02	4.208728589	-0.1636	-0.008	1.5074	3.0431	0.3527	0.6421			0.292670238	1.08287988	51.0	1.4599999999999999e-05	0.0	0.0	0.797396117	5.001967767	530.0	6.087693956	657.0	0.938346248	1.4512654269999998	408.7673077	-242.23076260000002	1284.991261	0.0	566.0	0.0	566.0	8.814850346890097	9.417995708849094	0.5111371987801955	7.110102254651672	8.28301577601011	1.3096795204372809	-1.7047480922384255	-1.1349799328389842	0.7985423216570853
13722.58cfa831e4b0c9d6adf6caee	58cfa831e4b0c9d6adf6caee	TCGA-E1-5303-01A-01D-1465_130806_SN1440_0159_BC29Y3ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-E1-5303-01A-01D-1465_130806_SN1440_0159_BC29Y3ACXX_s_3_rg.sorted	TCGA-E1-5303-01A-01D-1465_130806_SN1440_0159_BC29Y3ACXX_s_3_rg.sorted.bam	46.0	1.9	0.14	58cfa831e4b0c9d6adf6caee	TCGA-E1-5303-01A-01D-1465_130806_SN1440_0159_BC29Y3ACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-E1-5303-01A	44A5C3B4-62A7-407B-B492-7069E1A43A26	Primary Tumor	Illumina HiSeq	e94ddca3-3117-4958-85a6-cde716b710dc	Brain	38.0	150856F7-77DA-4AA5-A28B-310A505AEA24	287AB664-A970-437E-A7F9-EF6C20D2266E	TCGA-E1-5303-01A-01D-1465-02	HG19_Broad_variant	TCGA-E1-5303	TCGA-LGG	2052.0	s8137	Harvard Medical School	Duke	United States	NO			Astrocytoma		1465-02	True	LGG	C5	GBM_LGG.G-CIMP-high	0.135320152	0.54	0.1		-1.0608	-0.2445	0.7679	-2.5116	-0.9511	-0.9421	13.0	3.0	0.1378412	0.77191072	61.0	0.092286775	2.0	9.0				0.0	1.0		2.9951344189999998	37.55739709	-938.9291596	-1698.920485	1.0	2052.0	1.0	156.0	9.071078304642676	9.098056958364147	0.8690265993785852	6.7684932116486305	8.6627388871063	3.1434214447582765	-2.3025850929940455	-0.4353180712578455	2.274394845379691
13722.58cfa831e4b0c9d6adf6caf0	58cfa831e4b0c9d6adf6caf0	TCGA-DU-7006-01A-11D-2022_130910_SN208_0494_AC2A1DACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DU-7006-01A-11D-2022_130910_SN208_0494_AC2A1DACXX_s_5_rg.sorted	TCGA-DU-7006-01A-11D-2022_130910_SN208_0494_AC2A1DACXX_s_5_rg.sorted.bam	301.7		0.16	58cfa831e4b0c9d6adf6caf0	TCGA-DU-7006-01A-11D-2022_130910_SN208_0494_AC2A1DACXX_s_5_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-7006-01A	215E117C-4D76-463C-8F8A-FD6A28D23929	Primary Tumor	Illumina HiSeq	a423d9b3-2389-45d5-b834-d5cf57e5e647	Brain	60.0	21E471E0-6B87-4D98-A7E0-DE0F34598460	FDA752F3-371F-460B-8D81-216E0AC53B0E	TCGA-DU-7006-01A-11D-2022-02	HG19_Broad_variant	TCGA-DU-7006	TCGA-LGG	349.0	s8357	Harvard Medical School	Henry Ford Hospital	United States	NO			Astrocytoma		2022-02	True	LGG	C4	GBM_LGG.Mesenchymal-like	0.32243777	0.27	0.16		-0.3191	-0.145	0.8216	-1.3236	-0.636	-0.0218	19.0	2.0	0.270942957	1.7159720630000002	87.0	0.5610548120000001	6.0	13.0				1.386294361	4.0	1.0	3.017273453	137.7072726	-437.0373223	-2120.375713	1.0	349.0	1.0	349.0	8.64549845156916	8.301108004469475	0.4376589579877138	6.342913358575116	7.048345035974107	2.8517801486837353	-2.3025850929940455	-1.252762968495368	2.4141211906960214
13722.58cfa831e4b0c9d6adf6caf8	58cfa831e4b0c9d6adf6caf8	TCGA-EA-A3HR-01A-11D-A20X_140417_SN590_0248_AC3EUFACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EA-A3HR-01A-11D-A20X_140417_SN590_0248_AC3EUFACXX_s_1_rg.sorted	TCGA-EA-A3HR-01A-11D-A20X_140417_SN590_0248_AC3EUFACXX_s_1_rg.sorted.bam	47.83		0.16	58cfa831e4b0c9d6adf6caf8	TCGA-EA-A3HR-01A-11D-A20X_140417_SN590_0248_AC3EUFACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EA-A3HR-01A	638035F6-2909-4A44-980F-468AC5D74E18	Primary Tumor	Illumina HiSeq	a2c5a51a-5933-4597-b207-2c761c54f7c2	Cervix	57.0	1FBFA952-F272-4531-9F9D-1B8BD1DD0845	2B1D8BBD-0F37-40D4-AF38-C78C4BB556BB	TCGA-EA-A3HR-01A-11D-A20X-26	HG19_Broad_variant	TCGA-EA-A3HR	TCGA-CESC		s1179	MD Anderson - Institute for Applied Cancer Science	Asterand	Russia	NO	T2a	N0	Cervical Squamous Cell Carcinoma		A20X-26	True	CESC	C1		0.153636868	0.25	0.19	9.542587807	1.0123	0.222	-0.3406	-0.2466	-0.0931	-0.0828	7.0	0.0	0.7314458420000001	1.302887906	111.0	0.359182758	7.0	27.0	0.91244118	0.632456031	2.0	1.9459101490000001	7.0	1.0	3.13717717	-1180.656375	531.3096360000001	-1626.101937	0.0	940.0	0.0	940.0	7.6636424893632675	8.179526908872509	0.0356710470196524	6.005414412759736	7.138073034044347	0.9502571638457132	-1.6582280766035324	-1.0414538748281612	0.9145861168260608
13722.58cfa831e4b0c9d6adf6cb00	58cfa831e4b0c9d6adf6cb00	TCGA-EA-A3QE-01A-21D-A245_140124_SN1440_0178_AC2PL6ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EA-A3QE-01A-21D-A245_140124_SN1440_0178_AC2PL6ACXX_s_5_rg.sorted	TCGA-EA-A3QE-01A-21D-A245_140124_SN1440_0178_AC2PL6ACXX_s_5_rg.sorted.bam	67.0		0.14	58cfa831e4b0c9d6adf6cb00	TCGA-EA-A3QE-01A-21D-A245_140124_SN1440_0178_AC2PL6ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EA-A3QE-01A	A4E444B5-BBCA-4EF0-B92F-908D608CBB91	Primary Tumor	Illumina HiSeq	14055776-9bfb-42c1-a760-39fb0c8dba92	Cervix	45.0	36FFA53D-1404-49C0-B9C1-A3EB1ECBC6B9	80A263E0-9F91-48FD-B53C-7E2A25710BF3	TCGA-EA-A3QE-01A-21D-A245-26	HG19_Broad_variant	TCGA-EA-A3QE	TCGA-CESC		s1524	MD Anderson - Institute for Applied Cancer Science	Asterand	Russia	NO	T1b	N0	Cervical Squamous Cell Carcinoma		A245-26	True	CESC	C2		0.46915161	0.56	0.01	16.62912033	0.7463	0.0765	0.6836	1.9493	1.4432	-0.0843	30.0	1.0	0.489696277	1.142624647	89.0	0.280390578	3.0	15.0	0.789543433	3.232662861	60.0	3.79909724	88.0	0.848517187	2.582218408	-582.0972704	232.20165350000002	-1474.244884	0.0	761.0	0.0	761.0	8.18660361795318	7.062269529073353	0.14202751066594455	6.682526221176906	6.569793043975559	0.9573144655744849	-1.504077396776274	-0.49247648509779385	0.8152869549085403
13722.58cfa831e4b0c9d6adf6cb04	58cfa831e4b0c9d6adf6cb04	TCGA-EA-A3HT-01A-61D-A245_140124_SN1440_0178_AC2PL6ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EA-A3HT-01A-61D-A245_140124_SN1440_0178_AC2PL6ACXX_s_2_rg.sorted	TCGA-EA-A3HT-01A-61D-A245_140124_SN1440_0178_AC2PL6ACXX_s_2_rg.sorted.bam	54.34		0.15	58cfa831e4b0c9d6adf6cb04	TCGA-EA-A3HT-01A-61D-A245_140124_SN1440_0178_AC2PL6ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EA-A3HT-01A	3C5B2452-014B-495F-B86A-F522ED84BC3B	Primary Tumor	Illumina HiSeq	e0e70b08-26f3-48d5-80c3-4836e9faa569	Cervix	68.0	8460C1E5-0029-4D66-AF11-373324347800	CE1A5984-E350-46A3-BF53-B32DEC8F8AF0	TCGA-EA-A3HT-01A-61D-A245-26	HG19_Broad_variant	TCGA-EA-A3HT	TCGA-CESC		s1182	MD Anderson - Institute for Applied Cancer Science	Asterand	Russia	NO	T1b	N0	Cervical Squamous Cell Carcinoma		A245-26	True	CESC	C1		0.261994562	0.43	0.05	10.766558199999999	0.9476	0.2915	0.1374	-0.1021	0.3644	0.6503	52.0	0.0	0.8562745490000001	1.943974651	70.0	0.19338431	3.0	12.0	0.957009509	2.525602959	14.0	3.08704235	23.0	0.984547295	2.403096536	-101.5868555	1105.5898710000001	-278.22172620000003	0.0	954.0	0.0	954.0	7.471363088187097	5.545502912342485	0.2558416566436922	5.220071289580602	5.197196218074269	1.4839687503161985	-2.251291798606495	-0.3483066942682158	1.2281270936725064
13722.58cfa831e4b0c9d6adf6cb0e	58cfa831e4b0c9d6adf6cb0e	TCGA-EA-A3Y4-01A-51D-A245_140124_SN1440_0178_AC2PL6ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EA-A3Y4-01A-51D-A245_140124_SN1440_0178_AC2PL6ACXX_s_1_rg.sorted	TCGA-EA-A3Y4-01A-51D-A245_140124_SN1440_0178_AC2PL6ACXX_s_1_rg.sorted.bam	30.33		0.15	58cfa831e4b0c9d6adf6cb0e	TCGA-EA-A3Y4-01A-51D-A245_140124_SN1440_0178_AC2PL6ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EA-A3Y4-01A	3AC62513-B5F4-4063-AABD-DAD08A1F56FB	Primary Tumor	Illumina HiSeq	32cd0b72-100c-4e6c-81f1-6be30738cafb	Cervix	40.0	FF97C148-76BA-480E-9456-5DD7D7238373	A7529CB6-2386-410F-B09A-62E10BAFF8CB	TCGA-EA-A3Y4-01A-51D-A245-26	HG19_Broad_variant	TCGA-EA-A3Y4	TCGA-CESC		s1362	MD Anderson - Institute for Applied Cancer Science	Asterand	Ukraine	NO	T1b	N0	Cervical Squamous Cell Carcinoma		A245-26	True	CESC	C2		0.38110998700000004	0.43	0.04	13.1796263	0.526	0.299	0.4506	1.4757	0.6374	0.1038	66.0	0.0	0.915958363	2.457449266	94.0	0.115045106	4.0	12.0	0.73880528	1.024201593	4.0	3.3690456269999998	35.0	0.947599382	2.2112870940000002	426.7506868	797.4345433999999	404.7840149	0.0	1122.0	0.0	1122.0	9.2120888425103	4.420946821904541	0.6971590304340759	6.9607970439038045	6.774825209286137	0.894601998639705	-2.251291798606495	2.353878387381596	0.19744296820562912
13722.58cfa831e4b0c9d6adf6cb12	58cfa831e4b0c9d6adf6cb12	TCGA-EA-A3HS-01A-11D-A20X_140106_SN590_0243_AC371BACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EA-A3HS-01A-11D-A20X_140106_SN590_0243_AC371BACXX_s_3_rg.sorted	TCGA-EA-A3HS-01A-11D-A20X_140106_SN590_0243_AC371BACXX_s_3_rg.sorted.bam	76.91		0.16	58cfa831e4b0c9d6adf6cb12	TCGA-EA-A3HS-01A-11D-A20X_140106_SN590_0243_AC371BACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EA-A3HS-01A	753EE373-FBCF-4349-B9B2-5A41936E27E9	Primary Tumor	Illumina HiSeq	684e83c6-0894-4bfd-a2ee-6b1877c74f82	Cervix	35.0	0835FA38-9870-472E-B9A0-2A2652807BC5	E87CC37B-FD44-4DD9-9D14-455B89C6D4C2	TCGA-EA-A3HS-01A-11D-A20X-26	HG19_Broad_variant	TCGA-EA-A3HS	TCGA-CESC		s1522	MD Anderson - Institute for Applied Cancer Science	Asterand	Russia	NO	T1b	N0	Cervical Squamous Cell Carcinoma		A20X-26	True	CESC	C2		0.10313587	0.16	0.05	4.653211548	0.8712	0.0965	-0.2295	0.2253	1.1197	-0.1442	339.0	266.0	4.991168822	15.33815807	83.0	0.139419441	5.0	9.0	0.782075257	2.215786054	17.0	2.351673302	11.0	0.9807239409999999	1.8354517259999998	-162.83830830000002	577.7006193	-794.2638315	0.0	959.0	0.0	959.0	8.750128645192916	8.211482916445066	-0.5100925479162045	6.447543552198871	7.112870627776956	1.8770300234955344	-2.3025850929940455	-1.0986122886681096	2.387122571411739
13722.58cfa831e4b0c9d6adf6cb17	58cfa831e4b0c9d6adf6cb17	TCGA-EA-A3QD-01A-32D-A232_140124_SN1120_0291_AC2PHAACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EA-A3QD-01A-32D-A232_140124_SN1120_0291_AC2PHAACXX_s_2_rg.sorted	TCGA-EA-A3QD-01A-32D-A232_140124_SN1120_0291_AC2PHAACXX_s_2_rg.sorted.bam	58.49		0.15	58cfa831e4b0c9d6adf6cb17	TCGA-EA-A3QD-01A-32D-A232_140124_SN1120_0291_AC2PHAACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EA-A3QD-01A	9E2E29E8-D94A-499F-A98A-5B53B2C38F3B	Primary Tumor	Illumina HiSeq	d97f385a-fc08-43a1-9481-35f9ffdfcc05	Cervix	59.0	987E1913-A506-4A06-B247-9FF778CE552B	677FE002-1736-4263-B2CE-D93983F0BF95	TCGA-EA-A3QD-01A-32D-A232-26	HG19_Broad_variant	TCGA-EA-A3QD	TCGA-CESC		s1185	MD Anderson - Institute for Applied Cancer Science	Asterand	United States	NO	T1b1	N1	Cervical Squamous Cell Carcinoma		A232-26	True	CESC	C2		0.35593778299999995	0.47	0.11	30.87029741	0.9589	0.35600000000000004	1.0662	2.4114	1.8536	-0.0627	53.0		0.822700068	1.896780713	110.0	0.23469763300000002	5.0	26.0	0.767758811	3.18092819	63.0	4.913180885	149.0	0.9818612320000001	1.8856921309999999	-329.13056539999997	60.740397800000004	-1974.1759309999998	0.0	397.0	0.0	397.0	9.082961442646353	8.521434185673492	0.13220131040670857	6.685066169847982	7.5563532896299055	2.7389977778037458	-2.3978952727983707	-0.9650808960435873	2.606796467397037
13722.58cfa831e4b0c9d6adf6cb1a	58cfa831e4b0c9d6adf6cb1a	TCGA-E7-A3X6-01A-12D-A233_120829_SN1120_0184_BD1DRAACXX_s_5_rg.sorted.filtered.	WGS	TCGA-E7-A3X6-01A-12D-A233_120829_SN1120_0184_BD1DRAACXX_s_5_rg.sorted	TCGA-E7-A3X6-01A-12D-A233_120829_SN1120_0184_BD1DRAACXX_s_5_rg.sorted.bam	39.5		0.15	58cfa831e4b0c9d6adf6cb1a	TCGA-E7-A3X6-01A-12D-A233_120829_SN1120_0184_BD1DRAACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-E7-A3X6-01A	C871EA6B-FBD2-4E6F-AB29-F43F6E3DDCBB	Primary Tumor	Illumina HiSeq	548e206a-eaec-49d3-a405-664cf76d0e16	Bladder	70.0	554AE735-9991-4CB3-AFE8-4951490BD709	AE6DC0A6-7405-44C2-886F-E10BAD336295	TCGA-E7-A3X6-01A-12D-A233-26	HG19_Broad_variant	TCGA-E7-A3X6	TCGA-BLCA		s3291	MD Anderson - Institute for Applied Cancer Science	Asterand	Ukraine	NO	T2	NX	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A233-26	True	BLCA	C2	BLCA.1	0.28188985	0.29	0.03	13.71118517	0.4757	0.1225	-0.04	0.2669	1.2307	0.0476	56.0	9.0	0.9297625690000001	3.050783428	143.0	0.921494853	10.0	23.0				2.648438335	16.0	0.955222213	2.8720911239999998	-1170.9718269999998	-116.81469569999999	610.8126465	1.0	904.0	1.0	369.0	7.084884809073666	8.716535732544495	1.1538877746147622	6.197581614072763	7.176090691597345	1.2225525441684373	-0.8873031950009032	-1.5404450409471488	0.06866476955367484
13722.58cfa831e4b0c9d6adf6cb22	58cfa831e4b0c9d6adf6cb22	TCGA-E5-A2PC-01A-11D-A204_120926_SN1222_0153_BD1D4MACXX_s_1_rg.sorted.filtered.	WGS	TCGA-E5-A2PC-01A-11D-A204_120926_SN1222_0153_BD1D4MACXX_s_1_rg.sorted	TCGA-E5-A2PC-01A-11D-A204_120926_SN1222_0153_BD1D4MACXX_s_1_rg.sorted.bam	63.68		0.16	58cfa831e4b0c9d6adf6cb22	TCGA-E5-A2PC-01A-11D-A204_120926_SN1222_0153_BD1D4MACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-E5-A2PC-01A	4107AE6F-502C-4BDC-BF14-E4B3711CBA38	Primary Tumor	Illumina HiSeq	496052c5-5ab2-4852-88e1-348116a86746	Bladder	61.0	2195B75E-157F-4547-9705-1E7E75666CA8	FABA82E6-FF3D-468C-91EC-A88794619697	TCGA-E5-A2PC-01A-11D-A204-02	HG19_Broad_variant	TCGA-E5-A2PC	TCGA-BLCA		s3289	Harvard Medical School	Roswell Park	United States	NO	T2b	N1	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A204-02	True	BLCA	C2	BLCA.1	0.117345189	0.21	0.12	4.326464247	0.5723	0.24600000000000002	-0.8158	-0.9196	0.3075	-0.1957	83.0	131.0	2.240180285	6.014730628	209.0	0.8487759890000001	22.0	22.0				2.079151273	10.0	0.902963925	5.848619045	-1120.959233	755.7418597999999	342.263283	0.0	1326.0	0.0	1326.0	7.089243155027514	5.0358193722088735	0.6295933960849135	5.513706794269095	6.157962158287177	1.0730695341076828	-1.5755363607584187	1.1221427860783035	0.4434761380227692
13722.58cfa831e4b0c9d6adf6cb25	58cfa831e4b0c9d6adf6cb25	TCGA-E8-A242-01A-21D-A16N_121204_SN208_0442_BC1F7YACXX_s_3_rg.sorted.filtered.	WGS	TCGA-E8-A242-01A-21D-A16N_121204_SN208_0442_BC1F7YACXX_s_3_rg.sorted	TCGA-E8-A242-01A-21D-A16N_121204_SN208_0442_BC1F7YACXX_s_3_rg.sorted.bam	17.09	1.94	0.18	58cfa831e4b0c9d6adf6cb25	TCGA-E8-A242-01A-21D-A16N_121204_SN208_0442_BC1F7YACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-E8-A242-01A	4D9DE9A1-7DF1-412E-9F16-15DD51B4C5F5	Primary Tumor	Illumina HiSeq	0e5bb14f-1671-4b8a-9a38-e1d389ecd440	Thyroid	56.0	225B76AD-DB11-457A-9A77-E1F333895E5C	EA178797-16FB-41AB-B71F-3B397153CE63	TCGA-E8-A242-01A-21D-A16N-02	HG19_Broad_variant	TCGA-E8-A242	TCGA-THCA		s12378	Harvard Medical School	Asterand	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A16N-02	True	THCA	C3	THCA.4	0.34663934700000004	0.36	0.0		-1.6367	-0.256	0.5924	0.9954	0.6873	0.4298	11.0		0.05855578	0.322056788	57.0	2.18e-05	0.0	0.0	0.7426372729999999	3.427360513	101.0	3.0538432999999996	24.0	0.960916165	1.5674765069999999	1281.990481	-998.6074371	1185.34193	0.0	950.0	0.0	950.0	8.033074410478811	8.382122953038035	-0.09335694197991207	2.8660053305407276	7.37882084417425	5.0005849582427535	-5.1670690799380825	-1.0033021088637848	5.093941900222665
13722.58cfa831e4b0c9d6adf6cb28	58cfa831e4b0c9d6adf6cb28	TCGA-E7-A3Y1-01A-11D-A233_120829_SN1120_0184_BD1DRAACXX_s_7_rg.sorted.filtered.	WGS	TCGA-E7-A3Y1-01A-11D-A233_120829_SN1120_0184_BD1DRAACXX_s_7_rg.sorted	TCGA-E7-A3Y1-01A-11D-A233_120829_SN1120_0184_BD1DRAACXX_s_7_rg.sorted.bam	43.56		0.17	58cfa831e4b0c9d6adf6cb28	TCGA-E7-A3Y1-01A-11D-A233_120829_SN1120_0184_BD1DRAACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-E7-A3Y1-01A	F7C891EB-3B09-4E01-BB8A-53D570518CBE	Primary Tumor	Illumina HiSeq	aaeb4857-84bb-4a72-9e0d-81280de1ca61	Bladder	57.0	FABE5B98-4586-445D-9513-598BB7FD1909	46542747-5AF3-4F7E-AE97-7E0689976D0A	TCGA-E7-A3Y1-01A-11D-A233-26	HG19_Broad_variant	TCGA-E7-A3Y1	TCGA-BLCA		s3109	MD Anderson - Institute for Applied Cancer Science	Asterand	Ukraine	NO		N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A233-26	True	BLCA	C3	BLCA.1	0.100777811	0.18	0.07	1.587579211	-0.5146	-0.1245	-1.1099	-0.5798	-0.705	-0.4314	74.0	506.0	1.516009226	4.098839759	38.0	0.104053971	1.0	9.0				1.098612289	3.0	1.0	1.4663395380000002	-2755.581738	-507.74731060000005	-3017.041342	0.0	163.0	0.0	163.0	7.1484886725074706	8.176649343691635	0.6208598851236967	5.935466032661617	7.4426801686114334	1.3628973349635238	-1.2130226398458537	-0.7339691750802002	0.742037449839827
13722.58cfa831e4b0c9d6adf6cb2a	58cfa831e4b0c9d6adf6cb2a	TCGA-E1-5307-01A-01D-1891_130919_SN590_0238_AC29TRACXX_s_4_rg.sorted.filtered.	WGS	TCGA-E1-5307-01A-01D-1891_130919_SN590_0238_AC29TRACXX_s_4_rg.sorted	TCGA-E1-5307-01A-01D-1891_130919_SN590_0238_AC29TRACXX_s_4_rg.sorted.bam	138.7	1.9	0.14	58cfa831e4b0c9d6adf6cb2a	TCGA-E1-5307-01A-01D-1891_130919_SN590_0238_AC29TRACXX_s_4_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-E1-5307-01A	A6EE311C-0A7B-4F47-86F1-F2164B128F9C	Primary Tumor	Illumina HiSeq	80d2e037-eb0e-4514-bdd4-caa1fc77176d	Brain	62.0	DED0F767-9CEE-4F1D-8E91-CB242D30B57E	A95622B9-01E0-4625-AAB8-2193C2594976	TCGA-E1-5307-01A-01D-1891-02	HG19_Broad_variant	TCGA-E1-5307	TCGA-LGG	1762.0	s8363	Harvard Medical School	Duke	United States	NO			Astrocytoma		1891-02	True	LGG	C5	GBM_LGG.G-CIMP-high	0.059853038	0.81	0.28		-1.8169	-0.467	-0.1175	-3.0216	-1.1379	-1.2792	41.0	91.0	0.42940717799999994	1.689001565	108.0	0.278298962	6.0	26.0					0.0		3.263178632	-77.02995459	-433.48720489999994	-2991.460982	1.0	1762.0	1.0	1452.0	7.562161631225651	7.400391473547916	-0.02851326605573079	5.210786374062174	5.608632004319862	1.0740237650391977	-2.3513752571634776	-1.7917594692280554	1.1025370310949287
13722.58cfa831e4b0c9d6adf6cb2c	58cfa831e4b0c9d6adf6cb2c	TCGA-ED-A4XI-01A-11D-A25V-10_wgs_Illumina.filtered.	WGS	TCGA-ED-A4XI-01A-11D-A25V-10_wgs_Illumina	TCGA-ED-A4XI-01A-11D-A25V-10_wgs_Illumina.bam	23.36		0.08	58cfa831e4b0c9d6adf6cb2c	TCGA-ED-A4XI-01A-11D-A25V-10_wgs_Illumina.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-ED-A4XI-01A	C52ABAC9-07DA-4B3D-BF8A-2161CACF9682	Primary Tumor	Illumina HiSeq	a2c23e6e-f1ad-454f-999a-c07f31a63536	Liver	58.0	25EB5AFD-E7A6-4F3C-82B4-A3DE1F8F9BE1	670F971F-A525-4EF8-91BA-610CFBAEB914	TCGA-ED-A4XI-01A-11D-A25V-10	GRCh37-lite	TCGA-ED-A4XI	TCGA-LIHC		s16589	Baylor College of Medicine	Asterand	Vietnam	NO	T2	N0	Hepatocellular Carcinoma	Stage II	A25V-10	True	LIHC	C4	LIHC.iCluster:1	0.296471049	0.7	0.04		-1.4772	-0.3505	0.2666	0.3763	0.9998	-0.1215	91.0	12.0	0.724212231	3.486947778	81.0	0.103810866	1.0	12.0				2.205598359	10.0	0.957879197	0.866217867	-868.9133582999999	-621.057451	4098.1423509999995	0.0	819.0	0.0	819.0	6.736119284813858	3.9261577127495206	0.5432290478206501	5.15566890925301	4.579080091998957		-1.5804503755608483	0.6529223792494365	
13722.58cfa831e4b0c9d6adf6cb30	58cfa831e4b0c9d6adf6cb30	TCGA-EA-A3HQ-01A-11D-A20X_140131_SN590_0247_AC3FDBACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EA-A3HQ-01A-11D-A20X_140131_SN590_0247_AC3FDBACXX_s_3_rg.sorted	TCGA-EA-A3HQ-01A-11D-A20X_140131_SN590_0247_AC3FDBACXX_s_3_rg.sorted.bam	14.36		0.15	58cfa831e4b0c9d6adf6cb30	TCGA-EA-A3HQ-01A-11D-A20X_140131_SN590_0247_AC3FDBACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EA-A3HQ-01A	6BF00B63-89F8-420C-8D36-F680FB0908B1	Primary Tumor	Illumina HiSeq	33c80031-f923-4aa0-adfa-9e229f413f83	Cervix	60.0	E4B391D9-2F3E-474C-AFA0-FDF4FD11FDF9	0032959A-5D7B-4D74-927E-25F79EF25D49	TCGA-EA-A3HQ-01A-11D-A20X-26	HG19_Broad_variant	TCGA-EA-A3HQ	TCGA-CESC		s1180	MD Anderson - Institute for Applied Cancer Science	Asterand	Russia	NO	T2a	N0	Cervical Squamous Cell Carcinoma		A20X-26	True	CESC	C2		0.139287209	0.21	0.03	25.11239723	1.2574	0.3595	0.4707	0.2819	0.3018	0.0132	43.0	198.0	0.699353181	1.7483829530000001	122.0	0.918013052	8.0	13.0	0.6964218459999999	2.086293401	20.0	3.535983082	35.0	0.994553282	1.5329800709999999	-304.02066210000004	752.6072124	-1829.213188	0.0	1136.0	0.0	1136.0	8.437572616854203	7.869369856819956	0.6164072205112308	6.3581310751743665	7.409837527441516	1.3125740309448959	-2.079441541679836	-0.4595323293784399	0.6961668104336651
13722.58cfa831e4b0c9d6adf6cb58	58cfa831e4b0c9d6adf6cb58	TCGA-EB-A299-01A-21D-A18Y_120730_SN208_0420_BC12YJACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EB-A299-01A-21D-A18Y_120730_SN208_0420_BC12YJACXX_s_5_rg.sorted	TCGA-EB-A299-01A-21D-A18Y_120730_SN208_0420_BC12YJACXX_s_5_rg.sorted.bam	56.25		0.15	58cfa831e4b0c9d6adf6cb58	TCGA-EB-A299-01A-21D-A18Y_120730_SN208_0420_BC12YJACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EB-A299-01A	90402C32-9548-432E-85B8-A4F80E14401E	Primary Tumor	Illumina HiSeq	8780c547-110c-4e3a-88fa-1feeb9a57ad0	Skin	63.0	5678AE8F-382C-4167-839E-A160CE6710C7	C164DE0A-E762-48BE-B940-9E5EA31AD026	TCGA-EB-A299-01A-21D-A18Y-02	HG19_Broad_variant	TCGA-EB-A299	TCGA-SKCM		s7844	Harvard Medical School	Asterand	Russia	NO	T2b	N0		Stage IIA	A18Y-02	True	SKCM	C1	SKCM.BRAF_Hotspot_Mutants	0.22905712399999997	0.3	0.19	9.594718504	-0.2637	0.005	-0.0405	-0.142	0.1924	0.4731	48.0	3.0	2.2426781780000002	3.6251510280000003			8.0	6.0				2.025326221	8.0	0.973976032	6.110696589	-737.0540384999999	-159.9947999	-1599.944592	0.0	378.0	0.0	378.0	7.199595361582581	1.7719131728561255	0.8378860262048571	5.841471877429388	7.410429589056378	2.213545760335136	-1.358123484153194	5.638516416200252	1.3756597341302788
13722.58cfa831e4b0c9d6adf6cb5e	58cfa831e4b0c9d6adf6cb5e	TCGA-DU-7018-01A-11D-2022_130910_SN208_0495_BD2FGNACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DU-7018-01A-11D-2022_130910_SN208_0495_BD2FGNACXX_s_5_rg.sorted	TCGA-DU-7018-01A-11D-2022_130910_SN208_0495_BD2FGNACXX_s_5_rg.sorted.bam	193.7		0.15	58cfa831e4b0c9d6adf6cb5e	TCGA-DU-7018-01A-11D-2022_130910_SN208_0495_BD2FGNACXX_s_5_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-7018-01A	F18DAB99-26B0-4727-89A9-7F16BD382356	Primary Tumor	Illumina HiSeq	2736e751-ccc3-4721-b516-238f987ad26f	Brain	57.0	FE98F78B-2C80-4999-B430-E1D95A53F356	02FCFCBB-05D7-4671-BDDF-DED65316FCC6	TCGA-DU-7018-01A-11D-2022-02	HG19_Broad_variant	TCGA-DU-7018	TCGA-LGG	933.0	s8567	Harvard Medical School	Henry Ford Hospital	United States	NO			Oligodendroglioma		2022-02	True	LGG	C5	GBM_LGG.Codel	0.025080432000000003	0.13	0.09		-0.5027	-0.2045	-1.3792	-3.1135	-1.1049	-1.1021	15.0	70.0	0.269652467	0.958764325	49.0	0.237836562	6.0	5.0					0.0		3.1727818830000003	103.416517	285.0978766	-3588.1453109999998	1.0	933.0	1.0	338.0	7.564929799083264	7.412361602934212	-0.020748529065692023	5.7191031085849335	6.37090772810605	1.8158516942775358	-1.8458266904983305	-1.0414538748281612	1.8366002233432277
13722.58cfa831e4b0c9d6adf6cb9a	58cfa831e4b0c9d6adf6cb9a	TCGA-EJ-7317-01A-31D-2111_130422_SN590_0225_BD23TLACXX_s_6_rg.sorted.filtered.	WGS	TCGA-EJ-7317-01A-31D-2111_130422_SN590_0225_BD23TLACXX_s_6_rg.sorted	TCGA-EJ-7317-01A-31D-2111_130422_SN590_0225_BD23TLACXX_s_6_rg.sorted.bam	61.4		0.16	58cfa831e4b0c9d6adf6cb9a	TCGA-EJ-7317-01A-31D-2111_130422_SN590_0225_BD23TLACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-7317-01A	68FC3693-0910-4EE8-8997-99C6333B65F4	Primary Tumor	Illumina HiSeq	7c1cef2b-4606-4c6c-ad6d-b49ca86b9f74	Prostate	71.0	AEEA2F28-0766-42D7-9E6A-C14BEB03E692	B25F2F78-DB49-49DF-9150-DF43F23589A4	TCGA-EJ-7317-01A-31D-2111-02	HG19_Broad_variant	TCGA-EJ-7317	TCGA-PRAD		s3959	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		2111-02	True	PRAD	C3	PRAD.8-other	0.032598887	0.33	0.04	0.7451771340000001	-1.5248	-0.1925	-1.3692	-1.567	-1.4680000000000002	-0.4862	20.0	26.0	0.454718068	0.788177985	67.0	0.028061004	0.0	2.0				1.153741943	4.0	0.83224889	1.916192374	19.81997029	-1013.791275	2409.579198	0.0	771.0	0.0	771.0	9.251434329511143	8.882199486908862	0.02684725003618804	6.809087294141939	8.451416570816408	3.401799609924861	-2.4423470353692043	-0.4307829160924541	3.374952359888673
13722.58cfa831e4b0c9d6adf6cb9e	58cfa831e4b0c9d6adf6cb9e	TCGA-EJ-7328-01A-31D-2111_130502_SN590_0228_AD24A9ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EJ-7328-01A-31D-2111_130502_SN590_0228_AD24A9ACXX_s_2_rg.sorted	TCGA-EJ-7328-01A-31D-2111_130502_SN590_0228_AD24A9ACXX_s_2_rg.sorted.bam	282.3		0.16	58cfa831e4b0c9d6adf6cb9e	TCGA-EJ-7328-01A-31D-2111_130502_SN590_0228_AD24A9ACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-7328-01A	42B7D14F-09E5-4D91-BB98-5FE35907A6A9	Primary Tumor	Illumina HiSeq	09a1120f-21a6-48c2-a9e8-3b229a16fc7f	Prostate	70.0	4539A7C3-CCA2-4ED0-9310-92CD843AA1CD	C4D292D4-D001-4704-94C9-CC1674F6F16E	TCGA-EJ-7328-01A-31D-2111-02	HG19_Broad_variant	TCGA-EJ-7328	TCGA-PRAD		s3960	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		2111-02	True	PRAD	C3	PRAD.1-ERG	0.12613996800000002	0.58	0.03	12.76839691	-1.6497	-0.1475	0.111	0.8522	-0.4615	-0.0085	5.0	0.0	0.365888641	0.670795842	76.0	0.036216392	0.0	11.0	0.5933092320000001	0.41125062100000004	2.0	3.476845417	35.0	0.977919843	2.002175269	-153.133382	-815.7154632999999	2550.324732	0.0	842.0	0.0	842.0	6.833031732786201	6.7072115595851685	-0.12133039659518186	4.635807155449982	5.819908364584266	5.745137660338115	-2.197224577336219	-0.8873031950009029	5.8664680569332965
13722.58cfa831e4b0c9d6adf6cba0	58cfa831e4b0c9d6adf6cba0	TCGA-EJ-5519-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EJ-5519-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_1_rg.sorted	TCGA-EJ-5519-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_1_rg.sorted.bam	233.7	1.9	0.15	58cfa831e4b0c9d6adf6cba0	TCGA-EJ-5519-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5519-01A	5313A055-C2D7-4CBD-A8C1-57AC85912D89	Primary Tumor	Illumina HiSeq	75f448c7-b10b-4c15-ae49-4eb217c65391	Prostate	64.0	EEE1828E-D25F-462B-9735-89CA2ECCC7E1	4C2E88A3-B668-40A8-B625-B6D7A48DEAF5	TCGA-EJ-5519-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5519	TCGA-PRAD		s3949	Harvard Medical School	University of Pittsburgh	United States	NO	T3b	N1	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.2-ETV1	0.079204774	0.33	0.01	0.270305783	-0.9562	-0.2205	-0.8219	-1.053	-1.1478	-0.3184	34.0	55.0	0.801726415	1.861150606	196.0	0.128903716	3.0	26.0		0.0	1.0	1.386294361	4.0	1.0	2.472351448	-1163.362607	-831.1863141	3001.454728	0.0	1962.0	0.0	1962.0	8.025058466093737	10.031294257023784	-1.0789153039020858	6.5899739408044145	8.989840382195624	2.1045405757348545	-1.4350845252893227	-1.0414538748281612	3.1834558796369405
13722.58cfa831e4b0c9d6adf6cba4	58cfa831e4b0c9d6adf6cba4	TCGA-EJ-5521-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EJ-5521-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_3_rg.sorted	TCGA-EJ-5521-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_3_rg.sorted.bam	72.7	1.9	0.14	58cfa831e4b0c9d6adf6cba4	TCGA-EJ-5521-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5521-01A	D44D4BCB-BEB1-4464-ACD2-9972751F5018	Primary Tumor	Illumina HiSeq	c9a43591-8317-4ff5-a2e9-33c98c6a6012	Prostate	63.0	9EEBD2EC-AF9D-493C-A006-A436C28D4CD3	83248990-416D-48F0-B6F4-59C4C7CEEBD8	TCGA-EJ-5521-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5521	TCGA-PRAD		s4134	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.1-ERG	0.071792782	0.57	0.17	1.14397625	-1.2391	-0.028999999999999998	-0.7426	-0.0994	-0.7645	-0.2048	29.0	36.0	0.514925384	1.029850768	145.0	0.14220545699999998	0.0	12.0		0.0	1.0	1.549826046	5.0	0.962961065	2.513575969	-602.1462769999999	-336.12784389999996	3509.871774	0.0	2279.0	0.0	2279.0	8.45538870716912	7.599545607230792	-0.3304005725526631	6.120013791352084	8.843869707080295	3.513848330582661	-2.3353749158170363	1.2443240998495035	3.844248903135324
13722.58cfa831e4b0c9d6adf6cba5	58cfa831e4b0c9d6adf6cba5	TCGA-EJ-7331-01A-11D-2111_130502_SN590_0228_AD24A9ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-EJ-7331-01A-11D-2111_130502_SN590_0228_AD24A9ACXX_s_4_rg.sorted	TCGA-EJ-7331-01A-11D-2111_130502_SN590_0228_AD24A9ACXX_s_4_rg.sorted.bam	214.3		0.15	58cfa831e4b0c9d6adf6cba5	TCGA-EJ-7331-01A-11D-2111_130502_SN590_0228_AD24A9ACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-7331-01A	B424B73A-2DFA-473F-AB56-AB382CD1CDEF	Primary Tumor	Illumina HiSeq	a85ad241-998c-4d85-a63b-903ddeb62201	Prostate	64.0	5AA2E382-C8DF-44E3-8802-994188B11D55	F2DA114D-161B-46CD-BAA7-46E63DBC5D5C	TCGA-EJ-7331-01A-11D-2111-02	HG19_Broad_variant	TCGA-EJ-7331	TCGA-PRAD		s4139	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		2111-02	True	PRAD	C3	PRAD.8-other	0.17008341300000002	0.52	0.01	1.5963949030000002	-1.3922	-0.271	-0.3129	-0.1833	-0.1952	-0.0722	10.0	0.0	0.270575444	0.571214825	79.0	0.032189905	0.0	9.0	0.985526053	0.683114605	2.0	2.9785084210000004	20.0	0.994250537	2.054988139	25.06714507	-678.1955307999999	1844.984927	0.0	742.0	0.0	742.0	8.585038738311306	8.896884547157427	-0.4570480629367074	7.058982434816256	8.386058923391436	2.909247766966433	-1.5260563034950494	-0.5108256237659905	3.3662958299031405
13722.58cfa831e4b0c9d6adf6cba6	58cfa831e4b0c9d6adf6cba6	TCGA-EJ-7784-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EJ-7784-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_2_rg.sorted	TCGA-EJ-7784-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_2_rg.sorted.bam	456.3		0.15	58cfa831e4b0c9d6adf6cba6	TCGA-EJ-7784-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-7784-01A	4BC71292-60BB-4B63-86C1-0FE021083804	Primary Tumor	Illumina HiSeq	a2c5ffab-f279-44fb-a025-079de410f1c4	Prostate	63.0	0D3EC78C-3DA8-443F-BAA6-93CAED5B065C	2B122D7B-B5CE-44CE-B1EA-7E39E42B2A63	TCGA-EJ-7784-01A-11D-2111-02	HG19_Broad_variant	TCGA-EJ-7784	TCGA-PRAD		s3958	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		2111-02	True	PRAD	C3	PRAD.1-ERG	0.04247675	0.31	0.47	0.9849383840000001	-0.9267	-0.2885	-0.8982	-0.7776	-0.9647	-0.4955	16.0	17.0	0.208245598	1.011478616	72.0	0.314794893	6.0	18.0				2.8674404989999998	19.0	0.973849524	2.425482084	-933.9902596000001	-93.40990476	3141.82531	0.0	781.0	0.0	781.0	6.466144724237619	6.2766434893416445	-0.3090917509393297	4.163559631243574	5.5228716869652645	2.4052790129654698	-2.3025850929940455	-0.7537718023763804	2.7143707639047996
13722.58cfa831e4b0c9d6adf6cba8	58cfa831e4b0c9d6adf6cba8	TCGA-EJ-5525-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EJ-5525-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_1_rg.sorted	TCGA-EJ-5525-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_1_rg.sorted.bam	333.7	1.9	0.15	58cfa831e4b0c9d6adf6cba8	TCGA-EJ-5525-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5525-01A	554A7381-46FD-4301-B91B-5AF7F173C350	Primary Tumor	Illumina HiSeq	10ab041f-88f9-463c-873d-508073d1672b	Prostate	67.0	351AF15C-B213-4621-8BCB-3F4DDCF72553	333DDE15-F4B2-4301-A6AC-59C7F4CD6639	TCGA-EJ-5525-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5525	TCGA-PRAD		s3602	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C1	PRAD.1-ERG	0.052415502	0.13	0.0	2.6414762080000003	-0.3371	-0.0705	-0.6701	-0.8669	-1.6467	0.1264	36.0	6.0	0.358973999	1.4082826130000001	169.0	0.217216678	4.0	23.0		0.0	1.0	1.386294361	4.0	1.0	1.412344725	-344.31931660000004	459.386268	1705.325664	0.0	1115.0	1.0	546.0	8.986071187374463	9.642459213504567	-0.19677597353411458	6.683486094380417	9.149982728406773	2.508634210948955	-2.302585092994046	-0.49247648509779385	2.7054101844830694
13722.58cfa831e4b0c9d6adf6cbaa	58cfa831e4b0c9d6adf6cbaa	TCGA-EJ-5526-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EJ-5526-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_3_rg.sorted	TCGA-EJ-5526-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_3_rg.sorted.bam	378.7	1.9	0.15	58cfa831e4b0c9d6adf6cbaa	TCGA-EJ-5526-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5526-01A	EEC48399-5660-4B25-8D34-191B54315C72	Primary Tumor	Illumina HiSeq	e57f50b5-06be-4be0-8b02-706bfb439f25	Prostate	56.0	4DBE4FA2-308F-4D5B-BF33-4C051F7DC537	4AC5F198-9558-42C9-8285-91D3F826E0E9	TCGA-EJ-5526-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5526	TCGA-PRAD		s4143	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N1	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.1-ERG	0.052766369	0.46	0.07	2.215161144	-0.922	-0.2415	-0.2937	-0.2806	0.0862	-0.1179	11.0	3.0	0.222168815	0.694277548	123.0	0.12077979	4.0	10.0	0.90675411	1.25702811	4.0	2.685945325	15.0	0.991837346	1.8605248230000002	30.57802568	-175.59105459999998	2686.449298	0.0	1909.0	1.0	537.0	7.738270233834887	8.57347900242683	-0.3626904445498117	5.486978435228393	7.532025127598668	3.342144949880455	-2.251291798606495	-1.0414538748281612	3.7048353944302668
13722.58cfa831e4b0c9d6adf6cbaf	58cfa831e4b0c9d6adf6cbaf	TCGA-EK-A3GN-01A-11D-A20X_140417_SN590_0248_AC3EUFACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EK-A3GN-01A-11D-A20X_140417_SN590_0248_AC3EUFACXX_s_2_rg.sorted	TCGA-EK-A3GN-01A-11D-A20X_140417_SN590_0248_AC3EUFACXX_s_2_rg.sorted.bam	50.85		0.14	58cfa831e4b0c9d6adf6cbaf	TCGA-EK-A3GN-01A-11D-A20X_140417_SN590_0248_AC3EUFACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EK-A3GN-01A	F727FCB9-E457-4643-9468-F739133B7E9C	Primary Tumor	Illumina HiSeq	b9e845ee-3e61-4ccf-b14e-f8a6b8481bd3	Cervix	47.0	EB5034E2-D4A7-48E0-9524-31DDD63C9D94	49F2E671-D283-4B5C-B8A3-490C0A383FC1	TCGA-EK-A3GN-01A-11D-A20X-26	HG19_Broad_variant	TCGA-EK-A3GN	TCGA-CESC		s1364	MD Anderson - Institute for Applied Cancer Science	Gynecologic Oncology Group	United States	NO	TX	NX	Cervical Squamous Cell Carcinoma		A20X-26	True	CESC	C2		0.190928388	0.3	0.06		1.306	0.48700000000000004	-1.36	-1.3817	0.0956	-0.3595	16.0	0.0	0.745973225	0.9790898579999999	194.0	0.433984692	6.0	27.0					0.0		2.322191728	-924.5042377999998	966.9863718	-110.98567820000001	0.0	27.0	0.0	27.0	7.434257382133135	3.7080784181088084	-0.6294698269726731	5.18296558352664	6.955433714298878	1.60636571339713	-2.251291798606495	3.2473552961900696	2.2358355403698034
13722.58cfa831e4b0c9d6adf6cbb4	58cfa831e4b0c9d6adf6cbb4	TCGA-EK-A2RN-01A-12D-A20X_140117_SN590_0246_BC37BDACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EK-A2RN-01A-12D-A20X_140117_SN590_0246_BC37BDACXX_s_2_rg.sorted	TCGA-EK-A2RN-01A-12D-A20X_140117_SN590_0246_BC37BDACXX_s_2_rg.sorted.bam	17.97		0.17	58cfa831e4b0c9d6adf6cbb4	TCGA-EK-A2RN-01A-12D-A20X_140117_SN590_0246_BC37BDACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE		Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EK-A2RN-01A	B610D391-0C9D-4114-94D6-5E4AA4270122	Primary Tumor	Illumina HiSeq	def278f8-93eb-4373-a525-98b2cf12af7a	Cervix	45.0	24BACABF-8C6F-416A-B1F3-B0BAAA2F0AD9	3B5905A9-4B73-4946-A10B-D3E7ECAFFC7C	TCGA-EK-A2RN-01A-12D-A20X-26	HG19_Broad_variant	TCGA-EK-A2RN	TCGA-CESC		s1368	MD Anderson - Institute for Applied Cancer Science	Gynecologic Oncology Group	United States	NO	T2b	N1	Cervical Squamous Cell Carcinoma		A20X-26	True	CESC	C4		0.24159294899999997	0.37	0.1		0.5976	0.1345	0.3396	-0.2612	1.5943	-0.4571	54.0	5.0	1.01195793	2.8711364539999997	110.0	0.6175066920000001	18.0	3.0		0.0	1.0	0.673011667	2.0	0.9709505940000001	1.313668425	-1129.4675220000001	-599.9313857000001	-662.7178044	0.0	71.0	0.0	71.0	8.692238339239415	7.504501685255728	1.5500711796989233	6.38965324624537	6.916715020353609	1.3403506487168542	-2.3025850929940455	-0.5877866649021186	-0.2097205309820691
13722.58cfa831e4b0c9d6adf6cbb5	58cfa831e4b0c9d6adf6cbb5	TCGA-EJ-5507-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EJ-5507-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_7_rg.sorted	TCGA-EJ-5507-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_7_rg.sorted.bam	347.7	1.9	0.15	58cfa831e4b0c9d6adf6cbb5	TCGA-EJ-5507-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5507-01A	607200F5-DF80-4F5D-90FB-FDC455A7415B	Primary Tumor	Illumina HiSeq	0dbb7308-269c-4ad8-97c7-e7475ae08189	Prostate	54.0	F93327F7-0290-4915-97BB-E31BAE2697DD	D2336094-05BD-4E89-84A3-91D641DC31D0	TCGA-EJ-5507-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5507	TCGA-PRAD		s3787	Harvard Medical School	University of Pittsburgh	United States	NO	T3b	N1	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.1-ERG	0.132410587	0.32	0.15	2.471370208	-0.726	-0.1275	-0.5241	-0.2534	-0.2676	-0.3256	10.0	4.0	0.196854878	0.787419511	136.0	0.7185911220000001	3.0	16.0				2.6156305769999997	14.0	0.99112306	2.7375434989999996	-808.5682867	-679.1473357000001	1956.643922	0.0	1457.0	0.0	1457.0	9.640335477827625	8.604221234933647	-0.14554632459133998	7.075386120366089	8.006384234178027	1.7861961725427267	-2.5649493574615367	-0.5978370007556202	1.9317424971340666
13722.58cfa831e4b0c9d6adf6cbbe	58cfa831e4b0c9d6adf6cbbe	TCGA-EK-A3GM-01A-11D-A20X_140131_SN590_0247_AC3FDBACXX_s_4_rg.sorted.filtered.	WGS	TCGA-EK-A3GM-01A-11D-A20X_140131_SN590_0247_AC3FDBACXX_s_4_rg.sorted	TCGA-EK-A3GM-01A-11D-A20X_140131_SN590_0247_AC3FDBACXX_s_4_rg.sorted.bam	59.88		0.15	58cfa831e4b0c9d6adf6cbbe	TCGA-EK-A3GM-01A-11D-A20X_140131_SN590_0247_AC3FDBACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EK-A3GM-01A	CB780C10-8810-4384-B829-954AAB1C16C8	Primary Tumor	Illumina HiSeq	2ec77e09-5fb7-4247-9027-1db441eab2b8	Cervix	65.0	A4B92B76-FF87-475E-924B-840F652FC019	4981CFD4-2A8C-4CF8-8AC2-31BDF9DC02CD	TCGA-EK-A3GM-01A-11D-A20X-26	HG19_Broad_variant	TCGA-EK-A3GM	TCGA-CESC		s1186	MD Anderson - Institute for Applied Cancer Science	Gynecologic Oncology Group	United States	NO			Endocervical Type of Adenocarcinoma		A20X-26	True	CESC	C4		0.096427082	0.21	0.22		0.6278	0.05	-1.2983	-0.9522	0.8648	-0.5473	74.0	28.0	1.289133864	3.460306686	139.0	0.607835283	17.0	21.0				1.098612289	3.0	1.0		-506.5579166	335.13794900000005	755.4989853	0.0	0.0	0.0	0.0	9.050992878742049	7.880552360296598	-0.46926744579764723	6.699617621578572	6.899723107284872	1.5864356512164548	-2.3513752571634776	-0.9808292530117262	2.055703097014102
13722.58cfa831e4b0c9d6adf6cbc7	58cfa831e4b0c9d6adf6cbc7	TCGA-EJ-7327-01A-11D-2111_130422_SN590_0225_BD23TLACXX_s_8_rg.sorted.filtered.	WGS	TCGA-EJ-7327-01A-11D-2111_130422_SN590_0225_BD23TLACXX_s_8_rg.sorted	TCGA-EJ-7327-01A-11D-2111_130422_SN590_0225_BD23TLACXX_s_8_rg.sorted.bam	261.3		0.14	58cfa831e4b0c9d6adf6cbc7	TCGA-EJ-7327-01A-11D-2111_130422_SN590_0225_BD23TLACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-7327-01A	E90AB72A-4BBB-4C37-B48A-8A1A85D79D04	Primary Tumor	Illumina HiSeq	fe462cbb-5d52-4a0e-8cb8-a7e6c0f39c7c	Prostate	61.0	992415EF-53DE-4C52-A538-07931E68182B	0FC53595-F61A-4171-B982-335AEE13CC85	TCGA-EJ-7327-01A-11D-2111-02	HG19_Broad_variant	TCGA-EJ-7327	TCGA-PRAD		s4145	Harvard Medical School	University of Pittsburgh	United States	NO	T3b	N0	Prostate Adenocarcinoma Acinar Type		2111-02	True	PRAD	C3	PRAD.1-ERG	0.057106749000000005	0.52	0.01	0.690223211	-0.8271	-0.265	-0.4586	-0.7406	-0.4309	0.0304	10.0	53.0	0.18460396199999998	0.6461138670000001	132.0	0.019148994	0.0	3.0				2.954673212	20.0	0.986294149	1.807590918	-478.3076217	-252.6175392	3792.1878560000005	0.0	923.0	0.0	923.0	8.365020553972608	8.71185011844182	-0.41060386556226525	6.929936028683285	8.600624483331595	2.6843759377427334	-1.4350845252893227	-0.1112256351102241	3.094979803304999
13722.58cfa831e4b0c9d6adf6cbc9	58cfa831e4b0c9d6adf6cbc9	TCGA-EJ-5514-01A-01D-1572_130131_SN1120_0234_AD1PVUACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EJ-5514-01A-01D-1572_130131_SN1120_0234_AD1PVUACXX_s_7_rg.sorted	TCGA-EJ-5514-01A-01D-1572_130131_SN1120_0234_AD1PVUACXX_s_7_rg.sorted.bam	271.7	1.9	0.15	58cfa831e4b0c9d6adf6cbc9	TCGA-EJ-5514-01A-01D-1572_130131_SN1120_0234_AD1PVUACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5514-01A	F82D53B1-3DF8-4249-A615-464C9F4E0A32	Primary Tumor	Illumina HiSeq	581bee6a-6abe-4b55-8dc4-63bb242df1cf	Prostate	66.0	29AD80A4-B429-495C-885E-A92CFE2E4501	6F8F8AAC-C0DE-46F6-A7CF-502893CC57CB	TCGA-EJ-5514-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5514	TCGA-PRAD		s3439	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.8-other	0.16846333600000002	0.4	0.22	1.787107426	-0.4087	-0.0875	-0.027000000000000003	-0.2099	-0.0845	-0.0869	16.0	92.0	0.30778073300000003	0.727481733	152.0	0.386021745	4.0	19.0	0.9125910490000001	3.040940009	28.0	2.7516666169999997	16.0	0.9924539459999999	2.303251738	-632.1239244	-200.14603390000002	1710.9561429999999	0.0	1829.0	0.0	1829.0	9.749665985212074	8.514821149578864	0.0829137609476942	7.398290728048597	8.189398749144235	6.359766083954084	-2.3513752571634776	-0.3254224004346278	6.27685232300639
13722.58cfa831e4b0c9d6adf6cbca	58cfa831e4b0c9d6adf6cbca	TCGA-EJ-5517-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EJ-5517-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_5_rg.sorted	TCGA-EJ-5517-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_5_rg.sorted.bam	52.7	1.9	0.15	58cfa831e4b0c9d6adf6cbca	TCGA-EJ-5517-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5517-01A	4B9AA301-D2E3-47F3-B724-A34F420B2B6B	Primary Tumor	Illumina HiSeq	add98c6f-07de-48db-b930-82504d0dd976	Prostate	55.0	B5FE6254-D1C6-4BA2-BD75-5CAF4FB2E2B7	62E5A068-01A5-40EC-8FF9-097D627127A0	TCGA-EJ-5517-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5517	TCGA-PRAD		s3437	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.8-other	0.17162207100000001	0.29	0.04	2.409458246	-1.829	-0.1385	-0.5048	0.2147	-0.4477	-0.3289	11.0	31.0	0.194560462	0.44470962700000005	97.0	0.070840819	0.0	7.0				2.995732274	20.0	1.0	2.0211486080000003	-191.7221446	-841.1856075999999	1010.473146	0.0	1889.0	0.0	1889.0	7.957352378164517	9.255393403024254	-0.2975086332695164	5.760127800828298	8.213939528196093	1.8773173575897015	-2.197224577336219	-1.0414538748281612	2.174825990859218
13722.58cfa831e4b0c9d6adf6cbd0	58cfa831e4b0c9d6adf6cbd0	TCGA-EJ-7125-01A-11D-1957_130221_SN1120_0239_BD1V59ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EJ-7125-01A-11D-1957_130221_SN1120_0239_BD1V59ACXX_s_7_rg.sorted	TCGA-EJ-7125-01A-11D-1957_130221_SN1120_0239_BD1V59ACXX_s_7_rg.sorted.bam	118.7		0.15	58cfa831e4b0c9d6adf6cbd0	TCGA-EJ-7125-01A-11D-1957_130221_SN1120_0239_BD1V59ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-7125-01A	ACA312AB-6DBD-4183-8B22-8F37834F3426	Primary Tumor	Illumina HiSeq	c476525e-5147-4afb-bed0-f9ad34226240	Prostate	44.0	08E17DE6-FE0D-4FF0-B588-1CF1AB03F594	4BAD4379-B8AB-4D28-968E-5729602757EB	TCGA-EJ-7125-01A-11D-1957-02	HG19_Broad_variant	TCGA-EJ-7125	TCGA-PRAD		s3442	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1957-02	True	PRAD	C3	PRAD.7-IDH1	0.132705142	0.33	0.11		-1.0092	-0.1995	-0.633	-0.6302	-1.3121	-0.35700000000000004	14.0	1.0	0.11604481400000001	0.522201665	61.0	0.053393826	0.0	1.0		0.0	1.0	2.25385759	10.0	0.9788379140000001	1.30690506	-197.38180269999998	-758.2808711	2837.1437539999997	0.0	2850.0	0.0	2850.0	9.251434329511143	8.39646519862729	-0.014607810419075662	6.853539056712773	7.801758090880597	2.8503542319517203	-2.3978952727983707	-0.594707107746693	2.864962042370796
13722.58cfa831e4b0c9d6adf6cbd9	58cfa831e4b0c9d6adf6cbd9	TCGA-EJ-5515-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EJ-5515-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_1_rg.sorted	TCGA-EJ-5515-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_1_rg.sorted.bam	150.7	1.9	0.14	58cfa831e4b0c9d6adf6cbd9	TCGA-EJ-5515-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5515-01A	19CF56B2-A85B-43E7-971F-5680B9B1A67A	Primary Tumor	Illumina HiSeq	25dbfef2-277f-4974-a326-2747d9494a2d	Prostate	60.0	5FBA6E4A-3D7D-478E-AFA6-E66C816E7852	C124D41D-EBD2-4DAE-A344-8518DB3354A4	TCGA-EJ-5515-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5515	TCGA-PRAD		s4132	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.8-other	0.079642909			2.8058051139999995	-1.5905	-0.207	-0.9643	-0.8308	-0.7162	-0.4065	6.0		0.029456499	0.23565199	47.0	3.229999999999999e-05						0.693147181	2.0	1.0	2.001967213	73.98703187	-178.2003437	2767.504588	0.0	1832.0	0.0	1832.0	8.997827613017998	8.674476621391198	-0.21232288667349308	6.646452355854521	8.182000136293404	5.144807506992628	-2.3513752571634776	-0.49247648509779385	5.357130393666121
13722.58cfa831e4b0c9d6adf6cbdd	58cfa831e4b0c9d6adf6cbdd	TCGA-EJ-5532-01A-01D-1572_130221_SN1120_0239_BD1V59ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EJ-5532-01A-01D-1572_130221_SN1120_0239_BD1V59ACXX_s_3_rg.sorted	TCGA-EJ-5532-01A-01D-1572_130221_SN1120_0239_BD1V59ACXX_s_3_rg.sorted.bam	188.7	1.9	0.15	58cfa831e4b0c9d6adf6cbdd	TCGA-EJ-5532-01A-01D-1572_130221_SN1120_0239_BD1V59ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5532-01A	AE3A0C92-148D-4F1C-8563-06AC1050F53E	Primary Tumor	Illumina HiSeq	e7c833a1-c77a-4c65-b268-1db73a7028e3	Prostate	57.0	F32F7738-BAD4-40C9-B49F-084BB098A05A	E5F35020-2A9F-47B3-8271-FEF8E1883567	TCGA-EJ-5532-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5532	TCGA-PRAD		s3956	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.8-other	0.087078375	0.32	0.02	1.8569326430000002	-1.1804	-0.1525	-0.8311	-0.8302	-0.5998	-0.3098	8.0	5.0	0.230299511	0.518173899	67.0	0.072221395	3.0	4.0				2.2718685130000003	10.0	0.986659959	2.07357042	-762.2791591	-762.7916008999999	1286.868718	0.0	1828.0	0.0	1828.0	9.384209641955154	9.413617893984348	-0.5773788039614582	6.819260284493618	8.548620456497744		-2.5649493574615367	-0.8649974374866045	
13722.58cfa831e4b0c9d6adf6cbe9	58cfa831e4b0c9d6adf6cbe9	TCGA-ED-A459-01A-11D-A25V-10_wgs_Illumina.filtered.	WGS	TCGA-ED-A459-01A-11D-A25V-10_wgs_Illumina	TCGA-ED-A459-01A-11D-A25V-10_wgs_Illumina.bam	19.74		0.08	58cfa831e4b0c9d6adf6cbe9	TCGA-ED-A459-01A-11D-A25V-10_wgs_Illumina.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-ED-A459-01A	56403463-1727-4C23-A709-DE5F168C4073	Primary Tumor	Illumina HiSeq	eefae457-c645-4b48-b599-b479b7be4414	Liver	47.0	97FA4D8B-1C05-41A6-97C4-0B27DC70EB4C	7FC7B316-F3D3-4E71-9417-423FE334E6BC	TCGA-ED-A459-01A-11D-A25V-10	GRCh37-lite	TCGA-ED-A459	TCGA-LIHC		s16980	Baylor College of Medicine	Asterand	Vietnam	NO	T2	N0	Hepatocellular Carcinoma	Stage II	A25V-10	True	LIHC	C4	LIHC.iCluster:2	0.24970074399999997	0.48	0.34		0.0836	0.0135	-0.226	-1.5174	0.0296	-0.5139	126.0	179.0	1.759430663	5.630178122999999	348.0	0.882000088	14.0	42.0				0.693147181	2.0	1.0	1.4055170209999999	-1252.287683	47.62700118	3131.089389	0.0	910.0	0.0	910.0	6.726918333892373	2.0994215540357875	-0.6352414669572013	5.652403596803324	4.188850929615918	2.7157585108380404	-1.0745147370890495	2.0894293755801305	3.350999977795242
13722.58cfa831e4b0c9d6adf6cbeb	58cfa831e4b0c9d6adf6cbeb	TCGA-EM-A1CW-01A-21D-A13U_120706_SN1222_0122_AC0WPYACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EM-A1CW-01A-21D-A13U_120706_SN1222_0122_AC0WPYACXX_s_7_rg.sorted	TCGA-EM-A1CW-01A-21D-A13U_120706_SN1222_0122_AC0WPYACXX_s_7_rg.sorted.bam	29.55	2.05	0.18	58cfa831e4b0c9d6adf6cbeb	TCGA-EM-A1CW-01A-21D-A13U_120706_SN1222_0122_AC0WPYACXX_s_7_rg.sorted.bam	Alive	FEMALE			Thyroid Carcinoma	Aligned reads	TCGA-EM-A1CW-01A	22EB9F00-6869-4D8F-B657-DFD64F81E9E9	Primary Tumor	Illumina HiSeq	9c39283e-3646-4154-8265-d68a2f7de106	Thyroid	39.0	7045F3E1-5239-4159-9B38-31E4168853D0	2CC2002C-4F0A-47A6-AA0A-35FE1B545A7A	TCGA-EM-A1CW-01A-21D-A13U-02	HG19_Broad_variant	TCGA-EM-A1CW	TCGA-THCA		s12253	Harvard Medical School	University Health Network	Canada	NO	T3	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A13U-02	True	THCA	C3	THCA.1	0.246648058	0.46	0.0		-1.9180000000000001	-0.298	0.0082	0.9743	-0.1129	-0.5972	2.0	1.0	0.0	0.234975933	43.0	1.73e-05	0.0	0.0	0.8424980129999999	4.384365291	182.0	3.461048252	33.0	0.9898586490000001	1.313257257	-78.06519278	-1285.242509	2149.75864	0.0	549.0	0.0	549.0	6.227318642781372	8.769109907421274	0.4091058349462888	5.879011948513155	7.532347280272348	2.22108435122765	-0.3483066942682158	-1.2367626271489267	1.8119785162813613
13722.58cfa831e4b0c9d6adf6cbee	58cfa831e4b0c9d6adf6cbee	TCGA-EK-A2PM-01A-11D-A18I_140204_SN208_0508_BC2R1UACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EK-A2PM-01A-11D-A18I_140204_SN208_0508_BC2R1UACXX_s_2_rg.sorted	TCGA-EK-A2PM-01A-11D-A18I_140204_SN208_0508_BC2R1UACXX_s_2_rg.sorted.bam	43.27		0.16	58cfa831e4b0c9d6adf6cbee	TCGA-EK-A2PM-01A-11D-A18I_140204_SN208_0508_BC2R1UACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE		Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EK-A2PM-01A	085FB6D8-6265-484E-9307-8292386714B7	Primary Tumor	Illumina HiSeq	332b29bf-f948-4e2c-bf51-f768f819e9e9	Cervix	81.0	2E7F29FB-97DE-4EE0-BCA7-6A51C4C3E5CF	C32BE42D-CF78-4F46-B461-748796CEDA4A	TCGA-EK-A2PM-01A-11D-A18I-02	HG19_Broad_variant	TCGA-EK-A2PM	TCGA-CESC		s1195	Harvard Medical School	Gynecologic Oncology Group	United States	NO			Cervical Squamous Cell Carcinoma		A18I-02	True	CESC	C1		0.11683952800000001	0.3	0.17		1.064	0.377	-1.725	-2.0937	-1.9226	-0.3045	136.0	5.0	2.0964700119999997	5.828647397	273.0	0.866312077	19.0	52.0					0.0		2.549585568	-2266.76024	393.3367045	-2434.5391449999997	0.0	18.0	0.0	18.0	7.571473648851271	6.771744625051433	0.2890765783255139	5.3742490715150515	5.730290750223271	1.0748582026600024	-2.197224577336219	-1.0414538748281612	0.7857816243344886
13722.58cfa831e4b0c9d6adf6cbf1	58cfa831e4b0c9d6adf6cbf1	TCGA-EM-A3O3-01A-11D-A221_120611_SN1222_0115_BD141KACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EM-A3O3-01A-11D-A221_120611_SN1222_0115_BD141KACXX_s_5_rg.sorted	TCGA-EM-A3O3-01A-11D-A221_120611_SN1222_0115_BD141KACXX_s_5_rg.sorted.bam	48.3		0.16	58cfa831e4b0c9d6adf6cbf1	TCGA-EM-A3O3-01A-11D-A221_120611_SN1222_0115_BD141KACXX_s_5_rg.sorted.bam	Alive	FEMALE			Thyroid Carcinoma	Aligned reads	TCGA-EM-A3O3-01A	2A398AF1-AEA5-4AAE-AB00-A2DC152F965A	Primary Tumor	Illumina HiSeq	52b6fd69-3b74-441b-a40b-77c172dd0979	Thyroid	83.0	60C1BA59-C04E-4237-A8B9-FA0D894BBAFA	EEBDC565-A071-4356-8CBF-1560A8BB034D	TCGA-EM-A3O3-01A-11D-A221-26	HG19_Broad_variant	TCGA-EM-A3O3	TCGA-THCA		s12111	MD Anderson - Institute for Applied Cancer Science	University Health Network	Canada	NO	T2	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A221-26	True	THCA	C3	THCA.4	0.316291654	0.35	0.0		-0.6517	-0.1495	0.5067	1.3942	-0.3967	-0.0821	16.0	41.0	0.331216768	0.843097227	83.0	0.112283685	4.0	4.0	0.93030786	3.384074995	38.0	2.45831133	12.0	0.989297256	1.9065488680000002	782.909535	-785.5157312000001	-389.4161285	0.0	441.0	0.0	441.0	6.6198065043018115	8.388427567312089	-0.19086680952000634	5.572487510021252	7.323716830319659	1.0816777249937526	-1.0473189942805594	-1.0647107369924282	1.272544534513759
13722.58cfa831e4b0c9d6adf6cbf4	58cfa831e4b0c9d6adf6cbf4	TCGA-EJ-7782-01A-11D-2111_130502_SN590_0228_AD24A9ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-EJ-7782-01A-11D-2111_130502_SN590_0228_AD24A9ACXX_s_8_rg.sorted	TCGA-EJ-7782-01A-11D-2111_130502_SN590_0228_AD24A9ACXX_s_8_rg.sorted.bam	344.3		0.16	58cfa831e4b0c9d6adf6cbf4	TCGA-EJ-7782-01A-11D-2111_130502_SN590_0228_AD24A9ACXX_s_8_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-7782-01A	1426B4BF-F4A5-477C-BBBB-E0E656549764	Primary Tumor	Illumina HiSeq	f92312ba-ec6b-477e-a08c-12c8af6d1775	Prostate	71.0	951C894E-9354-45AD-834A-FFC04441A3A9	47FB5E53-DD88-4B25-B6EF-C1ABE55FD5BA	TCGA-EJ-7782-01A-11D-2111-02	HG19_Broad_variant	TCGA-EJ-7782	TCGA-PRAD		s3794	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		2111-02	True	PRAD	C3	PRAD.5-SPOP	0.103390026	0.25	0.0	4.085057653	-0.8521	-0.233	-0.6456	-0.6004	-1.0046	-0.2104	166.0	800.0	4.010866288	9.844853615	531.0	0.137439228	1.0	20.0	0.9150255359999999	0.63424737	2.0	2.523210953	13.0	0.9837273959999999	3.702801687	-1418.692399	-755.1066787999999	3080.1495809999997	0.0	1167.0	0.0	1167.0	8.823942326585245	9.494533030163694	-0.48110674315672886	6.703678790385153	8.858544263443697	2.1724053913214347	-2.120263536200091	-0.6359887667199966	2.653512134478164
13722.58cfa831e4b0c9d6adf6cbf7	58cfa831e4b0c9d6adf6cbf7	TCGA-EK-A2PL-01A-11D-A18I_140204_SN208_0508_BC2R1UACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EK-A2PL-01A-11D-A18I_140204_SN208_0508_BC2R1UACXX_s_1_rg.sorted	TCGA-EK-A2PL-01A-11D-A18I_140204_SN208_0508_BC2R1UACXX_s_1_rg.sorted.bam	72.21		0.16	58cfa831e4b0c9d6adf6cbf7	TCGA-EK-A2PL-01A-11D-A18I_140204_SN208_0508_BC2R1UACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE		Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EK-A2PL-01A	45CADCF3-EA98-4063-9255-5C18D6A5CBAB	Primary Tumor	Illumina HiSeq	ca898dd4-73fc-4fa3-8d2b-3d4f27be4736	Cervix	36.0	6EE33187-69A7-4328-9521-173CFCDE7A1B	2AC0C1AB-11A3-4806-82FE-08529AD8BBDD	TCGA-EK-A2PL-01A-11D-A18I-02	HG19_Broad_variant	TCGA-EK-A2PL	TCGA-CESC		s1187	Harvard Medical School	Gynecologic Oncology Group	United States	NO			Cervical Squamous Cell Carcinoma		A18I-02	True	CESC	C2		0.212072432	0.39	0.08		0.6198	0.1445	-0.8296	-0.1598	0.6599	-0.2922	79.0	1.0	0.873071107	3.561211096	114.0	0.376956456	8.0	26.0				1.906154747	7.0	0.979569765	1.403346595	-876.8581337999999	660.0492125	-1783.0956350000001	0.0	13.0	0.0	13.0	7.3990922261642655	6.81106080815562	-0.8775499035577243	4.914185576376266	6.30023518438963	1.7931890620376494	-2.4849066497880004	-0.5108256237659905	2.670738965595374
13722.58cfa831e4b0c9d6adf6cbf9	58cfa831e4b0c9d6adf6cbf9	TCGA-EJ-7785-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-EJ-7785-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_4_rg.sorted	TCGA-EJ-7785-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_4_rg.sorted.bam	160.3		0.15	58cfa831e4b0c9d6adf6cbf9	TCGA-EJ-7785-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-7785-01A	2DEF2A53-D2E8-46F0-8B07-F32DBF1833A4	Primary Tumor	Illumina HiSeq	dfbfaf44-ade6-4c48-88fb-a3898d878853	Prostate	54.0	63EBD9B1-F118-4315-8722-708F47A07063	196C6111-FF69-40F1-A7AA-973C5AC9106E	TCGA-EJ-7785-01A-11D-2111-02	HG19_Broad_variant	TCGA-EJ-7785	TCGA-PRAD		s3966	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		2111-02	True	PRAD	C3	PRAD.1-ERG	0.178174135	0.59	0.0	0.93708166	-1.2493	-0.3485	-0.1726	0.2411	-0.6377	-0.0475	9.0	58.0	0.178520232	0.446300579	98.0	0.020588671	0.0	4.0				2.995732274	20.0	1.0	2.16789288	92.65130659	8.34215914	3890.984416	0.0	1177.0	0.0	1177.0	8.059750344215361	9.114845559743726	-0.4257639069048458	6.632633988575215	8.544300701276113	3.1468844503849924	-1.4271163556401456	-0.5705448584676129	3.572648357289838
13722.58cfa831e4b0c9d6adf6cbfc	58cfa831e4b0c9d6adf6cbfc	TCGA-EJ-5506-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EJ-5506-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_5_rg.sorted	TCGA-EJ-5506-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_5_rg.sorted.bam	238.7	1.9	0.15	58cfa831e4b0c9d6adf6cbfc	TCGA-EJ-5506-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5506-01A	E5E4D3B6-8E58-4DCF-8F67-A00E656A8E27	Primary Tumor	Illumina HiSeq	bd66d4a0-aa1a-4bf3-a764-cb7292bc89b1	Prostate	67.0	9EBDA113-B0FC-4233-87AC-DAD0E7D033DE	CED987BC-B780-487A-A82E-2EB589AD3796	TCGA-EJ-5506-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5506	TCGA-PRAD		s3780	Harvard Medical School	University of Pittsburgh	United States	NO	T3b	N1	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.1-ERG	0.036139751			6.2418773000000005	-1.7506	-0.2535	-0.8787	-0.762	-0.0046	-0.4267	2.0		0.0	0.2225547	47.0	6.2e-06				0.0	1.0	2.043191871	8.0	0.982567593	1.764010957	-881.2398937	-784.8122744	2942.664928	0.0	1381.0	0.0	1381.0	7.760893195851024	8.474668359001237	-0.636387902509554	5.458308102856979	7.433214484173075	2.7955713783416822	-2.3025850929940455	-1.0414538748281612	3.431959280851236
13722.58cfa831e4b0c9d6adf6cbfe	58cfa831e4b0c9d6adf6cbfe	TCGA-DU-6405-01A-11D-1703_130813_SN1440_0160_AD2B87ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-DU-6405-01A-11D-1703_130813_SN1440_0160_AD2B87ACXX_s_6_rg.sorted	TCGA-DU-6405-01A-11D-1703_130813_SN1440_0160_AD2B87ACXX_s_6_rg.sorted.bam	241.3	1.9	0.14	58cfa831e4b0c9d6adf6cbfe	TCGA-DU-6405-01A-11D-1703_130813_SN1440_0160_AD2B87ACXX_s_6_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-6405-01A	9239A22E-80B1-49A2-B0D5-CBAB7E415254	Primary Tumor	Illumina HiSeq	2d1d4000-347f-44e4-8ff3-b61fea3daeb3	Brain	51.0	54BFF4F3-312D-4E1A-8327-F08F5A270EAC	9593D4DE-0DAB-4D1E-B86C-AF91CAC938E6	TCGA-DU-6405-01A-11D-1703-02	HG19_Broad_variant	TCGA-DU-6405	TCGA-LGG	605.0	s8359	Harvard Medical School	Henry Ford Hospital	United States	NO			Astrocytoma		1703-02	True	LGG	C4	GBM_LGG.Classic-like	0.062348134000000006	0.13	0.0		0.0053	-0.213	0.0064	-2.3233	0.0655	-0.4244	26.0	19.0	0.394654005	1.396468017	115.0	0.138420825	4.0	6.0				1.386294361	4.0	1.0	2.557763935	-64.72467697	282.6746488	-3210.4854649999997	1.0	605.0	1.0	486.0	7.890395391397826	6.87643659572471	1.2006726184827148	5.639103592791331	5.7778243070566	3.2408249515128214	-2.251291798606495	-1.0986122886681096	2.0401523330301066
13722.58cfa831e4b0c9d6adf6cc03	58cfa831e4b0c9d6adf6cc03	TCGA-DU-7010-01A-11D-2022_130910_SN208_0495_BD2FGNACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DU-7010-01A-11D-2022_130910_SN208_0495_BD2FGNACXX_s_3_rg.sorted	TCGA-DU-7010-01A-11D-2022_130910_SN208_0495_BD2FGNACXX_s_3_rg.sorted.bam	193.0		0.16	58cfa831e4b0c9d6adf6cc03	TCGA-DU-7010-01A-11D-2022_130910_SN208_0495_BD2FGNACXX_s_3_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-7010-01A	834E560A-A506-456D-BAF2-A206CA058153	Primary Tumor	Illumina HiSeq	61859b0d-b4a7-4c67-bf02-21422618f2f2	Brain	58.0	A6DA348E-A70C-4620-BFCB-2AFBE893284B	3EF3E4F1-9B47-4F11-9024-85242ECEE397	TCGA-DU-7010-01A-11D-2022-02	HG19_Broad_variant	TCGA-DU-7010	TCGA-LGG	456.0	s8355	Harvard Medical School	Henry Ford Hospital	United States	NO			Astrocytoma		2022-02	True	LGG	C4	GBM_LGG.G-CIMP-low	0.03390865	0.25	0.18		0.35700000000000004	-0.016	-0.3294	-2.3791	-0.6263	-0.6482	33.0	38.0	0.625607435	2.383266419	272.0	0.845433001	15.0	21.0					0.0		4.045835929	-58.18375397	959.7883817	-5067.247579999999	1.0	456.0	1.0	193.0	7.68937110752969	5.3230099791384085	-0.6972003272931113	4.277123889680951	4.105614154480331		-3.4122472178487397	-1.2173958246580772	
13722.58cfa831e4b0c9d6adf6cc0b	58cfa831e4b0c9d6adf6cc0b	TCGA-DU-6403-01A-11D-1703_130813_SN1440_0160_AD2B87ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DU-6403-01A-11D-1703_130813_SN1440_0160_AD2B87ACXX_s_5_rg.sorted	TCGA-DU-6403-01A-11D-1703_130813_SN1440_0160_AD2B87ACXX_s_5_rg.sorted.bam	180.3	1.9	0.14	58cfa831e4b0c9d6adf6cc0b	TCGA-DU-6403-01A-11D-1703_130813_SN1440_0160_AD2B87ACXX_s_5_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-6403-01A	8DAA29C0-F652-4130-A004-5183BBE30C63	Primary Tumor	Illumina HiSeq	d17b6f47-d1c9-4916-8722-8b6908f8552a	Brain	60.0	664226B3-6C8B-4E0A-A75B-955D65E62DA9	97CFB7E8-82E2-43BD-A458-376AD3CD7CFE	TCGA-DU-6403-01A-11D-1703-02	HG19_Broad_variant	TCGA-DU-6403	TCGA-LGG	354.0	s8135	Harvard Medical School	Henry Ford Hospital	United States	NO			Oligoastrocytoma		1703-02	True	LGG	C4	GBM_LGG.Classic-like	0.10410078199999999	0.29	0.0		0.6506	-0.09699999999999999	0.3981	-1.9073	0.0591	-0.5856	31.0	107.0	0.336508845	1.5601773719999998	103.0	0.122333946	4.0	11.0					0.0		4.562724394	209.02097	840.3245122000002	-3568.7591979999997	1.0	354.0	1.0	354.0	8.945202263959295	7.44168125399146	1.0350926163196414	6.6939104653528005	6.91558815809468	5.90876205534274	-2.251291798606495	-0.5260930958967793	4.873669439023098
13722.58cfa831e4b0c9d6adf6cc13	58cfa831e4b0c9d6adf6cc13	TCGA-DU-6402-01A-11D-1703_130813_SN1440_0160_AD2B87ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-DU-6402-01A-11D-1703_130813_SN1440_0160_AD2B87ACXX_s_4_rg.sorted	TCGA-DU-6402-01A-11D-1703_130813_SN1440_0160_AD2B87ACXX_s_4_rg.sorted.bam	234.3	1.9	0.15	58cfa831e4b0c9d6adf6cc13	TCGA-DU-6402-01A-11D-1703_130813_SN1440_0160_AD2B87ACXX_s_4_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-6402-01A	152F028E-EE29-40E0-8E75-5CAFFFACBD45	Primary Tumor	Illumina HiSeq	d556f16a-ad20-42eb-8e92-57114d46e174	Brain	52.0	0E594B0A-05E4-40C8-80BA-0D4BB08E437D	A60A9995-6A02-4035-9C3E-2FEE0E6E87C5	TCGA-DU-6402-01A-11D-1703-02	HG19_Broad_variant	TCGA-DU-6402	TCGA-LGG	214.0	s8563	Harvard Medical School	Henry Ford Hospital	United States	NO			Astrocytoma		1703-02	True	LGG	C4	GBM_LGG.Classic-like	0.36536135	0.36	0.01		-0.1939	0.004	0.5978	-0.6913	-0.6692	0.1838	19.0	3.0	0.369423745	1.262197795	152.0	0.157732603	5.0	13.0				2.63905733	14.0	1.0	2.7480562139999996	503.85578399999997	-414.5736928	-3088.514219	1.0	214.0	1.0	103.0	8.976072676159038	9.040684926909087	0.022198691769880985	6.578177403360668	8.347537746349143		-2.3978952727983707	-0.693147180559945	
13722.58cfa831e4b0c9d6adf6cc15	58cfa831e4b0c9d6adf6cc15	TCGA-DU-7290-01A-11D-2022_130910_SN208_0495_BD2FGNACXX_s_7_rg.sorted.filtered.	WGS	TCGA-DU-7290-01A-11D-2022_130910_SN208_0495_BD2FGNACXX_s_7_rg.sorted	TCGA-DU-7290-01A-11D-2022_130910_SN208_0495_BD2FGNACXX_s_7_rg.sorted.bam	157.7		0.14	58cfa831e4b0c9d6adf6cc15	TCGA-DU-7290-01A-11D-2022_130910_SN208_0495_BD2FGNACXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-7290-01A	E00A9855-C15E-46EF-988F-25CA64EC4717	Primary Tumor	Illumina HiSeq	827baf09-e242-460a-8d97-75059c6c3a98	Brain	45.0	942B676C-CCFD-4005-A564-C48F558D5D3B	9A452E24-A4D1-4229-9256-6A30800A5DDF	TCGA-DU-7290-01A-11D-2022-02	HG19_Broad_variant	TCGA-DU-7290	TCGA-LGG	315.0	s8353	Harvard Medical School	Henry Ford Hospital	United States	NO			Astrocytoma		2022-02	True	LGG	C5	GBM_LGG.Mesenchymal-like	0.23251691800000002				-0.579	-0.249	0.8626	-1.0982	0.1599	-0.5734	19.0	0.0	0.20925776699999998	0.9267129679999999	97.0	0.200639336	4.0	1.0				2.079441542	8.0	1.0	4.022520705	-143.10820769999998	-381.24199710000005	-478.76737599999996	1.0	315.0	1.0	315.0	7.3374250757871184	6.792811957518131	1.0254000016384501	5.779280457740569	6.28198633375214	1.887401930145256	-1.5581446180465497	-0.5108256237659905	0.8620019285068061
13722.58cfa831e4b0c9d6adf6cc16	58cfa831e4b0c9d6adf6cc16	TCGA-DU-7294-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DU-7294-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_3_rg.sorted	TCGA-DU-7294-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_3_rg.sorted.bam	62.7		0.17	58cfa831e4b0c9d6adf6cc16	TCGA-DU-7294-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-7294-01A	3F6FFB08-32A9-4555-BFD1-243B7F526105	Primary Tumor	Illumina HiSeq	2df0ab9f-8d32-40e9-883d-f5afad653272	Brain	53.0	C2D0A3C8-2354-475C-9027-5DF9523391CE	E6552DAE-BDEA-4945-9BA9-9C88D34CEBBC	TCGA-DU-7294-01A-11D-2022-02	HG19_Broad_variant	TCGA-DU-7294	TCGA-LGG		s8362	Harvard Medical School	Henry Ford Hospital	United States	NO			Oligodendroglioma		2022-02	True	LGG	C5	GBM_LGG.Codel	0.026835732999999997	0.07	0.05		-1.2142	-0.264	-0.6923	-2.6553	-1.2532	-1.2755	13.0		0.439575055	0.627964365	75.0	0.22679984	4.0	9.0					0.0		3.5407525189999998	-116.65586869999998	-117.93868159999998	-3647.14893	0.0	2869.0	0.0	2869.0	8.403427077117788	7.39839967747699	0.44934111842560864	6.457516928062475	7.39839967747699	1.3742641408433485	-1.9459101490553132	0.0	0.9249230224177398
13722.58cfa831e4b0c9d6adf6cc1c	58cfa831e4b0c9d6adf6cc1c	TCGA-EP-A2KA-01A-11D-A183-10_wgs_Illumina.filtered.	WGS	TCGA-EP-A2KA-01A-11D-A183-10_wgs_Illumina	TCGA-EP-A2KA-01A-11D-A183-10_wgs_Illumina.bam	69.11		0.07	58cfa831e4b0c9d6adf6cc1c	TCGA-EP-A2KA-01A-11D-A183-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-EP-A2KA-01A	440375D7-CDCD-418A-8992-0A8CA42D290D	Primary Tumor	Illumina HiSeq	e0364f92-b574-4946-8ba1-2504614f0845	Liver	52.0	E6E1BF11-DA29-4052-85A1-584401F0FA3D	484A41C8-FCAF-488D-97DC-BFE6A4B88A95	TCGA-EP-A2KA-01A-11D-A183-10	GRCh37-lite	TCGA-EP-A2KA	TCGA-LIHC		s16983	Baylor College of Medicine	Christiana Healthcare	United States	NO	T3a	NX	Hepatocellular Carcinoma	Stage IIIA	A183-10	True	LIHC	C2	LIHC.iCluster:2	0.289912927	0.38	0.06		0.0296	0.0075	0.1994	1.0032	0.2808	-0.6386	41.0	123.0	0.9074025509999999	2.56665293	1020.0	0.68986212	5.0	14.0	0.830955958	2.853492127	31.0	3.321477718	31.0	0.967236487	1.085873813	-815.0371054	-141.27950990000002	3074.727947	1.0	627.0	1.0	293.0	6.665137617832547	1.6970203628893739	0.40684299327277185	5.084687242271699	2.1751212023677287	2.895894726715941	-1.5804503755608483	0.4781008394783548	2.489051733443169
13722.58cfa831e4b0c9d6adf6cc1e	58cfa831e4b0c9d6adf6cc1e	TCGA-EM-A3OB-01A-11D-A221_120610_SN1120_0152_BD13TDACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EM-A3OB-01A-11D-A221_120610_SN1120_0152_BD13TDACXX_s_7_rg.sorted	TCGA-EM-A3OB-01A-11D-A221_120610_SN1120_0152_BD13TDACXX_s_7_rg.sorted.bam	51.44		0.15	58cfa831e4b0c9d6adf6cc1e	TCGA-EM-A3OB-01A-11D-A221_120610_SN1120_0152_BD13TDACXX_s_7_rg.sorted.bam	Alive	FEMALE			Thyroid Carcinoma	Aligned reads	TCGA-EM-A3OB-01A	8CFC2589-B0AD-4FE6-8420-8F6FE0178BCC	Primary Tumor	Illumina HiSeq	2d07ef47-3523-49c8-9f8e-64e984c3ceda	Thyroid	33.0	8133FCFE-ECC4-4503-B81E-00FDF6F87426	F90A631C-4556-43E2-8AA2-1114326B6984	TCGA-EM-A3OB-01A-11D-A221-26	HG19_Broad_variant	TCGA-EM-A3OB	TCGA-THCA		s12384	MD Anderson - Institute for Applied Cancer Science	University Health Network	Canada	NO	T2	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A221-26	True	THCA	C3	THCA.1	0.03013121	0.1	0.0		-2.089	-0.402	-1.3969999999999998	-1.8582	-1.1987	-0.7135	2.0		0.08809584599999999	0.14682641	30.0	0.027540862000000003	1.0	1.0				0.0	1.0		1.5316870530000002	-742.722185	-1196.037495	3084.442815	0.0	1176.0	0.0	1176.0	6.3687359208453636	7.464044110157872	-0.6960574493884815	5.133264449460057	6.770896929597926	1.4588093420964428	-1.2354714713853068	-0.6931471805599454	2.154866791484924
13722.58cfa831e4b0c9d6adf6cc23	58cfa831e4b0c9d6adf6cc23	TCGA-EJ-5503-01A-01D-1572_130223_SN590_0214_BC1UJ3ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EJ-5503-01A-01D-1572_130223_SN590_0214_BC1UJ3ACXX_s_7_rg.sorted	TCGA-EJ-5503-01A-01D-1572_130223_SN590_0214_BC1UJ3ACXX_s_7_rg.sorted.bam	172.7	1.9	0.16	58cfa831e4b0c9d6adf6cc23	TCGA-EJ-5503-01A-01D-1572_130223_SN590_0214_BC1UJ3ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5503-01A	AA252F78-EBF3-42F9-86AF-BB6E57345706	Primary Tumor	Illumina HiSeq	4eba210f-0895-487c-9b48-db8a8c629cc4	Prostate	50.0	627B9FF8-2557-4470-824A-B76A8BCD1E9F	68211C41-2971-4B41-8EEE-75FFB78175BC	TCGA-EJ-5503-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5503	TCGA-PRAD		s3782	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.1-ERG	0.14182473	0.1	0.0	0.914924985	-1.5471	-0.2545	-0.5181	0.2384	-0.7117	-0.0724	2.0		0.0	0.140818616	41.0	0.00016795599999999998	0.0	0.0				3.282693997	27.0	0.996012282	2.0646619530000003	142.5388357	-541.8843236	3425.879246	0.0	1391.0	0.0	1391.0	8.69678881400296	8.641171140326561	-0.5596157879354228	6.750878664947647	8.641171140326561	4.61181472870676	-1.9459101490553132	0.0	5.171430516642182
13722.58cfa831e4b0c9d6adf6cc24	58cfa831e4b0c9d6adf6cc24	TCGA-DU-7292-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DU-7292-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_1_rg.sorted	TCGA-DU-7292-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_1_rg.sorted.bam	28.0		0.14	58cfa831e4b0c9d6adf6cc24	TCGA-DU-7292-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-7292-01A	145F87A3-5E86-4A87-8E49-B166A2271D02	Primary Tumor	Illumina HiSeq	06fe9cf9-6572-4026-9990-7ec39cd21278	Brain	69.0	BD3011C5-FCF0-4B28-8D82-1175F69B118B	A3B00BDD-7250-4E6F-8F83-6CC01D672EF4	TCGA-DU-7292-01A-11D-2022-02	HG19_Broad_variant	TCGA-DU-7292	TCGA-LGG	242.0	s8361	Harvard Medical School	Henry Ford Hospital	United States	NO			Astrocytoma		2022-02	True	LGG	C3	GBM_LGG.Classic-like	0.06411682099999999	0.01	0.06		-0.4777	-0.3455	-0.5369	-2.4223	-0.6617	-0.466	10.0	0.0	0.455315407	1.032048255	97.0	0.12158354800000001	4.0	10.0				0.0	1.0		3.2847920139999998	442.42800880000004	129.5940603	-4828.718637	1.0	242.0	1.0	91.0	8.150612201358038	7.787050021169566	-0.6979448373674793	5.752716928559668	7.4993679487177864	2.370957617066562	-2.3978952727983707	-0.2876820724517808	3.068902454434041
13722.58cfa831e4b0c9d6adf6cc2f	58cfa831e4b0c9d6adf6cc2f	TCGA-DU-7008-01A-11D-2022_130910_SN208_0495_BD2FGNACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DU-7008-01A-11D-2022_130910_SN208_0495_BD2FGNACXX_s_1_rg.sorted	TCGA-DU-7008-01A-11D-2022_130910_SN208_0495_BD2FGNACXX_s_1_rg.sorted.bam	111.0		0.15	58cfa831e4b0c9d6adf6cc2f	TCGA-DU-7008-01A-11D-2022_130910_SN208_0495_BD2FGNACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-7008-01A	427C40F6-D1BD-49F2-B303-A975793B937E	Primary Tumor	Illumina HiSeq	3a51e8e7-621e-4d62-bb3d-cb6700af6a43	Brain	41.0	7A0C3571-4265-4D36-AFBC-FA234970F94B	7602BA72-B5E0-49C7-940A-6E9EFBDB5C58	TCGA-DU-7008-01A-11D-2022-02	HG19_Broad_variant	TCGA-DU-7008	TCGA-LGG		s8566	Harvard Medical School	Henry Ford Hospital	United States	NO			Oligodendroglioma		2022-02	True	LGG	C5	GBM_LGG.G-CIMP-high	0.027440465	0.17	0.12		-0.4367	-0.2075	-0.6797	-2.0669999999999997	-1.266	-1.2647	13.0	3.0	0.41257612200000005	0.677803629	110.0	0.14009491300000002	0.0	5.0	0.493777863	0.542470428	3.0	0.0	1.0		3.3663485160000004	-72.49472209999999	336.2573123	-4475.111189	0.0	4752.0	1.0	330.0	7.364335887895732	7.287560640309724	-0.8222242228350877	5.518509197397401	6.188948351641614	-0.5081553952101119	-1.8458266904983305	-1.0986122886681096	0.3140688276249758
13722.58cfa831e4b0c9d6adf6cc38	58cfa831e4b0c9d6adf6cc38	TCGA-EP-A26S-01A-11D-A16V-10_wgs_Illumina.filtered.	WGS	TCGA-EP-A26S-01A-11D-A16V-10_wgs_Illumina	TCGA-EP-A26S-01A-11D-A16V-10_wgs_Illumina.bam	64.0		0.07	58cfa831e4b0c9d6adf6cc38	TCGA-EP-A26S-01A-11D-A16V-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-EP-A26S-01A	B7D6621C-8BCE-4A01-8588-9D7761D9372B	Primary Tumor	Illumina HiSeq	e3122147-a994-4b8f-aa05-ddb36413802a	Liver	70.0	A0B2FF38-E6BF-4F27-98AB-5CF924B0E236	463BF060-8BA6-4A73-8173-172025F7B527	TCGA-EP-A26S-01A-11D-A16V-10	GRCh37-lite	TCGA-EP-A26S	TCGA-LIHC		s16982	Baylor College of Medicine	Christiana Healthcare	United States	NO	T1	N0	Hepatocellular Carcinoma	Stage I	A16V-10	True	LIHC	C4	LIHC.iCluster:3	0.050615797000000004	0.02	0.0		-1.3016	-0.248	-0.8714	-1.2881	-0.374	-1.0429	51.0	65.0	0.8772677720000001	2.193169429	97.0	0.08447616	3.0	5.0				0.693147181	2.0	1.0	1.538424489	-1654.459877	-811.2476002000001	3954.4377299999996	0.0	608.0	0.0	608.0	6.462249121336789	3.288674573099631	0.31107186642733764	4.958171724560515	3.8386470847632497	5.256279355201139	-1.5040773967762742	0.5499725116636185	4.945207488773801
13722.58cfa831e4b0c9d6adf6cc3c	58cfa831e4b0c9d6adf6cc3c	TCGA-EP-A2KB-01A-11D-A183-10_wgs_Illumina.filtered.	WGS	TCGA-EP-A2KB-01A-11D-A183-10_wgs_Illumina	TCGA-EP-A2KB-01A-11D-A183-10_wgs_Illumina.bam	51.77		0.08	58cfa831e4b0c9d6adf6cc3c	TCGA-EP-A2KB-01A-11D-A183-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-EP-A2KB-01A	18C08546-BED3-4ED9-B223-479AFE633C8E	Primary Tumor	Illumina HiSeq	41e9afd1-d090-475a-ba8a-48976ddc9d52	Liver	46.0	E2895132-DA4F-4DB5-B417-510E99FCE776	305A5074-5384-45A0-985D-289B178D09F6	TCGA-EP-A2KB-01A-11D-A183-10	GRCh37-lite	TCGA-EP-A2KB	TCGA-LIHC		s16781	Baylor College of Medicine	Christiana Healthcare	United States	NO	T1	NX	Hepatocellular Carcinoma	Stage I	A183-10	True	LIHC	C3	LIHC.iCluster:2	0.039101123	0.09	0.35		-0.1502	-0.2145	-0.9520000000000001	-0.9659	-0.7266	-0.98	33.0	5.0	0.5884613329999999	1.8933103740000001	58.0	0.642665892	7.0	5.0				1.609437912	5.0	1.0	0.854650992	-1188.234604	226.49779109999997	3307.719579	1.0	596.0	1.0	161.0	6.867280446416419	1.725893771936521	0.6025037556653283	5.400943377622992	2.396162170111535	2.360361673217702	-1.4663370687934272	0.6702683981750139	1.7578579175523739
13722.58cfa831e4b0c9d6adf6cc3e	58cfa831e4b0c9d6adf6cc3e	TCGA-EM-A3FR-01A-11D-A221_120610_SN1120_0152_BD13TDACXX_s_6_rg.sorted.filtered.	WGS	TCGA-EM-A3FR-01A-11D-A221_120610_SN1120_0152_BD13TDACXX_s_6_rg.sorted	TCGA-EM-A3FR-01A-11D-A221_120610_SN1120_0152_BD13TDACXX_s_6_rg.sorted.bam	45.93		0.15	58cfa831e4b0c9d6adf6cc3e	TCGA-EM-A3FR-01A-11D-A221_120610_SN1120_0152_BD13TDACXX_s_6_rg.sorted.bam	Alive	FEMALE			Thyroid Carcinoma	Aligned reads	TCGA-EM-A3FR-01A	2B84CFBC-7CF6-4CB1-A1E3-BA85DAFB89F4	Primary Tumor	Illumina HiSeq	0430ed44-5b5d-4b22-b78a-9b9ecd259736	Thyroid	55.0	319E3498-D5FB-4142-A09F-ABA779DBC094	FEA6D565-EDBC-4FB7-ADB8-090914F4259E	TCGA-EM-A3FR-01A-11D-A221-26	HG19_Broad_variant	TCGA-EM-A3FR	TCGA-THCA		s12247	MD Anderson - Institute for Applied Cancer Science	University Health Network	Canada	NO	T2	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A221-26	True	THCA	C3	THCA.1	0.046002854	0.26	0.0		-2.0695	-0.3215	-1.1418	-1.2919999999999998	-0.6189	-0.7329	9.0	1.0	0.029075955	0.436139331	51.0	4.74e-05	0.0	0.0	0.97128675	0.673244673	2.0	1.098612289	3.0	1.0	1.220903404	-51.27688588	-1553.6548380000002	2981.002408	0.0	457.0	0.0	457.0	6.006912788023076	8.138954069561663	0.5334370701525376	5.647967695549805	6.870442744098156	1.859508714140098	-0.35894509247327155	-1.268511325463507	1.3260716439875604
13722.58cfa831e4b0c9d6adf6cc40	58cfa831e4b0c9d6adf6cc40	TCGA-EK-A2R7-01A-11D-A18I_140204_SN208_0508_BC2R1UACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EK-A2R7-01A-11D-A18I_140204_SN208_0508_BC2R1UACXX_s_3_rg.sorted	TCGA-EK-A2R7-01A-11D-A18I_140204_SN208_0508_BC2R1UACXX_s_3_rg.sorted.bam	66.58		0.17	58cfa831e4b0c9d6adf6cc40	TCGA-EK-A2R7-01A-11D-A18I_140204_SN208_0508_BC2R1UACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EK-A2R7-01A	D7A75BF5-5189-4978-99D9-FCEF91C9FBD2	Primary Tumor	Illumina HiSeq	b998e76d-dff1-4454-abce-bbe7b5a6c398	Cervix	45.0	EE9A22DF-8612-4B71-AF3A-6B16C73197EA	9C763A04-CC5B-41E1-A5AC-2CB06B9E80C3	TCGA-EK-A2R7-01A-11D-A18I-02	HG19_Broad_variant	TCGA-EK-A2R7	TCGA-CESC		s1526	Harvard Medical School	Gynecologic Oncology Group	United States	NO	T1b1	N1	Cervical Squamous Cell Carcinoma		A18I-02	True	CESC	C1		0.234168803	0.31	0.11		1.2409	0.35600000000000004	0.1018	1.3097	-0.1405	-0.1854	60.0	2.0	0.648218132	2.4076673459999998	132.0	0.34280948899999997	10.0	8.0	0.898638355	4.0827789469999995	94.0	3.0832811739999997	28.0	0.925297701	2.512720657	-625.7500784	1055.377034	-3434.300444	0.0	27.0	0.0	27.0	8.925720273560222	8.2603204873579	-0.12834737820328823	6.122359892653687	7.090249234707645	1.609204240275075	-2.803360380906535	-1.1700712526502546	1.7375516184783633
13722.58cfa831e4b0c9d6adf6cc42	58cfa831e4b0c9d6adf6cc42	TCGA-DV-5566-01A-01D-2104-10_wgs_Illumina.filtered.	WGS	TCGA-DV-5566-01A-01D-2104-10_wgs_Illumina	TCGA-DV-5566-01A-01D-2104-10_wgs_Illumina.bam	124.4	1.9	0.16	58cfa831e4b0c9d6adf6cc42	TCGA-DV-5566-01A-01D-2104-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-DV-5566-01A	4B2EC8AA-8460-440E-B75B-6B92AE7A3FFC	Primary Tumor	Illumina HiSeq	67e2d2b4-5d60-46c8-85b0-236331ed66a8	Kidney	67.0	58578D50-1E0C-4F5E-929A-C969C5346B05	BCF54C96-2B62-4E24-926F-D77576250DD1	TCGA-DV-5566-01A-01D-2104-10	GRCh37-lite	TCGA-DV-5566	TCGA-KIRC		s8844	Baylor College of Medicine	NCI Urologic Oncology Branch	None	NO	T1a	NX	Kidney Clear Cell Renal Carcinoma	Stage I	2104-10	False	KIRC	C3	KIRC.4	0.206174353	0.4	0.06		-0.6133	-0.126	0.3094	0.0529	0.0687	0.1141	21.0	7.0	0.48631555200000004	1.144271888	37.0	0.07801435400000001	3.0	3.0				2.833213344	17.0	1.0	1.947053631	322.70270530000005	-796.596361	1756.9045649999998	0.0	1398.0	0.0	1398.0	7.3714793121355955	-0.174339039839559	0.8034269939816174	5.425569163080282	2.46080909820894	4.245283091528674	-1.9459101490553135	2.635148138048499	3.441856097547057
13722.58cfa831e4b0c9d6adf6cc4a	58cfa831e4b0c9d6adf6cc4a	TCGA-EB-A24C-01A-11D-A18Y_120730_SN208_0420_BC12YJACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EB-A24C-01A-11D-A18Y_120730_SN208_0420_BC12YJACXX_s_3_rg.sorted	TCGA-EB-A24C-01A-11D-A18Y_120730_SN208_0420_BC12YJACXX_s_3_rg.sorted.bam	54.37		0.17	58cfa831e4b0c9d6adf6cc4a	TCGA-EB-A24C-01A-11D-A18Y_120730_SN208_0420_BC12YJACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EB-A24C-01A	2F1BBE96-49D9-417B-BC9C-A09992489340	Primary Tumor	Illumina HiSeq	536296fc-5bec-4776-8ce4-7eee8581fbc3	Skin	56.0	67D59A46-5944-4B23-AA7B-9561C6F7B956	B48D03D1-E323-4119-B62E-1952163AAB2A	TCGA-EB-A24C-01A-11D-A18Y-02	HG19_Broad_variant	TCGA-EB-A24C	TCGA-SKCM		s7333	Harvard Medical School	Asterand	Ukraine	NO	T4b	NX			A18Y-02	True	SKCM	C4	SKCM.BRAF_Hotspot_Mutants	0.081689867	0.09	0.15	3.39627947	-0.2819	-0.1225	-0.7808	-1.9748	0.3069	0.1551	2.0	0.0	0.272845613	0.697272123			9.0	16.0	0.246870746	0.39732313700000005	5.0	1.098612289	3.0	1.0	1.9498391769999999	-1054.601507	734.813246	-1950.6499469999999	0.0	632.0	1.0	465.0	6.7825500298785215	8.627421838470925	0.8345723440156982	6.171640947555549	7.423449034144989	2.40508679640973	-0.6109090823229733	-1.203972804325936	1.570514452394032
13722.58cfa831e4b0c9d6adf6cc4c	58cfa831e4b0c9d6adf6cc4c	TCGA-EA-A1QS-01A-61D-A232_140124_SN208_0506_BC2PD5ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EA-A1QS-01A-61D-A232_140124_SN208_0506_BC2PD5ACXX_s_2_rg.sorted	TCGA-EA-A1QS-01A-61D-A232_140124_SN208_0506_BC2PD5ACXX_s_2_rg.sorted.bam	36.95		0.15	58cfa831e4b0c9d6adf6cc4c	TCGA-EA-A1QS-01A-61D-A232_140124_SN208_0506_BC2PD5ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EA-A1QS-01A	6F9D21C0-3B88-450D-A249-3E9BAFBA2DFA	Primary Tumor	Illumina HiSeq	c7f62ea9-e05f-40ea-9e4c-1771bd722b74	Cervix	46.0	8389C79E-164E-4462-ADCD-364DB3AFB463	109962B4-F4A5-4C72-B902-92516110FE7E	TCGA-EA-A1QS-01A-61D-A232-26	HG19_Broad_variant	TCGA-EA-A1QS	TCGA-CESC		s1361	MD Anderson - Institute for Applied Cancer Science	Asterand	Russia	NO	T1b1	N0	Cervical Squamous Cell Carcinoma		A232-26	True	CESC	C1		0.22144650100000002	0.7	0.68	13.26495199	0.1869	0.127	-0.0626	-0.1617	-0.3799	0.9279999999999999	29.0		0.290193722	1.116129702	66.0	0.34635050100000003	9.0	37.0	0.909404962	2.180657859	11.0	1.7478680969999998	6.0	0.9755037590000001	1.431792564	-432.493885	886.5356065999999	-2057.60497	0.0	1203.0	0.0	1203.0	7.592366128519796	6.933910236458988	0.04993628334661848	5.341074329913301	5.781230726520603	1.2994312750773704	-2.251291798606495	-1.1526795099383853	1.249494991730752
13722.58cfa831e4b0c9d6adf6cc4e	58cfa831e4b0c9d6adf6cc4e	TCGA-DU-7007-01A-11D-2022_130910_SN208_0494_AC2A1DACXX_s_7_rg.sorted.filtered.	WGS	TCGA-DU-7007-01A-11D-2022_130910_SN208_0494_AC2A1DACXX_s_7_rg.sorted	TCGA-DU-7007-01A-11D-2022_130910_SN208_0494_AC2A1DACXX_s_7_rg.sorted.bam	200.7		0.17	58cfa831e4b0c9d6adf6cc4e	TCGA-DU-7007-01A-11D-2022_130910_SN208_0494_AC2A1DACXX_s_7_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-7007-01A	8E2DCC00-9F7E-4DEE-B24D-43C8B30294C5	Primary Tumor	Illumina HiSeq	84edb90d-0a24-46dd-bed3-126c5fdcda42	Brain	33.0	E8E363D0-D9EA-478F-880C-7ADED5846237	A15321DD-20AE-4D64-9D89-C64A92468ECA	TCGA-DU-7007-01A-11D-2022-02	HG19_Broad_variant	TCGA-DU-7007	TCGA-LGG	1915.0	s8352	Harvard Medical School	Henry Ford Hospital	United States	NO			Astrocytoma		2022-02	True	LGG	C4	GBM_LGG.G-CIMP-high	0.14916989	0.16	0.17		-1.4503	-0.2	0.4174	-0.4992	-0.7523	-0.35	17.0	4.0	0.393500045	0.968615496	60.0	0.491702311	2.0	15.0	0.9895023999999999	1.087079497	3.0	2.351673302	11.0	0.9807239409999999	3.181843932	-637.1143897000001	-651.5321446	-3558.7839719999997	1.0	1915.0	0.0	1915.0	8.748463629942055	9.001977668728657	0.7705285932741794	6.44587853694801	8.19104745251233	2.81855054640051	-2.3025850929940455	-0.8109302162163288	2.04802195312633
13722.58cfa831e4b0c9d6adf6cc59	58cfa831e4b0c9d6adf6cc59	TCGA-EP-A3RK-01A-11D-A22F-10_wgs_Illumina.filtered.	WGS	TCGA-EP-A3RK-01A-11D-A22F-10_wgs_Illumina	TCGA-EP-A3RK-01A-11D-A22F-10_wgs_Illumina.bam	46.15		0.08	58cfa831e4b0c9d6adf6cc59	TCGA-EP-A3RK-01A-11D-A22F-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-EP-A3RK-01A	F15279DD-5D12-460B-9BD1-B4F95681CA65	Primary Tumor	Illumina HiSeq	3b2093f5-b5ba-4e57-b4a1-47a180f9bb81	Liver	73.0	253DA6EE-8786-4A20-A0DC-58816A8A9C39	0D259AC2-03D1-4814-9B0B-D05E3A6029B7	TCGA-EP-A3RK-01A-11D-A22F-10	GRCh37-lite	TCGA-EP-A3RK	TCGA-LIHC		s16682	Baylor College of Medicine	Christiana Healthcare	United States	NO	T3a	NX	Hepatocellular Carcinoma	Stage IIIA	A22F-10	True	LIHC	C2	LIHC.iCluster:2	0.508751309	0.56	0.04		0.0471	0.067	0.6997	1.4636	-0.2095	-0.5637	39.0	0.0	0.415142488	1.323266682	58.0	0.233153193	5.0	17.0	0.855940154	3.750752554	80.0	2.956488663	23.0	0.94290994	2.6286462580000003	-1059.9116980000001	-128.6403681	3370.129458	0.0	363.0	1.0	320.0	6.770461716221302	2.330369973227217	-0.00706288880961381	5.695946979132253	4.4755719351104055	4.016079300172985	-1.0745147370890495	2.1452019618831883	4.0231421889825985
13722.58cfa831e4b0c9d6adf6cc5c	58cfa831e4b0c9d6adf6cc5c	TCGA-EJ-5502-01A-01D-1572_130329_SN590_0221_BD1WHDACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EJ-5502-01A-01D-1572_130329_SN590_0221_BD1WHDACXX_s_5_rg.sorted	TCGA-EJ-5502-01A-01D-1572_130329_SN590_0221_BD1WHDACXX_s_5_rg.sorted.bam	238.7	1.9	0.17	58cfa831e4b0c9d6adf6cc5c	TCGA-EJ-5502-01A-01D-1572_130329_SN590_0221_BD1WHDACXX_s_5_rg.sorted.bam	Alive	MALE			Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5502-01A	48E83A4C-C602-494A-80CD-E2F4B4DD701E	Primary Tumor	Illumina HiSeq	40f605db-50a6-4ed1-b652-61045959ba2e	Prostate	50.0	D36A0B54-6E09-4EE2-923B-C1516D78BB03	0432A271-DB73-434C-971A-B3B2C3FD2285	TCGA-EJ-5502-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5502	TCGA-PRAD		s3785	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.1-ERG	0.175692144	0.06	0.0	3.8476752889999997	-1.3853	-0.263	-0.2474	0.1671	-0.7386	0.0209	6.0		0.028330813	0.283308134	87.0	6.4e-05	0.0	0.0				3.4678540960000004	34.0	0.983408835	2.177239196	-383.86375560000005	-275.9450228	2969.979739	0.0	1171.0	0.0	1171.0	8.627033657095769	9.423215381813595	-0.08679899512624223	6.835274187867714	8.7813614956412	3.420278247829925	-1.7917594692280552	-0.6418538861723944	3.5070772429561674
13722.58cfa831e4b0c9d6adf6cc60	58cfa831e4b0c9d6adf6cc60	TCGA-EJ-5501-01A-01D-1572_130223_SN590_0214_BC1UJ3ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EJ-5501-01A-01D-1572_130223_SN590_0214_BC1UJ3ACXX_s_3_rg.sorted	TCGA-EJ-5501-01A-01D-1572_130223_SN590_0214_BC1UJ3ACXX_s_3_rg.sorted.bam	153.7	1.9	0.16	58cfa831e4b0c9d6adf6cc60	TCGA-EJ-5501-01A-01D-1572_130223_SN590_0214_BC1UJ3ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5501-01A	8DF0C1E8-966C-4F46-AD15-FAE9E745A32E	Primary Tumor	Illumina HiSeq	6e2cf9a5-b8c5-4f44-8800-c95ad84bc9a8	Prostate	55.0	A1E37A0A-67F5-4A19-A540-A45CB89C4203	759BD886-73F1-4DEF-A446-98DAAC2C5B88	TCGA-EJ-5501-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5501	TCGA-PRAD		s3790	Harvard Medical School	University of Pittsburgh	United States	NO	T3b	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.2-ETV1	0.112724614	0.63	0.0	4.595385024	-1.0255	-0.191	-0.8626	-0.6634	-0.637	-0.0222	9.0	42.0	0.197244267	0.45084403799999995	123.0	0.070897618	2.0	12.0				2.110016553	11.0	0.879945249	1.862517426	-445.9800968	-508.1396407	3820.4725729999996	0.0	1365.0	0.0	1365.0	9.204523486654617	9.558444692827102	-1.1534706492201563	6.85314822949114	8.865297512267158	4.784988612563927	-2.3513752571634776	-0.693147180559945	5.938459261784083
13722.58cfa831e4b0c9d6adf6cc63	58cfa831e4b0c9d6adf6cc63	TCGA-EA-A3HU-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EA-A3HU-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_3_rg.sorted	TCGA-EA-A3HU-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_3_rg.sorted.bam	40.2		0.16	58cfa831e4b0c9d6adf6cc63	TCGA-EA-A3HU-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EA-A3HU-01A	9912432E-74BC-4846-93B4-FA2BF8070BD1	Primary Tumor	Illumina HiSeq	4f5312e3-89a9-41d7-a296-8b90e22cb408	Cervix	43.0	05409DA8-60DC-4073-91F0-F91832F3A607	B66F8B97-9149-4C12-A66E-4BC7D1352269	TCGA-EA-A3HU-01A-11D-A20X-26	HG19_Broad_variant	TCGA-EA-A3HU	TCGA-CESC		s1520	MD Anderson - Institute for Applied Cancer Science	Asterand	Russia	NO	T2a2	N0	Cervical Squamous Cell Carcinoma		A20X-26	True	CESC	C2		0.442189603				1.0462	0.319	0.7329	1.8768	1.7251	-0.1262	451.0	676.0	7.887437564	21.03316684					0.74194664	3.313465522	87.0	3.6858417560000003	44.0	0.9740108479999999	2.14895844	193.15250590000002	969.9863991000001	-2802.83165	0.0	1013.0	0.0	1013.0	8.371010681238156	8.353811144441678	0.18493880679993413	6.173786103901937	7.2551988557735685	1.2853279711735266	-2.197224577336219	-1.0986122886681096	1.1003891643735926
13722.58cfa831e4b0c9d6adf6cc66	58cfa831e4b0c9d6adf6cc66	TCGA-EB-A24D-01A-11D-A18Y_120730_SN208_0420_BC12YJACXX_s_4_rg.sorted.filtered.	WGS	TCGA-EB-A24D-01A-11D-A18Y_120730_SN208_0420_BC12YJACXX_s_4_rg.sorted	TCGA-EB-A24D-01A-11D-A18Y_120730_SN208_0420_BC12YJACXX_s_4_rg.sorted.bam	62.95		0.16	58cfa831e4b0c9d6adf6cc66	TCGA-EB-A24D-01A-11D-A18Y_120730_SN208_0420_BC12YJACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-EB-A24D-01A	D7EE2693-39A8-4E3A-B6F6-E4729800E34E	Primary Tumor	Illumina HiSeq	44c42419-04e6-439f-aceb-e330fd514f35	Skin	72.0	A74E2FEC-291C-4967-AFE3-101955578225	0FD8F30A-936E-4A72-AA69-4DAC1E4BCE49	TCGA-EB-A24D-01A-11D-A18Y-02	HG19_Broad_variant	TCGA-EB-A24D	TCGA-SKCM		s7508	Harvard Medical School	Asterand	Ukraine	NO	T4a	N2b		Stage IIIB	A18Y-02	True	SKCM	C1	SKCM.BRAF_Hotspot_Mutants	0.116470556	0.21	0.17	8.305118014	0.3279	0.0265	-0.4598	0.2967	-1.101	-0.2059	233.0	24.0	8.04194951	14.61056476			25.0	18.0	0.658348171	3.194325248	128.0	2.51265853	13.0	0.97961331	3.819839538	-362.70484239999996	275.5946233	-1443.198468	0.0	645.0	1.0	500.0	7.984524678616674	4.936128381977707	0.18032477542999836	7.050215441239841	6.776678015375195	1.5878492600064233	-0.9343092373768331	1.8405496333974871	1.4075244845764248
13722.58cfa831e4b0c9d6adf6cc68	58cfa831e4b0c9d6adf6cc68	TCGA-EK-A2R8-01A-21D-A18I_140204_SN208_0508_BC2R1UACXX_s_4_rg.sorted.filtered.	WGS	TCGA-EK-A2R8-01A-21D-A18I_140204_SN208_0508_BC2R1UACXX_s_4_rg.sorted	TCGA-EK-A2R8-01A-21D-A18I_140204_SN208_0508_BC2R1UACXX_s_4_rg.sorted.bam	58.64		0.17	58cfa831e4b0c9d6adf6cc68	TCGA-EK-A2R8-01A-21D-A18I_140204_SN208_0508_BC2R1UACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EK-A2R8-01A	D4510801-8CE4-4F10-8B31-25C0A39B5135	Primary Tumor	Illumina HiSeq	d050a7c3-8fe5-472e-bc71-4dff85991e92	Cervix	48.0	6B8E0AF3-1632-4FED-9A37-879EA013AE24	80B2C20E-8EFB-4105-8A96-A695FCFB73CB	TCGA-EK-A2R8-01A-21D-A18I-02	HG19_Broad_variant	TCGA-EK-A2R8	TCGA-CESC		s1190	Harvard Medical School	Gynecologic Oncology Group	United States	NO	T1b2	N1	Cervical Squamous Cell Carcinoma		A18I-02	True	CESC	C2		0.33644268200000005	0.56	0.15		1.1740000000000002	0.5105	-0.7829	-0.5128	0.1934	0.2861	96.0	29.0	2.19663552	5.5708488439999995	81.0	0.273735709	8.0	10.0	0.996791632	0.6909233090000001	2.0	2.3933121230000003	12.0	0.963139651	1.3796975180000002	-125.87244009999998	1088.1006830000001	606.2338432	0.0	44.0	0.0	44.0	7.466227556215481	4.125973349270874	0.2656212119548905	5.269002978879262	6.170075524505401	0.5280162083020995	-2.197224577336219	2.044102175234527	0.262394996347209
13722.58cfa831e4b0c9d6adf6cc76	58cfa831e4b0c9d6adf6cc76	TCGA-ER-A194-01A-11D-A18Y_120723_SN1120_0178_BD1887ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-ER-A194-01A-11D-A18Y_120723_SN1120_0178_BD1887ACXX_s_4_rg.sorted	TCGA-ER-A194-01A-11D-A18Y_120723_SN1120_0178_BD1887ACXX_s_4_rg.sorted.bam	30.36		0.17	58cfa831e4b0c9d6adf6cc76	TCGA-ER-A194-01A-11D-A18Y_120723_SN1120_0178_BD1887ACXX_s_4_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-ER-A194-01A	2BBF00F4-7798-4DAD-9894-96202C9132BE	Primary Tumor	Illumina HiSeq	40a52169-d476-4650-a043-d5fda21a4213	Skin	77.0	EA15A5B0-8BA7-4114-853F-E3396E81CCEB	411370DC-4C66-484F-AC7E-42A19E486DFC	TCGA-ER-A194-01A-11D-A18Y-02	HG19_Broad_variant	TCGA-ER-A194	TCGA-SKCM	1354.0	s7693	Harvard Medical School	University of Pittsburgh	United States	NO		N0			A18Y-02	True	SKCM	C3	SKCM.RAS_Hotspot_Mutants	0.31611448	0.4	0.0	1.405107757	-1.0834	-0.4135	0.0116	0.39299999999999996	-0.4515	-0.1827	569.0	46.0	16.45771415	32.67560733			3.0	22.0		0.0	1.0	1.9927834619999998	12.0	0.80195506	4.537959601	-647.5154539	-848.0766691	-1059.22768	1.0	1354.0	1.0	1354.0	6.695538652888892	4.952468317153331	1.1405452831114045	6.4211018071871315	8.779037174040454	1.990732659614452	-0.2744368457017603	3.8265688568871226	0.8501873765030472
13722.58cfa831e4b0c9d6adf6cc7c	58cfa831e4b0c9d6adf6cc7c	TCGA-EM-A1CU-01A-11D-A13U_120706_SN1120_0170_BD1422ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EM-A1CU-01A-11D-A13U_120706_SN1120_0170_BD1422ACXX_s_3_rg.sorted	TCGA-EM-A1CU-01A-11D-A13U_120706_SN1120_0170_BD1422ACXX_s_3_rg.sorted.bam	50.69	1.91	0.18	58cfa831e4b0c9d6adf6cc7c	TCGA-EM-A1CU-01A-11D-A13U_120706_SN1120_0170_BD1422ACXX_s_3_rg.sorted.bam	Alive	MALE			Thyroid Carcinoma	Aligned reads	TCGA-EM-A1CU-01A	4E80F403-0E10-4725-854D-F023C12EE1E2	Primary Tumor	Illumina HiSeq	a03be55f-c2fb-41d6-88ae-f1063ed587f6	Thyroid	31.0	C285C3AC-26D7-4481-BAAF-769F49AED55A	A9886789-6859-4FC9-812A-D9813FD1C20D	TCGA-EM-A1CU-01A-11D-A13U-02	HG19_Broad_variant	TCGA-EM-A1CU	TCGA-THCA		s12379	Harvard Medical School	University Health Network	Canada	NO	T3	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A13U-02	True	THCA	C3	THCA.3	0.09849980400000001	0.27	0.0		-1.2859	-0.321	-0.2552	-0.9285	-0.3645	0.2126	5.0	5.0	0.088330449	0.382765281	65.0	0.00020925099999999998	0.0	0.0	0.813522813	2.681238477	27.0	0.693147181	2.0	1.0	1.053615646	241.0361625	-874.8245155999999	2104.7822699999997	0.0	636.0	0.0	636.0	6.665750762132271	9.016118283923841	-0.6961729014764824	5.639897827746589	7.7997229595993485	1.6925421865589216	-1.0258529343856817	-1.2163953243244934	2.388715088035404
13722.58cfa831e4b0c9d6adf6cc80	58cfa831e4b0c9d6adf6cc80	TCGA-EL-A3T6-01A-11D-A221_120523_SN1222_0108_AC0VL4ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EL-A3T6-01A-11D-A221_120523_SN1222_0108_AC0VL4ACXX_s_7_rg.sorted	TCGA-EL-A3T6-01A-11D-A221_120523_SN1222_0108_AC0VL4ACXX_s_7_rg.sorted.bam	40.31		0.15	58cfa831e4b0c9d6adf6cc80	TCGA-EL-A3T6-01A-11D-A221_120523_SN1222_0108_AC0VL4ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-EL-A3T6-01A	90507BAA-B716-4BCF-A18E-9D8AE97D809A	Primary Tumor	Illumina HiSeq	fb31d05f-8a2e-416d-92b9-fd333e80561f	Thyroid	34.0	61367375-8317-4CAE-86CF-2FD65AB8ABC8	C1FE07E8-83AC-47A7-B8E5-FA62DE03BB17	TCGA-EL-A3T6-01A-11D-A221-26	HG19_Broad_variant	TCGA-EL-A3T6	TCGA-THCA		s12518	MD Anderson - Institute for Applied Cancer Science	MD Anderson	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A221-26	True	THCA	C3	THCA.4	0.302968353	0.5	0.0		-1.1897	-0.2195	0.5828	1.2783	0.7696	-0.0795	4.0		0.030275249	0.181651492	53.0	5.17e-05	0.0	0.0	0.919207474	4.568289527	144.0	3.925898107	53.0	0.988818503	1.690897275	1213.282793	-663.7372392999999	-752.1159611	0.0	2988.0	0.0	2988.0	5.936853595667766	7.886913493729647	0.15773457501481125	6.259626987930817	7.307094998476705	3.547097499029964	0.3227733922630507	-0.5798184952529422	3.3893629240151526
13722.58cfa831e4b0c9d6adf6cc87	58cfa831e4b0c9d6adf6cc87	TCGA-EM-A3O6-01A-11D-A221_120524_SN1120_0144_AC0VNCACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EM-A3O6-01A-11D-A221_120524_SN1120_0144_AC0VNCACXX_s_1_rg.sorted	TCGA-EM-A3O6-01A-11D-A221_120524_SN1120_0144_AC0VNCACXX_s_1_rg.sorted.bam	44.88		0.15	58cfa831e4b0c9d6adf6cc87	TCGA-EM-A3O6-01A-11D-A221_120524_SN1120_0144_AC0VNCACXX_s_1_rg.sorted.bam	Alive	FEMALE			Thyroid Carcinoma	Aligned reads	TCGA-EM-A3O6-01A	398D5C2E-F877-4BBF-A10C-486B8523C9CE	Primary Tumor	Illumina HiSeq	efd1fae6-df5c-4d7d-9579-296f0077b186	Thyroid	54.0	B3E6F726-256B-450B-B3F5-A1BB9AAB9C15	FA63C656-1DD5-4A92-9AE8-36B3408E00C7	TCGA-EM-A3O6-01A-11D-A221-26	HG19_Broad_variant	TCGA-EM-A3O6	TCGA-THCA		s12114	MD Anderson - Institute for Applied Cancer Science	University Health Network	Canada	NO	T2	NX	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage II	A221-26	True	THCA	C3	THCA.1	0.050887771	0.29	0.0		-1.3463	-0.1995	-1.1037	-1.5083	-0.6182	-0.4307	3.0		0.087570265	0.233520707	41.0	0.00907775	0.0	3.0					0.0		1.4969044969999998	-667.2087449	-1145.637841	2325.246938	0.0	458.0	0.0	458.0	6.76305058575949	8.250437297846634	0.41881644128302853	6.395325805634172	7.719809046784463		-0.3677247801253176	-0.5306282510621703	
13722.58cfa831e4b0c9d6adf6cc90	58cfa831e4b0c9d6adf6cc90	TCGA-EJ-5518-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EJ-5518-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_7_rg.sorted	TCGA-EJ-5518-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_7_rg.sorted.bam	131.7	1.9	0.15	58cfa831e4b0c9d6adf6cc90	TCGA-EJ-5518-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5518-01A	2B35C119-CDC1-49E2-8229-CA5CDE9E63D0	Primary Tumor	Illumina HiSeq	02ae3fcb-c1fe-400a-8172-0c62a8d4639c	Prostate	66.0	F12FA61C-FF1B-48E2-BE19-1D52D50DC261	BD026793-2032-4D13-9A6A-A189583A537C	TCGA-EJ-5518-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5518	TCGA-PRAD		s3430	Harvard Medical School	University of Pittsburgh	United States	NO	T4	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.8-other	0.185087305	0.47	0.16	0.44293903100000004	-0.7003	-0.133	-0.4093	-0.7265	-0.8346	-0.0736	16.0		0.314786837	0.82989257	687.0	0.325192064	1.0	26.0				2.599301927	14.0	0.9849357559999999	1.817075692	-329.9673704	-1129.490928	3216.1914699999998	0.0	2118.0	1.0	2104.0	9.231253493556391	9.098139050955192	-0.13586793862479973	6.895878577739354	8.846824622674287	2.8798591775070776	-2.3353749158170363	-0.2513144282809061	3.0157271161318775
13722.58cfa831e4b0c9d6adf6cc92	58cfa831e4b0c9d6adf6cc92	TCGA-EJ-5510-01A-01D-1572_130308_SN590_0219_BC1UVPACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EJ-5510-01A-01D-1572_130308_SN590_0219_BC1UVPACXX_s_5_rg.sorted	TCGA-EJ-5510-01A-01D-1572_130308_SN590_0219_BC1UVPACXX_s_5_rg.sorted.bam	52.7	1.9	0.15	58cfa831e4b0c9d6adf6cc92	TCGA-EJ-5510-01A-01D-1572_130308_SN590_0219_BC1UVPACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5510-01A	4A3D9EFE-F24E-4135-8A70-E202651E7A81	Primary Tumor	Illumina HiSeq	95ce00b3-cfc9-4400-ab07-de043b39cccf	Prostate	48.0	3EAE6B68-D333-4B36-9E70-D2BED19C1DFA	495CB006-3042-4F8A-9AFA-9C10415DBB26	TCGA-EJ-5510-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5510	TCGA-PRAD		s3603	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.2-ETV1	0.181962605	0.62	0.02	1.89825769	-1.5745	-0.2285	-0.6141	-0.0712	-0.4196	-0.2143	9.0	2.0	0.1981403	0.537809387	82.0	0.108471816	2.0	15.0	0.8987837670000001	1.868968301	8.0	2.8674404989999998	19.0	0.973849524	2.103724645	-295.771173	-1091.936089	2259.608707	0.0	1887.0	0.0	1887.0	8.640472207576408	8.64709641929468	-0.3572557300363932	6.6480420428862015	8.405934362477792	2.3383261384995553	-1.9924301646902063	-0.24116205681688774	2.6955818685359487
13722.58cfa831e4b0c9d6adf6cc9c	58cfa831e4b0c9d6adf6cc9c	TCGA-FD-A3SM-01A-11D-A233_120830_SN208_0423_AC190AACXX_s_5_rg.sorted.filtered.	WGS	TCGA-FD-A3SM-01A-11D-A233_120830_SN208_0423_AC190AACXX_s_5_rg.sorted	TCGA-FD-A3SM-01A-11D-A233_120830_SN208_0423_AC190AACXX_s_5_rg.sorted.bam	22.6		0.16	58cfa831e4b0c9d6adf6cc9c	TCGA-FD-A3SM-01A-11D-A233_120830_SN208_0423_AC190AACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3SM-01A	474582F2-8DEC-4FBC-803F-4FD9BA2E0957	Primary Tumor	Illumina HiSeq	bacf3136-6605-4a66-a869-8d91e4003a0d	Bladder	70.0	5F7DE481-C011-43A8-844B-F47569499F0D	AF7DFCCA-999E-4EA2-A14B-1E923C2ECE38	TCGA-FD-A3SM-01A-11D-A233-26	HG19_Broad_variant	TCGA-FD-A3SM	TCGA-BLCA		s3299	MD Anderson - Institute for Applied Cancer Science	BLN - University Of Chicago	United States	NO	T3a	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A233-26	True	BLCA	C1	BLCA.2	0.154579034	0.31	0.01	2.173964807	0.1181	-0.0305	-0.5227	-1.0364	-0.3962	0.5425	107.0	114.0	1.482139866	5.172958748	91.0	0.20102247399999998	6.0	7.0	0.623617296	0.6851136240000001	3.0	1.9730014059999998	8.0	0.948813115	4.802973828	-986.1636269999999	638.3352967999999	760.6888951000001	1.0	547.0	1.0	144.0	6.856812800244562	8.759965062897024	-1.4189757616127796	5.845211888566082	7.7791358098852985	3.2906795569971843	-1.0116009116784799	-0.9808292530117262	4.709655318609964
13722.58cfa831e4b0c9d6adf6cca3	58cfa831e4b0c9d6adf6cca3	TCGA-EJ-5499-01A-01D-1572_130223_SN590_0214_BC1UJ3ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EJ-5499-01A-01D-1572_130223_SN590_0214_BC1UJ3ACXX_s_1_rg.sorted	TCGA-EJ-5499-01A-01D-1572_130223_SN590_0214_BC1UJ3ACXX_s_1_rg.sorted.bam	91.7	1.9	0.15	58cfa831e4b0c9d6adf6cca3	TCGA-EJ-5499-01A-01D-1572_130223_SN590_0214_BC1UJ3ACXX_s_1_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5499-01A	FD1AA612-DF86-4D48-892D-2ACEBD76EA96	Primary Tumor	Illumina HiSeq	21f9da4c-83ce-44b4-b002-e18cd232ac6b	Prostate	61.0	22C4F5C2-1B1E-4212-8110-09DBD5CE10A9	0F4314C9-967C-4EF1-9CF2-A7B206E6129E	TCGA-EJ-5499-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5499	TCGA-PRAD		s3789	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C1	PRAD.1-ERG	0.145530345	0.53	0.0	2.8328084839999996	-0.3942	0.0085	-0.4397	0.1197	-0.7361	-0.2241	5.0	56.0	0.224188122	0.8126819409999999	136.0	0.04378283400000001	1.0	8.0				3.521377609	35.0	0.990445253	1.7663656559999998	-388.8537736	90.50359527	2216.642819	0.0	1415.0	0.0	1415.0	8.547334348328224	9.707852766680048	0.3547976945998266	6.467892806648388	8.791562034805894	2.076887261874739	-2.079441541679836	-0.9162907318741551	1.7220895672749124
13722.58cfa831e4b0c9d6adf6cca6	58cfa831e4b0c9d6adf6cca6	TCGA-EJ-5497-01A-02D-1572_130125_SN1120_0233_AD1K3HACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EJ-5497-01A-02D-1572_130125_SN1120_0233_AD1K3HACXX_s_5_rg.sorted	TCGA-EJ-5497-01A-02D-1572_130125_SN1120_0233_AD1K3HACXX_s_5_rg.sorted.bam	209.7	1.9	0.16	58cfa831e4b0c9d6adf6cca6	TCGA-EJ-5497-01A-02D-1572_130125_SN1120_0233_AD1K3HACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5497-01A	DEE02265-D8DD-4379-AE08-72D72B03A570	Primary Tumor	Illumina HiSeq	453a9559-644e-46b9-8be3-7e4511448e7e	Prostate	47.0	317BE3B2-B7C1-4772-9E33-D55EB4B9FAA9	0B2246C7-CE2E-427D-BA10-4A2C942D0986	TCGA-EJ-5497-01A-02D-1572-02	HG19_Broad_variant	TCGA-EJ-5497	TCGA-PRAD		s3944	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.1-ERG	0.153488713	0.55	0.01	2.086542377	-1.4181	-0.2365	-0.6062	-0.3424	-1.0527	-0.2179	7.0	22.0	0.168222552	0.392519289	63.0	0.02831258	0.0	9.0		0.0	1.0	1.6674619330000002	6.0	0.9306282240000001	2.143692686	202.5012659	-395.7564986	3088.363315	0.0	405.0	0.0	405.0	8.241703159729818	8.368693183097793	-0.5478276719072568	5.990411361123323	7.503695745611189	2.2190331891605917	-2.251291798606495	-0.8649974374866045	2.766860861067848
13722.58cfa831e4b0c9d6adf6cca9	58cfa831e4b0c9d6adf6cca9	TCGA-ER-A196-01A-11D-A18Y_120723_SN1120_0178_BD1887ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-ER-A196-01A-11D-A18Y_120723_SN1120_0178_BD1887ACXX_s_3_rg.sorted	TCGA-ER-A196-01A-11D-A18Y_120723_SN1120_0178_BD1887ACXX_s_3_rg.sorted.bam	32.16		0.17	58cfa831e4b0c9d6adf6cca9	TCGA-ER-A196-01A-11D-A18Y_120723_SN1120_0178_BD1887ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-ER-A196-01A	A9EB1022-FFD3-42DE-A39D-2126FC7EC0CE	Primary Tumor	Illumina HiSeq	ef8b8b6f-6812-446b-b27c-03db8997900d	Skin	64.0	239F69F7-E78A-4B09-BF00-E521F63A3BB4	77937F29-C94F-4251-A0AB-9D07DED92796	TCGA-ER-A196-01A-11D-A18Y-02	HG19_Broad_variant	TCGA-ER-A196	TCGA-SKCM		s8021	Harvard Medical School	University of Pittsburgh	United States	NO	T4b	N0		Stage IIC	A18Y-02	True	SKCM	C1	SKCM.Triple_WT	0.555601077	0.74	0.06	1.6870848000000003	-0.379	-0.0375	-0.5168	-0.8249	-1.0622	0.5673	5.0	68.0	0.238621455	0.536898274			1.0	9.0	0.591151157	1.150327037	7.0	0.0	1.0		2.9664738219999998	68.16784638	386.5299812	-350.9059554	0.0	1785.0	0.0	1785.0	6.7308011101373015	2.166369486508705	-0.7984684489797912	6.686349347566468	7.147690392936184	0.35309311785725317	-0.04445176257083361	4.981320906427479	1.1515615668370445
13722.58cfa831e4b0c9d6adf6ccb4	58cfa831e4b0c9d6adf6ccb4	TCGA-EI-6917-01A-11D-1924-10_wgs_Illumina.filtered.	WGS	TCGA-EI-6917-01A-11D-1924-10_wgs_Illumina	TCGA-EI-6917-01A-11D-1924-10_wgs_Illumina.bam	325.0	1.9	0.05	58cfa831e4b0c9d6adf6ccb4	TCGA-EI-6917-01A-11D-1924-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Rectum Adenocarcinoma	Aligned reads	TCGA-EI-6917-01A	0CB21FB0-520F-4105-99EC-697A335115B5	Primary Tumor	Illumina HiSeq	e00d5548-a577-4019-9f7c-5bad23811d4e	Colorectal	33.0	37BB8CE7-6C55-4237-A7AD-ADC42E6FF6A8	8853CBEE-7931-49A6-B063-A806943A10AD	TCGA-EI-6917-01A-11D-1924-10	GRCh37-lite	TCGA-EI-6917	TCGA-READ		s2011	Baylor College of Medicine	Greater Poland Cancer Center	Poland	NO	T3	N1	Rectal Adenocarcinoma	Stage IIIA	1924-10	False	READ	C2	GI.HM-SNV	0.276705711	0.48	0.03	4.303294065	0.9963	0.3205	0.695	0.5749	0.0829	0.2957	2205.0	36.0	37.64592358	131.57005130000002	113.0	0.000929259	0.0	0.0	0.93497932	2.531970937	15.0	3.204777524	25.0	0.9956201170000001	1.352071824	-392.5101492	1287.786151	-1990.067261	0.0	531.0	0.0	531.0	7.164256233950343	3.1805285165935775	-0.21842270307857925	5.515597608362961	4.510203983713961	2.4368828585464697	-1.6486586255873819	1.3296754671203832	2.655305561625049
13722.58cfa831e4b0c9d6adf6ccc0	58cfa831e4b0c9d6adf6ccc0	TCGA-EJ-5531-01A-01D-1572_130221_SN1120_0239_BD1V59ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EJ-5531-01A-01D-1572_130221_SN1120_0239_BD1V59ACXX_s_1_rg.sorted	TCGA-EJ-5531-01A-01D-1572_130221_SN1120_0239_BD1V59ACXX_s_1_rg.sorted.bam	81.7	1.9	0.15	58cfa831e4b0c9d6adf6ccc0	TCGA-EJ-5531-01A-01D-1572_130221_SN1120_0239_BD1V59ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5531-01A	ADF3C2F7-D5F9-41C3-BD8C-7F9F1F22FF73	Primary Tumor	Illumina HiSeq	0993d456-af78-4078-aa16-bd810177c278	Prostate	62.0	48F3A8B8-110C-49AB-BD85-CE33328C2CF6	90219925-E6E8-40BC-8DD0-BD76F942B48C	TCGA-EJ-5531-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5531	TCGA-PRAD		s3445	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.5-SPOP	0.166880958	0.74	0.04	0.52955932	-0.8884	-0.195	-0.0851	0.4918	-0.2323	-0.1466	13.0	6.0	0.14302293900000002	0.772323871	91.0	0.045863917000000004	2.0	14.0	0.9648636420000001	3.343962566	32.0	2.491493722	14.0	0.944084728	2.170520508	-511.392779	-592.335868	2146.758075	0.0	1273.0	0.0	1273.0	7.737470902324101	9.444595296045103	-0.2537208602445067	5.945711433096046	8.291915786106717	4.030671467360958	-1.7917594692280547	-1.1526795099383853	4.284392327605465
13722.58cfa831e4b0c9d6adf6ccc6	58cfa831e4b0c9d6adf6ccc6	TCGA-EM-A1CS-01A-11D-A13U_120711_SN1120_0173_AC0WN6ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EM-A1CS-01A-11D-A13U_120711_SN1120_0173_AC0WN6ACXX_s_5_rg.sorted	TCGA-EM-A1CS-01A-11D-A13U_120711_SN1120_0173_AC0WN6ACXX_s_5_rg.sorted.bam	69.84	1.88	0.18	58cfa831e4b0c9d6adf6ccc6	TCGA-EM-A1CS-01A-11D-A13U_120711_SN1120_0173_AC0WN6ACXX_s_5_rg.sorted.bam	Alive	FEMALE			Thyroid Carcinoma	Aligned reads	TCGA-EM-A1CS-01A	E92BDB0D-969A-4D98-ADA8-5DFEC68119B5	Primary Tumor	Illumina HiSeq	b6cf1366-a645-4bd9-ac5f-0e8c5d18a4ca	Thyroid	55.0	C1DAF740-06E2-4509-86BE-5BFCC52B508A	67082C81-DE62-42A4-82B7-CB6BE2C961D3	TCGA-EM-A1CS-01A-11D-A13U-02	HG19_Broad_variant	TCGA-EM-A1CS	TCGA-THCA		s12251	Harvard Medical School	University Health Network	Canada	NO	T1	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A13U-02	True	THCA	C3	THCA.5	0.060736063	0.2	0.0		-1.5475	-0.3975	-0.3713	-0.9793	-0.7459	-0.0597	3.0		0.0	0.115246495	53.0	0.010997861000000001	0.0	0.0		0.0	1.0	1.609437912	5.0	1.0	1.64331173	-212.0594199	-588.6612247	1879.92947	0.0	817.0	0.0	817.0	6.194738530110001	7.811519885490885	0.2897604480448943	4.834285400173998	6.660947857892064	1.3440026815945187	-1.3604531299360034	-1.150572027598821	1.0542422335496244
13722.58cfa831e4b0c9d6adf6cccc	58cfa831e4b0c9d6adf6cccc	TCGA-EJ-5530-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EJ-5530-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_7_rg.sorted	TCGA-EJ-5530-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_7_rg.sorted.bam	388.7	1.9	0.14	58cfa831e4b0c9d6adf6cccc	TCGA-EJ-5530-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5530-01A	E4A755E3-4938-4321-B5A9-27A445036791	Primary Tumor	Illumina HiSeq	83b4e2b0-670b-441b-9b17-fa5c1da740c5	Prostate	61.0	27D61473-39D6-478A-A576-427D1AEDA01F	CBA52846-FAD3-4D21-8949-0105BD2AE713	TCGA-EJ-5530-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5530	TCGA-PRAD		s3961	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.1-ERG	0.04597441	0.49	0.03	1.508314189	-1.347	-0.2115	-0.9125	-0.6456	-1.3023	-0.2399	30.0		0.341805271	1.082383359	61.0	0.015010839	1.0	2.0	0.967716472	1.557479579	5.0	1.886696785	7.0	0.96957035	1.687188526	-453.1210274	-556.5675282000001	3940.732581	0.0	1832.0	0.0	1832.0	7.779646194988153	9.246873181078008	-0.18983268804395104	6.547502513695521	8.640737377507692	2.585026182730369	-1.2321436812926325	-0.6061358035703157	2.7748588707743203
13722.58cfa831e4b0c9d6adf6ccd0	58cfa831e4b0c9d6adf6ccd0	TCGA-EM-A1YA-01A-11D-A14U_120629_SN1222_0121_BD143UACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EM-A1YA-01A-11D-A14U_120629_SN1222_0121_BD143UACXX_s_2_rg.sorted	TCGA-EM-A1YA-01A-11D-A14U_120629_SN1222_0121_BD143UACXX_s_2_rg.sorted.bam	45.94	1.87	0.18	58cfa831e4b0c9d6adf6ccd0	TCGA-EM-A1YA-01A-11D-A14U_120629_SN1222_0121_BD143UACXX_s_2_rg.sorted.bam	Alive	FEMALE			Thyroid Carcinoma	Aligned reads	TCGA-EM-A1YA-01A	567E4D90-5C5A-44F0-A462-90C831F3C096	Primary Tumor	Illumina HiSeq	69cba75e-7be6-4707-b524-255288547622	Thyroid	74.0	D0880877-36CF-4DED-87B2-898C3446F90D	D1BD818E-62BF-4375-A171-ED388341014F	TCGA-EM-A1YA-01A-11D-A14U-02	HG19_Broad_variant	TCGA-EM-A1YA	TCGA-THCA		s12754	Harvard Medical School	University Health Network	Canada	NO	T2	NX	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage II	A14U-02	True	THCA	C3	THCA.1	0.063026791	0.36	0.0		-1.6179	-0.2235	-0.9365	-1.3981	-0.9233	-0.4786	3.0		0.03019583	0.211370807	45.0	8.88e-06	0.0	0.0				1.386294361	4.0	1.0	1.390843161	-1361.870071	-1266.321256	3381.7782	0.0	602.0	0.0	602.0	6.277864548057207	7.786381903744784	0.9269985470832006	5.452228184451182	6.799886913197381	1.315162546208719	-0.8256363636060247	-0.9864949905474036	0.38816399912551836
13722.58cfa831e4b0c9d6adf6ccd2	58cfa831e4b0c9d6adf6ccd2	TCGA-EM-A3OA-01A-11D-A221_120610_SN1120_0151_AC0WN0ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-EM-A3OA-01A-11D-A221_120610_SN1120_0151_AC0WN0ACXX_s_6_rg.sorted	TCGA-EM-A3OA-01A-11D-A221_120610_SN1120_0151_AC0WN0ACXX_s_6_rg.sorted.bam	47.85		0.16	58cfa831e4b0c9d6adf6ccd2	TCGA-EM-A3OA-01A-11D-A221_120610_SN1120_0151_AC0WN0ACXX_s_6_rg.sorted.bam	Alive	FEMALE			Thyroid Carcinoma	Aligned reads	TCGA-EM-A3OA-01A	24CF6397-60EF-4635-81F0-78A67157AAC0	Primary Tumor	Illumina HiSeq	ddf917ff-6b4d-45ca-a503-8d6449f76e72	Thyroid	55.0	8B048263-6C2F-4BF6-8F37-C69DA9F3839F	2604E6C9-A117-49DC-A06E-082E63859DCA	TCGA-EM-A3OA-01A-11D-A221-26	HG19_Broad_variant	TCGA-EM-A3OA	TCGA-THCA		s12249	MD Anderson - Institute for Applied Cancer Science	University Health Network	Canada	NO	T2	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage II	A221-26	True	THCA	C3	THCA.1	0.059459528	0.14	0.0		-1.6705	-0.17300000000000001	-1.3953	-1.1346	-0.9525	-0.9462	8.0		0.206069422	0.23550791	41.0	2.25e-05	0.0	0.0	0.873836031	3.2234757810000003	40.0	1.386294361	4.0	1.0	1.182307335	-1514.085839	-1190.619165	2756.385511	0.0	822.0	0.0	822.0	6.43227460912988	8.105428281159544	1.144547573816844	5.722032995210635	6.942277471353863	2.3701872698166144	-0.7102416139192456	-1.1631508098056806	1.2256396959997704
13722.58cfa831e4b0c9d6adf6ccdc	58cfa831e4b0c9d6adf6ccdc	TCGA-EM-A1YC-01A-11D-A14U_120629_SN1120_0167_AC0WMBACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EM-A1YC-01A-11D-A14U_120629_SN1120_0167_AC0WMBACXX_s_7_rg.sorted	TCGA-EM-A1YC-01A-11D-A14U_120629_SN1120_0167_AC0WMBACXX_s_7_rg.sorted.bam	43.33	1.93	0.17	58cfa831e4b0c9d6adf6ccdc	TCGA-EM-A1YC-01A-11D-A14U_120629_SN1120_0167_AC0WMBACXX_s_7_rg.sorted.bam	Alive	FEMALE			Thyroid Carcinoma	Aligned reads	TCGA-EM-A1YC-01A	0AD2A2B3-C1BB-4597-B28E-A6385F93D09C	Primary Tumor	Illumina HiSeq	256cee86-6dd3-4d12-bb0b-e3ab680044aa	Thyroid	71.0	17610B7B-F2EC-4B55-808C-1C2219A0D1BA	3D02FB7F-EB7D-49F9-BD40-20E9BDA1FBAB	TCGA-EM-A1YC-01A-11D-A14U-02	HG19_Broad_variant	TCGA-EM-A1YC	TCGA-THCA		s12752	Harvard Medical School	University Health Network	Canada	NO	T3	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage III	A14U-02	True	THCA	C4	THCA.1	0.052749745				-2.1253	-0.3065	-0.937	-2.0364	-1.5632	-0.8058	5.0		0.21027916	0.18023928	31.0	0.9477264940000001							0.0		1.3792485980000002	-586.2421469999999	-1010.108298	2612.642929	0.0	2391.0	0.0	2391.0	6.7606943499014935	7.604645445820918	0.7420690623270386	5.953602909992331	7.268173209199704	1.7715501764860555	-0.8070914399091627	-0.33647223662121295	1.0294811141590168
13722.58cfa831e4b0c9d6adf6ccde	58cfa831e4b0c9d6adf6ccde	TCGA-EM-A1CV-01A-11D-A13U_120706_SN1222_0122_AC0WPYACXX_s_4_rg.sorted.filtered.	WGS	TCGA-EM-A1CV-01A-11D-A13U_120706_SN1222_0122_AC0WPYACXX_s_4_rg.sorted	TCGA-EM-A1CV-01A-11D-A13U_120706_SN1222_0122_AC0WPYACXX_s_4_rg.sorted.bam	104.75	1.89	0.17	58cfa831e4b0c9d6adf6ccde	TCGA-EM-A1CV-01A-11D-A13U_120706_SN1222_0122_AC0WPYACXX_s_4_rg.sorted.bam	Alive	FEMALE			Thyroid Carcinoma	Aligned reads	TCGA-EM-A1CV-01A	762EDDB5-1B47-4B79-B20A-1EDFB07C0705	Primary Tumor	Illumina HiSeq	54060b82-ddf3-4449-aa9c-baaa4d66f1b7	Thyroid	32.0	95D077B1-E4F3-48EA-84BC-F663FD438693	DEC98438-085F-40C3-8751-D50BA12C8584	TCGA-EM-A1CV-01A-11D-A13U-02	HG19_Broad_variant	TCGA-EM-A1CV	TCGA-THCA		s12521	Harvard Medical School	University Health Network	Canada	NO	T1	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A13U-02	True	THCA	C3	THCA.5	0.046811768	0.11	0.0		-1.7536	-0.389	-0.3846	-1.5046	-0.8204	-0.247	3.0		0.060921612	0.21322564300000002	45.0	2.72e-05	0.0	0.0				1.098612289	3.0	1.0	1.036498989	-236.7101505	-891.6591372000001	2306.850268	0.0	1475.0	0.0	1475.0	6.722941730866534	8.005213055303422	-0.6629550800653148	5.374387697729491	6.808962297071396	5.422303346329027	-1.3485540331370434	-1.1962507582320256	6.085258426394343
13722.58cfa831e4b0c9d6adf6ccdf	58cfa831e4b0c9d6adf6ccdf	TCGA-EM-A3O7-01A-11D-A221_120524_SN1120_0145_BD12MWACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EM-A3O7-01A-11D-A221_120524_SN1120_0145_BD12MWACXX_s_1_rg.sorted	TCGA-EM-A3O7-01A-11D-A221_120524_SN1120_0145_BD12MWACXX_s_1_rg.sorted.bam	34.81		0.15	58cfa831e4b0c9d6adf6ccdf	TCGA-EM-A3O7-01A-11D-A221_120524_SN1120_0145_BD12MWACXX_s_1_rg.sorted.bam	Alive	FEMALE			Thyroid Carcinoma	Aligned reads	TCGA-EM-A3O7-01A	3A211D5A-085F-4902-86B6-50E4EB36B897	Primary Tumor	Illumina HiSeq	c3515173-4e8f-4198-a9de-0bf2232c3fbd	Thyroid	46.0	362F0CC2-B884-404B-8DF1-2BFC2A75E9C3	AF35D79C-4F32-4B6E-8FDE-BDA9D715A542	TCGA-EM-A3O7-01A-11D-A221-26	HG19_Broad_variant	TCGA-EM-A3O7	TCGA-THCA		s12383	MD Anderson - Institute for Applied Cancer Science	University Health Network	Canada	NO	T3	NX	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A221-26	True	THCA	C3	THCA.5	0.057499145999999994	0.05	0.0		-2.0031	-0.2935	-0.5069	-0.7131	-0.9039	-0.3159	3.0	5.0	0.12054590800000001	0.24109181600000001	81.0	2.57e-05	0.0	0.0				1.5607104090000001	5.0	0.9697239	1.259135498	-372.1654974	-895.6828691	1591.9951039999999	0.0	223.0	0.0	223.0	7.1164482551835455	8.947637050035201	0.4783279751708167	6.269150394796343	8.254489869475258	2.1044825256376045	-0.8472978603872034	-0.693147180559945	1.6261545504667878
13722.58cfa831e4b0c9d6adf6cce7	58cfa831e4b0c9d6adf6cce7	TCGA-EK-A3GJ-01A-21D-A20X_140106_SN590_0243_AC371BACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EK-A3GJ-01A-21D-A20X_140106_SN590_0243_AC371BACXX_s_1_rg.sorted	TCGA-EK-A3GJ-01A-21D-A20X_140106_SN590_0243_AC371BACXX_s_1_rg.sorted.bam	68.37		0.16	58cfa831e4b0c9d6adf6cce7	TCGA-EK-A3GJ-01A-21D-A20X_140106_SN590_0243_AC371BACXX_s_1_rg.sorted.bam	Alive	FEMALE	NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER		Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EK-A3GJ-01A	DEDA68DD-E9AD-45CC-9DBB-1C5836EF6519	Primary Tumor	Illumina HiSeq	dde88a3f-8602-42a1-9b43-037c49cb3d34	Cervix	51.0	93AB0265-4851-4A8E-BEE3-496EA8DE56F7	1DE48F6B-49E4-4FE8-9D1B-0C7773DD7671	TCGA-EK-A3GJ-01A-21D-A20X-26	HG19_Broad_variant	TCGA-EK-A3GJ	TCGA-CESC		s1192	MD Anderson - Institute for Applied Cancer Science	Gynecologic Oncology Group	United States	NO	T1b1	N0	Cervical Squamous Cell Carcinoma		A20X-26	True	CESC	C2		0.151625606	0.31	0.01		1.1368	0.33399999999999996	0.2273	0.1502	1.8289	-0.5908	91.0	1.0	1.891311058	4.7040300660000005	148.0	0.25290468899999996	6.0	29.0				2.7949796239999998	19.0	0.949240125	2.006928196	-20.80121901	662.2998102999999	807.4133279	0.0	3.0	0.0	3.0	7.468513271496336	7.005789019253502	1.1043787630805117	5.217221472889841	6.007260189142375	1.3239143730185226	-2.251291798606495	-0.998528830111127	0.2195356099380108
13722.58cfa831e4b0c9d6adf6ccf0	58cfa831e4b0c9d6adf6ccf0	TCGA-EJ-5512-01A-01D-1572_130131_SN1120_0234_AD1PVUACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EJ-5512-01A-01D-1572_130131_SN1120_0234_AD1PVUACXX_s_5_rg.sorted	TCGA-EJ-5512-01A-01D-1572_130131_SN1120_0234_AD1PVUACXX_s_5_rg.sorted.bam	100.7	1.9	0.13	58cfa831e4b0c9d6adf6ccf0	TCGA-EJ-5512-01A-01D-1572_130131_SN1120_0234_AD1PVUACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5512-01A	C28F931F-5AB2-4899-9FE9-54024F082D92	Primary Tumor	Illumina HiSeq	1df8e29c-5be8-4dbf-abb8-f0ded9419a14	Prostate	46.0	D0B41403-8458-45E1-946E-21054FBA65B8	D5F126D6-7AAF-425A-BBEA-E7587A25529D	TCGA-EJ-5512-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5512	TCGA-PRAD		s3954	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.1-ERG	0.055491760999999994	0.64	0.0	1.1328715040000001	-1.9421	-0.13	-1.1483	-0.4448	-0.4677	-0.40700000000000003	6.0		0.08368239400000001	0.362623705	117.0	0.030881798	0.0	7.0		0.0	1.0	1.791759469	6.0	1.0	2.300867044	-14.31946816	-281.2441998	2732.996598	0.0	1733.0	0.0	1733.0	8.060382155956486	8.445455484885294	-1.0398503926382996	5.662486883158115	7.634525268668965	2.782756975669034	-2.3978952727983707	-0.8109302162163288	3.8226073683073336
13722.58cfa831e4b0c9d6adf6ccf8	58cfa831e4b0c9d6adf6ccf8	TCGA-FD-A3SP-01A-31D-A233_120830_SN208_0424_BD1DKLACXX_s_3_rg.sorted.filtered.	WGS	TCGA-FD-A3SP-01A-31D-A233_120830_SN208_0424_BD1DKLACXX_s_3_rg.sorted	TCGA-FD-A3SP-01A-31D-A233_120830_SN208_0424_BD1DKLACXX_s_3_rg.sorted.bam	26.79		0.15	58cfa831e4b0c9d6adf6ccf8	TCGA-FD-A3SP-01A-31D-A233_120830_SN208_0424_BD1DKLACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3SP-01A	5F99DCFF-D809-4C87-8024-C9B30BD565E9	Primary Tumor	Illumina HiSeq	2da38f98-8b94-404e-99e7-7a8d58aa25c1	Bladder	60.0	3592A9C5-124E-428F-B1F9-40429C591429	9BE9B27C-A33C-450E-806D-7C791472DAE6	TCGA-FD-A3SP-01A-31D-A233-26	HG19_Broad_variant	TCGA-FD-A3SP	TCGA-BLCA		s3112	MD Anderson - Institute for Applied Cancer Science	BLN - University Of Chicago	United States	NO	T3b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A233-26	True	BLCA	C1	BLCA.4	0.41916418299999997	0.68	0.47	5.424965519	0.4714	0.08	0.9564	0.7999	0.5117	1.0087	52.0	33.0	1.225514083	2.917890673	96.0	0.25228893	6.0	19.0	0.728468637	2.589959555	35.0	3.2945673010000003	30.0	0.9686492520000001	4.223287244	-640.4650319	1083.569469	-1477.588948	0.0	783.0	0.0	783.0	6.49722179276241	9.28652333270847	-0.5215944174624834	6.296551097300259	8.544585987979094	3.3343831602744265	-0.2006706954621511	-0.7419373447293771	3.85597757773691
13722.58cfa831e4b0c9d6adf6cd06	58cfa831e4b0c9d6adf6cd06	TCGA-EJ-5496-01A-01D-1572_130125_SN1120_0233_AD1K3HACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EJ-5496-01A-01D-1572_130125_SN1120_0233_AD1K3HACXX_s_3_rg.sorted	TCGA-EJ-5496-01A-01D-1572_130125_SN1120_0233_AD1K3HACXX_s_3_rg.sorted.bam	253.7	1.9	0.14	58cfa831e4b0c9d6adf6cd06	TCGA-EJ-5496-01A-01D-1572_130125_SN1120_0233_AD1K3HACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5496-01A	6755C231-355F-4CC3-85F1-6306C7F5D44B	Primary Tumor	Illumina HiSeq	00039222-b24d-4c86-b6ac-ffc00b3b6ece	Prostate	59.0	D0873929-EAC8-42E2-AF6F-DF3CB9CE698C	0A4FA030-2417-4F6F-8B86-5036FCA48F1E	TCGA-EJ-5496-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5496	TCGA-PRAD		s3598	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.1-ERG	0.090094147	0.51	0.01	1.5870987890000001	-1.3712	-0.177	-1.2032	-0.7539	-0.7479	-0.662	17.0		0.223273169	0.86518353	89.0	0.068727736	1.0	13.0				1.5607104090000001	5.0	0.9697239	2.084714714	-288.98650699999996	-304.793976	2922.716468	0.0	595.0	0.0	595.0	9.269018001593595	8.467092168446705	-1.0386123872252129	7.323107852538282	7.956266544680714	1.4774784883896661	-1.9459101490553132	-0.5108256237659905	2.516090875614879
13722.58cfa831e4b0c9d6adf6cd09	58cfa831e4b0c9d6adf6cd09	TCGA-EX-A3L1-01A-11D-A245_140124_SN1440_0178_AC2PL6ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-EX-A3L1-01A-11D-A245_140124_SN1440_0178_AC2PL6ACXX_s_6_rg.sorted	TCGA-EX-A3L1-01A-11D-A245_140124_SN1440_0178_AC2PL6ACXX_s_6_rg.sorted.bam	44.57		0.14	58cfa831e4b0c9d6adf6cd09	TCGA-EX-A3L1-01A-11D-A245_140124_SN1440_0178_AC2PL6ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EX-A3L1-01A	F5D90810-8C4B-4CED-9360-383E42CB54B3	Primary Tumor	Illumina HiSeq	73141d26-4c6a-46e1-ab5f-b431f2f35c23	Cervix	32.0	89AD6395-973B-4011-BFBD-6759209406BE	6F24A0BE-76D7-4388-B73A-32BE2E902470	TCGA-EX-A3L1-01A-11D-A245-26	HG19_Broad_variant	TCGA-EX-A3L1	TCGA-CESC		s1530	MD Anderson - Institute for Applied Cancer Science	University of North Carolina	United States	NO	T2a1	N0	Cervical Squamous Cell Carcinoma		A245-26	True	CESC	C1		0.5321967710000001	0.73	0.28	4.709649037	0.7642	0.2555	0.1426	-0.0864	-0.0859	0.7273	18.0	4.0	0.27368122	0.798236891	114.0	0.354176977	15.0	24.0	0.944499089	3.7849225410000003	55.0	2.0198149919999997	8.0	0.971325691	1.6587176119999998	32.57727012	565.1374467	1264.503447	0.0	463.0	0.0	463.0	7.7122201956740355	6.016505531065751	-1.0159291420602918	5.514995618337816	5.0720439222249	-0.18876200511496455	-2.197224577336219	-0.9444616088408513	0.8271671369453273
13722.58cfa831e4b0c9d6adf6cd12	58cfa831e4b0c9d6adf6cd12	TCGA-FD-A3SJ-01A-12D-A233_120830_SN208_0423_AC190AACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FD-A3SJ-01A-12D-A233_120830_SN208_0423_AC190AACXX_s_1_rg.sorted	TCGA-FD-A3SJ-01A-12D-A233_120830_SN208_0423_AC190AACXX_s_1_rg.sorted.bam	30.78		0.17	58cfa831e4b0c9d6adf6cd12	TCGA-FD-A3SJ-01A-12D-A233_120830_SN208_0423_AC190AACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3SJ-01A	6D8D8169-0C1A-4CDB-BE6F-9761C981A369	Primary Tumor	Illumina HiSeq	2635ae0a-878a-4237-ad5c-5f0092134ee3	Bladder	59.0	491A8898-7CC5-45D9-9502-FD24399C239D	E9F8EE08-E951-41A8-88AB-E7A98618EECC	TCGA-FD-A3SJ-01A-12D-A233-26	HG19_Broad_variant	TCGA-FD-A3SJ	TCGA-BLCA	739.0	s2909	MD Anderson - Institute for Applied Cancer Science	BLN - University Of Chicago	United States	NO	T2b	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A233-26	True	BLCA	C1	BLCA.2	0.24114507699999999	0.54	0.21	2.430510211	0.7118	0.27	-0.3997	0.1421	0.1833	0.0841	99.0	84.0	2.239718706	6.450389872000001	376.0	0.662293424	14.0	55.0	0.997448223	0.691378424	2.0	1.846220219	7.0	0.94876951	4.564163892	-2124.811209	857.3162955	-5125.454597	1.0	739.0	1.0	281.0	7.485996531040725	8.220492798099462	0.31044979331850786	6.610527793686826	7.0678132881610765	1.7466278124292016	-0.8754687373538999	-1.1526795099383853	1.4361780191106939
13722.58cfa831e4b0c9d6adf6cd16	58cfa831e4b0c9d6adf6cd16	TCGA-FD-A3SL-01A-21D-A233_120830_SN208_0423_AC190AACXX_s_3_rg.sorted.filtered.	WGS	TCGA-FD-A3SL-01A-21D-A233_120830_SN208_0423_AC190AACXX_s_3_rg.sorted	TCGA-FD-A3SL-01A-21D-A233_120830_SN208_0423_AC190AACXX_s_3_rg.sorted.bam	18.6		0.16	58cfa831e4b0c9d6adf6cd16	TCGA-FD-A3SL-01A-21D-A233_120830_SN208_0423_AC190AACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3SL-01A	4570B6E2-D430-41CA-AAB1-CE4D14C36463	Primary Tumor	Illumina HiSeq	764ae567-a7b6-4d13-bef1-8cc55afb4524	Bladder	60.0	0A1E88E0-3593-40BA-86E5-751074885578	2BF89FED-C215-4893-BA35-2FE0C7DD5DD0	TCGA-FD-A3SL-01A-21D-A233-26	HG19_Broad_variant	TCGA-FD-A3SL	TCGA-BLCA		s2720	MD Anderson - Institute for Applied Cancer Science	BLN - University Of Chicago	United States	NO	T4a	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A233-26	True	BLCA	C1	BLCA.2	0.11667252	0.58	0.1	1.171345797	0.0978	0.034	0.1745	0.0242	-0.1365	0.5067	42.0	39.0	1.799484906	5.68869422	117.0	0.477511185	14.0	44.0	0.366918335	0.254328409	2.0	1.5607104090000001	5.0	0.9697239	1.627148419	-841.9963336000001	429.59283519999997	-401.71280310000003	1.0	712.0	1.0	260.0	6.814981878829782	9.626585264111542	-0.0036266706417161787	6.057296177132265	8.68212365527069	2.013088041129815	-0.7576857016975165	-0.9444616088408513	2.016714711771531
13722.58cfa831e4b0c9d6adf6cd18	58cfa831e4b0c9d6adf6cd18	TCGA-ET-A25N-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-ET-A25N-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_7_rg.sorted	TCGA-ET-A25N-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_7_rg.sorted.bam	26.49	1.71	0.15	58cfa831e4b0c9d6adf6cd18	TCGA-ET-A25N-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-ET-A25N-01A	EBCCFB5F-C0A8-4263-AAFF-B5DD83585191	Primary Tumor	Illumina HiSeq	2e9fb20e-cc3d-4aa3-a188-6695dc2532a3	Thyroid	28.0	0CD93B1F-1CBB-4C1E-A4F6-940F95C41683	1A00F009-28F5-406B-8F47-4BB9D55D25D6	TCGA-ET-A25N-01A-11D-A16N-02	HG19_Broad_variant	TCGA-ET-A25N	TCGA-THCA		s12525	Harvard Medical School	Johns Hopkins	United States	NO	T2	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	True	THCA	C3	THCA.3	0.118517096				-2.0874	-0.3085	-0.1464	-0.8096	-0.5124	0.0567					41.0	1.34e-05						0.693147181	2.0	1.0	1.516489143	918.8894778999999	-373.0915676	1668.504339	0.0	1928.0	0.0	1928.0	7.142262588946661	8.090402296593322	-0.553847403961438	5.849494285837594	7.134890851565885	1.416879636918418	-1.2927683031090673	-0.9555114450274362	1.970727040879856
13722.58cfa831e4b0c9d6adf6cd1e	58cfa831e4b0c9d6adf6cd1e	TCGA-EX-A1H6-01B-11D-A232_140124_SN208_0506_BC2PD5ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EX-A1H6-01B-11D-A232_140124_SN208_0506_BC2PD5ACXX_s_3_rg.sorted	TCGA-EX-A1H6-01B-11D-A232_140124_SN208_0506_BC2PD5ACXX_s_3_rg.sorted.bam	47.39		0.16	58cfa831e4b0c9d6adf6cd1e	TCGA-EX-A1H6-01B-11D-A232_140124_SN208_0506_BC2PD5ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE		Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EX-A1H6-01B	1FE594D9-4240-49EE-8AFD-C7D16A377181	Primary Tumor	Illumina HiSeq	32948425-770d-4a87-8c3d-ade77ab0391d	Cervix	38.0	FE018D31-EEE8-4335-96A1-95ECEABFADF1	DD730721-CEC0-4034-B18D-588A200D4D76	TCGA-EX-A1H6-01B-11D-A232-26	HG19_Broad_variant	TCGA-EX-A1H6	TCGA-CESC		s1197	MD Anderson - Institute for Applied Cancer Science	University of North Carolina	United States	NO	T1b1	N0	Endocervical Type of Adenocarcinoma		A232-26	True	CESC	C2		0.09608953699999999	0.38	0.0	20.48613749	0.5907	0.20199999999999999	-0.6824	0.3022	0.9117	-0.0046	27.0	3.0	0.708748553	1.7275745980000001	64.0	0.195820832	4.0	15.0				2.098147389	9.0	0.954908028	2.81701568	-339.3531745	-108.97728640000001	-2535.930882	0.0	241.0	0.0	241.0	7.918992488165246	7.1042810323920556	0.2896073377703702	5.721767910829027	6.062827157563894		-2.197224577336219	-1.0414538748281612	
13722.58cfa831e4b0c9d6adf6cd23	58cfa831e4b0c9d6adf6cd23	TCGA-F1-6874-01A-11D-1880_121220_SN1120_0207_BC1JALACXX_s_7_rg.sorted.filtered.	WGS	TCGA-F1-6874-01A-11D-1880_121220_SN1120_0207_BC1JALACXX_s_7_rg.sorted	TCGA-F1-6874-01A-11D-1880_121220_SN1120_0207_BC1JALACXX_s_7_rg.sorted.bam	373.7	1.9	0.14	58cfa831e4b0c9d6adf6cd23	TCGA-F1-6874-01A-11D-1880_121220_SN1120_0207_BC1JALACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-F1-6874-01A	106F3344-F699-4B2C-8F62-4AC6C948DDE4	Primary Tumor	Illumina HiSeq	734d68fe-de19-4aef-8031-8ba255233eba	Stomach	79.0	C28FEBB9-E845-462F-B6A0-CB565EE6A049	273DDC2E-8E77-4F81-85C2-B9A8583D9E1D	TCGA-F1-6874-01A-11D-1880-02	HG19_Broad_variant	TCGA-F1-6874	TCGA-STAD		s14773	Harvard Medical School	UNC	United States	NO	T2	N0	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1880-02	True	STAD	C1	GI.HM-indel	0.321982535	0.4	0.07	4.945781243	0.6074	0.0515	0.5148	0.2171	0.2822	0.5878			8.041991142	23.35049571	71.0	0.08567262	4.0	5.0	0.542053354	2.141784912	52.0	4.71316732	119.0	0.986199107	2.717645587	155.93292030000003	293.78787880000004	1738.895105	0.0	440.0	0.0	440.0	7.959325874014931	8.229415876333784	-2.4508137746315612	7.01486426517408	7.107273090255481	-0.23937722738918144	-0.9444616088408513	-1.122142786078304	2.21143654724238
13722.58cfa831e4b0c9d6adf6cd2c	58cfa831e4b0c9d6adf6cd2c	TCGA-EJ-5495-01A-01D-1572_130125_SN1120_0233_AD1K3HACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EJ-5495-01A-01D-1572_130125_SN1120_0233_AD1K3HACXX_s_1_rg.sorted	TCGA-EJ-5495-01A-01D-1572_130125_SN1120_0233_AD1K3HACXX_s_1_rg.sorted.bam	176.7	1.9	0.15	58cfa831e4b0c9d6adf6cd2c	TCGA-EJ-5495-01A-01D-1572_130125_SN1120_0233_AD1K3HACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5495-01A	962DD3D5-8501-4658-8CB9-2424B476124C	Primary Tumor	Illumina HiSeq	a2c14576-771c-460f-a71b-e25651274ca1	Prostate	68.0	8E53414F-455E-4665-AE0E-9E7405262A96	5644F0E3-3A3B-411A-B28D-C93C3BBD8F86	TCGA-EJ-5495-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5495	TCGA-PRAD		s3597	Harvard Medical School	University of Pittsburgh	United States	NO	T3b	N1	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.1-ERG	0.244164894	0.58	0.16	2.073010251	-0.8433	-0.249	-0.0284	0.4602	-0.4908	0.099	31.0	61.0	0.46705701299999997	1.758332283	78.0	0.12194481800000001	3.0	17.0	0.708707801	1.140621203	5.0	3.7616607280000003	44.0	0.99404657	1.9623458409999999	389.2438346	8.266161935	1572.78602	0.0	1760.0	0.0	1760.0	9.005527777346696	8.740304742218436	-0.5617223127432187	6.479799133038441	8.452622669766656	1.9613691123012766	-2.525728644308255	-0.2876820724517808	2.5230914250444956
13722.58cfa831e4b0c9d6adf6cd39	58cfa831e4b0c9d6adf6cd39	TCGA-ET-A25L-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-ET-A25L-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_6_rg.sorted	TCGA-ET-A25L-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_6_rg.sorted.bam	63.41	1.93	0.17	58cfa831e4b0c9d6adf6cd39	TCGA-ET-A25L-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-ET-A25L-01A	4481D84D-109E-44A0-BCB4-E6E61BDCE796	Primary Tumor	Illumina HiSeq	bd558097-490f-4ee3-af4a-093fd4aebaf1	Thyroid	52.0	7D90939F-BAB7-4A39-8D57-79540142BB63	3490DBDC-8BFC-476F-BC1F-2D142365D9A2	TCGA-ET-A25L-01A-11D-A16N-02	HG19_Broad_variant	TCGA-ET-A25L	TCGA-THCA		s12524	Harvard Medical School	Johns Hopkins	United States	NO	T3	N1b	Thyroid Papillary Carcinoma - Tall Cell (>= 50% tall cell features)	Stage IVA	A16N-02	True	THCA	C3	THCA.4	0.13111995199999998				-1.829	-0.3055	-0.0454	-0.4168	-0.4421	0.4084					73.0	0.011190324	0.0	0.0				1.098612289	3.0	1.0	1.22657394	732.7022504	-1092.967291	1035.147625	0.0	1721.0	0.0	1721.0	6.929136180844689	7.023066125493131	-0.28560129992386796	6.155946292611207	6.084796486900201	1.6661962462527091	-0.7731898882334818	-0.9382696385929301	1.9517975461765773
13722.58cfa831e4b0c9d6adf6cd3c	58cfa831e4b0c9d6adf6cd3c	TCGA-ET-A25M-01A-11D-A16N_120718_SN590_0170_BD141RACXX_s_6_rg.sorted.filtered.	WGS	TCGA-ET-A25M-01A-11D-A16N_120718_SN590_0170_BD141RACXX_s_6_rg.sorted	TCGA-ET-A25M-01A-11D-A16N_120718_SN590_0170_BD141RACXX_s_6_rg.sorted.bam	54.33	1.96	0.17	58cfa831e4b0c9d6adf6cd3c	TCGA-ET-A25M-01A-11D-A16N_120718_SN590_0170_BD141RACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-ET-A25M-01A	8023D4C9-B56D-417A-9A52-D45B59C756ED	Primary Tumor	Illumina HiSeq	893b646b-2fc5-4163-905e-37bfeb036280	Thyroid	33.0	0C601625-ED21-47E5-BC3D-A0057D6A148F	7DE80DCB-BBFD-4D87-AD80-EE29258EFFD1	TCGA-ET-A25M-01A-11D-A16N-02	HG19_Broad_variant	TCGA-ET-A25M	TCGA-THCA		s12002	Harvard Medical School	Johns Hopkins	United States	NO	T2	N1	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	True	THCA	C3	THCA.4	0.062448307				-1.736	-0.3785	-0.4951	-1.2443	-0.8037	0.2539					29.0	1.61e-06						1.098612289	3.0	1.0	1.185013584	473.01940470000005	-940.4152196	2482.143072	0.0	1831.0	0.0	1831.0	7.286739509840704	8.51830685677499	-0.046206486866060215	6.560802506457768	7.373174552471987	0.8770463357879784	-0.7259370033829362	-1.1451323043030028	0.9232528226540386
13722.58cfa831e4b0c9d6adf6cd50	58cfa831e4b0c9d6adf6cd50	TCGA-FD-A3SQ-01A-21D-A233_120830_SN208_0424_BD1DKLACXX_s_5_rg.sorted.filtered.	WGS	TCGA-FD-A3SQ-01A-21D-A233_120830_SN208_0424_BD1DKLACXX_s_5_rg.sorted	TCGA-FD-A3SQ-01A-21D-A233_120830_SN208_0424_BD1DKLACXX_s_5_rg.sorted.bam	35.93		0.14	58cfa831e4b0c9d6adf6cd50	TCGA-FD-A3SQ-01A-21D-A233_120830_SN208_0424_BD1DKLACXX_s_5_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3SQ-01A	3071CB51-DCF5-41F7-B047-AFC2DCBF0AAF	Primary Tumor	Illumina HiSeq	104a1ca4-a3b6-42e6-b6ba-1b0916160573	Bladder	62.0	A78A8C62-06ED-4562-B529-D30A5D1508E7	749C6741-66D9-4BEE-B5D6-7F6C4F9F0F88	TCGA-FD-A3SQ-01A-21D-A233-26	HG19_Broad_variant	TCGA-FD-A3SQ	TCGA-BLCA	1423.0	s3295	MD Anderson - Institute for Applied Cancer Science	BLN - University Of Chicago	United States	NO	T3a	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A233-26	True	BLCA	C2	BLCA.2	0.24071960399999998	0.5	0.36	4.15622321	-0.8269	-0.1925	0.1214	0.3905	1.3736	0.7066	28.0	1.0	0.8177707190000001	1.81077802	73.0	0.36449842200000004	9.0	18.0	0.860249918	3.522159572	60.0	2.441015278	12.0	0.982336813	1.672526881	-1026.294732	-308.78419360000004	1849.3559559999999	1.0	1423.0	1.0	991.0	6.487176533063925	9.439253911512306	-0.14156443331988855	6.1098823019224575	8.83311810794199	3.8911687615472377	-0.37729423114146776	-0.6061358035703157	4.032733194867126
13722.58cfa831e4b0c9d6adf6cd5c	58cfa831e4b0c9d6adf6cd5c	TCGA-EJ-5494-01A-01D-1572_130125_SN208_0451_BD1RB1ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EJ-5494-01A-01D-1572_130125_SN208_0451_BD1RB1ACXX_s_7_rg.sorted	TCGA-EJ-5494-01A-01D-1572_130125_SN208_0451_BD1RB1ACXX_s_7_rg.sorted.bam	107.7	1.9	0.15	58cfa831e4b0c9d6adf6cd5c	TCGA-EJ-5494-01A-01D-1572_130125_SN208_0451_BD1RB1ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5494-01A	E27C50E2-2A41-4F8C-9EF8-2BC51FB0C23E	Primary Tumor	Illumina HiSeq	01d186ab-6289-40da-9715-4f766da74b10	Prostate	50.0	37103479-02BD-45E8-95B3-7A4A78523999	9AA32D54-78ED-4DFC-ACA4-E1A88404F791	TCGA-EJ-5494-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5494	TCGA-PRAD		s4131	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.6-FOXA1	0.12134226199999999	0.26	0.06	5.580238357000001	-1.2638	-0.12	-0.4996	-0.2194	-0.7478	-0.2624	18.0	1.0	0.22681086399999997	0.7087839509999999	59.0	0.0008188080000000001	0.0	0.0	0.966846332	0.670166809	2.0	2.36938212	11.0	0.9881090920000001	3.284462574	-415.17307650000004	-1484.0379560000001	3211.748678	0.0	1477.0	0.0	1477.0	7.414572881350589	8.046282484233004	-0.33146759860897235	5.2173483040143696	7.004828609404842	7.238975653448401	-2.197224577336219	-1.0414538748281612	7.570443252057373
13722.58cfa831e4b0c9d6adf6cd62	58cfa831e4b0c9d6adf6cd62	TCGA-EJ-5498-01A-01D-1572_130125_SN1120_0233_AD1K3HACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EJ-5498-01A-01D-1572_130125_SN1120_0233_AD1K3HACXX_s_7_rg.sorted	TCGA-EJ-5498-01A-01D-1572_130125_SN1120_0233_AD1K3HACXX_s_7_rg.sorted.bam	52.7	1.9	0.17	58cfa831e4b0c9d6adf6cd62	TCGA-EJ-5498-01A-01D-1572_130125_SN1120_0233_AD1K3HACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5498-01A	79EC7468-9AAF-4BB0-94C7-72BE4F497868	Primary Tumor	Illumina HiSeq	1ea5110e-6493-415f-ae21-019a8d1e2a17	Prostate	56.0	AAF0AF43-DAE0-4AA7-9D4C-6CAF1F039857	24F583BD-C378-4981-A661-97B8E39CE600	TCGA-EJ-5498-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5498	TCGA-PRAD		s3948	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.1-ERG	0.149044139	0.7	0.02	0.7157620109999999	-1.6406	-0.282	-0.2739	0.1617	-0.3853	0.0099	18.0		0.335174718	0.64241821	54.0	0.031808824	2.0	0.0	0.965636133	0.669327963	2.0	2.48490665	12.0	1.0	2.039492696	910.2795447000001	-346.9083006	3066.468215	0.0	1720.0	0.0	1720.0	7.960847052348438	7.349025015654773	-0.2363640274269001	5.709555253741943	7.734687496466758	2.4665019369207526	-2.251291798606495	0.3856624808119844	2.7028659643476525
13722.58cfa831e4b0c9d6adf6cd64	58cfa831e4b0c9d6adf6cd64	TCGA-FD-A3SS-01A-12D-A233_120905_SN1120_0187_AD1E4NACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FD-A3SS-01A-12D-A233_120905_SN1120_0187_AD1E4NACXX_s_1_rg.sorted	TCGA-FD-A3SS-01A-12D-A233_120905_SN1120_0187_AD1E4NACXX_s_1_rg.sorted.bam	37.16		0.15	58cfa831e4b0c9d6adf6cd64	TCGA-FD-A3SS-01A-12D-A233_120905_SN1120_0187_AD1E4NACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3SS-01A	7B98B829-FDC7-4719-BEE9-C83F6154019C	Primary Tumor	Illumina HiSeq	23aab0ed-a2ae-43db-9050-527db1729aa5	Bladder	66.0	015E6B08-AB3C-4D1D-99E4-77B5E10BD7FC	315B09D3-D014-4EF1-9CAC-AD5F63F6024A	TCGA-FD-A3SS-01A-12D-A233-26	HG19_Broad_variant	TCGA-FD-A3SS	TCGA-BLCA		s3302	MD Anderson - Institute for Applied Cancer Science	BLN - University Of Chicago	United States	NO	T4	N3	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A233-26	True	BLCA	C2	BLCA.2	0.153883236	0.24	0.25	3.8887907260000003	0.9554	0.2515	-1.1765	-1.5671	0.2457	-0.0985	177.0	79.0	4.3546082230000005	12.09286473	146.0	0.779887578	8.0	34.0	0.9998853609999999	1.098486345	3.0		0.0		2.311242509	-1423.048036	761.9658032000001	-3248.267639	1.0	391.0	1.0	220.0	7.02814928217924	8.617239612250295	0.4077261068595254	6.100162510541894	7.678969973657365	1.2096184570815245	-0.9279867716373462	-0.9382696385929301	0.801892350221999
13722.58cfa831e4b0c9d6adf6cd65	58cfa831e4b0c9d6adf6cd65	TCGA-FE-A232-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_5_rg.sorted.filtered.	WGS	TCGA-FE-A232-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_5_rg.sorted	TCGA-FE-A232-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_5_rg.sorted.bam	72.56	2.05	0.18	58cfa831e4b0c9d6adf6cd65	TCGA-FE-A232-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FE-A232-01A	5EB0D577-223B-4409-89D1-5C5D196AFFC3	Primary Tumor	Illumina HiSeq	ca8aaa05-1546-46a2-aee9-1ad97cadf087	Thyroid	44.0	213BE6EE-1E61-4FA0-9B73-66B696086397	AD42DF5B-2665-4CA1-8049-943F684B6BFD	TCGA-FE-A232-01A-11D-A14U-02	HG19_Broad_variant	TCGA-FE-A232	TCGA-THCA		s12530	Harvard Medical School	Ohio State University	United States	NO	T3	NX	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A14U-02	True	THCA	C3	THCA.	0.102101662	0.47	0.0		-1.6989	-0.29100000000000004	0.1859	0.2381	0.2599	0.0298	5.0		0.0	0.237612136	43.0	8.31e-06	0.0	0.0	0.8993323759999999	2.7380375960000003	21.0	2.6156305769999997	14.0	0.99112306	1.315745052	608.2516668	-1292.75116	2187.011894	0.0	2424.0	0.0	2424.0	5.738403464443907	6.008853463360231	-0.05314265160270237	4.511957804265913	5.829267886385152	2.798085550657291	-1.2264456601779945	-0.1795855769750796	2.851228202259993
13722.58cfa831e4b0c9d6adf6cd6c	58cfa831e4b0c9d6adf6cd6c	TCGA-ET-A25R-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_4_rg.sorted.filtered.	WGS	TCGA-ET-A25R-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_4_rg.sorted	TCGA-ET-A25R-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_4_rg.sorted.bam	101.84	1.93	0.17	58cfa831e4b0c9d6adf6cd6c	TCGA-ET-A25R-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-ET-A25R-01A	097B9CF1-EC0C-487C-9ADE-2BDAB12EB4CA	Primary Tumor	Illumina HiSeq	442f6193-a979-40e4-89db-2e541d3ebdb7	Thyroid	51.0	C29162A3-F162-4D32-AB9A-421BE1FEB13C	77A80565-1BC9-4F0A-AFB3-23955FE283EB	TCGA-ET-A25R-01A-11D-A16N-02	HG19_Broad_variant	TCGA-ET-A25R	TCGA-THCA		s12003	Harvard Medical School	Johns Hopkins	United States	NO	T3	NX	Thyroid Papillary Carcinoma - Tall Cell (>= 50% tall cell features)	Stage III	A16N-02	True	THCA	C3	THCA.4	0.11599511300000001	0.33	0.0		-1.6916	-0.349	-0.1729	-0.3257	-0.1219	0.1721	3.0		0.116433757	0.232867515	41.0	4.42e-06	0.0	0.0	0.298167105	0.206673688	2.0	2.36938212	11.0	0.9881090920000001	0.983848713	496.95723330000004	-910.1564356	2820.999879	0.0	1930.0	0.0	1930.0	7.372013266931794	8.085692068757233	-0.36706257230031014	6.736024500211797	6.933012558818847	0.855362420223934	-0.635988766719997	-1.1526795099383853	1.2224249925242443
13722.58cfa831e4b0c9d6adf6cd6e	58cfa831e4b0c9d6adf6cd6e	TCGA-F5-6814-01A-31D-1924-10_wgs_Illumina.filtered.	WGS	TCGA-F5-6814-01A-31D-1924-10_wgs_Illumina	TCGA-F5-6814-01A-31D-1924-10_wgs_Illumina.bam	336.7		0.05	58cfa831e4b0c9d6adf6cd6e	TCGA-F5-6814-01A-31D-1924-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Rectum Adenocarcinoma	Aligned reads	TCGA-F5-6814-01A	8FEB0E8F-D09B-437D-8651-0CDECFE776BF	Primary Tumor	Illumina HiSeq	4980286e-15f8-4cb0-b7f7-8e68f04c699f	Colorectal	57.0	81AB66E0-6470-409B-AA27-846C869D2C8F	14C5B81D-DA49-4DB1-9834-77711C2B1D38	TCGA-F5-6814-01A-31D-1924-10	GRCh37-lite	TCGA-F5-6814	TCGA-READ		s2012	Baylor College of Medicine	Asterand	Russia	NO	T2	N0	Rectal Adenocarcinoma	Stage IIA	1924-10	False	READ	C2	GI.HM-SNV	0.18912105899999998	0.28	0.37		1.0631	0.4305	-0.1398	0.2059	0.2422	-0.0353	4595.0	74.0	54.95490756	252.4305455	186.0	0.09191573	0.0	7.0	0.970330046	2.906849034	20.0	3.3445488589999997	29.0	0.993244736	2.378872456	-343.5859438	915.5921673	-2029.714898	0.0	1131.0	0.0	1131.0	7.511758941023434	4.702787378887647	-0.07239234139615636	6.090373260092273	5.577555055061182	2.065015061969613	-1.421385680931161	0.8747676761735343	2.1374074033657693
13722.58cfa831e4b0c9d6adf6cd74	58cfa831e4b0c9d6adf6cd74	TCGA-ET-A25K-01A-11D-A16N_120717_SN1120_0176_BC1178ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-ET-A25K-01A-11D-A16N_120717_SN1120_0176_BC1178ACXX_s_7_rg.sorted	TCGA-ET-A25K-01A-11D-A16N_120717_SN1120_0176_BC1178ACXX_s_7_rg.sorted.bam	57.24	2.0	0.17	58cfa831e4b0c9d6adf6cd74	TCGA-ET-A25K-01A-11D-A16N_120717_SN1120_0176_BC1178ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-ET-A25K-01A	2F9ED09D-2626-4C23-BA47-1850D36F812A	Primary Tumor	Illumina HiSeq	81720382-db9a-41e3-814e-ee8ec59ce22d	Thyroid	36.0	343311B1-D586-4F92-9984-32AF1AFB1F62	663173D3-A9EE-4E73-8444-52F01727BE6D	TCGA-ET-A25K-01A-11D-A16N-02	HG19_Broad_variant	TCGA-ET-A25K	TCGA-THCA		s12115	Harvard Medical School	Johns Hopkins	United States	NO	T2	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	True	THCA	C3	THCA.5	0.08442087	0.3	0.0		-1.6163	-0.3405	-0.5963	-1.1468	-0.2387	0.2185	1.0		0.059312616	0.14828154	35.0	7.47e-06	0.0	0.0				0.0	1.0		1.332405527	957.8374697999999	-598.9532829	609.7579384	0.0	2142.0	0.0	2142.0	7.697178082247303	7.433370988220762	-0.566726891162422	6.3754222422649836	6.622440772004434	1.474748052593563	-1.3217558399823197	-0.8109302162163288	2.041474943755985
13722.58cfa831e4b0c9d6adf6cd7a	58cfa831e4b0c9d6adf6cd7a	TCGA-EY-A1GC-01A-11D-A13I_120516_SN1222_0107_BD12HYACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EY-A1GC-01A-11D-A13I_120516_SN1222_0107_BD12HYACXX_s_5_rg.sorted	TCGA-EY-A1GC-01A-11D-A13I_120516_SN1222_0107_BD12HYACXX_s_5_rg.sorted.bam	63.8	1.81	0.16	58cfa831e4b0c9d6adf6cd7a	TCGA-EY-A1GC-01A-11D-A13I_120516_SN1222_0107_BD12HYACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-EY-A1GC-01A	EBC25A41-BECB-4395-AE33-483A304B07D8	Primary Tumor	Illumina HiSeq	e6c7f95a-f103-4fbc-a123-91eefcfbf4c2	Uterus	62.0	06BE0E15-E48E-4243-AD8D-86CCA9DA68F9	C8E60958-98D8-4EE6-BAA1-DEEEECFF141F	TCGA-EY-A1GC-01A-11D-A13I-02	HG19_Broad_variant	TCGA-EY-A1GC	TCGA-UCEC		s4620	Harvard Medical School	University of North Carolina	United States	NO			Endometrioid endometrial adenocarcinoma		A13I-02	False	UCEC	C2	UCEC.CN_HIGH	0.306387836	0.42	0.26		0.2679	0.2	0.4512	1.5816	0.4538	-0.7404	12.0	7.0	0.325910674	0.695276105	302.0	0.653068568	16.0	49.0							2.270095247	-1303.410863	-554.0770848	2721.959167	0.0	1647.0	0.0	1647.0	4.059337182721688	8.087300567155483	0.7762459477930881	3.016376148602956	6.589088289831606	2.9354014120045866	-1.0429610341187319	-1.4982122773238764	2.1591554642114987
13722.58cfa831e4b0c9d6adf6cd7c	58cfa831e4b0c9d6adf6cd7c	TCGA-FD-A3B3-01A-12D-A204_121002_SN1222_0155_BD1ERHACXX_s_7_rg.sorted.filtered.	WGS	TCGA-FD-A3B3-01A-12D-A204_121002_SN1222_0155_BD1ERHACXX_s_7_rg.sorted	TCGA-FD-A3B3-01A-12D-A204_121002_SN1222_0155_BD1ERHACXX_s_7_rg.sorted.bam	42.39		0.15	58cfa831e4b0c9d6adf6cd7c	TCGA-FD-A3B3-01A-12D-A204_121002_SN1222_0155_BD1ERHACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3B3-01A	4B5D873B-BFDA-482E-92A0-BF84C0F9032A	Primary Tumor	Illumina HiSeq	6b702a7f-ff83-4ff2-96a8-9da2f015ebcc	Bladder	74.0	769EE027-5ED7-4EC2-86B5-FE40F9D6FB5A	57731F40-BBEF-4C7B-BFDC-CE75DA6EB1EB	TCGA-FD-A3B3-01A-12D-A204-02	HG19_Broad_variant	TCGA-FD-A3B3	TCGA-BLCA		s2903	Harvard Medical School	BLN - University Of Chicago	United States	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A204-02	True	BLCA	C2	BLCA.3	0.578241175	0.79	0.43	11.492580300000002	1.1164	0.3965	0.7826	1.6164	1.4092	0.7329	49.0	2.0	1.467052118	4.462283527	106.0	0.22176967	10.0	11.0	0.821778692	4.149864066	156.0	3.737175228	51.0	0.950493632	5.948896846	437.1266597	1339.20725	-2584.945432	1.0	974.0	0.0	974.0	7.782062627899782	6.987426564902007	0.0682445167318887	6.54991894660715	6.987426564902007	2.109904986443703	-1.2321436812926327	0.0	2.041660469711814
13722.58cfa831e4b0c9d6adf6cd7e	58cfa831e4b0c9d6adf6cd7e	TCGA-FE-A3PD-01A-11D-A221_120611_SN1222_0115_BD141KACXX_s_7_rg.sorted.filtered.	WGS	TCGA-FE-A3PD-01A-11D-A221_120611_SN1222_0115_BD141KACXX_s_7_rg.sorted	TCGA-FE-A3PD-01A-11D-A221_120611_SN1222_0115_BD141KACXX_s_7_rg.sorted.bam	59.24		0.15	58cfa831e4b0c9d6adf6cd7e	TCGA-FE-A3PD-01A-11D-A221_120611_SN1222_0115_BD141KACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FE-A3PD-01A	39D90499-8549-4DA5-B391-C421F18FACF1	Primary Tumor	Illumina HiSeq	66155739-2eb1-4230-8b24-645dca4e0c0d	Thyroid	17.0	A6C23CA9-E6F4-4A2C-BB86-25EF76076381	3F63EB17-5F71-4EEC-AEF5-1D4FF328043C	TCGA-FE-A3PD-01A-11D-A221-26	HG19_Broad_variant	TCGA-FE-A3PD	TCGA-THCA		s12390	MD Anderson - Institute for Applied Cancer Science	Ohio State University	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A221-26	True	THCA	C3	THCA.5	0.099758975	0.15	0.0		-1.7547	-0.1705	-0.0747	0.4551	-0.1749	-0.154	4.0		0.029040572999999997	0.17424343899999997	51.0	7.11e-05	0.0	0.0	0.938546397	2.982750973	24.0	2.665069073	17.0	0.94065245	1.7568116619999998	310.8156518	-817.0878644999999	-1193.119593	0.0	2396.0	0.0	2396.0	6.823389749298785	8.581133319266538	0.28510142585828957	6.061249697251888	7.391549252392702	1.9748754424514643	-0.7621400520468966	-1.1895840668738364	1.6897740165931747
13722.58cfa831e4b0c9d6adf6cd82	58cfa831e4b0c9d6adf6cd82	TCGA-FE-A230-01A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-FE-A230-01A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_2_rg.sorted	TCGA-FE-A230-01A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_2_rg.sorted.bam	73.25	2.05	0.17	58cfa831e4b0c9d6adf6cd82	TCGA-FE-A230-01A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FE-A230-01A	B1D71782-2443-43F3-BD0E-8B7220515CB6	Primary Tumor	Illumina HiSeq	5aeaadf5-f228-4383-97ce-9048120f8b41	Thyroid	30.0	12FC3F30-08FB-47C6-92F1-009D961C1E94	001C6478-B20D-40D8-AF62-C45C64269129	TCGA-FE-A230-01A-11D-A14U-02	HG19_Broad_variant	TCGA-FE-A230	TCGA-THCA		s12389	Harvard Medical School	Ohio State University	United States	NO	T3	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A14U-02	True	THCA	C3	THCA.4	0.172178353	0.37	0.0		-1.2632	-0.3815	0.3048	1.0713	0.3576	-0.0869	2.0	8.0	0.029499662000000003	0.11799865	53.0	2.9600000000000005e-05	0.0	0.0	0.8826558729999999	4.5331426519999996	170.0	3.295836866	27.0	1.0	1.197127098	736.3596175	-771.0178695000001	1782.3474170000002	0.0	2173.0	1.0	526.0	6.877715990955414	7.108499835352868	0.02376674047165328	5.925057614910384	6.217526911463003	3.03264748686915	-0.9526583760450302	-0.8909729238898652	3.008880746397497
13722.58cfa831e4b0c9d6adf6cd84	58cfa831e4b0c9d6adf6cd84	TCGA-FE-A235-01A-11D-A16N_121204_SN208_0442_BC1F7YACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FE-A235-01A-11D-A16N_121204_SN208_0442_BC1F7YACXX_s_1_rg.sorted	TCGA-FE-A235-01A-11D-A16N_121204_SN208_0442_BC1F7YACXX_s_1_rg.sorted.bam	74.82	2.0	0.17	58cfa831e4b0c9d6adf6cd84	TCGA-FE-A235-01A-11D-A16N_121204_SN208_0442_BC1F7YACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FE-A235-01A	C781B49E-D08F-49E6-B774-7CFE4100E92D	Primary Tumor	Illumina HiSeq	7eafbe04-60be-48a5-8e8a-937b1dde35e8	Thyroid	26.0	377A0CBF-6A82-43FA-BC95-DADECED8916D	F3F4F8FB-6FAD-46B7-85D0-C591EB926DD7	TCGA-FE-A235-01A-11D-A16N-02	HG19_Broad_variant	TCGA-FE-A235	TCGA-THCA		s12528	Harvard Medical School	Ohio State University	United States	NO	T2	N1	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	True	THCA	C3	THCA.5	0.08637805	0.13	0.0		-1.6994	-0.096	-0.253	0.2669	-0.7129	0.2265	4.0	0.0	0.029406742000000003	0.323474164	47.0	0.02305229	0.0	3.0	0.9409893490000001	1.686026576	6.0	0.0	1.0		1.547284951	916.9463515000001	-926.2127785	98.70438379	0.0	3571.0	0.0	3571.0	7.972580951897914	7.132963364345226	0.02895207315558712	4.503378841121702	5.904297947428918	3.2653575622585294	-3.4692021107762128	-1.2286654169163076	3.236405489102942
13722.58cfa831e4b0c9d6adf6cd8c	58cfa831e4b0c9d6adf6cd8c	TCGA-EJ-7781-01A-11D-2111_130502_SN590_0228_AD24A9ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-EJ-7781-01A-11D-2111_130502_SN590_0228_AD24A9ACXX_s_6_rg.sorted	TCGA-EJ-7781-01A-11D-2111_130502_SN590_0228_AD24A9ACXX_s_6_rg.sorted.bam	168.3		0.16	58cfa831e4b0c9d6adf6cd8c	TCGA-EJ-7781-01A-11D-2111_130502_SN590_0228_AD24A9ACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-7781-01A	33283111-9A2F-4D5E-92A5-3435846404F7	Primary Tumor	Illumina HiSeq	bf6c4719-7b88-4975-9591-8bd34c19e3cf	Prostate	65.0	B5504343-6915-4D15-A81E-641B03C77F24	193083B4-B2E1-486C-A4F5-F62818AEBBC2	TCGA-EJ-7781-01A-11D-2111-02	HG19_Broad_variant	TCGA-EJ-7781	TCGA-PRAD		s4141	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		2111-02	True	PRAD	C3	PRAD.8-other	0.137917411	0.41	0.28		-1.1231	-0.2645	-0.4352	-0.0055	-0.6531	-0.2611	22.0	19.0	0.531660878	1.417762341	64.0	0.106511865	1.0	8.0	0.7491403190000001	1.977024251	14.0	2.685945325	15.0	0.991837346	2.248156808	-384.2889031	-379.72301880000003	3377.102039	0.0	1073.0	0.0	1073.0	6.715989263360183	6.5335465605245275	-0.6014548775635046	4.413404170366137	5.492092685696366	3.5269314638266462	-2.3025850929940455	-1.0414538748281612	4.128386341390151
13722.58cfa831e4b0c9d6adf6cd90	58cfa831e4b0c9d6adf6cd90	TCGA-FE-A3PA-01A-12D-A221_120611_SN1222_0114_AC0WL3ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FE-A3PA-01A-12D-A221_120611_SN1222_0114_AC0WL3ACXX_s_1_rg.sorted	TCGA-FE-A3PA-01A-12D-A221_120611_SN1222_0114_AC0WL3ACXX_s_1_rg.sorted.bam	44.72		0.15	58cfa831e4b0c9d6adf6cd90	TCGA-FE-A3PA-01A-12D-A221_120611_SN1222_0114_AC0WL3ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FE-A3PA-01A	10BDAFBB-831D-48B5-B9A3-AD374FC50235	Primary Tumor	Illumina HiSeq	0d67cded-ff5a-4b7c-bc1e-2bda8ee44700	Thyroid	16.0	D37BED2A-BF63-43E0-91D0-6C95E4CA2D45	DBD2621E-9F39-45C6-B9AE-67873AECA03D	TCGA-FE-A3PA-01A-12D-A221-26	HG19_Broad_variant	TCGA-FE-A3PA	TCGA-THCA		s12760	MD Anderson - Institute for Applied Cancer Science	Ohio State University	United States	NO	T4	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage II	A221-26	True	THCA	C3	THCA.5	0.072332544	0.19	0.0		-1.6717	-0.247	-0.2156	-0.5993	-0.4076	-0.0428	2.0		0.02789262	0.05578524	79.0	5.8200000000000005e-05	0.0	0.0				1.475076311	5.0	0.916516443	2.156251348	-87.44169694	-1295.249301	1008.660624	0.0	3235.0	0.0	3235.0	7.266319346493663	9.454096679859559	0.474121685854653	5.903014503598472	8.250123875533623	2.4109943915012306	-1.3633048428951917	-1.203972804325936	1.9368727056465778
13722.58cfa831e4b0c9d6adf6cd9c	58cfa831e4b0c9d6adf6cd9c	TCGA-FD-A3SR-01A-11D-A233_120830_SN208_0424_BD1DKLACXX_s_7_rg.sorted.filtered.	WGS	TCGA-FD-A3SR-01A-11D-A233_120830_SN208_0424_BD1DKLACXX_s_7_rg.sorted	TCGA-FD-A3SR-01A-11D-A233_120830_SN208_0424_BD1DKLACXX_s_7_rg.sorted.bam	39.24		0.14	58cfa831e4b0c9d6adf6cd9c	TCGA-FD-A3SR-01A-11D-A233_120830_SN208_0424_BD1DKLACXX_s_7_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3SR-01A	72D6E9AA-4A99-4FC9-A67B-4631E95FB043	Primary Tumor	Illumina HiSeq	e8c95d25-27f4-4cba-b644-eb39019c6cc0	Bladder	68.0	8E9683F4-52B4-4646-921E-7BF89F56774A	93A2B3C4-915C-46BE-9D36-C244036B7A0C	TCGA-FD-A3SR-01A-11D-A233-26	HG19_Broad_variant	TCGA-FD-A3SR	TCGA-BLCA	602.0	s3116	MD Anderson - Institute for Applied Cancer Science	BLN - University Of Chicago	United States	NO	T4a	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A233-26	True	BLCA	C2	BLCA.2	0.199031751	0.43	0.17	3.0650938360000004	0.1955	-0.0515	0.2402	0.6781	1.796	0.1974	50.0	39.0	0.798291821	3.754928195	255.0	0.642114081	12.0	45.0	0.9787899440000001	0.67844549	2.0	3.35498757	29.0	0.996344764	3.7030625269999997	-2041.309471	593.7528674	-2864.885686	1.0	602.0	1.0	372.0	6.718380333998832	7.7859897958823305	-0.098473071212833	6.236542247106093	7.441149309590601	4.749164938915871	-0.48183808689273855	-0.3448404862917296	4.847638010128704
13722.58cfa831e4b0c9d6adf6cd9e	58cfa831e4b0c9d6adf6cd9e	TCGA-FE-A238-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-FE-A238-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_5_rg.sorted	TCGA-FE-A238-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_5_rg.sorted.bam	71.81	1.88	0.16	58cfa831e4b0c9d6adf6cd9e	TCGA-FE-A238-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FE-A238-01A	DFFC4F7A-C67A-4AC5-A338-717DFFDE686D	Primary Tumor	Illumina HiSeq	004a2d8a-2dac-4e95-b287-dde59c5f0561	Thyroid	36.0	D68C3B99-CB82-48BD-A1F8-BEE0A9A9E8C3	BA986EBD-8E2D-4BAF-AC16-FCEB1286F590	TCGA-FE-A238-01A-11D-A16N-02	HG19_Broad_variant	TCGA-FE-A238	TCGA-THCA		s12004	Harvard Medical School	Ohio State University	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	True	THCA	C2	THCA.3	0.16692726800000002				-0.9107	-0.1875	-0.1612	-0.0987	0.794	0.0017					50.0	0.027499767				0.0	1.0	2.871476118	18.0	0.9934625570000001	1.149515866	412.5019952	-563.778936	1693.7062059999998	0.0	1215.0	1.0	431.0	6.4360613330668714	6.8361399241707606	-0.23824335776996064	5.497791694473941	5.8144886766387796	3.318922886038511	-0.9382696385929306	-1.021651247531981	3.5571662438084717
13722.58cfa831e4b0c9d6adf6cda0	58cfa831e4b0c9d6adf6cda0	TCGA-FE-A233-01A-11D-A14U_120629_SN1222_0121_BD143UACXX_s_3_rg.sorted.filtered.	WGS	TCGA-FE-A233-01A-11D-A14U_120629_SN1222_0121_BD143UACXX_s_3_rg.sorted	TCGA-FE-A233-01A-11D-A14U_120629_SN1222_0121_BD143UACXX_s_3_rg.sorted.bam	92.7	2.05	0.18	58cfa831e4b0c9d6adf6cda0	TCGA-FE-A233-01A-11D-A14U_120629_SN1222_0121_BD143UACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FE-A233-01A	E70FEAFD-1390-4F4C-A635-DA65C1A7DAEB	Primary Tumor	Illumina HiSeq	3609a0f8-b027-4392-adea-96eab2e1d78f	Thyroid	18.0	76A6F76D-F33E-4B4A-B0EE-FB863345F194	4336BC49-7D28-4EB6-8B41-F43127ED8EC1	TCGA-FE-A233-01A-11D-A14U-02	HG19_Broad_variant	TCGA-FE-A233	TCGA-THCA		s12758	Harvard Medical School	Ohio State University	United States	NO	T2	NX	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A14U-02	True	THCA	C3	THCA.3	0.072457265	0.19	0.0		-1.3579	-0.306	-0.6356	-1.4204	-0.0104	-0.0556	7.0		0.058615874000000005	0.263771433	33.0	6.96e-06	0.0	0.0				1.791759469	6.0	1.0	1.2526700640000001	404.3313962	-659.3376479	3005.044725	0.0	751.0	1.0	567.0	5.80076470672888	6.150503591613907	-0.4268328923797269	4.936553123899614	6.4777165028223225	2.659297210963005	-0.8642115828292658	0.32721291120841567	3.0861301033427315
13722.58cfa831e4b0c9d6adf6cda9	58cfa831e4b0c9d6adf6cda9	TCGA-FG-7636-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_3_rg.sorted.filtered.	WGS	TCGA-FG-7636-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_3_rg.sorted	TCGA-FG-7636-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_3_rg.sorted.bam	103.7		0.15	58cfa831e4b0c9d6adf6cda9	TCGA-FG-7636-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-FG-7636-01A	B342E980-8383-4F1B-BF57-4098C37A536C	Primary Tumor	Illumina HiSeq	336bd48f-3c20-4a2f-a2ef-38bb94e30e11	Brain	48.0	BF70C0A6-CA2D-4355-B5BA-738094382E28	CE49A704-BECD-4A35-978B-4E21572CC5B2	TCGA-FG-7636-01A-11D-2088-02	HG19_Broad_variant	TCGA-FG-7636	TCGA-LGG		s8573	Harvard Medical School	Case Western	United States	NO			Astrocytoma		2088-02	False	LGG	C5	GBM_LGG.G-CIMP-high	0.107602128	0.19	0.25		-1.4158	-0.27699999999999997	-0.4349	-2.6043	-0.8137	-1.0716	17.0	55.0	0.241984681	1.058682979	135.0	0.241884076	3.0	6.0					0.0		3.291301639	-55.70347322	-523.8860737	-3936.6298909999996	0.0	544.0	0.0	544.0	8.417593826193482	8.729828389545107	0.8654484635785923	6.115008733199437	7.688374514716945	2.4983743573199066	-2.3025850929940455	-1.0414538748281612	1.6329258937413142
13722.58cfa831e4b0c9d6adf6cdab	58cfa831e4b0c9d6adf6cdab	TCGA-FE-A234-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-FE-A234-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_2_rg.sorted	TCGA-FE-A234-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_2_rg.sorted.bam	101.34	2.14	0.18	58cfa831e4b0c9d6adf6cdab	TCGA-FE-A234-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FE-A234-01A	E4C85BDD-7B7C-414F-9503-647D9B825915	Primary Tumor	Illumina HiSeq	f1eeb2ea-cc97-40b1-ac5b-fa027012fff2	Thyroid	26.0	8765B072-83E1-40B2-B1C9-15F38D799FC3	D4A41A96-02D5-455E-BB12-7225EBEA15A5	TCGA-FE-A234-01A-11D-A14U-02	HG19_Broad_variant	TCGA-FE-A234	TCGA-THCA		s12388	Harvard Medical School	Ohio State University	United States	NO	T2	N1	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A14U-02	True	THCA	C3	THCA.4	0.13634516300000002	0.42	0.0		-1.6214	-0.2795	0.0163	-0.2941	-0.5235	0.0411	4.0		0.03027922	0.12111687900000001	47.0	2.3899999999999998e-05	0.0	0.0	0.9940302109999999	0.689009238	2.0	2.857102837	18.0	0.9884897429999999	0.9100583170000001	-69.92249942	-916.0981918	1392.222904	0.0	2075.0	1.0	483.0	6.826397312795816	7.365755334549958	-0.05989022602422944	5.94714785260201	6.767918333794338	1.5720253995664655	-0.8792494601938059	-0.5978370007556202	1.631915625590695
13722.58cfa831e4b0c9d6adf6cdaf	58cfa831e4b0c9d6adf6cdaf	TCGA-FE-A22Z-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_3_rg.sorted.filtered.	WGS	TCGA-FE-A22Z-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_3_rg.sorted	TCGA-FE-A22Z-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_3_rg.sorted.bam	78.59	2.03	0.16	58cfa831e4b0c9d6adf6cdaf	TCGA-FE-A22Z-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FE-A22Z-01A	78D14F86-896A-4F98-9274-B2E8E387ADD9	Primary Tumor	Illumina HiSeq	ae24ab9d-6983-466a-a7f4-50da56438303	Thyroid	61.0	D206D300-E0CE-4A40-AF1F-45A685346A6E	B7A31BAC-FD92-47AF-8C9C-E78E3FC1609A	TCGA-FE-A22Z-01A-11D-A16N-02	HG19_Broad_variant	TCGA-FE-A22Z	TCGA-THCA		s12648	Harvard Medical School	Ohio State University	United States	NO	T4a	N1	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage IVA	A16N-02	True	THCA	C3	THCA.4	0.09831236900000001	0.23	0.01		-0.9712	-0.2345	-0.2843	-1.1467	-0.8640000000000001	0.4701	10.0		0.153832967	0.43073230700000004	73.0	0.036903179	1.0	10.0				0.6365141679999999	2.0	0.918295834	1.297964296	276.40339869999997	-603.0905636	1741.465752	0.0	2243.0	1.0	1215.0	7.00435649107423	7.493873886783558	-0.38602029000127513	6.547598088578514	6.90608722188144	2.4606630381780077	-0.4567584024957152	-0.5877866649021186	2.8466833281792825
13722.58cfa831e4b0c9d6adf6cdb1	58cfa831e4b0c9d6adf6cdb1	TCGA-FG-6692-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_6_rg.sorted.filtered.	WGS	TCGA-FG-6692-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_6_rg.sorted	TCGA-FG-6692-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_6_rg.sorted.bam	270.7	1.9	0.15	58cfa831e4b0c9d6adf6cdb1	TCGA-FG-6692-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-FG-6692-01A	5F10CD91-1E03-4016-B35A-8629A1A8FCC9	Primary Tumor	Illumina HiSeq	66eb8fac-6ead-47b2-be40-effbb245f499	Brain	63.0	FDDB3709-5F1C-40C8-A39A-48329DFE9C97	5BB5BFCC-DB34-474C-95E6-3A84C3A7DBAA	TCGA-FG-6692-01A-11D-1891-02	HG19_Broad_variant	TCGA-FG-6692	TCGA-LGG		s8367	Harvard Medical School	Case Western	United States	NO			Oligodendroglioma		1891-02	True	LGG	C4	GBM_LGG.Classic-like	0.177779687	0.16	0.02		-0.1667	0.0335	-0.0006	-1.0788	0.5678	-0.2258	24.0	21.0	0.858634305	1.688647466	98.0	0.175428576	7.0	3.0				0.693147181	2.0	1.0	2.80320207	-123.2474205	-110.55633190000002	-4781.565324	1.0	561.0	1.0	561.0	8.040607950804947	8.435223628548988	-0.12991650832985224	5.68923269364147	6.9688865597555605	4.1662344678183265	-2.3513752571634776	-1.4663370687934272	4.296150976148179
13722.58cfa831e4b0c9d6adf6cdb4	58cfa831e4b0c9d6adf6cdb4	TCGA-FE-A231-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FE-A231-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_1_rg.sorted	TCGA-FE-A231-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_1_rg.sorted.bam	101.76	2.16	0.16	58cfa831e4b0c9d6adf6cdb4	TCGA-FE-A231-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FE-A231-01A	7044DEE0-FD6C-4E75-B731-DC60A386A1AB	Primary Tumor	Illumina HiSeq	2983a837-7d6a-4e9d-a68a-a3aa674fbb8b	Thyroid	70.0	96C298EB-0699-42AE-B2EA-63A192353D69	056B3922-279A-4869-A933-0C53C1137450	TCGA-FE-A231-01A-11D-A14U-02	HG19_Broad_variant	TCGA-FE-A231	TCGA-THCA		s12256	Harvard Medical School	Ohio State University	United States	NO	T3	N1b	Thyroid Papillary Carcinoma - Classical/usual	Stage IVA	A14U-02	True	THCA	C3	THCA.3	0.047320087999999996	0.09	0.0		-0.8705	-0.2675	-0.1372	-1.2217	-0.4935	-0.4727	6.0		0.11926248699999999	0.268340595	60.0	0.058500328	2.0	4.0				1.609437912	5.0	1.0	1.084746797	-442.7924829	-854.3444419	2220.102838	0.0	961.0	0.0	961.0	5.7846901927157415	8.476058648057682	-0.6244535138809156	4.462934352733423	7.579970623501046	1.0334294376113398	-1.3217558399823193	-0.8960880245566356	1.6578829514922555
13722.58cfa831e4b0c9d6adf6cdb6	58cfa831e4b0c9d6adf6cdb6	TCGA-FG-5963-01A-11D-1703_130813_SN1440_0161_BC29ENACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FG-5963-01A-11D-1703_130813_SN1440_0161_BC29ENACXX_s_1_rg.sorted	TCGA-FG-5963-01A-11D-1703_130813_SN1440_0161_BC29ENACXX_s_1_rg.sorted.bam	7.3	2.0	0.13	58cfa831e4b0c9d6adf6cdb6	TCGA-FG-5963-01A-11D-1703_130813_SN1440_0161_BC29ENACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-FG-5963-01A	68F550CA-3A33-45E4-B1C9-14F99E543263	Primary Tumor	Illumina HiSeq	11f814ba-95e7-4824-ab33-1e14947dcbd5	Brain	23.0	41C647E8-6A53-464B-9EFC-78547C514519	166F687B-F395-4AC7-A06A-78826A0722E7	TCGA-FG-5963-01A-11D-1703-02	HG19_Broad_variant	TCGA-FG-5963	TCGA-LGG		s8148	Harvard Medical School	Case Western	United States	NO			Astrocytoma		1703-02	True	LGG	C4	GBM_LGG.PA-like	0.152312001	0.58	0.01		-0.1336	-0.19899999999999998	0.9286	-0.4841	0.2879	-0.2009	16.0		0.030520653	0.38150815899999996	461.0	0.301125605	4.0	30.0				1.9459101490000001	7.0	1.0	4.151997552	-62.34705309	-688.7402216	-2672.1338969999997	1.0	775.0	1.0	395.0	9.06323150693797	8.268598489894725	0.2499351177174005	6.711856249774494	8.597102556866762	4.568112648723279	-2.3513752571634776	0.32850406697203605	4.318177531005879
13722.58cfa831e4b0c9d6adf6cdb8	58cfa831e4b0c9d6adf6cdb8	TCGA-FG-6691-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_8_rg.sorted.filtered.	WGS	TCGA-FG-6691-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_8_rg.sorted	TCGA-FG-6691-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_8_rg.sorted.bam	105.7	1.9	0.16	58cfa831e4b0c9d6adf6cdb8	TCGA-FG-6691-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-FG-6691-01A	E4D9B696-3311-44E7-9191-FDE56C080A00	Primary Tumor	Illumina HiSeq	b404ac67-1c7f-4b01-8038-7432d3d6e489	Brain	23.0	87800B98-1FD3-4A09-AC98-3125962BFA72	B4968770-4D21-4C51-9ECA-47E23D5C240E	TCGA-FG-6691-01A-11D-1891-02	HG19_Broad_variant	TCGA-FG-6691	TCGA-LGG		s8368	Harvard Medical School	Case Western	United States	NO			Astrocytoma		1891-02	True	LGG	C5	GBM_LGG.G-CIMP-high	0.223097577	0.17	0.03		-0.9018	-0.34700000000000003	0.6202	-2.5488	-0.4885	-0.8198	10.0	3.0	0.087387105	0.320419384	64.0	0.093172837	3.0	2.0					0.0		3.2374823569999998	-125.88991770000001	-662.9930986	-1792.907186	0.0	1257.0	1.0	913.0	8.430181814426609	8.182559264068665	3.521682789679243	6.584355123928278	6.978586459742729	2.7994426481776333	-1.8458266904983305	-1.203972804325936	-0.7222401415016098
13722.58cfa831e4b0c9d6adf6cdba	58cfa831e4b0c9d6adf6cdba	TCGA-ER-A19K-01A-21D-A18Y_120723_SN1120_0177_AC11GTACXX_s_1_rg.sorted.filtered.	WGS	TCGA-ER-A19K-01A-21D-A18Y_120723_SN1120_0177_AC11GTACXX_s_1_rg.sorted	TCGA-ER-A19K-01A-21D-A18Y_120723_SN1120_0177_AC11GTACXX_s_1_rg.sorted.bam	38.56		0.15	58cfa831e4b0c9d6adf6cdba	TCGA-ER-A19K-01A-21D-A18Y_120723_SN1120_0177_AC11GTACXX_s_1_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-ER-A19K-01A	F9E36BC2-484F-48E8-82BA-99026957277A	Primary Tumor	Illumina HiSeq	7f909731-9b4e-45a5-b8e0-ae6d67969159	Skin	79.0	E358B11D-2A35-45AE-8910-AE2DC06D39F4	EB5E15F5-55E7-433C-8DD2-AA3DF568F0CF	TCGA-ER-A19K-01A-21D-A18Y-02	HG19_Broad_variant	TCGA-ER-A19K	TCGA-SKCM	469.0	s7862	Harvard Medical School	University of Pittsburgh	United States	NO	T4b	N0		Stage IIC	A18Y-02	True	SKCM	C4	SKCM.BRAF_Hotspot_Mutants	0.363714341	0.42	0.0	3.06310456	0.5006	0.1755	-0.1218	-0.6875	-0.0355	-0.1069	145.0	55.0	4.602661987	9.516314649			5.0	13.0				2.079441542	8.0	1.0	2.208316112	-650.8491312000001	886.7801035	-2524.3359609999998	1.0	469.0	1.0	211.0	6.771088541514281	7.503228376808412	1.119945166876644	6.323063818987321	6.704720680590642	1.4395975077515277	-0.44802472252696024	-0.7985076962177713	0.3196523408748837
13722.58cfa831e4b0c9d6adf6cdc0	58cfa831e4b0c9d6adf6cdc0	TCGA-FI-A2CY-01A-11D-A17E_120511_SN1120_0140_AD12J0ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FI-A2CY-01A-11D-A17E_120511_SN1120_0140_AD12J0ACXX_s_1_rg.sorted	TCGA-FI-A2CY-01A-11D-A17E_120511_SN1120_0140_AD12J0ACXX_s_1_rg.sorted.bam	72.14		0.16	58cfa831e4b0c9d6adf6cdc0	TCGA-FI-A2CY-01A-11D-A17E_120511_SN1120_0140_AD12J0ACXX_s_1_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-FI-A2CY-01A	B9AB4AB9-BA9C-4A01-9F61-55C82B924936	Primary Tumor	Illumina HiSeq	d1004865-f030-4d10-90a0-3d6d105408a0	Uterus	60.0	047B688C-AA29-4A63-B555-9275AF4B0CEE	4BCC9DA0-4F58-4BB8-B660-D8591AD1CE18	TCGA-FI-A2CY-01A-11D-A17E-02	HG19_Broad_variant	TCGA-FI-A2CY	TCGA-UCEC		s5398	Harvard Medical School	Washington University	United States	NO			Mixed serous and endometrioid		A17E-02	True	UCEC	C2	UCEC.CN_HIGH	0.20616758	0.17	0.02	6.160999341	1.1619	0.273	0.5603	0.5048	1.1466	-0.036000000000000004	19.0		0.298980898	0.640673353	334.0	0.39517478	5.0	27.0							2.214033145	-1340.2554949999999	392.1906495	-1829.966215	0.0	2080.0	0.0	2080.0	6.683569518089484	8.331792613584021	-0.7431002915885396	6.395887445637703	6.640116602912949	3.4936919800663166	-0.28768207245178123	-1.6916760106710724	4.236792271654856
13722.58cfa831e4b0c9d6adf6cdc4	58cfa831e4b0c9d6adf6cdc4	TCGA-FG-6690-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_7_rg.sorted.filtered.	WGS	TCGA-FG-6690-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_7_rg.sorted	TCGA-FG-6690-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_7_rg.sorted.bam	113.7	1.9	0.16	58cfa831e4b0c9d6adf6cdc4	TCGA-FG-6690-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-FG-6690-01A	AD202887-88B3-4E0F-A4C3-7E135D4CB258	Primary Tumor	Illumina HiSeq	e33fa79f-3d33-4f0b-81d9-705ab9c8a19c	Brain	70.0	F6C7B8C5-02DF-4B89-B527-F647762A98B7	BA96EFD0-90DE-4458-89DE-8B16639760B8	TCGA-FG-6690-01A-11D-1891-02	HG19_Broad_variant	TCGA-FG-6690	TCGA-LGG		s8146	Harvard Medical School	Case Western	United States	NO			Oligodendroglioma		1891-02	True	LGG	C5	GBM_LGG.G-CIMP-high	0.15654658400000002	0.48	0.07		-1.4557	-0.359	0.1974	-2.1137	-1.0651	-0.9728	10.0		0.20016240600000001	0.8006496240000001	95.0	0.054411715	0.0	3.0					0.0		3.1771490780000002	254.7344641	-685.2206297	-3522.0612130000004	0.0	1294.0	0.0	1294.0	7.942362237674335	8.690401923693521	2.7270770761569043	5.63977714468029	7.417436247880634	3.143620269438223	-2.3025850929940455	-1.2729656758128873	0.41654319328131884
13722.58cfa831e4b0c9d6adf6cdc5	58cfa831e4b0c9d6adf6cdc5	TCGA-FD-A3SO-01A-11D-A233_120830_SN208_0424_BD1DKLACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FD-A3SO-01A-11D-A233_120830_SN208_0424_BD1DKLACXX_s_1_rg.sorted	TCGA-FD-A3SO-01A-11D-A233_120830_SN208_0424_BD1DKLACXX_s_1_rg.sorted.bam	39.92		0.14	58cfa831e4b0c9d6adf6cdc5	TCGA-FD-A3SO-01A-11D-A233_120830_SN208_0424_BD1DKLACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3SO-01A	94809FBF-4895-42C0-A7C6-F39EE1A41F1A	Primary Tumor	Illumina HiSeq	6b296020-484a-4cc2-a114-6c8a34ed5712	Bladder	68.0	869E3D55-CAD8-436E-B6A8-7ED90AD0A535	3D37A593-EFD7-4250-961D-D914E0AB8C13	TCGA-FD-A3SO-01A-11D-A233-26	HG19_Broad_variant	TCGA-FD-A3SO	TCGA-BLCA	168.0	s2911	MD Anderson - Institute for Applied Cancer Science	BLN - University Of Chicago	United States	NO	T3a	N1	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A233-26	True	BLCA	C1	BLCA.3	0.30331356	0.43	0.01	6.760785232999999	0.9538	0.2795	0.2333	-0.0562	0.3448	0.4381	127.0	60.0	3.67500173	9.112809168	88.0	0.264250084	10.0	18.0	0.7185338459999999	1.785489533	12.0	2.205598359	10.0	0.957879197	1.1032362629999999	-1026.987203	691.9658359	2110.262363	1.0	168.0	1.0	143.0	6.447488705753669	8.359616278379335	-1.0140155464424248	6.0946673311309265	7.8826922062890254	-0.232631762321045	-0.3528213746227422	-0.4769240720903096	0.7813837841213797
13722.58cfa831e4b0c9d6adf6cdcc	58cfa831e4b0c9d6adf6cdcc	TCGA-FG-6689-01A-11D-1891_130923_SN1222_0220_BC2DUUACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FG-6689-01A-11D-1891_130923_SN1222_0220_BC2DUUACXX_s_1_rg.sorted	TCGA-FG-6689-01A-11D-1891_130923_SN1222_0220_BC2DUUACXX_s_1_rg.sorted.bam	86.7	1.9	0.16	58cfa831e4b0c9d6adf6cdcc	TCGA-FG-6689-01A-11D-1891_130923_SN1222_0220_BC2DUUACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-FG-6689-01A	8D07B1E8-5D1D-4A43-B616-D29DD58CE5FE	Primary Tumor	Illumina HiSeq	9e07a7ab-1033-43c4-a4f4-49ba35319fea	Brain	30.0	D81C3F19-BBCF-4071-8BA4-CB8C505307D7	2FD05E93-48E8-460E-80E0-C3262EAEE72B	TCGA-FG-6689-01A-11D-1891-02	HG19_Broad_variant	TCGA-FG-6689	TCGA-LGG		s8144	Harvard Medical School	Case Western	United States	NO			Astrocytoma		1891-02	True	LGG	C5	GBM_LGG.G-CIMP-high	0.16540893	0.41	0.05		-2.5618	-0.324	0.1163	-2.2432	-0.8805	-1.0598	7.0	1.0	0.17153781199999998	0.4860238	53.0	0.069665744	3.0	6.0					0.0		3.186166267	203.4370358	-702.5500405	-4170.480624	0.0	454.0	1.0	119.0	8.423980809694058	8.438718004539792	1.541414651392841	6.026085536895687	7.0524236434199015	1.151074066376554	-2.3978952727983707	-1.3862943611198908	-0.3903405850162871
13722.58cfa831e4b0c9d6adf6cde4	58cfa831e4b0c9d6adf6cde4	TCGA-ES-A2HS-01A-11D-A183-10_wgs_Illumina.filtered.	WGS	TCGA-ES-A2HS-01A-11D-A183-10_wgs_Illumina	TCGA-ES-A2HS-01A-11D-A183-10_wgs_Illumina.bam	48.99		0.09	58cfa831e4b0c9d6adf6cde4	TCGA-ES-A2HS-01A-11D-A183-10_wgs_Illumina.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-ES-A2HS-01A	728AEDB3-551A-4C16-9BE3-7733A9539E9E	Primary Tumor	Illumina HiSeq	a3182ffa-89ac-4c42-a051-93cb3aa08207	Liver	80.0	A06FE860-8D5F-4ED0-B7FC-72F74567FB7E	DCF45005-7E6D-4C26-9994-F973DA7E814F	TCGA-ES-A2HS-01A-11D-A183-10	GRCh37-lite	TCGA-ES-A2HS	TCGA-LIHC	695.0	s16984	Baylor College of Medicine	University of Florida	United States	NO	T1	NX	Hepatocellular Carcinoma	Stage I	A183-10	True	LIHC	C3	LIHC.iCluster:2	0.054139402	0.34	0.14		-1.2064	-0.2825	-1.0953	-1.3033	-1.2009	-0.9621	28.0	68.0	0.699646663	1.580683201	117.0	0.711757518	21.0	9.0					0.0		0.35006709700000005	-1234.02615	-767.6573278	3229.128224	1.0	688.0	0.0	688.0	5.860786223465865	3.4014859403137034	0.21846580063911059	4.703333434774823	4.046049121017904	2.042245602920066	-1.1574527886910428	0.6445631807042007	1.8237798022809555
13722.58cfa832e4b0c9d6adf6cdfc	58cfa832e4b0c9d6adf6cdfc	TCGA-FD-A3SN-01A-12D-A233_120830_SN208_0423_AC190AACXX_s_7_rg.sorted.filtered.	WGS	TCGA-FD-A3SN-01A-12D-A233_120830_SN208_0423_AC190AACXX_s_7_rg.sorted	TCGA-FD-A3SN-01A-12D-A233_120830_SN208_0423_AC190AACXX_s_7_rg.sorted.bam	33.16		0.15	58cfa832e4b0c9d6adf6cdfc	TCGA-FD-A3SN-01A-12D-A233_120830_SN208_0423_AC190AACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3SN-01A	0FB043D3-D86B-4CD8-8C01-9E2B3E965BB0	Primary Tumor	Illumina HiSeq	2281a267-dad6-42d6-9df2-8d37a696c507	Bladder	79.0	127892ED-8A7A-41CB-8ABE-353E09E6D327	B0AD1373-0C51-41A3-9F8B-BDE28C67CFB8	TCGA-FD-A3SN-01A-12D-A233-26	HG19_Broad_variant	TCGA-FD-A3SN	TCGA-BLCA		s2719	MD Anderson - Institute for Applied Cancer Science	BLN - University Of Chicago	United States	NO	T3b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A233-26	True	BLCA	C2	BLCA.2	0.163970224	0.27	0.03	3.493868975	0.7452	0.254	-0.5697	-0.5799	0.2709	0.5009	110.0	11.0	3.956527237	9.501660108	102.0	0.947698193	8.0	37.0	0.994273347	0.689177767	2.0	1.893788232	7.0	0.973214633	1.443829587	-132.4189639	554.998868	-2802.010281	0.0	887.0	1.0	110.0	6.933910236458988	8.699264716954984	0.22389383270491414	6.205671736087773	7.446501748459616	1.6074399097714278	-0.7282385003712157	-1.252762968495368	1.3835460770665136
13722.58cfa832e4b0c9d6adf6ce02	58cfa832e4b0c9d6adf6ce02	TCGA-EJ-5524-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EJ-5524-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_7_rg.sorted	TCGA-EJ-5524-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_7_rg.sorted.bam	248.7	1.9	0.14	58cfa832e4b0c9d6adf6ce02	TCGA-EJ-5524-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5524-01A	4048C139-1329-4E6A-8D2F-C0AA104A68EE	Primary Tumor	Illumina HiSeq	bc7b862d-c88b-41f2-9061-6c4895d6b5be	Prostate	57.0	C197A81D-2AA5-4285-88E3-761798E2C190	4B173FC3-DBE0-47AA-8ACC-D36466B5522D	TCGA-EJ-5524-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5524	TCGA-PRAD		s3435	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.1-ERG	0.16553332	0.39	0.08	2.76179013	-1.0064	-0.1765	-0.1959	0.1342	-0.5482	-0.187	17.0		0.223095082	0.9202672120000001	325.0	0.11622514099999999	0.0	18.0	0.927189395	1.6613003780000002	6.0	3.031590576	22.0	0.9807663990000001	1.9807327380000002	-679.1346557999999	-611.5449891	2872.23377	0.0	1882.0	1.0	265.0	8.374861282838442	9.51034002064851	-0.4699354884668603	6.47774129795256	9.05080769127007	2.0742763813586333	-1.897119984885881	-0.4595323293784399	2.5442118698254936
13722.58cfa832e4b0c9d6adf6ce0c	58cfa832e4b0c9d6adf6ce0c	TCGA-FD-A3B6-01A-21D-A210_120912_SN1120_0192_AC18ALACXX_s_3_rg.sorted.filtered.	WGS	TCGA-FD-A3B6-01A-21D-A210_120912_SN1120_0192_AC18ALACXX_s_3_rg.sorted	TCGA-FD-A3B6-01A-21D-A210_120912_SN1120_0192_AC18ALACXX_s_3_rg.sorted.bam	61.5		0.16	58cfa832e4b0c9d6adf6ce0c	TCGA-FD-A3B6-01A-21D-A210_120912_SN1120_0192_AC18ALACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3B6-01A	36054200-3FA4-4541-A25C-47282E4EF88D	Primary Tumor	Illumina HiSeq	15aeae5e-1ef3-4574-a7af-025ac4d4be89	Bladder	75.0	D6818C85-5857-44B0-AD64-1EEB53B80606	D8D4A23A-F993-4A8F-9414-AD25149B4CB3	TCGA-FD-A3B6-01A-21D-A210-26	HG19_Broad_variant	TCGA-FD-A3B6	TCGA-BLCA		s3298	MD Anderson - Institute for Applied Cancer Science	BLN - University Of Chicago	United States	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A210-26	True	BLCA	C2	BLCA.4	0.4363852	0.58	0.26	0.393310679	0.9852	0.449	0.507	0.5078	1.0399	0.1545	114.0	47.0	2.202244081	7.451428602000001	239.0	0.631577547	14.0	32.0	0.711750267	1.385002069	7.0	2.79129457	18.0	0.965721645	5.380277915	-472.4297266	984.3439616000001	653.3289818	1.0	1005.0	0.0	1005.0	5.303496240691439	7.199971698583468	0.3515466587262269	5.265755912708592	7.396681992829523	1.7108909079444568	-0.03774032798284699	0.19671029424605413	1.3593442492182297
13722.58cfa832e4b0c9d6adf6ce0e	58cfa832e4b0c9d6adf6ce0e	TCGA-FD-A3N5-01A-11D-A21C_120830_SN590_0177_BD141PACXX_s_5_rg.sorted.filtered.	WGS	TCGA-FD-A3N5-01A-11D-A21C_120830_SN590_0177_BD141PACXX_s_5_rg.sorted	TCGA-FD-A3N5-01A-11D-A21C_120830_SN590_0177_BD141PACXX_s_5_rg.sorted.bam	30.45		0.15	58cfa832e4b0c9d6adf6ce0e	TCGA-FD-A3N5-01A-11D-A21C_120830_SN590_0177_BD141PACXX_s_5_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3N5-01A	A658BECF-3934-49F2-9E74-291DCA61D4BB	Primary Tumor	Illumina HiSeq	b9214ac8-956d-471d-8cad-a44ddc8825e8	Bladder	69.0	66559B5F-AB2F-406B-9EDB-0F5085EEC7C5	BA548041-624F-4357-A9F9-3BE29A3FF4FD	TCGA-FD-A3N5-01A-11D-A21C-26	HG19_Broad_variant	TCGA-FD-A3N5	TCGA-BLCA		s2907	MD Anderson - Institute for Applied Cancer Science	BLN - University Of Chicago	United States	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A21C-26	True	BLCA	C2	BLCA.3	0.1514421	0.34	0.1	16.51359681	1.1331	0.289	-0.605	-0.9111	1.0125	0.2652	126.0	84.0	3.708523258	8.367949915	247.0	0.400355561	7.0	33.0	0.9980008840000001	0.6917614990000001	2.0	1.886696785	7.0	0.96957035	1.025551211	-424.38294	1545.305055	-1106.801115	1.0	685.0	1.0	346.0	7.157346000311194	7.136896806419982	-1.3248492825365235	5.9335705686890785	7.136896806419982	0.347577964048319	-1.2237754316221157	0.0	1.6724272465848424
13722.58cfa832e4b0c9d6adf6ce0f	58cfa832e4b0c9d6adf6ce0f	TCGA-FD-A3B8-01A-31D-A210_120912_SN1120_0192_AC18ALACXX_s_7_rg.sorted.filtered.	WGS	TCGA-FD-A3B8-01A-31D-A210_120912_SN1120_0192_AC18ALACXX_s_7_rg.sorted	TCGA-FD-A3B8-01A-31D-A210_120912_SN1120_0192_AC18ALACXX_s_7_rg.sorted.bam	26.04		0.16	58cfa832e4b0c9d6adf6ce0f	TCGA-FD-A3B8-01A-31D-A210_120912_SN1120_0192_AC18ALACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3B8-01A	537CA5D1-5B26-496F-B7B4-05FEA7B46353	Primary Tumor	Illumina HiSeq	c0aadcb9-2d54-45c7-9585-575ed21ea52f	Bladder	56.0	9A27AA84-D541-4FA3-A798-D7559A5AE70C	582B2439-02F1-4E2A-9A4E-771603658FB5	TCGA-FD-A3B8-01A-31D-A210-26	HG19_Broad_variant	TCGA-FD-A3B8	TCGA-BLCA		s3296	MD Anderson - Institute for Applied Cancer Science	BLN - University Of Chicago	United States	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A210-26	True	BLCA	C2	BLCA.4	0.6989328909999999			6.836923463	0.4601	0.098	1.351	2.1101	1.4526	0.8964	20.0		0.268298102	0.626028905	60.0	0.0015184729999999998			0.6261439639999999	1.8097888309999999	18.0	3.793475552	57.0	0.938270455	4.271296624	304.24631969999996	597.3310954	-2075.425479	0.0	384.0	0.0	384.0	7.806852898888366	9.629754406548056	0.09715973663482946	6.634132638066534	8.796845283612953	2.8373500583173605	-1.1727202608218317	-0.8329091229351038	2.740190321682531
13722.58cfa832e4b0c9d6adf6ce11	58cfa832e4b0c9d6adf6ce11	TCGA-EM-A1YE-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EM-A1YE-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_3_rg.sorted	TCGA-EM-A1YE-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_3_rg.sorted.bam	72.49	1.98	0.17	58cfa832e4b0c9d6adf6ce11	TCGA-EM-A1YE-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_3_rg.sorted.bam	Alive	FEMALE			Thyroid Carcinoma	Aligned reads	TCGA-EM-A1YE-01A	E632B443-CF6A-4592-96C6-C3493EC86FEA	Primary Tumor	Illumina HiSeq	a16ef214-00f5-4385-81e9-e66da356395c	Thyroid	47.0	A5DE766B-9CCC-4B56-8D9B-25704C1C91D0	4AE46D2E-BA86-426F-A127-4C1AAF92AB5B	TCGA-EM-A1YE-01A-11D-A14U-02	HG19_Broad_variant	TCGA-EM-A1YE	TCGA-THCA		s12519	Harvard Medical School	University Health Network	Canada	NO	T2	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage II	A14U-02	True	THCA	C3	THCA.1	0.045183544000000006	0.32	0.0		-2.5123	-0.325	-1.1883	-1.3716	-0.309	-0.5639	0.0	0.0	0.09156254800000001	0.244166794	93.0	0.9144441590000001	11.0	4.0					0.0		1.136888924	-571.2049182999999	-1536.137274	1452.7908009999999	0.0	1645.0	0.0	1645.0	6.077546673033101	6.19268054840933	0.7329572852898367	5.096717420021375	6.261673419896281	3.271088696315135	-0.9808292530117257	0.06899287148695121	2.538131411025298
13722.58cfa832e4b0c9d6adf6ce14	58cfa832e4b0c9d6adf6ce14	TCGA-EJ-5511-01A-01D-1572_130308_SN590_0219_BC1UVPACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EJ-5511-01A-01D-1572_130308_SN590_0219_BC1UVPACXX_s_7_rg.sorted	TCGA-EJ-5511-01A-01D-1572_130308_SN590_0219_BC1UVPACXX_s_7_rg.sorted.bam	398.7	1.9	0.15	58cfa832e4b0c9d6adf6ce14	TCGA-EJ-5511-01A-01D-1572_130308_SN590_0219_BC1UVPACXX_s_7_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5511-01A	F8A42FEB-FBC9-4A13-BAD5-1DCEFCA2A9BF	Primary Tumor	Illumina HiSeq	dfa7170d-3cc1-43b7-9d24-7be107cf2896	Prostate	55.0	1DA89009-5DBE-4D62-9406-36330F47B738	5D753860-8965-45E5-A919-C076B53334D4	TCGA-EJ-5511-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5511	TCGA-PRAD		s3600	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.3-ETV4	0.035886808	0.2	0.06	0.631258539	-1.7818	-0.3065	-0.9877	-1.0396	-1.133	-0.2708	14.0	2.0	0.34083433	0.9941001290000001	70.0	0.18054689100000001	3.0	11.0				2.63905733	14.0	1.0	1.380631682	-521.3833606000001	-1178.652866	3832.5308119999995	0.0	1476.0	0.0	1476.0	9.123946985809065	8.45156963739889	-0.1514681241776098	7.0445054441292285	8.046104529290727	4.074054636728258	-2.079441541679836	-0.40546510810816416	4.225522760905868
13722.58cfa832e4b0c9d6adf6ce18	58cfa832e4b0c9d6adf6ce18	TCGA-FD-A3B5-01A-11D-A210_120912_SN1120_0192_AC18ALACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FD-A3B5-01A-11D-A210_120912_SN1120_0192_AC18ALACXX_s_1_rg.sorted	TCGA-FD-A3B5-01A-11D-A210_120912_SN1120_0192_AC18ALACXX_s_1_rg.sorted.bam	33.2		0.17	58cfa832e4b0c9d6adf6ce18	TCGA-FD-A3B5-01A-11D-A210_120912_SN1120_0192_AC18ALACXX_s_1_rg.sorted.bam	Dead	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3B5-01A	462D5A6B-9F39-4AAE-A35B-D06A7811D053	Primary Tumor	Illumina HiSeq	d7af6a65-2c95-4a83-8e6f-756aef5309bd	Bladder	86.0	F9DEDC8C-327D-456A-9C0B-E1EC58AE3169	0D51FF4C-41D7-4296-BDDC-F9DB7F41276A	TCGA-FD-A3B5-01A-11D-A210-26	HG19_Broad_variant	TCGA-FD-A3B5	TCGA-BLCA	272.0	s2721	MD Anderson - Institute for Applied Cancer Science	BLN - University Of Chicago	United States	NO	T2b	N1	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A210-26	True	BLCA	C2	BLCA.3	0.122927715	0.48	0.44	2.734181082	0.6203	0.2075	-0.8764	-1.5029	0.6871	0.4259	101.0	239.0	1.009245515	4.189898046000001	196.0	0.754335854	13.0	47.0					0.0		6.335107953	-229.16137519999998	421.311753	-1408.767838	1.0	272.0	1.0	272.0	6.629303205999955	7.361393076710939	-0.062081568031775	6.031466205244335	7.389563953677635	2.0464323965618547	-0.5978370007556202	0.0281708769666964	2.10851396459363
13722.58cfa832e4b0c9d6adf6ce20	58cfa832e4b0c9d6adf6ce20	TCGA-FG-6688-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_5_rg.sorted.filtered.	WGS	TCGA-FG-6688-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_5_rg.sorted	TCGA-FG-6688-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_5_rg.sorted.bam	62.7	2.0	0.17	58cfa832e4b0c9d6adf6ce20	TCGA-FG-6688-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_5_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-FG-6688-01A	DADD7428-9E4D-4652-9469-AB521B88D529	Primary Tumor	Illumina HiSeq	3b45431a-1066-4467-bc8a-f1aa3342c5f0	Brain	59.0	8594744F-F317-4022-991B-21891DA7F80A	5977877C-7B55-4666-AC08-54FEF233FB2F	TCGA-FG-6688-01A-11D-1891-02	HG19_Broad_variant	TCGA-FG-6688	TCGA-LGG		s8570	Harvard Medical School	Case Western	United States	NO			Astrocytoma		1891-02	True	LGG	C4	GBM_LGG.Mesenchymal-like	0.190761205	0.62	0.0		-0.7602	-0.203	0.6517	-1.735	0.18100000000000002	-0.4738	29.0	46.0	0.487683916	1.4343644580000001	57.0	0.137086658	4.0	6.0				0.0	1.0		3.4316033839999998	433.3039021000001	-865.8817539999999	-3963.009622	0.0	571.0	1.0	405.0	7.539558829301031	6.982244130972877	0.7773553212125448	5.236973736306986	5.163085687556707	3.685322840999089	-2.3025850929940455	-1.8191584434161694	2.907967519786544
13722.58cfa832e4b0c9d6adf6ce2a	58cfa832e4b0c9d6adf6ce2a	TCGA-FN-7833-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_4_rg.sorted.filtered.	WGS	TCGA-FN-7833-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_4_rg.sorted	TCGA-FN-7833-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_4_rg.sorted.bam	141.7		0.14	58cfa832e4b0c9d6adf6ce2a	TCGA-FN-7833-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-FN-7833-01A	5B9D7565-A933-449D-8FFA-EC5F82DB2E77	Primary Tumor	Illumina HiSeq	91f0d100-c921-4319-9d82-98819189b525	Brain	25.0	CF2E4A0A-59C5-41DA-9F24-DE83EEB856E5	1C69F8E8-7D70-4BD1-8B42-7E93DC23DA7B	TCGA-FN-7833-01A-11D-2088-02	HG19_Broad_variant	TCGA-FN-7833	TCGA-LGG		s8366	Harvard Medical School	International Genomics Consortium	United States	NO			Oligoastrocytoma		2088-02	False	LGG	C4	GBM_LGG.G-CIMP-high	0.054698264	0.09	0.0		-0.4891	-0.3055	0.7553	-1.7732	2.2619	-0.7431	6.0	76.0	0.119598724	0.508294575	100.0	0.021220744	0.0	3.0				0.0	1.0		3.289506563	768.7170901000001	-844.9305749	-2362.243668	0.0	837.0	0.0	837.0	8.592764378263311	8.536042983957145	2.590106380816491	6.241389121099834	7.537514153846018	2.0327899730617895	-2.3513752571634776	-0.998528830111127	-0.5573164077547013
13722.58cfa832e4b0c9d6adf6ce34	58cfa832e4b0c9d6adf6ce34	TCGA-ER-A19T-01A-11D-A18Z_120516_SN1222_0107_BD12HYACXX_s_8_rg.sorted.filtered.	WGS	TCGA-ER-A19T-01A-11D-A18Z_120516_SN1222_0107_BD12HYACXX_s_8_rg.sorted	TCGA-ER-A19T-01A-11D-A18Z_120516_SN1222_0107_BD12HYACXX_s_8_rg.sorted.bam	76.29		0.18	58cfa832e4b0c9d6adf6ce34	TCGA-ER-A19T-01A-11D-A18Z_120516_SN1222_0107_BD12HYACXX_s_8_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-ER-A19T-01A	B85B14D7-3B5A-4800-AF12-622EC03B9FE5	Primary Tumor	Illumina HiSeq	f16ac608-e77d-4717-aeea-b71439dc385a	Skin	51.0	11E2F891-251A-4813-AA90-E944F350C54D	9C1427B0-B112-4BB7-89B3-27934F92E077	TCGA-ER-A19T-01A-11D-A18Z-02	HG19_Broad_variant	TCGA-ER-A19T	TCGA-SKCM	270.0	s8022	Harvard Medical School	University of Pittsburgh	United States	NO	T4a	N3		Stage IV	A18Z-02	True	SKCM	C1	SKCM.Triple_WT	0.154073404	0.03	0.2	1.5658038930000002	0.3533	0.11	-1.4043	-2.4681	-0.7099	0.2098	14.0		0.273886335	0.623852207	459.0	0.7313933290000001	17.0	36.0					0.0		3.911789681	-638.2968533	286.5978035	-1415.402458	1.0	270.0	1.0	118.0	6.4669531065842865	6.573746671798897	0.3388041193005965	5.773805926024341	6.250973279535845		-0.6931471805599454	-0.32277339226305113	
13722.58cfa832e4b0c9d6adf6ce3a	58cfa832e4b0c9d6adf6ce3a	TCGA-ES-A2HT-01A-12D-A183-10_wgs_Illumina.filtered.	WGS	TCGA-ES-A2HT-01A-12D-A183-10_wgs_Illumina	TCGA-ES-A2HT-01A-12D-A183-10_wgs_Illumina.bam	11.86		0.08	58cfa832e4b0c9d6adf6ce3a	TCGA-ES-A2HT-01A-12D-A183-10_wgs_Illumina.bam	Dead	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-ES-A2HT-01A	7DD3BDA9-3A0A-46FA-B052-A6D24B847804	Primary Tumor	Illumina HiSeq	f5b5c206-8657-4209-bc75-e3f064cecdd0	Liver	54.0	9B68C72D-30D4-4A7A-ADE7-A2BDE50A84F2	D6CCFD6F-2EA9-499D-A25D-4BA9D4A9258E	TCGA-ES-A2HT-01A-12D-A183-10	GRCh37-lite	TCGA-ES-A2HT	TCGA-LIHC	438.0	s16783	Baylor College of Medicine	University of Florida	United States	NO	T1	NX	Hepatocellular Carcinoma	Stage I	A183-10	True	LIHC	C4	LIHC.iCluster:1	0.249412506	0.78	0.1		-1.901	-0.152	-0.44	-0.1256	1.7292	-0.5667	44.0		0.574821106	1.6722068540000001	81.0	0.14887616	33.0	3.0	0.9034683920000001	3.355094982	41.0	0.0	1.0		0.716874708	-853.232605	-963.9936822999999	4121.913917	1.0	438.0	0.0	438.0	7.242940974077885	3.7295063076442077	0.3646223991468359	5.594282348490504	4.182580874789495	3.460398884019829	-1.6486586255873819	0.45307456714528715	3.095776484872993
13722.58cfa832e4b0c9d6adf6ce42	58cfa832e4b0c9d6adf6ce42	TCGA-ET-A25J-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-ET-A25J-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_1_rg.sorted	TCGA-ET-A25J-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_1_rg.sorted.bam	57.24	2.0	0.17	58cfa832e4b0c9d6adf6ce42	TCGA-ET-A25J-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-ET-A25K-01A	2F9ED09D-2626-4C23-BA47-1850D36F812A	Primary Tumor	Illumina HiSeq	970a6dab-c1e4-4446-968a-4b37d1506eeb	Thyroid	36.0	343311B1-D586-4F92-9984-32AF1AFB1F62	663173D3-A9EE-4E73-8444-52F01727BE6D	TCGA-ET-A25K-01A-11D-A16N-02	HG19_Broad_variant	TCGA-ET-A25K	TCGA-THCA		s12757	Harvard Medical School	Johns Hopkins	United States	NO	T2	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	True	THCA	C3	THCA.5	0.08442087	0.3	0.0		-1.6163	-0.3405	-0.5963	-1.1468	-0.2387	0.2185	1.0		0.059312616	0.14828154	35.0	7.47e-06	0.0	0.0				0.0	1.0		1.332405527	957.8374697999999	-598.9532829	609.7579384	0.0	2142.0	0.0	2142.0	7.08405876345053	7.84748348068374	-0.566726891162422	6.295601403086259	6.657899413809904	1.474748052593563	-0.7884573603642702	-1.1895840668738364	2.041474943755985
13722.58cfa832e4b0c9d6adf6ce46	58cfa832e4b0c9d6adf6ce46	TCGA-EJ-5504-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EJ-5504-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_1_rg.sorted	TCGA-EJ-5504-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_1_rg.sorted.bam	125.7	1.9	0.15	58cfa832e4b0c9d6adf6ce46	TCGA-EJ-5504-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5504-01A	E1C3D1BD-CF8F-4FA4-AC8E-BF9E54F7AAD4	Primary Tumor	Illumina HiSeq	ea018935-4ded-4def-a204-bda7035ba32c	Prostate	65.0	7D0C0A85-8459-43A3-AC22-F447BB042149	FB332EAD-214E-4D76-BD3C-0774D906F68B	TCGA-EJ-5504-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5504	TCGA-PRAD		s3953	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N1	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.2-ETV1	0.116195731	0.65	0.12	0.511104916	-0.9295	-0.11	-0.5534	-0.8374	-0.4986	-0.204	17.0		0.359569397	0.885093901	169.0	0.16952397	2.0	25.0	0.897427193	0.622049129	2.0	1.5607104090000001	5.0	0.9697239	2.003056125	108.6432176	-745.4907513999999	2544.662541	0.0	1427.0	0.0	1427.0	8.523241529950441	9.588185100916577	0.11400231281647744	6.443799988270605	8.850586157785798	2.4266265308388517	-2.079441541679836	-0.737598943130779	2.312624218022374
13722.58cfa832e4b0c9d6adf6ce58	58cfa832e4b0c9d6adf6ce58	TCGA-FU-A3HY-01A-11D-A245_140124_SN1440_0178_AC2PL6ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-FU-A3HY-01A-11D-A245_140124_SN1440_0178_AC2PL6ACXX_s_7_rg.sorted	TCGA-FU-A3HY-01A-11D-A245_140124_SN1440_0178_AC2PL6ACXX_s_7_rg.sorted.bam	37.56		0.16	58cfa832e4b0c9d6adf6ce58	TCGA-FU-A3HY-01A-11D-A245_140124_SN1440_0178_AC2PL6ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-FU-A3HY-01A	674E010C-7AD4-4DC2-86B0-284CD4560633	Primary Tumor	Illumina HiSeq	30d23ada-985e-43b1-9cc5-9e3931905b07	Cervix	47.0	A5879A60-AA8B-4DA0-904A-9FFE2968418C	0FD6C08E-8B41-422F-A6BA-1234E6596ADA	TCGA-FU-A3HY-01A-11D-A245-26	HG19_Broad_variant	TCGA-FU-A3HY	TCGA-CESC		s1531	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T1b2	N1	Cervical Squamous Cell Carcinoma		A245-26	True	CESC	C1		0.22800363	0.37	0.02	1.977224377	1.2701	0.435	-1.0851	-1.2836	-0.6195	-0.0441	71.0	3.0	1.377887605	3.4447190119999997	132.0	0.47895608700000003	9.0	18.0				1.039720771	3.0	0.94639463	2.092180892	-839.5889185000001	1367.890069	-1687.8137179999999	0.0	954.0	0.0	954.0	8.712376129371096	7.0646036155605465	-0.8217613819990812	6.9206166601430406	6.572127130462753	0.8904664199075853	-1.7917594692280547	-0.49247648509779385	1.7122278019066666
13722.58cfa832e4b0c9d6adf6ce5a	58cfa832e4b0c9d6adf6ce5a	TCGA-GV-A3QG-01A-11D-A221_120830_SN590_0178_AD143RACXX_s_3_rg.sorted.filtered.	WGS	TCGA-GV-A3QG-01A-11D-A221_120830_SN590_0178_AD143RACXX_s_3_rg.sorted	TCGA-GV-A3QG-01A-11D-A221_120830_SN590_0178_AD143RACXX_s_3_rg.sorted.bam	32.14		0.15	58cfa832e4b0c9d6adf6ce5a	TCGA-GV-A3QG-01A-11D-A221_120830_SN590_0178_AD143RACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GV-A3QG-01A	79F23A0E-5AAE-4618-8191-7DD7C0552408	Primary Tumor	Illumina HiSeq	2102b9a0-6afe-47a9-89ae-9778452a6dcd	Bladder	65.0	FB9B1639-242F-4019-937F-DD13C40D9C2B	27EDCB5C-D1E4-4683-A967-A436E22D1958	TCGA-GV-A3QG-01A-11D-A221-26	HG19_Broad_variant	TCGA-GV-A3QG	TCGA-BLCA		s3309	MD Anderson - Institute for Applied Cancer Science	BLN - Cleveland Clinic	United States	NO	T3a	N3	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A221-26	True	BLCA	C2	BLCA.4	0.463157242	0.54	0.21	3.63546529	0.5344	0.1015	1.2528	2.6647	1.3367	0.53	21.0	1.0	0.6004685160000001	2.371850637	86.0	0.276153013	2.0	24.0	0.829165425	4.048650529	132.0	4.816001798	132.0	0.986319305		121.55184750000001	941.3608593	-2339.419254	1.0		1.0	84.0	6.791353641696703	8.58326179138594	0.1088553985532752	5.434912243726494	7.014645873472096	2.403275379429326	-1.356441397970209	-1.5686159179138452	2.294419980876051
13722.58cfa832e4b0c9d6adf6ce60	58cfa832e4b0c9d6adf6ce60	TCGA-GV-A3QF-01A-31D-A233_120904_SN1120_0186_BC1911ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-GV-A3QF-01A-31D-A233_120904_SN1120_0186_BC1911ACXX_s_4_rg.sorted	TCGA-GV-A3QF-01A-31D-A233_120904_SN1120_0186_BC1911ACXX_s_4_rg.sorted.bam	21.58		0.16	58cfa832e4b0c9d6adf6ce60	TCGA-GV-A3QF-01A-31D-A233_120904_SN1120_0186_BC1911ACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GV-A3QF-01A	47990D5E-A0E1-4752-86F5-4F5B84E219DF	Primary Tumor	Illumina HiSeq	bcac19c7-1e8c-40ba-a577-39fce12db063	Bladder	79.0	6647C98E-7AA1-49E4-A067-D53AEBACFF9C	F7B433D0-F5DA-4E9C-9C32-A614FB4F614C	TCGA-GV-A3QF-01A-31D-A233-26	HG19_Broad_variant	TCGA-GV-A3QF	TCGA-BLCA		s2931	MD Anderson - Institute for Applied Cancer Science	BLN - Cleveland Clinic	United States	NO	T3b	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A233-26	True	BLCA	C1	BLCA.1	0.360582626	0.46	0.03		0.5849	0.1235	-1.5196	-1.6492	-1.1042	-0.6267	68.0	48.0	1.206323335	3.589547485	190.0	0.6500293189999999	17.0	30.0				0.693147181	2.0	1.0	3.974567431	-2296.290719	333.9023191	1265.215658	1.0	617.0	0.0	617.0	6.348862913524091	9.329677754564804	0.37582497169032414	5.859314688205385	8.076914786069436	0.1601770953838091	-0.489548225318706	-1.252762968495368	-0.21564787630651505
13722.58cfa832e4b0c9d6adf6ce62	58cfa832e4b0c9d6adf6ce62	TCGA-FV-A2QQ-01A-11D-A22F-10_wgs_Illumina.filtered.	WGS	TCGA-FV-A2QQ-01A-11D-A22F-10_wgs_Illumina	TCGA-FV-A2QQ-01A-11D-A22F-10_wgs_Illumina.bam	36.18		0.08	58cfa832e4b0c9d6adf6ce62	TCGA-FV-A2QQ-01A-11D-A22F-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-FV-A2QQ-01A	D680DF09-368E-42B5-B540-45C41ED31042	Primary Tumor	Illumina HiSeq	5e2beb4b-957f-4d8e-956f-798a63355329	Liver	80.0	A0096AF4-ABD3-4F6E-A6AC-2CF2E57C7BD9	4904D56F-0FE7-4482-8F6D-9E54D261F399	TCGA-FV-A2QQ-01A-11D-A22F-10	GRCh37-lite	TCGA-FV-A2QQ	TCGA-LIHC		s16861	Baylor College of Medicine	International Genomics Consortium	United States	NO	T1	N1	Hepatocellular Carcinoma	Stage IVA	A22F-10	True	LIHC	C3	LIHC.iCluster:2	0.291194448	0.34	0.14		-1.0179	-0.0655	-0.0381	0.4855	-0.1768	-0.7041	66.0	162.0	0.99461282	2.80531821	95.0	0.36967814	4.0	12.0				2.043191871	8.0	0.982567593	3.4309545210000003	-1301.817475	-1166.5824400000001	3134.34853	0.0	729.0	0.0	729.0	7.054881343872431	2.1208767801740986	-1.4526014339113764	5.843791071777631	4.275525217580264	3.932884954857285	-1.2110902720948	2.1546484374061654	5.385486388768661
13722.58cfa832e4b0c9d6adf6ce63	58cfa832e4b0c9d6adf6ce63	TCGA-GV-A3QH-01A-11D-A221_120830_SN590_0178_AD143RACXX_s_5_rg.sorted.filtered.	WGS	TCGA-GV-A3QH-01A-11D-A221_120830_SN590_0178_AD143RACXX_s_5_rg.sorted	TCGA-GV-A3QH-01A-11D-A221_120830_SN590_0178_AD143RACXX_s_5_rg.sorted.bam	38.38		0.14	58cfa832e4b0c9d6adf6ce63	TCGA-GV-A3QH-01A-11D-A221_120830_SN590_0178_AD143RACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GV-A3QH-01A	33BC6A7C-9844-41E3-96B3-1E34BB3FEDD5	Primary Tumor	Illumina HiSeq	5672aee8-638c-45c6-af4f-0ccc5e2a1b45	Bladder	67.0	DEB7311F-E747-44EC-92C3-1E56CD5CACF2	B14D2F40-53F3-4A3A-8FA8-1BE7F102CA25	TCGA-GV-A3QH-01A-11D-A221-26	HG19_Broad_variant	TCGA-GV-A3QH	TCGA-BLCA		s3129	MD Anderson - Institute for Applied Cancer Science	BLN - Cleveland Clinic	United States	NO		NX	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A221-26	True	BLCA	C2	BLCA.1	0.212922146	0.52	0.24	5.512406351	0.7778	0.11699999999999999	-1.655	-1.8491	1.4578	-0.6253	70.0	2.0	1.436502461	4.429215922	283.0	0.7661671170000001	24.0	36.0				0.0	1.0		5.320128448	-2239.610315	781.707386	1017.649135	1.0	258.0	1.0	125.0	6.448889394146858	6.336388363261015	-0.0660425816939122	5.244916589820922	7.345052415266186	1.9576893718159476	-1.203972804325936	1.0086640520051704	2.0237319535098597
13722.58cfa832e4b0c9d6adf6ce68	58cfa832e4b0c9d6adf6ce68	TCGA-G3-A25V-01A-11D-A16V-10_wgs_Illumina.filtered.	WGS	TCGA-G3-A25V-01A-11D-A16V-10_wgs_Illumina	TCGA-G3-A25V-01A-11D-A16V-10_wgs_Illumina.bam	62.02	1.79	0.08	58cfa832e4b0c9d6adf6ce68	TCGA-G3-A25V-01A-11D-A16V-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-G3-A25V-01A	F435EC00-0DB8-46B4-96BF-890A9D931DF3	Primary Tumor	Illumina HiSeq	ddbeb5de-c37a-4565-8b8d-8965c09eb657	Liver	68.0	634AB666-0845-4B62-A2A1-ABD408D8B829	4624FD20-E2AD-4826-B606-A694B04E1076	TCGA-G3-A25V-01A-11D-A16V-10	GRCh37-lite	TCGA-G3-A25V	TCGA-LIHC		s16688	Baylor College of Medicine	Alberta Health Services	Canada	NO	T1	N0	Hepatocellular Carcinoma	Stage I	A16V-10	True	LIHC	C3	LIHC.iCluster:2	0.45953025	0.73	0.11		-1.3398	-0.0935	0.2539	0.5573	0.2005	-0.261	33.0	47.0	0.36053513600000003	1.580807905	45.0	0.027641482000000002	0.0	1.0				2.397895273	11.0	1.0	2.937659063	-709.5148823	-545.2831967	3361.380946	0.0	860.0	1.0	489.0	7.305456996472468	2.8775933971936434	0.20693954530310055	5.359546847417155	3.6493682575979776	4.947850220525573	-1.9459101490553132	0.7717748604043342	4.740910675222472
13722.58cfa832e4b0c9d6adf6ce6a	58cfa832e4b0c9d6adf6ce6a	TCGA-H2-A26U-01A-11D-A16N_121204_SN208_0442_BC1F7YACXX_s_5_rg.sorted.filtered.	WGS	TCGA-H2-A26U-01A-11D-A16N_121204_SN208_0442_BC1F7YACXX_s_5_rg.sorted	TCGA-H2-A26U-01A-11D-A16N_121204_SN208_0442_BC1F7YACXX_s_5_rg.sorted.bam	65.58	1.91	0.17	58cfa832e4b0c9d6adf6ce6a	TCGA-H2-A26U-01A-11D-A16N_121204_SN208_0442_BC1F7YACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-H2-A26U-01A	E61FB24B-613A-4B6D-BB2B-00CCEDBD3DBC	Primary Tumor	Illumina HiSeq	91b791c7-9ac1-4a55-bb8a-110046b81a61	Thyroid	54.0	A4240AB1-970E-4A99-989E-8968903E3A25	79850C4D-71D0-4905-946A-F309DCDDA59F	TCGA-H2-A26U-01A-11D-A16N-02	HG19_Broad_variant	TCGA-H2-A26U	TCGA-THCA		s12762	Harvard Medical School	Christiana Healthcare	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A16N-02	True	THCA	C3	THCA.4	0.33617529	0.68	0.01		-1.2255	-0.33	1.0051	1.6075	0.5157	0.3762	3.0	3.0	0.0	0.172218681	54.0	0.044041557	1.0	1.0	0.9215128770000001	3.586362518	49.0	3.892911531	76.0	0.89890354	1.7797601019999998	1145.688322	-1076.184651	2086.7567489999997	0.0	517.0	0.0	517.0	7.549696880605666	7.410951875583636	0.7075860672059069	3.8140133602939263	5.906874478807362	1.8650692505718052	-3.735683520311739	-1.5040773967762737	1.1574831833658983
13722.58cfa832e4b0c9d6adf6ce6c	58cfa832e4b0c9d6adf6ce6c	TCGA-G3-A3CK-01A-11D-A20W-10_wgs_Illumina.filtered.	WGS	TCGA-G3-A3CK-01A-11D-A20W-10_wgs_Illumina	TCGA-G3-A3CK-01A-11D-A20W-10_wgs_Illumina.bam	43.11		0.08	58cfa832e4b0c9d6adf6ce6c	TCGA-G3-A3CK-01A-11D-A20W-10_wgs_Illumina.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-G3-A3CK-01A	39EB1DB0-2722-4AF4-8254-D0E10256C64D	Primary Tumor	Illumina HiSeq	210fd1fb-0012-410b-bfc8-bf53607bfe12	Liver	61.0	2F38C711-639F-4611-9076-DC99A1DB8239	1127B561-EA40-4D5E-95DF-DAA0A5EBC1E4	TCGA-G3-A3CK-01A-11D-A20W-10	GRCh37-lite	TCGA-G3-A3CK	TCGA-LIHC		s16988	Baylor College of Medicine	Alberta Health Services	Canada	NO	T1	N0	Hepatocellular Carcinoma	Stage I	A20W-10	False	LIHC	C4	LIHC.iCluster:2	0.262858424	0.35	0.03		-1.0646	-0.2175	-0.2202	0.2531	0.0653	-1.0042	69.0	18.0	1.473125979	4.978149859	62.0	0.078143499	1.0	4.0		0.0	1.0	1.745608564	9.0	0.794460695	0.9406040059999999	-1368.593282	-446.8300186000001	3829.973495	0.0	585.0	0.0	585.0	6.934807108996653	1.0059036005009396	0.36690489696040185	6.095056454244832	4.378805873877523	3.7354403453032097	-0.8397506547518208	3.3729022733765834	3.368535448342808
13722.58cfa832e4b0c9d6adf6ce6e	58cfa832e4b0c9d6adf6ce6e	TCGA-FV-A3R2-01A-11D-A22F-10_wgs_Illumina.filtered.	WGS	TCGA-FV-A3R2-01A-11D-A22F-10_wgs_Illumina	TCGA-FV-A3R2-01A-11D-A22F-10_wgs_Illumina.bam	43.8		0.07	58cfa832e4b0c9d6adf6ce6e	TCGA-FV-A3R2-01A-11D-A22F-10_wgs_Illumina.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-FV-A3R2-01A	17833039-0D7E-47F0-90E6-8CABAE94C124	Primary Tumor	Illumina HiSeq	b20c4bf4-6780-4ba0-ae12-ae33d48a60d2	Liver	75.0	04BECA9F-830C-4CA8-A947-1BF2D7DF1B26	B9098B7C-EAB0-4EF5-B968-8D3024BF32F7	TCGA-FV-A3R2-01A-11D-A22F-10	GRCh37-lite	TCGA-FV-A3R2	TCGA-LIHC	194.0	s16784	Baylor College of Medicine	International Genomics Consortium	United States	NO	T1	NX	Hepatocellular Carcinoma	Stage I	A22F-10	True	LIHC	C4	LIHC.	0.143576204	0.21	0.0		-0.5871	-0.188	-0.7576	-1.2809	0.4308	-1.0091	37.0	67.0	0.639414759	1.790361324	103.0	0.401820246	13.0	12.0				1.7478680969999998	6.0	0.9755037590000001	0.35656286200000004	-714.2236525000001	-810.914783	1094.396859	1.0	194.0	0.0	194.0	6.623733167361843	3.3299095626402098	-0.030308473914382406	4.608830146819578	4.567385609238672	2.774474526884557	-2.014903020542265	1.237476046598462	2.8047830007989396
13722.58cfa832e4b0c9d6adf6ce6f	58cfa832e4b0c9d6adf6ce6f	TCGA-GL-A4EM-01A-11D-A25F-10_wgs_Illumina.filtered.	WGS	TCGA-GL-A4EM-01A-11D-A25F-10_wgs_Illumina	TCGA-GL-A4EM-01A-11D-A25F-10_wgs_Illumina.bam	11.47		0.08	58cfa832e4b0c9d6adf6ce6f	TCGA-GL-A4EM-01A-11D-A25F-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-GL-A4EM-01A	2C084454-18E9-4837-9BBA-7E91A73A48E0	Primary Tumor	Illumina HiSeq	39550a3d-400e-427e-871c-7749ae5dc2f3	Kidney	61.0	353CDF9B-F87E-45ED-8263-B1720FAE4EEA	7815397B-AA39-4B79-BCAA-6859A3F115F8	TCGA-GL-A4EM-01A-11D-A25F-10	GRCh37-lite	TCGA-GL-A4EM	TCGA-KIRP		s11777	Baylor College of Medicine	ABS - IUPUI	United States	NO	T1b	NX	Kidney Papillary Renal Cell Carcinoma	Stage I	A25F-10	True	KIRP	C3	KIRP.C2a	0.451605598	0.64	0.0		-2.0404	-0.17	0.8667	0.7978	-0.3093	-0.039	18.0	224.0	0.57231049	1.553414188	55.0	0.215295729	10.0	0.0	0.912880623	3.219146191	34.0	2.098147389	9.0	0.954908028	2.0215752559999998	-379.52036150000004	-1848.733145	-806.9954892999999	0.0	32.0	0.0	32.0	6.742172838192459	3.5586378564255012	-0.3315600786238351	4.5449482608562395	3.244510728261229	5.199937261951647	-2.197224577336219	-0.31412712816427213	5.531497340575482
13722.58cfa832e4b0c9d6adf6ce70	58cfa832e4b0c9d6adf6ce70	TCGA-FV-A496-01A-11D-A25V-10_wgs_Illumina.filtered.	WGS	TCGA-FV-A496-01A-11D-A25V-10_wgs_Illumina	TCGA-FV-A496-01A-11D-A25V-10_wgs_Illumina.bam	36.61		0.07	58cfa832e4b0c9d6adf6ce70	TCGA-FV-A496-01A-11D-A25V-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-FV-A496-01A	8AFA3140-DCBD-44C0-AB13-4ADA6A0444D4	Primary Tumor	Illumina HiSeq	62727522-1644-478e-a555-06a870b68bab	Liver	84.0	FD1E3B28-C143-4EF6-A699-3A61CB20A5ED	6E6AD1A2-F1EB-44D1-9852-F5752AFCF5EB	TCGA-FV-A496-01A-11D-A25V-10	GRCh37-lite	TCGA-FV-A496	TCGA-LIHC		s16787	Baylor College of Medicine	International Genomics Consortium	United States	NO	T1	NX	Hepatocellular Carcinoma	Stage I	A25V-10	True	LIHC	C3	LIHC.iCluster:2	0.024135889	0.14	0.26		-1.0684	-0.16	-1.6667	-2.0507	-1.0205	-1.0144	65.0	1.0	0.849231541	2.794245717	517.0	0.9733182990000001	8.0	43.0					0.0		1.810699312	-2423.525551	-1228.154906	4209.09237	0.0	10.0	0.0	10.0	7.361587181228009	1.3005112664726122	-0.9176601508059536	5.821142140280859	3.3343450746743155	2.278710807454572	-1.5404450409471488	2.0338338082017033	3.196370958260526
13722.58cfa832e4b0c9d6adf6ce7c	58cfa832e4b0c9d6adf6ce7c	TCGA-G3-A5SL-01A-11D-A27I-10_wgs_Illumina.filtered.	WGS	TCGA-G3-A5SL-01A-11D-A27I-10_wgs_Illumina	TCGA-G3-A5SL-01A-11D-A27I-10_wgs_Illumina.bam	50.54		0.07	58cfa832e4b0c9d6adf6ce7c	TCGA-G3-A5SL-01A-11D-A27I-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-G3-A5SL-01A	9A56D8A8-DADD-442E-BC09-732CD619AEF7	Primary Tumor	Illumina HiSeq	f55def89-845d-40d8-a532-eb471f2c04d3	Liver	70.0	5AF5519D-73EE-481B-A47C-06F54DBD372F	70422E6D-CB1F-4284-8BE9-1D4517FFAD60	TCGA-G3-A5SL-01A-11D-A27I-10	GRCh37-lite	TCGA-G3-A5SL	TCGA-LIHC		s17064	Baylor College of Medicine	Alberta Health Services	Canada	NO	T2	NX	Hepatocellular Carcinoma	Stage II	A27I-10	True	LIHC	C3	LIHC.iCluster:2	0.100397115	0.23	0.18		-1.0647	-0.2265	-0.8663	-1.2468	-0.847	-0.7879999999999999	59.0	45.0	0.657483395	3.342207259	100.0	0.378621624	6.0	7.0				1.098612289	3.0	1.0	1.158982883	-1641.582609	-1084.922028	2897.134524	0.0	621.0	0.0	621.0	6.517536981634292	2.337051882205392	-0.6171075351117911	6.0628008245193445	4.131185488432968	2.7552372169285815	-0.4547361571149473	1.7941336062275761	3.3723447520403727
13722.58cfa832e4b0c9d6adf6ce7e	58cfa832e4b0c9d6adf6ce7e	TCGA-FV-A495-01A-11D-A25V-10_wgs_Illumina.filtered.	WGS	TCGA-FV-A495-01A-11D-A25V-10_wgs_Illumina	TCGA-FV-A495-01A-11D-A25V-10_wgs_Illumina.bam	17.43		0.08	58cfa832e4b0c9d6adf6ce7e	TCGA-FV-A495-01A-11D-A25V-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-FV-A495-01A	BD48FA5E-0152-46F0-A4FA-8CF723FF2DCD	Primary Tumor	Illumina HiSeq	bd95350e-cf5e-48c9-929a-3e397b36cd21	Liver	51.0	B7FC877D-6055-4A28-BBDF-50CE7236B7BF	84FE77B4-F6CC-49BF-A6B9-1621EC9394F8	TCGA-FV-A495-01A-11D-A25V-10	GRCh37-lite	TCGA-FV-A495	TCGA-LIHC		s16591	Baylor College of Medicine	International Genomics Consortium	United States	NO	T2	NX	Hepatocellular Carcinoma	Stage II	A25V-10	True	LIHC	C2	LIHC.iCluster:2	0.23015734699999998	0.44	0.07		-0.2947	0.077	0.0501	1.117	0.9328	-0.4028	67.0	13.0	0.768437822	2.552311336	339.0	0.194120596	5.0	20.0		0.0	1.0	1.6726254459999998	6.0	0.9335100359999999	2.830754316	-1324.433662	88.66298254	3422.997861	0.0	1.0	0.0	1.0	6.579868305519346	1.951635852213995	0.029900893171857956	5.481256016851237	2.827348224603818	5.002365902613749	-1.0986122886681096	0.875712372389823	4.9724650094418905
13722.58cfa832e4b0c9d6adf6ce87	58cfa832e4b0c9d6adf6ce87	TCGA-FV-A3R3-01A-11D-A22F-10_wgs_Illumina.filtered.	WGS	TCGA-FV-A3R3-01A-11D-A22F-10_wgs_Illumina	TCGA-FV-A3R3-01A-11D-A22F-10_wgs_Illumina.bam	16.97		0.08	58cfa832e4b0c9d6adf6ce87	TCGA-FV-A3R3-01A-11D-A22F-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-FV-A3R3-01A	3DD7C93D-8194-44EE-8014-10DD81EF6441	Primary Tumor	Illumina HiSeq	0f95ee88-7930-46cd-a565-bf3d91f5f505	Liver	38.0	8ABDA02F-AEDF-4599-9407-E253207D5D4C	C285C2FA-24B4-47A1-874D-86E74B002B05	TCGA-FV-A3R3-01A-11D-A22F-10	GRCh37-lite	TCGA-FV-A3R3	TCGA-LIHC		s16685	Baylor College of Medicine	International Genomics Consortium	United States	NO	T1	NX	Hepatocellular Carcinoma	Stage I	A22F-10	True	LIHC	C3	LIHC.	0.259537773	0.65	0.0		-1.7078	-0.3145	0.2196	-0.1625	-0.16399999999999998	0.07	30.0	5.0	0.310649709	1.268486311	43.0	0.096857797	1.0	7.0				2.197224577	9.0	1.0	1.039473919	-677.7395658	-837.6548998	1771.781366	1.0	366.0	0.0	366.0	6.332094793877859	1.9062379534469436	0.04755126250363828	4.945800432757968	2.6353171432329523	4.229395070675939	-1.3862943611198908	0.7290791897860087	4.181843808172301
13722.58cfa832e4b0c9d6adf6ce8b	58cfa832e4b0c9d6adf6ce8b	TCGA-FY-A3RA-01A-11D-A221_120611_SN1222_0114_AC0WL3ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-FY-A3RA-01A-11D-A221_120611_SN1222_0114_AC0WL3ACXX_s_6_rg.sorted	TCGA-FY-A3RA-01A-11D-A221_120611_SN1222_0114_AC0WL3ACXX_s_6_rg.sorted.bam	38.77		0.17	58cfa832e4b0c9d6adf6ce8b	TCGA-FY-A3RA-01A-11D-A221_120611_SN1222_0114_AC0WL3ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FY-A3RA-01A	58FF4366-20A3-40A2-A87A-551E17CDB5D3	Primary Tumor	Illumina HiSeq	a7a005ec-f27f-4c17-8bb6-879c800bb0ae	Thyroid	21.0	E67E2BBE-8C3F-41B1-BE3C-C89555A10AEE	40CA310C-DB41-44D5-A76C-72938CF4AED0	TCGA-FY-A3RA-01A-11D-A221-26	HG19_Broad_variant	TCGA-FY-A3RA	TCGA-THCA		s12651	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T2	NX	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A221-26	True	THCA	C3	THCA.3	0.060758572999999996	0.03	0.0		-2.2195	-0.29	-0.6064	-1.3371	-0.1759	-0.2995	2.0		0.0	0.117692886	39.0	4.85e-05	0.0	0.0				0.693147181	2.0	1.0	1.2308686340000001	592.4596253	-846.9780148	609.2714503999999	0.0	550.0	0.0	550.0	7.001772757579467	8.176930446553706	-0.13926422669200544	6.208542118462539	7.294541266355232	4.611886709991657	-0.7932306391169281	-0.8823891801984738	4.751150936683662
13722.58cfa832e4b0c9d6adf6ce92	58cfa832e4b0c9d6adf6ce92	TCGA-G2-A2EJ-01A-11D-A17R_120921_SN208_0430_AC18CWACXX_s_3_rg.sorted.filtered.	WGS	TCGA-G2-A2EJ-01A-11D-A17R_120921_SN208_0430_AC18CWACXX_s_3_rg.sorted	TCGA-G2-A2EJ-01A-11D-A17R_120921_SN208_0430_AC18CWACXX_s_3_rg.sorted.bam	36.89		0.16	58cfa832e4b0c9d6adf6ce92	TCGA-G2-A2EJ-01A-11D-A17R_120921_SN208_0430_AC18CWACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-G2-A2EJ-01A	C6227D39-D9E8-4E28-9E70-D7F720AB25E4	Primary Tumor	Illumina HiSeq	18abb4d7-25d0-477e-bda6-011263e96364	Bladder	56.0	FBAD20BA-EE08-4D46-825B-870126AAD539	8D99E3A4-DECB-49D7-9727-C5D7606D60DF	TCGA-G2-A2EJ-01A-11D-A17R-02	HG19_Broad_variant	TCGA-G2-A2EJ	TCGA-BLCA		s3304	Harvard Medical School	MD Anderson	United States	NO		N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A17R-02	True	BLCA	C2	BLCA.3	0.395041262	0.39	0.05	1.319117886	0.8365	0.336	-0.6881	-0.8628	2.737	-0.1839	121.0	16.0	2.55540269	8.230773782	234.0	0.201152093	7.0	20.0				1.33217904	4.0	0.960964047	6.644049588	97.85268271	275.4906952	-819.8445085	0.0	1460.0	1.0	910.0	7.746754515126058	-0.821688460230865	0.35058016886253074	6.276578670025465	6.121894544465132	1.1574344382153066	-1.4701758451005928	6.943583004695997	0.8068542693527758
13722.58cfa832e4b0c9d6adf6ce96	58cfa832e4b0c9d6adf6ce96	TCGA-G2-A2EC-01A-11D-A17R_120927_SN208_0433_BD1D5JACXX_s_5_rg.sorted.filtered.	WGS	TCGA-G2-A2EC-01A-11D-A17R_120927_SN208_0433_BD1D5JACXX_s_5_rg.sorted	TCGA-G2-A2EC-01A-11D-A17R_120927_SN208_0433_BD1D5JACXX_s_5_rg.sorted.bam	18.46		0.18	58cfa832e4b0c9d6adf6ce96	TCGA-G2-A2EC-01A-11D-A17R_120927_SN208_0433_BD1D5JACXX_s_5_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-G2-A2EC-01A	28E25FFB-8B0C-4839-A735-ED7B78E3213A	Primary Tumor	Illumina HiSeq	0d4b7559-34dc-4690-a8e9-144698537cdd	Bladder	58.0	2DA969E6-9A63-4C03-8347-01A51496C224	09ED2111-236D-47C1-A82D-7919C8EEA5B2	TCGA-G2-A2EC-01A-11D-A17R-02	HG19_Broad_variant	TCGA-G2-A2EC	TCGA-BLCA		s3303	Harvard Medical School	MD Anderson	United States	NO		N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A17R-02	True	BLCA	C3	BLCA.2	0.286323883			1.722262779	-0.8391	-0.146	-0.0961	1.0072	-0.5742	0.4852	50.0	90.0	1.5265646869999998	4.891237874					0.907280365	3.787339608	65.0	3.693778247	42.0	0.988257022	2.270407565	-1157.974127	-395.3777375	-1719.5355789999999	1.0	696.0	1.0	679.0	6.586252787465972	8.596887120324812	-0.32153372268280533	5.325121569300088	7.4268158676745575	2.1561630905384455	-1.2611312181658842	-1.1700712526502546	2.4776968132212507
13722.58cfa832e4b0c9d6adf6ce97	58cfa832e4b0c9d6adf6ce97	TCGA-G2-A2EF-01A-12D-A18D_120912_SN1222_0148_AC188PACXX_s_7_rg.sorted.filtered.	WGS	TCGA-G2-A2EF-01A-12D-A18D_120912_SN1222_0148_AC188PACXX_s_7_rg.sorted	TCGA-G2-A2EF-01A-12D-A18D_120912_SN1222_0148_AC188PACXX_s_7_rg.sorted.bam	40.86		0.15	58cfa832e4b0c9d6adf6ce97	TCGA-G2-A2EF-01A-12D-A18D_120912_SN1222_0148_AC188PACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-G2-A2EF-01A	2A142731-119C-495D-AD30-EB0B48BACB46	Primary Tumor	Illumina HiSeq	ac16538b-bd5d-496e-bccc-6f3374d226c6	Bladder	50.0	981F581E-32AF-486B-9B60-0C8F1047C879	CE2F4DE7-C8AE-4103-8084-5F783B1087A7	TCGA-G2-A2EF-01A-12D-A18D-02	HG19_Broad_variant	TCGA-G2-A2EF	TCGA-BLCA		s3118	Harvard Medical School	MD Anderson	United States	NO		N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A18D-02	True	BLCA	C2	BLCA.4	0.25314335	0.39	0.23	9.503835091000001	0.7962	0.37200000000000005	0.4626	0.4704	2.11	0.2311	117.0	193.0	2.233206792	6.758388975	398.0	0.541245161	12.0	40.0	0.803714162	2.121047751	14.0	2.51159468	14.0	0.951701447	4.342284501	-284.946139	233.0149702	-1657.4568	0.0	1884.0	0.0	1884.0	6.377526947941294	6.987900545498899	0.37767145375872224	5.382098895508415	6.007071292487174	0.9901297230685246	-0.9954280524328789	-0.9808292530117262	0.6124582693098024
13722.58cfa832e4b0c9d6adf6ce99	58cfa832e4b0c9d6adf6ce99	TCGA-FY-A3R8-01A-11D-A221_120524_SN1120_0144_AC0VNCACXX_s_3_rg.sorted.filtered.	WGS	TCGA-FY-A3R8-01A-11D-A221_120524_SN1120_0144_AC0VNCACXX_s_3_rg.sorted	TCGA-FY-A3R8-01A-11D-A221_120524_SN1120_0144_AC0VNCACXX_s_3_rg.sorted.bam	51.96		0.15	58cfa832e4b0c9d6adf6ce99	TCGA-FY-A3R8-01A-11D-A221_120524_SN1120_0144_AC0VNCACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FY-A3R8-01A	C77976B6-35EA-4623-A92A-6D9440A978E6	Primary Tumor	Illumina HiSeq	7d0e9d6d-fb33-481e-93f7-84ae9641ce75	Thyroid	62.0	BAA64E5A-237E-44AC-8B22-2D86E710F7DB	3D9D0EC4-8C81-40D9-886F-8813570E732D	TCGA-FY-A3R8-01A-11D-A221-26	HG19_Broad_variant	TCGA-FY-A3R8	TCGA-THCA		s12392	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T3	NX	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A221-26	True	THCA	C3	THCA.4	0.107006848	0.23	0.0		-1.2382	-0.2085	0.1908	-0.5597	-0.4635	-0.0052	4.0	0.0	0.157594289	0.315188578	35.0	0.000384966	0.0	0.0				2.553681558	14.0	0.967649141	1.208336405	163.836017	-896.0631569	1940.5336710000001	0.0	477.0	0.0	477.0	6.25133282168988	8.553235782763167	-0.8940488343351478	5.504118419859659	7.349262978437231	1.6887247050364917	-0.7472144018302211	-1.203972804325936	2.5827735393716393
13722.58cfa832e4b0c9d6adf6ce9c	58cfa832e4b0c9d6adf6ce9c	TCGA-FD-A3B7-01A-31D-A210_120912_SN1120_0192_AC18ALACXX_s_5_rg.sorted.filtered.	WGS	TCGA-FD-A3B7-01A-31D-A210_120912_SN1120_0192_AC18ALACXX_s_5_rg.sorted	TCGA-FD-A3B7-01A-31D-A210_120912_SN1120_0192_AC18ALACXX_s_5_rg.sorted.bam	28.25		0.16	58cfa832e4b0c9d6adf6ce9c	TCGA-FD-A3B7-01A-31D-A210_120912_SN1120_0192_AC18ALACXX_s_5_rg.sorted.bam	Dead	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3B7-01A	EF5DD4B3-B77A-444A-B5B0-C999A5A3D129	Primary Tumor	Illumina HiSeq	4a37fdf6-816c-46ca-b703-cf3d58b32149	Bladder	66.0	A307CA46-3A09-4F0C-84AB-9A9E8954DE38	6014D6A8-5495-4D71-AB6E-622E3E6C4DC6	TCGA-FD-A3B7-01A-31D-A210-26	HG19_Broad_variant	TCGA-FD-A3B7	TCGA-BLCA	122.0	s2901	MD Anderson - Institute for Applied Cancer Science	BLN - University Of Chicago	United States	NO	T3a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A210-26	True	BLCA	C2	BLCA.4	0.526987534	0.72	0.39	26.21341692	0.8079	0.3215	0.9384	1.8499	1.0934	0.8170000000000001	30.0	6.0	0.46796646299999994	1.7782725609999999	128.0	0.38270557200000005	9.0	28.0	0.867925532	4.516690271	182.0	3.179913112	31.0	0.926011928	3.754910592	266.2840107	1631.686449	-1501.966091	1.0	122.0	1.0	110.0	7.319443408109416	9.011287626186533	-0.035880324789459905	6.855137799978319	8.500462002420543	1.2879409972680633	-0.46430560813109745	-0.5108256237659905	1.3238213220575232
13722.58cfa832e4b0c9d6adf6cea0	58cfa832e4b0c9d6adf6cea0	TCGA-ER-A2NF-01A-11D-A18Z_120516_SN1222_0107_BD12HYACXX_s_7_rg.sorted.filtered.	WGS	TCGA-ER-A2NF-01A-11D-A18Z_120516_SN1222_0107_BD12HYACXX_s_7_rg.sorted	TCGA-ER-A2NF-01A-11D-A18Z_120516_SN1222_0107_BD12HYACXX_s_7_rg.sorted.bam	52.36		0.16	58cfa832e4b0c9d6adf6cea0	TCGA-ER-A2NF-01A-11D-A18Z_120516_SN1222_0107_BD12HYACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-ER-A2NF-01A	D32A4219-4CCA-470F-B6B3-11447D9F5E0B	Primary Tumor	Illumina HiSeq	cf624be8-7ec3-4fce-9ab0-1d9ac2fb1edb	Skin	53.0	52EDD1DB-F1C3-4B87-B959-B5B095E52463	DB2D94A9-5B22-4163-AE7A-1DA11F7037A6	TCGA-ER-A2NF-01A-11D-A18Z-02	HG19_Broad_variant	TCGA-ER-A2NF	TCGA-SKCM		s7861	Harvard Medical School	University of Pittsburgh	None	NO	T4b	N3		Stage IIIC	A18Z-02	True	SKCM	C2	SKCM.Triple_WT	0.181023465	0.42	0.0	11.7003573	-0.3817	-0.06	0.3696	1.7516	0.6595	-0.0034	17.0		0.167903479	0.41212672200000006	122.0	0.319590995	6.0	15.0	0.728074995	3.64324818	149.0	4.1544974660000005	67.0	0.988062111	2.39918123	-324.8296769	-113.1403722	-1885.385818	1.0	877.0	1.0	230.0	6.394466306201414	5.262267132314759	0.485379815781526	6.143151877920507	6.9850337300558625	2.3972127953789437	-0.2513144282809061	1.7227665977411033	1.9118329795974178
13722.58cfa832e4b0c9d6adf6cea9	58cfa832e4b0c9d6adf6cea9	TCGA-EJ-5516-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EJ-5516-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_3_rg.sorted	TCGA-EJ-5516-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_3_rg.sorted.bam	197.7	1.9	0.16	58cfa832e4b0c9d6adf6cea9	TCGA-EJ-5516-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5516-01A	1FD06207-54E0-4ABA-819C-C7F671871F39	Primary Tumor	Illumina HiSeq	80ba9751-2e29-4949-a07f-6e3542df8770	Prostate	49.0	84D2D822-204E-4031-AF83-E188BB72F3AF	7DBAAFC9-A93D-4FFB-9FF0-85FACD567555	TCGA-EJ-5516-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5516	TCGA-PRAD		s4136	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.1-ERG	0.17543341399999998	0.63	0.0	0.37502155299999995	-1.1568	-0.27399999999999997	-0.1994	-0.4592	-0.2551	-0.1679	7.0		0.139072387	0.500660594	166.0	0.048957284000000004	0.0	4.0				1.791759469	6.0	1.0	2.123268373	294.3065828	-317.98778639999995	2809.872139	0.0	1889.0	0.0	1889.0	7.347993353845347	9.489192953948475	-0.26112429280945415	6.734888880958938	8.735421151572094	2.246255212830605	-0.613104472886409	-0.7537718023763804	2.507379505640059
13722.58cfa832e4b0c9d6adf6ceac	58cfa832e4b0c9d6adf6ceac	TCGA-FD-A3NA-01A-11D-A21C_120830_SN590_0177_BD141PACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FD-A3NA-01A-11D-A21C_120830_SN590_0177_BD141PACXX_s_1_rg.sorted	TCGA-FD-A3NA-01A-11D-A21C_120830_SN590_0177_BD141PACXX_s_1_rg.sorted.bam	63.16		0.16	58cfa832e4b0c9d6adf6ceac	TCGA-FD-A3NA-01A-11D-A21C_120830_SN590_0177_BD141PACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3NA-01A	14917461-DAE4-44CB-909D-42AC45AEF450	Primary Tumor	Illumina HiSeq	8c4c1672-fea7-4c17-a6d0-d4a0f3c04558	Bladder	60.0	7BD000AB-6F48-4A9E-98A4-EAF47D6E3C05	37789FCA-0C64-49B7-A704-572A19BD2645	TCGA-FD-A3NA-01A-11D-A21C-26	HG19_Broad_variant	TCGA-FD-A3NA	TCGA-BLCA		s3114	MD Anderson - Institute for Applied Cancer Science	BLN - University Of Chicago	United States	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A21C-26	True	BLCA	C2		0.320085069			8.537913368	0.8436	0.311	-0.1296	-0.3068	0.9702	0.314	77.0	46.0	1.3232598770000001	4.541187306	285.0	0.465964028	16.0	27.0	0.64977213	1.264398182	7.0	2.441015278	12.0	0.982336813	2.917737875	-932.6751703	696.6092683999999	243.1700873	0.0	1845.0	1.0	1338.0	6.557172849042563	7.684886109440322	0.24914686676112707	5.4963008883573	6.624014148755061	1.943221975393513	-1.060871960685263	-1.0608719606852626	1.694075108632386
13722.58cfa832e4b0c9d6adf6ceb7	58cfa832e4b0c9d6adf6ceb7	TCGA-EJ-5522-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EJ-5522-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_5_rg.sorted	TCGA-EJ-5522-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_5_rg.sorted.bam	414.7	1.9	0.17	58cfa832e4b0c9d6adf6ceb7	TCGA-EJ-5522-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5522-01A	214884EF-A932-4FC3-B6FF-16CE5164DA3E	Primary Tumor	Illumina HiSeq	ee0fc9f9-f7ac-4f93-a066-2751ffaa3959	Prostate	51.0	8AC1E1E7-8266-48E0-8D4C-D78873111341	2312B3FC-1F68-43D5-8B19-D449089F153C	TCGA-EJ-5522-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5522	TCGA-PRAD		s4133	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.1-ERG	0.161319629	0.51	0.0	4.000443262	-1.0091	-0.203	-0.4421	0.1858	-0.5602	-0.2743	9.0		0.279432827	0.39120595799999996	124.0	0.024455901000000002	0.0	2.0		0.0	1.0	3.506502585	34.0	0.994368715	2.219173847	-202.16497769999998	-185.8530124	2267.2451739999997	0.0	2079.0	0.0	2079.0	8.0702808933939	7.580784782622983	-0.6178941315497373	5.8730563160576805	6.539330907794821	2.7784401140082453	-2.197224577336219	-1.0414538748281612	3.3963342455579824
13722.58cfa832e4b0c9d6adf6cec2	58cfa832e4b0c9d6adf6cec2	TCGA-HC-7080-01A-11D-1957_130422_SN590_0225_BD23TLACXX_s_2_rg.sorted.filtered.	WGS	TCGA-HC-7080-01A-11D-1957_130422_SN590_0225_BD23TLACXX_s_2_rg.sorted	TCGA-HC-7080-01A-11D-1957_130422_SN590_0225_BD23TLACXX_s_2_rg.sorted.bam	398.7		0.13	58cfa832e4b0c9d6adf6cec2	TCGA-HC-7080-01A-11D-1957_130422_SN590_0225_BD23TLACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7080-01A	FD50FF41-EC9D-4DB1-A673-36BA0CA1EAC8	Primary Tumor	Illumina HiSeq	4012de79-f9d8-4ee6-ab04-538482e6a66c	Prostate	66.0	E30730B8-81F1-49A8-8446-547B5C3CC730	CEF3C431-0329-4619-834B-DC57B33399A5	TCGA-HC-7080-01A-11D-1957-02	HG19_Broad_variant	TCGA-HC-7080	TCGA-PRAD		s3807	Harvard Medical School	International Genomics Consortium	United States	NO	T2a	N0	Prostate Adenocarcinoma Acinar Type		1957-02	True	PRAD	C3	PRAD.5-SPOP	0.033347768	0.1	0.0	1.518908865	-1.4724	-0.1045	-1.2433	-1.4236	-0.9496	-0.718	10.0	6.0	0.318461057	0.66587312	547.0	0.560592037	0.0	16.0							2.087458796	-1603.518239	-1434.240822	3050.281076	0.0	1106.0	1.0	894.0	7.614065446068363	7.546710230458656	-0.6319901566500544	5.311480353074318	6.792938428082276	5.154446996128335	-2.3025850929940455	-0.7537718023763804	5.786437152778389
13722.58cfa832e4b0c9d6adf6cec4	58cfa832e4b0c9d6adf6cec4	TCGA-EM-A1YB-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EM-A1YB-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_1_rg.sorted	TCGA-EM-A1YB-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_1_rg.sorted.bam	31.49	1.93	0.17	58cfa832e4b0c9d6adf6cec4	TCGA-EM-A1YB-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_1_rg.sorted.bam	Alive	FEMALE			Thyroid Carcinoma	Aligned reads	TCGA-EM-A1YB-01A	B43A4F92-7A13-4558-A97E-7B3FEB2D70C9	Primary Tumor	Illumina HiSeq	13add68c-df0c-4f19-8032-d084a8cedcab	Thyroid	73.0	13C7182D-EF93-48A7-9569-EED7714CEC40	59B09269-9CB6-4AD9-874D-5237896747A1	TCGA-EM-A1YB-01A-11D-A14U-02	HG19_Broad_variant	TCGA-EM-A1YB	TCGA-THCA		s12751	Harvard Medical School	University Health Network	Canada	NO	T2	NX	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage II	A14U-02	True	THCA	C3	THCA.1	0.123324332	0.31	0.0		-1.4676	-0.157	-0.615	-1.3706	-0.8348	-0.5446	13.0	5.0	0.328989938	0.8374289340000001	62.0	0.057636688	1.0	2.0				0.693147181	2.0	1.0	1.3437336009999998	-698.9731216	-728.1075331000001	273.7493583	0.0	592.0	0.0	592.0	6.12270673613837	8.639609919363965	0.7466727083477669	5.944458504732051	7.5409976306958555	2.996037105136903	-0.1782482314063185	-1.09861228866811	2.249364396789136
13722.58cfa832e4b0c9d6adf6ced1	58cfa832e4b0c9d6adf6ced1	TCGA-EJ-5542-01A-01D-1572_130221_SN1120_0239_BD1V59ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EJ-5542-01A-01D-1572_130221_SN1120_0239_BD1V59ACXX_s_5_rg.sorted	TCGA-EJ-5542-01A-01D-1572_130221_SN1120_0239_BD1V59ACXX_s_5_rg.sorted.bam	214.7	1.9	0.15	58cfa832e4b0c9d6adf6ced1	TCGA-EJ-5542-01A-01D-1572_130221_SN1120_0239_BD1V59ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5542-01A	5A92EC4C-36EE-4588-ACA2-E3303F29C7AD	Primary Tumor	Illumina HiSeq	45ba9a12-204e-4ab8-b544-61f2519b176f	Prostate	60.0	DFFC7994-E957-4451-A9DB-56D4560D6547	185234ED-0A19-490C-86D8-19762FB13C1A	TCGA-EJ-5542-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5542	TCGA-PRAD		s3964	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.1-ERG	0.10808431	0.42	0.07	0.828043564	-1.0847	-0.24	-0.6893	-0.2762	-1.1138	-0.2823	11.0	0.0	0.194584378	0.583753133	134.0	0.09199474099999999	2.0	4.0	0.8871811759999999	1.4278630209999998	5.0	2.3025850930000002	10.0	1.0	2.435684664	-428.04560719999995	-272.6088858	2967.404424	0.0	1513.0	0.0	1513.0	9.142846376612967	9.014082149443356	-0.30101195119147606	6.84026128361892	9.065375443830906	2.307499107796475	-2.302585092994046	0.05129329438755059	2.608511058987951
13722.58cfa832e4b0c9d6adf6ced3	58cfa832e4b0c9d6adf6ced3	TCGA-EJ-5527-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EJ-5527-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_5_rg.sorted	TCGA-EJ-5527-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_5_rg.sorted.bam	188.7	1.9	0.15	58cfa832e4b0c9d6adf6ced3	TCGA-EJ-5527-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5527-01A	BA0C9096-5F35-4F0A-AE98-EE1A695B55F0	Primary Tumor	Illumina HiSeq	62c0aaa3-44c3-4b25-b1cb-8e6196d66189	Prostate	69.0	15A638FE-4DFD-4280-AD40-5E0D5FDE3812	AE85C536-0580-4A34-B686-161D337E7951	TCGA-EJ-5527-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5527	TCGA-PRAD		s3443	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.1-ERG	0.16408208400000002	0.51	0.11	0.136503067	-1.4368	-0.2575	-0.242	0.0481	-0.7061	-0.1189	7.0	1.0	0.41614713	0.55486284	98.0	0.147481335	2.0	15.0		0.0	1.0	3.573450497	36.0	0.997190348	1.959343286	-153.5871878	-451.8727391	2109.685329	0.0	1778.0	0.0	1778.0	8.594663362183136	9.662259584456232	-0.4353336700567382	6.802903892955081	8.908487782079852	2.241134069951788	-1.7917594692280552	-0.7537718023763804	2.676467740008526
13722.58cfa832e4b0c9d6adf6ceda	58cfa832e4b0c9d6adf6ceda	TCGA-EJ-5505-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EJ-5505-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_3_rg.sorted	TCGA-EJ-5505-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_3_rg.sorted.bam	164.7	1.9	0.14	58cfa832e4b0c9d6adf6ceda	TCGA-EJ-5505-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5505-01A	1EA3B879-5451-49FB-B930-16E9B5627F18	Primary Tumor	Illumina HiSeq	156ad547-dfb8-48c9-88b9-6842c81fead1	Prostate	57.0	A31147E1-4A52-4233-BC27-B0DFA6708DC6	3AB7712C-40E4-4752-AC1D-0CB9D7345413	TCGA-EJ-5505-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5505	TCGA-PRAD		s3605	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.5-SPOP	0.06687762	0.53	0.0	0.36256950299999996	-1.2499	-0.192	-0.9628	-0.8658	-1.3156	-0.5827	16.0	40.0	0.139905767	0.6995288340000001	183.0	0.042133587	0.0	10.0				2.079441542	8.0	1.0	2.508814223	-616.0870157	-830.1765071000001	1372.663172	0.0	922.0	0.0	922.0	9.002783055113968	9.373339543282254	-0.21662154461306482	6.965901127852927	9.016664599343523		-2.0368819272610397	-0.35667494393873245	
13722.58cfa832e4b0c9d6adf6cedd	58cfa832e4b0c9d6adf6cedd	TCGA-EJ-5508-01A-02D-1572_130308_SN590_0219_BC1UVPACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EJ-5508-01A-02D-1572_130308_SN590_0219_BC1UVPACXX_s_1_rg.sorted	TCGA-EJ-5508-01A-02D-1572_130308_SN590_0219_BC1UVPACXX_s_1_rg.sorted.bam	256.7	1.9	0.15	58cfa832e4b0c9d6adf6cedd	TCGA-EJ-5508-01A-02D-1572_130308_SN590_0219_BC1UVPACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5508-01A	BD18DD01-D894-4BDD-9CE2-E25705A52A57	Primary Tumor	Illumina HiSeq	69098ac9-e4d2-44cd-ae04-e179d90a749e	Prostate	65.0	E3969BF5-B0CC-49E3-B8CB-3D9E98F1676D	706963B3-03D9-4990-AE75-09F8781D79B7	TCGA-EJ-5508-01A-02D-1572-02	HG19_Broad_variant	TCGA-EJ-5508	TCGA-PRAD		s3784	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.1-ERG	0.161388231	0.66	0.0	1.201460416	-1.1614	-0.2215	-0.1777	0.2508	-0.7636	-0.268	11.0	1.0	0.279605192	0.363486749	70.0	0.013565674	0.0	4.0	0.86452325	0.599241853	2.0	2.3025850930000002	10.0	1.0	1.7611944830000001	-335.0313758	-287.75822410000006	2701.132029	0.0	1965.0	0.0	1965.0	6.175867270105761	6.956862853089165	-0.44839454099381804	3.924575471499266	5.915408978261003	3.085834108251177	-2.251291798606495	-1.0414538748281612	3.5342286492449952
13722.58cfa832e4b0c9d6adf6cedf	58cfa832e4b0c9d6adf6cedf	TCGA-EM-A1YD-01A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EM-A1YD-01A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_5_rg.sorted	TCGA-EM-A1YD-01A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_5_rg.sorted.bam	41.17	1.98	0.17	58cfa832e4b0c9d6adf6cedf	TCGA-EM-A1YD-01A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_5_rg.sorted.bam	Alive	FEMALE			Thyroid Carcinoma	Aligned reads	TCGA-EM-A1YD-01A	8A3659A8-2A85-4BAB-8BF3-55795922474C	Primary Tumor	Illumina HiSeq	76d6fe1c-fb49-412c-bf6f-43229f7b7df6	Thyroid	53.0	AD5054BB-96D0-47CC-BB8C-F36E58784A31	CD27AF7E-F458-49BA-8C82-D18BDE252DB2	TCGA-EM-A1YD-01A-11D-A14U-02	HG19_Broad_variant	TCGA-EM-A1YD	TCGA-THCA		s12381	Harvard Medical School	University Health Network	Canada	NO	T2	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage II	A14U-02	True	THCA	C3	THCA.1	0.10907942699999999				-1.9358	-0.33399999999999996	-0.6072	-0.3421	-0.4138	-0.1384	2.0		0.060583749000000006	0.121167499	69.0	0.9478338559999999			0.957462356	0.663662333	2.0	1.386294361	4.0	1.0	1.4687359709999999	612.6220203	-975.4161968000001	1437.734842	0.0	1734.0	0.0	1734.0	6.917953103958583	7.4299905642996915	-0.09694556917940167	5.516154556302728	7.111536833181157	2.1126611819852297	-1.4017985476558557	-0.3184537311185345	2.2096067511646313
13722.58cfa832e4b0c9d6adf6cee4	58cfa832e4b0c9d6adf6cee4	TCGA-EM-A3O8-01A-11D-A221_120530_SN1222_0111_BD12L1ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EM-A3O8-01A-11D-A221_120530_SN1222_0111_BD12L1ACXX_s_2_rg.sorted	TCGA-EM-A3O8-01A-11D-A221_120530_SN1222_0111_BD12L1ACXX_s_2_rg.sorted.bam	55.95		0.15	58cfa832e4b0c9d6adf6cee4	TCGA-EM-A3O8-01A-11D-A221_120530_SN1222_0111_BD12L1ACXX_s_2_rg.sorted.bam	Alive	FEMALE			Thyroid Carcinoma	Aligned reads	TCGA-EM-A3O8-01A	97B5017C-2066-4472-AB3F-31CFE64A6762	Primary Tumor	Illumina HiSeq	63701f3e-e258-497f-a7b6-1dddce3369f2	Thyroid	33.0	7F540311-430C-46B2-98C8-F314B27ECB0E	F125CCA1-271D-4716-9746-9AB9DD2A1C43	TCGA-EM-A3O8-01A-11D-A221-26	HG19_Broad_variant	TCGA-EM-A3O8	TCGA-THCA		s12252	MD Anderson - Institute for Applied Cancer Science	University Health Network	Canada	NO	T1b	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A221-26	True	THCA	C3	THCA.1	0.043362048	0.19	0.0		-2.2539	-0.38799999999999996	-1.2893	-1.9884	-1.1961	-0.6508	1.0		0.029450268999999998	0.088350808	45.0	7.390000000000001e-05	0.0	0.0				0.0	1.0		1.53617145	-1050.46687	-1275.015255	1407.051697	0.0	381.0	0.0	381.0	6.169349192016577	8.049356102415237	0.2700636608895377	5.926403013406187	7.155538226393141	2.7674885290349414	-0.24294617861038947	-0.8938178760220965	2.4974248681454037
13722.58cfa832e4b0c9d6adf6cee6	58cfa832e4b0c9d6adf6cee6	TCGA-FI-A2D0-01A-11D-A17E_120511_SN1120_0140_AD12J0ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-FI-A2D0-01A-11D-A17E_120511_SN1120_0140_AD12J0ACXX_s_3_rg.sorted	TCGA-FI-A2D0-01A-11D-A17E_120511_SN1120_0140_AD12J0ACXX_s_3_rg.sorted.bam	65.38		0.17	58cfa832e4b0c9d6adf6cee6	TCGA-FI-A2D0-01A-11D-A17E_120511_SN1120_0140_AD12J0ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-FI-A2D0-01A	1B35D083-F7C9-47D2-9A9E-718788F9E39A	Primary Tumor	Illumina HiSeq	5d8357bd-6f87-41b8-af0f-a2bdcb483e07	Uterus	55.0	A2D2A29A-5ABC-48C3-AC17-76B8B9EE1717	9406B9B9-CC2D-470D-BFB6-2118C0B84982	TCGA-FI-A2D0-01A-11D-A17E-02	HG19_Broad_variant	TCGA-FI-A2D0	TCGA-UCEC		s5399	Harvard Medical School	Washington University	United States	NO			Endometrioid endometrial adenocarcinoma		A17E-02	True	UCEC	C2	UCEC.POLE	0.08639730300000001	0.25	0.06	2.9392793530000003	0.7485	0.214	-0.9447	-0.4895	0.501	0.4187	3110.0	836.0	60.59634472	143.0575852	51.0	1.3800000000000002e-05	0.0	0.0							2.091023746	-943.9955864	440.11583830000006	-1031.999747	0.0	1213.0	0.0	1213.0	6.967981631454617	8.232218561642696	-0.7825164930914794	6.354877158568208	6.497617506254589	1.0381543196309955	-0.613104472886409	-1.7346010553881066	1.8206708127224749
13722.58cfa832e4b0c9d6adf6ceed	58cfa832e4b0c9d6adf6ceed	TCGA-FY-A3R7-01A-11D-A221_120611_SN1222_0114_AC0WL3ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-FY-A3R7-01A-11D-A221_120611_SN1222_0114_AC0WL3ACXX_s_3_rg.sorted	TCGA-FY-A3R7-01A-11D-A221_120611_SN1222_0114_AC0WL3ACXX_s_3_rg.sorted.bam	10.86		0.15	58cfa832e4b0c9d6adf6ceed	TCGA-FY-A3R7-01A-11D-A221_120611_SN1222_0114_AC0WL3ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FY-A3R7-01A	B983A678-B0AE-42C2-8F37-D6ECAF07413B	Primary Tumor	Illumina HiSeq	8f5f6e5a-6274-4d57-8dbd-2dc9d5bc3544	Thyroid	50.0	E85B6BC8-C182-4483-8F53-F312D5A545CB	5F86B67F-ECBC-477C-B72A-F41F104E03A2	TCGA-FY-A3R7-01A-11D-A221-26	HG19_Broad_variant	TCGA-FY-A3R7	TCGA-THCA		s12009	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T3	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A221-26	True	THCA	C3	THCA.2	0.123742086	0.71	0.0		-1.8648	-0.315	0.057999999999999996	0.1971	-0.0883	-0.061	5.0		0.029361752	0.146808761	43.0	0.011053025	0.0	0.0	0.79421326	1.545467643	7.0	3.4365228310000004	32.0	0.991570889	1.822236803	914.3946221000001	-1263.4722359999998	2343.091895	0.0	495.0	0.0	495.0	7.656607436702098	7.69070507628396	0.11136443403706886	6.36383913359303	7.018611304921847	2.631613612580699	-1.2927683031090673	-0.6720937713621127	2.52024917854363
13722.58cfa832e4b0c9d6adf6cef7	58cfa832e4b0c9d6adf6cef7	TCGA-IG-A5B8-01A-11D-A28P_131120_SN1222_0230_BC29YPACXX_s_3_rg.sorted.filtered.	WGS	TCGA-IG-A5B8-01A-11D-A28P_131120_SN1222_0230_BC29YPACXX_s_3_rg.sorted	TCGA-IG-A5B8-01A-11D-A28P_131120_SN1222_0230_BC29YPACXX_s_3_rg.sorted.bam	23.16		0.14	58cfa832e4b0c9d6adf6cef7	TCGA-IG-A5B8-01A-11D-A28P_131120_SN1222_0230_BC29YPACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-IG-A5B8-01A	A4D36E09-5D8E-4006-855C-E466682B6813	Primary Tumor	Illumina HiSeq	948983f4-15f3-4b59-983e-18a248b1f4d9	Esophagus	72.0	C7E7425E-1F33-42B3-A2A2-ADDAAE6365E9	09D7FAFF-2E10-4C45-BB7E-E58B50911EFE	TCGA-IG-A5B8-01A-11D-A28P-26	HG19_Broad_variant	TCGA-IG-A5B8	TCGA-ESCA	24.0	s1817	MD Anderson - Institute for Applied Cancer Science	Asterand	Ukraine	NO	T3	N0		Stage IB	A28P-26	True	ESCA	C2	GI.ESCC	0.36960328299999995	0.64	0.08		0.5081	0.3055	-0.7398	-0.8966	1.0404	0.024			2.188255046	4.800763621000001	161.0	0.5642484879999999	16.0	27.0				1.50589939	7.0	0.7738792	4.1497389369999995	-204.3579898	207.7300495	-3738.1636359999998	1.0	24.0	0.0	24.0	8.58260632996447	9.800948449772449	-0.44693480416293474	6.140259294595266	8.527982773959561	1.2794004947910749	-2.4423470353692043	-1.2729656758128873	1.7263352989540097
13722.58cfa832e4b0c9d6adf6cefa	58cfa832e4b0c9d6adf6cefa	TCGA-HE-A5NH-01A-11D-A26P-10_wgs_Illumina.filtered.	WGS	TCGA-HE-A5NH-01A-11D-A26P-10_wgs_Illumina	TCGA-HE-A5NH-01A-11D-A26P-10_wgs_Illumina.bam	20.02		0.08	58cfa832e4b0c9d6adf6cefa	TCGA-HE-A5NH-01A-11D-A26P-10_wgs_Illumina.bam	Alive	MALE			Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-HE-A5NH-01A	98A639C2-D615-4DC1-98F0-298752B69B09	Primary Tumor	Illumina HiSeq	7d7c81dd-4888-4bac-a7d7-0859f946423b	Kidney	62.0	E8CD0D5D-2AF6-444F-B8B9-05B1874EDAE2	33B7E799-AD10-498F-9948-8CE433311539	TCGA-HE-A5NH-01A-11D-A26P-10	GRCh37-lite	TCGA-HE-A5NH	TCGA-KIRP		s11591	Baylor College of Medicine	Ontario Institute for Cancer Research (OICR)	Canada	NO	T1a	NX	Kidney Papillary Renal Cell Carcinoma	Stage I	A26P-10	True	KIRP	C3	KIRP.C1	0.19408302800000002	0.16	0.0		-1.5418	-0.275	-0.2385	-1.4289	-0.4021	-0.265	33.0	150.0	0.376325674	1.989149993	43.0	0.082014322	4.0	0.0				0.693147181	2.0	1.0	2.1233493119999998	-50.456863500000004	-1047.6775189999998	2118.07991	0.0	791.0	0.0	791.0	7.1605870739981725	2.3498948127598442	-0.055296641105811895	6.0619747853300625	4.014566780509469	3.018951976882812	-1.0986122886681096	1.6646719677496247	3.0742486179886237
13722.58cfa832e4b0c9d6adf6cefc	58cfa832e4b0c9d6adf6cefc	TCGA-H4-A2HQ-01A-11D-A17R_120921_SN208_0430_AC18CWACXX_s_5_rg.sorted.filtered.	WGS	TCGA-H4-A2HQ-01A-11D-A17R_120921_SN208_0430_AC18CWACXX_s_5_rg.sorted	TCGA-H4-A2HQ-01A-11D-A17R_120921_SN208_0430_AC18CWACXX_s_5_rg.sorted.bam	54.46		0.15	58cfa832e4b0c9d6adf6cefc	TCGA-H4-A2HQ-01A-11D-A17R_120921_SN208_0430_AC18CWACXX_s_5_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-H4-A2HQ-01A	CEDE5274-279D-4021-8ACA-5ECC4BF94D66	Primary Tumor	Illumina HiSeq	46adb3c9-ac82-4284-b0d1-f95b10435695	Bladder	64.0	CBEDC0DB-39FD-4661-9531-CC24D422FAC4	CD60EBC2-EF2A-4B47-8D42-C864AA095B8D	TCGA-H4-A2HQ-01A-11D-A17R-02	HG19_Broad_variant	TCGA-H4-A2HQ	TCGA-BLCA		s2735	Harvard Medical School	Medical College of Georgia	United States	NO		NX	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A17R-02	True	BLCA	C2	BLCA.1	0.06276086	0.2	0.34	7.513838397000001	0.6842	0.1515	-0.9369	-0.9674	1.0256	-0.2432	246.0	112.0	4.036825072	11.04360002	282.0	0.8527836790000001	22.0	36.0	0.711238557	1.478979001	8.0	1.386294361	4.0	1.0	5.115880269	-1251.18603	196.2283967	-3219.1581	0.0	590.0	1.0	318.0	7.079246797105789	7.191993929656158	0.34363326476632094	6.613883547416556	6.211164676644431	1.0076675663734247	-0.46536324968923326	-0.9808292530117262	0.6640343016071037
13722.58cfa832e4b0c9d6adf6cefe	58cfa832e4b0c9d6adf6cefe	TCGA-H2-A3RI-01A-11D-A221_120610_SN1120_0152_BD13TDACXX_s_2_rg.sorted.filtered.	WGS	TCGA-H2-A3RI-01A-11D-A221_120610_SN1120_0152_BD13TDACXX_s_2_rg.sorted	TCGA-H2-A3RI-01A-11D-A221_120610_SN1120_0152_BD13TDACXX_s_2_rg.sorted.bam	58.31		0.15	58cfa832e4b0c9d6adf6cefe	TCGA-H2-A3RI-01A-11D-A221_120610_SN1120_0152_BD13TDACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-H2-A3RI-01A	BF193C4F-FBAC-41BC-B1AF-19B6CE856F0F	Primary Tumor	Illumina HiSeq	24a690e4-62f0-4e09-bbb1-ec78dafcf3cd	Thyroid	29.0	EAAE1A05-7D7E-406A-A02B-282A8B66F95C	5E15CB1B-B0D3-4FB9-9B30-3AEBE4DFC96B	TCGA-H2-A3RI-01A-11D-A221-26	HG19_Broad_variant	TCGA-H2-A3RI	TCGA-THCA		s12259	MD Anderson - Institute for Applied Cancer Science	Christiana Healthcare	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A221-26	True	THCA	C3	THCA.3	0.077080412	0.21	0.0		-1.5928	-0.287	-0.1437	-0.0298	-0.2606	-0.2821	0.0		0.0	0.058935015	51.0	0.000525218	0.0	0.0	0.969063253	0.6717034609999999	2.0	3.0625292999999996	22.0	0.9907755540000001	1.000727918	-415.5480215	-1038.933048	3116.130757	0.0	335.0	1.0	279.0	6.7262747477373726	8.313716092549491	0.5158440844829386	5.903915835697422	7.1436448398992365	1.773204762226936	-0.822358912039951	-1.1700712526502546	1.2573606777439974
13722.58cfa832e4b0c9d6adf6cf07	58cfa832e4b0c9d6adf6cf07	TCGA-HC-7079-01A-11D-1957_130412_SN590_0224_BC1YMJACXX_s_8_rg.sorted.filtered.	WGS	TCGA-HC-7079-01A-11D-1957_130412_SN590_0224_BC1YMJACXX_s_8_rg.sorted	TCGA-HC-7079-01A-11D-1957_130412_SN590_0224_BC1YMJACXX_s_8_rg.sorted.bam	133.0		0.15	58cfa832e4b0c9d6adf6cf07	TCGA-HC-7079-01A-11D-1957_130412_SN590_0224_BC1YMJACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7079-01A	10FBE481-F111-4F88-AE45-4D67CB265567	Primary Tumor	Illumina HiSeq	5debd428-e42f-459c-8945-f3e0a3053b9e	Prostate	51.0	190EF71A-5B5D-4009-B707-68F10147CB65	3935531A-0F99-4617-A5B6-6774E74CEE5E	TCGA-HC-7079-01A-11D-1957-02	HG19_Broad_variant	TCGA-HC-7079	TCGA-PRAD		s3624	Harvard Medical School	International Genomics Consortium	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1957-02	True	PRAD	C3	PRAD.4-FLI1	0.481468756	0.09	0.0	9.467504547999999	-0.9766	-0.2965	1.3256	2.7194	0.3674	0.2207			0.0	0.0	55.0	1.99e-05	0.0	0.0	0.8893486890000001	5.130048715	320.0	4.657155136	115.0	0.9815008959999999	1.68273796	826.8209644	-396.5579541	2466.705853	0.0	1184.0	1.0	380.0	8.805225202632307	9.123801610558942	-0.5380585927056571	6.684961666432216	7.315512839379678	1.1154760947201143	-2.120263536200091	-1.8082887711792655	1.6535346874257715
13722.58cfa832e4b0c9d6adf6cf1a	58cfa832e4b0c9d6adf6cf1a	TCGA-H7-7774-01A-21D-2317_120623_SN1222_0119_BC0WLLACXX_s_4_rg.sorted.filtered.	WGS	TCGA-H7-7774-01A-21D-2317_120623_SN1222_0119_BC0WLLACXX_s_4_rg.sorted	TCGA-H7-7774-01A-21D-2317_120623_SN1222_0119_BC0WLLACXX_s_4_rg.sorted.bam	52.73		0.15	58cfa832e4b0c9d6adf6cf1a	TCGA-H7-7774-01A-21D-2317_120623_SN1222_0119_BC0WLLACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-H7-7774-01A	EEAE67AC-C9E0-468D-AAD6-052501F7B982	Primary Tumor	Illumina HiSeq	ab347312-e135-4dd6-9be3-fa5fdebbcd68	Head and Neck	75.0	50F6615A-49CC-4E14-B5DD-54784B66C27B	B9B2B6F5-57EB-4DD6-8FE2-1E8669840DAB	TCGA-H7-7774-01A-21D-2317-26	HG19_Broad_variant	TCGA-H7-7774	TCGA-HNSC		s16209	MD Anderson - Institute for Applied Cancer Science	ABS - IUPUI	United States	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	2317-26	True	HNSC	C2	HNSC.Atypical	0.33657615399999996	0.43	0.2		0.1912	-0.1025	-0.0878	0.4032	2.1178	-0.2356	54.0	31.0	1.159528088	3.753209337	43.0	0.093992575	3.0	3.0	0.8965503770000001	2.149833912	11.0	3.1224245980000003	24.0	0.982495818	2.440046948	-548.4903922	-65.31928767	-870.2839679	0.0	407.0	1.0	252.0	7.849973632866208	3.3512376813929023	0.7369931696249408	7.156826452306262	4.442760406413589	1.466507994355761	-0.6931471805599454	1.0915227250206865	0.7295148247308203
13722.58cfa832e4b0c9d6adf6cf22	58cfa832e4b0c9d6adf6cf22	TCGA-G9-6364-01A-21D-1784_130215_SN590_0211_AC1UJWACXX_s_7_rg.sorted.filtered.	WGS	TCGA-G9-6364-01A-21D-1784_130215_SN590_0211_AC1UJWACXX_s_7_rg.sorted	TCGA-G9-6364-01A-21D-1784_130215_SN590_0211_AC1UJWACXX_s_7_rg.sorted.bam	79.4	1.9	0.13	58cfa832e4b0c9d6adf6cf22	TCGA-G9-6364-01A-21D-1784_130215_SN590_0211_AC1UJWACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6364-01A	F8D8B417-5945-42A5-850A-FBC04B4F0E61	Primary Tumor	Illumina HiSeq	01dfbaf5-2c53-4f89-97c0-f845932cfde5	Prostate	72.0	242C8BCB-F8D3-4D3A-ABB1-0AB5D74D3BCB	6E0AAA4D-9ACC-4E63-AC7E-5B478D6406B5	TCGA-G9-6364-01A-21D-1784-02	HG19_Broad_variant	TCGA-G9-6364	TCGA-PRAD		s4147	Harvard Medical School	Roswell Park	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1784-02	True	PRAD	C3	PRAD.1-ERG	0.107951669	0.45	0.01	1.562232641	-1.6706	-0.168	-0.8569	-0.5568	-0.4656	-0.1628	10.0	1.0	0.116093738	0.49339838799999997	95.0	0.036840291000000004	2.0	6.0				2.6156305769999997	14.0	0.99112306	2.348188077	25.17809734	-394.1717505	1938.276423	0.0	1198.0	0.0	1198.0	8.02567987868262	8.775626663508895	-0.5150848331253868	5.723094785688575	7.622947153570509	2.324440824249218	-2.3025850929940455	-1.1526795099383853	2.8395256573746046
13722.58cfa832e4b0c9d6adf6cf34	58cfa832e4b0c9d6adf6cf34	TCGA-G9-6363-01A-21D-1784_130215_SN590_0211_AC1UJWACXX_s_5_rg.sorted.filtered.	WGS	TCGA-G9-6363-01A-21D-1784_130215_SN590_0211_AC1UJWACXX_s_5_rg.sorted	TCGA-G9-6363-01A-21D-1784_130215_SN590_0211_AC1UJWACXX_s_5_rg.sorted.bam	313.4	1.8	0.13	58cfa832e4b0c9d6adf6cf34	TCGA-G9-6363-01A-21D-1784_130215_SN590_0211_AC1UJWACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6363-01A	B5B3871C-078C-46A7-AC50-EF916D4A6781	Primary Tumor	Illumina HiSeq	a64da28b-c092-4dfb-9503-06c15e566ac3	Prostate	64.0	65D588FF-58E3-4932-A7F4-25EF23C433D5	DBF42C34-D2E5-4136-83F5-093453913D5B	TCGA-G9-6363-01A-21D-1784-02	HG19_Broad_variant	TCGA-G9-6363	TCGA-PRAD		s3452	Harvard Medical School	Roswell Park	United States	NO	T4	N0	Prostate Adenocarcinoma Acinar Type		1784-02	True	PRAD	C1	PRAD.1-ERG	0.183579374	0.53	0.03	0.762502252	-0.878	0.16699999999999998	-0.8817	-0.2482	-0.8154	-0.5036	15.0	0.0	0.145524939	0.902254624	114.0	0.085713073	1.0	14.0				1.791759469	6.0	1.0	2.284750474	-399.7948046	-742.9743495	1479.154434	0.0	1378.0	0.0	1378.0	8.8995488774707	9.145898815834324	-0.1926631456369997	6.70232430013448	8.408299872703545	2.6220674544107183	-2.197224577336219	-0.737598943130779	2.814730600047718
13722.58cfa832e4b0c9d6adf6cf3d	58cfa832e4b0c9d6adf6cf3d	TCGA-G9-6378-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_3_rg.sorted.filtered.	WGS	TCGA-G9-6378-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_3_rg.sorted	TCGA-G9-6378-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_3_rg.sorted.bam	245.4	1.9	0.13	58cfa832e4b0c9d6adf6cf3d	TCGA-G9-6378-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_3_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6378-01A	12F225D0-CBFF-44EB-9183-BACC7F33B090	Primary Tumor	Illumina HiSeq	cc75d8b4-ea9f-4b89-9c12-d370ba7a227f	Prostate	54.0	940BBB5C-7280-41ED-9332-47C2072AE072	CA3B6408-29B5-4DB1-A56D-7B47F966177D	TCGA-G9-6378-01A-11D-1784-02	HG19_Broad_variant	TCGA-G9-6378	TCGA-PRAD		s3801	Harvard Medical School	Roswell Park	United States	NO	T2c		Prostate Adenocarcinoma Acinar Type		1784-02	True	PRAD	C3	PRAD.8-other	0.046658905	0.74	0.0	1.7492594869999998	-1.9031	-0.2135	-0.8318	-0.4912	-0.4265	-0.0472	15.0	0.0	0.37041462	0.484388349	83.0	0.045242125999999994	1.0	5.0				2.210253578	10.0	0.959900932	2.47827834	-229.32756630000003	-767.902893	970.232426	0.0	1155.0	0.0	1155.0	8.284672478289432	9.24344197414793	-0.4530373000913399	6.2052309366095955	7.803080391757764		-2.079441541679836	-1.440361582390166	
13722.58cfa832e4b0c9d6adf6cf46	58cfa832e4b0c9d6adf6cf46	TCGA-G9-6371-01A-11D-1784_130215_SN590_0212_BC1NP2ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-G9-6371-01A-11D-1784_130215_SN590_0212_BC1NP2ACXX_s_7_rg.sorted	TCGA-G9-6371-01A-11D-1784_130215_SN590_0212_BC1NP2ACXX_s_7_rg.sorted.bam	59.4	2.0	0.17	58cfa832e4b0c9d6adf6cf46	TCGA-G9-6371-01A-11D-1784_130215_SN590_0212_BC1NP2ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6371-01A	D5C43A14-21AB-4178-AE33-2D8B7BAA256F	Primary Tumor	Illumina HiSeq	46c365e2-d78e-45ed-8356-c9ad57629c34	Prostate	58.0	2F91086C-ADCD-4A79-96AA-58819AB28A57	570A6B67-7527-4F71-B37F-5D9102648470	TCGA-G9-6371-01A-11D-1784-02	HG19_Broad_variant	TCGA-G9-6371	TCGA-PRAD		s3798	Harvard Medical School	Roswell Park	United States	NO	T2c		Prostate Adenocarcinoma Acinar Type		1784-02	True	PRAD	C4	PRAD.3-ETV4	0.08667555800000001	0.72	0.03	0.484354055	-1.7415	-0.026000000000000002	-1.3058	-0.8167	-0.675	-0.5895	18.0	1.0	0.14550437	0.7566227259999999	57.0	0.068063663	3.0	2.0		0.0	1.0	2.2718685130000003	10.0	0.986659959	1.671131343	-435.1623294	-1114.43645	1958.338525	0.0	1226.0	0.0	1226.0	7.674849704494164	8.739829947664854	-0.8165334843786203	5.276954431695794	7.235752550888579		-2.3978952727983707	-1.5040773967762742	
13722.58cfa832e4b0c9d6adf6cf48	58cfa832e4b0c9d6adf6cf48	TCGA-HC-7075-01A-11D-1957_130412_SN590_0224_BC1YMJACXX_s_4_rg.sorted.filtered.	WGS	TCGA-HC-7075-01A-11D-1957_130412_SN590_0224_BC1YMJACXX_s_4_rg.sorted	TCGA-HC-7075-01A-11D-1957_130412_SN590_0224_BC1YMJACXX_s_4_rg.sorted.bam	242.7		0.15	58cfa832e4b0c9d6adf6cf48	TCGA-HC-7075-01A-11D-1957_130412_SN590_0224_BC1YMJACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7075-01A	5DD69C3E-9A3D-450C-9F10-10B4D6DAEEBA	Primary Tumor	Illumina HiSeq	7fee8465-32e2-4bef-bd48-102b2534003a	Prostate	63.0	1FA3E5C2-E415-42FA-AEA3-F6C84959522A	CFC425B3-7570-4FD2-8DB6-611EF4D627DF	TCGA-HC-7075-01A-11D-1957-02	HG19_Broad_variant	TCGA-HC-7075	TCGA-PRAD		s3811	Harvard Medical School	International Genomics Consortium	United States	NO	T2a		Prostate Adenocarcinoma Acinar Type		1957-02	True	PRAD	C4	PRAD.8-other	0.105183388	0.22	0.0	0.273507498	-1.6671	-0.09699999999999999	-1.0137	0.0063	0.5726	-0.6588	9.0	0.0	0.143322684	0.659284345	91.0	0.005842615	0.0	0.0							1.497085829	-877.9682638	-757.0618403	3146.1778440000003	0.0	601.0	0.0	601.0	9.336223843666435	9.004709245746605	-0.5331422032120159	6.810495199358179	8.39857344217629	3.8382265718882604	-2.525728644308255	-0.6061358035703157	4.371368775100276
13722.58cfa832e4b0c9d6adf6cf4e	58cfa832e4b0c9d6adf6cf4e	TCGA-G9-6356-01A-11D-1784_130215_SN590_0211_AC1UJWACXX_s_1_rg.sorted.filtered.	WGS	TCGA-G9-6356-01A-11D-1784_130215_SN590_0211_AC1UJWACXX_s_1_rg.sorted	TCGA-G9-6356-01A-11D-1784_130215_SN590_0211_AC1UJWACXX_s_1_rg.sorted.bam	144.4	1.9	0.15	58cfa832e4b0c9d6adf6cf4e	TCGA-G9-6356-01A-11D-1784_130215_SN590_0211_AC1UJWACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6356-01A	1D7FFBE7-6139-412B-8739-8082A63A2B33	Primary Tumor	Illumina HiSeq	4c78b0a9-d4e9-4656-95bf-0306c7bb406e	Prostate	60.0	C6E0F83F-ABA3-4705-ABAC-C81C885B53BA	E43C07B2-F48D-4780-9766-15CC08CE6FE2	TCGA-G9-6356-01A-11D-1784-02	HG19_Broad_variant	TCGA-G9-6356	TCGA-PRAD		s4146	Harvard Medical School	Roswell Park	United States	NO	T3b	N0	Prostate Adenocarcinoma Acinar Type		1784-02	True	PRAD	C3	PRAD.1-ERG	0.12266368	0.79	0.1	0.24000184600000002	-1.3085	-0.0925	-0.2381	0.0785	-0.4285	0.011000000000000001	9.0	0.0	0.14558911900000002	0.611474298	61.0	0.035598527000000005	1.0	3.0				2.7555497910000004	17.0	0.972588173	2.149975567	-205.76455280000002	-623.4721542000001	2221.161705	0.0	1434.0	0.0	1434.0	8.346879253746561	9.150393199210741	-0.1708141186361506	5.302356816023138	8.26309000420984		-3.0445224377234226	-0.8873031950009029	
13722.58cfa832e4b0c9d6adf6cf6a	58cfa832e4b0c9d6adf6cf6a	TCGA-GC-A3OO-01A-11D-A233_120905_SN1120_0187_AD1E4NACXX_s_5_rg.sorted.filtered.	WGS	TCGA-GC-A3OO-01A-11D-A233_120905_SN1120_0187_AD1E4NACXX_s_5_rg.sorted	TCGA-GC-A3OO-01A-11D-A233_120905_SN1120_0187_AD1E4NACXX_s_5_rg.sorted.bam	11.56		0.16	58cfa832e4b0c9d6adf6cf6a	TCGA-GC-A3OO-01A-11D-A233_120905_SN1120_0187_AD1E4NACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GC-A3OO-01A	1FF60FD9-3CA3-43BE-92A8-8DBA2CD4D4DF	Primary Tumor	Illumina HiSeq	8c665767-edb1-4860-b26a-4171237962fa	Bladder	79.0	91E7F41C-17B3-4724-96EF-D3C207B964E1	67B2932F-8C9D-4D38-8791-D4D8AAB7F3B2	TCGA-GC-A3OO-01A-11D-A233-26	HG19_Broad_variant	TCGA-GC-A3OO	TCGA-BLCA		s3306	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A233-26	True	BLCA	C1	BLCA.2	0.378833278	0.67	0.55	5.990802941	0.516	0.10400000000000001	-0.2879	-0.5134	-0.0273	0.4211	68.0		1.415484552	3.2065058210000004	59.0	0.368895178	12.0	7.0	0.9926430759999999	1.090529882	3.0	1.886696785	7.0	0.96957035	1.108606368	-1397.2593259999999	1199.613165	-782.3664388	0.0	481.0	0.0	481.0	5.378596732606302	6.735962712699033	-1.5016793140922613	3.888866784238169	6.356473090994129	0.6943455030520538	-1.489729948368133	-0.3794896217049035	2.1960248171443153
13722.58cfa832e4b0c9d6adf6cf6e	58cfa832e4b0c9d6adf6cf6e	TCGA-G9-6384-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_5_rg.sorted.filtered.	WGS	TCGA-G9-6384-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_5_rg.sorted	TCGA-G9-6384-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_5_rg.sorted.bam	146.4	1.9	0.15	58cfa832e4b0c9d6adf6cf6e	TCGA-G9-6384-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6384-01A	A279D5AA-51F7-4E75-9E14-B206B97EC4BD	Primary Tumor	Illumina HiSeq	75df59ac-7525-45fc-843a-5210bd036dca	Prostate	53.0	1ABCBE00-5A6F-4E0F-A61C-D158545C2293	1F750885-56C4-4953-8D22-BC7719F57F9F	TCGA-G9-6384-01A-11D-1784-02	HG19_Broad_variant	TCGA-G9-6384	TCGA-PRAD		s4152	Harvard Medical School	Roswell Park	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1784-02	True	PRAD	C3	PRAD.1-ERG	0.139542442	0.55	0.0	1.367727955	-1.5489	-0.244	-0.6557	0.0077	-0.599	-0.1415	10.0		0.115918953	0.5216352870000001	57.0	0.053716457	1.0	14.0	0.984587931	1.0816804009999998	3.0	2.70726971	16.0	0.976441146	2.042434825	462.0170602	-684.8316443	3777.6277649999997	0.0	765.0	0.0	765.0	7.768956044538332	7.914017288728434	-0.16656742990154594	5.82304589548302	7.662702860447529	8.430545384690564	-1.9459101490553132	-0.2513144282809061	8.59711281459211
13722.58cfa832e4b0c9d6adf6cf76	58cfa832e4b0c9d6adf6cf76	TCGA-FV-A23B-01A-11D-A16V-10_wgs_Illumina.filtered.	WGS	TCGA-FV-A23B-01A-11D-A16V-10_wgs_Illumina	TCGA-FV-A23B-01A-11D-A16V-10_wgs_Illumina.bam	76.29	1.85	0.08	58cfa832e4b0c9d6adf6cf76	TCGA-FV-A23B-01A-11D-A16V-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-FV-A23B-01A	C95ED407-BCC2-44AA-BC59-BF7549F2D665	Primary Tumor	Illumina HiSeq	1727600d-b6d6-4ab4-9eb1-03b214f5be2c	Liver	70.0	D056433D-C3E2-467A-8151-DDF2A6D8683A	63ADC09C-E1B1-40DD-9C35-2F8276B656FC	TCGA-FV-A23B-01A-11D-A16V-10	GRCh37-lite	TCGA-FV-A23B	TCGA-LIHC		s16786	Baylor College of Medicine	International Genomics Consortium	United States	NO	T2	N0	Hepatocellular Carcinoma	Stage II	A16V-10	True	LIHC	C3	LIHC.iCluster:2	0.149916251	0.14	0.13		-0.1066	-0.171	-0.2313	-0.0524	-0.9861	-0.7834	36.0	7.0	0.9660884759999999	2.301563722	130.0	0.20188924100000002	5.0	19.0		0.0	1.0	2.2931186009999998	13.0	0.894021005	2.616364459	-1125.826217	-17.70076913	2711.912368	1.0	1852.0	1.0	1453.0	7.240086299531352	1.4447745614520535	0.32944138018405245	6.215581983016965	3.5733636212367053	1.5194104770949877	-1.024504316514388	2.1285890597846517	1.1899690969109353
13722.58cfa832e4b0c9d6adf6cf7a	58cfa832e4b0c9d6adf6cf7a	TCGA-G9-6499-01A-12D-1957_130412_SN590_0224_BC1YMJACXX_s_2_rg.sorted.filtered.	WGS	TCGA-G9-6499-01A-12D-1957_130412_SN590_0224_BC1YMJACXX_s_2_rg.sorted	TCGA-G9-6499-01A-12D-1957_130412_SN590_0224_BC1YMJACXX_s_2_rg.sorted.bam	62.7	2.0	0.14	58cfa832e4b0c9d6adf6cf7a	TCGA-G9-6499-01A-12D-1957_130412_SN590_0224_BC1YMJACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6499-01A	ACD5CEEF-C5CF-4E95-9394-C50FDBC70C8D	Primary Tumor	Illumina HiSeq	db7d4277-9d52-4996-ab7f-5e6ddc01c234	Prostate	66.0	424FB9D8-F70E-4A36-B895-A766176EEE7C	24062AD0-10DD-4BFB-B805-CA18C57D1FA0	TCGA-G9-6499-01A-12D-1957-02	HG19_Broad_variant	TCGA-G9-6499	TCGA-PRAD		s3459	Harvard Medical School	Roswell Park	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1957-02	True	PRAD	C3	PRAD.8-other	0.105394525	0.7	0.3	1.6974983280000002	-1.7658	-0.013000000000000001	-0.8982	-0.3375	-1.2481	-0.4672	17.0	56.0	0.286860465	0.83189535	199.0	0.47454588799999997	17.0	30.0				1.886696785	7.0	0.96957035	2.224566903	-304.9292787	-994.0165726	2323.1703620000003	0.0	1543.0	0.0	1543.0	7.840256760904271	8.613887028909222	-0.556810737007814	6.608113079611639	7.8115405563842835	1.9775472339984959	-1.2321436812926325	-0.8023464725249374	2.53435797100631
13722.58cfa832e4b0c9d6adf6cf7f	58cfa832e4b0c9d6adf6cf7f	TCGA-GD-A3OP-01A-21D-A221_120902_SN1222_0147_AC195DACXX_s_1_rg.sorted.filtered.	WGS	TCGA-GD-A3OP-01A-21D-A221_120902_SN1222_0147_AC195DACXX_s_1_rg.sorted	TCGA-GD-A3OP-01A-21D-A221_120902_SN1222_0147_AC195DACXX_s_1_rg.sorted.bam	15.89		0.17	58cfa832e4b0c9d6adf6cf7f	TCGA-GD-A3OP-01A-21D-A221_120902_SN1222_0147_AC195DACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GD-A3OP-01A	31DA07BB-6752-49A3-A7EA-5427C04A9458	Primary Tumor	Illumina HiSeq	e01f55a8-4fbe-4f9a-8617-ce0e6900f177	Bladder	84.0	C0773229-5A20-4451-9DB5-F757E34921AE	AB6D114E-DF58-4912-85F4-3C385CAA3749	TCGA-GD-A3OP-01A-21D-A221-26	HG19_Broad_variant	TCGA-GD-A3OP	TCGA-BLCA		s3125	MD Anderson - Institute for Applied Cancer Science	ABS - IUPUI	United States	NO	T4a	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A221-26	True	BLCA	C3	BLCA.2	0.228852794	0.76	0.64	9.681210985	-0.4403	-0.175	-0.1946	0.1255	0.2573	0.1947	164.0	88.0	3.2253888410000005	8.847626269	59.0	0.390325611	15.0	11.0	0.8908722	2.136218236	11.0	2.598605178	15.0	0.959585305	1.355036651	-1390.8800880000001	67.67467335	1158.0789869999999	0.0	64.0	0.0	64.0	7.925570607345728	8.786284776633154	0.28841226598550274	6.207919110271395	7.730232102383841	2.5829944061167467	-1.717651497074333	-1.056052674249314	2.294582140131244
13722.58cfa832e4b0c9d6adf6cf82	58cfa832e4b0c9d6adf6cf82	TCGA-G9-6348-01A-11D-1784_130115_SN590_0208_BD1TAGACXX_s_7_rg.sorted.filtered.	WGS	TCGA-G9-6348-01A-11D-1784_130115_SN590_0208_BD1TAGACXX_s_7_rg.sorted	TCGA-G9-6348-01A-11D-1784_130115_SN590_0208_BD1TAGACXX_s_7_rg.sorted.bam	59.4	1.9	0.14	58cfa832e4b0c9d6adf6cf82	TCGA-G9-6348-01A-11D-1784_130115_SN590_0208_BD1TAGACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6348-01A	8AD78C4F-C84C-4F9E-88C9-42A05EB65498	Primary Tumor	Illumina HiSeq	32ce4cfa-ee58-4c85-8e6b-9e7fd9bb6b8e	Prostate	68.0	A692E125-CCFC-4376-9CEA-2410511882BF	68D451D5-F3A1-46C9-BD28-05D71D2C94FC	TCGA-G9-6348-01A-11D-1784-02	HG19_Broad_variant	TCGA-G9-6348	TCGA-PRAD		s3447	Harvard Medical School	Roswell Park	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1784-02	True	PRAD	C1	PRAD.2-ETV1	0.121743277	0.64	0.0	0.923300138	-1.659	0.0	-0.5475	-0.2032	-0.8309	-0.0103	18.0	42.0	0.347617406	0.8980116309999999	87.0	0.082027793	1.0	11.0		0.0	1.0	2.649158683	15.0	0.9782531659999999	1.8512746469999999	-145.134224	-919.0147107999999	2359.7759899999996	0.0	1515.0	0.0	1515.0	8.562867394907412	8.969277610928607	-0.07385569984668927	6.616957245852099	8.398732752460994	7.092989257223127	-1.9459101490553132	-0.5705448584676129	7.166844957069816
13722.58cfa832e4b0c9d6adf6cf91	58cfa832e4b0c9d6adf6cf91	TCGA-G9-6365-01A-11D-1784_130215_SN590_0212_BC1NP2ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-G9-6365-01A-11D-1784_130215_SN590_0212_BC1NP2ACXX_s_1_rg.sorted	TCGA-G9-6365-01A-11D-1784_130215_SN590_0212_BC1NP2ACXX_s_1_rg.sorted.bam	59.4	1.9	0.17	58cfa832e4b0c9d6adf6cf91	TCGA-G9-6365-01A-11D-1784_130215_SN590_0212_BC1NP2ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6365-01A	6845076E-E940-4437-8618-81DB4A447544	Primary Tumor	Illumina HiSeq	9d7979c6-8197-4347-806d-4bb667d5cb2b	Prostate	71.0	95D6E1D3-91C1-40E5-986D-1C5ABB33A03F	CD30C4FA-8BBF-4A8A-A1F7-4FA0D45CA380	TCGA-G9-6365-01A-11D-1784-02	HG19_Broad_variant	TCGA-G9-6365	TCGA-PRAD		s3973	Harvard Medical School	Roswell Park	United States	NO	T4	N0	Prostate Adenocarcinoma Acinar Type		1784-02	True	PRAD	C1	PRAD.1-ERG	0.098712231			0.808671279	-1.5134	-0.051	-0.7191	-0.3814	-0.7803	0.1009	8.0	3.0	0.11626795699999999	0.523205805	57.0	0.014247137	0.0	3.0				2.245952081	11.0	0.936634767	1.97161206	163.08465780000003	-212.72381580000004	1429.102141	0.0	1363.0	0.0	1363.0	8.091321273530411	8.676928249537395	0.14283301040989627	5.428733446504959	7.531795945234393	2.6896483017301733	-2.662587827025453	-1.1451323043030028	2.5468152913202773
13722.58cfa832e4b0c9d6adf6cf94	58cfa832e4b0c9d6adf6cf94	TCGA-FU-A3NI-01A-11D-A245_140124_SN1440_0178_AC2PL6ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-FU-A3NI-01A-11D-A245_140124_SN1440_0178_AC2PL6ACXX_s_8_rg.sorted	TCGA-FU-A3NI-01A-11D-A245_140124_SN1440_0178_AC2PL6ACXX_s_8_rg.sorted.bam	36.82		0.16	58cfa832e4b0c9d6adf6cf94	TCGA-FU-A3NI-01A-11D-A245_140124_SN1440_0178_AC2PL6ACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-FU-A3NI-01A	DAC27C24-CDBF-4527-9214-178FDE3D098A	Primary Tumor	Illumina HiSeq	e3d152ec-0ab5-4fb6-b2ca-ecdb79e43095	Cervix	45.0	C75C6FD3-79EF-48B8-B3BD-D097EF2A73AD	90DC57B8-74B7-4FB0-9EE7-52A4264D395F	TCGA-FU-A3NI-01A-11D-A245-26	HG19_Broad_variant	TCGA-FU-A3NI	TCGA-CESC		s1204	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T1b1	N1	Cervical Squamous Cell Carcinoma		A245-26	True	CESC	C2		0.14022036400000001	0.35	0.12	15.44838348	1.1196	0.293	-0.1776	-0.0212	0.2121	-0.0497	44.0	7.0	0.728059972	1.878864443	188.0	0.712727118	18.0	42.0	0.92219208	1.91764452	8.0	3.091042453	22.0	1.0	2.044678536	-1243.316877	598.5652446	-147.5304937	1.0	638.0	0.0	638.0	7.649454500124248	6.95256929477193	-0.4649155685778854	5.452229922788029	5.748596490445994	3.0992489851862386	-2.197224577336219	-1.203972804325936	3.564164553764124
13722.58cfa832e4b0c9d6adf6cf96	58cfa832e4b0c9d6adf6cf96	TCGA-G9-6351-01A-21D-1957_130405_SN590_0222_BD21LGACXX_s_2_rg.sorted.filtered.	WGS	TCGA-G9-6351-01A-21D-1957_130405_SN590_0222_BD21LGACXX_s_2_rg.sorted	TCGA-G9-6351-01A-21D-1957_130405_SN590_0222_BD21LGACXX_s_2_rg.sorted.bam	149.7	1.9	0.15	58cfa832e4b0c9d6adf6cf96	TCGA-G9-6351-01A-21D-1957_130405_SN590_0222_BD21LGACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6351-01A	F59B9C65-46E8-4CC3-AA71-8844F6C2273C	Primary Tumor	Illumina HiSeq	ddf40c8c-cec5-4f4b-853a-1541566f51b5	Prostate	51.0	92436584-12D6-4CF2-9AB1-CDF98E4E8260	DE6145E0-8D30-4CA1-A169-0BDC7E5BC57A	TCGA-G9-6351-01A-21D-1957-02	HG19_Broad_variant	TCGA-G9-6351	TCGA-PRAD		s3618	Harvard Medical School	Roswell Park	United States	NO	T2c		Prostate Adenocarcinoma Acinar Type		1957-02	True	PRAD	C3	PRAD.1-ERG	0.051953963	0.67	0.02	0.385015117	-1.9439	-0.1515	-1.3537	-0.8153	-1.0657	-0.3701	7.0		0.116460145	0.524070652	53.0	0.03348123	0.0	4.0	0.920791039	0.6382437129999999	2.0	1.609437912	5.0	1.0	1.851766188	73.63864701	-613.0096681	2507.833596	0.0	2048.0	0.0	2048.0	7.914983005848394	8.337758891054479	-0.9210840304464349	6.305545093414294	7.932293782946315	1.4198853055559262	-1.6094379124341003	-0.4054651081081646	2.3409693360023613
13722.58cfa832e4b0c9d6adf6cf9f	58cfa832e4b0c9d6adf6cf9f	TCGA-H2-A3RH-01A-11D-A221_120610_SN1120_0151_AC0WN0ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-H2-A3RH-01A-11D-A221_120610_SN1120_0151_AC0WN0ACXX_s_2_rg.sorted	TCGA-H2-A3RH-01A-11D-A221_120610_SN1120_0151_AC0WN0ACXX_s_2_rg.sorted.bam	62.17		0.15	58cfa832e4b0c9d6adf6cf9f	TCGA-H2-A3RH-01A-11D-A221_120610_SN1120_0151_AC0WN0ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-H2-A3RH-01A	0314B145-2F3A-4A90-A580-375B5F0A63A4	Primary Tumor	Illumina HiSeq	dddfb702-cb09-4a5f-b023-b31d89ec07a8	Thyroid	41.0	1A9E811D-1C60-409C-A7D2-1D58AFA473E9	8358E269-BD6E-4189-86AB-520C84405DAA	TCGA-H2-A3RH-01A-11D-A221-26	HG19_Broad_variant	TCGA-H2-A3RH	TCGA-THCA		s12532	MD Anderson - Institute for Applied Cancer Science	Christiana Healthcare	United States	NO	T1b	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A221-26	True	THCA	C3	THCA.1	0.048972941	0.25	0.01		-2.1374	-0.26899999999999996	-0.5275	-1.123	-0.6589	-0.3478	6.0	3.0	0.11796438699999999	0.20643767600000001	43.0	1.85e-05	0.0	0.0					0.0		2.311307215	-249.6865349	-1150.383941	1739.3418579999998	0.0	379.0	0.0	379.0	5.797095095256734	7.677830431348358	-1.2229908101616978	4.837838327499136	6.4667401592535585	3.0458566607365594	-0.9592567677575978	-1.2110902720948	4.268847470898257
13722.58cfa832e4b0c9d6adf6cfa8	58cfa832e4b0c9d6adf6cfa8	TCGA-GV-A3JV-01A-11D-A221_120830_SN590_0178_AD143RACXX_s_1_rg.sorted.filtered.	WGS	TCGA-GV-A3JV-01A-11D-A221_120830_SN590_0178_AD143RACXX_s_1_rg.sorted	TCGA-GV-A3JV-01A-11D-A221_120830_SN590_0178_AD143RACXX_s_1_rg.sorted.bam	63.27		0.14	58cfa832e4b0c9d6adf6cfa8	TCGA-GV-A3JV-01A-11D-A221_120830_SN590_0178_AD143RACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GV-A3JV-01A	01EE41EF-1894-4408-9E96-A22A1F068190	Primary Tumor	Illumina HiSeq	8f626567-33e0-4b6a-974f-6b41b341c60e	Bladder	66.0	55072935-CD20-4355-897B-F60F77A18847	E5863D29-E61D-4EE2-B04E-FE61C9B9CA5E	TCGA-GV-A3JV-01A-11D-A221-26	HG19_Broad_variant	TCGA-GV-A3JV	TCGA-BLCA		s3308	MD Anderson - Institute for Applied Cancer Science	BLN - Cleveland Clinic	United States	NO	T3b	N1	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A221-26	True	BLCA	C1	BLCA.2	0.180333297	0.34	0.34	9.701851298	0.3266	0.1255	-0.2279	0.7188	-0.5756	0.1158	60.0	15.0	1.116734287	2.9578367610000003	247.0	0.552720623	16.0	11.0	0.689840094	2.346282322	30.0	2.8892064339999997	21.0	0.9489851009999999	1.2943801129999999	-1514.564337	980.3211207	-2226.140828	1.0	434.0	1.0	134.0	6.455676983196836	8.477440069892102	0.15641456477010474	5.548119931291436	7.719754368194586	1.3296307343548888	-0.9075570519054006	-0.7576857016975165	1.173216169584784
13722.58cfa832e4b0c9d6adf6cfac	58cfa832e4b0c9d6adf6cfac	TCGA-GE-A2C6-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_5_rg.sorted.filtered.	WGS	TCGA-GE-A2C6-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_5_rg.sorted	TCGA-GE-A2C6-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_5_rg.sorted.bam	75.85	1.8	0.17	58cfa832e4b0c9d6adf6cfac	TCGA-GE-A2C6-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-GE-A2C6-01A	7DEEDEBA-F05B-453C-9DF1-EEB20B0EC72E	Primary Tumor	Illumina HiSeq	4920d08d-433e-4371-8daa-641819a1e53f	Thyroid	33.0	D717EECF-11DC-4E15-851A-9EA18332A48B	A5FA44A2-8101-4A0C-982C-57337853BACA	TCGA-GE-A2C6-01A-11D-A16N-02	HG19_Broad_variant	TCGA-GE-A2C6	TCGA-THCA		s12123	Harvard Medical School	ABS - IUPUI	United States	NO	T2	N1b	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	True	THCA	C3	THCA.4	0.396653844	0.43	0.02		-1.2128	-0.2755	0.4507	0.9374	0.011000000000000001	0.4634	2.0		0.0	0.031414127	41.0	0.011052885	0.0	0.0	0.924935857	1.488626836	5.0	3.555595132	37.0	0.9846790259999999	1.119256582	531.4808335	-986.6390457999998	1414.417802	0.0	381.0	0.0	381.0	7.253470382684528	7.813115906063708	0.46471816641080554	6.560323202124582	7.650596976565934	1.6799226922184018	-0.6931471805599454	-0.1625189294977747	1.2152045258075963
13722.58cfa832e4b0c9d6adf6cfb6	58cfa832e4b0c9d6adf6cfb6	TCGA-G9-6342-01A-11D-1957_130222_SN1222_0174_BC1RNEACXX_s_7_rg.sorted.filtered.	WGS	TCGA-G9-6342-01A-11D-1957_130222_SN1222_0174_BC1RNEACXX_s_7_rg.sorted	TCGA-G9-6342-01A-11D-1957_130222_SN1222_0174_BC1RNEACXX_s_7_rg.sorted.bam	201.7	1.9	0.14	58cfa832e4b0c9d6adf6cfb6	TCGA-G9-6342-01A-11D-1957_130222_SN1222_0174_BC1RNEACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6342-01A	00E41E6A-9FE7-44F9-978B-7B05B179506A	Primary Tumor	Illumina HiSeq	2e8198a3-6874-4ea2-9d85-405122d87da4	Prostate	61.0	2C85548B-D1FD-4FC8-9908-60205A42E080	0C765D21-A6AE-4FE8-9B80-7DEBA8459E76	TCGA-G9-6342-01A-11D-1957-02	HG19_Broad_variant	TCGA-G9-6342	TCGA-PRAD		s3797	Harvard Medical School	Roswell Park	United States	NO	T3a		Prostate Adenocarcinoma Acinar Type		1957-02	True	PRAD	C3	PRAD.1-ERG	0.09520015300000001	0.52	0.0	0.52878505	-1.4695	-0.1395	-1.1394	-0.6665	-1.2317	-0.3466	10.0		0.231533081	0.46306616100000003	81.0	0.055939022000000005	1.0	14.0				2.3025850930000002	10.0	1.0	1.977504504	-92.51738617	-934.1374571	2936.252051	0.0	1696.0	0.0	1696.0	8.133587417660966	7.549568678504999	-0.979251599675355	5.882295619054471	7.023475582608219	3.0553373855736066	-2.251291798606495	-0.5260930958967793	4.034588985248961
13722.58cfa832e4b0c9d6adf6cfb8	58cfa832e4b0c9d6adf6cfb8	TCGA-GC-A3I6-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-GC-A3I6-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_5_rg.sorted	TCGA-GC-A3I6-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_5_rg.sorted.bam	65.0		0.16	58cfa832e4b0c9d6adf6cfb8	TCGA-GC-A3I6-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GC-A3I6-01A	74CBB078-9AAE-422A-A7AF-DD29EBCA949E	Primary Tumor	Illumina HiSeq	ec0a1f1d-c6e7-4b4a-a296-02087e0b6586	Bladder	45.0	DB9442F6-38F2-4092-9E85-F5EC0C924025	8B23B777-2BF2-422A-8AB3-1DF94EE61690	TCGA-GC-A3I6-01A-11D-A210-26	HG19_Broad_variant	TCGA-GC-A3I6	TCGA-BLCA		s2733	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T3a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A210-26	True	BLCA	C2	BLCA.3	0.173926408	0.27	0.29	1.462688155	1.0476	0.1205	-0.0066	-0.5178	1.2185	0.2713	104.0	112.0	1.8286941330000002	4.897180898	83.0	0.921147865	15.0	8.0		0.0	1.0	1.7351264569999998	6.0	0.968392514	1.210168911	-143.5336462	1276.044265	-1916.070216	1.0	630.0	1.0	546.0	7.9735688558988596	7.335233878191266	0.43795957924333184	7.018057410871424	7.9005476872413265	2.3811808318143384	-0.9555114450274362	0.5653138090500605	1.9432212525710066
13722.58cfa832e4b0c9d6adf6cfbe	58cfa832e4b0c9d6adf6cfbe	TCGA-G9-6385-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_7_rg.sorted.filtered.	WGS	TCGA-G9-6385-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_7_rg.sorted	TCGA-G9-6385-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_7_rg.sorted.bam	249.4	1.9	0.14	58cfa832e4b0c9d6adf6cfbe	TCGA-G9-6385-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6385-01A	E82A04CF-E81E-43C6-9CD9-0E29FA0F00AE	Primary Tumor	Illumina HiSeq	53da3cf6-b29e-4b1f-9d51-c1f9648b6634	Prostate	66.0	CFE4B1FA-B658-49D3-87AD-6DF7D75A58DF	00D3CD80-E6C2-4408-8F10-3656BD371157	TCGA-G9-6385-01A-11D-1784-02	HG19_Broad_variant	TCGA-G9-6385	TCGA-PRAD		s3456	Harvard Medical School	Roswell Park	United States	NO	T2c		Prostate Adenocarcinoma Acinar Type		1784-02	True	PRAD	C3	PRAD.1-ERG	0.035696583	0.8	0.0	2.2013238090000002	-1.7162	-0.19699999999999998	-0.9123	-0.7447	-0.9603	-0.1625	4.0		0.087572105	0.116762807	55.0	4.210000000000001e-05	0.0	0.0				1.039720771	3.0	0.94639463	1.5339662530000002	-167.4973772	-891.0004984	2804.723301	0.0	830.0	0.0	830.0	8.233967839681398	8.256884146870023	-0.8178011071676722	6.729890442905124	8.020495368805793		-1.504077396776274	-0.2363887780642302	
13722.58cfa832e4b0c9d6adf6cfc0	58cfa832e4b0c9d6adf6cfc0	TCGA-GF-A2C7-01A-11D-A18Y_120602_SN208_0304_BC0WTWACXX_s_3_rg.sorted.filtered.	WGS	TCGA-GF-A2C7-01A-11D-A18Y_120602_SN208_0304_BC0WTWACXX_s_3_rg.sorted	TCGA-GF-A2C7-01A-11D-A18Y_120602_SN208_0304_BC0WTWACXX_s_3_rg.sorted.bam	42.41		0.16	58cfa832e4b0c9d6adf6cfc0	TCGA-GF-A2C7-01A-11D-A18Y_120602_SN208_0304_BC0WTWACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-GF-A2C7-01A	285D8E2C-F183-49D5-BC1C-FD47C6670ACC	Primary Tumor	Illumina HiSeq	9e0dd24f-4e97-44c0-916f-03fc02fc29ac	Skin	48.0	053CAF96-E851-401D-A5CC-214DBA82FE05	12E86E5E-AA64-4E6F-B5BC-846DDCBF4A64	TCGA-GF-A2C7-01A-11D-A18Y-02	HG19_Broad_variant	TCGA-GF-A2C7	TCGA-SKCM		s7374	Harvard Medical School	ABS - IUPUI	United States	NO	T4b	N0		Stage IIC	A18Y-02	True	SKCM	C1	SKCM.BRAF_Hotspot_Mutants	0.072369815	0.15	0.08	15.23302111	0.6013	0.10400000000000001	-0.9501	-1.9908	-1.7306	0.1178	37.0	9.0	0.9516027140000001	1.8418117040000002			14.0	15.0				0.0	1.0		2.990285286	-1313.489033	875.7497030999999	-2752.605891	0.0	21.0	0.0	21.0	6.891078530263751	6.195832943095858	-0.20074261462504317	5.929667363109126	6.401276917310667	0.8805448903857603	-0.9614111671546248	0.2054439742148091	1.0812875050108035
13722.58cfa832e4b0c9d6adf6cfd2	58cfa832e4b0c9d6adf6cfd2	TCGA-GL-A59R-01A-11D-A26P-10_wgs_Illumina.filtered.	WGS	TCGA-GL-A59R-01A-11D-A26P-10_wgs_Illumina	TCGA-GL-A59R-01A-11D-A26P-10_wgs_Illumina.bam	21.08		0.08	58cfa832e4b0c9d6adf6cfd2	TCGA-GL-A59R-01A-11D-A26P-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-GL-A59R-01A	78412F82-CC55-43D5-96CA-1D02CF957725	Primary Tumor	Illumina HiSeq	78730e13-6aeb-4c56-8ac4-4a73dcd37bbd	Kidney	79.0	6F084D86-6CE0-431A-87D7-0E543392EA15	C504D5A9-29B0-4B7E-AC7B-5E543449A0F4	TCGA-GL-A59R-01A-11D-A26P-10	GRCh37-lite	TCGA-GL-A59R	TCGA-KIRP		s11647	Baylor College of Medicine	ABS - IUPUI	United States	NO	T3c	N0	Kidney Papillary Renal Cell Carcinoma	Stage III	A26P-10	True	KIRP	C4	KIRP.C1	0.120676904	0.0	0.07		-1.6694	-0.226	-0.2378	-1.9692	-0.6026	-0.3034	32.0	136.0	0.678747098	2.14484083	63.0	0.161037077	6.0	0.0					0.0		2.159915292	-182.6329131	-1915.563992	1095.571261	0.0	378.0	0.0	378.0	6.1925777283909	2.6057908407903447	-1.5695635434540156	5.64050914609086	3.815777809192915	3.4953413805762983	-0.55206858230004	1.2099869684025704	5.064904924030314
13722.58cfa832e4b0c9d6adf6cfd8	58cfa832e4b0c9d6adf6cfd8	TCGA-FU-A3TQ-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_3_rg.sorted.filtered.	WGS	TCGA-FU-A3TQ-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_3_rg.sorted	TCGA-FU-A3TQ-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_3_rg.sorted.bam	59.29		0.15	58cfa832e4b0c9d6adf6cfd8	TCGA-FU-A3TQ-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-FU-A3TQ-01A	7218AA6F-3345-484F-A329-A3B6169A67C7	Primary Tumor	Illumina HiSeq	87ede4e6-17e6-4287-8ee3-cde27de3aa7d	Cervix	55.0	2F3BFFB4-2C85-4B72-9AF5-4DB9DC358AE6	7018744F-49FF-4F47-AEE5-07F0DEA5D7D3	TCGA-FU-A3TQ-01A-11D-A232-26	HG19_Broad_variant	TCGA-FU-A3TQ	TCGA-CESC		s1199	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T2b	N1	Cervical Squamous Cell Carcinoma		A232-26	True	CESC	C2		0.301618756	0.34	0.02	22.29677524	1.0394	0.2985	-0.1039	0.6812	0.7426	0.2034	26.0	2.0	0.44696216200000005	1.095057298	75.0	0.15683112400000002	4.0	12.0	0.896641978	2.8861791869999998	25.0	3.16342405	24.0	0.995396623	2.012844765	-189.35055459999998	876.7145720000001	-1637.752201	0.0	795.0	0.0	795.0	7.895436006942965	6.99117688712121	-0.239926217318711	5.698211429606746	5.949723012293048	1.0550379940319843	-2.197224577336219	-1.0414538748281612	1.2949642113506954
13722.58cfa832e4b0c9d6adf6cfdc	58cfa832e4b0c9d6adf6cfdc	TCGA-HC-7232-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-HC-7232-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_4_rg.sorted	TCGA-HC-7232-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_4_rg.sorted.bam	168.3		0.16	58cfa832e4b0c9d6adf6cfdc	TCGA-HC-7232-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7232-01A	CE3585D3-7388-4D05-84C8-64E0883003B3	Primary Tumor	Illumina HiSeq	26e5268d-e95b-44da-ae7c-dfb6fe50a127	Prostate	66.0	0F4B7D00-1C4C-4634-A45E-10F8949ABB43	E847C3F1-CE33-494C-8D95-F82314C95F01	TCGA-HC-7232-01A-11D-2111-02	HG19_Broad_variant	TCGA-HC-7232	TCGA-PRAD		s4156	Harvard Medical School	International Genomics Consortium	United States	NO	T3b		Prostate Adenocarcinoma Acinar Type		2111-02	True	PRAD	C3	PRAD.1-ERG	0.076888	0.4	0.07	0.357256553	-1.7828	-0.218	-0.8941	-0.9696	-1.0997	-0.3108	10.0		0.332572146	0.665144293	98.0	0.128233278	2.0	17.0				1.791759469	6.0	1.0	2.578176841	-755.4193699	-642.5457465	3758.920368	0.0	1161.0	1.0	766.0	7.7571937038684515	8.25963071323157	-0.1764564373415567	5.911367013370121	7.106951203293184		-1.8458266904983305	-1.1526795099383853	
13722.58cfa832e4b0c9d6adf6cfe0	58cfa832e4b0c9d6adf6cfe0	TCGA-GC-A3WC-01A-31D-A233_120904_SN1120_0186_BC1911ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-GC-A3WC-01A-31D-A233_120904_SN1120_0186_BC1911ACXX_s_1_rg.sorted	TCGA-GC-A3WC-01A-31D-A233_120904_SN1120_0186_BC1911ACXX_s_1_rg.sorted.bam	23.27		0.17	58cfa832e4b0c9d6adf6cfe0	TCGA-GC-A3WC-01A-31D-A233_120904_SN1120_0186_BC1911ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GC-A3WC-01A	DB52C68A-ED44-4EC4-9381-D75F9BCBC29A	Primary Tumor	Illumina HiSeq	5d982317-5753-41de-85ef-30ee85c56ba9	Bladder	80.0	24F9D01B-1210-4716-9466-8FE9F3612B8B	50E62704-6262-4426-BDAE-0490DC108B61	TCGA-GC-A3WC-01A-31D-A233-26	HG19_Broad_variant	TCGA-GC-A3WC	TCGA-BLCA		s3307	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A233-26	True	BLCA	C2	BLCA.3	0.468092024	0.62	0.05	3.0053320410000004	0.6143	0.19699999999999998	0.6606	1.5607	1.3289	0.0121	52.0	0.0	1.191084663	3.800127259	62.0	0.274800295	7.0	21.0	0.844541746	3.4292136319999997	58.0	2.586935413	16.0	0.9330397229999999	5.549808202	-147.70644850000002	237.50663140000003	-1925.240428	0.0	540.0	0.0	540.0	7.171702001110025	2.113482468469769	0.3504758402345447	6.341353699036595	7.360694492890934	1.5056194171280894	-0.8303483020734301	5.247212024421165	1.1551435768935447
13722.58cfa832e4b0c9d6adf6cfe4	58cfa832e4b0c9d6adf6cfe4	TCGA-G9-6333-01A-12D-1957_130222_SN1222_0174_BC1RNEACXX_s_3_rg.sorted.filtered.	WGS	TCGA-G9-6333-01A-12D-1957_130222_SN1222_0174_BC1RNEACXX_s_3_rg.sorted	TCGA-G9-6333-01A-12D-1957_130222_SN1222_0174_BC1RNEACXX_s_3_rg.sorted.bam	157.7	1.9	0.14	58cfa832e4b0c9d6adf6cfe4	TCGA-G9-6333-01A-12D-1957_130222_SN1222_0174_BC1RNEACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6333-01A	64BF32C9-9466-404A-A147-E7A0B9E91E34	Primary Tumor	Illumina HiSeq	0e4674b7-f8ed-422c-909a-b2bfdf58ecf1	Prostate	66.0	98013499-4FAC-4378-9D7E-B3686003A4FC	F6373E03-914F-44B2-954D-E63DE95F89E8	TCGA-G9-6333-01A-12D-1957-02	HG19_Broad_variant	TCGA-G9-6333	TCGA-PRAD		s3611	Harvard Medical School	Roswell Park	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1957-02	True	PRAD	C3	PRAD.5-SPOP	0.096332921	0.56	0.0	1.118198986	-1.5803	-0.177	-0.7004	-0.6418	-0.2276	-0.3075	8.0	0.0	0.260171431	0.664882546	189.0	0.046392275	1.0	6.0				1.098612289	3.0	1.0	2.0088332490000003	307.83102169999995	-1216.840424	1334.609316	0.0	2465.0	0.0	2465.0	7.807645589488511	8.55329365704096	-0.22284305549384864	5.770763662227472	7.560041884030676	1.369904622499873	-2.0368819272610397	-0.9932517730102832	1.5927476779937215
13722.58cfa832e4b0c9d6adf6cfe8	58cfa832e4b0c9d6adf6cfe8	TCGA-GV-A3JX-01A-11D-A210_120912_SN1222_0148_AC188PACXX_s_1_rg.sorted.filtered.	WGS	TCGA-GV-A3JX-01A-11D-A210_120912_SN1222_0148_AC188PACXX_s_1_rg.sorted	TCGA-GV-A3JX-01A-11D-A210_120912_SN1222_0148_AC188PACXX_s_1_rg.sorted.bam	67.04		0.15	58cfa832e4b0c9d6adf6cfe8	TCGA-GV-A3JX-01A-11D-A210_120912_SN1222_0148_AC188PACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GV-A3JX-01A	D9DCBB57-F6C2-4465-8A60-AFE876E113CA	Primary Tumor	Illumina HiSeq	317cc3f0-7a98-402b-bb1f-81a0437fbaf8	Bladder	59.0	CE32612D-F504-4164-AE50-04C4AC2999FB	A8636E11-C752-46F4-A6A8-42D5B7DCBD02	TCGA-GV-A3JX-01A-11D-A210-26	HG19_Broad_variant	TCGA-GV-A3JX	TCGA-BLCA		s2736	MD Anderson - Institute for Applied Cancer Science	BLN - Cleveland Clinic	United States	NO	T3b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A210-26	True	BLCA	C2	BLCA.2	0.11057923300000001	0.1	0.25	15.35115036	0.8841	0.1805	-0.0655	0.1062	1.6127	-0.3167	139.0	58.0	2.171398103	7.720526587999999	133.0	0.7658577590000001	12.0	19.0	0.89161004	1.597550733	6.0	2.204785417	10.0	0.95752614	1.9639730169999998	-696.0426808	481.6877841	-898.5197743999998	0.0	581.0	0.0	581.0	5.580358559109731	8.579604451537634	0.3624448842162621	4.615277663066144	7.385681983065201	2.286887303647469	-0.9650808960435868	-1.1939224684724343	1.924442419431207
13722.58cfa832e4b0c9d6adf6cfea	58cfa832e4b0c9d6adf6cfea	TCGA-G9-6494-01A-11D-1784_130131_SN1120_0234_AD1PVUACXX_s_1_rg.sorted.filtered.	WGS	TCGA-G9-6494-01A-11D-1784_130131_SN1120_0234_AD1PVUACXX_s_1_rg.sorted	TCGA-G9-6494-01A-11D-1784_130131_SN1120_0234_AD1PVUACXX_s_1_rg.sorted.bam	129.4	1.9	0.13	58cfa832e4b0c9d6adf6cfea	TCGA-G9-6494-01A-11D-1784_130131_SN1120_0234_AD1PVUACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6494-01A	0C459149-0DFE-4206-B50B-DB79180EBB57	Primary Tumor	Illumina HiSeq	d55338b0-a49a-4c6e-ba7d-757df0a55dfe	Prostate	66.0	45DB5303-BBAB-4F8C-A2A2-9A9A9BFA2FD1	5BCBE988-68F6-48D0-8F2A-B34369A5FBB9	TCGA-G9-6494-01A-11D-1784-02	HG19_Broad_variant	TCGA-G9-6494	TCGA-PRAD		s3620	Harvard Medical School	Roswell Park	United States	NO	T4	N0	Prostate Adenocarcinoma Acinar Type		1784-02	True	PRAD	C3	PRAD.2-ETV1	0.062970678	0.43	0.01	2.24855212	-1.6531	-0.1905	-1.0965	-1.0459	-0.9946	-0.4062	9.0	4.0	0.17532694100000001	0.818192391	115.0	0.110195777	5.0	14.0		0.0	1.0	0.0	1.0		1.6183535390000001	-341.6256244	-1252.0088759999999	2522.5774530000003	0.0	1771.0	0.0	1771.0	8.234697645651757	8.837328624564021	-0.15184029632047602	6.0374730683155375	7.9500254295631185	3.013368627539	-2.197224577336219	-0.8873031950009029	3.1652089238594763
13722.58cfa832e4b0c9d6adf6cff0	58cfa832e4b0c9d6adf6cff0	TCGA-GD-A3OS-01A-12D-A221_120906_SN208_0426_BC194HACXX_s_7_rg.sorted.filtered.	WGS	TCGA-GD-A3OS-01A-12D-A221_120906_SN208_0426_BC194HACXX_s_7_rg.sorted	TCGA-GD-A3OS-01A-12D-A221_120906_SN208_0426_BC194HACXX_s_7_rg.sorted.bam	37.3		0.14	58cfa832e4b0c9d6adf6cff0	TCGA-GD-A3OS-01A-12D-A221_120906_SN208_0426_BC194HACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GD-A3OS-01A	2A41B7D4-132F-4FB6-87B5-487C445379C7	Primary Tumor	Illumina HiSeq	2a801113-8404-4c17-9d60-508761ec1659	Bladder	54.0	C629CD55-54D7-4E31-AB90-955EBFF0B20A	80DBF776-1B0B-454C-9DA6-9688816A294D	TCGA-GD-A3OS-01A-12D-A221-26	HG19_Broad_variant	TCGA-GD-A3OS	TCGA-BLCA		s2922	MD Anderson - Institute for Applied Cancer Science	ABS - IUPUI	United States	NO		NX	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A221-26	True	BLCA	C1	BLCA.4	0.294651276	0.28	0.12	14.40689486	0.8471	0.172	-0.3634	-0.079	0.1721	0.5885	30.0	4.0	0.7900637209999999	2.522126494	361.0	0.968518497	20.0	41.0	0.9524040709999999	1.532835219	5.0	2.197224577	9.0	1.0	5.466748416000001	-1302.805992	316.51721810000004	-88.07611617	0.0	638.0	1.0	223.0	7.094649697621227	2.7200910358008175	-0.2750058463747276	6.1138204446095	6.959852597881422	4.129235962000718	-0.9808292530117262	4.239761562080605	4.404241808375445
13722.58cfa832e4b0c9d6adf6cff5	58cfa832e4b0c9d6adf6cff5	TCGA-G9-6370-01A-11D-1784_130215_SN590_0212_BC1NP2ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-G9-6370-01A-11D-1784_130215_SN590_0212_BC1NP2ACXX_s_5_rg.sorted	TCGA-G9-6370-01A-11D-1784_130215_SN590_0212_BC1NP2ACXX_s_5_rg.sorted.bam	59.4	2.0	0.14	58cfa832e4b0c9d6adf6cff5	TCGA-G9-6370-01A-11D-1784_130215_SN590_0212_BC1NP2ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6370-01A	F947B0BC-BDAC-44E8-B5B9-FFAE4147740A	Primary Tumor	Illumina HiSeq	7b80e96d-c20b-4080-9382-26a778397c15	Prostate	52.0	644E1E7D-DFD1-4F83-82DC-AE0C7E010F6F	D97C0E4A-EB95-49BC-B430-EE0122726442	TCGA-G9-6370-01A-11D-1784-02	HG19_Broad_variant	TCGA-G9-6370	TCGA-PRAD		s3449	Harvard Medical School	Roswell Park	United States	NO	T3b	N0	Prostate Adenocarcinoma Acinar Type		1784-02	True	PRAD	C3	PRAD.8-other	0.108635854	0.62	0.0	1.424082012	-1.94	-0.266	-0.5815	-0.0584	-0.38299999999999995	-0.0557			0.029221999	0.0	49.0	1.65e-05	0.0	0.0		0.0	1.0	2.079441542	8.0	1.0	2.048537564	964.3487044999999	-734.2381425	2351.053943	0.0	1156.0	0.0	1156.0	7.725330037917134	8.48084036195044	-0.30756859001953485	5.528105460580915	7.439386487122278	4.096009841541162	-2.197224577336219	-1.0414538748281612	4.403578431560696
13722.58cfa832e4b0c9d6adf6d00c	58cfa832e4b0c9d6adf6d00c	TCGA-HC-7230-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-HC-7230-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_8_rg.sorted	TCGA-HC-7230-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_8_rg.sorted.bam	142.3		0.14	58cfa832e4b0c9d6adf6d00c	TCGA-HC-7230-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7230-01A	03C66CF8-BC68-4EE1-A322-689A29B72262	Primary Tumor	Illumina HiSeq	40ad0094-93d2-45aa-a8b1-070359637c85	Prostate	50.0	B8BAC212-127D-4EEE-8647-3BDDC13C9415	CE9AA8B5-5CDB-42F1-A810-7F48FC241D20	TCGA-HC-7230-01A-11D-2111-02	HG19_Broad_variant	TCGA-HC-7230	TCGA-PRAD		s3804	Harvard Medical School	International Genomics Consortium	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		2111-02	True	PRAD	C3	PRAD.1-ERG	0.025551307000000002	0.16	0.01	0.168135731	-1.1214	-0.042	-1.4172	-1.4111	-1.5095	-0.5781	13.0		0.271972804	0.543945607	76.0	0.054798970999999995	2.0	6.0				1.906154747	7.0	0.979569765	1.547675787	-1055.022182	-756.576202	3536.026557	0.0	1001.0	0.0	1001.0	7.197934231632504	8.03031658212112	-0.15452215085679	5.352107541134174	6.718130193154952		-1.8458266904983305	-1.312186388966169	
13722.58cfa832e4b0c9d6adf6d011	58cfa832e4b0c9d6adf6d011	TCGA-G3-A25Y-01A-11D-A16V-10_wgs_Illumina.filtered.	WGS	TCGA-G3-A25Y-01A-11D-A16V-10_wgs_Illumina	TCGA-G3-A25Y-01A-11D-A16V-10_wgs_Illumina.bam	84.29	1.88	0.08	58cfa832e4b0c9d6adf6d011	TCGA-G3-A25Y-01A-11D-A16V-10_wgs_Illumina.bam	Dead	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-G3-A25Y-01A	239B4298-B090-480A-A19F-9758A827AA30	Primary Tumor	Illumina HiSeq	e3c5b76f-1e3c-4536-92be-2851b2d6f589	Liver	52.0	433DF923-691A-41F8-8718-6F9783F59873	6B50391F-D890-4CA0-B942-BEAB0F8BF1C9	TCGA-G3-A25Y-01A-11D-A16V-10	GRCh37-lite	TCGA-G3-A25Y	TCGA-LIHC	452.0	s16864	Baylor College of Medicine	Alberta Health Services	Canada	NO	T1	N0	Hepatocellular Carcinoma	Stage I	A16V-10	True	LIHC	C2	LIHC.iCluster:1	0.186519643	0.28	0.11		0.0962	0.087	0.0386	0.0567	0.6837	-0.1887	57.0	1.0	0.32961029399999997	2.03259681	128.0	0.302606967	3.0	32.0				2.523210953	13.0	0.9837273959999999	0.888238324	-816.1053208	-484.7547471	3533.212343	1.0	452.0	1.0	355.0	6.971251590541264	1.0491238004479522	0.0980843720460628	5.702740265077757	2.8461326255621513	5.5671988095361	-1.268511325463507	1.7970088251141991	5.469114437490037
13722.58cfa832e4b0c9d6adf6d014	58cfa832e4b0c9d6adf6d014	TCGA-G9-6336-01A-11D-1784_130115_SN590_0208_BD1TAGACXX_s_5_rg.sorted.filtered.	WGS	TCGA-G9-6336-01A-11D-1784_130115_SN590_0208_BD1TAGACXX_s_5_rg.sorted	TCGA-G9-6336-01A-11D-1784_130115_SN590_0208_BD1TAGACXX_s_5_rg.sorted.bam	81.4	1.9	0.14	58cfa832e4b0c9d6adf6d014	TCGA-G9-6336-01A-11D-1784_130115_SN590_0208_BD1TAGACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6336-01A	59207BCD-F127-481F-B576-8716DA7D7D97	Primary Tumor	Illumina HiSeq	35e1082b-0264-4bb6-93d6-1d0e1b133135	Prostate	57.0	34C8B195-ECAB-492B-AED2-43ACFEDEF708	DB1475AB-0C9E-4D4C-B7F4-88DD8BB2F9B9	TCGA-G9-6336-01A-11D-1784-02	HG19_Broad_variant	TCGA-G9-6336	TCGA-PRAD		s3799	Harvard Medical School	Roswell Park	United States	NO		N0	Prostate Adenocarcinoma Acinar Type		1784-02	True	PRAD	C3	PRAD.1-ERG	0.056316803			1.536078482	-1.7309999999999999	-0.075	-0.9398	-0.9601	-1.0284	-0.2252	3.0		0.143869197	0.402833751	43.0	0.001128554						1.609437912	5.0	1.0	2.045780059	166.5833967	-782.8628164	3100.984711	0.0	2068.0	0.0	2068.0	7.29641326877392	8.376320632534823	-0.48126850502471263	4.993828175779875	7.334866757706661	1.6743506150540541	-2.3025850929940455	-1.0414538748281612	2.1556191200787667
13722.58cfa832e4b0c9d6adf6d018	58cfa832e4b0c9d6adf6d018	TCGA-FT-A3EE-01A-11D-A204_121002_SN1222_0155_BD1ERHACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FT-A3EE-01A-11D-A204_121002_SN1222_0155_BD1ERHACXX_s_1_rg.sorted	TCGA-FT-A3EE-01A-11D-A204_121002_SN1222_0155_BD1ERHACXX_s_1_rg.sorted.bam	35.79		0.15	58cfa832e4b0c9d6adf6d018	TCGA-FT-A3EE-01A-11D-A204_121002_SN1222_0155_BD1ERHACXX_s_1_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FT-A3EE-01A	CCE62116-3DCD-400D-ADA0-9839CA02466E	Primary Tumor	Illumina HiSeq	7bd31003-35c9-4165-b964-e3d1e803dbe9	Bladder	80.0	2356F78C-0653-468F-83DB-6CF6107BD259	0C871E11-F5FB-4B9E-B286-163187A68992	TCGA-FT-A3EE-01A-11D-A204-02	HG19_Broad_variant	TCGA-FT-A3EE	TCGA-BLCA	99.0	s2913	Harvard Medical School	BLN - University of Miami	United States	NO	T4a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A204-02	True	BLCA	C1	BLCA.1	0.21555016	0.39	0.04	5.6971280570000005	-0.0016	0.166	-0.9423	-0.7472	-0.7279	0.2819	47.0	56.0	0.9924108540000001	3.277963123	128.0	0.99999817	19.0	23.0	0.9076313309999999	2.5715131980000003	17.0	1.098612289	3.0	1.0	1.440850881	-741.9632392000001	316.6569538	-631.2800627	1.0	99.0	0.0	99.0	4.610315655484297	7.989645191505858	0.3667530038108844	4.9248089853867345	6.73688222301049	1.5633416640967683	0.3144933299024375	-1.252762968495368	1.196588660285884
13722.58cfa832e4b0c9d6adf6d01a	58cfa832e4b0c9d6adf6d01a	TCGA-G9-6353-01A-11D-1957_130405_SN590_0222_BD21LGACXX_s_4_rg.sorted.filtered.	WGS	TCGA-G9-6353-01A-11D-1957_130405_SN590_0222_BD21LGACXX_s_4_rg.sorted	TCGA-G9-6353-01A-11D-1957_130405_SN590_0222_BD21LGACXX_s_4_rg.sorted.bam	144.7	1.9	0.15	58cfa832e4b0c9d6adf6d01a	TCGA-G9-6353-01A-11D-1957_130405_SN590_0222_BD21LGACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6353-01A	BCC94953-CE79-428E-99C1-632E42C1B9BC	Primary Tumor	Illumina HiSeq	86ec03a4-f08e-474e-b887-c5e06822b414	Prostate	58.0	4CBA0BA5-58C3-455C-9CD5-7D9428D27F8C	758712E3-95F1-4BB5-A83A-D01C4844122D	TCGA-G9-6353-01A-11D-1957-02	HG19_Broad_variant	TCGA-G9-6353	TCGA-PRAD		s3970	Harvard Medical School	Roswell Park	United States	NO	T3a		Prostate Adenocarcinoma Acinar Type		1957-02	True	PRAD	C3	PRAD.1-ERG	0.083093002	0.0	0.0	1.7799671590000001	-2.0902	-0.191	-1.2772	-0.8834	-1.2947	-0.2422	4.0		0.028297231000000003	0.084891693	45.0	2.09e-05	0.0	0.0				1.609437912	5.0	1.0	1.86805637	72.83071141	-756.9075412000001	3226.918284	0.0	1542.0	0.0	1542.0	9.171027654590642	8.720718898360852	-0.1087178177692728	6.531970324975383	8.16110311042543		-2.6390573296152584	-0.5596157879354227	
13722.58cfa832e4b0c9d6adf6d01c	58cfa832e4b0c9d6adf6d01c	TCGA-FU-A3TX-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_4_rg.sorted.filtered.	WGS	TCGA-FU-A3TX-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_4_rg.sorted	TCGA-FU-A3TX-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_4_rg.sorted.bam	57.65		0.16	58cfa832e4b0c9d6adf6d01c	TCGA-FU-A3TX-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_4_rg.sorted.bam	Alive	FEMALE			Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-FU-A3TX-01A	B75644C2-B515-41CE-9B03-842EF5208A17	Primary Tumor	Illumina HiSeq	3692ce0d-daf2-4076-a86f-4d8e9ea25745	Cervix	78.0	D9146847-1E6A-4963-9BC2-C2041B36A84C	14CDA56B-E939-4F52-8F22-00F3E5EA0DA6	TCGA-FU-A3TX-01A-11D-A232-26	HG19_Broad_variant	TCGA-FU-A3TX	TCGA-CESC		s1371	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T1b2	N0	Cervical Squamous Cell Carcinoma		A232-26	True	CESC	C1		0.11487345199999999	0.32	0.32	1.749032111	1.0056	0.337	-0.195	0.6638	-0.6806	-0.1426	17.0	0.0	0.343111037	1.235199734	110.0	0.328541409	9.0	24.0	0.8515486999999999	2.774427872	26.0	3.043137605	25.0	0.945403852	1.537035076	-1652.924258	940.331457	-3296.0192190000002	0.0	45.0	0.0	45.0	7.319864929808969	5.3735762796136335	-0.23179275183388104	5.422744944923089	6.26966430417027	1.1730168471157874	-1.897119984885881	0.8960880245566356	1.4048095989496683
13722.58cfa832e4b0c9d6adf6d020	58cfa832e4b0c9d6adf6d020	TCGA-GV-A3JZ-01A-11D-A21C_120830_SN590_0178_AD143RACXX_s_7_rg.sorted.filtered.	WGS	TCGA-GV-A3JZ-01A-11D-A21C_120830_SN590_0178_AD143RACXX_s_7_rg.sorted	TCGA-GV-A3JZ-01A-11D-A21C_120830_SN590_0178_AD143RACXX_s_7_rg.sorted.bam	63.92		0.14	58cfa832e4b0c9d6adf6d020	TCGA-GV-A3JZ-01A-11D-A21C_120830_SN590_0178_AD143RACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GV-A3JZ-01A	9CC92795-7A24-4875-87F0-3EFCCBFCC970	Primary Tumor	Illumina HiSeq	d4d5d34c-9665-4291-a3d6-14bc9b48f2fa	Bladder	55.0	449E18FB-CBC0-4365-AEEC-EDC6A6B276BD	5A651606-6D92-445B-AA0B-B73CC9329402	TCGA-GV-A3JZ-01A-11D-A21C-26	HG19_Broad_variant	TCGA-GV-A3JZ	TCGA-BLCA		s2738	MD Anderson - Institute for Applied Cancer Science	BLN - Cleveland Clinic	United States	NO	T4a	N3	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A21C-26	True	BLCA	C1	BLCA.2	0.083568176	0.18	0.26	10.38257607	1.0636	0.21600000000000003	-0.3849	-0.6065	-0.804	0.2024	250.0	43.0	3.883698518	12.63743168	486.0	0.62731612	13.0	57.0	0.930403243	3.13294296	29.0	1.791759469	6.0	1.0	4.50936434	-2590.080998	1201.9313769999999	-3166.3001510000004	0.0	603.0	0.0	603.0	7.772284770741905	8.82355593848119	-0.03012030708924951	6.14086795158903	7.724943649813081	3.3430064432080173	-1.6314168191528755	-1.09861228866811	3.373126750297267
13722.58cfa832e4b0c9d6adf6d024	58cfa832e4b0c9d6adf6d024	TCGA-GC-A3BM-01A-11D-A23Q_120926_SN1222_0153_BD1D4MACXX_s_3_rg.sorted.filtered.	WGS	TCGA-GC-A3BM-01A-11D-A23Q_120926_SN1222_0153_BD1D4MACXX_s_3_rg.sorted	TCGA-GC-A3BM-01A-11D-A23Q_120926_SN1222_0153_BD1D4MACXX_s_3_rg.sorted.bam	51.48		0.15	58cfa832e4b0c9d6adf6d024	TCGA-GC-A3BM-01A-11D-A23Q_120926_SN1222_0153_BD1D4MACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GC-A3BM-01A	7840AEA9-40C4-473E-BE33-8FA0B9F332C9	Primary Tumor	Illumina HiSeq	1901f2a9-837a-482c-8073-472f3c4d9ba1	Bladder	70.0	5C631CE8-F96A-4C35-A459-556FC4AB21E1	5FE3FF9D-CCF4-4C76-820D-26FD5D1FCD15	TCGA-GC-A3BM-01A-11D-A23Q-26	HG19_Broad_variant	TCGA-GC-A3BM	TCGA-BLCA		s2924	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A23Q-26	True	BLCA	C1	BLCA.1	0.06312073	0.14	0.45	3.11718299	0.1563	0.0485	-0.8217	-0.8692	0.2842	-0.0558	24.0	21.0	1.371095826	3.142094601	130.0	0.72335054	24.0	21.0		0.0	1.0	0.0	1.0		4.153464048	-1614.385043	-171.4248969	-757.7585799999999	1.0	651.0	1.0	651.0	7.823045510522709	8.352621736761062	0.24001919954963824	6.644390514181063	7.040435347794894	0.7769781267341457	-1.178654996341646	-1.312186388966169	0.5369589271845074
13722.58cfa832e4b0c9d6adf6d026	58cfa832e4b0c9d6adf6d026	TCGA-GD-A3OQ-01A-32D-A221_120902_SN1222_0147_AC195DACXX_s_4_rg.sorted.filtered.	WGS	TCGA-GD-A3OQ-01A-32D-A221_120902_SN1222_0147_AC195DACXX_s_4_rg.sorted	TCGA-GD-A3OQ-01A-32D-A221_120902_SN1222_0147_AC195DACXX_s_4_rg.sorted.bam	40.42		0.15	58cfa832e4b0c9d6adf6d026	TCGA-GD-A3OQ-01A-32D-A221_120902_SN1222_0147_AC195DACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GD-A3OQ-01A	2E85C30C-C4C4-4096-9EEF-4EB2C7D991A3	Primary Tumor	Illumina HiSeq	a07d0456-032d-409c-af8d-c4d6349ef4db	Bladder	48.0	E3D22638-C0AE-48AA-A523-8C9A6CFBF063	F77305E9-430E-4E7D-97A6-C97FFDDC3B65	TCGA-GD-A3OQ-01A-32D-A221-26	HG19_Broad_variant	TCGA-GD-A3OQ	TCGA-BLCA		s2923	MD Anderson - Institute for Applied Cancer Science	ABS - IUPUI	United States	NO	T4a	N1	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A221-26	True	BLCA	C2	BLCA.1	0.09289664199999999	0.22	0.07	12.32080677	0.8094	0.1775	-1.0101	-1.452	0.3968	0.4618	42.0	3.0	0.568180204	2.930613684	78.0	0.08597452800000001	0.0	8.0				1.386294361	4.0	1.0	1.898790226	-918.082481	779.5746519999999	-1889.413326	0.0	95.0	0.0	95.0	7.459668004981371	8.43994182242477	0.03528181414463982	6.572364809980468	7.2077981411321375	0.7799602301103238	-0.8873031950009032	-1.2321436812926325	0.744678415965684
13722.58cfa832e4b0c9d6adf6d027	58cfa832e4b0c9d6adf6d027	TCGA-HE-A5NJ-01A-11D-A26P-10_wgs_Illumina.filtered.	WGS	TCGA-HE-A5NJ-01A-11D-A26P-10_wgs_Illumina	TCGA-HE-A5NJ-01A-11D-A26P-10_wgs_Illumina.bam	54.68		0.07	58cfa832e4b0c9d6adf6d027	TCGA-HE-A5NJ-01A-11D-A26P-10_wgs_Illumina.bam	Alive	MALE			Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-HE-A5NJ-01A	8D28F586-3DE5-4033-A9FD-4F67BE406FB4	Primary Tumor	Illumina HiSeq	ac395d4f-83c9-44e8-af57-fc5266ebef92	Kidney	58.0	DDB72D04-48F5-4AD5-95A7-8D2614BA0AE0	A9DBD55C-5DCC-48DB-8785-6BAEF3FDD7DB	TCGA-HE-A5NJ-01A-11D-A26P-10	GRCh37-lite	TCGA-HE-A5NJ	TCGA-KIRP		s11652	Baylor College of Medicine	Ontario Institute for Cancer Research (OICR)	Canada	NO	T1b	NX	Kidney Papillary Renal Cell Carcinoma		A26P-10	True	KIRP	C3	KIRP.C1	0.053315479000000006	0.1	0.02		-1.1001	-0.331	-1.0036	-2.1684	-0.6103	-0.0168	35.0	72.0	0.45991534700000003	1.487961418	74.0	0.240445209	7.0	7.0					0.0		2.058125532	-681.854101	-1155.609716	-292.6605751	0.0	1726.0	0.0	1726.0	6.69800379514008	1.8092791511819382	-0.6578709987084481	5.753542186299229	3.3251487547078575	1.5809882509660165	-0.9444616088408515	1.5158696035259194	2.238859249674465
13722.58cfa832e4b0c9d6adf6d029	58cfa832e4b0c9d6adf6d029	TCGA-HE-A5NI-01A-11D-A26P-10_wgs_Illumina.filtered.	WGS	TCGA-HE-A5NI-01A-11D-A26P-10_wgs_Illumina	TCGA-HE-A5NI-01A-11D-A26P-10_wgs_Illumina.bam	27.28		0.08	58cfa832e4b0c9d6adf6d029	TCGA-HE-A5NI-01A-11D-A26P-10_wgs_Illumina.bam	Alive	MALE			Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-HE-A5NI-01A	D61E22D8-C3CE-4237-83D7-DA188B9FD456	Primary Tumor	Illumina HiSeq	b85a3000-296d-44e9-8c6b-9a5db0104583	Kidney	73.0	520E4C08-E7C6-407F-94CD-A07681BC24A8	40A609BB-2C8F-4146-83C4-E7B0D1B23619	TCGA-HE-A5NI-01A-11D-A26P-10	GRCh37-lite	TCGA-HE-A5NI	TCGA-KIRP		s11651	Baylor College of Medicine	Ontario Institute for Cancer Research (OICR)	Canada	NO	T1a	NX	Kidney Papillary Renal Cell Carcinoma	Stage I	A26P-10	True	KIRP	C3	KIRP.C1	0.179173964	0.0	0.2		-1.6659	-0.43	0.1093	-0.4871	-0.7665	-0.2875	31.0	148.0	0.881667761	2.507242694	67.0	0.9477338120000001	14.0	0.0				1.098612289	3.0	1.0	2.2774470730000003	-1309.860894	-2002.0736510000002	1323.066858	0.0	360.0	0.0	360.0	7.199678345691172	2.5870556010636117	-0.18859116980755009	5.367096881942862	2.2162524746563657	4.369891902207888	-1.83258146374831	-0.370803126407246	4.558483072015438
13722.58cfa832e4b0c9d6adf6d02e	58cfa832e4b0c9d6adf6d02e	TCGA-G9-6367-01A-11D-1784_130215_SN590_0212_BC1NP2ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-G9-6367-01A-11D-1784_130215_SN590_0212_BC1NP2ACXX_s_3_rg.sorted	TCGA-G9-6367-01A-11D-1784_130215_SN590_0212_BC1NP2ACXX_s_3_rg.sorted.bam	59.4	1.9	0.14	58cfa832e4b0c9d6adf6d02e	TCGA-G9-6367-01A-11D-1784_130215_SN590_0212_BC1NP2ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6367-01A	9F751C9D-AD41-4F02-B7F8-12423857D418	Primary Tumor	Illumina HiSeq	d4203e0e-c16e-4638-a239-378ffed98124	Prostate	60.0	5BC98578-E4C7-4BE8-89DF-F26AA5D545A9	9667EB66-775F-4C37-9309-FF73E55D553B	TCGA-G9-6367-01A-11D-1784-02	HG19_Broad_variant	TCGA-G9-6367	TCGA-PRAD		s3612	Harvard Medical School	Roswell Park	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1784-02	True	PRAD	C3	PRAD.8-other	0.06759124799999999	0.73	0.0	3.060321207	-2.2314	-0.2645	-1.0282	-0.3368	-0.7529	-0.2306	2.0		0.028671064	0.057342128	47.0	8.69e-06	0.0	0.0				2.079441542	8.0	1.0	1.969460143	106.8399182	-1178.887878	1972.5096019999999	0.0	1222.0	0.0	1222.0	9.07383312732152	8.955190024526885	-0.9861080057161242	5.982790673963203	7.9996785794994505		-3.0910424533583156	-0.9555114450274362	
13722.58cfa832e4b0c9d6adf6d034	58cfa832e4b0c9d6adf6d034	TCGA-GC-A3RD-01A-12D-A233_120905_SN1120_0187_AD1E4NACXX_s_7_rg.sorted.filtered.	WGS	TCGA-GC-A3RD-01A-12D-A233_120905_SN1120_0187_AD1E4NACXX_s_7_rg.sorted	TCGA-GC-A3RD-01A-12D-A233_120905_SN1120_0187_AD1E4NACXX_s_7_rg.sorted.bam	46.83		0.16	58cfa832e4b0c9d6adf6d034	TCGA-GC-A3RD-01A-12D-A233_120905_SN1120_0187_AD1E4NACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GC-A3RD-01A	6A2155B3-915C-41B1-B730-32E55E0C1FBD	Primary Tumor	Illumina HiSeq	27573bf6-b72d-47e6-93f7-38d2887d8b32	Bladder	83.0	1C60F60E-A3C6-43A1-A56E-BA68801D2D90	C9E9DC46-2917-47BE-92DA-9C40C6F13500	TCGA-GC-A3RD-01A-12D-A233-26	HG19_Broad_variant	TCGA-GC-A3RD	TCGA-BLCA		s2731	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T3a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A233-26	True	BLCA	C1	BLCA.1	0.170109957	0.29	0.19		0.3623	0.1035	-0.7240000000000001	-1.6318	-0.1098	0.0576	36.0	5.0	0.9575337490000001	2.131284796	170.0	0.684753202	18.0	44.0					0.0		3.355468215	-1665.193904	-110.72547620000002	-2539.216037	0.0	428.0	0.0	428.0	5.700921242375168	6.801375725763339	-0.26390420336438225	5.382467511256634	5.954077865376135	1.7637122704508674	-0.3184537311185345	-0.8472978603872034	2.02761647381525
13722.58cfa832e4b0c9d6adf6d036	58cfa832e4b0c9d6adf6d036	TCGA-FU-A3WB-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_5_rg.sorted.filtered.	WGS	TCGA-FU-A3WB-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_5_rg.sorted	TCGA-FU-A3WB-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_5_rg.sorted.bam	44.44		0.16	58cfa832e4b0c9d6adf6d036	TCGA-FU-A3WB-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-FU-A3WB-01A	6868BA1D-B612-454C-8146-74AF2F573D76	Primary Tumor	Illumina HiSeq	39124a1d-9323-40ae-aee5-6fb32cf4a565	Cervix	43.0	0334B0B7-115E-40A0-960B-6A3365CDA3AD	52C1B6D6-A160-4FFB-945C-6FB3B29EFEF9	TCGA-FU-A3WB-01A-11D-A232-26	HG19_Broad_variant	TCGA-FU-A3WB	TCGA-CESC		s1203	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T2a2	N0	Cervical Squamous Cell Carcinoma		A232-26	True	CESC	C2		0.06251685400000001	0.12	0.05	19.32701097	1.4793	0.441	-1.0423	-0.4579	0.6738	-0.1343	30.0	0.0	0.376886575	1.35235771	63.0	0.12033731800000001	3.0	12.0	0.959483814	0.6650635	2.0	1.9459101490000001	7.0	1.0	1.8426595469999998	-1031.952098	933.4159687999999	-1368.055876	0.0	491.0	0.0	491.0	7.393878290107756	7.339212967364556	0.37279771427651165	5.602118820879702	6.186533457426171	1.568540019465932	-1.7917594692280547	-1.1526795099383853	1.1957423051894205
13722.58cfa832e4b0c9d6adf6d042	58cfa832e4b0c9d6adf6d042	TCGA-FU-A3EO-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FU-A3EO-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_1_rg.sorted	TCGA-FU-A3EO-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_1_rg.sorted.bam	43.71		0.16	58cfa832e4b0c9d6adf6d042	TCGA-FU-A3EO-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-FU-A3EO-01A	B7F2958F-256E-4C30-9C61-11E76DDB36BA	Primary Tumor	Illumina HiSeq	31874bb0-fa47-43d4-8135-1be05e8163eb	Cervix	55.0	59F1684E-5631-4E1E-A1DC-91739F7C159C	50DBFC58-57DC-4878-8506-7B6B21899DF5	TCGA-FU-A3EO-01A-11D-A20X-26	HG19_Broad_variant	TCGA-FU-A3EO	TCGA-CESC		s1201	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T2b	N0	Endocervical Type of Adenocarcinoma		A20X-26	True	CESC	C2		0.065379977	0.19	0.02	3.728362184	0.5522	0.23	-0.2459	0.2317	0.0101	-0.3755	27.0	0.0	0.390264812	1.0330539140000001	85.0	0.127596729	4.0	10.0				0.0	1.0		2.153542745	-14.87074375	-358.71707030000005	571.6594769	0.0	490.0	0.0	490.0	7.808661608812546	5.5592012458450935	0.8071566268326891	6.710049320144436	7.125621773195503	2.0478109977932304	-1.0986122886681096	1.5664205273504095	1.240654370960541
13722.58cfa832e4b0c9d6adf6d044	58cfa832e4b0c9d6adf6d044	TCGA-GD-A2C5-01A-12D-A17R_120927_SN208_0432_AC188LACXX_s_6_rg.sorted.filtered.	WGS	TCGA-GD-A2C5-01A-12D-A17R_120927_SN208_0432_AC188LACXX_s_6_rg.sorted	TCGA-GD-A2C5-01A-12D-A17R_120927_SN208_0432_AC188LACXX_s_6_rg.sorted.bam	40.79		0.16	58cfa832e4b0c9d6adf6d044	TCGA-GD-A2C5-01A-12D-A17R_120927_SN208_0432_AC188LACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GD-A2C5-01A	5D54C742-5A8E-4C40-8D62-95E75E210AB8	Primary Tumor	Illumina HiSeq	27e88ee3-dcb4-43c4-9653-c55aa1851cb1	Bladder	53.0	2CD62676-762C-461D-B111-1F81E7CD5877	EEB315EA-D1B6-4F92-91B0-9AAAC7083D68	TCGA-GD-A2C5-01A-12D-A17R-02	HG19_Broad_variant	TCGA-GD-A2C5	TCGA-BLCA		s2920	Harvard Medical School	ABS - IUPUI	United States	NO	T3a	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A17R-02	True	BLCA	C2	BLCA.2	0.155386876	0.0	0.35	4.815769378	0.3575	0.13699999999999998	-0.6532	-0.8233	0.5574	-0.145	139.0	38.0	2.325778716	6.747629608	262.0	0.5574628110000001	16.0	47.0	0.9716077329999999	0.6734671609999999	2.0	1.039720771	3.0	0.94639463	4.172233232	-2131.276343	317.9464784	1387.737479	0.0	812.0	1.0	214.0	7.139779282102285	6.694618312564369	-0.28128533348343454	6.397841937372908	7.044820741997484	2.5122254218667566	-0.7419373447293776	0.35020242943311475	2.7935107553501908
13722.58cfa832e4b0c9d6adf6d04e	58cfa832e4b0c9d6adf6d04e	TCGA-G9-6329-01A-13D-1957_130222_SN1222_0174_BC1RNEACXX_s_1_rg.sorted.filtered.	WGS	TCGA-G9-6329-01A-13D-1957_130222_SN1222_0174_BC1RNEACXX_s_1_rg.sorted	TCGA-G9-6329-01A-13D-1957_130222_SN1222_0174_BC1RNEACXX_s_1_rg.sorted.bam	41.7	1.9	0.15	58cfa832e4b0c9d6adf6d04e	TCGA-G9-6329-01A-13D-1957_130222_SN1222_0174_BC1RNEACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6329-01A	A08FD0A6-A89A-4ADB-B641-D4C1238ABB71	Primary Tumor	Illumina HiSeq	1971b9d7-8a67-4447-835d-23525622c037	Prostate	67.0	E004F38D-C874-4E03-830B-4E554EF3E274	46BEFA09-3AF0-415C-994E-330B07586058	TCGA-G9-6329-01A-13D-1957-02	HG19_Broad_variant	TCGA-G9-6329	TCGA-PRAD		s3796	Harvard Medical School	Roswell Park	United States	NO	T2c		Prostate Adenocarcinoma Acinar Type		1957-02	True	PRAD	C3	PRAD.1-ERG	0.12363560800000001	0.72	0.05	1.3644650459999998	-1.4166	-0.0415	-0.5922	0.259	-0.8102	-0.1622	16.0		0.200411686	0.543974575	49.0	0.07149404599999999	2.0	4.0	0.998069255	0.69180889	2.0	2.5164103	14.0	0.9535261970000001	2.23048699	-571.4622327000001	-698.6021592000001	2245.902638	0.0	1266.0	0.0	1266.0	7.841296364262819	8.217592757570875	0.1483020411757816	5.590004565656324	7.028008690697039	2.2613699394358977	-2.251291798606495	-1.1895840668738364	2.113067898260116
13722.58cfa832e4b0c9d6adf6d062	58cfa832e4b0c9d6adf6d062	TCGA-G3-A25T-01A-11D-A16V-10_wgs_Illumina.filtered.	WGS	TCGA-G3-A25T-01A-11D-A16V-10_wgs_Illumina	TCGA-G3-A25T-01A-11D-A16V-10_wgs_Illumina.bam	80.84	2.02	0.08	58cfa832e4b0c9d6adf6d062	TCGA-G3-A25T-01A-11D-A16V-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-G3-A25T-01A	F6E5979D-D6A9-4408-BD1B-1B37D1064E83	Primary Tumor	Illumina HiSeq	97875fbb-c05a-4e3b-89e6-28f20a7eb82f	Liver	45.0	D42D6E07-8E0E-4345-B1B9-1B8B4574D042	41840DC1-5EA2-4F01-A0D4-8B65ADD641C8	TCGA-G3-A25T-01A-11D-A16V-10	GRCh37-lite	TCGA-G3-A25T	TCGA-LIHC		s16690	Baylor College of Medicine	Alberta Health Services	Canada	NO	T3	N0	Hepatocellular Carcinoma	Stage IIIA	A16V-10	True	LIHC	C1	LIHC.iCluster:1	0.09958989900000001	0.31	0.17		-0.1881	0.035	-0.3891	-0.442	-0.4666	-0.19	35.0	14.0	0.33746705200000005	1.1530124259999999	63.0	0.530182168	15.0	13.0					0.0		1.137952736	-1767.1353010000003	-795.9462074	255.0297488	0.0	1553.0	1.0	452.0	6.356473090994129	1.5710643547725969	-0.04447848517682418	5.563242451877201	3.384467653741665	5.7850551947849365	-0.7932306391169281	1.8134032989690683	5.829533679961761
13722.58cfa832e4b0c9d6adf6d06c	58cfa832e4b0c9d6adf6d06c	TCGA-HC-7211-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-HC-7211-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_2_rg.sorted	TCGA-HC-7211-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_2_rg.sorted.bam	286.3		0.14	58cfa832e4b0c9d6adf6d06c	TCGA-HC-7211-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7211-01A	EC3870C9-4930-4AF7-B2EB-1E16C9EC9F14	Primary Tumor	Illumina HiSeq	c6d8e1f6-600a-4387-a51a-8812fee4f285	Prostate	62.0	79BF8C2C-470E-4BE8-8144-9C0B366ECADD	226F7F0E-AC30-4F20-87A2-EB8128402BE4	TCGA-HC-7211-01A-11D-2111-02	HG19_Broad_variant	TCGA-HC-7211	TCGA-PRAD		s3622	Harvard Medical School	International Genomics Consortium	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		2111-02	True	PRAD	C3	PRAD.1-ERG	0.066551113	0.31	0.0	0.186878728	-1.4543	-0.2835	-0.5113	-1.1634	-0.9873	-0.1991	13.0	3.0	0.119276509	0.566563419	87.0	0.048335022000000005	2.0	7.0				1.098612289	3.0	1.0	1.8084014080000002	36.08970338	-920.2195876000001	2211.816112	0.0	1221.0	0.0	1221.0	9.469738703949563	8.317766166719345	-1.4102981954696163	7.071843431151192	8.171162692527469	1.1035102576436568	-2.3978952727983707	-0.1466034741918758	2.513808453113273
13722.58cfa832e4b0c9d6adf6d078	58cfa832e4b0c9d6adf6d078	TCGA-HC-7081-01A-11D-1957_130422_SN590_0225_BD23TLACXX_s_4_rg.sorted.filtered.	WGS	TCGA-HC-7081-01A-11D-1957_130422_SN590_0225_BD23TLACXX_s_4_rg.sorted	TCGA-HC-7081-01A-11D-1957_130422_SN590_0225_BD23TLACXX_s_4_rg.sorted.bam	130.7		0.14	58cfa832e4b0c9d6adf6d078	TCGA-HC-7081-01A-11D-1957_130422_SN590_0225_BD23TLACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE		Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7081-01A	3DA2E90E-6450-4286-8C74-08DBECBFD788	Primary Tumor	Illumina HiSeq	f44b51c1-3e9f-49b0-817b-b31a58264c39	Prostate	62.0	D4EAA3C5-A0F0-4CD7-8B93-73DFB09B359A	AA4E666F-E577-4F00-82A7-EBC3B8739960	TCGA-HC-7081-01A-11D-1957-02	HG19_Broad_variant	TCGA-HC-7081	TCGA-PRAD		s3805	Harvard Medical School	International Genomics Consortium	United States	NO	T3b		Prostate Adenocarcinoma Acinar Type		1957-02	True	PRAD	C3	PRAD.1-ERG	0.14756493099999998	0.45	0.0	1.195159973	-1.1692	-0.2685	0.0612	-0.2411	-0.9595	0.2391	14.0	68.0	0.203194455	0.696666702	105.0	0.026533387999999998	0.0	5.0							1.843904941	-414.8910622	-145.0313094	3093.793907	0.0	1136.0	0.0	1136.0	7.384299968771254	7.88758403166028	0.03856998919994681	5.081714875777209	6.734904521721894	2.630953557552151	-2.3025850929940455	-1.1526795099383853	2.592383568352204
13722.58cfa832e4b0c9d6adf6d07e	58cfa832e4b0c9d6adf6d07e	TCGA-HE-A5NF-01A-11D-A26P-10_wgs_Illumina.filtered.	WGS	TCGA-HE-A5NF-01A-11D-A26P-10_wgs_Illumina	TCGA-HE-A5NF-01A-11D-A26P-10_wgs_Illumina.bam	17.39		0.08	58cfa832e4b0c9d6adf6d07e	TCGA-HE-A5NF-01A-11D-A26P-10_wgs_Illumina.bam	Alive	MALE			Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-HE-A5NF-01A	36B46540-472F-4A4D-A801-B8B6AE660DC9	Primary Tumor	Illumina HiSeq	ccad1f55-76d4-41fc-abf9-9409c743d7e8	Kidney	58.0	7C6B9F49-9EA0-4532-BDCE-F8987786BF5A	C14407AD-670E-4D1E-9417-2B76F4810FFF	TCGA-HE-A5NF-01A-11D-A26P-10	GRCh37-lite	TCGA-HE-A5NF	TCGA-KIRP		s11779	Baylor College of Medicine	Ontario Institute for Cancer Research (OICR)	Canada	NO	T1a	NX	Kidney Papillary Renal Cell Carcinoma	Stage I	A26P-10	True	KIRP	C4	KIRP.C1	0.53266988	0.62	0.02		-2.0591	-0.126	1.0039	0.2187	-0.3924	-0.2859	25.0	51.0	0.384045225	1.7282035130000002	37.0	0.319726482	12.0	0.0				1.039720771	3.0	0.94639463	2.27347215	-653.9013727000001	-1975.716657	174.9950219	0.0	2582.0	0.0	2582.0	6.523855948788532	4.541617926550624	0.6946475559351799	4.875197323201151	4.347641816760687		-1.6486586255873819	-0.1939761097899373	
13722.58cfa832e4b0c9d6adf6d082	58cfa832e4b0c9d6adf6d082	TCGA-HC-7210-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-HC-7210-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_8_rg.sorted	TCGA-HC-7210-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_8_rg.sorted.bam	131.3		0.15	58cfa832e4b0c9d6adf6d082	TCGA-HC-7210-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7210-01A	6A5AF80E-07AD-4CD3-AAAB-5DB1090835D9	Primary Tumor	Illumina HiSeq	e6934494-d8e1-44c6-a343-30a6aa2e6cbc	Prostate	74.0	9069FC65-9BAE-49F3-9329-B78C8CC6CF1E	D414D851-0AF6-4C8F-8E40-CCA9FDF79488	TCGA-HC-7210-01A-11D-2111-02	HG19_Broad_variant	TCGA-HC-7210	TCGA-PRAD		s3983	Harvard Medical School	International Genomics Consortium	United States	NO	T2a	N0	Prostate Adenocarcinoma Acinar Type		2111-02	True	PRAD	C3	PRAD.6-FOXA1	0.20600044899999997	0.53	0.0	0.758058803	-1.7525	-0.2825	-0.1594	0.2214	-0.7908	0.0206	9.0	40.0	0.34876204299999997	0.755651093	158.0	0.074319665	0.0	16.0	0.788943545	1.816609647	10.0	3.028029073	21.0	0.99458261	2.5130528819999998	403.7810912	-694.2128385	2362.6240239999997	0.0	868.0	0.0	868.0	8.233928016760647	9.150832982965545	-0.17680793860706523	6.547529063190417	8.4576858024056	1.6221891979212204	-1.6863989535702288	-0.6931471805599454	1.7989971365282855
13722.58cfa832e4b0c9d6adf6d086	58cfa832e4b0c9d6adf6d086	TCGA-HC-7212-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-HC-7212-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_4_rg.sorted	TCGA-HC-7212-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_4_rg.sorted.bam	333.3		0.15	58cfa832e4b0c9d6adf6d086	TCGA-HC-7212-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7212-01A	907B64D6-A26A-4092-A247-AC9AF444D1C7	Primary Tumor	Illumina HiSeq	4ff229a3-6637-4fdc-a3b6-079e28773187	Prostate	56.0	92888479-B534-432D-8F70-CAE857E0074B	9BF25BFC-4E07-4979-9169-F6CDADDB3A90	TCGA-HC-7212-01A-11D-2111-02	HG19_Broad_variant	TCGA-HC-7212	TCGA-PRAD		s4153	Harvard Medical School	International Genomics Consortium	United States	NO	T2a	N0	Prostate Adenocarcinoma Acinar Type		2111-02	True	PRAD	C3	PRAD.1-ERG	0.0960957	0.22	0.04	0.543038706	-1.1787	-0.177	-0.9273	-1.2836	-1.2106	-0.3153	8.0	2.0	0.217203046	0.775725164	71.0	0.12086919300000001	0.0	15.0				2.197224577	9.0	1.0	2.122541215	-886.8894666000001	-640.7298238	2789.0003699999997	0.0	870.0	0.0	870.0	9.033901478340384	8.211186671349457	-0.27715565946479337	6.59155444297118	7.613349670593838	2.8020523362465193	-2.4423470353692043	-0.5978370007556202	3.0792079957113128
13722.58cfa832e4b0c9d6adf6d0a2	58cfa832e4b0c9d6adf6d0a2	TCGA-IA-A40X-01A-11D-A25F-10_wgs_Illumina.filtered.	WGS	TCGA-IA-A40X-01A-11D-A25F-10_wgs_Illumina	TCGA-IA-A40X-01A-11D-A25F-10_wgs_Illumina.bam	35.98		0.08	58cfa832e4b0c9d6adf6d0a2	TCGA-IA-A40X-01A-11D-A25F-10_wgs_Illumina.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-IA-A40X-01A	0C151271-2CF9-43F4-9E9B-FE927DE43131	Primary Tumor	Illumina HiSeq	0d27ff83-40ce-4ea3-8368-b9f9f3b4fe26	Kidney	49.0	863393ED-42BB-4232-93F4-2B5759D9822C	E1217EBE-1826-41A9-B6C4-702100A66F5E	TCGA-IA-A40X-01A-11D-A25F-10	GRCh37-lite	TCGA-IA-A40X	TCGA-KIRP		s11862	Baylor College of Medicine	Cleveland Clinic	United States	NO	T1a	NX	Kidney Papillary Renal Cell Carcinoma	Stage I	A25F-10	True	KIRP	C3	KIRP.C2a	0.158395393	0.17	0.02		-1.604	-0.23600000000000002	0.0105	-0.16699999999999998	-0.2244	-0.5812	9.0		0.107454001	0.617860504	48.0	0.045098893	0.0	4.0				2.044931175	9.0	0.930688286	1.6668106759999999	-389.5333025	-1868.4793899999997	487.1554563	0.0	608.0	0.0	608.0	6.68633642998965	1.6319656516913117	-0.31617134470891683	5.603724482667981	3.3271165425007965	4.120232060843036	-1.0826119473216687	1.6951508908094848	4.436403405551953
13722.58cfa832e4b0c9d6adf6d0ac	58cfa832e4b0c9d6adf6d0ac	TCGA-IG-A3I8-01A-11D-A248_130101_SN590_0206_AC1H8RACXX_s_5_rg.sorted.filtered.	WGS	TCGA-IG-A3I8-01A-11D-A248_130101_SN590_0206_AC1H8RACXX_s_5_rg.sorted	TCGA-IG-A3I8-01A-11D-A248_130101_SN590_0206_AC1H8RACXX_s_5_rg.sorted.bam	64.11		0.16	58cfa832e4b0c9d6adf6d0ac	TCGA-IG-A3I8-01A-11D-A248_130101_SN590_0206_AC1H8RACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-IG-A3I8-01A	7BF3F18B-A013-48D2-A743-26A57FDBE4C4	Primary Tumor	Illumina HiSeq	d45e0e39-36b5-4628-9dae-7a185f129e6b	Esophagus	51.0	944A68B7-51D4-4831-88D4-D647BE17BC13	3A1FBCCE-BAB6-466C-AE4C-AADC4E5D357F	TCGA-IG-A3I8-01A-11D-A248-26	HG19_Broad_variant	TCGA-IG-A3I8	TCGA-ESCA		s1621	MD Anderson - Institute for Applied Cancer Science	Asterand	Russia	NO	T3	N0		Stage IIA	A248-26	True	ESCA	C1	GI.ESCC	0.074929257	0.38	0.14		0.8241	0.18100000000000002	-1.171	-1.4315	-0.4649	0.4548			0.81675567	1.7923249419999998	142.0	0.6389963120000001	19.0	13.0	0.458760104	1.325987248	18.0	2.528888682	36.0	0.7056998240000001	3.149440326	-1744.3746579999997	886.4416023	-3545.973389	0.0	1012.0	0.0	1012.0	8.695339376799712	7.473069088032197	-0.48833238450195204	5.7775686447154335	6.3203895780938115	1.0209871266375736	-2.917770732084279	-1.1526795099383853	1.5093195111395257
13722.58cfa832e4b0c9d6adf6d0c8	58cfa832e4b0c9d6adf6d0c8	TCGA-FS-A1ZN-01A-11D-A18Y_120605_SN1222_0112_AC0WJJACXX_s_2_rg.sorted.filtered.	WGS	TCGA-FS-A1ZN-01A-11D-A18Y_120605_SN1222_0112_AC0WJJACXX_s_2_rg.sorted	TCGA-FS-A1ZN-01A-11D-A18Y_120605_SN1222_0112_AC0WJJACXX_s_2_rg.sorted.bam	65.89		0.15	58cfa832e4b0c9d6adf6d0c8	TCGA-FS-A1ZN-01A-11D-A18Y_120605_SN1222_0112_AC0WJJACXX_s_2_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-FS-A1ZN-01A	9D86940D-50FB-4D2F-8B1E-539196885F46	Primary Tumor	Illumina HiSeq	497c930e-47cd-4669-a434-af770d331308	Skin	43.0	C6C66FAF-676B-4302-B825-143E1E72D04D	507A59F5-70A6-464C-ADA3-3E686414045A	TCGA-FS-A1ZN-01A-11D-A18Y-02	HG19_Broad_variant	TCGA-FS-A1ZN	TCGA-SKCM	730.0	s7372	Harvard Medical School	Essen	Germany	NO	T4b	N1a		Stage IIIA	A18Y-02	True	SKCM	C1	SKCM.BRAF_Hotspot_Mutants	0.059494897000000005	0.05	0.0	5.833910688	-0.0782	-0.032	-0.9117	-1.6182	-0.7455	0.1932	55.0	1.0	1.253713745	2.538005874			4.0	6.0		0.0	1.0	0.0	1.0		4.375358019	-1750.005607	474.99333039999993	-2893.867374	1.0	730.0	1.0	361.0	6.869252022680842	1.0602416139737105	-0.4627814499332801	6.1071119706339445	6.047169524267998	2.5670838299901697	-0.7621400520468966	4.986927910294288	3.02986527992345
13722.58cfa832e4b0c9d6adf6d0c9	58cfa832e4b0c9d6adf6d0c9	TCGA-IG-A3YB-01A-11D-A248_121207_SN1222_0162_BD1MA7ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-IG-A3YB-01A-11D-A248_121207_SN1222_0162_BD1MA7ACXX_s_3_rg.sorted	TCGA-IG-A3YB-01A-11D-A248_121207_SN1222_0162_BD1MA7ACXX_s_3_rg.sorted.bam	34.41		0.15	58cfa832e4b0c9d6adf6d0c9	TCGA-IG-A3YB-01A-11D-A248_121207_SN1222_0162_BD1MA7ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-IG-A3YB-01A	A1A233EA-5DDA-4EEB-BD92-6667E8B3EF57	Primary Tumor	Illumina HiSeq	6b51ea9f-5ca3-4973-bc0f-8df5ae95abbd	Esophagus	61.0	F936DE42-1441-4C4C-882A-DC67D332C125	335AAD40-B278-4EEC-BEE6-FC4F77C63370	TCGA-IG-A3YB-01A-11D-A248-26	HG19_Broad_variant	TCGA-IG-A3YB	TCGA-ESCA		s1911	MD Anderson - Institute for Applied Cancer Science	Asterand	Russia	NO	T3	N1		Stage IIIA	A248-26	True	ESCA	C3	GI.ESCC	0.142306403	0.42	0.11		-0.2755	-0.1335	0.1682	0.0928	0.4889	0.1112			0.402700095	1.4541947880000001	242.0	0.590715811	15.0	54.0	0.928317307	2.9502423739999997	24.0	4.762363101	142.0	0.9609623270000001	1.758071374	-1565.839191	-451.3902108	-2864.9781329999996	0.0	80.0	0.0	80.0	6.98100574072173	8.47391447792796	0.45441153448589955	4.988575576031524	7.726700076097739	1.891185249366067	-1.9924301646902063	-0.7472144018302207	1.4367737148801676
13722.58cfa832e4b0c9d6adf6d0cc	58cfa832e4b0c9d6adf6d0cc	TCGA-IG-A3QL-01A-11D-A248_121212_SN1120_0205_AC1F18ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-IG-A3QL-01A-11D-A248_121212_SN1120_0205_AC1F18ACXX_s_7_rg.sorted	TCGA-IG-A3QL-01A-11D-A248_121212_SN1120_0205_AC1F18ACXX_s_7_rg.sorted.bam	27.52		0.15	58cfa832e4b0c9d6adf6d0cc	TCGA-IG-A3QL-01A-11D-A248_121212_SN1120_0205_AC1F18ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-IG-A3QL-01A	0AC08ECF-4D70-48A4-9DFD-F44032551CB9	Primary Tumor	Illumina HiSeq	da10bdbe-12f7-41ed-b836-1689589d7ba2	Esophagus	54.0	D571A2B3-892B-46C4-883C-FDED4980492F	A48A75A1-B82B-4F4A-A04F-DFF6B1E801F1	TCGA-IG-A3QL-01A-11D-A248-26	HG19_Broad_variant	TCGA-IG-A3QL	TCGA-ESCA		s1824	MD Anderson - Institute for Applied Cancer Science	Asterand	Russia	NO	T2	N0		Stage IIA	A248-26	True	ESCA	C2	GI.ESCC	0.03676168				0.9666	0.336	-1.4948	-2.0336	0.3321	0.3765			0.996456129	1.9181780480000001	137.0	0.6946713290000001				0.0	1.0	1.820075975	7.0	0.935334027	3.136336498	-1858.212415	1072.5086900000001	-2550.800511	0.0	1071.0	0.0	1071.0	7.283791576399489	6.889761015609858	-0.8190427326494901	4.798884926611489	5.737081505671473	1.2365254073636847	-2.4849066497880004	-1.1526795099383853	2.055568140013175
13722.58cfa832e4b0c9d6adf6d0d0	58cfa832e4b0c9d6adf6d0d0	TCGA-IG-A3YA-01A-11D-A248_121211_SN208_0443_BC1H55ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-IG-A3YA-01A-11D-A248_121211_SN208_0443_BC1H55ACXX_s_1_rg.sorted	TCGA-IG-A3YA-01A-11D-A248_121211_SN208_0443_BC1H55ACXX_s_1_rg.sorted.bam	41.16		0.16	58cfa832e4b0c9d6adf6d0d0	TCGA-IG-A3YA-01A-11D-A248_121211_SN208_0443_BC1H55ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-IG-A3YA-01A	7AB6DE57-D659-47F1-A70F-1B67650E99D7	Primary Tumor	Illumina HiSeq	d20d3af7-3c79-446f-834f-9be861dc1490	Esophagus	53.0	AAADB48E-3C60-4AE4-B6EB-7B5F9C9D6544	A389CF30-6460-43E5-A895-6EBFC9555AF2	TCGA-IG-A3YA-01A-11D-A248-26	HG19_Broad_variant	TCGA-IG-A3YA	TCGA-ESCA		s1819	MD Anderson - Institute for Applied Cancer Science	Asterand	Russia	NO	T4	N0		Stage IIIA	A248-26	True	ESCA	C1	GI.ESCC	0.5311644670000001	0.77	0.1		0.8976	0.1785	0.617	1.0531	0.6428	0.6391	32.0		0.409166052	1.270568266	93.0	0.355351917	7.0	23.0	0.783525409	4.226044228	220.0	4.237556742	251.0	0.7669157240000001	3.7814715660000005	-373.20156569999995	1282.253734	-1682.496566	0.0	632.0	0.0	632.0	7.716906135298389	7.187063099344426	-0.28632052125727725	5.51968155796217	6.992907084903469	3.3722774557554276	-2.197224577336219	-0.19415601444095776	3.658597977012705
13722.58cfa832e4b0c9d6adf6d0d4	58cfa832e4b0c9d6adf6d0d4	TCGA-FY-A3I5-01B-11D-A221_120610_SN1120_0151_AC0WN0ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FY-A3I5-01B-11D-A221_120610_SN1120_0151_AC0WN0ACXX_s_1_rg.sorted	TCGA-FY-A3I5-01B-11D-A221_120610_SN1120_0151_AC0WN0ACXX_s_1_rg.sorted.bam	41.37		0.14	58cfa832e4b0c9d6adf6d0d4	TCGA-FY-A3I5-01B-11D-A221_120610_SN1120_0151_AC0WN0ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FY-A3I5-01B	52203FF5-57B2-4D56-8935-2FF1EB61D7B8	Primary Tumor	Illumina HiSeq	ed0cff3d-a985-40a9-b0df-ec57b3bcdd50	Thyroid	64.0	7AEC7C70-6A5A-48D5-A863-A8DB40D93097	C32A9B9D-B381-4492-9BBC-8F25B09D18C1	TCGA-FY-A3I5-01B-11D-A221-26	HG19_Broad_variant	TCGA-FY-A3I5	TCGA-THCA		s12119	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage III	A221-26	True	THCA	C3	THCA.1	0.18354059600000003	0.33	0.01		-1.8138	-0.3495	-0.1198	0.9082	-0.8449	-0.4002	4.0	0.0	0.058653094	0.32259201600000004	51.0	0.9367372509999999	14.0	0.0	0.925094535	2.9777644339999996	25.0	3.515739651	34.0	0.9969881490000001	1.48717949	80.1653088	-1382.820614	3090.105785	0.0	238.0	0.0	238.0	6.375058890797929	7.914343648837072	0.33465495543381807	5.856265097382762	7.160571846460692	1.0458731611256653	-0.5187937934151674	-0.7537718023763804	0.7112182056918472
13722.58cfa832e4b0c9d6adf6d0d8	58cfa832e4b0c9d6adf6d0d8	TCGA-G3-A25S-01A-11D-A16V-10_wgs_Illumina.filtered.	WGS	TCGA-G3-A25S-01A-11D-A16V-10_wgs_Illumina	TCGA-G3-A25S-01A-11D-A16V-10_wgs_Illumina.bam	82.14	1.93	0.08	58cfa832e4b0c9d6adf6d0d8	TCGA-G3-A25S-01A-11D-A16V-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-G3-A25S-01A	B865DEC4-F051-4FBE-9405-F832FF2010D7	Primary Tumor	Illumina HiSeq	95c222bc-3817-42a2-b237-911c68ec0cf0	Liver	64.0	D12BE3F6-68BC-4583-9478-FC01A0EB9387	C05ADC19-2E01-4712-A35A-69EEE4D40998	TCGA-G3-A25S-01A-11D-A16V-10	GRCh37-lite	TCGA-G3-A25S	TCGA-LIHC		s16686	Baylor College of Medicine	Alberta Health Services	Canada	NO	T1	N0	Hepatocellular Carcinoma	Stage I	A16V-10	True	LIHC	C4	LIHC.iCluster:3	0.134031874	0.33	0.26		-0.353	0.121	-0.4642	-0.7544	-0.8149	-1.3762	88.0	102.0	0.9407926409999999	3.39255528	228.0	0.9353563009999999	23.0	26.0				0.693147181	2.0	1.0	4.190898775	-1681.008836	-648.4079207000001	4208.804637	1.0	416.0	1.0	37.0	6.559048504692581	2.4368902309961777	0.40220068736375725	4.767289035464525	2.7626167214437922	1.9151439950413676	-1.7917594692280552	0.3257264904476145	1.5129433076776104
13722.58cfa832e4b0c9d6adf6d0dd	58cfa832e4b0c9d6adf6d0dd	TCGA-HW-7495-01A-11D-2022_130913_SN1440_0168_BD2B0UACXX_s_3_rg.sorted.filtered.	WGS	TCGA-HW-7495-01A-11D-2022_130913_SN1440_0168_BD2B0UACXX_s_3_rg.sorted	TCGA-HW-7495-01A-11D-2022_130913_SN1440_0168_BD2B0UACXX_s_3_rg.sorted.bam	107.0		0.15	58cfa832e4b0c9d6adf6d0dd	TCGA-HW-7495-01A-11D-2022_130913_SN1440_0168_BD2B0UACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HW-7495-01A	49967A57-7C12-46BB-8D71-CEBBB17C9935	Primary Tumor	Illumina HiSeq	10d85d7f-6926-453a-bfef-d1b9d129d9d1	Brain	45.0	1CCC7965-99A5-420A-B5AB-F9853B50E3B1	07DDE76E-E126-4D66-BA85-059F076B7D04	TCGA-HW-7495-01A-11D-2022-02	HG19_Broad_variant	TCGA-HW-7495	TCGA-LGG		s8577	Harvard Medical School	MSKCC	United States	NO			Oligodendroglioma		2022-02	True	LGG	C5	GBM_LGG.Codel	0.047911398	0.28	0.01		-1.7819	-0.446	-0.8379	-2.9591	-1.124	-0.9979	5.0	13.0	0.08890492300000001	0.444524617	44.0	0.078381093	2.0	5.0					0.0		3.4301969960000003	143.60698290000002	-362.9749838	-3451.693879	0.0	1078.0	0.0	1078.0	8.11661611738085	7.176973827138968	0.6180898982215047	6.270789426882519	3.6858282088138736	0.28295537309735497	-1.8458266904983305	-3.4911456183250946	-0.33513452512414976
13722.58cfa832e4b0c9d6adf6d0e2	58cfa832e4b0c9d6adf6d0e2	TCGA-IG-A3YC-01A-11D-A248_121207_SN1222_0161_AC1HJ0ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-IG-A3YC-01A-11D-A248_121207_SN1222_0161_AC1HJ0ACXX_s_5_rg.sorted	TCGA-IG-A3YC-01A-11D-A248_121207_SN1222_0161_AC1HJ0ACXX_s_5_rg.sorted.bam	24.61		0.15	58cfa832e4b0c9d6adf6d0e2	TCGA-IG-A3YC-01A-11D-A248_121207_SN1222_0161_AC1HJ0ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-IG-A3YC-01A	6A05288E-D051-40A5-9F4E-864AB806A5DC	Primary Tumor	Illumina HiSeq	a1261941-39f5-47ec-a6a4-ab07b298fb93	Esophagus	62.0	C754C363-924A-404A-9D60-4CA2A3930D2A	44EE541C-5657-43A9-9D56-6D88319E4617	TCGA-IG-A3YC-01A-11D-A248-26	HG19_Broad_variant	TCGA-IG-A3YC	TCGA-ESCA		s1622	MD Anderson - Institute for Applied Cancer Science	Asterand	Russia	NO	T3	N1		Stage IIIA	A248-26	True	ESCA	C2	GI.ESCC	0.401773573	0.75	0.31		0.5707	0.174	0.8222	1.5288	1.5736	0.5436	23.0		0.300955122	1.094382262	127.0	0.554292022	17.0	42.0	0.8311728420000001	4.278457611	172.0	4.608744422	167.0	0.90049824	5.035404379	-634.071289	583.1291259999999	-1624.631099	0.0	612.0	1.0	542.0	8.13402759080284	8.648171327253042	-0.5588097981151348	5.782652333639362	7.760868132252139	1.5157210572083375	-2.3513752571634776	-0.8873031950009029	2.0745308553234723
13722.58cfa832e4b0c9d6adf6d0f0	58cfa832e4b0c9d6adf6d0f0	TCGA-HC-7077-01A-11D-1957_130412_SN590_0224_BC1YMJACXX_s_6_rg.sorted.filtered.	WGS	TCGA-HC-7077-01A-11D-1957_130412_SN590_0224_BC1YMJACXX_s_6_rg.sorted	TCGA-HC-7077-01A-11D-1957_130412_SN590_0224_BC1YMJACXX_s_6_rg.sorted.bam	192.7		0.15	58cfa832e4b0c9d6adf6d0f0	TCGA-HC-7077-01A-11D-1957_130412_SN590_0224_BC1YMJACXX_s_6_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7077-01A	92252560-5984-41F6-A4B5-A3AA8654C0C8	Primary Tumor	Illumina HiSeq	bea10bd4-1049-4162-bb70-0bf5073199c6	Prostate	64.0	F3E4CC00-D6FE-4291-BB07-8E501E772CE1	EFC4EC34-58ED-40DE-8E0D-BCBA6320BF4C	TCGA-HC-7077-01A-11D-1957-02	HG19_Broad_variant	TCGA-HC-7077	TCGA-PRAD		s4154	Harvard Medical School	International Genomics Consortium	United States	NO	T3a		Prostate Adenocarcinoma Acinar Type		1957-02	True	PRAD	C4	PRAD.1-ERG	0.017088248	0.35	0.24	0.856085146	-1.1888	-0.2075	-1.7156	-1.5424	-0.7123	-0.7626	15.0	22.0	0.34526865700000003	1.35230224	190.0	0.09621801	2.0	8.0				1.098612289	3.0	1.0	1.701984269	-950.4115396	-1099.560477	3497.74452	0.0	2115.0	0.0	2115.0	8.174515071406839	8.837100411162755	-0.2796077689715005	6.830780324705744	8.298103910430068	3.6746584427989935	-1.3437347467010947	-0.5389965007326873	3.954266211770494
13722.58cfa832e4b0c9d6adf6d0f2	58cfa832e4b0c9d6adf6d0f2	TCGA-HC-7213-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-HC-7213-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_6_rg.sorted	TCGA-HC-7213-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_6_rg.sorted.bam	408.3		0.15	58cfa832e4b0c9d6adf6d0f2	TCGA-HC-7213-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7213-01A	26EEFAA1-1666-4CE1-8CF4-F6FABFF81FD2	Primary Tumor	Illumina HiSeq	14482ee6-0af5-43ad-bc2b-c9574446f6b9	Prostate	53.0	0CB3DFFD-1521-4887-B19C-94DCD340D306	6D368C2B-4F13-4006-A487-7DB0ADA55C6A	TCGA-HC-7213-01A-11D-2111-02	HG19_Broad_variant	TCGA-HC-7213	TCGA-PRAD		s3812	Harvard Medical School	International Genomics Consortium	United States	NO	T3b	N0	Prostate Adenocarcinoma Acinar Type		2111-02	True	PRAD	C3	PRAD.1-ERG	0.076176651	0.28	0.28	0.422280314	-0.2291	-0.0535	-0.5366	-0.3697	-0.5979	-0.0835	18.0	0.0	0.336892707	0.949424901	124.0	0.854934544	11.0	19.0		0.0	1.0	2.890371758	18.0	1.0	1.8332132540000001	-577.0603702999999	-240.67927790000002	1606.012038	0.0	1219.0	1.0	170.0	8.800505731350077	9.136938444220737	0.03393013290353286	7.274449427855027	8.539101443465118	2.2493252296344544	-1.5260563034950494	-0.5978370007556202	2.215395096730921
13722.58cfa832e4b0c9d6adf6d0f5	58cfa832e4b0c9d6adf6d0f5	TCGA-HC-7209-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-HC-7209-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_6_rg.sorted	TCGA-HC-7209-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_6_rg.sorted.bam	121.3		0.15	58cfa832e4b0c9d6adf6d0f5	TCGA-HC-7209-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7209-01A	582D1177-73B0-4A9C-8505-70D6B402BD01	Primary Tumor	Illumina HiSeq	d228a749-988a-4fcb-9f15-e334295216fb	Prostate	60.0	AA7850AC-FB78-433B-8D55-A24C05935DB5	3C59E423-E1A6-4C67-8A88-63A0817B856E	TCGA-HC-7209-01A-11D-2111-02	HG19_Broad_variant	TCGA-HC-7209	TCGA-PRAD		s3625	Harvard Medical School	International Genomics Consortium	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		2111-02	True	PRAD	C3	PRAD.1-ERG	0.098638016	0.45	0.0	2.585456805	-1.1836	-0.2585	-0.7964	-0.9136	-0.3903	-0.2904	6.0	0.0	0.150530305	0.481696975	133.0	0.042265110999999994	0.0	13.0				1.5607104090000001	5.0	0.9697239	1.8416419069999999	173.23169380000002	-474.7499368	3481.445996	0.0	440.0	0.0	440.0	8.761184575243286	8.77107931006496	-0.24201863107630073	6.601700325889913	8.408173816375593	2.5407789965337235	-2.1594842493533726	-0.36290549368936853	2.7827976276100244
13722.58cfa832e4b0c9d6adf6d10e	58cfa832e4b0c9d6adf6d10e	TCGA-HW-7489-01A-11D-2022_130913_SN1440_0168_BD2B0UACXX_s_2_rg.sorted.filtered.	WGS	TCGA-HW-7489-01A-11D-2022_130913_SN1440_0168_BD2B0UACXX_s_2_rg.sorted	TCGA-HW-7489-01A-11D-2022_130913_SN1440_0168_BD2B0UACXX_s_2_rg.sorted.bam	56.0		0.14	58cfa832e4b0c9d6adf6d10e	TCGA-HW-7489-01A-11D-2022_130913_SN1440_0168_BD2B0UACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HW-7489-01A	6957D45E-7CCB-457D-800D-C2A2037F4F01	Primary Tumor	Illumina HiSeq	e81e0ec5-b546-421b-a1ee-5adf17fd07c0	Brain	38.0	B4E032D1-B12E-4DC0-8978-899760F0A245	BBCC5F2C-08F5-424D-8A66-099084F3C47E	TCGA-HW-7489-01A-11D-2022-02	HG19_Broad_variant	TCGA-HW-7489	TCGA-LGG		s8578	Harvard Medical School	MSKCC	United States	NO			Oligoastrocytoma		2022-02	True	LGG	C5	GBM_LGG.G-CIMP-high	0.147318025	0.49	0.12		-1.7001	-0.3915	-0.3996	-2.5613	-1.1333	-1.0921	11.0	0.0	0.177864871	0.533594613	89.0	0.083681934	0.0	9.0					0.0		3.4333791089999997	409.7522453	-368.5659468	-4094.130815	1.0	1262.0	1.0	1262.0	7.08501502680141	7.734570060838501	2.94677542882746	6.973789391691186	2.423007467540444	1.4111036666329688	-0.1112256351102241	-5.311562593298057	-1.535671762194491
13722.58cfa832e4b0c9d6adf6d114	58cfa832e4b0c9d6adf6d114	TCGA-G2-A2ES-01A-11D-A17R_120921_SN208_0430_AC18CWACXX_s_7_rg.sorted.filtered.	WGS	TCGA-G2-A2ES-01A-11D-A17R_120921_SN208_0430_AC18CWACXX_s_7_rg.sorted	TCGA-G2-A2ES-01A-11D-A17R_120921_SN208_0430_AC18CWACXX_s_7_rg.sorted.bam	46.96		0.16	58cfa832e4b0c9d6adf6d114	TCGA-G2-A2ES-01A-11D-A17R_120921_SN208_0430_AC18CWACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-G2-A2ES-01A	72D8EAE8-9EFB-45B2-ACBD-82C6B5732E38	Primary Tumor	Illumina HiSeq	5922785f-2336-403c-9cb6-0843df3383b5	Bladder	85.0	C2288290-F17A-435C-90E7-5A4913F0C076	52FA3B0A-B5C7-4A74-A798-0DB359029147	TCGA-G2-A2ES-01A-11D-A17R-02	HG19_Broad_variant	TCGA-G2-A2ES	TCGA-BLCA		s2919	Harvard Medical School	MD Anderson	United States	NO	T3b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A17R-02	True	BLCA	C2	BLCA.3	0.330335698	0.45	0.03	11.26744067	0.8603	0.3135	-0.0369	-0.3484	1.7207	0.1367	152.0	86.0	4.131090246	11.06339922	230.0	0.237357608	4.0	16.0				2.630253356	15.0	0.971272008	1.8629172669999998	-467.9760653	825.3543193	-1454.2090779999999	1.0	1004.0	1.0	897.0	6.935273165018877	7.15955107286951	0.10309340833889402	5.574296611883276	6.782256841728042	0.8699131675092978	-1.3609765531356008	-0.37729423114146776	0.7668197591704038
13722.58cfa832e4b0c9d6adf6d116	58cfa832e4b0c9d6adf6d116	TCGA-JX-A3Q0-01A-11D-A245_140124_SN1440_0179_BD2DRDACXX_s_3_rg.sorted.filtered.	WGS	TCGA-JX-A3Q0-01A-11D-A245_140124_SN1440_0179_BD2DRDACXX_s_3_rg.sorted	TCGA-JX-A3Q0-01A-11D-A245_140124_SN1440_0179_BD2DRDACXX_s_3_rg.sorted.bam	42.52		0.14	58cfa832e4b0c9d6adf6d116	TCGA-JX-A3Q0-01A-11D-A245_140124_SN1440_0179_BD2DRDACXX_s_3_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-JX-A3Q0-01A	20280122-A66A-4C83-8F25-0B9D97558DC2	Primary Tumor	Illumina HiSeq	20d5be50-f8a2-406a-9415-bc65cdff0cad	Cervix	63.0	04FFDFC0-A73F-47AE-9014-73870B69AD91	A7EE4E31-77DF-470B-A748-87BB4DF76FD5	TCGA-JX-A3Q0-01A-11D-A245-26	HG19_Broad_variant	TCGA-JX-A3Q0	TCGA-CESC		s1218	MD Anderson - Institute for Applied Cancer Science	Washington University	United States	NO	T3	N0	Cervical Squamous Cell Carcinoma		A245-26	True	CESC	C2		0.20212129899999998	0.24	0.02		0.9940000000000001	0.2555	0.2295	0.8715	1.7268	-0.4389			5.990398923	14.88312291	117.0	0.743989193	10.0	5.0	0.884732858	2.395900993	15.0	3.0904599239999997	23.0	0.9856372590000001	2.980928758	182.1313467	144.37855530000002	421.80718509999997	0.0	6375.0	0.0	6375.0	9.026177120302856	7.609614400144105	0.16099827161013724	6.674801863139379	7.261307705875889	1.682089653463084	-2.3513752571634776	-0.3483066942682158	1.5210913818529468
13722.58cfa832e4b0c9d6adf6d11e	58cfa832e4b0c9d6adf6d11e	TCGA-FV-A4ZQ-01A-11D-A25V-10_wgs_Illumina.filtered.	WGS	TCGA-FV-A4ZQ-01A-11D-A25V-10_wgs_Illumina	TCGA-FV-A4ZQ-01A-11D-A25V-10_wgs_Illumina.bam	41.34		0.08	58cfa832e4b0c9d6adf6d11e	TCGA-FV-A4ZQ-01A-11D-A25V-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-FV-A4ZQ-01A	65E430E1-0C9A-4045-83A9-653B7CFF811D	Primary Tumor	Illumina HiSeq	34884ff9-c16b-4800-9b84-dd3ec001b261	Liver	52.0	56DAAD30-A336-4311-9FEB-26CF3E48C734	D02597F8-3AC7-4165-A65F-0E134E5D215B	TCGA-FV-A4ZQ-01A-11D-A25V-10	GRCh37-lite	TCGA-FV-A4ZQ	TCGA-LIHC		s16592	Baylor College of Medicine	International Genomics Consortium	United States	NO	T1	NX	Hepatocellular Carcinoma	Stage I	A25V-10	True	LIHC	C2	LIHC.iCluster:2	0.318046916	0.36	0.05		0.4409	0.107	0.5786	1.6467	0.0257	-0.9656	34.0	0.0	0.646461181	1.831640014	120.0	0.9476795859999999	11.0	15.0	0.8153767590000001	3.903609503	120.0	3.5916999310000004	44.0	0.949133177	1.097625065	-804.5052413999999	113.8113511	1498.422467	0.0	12.0	0.0	12.0	6.909686745831884	2.287158374792938	1.0747355297355439	5.904164880229787	4.722788016258403	2.75891472656746	-1.0055218656020979	2.4356296414654652	1.684179196831916
13722.58cfa832e4b0c9d6adf6d11f	58cfa832e4b0c9d6adf6d11f	TCGA-IR-A3LK-01A-12D-A20X_140417_SN590_0248_AC3EUFACXX_s_3_rg.sorted.filtered.	WGS	TCGA-IR-A3LK-01A-12D-A20X_140417_SN590_0248_AC3EUFACXX_s_3_rg.sorted	TCGA-IR-A3LK-01A-12D-A20X_140417_SN590_0248_AC3EUFACXX_s_3_rg.sorted.bam	71.39		0.16	58cfa832e4b0c9d6adf6d11f	TCGA-IR-A3LK-01A-12D-A20X_140417_SN590_0248_AC3EUFACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE		Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-IR-A3LK-01A	B79558C5-1DB2-4B1E-A7B8-EFBD19AA855E	Primary Tumor	Illumina HiSeq	1c6981be-5fe3-4898-ba63-e0cd0eecc5e5	Cervix	69.0	DCA9FF1F-DD32-43DD-8FD4-446D014F5DB8	9E7C0BE8-042F-4B5F-BFE9-E993081589AD	TCGA-IR-A3LK-01A-12D-A20X-26	HG19_Broad_variant	TCGA-IR-A3LK	TCGA-CESC		s1376	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T1b2	N0	Cervical Squamous Cell Carcinoma		A20X-26	True	CESC	C2		0.130143932	0.16	0.02	23.41662726	1.2126	0.37	0.0467	0.0253	0.7478	-0.3536	632.0		8.65114789	25.48998932	183.0	0.20857507	6.0	27.0	0.6158941410000001	0.426905287	2.0	2.505289991	13.0	0.976740528	2.2480584180000003	-65.17325761	353.5809988	-2136.019929	1.0	908.0	1.0	574.0	7.556079415933762	6.737263473941759	1.8568361501554198	5.764319946705707	5.820972742067605	1.3494616241748467	-1.7917594692280547	-0.9162907318741551	-0.5073745259805731
13722.58cfa832e4b0c9d6adf6d126	58cfa832e4b0c9d6adf6d126	TCGA-FY-A3ON-01A-11D-A221_120610_SN1120_0152_BD13TDACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FY-A3ON-01A-11D-A221_120610_SN1120_0152_BD13TDACXX_s_1_rg.sorted	TCGA-FY-A3ON-01A-11D-A221_120610_SN1120_0152_BD13TDACXX_s_1_rg.sorted.bam	44.16		0.14	58cfa832e4b0c9d6adf6d126	TCGA-FY-A3ON-01A-11D-A221_120610_SN1120_0152_BD13TDACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FY-A3ON-01A	4D1AEC67-C345-4721-8EE8-356B0DFF009B	Primary Tumor	Illumina HiSeq	276539e6-e471-4dc2-96e7-0c80fb486af1	Thyroid	20.0	1392A49C-87BC-45E7-B7D2-ACD53E921467	68FEC551-495D-47E6-BF85-FBD422FC68D6	TCGA-FY-A3ON-01A-11D-A221-26	HG19_Broad_variant	TCGA-FY-A3ON	TCGA-THCA		s12121	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T2	N1	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A221-26	True	THCA	C3	THCA.3	0.116124497	0.05	0.0		-1.3796	-0.231	0.0357	0.3233	-0.1509	0.0547	2.0	1.0	0.0	0.147961835	63.0	6.720000000000001e-05	0.0	0.0	0.89323712	3.476318355	49.0	2.566598918	14.0	0.9725438279999999	1.2649733029999999	904.5574252999999	-926.3978890000001	1736.1373870000002	0.0	595.0	0.0	595.0	6.6009021039184095	8.579519039123742	0.4362041472651864	5.734091429307624	7.511678409122386	2.370609152690051	-0.8668106746107855	-1.0678406300013559	1.9344050054248645
13722.58cfa832e4b0c9d6adf6d128	58cfa832e4b0c9d6adf6d128	TCGA-G2-A3IE-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-G2-A3IE-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_3_rg.sorted	TCGA-G2-A3IE-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_3_rg.sorted.bam	48.07		0.15	58cfa832e4b0c9d6adf6d128	TCGA-G2-A3IE-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-G2-A3IE-01A	C65BA2B8-E867-42E8-BBD0-C2CDF5130CFB	Primary Tumor	Illumina HiSeq	171a2a97-43d5-41cc-a9ae-2f685c3ed80f	Bladder	51.0	FC529667-D055-4FC3-806D-C0431D9A6CFF	5C93720D-56AA-4324-8543-9B37351BC9B6	TCGA-G2-A3IE-01A-11D-A210-26	HG19_Broad_variant	TCGA-G2-A3IE	TCGA-BLCA	612.0	s2917	MD Anderson - Institute for Applied Cancer Science	MD Anderson	United States	NO		NX	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A210-26	True	BLCA	C3	BLCA.1	0.186864643	0.31	0.38	2.264162761	-0.2322	-0.0845	-1.0859999999999999	-0.5488	-1.5018	-0.3765	176.0	149.0	3.374835763	9.81488933	160.0	0.449689904	4.0	41.0	0.9640518240000001	1.551581555	5.0	1.33217904	4.0	0.960964047	2.339174589	-2265.957488	-446.35572869999993	1338.551878	1.0	612.0	1.0	612.0	6.777203569672932	6.959628708089298	0.9859749426912813	6.00401368143945	7.123931759380573	0.3455016433406072	-0.7731898882334818	0.16430305129127643	-0.6404732993506741
13722.58cfa832e4b0c9d6adf6d12c	58cfa832e4b0c9d6adf6d12c	TCGA-G2-A2EK-01A-22D-A18D_120913_SN208_0429_AC187FACXX_s_3_rg.sorted.filtered.	WGS	TCGA-G2-A2EK-01A-22D-A18D_120913_SN208_0429_AC187FACXX_s_3_rg.sorted	TCGA-G2-A2EK-01A-22D-A18D_120913_SN208_0429_AC187FACXX_s_3_rg.sorted.bam	16.85		0.18	58cfa832e4b0c9d6adf6d12c	TCGA-G2-A2EK-01A-22D-A18D_120913_SN208_0429_AC187FACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-G2-A2EK-01A	5DA1CB68-C438-4DDC-999F-90AED0C4BD7A	Primary Tumor	Illumina HiSeq	f98c8702-90e5-4e7a-ad12-d11a9af57bf5	Bladder	57.0	FF1691F2-DF11-4068-8D8D-A778F384EC60	8A75CF19-7645-489D-AAEC-5D9AD293C4B1	TCGA-G2-A2EK-01A-22D-A18D-02	HG19_Broad_variant	TCGA-G2-A2EK	TCGA-BLCA		s2725	Harvard Medical School	MD Anderson	United States	NO		N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A18D-02	True	BLCA	C3	BLCA.2	0.310219233	0.46	0.04	2.854581874	-0.47200000000000003	-0.14300000000000002	-0.537	0.5576	-0.6163	-0.0656	38.0	1.0	0.441904795	1.7970794980000002	152.0	0.22885976100000002	4.0	21.0		0.0	1.0	2.770973881	17.0	0.9780322	5.162585058	-1609.815811	-403.71783700000003	1628.487077	0.0	485.0	1.0	485.0	5.119350999546732	9.807939844524212	-0.3819489839866509	5.86542058156102	8.942942407037608	0.5924458570658202	0.7460695820142877	-0.8649974374866045	0.9743948410524711
13722.58cfa832e4b0c9d6adf6d12e	58cfa832e4b0c9d6adf6d12e	TCGA-G2-A3IB-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-G2-A3IB-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_1_rg.sorted	TCGA-G2-A3IB-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_1_rg.sorted.bam	39.31		0.15	58cfa832e4b0c9d6adf6d12e	TCGA-G2-A3IB-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_1_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-G2-A3IB-01A	AF53D51E-0B5C-437F-A1C0-EC5F55C49364	Primary Tumor	Illumina HiSeq	f78443a3-8c1b-429a-93c3-fcd93f3c6d55	Bladder	66.0	791E4058-E872-4AF8-A431-F5782811F02A	80F634F1-C34C-40CD-9F9B-BBFC18E9DE6E	TCGA-G2-A3IB-01A-11D-A210-26	HG19_Broad_variant	TCGA-G2-A3IB	TCGA-BLCA		s2726	MD Anderson - Institute for Applied Cancer Science	MD Anderson	United States	NO		NX	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A210-26	True	BLCA	C2	BLCA.3	0.087293126	0.09	0.05	0.740084697	0.7584	0.1945	-1.0832	-1.8313	0.6045	0.0552	40.0	10.0	0.7187844790000001	2.593874425	140.0	0.854945339	6.0	16.0					0.0		1.9778316569999999	-979.9105225	998.4914572999999	-1898.908909	1.0	220.0	1.0	220.0	7.129845644311688	8.773055595293172	-0.4612747140292497	6.490765685022018	7.717002921043859	2.0395107643821078	-0.6390799592896697	-1.056052674249314	2.5007854784113572
13722.58cfa832e4b0c9d6adf6d130	58cfa832e4b0c9d6adf6d130	TCGA-FV-A3I1-01A-11D-A22F-10_wgs_Illumina.filtered.	WGS	TCGA-FV-A3I1-01A-11D-A22F-10_wgs_Illumina	TCGA-FV-A3I1-01A-11D-A22F-10_wgs_Illumina.bam	39.14		0.08	58cfa832e4b0c9d6adf6d130	TCGA-FV-A3I1-01A-11D-A22F-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-FV-A3I1-01A	BFD20D71-18A5-4F01-8D56-84378AD92359	Primary Tumor	Illumina HiSeq	137dd060-0c76-4ad8-b447-bcf55d593f0c	Liver	81.0	A744BE68-D008-4847-A11D-89918A419A5F	992D9566-B1DA-421A-BF36-D23382B115FA	TCGA-FV-A3I1-01A-11D-A22F-10	GRCh37-lite	TCGA-FV-A3I1	TCGA-LIHC		s16986	Baylor College of Medicine	International Genomics Consortium	United States	NO	T2	N0	Hepatocellular Carcinoma	Stage II	A22F-10	True	LIHC	C3	LIHC.iCluster:3	0.270235312	0.31	0.25		-0.2585	-0.156	0.1057	0.132	0.267	-0.2736	11.0	1.0	0.472103503	1.615090933	141.0	0.31294987399999996	9.0	15.0	0.815088343	2.151064867	14.0	2.6156305769999997	14.0	0.99112306	2.944539602	-795.0220491	-369.3485247	4882.041035	1.0	247.0	0.0	247.0	6.576005208696254	1.6104271719834031	-0.7659674290300422	5.459043781359948	4.574499121576634	1.866198074547295	-1.1169614273363067	2.9640719495932313	2.6321655035773373
13722.58cfa832e4b0c9d6adf6d132	58cfa832e4b0c9d6adf6d132	TCGA-FY-A3R6-01A-11D-A221_120611_SN1222_0115_BD141KACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FY-A3R6-01A-11D-A221_120611_SN1222_0115_BD141KACXX_s_1_rg.sorted	TCGA-FY-A3R6-01A-11D-A221_120611_SN1222_0115_BD141KACXX_s_1_rg.sorted.bam	10.85		0.16	58cfa832e4b0c9d6adf6d132	TCGA-FY-A3R6-01A-11D-A221_120611_SN1222_0115_BD141KACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FY-A3R6-01A	905469D2-4C97-4293-A20C-1B1F0462A25D	Primary Tumor	Illumina HiSeq	bd320251-720a-4498-a699-419a2544fe75	Thyroid	57.0	65414BA0-8800-4626-9488-10D79274CF32	EFF7FEA8-DF07-4DAD-BD26-7384906844E9	TCGA-FY-A3R6-01A-11D-A221-26	HG19_Broad_variant	TCGA-FY-A3R6	TCGA-THCA		s12258	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T2	N1b	Thyroid Papillary Carcinoma - Classical/usual	Stage IVA	A221-26	True	THCA	C3	THCA.2	0.331763037	0.52	0.01		-1.0914	-0.213	0.7571	2.0103	0.21600000000000003	0.0435	6.0		0.08695315	0.173906299	55.0	1.7899999999999998e-05	0.0	0.0	0.886360447	4.988100768	278.0	3.6716556010000003	40.0	0.995330871	1.559055595	918.6512104000001	-326.3112202	2050.366426	0.0	423.0	0.0	423.0	7.5256399750415355	8.503060459839181	0.15912982682998467	5.733880505813481	6.962615418892032	1.401732967434827	-1.791759469228055	-1.5404450409471488	1.2426031406048423
13722.58cfa832e4b0c9d6adf6d134	58cfa832e4b0c9d6adf6d134	TCGA-G2-A3VY-01A-11D-A233_120913_SN208_0428_BC188KACXX_s_6_rg.sorted.filtered.	WGS	TCGA-G2-A3VY-01A-11D-A233_120913_SN208_0428_BC188KACXX_s_6_rg.sorted	TCGA-G2-A3VY-01A-11D-A233_120913_SN208_0428_BC188KACXX_s_6_rg.sorted.bam	27.44		0.15	58cfa832e4b0c9d6adf6d134	TCGA-G2-A3VY-01A-11D-A233_120913_SN208_0428_BC188KACXX_s_6_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-G2-A3VY-01A	CD50C69F-0F45-4C57-B61A-8C6B41AB4F7E	Primary Tumor	Illumina HiSeq	fc9767fe-ddfb-4540-b151-0a80300c0a1d	Bladder	66.0	5A66149F-8FB0-41BC-880C-56D5541E3D94	8263C8A3-7CE5-4487-B8A1-29CE9417D1E3	TCGA-G2-A3VY-01A-11D-A233-26	HG19_Broad_variant	TCGA-G2-A3VY	TCGA-BLCA		s2914	MD Anderson - Institute for Applied Cancer Science	MD Anderson	United States	NO			Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A233-26	True	BLCA	C4	BLCA.1	0.048072164	0.1	0.28	16.94879183	0.5767	0.0425	-1.601	-2.2341	-1.4483	-0.7554	173.0	148.0	5.976801137000001	19.28876731	494.0	0.780450214	17.0	59.0				0.0	1.0		6.616884005	-2612.834609	-36.28823114	-1686.054707	0.0	536.0	0.0	536.0	6.939403010661296	9.229347475955903	2.2472193026500644	6.137056538136358	8.3820496155687	0.06730368189610658	-0.8023464725249374	-0.8472978603872034	-2.179915620753958
13722.58cfa832e4b0c9d6adf6d144	58cfa832e4b0c9d6adf6d144	TCGA-KL-8325-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KL-8325-01A-11D-2310-10_wgs_Illumina	TCGA-KL-8325-01A-11D-2310-10_wgs_Illumina.bam	258.3		0.05	58cfa832e4b0c9d6adf6d144	TCGA-KL-8325-01A-11D-2310-10_wgs_Illumina.bam	Dead	FEMALE	WHITE		Kidney Chromophobe	Aligned reads	TCGA-KL-8325-01A	6101FFE6-2EF6-4256-9D6B-A7C545836995	Primary Tumor	Illumina HiSeq	61d8317e-d85d-4447-8c11-18c8f719fbdd	Kidney	56.0	79C48BEA-33E0-49E6-84F7-6103DA654642	9FC0E0E8-1B0F-400C-B4CF-126193283695	TCGA-KL-8325-01A-11D-2310-10	GRCh37-lite	TCGA-KL-8325	TCGA-KICH	725.0	s16423	Baylor College of Medicine	MSKCC	United States	NO	T2	NX	Kidney Chromophobe	Stage II	2310-10	True	KICH	C5	KICH.Eosin.0	0.00594651	0.04	0.0		-2.2882	-0.4745	-1.0179	-2.3245	-0.9968	-1.1136	5.0		0.156450399	0.417201064	83.0	0.947724256	12.0	0.0				0.693147181	2.0	1.0	1.093723607	-882.8772905999999	-1745.264602	3172.797257	1.0	725.0	0.0	725.0	5.469114437490038	2.496894326308462	-0.019025306001269282	4.1473585975077185	3.9230463617195888	5.867277118466102	-1.3217558399823197	1.4261520354111266	5.886302424467372
13722.58cfa832e4b0c9d6adf6d153	58cfa832e4b0c9d6adf6d153	TCGA-FU-A3YQ-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_6_rg.sorted.filtered.	WGS	TCGA-FU-A3YQ-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_6_rg.sorted	TCGA-FU-A3YQ-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_6_rg.sorted.bam	36.15		0.15	58cfa832e4b0c9d6adf6d153	TCGA-FU-A3YQ-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-FU-A3YQ-01A	6E01248B-C551-4F52-8066-CB2D26EB6394	Primary Tumor	Illumina HiSeq	104b02af-20c0-4d30-ba14-f5028b3a3ee4	Cervix	35.0	84A97589-63AE-4151-89F3-40F5AA9DE72E	5C95B361-B203-400F-B18A-8375849F5B84	TCGA-FU-A3YQ-01A-11D-A232-26	HG19_Broad_variant	TCGA-FU-A3YQ	TCGA-CESC		s1205	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T1b1	N0	Cervical Squamous Cell Carcinoma		A232-26	True	CESC	C2		0.49629922600000004	0.66	0.05	61.64500427	0.9074	0.1955	0.5877	1.5389	1.4356	0.2615	35.0	1.0	0.512107616	1.3136673620000001	54.0	0.135328857	4.0	13.0	0.888062968	4.631191327	184.0	3.689669564	41.0	0.9935634740000001	1.5077724559999999	130.82683640000002	627.529261	-2641.4259	0.0	861.0	0.0	861.0	7.772542167989176	6.903460354699256	-0.2799571630425237	5.575317590652957	5.904931524588129	1.972358796539857	-2.197224577336219	-0.998528830111127	2.2523159595823805
13722.58cfa832e4b0c9d6adf6d155	58cfa832e4b0c9d6adf6d155	TCGA-G9-6361-01A-21D-1957_130405_SN590_0222_BD21LGACXX_s_6_rg.sorted.filtered.	WGS	TCGA-G9-6361-01A-21D-1957_130405_SN590_0222_BD21LGACXX_s_6_rg.sorted	TCGA-G9-6361-01A-21D-1957_130405_SN590_0222_BD21LGACXX_s_6_rg.sorted.bam	19.7	1.9	0.15	58cfa832e4b0c9d6adf6d155	TCGA-G9-6361-01A-21D-1957_130405_SN590_0222_BD21LGACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6361-01A	71D14304-CCB0-4A4C-B935-8C014CA75FD0	Primary Tumor	Illumina HiSeq	4fc66c05-8bf3-4a56-8bfe-6d20c3195258	Prostate	61.0	A369C190-964E-471C-878A-D8FADE7CF992	54B8E171-9BCC-469D-9315-114FE2C57DC1	TCGA-G9-6361-01A-21D-1957-02	HG19_Broad_variant	TCGA-G9-6361	TCGA-PRAD		s3795	Harvard Medical School	Roswell Park	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1957-02	True	PRAD	C3	PRAD.1-ERG	0.060667773	0.27	0.11	3.1011793589999996	-1.7745	-0.095	-1.1485	-1.163	-1.2046	-0.1742	12.0	2.0	0.201333449	0.8628576370000001	216.0	0.10454984	1.0	7.0							2.075722618	-259.4347017	-681.7078629	2946.916482	0.0	1415.0	0.0	1415.0	7.940049686612598	7.857722537215675	0.18331160142682856	5.542154413814227	7.046792320999347		-2.3978952727983707	-0.8109302162163288	
13722.58cfa832e4b0c9d6adf6d158	58cfa832e4b0c9d6adf6d158	TCGA-IR-A3LF-01A-21D-A232_140124_SN1120_0292_BD2F1HACXX_s_7_rg.sorted.filtered.	WGS	TCGA-IR-A3LF-01A-21D-A232_140124_SN1120_0292_BD2F1HACXX_s_7_rg.sorted	TCGA-IR-A3LF-01A-21D-A232_140124_SN1120_0292_BD2F1HACXX_s_7_rg.sorted.bam	36.63		0.15	58cfa832e4b0c9d6adf6d158	TCGA-IR-A3LF-01A-21D-A232_140124_SN1120_0292_BD2F1HACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE		Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-IR-A3LF-01A	785DDEA1-399D-47D8-B2B0-39E95EAA24B5	Primary Tumor	Illumina HiSeq	aba44461-5b2e-40f7-9e8e-262aee825e6c	Cervix	64.0	B6A74A02-CD3B-4F0A-BB2F-F90C1D3F6D14	02D65CAC-E751-493F-A4FB-3DDB1400EFAC	TCGA-IR-A3LF-01A-21D-A232-26	HG19_Broad_variant	TCGA-IR-A3LF	TCGA-CESC		s1216	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T1b1	N0	Endocervical Adenocarcinoma of the Usual Type		A232-26	True	CESC	C2		0.089295753	0.75	0.16	7.410856037	1.0563	0.1715	-0.1221	0.9899	0.9134	-0.0425	41.0	17.0	0.9579188259999999	2.071777927	66.0	0.143262264	6.0	22.0	0.9279757009999999	1.286447482	4.0	3.233239348	28.0	0.970300394	2.8818972080000003	-525.6124524	801.3404017000001	-1478.588185	0.0	2949.0	0.0	2949.0	8.005450480587763	8.649423738307712	-0.07384797566985657	6.347222403984231	7.550811449639603	2.742018195753232	-1.6582280766035324	-1.0986122886681098	2.815866171423089
13722.58cfa832e4b0c9d6adf6d160	58cfa832e4b0c9d6adf6d160	TCGA-IG-A4P3-01A-11D-A267_131018_SN590_0240_AC2MW5ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-IG-A4P3-01A-11D-A267_131018_SN590_0240_AC2MW5ACXX_s_3_rg.sorted	TCGA-IG-A4P3-01A-11D-A267_131018_SN590_0240_AC2MW5ACXX_s_3_rg.sorted.bam	40.74		0.15	58cfa832e4b0c9d6adf6d160	TCGA-IG-A4P3-01A-11D-A267_131018_SN590_0240_AC2MW5ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-IG-A4P3-01A	6594ACD5-4D2A-4CC5-8CF8-4064E252C5F6	Primary Tumor	Illumina HiSeq	a5b7767c-9dba-49bf-8711-9a76a0ab0e4f	Esophagus	48.0	784021B2-5F94-48F9-9DF7-854B4FBDF802	84882FB6-6ED6-42E8-9179-90CE089C4664	TCGA-IG-A4P3-01A-11D-A267-26	HG19_Broad_variant	TCGA-IG-A4P3	TCGA-ESCA		s1826	MD Anderson - Institute for Applied Cancer Science	Asterand	Ukraine	NO	T2	N1		Stage IIB	A267-26	True	ESCA	C2	GI.ESCC	0.42491610700000004	0.52	0.32		0.7478	0.243	0.4802	1.7195	1.4646	0.2833	114.0		0.9369130309999999	3.841343428	229.0	0.502236994	8.0	52.0	0.8401172579999999	4.789041027	299.0				3.323513123	77.45434428	787.4762757999999	-1590.275649	1.0	567.0	1.0	567.0	7.910774014366115	8.200471293142462	0.20497958068653854	5.6594822157596205	7.047791783204076	1.5041792349554957	-2.251291798606495	-1.1526795099383853	1.299199654268957
13722.58cfa832e4b0c9d6adf6d164	58cfa832e4b0c9d6adf6d164	TCGA-KL-8327-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KL-8327-01A-11D-2310-10_wgs_Illumina	TCGA-KL-8327-01A-11D-2310-10_wgs_Illumina.bam	112.3		0.05	58cfa832e4b0c9d6adf6d164	TCGA-KL-8327-01A-11D-2310-10_wgs_Illumina.bam	Alive	FEMALE	WHITE		Kidney Chromophobe	Aligned reads	TCGA-KL-8327-01A	02979422-5149-4750-AD5F-483E0BEC6AC5	Primary Tumor	Illumina HiSeq	791eea87-33dd-4932-9e4e-d31487fc9a39	Kidney	46.0	F35E66EC-7AA5-477C-ABF7-07C35C90F7DE	D72A7338-C144-4C62-A70E-2177A3B4B77E	TCGA-KL-8327-01A-11D-2310-10	GRCh37-lite	TCGA-KL-8327	TCGA-KICH		s16521	Baylor College of Medicine	MSKCC	United States	NO	T1b	N0	Kidney Chromophobe	Stage I	2310-10	True	KICH	C4	KICH.Eosin.0	0.023419338999999997				-2.1316	-0.53	-0.6781	-1.2688	-0.9	-0.8344	11.0		0.15496026300000001	0.413227367	63.0	0.803102544	28.0	0.0					0.0		1.180406369	-950.3178341	-1521.025817	3248.906762	0.0	4169.0	0.0	4169.0	7.493367865115035	1.4551594742686618	-0.7331156114002293	6.457275933428259	3.0589356589107615	2.885365489618021	-1.0360919316867756	1.6037761846420997	3.61848110101825
13722.58cfa832e4b0c9d6adf6d168	58cfa832e4b0c9d6adf6d168	TCGA-KL-8328-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KL-8328-01A-11D-2310-10_wgs_Illumina	TCGA-KL-8328-01A-11D-2310-10_wgs_Illumina.bam	110.3		0.05	58cfa832e4b0c9d6adf6d168	TCGA-KL-8328-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	WHITE		Kidney Chromophobe	Aligned reads	TCGA-KL-8328-01A	452135F2-6DE6-4593-A091-DDF6344EE431	Primary Tumor	Illumina HiSeq	c5c55965-aec9-4c64-9d09-4dbba956669c	Kidney	60.0	BBCD6B07-862B-4DA1-8880-9D98B643898C	2CCD028D-E7E0-4F77-A512-F658A31819A4	TCGA-KL-8328-01A-11D-2310-10	GRCh37-lite	TCGA-KL-8328	TCGA-KICH		s16518	Baylor College of Medicine	MSKCC	United States	NO	T2b	N0	Kidney Chromophobe	Stage II	2310-10	True	KICH	C3	KICH.Eosin.0	0.020117873999999997	0.06	0.01		-1.2279	-0.369	-1.4477	-2.5136	-1.6815	-0.9725	6.0		0.209711493	0.44563692200000005	62.0	0.93083132	14.0	5.0					0.0		1.169912328	-2035.2263440000002	-1724.7700280000001	3499.9740479999996	0.0	3127.0	0.0	3127.0	7.2019163175316265	2.6119270498426044	0.11526123401997657	5.410156848303572	2.037268571470337	1.447450699862768	-1.7917594692280552	-0.5746584783722675	1.3321894658427915
13722.58cfa832e4b0c9d6adf6d16e	58cfa832e4b0c9d6adf6d16e	TCGA-IG-A5S3-01A-11D-A28P_131120_SN1222_0230_BC29YPACXX_s_7_rg.sorted.filtered.	WGS	TCGA-IG-A5S3-01A-11D-A28P_131120_SN1222_0230_BC29YPACXX_s_7_rg.sorted	TCGA-IG-A5S3-01A-11D-A28P_131120_SN1222_0230_BC29YPACXX_s_7_rg.sorted.bam	45.06		0.15	58cfa832e4b0c9d6adf6d16e	TCGA-IG-A5S3-01A-11D-A28P_131120_SN1222_0230_BC29YPACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-IG-A5S3-01A	DF0125B2-5278-4DED-B3B7-9FC829FE9F63	Primary Tumor	Illumina HiSeq	736bee98-6905-4aea-a839-1157081fd524	Esophagus	69.0	9595654D-B5F8-4571-A80A-BDD179881D91	AC4D24CB-89FC-4744-9227-4F65D8893F90	TCGA-IG-A5S3-01A-11D-A28P-26	HG19_Broad_variant	TCGA-IG-A5S3	TCGA-ESCA		s1827	MD Anderson - Institute for Applied Cancer Science	Asterand	Russia	NO	T3	N0		Stage IIB	A28P-26	True	ESCA	C2	GI.ESCC	0.162997173	0.45	0.29		1.03	0.11599999999999999	-0.5809	0.0965	0.6686	0.1362	28.0				110.0	0.789974185	27.0	22.0	0.919824292	3.8254416860000005	64.0	4.151596496	70.0	0.97719222	3.858054295	-609.4123477	1366.165021	-3769.2676969999998	0.0	712.0	0.0	712.0	8.955125489661903	7.918810587300715	0.08007756120158827	6.280976840235374	6.619527603170454	1.7842594340715083	-2.6741486494265287	-1.299282984130261	1.70418187286992
13722.58cfa832e4b0c9d6adf6d170	58cfa832e4b0c9d6adf6d170	TCGA-J8-A3YH-01A-11D-A23Q_120927_SN208_0432_AC188LACXX_s_3_rg.sorted.filtered.	WGS	TCGA-J8-A3YH-01A-11D-A23Q_120927_SN208_0432_AC188LACXX_s_3_rg.sorted	TCGA-J8-A3YH-01A-11D-A23Q_120927_SN208_0432_AC188LACXX_s_3_rg.sorted.bam	48.6		0.15	58cfa832e4b0c9d6adf6d170	TCGA-J8-A3YH-01A-11D-A23Q_120927_SN208_0432_AC188LACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE		Thyroid Carcinoma	Aligned reads	TCGA-J8-A3YH-01A	A09B20B5-C187-4632-B996-0D5314A9885C	Primary Tumor	Illumina HiSeq	f6ec340c-1c9c-4c8d-9266-4728709a90e6	Thyroid	39.0	EFDAD0C2-A44D-48F8-A908-E8C9747E78B8	BF118D4C-A2DF-4617-92E2-3475E07D9BE7	TCGA-J8-A3YH-01A-11D-A23Q-26	HG19_Broad_variant	TCGA-J8-A3YH	TCGA-THCA		s12535	MD Anderson - Institute for Applied Cancer Science	Mayo Clinic	United States	NO	T3	N1b	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A23Q-26	True	THCA	C3	THCA.5	0.252355276	0.33	0.01		-1.5669	-0.299	-0.4601	-1.2178	-0.4116	-0.0248	2.0		0.0	0.096072197	45.0	0.010998581	0.0	0.0				0.693147181	2.0	1.0	1.407154625	40.0177735	-1395.404497	2161.190271	0.0	175.0	0.0	175.0	6.993219162925507	7.85703954807241	0.8604943742324499	5.6788983014307055	8.138890700213398	1.6664825541594714	-1.3143208614948012	0.2818511521409879	0.8059881799270214
13722.58cfa832e4b0c9d6adf6d174	58cfa832e4b0c9d6adf6d174	TCGA-HC-7231-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-HC-7231-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_2_rg.sorted	TCGA-HC-7231-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_2_rg.sorted.bam	61.3		0.17	58cfa832e4b0c9d6adf6d174	TCGA-HC-7231-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE		Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7231-01A	B182BDA9-3D9F-4958-96EB-BD6CC441830C	Primary Tumor	Illumina HiSeq	4b0f4fcc-c7c6-44bc-95d3-e693b0fbc7c7	Prostate	66.0	6AC7857C-5446-4297-95A9-5F2C11C28220	9826D5D9-D6D3-4216-9CA1-FE010711E13E	TCGA-HC-7231-01A-11D-2111-02	HG19_Broad_variant	TCGA-HC-7231	TCGA-PRAD		s3806	Harvard Medical School	International Genomics Consortium	United States	NO	T2c		Prostate Adenocarcinoma Acinar Type		2111-02	True	PRAD	C3	PRAD.1-ERG	0.12252459199999999	0.29	0.03	2.1310181530000003	-1.4404	-0.1505	-0.5077	0.2617	-0.3234	-0.3499	17.0	11.0	0.424706873	0.788741336	104.0	0.0964726	0.0	10.0	0.9520559270000001	1.979744645	8.0	2.698879929	17.0	0.9525861990000001	2.91348111	-690.5839581	-974.1775802000001	2755.112393	0.0	939.0	0.0	939.0	8.859363449152088	7.296675672833941	-0.1813588148306935	6.866933284461881	8.204934233010832	2.20162222358562	-1.9924301646902063	0.9082585601768911	2.3829810384163137
13722.58cfa832e4b0c9d6adf6d17e	58cfa832e4b0c9d6adf6d17e	TCGA-HD-7753-01A-11D-A32X-10_wgs_Illumina.filtered.	WGS	TCGA-HD-7753-01A-11D-A32X-10_wgs_Illumina	TCGA-HD-7753-01A-11D-A32X-10_wgs_Illumina.bam	103.73		0.07	58cfa832e4b0c9d6adf6d17e	TCGA-HD-7753-01A-11D-A32X-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-HD-7753-01A	E8AC39E6-377A-412C-B18D-F6C4FC654EC6	Primary Tumor	Illumina HiSeq	393b4af8-b44d-4c3f-b5ca-f7032b687a16	Head and Neck	62.0	E723F1BB-73A3-4D65-BD25-DE76138515E9	54E78DE0-D357-4125-A904-AB35E461572B	TCGA-HD-7753-01A-11D-A32X-10	GRCh37-lite	TCGA-HD-7753	TCGA-HNSC		s15534	Baylor College of Medicine	International Genomics Consortium	United States	NO	T1	N0	Head and Neck Squamous Cell Carcinoma	Stage I	A32X-10	True	HNSC	C2	HNSC.Basal	0.269534406	0.37	0.2		0.7801	0.2545	-0.1281	0.3219	1.0698	0.9099	19.0	31.0	0.631302978	2.645460097	276.0	0.76360792	12.0	37.0	0.875126227	3.3693651460000003	47.0	2.857102837	18.0	0.9884897429999999	3.6070972560000003	155.1123012	762.85448	-567.6613742000001	0.0	866.0	0.0	866.0	6.684846075206398	3.3188156266739135	-0.20342453000549088	5.768555343332244	6.617380250443482	1.128627478495165	-0.9162907318741551	3.2985646237695683	1.332052008500656
13722.58cfa832e4b0c9d6adf6d186	58cfa832e4b0c9d6adf6d186	TCGA-IR-A3L7-01A-21D-A20X_140117_SN590_0245_AC371LACXX_s_3_rg.sorted.filtered.	WGS	TCGA-IR-A3L7-01A-21D-A20X_140117_SN590_0245_AC371LACXX_s_3_rg.sorted	TCGA-IR-A3L7-01A-21D-A20X_140117_SN590_0245_AC371LACXX_s_3_rg.sorted.bam	59.39		0.15	58cfa832e4b0c9d6adf6d186	TCGA-IR-A3L7-01A-21D-A20X_140117_SN590_0245_AC371LACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE		Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-IR-A3L7-01A	66229DD6-C771-4455-A90C-C66FB40CF7FE	Primary Tumor	Illumina HiSeq	c50ab1fa-015d-4420-a67f-b023a5377b16	Cervix	37.0	F571523C-758C-4F34-A44B-F8E6A3EEBE0F	27168C7B-D67E-4B11-B5BA-A79FB523400B	TCGA-IR-A3L7-01A-21D-A20X-26	HG19_Broad_variant	TCGA-IR-A3L7	TCGA-CESC		s1211	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T1b1	N0	Cervical Squamous Cell Carcinoma		A20X-26	True	CESC	C1		0.055927906	0.16	0.05	8.082536385	0.9344	0.0665	-1.2515	-1.4448	-0.1116	-0.2637	11.0	4.0	0.22905693	0.534466171	74.0	0.18075624199999998	1.0	10.0				1.609437912	5.0	1.0	1.527381945	-1209.675999	1146.268867	-1394.820891	0.0	4483.0	0.0	4483.0	7.607133009292719	6.64183469831187	0.6259897142327466	5.4099084319565	5.600380823483708	3.95732276465781	-2.197224577336219	-1.0414538748281612	3.331333050425063
13722.58cfa832e4b0c9d6adf6d188	58cfa832e4b0c9d6adf6d188	TCGA-HC-7233-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-HC-7233-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_6_rg.sorted	TCGA-HC-7233-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_6_rg.sorted.bam	207.3		0.14	58cfa832e4b0c9d6adf6d188	TCGA-HC-7233-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE		Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7233-01A	E2B33861-2247-413F-B2E5-9BE3B604666C	Primary Tumor	Illumina HiSeq	b16d1760-889f-44f7-a1c1-1dfa3f31efc3	Prostate	73.0	848C2C7B-918E-4A09-BAD9-3B3D59BBC101	8262CCFE-6E66-412E-A8C8-E4FA91979764	TCGA-HC-7233-01A-11D-2111-02	HG19_Broad_variant	TCGA-HC-7233	TCGA-PRAD		s3813	Harvard Medical School	International Genomics Consortium	Yemen	NO	T2a	N0	Prostate Adenocarcinoma Acinar Type		2111-02	True	PRAD	C3	PRAD.8-other	0.185726544	0.46	0.04	0.142500891	-1.3934	-0.163	0.0839	0.1952	0.5214	-0.1133	12.0	0.0	0.302153143	0.7553828579999999	55.0	0.00092046	0.0	0.0	0.9802595540000001	0.6794641459999999	2.0	3.6834363239999997	41.0	0.991884972	1.5579944780000001	-110.9447182	-647.3199217	2684.883173	0.0	1355.0	0.0	1355.0	7.695530588620866	7.912423121473704	-0.04362436406899828	5.210623938832866	6.6960277971492115	6.885305150144545	-2.4849066497880004	-1.2163953243244934	6.928929514213543
13722.58cfa832e4b0c9d6adf6d18e	58cfa832e4b0c9d6adf6d18e	TCGA-FI-A2D4-01A-12D-A17E_120511_SN1120_0140_AD12J0ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-FI-A2D4-01A-12D-A17E_120511_SN1120_0140_AD12J0ACXX_s_7_rg.sorted	TCGA-FI-A2D4-01A-12D-A17E_120511_SN1120_0140_AD12J0ACXX_s_7_rg.sorted.bam	28.14		0.16	58cfa832e4b0c9d6adf6d18e	TCGA-FI-A2D4-01A-12D-A17E_120511_SN1120_0140_AD12J0ACXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-FI-A2D4-01A	490AE247-EE67-48D4-94ED-93DF5B9BBEFE	Primary Tumor	Illumina HiSeq	8f265179-0deb-4bbd-bd06-f6a211fae179	Uterus	44.0	A8393121-29DF-4525-BF4F-FCE0DEAF25F5	6DA2AADF-7B34-4F4F-93E4-0963248B3DEB	TCGA-FI-A2D4-01A-12D-A17E-02	HG19_Broad_variant	TCGA-FI-A2D4	TCGA-UCEC	243.0	s5232	Harvard Medical School	Washington University	United States	NO			Endometrioid endometrial adenocarcinoma		A17E-02	True	UCEC	C1	UCEC.MSI	0.057166228	0.11	0.0	0.226215005	0.9229	0.449	-1.0126	-0.9295	-1.8921	-0.1557	102.0	622.0	2.6412302640000003	7.12898434	71.0	0.866459877	6.0	3.0							1.833155735	-2313.332231	548.3932405	-2445.056491	1.0	243.0	1.0	243.0	5.848326720534928	7.93741040981127	-0.17430012340937928	5.2777818620673145	6.743487941338836	3.553352716630518	-0.5705448584676129	-1.1939224684724343	3.727652840039897
13722.58cfa832e4b0c9d6adf6d190	58cfa832e4b0c9d6adf6d190	TCGA-IR-A3LH-01A-21D-A20X_140117_SN590_0246_BC37BDACXX_s_8_rg.sorted.filtered.	WGS	TCGA-IR-A3LH-01A-21D-A20X_140117_SN590_0246_BC37BDACXX_s_8_rg.sorted	TCGA-IR-A3LH-01A-21D-A20X_140117_SN590_0246_BC37BDACXX_s_8_rg.sorted.bam	62.48		0.15	58cfa832e4b0c9d6adf6d190	TCGA-IR-A3LH-01A-21D-A20X_140117_SN590_0246_BC37BDACXX_s_8_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN		Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-IR-A3LH-01A	F24ED9C0-92BB-4003-86D2-42AB26617A05	Primary Tumor	Illumina HiSeq	159f94e1-d4e4-45d7-9220-90578144802f	Cervix	49.0	D95E5389-DD55-4D55-AB01-6A770C66502F	7BDB76AA-01BA-48A8-A58A-29B118B8118A	TCGA-IR-A3LH-01A-21D-A20X-26	HG19_Broad_variant	TCGA-IR-A3LH	TCGA-CESC		s1535	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T2a1	N0	Cervical Squamous Cell Carcinoma		A20X-26	True	CESC	C2		0.42537745200000004	0.51	0.09	15.92581205	0.7120000000000001	0.2925	1.3921	2.0013	1.5956	0.5114	258.0	142.0	6.128416773	16.43425622	198.0	0.375202215	9.0	44.0	0.902378573	4.349718801	124.0	4.241149182	93.0	0.935699081	2.0478617519999998	279.4008377	860.1313889	499.58286039999996	0.0	2394.0	0.0	2394.0	8.6648370333288	7.00488198971286	0.24302188170289696	6.139108389020544	6.4070449889572405	2.225049455986206	-2.525728644308255	-0.5978370007556202	1.982027574283309
13722.58cfa832e4b0c9d6adf6d191	58cfa832e4b0c9d6adf6d191	TCGA-FE-A3PC-01A-11D-A221_120524_SN1120_0145_BD12MWACXX_s_2_rg.sorted.filtered.	WGS	TCGA-FE-A3PC-01A-11D-A221_120524_SN1120_0145_BD12MWACXX_s_2_rg.sorted	TCGA-FE-A3PC-01A-11D-A221_120524_SN1120_0145_BD12MWACXX_s_2_rg.sorted.bam	48.5		0.15	58cfa832e4b0c9d6adf6d191	TCGA-FE-A3PC-01A-11D-A221_120524_SN1120_0145_BD12MWACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FE-A3PC-01A	A86AC3B5-B5E9-4420-8DE0-A358FCAD85B6	Primary Tumor	Illumina HiSeq	7072b927-397f-4821-a834-0b1e21ec3434	Thyroid	37.0	7A5628FF-C5C2-4F25-809B-640415323477	8B0BF4B5-9846-473B-A2DB-8390B0DB90A7	TCGA-FE-A3PC-01A-11D-A221-26	HG19_Broad_variant	TCGA-FE-A3PC	TCGA-THCA		s12647	MD Anderson - Institute for Applied Cancer Science	Ohio State University	United States	NO	T3	N1	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A221-26	True	THCA	C3	THCA.3	0.06189482	0.18	0.0		-1.4385	-0.2065	-0.1421	-0.0089	-0.3982	-0.0725	12.0		0.116648506	0.40826977299999995	59.0	2.36e-05	0.0	0.0				1.039720771	3.0	0.94639463	1.4257443930000002	106.7299381	-1132.7578720000001	49.78327173	0.0	2606.0	0.0	2606.0	6.5409672580285445	8.435766192720507	-0.6723099477119907	6.380624607953365	7.624835976504179	3.520401031412179	-0.16034265007517945	-0.8109302162163288	4.19271097912417
13722.58cfa832e4b0c9d6adf6d194	58cfa832e4b0c9d6adf6d194	TCGA-G9-6377-01A-11D-1957_130405_SN590_0222_BD21LGACXX_s_8_rg.sorted.filtered.	WGS	TCGA-G9-6377-01A-11D-1957_130405_SN590_0222_BD21LGACXX_s_8_rg.sorted	TCGA-G9-6377-01A-11D-1957_130405_SN590_0222_BD21LGACXX_s_8_rg.sorted.bam	95.7	1.9	0.15	58cfa832e4b0c9d6adf6d194	TCGA-G9-6377-01A-11D-1957_130405_SN590_0222_BD21LGACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6377-01A	007F9081-5093-4323-B4F8-CD510BF20705	Primary Tumor	Illumina HiSeq	126d92ca-d172-491d-9366-11555d88901b	Prostate	61.0	8F105D0D-0630-46FC-8168-DCBA11A5197F	811D74B4-6F98-4B1F-9ADD-CB949E4B5B20	TCGA-G9-6377-01A-11D-1957-02	HG19_Broad_variant	TCGA-G9-6377	TCGA-PRAD		s3977	Harvard Medical School	Roswell Park	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1957-02	True	PRAD	C1	PRAD.1-ERG	0.096965977	0.34	0.21	0.017717931	-1.7348	-0.0195	-0.7796	-0.0486	-0.3938	-0.2462	12.0	0.0	0.203000569	0.667001869	91.0	0.166743255	3.0	12.0							2.6673900880000003	-304.8226234	-1087.753644	2749.19	0.0	958.0	0.0	958.0	7.082068665326894	8.640626898581434	-0.10256916702055574	6.463029456920671	6.037937213137051	2.66374994220563	-0.6190392084062237	-2.602689685444384	2.7663191092261856
13722.58cfa832e4b0c9d6adf6d196	58cfa832e4b0c9d6adf6d196	TCGA-K4-A3WV-01A-11D-A23Q_120926_SN1222_0153_BD1D4MACXX_s_6_rg.sorted.filtered.	WGS	TCGA-K4-A3WV-01A-11D-A23Q_120926_SN1222_0153_BD1D4MACXX_s_6_rg.sorted	TCGA-K4-A3WV-01A-11D-A23Q_120926_SN1222_0153_BD1D4MACXX_s_6_rg.sorted.bam	33.77		0.15	58cfa832e4b0c9d6adf6d196	TCGA-K4-A3WV-01A-11D-A23Q_120926_SN1222_0153_BD1D4MACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-K4-A3WV-01A	D53EADE8-A845-4252-AECE-92F3573486A7	Primary Tumor	Illumina HiSeq	ca7a6b06-a6fa-4314-80ef-725b81781598	Bladder	77.0	3ADFA409-A9F8-4EDB-AAF7-C5285AE5F895	9A7CA3A1-631F-41BA-A490-04D470C4AF8E	TCGA-K4-A3WV-01A-11D-A23Q-26	HG19_Broad_variant	TCGA-K4-A3WV	TCGA-BLCA		s2937	MD Anderson - Institute for Applied Cancer Science	ABS - Lahey Clinic	United States	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A23Q-26	True	BLCA	C1	BLCA.3	0.14351857099999998	0.33	0.07	0.907025357	0.6085	0.1655	-1.4335	-2.4803	-0.4795	0.0637	26.0	0.0	0.6364342279999999	1.59108557	566.0	0.660984211	14.0	59.0	0.9988455359999999	0.692346967	2.0		0.0		5.101311573	-619.8847619	85.32705455	-2934.042507	0.0	646.0	0.0	646.0	7.079465175181497	6.5742037728719005	0.0059491792554465794	5.470027262747397	5.562602861193421	0.3529458198048009	-1.6094379124341	-1.0116009116784803	0.3469966405493543
13722.58cfa832e4b0c9d6adf6d19a	58cfa832e4b0c9d6adf6d19a	TCGA-IR-A3LC-01A-11D-A20X_140117_SN590_0246_BC37BDACXX_s_3_rg.sorted.filtered.	WGS	TCGA-IR-A3LC-01A-11D-A20X_140117_SN590_0246_BC37BDACXX_s_3_rg.sorted	TCGA-IR-A3LC-01A-11D-A20X_140117_SN590_0246_BC37BDACXX_s_3_rg.sorted.bam	81.15		0.15	58cfa832e4b0c9d6adf6d19a	TCGA-IR-A3LC-01A-11D-A20X_140117_SN590_0246_BC37BDACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE		Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-IR-A3LC-01A	58BDCACE-0047-456E-A225-68953EDAFE5E	Primary Tumor	Illumina HiSeq	8b84ea0a-0512-427e-8456-2facdcd978b9	Cervix	40.0	AC6D15A0-67CF-42AA-97DC-BA50D0E9F409	47A900B4-52E8-448E-B092-EEE4E394A309	TCGA-IR-A3LC-01A-11D-A20X-26	HG19_Broad_variant	TCGA-IR-A3LC	TCGA-CESC		s1375	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T1b1	N0	Cervical Squamous Cell Carcinoma		A20X-26	True	CESC	C2		0.164727138	0.22	0.05	28.75640493	1.0319	0.5175	-0.4924	-0.4669	0.405	-0.1775	16.0	36.0	0.262940516	0.7171104979999999	106.0	0.259386727	4.0	12.0		0.0	1.0		0.0		1.665964805	-528.4059454	878.9799886	1886.3873629999998	0.0	3935.0	0.0	3935.0	8.643208911999098	8.005795975751289	-0.6065142944775348	6.200861876629894	7.118492780750386	1.9611959254766278	-2.4423470353692043	-0.8873031950009029	2.567710219954163
13722.58cfa832e4b0c9d6adf6d19c	58cfa832e4b0c9d6adf6d19c	TCGA-HG-A2PA-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_4_rg.sorted.filtered.	WGS	TCGA-HG-A2PA-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_4_rg.sorted	TCGA-HG-A2PA-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_4_rg.sorted.bam	61.98		0.15	58cfa832e4b0c9d6adf6d19c	TCGA-HG-A2PA-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-HG-A2PA-01A	E2FF7CFD-A101-45B9-895F-26F403E7BDFB	Primary Tumor	Illumina HiSeq	2c605f98-0c77-45ff-bcea-2fcf6094ca2d	Cervix	38.0	235DBD13-5052-4E19-9C1C-A72A1A9A79CE	ECE06317-01F9-4EF2-ACE0-E9B18C7F4DE1	TCGA-HG-A2PA-01A-11D-A20X-26	HG19_Broad_variant	TCGA-HG-A2PA	TCGA-CESC		s1534	MD Anderson - Institute for Applied Cancer Science	Roswell Park	United States	NO	T1b2	N0	Cervical Squamous Cell Carcinoma		A20X-26	True	CESC	C2		0.25278842	0.5	0.0	10.41855491	0.8479	0.1805	-0.0729	0.9059	1.0929	0.2766	28.0	29.0	0.5510211970000001	1.245787054	94.0	0.233595489	6.0	12.0	0.9417705340000001	4.103019999	78.0	2.7379755560000003	19.0	0.929880217	2.275336995	536.3286853999999	747.7080619	-1689.4649829999998	1.0	773.0	1.0	773.0	7.826243594399779	5.53281556402344	-0.15872107169520255	5.574951795793284	3.7250557534489435	2.1335596626014603	-2.251291798606495	-1.8077598105744963	2.292280734296663
13722.58cfa832e4b0c9d6adf6d1a2	58cfa832e4b0c9d6adf6d1a2	TCGA-HI-7168-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-HI-7168-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_8_rg.sorted	TCGA-HI-7168-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_8_rg.sorted.bam	116.3		0.14	58cfa832e4b0c9d6adf6d1a2	TCGA-HI-7168-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HI-7168-01A	25D70934-01A5-45A2-9960-68D3058B6965	Primary Tumor	Illumina HiSeq	97c2b4ae-c671-4cf5-8b44-5c36e7e8fb57	Prostate	62.0	DD410832-95AA-4FA6-A2B9-3FECA6F70E1D	9FD5990D-22E1-4D64-996D-543BCD447500	TCGA-HI-7168-01A-11D-2111-02	HG19_Broad_variant	TCGA-HI-7168	TCGA-PRAD		s3633	Harvard Medical School	Fox Chase	United States	NO	T3b	N0	Prostate Adenocarcinoma Acinar Type		2111-02	True	PRAD	C1	PRAD.3-ETV4	0.081265228	0.43	0.48	6.371426461	-0.8545	-0.111	-0.8598	-1.4223	-0.7255	0.2707	17.0	4.0	0.49550654299999997	1.020160529	190.0	0.659195922	22.0	23.0				0.693147181	2.0	1.0	2.44816311	51.21267434	-631.2259786000001	1755.8852949999998	0.0	3323.0	1.0	2505.0	9.245369620895577	8.948358534374215	0.034199913400797866	6.571220971469048	7.562064173254324		-2.6741486494265287	-1.3862943611198908	
13722.58cfa832e4b0c9d6adf6d1a4	58cfa832e4b0c9d6adf6d1a4	TCGA-IG-A50L-01A-11D-A267_131120_SN1222_0230_BC29YPACXX_s_1_rg.sorted.filtered.	WGS	TCGA-IG-A50L-01A-11D-A267_131120_SN1222_0230_BC29YPACXX_s_1_rg.sorted	TCGA-IG-A50L-01A-11D-A267_131120_SN1222_0230_BC29YPACXX_s_1_rg.sorted.bam	22.45		0.17	58cfa832e4b0c9d6adf6d1a4	TCGA-IG-A50L-01A-11D-A267_131120_SN1222_0230_BC29YPACXX_s_1_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-IG-A50L-01A	9E54A27F-D0FA-4A5B-91BC-13E27FED2A3D	Primary Tumor	Illumina HiSeq	3e7102a5-f6cf-4918-83d4-8bc4a36d6eda	Esophagus	58.0	5B30B4D1-4FC6-4712-92B4-E3BE5131551E	62296F7F-6BE0-41E3-A2AA-27B3D1ACE0C7	TCGA-IG-A50L-01A-11D-A267-26	HG19_Broad_variant	TCGA-IG-A50L	TCGA-ESCA		s1815	MD Anderson - Institute for Applied Cancer Science	Asterand	Vietnam	NO	T3	N1		Stage IIIA	A267-26	True	ESCA	C1	GI.ESCC	0.281071456	0.43	0.48		0.9747	0.314	-0.2393	-0.9432	0.3265	0.7344	67.0		0.59813339	2.2679224380000003	297.0	0.7117673959999999	13.0	48.0	0.775027026	3.077083534	53.0	3.5454494989999996	44.0	0.93691116	5.5288865089999994	-981.7524876	1293.1169380000001	-2721.499382	0.0	16.0	0.0	16.0	8.226840890408578	6.046285200828682	-0.8719311582644169	5.784493855039374	7.803532617751593	1.4697232130374627	-2.4423470353692043	1.7572474169229109	2.3416543713018796
13722.58cfa832e4b0c9d6adf6d1a8	58cfa832e4b0c9d6adf6d1a8	TCGA-HT-7472-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_7_rg.sorted.filtered.	WGS	TCGA-HT-7472-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_7_rg.sorted	TCGA-HT-7472-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_7_rg.sorted.bam	62.7		0.17	58cfa832e4b0c9d6adf6d1a8	TCGA-HT-7472-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HT-7472-01A	482D4078-7576-48CF-BF7C-29014935FD47	Primary Tumor	Illumina HiSeq	518f9b23-97da-447f-90e5-a03c5ae09642	Brain	38.0	F05081A2-2465-4EA4-9EC3-319810FE2D45	A68374D7-4782-4FF5-B921-35D45468A4D1	TCGA-HT-7472-01A-11D-2022-02	HG19_Broad_variant	TCGA-HT-7472	TCGA-LGG		s8574	Harvard Medical School	Case Western - St Joes	United States	NO			Oligodendroglioma		2022-02	True	LGG	C5	GBM_LGG.G-CIMP-high	0.18100470300000002	0.29	0.05		-0.8640000000000001	-0.3635	0.3817	-1.7401	-0.536	-0.9011	10.0	53.0	0.210517825	0.511257576	131.0	0.055342537000000004	0.0	5.0				0.693147181	2.0	1.0	3.065983998	16.5442291	-427.8138618	-3168.748534	0.0	1.0	0.0	1.0	8.235449010297833	8.726994800192495	0.6755514186695657	6.389622319799502	7.628382511524385	4.786127175820249	-1.8458266904983305	-1.0986122886681096	4.1105757571506825
13722.58cfa832e4b0c9d6adf6d1b5	58cfa832e4b0c9d6adf6d1b5	TCGA-HI-7170-01A-11D-2111_130607_SN590_0232_BD26R5ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-HI-7170-01A-11D-2111_130607_SN590_0232_BD26R5ACXX_s_5_rg.sorted	TCGA-HI-7170-01A-11D-2111_130607_SN590_0232_BD26R5ACXX_s_5_rg.sorted.bam	96.3		0.15	58cfa832e4b0c9d6adf6d1b5	TCGA-HI-7170-01A-11D-2111_130607_SN590_0232_BD26R5ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HI-7170-01A	6394E00A-1F6F-4EA2-B885-373BBB59DEF9	Primary Tumor	Illumina HiSeq	4eefa9f0-575b-4039-912a-7c0e58f4e508	Prostate	58.0	70BF0C3E-0C06-4168-996C-46783752FA37	1C5E0781-5295-427A-B94A-062B2708B62C	TCGA-HI-7170-01A-11D-2111-02	HG19_Broad_variant	TCGA-HI-7170	TCGA-PRAD		s3629	Harvard Medical School	Fox Chase	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		2111-02	True	PRAD	C3	PRAD.8-other	0.138996501	0.53	0.01	8.095639665	-1.4593	-0.12300000000000001	-0.2795	0.0885	-0.2134	0.2853	9.0	12.0	0.156812014	0.6899728629999999	51.0	0.042768253	3.0	2.0	0.94455273	1.5201989740000001	5.0	2.672351698	16.0	0.9638471359999999	1.790205325	337.5120183	-857.8585517000001	1616.250356	0.0	2522.0	0.0	2522.0	8.763844914310027	9.358041728123533	-0.42885407939475884	6.604360664956655	8.187970475473278		-2.1594842493533726	-1.1700712526502546	
13722.58cfa832e4b0c9d6adf6d1b9	58cfa832e4b0c9d6adf6d1b9	TCGA-HE-A5NL-01A-11D-A26P-10_wgs_Illumina.filtered.	WGS	TCGA-HE-A5NL-01A-11D-A26P-10_wgs_Illumina	TCGA-HE-A5NL-01A-11D-A26P-10_wgs_Illumina.bam	35.01		0.07	58cfa832e4b0c9d6adf6d1b9	TCGA-HE-A5NL-01A-11D-A26P-10_wgs_Illumina.bam	Alive	MALE			Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-HE-A5NL-01A	E4245FFF-1281-40E5-87B4-4E42A18A3A63	Primary Tumor	Illumina HiSeq	14b775e3-8ff9-4815-bb25-ebfc6c526e2f	Kidney	51.0	21B630BE-466D-46A3-801A-7EB593BDDDB6	A441697C-4CA0-4EAB-9B01-B9CB50223CE2	TCGA-HE-A5NL-01A-11D-A26P-10	GRCh37-lite	TCGA-HE-A5NL	TCGA-KIRP		s11589	Baylor College of Medicine	Ontario Institute for Cancer Research (OICR)	Canada	NO	T1a	NX	Kidney Papillary Renal Cell Carcinoma	Stage I	A26P-10	True	KIRP	C3	KIRP.C1	0.34365185	0.34	0.0		-1.7598	-0.284	0.7142	0.2119	-0.2713	-0.3392	35.0	34.0	0.6446545779999999	1.719078875	41.0	0.24543706199999998	10.0	0.0				2.106577333	9.0	0.9587446609999999	1.759456759	-857.853525	-2177.593763	1247.765906	0.0	767.0	0.0	767.0	5.983639896571209	2.5914218574310883	0.15706315283876038	5.449557410640951	3.766641267571395	6.193848649882163	-0.534082485930258	1.1752194101403068	6.036785497043403
13722.58cfa832e4b0c9d6adf6d1bb	58cfa832e4b0c9d6adf6d1bb	TCGA-EJ-5509-01A-01D-1572_130308_SN590_0219_BC1UVPACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EJ-5509-01A-01D-1572_130308_SN590_0219_BC1UVPACXX_s_3_rg.sorted	TCGA-EJ-5509-01A-01D-1572_130308_SN590_0219_BC1UVPACXX_s_3_rg.sorted.bam	116.7	1.9	0.14	58cfa832e4b0c9d6adf6d1bb	TCGA-EJ-5509-01A-01D-1572_130308_SN590_0219_BC1UVPACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5509-01A	13CE70A8-785C-4B59-B073-41922CB201F9	Primary Tumor	Illumina HiSeq	6fd44a89-a20c-4ecc-bafe-54da9b58cd9d	Prostate	63.0	99A7115E-046B-488E-95D2-48C35BD29867	4F3831BE-6C1C-4786-B953-2612753C1E5C	TCGA-EJ-5509-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5509	TCGA-PRAD		s3440	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.5-SPOP	0.17369689600000002	0.49	0.11	0.24890990000000002	-1.0359	-0.171	-0.0448	0.2772	-0.396	-0.0593	14.0		0.20257704	0.405154081	376.0	0.184175	2.0	15.0	0.7947336159999999	1.1017347309999999	4.0	3.721030401	44.0	0.983309707	2.884867618	-422.9164858	-1046.366146	2595.189878	0.0	1464.0	0.0	1464.0	9.006304762275475	9.325268052933263	-0.41740705475257733	7.013874597585268	8.999845652498635	3.9094881498249583	-1.9924301646902063	-0.3254224004346278	4.326895204577536
13722.58cfa832e4b0c9d6adf6d1bf	58cfa832e4b0c9d6adf6d1bf	TCGA-HP-A5MZ-01A-21D-A27I-10_wgs_Illumina.filtered.	WGS	TCGA-HP-A5MZ-01A-21D-A27I-10_wgs_Illumina	TCGA-HP-A5MZ-01A-21D-A27I-10_wgs_Illumina.bam	32.76		0.08	58cfa832e4b0c9d6adf6d1bf	TCGA-HP-A5MZ-01A-21D-A27I-10_wgs_Illumina.bam	Dead	MALE			Liver Hepatocellular Carcinoma	Aligned reads	TCGA-HP-A5MZ-01A	2D00F09F-0074-46C8-B357-B5F33567762A	Primary Tumor	Illumina HiSeq	bb9234a0-b13c-43f2-8d45-2ec940f73d34	Liver	78.0	9EC5013E-AABB-487A-87D7-49B4B6BD0F6A	C36213E4-C057-46F5-ADA5-F1F921855BB4	TCGA-HP-A5MZ-01A-21D-A27I-10	GRCh37-lite	TCGA-HP-A5MZ	TCGA-LIHC	91.0	s16789	Baylor College of Medicine	Ontario Institute for Cancer Research (OICR)	Canada	NO	T1	NX	Hepatocellular Carcinoma	Stage I	A27I-10	True	LIHC	C3	LIHC.iCluster:1	0.41693299799999994	0.06	0.21		-0.9326	-0.145	0.5714	0.9144	0.5078	-0.1014	18.0	22.0	0.34597052799999994	1.1709771709999999	43.0	0.155189954	5.0	2.0	0.964758949	0.6687199460000001	2.0	3.1224245980000003	24.0	0.982495818	0.9733199659999999	-467.413438	-539.391059	2305.688205	1.0	91.0	0.0	91.0	5.841513370344479	3.713724177238256	-0.02682423612021334	4.966044632990579	3.6473681818888517	4.08863724954281	-0.8754687373538999	-0.0663559953494044	4.115461485663023
13722.58cfa832e4b0c9d6adf6d1c5	58cfa832e4b0c9d6adf6d1c5	TCGA-HI-7171-01A-12D-2111_130607_SN590_0232_BD26R5ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-HI-7171-01A-12D-2111_130607_SN590_0232_BD26R5ACXX_s_7_rg.sorted	TCGA-HI-7171-01A-12D-2111_130607_SN590_0232_BD26R5ACXX_s_7_rg.sorted.bam	127.3		0.14	58cfa832e4b0c9d6adf6d1c5	TCGA-HI-7171-01A-12D-2111_130607_SN590_0232_BD26R5ACXX_s_7_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HI-7171-01A	931FEB14-3F69-41C1-8435-5FD4FB775BDF	Primary Tumor	Illumina HiSeq	0dc8ef7a-58a8-4b25-ad57-4c31592151e2	Prostate	56.0	B9D6C505-4D71-4189-925F-36914241B831	5A0710CB-B515-48F7-94B1-5DCD72B30F3F	TCGA-HI-7171-01A-12D-2111-02	HG19_Broad_variant	TCGA-HI-7171	TCGA-PRAD	1329.0	s3814	Harvard Medical School	Fox Chase	United States	NO	T3b	N0	Prostate Adenocarcinoma Acinar Type		2111-02	True	PRAD	C3	PRAD.1-ERG	0.058915967	0.12	0.17	40.55282839	-1.0878	-0.024	-0.9822	-0.235	-1.3807	-0.4455	19.0		0.337230605	0.8584051770000001	191.0	0.5702838920000001	2.0	19.0	0.9850107909999999	1.08214496	3.0	1.886696785	7.0	0.96957035	1.6088143119999998	-1182.781149	-457.6489621	2469.873496	1.0	1329.0	1.0	1329.0	9.087117567569436	8.90785294282405	-0.12420600020370565	7.189997582683555	8.214705762264106	4.866037604244316	-1.897119984885881	-0.693147180559945	4.990243604448022
13722.58cfa832e4b0c9d6adf6d1c9	58cfa832e4b0c9d6adf6d1c9	TCGA-HM-A3JK-01A-11D-A245_140124_SN1440_0179_BD2DRDACXX_s_1_rg.sorted.filtered.	WGS	TCGA-HM-A3JK-01A-11D-A245_140124_SN1440_0179_BD2DRDACXX_s_1_rg.sorted	TCGA-HM-A3JK-01A-11D-A245_140124_SN1440_0179_BD2DRDACXX_s_1_rg.sorted.bam	58.55		0.15	58cfa832e4b0c9d6adf6d1c9	TCGA-HM-A3JK-01A-11D-A245_140124_SN1440_0179_BD2DRDACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-HM-A3JK-01A	7C4CD55F-750E-4941-A9F3-0632A75D6531	Primary Tumor	Illumina HiSeq	cc4a29a9-d389-4d17-b8c7-53fcc5731b22	Cervix	64.0	88C6E5CB-D33E-4042-BE7B-12A081ACDAFB	EDAC7C77-CA42-461B-9006-F65E3EB6B7AB	TCGA-HM-A3JK-01A-11D-A245-26	HG19_Broad_variant	TCGA-HM-A3JK	TCGA-CESC		s1208	MD Anderson - Institute for Applied Cancer Science	Christiana Healthcare	United States	NO	T2b	N1	Cervical Squamous Cell Carcinoma		A245-26	True	CESC	C1		0.20984313300000002	0.57	0.02	7.68432881	0.4806	0.1905	0.1741	0.8156	-0.1696	0.6743	10.0	1.0	0.438650685	1.015822638	62.0	0.298480986	12.0	12.0	0.7297192290000001	2.8832985210000004	52.0	2.441015278	12.0	0.982336813	1.8514786490000001	-860.1022406	487.433938	-78.55458679	0.0	632.0	0.0	632.0	7.181211644169935	6.587090772566437	-0.45516201455377825	4.983987066833716	5.545636897738276	1.844824549477004	-2.197224577336219	-1.0414538748281612	2.299986564030782
13722.58cfa832e4b0c9d6adf6d1d2	58cfa832e4b0c9d6adf6d1d2	TCGA-HQ-A2OE-01A-11D-A204_121002_SN1222_0155_BD1ERHACXX_s_5_rg.sorted.filtered.	WGS	TCGA-HQ-A2OE-01A-11D-A204_121002_SN1222_0155_BD1ERHACXX_s_5_rg.sorted	TCGA-HQ-A2OE-01A-11D-A204_121002_SN1222_0155_BD1ERHACXX_s_5_rg.sorted.bam	71.88		0.16	58cfa832e4b0c9d6adf6d1d2	TCGA-HQ-A2OE-01A-11D-A204_121002_SN1222_0155_BD1ERHACXX_s_5_rg.sorted.bam	Alive	MALE			Bladder Urothelial Carcinoma	Aligned reads	TCGA-HQ-A2OE-01A	353C5FCC-9C6A-4AC6-99DC-FB4573B2AE6C	Primary Tumor	Illumina HiSeq	21c45d2f-f8bc-45dc-85d2-790ea5506bc4	Bladder	69.0	65DBBE08-4645-4552-9A1A-E6F79A621013	B04D2557-D084-4445-97BB-10A6CB59DC6B	TCGA-HQ-A2OE-01A-11D-A204-02	HG19_Broad_variant	TCGA-HQ-A2OE	TCGA-BLCA		s2935	Harvard Medical School	Ontario Institute for Cancer Research (OICR)	Canada	NO	T2a	N2	Muscle invasive urothelial carcinoma (pT2 or above)		A204-02	True	BLCA	C1	BLCA.1	0.104720806	0.2	0.23		0.7589	0.2235	-1.0599	-0.6921	-0.5824	-0.5409	64.0	3.0	1.277230158	4.1120580680000005	366.0	0.886422877	22.0	47.0	0.905625001	1.762264881	7.0	2.599301927	14.0	0.9849357559999999	5.068174903	-971.7308213	845.7812124	-1710.4188530000001	0.0	1174.0	0.0	1174.0	5.763099051812621	7.883771833151499	0.333991871562881	5.357633943704457	6.949462595774666	1.0405230168202104	-0.4054651081081646	-0.9343092373768336	0.7065311452573293
13722.58cfa832e4b0c9d6adf6d1dc	58cfa832e4b0c9d6adf6d1dc	TCGA-HT-7473-01A-11D-2022_130913_SN1440_0167_AC2A6PACXX_s_4_rg.sorted.filtered.	WGS	TCGA-HT-7473-01A-11D-2022_130913_SN1440_0167_AC2A6PACXX_s_4_rg.sorted	TCGA-HT-7473-01A-11D-2022_130913_SN1440_0167_AC2A6PACXX_s_4_rg.sorted.bam	122.7		0.15	58cfa832e4b0c9d6adf6d1dc	TCGA-HT-7473-01A-11D-2022_130913_SN1440_0167_AC2A6PACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HT-7473-01A	DBFACCB0-E8C0-48E8-9AEF-570267574822	Primary Tumor	Illumina HiSeq	0c3613f1-9a5e-42d1-a1a9-884cf56894f4	Brain	28.0	D302390B-4B66-48E6-92DE-612504B34FA3	A664FDA7-9BF1-4016-A16A-BCA75C6D139C	TCGA-HT-7473-01A-11D-2022-02	HG19_Broad_variant	TCGA-HT-7473	TCGA-LGG		s8154	Harvard Medical School	Case Western - St Joes	United States	NO			Oligoastrocytoma		2022-02	True	LGG	C4	GBM_LGG.G-CIMP-high	0.19333706899999997	0.26	0.04		-2.025	-0.3625	1.0493	-0.8855	0.1315	-0.8206	9.0	1.0	0.122423225	0.45908709200000003	149.0	0.146665724	4.0	10.0				0.693147181	2.0	1.0	3.453858564	-282.45780160000004	-1033.297636	-1824.2165989999999	0.0	503.0	0.0	503.0	7.669495251007694	8.15003491746266	1.1546023961854832	5.366910158013649	7.108581042634499	4.624972813284272	-2.3025850929940455	-1.0414538748281612	3.4703704170987884
13722.58cfa832e4b0c9d6adf6d1e0	58cfa832e4b0c9d6adf6d1e0	TCGA-KL-8323-01A-21D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KL-8323-01A-21D-2310-10_wgs_Illumina	TCGA-KL-8323-01A-21D-2310-10_wgs_Illumina.bam	4.8		0.05	58cfa832e4b0c9d6adf6d1e0	TCGA-KL-8323-01A-21D-2310-10_wgs_Illumina.bam	Dead	FEMALE	WHITE		Kidney Chromophobe	Aligned reads	TCGA-KL-8323-01A	83B3060C-2449-4581-88EF-817D126E4525	Primary Tumor	Illumina HiSeq	8854b195-7eb9-4554-8702-96ed5dd9029f	Kidney	57.0	8AA1A5F6-3548-494A-857B-E08124AEB9A9	FAE88D21-171C-4DF4-B258-3C5948A1034B	TCGA-KL-8323-01A-21D-2310-10	GRCh37-lite	TCGA-KL-8323	TCGA-KICH	1158.0	s16471	Baylor College of Medicine	MSKCC	United States	NO	T3b	NX	Kidney Chromophobe	Stage III	2310-10	True	KICH	C3	KICH.Eosin.0	0.037431274	0.08	0.01		-0.6399	-0.3005	-0.7391	-1.4178	-0.9137	-0.5576	10.0	1.0	0.165586066	0.57955123	88.0	0.947669386	11.0	4.0				1.386294361	4.0	1.0	1.5950741119999998	-1381.651594	-600.8601171	3778.902239	1.0	1158.0	1.0	758.0	6.893047650109863	2.29908691801632	-0.8196936786625171	5.366991346614814	3.9573149946198525	3.121669110937307	-1.5260563034950494	1.6582280766035327	3.9413627895998244
13722.58cfa832e4b0c9d6adf6d1f4	58cfa832e4b0c9d6adf6d1f4	TCGA-IG-A51D-01A-11D-A267_131001_SN1120_0279_AC2DKPACXX_s_3_rg.sorted.filtered.	WGS	TCGA-IG-A51D-01A-11D-A267_131001_SN1120_0279_AC2DKPACXX_s_3_rg.sorted	TCGA-IG-A51D-01A-11D-A267_131001_SN1120_0279_AC2DKPACXX_s_3_rg.sorted.bam	23.75		0.16	58cfa832e4b0c9d6adf6d1f4	TCGA-IG-A51D-01A-11D-A267_131001_SN1120_0279_AC2DKPACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-IG-A51D-01A	F8DBAB24-B9F4-4B8A-BFEA-57856CCF6364	Primary Tumor	Illumina HiSeq	c422f0b8-8f83-4d33-b800-bab29faa7b7b	Esophagus	63.0	3889C9FE-3777-4B3D-9CF1-12135D4D7F7D	02AA44BC-DD51-4A76-B94E-FF273011E904	TCGA-IG-A51D-01A-11D-A267-26	HG19_Broad_variant	TCGA-IG-A51D	TCGA-ESCA		s1825	MD Anderson - Institute for Applied Cancer Science	Asterand	Russia	NO	T1	N1		Stage IIB	A267-26	True	ESCA	C2	GI.ESCC	0.318990194	0.62	0.08		1.2157	0.3655	-0.0518	0.2633	2.0005	0.4146	63.0				173.0	0.43538212	13.0	18.0	0.840856165	4.504118591	212.0	3.9835525869999997	93.0	0.8788671029999999	5.6299917939999995	-407.3546947	849.3390954	-283.5334182	0.0	518.0	0.0	518.0	8.332188036993081	8.456885706806482	0.4183022548688453	6.134963459656862	7.445284795128002	1.8079244060814108	-2.197224577336219	-1.0116009116784803	1.3896221512125655
13722.58cfa832e4b0c9d6adf6d1fa	58cfa832e4b0c9d6adf6d1fa	TCGA-GV-A3JW-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-GV-A3JW-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_7_rg.sorted	TCGA-GV-A3JW-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_7_rg.sorted.bam	45.77		0.15	58cfa832e4b0c9d6adf6d1fa	TCGA-GV-A3JW-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GV-A3JW-01A	3D644EAF-82FC-4BC7-93B7-3E600E8C6511	Primary Tumor	Illumina HiSeq	586abfdd-f50a-4834-8143-3bda5638ea60	Bladder	74.0	B02C03B6-24AA-42D3-9310-741DE1EF0D30	D7EFF32B-E9EB-4891-93D7-4C3D10BE21EA	TCGA-GV-A3JW-01A-11D-A210-26	HG19_Broad_variant	TCGA-GV-A3JW	TCGA-BLCA		s2737	MD Anderson - Institute for Applied Cancer Science	BLN - Cleveland Clinic	United States	NO	T2	NX	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A210-26	True	BLCA	C1	BLCA.1	0.047649042	0.16	0.3	4.907948309	0.5683	0.027000000000000003	-1.7288	-1.6158	-1.3895	-0.4415	34.0	10.0	0.669652082	2.200285412	380.0	0.8392515290000001	12.0	67.0					0.0		1.8892960630000002	-1801.8998510000001	-105.9703101	-736.2762736000001	0.0	649.0	1.0	271.0	5.7906794660190775	6.807594894389501	-0.6139795901454551	4.572107862271989	5.329492984016487	-0.36461929016710304	-1.2185716037470886	-1.4781019103730135	0.24936029997835207
13722.58cfa832e4b0c9d6adf6d20e	58cfa832e4b0c9d6adf6d20e	TCGA-HT-7468-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_5_rg.sorted.filtered.	WGS	TCGA-HT-7468-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_5_rg.sorted	TCGA-HT-7468-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_5_rg.sorted.bam	188.0		0.13	58cfa832e4b0c9d6adf6d20e	TCGA-HT-7468-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HT-7468-01A	E6C55BA6-4C8A-4EA4-8DDE-74D01915DB02	Primary Tumor	Illumina HiSeq	e1855a2f-1904-41ee-ba33-a27e1c202d99	Brain	30.0	D2775F99-CC96-4C72-94FF-E3BA985DC151	143CEFE3-F477-4CDE-AEA6-CE0610835570	TCGA-HT-7468-01A-11D-2022-02	HG19_Broad_variant	TCGA-HT-7468	TCGA-LGG		s8759	Harvard Medical School	Case Western - St Joes	United States	NO			Oligodendroglioma		2022-02	True	LGG	C5	GBM_LGG.Codel	0.02037538	0.01	0.07		-0.7162	-0.267	-0.4442	-2.1277	-0.804	-0.9673	4.0	0.0	0.060070125999999995	0.39045581799999995	80.0	0.212282396	2.0	4.0				0.693147181	2.0	1.0	3.308529886	-118.299943	-83.62748799	-3371.1614520000003	0.0	203.0	0.0	203.0	8.682368589375223	9.280092954809376	-0.8616738026707587	6.485144012039003	8.2302708303107	2.1512746871443635	-2.197224577336219	-1.0498221244986776	3.0129484898151224
13722.58cfa832e4b0c9d6adf6d222	58cfa832e4b0c9d6adf6d222	TCGA-IR-A3LI-01A-11D-A20X_140131_SN590_0247_AC3FDBACXX_s_5_rg.sorted.filtered.	WGS	TCGA-IR-A3LI-01A-11D-A20X_140131_SN590_0247_AC3FDBACXX_s_5_rg.sorted	TCGA-IR-A3LI-01A-11D-A20X_140131_SN590_0247_AC3FDBACXX_s_5_rg.sorted.bam	19.9		0.16	58cfa832e4b0c9d6adf6d222	TCGA-IR-A3LI-01A-11D-A20X_140131_SN590_0247_AC3FDBACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE		Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-IR-A3LI-01A	75BC22D8-738D-45F8-B6C0-C664F5FEF47C	Primary Tumor	Illumina HiSeq	3a9d3f81-919f-44e3-a9cc-813b4dcaf027	Cervix	48.0	EBFA4682-49C9-4AC1-8147-E3860D852D28	689630AD-8262-403B-9983-B4BAE99B8A45	TCGA-IR-A3LI-01A-11D-A20X-26	HG19_Broad_variant	TCGA-IR-A3LI	TCGA-CESC		s1210	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T2b	N1	Endocervical Type of Adenocarcinoma		A20X-26	True	CESC	C4		0.038196696	0.07	0.0	7.141930016	0.5996	0.20199999999999999	-1.7835	-1.9466	0.3333	-0.7559999999999999	146.0	0.0	3.021055325	6.564548788	116.0	0.099706705	1.0	9.0					0.0		2.339731327	-174.6694561	-249.3946954	1399.580354	0.0	2493.0	0.0	2493.0	7.908387159290044	7.308319508490591	1.4298889789535028	5.657095360683549	6.266865633662429	1.782371044632199	-2.251291798606495	-1.0414538748281612	0.3524820656786962
13722.58cfa832e4b0c9d6adf6d234	58cfa832e4b0c9d6adf6d234	TCGA-JX-A3Q8-01A-11D-A245_140206_SN1222_0239_BC2RAKACXX_s_3_rg.sorted.filtered.	WGS	TCGA-JX-A3Q8-01A-11D-A245_140206_SN1222_0239_BC2RAKACXX_s_3_rg.sorted	TCGA-JX-A3Q8-01A-11D-A245_140206_SN1222_0239_BC2RAKACXX_s_3_rg.sorted.bam	63.47		0.14	58cfa832e4b0c9d6adf6d234	TCGA-JX-A3Q8-01A-11D-A245_140206_SN1222_0239_BC2RAKACXX_s_3_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-JX-A3Q8-01A	34629EB8-0C5E-4910-8E13-BF7D6A1E337F	Primary Tumor	Illumina HiSeq	e8f02d77-0077-4817-a34b-ab4ddd64bbd5	Cervix	40.0	28954012-3732-40B0-8EA7-F48CBEEF4105	52CB86FE-6EFF-4FF4-BC53-FD82E04854FB	TCGA-JX-A3Q8-01A-11D-A245-26	HG19_Broad_variant	TCGA-JX-A3Q8	TCGA-CESC		s1380	MD Anderson - Institute for Applied Cancer Science	Washington University	United States	NO	T1b1	N0	Endocervical Type of Adenocarcinoma		A245-26	True	CESC	C2		0.077116197	0.14	0.07		0.9895	0.3915	-0.1903	0.4909	0.6094	-0.5287	28.0	10.0	0.357376505	1.119779715	195.0	0.599271335	15.0	17.0		0.0	1.0	2.884467065	21.0	0.9474284140000001	1.290899751	968.9921142999999	524.6080651000001	-1416.452167	0.0	1357.0	0.0	1357.0	7.360739903058277	7.35158603392385	0.9779920497239486	5.463619918172396	6.198906523985464	1.1126897743669053	-1.897119984885881	-1.1526795099383853	0.13469772464295682
13722.58cfa832e4b0c9d6adf6d246	58cfa832e4b0c9d6adf6d246	TCGA-IA-A40Y-01A-11D-A25F-10_wgs_Illumina.filtered.	WGS	TCGA-IA-A40Y-01A-11D-A25F-10_wgs_Illumina	TCGA-IA-A40Y-01A-11D-A25F-10_wgs_Illumina.bam	22.07		0.08	58cfa832e4b0c9d6adf6d246	TCGA-IA-A40Y-01A-11D-A25F-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-IA-A40Y-01A	1DB41963-A520-47F0-828C-ED5C626507B1	Primary Tumor	Illumina HiSeq	2157f13c-f876-4b2f-91eb-f3ada3c0b2e7	Kidney	60.0	05ACDAC8-480B-43B6-82F5-B0DDC4A1C36F	AD9455E9-7147-489E-9B1F-3540C457C260	TCGA-IA-A40Y-01A-11D-A25F-10	GRCh37-lite	TCGA-IA-A40Y	TCGA-KIRP		s11863	Baylor College of Medicine	Cleveland Clinic	United States	NO	T3a	N1	Kidney Papillary Renal Cell Carcinoma	Stage III	A25F-10	True	KIRP	C4	KIRP.C2b	0.165072608	0.22	0.25		-0.187	0.068	-0.4131	-1.3854	-0.7809999999999999	0.051			0.548457209	1.755063069	99.0	0.77440547	25.0	23.0				0.0	1.0		2.020696987	-1286.643226	-1140.188261	162.5037106	0.0	62.0	0.0	62.0	6.534104763756588	1.6861134212701927	-0.1579282557891758	5.450091274509631	3.38399218782971	2.59943947244025	-1.0840134892469573	1.6978787665595174	2.757367728229426
13722.58cfa832e4b0c9d6adf6d254	58cfa832e4b0c9d6adf6d254	TCGA-IR-A3LA-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_7_rg.sorted.filtered.	WGS	TCGA-IR-A3LA-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_7_rg.sorted	TCGA-IR-A3LA-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_7_rg.sorted.bam	56.17		0.15	58cfa832e4b0c9d6adf6d254	TCGA-IR-A3LA-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE		Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-IR-A3LA-01A	7B8C04D7-824D-493D-8F2C-9ED87A907192	Primary Tumor	Illumina HiSeq	96c944ec-9e55-4b27-aa91-b936b4d7cff5	Cervix	60.0	7925EA80-8AAE-4D99-AFE2-74AD1AAE6D9D	B541AE4A-279F-49A1-9877-1F2226A51737	TCGA-IR-A3LA-01A-11D-A232-26	HG19_Broad_variant	TCGA-IR-A3LA	TCGA-CESC		s1377	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T1b1	N0	Endometrioid Adenocarcinoma of Endocervix		A232-26	True	CESC	C1		0.073300722	0.12	0.16	19.54223941	1.0765	0.2975	-0.3463	0.0407	-0.3879	-0.4357	401.0	25.0	8.235274902999999	21.48532614	197.0	0.333050219	3.0	40.0	0.9434399640000001	1.518408046	5.0	2.48490665	12.0	1.0	5.6940099360000005	-1545.4830789999999	920.3248129000001	214.0363477	0.0	4172.0	0.0	4172.0	9.05118831720887	8.494666356834626	-0.373688538259059	7.105278168153557	7.740894554458246	1.9756374465696678	-1.9459101490553132	-0.7537718023763804	2.349325984828727
13722.58cfa832e4b0c9d6adf6d25c	58cfa832e4b0c9d6adf6d25c	TCGA-JX-A3PZ-01A-11D-A245_140124_SN1440_0179_BD2DRDACXX_s_2_rg.sorted.filtered.	WGS	TCGA-JX-A3PZ-01A-11D-A245_140124_SN1440_0179_BD2DRDACXX_s_2_rg.sorted	TCGA-JX-A3PZ-01A-11D-A245_140124_SN1440_0179_BD2DRDACXX_s_2_rg.sorted.bam	19.49		0.14	58cfa832e4b0c9d6adf6d25c	TCGA-JX-A3PZ-01A-11D-A245_140124_SN1440_0179_BD2DRDACXX_s_2_rg.sorted.bam	Dead	FEMALE	WHITE		Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-JX-A3PZ-01A	3DF6ABE2-2123-4BFA-A4E4-88DF5F940C04	Primary Tumor	Illumina HiSeq	ecad03c2-29cd-48c4-8c37-7eade85970f7	Cervix	25.0	BD39C4C4-A4DD-4B2D-9F3C-608CA8708958	1B04D621-E036-4D1E-9D57-6CCCD0C020D8	TCGA-JX-A3PZ-01A-11D-A245-26	HG19_Broad_variant	TCGA-JX-A3PZ	TCGA-CESC	642.0	s1540	MD Anderson - Institute for Applied Cancer Science	Washington University	United States	NO	T1b	N0	Cervical Squamous Cell Carcinoma		A245-26	True	CESC	C1		0.139714258	0.3	0.07		0.7481	0.545	0.2792	0.0491	0.0338	0.3326	18.0		0.369522394	0.993091432	139.0	0.525050763	9.0	23.0	0.998410969	0.692045748	2.0	0.693147181	2.0	1.0	1.5070861930000001	-443.32024900000005	325.5706351	1076.244691	1.0	642.0	1.0	491.0	6.999878567857943	6.028622695074914	0.5052214654288796	4.748586769251448	5.030093864963788	2.3029257504662546	-2.251291798606495	-0.998528830111127	1.7977042850373752
13722.58cfa832e4b0c9d6adf6d269	58cfa832e4b0c9d6adf6d269	TCGA-K4-A3WS-01A-11D-A23Q_120927_SN208_0432_AC188LACXX_s_1_rg.sorted.filtered.	WGS	TCGA-K4-A3WS-01A-11D-A23Q_120927_SN208_0432_AC188LACXX_s_1_rg.sorted	TCGA-K4-A3WS-01A-11D-A23Q_120927_SN208_0432_AC188LACXX_s_1_rg.sorted.bam	18.56		0.16	58cfa832e4b0c9d6adf6d269	TCGA-K4-A3WS-01A-11D-A23Q_120927_SN208_0432_AC188LACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-K4-A3WS-01A	68ADACD1-A16E-4489-9E68-792A6BD8811C	Primary Tumor	Illumina HiSeq	891c215b-20ad-4eb3-9e53-87910b1d06f4	Bladder	66.0	54070AE0-0C10-4C10-B8BB-A7313B80A45F	F1840542-AEBE-4B4C-BA50-1686740847D4	TCGA-K4-A3WS-01A-11D-A23Q-26	HG19_Broad_variant	TCGA-K4-A3WS	TCGA-BLCA		s3131	MD Anderson - Institute for Applied Cancer Science	ABS - Lahey Clinic	United States	NO	T3a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A23Q-26	True	BLCA	C1	BLCA.2	0.34563909299999995	0.6	0.29	3.6072205860000004	0.19699999999999998	0.021	0.2424	0.9384	0.4838	0.6956	152.0	39.0	2.076240254	7.266840889	135.0	0.468820994	14.0	52.0	0.87688419	3.4477557360000004	51.0	2.523210953	13.0	0.9837273959999999	3.889953091	-946.9574560000001	759.9063158	-3316.911619	0.0	761.0	0.0	761.0	8.431496652127883	7.891309387629086	0.6912060605716006	7.068191809232692	7.980921546318772	2.1353815575621753	-1.3633048428951917	0.08961215868968697	1.4441754969905747
13722.58cfa832e4b0c9d6adf6d279	58cfa832e4b0c9d6adf6d279	TCGA-HT-7475-01A-11D-2022_130913_SN1440_0167_AC2A6PACXX_s_5_rg.sorted.filtered.	WGS	TCGA-HT-7475-01A-11D-2022_130913_SN1440_0167_AC2A6PACXX_s_5_rg.sorted	TCGA-HT-7475-01A-11D-2022_130913_SN1440_0167_AC2A6PACXX_s_5_rg.sorted.bam	79.7		0.15	58cfa832e4b0c9d6adf6d279	TCGA-HT-7475-01A-11D-2022_130913_SN1440_0167_AC2A6PACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HT-7475-01A	41456932-436E-4CDB-BFE8-97D089656786	Primary Tumor	Illumina HiSeq	13942ed5-f37e-4807-b133-369aab923f17	Brain	67.0	5E11FC94-CCDB-4E53-9A9D-5D7707157674	B59DECE1-1DE9-46D3-B5CD-0EFD8F453F8D	TCGA-HT-7475-01A-11D-2022-02	HG19_Broad_variant	TCGA-HT-7475	TCGA-LGG		s8372	Harvard Medical School	Case Western - St Joes	United States	NO			Oligoastrocytoma		2022-02	True	LGG	C5	GBM_LGG.G-CIMP-high	0.049734165999999996	0.16	0.03		-0.7797	-0.276	-0.9356	-2.2887	-0.7671	-1.1737	18.0	60.0	0.42381432	1.331987864	128.0	0.18455729199999998	4.0	22.0				0.0	1.0		3.5431876489999996	-15.39288268	108.942761	-4466.37514	0.0	530.0	0.0	530.0	8.286269452783067	9.161231823794605	-1.778484938019359	6.951268386050726	8.468084643234661	0.9053616613419646	-1.33500106673234	-0.693147180559945	2.6838465993613236
13722.58cfa832e4b0c9d6adf6d284	58cfa832e4b0c9d6adf6d284	TCGA-HT-7481-01A-11D-2022_130913_SN1440_0168_BD2B0UACXX_s_1_rg.sorted.filtered.	WGS	TCGA-HT-7481-01A-11D-2022_130913_SN1440_0168_BD2B0UACXX_s_1_rg.sorted	TCGA-HT-7481-01A-11D-2022_130913_SN1440_0168_BD2B0UACXX_s_1_rg.sorted.bam	22.0		0.13	58cfa832e4b0c9d6adf6d284	TCGA-HT-7481-01A-11D-2022_130913_SN1440_0168_BD2B0UACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HT-7481-01A	BFF37DE3-DC68-4E69-BDFC-8B524DD7774F	Primary Tumor	Illumina HiSeq	fbc2ca18-8dd6-41c3-9ec3-0189f96877ce	Brain	39.0	712405B3-14C4-4C26-9839-1749763D816B	AF69E75D-03C6-4EB0-A0B8-129BE37E30A2	TCGA-HT-7481-01A-11D-2022-02	HG19_Broad_variant	TCGA-HT-7481	TCGA-LGG		s8762	Harvard Medical School	Case Western - St Joes	United States	NO			Oligodendroglioma		2022-02	True	LGG	C5	GBM_LGG.Codel	0.09890927199999999	0.42	0.0		-0.4493	-0.2755	-0.6328	-2.4383	-1.0183	-1.2022	16.0	1.0	0.20655633399999998	0.678685098	57.0	0.051685653	2.0	4.0					0.0		3.3368927680000002	44.68922026	186.16852450000002	-4213.541163	0.0	2918.0	1.0	880.0	7.354362330421477	7.521760860899342	1.5238144607193187	5.157137753085258	6.784161917768563	3.1437236730207143	-2.197224577336219	-0.737598943130779	1.6199092123013956
13722.58cfa832e4b0c9d6adf6d288	58cfa832e4b0c9d6adf6d288	TCGA-HT-7476-01A-11D-2022_130913_SN1440_0167_AC2A6PACXX_s_6_rg.sorted.filtered.	WGS	TCGA-HT-7476-01A-11D-2022_130913_SN1440_0167_AC2A6PACXX_s_6_rg.sorted	TCGA-HT-7476-01A-11D-2022_130913_SN1440_0167_AC2A6PACXX_s_6_rg.sorted.bam	31.7		0.15	58cfa832e4b0c9d6adf6d288	TCGA-HT-7476-01A-11D-2022_130913_SN1440_0167_AC2A6PACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HT-7476-01A	27D0D3CB-16C0-4BA8-9662-95917F665004	Primary Tumor	Illumina HiSeq	8eda6747-01ab-4378-b3c9-6f638de37412	Brain	26.0	50823838-03B8-4CD8-A40D-8439011C9B38	06ABBC57-F759-43B4-AD0A-3CEE74E012B5	TCGA-HT-7476-01A-11D-2022-02	HG19_Broad_variant	TCGA-HT-7476	TCGA-LGG		s8370	Harvard Medical School	Case Western - St Joes	United States	NO			Astrocytoma		2022-02	True	LGG	C4	GBM_LGG.G-CIMP-high	0.162230032	0.29	0.06		-0.9563	-0.1665	-0.2399	-1.6899	-0.8213	-0.4852	4.0	1.0	0.091330576	0.639314032	132.0	0.238811888	3.0	8.0				0.0	1.0		3.409640112	395.4571001	192.6012781	-2872.137093	0.0	199.0	0.0	199.0	8.516259422256146	7.618853998516839	1.1018311004878703	6.670432731757815	7.3776919416999505	2.7338087721512414	-1.8458266904983305	-0.24116205681688774	1.631977671663371
13722.58cfa832e4b0c9d6adf6d28b	58cfa832e4b0c9d6adf6d28b	TCGA-HT-7601-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_5_rg.sorted.filtered.	WGS	TCGA-HT-7601-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_5_rg.sorted	TCGA-HT-7601-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_5_rg.sorted.bam	56.0		0.15	58cfa832e4b0c9d6adf6d28b	TCGA-HT-7601-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HT-7601-01A	E7FDF164-A85D-4FF5-9676-D2215CA35403	Primary Tumor	Illumina HiSeq	5faa261d-a169-4ab5-a52b-de3b50c46299	Brain	30.0	7F6B5679-49E1-498D-BD1F-A757CD7DB4CC	5F766AF5-08F5-4E10-AAED-4B582275CFC1	TCGA-HT-7601-01A-11D-2088-02	HG19_Broad_variant	TCGA-HT-7601	TCGA-LGG		s8153	Harvard Medical School	Case Western - St Joes	United States	NO			Astrocytoma		2088-02	False	LGG	C5	GBM_LGG.G-CIMP-high	0.22869171300000002	0.35	0.0		-0.8169	-0.3055	0.9086	-1.1692	-0.0787	-0.7152	13.0	5.0	0.208515654	0.595759012	49.0	0.04528308599999999	1.0	7.0				1.6674619330000002	6.0	0.9306282240000001	3.100530491	-66.86349039	-374.8939833	-2411.559736	0.0	153.0	0.0	153.0	7.962241509607692	7.254177846456519	0.8685311051426676	5.765016932271473	6.0502050421305835	4.329158874921361	-2.197224577336219	-1.203972804325936	3.460627769778693
13722.58cfa832e4b0c9d6adf6d291	58cfa832e4b0c9d6adf6d291	TCGA-KL-8340-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KL-8340-01A-11D-2310-10_wgs_Illumina	TCGA-KL-8340-01A-11D-2310-10_wgs_Illumina.bam	71.3		0.05	58cfa832e4b0c9d6adf6d291	TCGA-KL-8340-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	WHITE		Kidney Chromophobe	Aligned reads	TCGA-KL-8340-01A	3129E869-BB2F-423A-BD20-D0DAAE33B11A	Primary Tumor	Illumina HiSeq	24326cad-efd9-4017-90e3-2ae8ac037b99	Kidney	34.0	07C3C6E6-D297-4D80-9C28-974FA470A132	D113CE88-04AB-4675-B363-92F80C28DE34	TCGA-KL-8340-01A-11D-2310-10	GRCh37-lite	TCGA-KL-8340	TCGA-KICH		s16477	Baylor College of Medicine	MSKCC	United States	NO	T2	N0	Kidney Chromophobe	Stage II	2310-10	True	KICH	C3	KICH.Eosin.0	0.07512591	0.19	0.0		-1.7711	-0.3915	-0.8004	-1.7934	-0.7290000000000001	-0.6073	3.0		0.127766463	0.332192805	71.0	0.947731639	10.0	1.0					0.0		1.10486454	-1768.871585	-1332.403627	1961.476521	0.0	2024.0	0.0	2024.0	6.8768273581070805	2.078174777541612	-0.04940510730657233	6.278990357351461	3.7254546388112466		-0.5978370007556202	1.6472798612696344	
13722.58cfa832e4b0c9d6adf6d296	58cfa832e4b0c9d6adf6d296	TCGA-KM-8439-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KM-8439-01A-11D-2310-10_wgs_Illumina	TCGA-KM-8439-01A-11D-2310-10_wgs_Illumina.bam	96.3		0.05	58cfa832e4b0c9d6adf6d296	TCGA-KM-8439-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KM-8439-01A	739DEED4-D1DC-458F-BD0F-1E24D2BFD305	Primary Tumor	Illumina HiSeq	1da1e41d-ec72-4c5f-9c1f-50f9606970e1	Kidney	30.0	A59051E9-5155-4073-A4D6-C9A8C54AD118	9D3B0B87-5FC5-4D09-9C63-4D5FC4BC46D0	TCGA-KM-8439-01A-11D-2310-10	GRCh37-lite	TCGA-KM-8439	TCGA-KICH		s16484	Baylor College of Medicine	NCI Urologic Oncology Branch	United States	NO	T1b	NX	Kidney Chromophobe	Stage I	2310-10	True	KICH	C4	KICH.Eosin.1	0.158513436	0.33	0.0		-1.9666	-0.2855	-0.3589	-1.2953	-1.1537	-1.0271	4.0		0.0	0.228772173	51.0	5.2300000000000004e-05	0.0	0.0				0.0	1.0		0.7621871859999999	-1962.713768	-1061.700673	3355.7485810000003	0.0	708.0	0.0	708.0	7.092850762658817	4.4284527315484326	0.9737094967012468	5.100420597968611	3.856710841575664	5.222570972045306	-1.9924301646902063	-0.5717418899727686	4.248861475344059
13722.58cfa832e4b0c9d6adf6d29a	58cfa832e4b0c9d6adf6d29a	TCGA-KL-8343-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KL-8343-01A-11D-2310-10_wgs_Illumina	TCGA-KL-8343-01A-11D-2310-10_wgs_Illumina.bam	71.3		0.05	58cfa832e4b0c9d6adf6d29a	TCGA-KL-8343-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KL-8343-01A	B4A0BF74-1381-4C17-B97D-206810D9E59A	Primary Tumor	Illumina HiSeq	a7a4a6a6-4a0b-4611-9bd4-1d86b0ddf49c	Kidney	72.0	FFE4DFE1-B2FE-448E-8664-8299484FC809	34739BD6-B3BE-441D-8CDB-E4233BF14080	TCGA-KL-8343-01A-11D-2310-10	GRCh37-lite	TCGA-KL-8343	TCGA-KICH		s16394	Baylor College of Medicine	MSKCC	United States	NO	T3	N0	Kidney Chromophobe	Stage III	2310-10	True	KICH	C5	KICH.Eosin.1	0.060719256	0.25	0.06		-1.97	-0.36	-0.6861	-1.9880000000000002	-0.5162	-0.7387	13.0	26.0	0.17598316100000003	0.678792191	43.0	0.40611381799999996	7.0	5.0					0.0		1.43592782	-1350.90827	-1514.243306	4363.6979200000005	1.0	2172.0	1.0	2172.0	6.626055278207904	4.435737584286888	0.8732227407835206	4.754253101306313	3.580969667539285	2.7880929087757464	-1.8718021769015916	-0.854767916747603	1.914870167992226
13722.58cfa832e4b0c9d6adf6d29d	58cfa832e4b0c9d6adf6d29d	TCGA-KM-8438-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KM-8438-01A-11D-2310-10_wgs_Illumina	TCGA-KM-8438-01A-11D-2310-10_wgs_Illumina.bam	40.3		0.05	58cfa832e4b0c9d6adf6d29d	TCGA-KM-8438-01A-11D-2310-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KM-8438-01A	23656226-2D99-4548-959F-5C2EED803E33	Primary Tumor	Illumina HiSeq	171af111-4e87-4e89-af1b-ee3fbed93db6	Kidney	45.0	3CBDEE56-19F7-4A7A-850E-A7664E67C919	148536CE-EE2A-4952-A19D-10D6F44146B9	TCGA-KM-8438-01A-11D-2310-10	GRCh37-lite	TCGA-KM-8438	TCGA-KICH		s16399	Baylor College of Medicine	NCI Urologic Oncology Branch	United States	NO	T2	N0	Kidney Chromophobe	Stage II	2310-10	True	KICH	C3	KICH.Eosin.0	0.081179352	0.28	0.0		-2.1352	-0.4445	-0.6159	-1.3762	-0.8139	-0.5527	11.0	30.0	0.127459467	0.58631355	81.0	0.833996947	30.0	0.0				0.0	1.0		1.056907584	-1189.076358	-1280.32439	2154.461841	0.0	4622.0	1.0	2317.0	6.905586261697298	1.0601239080265046	0.17834540841431523	5.956505707000152	2.6774116539165185	2.8047842740703626	-0.9490805546971459	1.617287745890014	2.6264388656560476
13722.58cfa832e4b0c9d6adf6d2a0	58cfa832e4b0c9d6adf6d2a0	TCGA-KM-8477-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KM-8477-01A-11D-2310-10_wgs_Illumina	TCGA-KM-8477-01A-11D-2310-10_wgs_Illumina.bam	26.3		0.05	58cfa832e4b0c9d6adf6d2a0	TCGA-KM-8477-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KM-8477-01A	9680B5FF-1882-434F-9981-E8AC33764B93	Primary Tumor	Illumina HiSeq	af92bfa8-a70f-4436-b545-46899487c859	Kidney	56.0	50DA0237-8E9D-4C08-AE44-F32103E8F095	4ECBFD89-393F-4126-AA1C-951A2C23EF89	TCGA-KM-8477-01A-11D-2310-10	GRCh37-lite	TCGA-KM-8477	TCGA-KICH		s16397	Baylor College of Medicine	NCI Urologic Oncology Branch	United States	NO	T1a	NX	Kidney Chromophobe	Stage I	2310-10	True	KICH	C3	KICH.Eosin.1	0.12120508099999999	0.35	0.0		-1.8079	-0.505	-0.4328	-1.6191	-0.5631	-0.629	6.0	0.0	0.22989245600000002	0.40869770000000005	37.0	7.34e-06	0.0	0.0					0.0		0.846918355	-554.920388	-1035.084507	4355.45198	0.0	1553.0	0.0	1553.0	6.906879895946183	1.9190558592127047	0.09611614398254908	6.041882458459579	3.493890534493886	2.248676892158231	-0.8649974374866045	1.5748346752811813	2.152560748175682
13722.58cfa832e4b0c9d6adf6d2a6	58cfa832e4b0c9d6adf6d2a6	TCGA-IR-A3LL-01A-11D-A20X_140117_SN590_0245_AC371LACXX_s_4_rg.sorted.filtered.	WGS	TCGA-IR-A3LL-01A-11D-A20X_140117_SN590_0245_AC371LACXX_s_4_rg.sorted	TCGA-IR-A3LL-01A-11D-A20X_140117_SN590_0245_AC371LACXX_s_4_rg.sorted.bam	66.26		0.15	58cfa832e4b0c9d6adf6d2a6	TCGA-IR-A3LL-01A-11D-A20X_140117_SN590_0245_AC371LACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE		Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-IR-A3LL-01A	7C4AB1CA-4BDD-4EF7-9A42-F6C0C7136D26	Primary Tumor	Illumina HiSeq	817ccf3b-ceaa-45cf-a938-67e531a9f57a	Cervix	60.0	A0FB972A-CE8F-441F-8707-C3CC1081DEE0	5457562E-E184-4D13-B11C-49728B689275	TCGA-IR-A3LL-01A-11D-A20X-26	HG19_Broad_variant	TCGA-IR-A3LL	TCGA-CESC		s1378	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T1b1	N0	Cervical Squamous Cell Carcinoma		A20X-26	True	CESC	C2		0.391936965	0.5	0.03		0.7944	0.3585	0.7435	1.3838	2.0299	-0.4066	182.0		3.221483865	8.148459187	115.0	0.79974405	13.0	11.0				3.314981313	42.0	0.8869112709999999	1.181464216	190.0436749	180.9455881	-2832.605311	0.0	1106.0	0.0	1106.0	8.17287021825031	7.67252520321505	1.1893572697634964	5.870285125256265	6.631071328386889	1.9732730384441457	-2.3025850929940455	-1.0414538748281612	0.7839157686806493
13722.58cfa832e4b0c9d6adf6d2a8	58cfa832e4b0c9d6adf6d2a8	TCGA-HT-7604-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_6_rg.sorted.filtered.	WGS	TCGA-HT-7604-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_6_rg.sorted	TCGA-HT-7604-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_6_rg.sorted.bam	175.0		0.13	58cfa832e4b0c9d6adf6d2a8	TCGA-HT-7604-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_6_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HT-7604-01A	019C5DE9-74FD-48B7-95A3-227532E16C5A	Primary Tumor	Illumina HiSeq	b3d0b563-b12d-4872-9a0c-f795ca13842f	Brain	50.0	9CA3488A-91F8-4EB2-8B03-24E8629757E1	31412731-7A51-4E73-BFC4-0098275D633B	TCGA-HT-7604-01A-11D-2088-02	HG19_Broad_variant	TCGA-HT-7604	TCGA-LGG		s8575	Harvard Medical School	Case Western - St Joes	United States	NO			Astrocytoma		2088-02	False	LGG	C5	GBM_LGG.G-CIMP-high	0.041001539	0.05	0.99		-0.1788	-0.289	-0.4402	-2.7727	-0.8568	-1.1954	24.0	34.0	0.391420119	1.144151118	109.0	0.111379801	1.0	8.0					0.0		3.06692573	-194.6674716	-53.73325903	-4609.888405	0.0	3725.0	0.0	3725.0	7.53955882930103	7.421875469697559	2.0285928486621816	5.64243884441515	6.323263181029449	1.7396690027986288	-1.897119984885881	-1.0986122886681096	-0.2889238458635526
13722.58cfa832e4b0c9d6adf6d2aa	58cfa832e4b0c9d6adf6d2aa	TCGA-KL-8326-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KL-8326-01A-11D-2310-10_wgs_Illumina	TCGA-KL-8326-01A-11D-2310-10_wgs_Illumina.bam	71.3		0.05	58cfa832e4b0c9d6adf6d2aa	TCGA-KL-8326-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	WHITE		Kidney Chromophobe	Aligned reads	TCGA-KL-8326-01A	03F3DD32-E1D1-485B-A968-3F55798F4D46	Primary Tumor	Illumina HiSeq	b96eaa8e-2627-4ac2-a3fb-1140269babf6	Kidney	69.0	59703768-8BE1-47A7-8C7D-D794C0936019	4729FE4B-C1AC-489B-A67E-91E5C5E3FF8C	TCGA-KL-8326-01A-11D-2310-10	GRCh37-lite	TCGA-KL-8326	TCGA-KICH		s16519	Baylor College of Medicine	MSKCC	United States	NO	T3a	N0	Kidney Chromophobe	Stage III	2310-10	True	KICH	C3	KICH.Eosin.1	0.036064703	0.18	0.01		-2.3009	-0.4215	-1.6091	-2.0141	-1.2862	-1.0108	10.0	2.0	0.18136196	0.54408588	55.0	0.04919083	1.0	5.0		0.0	1.0		0.0		1.19399497	-1541.3177779999999	-1497.8583019999999	4177.40299	0.0	3322.0	0.0	3322.0	6.3953659332399635	2.6754063530258474	-0.7760059101194279	5.702218752680018	3.9470234936337576	1.5081590350959229	-0.6931471805599454	1.2716171406079102	2.2841649452153505
13722.58cfa832e4b0c9d6adf6d2b6	58cfa832e4b0c9d6adf6d2b6	TCGA-KL-8332-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KL-8332-01A-11D-2310-10_wgs_Illumina	TCGA-KL-8332-01A-11D-2310-10_wgs_Illumina.bam	71.3		0.05	58cfa832e4b0c9d6adf6d2b6	TCGA-KL-8332-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	WHITE		Kidney Chromophobe	Aligned reads	TCGA-KL-8332-01A	3EC3BCB3-492C-4942-BE02-76A67F57E38F	Primary Tumor	Illumina HiSeq	b51b4316-5d7e-4f98-96f9-01d644b87e6d	Kidney	55.0	CD734D15-92C6-4B43-A5D3-EC823F6B9DC2	C6D6F49E-6E95-4E41-8388-71F6FE017D80	TCGA-KL-8332-01A-11D-2310-10	GRCh37-lite	TCGA-KL-8332	TCGA-KICH		s16520	Baylor College of Medicine	MSKCC	United States	NO	T1b	N0	Kidney Chromophobe	Stage I	2310-10	True	KICH	C3	KICH.Eosin.0	0.158036688	0.24	0.0		-1.8473	-0.4935	-0.2075	-0.8272	-0.3764	-0.6653	11.0	46.0	0.077956687	0.519711244	43.0	0.94771526	13.0	0.0				1.039720771	3.0	0.94639463	1.0089394059999999	-553.2380228999999	-1608.2819359999999	3203.338748	0.0	2582.0	0.0	2582.0	6.627159152919841	2.6398983725580223	0.397554662595356	5.901222149536905	3.8475238923810613		-0.7259370033829362	1.207625519823039	
13722.58cfa832e4b0c9d6adf6d2b8	58cfa832e4b0c9d6adf6d2b8	TCGA-KL-8331-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KL-8331-01A-11D-2310-10_wgs_Illumina	TCGA-KL-8331-01A-11D-2310-10_wgs_Illumina.bam	125.3		0.05	58cfa832e4b0c9d6adf6d2b8	TCGA-KL-8331-01A-11D-2310-10_wgs_Illumina.bam	Alive	FEMALE	WHITE		Kidney Chromophobe	Aligned reads	TCGA-KL-8331-01A	8AC7F218-BD7B-4DDA-8879-2CEC49748E42	Primary Tumor	Illumina HiSeq	30f11cbf-417b-4a4a-b440-1c22bfc3b225	Kidney	48.0	EEA84BEB-0F41-4120-A350-6F31EC8712BB	7087A2B6-7FC4-45B0-8C48-248864F03DEB	TCGA-KL-8331-01A-11D-2310-10	GRCh37-lite	TCGA-KL-8331	TCGA-KICH		s16421	Baylor College of Medicine	MSKCC	United States	NO	T2	N0	Kidney Chromophobe	Stage II	2310-10	True	KICH	C3	KICH.Eosin.0	0.024798271	0.06	0.05		-1.2425	-0.3965	-1.1102	-1.8278	-1.2735	-0.8289	13.0	0.0	0.33633040799999997	0.46568825700000005	75.0	0.9477302459999999	13.0	1.0					0.0		1.32948976	-1389.416461	-1610.099234	3406.1017229999998	0.0	3010.0	0.0	3010.0	6.499142364583241	1.8757668604153128	-0.13342108431267952	5.672463791398773	2.1795401461296313	2.7561787708049037	-0.8266785731844681	0.3037732857143185	2.889599855117583
13722.58cfa832e4b0c9d6adf6d2bd	58cfa832e4b0c9d6adf6d2bd	TCGA-KL-8341-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KL-8341-01A-11D-2310-10_wgs_Illumina	TCGA-KL-8341-01A-11D-2310-10_wgs_Illumina.bam	167.0		0.05	58cfa832e4b0c9d6adf6d2bd	TCGA-KL-8341-01A-11D-2310-10_wgs_Illumina.bam	Dead	MALE	ASIAN		Kidney Chromophobe	Aligned reads	TCGA-KL-8341-01A	70E306EE-9584-49D6-81A1-A49D837AB6AA	Primary Tumor	Illumina HiSeq	507c9643-76a6-4c30-9802-a174ce2a0c8f	Kidney	41.0	EDF08A41-2AD2-4D1A-B567-5BE518A33469	E9032DF3-8692-4146-A867-B9B64C9B310A	TCGA-KL-8341-01A-11D-2310-10	GRCh37-lite	TCGA-KL-8341	TCGA-KICH	754.0	s16481	Baylor College of Medicine	MSKCC	United States	NO	T3b	N2	Kidney Chromophobe	Stage IV	2310-10	True	KICH	C5	KICH.Eosin.0	0.012599164	0.04	0.15		-0.2675	-0.294	-1.4316	-2.8632	-1.4339	-1.0755	18.0	4.0	0.279470579	0.9146309859999999	218.0	0.826196488	12.0	14.0					0.0		1.017869415	-1944.911484	-411.48810530000003	2376.654913	1.0	754.0	1.0	175.0	6.970917853939777	2.904443343050686	-0.52804348871349	5.361479941505676	5.015221036779469	0.87378947583418	-1.6094379124341003	2.1107776937287825	1.40183296454767
13722.58cfa832e4b0c9d6adf6d2c4	58cfa832e4b0c9d6adf6d2c4	TCGA-KL-8337-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KL-8337-01A-11D-2310-10_wgs_Illumina	TCGA-KL-8337-01A-11D-2310-10_wgs_Illumina.bam	168.3		0.05	58cfa832e4b0c9d6adf6d2c4	TCGA-KL-8337-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN		Kidney Chromophobe	Aligned reads	TCGA-KL-8337-01A	5F633C79-FCF8-47DA-B349-ADA3FB794819	Primary Tumor	Illumina HiSeq	283efb4c-4edf-48c2-975a-9578517c0270	Kidney	26.0	988D64CE-EE26-4837-8161-86C4831BE203	A3FD2EE0-3DD0-4992-9A9F-75E487B43441	TCGA-KL-8337-01A-11D-2310-10	GRCh37-lite	TCGA-KL-8337	TCGA-KICH		s16390	Baylor College of Medicine	MSKCC	United States	NO	T2	N0	Kidney Chromophobe	Stage II	2310-10	True	KICH	C5	KICH.Eosin.0	0.031441002999999995	0.06	0.82		-1.8926	-0.45299999999999996	-1.1676	-2.3721	-1.028	-0.8715	8.0		0.076791521	0.40955478	94.0	0.95454635	12.0	0.0					0.0		1.4504347169999998	-955.3516055	-1614.571342	3832.715243	0.0	1364.0	0.0	1364.0	7.244227515603351	3.570284753743125	-0.30892941765909554	5.539479423364925	3.1057307292649545	2.1127611307558634	-1.7047480922384255	-0.4645540244781703	2.4216905484149587
13722.58cfa832e4b0c9d6adf6d2d0	58cfa832e4b0c9d6adf6d2d0	TCGA-KL-8333-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KL-8333-01A-11D-2310-10_wgs_Illumina	TCGA-KL-8333-01A-11D-2310-10_wgs_Illumina.bam	46.3		0.05	58cfa832e4b0c9d6adf6d2d0	TCGA-KL-8333-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	WHITE		Kidney Chromophobe	Aligned reads	TCGA-KL-8333-01A	02EC7A3A-2812-4A65-93CD-07BF655CC91B	Primary Tumor	Illumina HiSeq	824e5509-79ee-455a-8650-3c757cdf6fbf	Kidney	69.0	77186D62-B354-49A4-8A2A-12F5F6B938F6	C56505CB-E150-408D-9DF6-3AF4E608C376	TCGA-KL-8333-01A-11D-2310-10	GRCh37-lite	TCGA-KL-8333	TCGA-KICH		s16434	Baylor College of Medicine	MSKCC	United States	NO	T2	N0	Kidney Chromophobe	Stage II	2310-10	True	KICH	C3	KICH.Eosin.0	0.406402111				-1.8488	-0.3185	0.5338	0.9354	-0.4112	-0.1346	7.0	6.0	0.127867407	0.332455259	57.0	0.226097353	7.0	5.0	0.8728066440000001	3.55890177	59.0	2.8943995439999997	19.0	0.9830054429999999	1.4468561290000002	669.030057	-1028.789072	3037.029382	0.0	2991.0	0.0	2991.0	7.881219980130809	2.086253041564323	0.9746234888041799	6.572887160480631	3.947178978321775	1.5194381877678542	-1.3083328196501784	1.860925936757452	0.5448146989636744
13722.58cfa832e4b0c9d6adf6d2d4	58cfa832e4b0c9d6adf6d2d4	TCGA-KL-8346-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KL-8346-01A-11D-2310-10_wgs_Illumina	TCGA-KL-8346-01A-11D-2310-10_wgs_Illumina.bam	69.8		0.05	58cfa832e4b0c9d6adf6d2d4	TCGA-KL-8346-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	WHITE		Kidney Chromophobe	Aligned reads	TCGA-KL-8346-01A	A122D361-835E-4CF2-850F-AF7864AA112C	Primary Tumor	Illumina HiSeq	bed80d0d-f127-4c4f-9a1f-2c032aa9b498	Kidney	62.0	ABCF54FE-D93E-4C3B-ACD0-757CDD6A3D3B	BD2EC47B-A120-4B3B-B10D-AEE09805AB33	TCGA-KL-8346-01A-11D-2310-10	GRCh37-lite	TCGA-KL-8346	TCGA-KICH		s16429	Baylor College of Medicine	MSKCC	United States	NO	T2b	N0	Kidney Chromophobe	Stage II	2310-10	True	KICH	C3	KICH.Eosin.0	0.002557745	0.01	0.03		-1.3519999999999999	-0.48700000000000004	-2.1043	-2.9089	-1.6209	-0.6899	5.0	3.0	0.105061523	0.420246091	93.0	0.9476898690000001	17.0	5.0					0.0		1.226677635	-2045.5190079999998	-1983.91093	3814.6869469999997	0.0	1897.0	0.0	1897.0	7.095478885065086	3.3215764869593096	-1.2599507198585638	5.185936380180648	3.2386384353573163	1.6352519653072664	-1.9095425048844386	-0.0829380516019933	2.89520268516583
13722.58cfa832e4b0c9d6adf6d2da	58cfa832e4b0c9d6adf6d2da	TCGA-KL-8334-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KL-8334-01A-11D-2310-10_wgs_Illumina	TCGA-KL-8334-01A-11D-2310-10_wgs_Illumina.bam	71.3		0.05	58cfa832e4b0c9d6adf6d2da	TCGA-KL-8334-01A-11D-2310-10_wgs_Illumina.bam	Alive	FEMALE	WHITE		Kidney Chromophobe	Aligned reads	TCGA-KL-8334-01A	9AABCBD7-A26A-49B1-ABF1-02C0DC3ADCF2	Primary Tumor	Illumina HiSeq	8f7d6dce-86ff-4bee-b2df-12b2ff95f653	Kidney	37.0	E9938C51-8FC6-4ED0-9201-E51C0E943D1F	94434272-4CBD-4B4D-BD98-44F18526DD69	TCGA-KL-8334-01A-11D-2310-10	GRCh37-lite	TCGA-KL-8334	TCGA-KICH		s16485	Baylor College of Medicine	MSKCC	United States	NO	T3a	N0	Kidney Chromophobe	Stage III	2310-10	True	KICH	C3	KICH.Eosin.0	0.139558648	0.2	0.0		-1.871	-0.32	-0.0418	-0.6112	-0.2095	-0.5205	4.0	39.0	0.10258866300000001	0.23082449300000002	76.0	0.9477271290000001	10.0	0.0				1.33217904	4.0	0.960964047	1.554013579	-1692.047285	-1288.842468	1889.251161	0.0	2949.0	0.0	2949.0	7.487259878821222	1.1877317363375806	0.4720837131990634	6.363329782168822	2.6687946981586697		-1.1239300966523995	1.481062961821089	
13722.58cfa832e4b0c9d6adf6d2dc	58cfa832e4b0c9d6adf6d2dc	TCGA-KL-8342-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KL-8342-01A-11D-2310-10_wgs_Illumina	TCGA-KL-8342-01A-11D-2310-10_wgs_Illumina.bam	71.3		0.05	58cfa832e4b0c9d6adf6d2dc	TCGA-KL-8342-01A-11D-2310-10_wgs_Illumina.bam	Alive	FEMALE	WHITE		Kidney Chromophobe	Aligned reads	TCGA-KL-8342-01A	C689AE1D-4A6B-45DB-B4D1-6B34C5C61522	Primary Tumor	Illumina HiSeq	1f1d17e4-280b-4955-97a5-75180878dc8e	Kidney	45.0	BC04E860-2CB8-4D90-BC17-F3A4D6A09881	F38FC6AC-2AF8-4D89-A514-4E2C5FDF08DE	TCGA-KL-8342-01A-11D-2310-10	GRCh37-lite	TCGA-KL-8342	TCGA-KICH		s16483	Baylor College of Medicine	MSKCC	United States	NO	T2b	N0	Kidney Chromophobe	Stage II	2310-10	True	KICH	C3	KICH.Eosin.0	0.083268017				-1.858	-0.4365	-0.1059	-0.6316	-0.20600000000000002	-0.4981	11.0		0.12756451900000002	0.48474517200000006	79.0	0.9476599309999999	10.0	0.0				1.791759469	6.0	1.0	1.2500036559999999	-1130.987294	-1428.761825	2690.5364280000003	0.0	2248.0	0.0	2248.0	6.857664269079656	1.5969511086477537	0.28495258639240306	5.436278588148495	2.4676242086392532	3.4906424420140816	-1.421385680931161	0.8706730999914996	3.2056898556216784
13722.58cfa832e4b0c9d6adf6d2e0	58cfa832e4b0c9d6adf6d2e0	TCGA-KL-8330-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KL-8330-01A-11D-2310-10_wgs_Illumina	TCGA-KL-8330-01A-11D-2310-10_wgs_Illumina.bam	210.3		0.05	58cfa832e4b0c9d6adf6d2e0	TCGA-KL-8330-01A-11D-2310-10_wgs_Illumina.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KL-8330-01A	0F3C4F8F-0766-46B0-81B4-18CA4F6EA20A	Primary Tumor	Illumina HiSeq	ee57fec3-c6dc-4fef-9340-d24a48421fe8	Kidney	44.0	81431ED0-D762-4131-895B-852B2F78786D	09537DCE-C797-4B60-962A-D4C3CD6AB00A	TCGA-KL-8330-01A-11D-2310-10	GRCh37-lite	TCGA-KL-8330	TCGA-KICH		s16522	Baylor College of Medicine	MSKCC	United States	NO	T2b	N0	Kidney Chromophobe	Stage II	2310-10	True	KICH	C5	KICH.Eosin.1	0.007333841999999999	0.03	0.79		-1.8254	-0.506	-1.5398	-2.665	-1.3869	-0.9422	10.0	1.0	0.181118355	0.49160696299999995	75.0	0.947728131	12.0	0.0					0.0		1.215868583	-1545.496634	-1284.441934	3016.539657	0.0	3304.0	0.0	3304.0	6.184759624600256	2.1609107978653466	-0.32962399989312396	5.869678577960361	3.64448967309328	2.197724952628121	-0.3150810466398952	1.4835788752279333	2.527348952521245
13722.58cfa832e4b0c9d6adf6d2e2	58cfa832e4b0c9d6adf6d2e2	TCGA-KL-8344-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KL-8344-01A-11D-2310-10_wgs_Illumina	TCGA-KL-8344-01A-11D-2310-10_wgs_Illumina.bam	156.3		0.05	58cfa832e4b0c9d6adf6d2e2	TCGA-KL-8344-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	WHITE		Kidney Chromophobe	Aligned reads	TCGA-KL-8344-01A	A5AF1391-89D3-4F41-930E-7E8272AFEC98	Primary Tumor	Illumina HiSeq	85c6bd93-8e9d-43f8-ad70-a8d080e1c284	Kidney	51.0	4CEA843F-80AE-4284-B70F-8989717EEE7C	3ACE181A-23BD-424E-A87E-E0C01A2A2CB8	TCGA-KL-8344-01A-11D-2310-10	GRCh37-lite	TCGA-KL-8344	TCGA-KICH		s16474	Baylor College of Medicine	MSKCC	United States	NO	T3a	N0	Kidney Chromophobe	Stage III	2310-10	True	KICH	C3	KICH.Eosin.1	0.062934217	0.26	0.0		-1.3780000000000001	-0.307	-0.3989	-1.4185	-0.9552	-0.0542	11.0		0.176797188	0.353594375	81.0	0.181572801	2.0	0.0		0.0	1.0	0.0	1.0		0.952193338	-1131.0745630000001	-1081.5417929999999	1251.960102	0.0	876.0	0.0	876.0	7.211966653385128	1.0453843546601131	-0.894898423917982	5.720311776607412	2.73681233236909		-1.4916548767777167	1.691427977708977	
13722.58cfa832e4b0c9d6adf6d2e6	58cfa832e4b0c9d6adf6d2e6	TCGA-KM-8476-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KM-8476-01A-11D-2310-10_wgs_Illumina	TCGA-KM-8476-01A-11D-2310-10_wgs_Illumina.bam	50.3		0.05	58cfa832e4b0c9d6adf6d2e6	TCGA-KM-8476-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KM-8476-01A	4E4FAF51-2CBF-4910-A093-186660E4A19B	Primary Tumor	Illumina HiSeq	bcb52a60-30eb-4af3-8ec1-512d6157e6be	Kidney	47.0	450DFCB0-F059-4427-9A72-EA51DC48956E	5BEBC389-DE0D-45B8-9D2F-6476988C358A	TCGA-KM-8476-01A-11D-2310-10	GRCh37-lite	TCGA-KM-8476	TCGA-KICH		s16391	Baylor College of Medicine	NCI Urologic Oncology Branch	United States	NO	T1	NX	Kidney Chromophobe	Stage I	2310-10	True	KICH	C3	KICH.Eosin.0	0.030243729	0.12	0.0		-2.0884	-0.42	-0.6776	-1.4801	-1.0722	-0.897	15.0		0.282956147	0.6688054379999999	69.0	0.9477299640000001	12.0	0.0				0.693147181	2.0	1.0	0.991671731	-1268.6597140000001	-1244.884791	3635.639025	0.0	3745.0	0.0	3745.0	7.5940792341939565	2.7816404409119837	1.034565213832976	5.802319764965901	2.3476019603597633		-1.7917594692280552	-0.4340384805522204	
13722.58cfa832e4b0c9d6adf6d2f5	58cfa832e4b0c9d6adf6d2f5	TCGA-KN-8424-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KN-8424-01A-11D-2310-10_wgs_Illumina	TCGA-KN-8424-01A-11D-2310-10_wgs_Illumina.bam	71.3		0.05	58cfa832e4b0c9d6adf6d2f5	TCGA-KN-8424-01A-11D-2310-10_wgs_Illumina.bam	Alive	FEMALE	WHITE		Kidney Chromophobe	Aligned reads	TCGA-KN-8424-01A	8C9E1F60-1838-4AA4-A667-C1CEF7DDDBDF	Primary Tumor	Illumina HiSeq	5c114c89-2e86-497d-a02e-e309eee59dc0	Kidney	42.0	93B1AE00-43E1-466C-BBC1-8755CB1A1A0C	1E8AE8DD-74C1-44D5-A74E-BFDCE801C736	TCGA-KN-8424-01A-11D-2310-10	GRCh37-lite	TCGA-KN-8424	TCGA-KICH		s16524	Baylor College of Medicine	Harvard	United States	NO	T1b	N0	Kidney Chromophobe	Stage I	2310-10	True	KICH	C3	KICH.Eosin.0	0.131341227	0.15	0.03		-1.5072	-0.331	0.2748	-0.7721	-0.3293	-0.4062	11.0	8.0	0.209427587	0.6806396579999999	73.0	0.905015195	11.0	4.0				1.039720771	3.0	0.94639463	1.023898166	-1220.3365800000001	-1605.92939	2565.127628	0.0	1983.0	0.0	1983.0	7.193497972052866	1.0580585480740101	0.12142928177281642	6.355168781648423	4.235217294927632	3.1600904197462483	-0.8383291904044432	3.177158746853622	3.038661137973432
13722.58cfa832e4b0c9d6adf6d2f9	58cfa832e4b0c9d6adf6d2f9	TCGA-KN-8426-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KN-8426-01A-11D-2310-10_wgs_Illumina	TCGA-KN-8426-01A-11D-2310-10_wgs_Illumina.bam	110.3		0.05	58cfa832e4b0c9d6adf6d2f9	TCGA-KN-8426-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	WHITE		Kidney Chromophobe	Aligned reads	TCGA-KN-8426-01A	B08DFBA8-6AFB-4217-9259-72BE6F1F3363	Primary Tumor	Illumina HiSeq	d5461fca-308e-41be-a207-bdb698350564	Kidney	50.0	8A7FAD85-8756-4411-BE2B-A87159B843A5	A3DEAFCB-B54F-4B7E-89AC-C92C16FB919F	TCGA-KN-8426-01A-11D-2310-10	GRCh37-lite	TCGA-KN-8426	TCGA-KICH		s16473	Baylor College of Medicine	Harvard	United States	NO	T3a	NX	Kidney Chromophobe	Stage IV	2310-10	True	KICH	C4	KICH.Eosin.0	0.136817827	0.13	0.06		-1.0493	-0.3985	-0.1081	-1.1332	-1.0521	-0.61	15.0		0.179514245	0.794991655	108.0	0.903191242	21.0	5.0				1.386294361	4.0	1.0	1.5525870169999998	-2011.2444670000002	-943.9140719000001	3837.566969	0.0	108.0	0.0	108.0	5.596362226035364	2.8522166642499682	0.3940286089595447	4.749064365648161	2.3882961899576385	3.1564855322689187	-0.8472978603872034	-0.46392047429232974	2.762456923309374
13722.58cfa832e4b0c9d6adf6d2fa	58cfa832e4b0c9d6adf6d2fa	TCGA-KM-8443-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KM-8443-01A-11D-2310-10_wgs_Illumina	TCGA-KM-8443-01A-11D-2310-10_wgs_Illumina.bam	71.3		0.05	58cfa832e4b0c9d6adf6d2fa	TCGA-KM-8443-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KM-8443-01A	2F1C4DB6-88A7-4A5D-A5FE-94D85F569440	Primary Tumor	Illumina HiSeq	eecb2ae5-92c3-432e-be0c-d7463b8efbb1	Kidney	57.0	F606FE9C-7D9F-4615-AB16-0BB4C796ADEA	C00DE7A0-0B09-4E07-988C-EF2A7F8E932A	TCGA-KM-8443-01A-11D-2310-10	GRCh37-lite	TCGA-KM-8443	TCGA-KICH		s16528	Baylor College of Medicine	NCI Urologic Oncology Branch	United States	NO	T2	N0	Kidney Chromophobe	Stage II	2310-10	True	KICH	C5	KICH.Eosin.1	0.008661707	0.12	0.0		-1.12	-0.4255	-1.7263	-2.7460000000000004	-1.4637	-1.0924	17.0	1.0	0.077268113	0.772681127	324.0	0.859755652	29.0	0.0					0.0		0.967626668	-1420.129269	-1321.069327	3569.292129	0.0	1520.0	0.0	1520.0	6.457656573590391	1.736753981549251	-0.47899090024597213	6.066790264903379	3.351577558087829	1.813664304616105	-0.3908663086870119	1.614823576538578	2.292655204862077
13722.58cfa832e4b0c9d6adf6d2fc	58cfa832e4b0c9d6adf6d2fc	TCGA-KM-8442-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KM-8442-01A-11D-2310-10_wgs_Illumina	TCGA-KM-8442-01A-11D-2310-10_wgs_Illumina.bam	71.3		0.05	58cfa832e4b0c9d6adf6d2fc	TCGA-KM-8442-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE		HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KM-8442-01A	40F79CFE-A51F-497B-B06E-7A4F9004F092	Primary Tumor	Illumina HiSeq	7555ac98-9d69-49ff-a604-7ee15dbf1190	Kidney	38.0	839592BE-2687-4996-ACF8-0BFDE2B2BE22	9FB73D89-F7C4-47B2-810B-3CE37CD8A3C9	TCGA-KM-8442-01A-11D-2310-10	GRCh37-lite	TCGA-KM-8442	TCGA-KICH		s16392	Baylor College of Medicine	NCI Urologic Oncology Branch	United States	NO	T2	NX	Kidney Chromophobe	Stage II	2310-10	True	KICH	C3	KICH.Eosin.0	0.033226583	0.06	0.0		-2.3108	-0.4355	-0.6076	-1.4949	-0.7386	-0.3745	10.0	1.0	0.234595104	0.36492571700000004	77.0	0.9476700140000001	12.0	0.0				0.0	1.0		1.453100354	-189.00453149999998	-1604.345408	3104.532752	0.0	1437.0	0.0	1437.0	6.754604099487963	4.181252285415318	0.8302967264377491	6.1040165333468135	4.068456791269973	3.6776899164547183	-0.6505875661411493	-0.1127954941453444	2.8473931900169696
13722.58cfa832e4b0c9d6adf6d2fe	58cfa832e4b0c9d6adf6d2fe	TCGA-KM-8441-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KM-8441-01A-11D-2310-10_wgs_Illumina	TCGA-KM-8441-01A-11D-2310-10_wgs_Illumina.bam	28.3		0.05	58cfa832e4b0c9d6adf6d2fe	TCGA-KM-8441-01A-11D-2310-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KM-8441-01A	F31BA8EC-A3DD-4DD8-8D15-F6C5975EBE44	Primary Tumor	Illumina HiSeq	a15ce5fc-4e2f-4fe0-b799-1be690aa31b9	Kidney	61.0	566A0F2C-743C-4F18-B14E-1667A8666008	97C1A300-978D-4DF1-9E97-CE2F92B9EFF1	TCGA-KM-8441-01A-11D-2310-10	GRCh37-lite	TCGA-KM-8441	TCGA-KICH		s16570	Baylor College of Medicine	NCI Urologic Oncology Branch	United States	NO	T1b	NX	Kidney Chromophobe	Stage I	2310-10	True	KICH	C3	KICH.Eosin.1	0.344452959	0.41	0.0		-1.7841	-0.3405	0.0184	-0.8565	-0.836	-0.3758	13.0	2.0	0.05163380099999999	0.542154906	51.0	0.000247197	0.0	0.0		0.0	1.0	0.6365141679999999	2.0	0.918295834	0.792105492	-667.3318504	-393.507611	2682.880839	0.0	876.0	1.0	876.0	5.273640378835596	1.903259761704943	0.893218935273655	5.23281838431534	1.3878517512493431	2.0294123335417895	-0.04082199452025481	-0.5154080104555998	1.1361933982681343
13722.58cfa832e4b0c9d6adf6d300	58cfa832e4b0c9d6adf6d300	TCGA-KM-8440-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KM-8440-01A-11D-2310-10_wgs_Illumina	TCGA-KM-8440-01A-11D-2310-10_wgs_Illumina.bam	38.6		0.05	58cfa832e4b0c9d6adf6d300	TCGA-KM-8440-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KM-8440-01A	872092B3-D31E-44D7-BD03-E29F52F8AB5A	Primary Tumor	Illumina HiSeq	e0e06c60-542a-4e20-928f-7fed440fcd2a	Kidney	37.0	614E4163-7DA8-4F77-A58D-405B004BE3E0	CDF313C8-59F9-41C6-9BD2-F47CB4287DA5	TCGA-KM-8440-01A-11D-2310-10	GRCh37-lite	TCGA-KM-8440	TCGA-KICH		s16478	Baylor College of Medicine	NCI Urologic Oncology Branch	United States	NO	T3a	NX	Kidney Chromophobe	Stage III	2310-10	True	KICH	C5	KICH.Eosin.0	0.036748882999999996	0.09	0.0		-1.8874	-0.4205	-1.1006	-2.3006	-1.2043	-1.058	7.0	65.0	0.077718234	0.310872936	96.0	0.94773044	10.0	0.0				1.098612289	3.0	1.0	1.043566432	-1897.9529530000002	-1307.68733	2694.767627	0.0	1366.0	0.0	1366.0	7.053585727193677	2.0260361935345985	0.5171837463760097	5.330819129452573	3.74771995413687	4.179394953407785	-1.7227665977411035	1.7216837606022715	3.662211207031775
13722.58cfa832e4b0c9d6adf6d30e	58cfa832e4b0c9d6adf6d30e	TCGA-KN-8431-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KN-8431-01A-11D-2310-10_wgs_Illumina	TCGA-KN-8431-01A-11D-2310-10_wgs_Illumina.bam	71.3		0.05	58cfa832e4b0c9d6adf6d30e	TCGA-KN-8431-01A-11D-2310-10_wgs_Illumina.bam	Alive	FEMALE			Kidney Chromophobe	Aligned reads	TCGA-KN-8431-01A	04E9A63A-D742-488C-8564-BF9D79AA2091	Primary Tumor	Illumina HiSeq	335b2e98-ed12-462c-8a68-11724a840ad0	Kidney	35.0	2BBA3FAA-8D55-4AEC-863D-AAE1CEA6FEAB	93B51C61-6EEA-4228-A102-840A2E118522	TCGA-KN-8431-01A-11D-2310-10	GRCh37-lite	TCGA-KN-8431	TCGA-KICH		s16403	Baylor College of Medicine	Harvard	United States	NO	T2	NX	Kidney Chromophobe	Stage II	2310-10	True	KICH	C4	KICH.Eosin.0	0.060097473	0.15	0.0		-2.2651	-0.581	-0.9942	-1.531	-1.2967	-1.0429	8.0	3.0	0.077276385	0.257587949	80.0	0.9477102940000001	10.0	0.0					0.0		0.684080328	-684.6910999	-1069.46398	3807.82653	0.0	588.0	0.0	588.0	7.893198869544609	1.6062901061433692	-0.3794760742311686	5.912197400678025	2.7383114569426086	2.1872360194527136	-1.9810014688665836	1.1320213507992394	2.5667120936838823
13722.58cfa832e4b0c9d6adf6d317	58cfa832e4b0c9d6adf6d317	TCGA-KN-8428-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KN-8428-01A-11D-2310-10_wgs_Illumina	TCGA-KN-8428-01A-11D-2310-10_wgs_Illumina.bam	260.3		0.05	58cfa832e4b0c9d6adf6d317	TCGA-KN-8428-01A-11D-2310-10_wgs_Illumina.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KN-8428-01A	455FD7D4-5FF4-423F-83CE-4630AEF89BB7	Primary Tumor	Illumina HiSeq	1b52b2f7-d6a9-41f9-870c-f1456fda197e	Kidney	71.0	FFE3D692-7B81-45D9-BE76-2C580A091539	322F0B01-2118-4DBE-ABA1-3875A54EE71B	TCGA-KN-8428-01A-11D-2310-10	GRCh37-lite	TCGA-KN-8428	TCGA-KICH	1590.0	s16538	Baylor College of Medicine	Harvard	United States	NO	T2	N0	Kidney Chromophobe	Stage II	2310-10	True	KICH	C1	KICH.Eosin.1	0.117245371	0.22	0.44		0.6342	0.1455	-0.6629999999999999	-0.3035	-1.0907	-0.4943	343.0	16.0	6.738846618999999	16.49313044	172.0	0.827036085	21.0	22.0	0.792161357	2.580938174	26.0	2.311423445	11.0	0.963938447	1.77726025	-1847.542473	887.7947187999999	2629.158436	1.0	1590.0	1.0	478.0	6.928973026527536	1.379914953657078	-0.55705578653732	6.105772717719392	3.1475293721373	2.972513983451983	-0.8232003088081434	1.767614418480222	3.5295697699893034
13722.58cfa832e4b0c9d6adf6d319	58cfa832e4b0c9d6adf6d319	TCGA-KN-8429-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KN-8429-01A-11D-2310-10_wgs_Illumina	TCGA-KN-8429-01A-11D-2310-10_wgs_Illumina.bam	71.3		0.05	58cfa832e4b0c9d6adf6d319	TCGA-KN-8429-01A-11D-2310-10_wgs_Illumina.bam	Alive	FEMALE	WHITE		Kidney Chromophobe	Aligned reads	TCGA-KN-8429-01A	366219B9-FDE3-4D2D-82D3-15FE6245AA98	Primary Tumor	Illumina HiSeq	a527b958-1e44-4a4f-99e9-ba45c80bd326	Kidney	38.0	B802658C-4715-4878-97CA-99576F08AF6A	58C7E9C3-1345-48C0-A758-0887358B8696	TCGA-KN-8429-01A-11D-2310-10	GRCh37-lite	TCGA-KN-8429	TCGA-KICH		s16492	Baylor College of Medicine	Harvard	United States	NO	T3a	N0	Kidney Chromophobe	Stage III	2310-10	True	KICH	C3	KICH.Eosin.0	0.08015309400000001	0.13	0.03		-2.0028	-0.4475	-0.3926	-0.9506	-0.675	-0.6903	7.0		0.051343069000000005	0.308058415	69.0	0.9477282659999999	12.0	1.0				1.386294361	4.0	1.0	1.546348602	-1676.0568349999999	-1693.048945	3129.872766	0.0	2650.0	1.0	1989.0	7.234898420314832	1.231849520384495	-0.4984712411655307	5.873921867179232	4.547717611240005		-1.3609765531356004	3.31586809085551	
13722.58cfa832e4b0c9d6adf6d31d	58cfa832e4b0c9d6adf6d31d	TCGA-KN-8434-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KN-8434-01A-11D-2310-10_wgs_Illumina	TCGA-KN-8434-01A-11D-2310-10_wgs_Illumina.bam	71.3		0.05	58cfa832e4b0c9d6adf6d31d	TCGA-KN-8434-01A-11D-2310-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KN-8434-01A	E1E15226-9F8E-4035-8F08-EB1FED57080E	Primary Tumor	Illumina HiSeq	46dd26b0-c7e3-4280-b67c-5141df9048cf	Kidney	65.0	F75DE9FC-5DE8-4CAE-B1E1-8C37D1915C17	24F887E1-CE82-40F3-9674-11102BD076C0	TCGA-KN-8434-01A-11D-2310-10	GRCh37-lite	TCGA-KN-8434	TCGA-KICH		s16488	Baylor College of Medicine	Harvard	United States	NO	T2	NX	Kidney Chromophobe	Stage II	2310-10	True	KICH	C3	KICH.Eosin.0	0.11203892	0.19	0.03		-1.7379	-0.4735	0.0156	-1.0556	-0.6224	-0.4148	9.0	0.0	0.232917898	0.362316731	58.0	1.0	10.0	0.0		0.0	1.0	0.0	1.0		1.263967424	-1376.367242	-1431.966908	3115.783637	0.0	1797.0	0.0	1797.0	6.798737289262219	1.5355649302943837	-0.4290916001427332	5.310660233832386	2.9786721508086824	3.1208954165079965	-1.488077055429833	1.4431072205142987	3.5499870166507295
13722.58cfa832e4b0c9d6adf6d320	58cfa832e4b0c9d6adf6d320	TCGA-KN-8425-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KN-8425-01A-11D-2310-10_wgs_Illumina	TCGA-KN-8425-01A-11D-2310-10_wgs_Illumina.bam	71.3		0.05	58cfa832e4b0c9d6adf6d320	TCGA-KN-8425-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	WHITE		Kidney Chromophobe	Aligned reads	TCGA-KN-8425-01A	CC316FAF-DCB1-4DEA-B8B0-A17D000FF40F	Primary Tumor	Illumina HiSeq	60135711-8234-4e49-8d15-e9a5a0726f68	Kidney	53.0	84ED1792-CEC8-4F98-9988-74B3F5F6F516	81BB13FC-F082-4C0B-8066-1729F11EF617	TCGA-KN-8425-01A-11D-2310-10	GRCh37-lite	TCGA-KN-8425	TCGA-KICH		s16527	Baylor College of Medicine	Harvard	United States	NO	T1b	N0	Kidney Chromophobe	Stage I	2310-10	True	KICH	C3	KICH.Eosin.0	0.19477144300000002	0.34	0.12		-2.4035	-0.49700000000000005	0.3067	-0.1376	-0.1979	-0.67	7.0		0.0	0.355948849	74.0	0.731459414	24.0	0.0		0.0	1.0	1.609437912	5.0	1.0	1.5415371169999998	-1450.877493	-1323.38184	2799.530592	0.0	3179.0	0.0	3179.0	5.568012553550579	2.3895461556588984	1.0759066727279836	5.658984331756306	4.028945455833482	6.142843532192881	0.09097177820572666	1.639399300174584	5.066936859464897
13722.58cfa832e4b0c9d6adf6d322	58cfa832e4b0c9d6adf6d322	TCGA-L5-A43C-01A-11D-A248_121207_SN1222_0161_AC1HJ0ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-L5-A43C-01A-11D-A248_121207_SN1222_0161_AC1HJ0ACXX_s_1_rg.sorted	TCGA-L5-A43C-01A-11D-A248_121207_SN1222_0161_AC1HJ0ACXX_s_1_rg.sorted.bam	21.33		0.16	58cfa832e4b0c9d6adf6d322	TCGA-L5-A43C-01A-11D-A248_121207_SN1222_0161_AC1HJ0ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE		Esophageal Carcinoma	Aligned reads	TCGA-L5-A43C-01A	A935DAEB-1EFD-4113-A614-A5E4D446C72B	Primary Tumor	Illumina HiSeq	f5b917a1-f719-4ee6-b994-c4bc7dbbc159	Esophagus	81.0	2DD3A5ED-42EF-4CA1-AC40-B2F486F0395A	74016C2E-EEC8-4FE9-A297-A4E64D797DEE	TCGA-L5-A43C-01A-11D-A248-26	HG19_Broad_variant	TCGA-L5-A43C	TCGA-ESCA		s1646	MD Anderson - Institute for Applied Cancer Science	University of Michigan	United States	NO					A248-26	True	ESCA	C1	GI.CIN	0.539984162	0.78	0.16		0.3441	0.03	0.9872	1.1283	-0.2857	0.9259999999999999	71.0		0.865822743	2.483544184	127.0	0.5278682029999999	22.0	29.0	0.5426570239999999	3.3999097089999997	526.0	4.248918734	98.0	0.926706406	3.035772174	341.1228593	362.76980679999997	-2499.874504	0.0	96.0	0.0	96.0	8.779249716229046	7.105281174600885	-0.7249877864156042	6.527957917622551	7.227883496693217	0.49200868009711507	-2.251291798606495	0.12260232209233246	1.2169964665127193
13722.58cfa832e4b0c9d6adf6d326	58cfa832e4b0c9d6adf6d326	TCGA-KO-8407-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KO-8407-01A-11D-2310-10_wgs_Illumina	TCGA-KO-8407-01A-11D-2310-10_wgs_Illumina.bam	150.2		0.05	58cfa832e4b0c9d6adf6d326	TCGA-KO-8407-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KO-8407-01A	151F07F5-1529-4FCD-912C-E55B2FF8ABEF	Primary Tumor	Illumina HiSeq	33c518fb-d4b6-4ec8-8125-6fd6c0032563	Kidney	42.0	24992BE3-78D6-4193-ACF3-F0A5AC959BB6	64F696A6-58B2-40A8-B848-FD775CD52529	TCGA-KO-8407-01A-11D-2310-10	GRCh37-lite	TCGA-KO-8407	TCGA-KICH		s16438	Baylor College of Medicine	MD Anderson Cancer Center	United States	NO	T2	N0	Kidney Chromophobe	Stage II	2310-10	True	KICH	C3	KICH.Eosin.0	0.11104008900000001	0.15	0.0		-1.7249	-0.426	-0.094	-0.125	-0.4826	-0.5532	6.0		0.153791731	0.53827106	89.0	0.9477271620000001	10.0	0.0				2.079441542	8.0	1.0	1.411213581	-645.8267807	-1639.497742	3605.2837170000003	0.0	2820.0	0.0	2820.0	7.118502309959795	2.3983386334795425	0.5457766520360421	5.432103356389566	3.834643415174094	4.326125403317511	-1.6863989535702288	1.4363047816945516	3.780348751281469
13722.58cfa832e4b0c9d6adf6d32e	58cfa832e4b0c9d6adf6d32e	TCGA-KN-8421-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KN-8421-01A-11D-2310-10_wgs_Illumina	TCGA-KN-8421-01A-11D-2310-10_wgs_Illumina.bam	112.3		0.05	58cfa832e4b0c9d6adf6d32e	TCGA-KN-8421-01A-11D-2310-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KN-8421-01A	2FC175D1-9D95-44FD-A53E-820F6F404551	Primary Tumor	Illumina HiSeq	2b4a72cf-171d-4cea-ac2a-528687128d7c	Kidney	47.0	D4694662-8330-4F19-A25D-9A12751C1B57	BA686386-8113-4885-B20F-6AD09A295604	TCGA-KN-8421-01A-11D-2310-10	GRCh37-lite	TCGA-KN-8421	TCGA-KICH		s16476	Baylor College of Medicine	Harvard	United States	NO	T2	N0	Kidney Chromophobe	Stage II	2310-10	True	KICH	C4	KICH.Eosin.1	0.01939499	0.04	0.83		-1.1356	-0.39799999999999996	-2.0333	-2.5112	-0.1684	-1.4122	2.0		0.18258117199999999	0.391245368	89.0	0.947728308	10.0	0.0				0.0	1.0		1.419005422	-470.3673176	-1020.055025	1030.036358	0.0	2674.0	0.0	2674.0	5.660390756100735	2.0049117531786953	-0.27532616283896594	5.463680461854681	1.8114439700106022		-0.19671029424605413	-0.1934677831680931	
13722.58cfa832e4b0c9d6adf6d332	58cfa832e4b0c9d6adf6d332	TCGA-KN-8432-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KN-8432-01A-11D-2310-10_wgs_Illumina	TCGA-KN-8432-01A-11D-2310-10_wgs_Illumina.bam	205.3		0.05	58cfa832e4b0c9d6adf6d332	TCGA-KN-8432-01A-11D-2310-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KN-8432-01A	AF1111AF-9384-4E37-9B16-227D38007EBD	Primary Tumor	Illumina HiSeq	be9bfce6-c244-4dcb-b5df-36fab219e0f6	Kidney	86.0	F27E987E-DA76-40C2-B7B8-5DEE724D7EB7	85ED2434-DA94-4333-90CA-6CA4691CBDD3	TCGA-KN-8432-01A-11D-2310-10	GRCh37-lite	TCGA-KN-8432	TCGA-KICH		s16406	Baylor College of Medicine	Harvard	United States	NO	T2b	NX	Kidney Chromophobe	Stage II	2310-10	True	KICH	C4	KICH.Eosin.0	0.061453593	0.11	0.0		-2.3458	-0.5870000000000001	-0.4135	-1.3122	-0.4183	-0.8361	18.0	7.0	0.465313226	1.111581595	74.0	0.9471703109999999	13.0	5.0					0.0		0.9838085409999999	-1513.763334	-1709.663532	4581.364094	0.0	76.0	0.0	76.0	6.413786772282569	2.312917288231251	-0.9793876940185664	4.727387818712341	1.527702297635411	2.9136898508875486	-1.6863989535702288	-0.7852149905958399	3.893077544906115
13722.58cfa832e4b0c9d6adf6d334	58cfa832e4b0c9d6adf6d334	TCGA-KM-8639-01A-11D-2397-10_wgs_Illumina.filtered.	WGS	TCGA-KM-8639-01A-11D-2397-10_wgs_Illumina	TCGA-KM-8639-01A-11D-2397-10_wgs_Illumina.bam	157.0		0.05	58cfa832e4b0c9d6adf6d334	TCGA-KM-8639-01A-11D-2397-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KM-8639-01A	2EA84E23-6A0A-4C5D-9C70-D5355A85DF35	Primary Tumor	Illumina HiSeq	f1dafc21-d5b0-48e6-ab3e-2fffa2d599e4	Kidney	67.0	E1D3EE37-402B-4727-8E27-B797D42F46BA	0B811C6A-8F05-44BD-AC33-FB720D189E71	TCGA-KM-8639-01A-11D-2397-10	GRCh37-lite	TCGA-KM-8639	TCGA-KICH		s16572	Baylor College of Medicine	NCI Urologic Oncology Branch	United States	NO	T1a	NX	Kidney Chromophobe	Stage I	2397-10	False	KICH	C3	KICH.Eosin.1	0.253254238	0.38	0.01		-2.0623	-0.348	-0.3017	-0.8458	-0.755	-0.9116	8.0	1.0	0.083281068	0.527446761	45.0	0.09611201400000001	4.0	2.0				1.5607104090000001	5.0	0.9697239	0.577206198	-1910.6224670000001	-1420.4458240000001	3502.288939	0.0	953.0	0.0	953.0	5.3324168153074645	2.626223408791107	0.05895535951665021	5.2146337796510815	2.4255527133289565	2.95526940994081	-0.11778303565638337	-0.20067069546215066	2.89631405042416
13722.58cfa832e4b0c9d6adf6d338	58cfa832e4b0c9d6adf6d338	TCGA-KN-8427-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KN-8427-01A-11D-2310-10_wgs_Illumina	TCGA-KN-8427-01A-11D-2310-10_wgs_Illumina.bam	198.3		0.05	58cfa832e4b0c9d6adf6d338	TCGA-KN-8427-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	WHITE		Kidney Chromophobe	Aligned reads	TCGA-KN-8427-01A	955D428C-8FE8-456B-B86D-65EA6C2A1B18	Primary Tumor	Illumina HiSeq	1ab3dc9e-2973-4b02-bf13-e2f1f27c0f05	Kidney	54.0	8719FECD-7AB5-4468-A978-5C6BF1D4A1D7	07E0E938-F61F-477A-92A2-5B7E74B78943	TCGA-KN-8427-01A-11D-2310-10	GRCh37-lite	TCGA-KN-8427	TCGA-KICH		s16442	Baylor College of Medicine	Harvard	United States	NO	T4	N1	Kidney Chromophobe	Stage IV	2310-10	True	KICH	C1	KICH.Eosin.1	0.319671567	0.44	0.02		0.1959	0.076	-0.1161	-0.2677	-1.7679	0.3321	26.0	2.0	0.591771637	1.312189281	163.0	0.8629640829999999	22.0	15.0	0.9812391709999999	0.680143165	2.0	2.7184734010000002	16.0	0.9804820240000001	0.57825293	-473.1420797	99.63006587	-294.8980673	0.0	30.0	0.0	30.0	6.394704960194035	3.514578741519463	0.37537196882816726	4.928367891400608	3.0019847706967298	1.1107852935186688	-1.4663370687934272	-0.5125939708227332	0.7354133246905015
13722.58cfa832e4b0c9d6adf6d33e	58cfa832e4b0c9d6adf6d33e	TCGA-KN-8435-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KN-8435-01A-11D-2310-10_wgs_Illumina	TCGA-KN-8435-01A-11D-2310-10_wgs_Illumina.bam	134.0		0.05	58cfa832e4b0c9d6adf6d33e	TCGA-KN-8435-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KN-8435-01A	F2B58595-DEC0-4194-AB33-7C7DC6C058A6	Primary Tumor	Illumina HiSeq	28eaaad9-76f1-4c47-9af6-d8dc853ae96c	Kidney	59.0	B2D2BE13-C233-409A-A793-21D9CD3CFCE7	715F59DD-A80F-422D-988C-F73F4B987BAF	TCGA-KN-8435-01A-11D-2310-10	GRCh37-lite	TCGA-KN-8435	TCGA-KICH		s16489	Baylor College of Medicine	Harvard	United States	NO	T2	NX	Kidney Chromophobe	Stage II	2310-10	True	KICH	C3	KICH.Eosin.1	0.012497753	0.05	0.0		-0.8215	-0.3315	-1.1533	-2.2697	-1.4256	-0.7461	4.0	7.0	0.050768111	0.583833281	138.0	0.947612875	11.0	3.0				0.693147181	2.0	1.0	1.0458776159999998	-1146.273406	-1315.370488	2781.0733579999996	0.0	3498.0	0.0	3498.0	6.286538586369605	2.542016604791991	-0.845304469389822	5.982856172571383	5.772422342668286	1.0797163776102983	-0.30368241379822214	3.2304057378762954	1.9250208470001202
13722.58cfa832e4b0c9d6adf6d354	58cfa832e4b0c9d6adf6d354	TCGA-KO-8409-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KO-8409-01A-11D-2310-10_wgs_Illumina	TCGA-KO-8409-01A-11D-2310-10_wgs_Illumina.bam	151.2		0.05	58cfa832e4b0c9d6adf6d354	TCGA-KO-8409-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KO-8409-01A	08A96DEC-E658-493A-9308-83F7ACE3B3B6	Primary Tumor	Illumina HiSeq	a6a7348b-80db-4f3a-b7eb-77e0575ab072	Kidney	69.0	56B3AC6B-BD6E-4960-8610-292CF154A705	8DF1EEB4-DFC9-4A0A-8F93-98460C3AB489	TCGA-KO-8409-01A-11D-2310-10	GRCh37-lite	TCGA-KO-8409	TCGA-KICH		s16445	Baylor College of Medicine	MD Anderson Cancer Center	United States	NO	T2b	N0	Kidney Chromophobe	Stage II	2310-10	True	KICH	C4	KICH.Eosin.1	0.042523889	0.1	0.01		-2.2432	-0.45399999999999996	-0.5334	-1.4119	-0.9438	-0.9737	6.0		0.154583517	0.257639195	87.0	0.94771086	14.0	0.0					0.0		1.1414185559999999	-1592.5398369999998	-1347.9132029999998	3487.6197020000004	0.0	3180.0	0.0	3180.0	7.82064021772146	2.4496309471975604	0.746133692386727	5.839638748854876	2.402105805334715		-1.9810014688665836	-0.04752514186284529	
13722.58cfa832e4b0c9d6adf6d356	58cfa832e4b0c9d6adf6d356	TCGA-KO-8416-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KO-8416-01A-11D-2310-10_wgs_Illumina	TCGA-KO-8416-01A-11D-2310-10_wgs_Illumina.bam	74.8		0.05	58cfa832e4b0c9d6adf6d356	TCGA-KO-8416-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KO-8416-01A	0EC3CAA1-7C51-417B-A89C-18E9FCEB80C4	Primary Tumor	Illumina HiSeq	3f5f5abf-4e3b-409e-9e2b-c8543d51100b	Kidney	41.0	545486B9-EF3E-45AD-810A-F4594A2DB883	9D29543E-8601-4FD0-8E76-3DF3DE465CAB	TCGA-KO-8416-01A-11D-2310-10	GRCh37-lite	TCGA-KO-8416	TCGA-KICH		s16576	Baylor College of Medicine	MD Anderson Cancer Center	United States	NO	T3a	N0	Kidney Chromophobe	Stage III	2310-10	True	KICH	C3	KICH.Eosin.0	0.059935037999999996	0.09	0.0		-1.6162	-0.4665	-0.2901	-0.7433	-0.9218	-0.6085	12.0		0.131574418	0.36840837200000004	59.0	0.947729006	12.0	0.0				1.386294361	4.0	1.0	1.1475735740000002	-890.2488274	-1742.8622269999998	2823.9644510000003	0.0	2752.0	0.0	2752.0	6.973141654874977	1.33551692952428	-0.3045746622391634	5.623214937925962	2.864912134284844	6.4066442204192775	-1.349926716949016	1.5293952047605641	6.71121888265844
13722.58cfa832e4b0c9d6adf6d362	58cfa832e4b0c9d6adf6d362	TCGA-L5-A4OH-01A-11D-A267_131001_SN1222_0222_BC2CN2ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-L5-A4OH-01A-11D-A267_131001_SN1222_0222_BC2CN2ACXX_s_5_rg.sorted	TCGA-L5-A4OH-01A-11D-A267_131001_SN1222_0222_BC2CN2ACXX_s_5_rg.sorted.bam	43.66		0.17	58cfa832e4b0c9d6adf6d362	TCGA-L5-A4OH-01A-11D-A267_131001_SN1222_0222_BC2CN2ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE		Esophageal Carcinoma	Aligned reads	TCGA-L5-A4OH-01A	3FA7FC16-49DA-4BF6-90C4-74DF5CF68B65	Primary Tumor	Illumina HiSeq	ba83865e-0ba3-48ab-841f-de07856ee9bc	Esophagus	71.0	4029F7BA-1D2D-49B8-A37B-4D4A5D0ACB79	C886B6DD-1595-49DD-B4DA-B69AA9C813E4	TCGA-L5-A4OH-01A-11D-A267-26	HG19_Broad_variant	TCGA-L5-A4OH	TCGA-ESCA		s1747	MD Anderson - Institute for Applied Cancer Science	University of Michigan	United States	NO	T1	N0		Stage I	A267-26	True	ESCA	C2	GI.CIN	0.164829529	0.37	0.22		0.6805	0.1215	-1.0014	-1.12	1.2636	-0.2044	61.0		0.553079523	2.476834384	278.0	0.677437057	16.0	36.0	0.966907228	2.124512325	9.0	3.48873742	36.0	0.973550714	2.774599648	-892.9655047	687.4940232999999	-2561.287478	0.0	992.0	0.0	992.0	7.641404402851411	7.454141078146678	-0.35491282894533305	5.744284417965531	6.412687203318517	2.41873465464269	-1.897119984885881	-1.0414538748281612	2.773647483588023
13722.58cfa832e4b0c9d6adf6d36c	58cfa832e4b0c9d6adf6d36c	TCGA-KN-8418-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KN-8418-01A-11D-2310-10_wgs_Illumina	TCGA-KN-8418-01A-11D-2310-10_wgs_Illumina.bam	106.3		0.05	58cfa832e4b0c9d6adf6d36c	TCGA-KN-8418-01A-11D-2310-10_wgs_Illumina.bam	Alive	FEMALE	WHITE		Kidney Chromophobe	Aligned reads	TCGA-KN-8418-01A	F3BA1CF8-AC67-4DA8-96F3-8680DC55F247	Primary Tumor	Illumina HiSeq	29118d80-8a70-4ed3-8742-d2c69bbeffb7	Kidney	41.0	D6F68966-D6A2-4B24-B1D5-15CB8F4ACB8F	9A90F951-AD96-4883-B97F-AC43395DAE5D	TCGA-KN-8418-01A-11D-2310-10	GRCh37-lite	TCGA-KN-8418	TCGA-KICH		s16396	Baylor College of Medicine	Harvard	United States	NO	T2	N0	Kidney Chromophobe	Stage II	2310-10	True	KICH	C3	KICH.Eosin.0	0.023179203	0.07	0.0		-1.5155	-0.3955	-1.1066	-1.9899	-1.3682	-0.8998	6.0	2.0	0.18059119399999998	0.25798742	81.0	0.94252975	10.0	0.0					0.0		1.293167677	-1634.211235	-1219.124227	2489.445181	0.0	3935.0	0.0	3935.0	6.8761499395668055	1.8093281134303787	0.6293414270391087	6.052949630758662	5.2504927554996	2.9790835459879212	-0.8232003088081434	3.4411646420692215	2.3497421189488126
13722.58cfa832e4b0c9d6adf6d374	58cfa832e4b0c9d6adf6d374	TCGA-LN-A49M-01A-21D-A267_131001_SN1222_0222_BC2CN2ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-LN-A49M-01A-21D-A267_131001_SN1222_0222_BC2CN2ACXX_s_1_rg.sorted	TCGA-LN-A49M-01A-21D-A267_131001_SN1222_0222_BC2CN2ACXX_s_1_rg.sorted.bam	23.64		0.16	58cfa832e4b0c9d6adf6d374	TCGA-LN-A49M-01A-21D-A267_131001_SN1222_0222_BC2CN2ACXX_s_1_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A49M-01A	B3E248B5-5D40-495C-BD10-90ECF0ED6A95	Primary Tumor	Illumina HiSeq	821eaabe-92ee-4e30-9254-77b2ce89ea42	Esophagus	62.0	E6BEF2C0-1C6A-4137-A099-920F1F811489	9C284314-4356-44EA-8087-E64F5A614179	TCGA-LN-A49M-01A-21D-A267-26	HG19_Broad_variant	TCGA-LN-A49M	TCGA-ESCA		s1862	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T2	N0		Stage IIA	A267-26	True	ESCA	C2	GI.ESCC	0.148954626				0.8237	0.1895	-0.8971	-1.8094	1.7031	0.5152	83.0		1.6382636609999999	4.51692695	283.0	0.9618968109999999				0.0	1.0	2.45831133	12.0	0.989297256	5.560553441000001	-356.37899060000007	495.7822867	-1893.333066	0.0	385.0	0.0	385.0	7.086319786898379	7.321276736273065	-1.4582470234059832	5.476881874464279	6.984804499651853	1.854227032080084	-1.6094379124341003	-0.33647223662121295	3.312474055486067
13722.58cfa832e4b0c9d6adf6d386	58cfa832e4b0c9d6adf6d386	TCGA-LN-A4A3-01A-11D-A267_131001_SN1120_0280_BD2FDEACXX_s_5_rg.sorted.filtered.	WGS	TCGA-LN-A4A3-01A-11D-A267_131001_SN1120_0280_BD2FDEACXX_s_5_rg.sorted	TCGA-LN-A4A3-01A-11D-A267_131001_SN1120_0280_BD2FDEACXX_s_5_rg.sorted.bam	20.45		0.16	58cfa832e4b0c9d6adf6d386	TCGA-LN-A4A3-01A-11D-A267_131001_SN1120_0280_BD2FDEACXX_s_5_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A4A3-01A	3C0BB5E2-AD33-4D91-A31E-2A18F1C94D2D	Primary Tumor	Illumina HiSeq	e04a9b3d-9bc4-4857-9030-288efed94e80	Esophagus	61.0	3C85B0AB-C83E-4371-9F53-6A71D3763F3F	5402975D-7AE7-46FC-847A-4EE7DEBCD553	TCGA-LN-A4A3-01A-11D-A267-26	HG19_Broad_variant	TCGA-LN-A4A3	TCGA-ESCA		s1770	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T3	N1		Stage III	A267-26	True	ESCA	C2	GI.ESCC	0.468436853	0.49	0.7		0.9065	0.242	-0.6837	-0.2418	1.3474	0.2351	38.0		0.297897925	1.1686764729999999	143.0	0.648806694	17.0	27.0	0.867009338	3.031504707	33.0	3.044820482	22.0	0.985046478	6.295975402000001	-677.9819185	829.2459163	-1711.649386	0.0	388.0	0.0	388.0	1.1094248511785905	5.78322863450825	-0.06488186878042923	5.799395638859147	6.059737406361905	0.38533932682629946	4.689970787680556	0.2765087718536554	0.4502211956067287
13722.58cfa832e4b0c9d6adf6d388	58cfa832e4b0c9d6adf6d388	TCGA-L5-A4OP-01A-11D-A267_131001_SN1120_0280_BD2FDEACXX_s_1_rg.sorted.filtered.	WGS	TCGA-L5-A4OP-01A-11D-A267_131001_SN1120_0280_BD2FDEACXX_s_1_rg.sorted	TCGA-L5-A4OP-01A-11D-A267_131001_SN1120_0280_BD2FDEACXX_s_1_rg.sorted.bam	41.04		0.17	58cfa832e4b0c9d6adf6d388	TCGA-L5-A4OP-01A-11D-A267_131001_SN1120_0280_BD2FDEACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE		Esophageal Carcinoma	Aligned reads	TCGA-L5-A4OP-01A	97031483-1185-41D6-9722-0A03B63CAA19	Primary Tumor	Illumina HiSeq	940f64ee-414a-4190-9fc9-c697ad112dfe	Esophagus	67.0	BA02D5B4-9CA9-4455-81D4-E5F2C8C0DF74	5D8E8DA5-04FF-4548-96EC-AE1E80C57CD1	TCGA-L5-A4OP-01A-11D-A267-26	HG19_Broad_variant	TCGA-L5-A4OP	TCGA-ESCA		s1923	MD Anderson - Institute for Applied Cancer Science	University of Michigan	United States	NO	T1	N0		Stage IA	A267-26	True	ESCA	C1	GI.CIN	0.25047922100000003	0.28	0.01		0.1837	-0.043	-0.3103	0.2017	0.013999999999999999	-0.1346	57.0		0.567451855	2.1752321119999998	133.0	0.930238036	10.0	28.0	0.6873004340000001	2.9000694780000003	68.0	3.937853141	82.0	0.8936020020000001	3.9094660169999997	-979.5138562999999	-207.69396569999998	209.13120849999999	0.0	218.0	0.0	218.0	8.211347148336785	7.34547243092749	-0.7531699949948124	5.90876205534274	6.3040185560993285	1.7400043877161588	-2.3025850929940455	-1.0414538748281612	2.493174382710971
13722.58cfa832e4b0c9d6adf6d394	58cfa832e4b0c9d6adf6d394	TCGA-KO-8411-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KO-8411-01A-11D-2310-10_wgs_Illumina	TCGA-KO-8411-01A-11D-2310-10_wgs_Illumina.bam	133.2		0.05	58cfa832e4b0c9d6adf6d394	TCGA-KO-8411-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KO-8411-01A	EE8C1919-17A9-4DF1-8AA5-79546621B23C	Primary Tumor	Illumina HiSeq	bcee9ae3-609f-4f6c-bf6e-9bf33233592d	Kidney	58.0	9E2CDD77-110D-498A-83E8-DF2E044303D6	9DFCBABF-2BC0-43A2-BDDE-D0B2AACA3F6B	TCGA-KO-8411-01A-11D-2310-10	GRCh37-lite	TCGA-KO-8411	TCGA-KICH		s16402	Baylor College of Medicine	MD Anderson Cancer Center	United States	NO	T1b	NX	Kidney Chromophobe	Stage I	2310-10	True	KICH	C5	KICH.Eosin.0	0.031389718	0.09	0.0		-1.8565	-0.342	-0.7722	-2.2294	-0.9654	-1.1445	4.0	7.0	0.203999533	0.254999417	77.0	0.9477278370000001	12.0	0.0				0.0	1.0		0.904813675	-1573.5463730000001	-999.7182443	3243.4592079999998	0.0	3958.0	0.0	3958.0	7.343943559733142	2.083974347472334	-0.18269144768036183	5.695284934145761	3.897781953922152	3.9470350513878545	-1.6486586255873819	1.813807606449818	4.129726499068217
13722.58cfa832e4b0c9d6adf6d3ad	58cfa832e4b0c9d6adf6d3ad	TCGA-NH-A50V-01A-11D-A28G-10_wgs_Illumina.filtered.	WGS	TCGA-NH-A50V-01A-11D-A28G-10_wgs_Illumina	TCGA-NH-A50V-01A-11D-A28G-10_wgs_Illumina.bam	33.86		0.08	58cfa832e4b0c9d6adf6d3ad	TCGA-NH-A50V-01A-11D-A28G-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-NH-A50V-01A	D3B7ADA6-5395-4212-A921-8E97C92B605D	Primary Tumor	Illumina HiSeq	80f9989d-1696-49b8-a893-f045bc8615ea	Colorectal	69.0	A7A71B11-5E34-49A4-8D54-BE27D9C8DAF0	55345803-83D4-4FDB-B0EE-328753801DA1	TCGA-NH-A50V-01A-11D-A28G-10	GRCh37-lite	TCGA-NH-A50V	TCGA-COAD		s13043	Baylor College of Medicine	Candler	United States	NO	T3	N2a	Colon Adenocarcinoma	Stage IIIB	A28G-10	True	COAD	C1	GI.CIN	0.253120747	0.38	0.09	7.536855899	0.1843	0.0495	-0.0329	0.4807	0.3095	0.3841	77.0	116.0	1.3486072269999998	3.722155947	166.0	0.20496194	5.0	17.0	0.837989303	2.7302500469999997	26.0	2.7080502010000003	15.0	1.0	0.896399398	-548.7625671	-80.81193934	1114.10675	0.0	588.0	0.0	588.0	7.908999716736456	5.419023981146387	-0.31744775652656476	5.872117789475416	5.885558122603372	1.1279013673746405	-2.0368819272610397	0.466534141456985	1.4453491239012055
13722.58cfa832e4b0c9d6adf6d3b6	58cfa832e4b0c9d6adf6d3b6	TCGA-L5-A4ON-01A-11D-A267_131120_SN1222_0229_AD2FDGACXX_s_7_rg.sorted.filtered.	WGS	TCGA-L5-A4ON-01A-11D-A267_131120_SN1222_0229_AD2FDGACXX_s_7_rg.sorted	TCGA-L5-A4ON-01A-11D-A267_131120_SN1222_0229_AD2FDGACXX_s_7_rg.sorted.bam	47.01		0.17	58cfa832e4b0c9d6adf6d3b6	TCGA-L5-A4ON-01A-11D-A267_131120_SN1222_0229_AD2FDGACXX_s_7_rg.sorted.bam	Dead	MALE	WHITE		Esophageal Carcinoma	Aligned reads	TCGA-L5-A4ON-01A	CABA34F2-3877-48CA-9FBC-665C3960F574	Primary Tumor	Illumina HiSeq	9bb22695-702d-410d-98a3-d4adcf022a94	Esophagus	65.0	B801A0D7-09E8-48D8-9C8E-C6D52767F7C1	469616E0-7C5B-491E-8D25-E71CCDB27D18	TCGA-L5-A4ON-01A-11D-A267-26	HG19_Broad_variant	TCGA-L5-A4ON	TCGA-ESCA	558.0	s1843	MD Anderson - Institute for Applied Cancer Science	University of Michigan	United States	NO	T1	N1		Stage IIB	A267-26	True	ESCA	C4	GI.CIN	0.133372106				0.2234	-0.0875	-0.6081	-1.3371	0.5317	-0.0011	67.0				338.0	0.949741809			0.713154321	0.9886418140000001	4.0	3.3704808010000002	30.0	0.990968892	2.140435915	-1162.149877	351.5464271	-2183.513399	1.0	558.0	0.0	558.0	7.568379267836523	6.5799454154395765	-0.7117673999949274	5.126032232467319	5.427265905501191	2.678663329781055	-2.4423470353692043	-1.1526795099383853	3.3904307297759826
13722.58cfa832e4b0c9d6adf6d3c2	58cfa832e4b0c9d6adf6d3c2	TCGA-KO-8406-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KO-8406-01A-11D-2310-10_wgs_Illumina	TCGA-KO-8406-01A-11D-2310-10_wgs_Illumina.bam	131.2		0.05	58cfa832e4b0c9d6adf6d3c2	TCGA-KO-8406-01A-11D-2310-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KO-8406-01A	9AA02D46-294B-4E99-B9EE-56EDCBFB5275	Primary Tumor	Illumina HiSeq	1980f1bf-6afb-4a53-97a5-f069b4200e14	Kidney	17.0	2141972F-8CA9-4E82-B410-B1E3BBB2934A	C29F6ED6-880D-4F03-977E-1087738E5E60	TCGA-KO-8406-01A-11D-2310-10	GRCh37-lite	TCGA-KO-8406	TCGA-KICH		s16408	Baylor College of Medicine	MD Anderson Cancer Center	United States	NO	T1	N0	Kidney Chromophobe	Stage I	2310-10	True	KICH	C5	KICH.Eosin.0	0.022019927	0.08	0.0		-0.9956	-0.4445	-0.7986	-2.0699	-0.9372	-0.9079	5.0		0.10207049800000001	0.22965861899999998	61.0	0.9477283190000001	10.0	0.0					0.0		1.6511430580000002	-1649.055141	-928.3355427000001	4109.465754999999	0.0	3145.0	0.0	3145.0	6.827448647594913	1.7214279366077836	-0.6128636656995587	5.483713900893818	3.1179904997548746	3.13203300682042	-1.3437347467010947	1.396562563147091	3.744896672519979
13722.58cfa832e4b0c9d6adf6d3d0	58cfa832e4b0c9d6adf6d3d0	TCGA-L5-A43J-01A-12D-A248_121211_SN208_0443_BC1H55ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-L5-A43J-01A-12D-A248_121211_SN208_0443_BC1H55ACXX_s_5_rg.sorted	TCGA-L5-A43J-01A-12D-A248_121211_SN208_0443_BC1H55ACXX_s_5_rg.sorted.bam	17.75		0.17	58cfa832e4b0c9d6adf6d3d0	TCGA-L5-A43J-01A-12D-A248_121211_SN208_0443_BC1H55ACXX_s_5_rg.sorted.bam	Dead	MALE	WHITE		Esophageal Carcinoma	Aligned reads	TCGA-L5-A43J-01A	209E2E16-CB88-4A8F-9CDB-10E152CAA26C	Primary Tumor	Illumina HiSeq	ed639604-bac1-4406-ad55-5a821261a54a	Esophagus	90.0	EEA7BE16-BAF9-4101-A712-CFAF5349476E	9BDD056B-DEC2-4856-9093-94FD133CF06B	TCGA-L5-A43J-01A-12D-A248-26	HG19_Broad_variant	TCGA-L5-A43J	TCGA-ESCA	131.0	s1739	MD Anderson - Institute for Applied Cancer Science	University of Michigan	United States	NO	T3	N0		Stage IIB	A248-26	True	ESCA	C1	GI.ESCC	0.09993306099999999	0.36	0.18		0.725	0.214	-0.316	-1.3093	0.2415	0.6968	304.0		5.225055579	14.7168596	268.0	0.751449948	19.0	51.0				1.609437912	5.0	1.0	1.949420352	-169.9157169	1059.844267	-1674.2910000000002	1.0	131.0	1.0	98.0	8.837427155161741	9.004484032048564	-0.3526445405417694	7.004845691413431	8.193553815832235		-1.83258146374831	-0.8109302162163288	
13722.58cfa832e4b0c9d6adf6d3d3	58cfa832e4b0c9d6adf6d3d3	TCGA-KO-8417-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KO-8417-01A-11D-2310-10_wgs_Illumina	TCGA-KO-8417-01A-11D-2310-10_wgs_Illumina.bam	186.5		0.05	58cfa832e4b0c9d6adf6d3d3	TCGA-KO-8417-01A-11D-2310-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KO-8417-01A	0B77657A-0297-4CEE-B9F2-5DE72E182016	Primary Tumor	Illumina HiSeq	c1d96592-c2a1-4638-8ee3-0515f3a8c96a	Kidney	30.0	C6D5A991-4018-4D78-BF0C-4D240E7987B5	0C7AF04B-E171-47C4-8BE5-5DB33F20148E	TCGA-KO-8417-01A-11D-2310-10	GRCh37-lite	TCGA-KO-8417	TCGA-KICH		s16574	Baylor College of Medicine	MD Anderson Cancer Center	United States	NO	T1	N0	Kidney Chromophobe	Stage I	2310-10	True	KICH	C5	KICH.Eosin.0	0.021501112000000003	0.07	0.0		-1.4080000000000001	-0.39899999999999997	-1.2796	-2.1872	-0.9405	-0.982	8.0		0.13562172	0.40686516100000003	63.0	0.947726972	12.0	0.0					0.0		1.117399093	-1356.720269	-1450.544288	3595.260846	0.0	2815.0	0.0	2815.0	6.976348070447749	2.053313689098802	-0.21627665455944556	5.797693074106103	3.853529868345081	1.7840782024642203	-1.1786549963416464	1.800216179246279	2.000354857023666
13722.58cfa832e4b0c9d6adf6d3d7	58cfa832e4b0c9d6adf6d3d7	TCGA-V4-A9EJ-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_7_rg.sorted.filtered.	WGS	TCGA-V4-A9EJ-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_7_rg.sorted	TCGA-V4-A9EJ-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_7_rg.sorted.bam	36.7		0.17	58cfa832e4b0c9d6adf6d3d7	TCGA-V4-A9EJ-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EJ-01A	D9CCBA9B-6BF0-44D9-8097-A97AB747F0BD	Primary Tumor	Illumina HiSeq	9a75e8fd-7cbd-4d0f-a91b-22e52e02c00d	Eye	38.0	6D2FBFD2-E1BF-483E-B0A0-A308F93871D4	42B46C86-61F4-4C2E-9EC3-0ED0113F3EC3	TCGA-V4-A9EJ-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EJ	TCGA-UVM		s206	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T3a	N0		Stage IIB	A40D-26	True	UVM	C4		0.02823113	0.05	0.01	0.0	-1.2037	-0.195	-1.3152	-1.8702	-1.8638	-0.8702	11.0		0.122914834	0.583845463	71.0	0.05814433	1.0	7.0				0.0	1.0		2.0947099419999997	-2295.460771	-1539.343607	-606.8028797999999	0.0	746.0	0.0	746.0	8.771525284186463	8.794698657416458	-0.8565017909840886	6.520233485579968	7.753244782588296	1.421796717262283	-2.251291798606495	-1.0414538748281612	2.2782985082463716
13722.58cfa832e4b0c9d6adf6d3e3	58cfa832e4b0c9d6adf6d3e3	TCGA-V4-A9EL-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_1_rg.sorted.filtered.	WGS	TCGA-V4-A9EL-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_1_rg.sorted	TCGA-V4-A9EL-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_1_rg.sorted.bam	36.66		0.17	58cfa832e4b0c9d6adf6d3e3	TCGA-V4-A9EL-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EL-01A	8DE236F1-C029-44DF-A2A9-319145488BAA	Primary Tumor	Illumina HiSeq	37f105ff-ac0b-4651-9c5f-008d937dc883	Eye	60.0	DB91E719-82B1-4E9A-AB28-AC67B726340B	50022AEA-CB52-4402-9FC2-C8A4EC1600FF	TCGA-V4-A9EL-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EL	TCGA-UVM		s199	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4a	N0		Stage IIIA	A40D-26	True	UVM	C4		0.134331531	0.14	0.01	0.0	-0.6437	-0.0535	0.1387	0.4896	0.27	-0.6133	0.0	7.0	0.062338279	0.187014837	72.0	0.169047904	6.0	8.0	0.60989514	0.670038295	3.0	2.464507779	15.0	0.910067243	2.025683319	-320.5213598	-583.9490174	-3039.2109579999997	0.0	982.0	1.0	413.0	8.189244525735901	7.498869733976932	1.516945843910997	5.886659432741856	6.45741585914877	2.067401262447755	-2.3025850929940455	-1.0414538748281612	0.5504554185367581
13722.58cfa832e4b0c9d6adf6d3ea	58cfa832e4b0c9d6adf6d3ea	TCGA-V4-A9EO-01A-12D-A40D_140808_SN590_0253_AC499NACXX_s_3_rg.sorted.filtered.	WGS	TCGA-V4-A9EO-01A-12D-A40D_140808_SN590_0253_AC499NACXX_s_3_rg.sorted	TCGA-V4-A9EO-01A-12D-A40D_140808_SN590_0253_AC499NACXX_s_3_rg.sorted.bam	16.22		0.17	58cfa832e4b0c9d6adf6d3ea	TCGA-V4-A9EO-01A-12D-A40D_140808_SN590_0253_AC499NACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EO-01A	BCB87378-9F43-45E4-BDF2-F6DFA6AC5B8C	Primary Tumor	Illumina HiSeq	e433357d-cafe-49f8-b481-e9b804bd4a06	Eye	74.0	C46DB8A8-DAF3-4E99-9307-E6C6CD8F79D5	B0A67E95-2ED2-43EB-9490-5F94BB8E21F4	TCGA-V4-A9EO-01A-12D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EO	TCGA-UVM		s240	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4a	N0		Stage IIIA	A40D-26	True	UVM	C4		0.017379983	0.02	0.0	0.010457566	-1.0548	-0.139	-1.4362	-2.5721	-1.8431	-0.7016	5.0		0.129384928	0.388154784	67.0	0.9476552770000001	20.0	3.0					0.0		1.94752728	-1867.601547	-815.4450099	-2707.137411	0.0	773.0	0.0	773.0	7.883634802267949	8.258348440474313	-0.8007711425415864	5.68641022493173	6.093384725356315	2.873761703330545	-2.197224577336219	-2.164963715117998	3.674532845872131
13722.58cfa832e4b0c9d6adf6d3ee	58cfa832e4b0c9d6adf6d3ee	TCGA-V4-A9ES-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_4_rg.sorted.filtered.	WGS	TCGA-V4-A9ES-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_4_rg.sorted	TCGA-V4-A9ES-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_4_rg.sorted.bam	57.9		0.15	58cfa832e4b0c9d6adf6d3ee	TCGA-V4-A9ES-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9ES-01A	C510A423-6AB1-431E-9248-D2AC91FDEDBA	Primary Tumor	Illumina HiSeq	0edc5349-7b58-4f3e-ae40-3c517bcc8d47	Eye	54.0	1BC52C96-A28E-4E9C-AD3F-0797234C5A12	B16AE1A2-403B-4573-A6B0-9CBB05CEA149	TCGA-V4-A9ES-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9ES	TCGA-UVM		s201	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T3b	N0		Stage IIIA	A40D-26	True	UVM	C4		0.010314955	0.0	0.03	0.0	-0.5067	-0.079	-1.7431	-2.8826	-1.7371	-1.0595	11.0		0.0	0.381690753	98.0	0.99987896	4.0	5.0					0.0		1.474262584	-1979.813685	-524.7394929	-3178.4062489999997	0.0	1511.0	1.0	1299.0	8.665009566110456	7.680945167215619	-0.7478039375879002	6.413717767503961	6.639491292387457		-2.251291798606495	-1.0414538748281612	
13722.58cfa832e4b0c9d6adf6d3f0	58cfa832e4b0c9d6adf6d3f0	TCGA-V4-A9ED-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_2_rg.sorted.filtered.	WGS	TCGA-V4-A9ED-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_2_rg.sorted	TCGA-V4-A9ED-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_2_rg.sorted.bam	53.75		0.17	58cfa832e4b0c9d6adf6d3f0	TCGA-V4-A9ED-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9ED-01A	367869F9-BBE7-4E57-A16F-F2B63F2DE697	Primary Tumor	Illumina HiSeq	db951476-e1a5-4731-8c40-dbe710922b60	Eye	45.0	F1A146CE-B2C6-4CD5-9153-F640D38ABAF1	8CDB01C8-C2D9-40DB-84EE-00B50B9EC314	TCGA-V4-A9ED-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9ED	TCGA-UVM		s220	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T3b	N0		Stage IIIA	A40D-26	True	UVM	C3		0.045010145999999994	0.08	0.03	0.0	-1.6065	-0.3595	-0.5164	-0.7772	-0.8358	-0.3642	3.0		0.061020938	0.183062815	67.0	0.109729484	2.0	0.0				1.33217904	4.0	0.960964047	2.022334624	-1463.395843	-1339.978102	-1607.598966	0.0	1078.0	0.0	1078.0	8.229244416735911	8.080306213299732	-0.39529750655558316	5.786897381366707	7.387159032739787	5.814130531825067	-2.4423470353692043	-0.693147180559945	6.20942803838065
13722.58cfa832e4b0c9d6adf6d400	58cfa832e4b0c9d6adf6d400	TCGA-V4-A9EK-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_8_rg.sorted.filtered.	WGS	TCGA-V4-A9EK-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_8_rg.sorted	TCGA-V4-A9EK-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_8_rg.sorted.bam	48.23		0.16	58cfa832e4b0c9d6adf6d400	TCGA-V4-A9EK-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EK-01A	4464418C-EC35-4826-B3D5-152AC2A27A04	Primary Tumor	Illumina HiSeq	9f84d9e1-572c-43b9-8fa8-695decf3b44e	Eye	37.0	9F324851-EAAE-41B8-BB0E-5D5CEB9E5B23	01AA5AFA-5877-45CA-98DB-9547B99B30C5	TCGA-V4-A9EK-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EK	TCGA-UVM		s234	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T3a	N0		Stage IIB	A40D-26	True	UVM	C3		0.037184737	0.07	0.01	0.0	-1.4959	-0.23800000000000002	-0.1453	-0.0076	-0.7286	-0.9735	9.0	2.0	0.06504215	0.422773976	156.0	0.646218391	5.0	11.0	0.8919102529999999	3.333665856	42.0	1.609437912	5.0	1.0	1.71699978	-1413.696082	-1092.103187	-3144.2059870000003	0.0	1028.0	0.0	1028.0	7.844240718141812	7.824046010856293	0.7570676855097452	5.647016140805593	6.879584402015442	3.625987516687959	-2.197224577336219	-0.9444616088408513	2.8689198311782134
13722.58cfa832e4b0c9d6adf6d401	58cfa832e4b0c9d6adf6d401	TCGA-V4-A9EH-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_5_rg.sorted.filtered.	WGS	TCGA-V4-A9EH-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_5_rg.sorted	TCGA-V4-A9EH-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_5_rg.sorted.bam	32.48		0.17	58cfa832e4b0c9d6adf6d401	TCGA-V4-A9EH-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EH-01A	5E54122F-1C4D-45CC-8842-CD1C1DF0EED8	Primary Tumor	Illumina HiSeq	f23ae536-eb5e-4d13-baf2-94a4eb03d083	Eye	53.0	A320EAC2-C0FB-44D0-9849-DD541C2428E1	AC2BA0CC-C007-44BF-8C99-4C88D55C022E	TCGA-V4-A9EH-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EH	TCGA-UVM		s222	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4c	N0		Stage IIIB	A40D-26	True	UVM	C4		0.029723937000000002	0.29	0.03	0.10383018	-1.7094	-0.2415	-0.5379999999999999	-0.1268	1.6261	-0.9440000000000001	4.0	1.0	0.063685435	0.286584456	85.0	0.021854703	2.0	0.0				2.3025850930000002	10.0	1.0	1.432997366	-1594.360638	-1938.148947	-2197.252442	0.0	670.0	0.0	670.0	7.5613817013797995	7.093266188822792	-0.886072248863485	5.2587966083857545	5.889293384496856	2.8084272214835857	-2.3025850929940455	-1.203972804325936	3.6944994703470706
13722.58cfa832e4b0c9d6adf6d407	58cfa832e4b0c9d6adf6d407	TCGA-VD-A8KJ-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-VD-A8KJ-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_6_rg.sorted	TCGA-VD-A8KJ-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_6_rg.sorted.bam	45.14		0.16	58cfa832e4b0c9d6adf6d407	TCGA-VD-A8KJ-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_6_rg.sorted.bam	Alive	MALE			Uveal Melanoma	Aligned reads	TCGA-VD-A8KJ-01A	7289BC25-2551-4C6D-B2FA-C7E13859B9B3	Primary Tumor	Illumina HiSeq	fc31e7c7-1135-4bd9-b27a-14853ce2751f	Eye	53.0	81194B66-EBA6-4AD8-A745-6CABD69218F0	EB63AF0F-8072-47F0-8CC6-02A5B28126C7	TCGA-VD-A8KJ-01A-11D-A40D-26	HG19_Broad_variant	TCGA-VD-A8KJ	TCGA-UVM		s274	MD Anderson - Institute for Applied Cancer Science	University of Liverpool	United Kingdom	NO	T3a	NX		Stage IIB	A40D-26	True	UVM	C4		0.020501045	0.01	0.11		-0.6081	-0.054000000000000006	-1.376	-2.4537	-2.0632	-0.8482	9.0		0.031490649	0.283415837	1444.0	0.18735535	5.0	7.0				0.0	1.0		1.8231259930000001	-2356.167303	-1181.945693	-1156.575883	0.0	1150.0	0.0	1150.0	8.422552787262116	8.38630320516353	0.5445597974180159	6.813114874828017	7.387774375052404	3.273752435094035	-1.6094379124341003	-0.998528830111127	2.7291926376760194
13722.58cfa832e4b0c9d6adf6d40a	58cfa832e4b0c9d6adf6d40a	TCGA-V4-A9F3-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-V4-A9F3-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_3_rg.sorted	TCGA-V4-A9F3-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_3_rg.sorted.bam	49.28		0.16	58cfa832e4b0c9d6adf6d40a	TCGA-V4-A9F3-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9F3-01A	E21D8018-8FE9-4C92-8B36-28D7D3F7DF2B	Primary Tumor	Illumina HiSeq	cae118e4-484b-45f4-b225-3d7297583648	Eye	49.0	6805D6DB-775C-4817-9F1B-5BE44AE2DA45	395ECE1C-9831-48BF-A933-A4A94566CD9D	TCGA-V4-A9F3-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9F3	TCGA-UVM		s229	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4a	N0		Stage IIIA	A40D-26	True	UVM	C3		0.283276682	0.28	0.1	0.536963902	-0.6274	-0.0745	0.1598	0.8235	0.1571	-0.3873			0.064303924	0.225063734	49.0	0.23622806100000002	6.0	7.0	0.693330989	2.110861753	21.0	2.591663736	24.0	0.815487677	2.5778292769999998	-1011.649208	-249.01840299999998	-2710.988667	1.0	873.0	1.0	329.0	8.983523415295664	8.745815042738474	1.2442910116446182	6.9910932506054575	7.704361167910313	2.1359962680461586	-1.9924301646902063	-1.0414538748281612	0.8917052564015406
13722.58cfa832e4b0c9d6adf6d40e	58cfa832e4b0c9d6adf6d40e	TCGA-VD-A8KF-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-VD-A8KF-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_3_rg.sorted	TCGA-VD-A8KF-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_3_rg.sorted.bam	45.75		0.16	58cfa832e4b0c9d6adf6d40e	TCGA-VD-A8KF-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_3_rg.sorted.bam	Dead	MALE			Uveal Melanoma	Aligned reads	TCGA-VD-A8KF-01A	78039723-94A9-4903-8BB4-C00852E8E889	Primary Tumor	Illumina HiSeq	29607312-d3fc-46a7-97ec-8515bd642e3a	Eye	68.0	B48C5179-16E6-47F1-87C7-EE8B71989BF9	8EB5960A-3FDC-4641-AF72-C80755429C8D	TCGA-VD-A8KF-01A-11D-A40D-26	HG19_Broad_variant	TCGA-VD-A8KF	TCGA-UVM	40.0	s266	MD Anderson - Institute for Applied Cancer Science	University of Liverpool	United Kingdom	NO	T4b	NX		Stage IIIB	A40D-26	True	UVM	C4		0.024269034	0.0	0.11		-1.2646	-0.215	-0.9116	-1.5246	-1.4489	-0.8976	1.0		0.031957192999999995	0.127828771	90.0	0.170136084	6.0	4.0				0.693147181	2.0	1.0	1.688490314	-1945.450384	-624.5839798	-2715.13763	1.0	40.0	1.0	40.0	8.610364722304032	8.642692412343496	0.9157868265976823	6.9521366457005005	7.64416358223237	3.2216157501528477	-1.6582280766035324	-0.998528830111127	2.305828923555165
13722.58cfa832e4b0c9d6adf6d412	58cfa832e4b0c9d6adf6d412	TCGA-V4-A9EX-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_1_rg.sorted.filtered.	WGS	TCGA-V4-A9EX-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_1_rg.sorted	TCGA-V4-A9EX-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_1_rg.sorted.bam	48.32		0.15	58cfa832e4b0c9d6adf6d412	TCGA-V4-A9EX-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_1_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EX-01A	892E7630-B11E-47BD-987C-327D33258E11	Primary Tumor	Illumina HiSeq	9f56ee51-fd1c-43d8-9e64-faacd67069e0	Eye	55.0	69F3ECE7-394D-4FA7-93E7-B6DCD538831A	9A4969D9-222E-4BA3-B0F4-34F42C0D1A19	TCGA-V4-A9EX-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EX	TCGA-UVM	730.0	s210	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4a	N0		Stage IIIA	A40D-26	True	UVM	C4		0.047326317	0.07	0.08	0.0	-0.4604	-0.046	-0.9383	-1.7809	-0.2407	-0.5599	2.0	0.0	0.156943125	0.219720374	117.0	0.228602153	7.0	14.0				0.0	1.0		2.344703022	-739.678684	-781.5124748	-2449.105664	1.0	730.0	1.0	381.0	7.945697111450099	8.547463714434485	-1.405712446976992	6.464092570525883	7.3947842044961	2.506816759423745	-1.4816045409242158	-1.1526795099383853	3.9125292064007366
13722.58cfa832e4b0c9d6adf6d414	58cfa832e4b0c9d6adf6d414	TCGA-VD-A8KB-01A-11D-A40D_140716_SN208_0518_AC59RNACXX_s_4_rg.sorted.filtered.	WGS	TCGA-VD-A8KB-01A-11D-A40D_140716_SN208_0518_AC59RNACXX_s_4_rg.sorted	TCGA-VD-A8KB-01A-11D-A40D_140716_SN208_0518_AC59RNACXX_s_4_rg.sorted.bam	41.19		0.15	58cfa832e4b0c9d6adf6d414	TCGA-VD-A8KB-01A-11D-A40D_140716_SN208_0518_AC59RNACXX_s_4_rg.sorted.bam	Alive	FEMALE			Uveal Melanoma	Aligned reads	TCGA-VD-A8KB-01A	31771082-C094-4749-A9C7-80B67762F4D1	Primary Tumor	Illumina HiSeq	55fb2927-8427-4ec7-a0cd-d9250ff855be	Eye	66.0	3106274B-1330-4C1D-9D6F-EE36138BC929	DEE2EF23-9722-4006-AC98-0F262EB9ECF7	TCGA-VD-A8KB-01A-11D-A40D-26	HG19_Broad_variant	TCGA-VD-A8KB	TCGA-UVM		s273	MD Anderson - Institute for Applied Cancer Science	University of Liverpool	United Kingdom	NO	T3a	NX		Stage IIB	A40D-26	True	UVM	C4		0.006409458000000001	0.01	0.04		-1.0962	-0.24600000000000002	-2.0607	-2.8486	-2.5952	-0.9762	11.0		0.19152180800000002	0.47880452100000004	84.0	0.09437478099999999	2.0	7.0					0.0		2.017010306	-2136.603295	-1493.854736	-108.08606	0.0	1354.0	1.0	1032.0	8.391554379794272	7.772963220626975	0.34222276343203983	6.4944343949083905	7.019191418250595	4.058717384578949	-1.897119984885881	-0.7537718023763804	3.716494621146909
13722.58cfa832e4b0c9d6adf6d416	58cfa832e4b0c9d6adf6d416	TCGA-VD-A8K9-01A-11D-A40D_140716_SN208_0518_AC59RNACXX_s_2_rg.sorted.filtered.	WGS	TCGA-VD-A8K9-01A-11D-A40D_140716_SN208_0518_AC59RNACXX_s_2_rg.sorted	TCGA-VD-A8K9-01A-11D-A40D_140716_SN208_0518_AC59RNACXX_s_2_rg.sorted.bam	33.22		0.15	58cfa832e4b0c9d6adf6d416	TCGA-VD-A8K9-01A-11D-A40D_140716_SN208_0518_AC59RNACXX_s_2_rg.sorted.bam	Alive	FEMALE			Uveal Melanoma	Aligned reads	TCGA-VD-A8K9-01A	FA9089FA-9AF9-4932-8AB7-0E7F2FD6B121	Primary Tumor	Illumina HiSeq	bd825a81-851e-4e11-a617-ff32ec721c33	Eye	71.0	25BDDCB7-2759-42F7-A8EB-D67F0D973802	03211DE4-51EB-4AB9-84CB-30D7A6F12025	TCGA-VD-A8K9-01A-11D-A40D-26	HG19_Broad_variant	TCGA-VD-A8K9	TCGA-UVM		s277	MD Anderson - Institute for Applied Cancer Science	University of Liverpool	United Kingdom	NO	T2a	NX		Stage IIA	A40D-26	True	UVM	C4		0.021552114	0.01	0.01		-0.9317	-0.159	-1.5907	-2.7146	0.1238	-0.9419	5.0		0.127984396	0.223972693	87.0	0.11904742	1.0	12.0					0.0		2.34719716	-1539.4226099999998	-1101.1145900000001	163.06516059999998	0.0	1424.0	0.0	1424.0	8.673427413446873	8.275928098988333	-0.041690247881255194	6.370842320452828	7.177315810320223	2.2322314334725784	-2.3025850929940455	-1.0986122886681096	2.2739216813538334
13722.58cfa832e4b0c9d6adf6d418	58cfa832e4b0c9d6adf6d418	TCGA-V4-A9F2-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-V4-A9F2-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_2_rg.sorted	TCGA-V4-A9F2-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_2_rg.sorted.bam	38.01		0.16	58cfa832e4b0c9d6adf6d418	TCGA-V4-A9F2-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9F2-01A	411DDF79-FE92-44AD-8D10-EEB703F11BE7	Primary Tumor	Illumina HiSeq	c4fcd1a4-5246-4a6b-b5b0-45b8b838edf2	Eye	78.0	2F2FF6C7-9568-47E4-AB09-6050F84BBF5C	87781EA6-C3E9-476A-B5D2-E58FC557FC7A	TCGA-V4-A9F2-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9F2	TCGA-UVM		s207	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T3b	N0		Stage IIIA	A40D-26	True	UVM	C3		0.037550578	0.1	0.02	0.001718272	-2.2281	-0.3345	-0.6056	-0.7458	0.063	-0.5558	1.0		0.064695469	0.161738673	54.0	0.947194357	12.0	2.0		0.0	1.0	0.0	1.0		1.454240882	-1076.456568	-1940.423574	-2092.018099	0.0	734.0	0.0	734.0	7.915713199382116	7.549872288429304	0.7468869355972496	5.613128106388071	6.345899484103368		-2.3025850929940455	-1.203972804325936	
13722.58cfa832e4b0c9d6adf6d426	58cfa832e4b0c9d6adf6d426	TCGA-V4-A9F0-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_4_rg.sorted.filtered.	WGS	TCGA-V4-A9F0-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_4_rg.sorted	TCGA-V4-A9F0-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_4_rg.sorted.bam	54.63		0.15	58cfa832e4b0c9d6adf6d426	TCGA-V4-A9F0-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9F0-01A	92FCA97D-6123-46A7-9C34-7A6F877FE612	Primary Tumor	Illumina HiSeq	96f55937-5d74-4e04-8ab5-f928a9a23da4	Eye	59.0	62859C7E-4B8D-4122-9365-B1595E944C42	C752F975-1E44-4EDF-87BA-4823698AC3F5	TCGA-V4-A9F0-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9F0	TCGA-UVM		s227	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4b	N0		Stage IIIB	A40D-26	True	UVM	C3		0.04008907	0.18	0.06	0.0	-1.1327	-0.155	-0.4932	-0.9063	-1.2570000000000001	-0.2804	2.0	10.0	0.031073161000000002	0.217512125	87.0	0.225543277	5.0	2.0				1.475076311	5.0	0.916516443	2.538474632	-1453.014058	-925.5412280999999	-2024.76085	1.0	945.0	1.0	489.0	8.208582524671955	8.703838719690246	-0.6165902182484542	6.262672375616642	7.950066917313866	2.127221814772259	-1.9459101490553132	-0.7537718023763804	2.7438120330207134
13722.58cfa832e4b0c9d6adf6d42a	58cfa832e4b0c9d6adf6d42a	TCGA-VD-AA8O-01A-11D-A40D_140807_SN1440_0194_AC5B5RACXX_s_3_rg.sorted.filtered.	WGS	TCGA-VD-AA8O-01A-11D-A40D_140807_SN1440_0194_AC5B5RACXX_s_3_rg.sorted	TCGA-VD-AA8O-01A-11D-A40D_140807_SN1440_0194_AC5B5RACXX_s_3_rg.sorted.bam	48.76		0.16	58cfa832e4b0c9d6adf6d42a	TCGA-VD-AA8O-01A-11D-A40D_140807_SN1440_0194_AC5B5RACXX_s_3_rg.sorted.bam	Alive	MALE			Uveal Melanoma	Aligned reads	TCGA-VD-AA8O-01A	99D1BFCC-1989-4DD2-A5E9-78E08F6CE7CF	Primary Tumor	Illumina HiSeq	cfc969dd-923b-4187-808c-584f86e0c276	Eye	77.0	9C21476F-E62A-4259-BD84-52E539EB5806	9E3B6CA4-5102-4C1E-99FD-3E149D0E4B6D	TCGA-VD-AA8O-01A-11D-A40D-26	HG19_Broad_variant	TCGA-VD-AA8O	TCGA-UVM		s269	MD Anderson - Institute for Applied Cancer Science	University of Liverpool	United Kingdom	NO	T3a	N0		Stage IIB	A40D-26	True	UVM	C3		0.047422999	0.1	0.0	0.0	-1.3406	-0.226	-0.6264	-0.5333	-0.5818	-0.8098	9.0		0.123945626	0.371836877	94.0	0.9136265720000001	21.0	2.0				1.246977153	6.0	0.6959512	1.164132194	-1111.797424	-1400.7461640000001	-968.738149	1.0	606.0	1.0	606.0	7.066751343805872	8.910698172605686	0.6163294516297023	5.274991874577817	7.812085883937576	1.5204792007002341	-1.7917594692280547	-1.0986122886681096	0.9041497490705317
13722.58cfa832e4b0c9d6adf6d42e	58cfa832e4b0c9d6adf6d42e	TCGA-VD-A8K8-01A-11D-A40D_140716_SN208_0518_AC59RNACXX_s_1_rg.sorted.filtered.	WGS	TCGA-VD-A8K8-01A-11D-A40D_140716_SN208_0518_AC59RNACXX_s_1_rg.sorted	TCGA-VD-A8K8-01A-11D-A40D_140716_SN208_0518_AC59RNACXX_s_1_rg.sorted.bam	51.97		0.15	58cfa832e4b0c9d6adf6d42e	TCGA-VD-A8K8-01A-11D-A40D_140716_SN208_0518_AC59RNACXX_s_1_rg.sorted.bam	Alive	FEMALE			Uveal Melanoma	Aligned reads	TCGA-VD-A8K8-01A	9B1ECFB2-9DFB-4E71-B51A-D2A0C5A7940E	Primary Tumor	Illumina HiSeq	874e4766-c478-4406-91cf-977d43d9ed07	Eye	56.0	F23780FD-DFEB-472B-B747-84ECE2A6226D	E0DBB55F-2753-4B23-B621-F8003B05D814	TCGA-VD-A8K8-01A-11D-A40D-26	HG19_Broad_variant	TCGA-VD-A8K8	TCGA-UVM		s283	MD Anderson - Institute for Applied Cancer Science	University of Liverpool	United Kingdom	NO	T3a	NX		Stage IIB	A40D-26	True	UVM	C3		0.104013337	0.07	0.03		-0.8612	-0.0455	-0.128	0.2271	-0.2137	-0.8063			0.064018829	0.38411297200000005	74.0	0.11572660900000001	4.0	2.0				2.735415895	23.0	0.872403426	1.340930054	-575.6749516	-741.7054487	-1907.130895	1.0	1377.0	1.0	1377.0	8.39472419376914	7.554509419972371	1.5456630295580616	6.497604208883258	6.756001723754601	3.082766544054456	-1.897119984885881	-0.7985076962177713	1.5371035144963947
13722.58cfa832e4b0c9d6adf6d437	58cfa832e4b0c9d6adf6d437	TCGA-QG-A5Z1-01A-11D-A28G-10_wgs_Illumina.filtered.	WGS	TCGA-QG-A5Z1-01A-11D-A28G-10_wgs_Illumina	TCGA-QG-A5Z1-01A-11D-A28G-10_wgs_Illumina.bam	39.63		0.08	58cfa832e4b0c9d6adf6d437	TCGA-QG-A5Z1-01A-11D-A28G-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-QG-A5Z1-01A	9C45EAEC-D854-4F51-80A3-2D80D6B4AEBC	Primary Tumor	Illumina HiSeq	cc89a29c-287c-4a64-87c1-40ea6c90f58a	Colorectal	71.0	95601410-9608-4DDA-BA3F-462BE0E8C35F	D3AFF5D3-23C0-43AE-9C01-8DDD776B530B	TCGA-QG-A5Z1-01A-11D-A28G-10	GRCh37-lite	TCGA-QG-A5Z1	TCGA-COAD		s13041	Baylor College of Medicine	BLN - Baylor	United States	NO	T3	N1b	Colon Adenocarcinoma	Stage IIIB	A28G-10	True	COAD	C1	GI.CIN	0.067999771	0.2	0.14	4.710975298999999	0.4355	0.0045	-0.6156	-1.3869999999999998	-0.9919	0.1565	60.0	167.0	0.792915522	2.4051770830000003	132.0	0.27366084399999996	9.0	17.0	0.9767727979999999	1.0730946000000001	3.0	1.386294361	4.0	1.0	0.980764359	-1708.658299	-196.41826930000002	710.9734196	1.0	256.0	0.0	256.0	6.0786698708059745	2.1198371846210797	-2.730579314162238	5.533942695364303	3.9438918321402285	-0.5536564491433715	-0.5447271754416718	1.8240546475191488	2.1769228650188666
13722.58cfa832e4b0c9d6adf6d43a	58cfa832e4b0c9d6adf6d43a	TCGA-QG-A5YV-01A-11D-A28G-10_wgs_Illumina.filtered.	WGS	TCGA-QG-A5YV-01A-11D-A28G-10_wgs_Illumina	TCGA-QG-A5YV-01A-11D-A28G-10_wgs_Illumina.bam	62.92		0.07	58cfa832e4b0c9d6adf6d43a	TCGA-QG-A5YV-01A-11D-A28G-10_wgs_Illumina.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-QG-A5YV-01A	C83D38FC-E011-4F75-A100-96513611F3E9	Primary Tumor	Illumina HiSeq	fc951188-ba57-4cd7-a209-28726710bb92	Colorectal	64.0	69EF3E70-5D7A-4E30-ABDE-0F9F76EA3141	E3EF5CAD-4D6E-4F04-BABB-A908EE02644B	TCGA-QG-A5YV-01A-11D-A28G-10	GRCh37-lite	TCGA-QG-A5YV	TCGA-COAD		s13220	Baylor College of Medicine	BLN - Baylor	United States	NO	T4b	N1a	Colon Adenocarcinoma	Stage IIIC	A28G-10	True	COAD	C1	GI.CIN	0.056318334000000005	0.41	0.15	1.862193113	0.9303	0.3235	-0.8871	-0.3961	-0.4354	-0.2161	105.0	277.0	1.358272929	4.181349997	183.0	0.536593187	15.0	9.0	0.7051978259999999	1.861057491	14.0	0.0	1.0		0.9886892759999999	-1925.2058670000001	466.1738302	-1002.0687949999999	0.0	1301.0	0.0	1301.0	7.119365914482622	2.197224577336219	-0.5056966965259287	5.082483987221583	2.0393215478904105	0.22461369470175452	-2.0368819272610397	-0.15790302944580858	0.7303103912276833
13722.58cfa832e4b0c9d6adf6d448	58cfa832e4b0c9d6adf6d448	TCGA-QG-A5YW-01A-11D-A28G-10_wgs_Illumina.filtered.	WGS	TCGA-QG-A5YW-01A-11D-A28G-10_wgs_Illumina	TCGA-QG-A5YW-01A-11D-A28G-10_wgs_Illumina.bam	63.92		0.08	58cfa832e4b0c9d6adf6d448	TCGA-QG-A5YW-01A-11D-A28G-10_wgs_Illumina.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-QG-A5YW-01A	9F45A227-1FD5-478C-A194-4A5C61B68CC3	Primary Tumor	Illumina HiSeq	32a205bb-36f6-42a4-8bc1-42318eeccd0f	Colorectal	55.0	D8DCE266-1073-4BF2-A714-748E7E942635	4CFB0AEE-6661-478A-8694-9D8BA15E46B7	TCGA-QG-A5YW-01A-11D-A28G-10	GRCh37-lite	TCGA-QG-A5YW	TCGA-COAD		s12894	Baylor College of Medicine	BLN - Baylor	United States	NO	T3	N2b	Colon Mucinous Adenocarcinoma	Stage IIIC	A28G-10	True	COAD	C1	GI.CIN	0.17210346	0.39	0.12	0.14035583699999998	0.3767	0.217	-0.1226	0.5722	-0.3376	0.1098	66.0	9.0	1.159814162	3.948891077	115.0	0.558197987	16.0	6.0	0.713059036	3.106590597	78.0	2.821563808	18.0	0.976194083	3.422074453	-1393.35565	86.39397699	52.06094318	0.0	896.0	0.0	896.0	6.889319716826451	2.440296453652717	-0.5239506376466165	3.670443891958251	4.044286616828864	0.19277658279877397	-3.2188758248682006	1.6039901631761468	0.7167272204453905
13722.58cfa832e4b0c9d6adf6d44e	58cfa832e4b0c9d6adf6d44e	TCGA-VD-A8KG-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-VD-A8KG-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_4_rg.sorted	TCGA-VD-A8KG-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_4_rg.sorted.bam	43.78		0.17	58cfa832e4b0c9d6adf6d44e	TCGA-VD-A8KG-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_4_rg.sorted.bam	Alive	FEMALE			Uveal Melanoma	Aligned reads	TCGA-VD-A8KG-01A	9F57834A-4DC4-45ED-97DE-ED4DA9D0598D	Primary Tumor	Illumina HiSeq	4a7b8d85-7b0f-4e37-b941-e61363166648	Eye	47.0	75A06E1E-CF06-418C-BFB7-3B9147D19078	376A6943-6FCC-406B-B543-4C0C385D2E22	TCGA-VD-A8KG-01A-11D-A40D-26	HG19_Broad_variant	TCGA-VD-A8KG	TCGA-UVM		s272	MD Anderson - Institute for Applied Cancer Science	University of Liverpool	United Kingdom	NO	T2a	NX		Stage IIA	A40D-26	True	UVM	C3		0.055973383	0.07	0.02		-1.8623	-0.3065	-0.9187	-0.8476	-0.4453	-0.8971	8.0		0.127587287	0.510349147	141.0	0.145746611	3.0	4.0				1.5607104090000001	5.0	0.9697239	1.588694375	-1175.215041	-1839.0679089999999	-303.226682	0.0	19.0	0.0	19.0	7.358193752733032	7.017207412543218	-0.272545840282037	5.512367062234702	5.918595123875108	1.8357392633445897	-1.8458266904983305	-1.0986122886681096	2.108285103626627
13722.58cfa832e4b0c9d6adf6d470	58cfa832e4b0c9d6adf6d470	TCGA-QG-A5Z2-01A-11D-A28G-10_wgs_Illumina.filtered.	WGS	TCGA-QG-A5Z2-01A-11D-A28G-10_wgs_Illumina	TCGA-QG-A5Z2-01A-11D-A28G-10_wgs_Illumina.bam	58.77		0.07	58cfa832e4b0c9d6adf6d470	TCGA-QG-A5Z2-01A-11D-A28G-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-QG-A5Z2-01A	84959E50-17F5-4F2B-8E0C-5EBB139D2C3A	Primary Tumor	Illumina HiSeq	2113677f-10e1-4987-bde0-35d29025de2e	Colorectal	61.0	3D753B5B-8E33-4307-9321-E4AD4821F3BF	31E63F89-A6A9-40FB-823D-F41587BD73D8	TCGA-QG-A5Z2-01A-11D-A28G-10	GRCh37-lite	TCGA-QG-A5Z2	TCGA-COAD		s13042	Baylor College of Medicine	BLN - Baylor	United States	NO	T2	N0	Colon Adenocarcinoma	Stage I	A28G-10	True	COAD	C2	GI.HM-indel	0.308172285	0.5	0.03	12.49707965	0.5867	0.1685	-0.2138	1.4814	0.2228	-0.3108	472.0	1981.0	9.031318948	25.71453349	67.0	0.00022790900000000002	0.0	0.0	0.901203607	3.4503854360000004	46.0	3.308777758	28.0	0.992969593	1.247776017	-1069.027251	696.7299182	1306.780653	0.0	952.0	0.0	952.0	7.111466800986917	3.910491066061539	0.6784960964151885	6.288266492178773	6.586153015351977	2.0186818798817154	-0.8232003088081434	2.675661949290438	1.340185783466527
13722.58cfa832e4b0c9d6adf6d474	58cfa832e4b0c9d6adf6d474	TCGA-V4-A9EI-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_6_rg.sorted.filtered.	WGS	TCGA-V4-A9EI-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_6_rg.sorted	TCGA-V4-A9EI-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_6_rg.sorted.bam	32.62		0.17	58cfa832e4b0c9d6adf6d474	TCGA-V4-A9EI-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_6_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EI-01A	B533E555-90CF-4657-80C6-15B67DA8AD26	Primary Tumor	Illumina HiSeq	ffc1ec43-7da7-4a9b-ab87-1ad3a3ba5c42	Eye	78.0	0077CCB8-615D-4725-95E7-72708732E963	B0CCF5D2-B334-4B7C-858E-53005B6FD0D7	TCGA-V4-A9EI-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EI	TCGA-UVM	389.0	s203	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4c	N0		Stage IIIB	A40D-26	True	UVM	C4		0.060905007000000004	0.07	0.18	0.0	-0.2344	0.0085	-0.9154	-1.4434	-0.7074	-0.6552	6.0	2.0	0.124034465	0.558155094	88.0	0.286780697	9.0	8.0				0.6365141679999999	2.0	0.918295834	2.078744393	-695.5161307999999	-284.7061682	-2697.0403530000003	1.0	389.0	1.0	203.0	8.357493812658563	7.975761073914443	0.7687084709882668	6.460373827772681	6.925938949415766	2.8289593115089904	-1.897119984885881	-1.0498221244986776	2.060250840520724
13722.58cfa832e4b0c9d6adf6d478	58cfa832e4b0c9d6adf6d478	TCGA-VD-A8KD-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-VD-A8KD-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_1_rg.sorted	TCGA-VD-A8KD-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_1_rg.sorted.bam	49.59		0.17	58cfa832e4b0c9d6adf6d478	TCGA-VD-A8KD-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_1_rg.sorted.bam	Dead	MALE			Uveal Melanoma	Aligned reads	TCGA-VD-A8KD-01A	73B3E4DD-C53D-4FE3-8607-EE462C9CBBD1	Primary Tumor	Illumina HiSeq	32e66b83-1d91-4ed8-b672-cc125bbe3b57	Eye	72.0	4F0319B2-722C-48E1-A5E1-798463E9EA02	347DBA4E-7CA8-4432-A0F7-90F9009F8AA3	TCGA-VD-A8KD-01A-11D-A40D-26	HG19_Broad_variant	TCGA-VD-A8KD	TCGA-UVM	114.0	s270	MD Anderson - Institute for Applied Cancer Science	University of Liverpool	United Kingdom	NO	T4a	NX		Stage IV	A40D-26	True	UVM	C3		0.19601727600000002	0.17	0.03		-1.3454	-0.1295	0.34299999999999997	1.6633	0.009000000000000001	-0.7158	8.0	10.0	0.1880277	0.47006924899999997	66.0	0.12519908300000002	4.0	3.0	0.6435804270000001	2.71559257	68.0	3.41739464	40.0	0.926404531	1.382784962	-371.6927736	-701.8057209	-2284.152972	1.0	114.0	1.0		8.49596955496461	8.740416739530618	-0.3815238149809005	6.791221462726185	7.698962864702456		-1.7047480922384255	-1.0414538748281612	
13722.58cfa832e4b0c9d6adf6d47f	58cfa832e4b0c9d6adf6d47f	TCGA-V4-A9EC-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_1_rg.sorted.filtered.	WGS	TCGA-V4-A9EC-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_1_rg.sorted	TCGA-V4-A9EC-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_1_rg.sorted.bam	44.61		0.16	58cfa832e4b0c9d6adf6d47f	TCGA-V4-A9EC-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EC-01A	EEAB0529-31E6-4EDB-BD2C-A21F2A169381	Primary Tumor	Illumina HiSeq	b19262ce-546a-4f20-b2c6-542d12745c33	Eye	75.0	3234E814-AD34-48F0-AEBD-19E1A694ED8E	3ED594C4-5AF5-4461-838D-367758D3BA55	TCGA-V4-A9EC-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EC	TCGA-UVM		s232	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T3a	N0		Stage IIB	A40D-26	True	UVM	C4		0.013052313000000001	0.0	0.01	0.08608507800000001	-1.5931	-0.2615	-1.4472	-2.0919	-2.2401	-0.8646	10.0	62.0	0.129054626	0.6130094739999999	39.0	0.030769526000000002	1.0	2.0					0.0		1.177342191	-1958.7535010000001	-1709.3364609999999	2165.716186	0.0	743.0	0.0	743.0	7.776954403322442	7.1276936993473985	0.06502239316940084	5.525662604715947	6.086239824519237	3.7246153656827388	-2.251291798606495	-1.0414538748281612	3.659592972513338
13722.58cfa832e4b0c9d6adf6d48a	58cfa832e4b0c9d6adf6d48a	TCGA-NH-A50T-01A-11D-A28G-10_wgs_Illumina.filtered.	WGS	TCGA-NH-A50T-01A-11D-A28G-10_wgs_Illumina	TCGA-NH-A50T-01A-11D-A28G-10_wgs_Illumina.bam	43.71		0.08	58cfa832e4b0c9d6adf6d48a	TCGA-NH-A50T-01A-11D-A28G-10_wgs_Illumina.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-NH-A50T-01A	490EABCA-4575-4BD6-9604-6B6E23D069CE	Primary Tumor	Illumina HiSeq	2893d404-6a2e-482b-86f7-eb3ae051faf4	Colorectal	68.0	9F5AD422-C94D-4914-B6F0-071596ECB589	8A929C55-35A6-4645-BB70-4B85D281B139	TCGA-NH-A50T-01A-11D-A28G-10	GRCh37-lite	TCGA-NH-A50T	TCGA-COAD		s13547	Baylor College of Medicine	Candler	United States	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	A28G-10	True	COAD	C1	GI.CIN	0.07324094	0.25	0.43	8.489508626000001	1.0781	0.46399999999999997	-1.4535	-1.8647	-2.065	-0.3646	58.0	2.0	0.9030436829999999	3.018746026	114.0	0.565363029	15.0	15.0				0.0	1.0		2.284964444	-2125.1918920000003	771.9147954	-1342.5264769999999	0.0	553.0	0.0	553.0	6.525029657843463	3.625520178396041	-0.517430897216437	5.321056853517527	3.955377175898535	0.20954614786191317	-1.203972804325936	0.3298569975024943	0.7269770450783501
13722.58cfa832e4b0c9d6adf6d490	58cfa832e4b0c9d6adf6d490	TCGA-VD-AA8M-01A-11D-A40D_140807_SN1440_0194_AC5B5RACXX_s_1_rg.sorted.filtered.	WGS	TCGA-VD-AA8M-01A-11D-A40D_140807_SN1440_0194_AC5B5RACXX_s_1_rg.sorted	TCGA-VD-AA8M-01A-11D-A40D_140807_SN1440_0194_AC5B5RACXX_s_1_rg.sorted.bam	57.94		0.15	58cfa832e4b0c9d6adf6d490	TCGA-VD-AA8M-01A-11D-A40D_140807_SN1440_0194_AC5B5RACXX_s_1_rg.sorted.bam	Alive	MALE			Uveal Melanoma	Aligned reads	TCGA-VD-AA8M-01A	9DC5CC23-C903-4FE2-8354-64F8316FF0D4	Primary Tumor	Illumina HiSeq	4a38e73e-520a-4721-a89a-7a2b3b334ee6	Eye	64.0	DDC9047A-FD34-4874-87B0-72DAB50311E6	ABFED748-0BF8-4E64-8AB1-2A4DA1BB5A62	TCGA-VD-AA8M-01A-11D-A40D-26	HG19_Broad_variant	TCGA-VD-AA8M	TCGA-UVM		s271	MD Anderson - Institute for Applied Cancer Science	University of Liverpool	United Kingdom	NO	T2a	N0		Stage IIA	A40D-26	True	UVM	C3		0.021030226000000003	0.0	0.01	0.0	-1.6602	-0.3055	-1.3226	-1.6702	-0.8034	-0.7924	14.0		0.06420896599999999	0.609985175	81.0	0.020517964	0.0	3.0				0.6365141679999999	2.0	0.918295834	1.606855409	-1260.058565	-1774.6525600000002	-748.0068427	0.0	6.0	0.0	6.0	7.05444965813294	8.714166149575803	-1.6044769245837864	6.954366199575958	7.8668682891886	2.83805303892318	-0.10008345855698275	-0.8472978603872034	4.442529963506967
13722.58cfa832e4b0c9d6adf6d498	58cfa832e4b0c9d6adf6d498	TCGA-V4-A9EF-01A-21D-A40D_140725_SN590_0251_AC41YJACXX_s_4_rg.sorted.filtered.	WGS	TCGA-V4-A9EF-01A-21D-A40D_140725_SN590_0251_AC41YJACXX_s_4_rg.sorted	TCGA-V4-A9EF-01A-21D-A40D_140725_SN590_0251_AC41YJACXX_s_4_rg.sorted.bam	37.33		0.17	58cfa832e4b0c9d6adf6d498	TCGA-V4-A9EF-01A-21D-A40D_140725_SN590_0251_AC41YJACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EF-01A	A18D3BA3-E2F4-4144-9C25-2019CAD193F4	Primary Tumor	Illumina HiSeq	bf602ec4-fef9-41b6-9f28-a773493f4507	Eye	56.0	0966DF5C-5838-4E92-ADA6-304241CCAEF1	0CE78DDD-32D4-43DB-B7A4-FE7C3AD9563D	TCGA-V4-A9EF-01A-21D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EF	TCGA-UVM		s215	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4b	N0		Stage IIIB	A40D-26	True	UVM	C4		0.018500164	0.03	0.01	0.0	-1.0873	-0.2145	-1.1103	-1.6733	-2.1831	-0.7648	1.0	19.0	0.0	0.242240705	42.0	0.101158489	3.0	1.0				0.0	1.0		1.704038076	-1705.8397929999999	-1253.115175	-1528.1319210000001	0.0	1165.0	0.0	1165.0	8.073714641109857	8.367134129492232	-0.3268764023109625	5.822422842503363	7.479830934491329	2.230189022538759	-2.251291798606495	-0.8873031950009029	2.5570654248497218
13722.58cfa832e4b0c9d6adf6d49c	58cfa832e4b0c9d6adf6d49c	TCGA-V4-A9F4-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-V4-A9F4-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_4_rg.sorted	TCGA-V4-A9F4-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_4_rg.sorted.bam	55.04		0.16	58cfa832e4b0c9d6adf6d49c	TCGA-V4-A9F4-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9F4-01A	4B9FD822-17AA-4A22-8E17-175A72931D5D	Primary Tumor	Illumina HiSeq	1f82d81a-7827-4bb8-89b2-fc4bd009cdde	Eye	41.0	AD550F5E-1469-4A09-9CDA-3F069B1AE258	1837571E-8D54-4BA2-A9FB-B7160BFD38BB	TCGA-V4-A9F4-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9F4	TCGA-UVM		s236	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4a	N0		Stage IIIA	A40D-26	True	UVM	C4		0.022319067999999997	0.09	0.09	0.0	-1.0592	-0.2255	-1.0513	-1.6981	-1.7314	-0.6234	7.0		0.062860248	0.471451861	92.0	0.164198806	3.0	4.0					0.0		1.636001055	-1773.5278219999998	-1112.304652	-1935.724216	0.0	634.0	0.0	634.0	7.997494989146649	8.476093380530813	0.062048056742786684	5.80027041181043	7.434639505702651	3.2394703745973734	-2.197224577336219	-1.0414538748281612	3.1774223178545866
13722.58cfa832e4b0c9d6adf6d4a2	58cfa832e4b0c9d6adf6d4a2	TCGA-V4-A9F8-01A-11D-A40D_140716_SN208_0519_BC5946ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-V4-A9F8-01A-11D-A40D_140716_SN208_0519_BC5946ACXX_s_3_rg.sorted	TCGA-V4-A9F8-01A-11D-A40D_140716_SN208_0519_BC5946ACXX_s_3_rg.sorted.bam	54.24		0.17	58cfa832e4b0c9d6adf6d4a2	TCGA-V4-A9F8-01A-11D-A40D_140716_SN208_0519_BC5946ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9F8-01A	64BD88BD-1D5A-4569-9F46-F668D448C336	Primary Tumor	Illumina HiSeq	05bff1f2-adb9-4252-892d-c86207753ca1	Eye	68.0	6B903079-A499-4AE3-B399-59276DCB9C70	5FABEAFA-9ADE-43AA-B4EB-979826FAE9BF	TCGA-V4-A9F8-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9F8	TCGA-UVM		s252	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4a	N0		Stage IIIA	A40D-26	True	UVM	C3		0.022781981	0.0	0.14	0.00120805	-1.1595	-0.358	-1.0352	-1.5553	-1.2506	-0.4404	9.0	2.0	0.216444307	0.556571075	71.0	0.23646163	7.0	8.0				0.693147181	2.0	1.0	1.9142507690000001	-1563.153261	-982.814474	-318.8887498	0.0	597.0	0.0	597.0	8.594586237990011	8.149938671071826	-0.7153856554867808	6.802826768761956	7.051326382403716	2.8634423460175333	-1.7917594692280547	-1.0986122886681096	3.578828001504314
13722.58cfa832e4b0c9d6adf6d4a6	58cfa832e4b0c9d6adf6d4a6	TCGA-V4-A9EW-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_8_rg.sorted.filtered.	WGS	TCGA-V4-A9EW-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_8_rg.sorted	TCGA-V4-A9EW-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_8_rg.sorted.bam	43.67		0.16	58cfa832e4b0c9d6adf6d4a6	TCGA-V4-A9EW-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EW-01A	6BE5176C-4980-4663-ADFF-D04F05737DA0	Primary Tumor	Illumina HiSeq	3dd4d560-67ce-426b-9eeb-63fec58eaf05	Eye	44.0	685D5387-B35F-40EE-8F14-491CE212F0DE	6B52C651-649F-41C5-B0DD-197F77F2AA10	TCGA-V4-A9EW-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EW	TCGA-UVM		s216	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4a	N0		Stage IIIA	A40D-26	True	UVM	C3		0.015748502	0.32	0.24	0.10429308300000001	-0.9539	-0.16899999999999998	-1.2802	-2.3076	-1.1157	-0.8827	4.0	1.0	0.15425860800000002	0.24681377300000001	37.0	0.299377892	2.0	17.0					0.0		1.876113965	-1598.122016	-1369.749357	2818.0253399999997	0.0	1211.0	1.0	197.0	7.650803117995541	7.6581488324764795	0.7372764318400886	5.704892968940229	6.505469322538094		-1.9459101490553132	-1.1526795099383853	
13722.58cfa832e4b0c9d6adf6d4a7	58cfa832e4b0c9d6adf6d4a7	TCGA-VD-A8KH-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-VD-A8KH-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_5_rg.sorted	TCGA-VD-A8KH-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_5_rg.sorted.bam	39.6		0.17	58cfa832e4b0c9d6adf6d4a7	TCGA-VD-A8KH-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_5_rg.sorted.bam	Alive	MALE			Uveal Melanoma	Aligned reads	TCGA-VD-A8KH-01A	39AF6E0F-908C-4B2B-97B8-A4D1966E47E1	Primary Tumor	Illumina HiSeq	c1aaf5dd-316d-42b5-9471-88f8c886efd8	Eye	69.0	98A73F7B-83C7-4160-944E-7A19B07AD696	4A25E140-632B-481F-8D50-49433ECEF545	TCGA-VD-A8KH-01A-11D-A40D-26	HG19_Broad_variant	TCGA-VD-A8KH	TCGA-UVM		s251	MD Anderson - Institute for Applied Cancer Science	University of Liverpool	United Kingdom	NO	T4b	NX		Stage IIIB	A40D-26	True	UVM	C4		0.045733355999999996	0.05	0.01		-1.0203	-0.14400000000000002	-1.2801	-2.3574	-1.7087	-1.0259	7.0	5.0	0.186955865	0.405071041	203.0	0.6854126970000001	2.0	10.0					0.0		2.071007701	-1195.3810349999999	-1121.012081	1877.3404739999999	0.0	1158.0	0.0	1158.0	8.992806059426483	8.67387400109712	-0.7652847087263686	6.5949107866281125	8.037885234377125		-2.3978952727983707	-0.6359887667199966	
13722.58cfa832e4b0c9d6adf6d4aa	58cfa832e4b0c9d6adf6d4aa	TCGA-V4-A9ET-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_5_rg.sorted.filtered.	WGS	TCGA-V4-A9ET-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_5_rg.sorted	TCGA-V4-A9ET-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_5_rg.sorted.bam	57.02		0.17	58cfa832e4b0c9d6adf6d4aa	TCGA-V4-A9ET-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9ET-01A	5383FB57-69C2-4B34-AF7F-C67208EFB2B5	Primary Tumor	Illumina HiSeq	98f43560-a2c1-4edb-a936-9c84114cf0c2	Eye	57.0	C16B2576-AB56-4BEB-B621-22EA9FC4E898	D544884F-7E0D-4029-B778-55E14B5C2C38	TCGA-V4-A9ET-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9ET	TCGA-UVM		s244	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4b	N0		Stage IIIB	A40D-26	True	UVM	C4		0.005620551999999999	0.0	0.02	0.0	-1.7904	-0.39	-1.9283	-2.7893	-2.1489	-0.9205	3.0		0.15538201699999998	0.21753482300000002	100.0	0.12283159	3.0	9.0					0.0		1.680287505	-2022.226115	-1846.2416850000002	-1007.008364	0.0	1362.0	0.0	1362.0	8.10711747075039	8.19430822830354	0.22847111820657806	6.315358001522335	7.307005033302638	5.220716120524486	-1.7917594692280547	-0.8873031950009029	4.992245002317907
13722.58cfa832e4b0c9d6adf6d4b4	58cfa832e4b0c9d6adf6d4b4	TCGA-V4-A9EV-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_7_rg.sorted.filtered.	WGS	TCGA-V4-A9EV-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_7_rg.sorted	TCGA-V4-A9EV-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_7_rg.sorted.bam	56.76		0.15	58cfa832e4b0c9d6adf6d4b4	TCGA-V4-A9EV-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EV-01A	DA6F0ED2-A6D5-4D87-823E-122EBD59AABA	Primary Tumor	Illumina HiSeq	463c617e-a31f-4ebe-9bb0-bdf35b3823f8	Eye	59.0	42BBB13B-DA94-44FF-A01C-4776A74AEA6F	A08A9A90-323B-48AB-89C8-4805FE59BC70	TCGA-V4-A9EV-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EV	TCGA-UVM		s204	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4a	N0		Stage IIIA	A40D-26	True	UVM	C3		0.278677954	0.25	0.04	0.667007817	-1.2695	-0.1445	0.6547	1.1059999999999999	0.3338	-0.6737	3.0		0.06460182	0.22610637100000003	52.0	0.10118976699999999	3.0	4.0				3.958099382	64.0	0.951721725	1.958330352	-360.351407	-703.7966554	-2725.288848	1.0	1269.0	1.0	1269.0	8.333270353255308	7.693785453688797	1.2117782532848183	6.030685260261263	6.652331578860635	2.839607488690342	-2.3025850929940455	-1.0414538748281612	1.6278292354055237
13722.58cfa832e4b0c9d6adf6d4ba	58cfa832e4b0c9d6adf6d4ba	TCGA-VD-A8K7-01B-11D-A40D_140716_SN208_0519_BC5946ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-VD-A8K7-01B-11D-A40D_140716_SN208_0519_BC5946ACXX_s_4_rg.sorted	TCGA-VD-A8K7-01B-11D-A40D_140716_SN208_0519_BC5946ACXX_s_4_rg.sorted.bam	27.7		0.16	58cfa832e4b0c9d6adf6d4ba	TCGA-VD-A8K7-01B-11D-A40D_140716_SN208_0519_BC5946ACXX_s_4_rg.sorted.bam	Alive	MALE			Uveal Melanoma	Aligned reads	TCGA-VD-A8K7-01B	6103E640-8B62-4E39-908B-B62A0DEBEB0E	Primary Tumor	Illumina HiSeq	649c4e6f-5b69-4d14-b5cc-99938c78d650	Eye	39.0	1B626599-EC44-409D-8123-ED69D8442C19	4208E47B-01BB-4C91-9411-F214F46F656C	TCGA-VD-A8K7-01B-11D-A40D-26	HG19_Broad_variant	TCGA-VD-A8K7	TCGA-UVM		s260	MD Anderson - Institute for Applied Cancer Science	University of Liverpool	United Kingdom	NO	T4a	NX		Stage IIIA	A40D-26	True	UVM	C4		0.012808799	0.0	0.01		-2.1282	-0.2245	-1.5693	-2.6413	-2.0540000000000003	-1.2691	3.0		0.065574665	0.09836199699999999	44.0	0.027471816	1.0	3.0					0.0		1.203933778	-2308.0261	-1605.635191	3473.721929	0.0	1459.0	0.0	1459.0	7.196187070324464	8.337747495367747	0.06870547387037351	5.350360379826133	7.296293620539585	2.545028379966982	-1.8458266904983305	-1.0414538748281612	2.4763229060966085
13722.58cfa832e4b0c9d6adf6d4be	58cfa832e4b0c9d6adf6d4be	TCGA-V4-A9F7-01A-11D-A40D_140716_SN208_0519_BC5946ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-V4-A9F7-01A-11D-A40D_140716_SN208_0519_BC5946ACXX_s_2_rg.sorted	TCGA-V4-A9F7-01A-11D-A40D_140716_SN208_0519_BC5946ACXX_s_2_rg.sorted.bam	49.86		0.16	58cfa832e4b0c9d6adf6d4be	TCGA-V4-A9F7-01A-11D-A40D_140716_SN208_0519_BC5946ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9F7-01A	64422CC5-5E5B-4EF9-A9E2-214CEBF8DFBC	Primary Tumor	Illumina HiSeq	8388df36-e4c1-4450-bc87-acc118ce705e	Eye	78.0	44AD0268-6B48-4264-A1DD-58C2302224D7	07397855-A0D5-4287-A21B-5AB83A4E0DE0	TCGA-V4-A9F7-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9F7	TCGA-UVM		s257	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T3a	N0		Stage IIB	A40D-26	True	UVM	C4		0.011472458999999999	0.0	0.0	0.0013887729999999998	-1.033	-0.1085	-1.5927	-2.6184	-1.7505	-1.0251	6.0		0.063113698	0.410239036	56.0	0.013805196	1.0	4.0					0.0		1.049799285	-2039.714062	-1352.28835	-407.1618123	0.0	1256.0	0.0	1256.0	7.777513296728075	7.284820912568604	-0.49677012963630807	5.98575382750002	6.186208623900494		-1.7917594692280547	-1.0986122886681096	
13722.58cfa832e4b0c9d6adf6d4c6	58cfa832e4b0c9d6adf6d4c6	TCGA-VD-A8KA-01B-11D-A40D_140716_SN208_0518_AC59RNACXX_s_3_rg.sorted.filtered.	WGS	TCGA-VD-A8KA-01B-11D-A40D_140716_SN208_0518_AC59RNACXX_s_3_rg.sorted	TCGA-VD-A8KA-01B-11D-A40D_140716_SN208_0518_AC59RNACXX_s_3_rg.sorted.bam	26.17		0.16	58cfa832e4b0c9d6adf6d4c6	TCGA-VD-A8KA-01B-11D-A40D_140716_SN208_0518_AC59RNACXX_s_3_rg.sorted.bam	Alive	MALE			Uveal Melanoma	Aligned reads	TCGA-VD-A8KA-01B	AF04CA52-8B71-497E-8135-6DDFCA9AB221	Primary Tumor	Illumina HiSeq	c48413ae-339d-4a00-8615-5fbb50dad7b2	Eye	22.0	F028A8C2-1AD9-4CCD-9EF4-076F90D73806	CE40220B-D109-4A14-9C17-3C7DFD0A737A	TCGA-VD-A8KA-01B-11D-A40D-26	HG19_Broad_variant	TCGA-VD-A8KA	TCGA-UVM		s262	MD Anderson - Institute for Applied Cancer Science	University of Liverpool	United Kingdom	NO	T3a	NX		Stage IIB	A40D-26	True	UVM	C4		0.006896254	0.0	0.08		-1.0239	-0.2685	-1.7698	-2.7146	-2.605	-0.9037	10.0		0.0	0.421601081	74.0	0.176918875	3.0	7.0				0.0	1.0		2.182307619	-2161.380361	-1441.5224380000002	-1382.512314	0.0	1178.0	1.0	1008.0	8.245559430941594	8.713927056813063	-0.7025052299827501	6.348439446055712	8.072073170640667	2.7566862464457222	-1.897119984885881	-0.6418538861723944	3.4591914764284724
13722.58cfa832e4b0c9d6adf6d4ca	58cfa832e4b0c9d6adf6d4ca	TCGA-V4-A9F5-01A-11D-A40D_140716_SN208_0519_BC5946ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-V4-A9F5-01A-11D-A40D_140716_SN208_0519_BC5946ACXX_s_1_rg.sorted	TCGA-V4-A9F5-01A-11D-A40D_140716_SN208_0519_BC5946ACXX_s_1_rg.sorted.bam	57.62		0.17	58cfa832e4b0c9d6adf6d4ca	TCGA-V4-A9F5-01A-11D-A40D_140716_SN208_0519_BC5946ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9F5-01A	BBF07E1F-8C17-4C2E-89ED-38332D82E455	Primary Tumor	Illumina HiSeq	11ec05e6-4b9a-4abf-8b47-45f259c5eaf3	Eye	85.0	16FCA21C-963E-4D77-8B5A-3C178DAC6168	38812469-1716-4B6F-8DBE-822654AC13F6	TCGA-V4-A9F5-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9F5	TCGA-UVM		s245	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4e	N0		Stage IV	A40D-26	True	UVM	C4		0.011101958	0.0	0.1	0.0	-1.068	-0.2125	-1.8029	-2.4776	-0.1651	-0.9607			0.063762006	0.223167019	116.0	0.933060188	6.0	7.0					0.0		1.7653337219999998	-1136.893276	-1381.255852	-2090.7435969999997	0.0	203.0	1.0	78.0	8.697290053188082	8.028455164114252	-1.3449962227952137	6.751379904132769	7.029926334003125	0.618578485062437	-1.9459101490553132	-0.998528830111127	1.9635747078576506
13722.58cfa832e4b0c9d6adf6d4cc	58cfa832e4b0c9d6adf6d4cc	TCGA-VD-A8KL-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-VD-A8KL-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_7_rg.sorted	TCGA-VD-A8KL-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_7_rg.sorted.bam	30.16		0.15	58cfa832e4b0c9d6adf6d4cc	TCGA-VD-A8KL-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_7_rg.sorted.bam	Alive	FEMALE			Uveal Melanoma	Aligned reads	TCGA-VD-A8KL-01A	A9F956A0-660F-4185-A843-D9911D2484DE	Primary Tumor	Illumina HiSeq	e7c1dbaa-f0ee-479a-b2ad-cbbb8555e36e	Eye	77.0	86E0C8DD-546C-4B53-A56B-2C985E58CE68	4D1068DC-E769-4374-B895-4430A9B03322	TCGA-VD-A8KL-01A-11D-A40D-26	HG19_Broad_variant	TCGA-VD-A8KL	TCGA-UVM		s263	MD Anderson - Institute for Applied Cancer Science	University of Liverpool	United Kingdom	NO	T3a	NX		Stage IIB	A40D-26	True	UVM	C4		0.016217476	0.02	0.05		-1.2685	-0.3175	-1.817	-2.1513	-2.596	-0.6003	11.0	13.0	0.061079064	0.580251111	64.0	0.67139353	17.0	3.0				0.0	1.0		1.7055219719999999	-1782.7077420000003	-843.9290300000001	-1814.2844289999998	0.0	638.0	0.0	638.0	8.155362120328133	7.316105111158892	-0.35327332108162823	5.904070321721639	6.2746512363307305	2.2028154432335265	-2.251291798606495	-1.0414538748281612	2.5560887643151546
13722.58cfa832e4b0c9d6adf6d4d4	58cfa832e4b0c9d6adf6d4d4	TCGA-VD-AA8P-01A-11D-A40D_140829_SN208_0523_BC5FKTACXX_s_7_rg.sorted.filtered.	WGS	TCGA-VD-AA8P-01A-11D-A40D_140829_SN208_0523_BC5FKTACXX_s_7_rg.sorted	TCGA-VD-AA8P-01A-11D-A40D_140829_SN208_0523_BC5FKTACXX_s_7_rg.sorted.bam	65.26		0.16	58cfa832e4b0c9d6adf6d4d4	TCGA-VD-AA8P-01A-11D-A40D_140829_SN208_0523_BC5FKTACXX_s_7_rg.sorted.bam	Alive	FEMALE			Uveal Melanoma	Aligned reads	TCGA-VD-AA8P-01A	B224E42D-8B6D-4578-963C-BF528B954900	Primary Tumor	Illumina HiSeq	c3957866-f525-4f68-b483-cf444a24bb38	Eye	64.0	6029915F-6337-4816-998A-9754C770ED93	6331804A-DC4D-4244-9C0D-A5CEC20E593C	TCGA-VD-AA8P-01A-11D-A40D-26	HG19_Broad_variant	TCGA-VD-AA8P	TCGA-UVM		s261	MD Anderson - Institute for Applied Cancer Science	University of Liverpool	United Kingdom	NO	T3a	N0		Stage IIB	A40D-26	True	UVM	C3		0.015486313	0.0	0.02	0.0	-0.8149	-0.2975	-1.3461	-2.5208	-1.4366	-0.7373	9.0	52.0	0.062220827	0.435545788	78.0	0.41161832600000003	8.0	8.0					0.0		1.449021565	-2018.902348	-952.9000304	-1241.096205	0.0	86.0	0.0	86.0	7.434847875212	6.760800866025475	-0.42009059732714327	5.237623297875781	5.719346991197313	1.4280375901594669	-2.197224577336219	-1.0414538748281612	1.8481281874866102
13722.58cfa832e4b0c9d6adf6d4d7	58cfa832e4b0c9d6adf6d4d7	TCGA-RZ-AB0B-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_1_rg.sorted.filtered.	WGS	TCGA-RZ-AB0B-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_1_rg.sorted	TCGA-RZ-AB0B-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_1_rg.sorted.bam	44.7		0.14	58cfa832e4b0c9d6adf6d4d7	TCGA-RZ-AB0B-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_1_rg.sorted.bam	Dead	FEMALE	WHITE		Uveal Melanoma	Aligned reads	TCGA-RZ-AB0B-01A	2BF47A88-DF0A-4102-AF2E-998C3D252B9C	Primary Tumor	Illumina HiSeq	e284c77f-87fb-456b-8707-5f7b1219d267	Eye	47.0	78DA02B6-41D6-4911-8762-A71657F26F3C	B2D03978-B98B-4FB4-BA5C-50CE935C0056	TCGA-RZ-AB0B-01A-11D-A40D-26	HG19_Broad_variant	TCGA-RZ-AB0B	TCGA-UVM	149.0	s187	MD Anderson - Institute for Applied Cancer Science	Wills Eye Institute	United States	NO	T4b			Stage IV	A40D-26	True	UVM	C3		0.046279324000000004	0.07	0.12	0.0	-0.7112	-0.0635	-0.9670000000000001	-1.4333	-0.9152	-0.5671	7.0		0.0	0.36536903200000004	70.0	0.22295237	5.0	6.0				1.098612289	3.0	1.0	2.5301371130000003	-1156.153153	-770.1889934	-2295.1700140000003	1.0	149.0	0.0	149.0	7.710653323501202	7.393775783829158	-1.1407454501465342	5.312758050702831	6.352321909000996	2.5645289244093057	-2.3978952727983707	-1.0414538748281612	3.70527437455584
13722.58cfa832e4b0c9d6adf6d4da	58cfa832e4b0c9d6adf6d4da	TCGA-VD-A8KE-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-VD-A8KE-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_2_rg.sorted	TCGA-VD-A8KE-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_2_rg.sorted.bam	35.8		0.15	58cfa832e4b0c9d6adf6d4da	TCGA-VD-A8KE-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_2_rg.sorted.bam	Alive	FEMALE			Uveal Melanoma	Aligned reads	TCGA-VD-A8KE-01A	C9BFC2A7-0914-4080-A0A3-1C6A4E58E1AB	Primary Tumor	Illumina HiSeq	54db22ce-0562-4448-825c-d4e883f4aca6	Eye	74.0	35DFEB9D-1F64-4D51-B27A-24AD8AA3327B	119B486A-77DF-49A2-80A0-19555DEB7573	TCGA-VD-A8KE-01A-11D-A40D-26	HG19_Broad_variant	TCGA-VD-A8KE	TCGA-UVM		s279	MD Anderson - Institute for Applied Cancer Science	University of Liverpool	United Kingdom	NO	T2a	NX		Stage IIA	A40D-26	True	UVM	C4		0.023811462999999998	0.04	0.0		-2.1905	-0.336	-1.1943	-2.0703	-1.7848	-0.6872	2.0		0.243448245	0.36517236700000005	62.0	0.11353204	4.0	0.0					0.0		1.476820024	-1860.306181	-1833.503287	-1440.169646	0.0	821.0	0.0	821.0	9.402075812130713	8.655214489313613	-1.2593347336586027	7.004180539332342	7.4656304224397765	1.977162692559418	-2.3978952727983707	-1.1895840668738364	3.2364974262180204
13722.58cfa832e4b0c9d6adf6d4dc	58cfa832e4b0c9d6adf6d4dc	TCGA-VD-A8KN-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-VD-A8KN-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_8_rg.sorted	TCGA-VD-A8KN-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_8_rg.sorted.bam	23.55		0.15	58cfa832e4b0c9d6adf6d4dc	TCGA-VD-A8KN-01A-11D-A40D_140731_SN208_0522_AC59K7ACXX_s_8_rg.sorted.bam	Alive	FEMALE			Uveal Melanoma	Aligned reads	TCGA-VD-A8KN-01A	B26CB5F2-4FF0-4476-8D02-7256ACE7D8A3	Primary Tumor	Illumina HiSeq	48635af7-70bf-40ad-8bc3-2acb2a60ab81	Eye	60.0	3DD23C74-0B1D-40F4-8E8E-A5032CC7C87D	CBCBD0D3-2964-4D54-9872-0442D37D9D04	TCGA-VD-A8KN-01A-11D-A40D-26	HG19_Broad_variant	TCGA-VD-A8KN	TCGA-UVM		s258	MD Anderson - Institute for Applied Cancer Science	University of Liverpool	United Kingdom	NO	T2a	NX		Stage IIA	A40D-26	True	UVM	C3		0.07926971299999999	0.09	0.05		-1.0446	-0.2235	-0.0078	-0.0881	-0.5385	-0.5724	5.0		0.063450237	0.285526065	76.0	0.120315369	3.0	1.0				1.992798144	9.0	0.9069615209999999	2.4382001559999997	-588.5872678999999	-747.5625008	-2127.092413	0.0	68.0	0.0	68.0	9.114600099695346	6.883633336861727	0.672608856696431	6.863308301088852	6.883633336861727	4.182660643270668	-2.251291798606495	0.0	3.510051786574237
13722.58cfa832e4b0c9d6adf6d4e4	58cfa832e4b0c9d6adf6d4e4	TCGA-V4-A9EE-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_3_rg.sorted.filtered.	WGS	TCGA-V4-A9EE-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_3_rg.sorted	TCGA-V4-A9EE-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_3_rg.sorted.bam	37.61		0.17	58cfa832e4b0c9d6adf6d4e4	TCGA-V4-A9EE-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EE-01A	EDBF6720-467E-4928-B1CB-0E7336358D18	Primary Tumor	Illumina HiSeq	88edb951-b2e0-476d-bc63-3f5883671a8f	Eye	86.0	1C5AB1BD-67EF-43AB-B46B-17E126DF2B82	0E1D56AE-4213-4443-BDD3-A652CFC60104	TCGA-V4-A9EE-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EE	TCGA-UVM	398.0	s223	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T3a	N0		Stage IIB	A40D-26	True	UVM	C4		0.119831156	0.08	0.12	0.0	-0.4645	-0.0135	-0.3999	-0.6484	-0.8387	-0.4331	5.0	1.0	0.218320815	0.40545294299999995	70.0	0.258074541	5.0	5.0				2.488327743	13.0	0.970127436	1.7318258480000002	-942.6019613	-410.31559480000004	-1691.569613	1.0	398.0	1.0	211.0	7.168965031102803	6.883804058159624	0.9864885776806278	4.971740453766584	5.842350183331463	3.2714471126830778	-2.197224577336219	-1.0414538748281612	2.28495853500245
13722.58cfa832e4b0c9d6adf6d4e5	58cfa832e4b0c9d6adf6d4e5	TCGA-V4-A9F1-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-V4-A9F1-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_1_rg.sorted	TCGA-V4-A9F1-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_1_rg.sorted.bam	51.84		0.17	58cfa832e4b0c9d6adf6d4e5	TCGA-V4-A9F1-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9F1-01A	94F3D9B0-0EE4-4F6A-A8FF-CE7A4D8FAB76	Primary Tumor	Illumina HiSeq	83f97de6-ac60-4cc0-bcff-bdecfe40f951	Eye	46.0	6C6A3062-B453-434B-9168-7837CAABC4EF	706721D2-3759-4664-BFB7-8FF7273C2786	TCGA-V4-A9F1-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9F1	TCGA-UVM		s226	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T3a	N0		Stage IIB	A40D-26	True	UVM	C4		0.114809601	0.11	0.02	0.0	-0.6648	-0.036000000000000004	-0.3307	-1.8323	-1.008	-0.6338	4.0	1.0	0.096663607	0.257769619	105.0	0.621398697	6.0	5.0				0.693147181	2.0	1.0	2.083729806	-879.1294549	-645.009006	-2275.162393	0.0	938.0	0.0	938.0	8.586594868219796	8.231741962115816	0.06604654253565279	6.740768177721465	7.315451230241662	4.36886345583989	-1.8458266904983305	-0.9162907318741551	4.3028169133042375
13722.58cfa832e4b0c9d6adf6d4f4	58cfa832e4b0c9d6adf6d4f4	TCGA-V3-A9ZX-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_2_rg.sorted.filtered.	WGS	TCGA-V3-A9ZX-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_2_rg.sorted	TCGA-V3-A9ZX-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_2_rg.sorted.bam	47.71		0.15	58cfa832e4b0c9d6adf6d4f4	TCGA-V3-A9ZX-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V3-A9ZX-01A	5019E7F1-DB46-4A07-9E7B-B6E5D1481B84	Primary Tumor	Illumina HiSeq	ad32c24c-f4fa-4356-95a8-15d394368122	Eye	56.0	A2DFEBBB-9A38-4CC2-A3F3-857C2A70DCF4	314EE286-7E1A-4CF8-A39D-D12E23C6DAAB	TCGA-V3-A9ZX-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V3-A9ZX	TCGA-UVM		s195	MD Anderson - Institute for Applied Cancer Science	Cleveland Clinic Foundation	United States	NO	T2b	NX		Stage IIB	A40D-26	True	UVM	C3		0.188621118	0.17	0.09	0.005304871	-0.4535	-0.0295	-0.0516	0.1246	-0.3654	-0.6241	2.0		0.063496202	0.126992404	73.0	0.20347684800000002	7.0	9.0				1.9459101490000001	7.0	1.0	2.695832165	-888.1852622000001	-524.9176282999999	-2374.518742	0.0	470.0	1.0	233.0	7.859413154693584	7.586634487744378	-0.039734984185443634	5.662188577357365	6.433954977805993	4.082074469630286	-2.197224577336219	-1.1526795099383853	4.12180945381573
13722.58cfa832e4b0c9d6adf6d4f6	58cfa832e4b0c9d6adf6d4f6	TCGA-L5-A4OI-01A-11D-A267_131018_SN590_0240_AC2MW5ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-L5-A4OI-01A-11D-A267_131018_SN590_0240_AC2MW5ACXX_s_1_rg.sorted	TCGA-L5-A4OI-01A-11D-A267_131018_SN590_0240_AC2MW5ACXX_s_1_rg.sorted.bam	40.07		0.16	58cfa832e4b0c9d6adf6d4f6	TCGA-L5-A4OI-01A-11D-A267_131018_SN590_0240_AC2MW5ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE		Esophageal Carcinoma	Aligned reads	TCGA-L5-A4OI-01A	CB2AF13B-CBED-4657-8FD4-FED8DB375CBA	Primary Tumor	Illumina HiSeq	61f0c88a-c61d-400f-b8cf-b9cacd5fcada	Esophagus	79.0	1B1CBB34-DA71-4441-B1A1-C936E8F04C73	8D5A0D62-D9C1-46D1-9B81-685293B45E6B	TCGA-L5-A4OI-01A-11D-A267-26	HG19_Broad_variant	TCGA-L5-A4OI	TCGA-ESCA		s1924	MD Anderson - Institute for Applied Cancer Science	University of Michigan	United States	NO	T3	N3		Stage IIIC	A267-26	True	ESCA	C4	GI.HM-indel	0.100657569	0.17	0.01		0.6191	-0.0215	-0.9938	-0.9014	0.4257	-0.2242			11.50495896	35.25640745	158.0	0.207532995	5.0	8.0	0.8582746040000001	2.82873308	27.0	3.222410678	27.0	0.9777215340000001	1.3742922690000001	-1020.1760539999999	532.3863052	869.691918	0.0	608.0	1.0	267.0	7.751260241130639	8.252706676567646	-0.39147886613342453	5.399884983967162	7.211252801739485	0.698518724361856	-2.3513752571634776	-1.0414538748281612	1.0899975904952806
13722.58cfa832e4b0c9d6adf6d4f8	58cfa832e4b0c9d6adf6d4f8	TCGA-L5-A4OT-01A-11D-A28P_140122_SN1222_0236_BD2CT4ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-L5-A4OT-01A-11D-A28P_140122_SN1222_0236_BD2CT4ACXX_s_7_rg.sorted	TCGA-L5-A4OT-01A-11D-A28P_140122_SN1222_0236_BD2CT4ACXX_s_7_rg.sorted.bam	28.48		0.14	58cfa832e4b0c9d6adf6d4f8	TCGA-L5-A4OT-01A-11D-A28P_140122_SN1222_0236_BD2CT4ACXX_s_7_rg.sorted.bam	Dead	MALE	WHITE		Esophageal Carcinoma	Aligned reads	TCGA-L5-A4OT-01A	9559F579-5D9A-4C96-9836-8A039D394795	Primary Tumor	Illumina HiSeq	7d4e10aa-fe0f-4c18-800f-98fde94f819b	Esophagus	77.0	6671C9B7-5445-40F1-ADB6-FCC8BAD25301	79E420D7-8852-45A0-BBEB-CAEEC5BE685F	TCGA-L5-A4OT-01A-11D-A28P-26	HG19_Broad_variant	TCGA-L5-A4OT	TCGA-ESCA	149.0	s1927	MD Anderson - Institute for Applied Cancer Science	University of Michigan	United States	NO	T3	N1		Stage IV	A28P-26	True	ESCA	C1	GI.CIN	0.275461759	0.53	0.18		0.4998	-0.0795	0.3574	0.3352	0.2035	0.5585			1.1593388759999999	4.43276629	258.0	0.5303357320000001	19.0	25.0	0.889085028	4.442946612	148.0	4.362885775	93.0	0.962557089	1.362419778	102.97717220000001	530.2192206	-539.7118885	1.0	149.0	1.0	149.0	8.282735880201754	7.827424911321829	-0.7490867693611556	5.980150787207709	7.347851831059943	1.7055726985356667	-2.3025850929940455	-0.4795730802618863	2.454659467896822
13722.58cfa832e4b0c9d6adf6d4fa	58cfa832e4b0c9d6adf6d4fa	TCGA-L5-A4OE-01A-11D-A267_131001_SN1120_0279_AC2DKPACXX_s_1_rg.sorted.filtered.	WGS	TCGA-L5-A4OE-01A-11D-A267_131001_SN1120_0279_AC2DKPACXX_s_1_rg.sorted	TCGA-L5-A4OE-01A-11D-A267_131001_SN1120_0279_AC2DKPACXX_s_1_rg.sorted.bam	43.86		0.16	58cfa832e4b0c9d6adf6d4fa	TCGA-L5-A4OE-01A-11D-A267_131001_SN1120_0279_AC2DKPACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE		Esophageal Carcinoma	Aligned reads	TCGA-L5-A4OE-01A	0A466142-C513-4257-85D4-4BD7CFD0EF29	Primary Tumor	Illumina HiSeq	49822c02-a9e7-4e7e-bd12-f1756b639beb	Esophagus	81.0	BD8CADB2-1382-4BF5-A68F-C5A71837FE95	C5F599A9-1398-4E49-9CC7-77129658E143	TCGA-L5-A4OE-01A-11D-A267-26	HG19_Broad_variant	TCGA-L5-A4OE	TCGA-ESCA		s1838	MD Anderson - Institute for Applied Cancer Science	University of Michigan	United States	NO	T3	N2		Stage IIIB	A267-26	True	ESCA	C2	GI.CIN	0.264285563	0.56	0.08		0.4181	0.0395	0.0459	0.49	1.7765	0.1872	145.0		2.007068662	5.507769818	118.0	0.81326207	18.0	24.0	0.907998667	4.412703186	129.0	4.7997544560000005	173.0	0.93139586	1.943109415	113.46769040000001	467.18368	-1424.246196	1.0	730.0	0.0	730.0	8.9572529442889	8.49157904323123	0.25737672295645186	6.760028366952681	7.6930713470134595	1.3830607285528258	-2.197224577336219	-0.7985076962177713	1.125684005596374
13722.58cfa832e4b0c9d6adf6d4fc	58cfa832e4b0c9d6adf6d4fc	TCGA-KN-8437-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KN-8437-01A-11D-2310-10_wgs_Illumina	TCGA-KN-8437-01A-11D-2310-10_wgs_Illumina.bam	88.3		0.05	58cfa832e4b0c9d6adf6d4fc	TCGA-KN-8437-01A-11D-2310-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KN-8437-01A	F1C1502E-1BD6-425A-B651-454363809668	Primary Tumor	Illumina HiSeq	b4d37e4e-5f70-4f9f-8577-67d22eef75a4	Kidney	42.0	05CC0766-7ED0-458E-B1D7-732B632C05A4	345A06D6-FA5C-4674-A847-88A6B537CF3C	TCGA-KN-8437-01A-11D-2310-10	GRCh37-lite	TCGA-KN-8437	TCGA-KICH		s16410	Baylor College of Medicine	Harvard	United States	NO	T1a	NX	Kidney Chromophobe	Stage I	2310-10	True	KICH	C5	KICH.Eosin.1	0.185170731	0.28	0.0		-1.5472	-0.379	-0.1647	-1.7946	-0.7913	-0.7961	3.0		0.104089529	0.104089529	41.0	0.00011742399999999999	0.0	0.0	0.944342272	1.309136367	4.0		0.0		0.816996708	-1122.537301	-500.15037580000006	3095.353019	0.0	3068.0	0.0	3068.0	6.412228692505316	1.8904798753429475	0.5957796892291031	5.960243568762259	3.4820293459209157	2.7032075766264225	-0.4519851237430572	1.5915494705779683	2.1074278873973196
13722.58cfa832e4b0c9d6adf6d4fe	58cfa832e4b0c9d6adf6d4fe	TCGA-L5-A4OG-01A-11D-A267_131001_SN1120_0280_BD2FDEACXX_s_7_rg.sorted.filtered.	WGS	TCGA-L5-A4OG-01A-11D-A267_131001_SN1120_0280_BD2FDEACXX_s_7_rg.sorted	TCGA-L5-A4OG-01A-11D-A267_131001_SN1120_0280_BD2FDEACXX_s_7_rg.sorted.bam	40.59		0.16	58cfa832e4b0c9d6adf6d4fe	TCGA-L5-A4OG-01A-11D-A267_131001_SN1120_0280_BD2FDEACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE		Esophageal Carcinoma	Aligned reads	TCGA-L5-A4OG-01A	EB4AD376-4CC1-4D2C-9B93-AD2B082C77C4	Primary Tumor	Illumina HiSeq	cef87877-7e34-43b9-9599-f98660d7b833	Esophagus	79.0	E8E44C65-B4E4-4688-A217-206905E68A7F	04C91C91-E55A-4075-B08A-F80568BB4A7B	TCGA-L5-A4OG-01A-11D-A267-26	HG19_Broad_variant	TCGA-L5-A4OG	TCGA-ESCA		s1926	MD Anderson - Institute for Applied Cancer Science	University of Michigan	United States	NO	T1	N0		Stage I	A267-26	True	ESCA	C1	GI.CIN	0.35184052299999996	0.56	0.05		0.525	0.046	0.131	0.6887	-0.1824	0.2322	88.0		0.9465991559999999	3.139938662	159.0	0.576327005	17.0	19.0	0.510461397	3.1047379619999997	438.0	4.707138902	128.0	0.9701379929999999	2.304870268	-738.5729018	250.06173330000001	-1327.401553	0.0	143.0	0.0	143.0	8.280204233279974	7.303768450536577	-1.1381940778318134	5.928828976116497	6.5565540487063565	0.5572711209761685	-2.3513752571634776	-0.7472144018302207	1.6954651988079819
13722.58cfa832e4b0c9d6adf6d514	58cfa832e4b0c9d6adf6d514	TCGA-V4-A9EU-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_6_rg.sorted.filtered.	WGS	TCGA-V4-A9EU-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_6_rg.sorted	TCGA-V4-A9EU-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_6_rg.sorted.bam	49.0		0.14	58cfa832e4b0c9d6adf6d514	TCGA-V4-A9EU-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EU-01A	DF685F8C-645A-47AE-A471-63BF1973A0AE	Primary Tumor	Illumina HiSeq	929aff65-5561-439c-9850-a5ce595efc28	Eye	83.0	2DAC7136-D3A0-4FFD-B22D-7F1F9B8B8E4C	4C43B0FD-D2D3-456F-AFDD-EC90DBBD5FBA	TCGA-V4-A9EU-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EU	TCGA-UVM		s213	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4d	N0		Stage IIIC	A40D-26	True	UVM	C3		0.04106746	0.03	0.01	0.0	-1.0071	-0.2025	-0.5683	-1.4299	-0.2951	-0.614	7.0		0.064905118	0.29207303100000004	129.0	0.261984361	9.0	8.0				1.609437912	5.0	1.0	2.325575316	-1162.4785570000001	-879.5986501	-2440.476419	0.0	709.0	1.0	86.0	8.617852674515415	8.035926369891792	-0.9289068546833233	6.36656087590892	5.470977012430255	1.5975595248114713	-2.251291798606495	-2.5649493574615367	2.526466379494795
13722.58cfa832e4b0c9d6adf6d517	58cfa832e4b0c9d6adf6d517	TCGA-PD-A5DF-01A-11D-A27I-10_wgs_Illumina.filtered.	WGS	TCGA-PD-A5DF-01A-11D-A27I-10_wgs_Illumina	TCGA-PD-A5DF-01A-11D-A27I-10_wgs_Illumina.bam	28.25		0.08	58cfa832e4b0c9d6adf6d517	TCGA-PD-A5DF-01A-11D-A27I-10_wgs_Illumina.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-PD-A5DF-01A	1987B453-F97D-45C7-9C89-B9A33313D645	Primary Tumor	Illumina HiSeq	b1a68eac-e070-4718-a0a6-095bb77bfeea	Liver	58.0	0B88D087-50FB-4893-AE37-2FC5990A5B15	F1A4F60A-5228-47CD-883F-FF8D2DFE1633	TCGA-PD-A5DF-01A-11D-A27I-10	GRCh37-lite	TCGA-PD-A5DF	TCGA-LIHC	639.0	s16865	Baylor College of Medicine	Fox Chase	United States	NO	T4	N0	Hepatocellular Carcinoma	Stage IIIB	A27I-10	True	LIHC	C4	LIHC.iCluster:3	0.21893753	0.27	0.07		-0.1345	0.0715	0.1079	-0.5985	0.0147	-0.1711	18.0	12.0	0.346088606	0.985021418	390.0	0.24180437100000002	3.0	28.0				1.609437912	5.0	1.0	2.839622832	-962.8954858	-38.6997923	3724.868213	1.0	639.0	1.0	639.0	5.972164918286856	1.8991879493129584	-1.6886885249747055	5.854381882630472	3.617747002763453	2.2800398546729888	-0.11778303565638337	1.7185590534504946	3.968728379647694
13722.58cfa832e4b0c9d6adf6d51c	58cfa832e4b0c9d6adf6d51c	TCGA-KO-8405-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KO-8405-01A-11D-2310-10_wgs_Illumina	TCGA-KO-8405-01A-11D-2310-10_wgs_Illumina.bam	91.2		0.05	58cfa832e4b0c9d6adf6d51c	TCGA-KO-8405-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	WHITE	HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KO-8405-01A	D52C3CB6-921E-4F26-B49C-E6E4F11F9C06	Primary Tumor	Illumina HiSeq	f0e77d93-bf81-460d-b8ea-9f6189208a33	Kidney	29.0	415C8373-535F-4CDD-883B-C7BD7CEB426E	6400C324-2C94-477D-ACB9-669D4EA46F1E	TCGA-KO-8405-01A-11D-2310-10	GRCh37-lite	TCGA-KO-8405	TCGA-KICH		s16535	Baylor College of Medicine	MD Anderson Cancer Center	United States	NO	T3a	N0	Kidney Chromophobe	Stage III	2310-10	True	KICH	C3	KICH.Eosin.0	0.37698381200000003	0.58	0.0		-2.0836	-0.29	1.0812	0.3921	0.4926	-0.1065	4.0		0.07646479	0.203906107	59.0	0.7741318359999999	28.0	0.0				2.6156305769999997	14.0	0.99112306	1.316070866	-260.6436375	-1582.3879769999999	1707.3962559999998	0.0	3056.0	0.0	3056.0	7.331496795841014	3.0687932920194365	0.5429569019487841	5.827419399064739	3.1610296446115447		-1.5040773967762742	0.09223635259210816	
13722.58cfa832e4b0c9d6adf6d523	58cfa832e4b0c9d6adf6d523	TCGA-KN-8419-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KN-8419-01A-11D-2310-10_wgs_Illumina	TCGA-KN-8419-01A-11D-2310-10_wgs_Illumina.bam	17.3		0.05	58cfa832e4b0c9d6adf6d523	TCGA-KN-8419-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KN-8419-01A	DC04B82C-E1E8-4917-BA19-C2FEA4A1B69A	Primary Tumor	Illumina HiSeq	14e44071-dc94-49f8-a105-4012aa8e1767	Kidney	43.0	65256F5D-63A8-49D3-9D76-A3D7E3DDC0E6	A592E80A-3B1A-46AA-BE30-BCD87D6BCA6F	TCGA-KN-8419-01A-11D-2310-10	GRCh37-lite	TCGA-KN-8419	TCGA-KICH		s16533	Baylor College of Medicine	Harvard	United States	NO	T2	N0	Kidney Chromophobe	Stage II	2310-10	True	KICH	C4	KICH.Eosin.1	0.162773469				-2.4546	-0.4905	-0.0364	-1.0899	-0.9383	-0.6171	9.0		0.15638997699999999	0.338844951	95.0	0.947732857	24.0	0.0				1.386294361	4.0	1.0	1.02118065	-488.78827340000004	-1551.653153	4136.204549	0.0	714.0	0.0	714.0	5.879516726150634	2.3576712422073065	0.3563336783651788	5.332973019782564	3.8534052405164845	1.9816449399555693	-0.5465437063680696	1.495733998309178	1.6253112615903906
13722.58cfa832e4b0c9d6adf6d528	58cfa832e4b0c9d6adf6d528	TCGA-L5-A4OJ-01A-11D-A267_131018_SN590_0241_BC30HBACXX_s_1_rg.sorted.filtered.	WGS	TCGA-L5-A4OJ-01A-11D-A267_131018_SN590_0241_BC30HBACXX_s_1_rg.sorted	TCGA-L5-A4OJ-01A-11D-A267_131018_SN590_0241_BC30HBACXX_s_1_rg.sorted.bam	44.72		0.17	58cfa832e4b0c9d6adf6d528	TCGA-L5-A4OJ-01A-11D-A267_131018_SN590_0241_BC30HBACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE		Esophageal Carcinoma	Aligned reads	TCGA-L5-A4OJ-01A	CB419344-6148-43D4-B549-570BD09B3E05	Primary Tumor	Illumina HiSeq	b8117191-ea00-451f-85ca-53357a42b44f	Esophagus	70.0	4F03824A-79D6-40E8-A9E0-4079B1209F38	74221A72-4B40-4943-877D-7979EB4BD268	TCGA-L5-A4OJ-01A-11D-A267-26	HG19_Broad_variant	TCGA-L5-A4OJ	TCGA-ESCA		s1651	MD Anderson - Institute for Applied Cancer Science	University of Michigan	United States	NO	T1	N0		Stage I	A267-26	True	ESCA	C1	GI.CIN	0.18386274600000002	0.22	0.08		0.7077	0.07200000000000001	-0.8845	-0.1495	-0.5986	-0.255	78.0		1.7265802019999998	4.818962654	230.0	0.828465294	2.0	27.0	0.7596667420000001	4.620459422	438.0	4.095791311	79.0	0.937370453	1.994013245	-1256.275325	569.9895515	2046.0571690000002	0.0	639.0	0.0	639.0	8.85030263733226	8.149261246976732	-0.6000495542063529	6.247612951887877	5.132326765772138	2.031580000260856	-2.6026896854443837	-3.016934481204594	2.631629554467209
13722.58cfa832e4b0c9d6adf6d52e	58cfa832e4b0c9d6adf6d52e	TCGA-LN-A4A8-01A-32D-A267_131018_SN590_0241_BC30HBACXX_s_5_rg.sorted.filtered.	WGS	TCGA-LN-A4A8-01A-32D-A267_131018_SN590_0241_BC30HBACXX_s_5_rg.sorted	TCGA-LN-A4A8-01A-32D-A267_131018_SN590_0241_BC30HBACXX_s_5_rg.sorted.bam	34.22		0.15	58cfa832e4b0c9d6adf6d52e	TCGA-LN-A4A8-01A-32D-A267_131018_SN590_0241_BC30HBACXX_s_5_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A4A8-01A	AA364B98-0097-43A4-976D-742FAA0276DF	Primary Tumor	Illumina HiSeq	fd30434f-5a9a-4128-99f1-85d8d06ead73	Esophagus	52.0	0C0582CA-A181-4EFB-8486-C4312B250BA9	E42ECB6E-825E-407C-9CC7-C153C8F40DDC	TCGA-LN-A4A8-01A-32D-A267-26	HG19_Broad_variant	TCGA-LN-A4A8	TCGA-ESCA		s1935	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T2	N0		Stage IIA	A267-26	True	ESCA	C2	GI.ESCC	0.16640333300000001	0.29	0.1		1.2843	0.23800000000000002	-0.1538	0.1212	0.7981	0.5702	59.0		0.93962452	2.067173945	187.0	0.372456215	9.0	20.0	0.799251681	4.4804467269999995	272.0	4.478751353	105.0	0.962352709	5.294696801000001	-1024.790118	1409.4569119999999	-3404.5632950000004	0.0	472.0	1.0	250.0	7.811973429622023	7.80064090240997	-0.7871349546236039	5.509388336627978	6.647961392471585	1.6988493644242635	-2.3025850929940455	-1.1526795099383853	2.4859843190478674
13722.58cfa832e4b0c9d6adf6d54e	58cfa832e4b0c9d6adf6d54e	TCGA-L5-A4OS-01A-11D-A28P_140122_SN1222_0236_BD2CT4ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-L5-A4OS-01A-11D-A28P_140122_SN1222_0236_BD2CT4ACXX_s_3_rg.sorted	TCGA-L5-A4OS-01A-11D-A28P_140122_SN1222_0236_BD2CT4ACXX_s_3_rg.sorted.bam	26.15		0.16	58cfa832e4b0c9d6adf6d54e	TCGA-L5-A4OS-01A-11D-A28P_140122_SN1222_0236_BD2CT4ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE		Esophageal Carcinoma	Aligned reads	TCGA-L5-A4OS-01A	D5AC647F-0C6D-40D7-87A8-FAA1CC968C82	Primary Tumor	Illumina HiSeq	5c0f7af4-2359-4784-8db9-a4acac6fbb09	Esophagus	86.0	8734680B-CA7B-49F4-A539-0182B45454F3	C3CAE2EF-E23F-4D72-8B4F-E9F9AF08340D	TCGA-L5-A4OS-01A-11D-A28P-26	HG19_Broad_variant	TCGA-L5-A4OS	TCGA-ESCA		s1849	MD Anderson - Institute for Applied Cancer Science	University of Michigan	United States	NO	T2	N1		Stage IIB	A28P-26	True	ESCA	C1	GI.CIN	0.551877369	0.63	0.31		0.9735	0.271	0.7390000000000001	1.1843	0.4478	0.4901			0.7084466429999999	1.416893287	335.0	0.25061658600000003	7.0	45.0	0.399674825	2.3720278009999998	378.0	4.860709377	152.0	0.967520895	6.307167845	341.6064726	486.8413023	-2692.483422	0.0	1782.0	0.0	1782.0	8.177515823846075	6.7802945652994255	-0.3278078164575581	5.980291246509856	7.481473917556635	1.7694913426222845	-2.197224577336219	0.7011793522572098	2.0972991590798427
13722.58cfa832e4b0c9d6adf6d558	58cfa832e4b0c9d6adf6d558	TCGA-L5-A4OM-01A-11D-A267_131120_SN1222_0229_AD2FDGACXX_s_1_rg.sorted.filtered.	WGS	TCGA-L5-A4OM-01A-11D-A267_131120_SN1222_0229_AD2FDGACXX_s_1_rg.sorted	TCGA-L5-A4OM-01A-11D-A267_131120_SN1222_0229_AD2FDGACXX_s_1_rg.sorted.bam	36.8		0.17	58cfa832e4b0c9d6adf6d558	TCGA-L5-A4OM-01A-11D-A267_131120_SN1222_0229_AD2FDGACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE		Esophageal Carcinoma	Aligned reads	TCGA-L5-A4OM-01A	1A578AE7-5C0B-48EF-8BAF-7189DF703A93	Primary Tumor	Illumina HiSeq	2069622c-925f-4886-8005-9b8680ecc584	Esophagus	54.0	01EF1408-F028-4F6C-B09E-9BBB8D738704	081DEE66-D2A2-4FF2-94A1-6E3219D878D7	TCGA-L5-A4OM-01A-11D-A267-26	HG19_Broad_variant	TCGA-L5-A4OM	TCGA-ESCA		s1842	MD Anderson - Institute for Applied Cancer Science	University of Michigan	United States	NO	T1	N0		Stage IA	A267-26	True	ESCA	C1	GI.ESCC	0.128539513	0.14	0.42		1.1347	0.057	-0.8942	-0.9627	-0.4019	0.2349	31.0		0.361823447	1.175926204	192.0	0.702098964	8.0	22.0	0.968524332	3.415365972	34.0	3.576011471	42.0	0.956748947	6.2184568239999995	-729.6043712000001	1441.371539	-1725.473216	1.0	1458.0	0.0	1458.0	7.501910510335131	7.01211529430638	-0.8317037093871413	5.304685932998912	5.970661419478218	1.2000223592530281	-2.197224577336219	-1.0414538748281612	2.0317260686401695
13722.58cfa832e4b0c9d6adf6d56c	58cfa832e4b0c9d6adf6d56c	TCGA-V4-A9EY-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_2_rg.sorted.filtered.	WGS	TCGA-V4-A9EY-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_2_rg.sorted	TCGA-V4-A9EY-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_2_rg.sorted.bam	24.77		0.16	58cfa832e4b0c9d6adf6d56c	TCGA-V4-A9EY-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EY-01A	15D19CCC-52B8-41F6-B1C1-2CC55691AED5	Primary Tumor	Illumina HiSeq	27c8b2d4-9133-49cb-a86b-84553dcf1c8e	Eye	66.0	E8C4DEFB-7781-4B3D-B209-7D444A1A1BB5	FDFEA8DC-451B-4493-B7ED-DBF97D7C1D78	TCGA-V4-A9EY-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EY	TCGA-UVM		s218	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4a	N0		Stage IIIA	A40D-26	True	UVM	C4		0.035347118999999996	0.35	0.0	0.0	-2.5537	-0.691	-1.1842	-1.5662	-1.9679	-0.608	5.0	0.0	0.06036651	0.422565569	59.0	0.009390164	0.0	2.0					0.0		1.505886905	-1313.664303	-2194.675082	-529.5768539	0.0	837.0	0.0	837.0	7.736743682453495	7.004493010777647	-0.21805997647324926	5.539519105117276	6.060031401936796		-2.197224577336219	-0.9444616088408513	
13722.58cfa832e4b0c9d6adf6d576	58cfa832e4b0c9d6adf6d576	TCGA-V4-A9EZ-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_3_rg.sorted.filtered.	WGS	TCGA-V4-A9EZ-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_3_rg.sorted	TCGA-V4-A9EZ-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_3_rg.sorted.bam	34.26		0.16	58cfa832e4b0c9d6adf6d576	TCGA-V4-A9EZ-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EZ-01A	39E494BC-7710-4F9F-98B0-0F509F7AEF1A	Primary Tumor	Illumina HiSeq	5c8725d3-7d4e-4fa4-9626-127c91f5ea5c	Eye	78.0	9FEE606B-30E8-4BD6-B4C3-E21EFE64870C	6C22A928-CD61-4D62-B401-A4BE19418177	TCGA-V4-A9EZ-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EZ	TCGA-UVM		s225	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T3a	N0		Stage IIB	A40D-26	True	UVM	C4		0.023513372999999997	0.04	0.11	0.0	-1.6316	-0.4705	-1.3186	-1.7734	0.5262	-0.862	11.0	0.0	0.30407529	0.395297877	88.0	0.874723026	4.0	13.0					0.0		1.790529303	-713.084976	-1584.490567	959.6965805	0.0	599.0	0.0	599.0	7.404887575616126	7.15292121433084	-0.670962614220385	5.153595777009631	6.0002417043924545	3.53174814614854	-2.251291798606495	-1.1526795099383853	4.202710760368925
13722.58cfa832e4b0c9d6adf6d578	58cfa832e4b0c9d6adf6d578	TCGA-V4-A9EM-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_2_rg.sorted.filtered.	WGS	TCGA-V4-A9EM-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_2_rg.sorted	TCGA-V4-A9EM-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_2_rg.sorted.bam	31.67		0.15	58cfa832e4b0c9d6adf6d578	TCGA-V4-A9EM-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EM-01A	711EB720-4CB7-48DE-9350-5C729BF9F0DA	Primary Tumor	Illumina HiSeq	f3dd06ee-2d71-4310-b226-e94b83da83f7	Eye	53.0	79658DC3-F2B6-4C5E-9BF7-2C0E440BA3BF	2A1955C2-F55D-48EF-A013-AA69288C3A0C	TCGA-V4-A9EM-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EM	TCGA-UVM		s233	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4a	N0		Stage IIIA	A40D-26	True	UVM	C4		0.035841694	0.03	0.04	0.0	-1.5099	-0.2345	-1.0469	-1.8342	-1.777	-0.5046	7.0	65.0	0.092571635	0.493715389	48.0	0.43080794899999997	4.0	2.0				0.0	1.0		1.623538039	-1451.4973730000002	-902.9105019	2757.363441	0.0	966.0	0.0	966.0	8.287842918192506	8.835123149025737	-1.6055086342942109	6.729698300145957	8.247336484123618	1.916922612182061	-1.5581446180465497	-0.5877866649021186	3.522431246476272
13722.58cfa832e4b0c9d6adf6d57a	58cfa832e4b0c9d6adf6d57a	TCGA-LN-A4MQ-01A-11D-A28P_131120_SN1222_0230_BC29YPACXX_s_4_rg.sorted.filtered.	WGS	TCGA-LN-A4MQ-01A-11D-A28P_131120_SN1222_0230_BC29YPACXX_s_4_rg.sorted	TCGA-LN-A4MQ-01A-11D-A28P_131120_SN1222_0230_BC29YPACXX_s_4_rg.sorted.bam	35.61		0.16	58cfa832e4b0c9d6adf6d57a	TCGA-LN-A4MQ-01A-11D-A28P_131120_SN1222_0230_BC29YPACXX_s_4_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A4MQ-01A	33C0199A-BE0C-46D1-BB1E-889BFAEDF20B	Primary Tumor	Illumina HiSeq	beb51eaa-d60f-4bae-a401-293cb0ff9121	Esophagus	46.0	23CF07BE-97E6-4F55-A8F2-FF03CDBBA74E	4B6D7228-2E11-44F6-A1F4-DABF2085BB05	TCGA-LN-A4MQ-01A-11D-A28P-26	HG19_Broad_variant	TCGA-LN-A4MQ	TCGA-ESCA		s1868	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T3	N1		Stage III	A28P-26	True	ESCA	C1	GI.ESCC	0.196427705	0.36	0.49		1.0267	0.121	-1.4609	-2.6073	-0.4538	0.0259	35.0		0.456538085	1.326134438	202.0	0.7224401840000001	12.0	50.0	0.835075605	1.3440023380000001	5.0	1.33217904	4.0	0.960964047	2.992260472	-2039.8891230000002	1202.373339	-1718.5054440000001	0.0	375.0	1.0	25.0	8.188411308079031	8.511024202270708	-0.6912281625079669	6.539752682491649	6.97954783130632	0.1760529023697759	-1.6486586255873819	-1.5314763709643886	0.8672810648777428
13722.58cfa832e4b0c9d6adf6d582	58cfa832e4b0c9d6adf6d582	TCGA-V4-A9EA-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_8_rg.sorted.filtered.	WGS	TCGA-V4-A9EA-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_8_rg.sorted	TCGA-V4-A9EA-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_8_rg.sorted.bam	33.08		0.17	58cfa832e4b0c9d6adf6d582	TCGA-V4-A9EA-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EA-01A	A9FE64A9-6D22-4E9F-96F3-F16AF7D298F8	Primary Tumor	Illumina HiSeq	35b1a08b-2b90-4f04-887c-7e95542f287e	Eye	66.0	1A18A8C2-C00F-42B2-B5C6-3AAB27BCE06D	10EEDA0C-C4C3-4F47-A3AF-599FDFCD62DF	TCGA-V4-A9EA-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EA	TCGA-UVM		s188	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4a	N0		Stage IIIA	A40D-26	True	UVM	C4		0.005013947	0.0	0.02	0.0	-1.9969999999999999	-0.762	-1.8584	-2.4874	-2.5292	-0.6008	7.0		0.060820038	0.304100192	60.0	0.09055841199999999	2.0	14.0					0.0		1.899791883	-1548.800091	-1818.3968109999998	3622.787411	0.0	1348.0	0.0	1348.0	7.025093771399371	8.5112038625695	0.5498085828184578	5.821120967073435	7.461381738070823	1.2021597939202844	-1.203972804325936	-1.0498221244986776	0.6523512111018266
13722.58cfa832e4b0c9d6adf6d586	58cfa832e4b0c9d6adf6d586	TCGA-V4-A9E8-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_6_rg.sorted.filtered.	WGS	TCGA-V4-A9E8-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_6_rg.sorted	TCGA-V4-A9E8-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_6_rg.sorted.bam	31.12		0.16	58cfa832e4b0c9d6adf6d586	TCGA-V4-A9E8-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_6_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9E8-01A	DF941BC1-6356-4F2E-A3F5-AE190266B441	Primary Tumor	Illumina HiSeq	20fb461e-733f-4247-b4ad-e78418cd1866	Eye	49.0	7C95738B-C7F2-470F-AB95-88CDABBEEF21	F5FF03D8-69DA-49EC-8BF3-8132071649AC	TCGA-V4-A9E8-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9E8	TCGA-UVM	808.0	s183	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4a	N0		Stage IIIA	A40D-26	True	UVM	C3		0.094941949	0.16	0.14	0.0	-1.8858	-0.3555	-0.3046	0.0151	-0.2511	-0.3661	7.0		0.128621842	0.321554606	106.0	0.5605700920000001	10.0	4.0	0.868837593	0.6022323279999999	2.0	1.791759469	6.0	1.0	1.912473963	-985.0586099	-1281.0827689999999	-1415.87115	1.0	808.0	1.0	557.0	8.45531778769815	8.13524927834942	0.4651728618194365	6.103942530534672	7.093795403521258	3.49501613687981	-2.3513752571634776	-1.0414538748281612	3.029843275060373
13722.58cfa832e4b0c9d6adf6d58a	58cfa832e4b0c9d6adf6d58a	TCGA-V4-A9E9-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_7_rg.sorted.filtered.	WGS	TCGA-V4-A9E9-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_7_rg.sorted	TCGA-V4-A9E9-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_7_rg.sorted.bam	31.06		0.16	58cfa832e4b0c9d6adf6d58a	TCGA-V4-A9E9-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9E9-01A	418152BD-7D33-4F0A-B890-2356B30D6F44	Primary Tumor	Illumina HiSeq	d8293c54-78cb-49a0-a69f-f36723632ddd	Eye	50.0	5CB8105A-6D8B-441B-A8F7-89308DD4FC92	3782E96A-456F-4747-B75B-A48597EDFD90	TCGA-V4-A9E9-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9E9	TCGA-UVM		s189	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4a	N0		Stage IIIA	A40D-26	True	UVM	C4		0.005347683000000001	0.0	0.02	0.00091591	-2.1698	-0.4125	-2.0061	-2.7319999999999998	-3.0325	-1.2112	4.0	0.0	0.06065824	0.333620318	92.0	0.10484082199999999	2.0	10.0					0.0		1.5993395719999999	-2505.432009	-1998.5210309999998	621.8855025	0.0	1246.0	0.0	1246.0	7.812782818577581	8.272144804713978	1.2162332944134173	5.561491019971086	7.230690929885816		-2.251291798606495	-1.0414538748281612	
13722.58cfa832e4b0c9d6adf6d58c	58cfa832e4b0c9d6adf6d58c	TCGA-V4-A9E7-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_5_rg.sorted.filtered.	WGS	TCGA-V4-A9E7-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_5_rg.sorted	TCGA-V4-A9E7-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_5_rg.sorted.bam	32.61		0.16	58cfa832e4b0c9d6adf6d58c	TCGA-V4-A9E7-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_5_rg.sorted.bam	Dead	MALE	WHITE		Uveal Melanoma	Aligned reads	TCGA-V4-A9E7-01A	B5C516BA-4785-41DC-BD07-B129D47808DD	Primary Tumor	Illumina HiSeq	18accc0b-97a3-4386-b4c6-9213eeb4da3e	Eye	76.0	76AF65DC-CCCD-4257-8D05-38334D3110DA	3D700A8D-7760-4095-B537-1171444D1A5D	TCGA-V4-A9E7-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9E7	TCGA-UVM	415.0	s193	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4a	N0		Stage IIIA	A40D-26	True	UVM	C4		0.010458596	0.0	0.07	0.0	-0.7589	-0.174	-1.9573	-2.6801	-2.4442	-1.0214	10.0	13.0	0.09698972	0.452618695	114.0	0.947291945	9.0	11.0					0.0		2.008542963	-2006.9918539999999	-740.6470801	-1922.047257	1.0	415.0	1.0	35.0	7.736743682453495	7.027314514039777	0.4703286739422427	5.485451883847	5.874635004101391		-2.251291798606495	-1.1526795099383853	
13722.58cfa832e4b0c9d6adf6d58e	58cfa832e4b0c9d6adf6d58e	TCGA-MR-A520-01A-11D-A25V-10_wgs_Illumina.filtered.	WGS	TCGA-MR-A520-01A-11D-A25V-10_wgs_Illumina	TCGA-MR-A520-01A-11D-A25V-10_wgs_Illumina.bam	24.04		0.08	58cfa832e4b0c9d6adf6d58e	TCGA-MR-A520-01A-11D-A25V-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-MR-A520-01A	25E893AD-A0FD-45AE-9AA9-9BCD7C2EC8E5	Primary Tumor	Illumina HiSeq	aa52c229-8251-4890-a772-fac2f7c1b7ca	Liver	58.0	D7F0E432-C20B-4B2B-8D73-2A235F339BE7	352FBBB4-88A5-4354-B1FA-3A01DA3FBFA7	TCGA-MR-A520-01A-11D-A25V-10	GRCh37-lite	TCGA-MR-A520	TCGA-LIHC		s16790	Baylor College of Medicine	University of Minnesota	United States	NO	T1	NX	Hepatocellular Carcinoma	Stage I	A25V-10	True	LIHC	C4	LIHC.iCluster:2	0.242350602	0.06	0.0		-1.8559	-0.3975	-0.7089	-0.7019	-1.219	-1.0323	12.0		0.264080613	0.369712859	51.0	9.55e-06	0.0	0.0				1.098612289	3.0	1.0	0.8260792579999999	-1570.641548	-960.7669488	3732.8682270000004	0.0	229.0	0.0	229.0	7.234177179749848	2.0121081355091324	0.3194901796480064	5.606720761813069	4.51824766356069		-1.627456417936779	2.5061395280515573	
13722.58cfa832e4b0c9d6adf6d590	58cfa832e4b0c9d6adf6d590	TCGA-V3-A9ZY-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_3_rg.sorted.filtered.	WGS	TCGA-V3-A9ZY-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_3_rg.sorted	TCGA-V3-A9ZY-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_3_rg.sorted.bam	50.6		0.15	58cfa832e4b0c9d6adf6d590	TCGA-V3-A9ZY-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V3-A9ZY-01A	2112A42A-9B85-475A-A31B-4CE7751CDEB9	Primary Tumor	Illumina HiSeq	00a09c4d-5a88-4562-b9f3-e397798bdc18	Eye	54.0	E835BB77-E3EE-41B0-B8E0-D39E966F91A7	CD97490D-738A-48A2-B014-F9DB48DE45FA	TCGA-V3-A9ZY-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V3-A9ZY	TCGA-UVM		s192	MD Anderson - Institute for Applied Cancer Science	Cleveland Clinic Foundation	United States	NO	T3a	NX		Stage IIB	A40D-26	True	UVM	C4		0.031308368999999996	0.02	0.0	0.0	-2.089	-0.4125	-1.1183	-1.4736	-1.7453	-0.8568	6.0	1.0	0.129023422	0.354814411	61.0	0.058549246	2.0	0.0				1.098612289	3.0	1.0	0.930620386	-1728.104952	-2091.806841	-1660.351592	0.0	459.0	0.0	459.0	8.023879992734878	7.313982001750118	1.1095533168463179	5.772588194128383	6.315453171638991	3.4955558925754042	-2.251291798606495	-0.998528830111127	2.386002575729086
13722.58cfa832e4b0c9d6adf6d59a	58cfa832e4b0c9d6adf6d59a	TCGA-MH-A55W-01A-11D-A26P-10_wgs_Illumina.filtered.	WGS	TCGA-MH-A55W-01A-11D-A26P-10_wgs_Illumina	TCGA-MH-A55W-01A-11D-A26P-10_wgs_Illumina.bam	41.46		0.07	58cfa832e4b0c9d6adf6d59a	TCGA-MH-A55W-01A-11D-A26P-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-MH-A55W-01A	2030E10B-A4C2-460F-9E29-90C8A76EA05E	Primary Tumor	Illumina HiSeq	02bc7316-2306-488a-9d16-c7a439636912	Kidney	50.0	7846E991-0D5F-4E97-ABE1-945C3BE9C9F9	2425A532-F562-423A-88F5-228642F53875	TCGA-MH-A55W-01A-11D-A26P-10	GRCh37-lite	TCGA-MH-A55W	TCGA-KIRP		s11593	Baylor College of Medicine	BLN - Baylor	United States	NO	T1b	NX	Kidney Papillary Renal Cell Carcinoma	Stage I	A26P-10	True	KIRP	C3	KIRP.C1	0.19610828600000002	0.23	0.04		-1.9672	-0.3185	-0.0146	0.0382	-0.5169	-0.4713	26.0	82.0	0.6757437070000001	2.054260868	58.0	0.94773164	12.0	2.0				2.6923109939999996	16.0	0.97104593	2.453573768	-846.9588640000001	-1945.3082769999999	-59.88767381	0.0	1043.0	0.0	1043.0	4.798149037256035	2.667781904660287	-0.8165334843786201	4.98047059404999	2.4975474179995176		0.1823215567939549	-0.17023448666076924	
13722.58cfa832e4b0c9d6adf6d59c	58cfa832e4b0c9d6adf6d59c	TCGA-MH-A562-01A-11D-A26P-10_wgs_Illumina.filtered.	WGS	TCGA-MH-A562-01A-11D-A26P-10_wgs_Illumina	TCGA-MH-A562-01A-11D-A26P-10_wgs_Illumina.bam	34.1		0.08	58cfa832e4b0c9d6adf6d59c	TCGA-MH-A562-01A-11D-A26P-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-MH-A562-01A	45BDCFD6-1E3F-4BE8-B843-AE949E8E43EB	Primary Tumor	Illumina HiSeq	6eae65c7-1a89-44c9-a3c5-b7af6d633f1b	Kidney	57.0	4306E07D-6FC1-4C69-ACB8-00A1DC78CAD8	DDDEA2E4-B8C3-4157-9D92-6DE472E8375A	TCGA-MH-A562-01A-11D-A26P-10	GRCh37-lite	TCGA-MH-A562	TCGA-KIRP		s11782	Baylor College of Medicine	BLN - Baylor	United States	NO	T1a	NX	Kidney Papillary Renal Cell Carcinoma	Stage I	A26P-10	True	KIRP	C3	KIRP.C1	0.262324053	0.26	0.0		-1.3936	-0.163	0.5267	0.5669	-0.4961	-0.4875	27.0	48.0	0.641600151	1.2297336220000001	71.0	0.24089156899999997	8.0	0.0				1.039720771	3.0	0.94639463	2.3653519640000003	-805.0390551	-2076.927768	187.17237509999998	0.0	616.0	0.0	616.0	6.328135176746411	2.223560789423951	1.0314659391852126	4.764159638389069	2.498227493763661		-1.5639755383573428	0.27466670433970997	
13722.58cfa832e4b0c9d6adf6d5a2	58cfa832e4b0c9d6adf6d5a2	TCGA-MH-A560-01A-11D-A26P-10_wgs_Illumina.filtered.	WGS	TCGA-MH-A560-01A-11D-A26P-10_wgs_Illumina	TCGA-MH-A560-01A-11D-A26P-10_wgs_Illumina.bam	8.04		0.07	58cfa832e4b0c9d6adf6d5a2	TCGA-MH-A560-01A-11D-A26P-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-MH-A560-01A	A40BEABE-496E-4324-A1D1-5A7D8B002AAB	Primary Tumor	Illumina HiSeq	b1efdb03-f6ae-443f-85cc-d545d7710c21	Kidney	62.0	2697D1DE-3D7E-4BD6-9EDE-7516BD10A701	CF5DEB22-F7EB-409D-A0E4-882716199C39	TCGA-MH-A560-01A-11D-A26P-10	GRCh37-lite	TCGA-MH-A560	TCGA-KIRP		s11594	Baylor College of Medicine	BLN - Baylor	United States	NO	T1a	NX	Kidney Papillary Renal Cell Carcinoma	Stage I	A26P-10	True	KIRP	C4	KIRP.C2a	0.169123165	0.25	0.0		-1.7733	-0.1085	-0.4266	-1.2692	-0.3781	-0.6258	7.0	22.0	0.386339925	1.214211194	70.0	0.135035285	6.0	0.0					0.0		1.5937678309999999	-895.0444071000001	-2252.407126	1072.127113	0.0	924.0	0.0	924.0	7.525478236895242	2.121457139395382	0.6284694708912841	5.306274752840247	3.6304163032993557	2.862757828869234	-2.2192034840549946	1.5089591639039739	2.23428835797795
13722.58cfa832e4b0c9d6adf6d5a8	58cfa832e4b0c9d6adf6d5a8	TCGA-LN-A49S-01A-11D-A248_121207_SN1222_0162_BD1MA7ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-LN-A49S-01A-11D-A248_121207_SN1222_0162_BD1MA7ACXX_s_5_rg.sorted	TCGA-LN-A49S-01A-11D-A248_121207_SN1222_0162_BD1MA7ACXX_s_5_rg.sorted.bam	29.69		0.17	58cfa832e4b0c9d6adf6d5a8	TCGA-LN-A49S-01A-11D-A248_121207_SN1222_0162_BD1MA7ACXX_s_5_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A49S-01A	E9F82800-647A-4D61-BD1F-2C17C4CCAFBA	Primary Tumor	Illumina HiSeq	f173addf-1b74-441d-b167-5eb17cdfe1c3	Esophagus	59.0	A83FF623-8AF0-44A9-8468-95457A017E5A	151B9A13-9D3D-4AF2-A779-24F62A13975B	TCGA-LN-A49S-01A-11D-A248-26	HG19_Broad_variant	TCGA-LN-A49S	TCGA-ESCA		s1680	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T3	N0		Stage IIA	A248-26	True	ESCA	C2	GI.ESCC	0.230650398	0.63	0.33		0.7575	0.2015	-0.2726	0.1169	0.8393	-0.2189			0.967461639	2.4647237	250.0	0.750677335	14.0	54.0	0.9060330679999999	4.096889979	92.0	3.8128398910000003	67.0	0.906805856	4.696459793	-1117.383343	165.884759	-2076.769613	0.0	400.0	1.0	49.0	5.681397027571298	8.271989922037296	-0.4380126199757839	6.209464457771794	7.83667185077945	2.0170512490805543	0.5280674302004966	-0.4353180712578455	2.455063869056338
13722.58cfa832e4b0c9d6adf6d5ad	58cfa832e4b0c9d6adf6d5ad	TCGA-MH-A55Z-01A-11D-A26P-10_wgs_Illumina.filtered.	WGS	TCGA-MH-A55Z-01A-11D-A26P-10_wgs_Illumina	TCGA-MH-A55Z-01A-11D-A26P-10_wgs_Illumina.bam	53.89		0.07	58cfa832e4b0c9d6adf6d5ad	TCGA-MH-A55Z-01A-11D-A26P-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-MH-A55Z-01A	F0F7E57F-1E9D-4F24-A685-A0811AACBBED	Primary Tumor	Illumina HiSeq	44cc1ed1-021d-4a1e-9a42-c6cb01ad7781	Kidney	65.0	1FC5BF90-235F-411C-AC1D-AEDC4DF1746F	B19EC4CD-2876-4A2B-BCB9-B3C8DB54FC15	TCGA-MH-A55Z-01A-11D-A26P-10	GRCh37-lite	TCGA-MH-A55Z	TCGA-KIRP		s11866	Baylor College of Medicine	BLN - Baylor	United States	NO	T1b	NX	Kidney Papillary Renal Cell Carcinoma	Stage I	A26P-10	True	KIRP	C3	KIRP.C1	0.132818891	0.12	0.0		-1.8741	-0.2765	-0.1417	-0.5337	-0.7322	-0.5373	43.0	30.0	0.734519192	2.040331089	49.0	0.147622303	6.0	0.0				1.098612289	3.0	1.0	1.98988736	-953.302664	-1817.2597719999999	1045.084786	0.0	845.0	0.0	845.0	6.917705609835305	2.5344736775863197	-0.060011819225988194	4.8895573625430195	2.1094193044816665	2.755937478628794	-2.028148247292285	-0.4250543731046532	2.815949297854782
13722.58cfa832e4b0c9d6adf6d5af	58cfa832e4b0c9d6adf6d5af	TCGA-MH-A561-01A-11D-A26P-10_wgs_Illumina.filtered.	WGS	TCGA-MH-A561-01A-11D-A26P-10_wgs_Illumina	TCGA-MH-A561-01A-11D-A26P-10_wgs_Illumina.bam	42.2		0.08	58cfa832e4b0c9d6adf6d5af	TCGA-MH-A561-01A-11D-A26P-10_wgs_Illumina.bam	Alive	MALE	WHITE	HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-MH-A561-01A	E6E6A773-B155-45A9-989F-75C12CE1702A	Primary Tumor	Illumina HiSeq	49516926-9793-4b88-bfa8-c631918a9b7a	Kidney	66.0	9E93686E-D150-404A-BD88-1DD4D2999ED3	2E8AD1CD-D5D5-4BB4-8BBD-E9BEF45088DA	TCGA-MH-A561-01A-11D-A26P-10	GRCh37-lite	TCGA-MH-A561	TCGA-KIRP		s11592	Baylor College of Medicine	BLN - Baylor	United States	NO	T1a	NX	Kidney Papillary Renal Cell Carcinoma	Stage I	A26P-10	True	KIRP	C3	KIRP.C1	0.147903108	0.32	0.19		-2.3965	-0.21600000000000003	0.2787	0.3978	-0.4146	-0.3002	27.0	46.0	0.574585493	2.4898704680000003	49.0	0.027574678	2.0	0.0	0.980644912	2.039193768	8.0	2.845638493	19.0	0.966445056	1.628983591	141.70376240000002	-2044.923229	2402.255078	0.0	841.0	0.0	841.0	6.763499922994638	2.795449939887341	0.2521271680203583	5.747579350171642	4.216181205072281		-1.015920572822996	1.4207312651849398	
13722.58cfa832e4b0c9d6adf6d5b4	58cfa832e4b0c9d6adf6d5b4	TCGA-LN-A49P-01A-11D-A248_121212_SN1120_0205_AC1F18ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-LN-A49P-01A-11D-A248_121212_SN1120_0205_AC1F18ACXX_s_3_rg.sorted	TCGA-LN-A49P-01A-11D-A248_121212_SN1120_0205_AC1F18ACXX_s_3_rg.sorted.bam	26.81		0.16	58cfa832e4b0c9d6adf6d5b4	TCGA-LN-A49P-01A-11D-A248_121212_SN1120_0205_AC1F18ACXX_s_3_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A49P-01A	B64A5F5A-5913-432E-9D08-0FF67A8C6B64	Primary Tumor	Illumina HiSeq	bc96d005-85da-45f9-924a-a168644b49c0	Esophagus	71.0	4B768A42-B383-40A9-9A6F-511974E9E4C8	044EA190-FCC0-41BE-99F7-274A1DDA540B	TCGA-LN-A49P-01A-11D-A248-26	HG19_Broad_variant	TCGA-LN-A49P	TCGA-ESCA		s1760	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T3	N0		Stage IIA	A248-26	True	ESCA	C2	GI.ESCC	0.336281726	0.59	0.1		0.8537	0.192	0.8593	1.0161	1.5297	0.3305	47.0		0.36518025200000004	1.417758625	172.0	0.376203534	8.0	39.0	0.894248787	4.303290022	123.0	4.622905657	192.0	0.879298093	2.964264796	-380.4604241	285.9997348	-2689.7384829999996	0.0	375.0	1.0	320.0	8.930428036788763	8.396192484603867	0.16401525283675988	6.488081001419559	7.354738609775706	1.524115637692011	-2.4423470353692043	-1.0414538748281612	1.3601003848552513
13722.58cfa832e4b0c9d6adf6d5b8	58cfa832e4b0c9d6adf6d5b8	TCGA-KO-8410-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KO-8410-01A-11D-2310-10_wgs_Illumina	TCGA-KO-8410-01A-11D-2310-10_wgs_Illumina.bam	71.2		0.05	58cfa832e4b0c9d6adf6d5b8	TCGA-KO-8410-01A-11D-2310-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KO-8410-01A	B5F6A0E3-F9AC-475F-9A34-B8B8834F1779	Primary Tumor	Illumina HiSeq	ccebf6d6-dff4-4e8b-b33c-391cf464f5ab	Kidney	74.0	3751E3F9-C61F-4D5A-8054-B08590539820	798BD17B-69B7-40D7-92FF-7C2389EDCCCF	TCGA-KO-8410-01A-11D-2310-10	GRCh37-lite	TCGA-KO-8410	TCGA-KICH		s16409	Baylor College of Medicine	MD Anderson Cancer Center	United States	NO	T1b	N0	Kidney Chromophobe	Stage I	2310-10	True	KICH	C3	KICH.Eosin.0	0.15213474800000001	0.23	0.0		-1.6806	-0.3435	-0.0602	-0.0945	-0.5233	-0.5855	11.0	2.0	0.077330621	0.41242998	87.0	0.9477269840000001	18.0	0.0		0.0	1.0	2.397895273	11.0	1.0	1.3852266069999999	-373.6452153	-950.3088166000001	2841.945995	0.0	3136.0	0.0	3136.0	6.386542562329659	1.8460730449277971	0.01680039515272924	5.734217376289969	3.4087290845031593		-0.6523251860396906	1.5626560395753621	
13722.58cfa832e4b0c9d6adf6d5bc	58cfa832e4b0c9d6adf6d5bc	TCGA-LN-A4A4-01A-11D-A267_131001_SN1222_0222_BC2CN2ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-LN-A4A4-01A-11D-A267_131001_SN1222_0222_BC2CN2ACXX_s_3_rg.sorted	TCGA-LN-A4A4-01A-11D-A267_131001_SN1222_0222_BC2CN2ACXX_s_3_rg.sorted.bam	24.3		0.16	58cfa832e4b0c9d6adf6d5bc	TCGA-LN-A4A4-01A-11D-A267_131001_SN1222_0222_BC2CN2ACXX_s_3_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A4A4-01A	E89D7900-915D-4936-B1B2-CAC3670EA2F4	Primary Tumor	Illumina HiSeq	8f2d7e64-e129-494b-9068-ad15dcb9457e	Esophagus	36.0	C7A31A25-A496-4D26-A9D2-C42ADB22BB45	655BFF55-E213-442B-8C1F-A1A959E89CDB	TCGA-LN-A4A4-01A-11D-A267-26	HG19_Broad_variant	TCGA-LN-A4A4	TCGA-ESCA		s1778	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T3	N1		Stage III	A267-26	True	ESCA	C1	GI.ESCC	0.11673825	0.36	0.05		0.7165	0.085	-0.8594	-1.6969	-0.06	0.6463	28.0		0.557199539	1.9966316819999999	239.0	0.947121194	23.0	35.0	0.543975233	1.058526927	7.0	1.906154747	7.0	0.979569765	5.651786513999999	-2056.6015429999998	1283.478242	-1161.954336	0.0	383.0	0.0	383.0	7.745002803515838	7.684554032037694	-0.7891053435393813	5.302655768146634	6.643100157209532	1.0086640520051702	-2.4423470353692043	-1.0414538748281612	1.7977693955445515
13722.58cfa832e4b0c9d6adf6d5d0	58cfa832e4b0c9d6adf6d5d0	TCGA-L7-A56G-01A-21D-A267_131001_SN1120_0280_BD2FDEACXX_s_3_rg.sorted.filtered.	WGS	TCGA-L7-A56G-01A-21D-A267_131001_SN1120_0280_BD2FDEACXX_s_3_rg.sorted	TCGA-L7-A56G-01A-21D-A267_131001_SN1120_0280_BD2FDEACXX_s_3_rg.sorted.bam	26.05		0.15	58cfa832e4b0c9d6adf6d5d0	TCGA-L7-A56G-01A-21D-A267_131001_SN1120_0280_BD2FDEACXX_s_3_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-L7-A56G-01A	70C5CE85-4022-46C0-8BD0-F5E9009DDF41	Primary Tumor	Illumina HiSeq	8e835c63-a680-469e-82b7-850d8f01da57	Esophagus	65.0	3DD6751A-6FA6-4365-8E5E-FCB3D17910F6	6AD8F7F3-2EEC-47F7-9176-B10EBEB78F7E	TCGA-L7-A56G-01A-21D-A267-26	HG19_Broad_variant	TCGA-L7-A56G	TCGA-ESCA		s1851	MD Anderson - Institute for Applied Cancer Science	Christiana Care	United States	NO					A267-26	True	ESCA	C1	GI.ESCC	0.11293075699999999	0.45	0.32		0.8468	0.122	-0.7382	-0.3167	0.1208	0.309	40.0		0.44830947	1.546667671	184.0	0.660489081	23.0	34.0	0.39853852799999995	1.405390532	34.0	3.352447775	37.0	0.928419825	3.251974227	-806.0057588999999	743.4832025000001	-1598.485067	1.0	330.0	1.0	270.0	7.945023937409195	5.472507535625696	-0.07098784481747833	5.7477993600729755	5.77513756951335	1.1300131891193002	-2.197224577336219	0.3026300338876542	1.2010010339367785
13722.58cfa832e4b0c9d6adf6d5e3	58cfa832e4b0c9d6adf6d5e3	TCGA-LN-A49U-01A-31D-A267_131001_SN1222_0222_BC2CN2ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-LN-A49U-01A-31D-A267_131001_SN1222_0222_BC2CN2ACXX_s_7_rg.sorted	TCGA-LN-A49U-01A-31D-A267_131001_SN1222_0222_BC2CN2ACXX_s_7_rg.sorted.bam	24.19		0.15	58cfa832e4b0c9d6adf6d5e3	TCGA-LN-A49U-01A-31D-A267_131001_SN1222_0222_BC2CN2ACXX_s_7_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A49U-01A	931A50FF-3149-4C4A-9456-45ED3A9DD457	Primary Tumor	Illumina HiSeq	c075129e-527d-4603-9336-8b26a5ce10d2	Esophagus	62.0	9B3E9E79-52EB-40F7-87EC-E1CB360004E6	FF6F10D6-874C-4281-AB3B-79FF2440A901	TCGA-LN-A49U-01A-31D-A267-26	HG19_Broad_variant	TCGA-LN-A49U	TCGA-ESCA		s1777	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T3	N0		Stage IIA	A267-26	True	ESCA	C1	GI.ESCC	0.053689975	0.24	0.05		1.112	0.242	-1.1263	-2.1315	-0.7745	0.6551			0.963001375	2.575468794	245.0	0.414878087	10.0	26.0		0.0	1.0	2.523210953	13.0	0.9837273959999999	5.983818244	-1083.3231130000001	1550.0238669999999	-2896.681461	0.0	467.0	0.0	467.0	5.605802066295997	7.078745269766542	-1.2547305693138	5.806472761758148	7.534762657037538	2.4225534190709475	0.20067069546215155	0.45601738727099583	3.6772839883847475
13722.58cfa832e4b0c9d6adf6d604	58cfa832e4b0c9d6adf6d604	TCGA-LN-A49W-01A-11D-A267_131018_SN590_0240_AC2MW5ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-LN-A49W-01A-11D-A267_131018_SN590_0240_AC2MW5ACXX_s_5_rg.sorted	TCGA-LN-A49W-01A-11D-A267_131018_SN590_0240_AC2MW5ACXX_s_5_rg.sorted.bam	22.73		0.15	58cfa832e4b0c9d6adf6d604	TCGA-LN-A49W-01A-11D-A267_131018_SN590_0240_AC2MW5ACXX_s_5_rg.sorted.bam	Alive	MALE	ASIAN		Esophageal Carcinoma	Aligned reads	TCGA-LN-A49W-01A	DAF211F2-941E-4244-8CF5-D31492269443	Primary Tumor	Illumina HiSeq	30b9eb80-84d4-4582-aa2d-a826faadd2f2	Esophagus	73.0	25E6A27B-B015-4936-B57E-CF39DD5AF9BA	38678D1B-A9D9-4231-95B8-95D5AB4D64F2	TCGA-LN-A49W-01A-11D-A267-26	HG19_Broad_variant	TCGA-LN-A49W	TCGA-ESCA		s1772	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T3	N1		Stage III	A267-26	True	ESCA	C2	GI.ESCC	0.39301384899999997				0.7976	0.1245	0.9484	1.4996	1.2675	0.7682	29.0		0.515957167	1.6952878340000002	405.0	0.634082205			0.819136346	5.125882964	522.0	4.694422083	217.0	0.872585809	2.675808527	279.04553230000005	1371.054916	228.0136986	0.0	403.0	0.0	403.0	7.7419678998206845	7.732076910092889	0.03165795262930082	5.216239255512429	6.528104105766953	1.632643857453281	-2.525728644308255	-1.203972804325936	1.6009859048239803
13722.58cfa832e4b0c9d6adf6d608	58cfa832e4b0c9d6adf6d608	TCGA-LN-A5U5-01A-21D-A28P_140122_SN1222_0236_BD2CT4ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-LN-A5U5-01A-21D-A28P_140122_SN1222_0236_BD2CT4ACXX_s_4_rg.sorted	TCGA-LN-A5U5-01A-21D-A28P_140122_SN1222_0236_BD2CT4ACXX_s_4_rg.sorted.bam	66.44		0.15	58cfa832e4b0c9d6adf6d608	TCGA-LN-A5U5-01A-21D-A28P_140122_SN1222_0236_BD2CT4ACXX_s_4_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A5U5-01A	656E3C14-1FC6-473A-813E-719753E7B408	Primary Tumor	Illumina HiSeq	d3861f7c-bb4e-48be-b15b-0c082a3b6ff5	Esophagus	57.0	945DA36D-32AD-4996-9D77-BE6D09B858F9	E9CE892D-BF42-4445-B566-A8D7AC73AED0	TCGA-LN-A5U5-01A-21D-A28P-26	HG19_Broad_variant	TCGA-LN-A5U5	TCGA-ESCA		s1682	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T3	N1		Stage IV	A28P-26	True	ESCA	C2	GI.ESCC	0.211008867				1.1335	0.3495	-0.21899999999999997	-0.0669	1.3530000000000002	-0.0134	7.0		0.491617003	0.9608877779999999	215.0	0.381667574			0.502156879	1.288006963	13.0	3.510665922	44.0	0.9277193429999999	3.365916082	-551.7400417	673.0448006	-1930.7985410000001	1.0	136.0	1.0	136.0	8.33098408789509	8.307418214507571	0.26365803812173805	6.13375951055887	7.208805925839461	1.8219282606399725	-2.197224577336219	-1.0986122886681096	1.5582702225182343
13722.58cfa832e4b0c9d6adf6d61a	58cfa832e4b0c9d6adf6d61a	TCGA-LN-A49X-01A-31D-A267_131018_SN590_0241_BC30HBACXX_s_3_rg.sorted.filtered.	WGS	TCGA-LN-A49X-01A-31D-A267_131018_SN590_0241_BC30HBACXX_s_3_rg.sorted	TCGA-LN-A49X-01A-31D-A267_131018_SN590_0241_BC30HBACXX_s_3_rg.sorted.bam	16.61		0.16	58cfa832e4b0c9d6adf6d61a	TCGA-LN-A49X-01A-31D-A267_131018_SN590_0241_BC30HBACXX_s_3_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A49X-01A	B05AEFC4-2D61-44B6-9451-E660D10D8A79	Primary Tumor	Illumina HiSeq	e3d2b395-b1fa-4edd-86a9-72ca75792159	Esophagus	44.0	F67F4ACC-E1DC-41F5-AF25-F4C03856B1AC	92F976C9-1D13-4347-ADDB-6C8F4C2E078F	TCGA-LN-A49X-01A-31D-A267-26	HG19_Broad_variant	TCGA-LN-A49X	TCGA-ESCA		s1683	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T3	N0		Stage IIA	A267-26	True	ESCA	C2	GI.ESCC	0.488629906	0.72	0.31		1.0721	0.2735	-0.07	0.2134	0.3732	0.8415	30.0		0.43908519100000004	1.20170684	211.0	0.387331676	10.0	32.0	0.8473009890000001	3.059534319	37.0	3.589151476	51.0	0.912846044	1.5936105880000002	-173.04495930000002	2075.198254	-3612.4525630000003	0.0	384.0	0.0	384.0	7.844044697362982	8.117141973152153	-0.6341488397979894	5.646820120026763	7.22983877815125	4.815662619748742	-2.197224577336219	-0.8873031950009029	5.449811459546732
13722.58cfa832e4b0c9d6adf6d630	58cfa832e4b0c9d6adf6d630	TCGA-LN-A49Y-01A-11D-A267_131120_SN1222_0229_AD2FDGACXX_s_5_rg.sorted.filtered.	WGS	TCGA-LN-A49Y-01A-11D-A267_131120_SN1222_0229_AD2FDGACXX_s_5_rg.sorted	TCGA-LN-A49Y-01A-11D-A267_131120_SN1222_0229_AD2FDGACXX_s_5_rg.sorted.bam	41.86		0.16	58cfa832e4b0c9d6adf6d630	TCGA-LN-A49Y-01A-11D-A267_131120_SN1222_0229_AD2FDGACXX_s_5_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A49Y-01A	87FABA0E-28E7-4A7E-A7E1-12582EC68FAC	Primary Tumor	Illumina HiSeq	61d40e9e-a5c9-4e35-8e7f-5e08661da9b6	Esophagus	77.0	E443EA94-586E-4A0B-8330-55336AAE9A15	9AAF77BB-57CB-4073-BA2E-380B80303B0B	TCGA-LN-A49Y-01A-11D-A267-26	HG19_Broad_variant	TCGA-LN-A49Y	TCGA-ESCA		s1870	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T3	N0		Stage IIA	A267-26	True	ESCA	C1	GI.ESCC	0.03373629	0.05	0.15		1.0559	0.3855	-0.8681	-0.7743	-0.6054	0.1487			1.980113936	5.133628722	298.0	0.885148632	10.0	46.0	0.946096162	2.7857224169999997	19.0	2.66539416	16.0	0.9613377340000001	6.16808943	-1837.0720410000001	1118.3877109999999	-3712.901539	0.0	379.0	1.0	90.0	8.052190370591877	7.880867330849457	-0.403382207959155	6.05976020590167	6.676894526523521		-1.9924301646902063	-1.203972804325936	
13722.58cfa832e4b0c9d6adf6d655	58cfa832e4b0c9d6adf6d655	TCGA-LN-A49O-01A-11D-A248_130101_SN590_0206_AC1H8RACXX_s_1_rg.sorted.filtered.	WGS	TCGA-LN-A49O-01A-11D-A248_130101_SN590_0206_AC1H8RACXX_s_1_rg.sorted	TCGA-LN-A49O-01A-11D-A248_130101_SN590_0206_AC1H8RACXX_s_1_rg.sorted.bam	20.64		0.16	58cfa832e4b0c9d6adf6d655	TCGA-LN-A49O-01A-11D-A248_130101_SN590_0206_AC1H8RACXX_s_1_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A49O-01A	3DF1B9DB-D900-47D2-839D-3900829CB2A9	Primary Tumor	Illumina HiSeq	e460c5ae-4179-406e-a1fd-fb7b1c7403ae	Esophagus	47.0	37A1045E-A566-4BC0-88CA-A54C5426A96D	C5253C04-01D3-40D9-85A2-155F9D0360C3	TCGA-LN-A49O-01A-11D-A248-26	HG19_Broad_variant	TCGA-LN-A49O	TCGA-ESCA		s1863	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T3	N0		Stage IIA	A248-26	True	ESCA	C2	GI.ESCC	0.217763565	0.42	0.15		1.3163	0.3815	0.1693	0.0207	1.6382	0.3331	22.0		0.461458343	1.360087749	270.0	0.551795186	17.0	39.0	0.859323835	3.89497078	93.0	4.275419488	100.0	0.928395546	2.435430041	196.9494459	1466.719603	-5011.445257	0.0	408.0	1.0	193.0	9.93056755693987	9.414341877762027	0.16144018074159905	7.040195799043706	8.67240453303265	2.8068066795501223	-2.8903717578961645	-0.7419373447293771	2.6453664988085235
13722.58cfa832e4b0c9d6adf6d6a6	58cfa832e4b0c9d6adf6d6a6	TCGA-V4-A9E5-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_4_rg.sorted.filtered.	WGS	TCGA-V4-A9E5-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_4_rg.sorted	TCGA-V4-A9E5-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_4_rg.sorted.bam	30.36		0.16	58cfa832e4b0c9d6adf6d6a6	TCGA-V4-A9E5-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9E5-01A	029CC59C-60DF-4411-A044-3A2EEEE7B110	Primary Tumor	Illumina HiSeq	6d4c51c2-0829-4ab2-9c4e-0a4653d8b744	Eye	51.0	9FD9F385-A009-44AE-836F-F18BAD96628F	CE4927D1-2A65-4BEF-98E5-EDD02A341820	TCGA-V4-A9E5-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9E5	TCGA-UVM		s190	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4b	N0		Stage IIIB	A40D-26	True	UVM	C4		0.014185365	0.0	0.0	0.011459786000000001	-1.8801	-0.425	-1.505	-2.1174	-2.3249	-0.8688	6.0	3.0	0.128570603	0.353569157	105.0	0.8193126479999999	10.0	4.0					0.0		1.97032006	-944.9223968	-1914.4553879999999	2066.246	0.0	2499.0	0.0	2499.0	6.990256500493881	6.9803859700170445	-0.5952264118908256	4.7930319231576615	5.8817736813489345	2.4837485720673733	-2.197224577336219	-1.0986122886681096	3.0789749839581986
